[
  {
    "chunk_id": "abortioncare_0",
    "text": "Abortion care guideline, second edition",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 1
  },
  {
    "chunk_id": "abortioncare_1",
    "text": "Abortion care guideline, second edition",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 3
  },
  {
    "chunk_id": "abortioncare_2",
    "text": "Abortion care guideline, second edition ISBN 978-92-4-010420-4 (electronic version) ISBN 978-92-4-010421-1 (print version) © World Health Organization 2024 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 4
  },
  {
    "chunk_id": "abortioncare_3",
    "text": " you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ( http://www.wipo.int/amc/en/mediation/rules/ ). Suggested citation. Abortion care guideline, second edition. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 4
  },
  {
    "chunk_id": "abortioncare_4",
    "text": "ganization; 2024. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party- owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 4
  },
  {
    "chunk_id": "abortioncare_5",
    "text": "solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the pu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 4
  },
  {
    "chunk_id": "abortioncare_6",
    "text": "ry products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. Design and layout: Little Unicorns (Seattle, WA)",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 4
  },
  {
    "chunk_id": "abortioncare_7",
    "text": "Contents Acknowledgements ...............................................................................................................................vii Acronyms and abbreviations ..................................................................................................................xi Glossary ...............................................................................................................................................xiii Executive summary ..............................................................................................................................xix Chapter 1. Introduction ............................................................................................................................1 1.1 Background and context .....................................................................................................................",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 5
  },
  {
    "chunk_id": "abortioncare_8",
    "text": "..................................1 1.1 Background and context ......................................................................................................................................1 1.2 Guideline objective, rationale, target audience, inclusivity and structure .......................................................2 1.2.1 Objective and rationale ...............................................................................................................................3 1.2.2 Target audience ..........................................................................................................................................3 1.2.3 Equity, inclusivity and people-centred care ...............................................................................................3 1.2.4 Conceptual structure of the guideline .....................................................",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 5
  },
  {
    "chunk_id": "abortioncare_9",
    "text": ".................................................................................3 1.2.4 Conceptual structure of the guideline .......................................................................................................4 1.3 An enabling environment for comprehensive abortion care ............................................................................5 1.3.1 Human rights including a supportive framework of law and policy ...........................................................7 1.3.2 Availability and accessibility of information .............................................................................................12 1.3.3 Health system factors ...............................................................................................................................12 1.4 Health system considerations ............................................................",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 5
  },
  {
    "chunk_id": "abortioncare_10",
    "text": "....................................................................................12 1.4 Health system considerations ...........................................................................................................................13 1.4.1 Universal health coverage and primary health care .................................................................................13 1.4.2 Health financing ........................................................................................................................................14 1.4.3. Health workforce competencies and training......................................................................................... 16 1.4.4 Commodities ............................................................................................................................................. 16 1.4.5 Monitoring and evaluation of quality abor",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 5
  },
  {
    "chunk_id": "abortioncare_11",
    "text": "................................................................................................................................. 16 1.4.5 Monitoring and evaluation of quality abortion care ................................................................................18 Chapter 2. Abortion regulation including relevant recommendations ....................................................21 2.1 Common approaches to abortion regulation ..................................................................................................22 2.2 Recommendations relating to regulation of abortion ....................................................................................22 2.2.1 Criminalization of abortion....................................................................................................................... 24 2.2.2 Grounds-based approaches to controlling access to aborti",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 5
  },
  {
    "chunk_id": "abortioncare_12",
    "text": ".................................................................................................................. 24 2.2.2 Grounds-based approaches to controlling access to abortion .............................................................26 2.2.3 Gestational age limits .............................................................................................................................28",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 5
  },
  {
    "chunk_id": "abortioncare_13",
    "text": "iv Chapter 3. Recommendations and best practice statements across the continuum of abortion care ......31 3.1 Background ....................................................................................................................................................... 32 3.1.1 Structure of information in this chapter ....................................................................................................32 3.1.2 Underlying principles and assumptions relating to recommendations on health worker roles ...........33 3.2 Services applicable across the continuum of care ..........................................................................................34 3.2.1 Providing information ................................................................................................................................34 3.2.2 Offering and providing counselling ...................",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_14",
    "text": ".....................................................................................................................34 3.2.2 Offering and providing counselling .........................................................................................................37 3.2.3 Links to additional services .................................................................................................................... 40 3.3 Pre-abortion ...................................................................................................................................................... 41 3.3.1 Mandatory waiting periods imposed by States, health-care facilities or health workers ......................41 3.3.2 Third-party authorization for abortion ....................................................................................................42 3.3.3 Rh isoimmunization ...............",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_15",
    "text": "ird-party authorization for abortion ....................................................................................................42 3.3.3 Rh isoimmunization ..................................................................................................................................44 3.3.4 Antibiotic prophylaxis ..............................................................................................................................46 3.3.5 Determining gestational age of pregnancy ............................................................................................47 3.3.6 Pain management for abortion ...............................................................................................................49 3.3.7 Cervical priming prior to surgical abortion .............................................................................................54 3.3.8 R",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_16",
    "text": "........................49 3.3.7 Cervical priming prior to surgical abortion .............................................................................................54 3.3.8 Restrictions (in law or policy) on health workers who may lawfully provide abortion care .................59 3.3.9 Conscientious objection or refusal by health workers to provide abortion care .................................60 3.4 Abortion ............................................................................................................................................................ 64 3.4.1 Methods of surgical abortion ...................................................................................................................65 3.4.2 Medical management of induced abortion ............................................................................................69 3.4.3 Missed abortion ....",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_17",
    "text": "...........65 3.4.2 Medical management of induced abortion ............................................................................................69 3.4.3 Missed abortion ........................................................................................................................................76 3.4.4 Intrauterine fetal demise (IUFD) ...............................................................................................................78 3.5 Post-abortion..................................................................................................................................................... 81 3.5.1 Follow-up care after abortion ...................................................................................................................81 3.5.2 Incomplete abortion ..................................................................................",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_18",
    "text": ".....................................................................81 3.5.2 Incomplete abortion ................................................................................................................................83 3.5.3 Management of non-life-threatening complications: infection and haemorrhage ................................87 3.5.4 Post-abortion contraception ...................................................................................................................90 3.6 Service-delivery options and self-management approaches ........................................................................96 3.6.1 Supported service-delivery approaches .................................................................................................96 3.6.2 Self-management approaches for medical abortion in whole or in part .............................................100 ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_19",
    "text": "......................................................96 3.6.2 Self-management approaches for medical abortion in whole or in part .............................................100 3.6.3 Self-management approaches for post-abortion contraception ..........................................................102 Chapter 4. Dissemination, applicability, research gaps and future updates of the guideline and recommendations .................................................................................107 4.1 Dissemination ................................................................................................................................................... 107 4.2 Implementation and impact evaluation of the guideline ...............................................................................107 4.3 Research gaps/topics for further research.........................................",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_20",
    "text": " guideline ...............................................................................107 4.3 Research gaps/topics for further research.....................................................................................................108 References ...........................................................................................................................................111 Annex 1. External experts and WHO staff involved in guideline development .......................................122 Annex 2. Selected human rights treaties and their treaty monitoring bodies .......................................128 Annex 3. References for the glossary ...................................................................................................129 Annex 4. Guideline development methods and process .......................................................................130 A",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_21",
    "text": ".................................................129 Annex 4. Guideline development methods and process .......................................................................130 Annex 5. Health worker categories and roles.......................................................................................139",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 6
  },
  {
    "chunk_id": "abortioncare_22",
    "text": "v Annex 6. Monitoring and evaluation of quality abortion care: identification of indicators ....................140 Annex 7. Systematic reviews and links to PICOs and recommendations ...............................................141 Annex 8. Law and policy domain PICO questions .................................................................................145 Annex 9. Clinical services domain PICO questions ...............................................................................153 Annex 10. Service delivery domain PICO questions ..............................................................................162 Annex 11. Details about guideline dissemination and updating ............................................................ 171 Supplementary materials and web annexes available online: • Web annex A. Key international human rights standards on abortion • Web annex B. Techn",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 7
  },
  {
    "chunk_id": "abortioncare_23",
    "text": "............................. 171 Supplementary materials and web annexes available online: • Web annex A. Key international human rights standards on abortion • Web annex B. Technical meetings during guideline development • Supplementary material 1. Evidence-to-Decision frameworks for the law and policy recommendations: • Supplementary material 2. Evidence-to-Decision frameworks for the clinical service recommendations: • Supplementary material 3. Evidence-to-Decision frameworks for the service delivery recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 7
  },
  {
    "chunk_id": "abortioncare_24",
    "text": "vii Acknowledgements United Nations Development Programme (UNDP)-United Nations Population Fund (UNFPA)-United Nations Children's Fund (UNICEF)-World Health Organization (WHO)-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) and the World Health Organization gratefully acknowledges the contributions of many individuals and organizations to the development of this consolidated guideline. WHO extends sincere thanks to the chair and members of the Guideline Development Group (GDG) : Laura Castleman (Chair) and Fauzia Akhter Huda, Karla Berdichevsky, Marge Berer, Michalina Drejza, Joanna Erdman, Kristina Gemzell Danielsson, Caitlin Gerdts, Laura Gil, Selma Hajri, Guyo Jaldesa, Godfrey Kangaude, Vinoj Manning, Hiromi Obara, Alongkone Phengsavanh, Akila Radhakrishnan, Michelle Remme and Chi Chi Undie; and also the human rights adviser for ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 9
  },
  {
    "chunk_id": "abortioncare_25",
    "text": "i, Guyo Jaldesa, Godfrey Kangaude, Vinoj Manning, Hiromi Obara, Alongkone Phengsavanh, Akila Radhakrishnan, Michelle Remme and Chi Chi Undie; and also the human rights adviser for the GDG meeting and all three Evidence and Recommendation Review Group (ERRG) meetings: Christina Zampas. Sincere thanks also to the following additional ERRG members : Nana Yaa Appiah, Suchitra Dalvie, Jemima Araba Dennis-Antwi, Surendra Dhital, Daniel Maceira, Sybil Nkeiru, Karan Parikh, Dhammika Perera, Judiac Ranape, Kitihoun Serge and Karthik Srinivasan; and to the following human rights advisers who contributed to the ERRG on law and policy: Abhijit Das, Sara Hossain, Karima Khalil, Primah Kwagala, Monica Arango Olaya and Xian Warner. Thanks are also due to the members of the External Review Group: Safia Ahsan, Traci Baird, Sharon Cameron, Jane Harries, Thoai Ngo, Yvette Raphael, Mariana Romero, Rachel Si",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 9
  },
  {
    "chunk_id": "abortioncare_26",
    "text": "arner. Thanks are also due to the members of the External Review Group: Safia Ahsan, Traci Baird, Sharon Cameron, Jane Harries, Thoai Ngo, Yvette Raphael, Mariana Romero, Rachel Simon-Kumar and Beverly Winikoff. Institutional affiliations for these and other contributors are provided in Annex 1 of this guideline. Special thanks are due to the Evidence Synthesis Teams, who prepared the Grading of Recommendations Assessment, Development and Evaluation (GRADE) systematic reviews, especially the lead researchers : Alison Edelman, Taylor King, Makalapua Motu’apuaka, Robyn Paynter, Maria Rodriguez (Clinical services domain); Nicholas Henschke, Yanina Sguassero and Gemma Villanueva (Service delivery domain); Scott Burris, Amanda Cleeve, Fiona de Londras and Maria Rodriguez (Law and policy domain). Special thanks also to the guideline methodologists, Jeppe Schroll (Clinical services domain); Nic",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 9
  },
  {
    "chunk_id": "abortioncare_27",
    "text": "ris, Amanda Cleeve, Fiona de Londras and Maria Rodriguez (Law and policy domain). Special thanks also to the guideline methodologists, Jeppe Schroll (Clinical services domain); Nicholas Henschke, Yanina Sguassero and Gemma Villanueva (Service delivery domain), and Maria Rodriguez (Law and policy domain). We also thank the team from the London School of Hygiene and Tropical Medicine, led by Veronique Filippi, for their work on monitoring and evaluation issues related to quality abortion care. We thank the “Economics of abortion” review team, led by Ernestina Coast, Samantha Lattof, Brittany Moore and Yana Rodgers, for their collaboration and contributions to the guideline. We also extend our thanks to the International Youth Alliance for Family Planning (IYAFP) for their close collaboration and contributions from their Youth Taskforce members to the guideline development process. We ackno",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 9
  },
  {
    "chunk_id": "abortioncare_28",
    "text": "ational Youth Alliance for Family Planning (IYAFP) for their close collaboration and contributions from their Youth Taskforce members to the guideline development process. We acknowledge the following GDG meeting observers including representatives from United Nations agencies: Patricia Lohr (British Pregnancy Advisory Service, and member of the Royal College of Obstetricians and Gynaecologists [RCOG] Making Abortion Safe Programme Advisory Group), Jaydeep Tank (Federation of Obstetrics and Gynaecological Societies of India and International Federation of Obstetrics and Gynaecology Acknowledgments",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 9
  },
  {
    "chunk_id": "abortioncare_29",
    "text": "Abortion care guideline, second edition viii [FIGO] Working Group for safe abortion, India), Francelle Toedtli (United Nations Population Fund, USA), Ann Yates (International Confederation of Midwives, the Netherlands); and the following individual reviewers from implementing organizations who provided feedback on the draft guidelines: Bethan Cobley (MSI Reproductive Choices, United Kingdom), Rasha Dabash (Ipas, USA), Eva Lathrop (Population Services International, USA), Steve Luboya (Pathfinder, USA) and Rebecca Wilkins (International Planned Parenthood Federation, United Kingdom of Great Britain and Northern Ireland). The following WHO staff members contributed as members of the WHO Guideline Steering Group , which managed the guideline development process (all from WHO’s Department of Sexual and Reproductive Health and Research [SRH], Prevention of Unsafe Abortion [PUA] Unit): Mekdes ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 10
  },
  {
    "chunk_id": "abortioncare_30",
    "text": " which managed the guideline development process (all from WHO’s Department of Sexual and Reproductive Health and Research [SRH], Prevention of Unsafe Abortion [PUA] Unit): Mekdes Daba Feyssa (provided support for the clinical services domain and overall guideline development process), Bela Ganatra (PUA Unit head, co-lead coordinator for the service delivery domain), Heidi Johnston (provided support for the service delivery domain, especially monitoring and evaluation work), Caron Kim (responsible technical officer, lead coordinator for the clinical services domain and co-lead for the service delivery domain, and overall coordinator for the guideline development process), Antonella Lavelanet (lead coordinator for the law and policy domain and human rights). During initial stages of guideline planning, Steering Group members also included Roopan Gill and Lemi Tolu (formerly with the PUA U",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 10
  },
  {
    "chunk_id": "abortioncare_31",
    "text": "or the law and policy domain and human rights). During initial stages of guideline planning, Steering Group members also included Roopan Gill and Lemi Tolu (formerly with the PUA Unit) and Rajat Khosla (formerly with the Office of the SRH Department’s Director). Writing was provided by Fiona de Londras, Bela Ganatra, Heidi Johnston, Caron Kim, Antonella Lavelanet, Jane Patten and Maria Rodriguez. WHO administrative support was provided by Claire Garabedian and Hannah Hatch, and communications support was provided by Sarah Kessler and Elizabeth Noble, all from the SRH Department, with additional communications support from Laura Keenan and Sarah Russell of the WHO Director of Communications Office and from Helen Palmer of Weber Shandwick. We are grateful to the following additional WHO headquarters staff and consultants, who provided input at various stages during the development of the g",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 10
  },
  {
    "chunk_id": "abortioncare_32",
    "text": " Palmer of Weber Shandwick. We are grateful to the following additional WHO headquarters staff and consultants, who provided input at various stages during the development of the guideline: Laurence Codjia, Fahdi Dkhimi, Carolin Ekman, Veloshnee Govender, Lisa Hedman, Laurence Läser, Bruno Meessen, Ulrika Rehnström Loi, Marta Schaaf, Patricia Titulaer; and also colleagues from WHO regional offices: Chilanga Asmani, Ibadat Dhillon, Rodolfo Gómez Ponce de León and Nilmini Hemachandra. Review and comments were kindly provided by Ian Askew, Director of the SRH Department. Special acknowledgement to the Office of the United Nations High Commissioner for Human Rights (OHCHR) for their review of the final draft of the guideline, in particular on the aspects relevant to international human rights standards and the integration of a human rights-based approach. Special thanks to the WHO Guidelines",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 10
  },
  {
    "chunk_id": "abortioncare_33",
    "text": " guideline, in particular on the aspects relevant to international human rights standards and the integration of a human rights-based approach. Special thanks to the WHO Guidelines Review Committee (GRC) and in particular to the WHO GRC Secretariat, Rebekah Thomas-Bosco, Marion Blacker and Maria Pura Solon, for their valuable feedback at every stage of the guideline development process. Editing and proofreading was provided by Green Ink, United Kingdom. Funding for the development of the guideline was provided by HRP , a cosponsored programme executed by the WHO.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 10
  },
  {
    "chunk_id": "abortioncare_34",
    "text": "ix Acknowledgments",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 11
  },
  {
    "chunk_id": "abortioncare_35",
    "text": "xi Acronyms and abbreviations AAAQ availability, accessibility, acceptability and quality AN auxiliary nurse ANM auxiliary nurse midwife CEDAW Convention on the Elimination of All Forms of Discrimination against Women CESCR United Nations Committee on Economic, Social and Cultural Rights CRC United Nations Convention on the Rights of the Child CRVS civil registration and vital statistics CSE comprehensive sexuality education D&C dilatation and (sharp) curettage D&E dilatation and evacuation EML WHO Model List of Essential Medicines (or Essential Medicines List) EmOC emergency obstetric care ERG External Review Group ERRG Evidence and Recommendation Review Group EST Evidence Synthesis Team EtD Evidence to Decision EVA electric vacuum aspiration GDG Guideline Development Group GRADE Grading of Recommendations Assessment, Development and Evaluation GRC Guidelines Review Committee HMIS Healt",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 13
  },
  {
    "chunk_id": "abortioncare_36",
    "text": "on EVA electric vacuum aspiration GDG Guideline Development Group GRADE Grading of Recommendations Assessment, Development and Evaluation GRC Guidelines Review Committee HMIS Health management information systems IUD intrauterine device IUFD intrauterine fetal demise IV intravenous LMIS logistics management information systems LMP last menstrual period MVA manual vacuum aspiration NEML national essential medicines list NGO nongovernmental organization NMRA national medicines regulatory authorities NSAID non-steroidal anti-inflammatory drug OCP oral contraceptive pill PCB paracervical block PHC primary health care PICO population, intervention, comparator, outcome(s) Rh Rhesus (blood group) SDG Sustainable Development Goal SRH sexual and reproductive health STI sexually transmitted infection UHC universal health coverage UNDP United Nations Development Programme UNFPA United Nations Popul",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 13
  },
  {
    "chunk_id": "abortioncare_37",
    "text": "opment Goal SRH sexual and reproductive health STI sexually transmitted infection UHC universal health coverage UNDP United Nations Development Programme UNFPA United Nations Population Fund VAS visual analogue scale WHO World Health Organization",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 13
  },
  {
    "chunk_id": "abortioncare_38",
    "text": "xiii Glossary For the sake of mutual understanding and consistency, below follows a list of how key terms and concepts are used throughout the guideline: • Community-based care: Services delivered by a broadly defined community health workforce, according to their training and capacity, encompassing a range of health workers, lay and professional, formal and informal, paid and unpaid, as well as facility-based personnel who support and supervise them and provide outreach services and campaigns (1). • Comprehensive abortion care (CAC): Provision of information, abortion management (including induced abortion and care related to pregnancy loss), and post-abortion care. • Concluding observations: Following submission of a State report and a constructive dialogue with the State party to the particular convention, treaty monitoring bodies issue concluding observations to the reporting State, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 15
  },
  {
    "chunk_id": "abortioncare_39",
    "text": "ion of a State report and a constructive dialogue with the State party to the particular convention, treaty monitoring bodies issue concluding observations to the reporting State, which are compiled in an annual report and sent to the United Nations General Assembly (2). • Conscious sedation: The use of a combination of medicines – a sedative to relax and an anaesthetic to block pain – to induce a depressed level of consciousness during a medical procedure. • Conscientious objection or conscientious refusal : The practice of health-care professionals refusing to provide abortion care on the basis of personal conscience or religious belief. • Decriminalization: Removing abortion from all penal/criminal laws, not applying other criminal offences (e.g. murder, manslaughter) to abortion, and ensuring there are no criminal penalties for having, assisting with, providing information about, or ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 15
  },
  {
    "chunk_id": "abortioncare_40",
    "text": " applying other criminal offences (e.g. murder, manslaughter) to abortion, and ensuring there are no criminal penalties for having, assisting with, providing information about, or providing abortion, for all relevant actors. • Dilatation and evacuation (D&E): D&E is used after 12–14 weeks of pregnancy. It is the safest and most effective surgical technique for later abortion, where skilled, experienced practitioners are available. D&E requires preparation of the cervix using osmotic dilators and/or pharmacological agents, and evacuating the uterus primarily with forceps, using vacuum aspiration (refer to entry in this list) to remove to remove any remaining blood or tissue. Glossary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 15
  },
  {
    "chunk_id": "abortioncare_41",
    "text": "Abortion care guideline, second edition xiv • Gestational age (duration of pregnancy): The number of days or weeks since the first day of the woman’s last normal menstrual period (LMP) in women with regular cycles (see Table 1). For women with irregular cycles or when LMP is unknown, gestational age is the size of the uterus, estimated in weeks, based on clinical examination or ultrasound, that corresponds to a pregnant uterus of the same gestational age dated by LMP. Table 1. Equivalent gestational ages in weeks and days during early pregnancy Weeks of gestation Days of gestation 0 0–6 1 7–13 2 14–20 3 21–27 4 28–34 5 35–41 6 42–48 7 49–55 8 56–62 9 63–69 10 70–76 11 77–83 12 84–90 13 91–97 14 98–104 Note: Day 0 is the first day of the last menstrual period (LMP), and is also the first day of Week 0 of gestation ( not Week 1). Source: Adapted from 2012 Safe abortion guidance (2) based o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 16
  },
  {
    "chunk_id": "abortioncare_42",
    "text": " 0 is the first day of the last menstrual period (LMP), and is also the first day of Week 0 of gestation ( not Week 1). Source: Adapted from 2012 Safe abortion guidance (2) based on International Statistical Classification of Diseases and Related Health Problems, tenth revision (ICD-10), 2004 (3) . • General comments/recommendations : A treaty monitoring body’s interpretation of the content and operation of human rights conventions. General comments seek to clarify the reporting duties of States Parties with respect to certain provisions, and suggest approaches to implementing treaty provisions (2). • Health: A state of complete physical, mental and social well-being and not merely the absence of disease or infirmity (4). • Health system: A health system consists of all organizations, people and actions whose primary intent is to promote, restore or maintain health (5). • Health workers:",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 16
  },
  {
    "chunk_id": "abortioncare_43",
    "text": "irmity (4). • Health system: A health system consists of all organizations, people and actions whose primary intent is to promote, restore or maintain health (5). • Health workers: All people engaged in actions whose primary intent is to enhance health. While, strictly speaking, this includes unpaid carers (e.g. parents caring for sick children, and self-carers), the data available on health worker numbers are generally limited to people engaged in paid activities (6; Chapter 1: Health workers). • Human rights standards: The meaning and scope of human rights as provided for in international human rights treaties and as interpreted and applied by the human rights bodies tasked with this work, which can include international, regional and national courts, and human rights committees (2). • Incomplete abortion: Clinical presence of an open cervical os and bleeding, whereby all products of c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 16
  },
  {
    "chunk_id": "abortioncare_44",
    "text": "nternational, regional and national courts, and human rights committees (2). • Incomplete abortion: Clinical presence of an open cervical os and bleeding, whereby all products of conception have not been expelled from the uterus, or the expelled products are not consistent with the estimated duration of pregnancy. Common symptoms include vaginal bleeding and abdominal pain. Uncomplicated incomplete abortion can result after an induced or spontaneous abortion (i.e. miscarriage). • International human rights treaty (also sometimes called a covenant or a convention): An international legal instrument adopted by the international community of States, normally at the United Nations General Assembly. Each treaty sets out a range of human rights and corresponding obligations which are legally binding on States that have ratified the treaty (2) (Annex 2 includes a list of relevant treaties).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 16
  },
  {
    "chunk_id": "abortioncare_45",
    "text": "xv • Intrauterine fetal demise (IUFD; fetal death): The intrauterine death of a fetus at any point in time during the pregnancy (7). • Mandatory waiting period: A requirement imposed by law or policy, or in practice, to wait a specified amount of time between requesting and receiving abortion care. • Medical methods of abortion (medical abortion) : Use of pharmacological agents to terminate a pregnancy (2). • Mental health: A state of well-being in which every individual realizes their own potential, can cope with the normal stresses of life, can work productively and fruitfully, and is able to make a contribution to their community (8). • Miscarriage (spontaneous abortion) : Spontaneous loss of a pregnancy before the fetus is usually viable outside the uterus. The clinical signs of miscarriage are vaginal bleeding, usually with abdominal pain and cramping. If the pregnancy has been expe",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 17
  },
  {
    "chunk_id": "abortioncare_46",
    "text": "ore the fetus is usually viable outside the uterus. The clinical signs of miscarriage are vaginal bleeding, usually with abdominal pain and cramping. If the pregnancy has been expelled, the miscarriage is termed “complete” or “incomplete” depending on whether or not tissues are retained in the uterus (9) . • Missed abortion: Arrest of pregnancy development where the embryo/fetus/embryonic tissue or empty gestational sac remains in the uterus and the cervical os is closed. Symptoms may include pain and/or bleeding, or there may be no symptoms at all (10). • Osmotic dilators: Short, thin rods made of seaweed (laminaria) or synthetic material. After placement in the cervical os, the dilators absorb moisture and expand, gradually dilating the cervix (2). • Policy: A law, regulation, procedure, administrative action, incentive or voluntary practice of governments and other institutions (11). ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 17
  },
  {
    "chunk_id": "abortioncare_47",
    "text": "pand, gradually dilating the cervix (2). • Policy: A law, regulation, procedure, administrative action, incentive or voluntary practice of governments and other institutions (11). • Post-abortion care: Provision of services after an abortion, such as contraceptive services and linkage to other needed services in the community or beyond. It can also include management of complications after an abortion. • Primary health care (PHC): A whole-of-society approach to health that aims at ensuring the highest possible level of health and well-being and their equitable distribution by focusing on people’s needs and preferences as early as possible along the continuum from health promotion and disease prevention to treatment, rehabilitation and palliative care, and as close as feasible to people’s everyday environment (12). • Quality of care: QOC encompasses six areas or dimensions of quality that",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 17
  },
  {
    "chunk_id": "abortioncare_48",
    "text": "ment, rehabilitation and palliative care, and as close as feasible to people’s everyday environment (12). • Quality of care: QOC encompasses six areas or dimensions of quality that are required in relation to health care: ☐ effective, delivering health care that is adherent to an evidence base and results in improved health outcomes for individuals and communities, based on need; ☐ efficient, delivering health care in a manner which optimizes resource use and avoids waste; ☐ accessible, delivering health care that is timely, geographically reachable, and provided in a setting where skills and resources are appropriate to medical need; ☐ acceptable/person-centred, delivering health care that takes into account the preferences and aspirations of individual service users and the cultures of their communities; ☐ equitable, delivering health care that does not vary in quality because of perso",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 17
  },
  {
    "chunk_id": "abortioncare_49",
    "text": "he preferences and aspirations of individual service users and the cultures of their communities; ☐ equitable, delivering health care that does not vary in quality because of personal characteristics such as gender, race, ethnicity, geographical location or socioeconomic status; ☐ safe, delivering health care that minimizes risks and harm to service users (13; p. 9). • Regulation of abortion: All formalized laws, policies and other instruments (e.g. facility-level protocol) that regulate pregnancy and abortion. • Self-care: The ability of individuals, families and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health worker. The scope of self-care thus includes health promotion, disease prevention and control, self-medication, providing care to dependent people, seeking hospital/specialist/primary car",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 17
  },
  {
    "chunk_id": "abortioncare_50",
    "text": " The scope of self-care thus includes health promotion, disease prevention and control, self-medication, providing care to dependent people, seeking hospital/specialist/primary care if necessary, and rehabilitation, including palliative care. It includes a range of self-care practices and approaches (14). Glossary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 17
  },
  {
    "chunk_id": "abortioncare_51",
    "text": "Abortion care guideline, second edition xvi • Self-management of abortion : Self-management of the entire process of medical abortion or one or more of its component steps, such as self-assessment of eligibility for medical abortion, self- administration of medicines without the direct supervision of a health worker, and self-assessment of the success of the abortion process. • Social enterprise (social business): Defined as a business that has specific social objectives that serve its primary purpose. Social enterprises seek to maximize profits while maximizing benefits to society and the environment. Their profits are principally used to fund social programmes (15). • Social franchising: Defined as a system of contractual relationships usually run by a nongovernmental organization which uses the structure of a commercial franchise to achieve social goals. The overarching difference bet",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 18
  },
  {
    "chunk_id": "abortioncare_52",
    "text": "f contractual relationships usually run by a nongovernmental organization which uses the structure of a commercial franchise to achieve social goals. The overarching difference between social and commercial franchising is that social franchising seeks to fulfil a social benefit whereas commercial franchising is driven by profit (16, 17). • Social marketing: Broadly defined as the application of marketing techniques to social problems. Aims to persuade or motivate people to adopt specific courses of action or behaviour which are generally accepted as being beneficial. It is the design, implementation and control of programmes seeking to increase acceptability of a social idea or practice in a target group(s). It cannot create the behaviour, it can only help to gain acceptance and a willingness to adopt the behaviour. Its strategy is predominately preventive (18). • Surgical methods of abo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 18
  },
  {
    "chunk_id": "abortioncare_53",
    "text": " cannot create the behaviour, it can only help to gain acceptance and a willingness to adopt the behaviour. Its strategy is predominately preventive (18). • Surgical methods of abortion (surgical abortion): Use of transcervical procedures for terminating pregnancy, including vacuum aspiration, and dilatation and evacuation (D&E). (See definitions in this list) (2). • Telemedicine (or Telehealth): A mode of health service delivery where providers and clients, or providers and consultants, are separated by distance (19). That interaction may take place in real time (synchronously), e.g. by telephone or video link. But it may also take place asynchronously (store-and- forward), when a query is submitted and an answer provided later, e.g. by email or text/voice/audio message. ☐ Client-to-provider telemedicine : Provision of health services at a distance; delivery of health services where cli",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 18
  },
  {
    "chunk_id": "abortioncare_54",
    "text": "wer provided later, e.g. by email or text/voice/audio message. ☐ Client-to-provider telemedicine : Provision of health services at a distance; delivery of health services where clients/patients and health workers are separated by distance (e.g. consultations between remote client/patient and health worker; clients/patients transmit medical data [images, notes, videos] to health worker) (20). • Third-party authorization : A requirement imposed by law or policy, or in practice, that a party other than the woman, girl or other pregnant person (typically a parent, guardian, spouse, partner, health worker, health authority or judicial authority) must authorize an abortion where other applicable legal requirements for lawful abortion have been met. • Treaty monitoring body: Each of the international human rights treaties (see above) is monitored by a designated treaty monitoring body (see Anne",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 18
  },
  {
    "chunk_id": "abortioncare_55",
    "text": "r lawful abortion have been met. • Treaty monitoring body: Each of the international human rights treaties (see above) is monitored by a designated treaty monitoring body (see Annex 2). The treaty monitoring bodies are committees composed of independent experts. Their main function is to monitor the States’ compliance with the treaty in question, including through the examination of State reports (2). • Universal health coverage (UHC): Ensuring that all people have access to needed promotive, preventive, curative, rehabilitative, and palliative health services, of sufficient quality to be effective, while also ensuring that the use of these services does not expose any users to financial hardship (12). • Vacuum aspiration (electrical or manual; EVA or MVA): Vacuum aspiration involves evacuation of the contents of the uterus through a plastic or metal cannula, attached to a vacuum source.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 18
  },
  {
    "chunk_id": "abortioncare_56",
    "text": " aspiration (electrical or manual; EVA or MVA): Vacuum aspiration involves evacuation of the contents of the uterus through a plastic or metal cannula, attached to a vacuum source. Electric vacuum aspiration (EVA) employs an electric vacuum pump. With manual vacuum aspiration (MVA), the vacuum is created using a hand-held, hand-activated, plastic 60 ml aspirator (also called a syringe). MVA aspirators accommodate 4–12 mm cannulae. Suction tubing for EVA can be used with cannulae up to 16 mm in diameter, permitting VA to be used up to 15–16 weeks of pregnancy or for post-abortion care cases presenting with dilated cervix where a higher number of cannulae is required for effective vacuum. References See Annex 3 for all references for this glossary.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 18
  },
  {
    "chunk_id": "abortioncare_57",
    "text": "xvii Glossary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 19
  },
  {
    "chunk_id": "abortioncare_58",
    "text": "xix Executive summary Executive summary Sexual and reproductive health is fundamental to individuals, couples and families, and to the social and economic development of communities and nations. As provided in the Constitution of the World Health Organization (WHO), the organization’s objective is “the attainment by all peoples of the highest possible level of health”, and to fulfil that objective, WHO’s functions include providing technical assistance to countries in the field of health. Universal access to sexual and reproductive health (SRH) information and services is central to both individual and community health, as well as the realization of human rights. In the wake of the COVID-19 pandemic and based on lessons learnt from previous disease outbreaks – when SRH services have been severely disrupted, causing individuals to feel disempowered and be exposed to preventable health ris",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 21
  },
  {
    "chunk_id": "abortioncare_59",
    "text": "n lessons learnt from previous disease outbreaks – when SRH services have been severely disrupted, causing individuals to feel disempowered and be exposed to preventable health risks – WHO has included comprehensive abortion care in the list of essential health services in certain recent technical publications. 1 Comprehensive abortion care includes the provision of information, abortion management (including induced abortion, and care related to pregnancy loss/spontaneous abortion and post-abortion care. Strengthening access to comprehensive abortion care within the health system is fundamental to meeting the Sustainable Development Goals (SDGs) relating to good health and well-being (SDG3) and gender equality (SDG5). WHO’s Global Reproductive Health Strategy, which seeks to accelerate progress towards achievement of international development goals, identifies elimination of unsafe abor",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 21
  },
  {
    "chunk_id": "abortioncare_60",
    "text": " (SDG5). WHO’s Global Reproductive Health Strategy, which seeks to accelerate progress towards achievement of international development goals, identifies elimination of unsafe abortion 2 as a priority mandate. The importance of quality abortion care to health is similarly underscored by the United Nations Global Strategy for Women’s, Children’s and Adolescents’ Health, which includes evidence-based interventions for abortion and post-abortion care as one effective way to help individuals thrive and communities transform. Quality of abortion care is foundational to this abortion care guideline. Quality of care (see Glossary) encompasses multiple components. It is defined as care that is: effective, efficient, accessible, acceptable/patient centred, equitable and safe. Effective care includes the delivery of evidence-based care that improves the health of individuals and communities, and i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 21
  },
  {
    "chunk_id": "abortioncare_61",
    "text": "cessible, acceptable/patient centred, equitable and safe. Effective care includes the delivery of evidence-based care that improves the health of individuals and communities, and is responsive to their needs. Efficient care optimizes resource use and minimizes waste. Quality abortion care must also be both accessible (timely, affordable, geographically reachable, and provided in a setting where skills and resources are appropriate to medical need) and acceptable (incorporating the preferences and values of individual service users and the cultures of their communities). It is imperative that access to abortion care is equitable, and that the quality of care does not vary based on the personal characteristics of the person seeking care, such as their gender, race, religion, ethnicity, socioeconomic status, education, if they are living with a disability, or based on their geographic locat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 21
  },
  {
    "chunk_id": "abortioncare_62",
    "text": " the person seeking care, such as their gender, race, religion, ethnicity, socioeconomic status, education, if they are living with a disability, or based on their geographic location within a country. And finally, quality abortion care implies that it is safely delivered and minimizes any risks and harms to service users. 1 When considering the concept of “essential health services”, it is important to note that different areas, even within the same country, may require different approaches to designate essential health services and to reorient health system components to maintain these services. Please refer to: Maintaining essential health services: operational guidance for the COVID-19 context, interim guidance, 1 June 2020 (https://www.who.int/publications/i/item/WHO-2019-nCoV-essential-health-services-2020.1 ). For additional relevant references, see Chapter 1, section 1.1. 2 “Unsa",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 21
  },
  {
    "chunk_id": "abortioncare_63",
    "text": "ance, 1 June 2020 (https://www.who.int/publications/i/item/WHO-2019-nCoV-essential-health-services-2020.1 ). For additional relevant references, see Chapter 1, section 1.1. 2 “Unsafe abortion” refers to abortion when it is carried out by a person lacking the necessary skills or in an environment that does not conform to minimal medical standards, or both. The second edition contains the updated remarks for Recommendation 22. There have been no other changes made to the recommendation itself nor any other recommendations contained in this document.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 21
  },
  {
    "chunk_id": "abortioncare_64",
    "text": "Abortion care guideline, second edition xx Abortion is a safe and non-complex health-care intervention that can be effectively managed using medication or a surgical procedure in a variety of settings. Complications are rare with both medical and surgical abortion, when abortions are safe – meaning that they are carried out using a method recommended by WHO, appropriate to the gestational age, and by someone with the necessary skills. Globally, abortion is a common procedure, with 6 out of 10 unintended pregnancies and 3 out of 10 of all pregnancies ending in induced abortion. However, global estimates demonstrate that 45% of all abortions are unsafe. This is a critical public health and human rights issue; unsafe abortion is increasingly concentrated in developing countries (97% of unsafe abortions) and among groups in vulnerable and marginalized situations. Legal restrictions and other",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 22
  },
  {
    "chunk_id": "abortioncare_65",
    "text": "afe abortion is increasingly concentrated in developing countries (97% of unsafe abortions) and among groups in vulnerable and marginalized situations. Legal restrictions and other barriers mean many women find it difficult or impossible to access quality abortion care and they may induce abortion themselves using unsafe methods or seek abortion from unskilled providers. The legal status of abortion makes no difference to a woman’s need for an abortion, but it dramatically affects her access to safe abortion. Between 4.7% and 13.2% of all maternal deaths are attributed to unsafe abortions, which equates to between 13 865 and 38 940 deaths caused annually by the failure to provide safe abortion. Medical abortion has revolutionized access to quality abortion care globally. Medicines for abortion can be safely and effectively administered at a health-care facility or self-administered outsi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 22
  },
  {
    "chunk_id": "abortioncare_66",
    "text": " has revolutionized access to quality abortion care globally. Medicines for abortion can be safely and effectively administered at a health-care facility or self-administered outside of a facility (e.g. at home) by individuals with a source of accurate information and quality-assured medicines. Those managing their abortions safely at home in the first 12 weeks of gestation may still need or want support from a trained health worker at some stage of the process. Service delivery with minimal medical supervision can significantly improve access to – and privacy, convenience and acceptability of – the abortion process, without compromising safety or effectiveness. Multiple actions are needed at the legal, health system and community levels so that everyone who needs it has access to comprehensive abortion care. A person’s environment plays a crucial role in shaping their access to care and",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 22
  },
  {
    "chunk_id": "abortioncare_67",
    "text": "system and community levels so that everyone who needs it has access to comprehensive abortion care. A person’s environment plays a crucial role in shaping their access to care and influencing their health outcomes. An enabling environment is the foundation of quality comprehensive abortion care. The three cornerstones of an enabling environment for abortion care are: 1. respect for human rights including a supportive framework of law and policy 2. availability and accessibility of information, and 3. a supportive, universally accessible, affordable and well functioning health system. Abortion is lawful in almost all countries, although there is variation in the specific circumstances under which an individual may access abortion. In addition, almost all countries where abortion is lawfully available regulate abortion differently to other forms of health care. Unlike other health service",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 22
  },
  {
    "chunk_id": "abortioncare_68",
    "text": "may access abortion. In addition, almost all countries where abortion is lawfully available regulate abortion differently to other forms of health care. Unlike other health services, abortion is commonly regulated to varying degrees through the criminal law in addition to regulation under health-care law. This has an impact on the rights of pregnant individuals, and can have a chilling effect (e.g. suppression of actions due to fear of reprisals or penalties) on the provision of quality care. This is why clear, accessible and rights-based law and policy is part of ensuring an enabling environment. Objectives, scope and conceptual structure of the guideline Guidelines are the fundamental means through which WHO fulfils its technical leadership in health. WHO guidelines are subject to a rigorous quality assurance process that generates recommendations for clinical practice or public health",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 22
  },
  {
    "chunk_id": "abortioncare_69",
    "text": "fulfils its technical leadership in health. WHO guidelines are subject to a rigorous quality assurance process that generates recommendations for clinical practice or public health policy with the aim of achieving the best possible individual or collective health outcomes. Towards this aim, WHO has made a commitment to integrate human rights into health-care programmes and policies at national and regional levels by looking at underlying determinants of health as part of a comprehensive approach to health and human rights.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 22
  },
  {
    "chunk_id": "abortioncare_70",
    "text": "xxi The objective of this guideline is to present the complete set of all WHO recommendations and best practice statements relating to abortion. While legal, regulatory, policy and service-delivery contexts may vary from country to country, the recommendations and best practices described in this document aim to enable evidence- based decision-making with respect to quality abortion care. This guideline updates and replaces the recommendations in the following previous WHO guidelines: • Safe abortion: technical and policy guidance for health systems, second edition (2012) • Health worker roles in providing safe abortion care and post-abortion contraception (previously known as the “task sharing” guidance) (2015), and • Medical management of abortion (2018). This guidance contains new recommendations consolidated here in an integrated manner with existing recommendations that remain uncha",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 23
  },
  {
    "chunk_id": "abortioncare_71",
    "text": "), and • Medical management of abortion (2018). This guidance contains new recommendations consolidated here in an integrated manner with existing recommendations that remain unchanged and those that have been updated after re-assessment using the same rigorous methods for both new and updated recommendations (see more information in the “Guideline development methods” section below). In this guideline, recommendations are presented across three domains that are essential to the provision of abortion care: Law and policy, Clinical services and Service delivery. The recommendations concerning the laws and policies that should or should not be in place in order to fully implement and sustain quality abortion care cover seven areas: criminalization of abortion, grounds-based approaches to permitting abortion, gestational age limits set for abortion, mandatory waiting periods before receivin",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 23
  },
  {
    "chunk_id": "abortioncare_72",
    "text": " cover seven areas: criminalization of abortion, grounds-based approaches to permitting abortion, gestational age limits set for abortion, mandatory waiting periods before receiving a requested abortion, third-party authorization for abortion, restrictions on which health workers can provide abortion services, and conscientious objection/ refusal by providers.3 Clinical service recommendations address methods of abortion and related clinical care – from provision of information, counselling and pain management to methods and regimens for abortion (including for different clinical indications) – and provision of post-abortion care, including all methods of contraception. 4 Service delivery recommendations include those relating to which categories of health workers can provide the relevant clinical services. Self-management recommendations are also presented relating to tasks that can be ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 23
  },
  {
    "chunk_id": "abortioncare_73",
    "text": "e those relating to which categories of health workers can provide the relevant clinical services. Self-management recommendations are also presented relating to tasks that can be managed by the woman herself: medical abortion in early gestation and use of many contraceptives, including self-administration of injectable contraceptives. A recommendation relating to telemedicine to facilitate early medical abortion has also been formulated, alongside best practice statements on other service-delivery approaches for abortion care. Together, the guidance presented in this document reflects recent changes in all these aspects of abortion care. Research gaps and priorities and emerging areas of interest are identified in the final chapter. As indicated by the arrangement of the guidance in this document, as a woman, girl or other pregnant person moves through the abortion care pathway – pre-ab",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 23
  },
  {
    "chunk_id": "abortioncare_74",
    "text": "d in the final chapter. As indicated by the arrangement of the guidance in this document, as a woman, girl or other pregnant person moves through the abortion care pathway – pre-abortion, abortion and post-abortion care – health services must be integrated within the health system to ensure that service delivery meets their needs equitably and without discrimination. The conceptual framework for abortion care in this guideline (see Figure 1) recognizes and acknowledges the needs of all individuals with respect to abortion and is centred on the values and preferences of abortion seekers, considering them as active participants in – as well as beneficiaries of – health services. Individual health preferences may vary; no one model of abortion care will meet the needs of everyone seeking abortion care. However, the core values of dignity, autonomy, equality, confidentiality, communication, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 23
  },
  {
    "chunk_id": "abortioncare_75",
    "text": "vary; no one model of abortion care will meet the needs of everyone seeking abortion care. However, the core values of dignity, autonomy, equality, confidentiality, communication, social support, supportive care and trust are foundational to abortion care and are reflected throughout this guidance. Important work is still needed to incorporate linkages to quality abortion care throughout the health system, and the focus on human rights and gender equality must be applied in all contexts providing services to people seeking health care. 3 The previous edition of the Safe abortion guidance (WHO, 2012) addressed these issues and related interventions and provided a composite recommendation. In this guideline, these have each been addressed separately as seven individual recommendations (Recommendations 1,2,3,6,7,21,22). 4 A full consideration of all contraceptive methods is beyond the scope",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 23
  },
  {
    "chunk_id": "abortioncare_76",
    "text": "e have each been addressed separately as seven individual recommendations (Recommendations 1,2,3,6,7,21,22). 4 A full consideration of all contraceptive methods is beyond the scope of this guideline, but all contraceptive methods can be considered after an abortion, including a range of self-administered methods. Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 23
  },
  {
    "chunk_id": "abortioncare_77",
    "text": "Abortion care guideline, second edition xxii Figure 1: Conceptual framework for abortion care Hom e P h a r m a c y C o m m u n i t y o u t r e a c h c e n t r e s P r i m a r y c a r e f a c i l i t y H i g h e r - le v e l fa cility F a c i l i t y - b a s e d h e a l t h w o r k e r s O t h e r h e a l t h w o rk e rsS e lf Abortion Pre-abortion Post-abortion Values & Preferences HOW WHERE WHO WHAT Availability and accessibility of information Supportive health systems Respect for human rights Prim in g , P a in m a n a g e m e n t , Supportive framework of law and policy Context-sp e c iﬁc s e r v i c e - d e l i v e r y a p p r o a c h e s In t e g r a t i o n w i t h i n h e a l t h s y s t e m s C o m m o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 24
  },
  {
    "chunk_id": "abortioncare_78",
    "text": "o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d e s i r e d ) Target audience and inclusivity This guidance seeks to provide recommendations for national and subnational policy-makers, implementers and managers of sexual and reproductive health (SRH) programmes, members of nongovernmental organizations and other civil society organizations and professional societies, as well as health workers and other stakeholders in the field of sexual and reproductive health and rights (SRHR), to support them in ensuring that evidence-based, quality abortion care is available and accessible globally. All individuals have the right to non-discrimination and equality in accessing SRH services. The righ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 24
  },
  {
    "chunk_id": "abortioncare_79",
    "text": "at evidence-based, quality abortion care is available and accessible globally. All individuals have the right to non-discrimination and equality in accessing SRH services. The right to be free from discrimination is stated in the Universal Declaration of Human Rights and in other universal human rights treaties and regional human rights instruments. It has been affirmed that the right to non-discrimination guaranteed by the International Covenant on Economic, Social and Cultural Rights (ICESCR) includes sexual orientation, gender identity and sex characteristics. As stated in the 2018 report of the Independent Expert on protection against violence and discrimination based on sexual orientation and gender identity to the United Nations General Assembly, “the right to effective recognition of one’s gender identity is linked to the right to equal recognition before the law”. In this guideli",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 24
  },
  {
    "chunk_id": "abortioncare_80",
    "text": "ty to the United Nations General Assembly, “the right to effective recognition of one’s gender identity is linked to the right to equal recognition before the law”. In this guideline, we recognize that most of the available evidence on abortion can be assumed to be derived from research among study populations of cisgender women, and we also recognize that cisgender women, transgender men, nonbinary, gender-fluid and intersex individuals with a female reproductive system and capable of becoming pregnant may require abortion care. To be concise and facilitate readability of this guideline, when referring to all gender diverse people who may require abortion care, we use the word “women” most often, although we also variously use the terms “individual”, “person” and “abortion seeker”. Providers of SRH services, including abortion care, must consider the needs of – and provide equal care to",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 24
  },
  {
    "chunk_id": "abortioncare_81",
    "text": "lso variously use the terms “individual”, “person” and “abortion seeker”. Providers of SRH services, including abortion care, must consider the needs of – and provide equal care to – all individuals; gender identity or its expression must not lead to discrimination.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 24
  },
  {
    "chunk_id": "abortioncare_82",
    "text": "xxiii Guideline development methods The WHO Guideline Steering Group and wider WHO Secretariat, including staff members from both WHO headquarters and regional offices, led a wide-ranging guideline development process involving a vast range of expert contributors and support personnel. The process began in September 2018 with an online survey on the subject of updating WHO guidance on safe abortion, followed by scoping meetings between November 2018 and June 2019 to determine the key topic areas and to formulate key questions to be assessed through searches and analysis of the evidence base, for each of the three domains: Law and policy, Clinical services and Service delivery. In order to ensure broad representation, the following meetings were convened to further inform our guideline: (i) Implementation considerations for abortion care in humanitarian settings, (ii) Global values and pr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 25
  },
  {
    "chunk_id": "abortioncare_83",
    "text": "ation, the following meetings were convened to further inform our guideline: (i) Implementation considerations for abortion care in humanitarian settings, (ii) Global values and preferences relating to abortion care, and (iii) Youth and safe abortion. Global experts were invited by the Steering Group to convene three expert panels – the Evidence and Recommendation Review Groups (ERRGs) for each domain – involving active participation in a series of two-day meetings to discuss and draft the new and updated recommendations, based on the evidence provided by the Evidence Synthesis Teams (ESTs). The Guideline Development Group (GDG) members were selected and invited by the Steering Group from among the ERRG members for each domain, to bring together a single multidisciplinary group, including a youth representative and a human rights adviser, to finalize the recommendations. In accordance wi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 25
  },
  {
    "chunk_id": "abortioncare_84",
    "text": " for each domain, to bring together a single multidisciplinary group, including a youth representative and a human rights adviser, to finalize the recommendations. In accordance with the WHO guideline development process, the formulation and refinement of recommendations by the ERRGs and the GDG was based on the available evidence (with quality of evidence ranging from high to very low), using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to recommendation development, with reference to the Evidence-to-Decision (EtD) tables prepared by the ESTs, and also guided by the participants’ own expertise and experience. The WHO-INTEGRATE framework was used as a basis for deciding on the direction and strength of each recommendation (see notes accompanying the summary table below). For the law and policy recommendations, this same framework was used but an ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 25
  },
  {
    "chunk_id": "abortioncare_85",
    "text": " on the direction and strength of each recommendation (see notes accompanying the summary table below). For the law and policy recommendations, this same framework was used but an innovative approach was developed to evaluate the evidence in a manner that effectively integrated human rights protection and enjoyment as part of health outcomes and analysis. After the conclusion of the ERRG and GDG meetings, the revised draft recommendations and full draft guideline were reviewed by GDG members and members of the External Review Group of peer reviewers. The GDG meeting observers and individual reviewers from several implementing organizations were also invited to comment on the same draft. Further revisions were made and the guideline was submitted to and approved by the WHO Guidelines Review Committee, followed by final revisions from the Office of the United Nations High Commissioner for ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 25
  },
  {
    "chunk_id": "abortioncare_86",
    "text": "ade and the guideline was submitted to and approved by the WHO Guidelines Review Committee, followed by final revisions from the Office of the United Nations High Commissioner for Human Rights (OHCHR), final editing and planning for publication and launch. The full guideline development methods are presented in Annex 4. Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 25
  },
  {
    "chunk_id": "abortioncare_87",
    "text": "Abortion care guideline, second edition xxiv Summary table of recommendations presented in this guideline Important notes: i. Each recommendation and its direction (for or against) and strength (strong or weak) has been determined by the panels of experts convened by WHO for this purpose. The determinations were based on the six substantive criteria of the WHO-INTEGRATE framework as applied to each intervention for the specified population – balance of health benefits and harms; human rights and sociocultural acceptability; health equity, equality and non- discrimination; societal implications; financial and economic considerations; and feasibility and health system considerations – while also taking into account the meta-criterion, quality of evidence (i.e. type, size and limitations of the available studies used as evidence). Wording used is as follows: • Recommend – a strong recommend",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 26
  },
  {
    "chunk_id": "abortioncare_88",
    "text": "nt the meta-criterion, quality of evidence (i.e. type, size and limitations of the available studies used as evidence). Wording used is as follows: • Recommend – a strong recommendation in favour of the intervention • Suggest – a weak recommendation in favour of the intervention • Recommend against – a strong recommendation against the intervention/in favour of the comparison. ii. Most of the recommendations are labelled as LP for “Law and policy”, CS for “Clinical services” or SD for “Service delivery”, referring to the broad domain under which the evidence for these recommendations was reviewed and evaluated by the respective expert panels (ERRGs). In addition, five recommendations are labelled as SELF-MANAGEMENT. iii. The SD recommendations that refer to health worker categories assume that the people working within the categories mentioned have the skills and competencies required fo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 26
  },
  {
    "chunk_id": "abortioncare_89",
    "text": "MENT. iii. The SD recommendations that refer to health worker categories assume that the people working within the categories mentioned have the skills and competencies required for the intervention specified. The roles, skills and competencies of each type of health worker mentioned in these recommendations are described in the table on health worker categories and roles in Annex 5, and further information can be found in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care, which describes the competencies (including skills and knowledge) required for each task. iv. Recommendations were considered “new” (as labelled in this table and in Chapter 3) if no recommendation existed in a previous WHO guideline on the specific topic or intervention in question. In particular it should be noted that the 2012 Safe abortion guidance provided a composite recomm",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 26
  },
  {
    "chunk_id": "abortioncare_90",
    "text": "ted in a previous WHO guideline on the specific topic or intervention in question. In particular it should be noted that the 2012 Safe abortion guidance provided a composite recommendation related to law and policy; in this guideline, this has been developed this into seven separate recommendations, but they are not considered to be “new” (i.e. Recommendations 1,2,3,6,7,21,22).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 26
  },
  {
    "chunk_id": "abortioncare_91",
    "text": "xxv SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number ABORTION REGULATION Criminalization 1 (LAW & POLICY; LP) Recommend the full decriminalization of abortion. Remarks: • Decriminalization means removing abortion from all penal/criminal laws, not applying other criminal offences (e.g. murder, manslaughter) to abortion, and ensuring there are no criminal penalties for having, assisting with, providing information about, or providing abortion, for all relevant actors. • Decriminalization would ensure that anyone who has experienced pregnancy loss does not come under suspicion of illegal abortion when they seek care. • Decriminalization of abortion does not make women, girls or other pregnant persons vulnerable to forced or coerced abortion. Forced or coerced abortion would constitute serious assaults as these",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 27
  },
  {
    "chunk_id": "abortioncare_92",
    "text": "ion of abortion does not make women, girls or other pregnant persons vulnerable to forced or coerced abortion. Forced or coerced abortion would constitute serious assaults as these would be non-consensual interventions. 24 Grounds-based approaches 2 (LP) a. Recommend against laws and other regulations that restrict abortion by grounds. b. Recommend that abortion be available on the request of the woman, girl or other pregnant person. Remarks: • Grounds-based approaches to restricting access to abortion should be revised in favour of making abortion available on the request of the woman, girl or other pregnant person. • Until they are replaced with abortion on request, any existing grounds should be formulated and applied in a manner consistent with international human rights law. This means that the content, interpretation and application of grounds-based law and policy should be revised",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 27
  },
  {
    "chunk_id": "abortioncare_93",
    "text": "nd applied in a manner consistent with international human rights law. This means that the content, interpretation and application of grounds-based law and policy should be revised to ensure human rights compliance. This requires that: i. existing grounds are defined, interpreted and applied in a human rights-compliant way; ii. abortion is available when carrying a pregnancy to term would cause the woman, girl or other pregnant person substantial pain or suffering, including but not limited to situations where the pregnancy is the result of rape or incest or the pregnancy is not viable; iii. abortion is available where the life and health of the woman, girl or other pregnant person is at risk; iv. health grounds reflect WHO’s definitions of health and mental health (see Glossary); and v. there are no procedural requirements to “prove” or “establish” satisfaction of grounds, such as requi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 27
  },
  {
    "chunk_id": "abortioncare_94",
    "text": "s reflect WHO’s definitions of health and mental health (see Glossary); and v. there are no procedural requirements to “prove” or “establish” satisfaction of grounds, such as requiring judicial orders or police reports in cases of rape or sexual assault (for sources to support this information, refer to Web annex A: Key international human rights standards on abortion). 26 Gestational age limits 3 (LP) Recommend against laws and other regulations that prohibit abortion based on gestational age limits. 28 SERVICES ACROSS THE CONTINUUM OF CARE Provision of information on abortion care 4 (SERVICE DELIVERY; SD) Across the continuum of abortion care: a. Recommend provision of information on abortion care by community health workers, pharmacists, traditional and complementary medicine professionals, auxiliary nurses/auxiliary nurse midwives (ANMs), nurses, midwives, associate/advanced associat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 27
  },
  {
    "chunk_id": "abortioncare_95",
    "text": "y health workers, pharmacists, traditional and complementary medicine professionals, auxiliary nurses/auxiliary nurse midwives (ANMs), nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest provision of information on abortion care by pharmacy workers. • Condition: In contexts where the pharmacy worker is under the direct supervision of a pharmacist and there is access or referral to appropriate health services. 35 Provision of counselling 5 (SD) Across the continuum of abortion care: a. Recommend provision of counselling by community health workers, traditional and complementary medicine professionals, auxiliary nurses/ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest provision of counselling by pharmacy wo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 27
  },
  {
    "chunk_id": "abortioncare_96",
    "text": "nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest provision of counselling by pharmacy workers and pharmacists. • Condition: Balanced counselling is provided (i.e. about both medical and surgical methods) and there is access or referral to appropriate health services should the woman choose a surgical method. 38 Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 27
  },
  {
    "chunk_id": "abortioncare_97",
    "text": "Abortion care guideline, second edition xxvi SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number PRE-ABORTION Mandatory waiting periods 6 (LP) Recommend against mandatory waiting periods for abortion. 41 Third-party authorization 7 (LP) Recommend that abortion be available on the request of the woman, girl or other pregnant person without the authorization of any other individual, body or institution. Remark: • While parental or partner involvement in abortion decision-making can support and assist women, girls or other pregnant persons, this must be based on the values and preferences of the person availing of abortion and not imposed by third-party authorization requirements. 43 Rh isoimmunization for abortion at gestational ages < 12 weeks 8 (CLINICAL SERVICES; CS) (NEW) For both medical and surgical aborti",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 28
  },
  {
    "chunk_id": "abortioncare_98",
    "text": "ed by third-party authorization requirements. 43 Rh isoimmunization for abortion at gestational ages < 12 weeks 8 (CLINICAL SERVICES; CS) (NEW) For both medical and surgical abortion at < 12 weeks: Recommend against anti-D immunoglobulin administration. Remark: • Standard of care applies for anti-D administration at gestational ages ≥ 12 weeks. 44 Antibiotic prophylaxis for surgical and medical abortion 9 (CS) a. For surgical abortion, regardless of the individual’s risk of pelvic inflammatory infection: Recommend appropriate prophylactic antibiotics pre- or perioperatively. b. For medical abortion: Recommend against the use of prophylactic antibiotics. Remark: • Lack of antibiotics should not limit access to abortion services. 46 Determining gestational age of pregnancy: pre-abortion ultrasound scanning 10 (CS) For both medical and surgical abortion: Recommend against the use of ultraso",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 28
  },
  {
    "chunk_id": "abortioncare_99",
    "text": "bortion services. 46 Determining gestational age of pregnancy: pre-abortion ultrasound scanning 10 (CS) For both medical and surgical abortion: Recommend against the use of ultrasound scanning as a prerequisite for providing abortion services.* Remark: • Legal regulation that limits the availability of abortion by gestational age may require or result in ultrasounds being used to verify gestational age prior to abortion, even though this is not necessary from a clinical perspective. Removing legal gestational age limits on access to abortion (see Recommendation 3) should result in unnecessary pre-abortion ultrasound being avoided, and increase the availability of abortion in settings where ultrasound is difficult to access. * On a case-by-case basis, there may be clinical reasons for using ultrasound scanning prior to abortion. 47`",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 28
  },
  {
    "chunk_id": "abortioncare_100",
    "text": "xxvii SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number Pain management for abortion 11–14 (CS) for surgical abortion and for prior cervical priming NOTE: NEW recommendations 12, 13 and 14 indicate pain management that is ADDITIONAL to NSAIDS (11a) 11. For pain management for surgical abortion at any gestational age: a. Recommend that pain medication should be offered routinely (e.g. non-steroidal anti-inflammatory drugs [NSAIDS]) and that it should be provided to those who want it; and b. Recommend against the routine use of general anaesthesia. 12. (NEW) For pain management for surgical abortion at < 14 weeks: a. Recommend the use of a paracervical block; and b. Suggest that the option of combination pain management using conscious sedation plus paracervical block should be offered, where conscious sedatio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 29
  },
  {
    "chunk_id": "abortioncare_101",
    "text": "e of a paracervical block; and b. Suggest that the option of combination pain management using conscious sedation plus paracervical block should be offered, where conscious sedation is available. 13. (NEW) For pain management for cervical priming with osmotic dilators prior to surgical abortion at ≥ 14 weeks: Suggest the use of a paracervical block. Remark: • For cervical priming, additional pain medication can be considered, such as the use of intravaginal gel. (See Recommendations 17–20 below on cervical priming) 14. (NEW) For pain management for surgical abortion at ≥ 14 weeks: a. Recommend the use of a paracervical block; and b. Suggest that the option of combination pain management using conscious sedation plus paracervical block should be offered, where conscious sedation is available. 49 15 and 16 (CS) for medical abortion NOTE: NEW recommendation 16 indicates pain management that",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 29
  },
  {
    "chunk_id": "abortioncare_102",
    "text": " plus paracervical block should be offered, where conscious sedation is available. 49 15 and 16 (CS) for medical abortion NOTE: NEW recommendation 16 indicates pain management that is ADDITIONAL to NSAIDS (15) 15. For medical abortion at any gestational age: Recommend that pain medication should be offered routinely (e.g. non-steroidal anti-inflammatory drugs [NSAIDs]) and that it should be provided for the individual to use if and when wanted. 16. (NEW) For pain management for medical abortion at ≥ 12 weeks: Suggest consideration of additional methods to control pain or discomfort due to increased pain with increasing gestational age. Such methods include certain anti-emetics and epidural anaesthesia, where available. Remark: • For medical abortion at gestational ages < 14 weeks, if NSAIDS (e.g. ibuprofen) are not available or not an option, then acetaminophen can be considered for pain",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 29
  },
  {
    "chunk_id": "abortioncare_103",
    "text": "ailable. Remark: • For medical abortion at gestational ages < 14 weeks, if NSAIDS (e.g. ibuprofen) are not available or not an option, then acetaminophen can be considered for pain control. 51 Cervical priming prior to surgical abortion 17 (CS) at < 12 weeks Prior to surgical abortion at < 12 weeks: a. If cervical priming is used: Suggest the following medication regimens: • Mifepristone 200 mg orally 24–48 hours prior to the procedure • Misoprostol 400 μg sublingually 1–2 hours prior to the procedure • Misoprostol 400 μg vaginally or buccally 2–3 hours prior to the procedure b. Recommend against the use of osmotic dilators for cervical priming. Remarks: • The sublingual route is more effective for misoprostol administration. • Appropriate pain medication should be provided. 54 Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 29
  },
  {
    "chunk_id": "abortioncare_104",
    "text": "Abortion care guideline, second edition xxviii SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number 18 (CS) (NEW) at ≥ 12 weeks Prior to surgical abortion at later gestational ages: a. For surgical abortion at ≥ 12 weeks: Suggest cervical priming prior to the procedure. b. For surgical abortion between 12 and 19 weeks: Suggest cervical priming with medication alone (a combination of mifepristone plus misoprostol is preferred) or with an osmotic dilator plus medication (mifepristone, misoprostol, or a combination of both). c. For surgical abortion between 12 and 19 weeks, when using an osmotic dilator for cervical priming: Suggest that the period between osmotic dilator placement and the procedure should not extend beyond two days. d. For surgical abortion at ≥ 19 weeks: Recommend cervical priming with an osmoti",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 30
  },
  {
    "chunk_id": "abortioncare_105",
    "text": " the period between osmotic dilator placement and the procedure should not extend beyond two days. d. For surgical abortion at ≥ 19 weeks: Recommend cervical priming with an osmotic dilator plus medication (mifepristone, misoprostol, or a combination of both). Remark: • There was limited evidence for cervical priming for gestational ages between 12 and 14 weeks and therefore health workers should use clinical judgement to decide on the most convenient method for cervical priming prior to vacuum aspiration for this gestational age range. 55 19 (SD) with medication, at any gestational age Prior to surgical abortion at any gestational age: a. Recommend cervical priming with medication by traditional and complementary medicine professionals, auxiliary nurses/ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 30
  },
  {
    "chunk_id": "abortioncare_106",
    "text": "ary medicine professionals, auxiliary nurses/ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest cervical priming with medication by community health workers, pharmacy workers and pharmacists. • Condition: Provision of medication for the purpose of cervical priming is part of the surgical abortion process so the health worker needs to ensure continuity of care of the woman obtaining the medicines prior to the abortion procedure. 56 20 (SD) with osmotic dilators, at ≥ 12 weeks Prior to dilatation and evacuation (D&E) at ≥ 12 weeks: a. Recommend cervical priming with osmotic dilators by auxiliary nurses/ANMs, nurses, midwives, associate/ advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest cervical priming with osmotic dilators by tradit",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 30
  },
  {
    "chunk_id": "abortioncare_107",
    "text": "dwives, associate/ advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest cervical priming with osmotic dilators by traditional and complementary medicine professionals. • Condition: Health worker ensures continuity of care from the time of cervical priming to the D&E. 57 Provider restrictions 21 (LP) Recommend against regulation on who can provide and manage abortion that is inconsistent with WHO guidance. Remark: • Where law or policy regulate who may provide or manage abortion, that regulation should be consistent with WHO guidance, which is presented throughout Chapter 3 of this guideline. 59 Conscientious objection 22 (LP) Recommend that access to and continuity of comprehensive abortion care be protected against barriers created by conscientious objection. Remarks: • Health services should be organized in such a way as to en",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 30
  },
  {
    "chunk_id": "abortioncare_108",
    "text": "nd continuity of comprehensive abortion care be protected against barriers created by conscientious objection. Remarks: • Health services should be organized in such a way as to ensure the exercise of conscientious objection does not prevent people from accessing available abortion services. • Where conscientious objection is permitted, international human rights law requires States to take steps to ensure that it does not operate as a barrier to access to abortion care. The mere existence of regulation of conscientious objection is not sufficient. In practice, this means that if States permit conscientious objection, they must regulate it in a way that is effective in ensuring that abortion is available and accessible in practice. • International human rights law provides some guidance as to how States can ensure that human rights of abortion seekers are respected, protected and fulfill",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 30
  },
  {
    "chunk_id": "abortioncare_109",
    "text": "cessible in practice. • International human rights law provides some guidance as to how States can ensure that human rights of abortion seekers are respected, protected and fulfilled (see details in main text). • Accordingly, States that permit conscientious objection should reform the regulation of conscientious objection to ensure that the human rights of pregnant people are respected, protected and fulfilled, and that abortion is available and accessible. • If it proves impossible to regulate conscientious objection in a way that respects, protects and fulfils abortion seekers’ rights, conscientious objection in abortion provision may become indefensible. In such circumstances, it may be appropriate to consider prohibiting conscientious objection and/or revising national law and policy frameworks that govern health workers’ professional and ethical obligations. Note on updating of the",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 30
  },
  {
    "chunk_id": "abortioncare_110",
    "text": "der prohibiting conscientious objection and/or revising national law and policy frameworks that govern health workers’ professional and ethical obligations. Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. 60",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 30
  },
  {
    "chunk_id": "abortioncare_111",
    "text": "xxix SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number ABORTION Methods of surgical abortion 23 (CS) at < 14 weeks For surgical abortion at < 14 weeks: a. Recommend vacuum aspiration. b. Recommend against the practice of dilatation and sharp curettage (D&C), including sharp curette checks (i.e. to “complete” the abortion) following vacuum aspiration. Remarks: • Observational studies indicate that vacuum aspiration is associated with fewer complications than D&C; however, randomized controlled trials were underpowered to detect a difference in complication rates. • No evidence supports the use of sharp curette checks following vacuum aspiration. • The quality of the evidence based on randomized controlled trials is low to moderate. 63 24 (SD) vacuum aspiration at < 14 weeks For surgical abortion at < 14 weeks",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 31
  },
  {
    "chunk_id": "abortioncare_112",
    "text": "m aspiration. • The quality of the evidence based on randomized controlled trials is low to moderate. 63 24 (SD) vacuum aspiration at < 14 weeks For surgical abortion at < 14 weeks: a. Recommend vacuum aspiration by traditional and complementary medicine professionals, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest vacuum aspiration by auxiliary nurses/ANMs. • Condition: In contexts where established health system mechanisms involve auxiliary nurses/ANMs in providing basic emergency obstetric care, and where referral and monitoring systems are strong. 64 25 (CS) at ≥ 14 weeks For surgical abortion at ≥ 14 weeks: Recommend dilatation and evacuation (D&E). Remark: • Vacuum aspiration can be used during a D&E (i.e. for the purpose of amniotomy or tissue removal at the end of the D&E). 65 26 (SD) D&",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 31
  },
  {
    "chunk_id": "abortioncare_113",
    "text": "end dilatation and evacuation (D&E). Remark: • Vacuum aspiration can be used during a D&E (i.e. for the purpose of amniotomy or tissue removal at the end of the D&E). 65 26 (SD) D&E at ≥ 14 weeks For surgical abortion at ≥ 14 weeks: a. Recommend D&E by generalist medical practitioners and specialist medical practitioners. b. Suggest D&E by traditional and complementary medicine professionals, midwives and associate/ advanced associate clinicians. • Condition: In settings where established health system mechanisms exist to include these health workers in other tasks related to maternal and reproductive health. 65 Medical management of induced abortion 27 (CS) at < 12 weeks For medical abortion at < 12 weeks: a. Recommend the use of 200 mg mifepristone administered orally, followed 1–2 days later by 800 μg misoprostol administered vaginally, sublingually or buccally. The minimum recommende",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 31
  },
  {
    "chunk_id": "abortioncare_114",
    "text": "Recommend the use of 200 mg mifepristone administered orally, followed 1–2 days later by 800 μg misoprostol administered vaginally, sublingually or buccally. The minimum recommended interval between use of mifepristone and misoprostol is 24 hours.* b. When using misoprostol alone: Recommend the use of 800 μg misoprostol administered vaginally, sublingually or buccally.* c. (NEW) Suggest the use of a combination regimen of letrozole plus misoprostol (letrozole 10 mg orally each day for 3 days followed by misoprostol 800 μg sublingually on the fourth day) as a safe and effective option.*ǂ Remarks: • Evidence from clinical studies demonstrates that the combination regimen (Recommendation 27a) is more effective than misoprostol alone. • All routes are included as options for misoprostol administration, in consideration of patient and provider preference. • The suggested combination regimen o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 31
  },
  {
    "chunk_id": "abortioncare_115",
    "text": "n misoprostol alone. • All routes are included as options for misoprostol administration, in consideration of patient and provider preference. • The suggested combination regimen of letrozole plus misoprostol may be safe and effective up to 14 weeks of gestation. * Repeat doses of misoprostol can be considered when needed to achieve success of the abortion process. In this guideline we do not provide a maximum number of doses of misoprostol. ǂ Further evidence is needed to determine the safety, effectiveness and acceptability of the letrozole plus misoprostol combination regimen at later gestational ages, especially in comparison with that of the mifepristone plus misoprostol combination regimen (the available evidence focused on comparison with the use of misoprostol alone). 68 Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 31
  },
  {
    "chunk_id": "abortioncare_116",
    "text": "Abortion care guideline, second edition xxx SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number 28 (SD) at < 12 weeks* in whole or in part (i.e. performing all or some of the subtasks)ǂ For medical abortion at < 12 weeks: Recommend medical management by self (see Recommendation 50), community health workers, pharmacy workers, pharmacists, traditional and complementary medicine professionals, auxiliary nurses/ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. * Available evidence for the independent provision of medical abortion by non-physicians is for pregnancy durations up to 10 weeks (70 days). ǂ For this recommendation, the medical abortion regimens covered in the available evidence were mifepristone plus misoprostol, or m",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 32
  },
  {
    "chunk_id": "abortioncare_117",
    "text": "or pregnancy durations up to 10 weeks (70 days). ǂ For this recommendation, the medical abortion regimens covered in the available evidence were mifepristone plus misoprostol, or misoprostol alone (the regimen using letrozole was not included). 69 29 (CS) at ≥ 12 weeks For medical abortion at ≥ 12 weeks: a. Suggest the use of 200 mg mifepristone administered orally, followed 1–2 days later by repeat doses of 400 μg misoprostol administered vaginally, sublingually or buccally every 3 hours.* ǂ The minimum recommended interval between use of mifepristone and misoprostol is 24 hours. b. When using misoprostol alone: Suggest the use of repeat doses of 400 μg misoprostol administered vaginally, sublingually or buccally every 3 hours.*ǂ Remarks: • The combination regimen (Recommendation 29a) is more effective than use of misoprostol alone. • Evidence suggests that the vaginal route is the most",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 32
  },
  {
    "chunk_id": "abortioncare_118",
    "text": "lly every 3 hours.*ǂ Remarks: • The combination regimen (Recommendation 29a) is more effective than use of misoprostol alone. • Evidence suggests that the vaginal route is the most effective. Consideration for patient and provider preference suggests the inclusion of all routes. • Pregnancy tissue should be treated in the same way as other biological material unless the individual expresses a desire for it to be managed otherwise. * Misoprostol can be repeated at the noted interval as needed to achieve success of the abortion process. Providers should use caution and clinical judgement to decide the maximum number of doses of misoprostol in pregnant individuals with prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness for emergency management of uterine rupture must be considered with later gestational age. ǂ The dose of misopr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 32
  },
  {
    "chunk_id": "abortioncare_119",
    "text": "rare complication; clinical judgement and health system preparedness for emergency management of uterine rupture must be considered with later gestational age. ǂ The dose of misoprostol should be reduced for induced abortion beyond 24 weeks due to limited data. Clinical judgement should be used to determine the appropriate dosage, recognizing the greater sensitivity of the uterus to prostaglandins. 71 30 (SD) at ≥ 12 weeks For medical abortion at ≥ 12 weeks: a. Recommend medical management by generalist medical practitioners and specialist medical practitioners. b. Suggest medical management by traditional and complementary medicine professionals, auxiliary nurses/ ANMs, nurses, midwives and associate/advanced associate clinicians. • Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 32
  },
  {
    "chunk_id": "abortioncare_120",
    "text": "associate clinicians. • Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. 71 Missed abortion 31 (CS) (NEW) Medical management at < 14 weeks For missed abortion at < 14 weeks, for individuals preferring medical management: Recommend the use of combination mifepristone plus misoprostol over misoprostol alone. • Recommended regimen: 200 mg mifepristone administered orally, followed by 800 μg misoprostol administered by any route (buccal, vaginal or sublingual).* • Alternative regimen: 800 μg misoprostol administered by any route (buccal, vaginal or sublingual). ǂ Remarks: • The decision about the mode of management (expectant, medical or surgical) of missed abortion should be based on the individual’s clinical condition and preference for treatment. • Expectant",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 32
  },
  {
    "chunk_id": "abortioncare_121",
    "text": "on about the mode of management (expectant, medical or surgical) of missed abortion should be based on the individual’s clinical condition and preference for treatment. • Expectant management can be offered as an option on the condition that the woman, girl or other pregnant person is informed of the longer time for expulsion of the pregnancy tissue and the increased risk of incomplete emptying of the uterus. • Pregnancy tissue should be treated in the same way as other biological material unless the individual expresses a desire for it to be managed otherwise. * The minimum recommended interval between use of mifepristone and misoprostol is 24 hours. ǂ If using the alternative regimen (misoprostol alone), it should be noted that at gestational ages ≥ 9 weeks, evidence shows that repeat dosing of misoprostol is more efficacious to achieve success of the abortion process. In this guidelin",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 32
  },
  {
    "chunk_id": "abortioncare_122",
    "text": "hould be noted that at gestational ages ≥ 9 weeks, evidence shows that repeat dosing of misoprostol is more efficacious to achieve success of the abortion process. In this guideline we do not provide a maximum number of doses of misoprostol. 74",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 32
  },
  {
    "chunk_id": "abortioncare_123",
    "text": "xxxi SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number Intrauterine fetal demise 32 (CS) Medical management at ≥ 14 to ≤ 28 weeks For medical management of IUFD at ≥ 14 to ≤ 28 weeks: Suggest the use of combination mifepristone plus misoprostol over misoprostol alone. • Suggested regimen: 200 mg mifepristone administered orally, followed 1–2 days later by repeat doses of 400 μg misoprostol administered sublingually or vaginally every 4–6 hours.* ǂ The minimum recommended interval between use of mifepristone and misoprostol is 24 hours. • Alternative regimen: repeat doses of 400 μg misoprostol administered sublingually or vaginally every 4–6 hours.*ǂ Remarks: • Evidence from clinical studies indicates that the combination regimen is more effective than the use of misoprostol alone. • Pregnancy tissue should b",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 33
  },
  {
    "chunk_id": "abortioncare_124",
    "text": "every 4–6 hours.*ǂ Remarks: • Evidence from clinical studies indicates that the combination regimen is more effective than the use of misoprostol alone. • Pregnancy tissue should be treated in the same way as other biological material unless the individual expresses a desire for it to be managed otherwise. * Misoprostol can be repeated at the noted interval as needed to achieve success of the abortion process. Providers should use caution and clinical judgement to decide the maximum number of doses of misoprostol in pregnant individuals with prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness for emergency management of uterine rupture must be considered with later gestational age. ǂ The dose of misoprostol should be reduced for IUFD beyond 28 weeks due to limited data. Clinical judgement should be used to determine the approp",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 33
  },
  {
    "chunk_id": "abortioncare_125",
    "text": "ered with later gestational age. ǂ The dose of misoprostol should be reduced for IUFD beyond 28 weeks due to limited data. Clinical judgement should be used to determine the appropriate dosage, recognizing the greater sensitivity of the uterus to prostaglandins. 76 33 (SD) (NEW) Medical management at ≥ 14 to ≤ 28 weeks For IUFD at ≥ 14 to ≤ 28 weeks: a. Recommend medical management by generalist medical practitioners and specialist medical practitioners. b. Suggest medical management by traditional and complementary medicine professionals, auxiliary nurses/ ANMs, nurses, midwives and associate/advanced associate clinicians. • Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. 76 POST-ABORTION Follow-up care or additional services 34 (CS) Following uncomplicat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 33
  },
  {
    "chunk_id": "abortioncare_126",
    "text": "p and proper infrastructure is available to address incomplete abortion or other complications. 76 POST-ABORTION Follow-up care or additional services 34 (CS) Following uncomplicated surgical abortion or medical abortion: Recommend that there is no medical need for a routine follow-up visit. However, information should be provided about the availability of additional services if they are needed or desired. Remarks: • Women, girls and other pregnant persons must be adequately informed about symptoms of ongoing pregnancy (which may or may not indicate failure of the abortion) and other medical reasons to return for follow-up, such as prolonged heavy bleeding, no bleeding at all with medical management of abortion, pain not relieved by medication, or fever. • The quality of the evidence was low (observational studies and indirect evidence). 80 Incomplete abortion 35 and 36 (CS) 35. For inco",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 33
  },
  {
    "chunk_id": "abortioncare_127",
    "text": ", pain not relieved by medication, or fever. • The quality of the evidence was low (observational studies and indirect evidence). 80 Incomplete abortion 35 and 36 (CS) 35. For incomplete abortion at < 14 weeks: Recommend either vacuum aspiration or medical management. 36a. For the medical management of incomplete abortion at < 14 weeks uterine size: Suggest the use of 600 μg misoprostol administered orally or 400 μg misoprostol administered sublingually. 36b. For the medical management of incomplete abortion at ≥ 14 weeks uterine size: Suggest the use of repeat doses of 400 μg misoprostol administered sublingually, vaginally or buccally every 3 hours.* Remarks: • The decision about the mode of management of incomplete abortion should be based on the individual’s clinical condition and preference for treatment. • Expectant management of incomplete abortion can be as effective as misoprost",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 33
  },
  {
    "chunk_id": "abortioncare_128",
    "text": "omplete abortion should be based on the individual’s clinical condition and preference for treatment. • Expectant management of incomplete abortion can be as effective as misoprostol; it can be offered as an option on the condition that the woman, girl or other pregnant person is informed of the longer time for expulsion of the pregnancy tissue and the increased risk of incomplete emptying of the uterus. • Recommendation 35 was extrapolated from research conducted in women with reported spontaneous abortion. * Misoprostol can be repeated at the noted interval as needed to achieve success of the abortion process. At gestational ages ≥ 14 weeks, providers should use caution and clinical judgement to decide the maximum number of doses of misoprostol in pregnant individuals with prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 33
  },
  {
    "chunk_id": "abortioncare_129",
    "text": "ximum number of doses of misoprostol in pregnant individuals with prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness for emergency management of uterine rupture must be considered with advanced gestational age. 81 Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 33
  },
  {
    "chunk_id": "abortioncare_130",
    "text": "Abortion care guideline, second edition xxxii SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number 37 (SD) Medical management with misoprostol at < 14 weeks For uncomplicated incomplete abortion at < 14 weeks: Recommend medical management with misoprostol by community health workers, pharmacy workers, pharmacists, traditional and complementary medicine professionals, auxiliary nurses/ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. 82 38 (SD) Vacuum aspiration at < 14 weeks For uncomplicated incomplete abortion at < 14 weeks: a. Recommend vacuum aspiration by traditional and complementary medicine professionals, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 34
  },
  {
    "chunk_id": "abortioncare_131",
    "text": "iration by traditional and complementary medicine professionals, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest vacuum aspiration by auxiliary nurses/ANMs. • Condition: In contexts where established health system mechanisms involve auxiliary nurses/ANMs in providing basic emergency obstetric care, and where referral and monitoring systems are strong. 83 Management of non-life-threatening complications 39 (SD) Infection For non-life-threatening post-abortion infection: Recommend initial management by traditional and complementary medicine professionals, auxiliary nurses/ ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners.* * For the pharmacists, pharmacy workers and community health workers, it is important that t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 34
  },
  {
    "chunk_id": "abortioncare_132",
    "text": "ate clinicians, generalist medical practitioners and specialist medical practitioners.* * For the pharmacists, pharmacy workers and community health workers, it is important that they are equipped with the knowledge to recognize signs and symptoms of this complication. 85 40 (SD) Haemorrhage For non-life-threatening post-abortion haemorrhage: Recommend initial management by traditional and complementary medicine professionals, auxiliary nurses/ ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners.* * For the pharmacists, pharmacy workers and community health workers, it is important that they are equipped with the knowledge to recognize signs and symptoms of this complication. 86 Timing of post-abortion contraception 41 (CS) Medical eligibility criteria (MEC) for contraceptive use The following contraceptiv",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 34
  },
  {
    "chunk_id": "abortioncare_133",
    "text": "ognize signs and symptoms of this complication. 86 Timing of post-abortion contraception 41 (CS) Medical eligibility criteria (MEC) for contraceptive use The following contraceptive methods may be started immediately (MEC Category 1 – no restrictions) after a surgical or medical abortion (first and second trimester, and also after a septic abortion): combined hormonal contraceptives (CHCs), progesterone-only contraceptives (POCs) and barrier methods (condoms, spermicide, diaphragm, cap – note: The diaphragm and cap are unsuitable until 6 weeks after second-trimester abortion). Intrauterine devices (IUDs) may be started immediately after a first-trimester surgical or medical abortion (MEC Category 1 – no restrictions) or after second-trimester abortion (MEC Category 2 – the advantages generally outweigh the risks), but should not be started immediately after septic abortion (MEC Category ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 34
  },
  {
    "chunk_id": "abortioncare_134",
    "text": "tions) or after second-trimester abortion (MEC Category 2 – the advantages generally outweigh the risks), but should not be started immediately after septic abortion (MEC Category 4 – insertion of an IUD may substantially worsen the condition). Fertility-awareness-based (FAB) methods: Symptom-based methods should only be started after abortion with “caution” (special counselling may be needed to ensure correct use of the method in this circumstance) and the use of calendar-based methods should be delayed (until the condition is evaluated; alternative temporary methods of contraception should be offered). 88 42 (CS) Contraception and surgical abortion For individuals undergoing surgical abortion and wishing to use contraception: Recommend the option of initiating the contraception at the time of surgical abortion. Remark: • The quality of evidence based on randomized controlled trials was",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 34
  },
  {
    "chunk_id": "abortioncare_135",
    "text": "se contraception: Recommend the option of initiating the contraception at the time of surgical abortion. Remark: • The quality of evidence based on randomized controlled trials was very low. 89",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 34
  },
  {
    "chunk_id": "abortioncare_136",
    "text": "xxxiii SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number 43 (CS) Contraception and medical abortion For individuals undergoing medical abortion with the combination mifepristone and misoprostol regimen or with misoprostol alone: a. For those who choose to use hormonal contraception (pills, patch, ring, implant or injections): Suggest that they be given the option of starting hormonal contraception immediately after the first pill of the medical abortion regimen. b. For those who choose to have an IUD inserted: Suggest IUD placement at the time that success of the abortion procedure is determined. Remark (for Recommendations 43a and b): • This recommendation applies to the combination mifepristone plus misoprostol regimen and the use of misoprostol alone. The letrozole plus misoprostol combination regimen is ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 35
  },
  {
    "chunk_id": "abortioncare_137",
    "text": " b): • This recommendation applies to the combination mifepristone plus misoprostol regimen and the use of misoprostol alone. The letrozole plus misoprostol combination regimen is not mentioned here because the included studies informing these recommendations did not assess this regimen. Remarks (for Recommendation 43a only): • Immediate initiation of intramuscular depot medroxyprogesterone acetate (DMPA) is associated with a slight decrease in the effectiveness of medical abortion regimens. However, immediate initiation of DMPA should still be offered as an available contraceptive method after an abortion. • Indirect evidence was used as a basis for decision-making on initiation of hormonal contraception as an option for individuals undergoing medical abortion with misoprostol alone. • No data were available on the use of combined hormonal contraception (pills or injections) by those un",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 35
  },
  {
    "chunk_id": "abortioncare_138",
    "text": " option for individuals undergoing medical abortion with misoprostol alone. • No data were available on the use of combined hormonal contraception (pills or injections) by those undergoing medical abortion. • Individuals who choose to initiate the contraceptive ring should be instructed to check for expulsion of the ring in the event of heavy bleeding during the medical abortion process. 89 44 (SD) Intrauterine devices (IUDs) For intrauterine devices (IUDs): a. Recommend insertion/removal by auxiliary nurse midwives, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest insertion/removal by traditional and complementary medicine professionals (TCMPs) and auxiliary nurses (ANs). • Condition (TCMPs): In contexts with established health system mechanisms for the participation of these professionals in oth",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 35
  },
  {
    "chunk_id": "abortioncare_139",
    "text": "ine professionals (TCMPs) and auxiliary nurses (ANs). • Condition (TCMPs): In contexts with established health system mechanisms for the participation of these professionals in other tasks related to maternal and reproductive health. • Condition (ANs): In the context of rigorous research. 90 45 (SD) Contraceptive implants For contraceptive implants: a. Recommend insertion/removal by nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest insertion/removal by community health workers (CHWs), traditional and complementary medicine professionals (TCMPs), auxiliary nurses (ANs)/ANMs. • Condition (CHWs): In the context of rigorous research. • Condition (TCMPs): In contexts with established health system mechanisms for the participation of these professionals in other tasks related to maternal and reproductive",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 35
  },
  {
    "chunk_id": "abortioncare_140",
    "text": "esearch. • Condition (TCMPs): In contexts with established health system mechanisms for the participation of these professionals in other tasks related to maternal and reproductive health and where training in implant removal is given along with training in insertion. • Condition (ANs/ANMs): In the context of targeted monitoring and evaluation. 90 46 (SD) Injectable contraceptives For injectable contraceptives (initiation and continuation): Recommend administration by self (see Recommendation 51), community health workers, pharmacy workers, pharmacists, traditional and complementary medicine professionals, auxiliary nurses/ANMs, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. 91 47 (SD) Tubal ligation For tubal ligation: a. Recommend tubal ligation by associate/advanced associate clinicians, generalist medi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 35
  },
  {
    "chunk_id": "abortioncare_141",
    "text": "itioners and specialist medical practitioners. 91 47 (SD) Tubal ligation For tubal ligation: a. Recommend tubal ligation by associate/advanced associate clinicians, generalist medical practitioners and specialist medical practitioners. b. Suggest tubal ligation by nurses and midwives. • Condition: In the context of rigorous research. 92 Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 35
  },
  {
    "chunk_id": "abortioncare_142",
    "text": "Abortion care guideline, second edition xxxiv SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number SERVICE-DELIVERY OPTIONS AND SELF-MANAGEMENT APPROACHES Telemedicine approaches to delivering medical abortion care 48 (SD) (NEW) Recommend the option of telemedicine as an alternative to in-person interactions with the health worker to deliver medical abortion services in whole or in part. Remarks: • The above recommendation applies to assessment of eligibility for medical abortion, counselling and/or instruction relating to the abortion process, providing instruction for and active facilitation of the administration of medicines, and follow-up post-abortion care, all through telemedicine. • Hotlines, digital apps or one-way modes of communication (e.g. reminder text messages) that simply provide information were",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 36
  },
  {
    "chunk_id": "abortioncare_143",
    "text": "ollow-up post-abortion care, all through telemedicine. • Hotlines, digital apps or one-way modes of communication (e.g. reminder text messages) that simply provide information were not included in the review of evidence for this recommendation. 95 Service-delivery approaches for provision of information, counselling and medical abortion 49 (SD) (NEW) Best Practice Statement on service delivery Part 1. There is no single recommended approach to providing abortion services. The choice of specific health worker(s) (from among the recommended options) or management by the individual themself, and the location of service provision (from among the recommended options) will depend on the values and preferences of the woman, girl or other pregnant person, available resources, and the national and local context. A plurality of service-delivery approaches can co-exist within any given context. Par",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 36
  },
  {
    "chunk_id": "abortioncare_144",
    "text": "woman, girl or other pregnant person, available resources, and the national and local context. A plurality of service-delivery approaches can co-exist within any given context. Part 2. Given that service-delivery approaches can be diverse, it is important to ensure that for the individual seeking care, the range of service-delivery options taken together will provide: • access to scientifically accurate, understandable information at all stages; • access to quality-assured medicines (including those for pain management); • back-up referral support if desired or needed; • linkages to an appropriate choice of contraceptive services for those who want post-abortion contraception. 96 Self-management of medical abortion at < 12 weeks 50 (SELF-MANAGEMENT) For medical abortion at < 12 weeks (using the combination of mifepristone plus misoprostol or using misoprostol alone): Recommend the option",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 36
  },
  {
    "chunk_id": "abortioncare_145",
    "text": "tion at < 12 weeks 50 (SELF-MANAGEMENT) For medical abortion at < 12 weeks (using the combination of mifepristone plus misoprostol or using misoprostol alone): Recommend the option of self-management of the medical abortion process in whole or any of the three component parts of the process: • self-assessment of eligibility (determining pregnancy duration; ruling out contraindications) • self-administration of abortion medicines and management of the abortion process outside of a health-care facility and without the direct supervision of a trained health worker • self-assessment of the success of the abortion. Remarks: • There was more evidence for self-management of medical abortion (with either of the regimens) for pregnancies before 10 weeks of gestation. • This recommendation applies to the combination regimen of mifepristone plus misoprostol, and the use of misoprostol alone. The in",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 36
  },
  {
    "chunk_id": "abortioncare_146",
    "text": "s) for pregnancies before 10 weeks of gestation. • This recommendation applies to the combination regimen of mifepristone plus misoprostol, and the use of misoprostol alone. The included studies informing these recommendations did not assess the letrozole plus misoprostol regimen. • All individuals engaging in self-management of medical abortion must also have access to accurate information, quality-assured medicines including for pain management, the support of trained health workers and access to a health-care facility and to referral services if they need or desire it. • Restrictions on prescribing and dispensing authority for abortion medicines may need to be modified or other mechanisms put in place for self- management within the regulatory framework of the health system. 98",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 36
  },
  {
    "chunk_id": "abortioncare_147",
    "text": "xxxv SECTION Topic area Recommendation or best practice statement number and type Recommendation or best practice statement Page number Self-management approaches for post-abortion contraception (see also Timing of post-abortion contraception, Recommendations 41–47 above) 51 (SELF-MANAGEMENT) Injectable contraception (initiation and continuation) Recommend the option of self-administration of injectable contraception in the post-abortion period. Remark: • The administration of an injectable contraceptive involves using a syringe and may be intramuscular or subcutaneous. Compact pre-filled auto- disable devices have been developed to facilitate the self-administration process. 100 52 (SELF-MANAGEMENT) Over-the-counter oral contraceptive pills Recommend that over-the-counter oral contraceptive pills (OCPs) should be made available without a prescription for individuals using OCPs. 101 53 (",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 37
  },
  {
    "chunk_id": "abortioncare_148",
    "text": "ounter oral contraceptive pills Recommend that over-the-counter oral contraceptive pills (OCPs) should be made available without a prescription for individuals using OCPs. 101 53 (SELF-MANAGEMENT) Over-the-counter emergency contraceptive pills Recommend making over-the-counter emergency contraceptive pills available without a prescription to individuals who wish to use emergency contraception. 101 54 (SELF-MANAGEMENT) Condom use The consistent and correct use of male and female condoms is highly effective in preventing the sexual transmission of HIV; reducing the risk of HIV transmission both from men to women and women to men in serodiscordant couples; reducing the risk of acquiring other STIs and associated conditions, including genital warts and cervical cancer; and preventing unintended pregnancy. 101 Executive summary",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 37
  },
  {
    "chunk_id": "abortioncare_149",
    "text": "1 Chapter 1. Introduction 1.1 Background and context Sexual and reproductive health is fundamental to individuals, couples and families, and to the social and economic development of communities and nations (1). As provided in the Constitution of the World Health Organization (WHO), the organization’s objective is “the attainment by all peoples of the highest possible level of health”, and to fulfil that objective, WHO’s functions include providing technical assistance to countries in the field of health (2, Articles 1 and 2). Universal access to sexual and reproductive health (SRH) information and services is central to both individual and community health, as well as the realization of human rights, including the right to the highest attainable standard of SRH (3). In addition, the increased SRH risks in humanitarian settings, including armed conflict, require specific attention from a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 39
  },
  {
    "chunk_id": "abortioncare_150",
    "text": " the right to the highest attainable standard of SRH (3). In addition, the increased SRH risks in humanitarian settings, including armed conflict, require specific attention from a human rights perspective (4 [para. 7], 5, 6 [paras 19-24]) . In the wake of the COVID-19 pandemic and based on lessons learnt from previous disease outbreaks – when SRH services have been severely disrupted, causing individuals to feel disempowered and be exposed to preventable health risks – WHO has included comprehensive abortion care in the list of essential health services in certain recent technical publications and guidance (7-12).1 Abortion care encompasses management of various clinical conditions including spontaneous and induced abortion (of both non-viable and viable pregnancies) and intrauterine fetal demise, and also post-abortion care, including management of incomplete abortion. Strengthening ac",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 39
  },
  {
    "chunk_id": "abortioncare_151",
    "text": "duced abortion (of both non-viable and viable pregnancies) and intrauterine fetal demise, and also post-abortion care, including management of incomplete abortion. Strengthening access to abortion care within the health system is fundamental to meeting the Sustainable Development Goals (SDGs) relating to good health and well-being (SDG3) and gender equality (SDG5) (13) . WHO’s Global Reproductive Health Strategy, which seeks to accelerate progress towards achievement of international development goals, identifies elimination of unsafe abortion 2 as a priority mandate (1). The importance of quality abortion care to health is similarly underscored by the United Nations Global Strategy for Women’s, Children’s and Adolescents’ Health, which includes evidence-based interventions for abortion and post-abortion care as one effective way to help individuals thrive and communities transform (14) ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 39
  },
  {
    "chunk_id": "abortioncare_152",
    "text": "Adolescents’ Health, which includes evidence-based interventions for abortion and post-abortion care as one effective way to help individuals thrive and communities transform (14) . Quality abortion care is foundational to this guidance. Quality of care (see Glossary) encompasses multiple components: effectiveness, efficiency, accessibility, acceptability (e.g. patient centred), equity and safety. Effective care includes the delivery of evidence-based care that improves the health of individuals and communities, and is responsive to their needs. Efficient care optimizes resource use and minimizes waste. Quality abortion care must be both accessible (timely, affordable, geographically reachable, and provided in a setting where skills and resources are appropriate to medical need) and acceptable (incorporating the preferences and values of individual service users and the cultures of their",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 39
  },
  {
    "chunk_id": "abortioncare_153",
    "text": "a setting where skills and resources are appropriate to medical need) and acceptable (incorporating the preferences and values of individual service users and the cultures of their communities). It is imperative that abortion care is equitable, and that health care does not vary in quality based on the personal characteristics of the person seeking care, such as their gender, race, ethnicity, socioeconomic status, education, if they are living with a disability, or based on 1 When considering the concept of “essential health services”, it is important to note that different areas, even within the same country, may require different approaches to designate essential health services and to reorient health system components to maintain these services (7). 2 “Unsafe abortion” refers to abortion when it is carried out by a person lacking the necessary skills or in an environment that does not",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 39
  },
  {
    "chunk_id": "abortioncare_154",
    "text": "components to maintain these services (7). 2 “Unsafe abortion” refers to abortion when it is carried out by a person lacking the necessary skills or in an environment that does not conform to minimal medical standards, or both. Chapter 1. Introduction The second edition contains the updated remarks for Recommendation 22. There have been no other changes made to the recommendation itself nor any other recommendations contained in this document.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 39
  },
  {
    "chunk_id": "abortioncare_155",
    "text": "Abortion care guideline, second edition 2 their geographic location within a country. And finally, quality abortion care implies that it is safely delivered and minimizes risks and harms to service users (15). Underpinning these components is the principle that provision of quality abortion care would be in compliance with human rights. Globally, abortion is a common procedure, with 6 out of 10 unintended pregnancies and 3 out of 10 of all pregnancies ending in induced abortion (16) . When abortion is safe – defined as being carried out using a method recommended by WHO, appropriate to the gestational age, and by someone with the necessary skills (17) – the risks are very low. However global estimates demonstrate that 45% of all abortions are unsafe, including 14.4% considered to be “least safe” (18). This is a critical public health and human rights issue; unsafe abortion is increasingl",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 40
  },
  {
    "chunk_id": "abortioncare_156",
    "text": "te that 45% of all abortions are unsafe, including 14.4% considered to be “least safe” (18). This is a critical public health and human rights issue; unsafe abortion is increasingly concentrated in developing countries and among groups in vulnerable and marginalized situations. In countries where induced abortion is highly restricted by law or unavailable due to other barriers, safe abortion has often become the privilege of the rich, while poor women have little choice but to resort to the services of unskilled providers in unsafe settings, or induce abortion themselves often using unsafe methods, leading to deaths and morbidities that become the social and financial responsibility of the public health system, and denial of women’s human rights. The legal status of abortion has no effect on a woman’s likelihood of seeking induced abortion, but it dramatically affects her access to safe ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 40
  },
  {
    "chunk_id": "abortioncare_157",
    "text": " and denial of women’s human rights. The legal status of abortion has no effect on a woman’s likelihood of seeking induced abortion, but it dramatically affects her access to safe abortion (19). Between 4.7% and 13.2% of all maternal deaths are attributed to unsafe abortions (20, 21) . This equates to between 13 865 and 38 940 lives lost annually, due to the failure to provide safe abortion, with many more experiencing serious morbidities. Developing countries bear the burden of 97% of unsafe abortions (18) . The proportion of abortions that are unsafe is also significantly higher in countries with highly restrictive abortion laws than in those with less restrictive laws (18) . Over half (53.8%) of all unsafe abortions occur in Asia (the majority of those in south and central Asia), while another quarter (24.8%) occur in Africa (mainly in eastern and western Africa), and a further fifth ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 40
  },
  {
    "chunk_id": "abortioncare_158",
    "text": "bortions occur in Asia (the majority of those in south and central Asia), while another quarter (24.8%) occur in Africa (mainly in eastern and western Africa), and a further fifth (19.5%) in Latin America and the Caribbean (18) . The subregions where the highest proportions of abortions have been categorized as “least safe” are northern, eastern, western and middle Africa (approximately 45–70% of all abortions are “least safe”), followed by the Caribbean, Oceania and Central America (approximately 25–30% of all abortions are “least safe”) (18). A review of facility-based treatment for complications of unsafe abortion in 26 developing countries in 2012 indicated that 7 million women were treated in developing countries for complications of unsafe abortion that year – a rate of 6.9 per 1000 women aged 15–44 years (22) . Abortion, using medication or a simple outpatient surgical procedure, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 40
  },
  {
    "chunk_id": "abortioncare_159",
    "text": "untries for complications of unsafe abortion that year – a rate of 6.9 per 1000 women aged 15–44 years (22) . Abortion, using medication or a simple outpatient surgical procedure, is a safe health-care intervention, when carried out with a method appropriate to the gestational age of pregnancy and – in the case of a facility-based procedure – by a person with the necessary skills. In these circumstances, complications or serious adverse effects are rare. Medical abortion has revolutionized access to quality abortion care globally. Studies have demonstrated that medicines for abortion can be safely and effectively self-administered outside of a facility (e.g. at home). Individuals with a source of accurate information and access to a trained health worker (in case they need or want support at any stage of the process) can safely self-manage their abortion process in the first 12 weeks of ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 40
  },
  {
    "chunk_id": "abortioncare_160",
    "text": "mation and access to a trained health worker (in case they need or want support at any stage of the process) can safely self-manage their abortion process in the first 12 weeks of gestation. Service delivery with minimal medical supervision can significantly improve access, particularly in restricted settings and crisis situations, as well as improve privacy, convenience and acceptability of the abortion process without compromising safety and effectiveness (23) . However, in both low- and high-resource settings, law, policy and practical barriers can make it difficult to access quality abortion care. Multiple actions are needed at the legal, health system and community levels so that everyone who needs it has access to comprehensive abortion care (CAC), i.e. information, abortion management (including induced abortion, and care related to pregnancy loss/spontaneous abortion) and post-ab",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 40
  },
  {
    "chunk_id": "abortioncare_161",
    "text": "access to comprehensive abortion care (CAC), i.e. information, abortion management (including induced abortion, and care related to pregnancy loss/spontaneous abortion) and post-abortion care. 1.2 Guideline objective, rationale, target audience, inclusivity and structure Guidelines are the fundamental means through which WHO fulfils its technical leadership in health (24). WHO guidelines are subject to a rigorous quality assurance process that generates recommendations for clinical practice or public health policy with the aim of achieving the best possible individual or collective health outcomes. Towards this aim, WHO has made a commitment to integrate human rights into health-care programmes and policies at national and regional levels by looking at underlying determinants of health as part of a comprehensive approach to health and human rights.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 40
  },
  {
    "chunk_id": "abortioncare_162",
    "text": "3 1.2.1 Objective and rationale The objective of this guideline is to present the complete set of all WHO recommendations and best practice statements relating to abortion, with the goal of enabling evidence-based quality abortion care globally. This guideline updates and replaces the recommendations in the following previous WHO guidance: • Safe abortion: technical and policy guidance for health systems, second edition (2012) • Health worker roles in providing safe abortion care and post-abortion contraception (previously known as the “task sharing” guidance) (2015), and • Medical management of abortion (2018). This guideline is intended to provide concrete information and guidance, integrating aspects of care across all domains needed to provide quality abortion care: Law and policy, Clinical services and Service delivery. This guidance contains new recommendations consolidated with ex",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 41
  },
  {
    "chunk_id": "abortioncare_163",
    "text": " across all domains needed to provide quality abortion care: Law and policy, Clinical services and Service delivery. This guidance contains new recommendations consolidated with existing recommendations that remain unchanged and some that have been updated after re-assessment, using the same rigorous methods for both new and updated recommendations (see Annex 4: Methods). Among the recommendations are seven concerning the laws and policies that should or should not be in place, in order to fully implement and sustain quality abortion care: three recommendations relating to abortion regulation are presented in Chapter 2 and four more relating to laws and policies affecting clinical and health worker practices are presented in Chapter 3. All the other recommendations address methods of abortion and related clinical care as well as service delivery by a range of health workers and approache",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 41
  },
  {
    "chunk_id": "abortioncare_164",
    "text": "e presented in Chapter 3. All the other recommendations address methods of abortion and related clinical care as well as service delivery by a range of health workers and approaches, including self-management by the abortion seeker, reflecting recent changes in all these aspects of abortion care. Emerging areas of interest and research priorities in abortion care are identified in Chapter 4. As a key part of the rationale for developing this updated and consolidated guideline, important contextual information – which is integral to this guidance, as context for the recommendations and best practice statements – is presented in the remainder of this first chapter. This information is not in the form of WHO recommendations but rather it describes the underlying determinants of quality abortion care, and thus must be carefully considered. Section 1.3 below describes an enabling environment ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 41
  },
  {
    "chunk_id": "abortioncare_165",
    "text": "mendations but rather it describes the underlying determinants of quality abortion care, and thus must be carefully considered. Section 1.3 below describes an enabling environment for comprehensive abortion care (i.e. a law and policy framework supportive of human rights; access to information; and health system factors) and section 1.4 delves further into key health system considerations (universal health coverage and primary health care; health financing; health workforce training; health-care commodities; and monitoring and evaluation). Where relevant, this document incorporates and builds upon considerations captured in other existing WHO guidance, including Consolidated guideline on the sexual and reproductive health and rights of women living with HIV (25) and WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights (26). 1.2.2 Tar",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 41
  },
  {
    "chunk_id": "abortioncare_166",
    "text": "tive health and rights of women living with HIV (25) and WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights (26). 1.2.2 Target audience This guidance seeks to provide recommendations for national and subnational policy-makers, implementers and managers of sexual and reproductive health (SRH) programmes, members of nongovernmental organizations and other civil society organizations and professional societies, as well as health workers and other stakeholders in the field of sexual and reproductive health and rights (SRHR), to support them in ensuring that evidence-based, quality abortion care is available and accessible globally. 1.2.3 Equity, inclusivity and people-centred care The needs of all individuals with respect to abortion are recognized and acknowledged in this guidance. A human rights approach that advances gender equality",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 41
  },
  {
    "chunk_id": "abortioncare_167",
    "text": "nd people-centred care The needs of all individuals with respect to abortion are recognized and acknowledged in this guidance. A human rights approach that advances gender equality is essential and must be applied in all contexts providing services to people seeking health care. To provide quality abortion care throughout the health system, services should also be integrated where possible with other SRH services, such as evidence-based HIV and sexually transmitted infection (STI) testing and treatment, and family planning/contraception, and should be friendly and welcoming to youth and people from sexual and gender minorities, people living with disabilities, and all groups in vulnerable and marginalized situations. WHO guidelines systematically incorporate consideration of the values and preferences of end-users of the recommended or suggested interventions into the process of developi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 41
  },
  {
    "chunk_id": "abortioncare_168",
    "text": "tions. WHO guidelines systematically incorporate consideration of the values and preferences of end-users of the recommended or suggested interventions into the process of developing the guidance. To gain more in-depth understanding of the values and preferences of individuals seeking abortion care, WHO conducted a global Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 41
  },
  {
    "chunk_id": "abortioncare_169",
    "text": "Abortion care guideline, second edition 4 survey and convened a technical meeting on this subject with stakeholders in September 2019 attended by 19 participants from 15 different countries/organizations. The key themes that emerged were the importance of equity, inclusivity and meeting the needs of those living in the most vulnerable and marginalized situations. In addition, a youth-led technical meeting was convened in April 2021 with 16 youths (representing 13 countries across all WHO regions) from the Youth for Abortion Task Force, to learn about the concerns of youth. The Task Force was formed by the International Youth Alliance for Family Planning (IYAFP) – a collective of young individuals, youth associations, organizations and communities with a common mission to support provision of and access to comprehensive reproductive health services (see Web annex B: Technical meetings dur",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 42
  },
  {
    "chunk_id": "abortioncare_170",
    "text": "tions, organizations and communities with a common mission to support provision of and access to comprehensive reproductive health services (see Web annex B: Technical meetings during guideline development). Women living with HIV are one example among many of a marginalized population with unique vulnerabilities in the context of abortion care. Women living with HIV face unique challenges and are vulnerable to SRH-related human rights violations within their families and communities, as well as at health-care facilities where they seek care. An enabling environment is essential to promote more effective interventions and better health outcomes for all abortion seekers (see section 1.3). All individuals have the right to non-discrimination and equality in SRH care and services. The right to be free from discrimination is stated in the Universal Declaration of Human Rights and in other uni",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 42
  },
  {
    "chunk_id": "abortioncare_171",
    "text": " right to non-discrimination and equality in SRH care and services. The right to be free from discrimination is stated in the Universal Declaration of Human Rights and in other universal human rights treaties and regional human rights instruments. It has been affirmed that the right to non-discrimination guaranteed by the International Covenant on Economic, Social and Cultural Rights (ICESCR) includes sexual orientation, gender identity and sex characteristics. The international human rights system has been strengthening the promotion and protection of human rights without distinction. The protection of persons based on their sexual orientation and gender identity are based on international law, complemented and supplemented by State practice (27). As stated in the 2018 report of the Independent Expert on protection against violence and discrimination based on sexual orientation and gend",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 42
  },
  {
    "chunk_id": "abortioncare_172",
    "text": "d supplemented by State practice (27). As stated in the 2018 report of the Independent Expert on protection against violence and discrimination based on sexual orientation and gender identity to the United Nations General Assembly, “The right to effective recognition of one’s gender identity is linked to the right to equal recognition before the law” (28, para. 20). In this guideline, we recognize that most of the available evidence on abortion can be assumed to be derived from research among study populations of cisgender women, and we also recognize that cisgender women, transgender men, nonbinary, gender-fluid and intersex individuals with a female reproductive system and capable of becoming pregnant may require abortion care. To be concise and facilitate readability of this guideline, when referring to all gender diverse people who may require abortion care, we use the word “women” m",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 42
  },
  {
    "chunk_id": "abortioncare_173",
    "text": "uire abortion care. To be concise and facilitate readability of this guideline, when referring to all gender diverse people who may require abortion care, we use the word “women” most often, although we also variously use the terms “individual”, “person” and “abortion seeker”. Providers of SRH services, including abortion care, must consider the needs of – and provide equal care to – all individuals; gender identity or its expression must not lead to discrimination. This guideline takes an integrated, people-centred approach to health services (29). People-centred care requires that individuals have the education and support they need to make decisions and participate in their own health care (30). Individual health preferences may vary; no one model of abortion care will meet the needs of everyone seeking abortion care. The core values of dignity, autonomy, equality, confidentiality, co",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 42
  },
  {
    "chunk_id": "abortioncare_174",
    "text": "ealth preferences may vary; no one model of abortion care will meet the needs of everyone seeking abortion care. The core values of dignity, autonomy, equality, confidentiality, communication, social support, supportive care, and trust are foundational to abortion care and are reflected throughout this guidance (31). 1.2.4 Conceptual structure of the guideline As illustrated in Figure 1.1, this guideline is centred on the values and preferences of abortion seekers, and considers them as active participants in as well as beneficiaries of health services. This guidance emphasizes that – as a woman, girl or other pregnant person moves through the abortion care pathway (pre-abortion, abortion, post-abortion) – health services must be integrated within the health sector to ensure that service delivery meets their needs equitably and without discrimination. As each individual moves through thi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 42
  },
  {
    "chunk_id": "abortioncare_175",
    "text": "th services must be integrated within the health sector to ensure that service delivery meets their needs equitably and without discrimination. As each individual moves through this pathway, the guideline provides specific recommendations on the interventions needed (i.e. the “what”), and guidance on the individuals who may safely carry them out (i.e. the “who”). The guideline also provides information on the locations where services can be provided (i.e. the “where”) and outlines service-delivery models that can be used (i.e. the “how”). The enabling environment, described in the remainder of this chapter, provides the context for the effective implementation of these interventions.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 42
  },
  {
    "chunk_id": "abortioncare_176",
    "text": "5 Figure 1.1: Conceptual framework for abortion care Hom e P h a r m a c y C o m m u n i t y o u t r e a c h c e n t r e s P r i m a r y c a r e f a c i l i t y H i g h e r - le v e l fa cility F a c i l i t y - b a s e d h e a l t h w o r k e r s O t h e r h e a l t h w o rk e rsS e lf Abortion Pre-abortion Post-abortion Values & Preferences HOW WHERE WHO WHAT Availability and accessibility of information Supportive health systems Respect for human rights Prim in g , P a in m a n a g e m e n t , Supportive framework of law and policy Context-sp e c iﬁc s e r v i c e - d e l i v e r y a p p r o a c h e s In t e g r a t i o n w i t h i n h e a l t h s y s t e m s C o m m o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 43
  },
  {
    "chunk_id": "abortioncare_177",
    "text": "o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d e s i r e d ) 1.3 An enabling environment for comprehensive abortion care A person’s environment plays a crucial role in shaping their access to care and influencing their health outcomes. An enabling environment is the foundation of quality, comprehensive abortion care. The three cornerstones of an enabling environment for abortion care are outlined in Box 1.1 and elaborated in the text of this section: 1. respect for human rights including a supportive framework of law and policy 2. the availability and accessibility of information, and 3. a supportive, universally accessible, affordable and well functioning health system. For clarification, this section of the guideline docume",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 43
  },
  {
    "chunk_id": "abortioncare_178",
    "text": "nd accessibility of information, and 3. a supportive, universally accessible, affordable and well functioning health system. For clarification, this section of the guideline document does not provide recommendations – rather it details the components and aspects that would comprise an overall enabling environment for quality abortion care, based on WHO best practices, which would provide the ideal context to best facilitate the recommendations in the later sections of this chapter and in Chapter 3. While this enabling environment represents an ideal context, complete implementation of the components of this enabling environment is not necessarily a precondition to implementation and application of the recommendations contained in this guideline. Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 43
  },
  {
    "chunk_id": "abortioncare_179",
    "text": "Abortion care guideline, second edition 6 BOX 1.1: Core components of an enabling environment for abortion care Respect for human rights including a supportive framework of law and policy • Countries ratify international and regional human rights treaties and conventions addressing health, including sexual and reproductive health (SRH). • Laws and policies promote SRH for all, and are consistent with sexual and reproductive health and rights. • There are appropriate administrative, political and judicial arrangements to facilitate quality abortion care, including accessible, transparent and effective mechanisms providing remedies. These include: ☐ accessible mechanisms for women to challenge denial of abortion in a timely manner, and ☐ appropriate monitoring mechanisms for failure to facilitate quality care, including regular review and reform of law and policy to recognize and remove ba",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 44
  },
  {
    "chunk_id": "abortioncare_180",
    "text": "in a timely manner, and ☐ appropriate monitoring mechanisms for failure to facilitate quality care, including regular review and reform of law and policy to recognize and remove barriers to quality abortion care. • Policies minimize the rate of unintended pregnancy by providing quality contraceptive information and services, including a full range of contraceptive methods (emergency, short-acting and long-acting methods). • All people and communities receive the health services they need, without suffering financial hardship and without any discrimination. Availability and accessibility of information • Evidence-based comprehensive sexuality education (CSE) is provided for all individuals and made available in multiple and accessible forms and languages. • Accurate, non-biased and evidence-based SRH information, including on abortion and contraceptive methods, is widely available in mult",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 44
  },
  {
    "chunk_id": "abortioncare_181",
    "text": "multiple and accessible forms and languages. • Accurate, non-biased and evidence-based SRH information, including on abortion and contraceptive methods, is widely available in multiple and accessible forms and languages. Supportive, universally accessible, affordable and well functioning health system • Universal health coverage (UHC) ensures that all individuals can receive the care they need without financial hardship (see section 1.4.1). • The health system is adequately resourced, meaning that resources including essential medicines, supplies, equipment, workforce and financial allocations are available, accessible, acceptable, affordable and of good quality. • Equitable access to quality-assured essential medicines and health products is ensured. • Leadership and clinical standards promote evidence-based SRH services. • The organization of the health system ensures respect for SRH a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 44
  },
  {
    "chunk_id": "abortioncare_182",
    "text": "medicines and health products is ensured. • Leadership and clinical standards promote evidence-based SRH services. • The organization of the health system ensures respect for SRH and human rights, including non- discrimination and equality, and for autonomy in decision-making. • The workforce is robust and receives competency-based training and is skilled in the provision of evidence-based SRH counselling and service delivery. • In addition to technical training, SRH services are provided by persons who are trained in the content and meaning of the law and trained and empowered to interpret and apply law and policy in rights-compliant ways. • Confidentiality and privacy of care are ensured, and there are efforts to counteract abortion stigma. • There is access to safe and timely comprehensive abortion care and women do not have to resort to unsafe abortion. • Health financing policies sh",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 44
  },
  {
    "chunk_id": "abortioncare_183",
    "text": "s to counteract abortion stigma. • There is access to safe and timely comprehensive abortion care and women do not have to resort to unsafe abortion. • Health financing policies should avoid making access to SRH services conditional on direct payment from patients at the point of service. • Care is always provided respectfully and with compassion. • Communities are engaged and supportive.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 44
  },
  {
    "chunk_id": "abortioncare_184",
    "text": "7 1.3.1 Human rights including a supportive framework of law and policy An enabling environment is one in which the human rights of individuals are respected, protected and fulfilled. This entails regular review and, where necessary, revision of regulatory, law and policy frameworks, and the adoption of measures to ensure compliance with evolving international human rights standards (see Annex 2). Throughout this guideline we refer to human rights standards in international law, the applicability of which in a specific setting will depend on factors such as the State’s ratification of relevant human rights instruments. The sources of these human rights standards are detailed in Web annex A: Key international human rights standards on abortion. (i) Sexual and reproductive health and rights Sexual and reproductive health and rights are grounded in a range of human rights recognized and gua",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 45
  },
  {
    "chunk_id": "abortioncare_185",
    "text": "man rights standards on abortion. (i) Sexual and reproductive health and rights Sexual and reproductive health and rights are grounded in a range of human rights recognized and guaranteed in national and international law, and are inextricably linked to the achievement of public health policy goals, including the SDGs (32, 33). People have a range of sexual and reproductive rights, which are relevant to information and services across the continuum of care for abortion (see Box 1.2). Overarching all of them are principles of non-discrimination and equality, and the right to the highest attainable standard of physical and mental health, including in the provision of SRH services (3, para. 7) . These are all underpinned by States’ obligations to ensure that laws and policies, institutional arrangements and social practices do not prevent people from the effective enjoyment of their right t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 45
  },
  {
    "chunk_id": "abortioncare_186",
    "text": "rpinned by States’ obligations to ensure that laws and policies, institutional arrangements and social practices do not prevent people from the effective enjoyment of their right to SRH (3, para. 8). Box 1.2 provides a general description of certain human rights as established by international law instruments and their associated obligations and principles relevant to SRH. (ii) Prevention of unsafe abortion and reduction of maternal mortality and morbidity Taking measures to prevent unsafe abortion is a core obligation of the right to SRH (3, para. 49). International human rights law requires States to take steps to reduce maternal mortality and also to effectively protect women from the physical and mental risks (morbidity) associated with unsafe abortion (43, paras 6, 9, 24, 30-33). Treaty monitoring bodies (see Annex 2) have confirmed that States must revise their laws to ensure this ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 45
  },
  {
    "chunk_id": "abortioncare_187",
    "text": "ks (morbidity) associated with unsafe abortion (43, paras 6, 9, 24, 30-33). Treaty monitoring bodies (see Annex 2) have confirmed that States must revise their laws to ensure this protection (36, para. 8). Thus, the United Nations Committee on Economic, Social and Cultural Rights (CESCR) has confirmed that States must liberalize restrictive abortion laws, guarantee access to quality abortion and post-abortion care, and respect the right of women to make autonomous decisions about their SRH (3, para. 28) . In all situations, States have a duty under international human rights law to ensure that the regulation of abortion (see Chapter 2) does not cause women and girls to resort to unsafe abortions (36, para. 8). As a matter of international human rights law, States must provide essential medicines listed under WHO’s Action Programme on Essential Drugs (46, para. 12a). States must also take",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 45
  },
  {
    "chunk_id": "abortioncare_188",
    "text": "As a matter of international human rights law, States must provide essential medicines listed under WHO’s Action Programme on Essential Drugs (46, para. 12a). States must also take steps to prevent the stigmatization of people seeking abortion (36, para. 8) . In addition, policies must seek to minimize the rate of unintended pregnancy by ensuring provision of quality contraceptive information and services, including a full range of contraceptive methods (emergency, short-acting and long- acting methods). (iii) Rights-based regulation of abortion The right to SRH requires States to ensure that health-care facilities, goods and services are available, accessible, acceptable and of good quality (46, paras 8, 12). This should inform all parts of the regulation of abortion. Treaty monitoring bodies have called for the decriminalization of abortion in all circumstances. They have further clari",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 45
  },
  {
    "chunk_id": "abortioncare_189",
    "text": "This should inform all parts of the regulation of abortion. Treaty monitoring bodies have called for the decriminalization of abortion in all circumstances. They have further clarified States’ human rights obligations in relation to abortion. These include that: • States may not regulate pregnancy or abortion in a manner that runs contrary to their core obligation to ensure that women and girls do not have to resort to unsafe abortions. If they do, their restrictions on access to abortion must be revised (36, para. 8) . • The regulation of abortion must not jeopardize the lives of pregnant women, subject them to physical or mental pain or suffering (including where this constitutes torture or cruel, inhuman or degrading treatment or punishment), discriminate against them, or interfere arbitrarily with their privacy (36, para. 8). • The regulation of abortion must be evidence based and pr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 45
  },
  {
    "chunk_id": "abortioncare_190",
    "text": "degrading treatment or punishment), discriminate against them, or interfere arbitrarily with their privacy (36, para. 8). • The regulation of abortion must be evidence based and proportionate to ensure respect for human rights (37, para. 18). Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 45
  },
  {
    "chunk_id": "abortioncare_191",
    "text": "Abortion care guideline, second edition 8 BOX 1.2: Selected human rights, as specified in relevant international law instruments, and their associated obligations and principles relevant to sexual and reproductive health and rights and abortion in particular Human right Selected human rights principles and obligations relevant to abortion The right to the highest attainable standard of physical and mental health, including sexual and reproductive health and rights • States have an obligation to respect, protect and fulfil the right of everyone to sexual and reproductive health and rights (34, Article 12). This includes: ☐ the removal of legal provisions, including criminal laws, which penalize women who have undergone abortion or medical practitioners who offer these services (3, 35-38); ☐ ensuring that women are not prevented from accessing health services by health professionals’ exerc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_192",
    "text": "dergone abortion or medical practitioners who offer these services (3, 35-38); ☐ ensuring that women are not prevented from accessing health services by health professionals’ exercise of conscientious objection (e.g. where abortion is legal, if a doctor refuses to perform it, the health system must provide a referral to an alternative health-care provider) (3, 39); ☐ eliminating barriers to the provision of abortion services including barriers that lead women to resort to unsafe abortions – this should include eliminating unacceptable delays in providing medical attention (3, 36, 38, 40-42); ☐ undertaking measures to prevent unsafe abortions and ensure access to post-abortion care in all circumstances, on a confidential basis and without the threat of criminal prosecution or punitive measures (3, 36-38, 40, 41, 42 [para. 33], 43-47); ☐ undertaking measures to prevent and eliminate discri",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_193",
    "text": "fidential basis and without the threat of criminal prosecution or punitive measures (3, 36-38, 40, 41, 42 [para. 33], 43-47); ☐ undertaking measures to prevent and eliminate discrimination, stigmatization and negative stereotyping that hinder access to sexual and reproductive health (SRH), including against people seeking abortion and health-care providers offering abortion care services (36, 38). • States must ensure that sexual and reproductive health-care facilities, goods and services are available, acceptable and of good quality. This includes: ☐ ensuring an adequate number of sexual and reproductive health-care facilities, goods and services (e.g. trained and skilled medical and health-care personnel [42, 46, 48] and scientifically approved and unexpired medicines for abortion and post-abortion care [49], as well as the availability of safe abortion in cases of rape and incest [3, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_194",
    "text": " 46, 48] and scientifically approved and unexpired medicines for abortion and post-abortion care [49], as well as the availability of safe abortion in cases of rape and incest [3, 36, 42, 50, 51]); ☐ ensuring that health care and services, including SRH and essential medicines are physically and geographically accessible and affordable to all individuals, either provided at no cost or based on ensuring that health expenses do not expose individuals to suffering financial hardship (46); ☐ ensuring that information about SRH is accessible (3, 52) (e.g. institutions and individuals should be able to provide accurate health-care information, including information on abortion, without fear of criminal sanction [41, 50, 51]); ☐ ensuring that delivery of services is respectful of the culture of individuals, minorities, peoples and communities, and sensitive to gender, age, disability, sexual di",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_195",
    "text": "50, 51]); ☐ ensuring that delivery of services is respectful of the culture of individuals, minorities, peoples and communities, and sensitive to gender, age, disability, sexual diversity and life-cycle requirements (53, para. 20). The right to non-discrimination and equality • States must ensure that individuals enjoy equal access to the same range, quality and standard of SRH information, goods and services (36, 45, 52). • States must acknowledge and take measures to address access to safe abortion and post-abortion care for particular groups of individuals, especially those who are marginalized, have limited resources, live in rural areas, and/or are from minorities, as they are more likely to experience intersecting forms of discrimination (3, 36-38, 40, 41, 42 [para. 33], 43-47, 49, 54 [para. 45]). • States must repeal or reform discriminatory laws, policies and practices that nulli",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_196",
    "text": "ersecting forms of discrimination (3, 36-38, 40, 41, 42 [para. 33], 43-47, 49, 54 [para. 45]). • States must repeal or reform discriminatory laws, policies and practices that nullify or impair the ability of individuals to access SRH, such as criminalization of abortion and restrictive abortion laws (3, 35-38, 41, 42 [para. 22], 55). • States must remove all legal, procedural, practical and social barriers impeding individuals’ equal and non- discriminatory access to SRH, including abortion, and should repeal measures such as third-party authorization requirements (i.e. from husbands, partners, parents or guardians, or health authorities), biased counselling, mandatory waiting periods, and restrictions based on being an unmarried woman (3, 35-38). • States must take steps to prevent the imposition of forced abortion, in particular on women and girls from marginalized groups (37, 40, 47, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_197",
    "text": " being an unmarried woman (3, 35-38). • States must take steps to prevent the imposition of forced abortion, in particular on women and girls from marginalized groups (37, 40, 47, 52, 56). The right to life • States must ensure that measures designed to regulate access to abortion do not jeopardize the life of the woman, girl or other pregnant person, subject them to physical or mental pain or suffering or discriminate against them, or arbitrarily interfere with their privacy (36). • States must provide effective and confidential access to safe, legal abortion where the life or health of the woman, girl or other pregnant person is at risk, or where carrying a pregnancy to term would cause the pregnant individual substantial pain or suffering, and in cases where the pregnancy is the result of rape or incest or where the pregnancy is not viable (36). • States must take steps to reduce mate",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_198",
    "text": "l substantial pain or suffering, and in cases where the pregnancy is the result of rape or incest or where the pregnancy is not viable (36). • States must take steps to reduce maternal morbidity and mortality, including addressing unsafe abortion, taking into account exacerbated challenges in certain settings (3, 36-38, 40, 43).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 46
  },
  {
    "chunk_id": "abortioncare_199",
    "text": "9 Human right Selected human rights principles and obligations relevant to abortion The right to privacy • States must respect the right of individuals to make autonomous decisions about their sexual and reproductive health, including whether or not to undergo an abortion (35, 36, 57). • SRH services including abortion and post-abortion care must be provided in a way that respects fully the woman’s, girl’s or other pregnant person’s privacy and guarantees confidentiality (35, 36). • Medical and health-care professionals must not be required or mandated to report cases of women who have undergone abortions (36, 37, 40, 48). • Denial of therapeutic abortion may interfere arbitrarily with the right to privacy (57). • Third-party authorization requirements may violate the right to privacy (3, 36, 38). The right to be free from torture, cruel, inhuman and degrading treatment and punishment, i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 47
  },
  {
    "chunk_id": "abortioncare_200",
    "text": ". • Third-party authorization requirements may violate the right to privacy (3, 36, 38). The right to be free from torture, cruel, inhuman and degrading treatment and punishment, including the right to physical and mental integrity • Forced abortion, criminalization of abortion, denial or delay of safe abortion care and/or post-abortion care, and abuse and mistreatment of women and girls seeking SRH information, goods and services are forms of gender-based violence (44, 55), which – depending on the circumstances – may amount to torture, cruel, inhuman or degrading treatment (55). • States must ensure that measures regulating abortion do not subject individuals to substantial physical or mental pain or suffering, such as where a pregnancy is the result of rape (36). • State laws and policies must not permit abortions without the free and informed consent of the concerned individual (40, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 47
  },
  {
    "chunk_id": "abortioncare_201",
    "text": "g, such as where a pregnancy is the result of rape (36). • State laws and policies must not permit abortions without the free and informed consent of the concerned individual (40, 41, 48, 52, 56, 58). • States must prevent and prosecute forced abortions conducted by public officials and private actors, including when conducted on women with disabilities or according with coercive family planning laws and policies as well as in the context of a conflict (40, 41, 48, 52, 56, 58). • States should ensure that individuals seeking a safe legal abortion are not subjected to humiliating and judgemental attitudes leading to the denial or delay of such services in a context of extreme vulnerability for these individuals and where timely health care is essential (35). • Criminalization of abortion may amount to torture, cruel, inhuman or degrading treatment, including the practice of extracting con",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 47
  },
  {
    "chunk_id": "abortioncare_202",
    "text": "and where timely health care is essential (35). • Criminalization of abortion may amount to torture, cruel, inhuman or degrading treatment, including the practice of extracting confessions for prosecution purposes from individuals seeking emergency medical care because of illegal abortion in a particular context (55). The right to decide freely and responsibly on the number, spacing and timing of children and to have the information and means to do so • States must ensure access to family planning and SRH information and services, including affordable contraceptive methods to enable women and adolescents to make autonomous and informed decisions on their reproductive health (42 [para. 33], 49 [para. 33]). • States must ensure that women with disabilities can exercise their right to decide on the number and spacing of children (52, 59 [Article 3(3)]). The right to information and educatio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 47
  },
  {
    "chunk_id": "abortioncare_203",
    "text": "tes must ensure that women with disabilities can exercise their right to decide on the number and spacing of children (52, 59 [Article 3(3)]). The right to information and education including on sexual and reproductive health • States must take measures to ensure up-to-date, accurate information on SRH is publicly available and accessible to all individuals, in appropriate languages and formats (3, 50-52). • States must ensure that educational institutions incorporate unbiased, scientifically accurate, evidence-based, age-appropriate and comprehensive sexuality education into their required curricula (3, para. 63). • States must make accurate, evidence-based abortion information available to individuals on a confidential basis (3 [para. 63], 50-52). • This information must be presented in a way that can be understood by the person receiving it (3, 52). • The choice by an individual to re",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 47
  },
  {
    "chunk_id": "abortioncare_204",
    "text": "nfidential basis (3 [para. 63], 50-52). • This information must be presented in a way that can be understood by the person receiving it (3, 52). • The choice by an individual to refuse information when offered must be respected. • States must ensure that informed consent is provided freely, safeguarded effectively, and based on complete provision of high-quality, accurate and accessible information. The right to benefit from scientific progress and its realization • States must ensure adequate access to essential medicines in an affordable manner (46, 49, 54). • States must ensure access to necessary, up-to-date scientific technologies, in particular contraception and medicines for abortion, without discrimination (42, 49). Note: For further information, see Web annex A: Key international human rights standards on abortion. Wording used in this box reflects original language used in the ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 47
  },
  {
    "chunk_id": "abortioncare_205",
    "text": "ion (42, 49). Note: For further information, see Web annex A: Key international human rights standards on abortion. Wording used in this box reflects original language used in the source documents (human rights treaties). Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 47
  },
  {
    "chunk_id": "abortioncare_206",
    "text": "Abortion care guideline, second edition 10 • Access to abortion must be available when carrying a pregnancy to term would cause the woman substantial pain or suffering. This includes but is not limited to situations where her life and health are at risk, where the pregnancy is the result of rape or incest, or where the pregnancy is not viable (36, para. 8) . Treaty monitoring bodies have also recommended making abortion available in cases of fetal impairment, while putting in place measures to protect against discrimination on the basis of disability in society (60) . • States should not criminalize having an abortion, those who have an abortion, or those who support someone having an abortion (3 [paras 20, 34], 36 [para. 8], 55 [para. 18], 61 [para. 51(l)], 62 [para. 60], 63 [paras 82, 107]). • States should not require health workers to report women who have had or who are suspected to",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 48
  },
  {
    "chunk_id": "abortioncare_207",
    "text": ", 36 [para. 8], 55 [para. 18], 61 [para. 51(l)], 62 [para. 60], 63 [paras 82, 107]). • States should not require health workers to report women who have had or who are suspected to have had an abortion (40, para. 20). • States must provide essential primary health care (64, para. 10) (see also section 1.4.1: Universal health coverage and primary health care; section 1.4.4: Commodities; Annex 2: Selected human rights treaties and their treaty monitoring bodies; and also Web annex A: Key international human rights standards on abortion). (iv) Accessibility of abortion care Where it is lawful, abortion must be accessible in practice. This requires both ensuring that health-care facilities, commodities and services are accessible (including sufficient providers; see section 3.3.8 on provider restrictions), and that law and policy on abortion is formulated, interpreted and applied in a way th",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 48
  },
  {
    "chunk_id": "abortioncare_208",
    "text": " are accessible (including sufficient providers; see section 3.3.8 on provider restrictions), and that law and policy on abortion is formulated, interpreted and applied in a way that is compatible with human rights. Thus, where abortion is currently available on the basis of grounds, meaning under specified circumstances, and in anticipation of moving to a system of abortion on request as recommended (see Recommendation 2: Grounds-based approaches, section 2.2.2), those grounds must be defined and interpreted in a way that gives full effect to women’s human rights and that aligns with the following WHO definitions: Health: a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity (2). Mental health: a state of well-being in which every individual realizes their own potential, can cope with the normal stresses of life, can work productiv",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 48
  },
  {
    "chunk_id": "abortioncare_209",
    "text": "disease or infirmity (2). Mental health: a state of well-being in which every individual realizes their own potential, can cope with the normal stresses of life, can work productively and fruitfully, and is able to make a contribution to their community (65). States must take effective steps to prevent third parties (e.g. parent, spouse, health authority) undermining a person’s enjoyment of their right to SRH (see section 3.3.2: Third-party authorization) (3, para. 59) , and must also ensure that provider refusal is not a barrier to accessing abortion care (see section 3.3.9: Conscientious objection) (3 [paras 14, 43], 39 [Ch.1, paras 11, 13]). (v) Free and informed consent International human rights law requires that the provision of abortion be based on the free and informed consent of the person having the abortion with no further authorization required. International human rights law",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 48
  },
  {
    "chunk_id": "abortioncare_210",
    "text": "es that the provision of abortion be based on the free and informed consent of the person having the abortion with no further authorization required. International human rights law obliges States to ensure that accurate, evidence-based abortion information (3 [para. 9], 36 [para. 8]) is available to individuals on a confidential basis (36 [para. 8], 43), and also that their choice to refuse such information when offered is respected (58, para. 15). Receipt of such information is vital as this underpins the right and the ability to make informed decisions and choices about matters regarding one’s body and SRH, and to give informed consent (see also section 1.3.2 below). As a matter of international human rights law, States are obligated to ensure that “informed consent” is: • documented in advance of a health-care intervention, and provided without coercion, undue influence or misrepresen",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 48
  },
  {
    "chunk_id": "abortioncare_211",
    "text": "law, States are obligated to ensure that “informed consent” is: • documented in advance of a health-care intervention, and provided without coercion, undue influence or misrepresentation (58, para. 13); • safeguarded through legislative, political and administrative means (58, para. 7) , as a fundamental aspect of a range of human rights (i.e. the rights to health, information, freedom from discrimination, and security and dignity of the person); • based on provision of complete information about the associated benefits, risks and alternatives; • based on information that is of high quality, accurate and accessible (including ensuring it is available in a range of formats and languages, and in forms that make it accessible to people with reduced capacity), and presented in a manner acceptable to the person consenting.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 48
  },
  {
    "chunk_id": "abortioncare_212",
    "text": "11 Further relevant information is provided in section 3.2 on information provision and counselling related to abortion for individual abortion seekers, and in section 3.5.1 on follow-up care and section 3.5.4 on post-abortion contraception. States are obliged to protect women from arbitrary interference when they seek SRH services, and to ensure respect for autonomous decision-making by women, including women with disabilities, regarding their SRH and well-being (60). Even though women have a right to accurate information, some health workers who object to abortion on the basis of conscience either provide deliberately misleading information or refuse to provide any information about abortion (66-68). States where health workers are allowed to invoke conscientious objection (3, para. 43) must regulate and monitor such refusals of abortion care to ensure that women can access accurate in",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_213",
    "text": "here health workers are allowed to invoke conscientious objection (3, para. 43) must regulate and monitor such refusals of abortion care to ensure that women can access accurate information and appropriate services (refer to section 3.3.9: Conscientious objection). As a matter of international human rights law, States may not restrict women’s access to health services on the ground that they do not have the authorization of husbands, partners, parents/guardians or health authorities, because they are unmarried, or because they are women (39 [Ch.1, paras 14, 21], 3 [paras 41, 43]). For adolescents, the authorization or consent of parents should not be required before the provision of abortion care (see also section 3.3.2: Third-party authorization). As a general matter, States must recognize children’s and adolescents’ evolving capacity and their associated ability to take decisions that ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_214",
    "text": "ion 3.3.2: Third-party authorization). As a general matter, States must recognize children’s and adolescents’ evolving capacity and their associated ability to take decisions that affect their lives (69, Article 5). In order to ensure protection of adolescents’ sexual and reproductive health and rights, the United Nations Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health has suggested that States should consider introducing “a legal presumption of competence that an adolescent seeking preventive or time-sensitive health goods or services, including for sexual and reproductive health, has the requisite capacity to access such goods and services” (35, para. 60) . The United Nations Committee on the Rights of the Child (CRC) has also urged States to “review and consider allowing children to consent to certain medica",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_215",
    "text": "ervices” (35, para. 60) . The United Nations Committee on the Rights of the Child (CRC) has also urged States to “review and consider allowing children to consent to certain medical treatments and interventions without the permission of a parent, caregiver or guardian, such as … sexual and reproductive health services, including … safe abortion” (45, para. 31). People with disabilities have a right to autonomy (59, Article 3a), but face continuing and systemic discrimination in access to SRH services. States are obliged to prohibit and prevent discriminatory denial of SRH services to people with disabilities (70, para. 66). States may not undertake, and must take steps to prevent forced or coerced abortion (40, para. 11), which constitutes torture, cruel, inhuman or degrading treatment (40 [para. 11], 52 [para. 62]). (vi) Post-abortion care Provision of post-abortion care is a core oblig",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_216",
    "text": " para. 11), which constitutes torture, cruel, inhuman or degrading treatment (40 [para. 11], 52 [para. 62]). (vi) Post-abortion care Provision of post-abortion care is a core obligation of States under the right to SRH (3, para. 49e) . Regardless of whether abortion is legal or restricted, States are required to ensure access to post-abortion care (45, para. 70). Such care must be available on a confidential basis, without discrimination, and without the threat of criminal prosecution or other punitive measures (36, para. 8) . States must also ensure access to a wide range of modern, safe and affordable contraceptive methods (36 [para. 8], 49 [para. 33]). (vii) Accountability for human rights violations Accountability mechanisms are essential to the protection, respect and fulfilment of sexual and reproductive health and rights. Monitoring and accountability for human rights compliance t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_217",
    "text": "ability mechanisms are essential to the protection, respect and fulfilment of sexual and reproductive health and rights. Monitoring and accountability for human rights compliance takes place at national, regional and international levels, as appropriate to the law in question. Monitoring and accountability involve a variety of actors, such as the State itself, civil society organizations, national human rights institutions or international or regional human rights mechanisms. Some such accountability mechanisms include administrative mechanisms for recording and monitoring relevant health outcomes relating to abortion law and policy, and including them in reports to human rights institutions (39, Ch.1, paras 9, 10, 12, 17) (see also section 1.4.5 on monitoring and evaluation of abortion care). States must ensure that all persons have access to justice and to a meaningful and effective re",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_218",
    "text": " 10, 12, 17) (see also section 1.4.5 on monitoring and evaluation of abortion care). States must ensure that all persons have access to justice and to a meaningful and effective remedy where their human rights are violated (39, Ch.1, para. 13) . These remedies can include adequate, effective and prompt reparation in the form of restitution, compensation, rehabilitation, satisfaction and guarantees of non-repetition (3, para. 64), including by reform of law and policy. Mindful of the above, an enabling environment for abortion care would ensure that there are appropriate accountability mechanisms for failures to facilitate quality abortion care, including accessible, transparent and effective accountability mechanisms for women to challenge denial of abortion in a timely manner. In addition, an enabling environment would include appropriate remedies for failure to facilitate quality abort",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_219",
    "text": "anisms for women to challenge denial of abortion in a timely manner. In addition, an enabling environment would include appropriate remedies for failure to facilitate quality abortion care, including regular review and reform of law and policy to recognize and remove barriers to quality abortion care. As confirmed by the Committee on the Elimination Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 49
  },
  {
    "chunk_id": "abortioncare_220",
    "text": "Abortion care guideline, second edition 12 of Discrimination against Women (CEDAW), such reform should include “[a]bolish[ing] discriminatory criminalization and review[ing] and monitor[ing] all criminal procedures… [and] decriminaliz[ing] forms of behaviour that can be performed only by women, such as abortion” (61, para. 51[l]). 1.3.2 Availability and accessibility of information An essential first step in improving access to and quality of abortion care is ensuring that all individuals can access relevant, accurate and evidence-based health information and counselling if and when desired. This is required by international human rights law – grounded in the right to information and the right to privacy (see Box 1.2) – and facilitates individual decision-making relating to SRH services, including abortion. Two different types of information about abortion must be available: (i) informat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_221",
    "text": "ox 1.2) – and facilitates individual decision-making relating to SRH services, including abortion. Two different types of information about abortion must be available: (i) information of a general nature for the public (described below), and (ii) specific information tailored to be relevant to each person seeking abortion (see section 3.2.1) and underpinning free and informed consent, which was described in section 1.3.1(v). States parties are to ensure that everyone has a right to receive accurate, non-biased and evidence-based information on SRH. Relatedly, as part of their obligation to reduce maternal mortality and morbidity, States must ensure the provision of comprehensive, non-discriminatory, scientifically accurate and age-appropriate education on sexuality and reproduction, including information on abortion, both in and out of schools (46, 71 [Articles 10, 16], 72) and must ensu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_222",
    "text": "lly accurate and age-appropriate education on sexuality and reproduction, including information on abortion, both in and out of schools (46, 71 [Articles 10, 16], 72) and must ensure that comprehensive sexuality education (CSE) is available to minors without the consent of their parents or guardians (45, para. 31). In an enabling environment all persons would be provided with all the necessary information to make an informed decision regarding the use of contraception, including information on where and how to obtain an abortion or contraception, the costs of services, and the specifics of any local laws. The growing use of self-management of abortion (see section 3.6.2) underlines the need to ensure that accurate information about abortion is available to all who may seek it. As a matter of international human rights law, the provision of information on abortion should not be criminaliz",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_223",
    "text": "ate information about abortion is available to all who may seek it. As a matter of international human rights law, the provision of information on abortion should not be criminalized, even in contexts where the procedure itself may be illegal (see section 2.2.1: Criminalization of abortion). To ensure that accurate information is broadly accessible, including for those with low literacy, an enabling environment would provide that such information is shared using a variety of formats/media as appropriate for the intended audience (e.g. videos, social media). The United Nations CESCR has confirmed that “[t]he dissemination of misinformation and the imposition of restrictions on the right of individuals to access information about SRH also violates the duty to respect human rights. … Such restrictions impede access to information and services, and can fuel stigma and discrimination” (3, par",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_224",
    "text": "information about SRH also violates the duty to respect human rights. … Such restrictions impede access to information and services, and can fuel stigma and discrimination” (3, para. 41). 1.3.3 Health system factors Within the health system, multiple actions are needed to realize human rights obligations. Actions to facilitate and strengthen abortion-related service delivery should be based on human rights, local health needs and a thorough understanding of the service-delivery system and the broader social, cultural, political and economic context. National standards and guidelines for abortion care should be evidence based and periodically updated, and should provide the necessary guidance to achieve equal access to comprehensive abortion care. Leadership should also promote evidence-based SRH services according to these standards and guidelines. The right to the highest attainable sta",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_225",
    "text": "cess to comprehensive abortion care. Leadership should also promote evidence-based SRH services according to these standards and guidelines. The right to the highest attainable standard of physical and mental health includes the right to respectful health care as well as the right to be free from violence and discrimination (73). The right to benefit from scientific progress and its realization entitles women to access to up-to-date scientific technologies necessary for women. This means States must ensure access to modern and safe forms of contraception (including emergency contraception), abortion medicines, assisted reproductive technologies, and other SRH goods and services, on the basis of non- discrimination and equality (49, para. 33). To achieve a high standard of respectful care, health systems should be organized and managed in a manner that ensures respect for people’s SRH and",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_226",
    "text": "ion and equality (49, para. 33). To achieve a high standard of respectful care, health systems should be organized and managed in a manner that ensures respect for people’s SRH and human rights (73). Respectful health care recognizes individuals’ rights, respects their agency and autonomy in decision-making, and incorporates their values and preferences into care. In addition to policy and regulatory barriers, other barriers may further limit the availability of abortion services, including: stigma; formal and informal costs; lack of commodities, services, trained providers and information; and/ or the unwillingness of some health workers to provide care. This leaves particular groups of people – such as those living in rural settings, those facing financial hardship, adolescents, unmarried, transgender or nonbinary individuals, those with less access to education and those living with H",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_227",
    "text": "living in rural settings, those facing financial hardship, adolescents, unmarried, transgender or nonbinary individuals, those with less access to education and those living with HIV – disproportionately vulnerable to",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 50
  },
  {
    "chunk_id": "abortioncare_228",
    "text": "13 SERVICE DELIVERY HEALTH WORKFORCE INFORMATION MEDICAL PRODUCTS, VACCINES & TECHNOLOGIES FINANCING LEADERSHIP/GOVERNANCE barriers to obtaining abortion care. As part of an enabling environment, a health system should be adequately resourced, meaning that resources (e.g. essential medicines, supplies, equipment, workforce, financial allocations) are available, fairly distributed and efficiently used. In this way, adequate and equitable access to quality-assured essential medicines and equipment should be assured. Relatedly, health financing policies should avoid making access to SRH services conditional on direct payment from patients at the point of service, and the health workforce should be skilled in providing evidence-based SRH services, including counselling. Abortion stigma is common, and has negative psychological consequences for individuals seeking abortion and health workers ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 51
  },
  {
    "chunk_id": "abortioncare_229",
    "text": "ding evidence-based SRH services, including counselling. Abortion stigma is common, and has negative psychological consequences for individuals seeking abortion and health workers providing abortion care (31, 74, 75), and can also be detrimental to health outcomes. Abortion stigma is a social process, and is dependent upon the context, but may be considered as an exercise of power and control of one group over members of a less powerful group, who are considered different, negatively stereotyped, discriminated against and marginalized within society (75, 76). Work is needed across sectors to counteract stigma; health systems should recognize the risks and effects of stigma, and implement solutions to not only ensure privacy and confidentiality, but also to support health workers. Care should always be provided respectfully and with compassion. In an enabling environment, communities are ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 51
  },
  {
    "chunk_id": "abortioncare_230",
    "text": "nsure privacy and confidentiality, but also to support health workers. Care should always be provided respectfully and with compassion. In an enabling environment, communities are also engaged and supportive. Those who assist and support abortion seekers – their partners, friends, family members – also require support within the health system and broader environment. More in-depth consideration of key health system factors is provided in section 1.4 below. 1.4 Health system considerations The health system refers to all organizations, people and actions whose primary intent is to promote, restore or maintain health (77). The health system consists of the six core building blocks, as listed in Figure 1.2, which support four overall goals and outcomes, as shown below. This section addresses in detail health system considerations relevant to an enabling environment for abortion care. Figure",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 51
  },
  {
    "chunk_id": "abortioncare_231",
    "text": "support four overall goals and outcomes, as shown below. This section addresses in detail health system considerations relevant to an enabling environment for abortion care. Figure 1.2: The WHO health system framework Source: WHO, 2007 (77). A well functioning health system, with all the “blocks” working in harmony, depends upon having trained and motivated health workers, a well maintained infrastructure and a reliable supply of medicines and technologies, backed by adequate financing, strong health plans and evidence-based policies. Health-care services provided via the health system are not restricted to those provided at a health-care facility; health care and services can also be received through community-based providers (e.g. health visitors, pharmacists), digital interventions or self-care approaches (e.g. telemedicine). 1.4.1 Universal health coverage and primary health care Uni",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 51
  },
  {
    "chunk_id": "abortioncare_232",
    "text": "-based providers (e.g. health visitors, pharmacists), digital interventions or self-care approaches (e.g. telemedicine). 1.4.1 Universal health coverage and primary health care Universal health coverage (UHC) means ensuring that all people have access to the promotive, preventive, curative, rehabilitative and palliative health services they need, which must be of sufficient quality to be effective, while also ensuring that the use of these services does not expose any users to financial hardship (30). UHC is integral to the achievement of SDG target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable SYSTEM BUILDING BLOCKS IMPROVED HEALTH (LEVEL AND EQUITY) RESPONSIVENESS SOCIAL AND FINANCIAL RISK PROTECTION IMPROVED EFFICIENCY OVERALL GOALS/OUTCOMES ACCESS COVE",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 51
  },
  {
    "chunk_id": "abortioncare_233",
    "text": " and affordable SYSTEM BUILDING BLOCKS IMPROVED HEALTH (LEVEL AND EQUITY) RESPONSIVENESS SOCIAL AND FINANCIAL RISK PROTECTION IMPROVED EFFICIENCY OVERALL GOALS/OUTCOMES ACCESS COVERAGE QUALITY SAFETY Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 51
  },
  {
    "chunk_id": "abortioncare_234",
    "text": "Abortion care guideline, second edition 14 essential medicines and vaccines for all. The aim of this target is to accelerate efforts to ensure that all people and communities receive the full spectrum of essential, quality health services they need across the life course, without suffering financial hardship. To establish an enabling environment, there is a need for abortion care to be integrated into the health system across all levels (including primary, secondary and tertiary) – and supported in the community – to allow for expansion of health worker roles, including self-management approaches. Such integration is a complex process that can occur through service delivery, financing mechanisms and/or inclusion in health benefits packages. While inclusion in health benefits packages may enhance access to and delivery of abortion care, in many countries abortion care is not explicitly re",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 52
  },
  {
    "chunk_id": "abortioncare_235",
    "text": "n in health benefits packages. While inclusion in health benefits packages may enhance access to and delivery of abortion care, in many countries abortion care is not explicitly recognized in the standard package, contributing to inequitable access to services (78). From a health financing perspective, improving access to comprehensive abortion care, as part of UHC, requires shifting the burden of financing away from individuals towards domestic public funding, which combines tax revenue and prepayment schemes to cover the costs of care (78). Further information is provided in section 1.4.2 below. Meanwhile, from a service-delivery perspective, integrating abortion care within national maternal care and family planning programmes is technically the most straightforward option as abortion services require few, if any, additional provider skills, medicines, equipment or supplies. Furthermo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 52
  },
  {
    "chunk_id": "abortioncare_236",
    "text": "planning programmes is technically the most straightforward option as abortion services require few, if any, additional provider skills, medicines, equipment or supplies. Furthermore, it is the most efficient option, as it minimizes any additional/marginal costs of implementing abortion services. Health systems strengthening, by improving performance across all six health system building blocks (see above), is essential to progress towards UHC (77). The use of new and innovative technologies and approaches for providing, facilitating or supporting abortion services must be incorporated into country programmes and health benefits packages. WHO’s UHC Compendium provides a list of all interventions related to abortion care to be considered for inclusion within a country’s UHC package (79).3 To ensure both access to abortion and achievement of UHC, abortion must be centred within primary hea",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 52
  },
  {
    "chunk_id": "abortioncare_237",
    "text": "tion care to be considered for inclusion within a country’s UHC package (79).3 To ensure both access to abortion and achievement of UHC, abortion must be centred within primary health care (PHC), which itself is fully integrated within the health system, facilitating referral pathways for higher-level care when needed. PHC is a multisectoral, societal approach to health that aims to ensure the highest possible level of health and well-being for all individuals, by focusing on people’s needs and preferences (as individuals, families and communities) along the continuum of care from health promotion and disease prevention to treatment, rehabilitation and palliative care (30) . Quality PHC is evidence-informed, community-delivered and person- centred. Making abortion available and accessible within PHC is a safe and effective strategy to advance equitable access to, and provide an enabling ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 52
  },
  {
    "chunk_id": "abortioncare_238",
    "text": "mmunity-delivered and person- centred. Making abortion available and accessible within PHC is a safe and effective strategy to advance equitable access to, and provide an enabling environment for, abortion. 1.4.2 Health financing Health financing is a core function of health systems that can enable progress towards UHC by improving effective service coverage and financial protection. To improve effective service coverage, health financing arrangements for abortion services should ensure the production costs are met so that health-care providers have the means to carry out these activities without financial constraints. To improve financial protection, the health system must guarantee that the share of the costs – production costs and the costs of access to services – borne by patients is not a barrier to full use of services. WHO’s approach to health financing focuses on the following co",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 52
  },
  {
    "chunk_id": "abortioncare_239",
    "text": " – production costs and the costs of access to services – borne by patients is not a barrier to full use of services. WHO’s approach to health financing focuses on the following core functions: • raising revenue – establishing sources of funds, including government budgets, compulsory or voluntary prepaid insurance schemes, direct out-of-pocket payments by users, and external aid; • pooling funds – the accumulation of prepaid funds on behalf of some or all of the population; and • purchasing services – the payment or allocation of resources to health-care providers. In addition, all countries have policies indicating which services the population is entitled to, even if not explicitly stated by the government, and by extension any services not covered are usually paid for out of pocket by patients as user fees or co-payments. To provide an enabling environment, financing of abortion serv",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 52
  },
  {
    "chunk_id": "abortioncare_240",
    "text": "and by extension any services not covered are usually paid for out of pocket by patients as user fees or co-payments. To provide an enabling environment, financing of abortion services should take into account costs to the health system while ensuring that services are free or affordable and readily available to all who need them, in support of the goal of achieving UHC. A recent scoping review captured the costs to the health system and to the woman 3 Available by selecting “Sexual and reproductive health” at this link: https://www.who.int/universal-health-coverage/compendium/ interventions-by-programme-area or by searching the database at this link: https://www.who.int/universal-health-coverage/compendium/ database",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 52
  },
  {
    "chunk_id": "abortioncare_241",
    "text": "15 by categorizing the economic consequences of abortion and abortion policies through three levels: micro-, meso- and macroeconomic. Assessment of the micro-, meso- and macroeconomic levels provided insight into the documented economic consequences of abortions at the individual, community and health system levels (80-82) . Cost to the facility or health system In regard to costs to the health-care facility and health system, the findings of the review on the mesoeconomic outcomes confirmed that limited resources negatively affect facilities’ ability to meet demand and provide quality services (81). Furthermore, the costs of post-abortion care, including treatment of post-abortion complications, consume a disproportionate amount of facilities’ resources in many settings, posing a burden to health systems by further depleting their overstretched resources. Therefore, financial savings ca",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 53
  },
  {
    "chunk_id": "abortioncare_242",
    "text": "roportionate amount of facilities’ resources in many settings, posing a burden to health systems by further depleting their overstretched resources. Therefore, financial savings can be made by maintaining or even improving the quality of abortion care services, and also by decentralizing services and legalizing abortion, as indicated in the macroeconomic assessment (82). Providing access to quality abortion care is considerably less costly than treating the complications of unsafe abortion (83-87). Costs for providing abortion care with vacuum aspiration include infrequent, modest capital investments, such as purchase of a suction machine for electric vacuum aspiration (EVA) or manual vacuum aspiration (MVA) equipment, an examination table, a steam sterilizer or autoclave, and possibly also renovation of waiting, consultation and recovery rooms, and toilets. Recurrent costs for surgical ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 53
  },
  {
    "chunk_id": "abortioncare_243",
    "text": "uipment, an examination table, a steam sterilizer or autoclave, and possibly also renovation of waiting, consultation and recovery rooms, and toilets. Recurrent costs for surgical or medical abortion include those associated with purchasing instruments and supplies that will need to be restocked regularly, such as cannulae and MVA aspirators, antiseptic solutions and high-level disinfectants used for instrument processing, and medicines for pain management, infection prevention and medical abortion. Decisions about which abortion methods to offer and how to organize services directly influence the cost of providing services and their affordability. Two organizational issues are of particular importance for both increasing safety and reducing costs: (i) preferential use of either vacuum aspiration or medical abortion, and (ii) facilitating the provision of abortion (e.g. improved access t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 53
  },
  {
    "chunk_id": "abortioncare_244",
    "text": " increasing safety and reducing costs: (i) preferential use of either vacuum aspiration or medical abortion, and (ii) facilitating the provision of abortion (e.g. improved access to abortion services, integration into primary health care). Expanding the role of health workers in abortion provision and exploring innovative modes of service- delivery, such as telemedicine and hotlines, have also been identified as cost-saving strategies for national health systems (82). Making services affordable for women In countries where legal access to abortion is available, it remains a challenge to provide abortion services that are publicly funded and free at the point of care (88). Furthermore, in some settings, financial protection is restricted to specific demographic groups of individuals seeking abortion or certain legal categories of abortion. Abortion seekers may be charged substantial addit",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 53
  },
  {
    "chunk_id": "abortioncare_245",
    "text": "l protection is restricted to specific demographic groups of individuals seeking abortion or certain legal categories of abortion. Abortion seekers may be charged substantial additional fees (on top of the official charges), creating a barrier for many, especially when combined with travel expenses and opportunity costs, such as time lost from paid and unpaid work. In some settings, reimbursement rates for private or public providers working with nongovernmental organizations are well below the cost of providing care. The barrier of high costs of abortion medicines and/or services is likely to generate higher costs for the health system, since these costs force many – especially among the adolescent population (89) – to present at a later gestational age or to use unsafe providers or methods, thus increasing the rates of hospitalization for serious complications (80, 90-92). Higher rates",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 53
  },
  {
    "chunk_id": "abortioncare_246",
    "text": "(89) – to present at a later gestational age or to use unsafe providers or methods, thus increasing the rates of hospitalization for serious complications (80, 90-92). Higher rates of complications, additional fees and high costs all also contribute to the stigmatization of abortion. Respect, protection and fulfilment of the right to health requires States to guarantee, at a minimum, universal and equitable access to affordable, acceptable and quality SRH services, goods and facilities, in particular for women and disadvantaged and marginalized groups (3, para. 49). Thus, in order to provide an enabling environment for abortion care, ability to pay should not have any bearing on women’s ability to access legal abortion services (3 [para. 17], 35 [para. 31], 39 [Ch.1, para. 21]). As part of an enabling environment, considerations of gender equality, human rights and equity should guide th",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 53
  },
  {
    "chunk_id": "abortioncare_247",
    "text": "abortion services (3 [para. 17], 35 [para. 31], 39 [Ch.1, para. 21]). As part of an enabling environment, considerations of gender equality, human rights and equity should guide the design of health financing policy to reduce if not eliminate the financial barriers for the most vulnerable, and to ensure equitable access to good-quality services (93). The CEDAW Committee has described fees for abortion as being burdensome to women’s informed choice and autonomy (94, para. 37). Where user fees are charged for abortion, this should be based on careful consideration of ability to pay, and fee waivers should be available for those who are facing financial hardship and adolescent abortion seekers. It should be noted, however, that evidence on the success of fee waivers in addressing financial barriers and improving access to quality Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 53
  },
  {
    "chunk_id": "abortioncare_248",
    "text": "Abortion care guideline, second edition 16 abortion care is mixed and inconclusive (95). Numerous treaty monitoring bodies (see Annex 2) have recognized that abortion services must be economically accessible, recommending that States lower the cost of abortion or otherwise provide financial support when needed (96 [paras 37(b), 38(b)], 97 [para. 24], 98 [paras 38, 39]). Relatedly, the Committee against Torture (CAT) has called on States to ensure free access to abortion in cases of rape (99, para. 15a). With the above in mind, as far as possible, abortion services and supplies should be mandated for coverage under insurance plans as inability to pay is not an acceptable reason to deny or delay abortion care. Furthermore, having transparent procedures in all health-care facilities can ensure that informal charges are not imposed by staff. 1.4.3 Health workforce competencies and training H",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 54
  },
  {
    "chunk_id": "abortioncare_249",
    "text": "rthermore, having transparent procedures in all health-care facilities can ensure that informal charges are not imposed by staff. 1.4.3 Health workforce competencies and training Health workers are all people engaged in actions whose primary intent is to enhance health (100). The delivery of high-quality care requires an adequate supply of competent health workers, who are equitably distributed, and with an optimal skills mix at the facility, outreach and community levels (101). All health workers need to be adequately supported to provide competent care. The competencies required to provide or support abortion care align with competencies required in many different areas of health (102, 103). WHO is currently developing a global competency framework for universal health coverage (UHC), which identifies the required competencies for primary health care workers to provide the full spectru",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 54
  },
  {
    "chunk_id": "abortioncare_250",
    "text": "developing a global competency framework for universal health coverage (UHC), which identifies the required competencies for primary health care workers to provide the full spectrum of promotive, preventive, diagnostic, curative and palliative care (104, 105). Delivery of care and treatment services should be accomplished in a people-centred, non-judgemental and non- directive way, allowing individuals to lead the decision-making about their own care in an informed and supported fashion (106). As part of ensuring an enabling environment, it is particularly important that training for health workers involved with SRH services incorporates: • the unique competencies required for SRH services, in particular for abortion care; • provision of people-centred care; • human rights, and the content and meaning of the law, and how to interpret and apply law and policy in rights-compliant ways; • c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 54
  },
  {
    "chunk_id": "abortioncare_251",
    "text": "ortion care; • provision of people-centred care; • human rights, and the content and meaning of the law, and how to interpret and apply law and policy in rights-compliant ways; • communication to enable informed decision-making; • values clarification; • interprofessional teamworking; and • empathetic and compassionate approaches to care (105). These skills should be included in training programmes and promoted by professional societies. It is especially critical that the attitudes and behaviours of health workers be inclusive, non-judgemental and non-stigmatizing, and that they promote safety and equality. Managers of health care – whether in the public or private sector – are responsible for delivering services appropriately and meeting standards based on professional ethics and internationally agreed human rights principles. 1.4.4 Commodities Provision of primary health care includes ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 54
  },
  {
    "chunk_id": "abortioncare_252",
    "text": "es appropriately and meeting standards based on professional ethics and internationally agreed human rights principles. 1.4.4 Commodities Provision of primary health care includes access to safe, effective, quality-assured and affordable medicines, including medicines for abortion and post-abortion care (i.e. antibiotics and pain control medicines as well as abortion medicines and post-abortion contraceptives). The WHO Model List of Essential Medicines (also known as the Essential Medicines List, or EML) includes the minimum medicines needed for a basic health-care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected based on current and estimated future public health relevance, and potential for safe and cost-effective treatment. Both mifepristone and misoprostol have been included in the WHO Model Lists of Ess",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 54
  },
  {
    "chunk_id": "abortioncare_253",
    "text": "nd estimated future public health relevance, and potential for safe and cost-effective treatment. Both mifepristone and misoprostol have been included in the WHO Model Lists of Essential Medicines since 2005. In 2019, these medicines were moved from the complementary to the core list of essential medicines in the 21st EML and the requirement for “close medical supervision” for their use was removed (107). The relevant abortion medicines included in the 21st EML and also the more recent 22nd EML are indicated in Table 1.1.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 54
  },
  {
    "chunk_id": "abortioncare_254",
    "text": "17 Table 1.1 Medicines included in the WHO Model List of Essential Medicines (EML) and their indications Indication included in EML Medicines included in the EML Induced abortion • Mifepristone (200 mg) and misoprostol (200 μg) • The medicines are available individually or co-packaged. • The EML specifically mentions the following co-packaged formulation: 1 tablet mifepristone (200 mg) + 4 tablets misoprostol (200 μg). Management of incomplete abortion and miscarriage • Misoprostol (200 μg) Source: WHO EML – 21st list, 2019 (107) , 22nd list, 2021 (108) . Within a country, the key elements of a commodity strategy include policy, regulation, procurement and supply chain, as well as links to financing and reimbursement systems (109) . Mifepristone and misoprostol should be listed in relevant national EMLs (NEMLs) or their equivalent, and should be included in the relevant clinical care/ser",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_255",
    "text": "sement systems (109) . Mifepristone and misoprostol should be listed in relevant national EMLs (NEMLs) or their equivalent, and should be included in the relevant clinical care/service delivery guidelines. In the case of pregnancy tests and MVA equipment, countries may have an Essential Medical Devices List or a similar list for medical devices. Pregnancy tests and quality MVA devices should be included on these lists as part of a commodity strategy. Inclusion in the NEML is one important component of ensuring that quality medicines are available. Misoprostol, mifepristone, surgical abortion equipment and other relevant health products should be included in national procurement tenders as well as in supply chain monitoring activities. Procurement activities should include forecasting methods that are appropriate to the products and to the country context with a goal of ensuring continuou",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_256",
    "text": "n monitoring activities. Procurement activities should include forecasting methods that are appropriate to the products and to the country context with a goal of ensuring continuous supply (110). Central Medical Stores (CMS) entities should ensure that specifications for the procurement of safe abortion medicines are coordinated with national medicines regulatory authorities (NMRAs) and that they clearly specify quality assurance standards and all other requirements, such as strength, packaging and shelf life. WHO recommends that the highest level of quality assurance be pursued but recognizes that risk-based approaches may be needed in countries where access to international markets is limited. Risk-based approaches will depend on the context of a given country but may include exceptions based on prior information about a manufacturer, or reliance on information from other regulators (1",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_257",
    "text": "oaches will depend on the context of a given country but may include exceptions based on prior information about a manufacturer, or reliance on information from other regulators (111) . Quality-assured medicines include those approved by stringent regulatory authorities (SRAs) (112) 4 or listed through WHO Prequalification (PQ). 5 Where such medicines are not available, approval by an NMRA that includes inspection and testing according to accepted standards should be undertaken for mifepristone and misoprostol. 6 NMRAs are the bodies that provide registration and market authorization for specific products. The NMRA reviews the safety, efficacy and quality of medicines as part of granting market authorization. Such authorization is specific to each medicine made in a particular location by a particular manufacturer. Market authorizations are granted based on an evaluation of a technical d",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_258",
    "text": "uch authorization is specific to each medicine made in a particular location by a particular manufacturer. Market authorizations are granted based on an evaluation of a technical dossier presented by the manufacturer, or their agent, confirming the efficacy, quality and safety of the product. Through prequalification, WHO supports a regulatory reliance mechanism where it provides detailed assessment information to NMRAs on products that have been prequalified by WHO, so that the regulatory decision can be made based on WHO’s assessment rather than having to duplicate it. Based on the same principle, WHO also supports the sharing of assessment information for SRA-approved products. These processes are both known as WHO Collaborative Registration Procedures (CRPs). 7 Regulators make determinations regarding the authority to prescribe and dispense medicines. There are examples, including em",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_259",
    "text": " as WHO Collaborative Registration Procedures (CRPs). 7 Regulators make determinations regarding the authority to prescribe and dispense medicines. There are examples, including emergency contraception, where regulators have made decisions to change the prescribing authority to improve access and appropriate use, including “over the counter” sales or prescription by a pharmacist without physician consultation. The information that is typically considered includes whether a condition can be reasonably self-diagnosed, the overall safety of the medicine, and the likelihood of misuse or complications with 4 SRAs are listed at this web page: https://www.who.int/initiatives/who-listed-authority-reg-authorities/SRAs. In the cited reference (pp. 34–35), SRAs are defined as “a regulatory authority which is a member or an observer of ICH [International Council for Harmonisation of Technical Requir",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_260",
    "text": "In the cited reference (pp. 34–35), SRAs are defined as “a regulatory authority which is a member or an observer of ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use], or is associated with an ICH member through a legally-binding mutual recognition agreement” (as before 23 October 2015). 5 WHO Prequalification is one standard for all types of products, including medicines (pharmaceuticals and biotherapeutics), vaccines and immunization devices, in vitro diagnostics and vector control products. This listing implies a recommendation but not market authorization. 6 For further information, refer to The International Pharmacopoeia, available at: https://digicollections.net/phint/2020/index.html#p/home 7 For further information, see: https://extranet.who.int/pqweb/medicines/collaborative-procedure-accelerated-registration Chapter 1. Intro",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_261",
    "text": "lections.net/phint/2020/index.html#p/home 7 For further information, see: https://extranet.who.int/pqweb/medicines/collaborative-procedure-accelerated-registration Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 55
  },
  {
    "chunk_id": "abortioncare_262",
    "text": "Abortion care guideline, second edition 18 less supervised or unsupervised use of the medicine, among others (113, 114) . National programmes should work with regulators to determine the most appropriate evidence-based prescribing and dispensing authorities for the medicines. Restrictions on prescribing authority for some categories of health workers may need to be modified or other mechanisms put in place to make the medicines available for these health workers within the regulatory framework of the health system. A comprehensive commodity strategy and effective approach to access will require: inclusion of the necessary commodities in the NEML; approval from the NMRA (i.e. market authorization or registration); development of mechanisms for forecasting, procurement, distribution and guidance on prescribing and dispensing; and a plan for post-marketing surveillance. 1.4.5 Monitoring and",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 56
  },
  {
    "chunk_id": "abortioncare_263",
    "text": "); development of mechanisms for forecasting, procurement, distribution and guidance on prescribing and dispensing; and a plan for post-marketing surveillance. 1.4.5 Monitoring and evaluation of quality abortion care Effective monitoring and evaluation (M&E) are essential for measuring abortion quality and trends, as a basis for policy dialogue and evidence-based decision-making to further improve service delivery and quality. To support national scale M&E of the quality of abortion care, WHO is developing a quality abortion care M&E framework based on WHO’s Monitoring and evaluation of health systems strengthening: an operational framework (115). The structure, domains and indicator areas of the framework, categories for inequality disaggregation and standard data sources are presented in Table 1.2. A set of abortion care indicators is under development and will be published in the near",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 56
  },
  {
    "chunk_id": "abortioncare_264",
    "text": "egories for inequality disaggregation and standard data sources are presented in Table 1.2. A set of abortion care indicators is under development and will be published in the near future (see Annex 6 for a summary about the progress of this M&E work). The quality abortion care M&E framework will support M&E at the levels of health system input, service delivery, population outcome and impact. M&E of abortion-related services remains weak in most national health systems. Specific gaps in data collection and use must be identified and addressed. Health system input monitoring covers governance, health financing, health workforce, health commodities and health information. Within these five categories, quality abortion care health system inputs to track over time include among others: • Governance: clarification of the legal status of abortion, adherence of induced abortion protocols in na",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 56
  },
  {
    "chunk_id": "abortioncare_265",
    "text": "ortion care health system inputs to track over time include among others: • Governance: clarification of the legal status of abortion, adherence of induced abortion protocols in national guidelines to global normative guidance (see also section 1.3.1[vii]); • Financing: inclusion of health financing arrangements for abortion-related care in leading health benefits packages (see section 1.4.2); • Health workforce: inclusion of competency-based induced abortion care (in line with global normative guidance) in national curricula for relevant categories of health workers (see section 1.4.3); • Health commodities: inclusion in national essential medicines lists (NEMLs) of mifepristone and misoprostol, monitoring of stock-outs of abortion service commodities at service-delivery points (see section 1.4.4); • Health management information systems (HMIS): integration of indicators for quality abo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 56
  },
  {
    "chunk_id": "abortioncare_266",
    "text": "stock-outs of abortion service commodities at service-delivery points (see section 1.4.4); • Health management information systems (HMIS): integration of indicators for quality abortion care into the national HMIS. For this level of input monitoring, data are typically available from administrative sources, including national policy documents, health finance tracking systems, national curricula, logistics management information systems (LMIS) and HMIS. Service-delivery monitoring tracks the availability of providers trained in and providing induced abortion care, availability of necessary medicines and products at service-delivery points, readiness of the system to provide abortion care to a defined minimum standard, and quality of service delivery, including person-centred care, assessed in part through user and community perspectives. National-level abortion service-delivery monitoring",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 56
  },
  {
    "chunk_id": "abortioncare_267",
    "text": "ndard, and quality of service delivery, including person-centred care, assessed in part through user and community perspectives. National-level abortion service-delivery monitoring data should be included in health-care facility-level assessments, HMIS and population-based surveys. Population outcome monitoring for abortion care assesses coverage including (i) access to quality, affordable abortion care, and (ii) population knowledge of access to quality, affordable abortion care. Efforts should be made to disaggregate data by dimensions of inequality, such as ability, age, caste, education, ethnicity, gender, geography and wealth. Population outcome data sources typically include health-care facility-level assessments and population-based surveys and can include HMIS and education management information systems. In many settings, abortion-related population outcome data is a neglected a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 56
  },
  {
    "chunk_id": "abortioncare_268",
    "text": "essments and population-based surveys and can include HMIS and education management information systems. In many settings, abortion-related population outcome data is a neglected area of data collection and reporting.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 56
  },
  {
    "chunk_id": "abortioncare_269",
    "text": "19 Impact measurement for quality abortion care includes abortion-related mortality and morbidity. Estimates in these areas should be disaggregated by dimensions of inequality as much as possible. Data sources include population-based surveys, HMIS and civil registration and vital statistics (CRVS) registries. Where gaps in data availability are identified, investment should be made to address these. In the short term, statistical modelling may be required to estimate indicator values, particularly at the impact level. Table 1.2 Monitoring and evaluation of the quality of abortion care Categories Indicator areas Inequality disaggregation Data sources Health system input Governance Geography: intranational, international Administrative sources (including national policy documents, health finance tracking systems, national curricula, LMIS and HMIS)Health financing Health workforce Health c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 57
  },
  {
    "chunk_id": "abortioncare_270",
    "text": "rnational Administrative sources (including national policy documents, health finance tracking systems, national curricula, LMIS and HMIS)Health financing Health workforce Health commodities Health information Service delivery Availability of services Geography: intranational, international Health-care facility assessment (including patient interviews), population-based survey, HMISReadiness for service delivery Quality of services Population outcome Access to quality, affordable abortion care Ability, age, caste, education, ethnicity, gender, geography, wealth Health-care facility assessment, population-based survey, HMIS, education management information systemsPopulation knowledge of access to quality, affordable abortion care Impact Abortion-related mortality Ability, age, caste, education, ethnicity, gender, geography, wealth CRVS, HMIS, population-based survey Abortion-related morb",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 57
  },
  {
    "chunk_id": "abortioncare_271",
    "text": "dable abortion care Impact Abortion-related mortality Ability, age, caste, education, ethnicity, gender, geography, wealth CRVS, HMIS, population-based survey Abortion-related morbidity CRVS: civil registration and vital statistics; HMIS: health management information system; LMIS: logistics management information system Chapter 1. Introduction",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 57
  },
  {
    "chunk_id": "abortioncare_272",
    "text": "21 Chapter 2. Abortion regulation including relevant recommendations As outlined in Chapter 1, section 1.3, one element of an enabling environment is that law and policy promote and protect sexual and reproductive health and rights (SRHR). A number of common approaches to law and policy on abortion mentioned in Chapter 1 (section 1.3.1) pose barriers to access to abortion, are inconsistent with international human rights legal instruments, and can have negative effects on the exercise of human rights. This chapter reflects evidence on the impacts of these law and policy approaches, considers their human rights implications, and presents evidence-based recommendations to improve law and policy relating to abortion as part of an enabling environment for universal access to quality abortion care. Box 2.1 summarizes the principles of abortion law and policy that would be consistent with key ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 59
  },
  {
    "chunk_id": "abortioncare_273",
    "text": "on as part of an enabling environment for universal access to quality abortion care. Box 2.1 summarizes the principles of abortion law and policy that would be consistent with key principles of human rights law. BOX 2.1: Abortion law and policy that are consistent with key principles of human rights law States must respect, protect and fulfil abortion seekers’ rights, including their sexual and reproductive health and rights (SRHR). States should take positive steps to secure an enabling regulatory and policy environment that will ensure the universal availability, accessibility, acceptability and quality (AAAQ) of abortion and post-abortion care. Abortion should be fully decriminalized. Regulatory, policy and programmatic barriers – as well as barriers in practice – that hinder access to and timely provision of quality abortion care should be removed. These include grounds-based approac",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 59
  },
  {
    "chunk_id": "abortioncare_274",
    "text": "programmatic barriers – as well as barriers in practice – that hinder access to and timely provision of quality abortion care should be removed. These include grounds-based approaches, gestational age limits, mandatory waiting periods, third-party authorization requirements and provider restrictions. States should also protect access to and continuity of abortion care against barriers created by conscientious objection (refer to Recommendations 1,2,3,6,7,21 and 22 in this guidance). The regulation of abortion should have the objective of respecting, protecting and fulfilling the SRHR of women; achieving positive health outcomes for women; providing good-quality contraceptive information and services; and meeting the particular needs of marginalized persons, including women facing financial hardship, adolescents, women with disabilities, survivors of sexual and gender-based violence, tran",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 59
  },
  {
    "chunk_id": "abortioncare_275",
    "text": "g the particular needs of marginalized persons, including women facing financial hardship, adolescents, women with disabilities, survivors of sexual and gender-based violence, transgender and non-binary persons, women from ethnic, religious and racial minorities, migrant and displaced women, and women living with HIV, among others. The regulation of abortion should be grounded on and should promote equality and non- discrimination. Source: Refer to Box 1.2 for references. Chapter 2. Abortion regulation including relevant recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 59
  },
  {
    "chunk_id": "abortioncare_276",
    "text": "Abortion care guideline, second edition 22 2.1 Common approaches to abortion regulation Almost all countries where abortion is lawfully available regulate abortion differently to other forms of health care (116). Unlike other essential health services, abortion is commonly regulated to varying degrees through the criminal law in addition to regulation under health-care law. Even where abortion is available on certain grounds or until specified gestational ages (often linked to particular grounds), it is usually designated in those cases as a criminal offence if it occurs outside of those specific permitted situations. As a result, people can experience significant barriers in accessing abortion and post-abortion care in such contexts. These barriers persist even though abortion is a safe, effective and non-complex part of sexual and reproductive health (SRH) care, in spite of significant",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_277",
    "text": "n care in such contexts. These barriers persist even though abortion is a safe, effective and non-complex part of sexual and reproductive health (SRH) care, in spite of significant advancements in international human rights law, and notwithstanding the growing frequency with which self-management of abortion occurs safely with little or no contact with the formal health system. Typical barriers to access to quality abortion care, which may or may not be codified in law, include lack of access to accurate information, the provision of biased information or counselling, the imposition of mandatory waiting periods, third-party authorization requirements, restrictions on the type of facilities or settings where abortion services can lawfully be provided, restrictions on the type of health workers that can lawfully provide services, lack of affordable services, breaches of confidentiality and",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_278",
    "text": "rtion services can lawfully be provided, restrictions on the type of health workers that can lawfully provide services, lack of affordable services, breaches of confidentiality and privacy, failure to safeguard access to and continuity of care where health workers refuse care on the basis of conscientious objection, failure to license or make available essential medicines, and failure to recognize women as individuals who can manage their own abortions. Restrictive laws, policies and practices often have the effect of making health workers, health-care facilities, committees, ethics boards, police, courts or others the “gatekeepers” for access to quality abortion care by requiring them to determine whether someone “qualifies” for legal abortion. In many cases, this introduces delay in accessing abortion. Such gatekeepers are not always sufficiently informed about the law or willing to in",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_279",
    "text": "one “qualifies” for legal abortion. In many cases, this introduces delay in accessing abortion. Such gatekeepers are not always sufficiently informed about the law or willing to interpret and apply law and policy in a way that respects, protects and fulfils abortion seekers’ rights. Criminalization of abortion can also have a “chilling effect” more broadly, as it can result in narrow interpretation of applicable law by health workers, including to avoid possible criminal liability (i.e. suppression of actions due to fear of reprisals or penalties). As a consequence, in many settings women’s experiences of seeking, accessing and managing abortion are highly variable, with much depending not only on the law but also on the approach of the gatekeeper with whom they interact. Thus, including information on relevant rights, laws and policies in the training and education of health workers is ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_280",
    "text": "lso on the approach of the gatekeeper with whom they interact. Thus, including information on relevant rights, laws and policies in the training and education of health workers is a crucial part of ensuring an enabling environment for quality abortion care (see also Chapter 1, section 1.4.3). As described above, clear, accessible and rights-based laws and policies are part of an enabling environment for abortion care (see section 1.3). However, in some countries the law on abortion is incoherent, with seemingly conflicting provisions articulated in constitutions, penal codes, health legislation or policy guidance (117) . Furthermore, in some cases domestic laws are inconsistent with international human rights standards and incompatible with current public health evidence. Additionally, in certain cases there is a lack of guidance from government to assist providers in identifying when ab",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_281",
    "text": "tandards and incompatible with current public health evidence. Additionally, in certain cases there is a lack of guidance from government to assist providers in identifying when abortion is lawful. Such incoherence can create uncertainty about the law for both those seeking and providing abortion care. The recommendations in this guideline build on human rights law and public health evidence to outline an approach under which abortion is regulated similarly to other health-care interventions, that is, by general health-care law and policy, best practice, training and evidence-based guidelines. 2.2 Recommendations relating to regulation of abortion Three recommendations relating specifically to the regulation of abortion are presented in this section (Recommendations 1–3) and four additional recommendations, also relating to law and policy and abortion, are presented in Chapter 3, section",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_282",
    "text": " abortion are presented in this section (Recommendations 1–3) and four additional recommendations, also relating to law and policy and abortion, are presented in Chapter 3, section 3.3: Pre-abortion (Recommendations 6,7,21 and 22). These seven recommendations were formulated by the expert panels formed for the development of this guideline, including expert human rights advisers (all contributors are listed in Annex 1 and the roles of the contributing groups are described in Annex 4).8 The evidence was first systematically reviewed for each prioritized topic and question, and 8 The expert panels included the Evidence and Recommendations Review Groups (ERRGs) for each of the three domains (Law and policy, Clinical services and Service delivery) and later the Guideline Development Group (GDG), and each phase and each meeting of these groups also involved at least one human rights adviser. ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_283",
    "text": "al services and Service delivery) and later the Guideline Development Group (GDG), and each phase and each meeting of these groups also involved at least one human rights adviser. For further details on the roles of these groups and the full methodology for the guideline development process, see Annex 4: Methods.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 60
  },
  {
    "chunk_id": "abortioncare_284",
    "text": "23 the level of certainty of that evidence was assessed (i.e. based on the quality of the evidence, including the types and sizes of studies conducted and their various limitations). The direction (in favour or against) and strength of each recommendation was determined by the panel of experts based on the six substantive criteria of the WHO-INTEGRATE framework as applied to each intervention for the specified population – balance of health benefits and harms; human rights and sociocultural acceptability; health equity, non-discrimination and equality; societal implications; financial and economic considerations; feasibility and health system considerations – while also taking into account the meta-criterion: quality of evidence (118) . Recommendations in favour of an intervention are qualified as either strong or weak (with the conditions of use specified for the latter), with the third",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 61
  },
  {
    "chunk_id": "abortioncare_285",
    "text": "uality of evidence (118) . Recommendations in favour of an intervention are qualified as either strong or weak (with the conditions of use specified for the latter), with the third alternative being a recommendation against the intervention. To clearly indicate the strength and direction of each recommendation, the following wording is used: • Recommend – a strong recommendation in favour of the intervention • Suggest – a weak recommendation in favour of the intervention (requiring additional wording to qualify the recommendation, specifying the conditions of use) • Recommend against – a strong recommendation against the intervention/in favour of the comparison. For each topic covered, both in this chapter and also in Chapter 3, first brief background information is presented, then the recommendation itself, followed next by a list of remarks (if any) from the expert panel that reviewed ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 61
  },
  {
    "chunk_id": "abortioncare_286",
    "text": "also in Chapter 3, first brief background information is presented, then the recommendation itself, followed next by a list of remarks (if any) from the expert panel that reviewed the evidence in detail, explaining the conditions and context relevant to the recommendation, and then the rationale, or summary of the evidence base and decision-making process for the recommendation, and finally a box listing any key human rights considerations relevant to the recommendation or broader topic. It should be noted that the 2012 Safe abortion guidance provided a composite recommendation related to law and policy; in this guideline, this has been developed into seven separate recommendations using GRADE methodology, but they are not considered to be “new” (i.e. Recommendations 1,2,3,6,7,21,22). The methods are described in full in Annex 4, including the differences in the methods applied for the s",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 61
  },
  {
    "chunk_id": "abortioncare_287",
    "text": "they are not considered to be “new” (i.e. Recommendations 1,2,3,6,7,21,22). The methods are described in full in Annex 4, including the differences in the methods applied for the seven recommendations relating to law and policy issues compared with the other types of recommendations. A summary table linking the topics covered, the research questions, the systematic reviews conducted and the recommendation numbers is provided in Annex 7. The full Evidence-to-Decision (EtD) frameworks are provided online as supplementary material and hyperlinked cross- references to these are supplied with the rationale for new and updated recommendation presented. 9 9 Supplementary material 1: EtD frameworks for law and policy topics, available at: https://www.who.int/publications/i/item/9789240039483. Chapter 2. Abortion regulation including relevant recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 61
  },
  {
    "chunk_id": "abortioncare_288",
    "text": "Abortion care guideline, second edition 24 2.2.1 Criminalization of abortion Unlike other health services, abortion is commonly regulated to varying degrees through the criminal law (i.e. criminalized), in addition to regulation under health-care law. Abortion remains a criminal offence in most countries, with penalties against those who have abortions and/or those who provide abortion services or assist with accessing or managing abortion, sometimes including those who provide information about abortion. In some countries, all of these actions are criminal offences. Decriminalization is a necessary step for the legalization of abortion, but ensuring that abortion is available, accessible and of high quality may require further legal or regulatory changes beyond decriminalization, including, as applicable, implementing the other recommendations contained in this guideline. LAW & POLICY R",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 62
  },
  {
    "chunk_id": "abortioncare_289",
    "text": "y require further legal or regulatory changes beyond decriminalization, including, as applicable, implementing the other recommendations contained in this guideline. LAW & POLICY Recommendation 1: Criminalization Recommend the full decriminalization of abortion. Remarks: • Decriminalization means removing abortion from all penal/criminal laws, not applying other criminal offences (e.g. murder, manslaughter) to abortion, and ensuring there are no criminal penalties for having, assisting with, providing information about, or providing abortion, for all relevant actors. • Decriminalization would ensure that anyone who has experienced pregnancy loss does not come under suspicion of illegal abortion when they seek care. • Decriminalization of abortion does not make women, girls or other pregnant persons vulnerable to forced or coerced abortion. Forced or coerced abortion would constitute seri",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 62
  },
  {
    "chunk_id": "abortioncare_290",
    "text": "are. • Decriminalization of abortion does not make women, girls or other pregnant persons vulnerable to forced or coerced abortion. Forced or coerced abortion would constitute serious assault as these are non- consensual interventions. Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. Rationale Numerous human rights bodies and mandate holders, including the CEDAW Committee (38) , the CESCR (3), the United Nations Human Rights Committee (36) , and the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health (37) , support the full decriminalization of abo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 62
  },
  {
    "chunk_id": "abortioncare_291",
    "text": "d the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health (37) , support the full decriminalization of abortion. They have clarified that States should not criminalize medical procedures needed only by women, including abortion nor criminalize those who have undergone an abortion, or punish or apply criminal sanctions against those who assist women in having abortions. Under international human rights law, States must not require health workers to report cases of women or girls who have had abortions, or whom they suspect of having had abortions, and States must provide post-abortion care in all circumstances and without the risk of criminal sanction. In addition, States must take steps, including revising laws, to reduce maternal morbidity and mortality (including abortion-related morbidity and mortality), and to ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 62
  },
  {
    "chunk_id": "abortioncare_292",
    "text": "nal sanction. In addition, States must take steps, including revising laws, to reduce maternal morbidity and mortality (including abortion-related morbidity and mortality), and to effectively protect women and girls from the physical and mental risks associated with resorting to unsafe abortion due to the criminalization of abortion (see also Chapter 1, section 1.3.1 on human rights, and Web annex A: Key international human rights standards on abortion, which provides further information as well as references for the above assertions). In order to identify the impacts of criminalization of abortion on abortion seekers and health workers, a systematic review of studies published between 2010 and 2019 was undertaken, identifying 22 studies conducted in Australia, Brazil, Chile, El Salvador, Ethiopia, Ireland, Mexico, Northern Ireland (United Kingdom), the Philippines, Rwanda, Senegal, the ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 62
  },
  {
    "chunk_id": "abortioncare_293",
    "text": "ken, identifying 22 studies conducted in Australia, Brazil, Chile, El Salvador, Ethiopia, Ireland, Mexico, Northern Ireland (United Kingdom), the Philippines, Rwanda, Senegal, the United Republic of Tanzania, Uruguay and Zambia. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Criminalization. The evidence from these studies demonstrated that criminalization delayed access to abortion, including in some cases causing providers to wait until a woman’s life was in danger so that abortion could be provided within the legal exceptions to criminal prohibitions. Furthermore, criminalization imposes a range of burdens on women including unnecessary travel and cost, delayed or no access to post-abortion care, distress and stigma. The evidence indicated that criminalization did not impact the decision to have an abortion, prevent women havin",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 62
  },
  {
    "chunk_id": "abortioncare_294",
    "text": "t, delayed or no access to post-abortion care, distress and stigma. The evidence indicated that criminalization did not impact the decision to have an abortion, prevent women having abortions, or prevent women from seeking information on and referral to services abroad where they can access abortion. Instead, criminalization limits",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 62
  },
  {
    "chunk_id": "abortioncare_295",
    "text": "25 access to safe and legal abortion, and increases recourse to unlawful and unsafe abortion. When prosecutions take place they may be disproportionately pursued against young, unmarried women and those facing financial hardship and with less access to education. Some countries require health workers to report women and girls when they seek abortion or post-abortion care. Criminalization can cause health workers to act cautiously, fearing criminal prosecution. As a result, they may be hesitant to provide abortion care even in cases of rape, incest and fatal fetal impairment, when denial of abortion could constitute torture, cruel and inhuman treatment or punishment. Criminalization contributes to the lower availability of trained abortion providers and a loss of relevant skills in the health workforce. This can have negative effects on health workers who do provide abortion, and can incr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 63
  },
  {
    "chunk_id": "abortioncare_296",
    "text": "lability of trained abortion providers and a loss of relevant skills in the health workforce. This can have negative effects on health workers who do provide abortion, and can increase bureaucracy within health systems. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO CRIMINALIZATION OF ABORTION • Availability, accessibility, acceptability and quality must be central to the regulation of sexual and reproductive health (SRH) services. • Seeking, having, assisting with, or providing abortion to which the pregnant person has provided free and informed consent should never be criminalized. • States must not require health workers to report cases of women or girls who have had abortions, or whom they suspect of having had abortions. • Post-abortion care must always be available without the risk of criminal sanction. • Seeking or providing accurate, evidence-based and non-biased information on abor",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 63
  },
  {
    "chunk_id": "abortioncare_297",
    "text": "d abortions. • Post-abortion care must always be available without the risk of criminal sanction. • Seeking or providing accurate, evidence-based and non-biased information on abortion must never be criminalized. • States must take steps, including revising laws, to reduce maternal morbidity and mortality, and to effectively protect women and girls from the physical and mental risks associated with resorting to unsafe abortion. • Everyone has a right to non-discrimination and equality in accessing SRH services. • SRH services must be provided in a way that ensures privacy and confidentiality. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Chapter 2. Abortion regulation including relevant recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 63
  },
  {
    "chunk_id": "abortioncare_298",
    "text": "Abortion care guideline, second edition 26 2.2.2 Grounds-based approaches to controlling access to abortion National laws in most countries permit some abortions, even in settings where abortion is criminalized. Usually abortions will still be permitted under prescribed “grounds”, or specific circumstances. The circumstances under which abortion is permitted vary widely across different countries. Some of these circumstances reflect clinical indications (e.g. risk to the health of the pregnant woman or fetal impairment), some relate to the circumstances of conception (e.g. rape), and some relate to socioeconomic circumstances (e.g. economic hardship). Grounds- based approaches are commonly accompanied by gestational age limits, often varying depending on the specific condition under which abortion is permitted. In some countries, abortion is available on request up to a specified gestati",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 64
  },
  {
    "chunk_id": "abortioncare_299",
    "text": "ional age limits, often varying depending on the specific condition under which abortion is permitted. In some countries, abortion is available on request up to a specified gestational age and then limited to specific grounds thereafter. LAW & POLICY Recommendation 2: Grounds-based approaches a. Recommend against laws and other regulations that restrict abortion by grounds. b. Recommend that abortion be available on the request of the woman, girl or other pregnant person. Remarks: • Grounds-based approaches to restricting access to abortion should be revised in favour of making abortion available on the request of the woman, girl or other pregnant person. • Until they are replaced with abortion on request, any existing grounds should be formulated and applied in a manner consistent with international human rights law. This means that the content, interpretation and application of grounds",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 64
  },
  {
    "chunk_id": "abortioncare_300",
    "text": "existing grounds should be formulated and applied in a manner consistent with international human rights law. This means that the content, interpretation and application of grounds-based law and policy should be revised to ensure human rights compliance. This requires that: i. existing grounds are defined, interpreted and applied in a human rights-compliant way; ii. abortion is available when carrying a pregnancy to term would cause the woman, girl or other pregnant person substantial pain or suffering, including but not limited to situations where the pregnancy is the result of rape or incest or the pregnancy is not viable; iii. abortion is available where the life and health of the woman, girl or other pregnant person is at risk; iv. health grounds reflect WHO’s definitions of health and mental health (see Glossary); and v. there are no procedural requirements to “prove” or “establish”",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 64
  },
  {
    "chunk_id": "abortioncare_301",
    "text": "nt person is at risk; iv. health grounds reflect WHO’s definitions of health and mental health (see Glossary); and v. there are no procedural requirements to “prove” or “establish” satisfaction of grounds, such as requiring judicial orders or police reports in cases of rape or sexual assault (for sources to support this information, refer to Web annex A: Key international human rights standards on abortion). Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. Rationale International human rights law requires that abortion be available where carrying a pregnancy to term would cause a woman substantial pain or suffering, or w",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 64
  },
  {
    "chunk_id": "abortioncare_302",
    "text": "methodology. Rationale International human rights law requires that abortion be available where carrying a pregnancy to term would cause a woman substantial pain or suffering, or where her life or health is at risk. States may not regulate abortion in a manner that forces women to resort to unsafe abortion and must take steps, including revising laws, to reduce maternal morbidity and mortality, and to effectively protect women and girls from the physical and mental risks associated with unsafe abortion (for further information, please refer to Chapter 1, section 1.3.1[i] and Web annex A: Key international human rights standards on abortion). Grounds-based approaches are often (i) too narrowly defined or (ii) too conservatively applied to ensure abortion is available in these circumstances. The aim to reduce maternal morbidity and mortality, and protect women and girls from the risks asso",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 64
  },
  {
    "chunk_id": "abortioncare_303",
    "text": "o conservatively applied to ensure abortion is available in these circumstances. The aim to reduce maternal morbidity and mortality, and protect women and girls from the risks associated with unsafe abortion, can be effectively achieved by making abortion available on the request of the pregnant woman or girl. In order to identify the impacts of grounds-based approaches on abortion seekers and health workers, a systematic review of studies published between 2010 and 2021 was undertaken, identifying 21 studies conducted in Argentina, Australia, Brazil, Chile, Colombia, Ethiopia, Ghana, the Islamic Republic of Iran, Ireland, Israel, Mexico, Rwanda, Thailand, the United Republic of Tanzania, the United Kingdom of Great Britain and Northern Ireland, Uruguay and Zambia. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Grounds-based appro",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 64
  },
  {
    "chunk_id": "abortioncare_304",
    "text": "Great Britain and Northern Ireland, Uruguay and Zambia. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Grounds-based approaches. The reviewed evidence showed that grounds-based laws contributed to delayed abortion, with delays occurring because of inconsistencies in interpretation or application of health grounds, women waiting for determination of their eligibility for abortion or having their claim that pregnancy resulted from rape",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 64
  },
  {
    "chunk_id": "abortioncare_305",
    "text": "27 questioned or disbelieved, overly restrictive interpretation of grounds, or disagreement within a medical team about whether a woman satisfies a legal ground. Misinterpretation of the law can also result in denial of abortion. In some cases, health workers waited for a health condition to deteriorate sufficiently to ensure that a woman satisfied a “risk to life” ground, clearly endangering the right to life and potentially violating the right to be free from torture, cruel, inhuman and degrading treatment. Interpretation of grounds, and thus eligibility for lawful abortion, varies between providers, and providers are not always certain about the law or how it should be applied; interpretation is often narrow and incompatible with human rights law and/or with WHO’s definitions of health and mental health, leading to denial of abortion. Women reported significant challenges in accessing",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 65
  },
  {
    "chunk_id": "abortioncare_306",
    "text": " and incompatible with human rights law and/or with WHO’s definitions of health and mental health, leading to denial of abortion. Women reported significant challenges in accessing care in circumstances where they could not obtain legal support and advice on the permitted grounds. Grounds-based approaches were found to have a particularly negative impact on women facing financial hardship and women with lower educational attainment. The evidence reviewed for this guidance showed that grounds-based approaches have a disproportionate negative impact on women who seek abortion following rape. These women were often subjected to questioning, protracted delay and bureaucratic processes due to requirements such as reporting the crime to the police or need for a court order, even though it is not human rights compliant to make such reporting or processes a prerequisite for accessing abortion. E",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 65
  },
  {
    "chunk_id": "abortioncare_307",
    "text": "porting the crime to the police or need for a court order, even though it is not human rights compliant to make such reporting or processes a prerequisite for accessing abortion. Even where the law provides that a woman’s claim of rape is sufficient to satisfy the legal requirement, providers may require a document or authorization (e.g. court order or police report). In reality this means that obtaining an abortion following rape is laborious and time-consuming. In some cases, delays are so long that women give birth before legal eligibility is determined; in others, women choose instead to resort to unsafe abortion. Thus, “rape grounds” do not satisfy the requirement from international human rights law that abortion be available and accessible in situations of rape. These restrictions also subject the individual to unnecessary trauma, may put them at increased risk from the perpetrator",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 65
  },
  {
    "chunk_id": "abortioncare_308",
    "text": "bortion be available and accessible in situations of rape. These restrictions also subject the individual to unnecessary trauma, may put them at increased risk from the perpetrator, and may cause women to resort to unsafe abortion. The evidence also showed that grounds-based approaches that require fetal impairments to be fatal for abortion to be lawful frustrate providers who wish to support patients and leave women no choice but to continue with pregnancy. Being required to continue with a pregnancy that causes significant distress violates numerous human rights. States are obligated to revise these laws to make them compatible with international human rights law. Under international human rights law, States are required to ensure that women do not have to resort to unsafe abortion. The evidence from the studies described above suggests that grounds-based laws may contribute to an incr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 65
  },
  {
    "chunk_id": "abortioncare_309",
    "text": "are required to ensure that women do not have to resort to unsafe abortion. The evidence from the studies described above suggests that grounds-based laws may contribute to an increase in the incidence of unsafe abortion, with people who do not satisfy a ground resorting to unlawful abortion, including unlawful self-management of abortion, some of which may be unsafe. The evidence from the studies also indirectly suggests that grounds-based laws contribute to maternal mortality, because when States shift from a grounds-based approach to permitting abortion on request in the first trimester there is a reduction in maternal mortality (especially for adolescents) as well as a reduction in fertility (birth rates). This suggests a connection between the international obligation to take steps to reduce maternal mortality and morbidity and a shift away from grounds- based approaches. KEY HUMAN ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 65
  },
  {
    "chunk_id": "abortioncare_310",
    "text": "This suggests a connection between the international obligation to take steps to reduce maternal mortality and morbidity and a shift away from grounds- based approaches. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO GROUNDS-BASED APPROACHES • Availability, accessibility, acceptability and quality must be central to the regulation of sexual and reproductive health (SRH) services. • Abortion must be available where carrying a pregnancy to full term would cause a woman substantial pain or suffering, where pregnancy is a result of rape or incest, or where her life or health is at risk. • States may not regulate abortion in a manner that forces women to resort to unsafe abortion. • States must take steps, including revising laws, to reduce maternal morbidity and mortality, and to effectively protect women and girls from the physical and mental risks associated with resorting to unsafe abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 65
  },
  {
    "chunk_id": "abortioncare_311",
    "text": "vising laws, to reduce maternal morbidity and mortality, and to effectively protect women and girls from the physical and mental risks associated with resorting to unsafe abortion. • Everyone has a right to non-discrimination and equality in accessing SRH services. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Chapter 2. Abortion regulation including relevant recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 65
  },
  {
    "chunk_id": "abortioncare_312",
    "text": "Abortion care guideline, second edition 28 2.2.3 Gestational age limits Gestational age limits are commonly specified in both liberal and restrictive abortion laws and policies. Imposed through formal law, institutional policy or personal practice by individual health workers, these limits restrict when lawful abortion may be accessed by reference to the gestational age of a pregnancy. In many countries gestational age limits are linked to grounds-based approaches, with gestational age limits varying according to the grounds or circumstances under which abortion is permitted. While methods of abortion may vary by gestational age (see Chapter 3, section 3.4), pregnancy can safely be ended regardless of gestational age. Gestational age limits are not evidence-based; they restrict when lawful abortion may be provided by any method. International human rights law requires that quality of car",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 66
  },
  {
    "chunk_id": "abortioncare_313",
    "text": "al age. Gestational age limits are not evidence-based; they restrict when lawful abortion may be provided by any method. International human rights law requires that quality of care be central to the provision and regulation of SRH, and thus that regulation of abortion is evidence-based, scientifically and medically appropriate, and up to date (3, para. 21). Under international human rights law, States may not regulate pregnancy or abortion in a manner that is contrary to their duty to ensure that women and girls do not have to resort to unsafe abortion, and are required to revise their laws accordingly (see Web annex A: Key international human rights standards on abortion). LAW & POLICY Recommendation 3: Gestational age limits Recommend against laws and other regulations that prohibit abortion based on gestational age limits. Note on updating of the recommendation: This and other law an",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 66
  },
  {
    "chunk_id": "abortioncare_314",
    "text": "tional age limits Recommend against laws and other regulations that prohibit abortion based on gestational age limits. Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. Rationale In order to identify the impacts of gestational age limits on abortion seekers and health workers, a systematic review of studies published between 2010 and 2020 was undertaken, identifying 21 studies conducted in Australia, Belgium, Mexico, Nepal, South Africa, the United Kingdom and the United States of America (USA). A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Gestational age limits.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 66
  },
  {
    "chunk_id": "abortioncare_315",
    "text": "ted Kingdom and the United States of America (USA). A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Gestational age limits. The reviewed evidence demonstrated that – alone or in combination with other regulatory requirements, including grounds-based approaches – gestational age limits delayed access to abortion, especially among women seeking abortions at later gestational ages, women close to the gestational age limit and those living in areas with limited access to clinics. Gestational age limits have been found to be associated with increased rates of maternal mortality and poor health outcomes. International human rights law requires States to reform law in order to prevent unsafe abortion and reduce maternal mortality and morbidity. The studies also showed that where women requested an abortion and were denied care due to gest",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 66
  },
  {
    "chunk_id": "abortioncare_316",
    "text": "law in order to prevent unsafe abortion and reduce maternal mortality and morbidity. The studies also showed that where women requested an abortion and were denied care due to gestational age this could result in the unwanted continuation of pregnancy, especially among women with cognitive impairments or those who presented at 20 weeks’ gestation or later. This outcome can be viewed as incompatible with the requirement in international human rights law to make abortion available when carrying a pregnancy to term would cause the woman substantial pain or suffering, regardless of pregnancy viability. The evidence from these studies showed that women with cognitive impairments, adolescents, younger women, women living further from clinics, women who need to travel for abortion, women with lower educational attainment, women facing financial hardship and unemployed women were disproportionat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 66
  },
  {
    "chunk_id": "abortioncare_317",
    "text": "ving further from clinics, women who need to travel for abortion, women with lower educational attainment, women facing financial hardship and unemployed women were disproportionately impacted by gestational age limits. This points to the disproportionate impact of gestational age limits on certain groups of women, with implications for States’ obligation to ensure non-discrimination and equality in provision of SRH services.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 66
  },
  {
    "chunk_id": "abortioncare_318",
    "text": "29 KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO GESTATIONAL AGE LIMITS • Availability, accessibility, acceptability and quality must be central to the regulation of sexual and reproductive health (SRH) services. • States may not regulate abortion in a manner that forces women to resort to unsafe abortion. • States must take steps, including revising laws, to reduce maternal morbidity and mortality, and to effectively protect women and girls from the physical and mental risks associated with resorting to unsafe abortion. • Everyone has a right to non-discrimination and equality in accessing SRH services. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Chapter 2. Abortion regulation including relevant recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 67
  },
  {
    "chunk_id": "abortioncare_319",
    "text": "31 Chapter 3. Recommendations and best practice statements across the continuum of abortion care 3.1 Background As a standard approach to human rights-based health care, all norms, standards and clinical practice related to abortion should promote and protect: • individuals’ health and human rights • informed and voluntary decision-making • autonomy in decision-making • non-discrimination (including intersectional discrimination) and equality • confidentiality and privacy • adequate referral mechanisms • the continuum of care. New and updated recommendations presented in this guideline were formulated by the expert panels formed for the development of this guideline, including expert human rights advisers (all contributors are listed in Annex 1, and the roles of the groups of contributors are described in Annex 4). 10 The evidence was first systematically reviewed for each prioritized to",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 69
  },
  {
    "chunk_id": "abortioncare_320",
    "text": "contributors are listed in Annex 1, and the roles of the groups of contributors are described in Annex 4). 10 The evidence was first systematically reviewed for each prioritized topic and question, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (24, 119), and the level of certainty of that evidence was assessed (i.e. based on the quality of the evidence, including the types and sizes of studies conducted and their various limitations). The direction (in favour or against) and strength of each recommendation was determined by the panel of experts based on the six substantive criteria of the WHO-INTEGRATE framework as applied to each intervention for the specified population – balance of health benefits and harms; human rights and sociocultural acceptability; health equity, non-discrimination and equality; societal implications; financial an",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 69
  },
  {
    "chunk_id": "abortioncare_321",
    "text": "population – balance of health benefits and harms; human rights and sociocultural acceptability; health equity, non-discrimination and equality; societal implications; financial and economic considerations; and feasibility and health system considerations – while also taking into account the meta-criterion: quality of evidence (118). The methods are described in full in Annex 4, including the differences in the methods applied for the recommendations relating to law and policy issues (Recommendations 1,2,3,6,7,21,22) compared with the other types of recommendations. The full Evidence-to-Decision (EtD) frameworks are provided online as supplementary materials, and hyperlinked cross-references to these are supplied with the rationale for each new and updated recommendation presented.11 10 The expert panels included the Evidence and Recommendations Review Groups (ERRGs) for each of the thre",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 69
  },
  {
    "chunk_id": "abortioncare_322",
    "text": "ed with the rationale for each new and updated recommendation presented.11 10 The expert panels included the Evidence and Recommendations Review Groups (ERRGs) for each of the three domains (Law and policy, Clinical services and Service delivery) and later the Guideline Development Group (GDG), and each phase and each meeting of these groups also involved at least one human rights adviser. For further details of the roles of these groups and the full methodology for the guideline development process, see Annex 4: Methods. 11 EtD frameworks for this guideline can be accessed online: Supplementary material 1: EtD frameworks for law and policy topics https:// www.who.int/publications/i/item/9789240039483; Supplementary material 2: EtD frameworks for clinical service topics https://www. who.int/publications/i/item/9789240039483; Supplementary material 3: EtD frameworks for service delivery t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 69
  },
  {
    "chunk_id": "abortioncare_323",
    "text": "ntary material 2: EtD frameworks for clinical service topics https://www. who.int/publications/i/item/9789240039483; Supplementary material 3: EtD frameworks for service delivery topics https://www.who.int/ publications/i/item/9789240039483. Chapter 3. Recommendations and best practice statements across the continuum of abortion care",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 69
  },
  {
    "chunk_id": "abortioncare_324",
    "text": "Abortion care guideline, second edition 32 Recommendations in favour of an intervention are qualified as either strong or weak (with the conditions of use specified for the latter), with the third alternative being a recommendation against the intervention. To clearly indicate the strength and direction of each recommendation, the following wording is used: • Recommend – a strong recommendation in favour of the intervention • Suggest – a weak recommendation in favour of the intervention (requiring additional wording to qualify the recommendation, specifying the conditions of use) • Recommend against – a strong recommendation against the intervention/in favour of the comparison. New and updated recommendations resulted from the review of the PICO questions (i.e. population, intervention, comparator, outcomes) that had been identified during the scoping meetings for this guideline. While 1",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 70
  },
  {
    "chunk_id": "abortioncare_325",
    "text": "esulted from the review of the PICO questions (i.e. population, intervention, comparator, outcomes) that had been identified during the scoping meetings for this guideline. While 10 recommendations in this guideline are completely “new” (as labelled in the Executive summary table and in this chapter), updated recommendations are those that had been published in prior WHO guidance but had undergone an updated process of scoping, search and review of relevant evidence, application of the GRADE methodology and reconsideration of the WHO-INTEGRATE criteria for the purposes of this guideline, which may or may not have resulted in any substantive change to the strength, direction or substance of the recommendation (19, 23, 120). Finally, there are some existing recommendations that are carried forward unchanged from previous WHO guidance;12 in these cases, the topic had not been scoped prior t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 70
  },
  {
    "chunk_id": "abortioncare_326",
    "text": "9, 23, 120). Finally, there are some existing recommendations that are carried forward unchanged from previous WHO guidance;12 in these cases, the topic had not been scoped prior to the development of this guideline and thus no new search or review was conducted or, in some cases, an updated literature search was conducted to review the current evidence base but did not lead to any change in the existing recommendation. In particular it should be noted that the 2012 Safe abortion guidance provided a composite recommendation related to law and policy; in this guideline, this has been developed into seven separate recommendations using GRADE methodology, but they are not considered to be “new” (i.e. Recommendations 1,2,3,6,7,21,22). A summary table linking the topics covered, the research/PICO questions, the systematic reviews conducted and the recommendation numbers is provided in Annex 7",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 70
  },
  {
    "chunk_id": "abortioncare_327",
    "text": "ns 1,2,3,6,7,21,22). A summary table linking the topics covered, the research/PICO questions, the systematic reviews conducted and the recommendation numbers is provided in Annex 7. 3.1.1 Structure of information in this chapter The information and recommendations in this chapter are presented in sections that reflect the continuum of abortion care and modes of service delivery: (i) services applicable across the continuum of care, (ii) pre-abortion, (iii) abortion, (iv) post-abortion, (v) service-delivery options and self-management approaches. In each section, the following aspects are covered as appropriate: “what” (specific clinical interventions), “who” (which type of health worker can provide the intervention, or self-management), “where” (facility-based versus off-site/ remote service-delivery models/no requirement for on-site versus off-site location), and “how” (service-delivery",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 70
  },
  {
    "chunk_id": "abortioncare_328",
    "text": "tion, or self-management), “where” (facility-based versus off-site/ remote service-delivery models/no requirement for on-site versus off-site location), and “how” (service-delivery models, implementation considerations). It should be noted that four recommendations relating to law and policy considerations are presented in the pre-abortion section (section 3.3), while three were presented in Chapter 2, section 2.2. For each topic covered in this chapter, brief background information is first supplied, followed by the recommendation boxes or tables, providing information on the “what” and the “who” for the intervention in question. Each recommendation is immediately followed by a list of related remarks (if any) from the expert panel that reviewed the evidence in detail, explaining the conditions and context in which the recommendation applies. When appropriate, there is also a section in",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 70
  },
  {
    "chunk_id": "abortioncare_329",
    "text": " from the expert panel that reviewed the evidence in detail, explaining the conditions and context in which the recommendation applies. When appropriate, there is also a section indicating where the intervention can be carried out – in particular whether the intervention must be undertaken at a particular level of health-care facility, or whether there is no such requirement and an “off-site” location (e.g. at home, or other location) would be appropriate if preferred by the individual or if that is the only option available (the “where” is often closely tied to the “who”, e.g. tasks provided by pharmacists would be provided in a pharmacy). The remarks for existing unchanged recommendations are repeated from the original cited guidance where still relevant, including revisions as appropriate, based on the results of any relevant updated evidence reviews conducted. 12 Existing recommendat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 70
  },
  {
    "chunk_id": "abortioncare_330",
    "text": "e original cited guidance where still relevant, including revisions as appropriate, based on the results of any relevant updated evidence reviews conducted. 12 Existing recommendations are presented exactly as in previous guidance or with wording updated to use the wording “recommend/ recommend against” for strong recommendations and “suggest” for weak recommendations (previously termed “conditional” recommendations), and reference is provided to the original guidance for further details.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 70
  },
  {
    "chunk_id": "abortioncare_331",
    "text": "33 For each of the new/updated recommendations, additional information is presented in the following order after the box presenting the recommendation(s) and remarks: i. Rationale: This includes a brief summary of the type and extent of the evidence included in the review(s) that form the evidence base, and an explanation of the rationale for the direction (for or against) and strength of the recommendation (strong or weak), with reference to the key judgements on effects of the intervention (benefits and risks), the level of certainty of the evidence and any relevant information on the other criteria of the WHO-INTEGRATE framework. Any additional evidence of potential harms or unintended consequences is highlighted. Such considerations may have been derived from studies and additional evidence that may not directly address the PICO question but provide pertinent information in the absen",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 71
  },
  {
    "chunk_id": "abortioncare_332",
    "text": "ghted. Such considerations may have been derived from studies and additional evidence that may not directly address the PICO question but provide pertinent information in the absence of direct evidence. This may be extracted from single studies, systematic reviews or other relevant sources. ii. Implementation considerations: Points to bear in mind regarding implementation, including those relating to “how”. Finally, in each topic section, a box is presented listing any key human rights considerations relevant to the recommendation or broader topic, as well as a box providing cross-references and hyperlinks to related topics within this guideline. Full details for all related PICO questions can be found in Annexes 8, 9 and 10, and the summaries of the evidence (i.e. from the systematic reviews; listed in Annex 7) and the EtD frameworks relevant to each new or updated recommendation are ma",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 71
  },
  {
    "chunk_id": "abortioncare_333",
    "text": "es 8, 9 and 10, and the summaries of the evidence (i.e. from the systematic reviews; listed in Annex 7) and the EtD frameworks relevant to each new or updated recommendation are made available online as supplementary material. 3.1.2 Underlying principles and assumptions relating to recommendations on health worker roles Health workers are all people engaged in actions whose primary intent is to enhance health (100). This includes all categories of health workers listed and described in Annex 5, from community health workers all the way through to specialist medical practitioners (e.g. obstetricians and gynaecologists), and including traditional and complementary medicine professionals (i.e. non-allopathic physicians). Abortions can be done safely using tablets (medical abortion) or a simple outpatient procedure, such that most no longer require a specialist or even a general practice doc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 71
  },
  {
    "chunk_id": "abortioncare_334",
    "text": "cians). Abortions can be done safely using tablets (medical abortion) or a simple outpatient procedure, such that most no longer require a specialist or even a general practice doctor. The recommendations presented in this guideline provide guidance on how to involve a wider range of health workers and pregnant individuals themselves in the provision or self-management of abortion care, to encourage optimization of the available health workforce, address health system shortages of specialized health-care professionals, reduce costs and improve affordability, improve equity and equality in access to health care and increase the acceptability of health services for those who need them. The following principles and assumptions apply to all health workers: • The recommendations are appropriate for and intended for all resource settings, i.e. high-, middle- and low-resource settings. • The re",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 71
  },
  {
    "chunk_id": "abortioncare_335",
    "text": "d assumptions apply to all health workers: • The recommendations are appropriate for and intended for all resource settings, i.e. high-, middle- and low-resource settings. • The recommendations refer to a range of types of health workers who can safely, effectively and satisfactorily perform some or all of the specific abortion-related tasks mentioned. The options for who can perform the same task are intended to be inclusive and do not imply either a preference for or an exclusion of any particular type of health worker. The choice of health worker for a specific task will depend upon the needs, preferences and conditions of the individual, and the local context. • Training of health workers must ensure that they have the competencies to provide good-quality, gender- sensitive care in accordance with national standards and guidelines and human rights. Ensuring quality abortion care requ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 71
  },
  {
    "chunk_id": "abortioncare_336",
    "text": "hey have the competencies to provide good-quality, gender- sensitive care in accordance with national standards and guidelines and human rights. Ensuring quality abortion care requires ongoing supervision, quality assurance, monitoring and evaluation, as well as access to the necessary equipment and commodities. • It is assumed that any health worker discussed in this guideline has the basic training required of that type of health worker (and in the case of individuals acting as their own provider – i.e. self-management – that they have the appropriate information and understanding). In addition, the recommendations all assume that health workers who are in a category that is recommended or suggested to perform specific tasks will have received the appropriate task-specific training and information prior to performing that task. Chapter 3. Recommendations and best practice statements ac",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 71
  },
  {
    "chunk_id": "abortioncare_337",
    "text": "m specific tasks will have received the appropriate task-specific training and information prior to performing that task. Chapter 3. Recommendations and best practice statements across the continuum of abortion care",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 71
  },
  {
    "chunk_id": "abortioncare_338",
    "text": "Abortion care guideline, second edition 34 3.2 Services applicable across the continuum of care Hom e P h a r m a c y C o m m u n i t y o u t r e a c h c e n t r e s P r i m a r y c a r e f a c i l i t y H i g h e r - le v e l fa cility F a c i l i t y - b a s e d h e a l t h w o r k e r s O t h e r h e a l t h w o rk e rsS e lf Abortion Pre-abortion Post-abortion Values & Preferences HOW WHERE WHO WHAT Availability and accessibility of information Supportive health systems Respect for human rights Prim in g , P a in m a n a g e m e n t , Supportive framework of law and policy Context-sp e c iﬁc s e r v i c e - d e l i v e r y a p p r o a c h e s In t e g r a t i o n w i t h i n h e a l t h s y s t e m s C o m m o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 72
  },
  {
    "chunk_id": "abortioncare_339",
    "text": "m o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d e s i r e d ) This section covers information, counselling and linkage to additional care or services, any or all of which may be needed or desired before, during and/or after the abortion procedure or process. The provision of scientifically accurate and easy-to-understand information to all women undergoing an abortion, and non-directive voluntary counselling to anyone who requests it, is a core element of good-quality, human rights-compliant abortion services (see Chapter 1, section 1.3.2). The provision of information and counselling (where desired), as well as access or referrals to other related services, starts pre-abortion but sh",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 72
  },
  {
    "chunk_id": "abortioncare_340",
    "text": "s (see Chapter 1, section 1.3.2). The provision of information and counselling (where desired), as well as access or referrals to other related services, starts pre-abortion but should continue across the continuum of care. In addition, everyone should be provided with all the necessary information to make an informed decision regarding the use of contraception. What 3.2.1 Providing information Abortion-related information for individuals considering or seeking abortion or in the post-abortion period should include: • the available options for abortion methods and pain management; • information related to free and informed consent; • what will occur before, during and after the abortion procedure or process, including any tests and/or pain relief that may be needed and any aspects of the care that could be self-managed if desired, with or without remote support; • what the individual is ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 72
  },
  {
    "chunk_id": "abortioncare_341",
    "text": "cluding any tests and/or pain relief that may be needed and any aspects of the care that could be self-managed if desired, with or without remote support; • what the individual is likely to experience during and after the abortion procedure or process, and how long the procedure/process and the recovery are likely to take;",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 72
  },
  {
    "chunk_id": "abortioncare_342",
    "text": "35 • when normal activities can be resumed, including sexual intercourse; • how to recognize potential side-effects and symptoms of ongoing pregnancy (which may persist temporarily even when abortion has been successful, or which may indicate failure of the abortion), and other medical reasons to return for follow-up care, including complications such as prolonged heavy bleeding or fever; and • when, where and how to access follow-up care or additional services that may be desired such as counselling (section 3.2.2), contraception (see section 3.5.4) and other services (section 3.2.3). Who SERVICE DELIVERY Recommendation 4: Provision of information on abortion care Type of health worker Recommendation Rationalea Community health workers (CHWs) Recommend Provision of health promotion interventions by CHWs is generally well accepted and feasible in many contexts where there is a strong CHW",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 73
  },
  {
    "chunk_id": "abortioncare_343",
    "text": "a Community health workers (CHWs) Recommend Provision of health promotion interventions by CHWs is generally well accepted and feasible in many contexts where there is a strong CHW programme (moderate-certainty evidence). The potential to expand equitable access to information and quality abortion care by equipping CHWs to provide essential information on abortion is high. Pharmacy workers Suggest Condition: In contexts where the pharmacy worker is under the direct supervision of a pharmacist and there is access or referral to appropriate health services. Insufficient direct evidence was found for the safety, effectiveness and acceptability of this option. However, in many contexts, pharmacy workers are often consulted by women seeking advice on how to deal with delayed menstruation (moderate-certainty evidence). Although the effectiveness of training interventions with pharmacy workers ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 73
  },
  {
    "chunk_id": "abortioncare_344",
    "text": "onsulted by women seeking advice on how to deal with delayed menstruation (moderate-certainty evidence). Although the effectiveness of training interventions with pharmacy workers is uncertain, the potential benefits of equipping them to provide essential information outweighs the potential harms of them not providing information or providing incorrect information. Pharmacists Recommend Pharmacists are qualified to provide information about the medicines they dispense. Evidence was found for the effectiveness of provision of education and counselling on chronic illnesses by pharmacists (low to moderate certainty). In many contexts, pharmacists are often consulted by women seeking advice on how to deal with delayed menstruation (moderate-certainty evidence). Traditional and complementary medicine professionals Auxiliary nurses/auxiliary nurse midwives (ANMs) Nurses Midwives Associate/adva",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 73
  },
  {
    "chunk_id": "abortioncare_345",
    "text": "yed menstruation (moderate-certainty evidence). Traditional and complementary medicine professionals Auxiliary nurses/auxiliary nurse midwives (ANMs) Nurses Midwives Associate/advanced associate clinicians Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to pharmacy workers was reviewed using GRADE methodology, since that was the only category of health worker that didn’t already have a strong recommendation (“recommend”) for this task. After review, no change was made to the existing weak recommendation (“suggest”). A summary of the evidence is presented in Supplementary material 3, EtD framework on Information provisi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 73
  },
  {
    "chunk_id": "abortioncare_346",
    "text": "review, no change was made to the existing weak recommendation (“suggest”). A summary of the evidence is presented in Supplementary material 3, EtD framework on Information provision by pharmacy workers. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. 3.2 Services applicable across the continuu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 73
  },
  {
    "chunk_id": "abortioncare_347",
    "text": "n and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. 3.2 Services applicable across the continuum of care",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 73
  },
  {
    "chunk_id": "abortioncare_348",
    "text": "Abortion care guideline, second edition 36 Where There is no requirement for location (on-site vs off-site), but privacy and confidentiality should be ensured during the provision of information, with particular attention needed to this requirement in the off-site (out-of-facility) settings, such as pharmacies and community-based sites, where infrastructure and procedures may make this more challenging. How Implementation considerations • Different modalities exist for the provision of information on abortion, e.g. remote access via hotlines and telemedicine, and through approaches such as harm reduction and community-based outreach (see section 3.6) as well as in-person interactions with health workers. • Information should be accessible and understandable, including formats catering to low-literacy and differently abled populations. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO THE PROVI",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 74
  },
  {
    "chunk_id": "abortioncare_349",
    "text": "rmation should be accessible and understandable, including formats catering to low-literacy and differently abled populations. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO THE PROVISION OF INFORMATION • Informed consent requires the provision of complete and accurate, evidence-based information. • Accurate information on abortion must be available to individuals in a way that respects privacy and confidentiality. • The right to refuse such information when offered must be respected. • Abortion information should be available to all persons without the consent or authorization of a third party. This includes abortion information being available to adolescents without the consent or authorization of a parent, guardian or other authority. • Information must be non-discriminatory and non-biased and presented in a respectful manner. It should not fuel stigma or discrimination. • Dissemination ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 74
  },
  {
    "chunk_id": "abortioncare_350",
    "text": "dian or other authority. • Information must be non-discriminatory and non-biased and presented in a respectful manner. It should not fuel stigma or discrimination. • Dissemination of misinformation, withholding of information and censorship should be prohibited. • Information should be acceptable to the person receiving it and of high quality; it should be presented in a way that can be understood and it must be accurate and evidence based. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 74
  },
  {
    "chunk_id": "abortioncare_351",
    "text": "37 What 3.2.2 Offering and providing counselling Some individuals may wish to receive counselling before or after an abortion. Counselling is more than information provision. It is a focused, interactive process through which a person voluntarily receives support, information and non-directive guidance from a trained person (122) , in an environment that is conducive to openly sharing thoughts, feelings, perceptions and personal experiences. In addition to the specific knowledge about abortion services and care required for both information provision and counselling, the latter also requires specialized counselling training. Counselling is a core element of provision of abortion and post-abortion care. When offering and providing counselling, it is essential to apply the following guiding principles: • ensure that the individual is requesting the counselling and make it clear that counse",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 75
  },
  {
    "chunk_id": "abortioncare_352",
    "text": "ering and providing counselling, it is essential to apply the following guiding principles: • ensure that the individual is requesting the counselling and make it clear that counselling is not required; • ensure privacy and confidentiality; • ask the individual what they want or need, what their concerns are, given them the time they need, and actively listen to their expressed needs and preferences; • highlight relevant information during the counselling session (such as the information provided in section 3.2.1); • communicate information respectfully and non-judgementally, and in a manner understandable to/tailored to the individual; • support the individual and check to ensure they receive adequate responses to their questions and that they understand the information provided; • present all suitable options tailored to individual’s needs, while avoiding imposing one’s personal values",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 75
  },
  {
    "chunk_id": "abortioncare_353",
    "text": "s to their questions and that they understand the information provided; • present all suitable options tailored to individual’s needs, while avoiding imposing one’s personal values and beliefs onto them; and • make it clear that the individual will need to decide what services to receive. Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Informed consent (section 1.3.1: Human rights) Availability and accessibility of information (section 1.3.2) 3.2 Services applicable across the continuum of care",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 75
  },
  {
    "chunk_id": "abortioncare_354",
    "text": "Abortion care guideline, second edition 38 Who SERVICE DELIVERY Recommendation 5: Provision of counselling Type of health worker Recommendation Rationalea Community health workers (CHWs) Recommend Insufficient direct evidence was found for the safety, effectiveness or acceptability of this option, but indirect evidence did show that health promotion interventions by CHWs are generally well accepted, effective and feasible in many contexts, and that CHWs are often intermediaries between the health system and women seeking abortion-related care (moderate- certainty evidence). The expert panel affirmed the feasibility of this option and its ability to expand equitable access to quality abortion care. Pharmacy workers Suggest Condition: Balanced counselling is provided (i.e. about both medical and surgical methods) and there is access or referral to appropriate health services should the wom",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 76
  },
  {
    "chunk_id": "abortioncare_355",
    "text": "ers Suggest Condition: Balanced counselling is provided (i.e. about both medical and surgical methods) and there is access or referral to appropriate health services should the woman choose a surgical method. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed the feasibility of this option and its ability to expand equitable access to quality abortion care. Pharmacists Suggest Condition: Balanced counselling is provided (i.e. about both medical and surgical methods) and there is access or referral to appropriate health services should the woman choose a surgical method. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skil",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 76
  },
  {
    "chunk_id": "abortioncare_356",
    "text": " appropriate health services should the woman choose a surgical method. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Pharmacists are qualified to provide information about the medicines they dispense. There is evidence for the effectiveness of provision of counselling on the management of chronic illnesses by pharmacists (low certainty evidence). In many contexts, pharmacists are often consulted by women seeking advice on how to deal with delayed menstruation (moderate-certainty evidence). Pharmacists have been recommended to provide medical abortion at < 12 weeks across all three subtasks (Recommendation 28). Therefore, the expert panel affirmed that it is feasible for pharmacists to provide bal",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 76
  },
  {
    "chunk_id": "abortioncare_357",
    "text": "ded to provide medical abortion at < 12 weeks across all three subtasks (Recommendation 28). Therefore, the expert panel affirmed that it is feasible for pharmacists to provide balanced counselling on abortion, including surgical options. Traditional and complementary medicine professionals Recommend Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Auxiliary nurses/ANMs Nurses Recommend Counselling is a core competency for these health workers a and this task is within their typical scope of practice.b Midwives Recommend Counselling is a core competency for midwives a and this task is within their typical scope of practice.b Associate/advanced associate clinicians Recommend Counselling is a core comp",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 76
  },
  {
    "chunk_id": "abortioncare_358",
    "text": "unselling is a core competency for midwives a and this task is within their typical scope of practice.b Associate/advanced associate clinicians Recommend Counselling is a core competency for these clinicians a and this task is within their typical scope of practice.b Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to traditional and complementary medicine professionals, pharmacists, pharmacy workers and community health workers was reviewed using GRADE methodology, since the other health workers already had a strong recommendation for this task. After review, the recommendations were upgraded for all four of th",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 76
  },
  {
    "chunk_id": "abortioncare_359",
    "text": "viewed using GRADE methodology, since the other health workers already had a strong recommendation for this task. After review, the recommendations were upgraded for all four of those health worker categories, from “recommend against” to “suggest” for pharmacists and pharmacy workers, and from “suggest” to “recommend” for traditional and complementary medicine professionals and CHWs. A summary of the evidence is presented in Supplementary material 3, EtD framework on Pre- and post-abortion counselling. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for e",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 76
  },
  {
    "chunk_id": "abortioncare_360",
    "text": "publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 76
  },
  {
    "chunk_id": "abortioncare_361",
    "text": "39 Where There is no requirement for location (on-site vs off-site), but privacy and confidentiality should be ensured during counselling, with particular attention needed to this requirement in the off-site (out-of-facility) settings, such as the pharmacies and community-based sites, where infrastructure and procedures may make this more challenging. How Implementation considerations • Counselling can be provided to those seeking abortion services but also jointly to their partners, family members or other individuals, should the woman wish them to be present. • While counselling should be made available and accessible, it should always be voluntary for women to choose whether or not they want to receive it. • Counselling should be person-centred and may need to be tailored according to the needs of the individual; young people, survivors of sexual and gender-based violence or members o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 77
  },
  {
    "chunk_id": "abortioncare_362",
    "text": " Counselling should be person-centred and may need to be tailored according to the needs of the individual; young people, survivors of sexual and gender-based violence or members of marginalized groups may have different information or counselling requirements. • The content of and approach to counselling will need to be adjusted depending on the reason for seeking abortion services (e.g. induced abortion, intrauterine fetal demise [IUFD], fetal anomaly). Therefore, it is important for the counsellor to be aware of and sensitive to the individual’s situation and needs. • Different service-delivery models exist for pre- and post-abortion counselling, e.g. remote access via hotlines and telemedicine and through approaches such as harm reduction counselling and community- based outreach. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO COUNSELLING • Counselling must be entered into freely and vo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 77
  },
  {
    "chunk_id": "abortioncare_363",
    "text": "pproaches such as harm reduction counselling and community- based outreach. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO COUNSELLING • Counselling must be entered into freely and voluntarily, i.e. it should not be mandatory. The right to refuse counselling when offered must be respected. • Where provided, counselling must be available to individuals in a way that respects privacy and confidentiality. • Counselling must be acceptable and of good quality, i.e. it must be provided in a way that can be understood by the recipient and it must be accurate and evidence based. • Counselling must be non-discriminatory and non-biased. • Dissemination of misinformation, withholding of information, and censorship should be prohibited. • Counselling should be available to all persons without the consent or authorization of a third party. This includes counselling being available to adolescents without",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 77
  },
  {
    "chunk_id": "abortioncare_364",
    "text": "prohibited. • Counselling should be available to all persons without the consent or authorization of a third party. This includes counselling being available to adolescents without the consent or authorization of a parent, guardian or other authority. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. 3.2 Services applicable across the continuum of care",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 77
  },
  {
    "chunk_id": "abortioncare_365",
    "text": "Abortion care guideline, second edition 40 All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Information provision (section 3.2.1) Recommendations 41, 42 and 43 on post-abortion contraception 3.2.3 Links to additional services Individuals seeking abortion may require additional services (122) . As needed, provide management or referral to other service providers for other health conditions or urgent needs. This includes facilitating linkages (access or referrals) to counselling and testing for sexually transmitted infections including HIV, contraception where desired, and support services for survivors of gender-based violence. Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 78
  },
  {
    "chunk_id": "abortioncare_366",
    "text": "41 3.3 Pre-abortion Hom e P h a r m a c y C o m m u n i t y o u t r e a c h c e n t r e s P r i m a r y c a r e f a c i l i t y H i g h e r - le v e l fa cility F a c i l i t y - b a s e d h e a l t h w o r k e r s O t h e r h e a l t h w o rk e rsS e lf Abortion Pre-abortion Post-abortion Values & Preferences HOW WHERE WHO WHAT Availability and accessibility of information Supportive health systems Respect for human rights Prim in g , P a in m a n a g e m e n t , Supportive framework of law and policy Context-sp e c iﬁc s e r v i c e - d e l i v e r y a p p r o a c h e s In t e g r a t i o n w i t h i n h e a l t h s y s t e m s C o m m o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d e",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 79
  },
  {
    "chunk_id": "abortioncare_367",
    "text": " a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d e s i r e d ) This section includes information and recommendations first on the issues of mandatory waiting periods and third-party authorization, followed by recommendations on Rh isoimmunization, antibiotic prophylaxis, determination of gestational age of pregnancy, pain management, and cervical priming prior to surgical abortion, and finally also recommendations on the issues of restrictions on health workers who can provide abortions and conscientious objection. 3.3.1 Mandatory waiting periods imposed by States, health-care facilities or health workers In a number of countries, health-care facilities or health workers require women to wait a specified amount of time between requesting and receiving an abort",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 79
  },
  {
    "chunk_id": "abortioncare_368",
    "text": "ties or health workers In a number of countries, health-care facilities or health workers require women to wait a specified amount of time between requesting and receiving an abortion. These imposed delays are known as mandatory waiting periods. In some cases, women must also receive (sometimes biased) counselling or advice (see sections 3.2.1 and 3.2.2), attend the facility at the start and end of the waiting period, and/or undergo mandated ultrasound during these waiting periods (see section 3.3.5, Recommendation 10 on pre-abortion ultrasound). LAW & POLICY Recommendation 6: Mandatory waiting periods Recommend against mandatory waiting periods for abortion. Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideli",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 79
  },
  {
    "chunk_id": "abortioncare_369",
    "text": "er law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. Rationale In order to identify the impacts of mandatory waiting periods on abortion seekers and health workers, a systematic review of studies published between 2010 and 2020 was undertaken, identifying 33 studies all conducted in the USA. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework on Mandatory waiting periods. The evidence reviewed showed that mandatory waiting periods delayed access to abortion, sometimes to the extent that women’s access to abortion or choice of abortion method was restricted in that setting. 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 79
  },
  {
    "chunk_id": "abortioncare_370",
    "text": "Abortion care guideline, second edition 42 The evidence also indicates that mandatory waiting periods increase the cost of abortion and they may make abortion unattainable, resulting in the continuation of pregnancy against the wishes of the abortion seeker, especially among women with fewer resources, adolescents, younger women, those from racial or ethnic minorities and those who need to travel further for an abortion. Among those seeking an abortion, the studies showed that mandatory waiting periods were experienced negatively, as a restriction on their access to abortion. For some women, the logistical and economic challenges of completing a mandatory waiting period, such as the need for time off work or education, extra travel and/ or childcare, meant that they were forced to disclose their pregnancy to others even though international human rights law requires States to ensure that",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 80
  },
  {
    "chunk_id": "abortioncare_371",
    "text": "ucation, extra travel and/ or childcare, meant that they were forced to disclose their pregnancy to others even though international human rights law requires States to ensure that SRH services are provided in a way that ensures privacy and confidentiality. The evidence did not establish any benefits of mandatory waiting periods for women. For health-care facilities, mandatory waiting periods increase staffing costs and logistical difficulties, by mandating additional visits or interventions outside of standard clinical practice (e.g. unnecessary ultrasound, specific counselling that is not evidence-based). KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO MANDATORY WAITING PERIODS • Availability, accessibility, acceptability and quality must be central to the regulation of sexual and reproductive health (SRH) services. • States may not regulate abortion in a manner that forces women to resort",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 80
  },
  {
    "chunk_id": "abortioncare_372",
    "text": "ptability and quality must be central to the regulation of sexual and reproductive health (SRH) services. • States may not regulate abortion in a manner that forces women to resort to unsafe abortion. • Everyone has a right to non-discrimination and equality in accessing SRH services. • SRH services must be provided in a way that ensures privacy and confidentiality. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. 3.3.2 Third-party authorization for abortion Third-party authorization requirements exist where there is a requirement imposed by law or policy, or in practice, that a party other than the pregnant woman must authorize an abortion, even though other applicable legal requirements for lawful abortion have been met (e.g. grounds or gestational age limits, see sections 2.2.2 and 2.2.3). Common third ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 80
  },
  {
    "chunk_id": "abortioncare_373",
    "text": "an abortion, even though other applicable legal requirements for lawful abortion have been met (e.g. grounds or gestational age limits, see sections 2.2.2 and 2.2.3). Common third parties required to provide authorization include a parent, guardian, spouse, partner, health worker, health authority or judicial authority. Third-party authorization requirements operate without regard to whether the person who seeks to end a pregnancy has capacity to consent to medical treatment. Regardless of whether third-party authorization requirements apply, informed consent of the person availing of abortion is a prerequisite for the provision of abortion (refer to Chapter 1, section 1.3.1[v] for information on free and informed consent, and also Web annex A: Key international human rights standards on abortion).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 80
  },
  {
    "chunk_id": "abortioncare_374",
    "text": "43 LAW & POLICY Recommendation 7: Third-party authorization Recommend that abortion be available on the request of the woman, girl or other pregnant person without the authorization of any other individual, body or institution. Remark: • While parental or partner involvement in abortion decision-making can support and assist women, girls or other pregnant persons, this must be based on the values and preferences of the person availing of abortion and not imposed by third-party authorization requirements. Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. Rationale In order to identify the impacts of third-party authorizati",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 81
  },
  {
    "chunk_id": "abortioncare_375",
    "text": " (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. Rationale In order to identify the impacts of third-party authorization requirements on abortion seekers and health workers, systematic reviews of studies published between 2010 and 2019 were undertaken. A total of 32 studies were included, conducted in Hong Kong Special Administrative Region (China), Türkiye and the USA. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Third-party authorization. The reviewed evidence showed that third-party authorization requirements were associated with delays to abortion. For minors, these delays were sometimes, although not always, reduced when judicial authorization was used to bypass parental authorization requirements. However, bypass can be burdensome and time-consuming, and minors ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 81
  },
  {
    "chunk_id": "abortioncare_376",
    "text": ", although not always, reduced when judicial authorization was used to bypass parental authorization requirements. However, bypass can be burdensome and time-consuming, and minors from ethnic minorities or of lower socioeconomic status are significantly more likely to need to use it. The evidence showed that adolescents and women sought to bypass parental/spousal authorization requirements to avoid anticipated violence, reproductive coercion and family disharmony. A number of studies described “parental notification” or “parental involvement” rather than using the term “parental authorization”. As these terms may encompass parental authorization requirements and mandate the disclosure of the fact that a minor is seeking an abortion, thus creating opportunities for parental veto, these studies were included within the evidence base for this topic. These studies reinforced the associations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 81
  },
  {
    "chunk_id": "abortioncare_377",
    "text": "s seeking an abortion, thus creating opportunities for parental veto, these studies were included within the evidence base for this topic. These studies reinforced the associations between mandated parental involvement (including authorization) and barriers to accessing abortion (including delay, continuation of pregnancy, anticipated interpersonal violence or exploitation, reproductive coercion, family disharmony and recourse to unsafe abortion). Third-party authorization requirements are incompatible with international human rights law, which provides that States may not restrict women’s access to health services on the ground that they do not have the authorization of husbands, partners, parents or health authorities, because they are unmarried, or because they are women. Therefore, the evidence underlines the importance of the requirements stated in international human rights law tha",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 81
  },
  {
    "chunk_id": "abortioncare_378",
    "text": "thorities, because they are unmarried, or because they are women. Therefore, the evidence underlines the importance of the requirements stated in international human rights law that SRH services be provided in a way that respects and maintains women’s and girls’ privacy and confidentiality, that States protect women and girls seeking abortion, and that States recognize adolescents’ evolving capacity (see section 1.3.1[v], Box 1.2 and Web annex A: Key international human rights standards on abortion). 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 81
  },
  {
    "chunk_id": "abortioncare_379",
    "text": "Abortion care guideline, second edition 44 KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO THIRD-PARTY AUTHORIZATION • States may not restrict women’s access to health services on the ground that they do not have the authorization of husbands, partners, parents or health authorities, because they are unmarried, or because they are women. • Sexual and reproductive health (SRH) services must be provided in a way that ensures privacy and confidentiality. • States may not regulate abortion in a manner that forces women to resort to unsafe abortion. • States must take steps, including revising laws, to reduce maternal morbidity and mortality, and to effectively protect women and girls from the physical and mental risks associated with resorting to unsafe abortion. • Everyone has a right to privacy and confidentiality in accessing SRH services. • Availability, accessibility, acceptability and qual",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 82
  },
  {
    "chunk_id": "abortioncare_380",
    "text": "associated with resorting to unsafe abortion. • Everyone has a right to privacy and confidentiality in accessing SRH services. • Availability, accessibility, acceptability and quality must be central to the regulation of SRH services. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. 3.3.3 Rh isoimmunization Rh isoimmunization is a type of haemolytic disease of the fetus and newborn (HDFN). Specifically, it is the development of antibodies against the Rh antigens on the surface of red blood cells of another individual (i.e. one’s own fetus) (123). What CLINICAL SERVICES Recommendation 8 (NEW): Rh isoimmunization for abortion at gestational ages < 12 weeks For both medical and surgical abortion at < 12 weeks: Recommend against anti-D immunoglobulin administration. Remark: • Standard of care applies for anti-",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 82
  },
  {
    "chunk_id": "abortioncare_381",
    "text": "stational ages < 12 weeks For both medical and surgical abortion at < 12 weeks: Recommend against anti-D immunoglobulin administration. Remark: • Standard of care applies for anti-D administration at gestational ages ≥ 12 weeks. Who Not applicable. Rationale A systematic review assessed the effect of routine anti-D administration among unsensitized Rh-negative individuals undergoing an abortion. There are few studies examining Rh isoimmunization in unsensitized Rh- negative individuals seeking abortion before 12 weeks of gestation. Only two studies, conducted in Israel and the USA, met the inclusion criteria for the review, both published in 1972 (124, 125). A summary of the evidence is presented in Supplementary material 2, EtD framework on Rh isoimmunization.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 82
  },
  {
    "chunk_id": "abortioncare_382",
    "text": "45 The evidence on the effectiveness of the intervention may favour the intervention, because fewer women in the intervention group (anti-D administration) had antibody formation after the initial pregnancy compared to the women in the comparison group (no anti-D), and no harms (undesirable effects) of the intervention were noted. However, after consideration of the resources required, cost-effectiveness and feasibility of administering anti-D, as well as the very low certainty of the evidence on effectiveness, the expert panel concluded that overall, the evidence does not favour the intervention and decided to recommend against it for gestational ages < 12 weeks, rather than < 9 weeks, as mentioned in the 2012 guidance (19) . The justification for this new recommendation is outlined in the following points: (i) The presence of fetal blood in Rh-negative women at early gestational ages d",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 83
  },
  {
    "chunk_id": "abortioncare_383",
    "text": " guidance (19) . The justification for this new recommendation is outlined in the following points: (i) The presence of fetal blood in Rh-negative women at early gestational ages does not necessarily correlate with development of Rh alloimmunization and if we apply the results of an experimental study to this scenario, then theoretically there is zero chance of antibody formation if the Rh-negative woman is exposed to the Rh antigen of the fetal blood cells (126); (ii) A study comparing Rh alloimmunization rates in two countries demonstrated the safety of not treating Rh-negative women with spontaneous abortion under 10 weeks of gestation (127); (iii) WHO only recommends antenatal prophylaxis with anti-D immunoglobulin in non- sensitized Rh-negative pregnant women at 28 and 34 weeks of gestation to prevent RhD alloimmunization in the context of rigorous research (128). How Implementation",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 83
  },
  {
    "chunk_id": "abortioncare_384",
    "text": "globulin in non- sensitized Rh-negative pregnant women at 28 and 34 weeks of gestation to prevent RhD alloimmunization in the context of rigorous research (128). How Implementation considerations • Routine laboratory testing, including Rh testing, is not a requirement for abortion services at any gestational age. • Determination of Rh status and the offer of anti-D prophylaxis are not considered prerequisites for early medical abortion at gestational ages before 12 weeks . KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO Rh ISOIMMUNIZATION • States must ensure access to up-to-date scientific technologies necessary for women. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Links to related topics/recommendations Services across the ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 83
  },
  {
    "chunk_id": "abortioncare_385",
    "text": "nal human rights standards on abortion. All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 83
  },
  {
    "chunk_id": "abortioncare_386",
    "text": "Abortion care guideline, second edition 46 3.3.4 Antibiotic prophylaxis The role of antibiotics is pertinent for surgical abortion. The presence of infection in the lower reproductive tract at the time of surgical abortion is a risk factor for post-abortion reproductive tract infections (129) . Provision of antibiotics at the time of abortion (prophylaxis) is to prevent such complications after a surgical abortion. What CLINICAL SERVICES Recommendation 9: Antibiotic prophylaxis for surgical and medical abortion a. For surgical abortion, regardless of the individual’s risk of pelvic inflammatory infection: Recommend appropriate prophylactic antibiotics pre- or perioperatively. b. For medical abortion: Recommend against the use of prophylactic antibiotics. Remark: • Lack of antibiotics should not limit access to abortion services. Source: Recommendation 11 carried forward from WHO (2012) (",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 84
  },
  {
    "chunk_id": "abortioncare_387",
    "text": "against the use of prophylactic antibiotics. Remark: • Lack of antibiotics should not limit access to abortion services. Source: Recommendation 11 carried forward from WHO (2012) (19). The wording has been revised to use the word “recommend” to clarify that these are strong recommendations, and the former wording “routine use” (in 9b) has been changed to “use”, following discussion among the expert panel. How Implementation consideration • Single-dose administration of nitroimidazoles, tetracyclines or penicillins has been shown to be effective when used as prophylactic antibiotics for surgical abortion. Who For information regarding which health workers can provide this intervention, refer to Recommendation 24 on vacuum aspiration (< 14 weeks) and Recommendation 26 on dilatation and evacuation (D&E) (≥ 14 weeks). KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO ANTIBIOTIC PROPHYLAXIS • State",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 84
  },
  {
    "chunk_id": "abortioncare_388",
    "text": " on vacuum aspiration (< 14 weeks) and Recommendation 26 on dilatation and evacuation (D&E) (≥ 14 weeks). KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO ANTIBIOTIC PROPHYLAXIS • States must ensure adequate access to essential medicines in an affordable and non-discriminatory manner. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 84
  },
  {
    "chunk_id": "abortioncare_389",
    "text": "47 3.3.5 Determining gestational age of pregnancy Determining the gestational age of the pregnancy is a preliminary step before selecting the most appropriate abortion method. There are multiple ways to determine gestational age. Pregnancy dating can be done based on last menstrual period (LMP) alone or in combination with the use of a validated tool (i.e. mobile app, checklist or pregnancy wheel), thus enabling the option of self-assessment of gestational age. When LMP is uncertain, gestational age can be determined by way of a clinical/physical examination (i.e. bimanual pelvic and abdominal examination) or by ultrasound, both of which are used to assess the size of the uterus, estimated in weeks, that corresponds to a pregnant uterus of the same gestational age dated by LMP. In general, the least invasive method that is appropriate in the circumstances and available in the setting sho",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 85
  },
  {
    "chunk_id": "abortioncare_390",
    "text": "ponds to a pregnant uterus of the same gestational age dated by LMP. In general, the least invasive method that is appropriate in the circumstances and available in the setting should be used. Routine screening for ectopic pregnancy is not necessary prior to medical abortion. The incidence of ectopic pregnancy is lower in abortion seekers then in the general population (130) . Even for continuing pregnancies, WHO only recommends one ultrasound scan before 24 weeks of gestation (early pregnancy ultrasound) to estimate gestational age, improve detection of fetal anomalies and multiple pregnancies, reduce induction of labour for post-term pregnancy, and improve a woman’s pregnancy experience (128). What CLINICAL SERVICES Recommendation 10: Pre-abortion ultrasound scanning For both medical and surgical abortion: Recommend against the use of ultrasound scanning as a prerequisite for providing",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 85
  },
  {
    "chunk_id": "abortioncare_391",
    "text": "ERVICES Recommendation 10: Pre-abortion ultrasound scanning For both medical and surgical abortion: Recommend against the use of ultrasound scanning as a prerequisite for providing abortion services.* Remark: • Legal regulation that limits the availability of abortion by gestational age may require or result in ultrasounds being used to verify gestational age prior to abortion, even though this is not necessary from a clinical perspective. Removing legal gestational age limits on access to abortion (see Recommendation 3) should result in unnecessary pre-abortion ultrasound being avoided, and increase the availability of abortion in settings where ultrasound is difficult to access. * On a case-by-case basis, there may be clinical reasons for using ultrasound scanning prior to abortion. Source: Recommendation 12 carried forward from WHO (2012) (19) . The wording has been revised to use the",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 85
  },
  {
    "chunk_id": "abortioncare_392",
    "text": "re may be clinical reasons for using ultrasound scanning prior to abortion. Source: Recommendation 12 carried forward from WHO (2012) (19) . The wording has been revised to use the word “recommend against” to clarify that this is a strong recommendation against the intervention, and the former wording “routine” has been changed to use “prerequisite” for greater clarity, following discussion among the expert panel. Who Not applicable. Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion Recommendations 24 (on vacuum aspiration) and 26 (on D&E) 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 85
  },
  {
    "chunk_id": "abortioncare_393",
    "text": "Abortion care guideline, second edition 48 Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Information provision (section 3.2.1) Self-management of medical abortion (section 3.6.2) KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO DETERMINING THE GESTATIONAL AGE OF PREGNANCY • Any information on gestational age should be complete, accurate and evidence based. It should not be provided with the aim of directing decision-making. • As a form of health information, information on gestational age should be of high quality, accurate and accessible. It should be presented a respectful manner and acceptable to the person receiving it. It should not fuel stigma and dis",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 86
  },
  {
    "chunk_id": "abortioncare_394",
    "text": "onal age should be of high quality, accurate and accessible. It should be presented a respectful manner and acceptable to the person receiving it. It should not fuel stigma and discrimination. • Where information on gestational age is made available, it must be provided to individuals in a way that respects privacy and confidentiality. • The right to refuse such information when offered must be respected. This includes the right to refuse to view ultrasound images. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 86
  },
  {
    "chunk_id": "abortioncare_395",
    "text": "49 3.3.6 Pain management for abortion There is generally some degree of pain with abortion. The need for pain management increases with gestational age. The degree of the pain varies with the age, parity, prior vaginal delivery, history of dysmenorrhoea and anxiety/fear level of the woman undergoing the abortion (131-134). A shorter procedure time has been associated with less pain (131). Neglecting this important element of care needlessly increases anxiety, discomfort and pain, thereby seriously compromising the quality of care and potentially increasing the difficulty of performing the procedure. Pain management should always be available and it should be administered in advance, in anticipation of the onset of pain, or provided to the woman in case it is needed for later use at home. What CLINICAL SERVICES Recommendations 11–14: Pain management for surgical abortion and for prior cer",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 87
  },
  {
    "chunk_id": "abortioncare_396",
    "text": " of pain, or provided to the woman in case it is needed for later use at home. What CLINICAL SERVICES Recommendations 11–14: Pain management for surgical abortion and for prior cervical priming 11. For pain management for surgical abortion at any gestational age: a. Recommend that pain management should be offered routinely (e.g. non-steroidal anti-inflammatory drugs [NSAIDS]) and that it should be provided to those who want it; and b. Recommend against the routine use of general anaesthesia . NEW RECOMMENDATIONS BELOW INDICATE PAIN MANAGEMENT THAT IS ADDITIONAL TO NSAIDS. 12. (NEW) For pain management for surgical abortion at < 14 weeks: a. Recommend the use of a paracervical block; and b. Suggest that the option of combination pain management using conscious sedation 13 plus paracervical block should be offered, where conscious sedation is available. 13. (NEW) For pain management for c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 87
  },
  {
    "chunk_id": "abortioncare_397",
    "text": "ion of combination pain management using conscious sedation 13 plus paracervical block should be offered, where conscious sedation is available. 13. (NEW) For pain management for cervical priming with osmotic dilators prior to surgical abortion at ≥ 14 weeks: Suggest the use of a paracervical block. (See also section 3.3.7 on cervical priming prior to surgical abortion.) Remark: • For cervical priming (Recommendation 13), additional pain medication can be considered, such as the use of intravaginal gel. 14. (NEW) For pain management for surgical abortion at ≥ 14 weeks: a. Recommend the use of a paracervical block; and b. Suggest that the option of combination pain management using conscious sedation plus paracervical block should be offered, where conscious sedation is available. Source: Recommendation 11 updated from WHO (2012) (19). Recommendations 12–14 are new. Note on updating of th",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 87
  },
  {
    "chunk_id": "abortioncare_398",
    "text": "rvical block should be offered, where conscious sedation is available. Source: Recommendation 11 updated from WHO (2012) (19). Recommendations 12–14 are new. Note on updating of the recommendation: Recommendation 11a was previously published as part of Recommendation 14 in WHO (2012) (19), and evidence for it was reviewed using GRADE methodology. After review, in this updated version, we have split the first part of the original recommendation wording to apply to surgical abortion here (11a) and medical abortion in a separate recommendation (15) and revised the wording to mention provision, and we have separated and revised the wording of the second part of the recommendation referring to general anaesthesia (Recommendation 11b). 13 Conscious sedation is also known as intravenous (IV) sedation or moderate sedation. See definition in Glossary. 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 87
  },
  {
    "chunk_id": "abortioncare_399",
    "text": "Abortion care guideline, second edition 50 Where In a health-care facility. Rationale for Recommendations 11b and 12 An update of an existing Cochrane Review 14 served as the evidence base for assessing the pain management regimens for surgical abortions at < 14 weeks of gestation. Thirty studies reporting on pain management for surgical abortion were identified by the search strategy. Of these studies, nine studies – conducted in France, the Islamic Republic of Iran, Norway, Türkiye and the USA – are the focus of the evidence base for these recommendations. Six studies compared the paracervical block (PCB) with a placebo. One study compared the PCB with general anaesthesia. Two studies compared conscious sedation 15 plus PCB versus PCB alone. A summary of the evidence is presented in Supplementary material 2, EtD framework for Pain management for surgical abortion < 14 weeks. Combinatio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 88
  },
  {
    "chunk_id": "abortioncare_400",
    "text": "ion 15 plus PCB versus PCB alone. A summary of the evidence is presented in Supplementary material 2, EtD framework for Pain management for surgical abortion < 14 weeks. Combination pain management using conscious sedation plus PCB : Mean pain scores were lower in the group of women who received conscious sedation and PCB compared with the women who received a PCB alone, based on moderate-certainty evidence. In addition, satisfaction with their pain management was higher among the former group of women, based on high-certainty evidence. Paracervical block (PCB): Both with and without conscious sedation, mean pain scores were lower in the group of women who received a PCB compared with the women who received a placebo, based on moderate-certainty evidence. Fewer women required additional analgesic medication, based on high-certainty evidence, and satisfaction in the former group of women ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 88
  },
  {
    "chunk_id": "abortioncare_401",
    "text": "lacebo, based on moderate-certainty evidence. Fewer women required additional analgesic medication, based on high-certainty evidence, and satisfaction in the former group of women was high, based on moderate-certainty evidence. General anaesthesia: Pain scores were lower in the group of women who received general anaesthesia compared with PCB alone, based on moderate-certainty evidence. However, discussions on the resources required, cost effectiveness, feasibility and equity related to administering general anaesthesia resulted in a conclusion that did not favour the intervention. In addition, Recommendation 11b aligns with the existing statement that vacuum aspiration does not require an operating theatre (19) . Rationale for Recommendations 13 and 14 A systematic review assessed the pain management regimens for surgical abortions at gestational ages ≥ 14 weeks. Three studies reporting",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 88
  },
  {
    "chunk_id": "abortioncare_402",
    "text": ") . Rationale for Recommendations 13 and 14 A systematic review assessed the pain management regimens for surgical abortions at gestational ages ≥ 14 weeks. Three studies reporting on pain management for D&E were identified by the search strategy, all of which focused on pain management during the cervical priming prior to the surgical procedure. A summary of the evidence is presented in Supplementary material 2, EtD framework for Pain management for surgical abortion ≥ 14 weeks. Mean pain scores were lower in the group of women who received a PCB compared with the women who received a placebo, based on high-certainty evidence. Satisfaction in the former group of women was high, based on moderate-certainty evidence. An intravaginal gel can be used as an alternative method of pain control; more women had a lower pain score after receiving the gel compared with those who had a PCB, based o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 88
  },
  {
    "chunk_id": "abortioncare_403",
    "text": "ence. An intravaginal gel can be used as an alternative method of pain control; more women had a lower pain score after receiving the gel compared with those who had a PCB, based on low- certainty evidence. Cervical priming was performed with laminaria. Discussions on the values and preferences of women regarding pain management during surgical abortion, and on the resources required and the feasibility of PCB administration resulted in a determination that favoured the intervention. No studies were identified that focused on pain management for the D&E procedure. Therefore, the the expert panel came to a consensus to align the recommendations to those for pain management for surgical abortion at < 14 weeks of gestation (see Recommendation 12). Who For information regarding which health workers can provide this intervention, refer to Recommendations 24 and 26 for surgical abortion (vacuu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 88
  },
  {
    "chunk_id": "abortioncare_404",
    "text": "gestation (see Recommendation 12). Who For information regarding which health workers can provide this intervention, refer to Recommendations 24 and 26 for surgical abortion (vacuum aspiration and D&E). 14 A Cochrane Review is a systematic review of research in health care and health policy that is published in the Cochrane Database of Systematic Reviews. 15 Conscious sedation is also known as intravenous (IV) sedation or moderate sedation. See definition in Glossary.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 88
  },
  {
    "chunk_id": "abortioncare_405",
    "text": "51 How Implementation considerations • Sufficient supplies and stocks of pain medications should be ensured. • Training of providers in abortion care should include pain management, in particular the technique for administration of paracervical block. What CLINICAL SERVICES Recommendations 15 and 16: Pain management for medical abortion 15. For medical abortion at any gestational age: Recommend that pain management should be offered routinely (e.g. non-steroidal anti-inflammatory drugs [NSAIDs]) and that it should be provided for the individual to use if and when wanted. NEW RECOMMENDATION BELOW INDICATES PAIN MANAGEMENT THAT IS ADDITIONAL TO NSAIDS. 16. (NEW) For pain management for medical abortion at ≥ 12 weeks: Suggest consideration of other methods to control pain or discomfort due to increased pain with increasing gestational age. Such methods include certain anti-emetics and epidu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 89
  },
  {
    "chunk_id": "abortioncare_406",
    "text": "eks: Suggest consideration of other methods to control pain or discomfort due to increased pain with increasing gestational age. Such methods include certain anti-emetics and epidural anaesthesia, where available. Remark: • For medical abortion at gestational ages < 14 weeks, if NSAIDS (e.g. ibuprofen) are not available or not an option, then acetaminophen can be considered for pain control. Source: Recommendation 15 updated from WHO (2012) (19). Recommendation 16 is new. Note on updating of the recommendation: Recommendation 15 was previously published as part of Recommendation 14 in WHO (2012) (19), and evidence for it was reviewed using GRADE methodology. After review, in this updated version, we have split the first part of the original recommendation wording to apply to surgical abortion (see Recommendation 11a) and medical abortion (here in Recommendation 15), and revised the wordi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 89
  },
  {
    "chunk_id": "abortioncare_407",
    "text": "the first part of the original recommendation wording to apply to surgical abortion (see Recommendation 11a) and medical abortion (here in Recommendation 15), and revised the wording to mention provision. Where No requirement for location (on-site vs off-site). Rationale for Recommendation 15 (specifically for gestational ages < 14 weeks) A Cochrane Review served as the evidence base for this key question. Five studies reporting on pain management for medical abortion at gestational ages < 14 weeks were identified by the search strategy, conducted in Israel, the United Kingdom and the USA. A summary of the evidence is presented in Supplementary material 2, EtD framework for Pain management for medical abortion < 14 weeks. Of these studies, three were assessed using the following comparisons: • ibuprofen versus placebo • prophylactic versus therapeutic NSAIDs • ibuprofen versus paracetamo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 89
  },
  {
    "chunk_id": "abortioncare_408",
    "text": "< 14 weeks. Of these studies, three were assessed using the following comparisons: • ibuprofen versus placebo • prophylactic versus therapeutic NSAIDs • ibuprofen versus paracetamol. Women who received NSAIDs had lower mean pain scores and fewer women from that group required additional analgesic medication, based on high-certainty evidence. Discussions on the values and preferences of women with pain management during medical abortion and the resources required, cost-effectiveness and feasibility for NSAID administration resulted in a determination that favoured the intervention. 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 89
  },
  {
    "chunk_id": "abortioncare_409",
    "text": "Abortion care guideline, second edition 52 Rationale for Recommendations 15 (specifically for gestational ages ≥ 14 weeks) and 16 A systematic review was undertaken to address this key question. Eleven studies reporting on pain management for medical abortion at gestational ages ≥ 14 weeks were identified by the search strategy, conducted in Belgium, Canada, Germany, Israel, Italy, Sweden, Thailand and the USA. A summary of the evidence is presented in Supplementary material 2, EtD framework for Pain management for medical abortion ≥ 14 weeks. Using data from these studies, the following comparisons were made: • paracervical block (PCB) versus oral pain medication • NSAIDs versus non-NSAIDs/placebo • anti-emetics versus placebo • anti-epileptics versus anxiolytics • intermittent versus continuous epidural • patient controlled epidural versus patient-controlled intravenous (IV) fentanyl •",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 90
  },
  {
    "chunk_id": "abortioncare_410",
    "text": "cs versus placebo • anti-epileptics versus anxiolytics • intermittent versus continuous epidural • patient controlled epidural versus patient-controlled intravenous (IV) fentanyl • patient controlled fentanyl versus patient-controlled morphine • patient controlled IV tramadol versus patient-controlled IV fentanyl. Comparison of PCB versus oral pain medication: In the studies that assessed this comparison, fewer women experienced severe pain and there was a lower expulsion time with the use of oral pain medication compared with PCB, based on moderate-certainty evidence. Comparison of NSAIDs versus non-NSAIDs/placebo: In the studies that assessed this comparison, fewer women required supplemental narcotics after the use of NSAIDs, based on high certainty of evidence. In addition, fewer women receiving NSAIDs experienced side-effects, based on moderate-certainty evidence. Comparison of anti",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 90
  },
  {
    "chunk_id": "abortioncare_411",
    "text": "the use of NSAIDs, based on high certainty of evidence. In addition, fewer women receiving NSAIDs experienced side-effects, based on moderate-certainty evidence. Comparison of anti-emetics versus placebo: In the studies that assessed this comparison, there was lower use of supplemental narcotics and lower expulsion time with the use of anti-emetics, based on moderate-certainty evidence. Comparison of anti-epileptics versus anxiolytics: In the studies that assessed this comparison, there were lower mean pain scores, lower use of additional analgesics and lower mean expulsion times with the use of anti- epileptics, based on moderate-certainty evidence. Comparison of intermittent versus continuous epidural: In the studies that assessed this comparison, there were fewer side-effects with the use of intermittent epidural, based on low- to high-certainty evidence. Satisfaction was higher among",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 90
  },
  {
    "chunk_id": "abortioncare_412",
    "text": " studies that assessed this comparison, there were fewer side-effects with the use of intermittent epidural, based on low- to high-certainty evidence. Satisfaction was higher among women who had intermittent epidural for their pain management, based on high- certainty evidence. Comparison of patient-controlled epidural (PCE) versus patient controlled IV fentanyl: In the studies that assessed this comparison, there were lower mean pain scores and fewer side-effects of vomiting and sedation with the use of PCE, based on moderate-certainty evidence. In addition, satisfaction was higher among women in the PCE group, based on moderate-certainty evidence. Comparison of patient-controlled morphine versus patient-controlled IV fentanyl: In the studies that assessed this comparison, there were lower pain scores and fewer side-effects with the use of patient-controlled fentanyl (50 μg), based on m",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 90
  },
  {
    "chunk_id": "abortioncare_413",
    "text": "olled IV fentanyl: In the studies that assessed this comparison, there were lower pain scores and fewer side-effects with the use of patient-controlled fentanyl (50 μg), based on moderate- to high-certainty evidence. Comparison of patient controlled IV tramadol versus patient controlled IV fentanyl: In the studies that assessed this comparison, pain control was comparable with the use of patient-controlled tramadol and fentanyl, based on low- to moderate-certainty evidence. Satisfaction ratings were also similar between the two groups, based on high-certainty evidence. Discussions on the values and preferences of women regarding pain management during medical abortion, and on the resources required, cost-effectiveness and feasibility for NSAID administration resulted in a determination that favoured the intervention.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 90
  },
  {
    "chunk_id": "abortioncare_414",
    "text": "53 Who For information regarding which health workers can provide this intervention, refer to Recommendations 28 and 30 on medical abortion. How Implementation consideration for Recommendations 15 and 16 • Regardless of the service modality, there should be clear communication to the woman on the pain she may experience, which may vary based on pain perceptions and tolerance. In any event, she should be provided with information on pain management, and access to adequate pain medicines should be ensured. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO PAIN MANAGEMENT • States must ensure adequate access to essential medicines in an affordable and non-discriminatory manner. • Denial of pain medication may violate a wide range of human rights, including the right to health and autonomy in decision- making. • Denial of pain medication as punishment for abortion or because it is part of abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 91
  },
  {
    "chunk_id": "abortioncare_415",
    "text": "wide range of human rights, including the right to health and autonomy in decision- making. • Denial of pain medication as punishment for abortion or because it is part of abortion care may violate the right to equality and non- discrimination. • Denial of pain medication may violate the right to be free from cruel, inhuman and degrading treatment. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Universal health coverage (UHC) (section 1.4.1) Commodities (section 1.4.4) Information provision (section 3.2.1) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 91
  },
  {
    "chunk_id": "abortioncare_416",
    "text": "Abortion care guideline, second edition 54 3.3.7 Cervical priming prior to surgical abortion Prior to surgical abortion, cervical priming (also known as cervical preparation) may be considered for all women with a pregnancy of any gestational age, in particular for women with a pregnancy over 12 weeks of gestation. Cervical priming before surgical abortion is especially beneficial for women with cervical anomalies or previous surgery, adolescents and those with advanced pregnancies, all of whom have a higher risk of cervical injury or uterine perforation that may cause haemorrhage (135, 136) . It may also facilitate the abortion procedure for inexperienced providers. However, cervical priming has disadvantages, including additional discomfort for the woman, and the extra cost and time required to administer it effectively. Whether osmotic dilators or medication is used for cervical primi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 92
  },
  {
    "chunk_id": "abortioncare_417",
    "text": " including additional discomfort for the woman, and the extra cost and time required to administer it effectively. Whether osmotic dilators or medication is used for cervical priming prior to the surgical abortion, this is done in advance of the procedure. As such, cervical priming may be initiated by a health worker other than the provider who will conduct the D&E. What CLINICAL SERVICES Recommendation 17: Cervical priming prior to surgical abortion at < 12 weeks of gestation Prior to surgical abortion at < 12 weeks: a. If cervical priming is used: Suggest the following medication regimens: ☐ Mifepristone 200 mg orally 24–48 hours prior to the procedure ☐ Misoprostol 400 μg sublingually 1–2 hours prior to the procedure ☐ Misoprostol 400 μg vaginally or buccally 2–3 hours prior to the procedure b. Recommend against the use of osmotic dilators for cervical priming. Remarks: • The sublingu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 92
  },
  {
    "chunk_id": "abortioncare_418",
    "text": "procedure ☐ Misoprostol 400 μg vaginally or buccally 2–3 hours prior to the procedure b. Recommend against the use of osmotic dilators for cervical priming. Remarks: • The sublingual route is more effective for misoprostol administration. • Appropriate pain medication should be provided. Source: Recommendation updated from Recommendation 7.2 in WHO (2012) (19). Note on updating of the recommendation: This recommendation was reviewed using GRADE methods. The suggested mifepristone regimen is unchanged, but the misoprostol regimens have been updated, in terms of timing and route of administration, and laminaria is no longer a recommended option; these recommendations therefore replace the prior recommendation. Rationale An update of an existing Cochrane Review serves as the evidence base for this key question. The update identified 8 new studies, which makes a total of 61 included studies ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 92
  },
  {
    "chunk_id": "abortioncare_419",
    "text": "tionale An update of an existing Cochrane Review serves as the evidence base for this key question. The update identified 8 new studies, which makes a total of 61 included studies that assessed cervical priming methods for vacuum aspiration. From this review, approximately half of the included studies were evaluated to contribute towards the development of the Evidence-to-Decision (EtD) framework. The review includes the following cervical priming methods: medication with mifepristone and/or misoprostol and mechanical methods (i.e. natural or synthetic osmotic dilators). A summary of the evidence is presented in Supplementary material 2, EtD framework for Cervical priming prior to surgical abortion < 12.16 For Recommendation 17a, we suggest the option of misoprostol or mifepristone as a cervical priming agent prior to surgical abortion less than 12–14 weeks. For the studies that compared",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 92
  },
  {
    "chunk_id": "abortioncare_420",
    "text": "Recommendation 17a, we suggest the option of misoprostol or mifepristone as a cervical priming agent prior to surgical abortion less than 12–14 weeks. For the studies that compared misoprostol versus mifepristone, time to complete the procedure was less for misoprostol, based on moderate-certainty evidence. However, the pre-procedure cervical dilation was greater with mifepristone use, based on moderate-certainty evidence. The side-effects profile was comparable between the two groups, based on very low-certainty evidence. Regarding the timing of misoprostol administration, studies that compared the interval timing for administration of misoprostol for cervical priming revealed that the highest efficacy was seen (i.e. greater pre-procedure cervical 16 For the sake of consistency across the recommendations, the cut-off gestational age is 12 weeks, but evidence did include women with pregn",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 92
  },
  {
    "chunk_id": "abortioncare_421",
    "text": "n (i.e. greater pre-procedure cervical 16 For the sake of consistency across the recommendations, the cut-off gestational age is 12 weeks, but evidence did include women with pregnancies up to 14 weeks of gestation who underwent vacuum aspiration.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 92
  },
  {
    "chunk_id": "abortioncare_422",
    "text": "55 dilation) with the 3-hour interval. This finding was based on high-certainty evidence. Although the 3-hour interval is considered optimal, the 1-hour interval is also included as a result of the expert panel members’ discussions on the feasibility and acceptability of the shorter duration of waiting time prior to a woman’s surgical abortion. For Recommendation 17b, the reasoning is due to the longer time to complete the procedure if osmotic dilators are used compared with when misoprostol is used for cervical priming, based on high-certainty evidence. In addition, satisfaction rates were higher among those who received misoprostol compared with the laminaria group, based on moderate-certainty evidence. The expert panel added the buccal route (this was added along with the vaginal route due to buccal and misoprostol concentration curves being similar in pharmacokinetics data), and thei",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 93
  },
  {
    "chunk_id": "abortioncare_423",
    "text": "xpert panel added the buccal route (this was added along with the vaginal route due to buccal and misoprostol concentration curves being similar in pharmacokinetics data), and their remark highlights the sublingual route as being the more effective route. What CLINICAL SERVICES Recommendation 18 (NEW): Cervical priming prior to surgical abortion (MVA or D&E) at ≥ 12 weeks of gestation Prior to surgical abortion at later gestational ages: a. For surgical abortion at ≥ 12 weeks: Suggest cervical priming prior to the procedure. b. For surgical abortion between 12 and 19 weeks: Suggest cervical priming with medication alone (a combination of mifepristone plus misoprostol is preferred) or with an osmotic dilator plus medication (mifepristone, misoprostol, or a combination of both). c. For surgical abortion between 12 and 19 weeks, when using an osmotic dilator for cervical priming: Suggest th",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 93
  },
  {
    "chunk_id": "abortioncare_424",
    "text": "s medication (mifepristone, misoprostol, or a combination of both). c. For surgical abortion between 12 and 19 weeks, when using an osmotic dilator for cervical priming: Suggest that the period between osmotic dilator placement and the procedure should not extend beyond two days. d. For surgical abortion at ≥ 19 weeks: Recommend cervical priming with an osmotic dilator plus medication (mifepristone, misoprostol, or a combination of both). Remark: • There was limited evidence for cervical priming for gestational ages between 12 and 14 weeks and therefore health workers should use clinical judgement to decide on the most convenient method for cervical priming prior to vacuum aspiration for this gestational age range. Note: These are new recommendations and they replace Recommendations 8.1 and 8.2 in WHO (2012) (19), which were for D&E after 14 weeks; these new recommendations now include i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 93
  },
  {
    "chunk_id": "abortioncare_425",
    "text": "nge. Note: These are new recommendations and they replace Recommendations 8.1 and 8.2 in WHO (2012) (19), which were for D&E after 14 weeks; these new recommendations now include information on methods/regimens for cervical priming at different gestational age ranges. Rationale A Cochrane Review provided the evidence base on cervical priming methods for surgical abortion at later gestational ages. From this review, 16 studies were included in the development of the EtD framework relating to the following cervical priming methods: medication with mifepristone and/or misoprostol; mechanical methods with osmotic dilators and synthetic dilators; one-day versus two-day procedures with laminaria. The study settings included Israel, South Africa, Spain, the United Kingdom and the USA. A summary of the evidence is presented in Supplementary material 2, EtD framework for Cervical priming prior to",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 93
  },
  {
    "chunk_id": "abortioncare_426",
    "text": "ncluded Israel, South Africa, Spain, the United Kingdom and the USA. A summary of the evidence is presented in Supplementary material 2, EtD framework for Cervical priming prior to surgical abortion ≥ 12 weeks. The inclusion of all medication options for cervical priming was based on the expert panel's discussion of the feasibility and acceptability of these interventions. The use of mifepristone with misoprostol is favoured over misoprostol alone for cervical priming due to higher pre-procedure cervical dilatation and shorter time to complete the procedure, based on moderate-certainty evidence. The combined use of medication and laminaria is favoured over laminaria alone due to the higher pre-procedure cervical dilatation, decreased need for further dilatation and shorter time to complete the procedure. This is based on high-certainty evidence. Sub-analyses of the included studies showe",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 93
  },
  {
    "chunk_id": "abortioncare_427",
    "text": "l dilatation, decreased need for further dilatation and shorter time to complete the procedure. This is based on high-certainty evidence. Sub-analyses of the included studies showed that the combined use of medication and laminaria appears to be more effective at higher gestational ages. 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 93
  },
  {
    "chunk_id": "abortioncare_428",
    "text": "Abortion care guideline, second edition 56 How Implementation consideration • The use of medication for cervical priming prior to surgical abortion beyond 12–14 weeks of gestation can be self-managed and can save travel time for the woman and staff time spent on insertion of osmotic dilators. Who SERVICE DELIVERY Recommendation 19: Cervical priming with medication prior to surgical abortion at any gestational age Type of health worker Recommendation Rationalea Community health workers (CHWs) Suggest Condition: Provision of medication for the purpose of cervical priming is part of the surgical abortion process so the health worker needs to ensure continuity of care of the woman obtaining the medicines prior to the abortion procedure Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 94
  },
  {
    "chunk_id": "abortioncare_429",
    "text": "he abortion procedure Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, CHWs have been recommended to provide medical abortion at < 12 weeks (see Recommendation 28), which requires similar skills and knowledge as for this task. Pharmacy workers Suggest Condition: Provision of medication for the purpose of cervical priming is part of the surgical abortion process so the health worker needs to ensure continuity of care of the woman obtaining the medicines prior to the abortion procedure Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 94
  },
  {
    "chunk_id": "abortioncare_430",
    "text": " was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, pharmacy workers have been recommended to provide medical abortion at < 12 weeks (see Recommendation 28), which requires similar skills and knowledge as for this task. Pharmacists Suggest Condition: Provision of medication for the purpose of cervical priming is part of the surgical abortion process so the health worker needs to ensure continuity of care of the woman obtaining the medicines prior to the abortion procedure Although no evidence was found on the safety, effectiveness or acceptability of this option, dispensing medicines with a prescription is within the typical scope of practice of pharmacists. The skills and knowledge for this task (according to the co",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 94
  },
  {
    "chunk_id": "abortioncare_431",
    "text": "ability of this option, dispensing medicines with a prescription is within the typical scope of practice of pharmacists. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, pharmacists have been recommended to provide medical abortion at < 12 weeks (see Recommendation 28), which requires similar skills and knowledge as for this task. Traditional and complementary medicine professionals Auxiliary nurses/ANMs Nurses Midwives Recommend Evidence was found for the safety and effectiveness of this option (low-certainty evidence). Cervical priming is part of the training for provision of manual vacuum aspiration. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Associate/advanced associate clinicians Recom",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 94
  },
  {
    "chunk_id": "abortioncare_432",
    "text": "kills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Associate/advanced associate clinicians Recommend Evidence was found for health workers with similar or less comprehensive basic training (e.g. midwives, nurses, ANMs) using such medicines to provide medical abortion (moderate- certainty evidence). Cervical priming is part of the training for provision of manual vacuum aspiration. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recom",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 94
  },
  {
    "chunk_id": "abortioncare_433",
    "text": "ce,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to all types of health workers was reviewed using GRADE methodology, except for specialist and generalist medical practitioners, which were already “recommend”. After review, the recommendations were upgraded for all reviewed health workers, from “recommend against” to “suggest” for pharmacists, pharmacy workers and CHWs, and from “suggest” to “recommend” for all other health worker categories. The gestational age for this recommendation was also amended from “beyond 12 weeks” to “at any gestational age” after conferring with the expert panel. A summary of the evidence is presented in Supplementary material 3, EtD framework for Cervical priming using medication and osmotic ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 94
  },
  {
    "chunk_id": "abortioncare_434",
    "text": "al age” after conferring with the expert panel. A summary of the evidence is presented in Supplementary material 3, EtD framework for Cervical priming using medication and osmotic dilators. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 94
  },
  {
    "chunk_id": "abortioncare_435",
    "text": "57 Where No requirement for location (on-site vs off-site). How Implementation consideration • Given that cervical priming initiates the process and is done prior to a surgical procedure, with an interval of up to 1–2 days, it is important that the health worker ensures the continuity of care for the woman by ensuring that there is a clear plan for the surgical abortion prior to the woman taking the priming agent and she has access to the existing health system should she desire or need additional support during that interval. Who Table Continues 3.3 Pre-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 95
  },
  {
    "chunk_id": "abortioncare_436",
    "text": "Abortion care guideline, second edition 58 SERVICE DELIVERY Recommendation 20: Cervical priming with osmotic dilators prior to D&E at gestational ages ≥ 12 weeks Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Suggest Condition: Health worker ensures continuity of care from the time of cervical priming to the D&E Although insufficient direct evidence was found for the safety and effectiveness of this option, these health workers have been suggested to do other transcervical procedures (e.g. inserting an IUD and vacuum aspiration; see Recommendations 43 and 24). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that this option has the potential to increase equitable access to quality abortion care in regions where these p",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_437",
    "text": "tencies for this type of health worker.a The expert panel affirmed that this option has the potential to increase equitable access to quality abortion care in regions where these professionals constitute a significant proportion of the health workforce. Auxiliary nurses/ANMs Recommend Although insufficient direct evidence was found for the safety and effectiveness of this option, ANMs have been recommended to do other transcervical procedures (e.g. inserting an IUD; see Recommendation 43), and auxiliary nurses have been recommended in certain contexts to do other transcervical procedures (e.g. inserting an IUD; see Recommendation 43). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that this option may help optimize workflow within a facility and decrease waiting times fo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_438",
    "text": ") align with the competencies for this type of health worker.a The expert panel affirmed that this option may help optimize workflow within a facility and decrease waiting times for women. Nurses Recommend Although insufficient direct evidence was found for the safety or effectiveness of this option, nurses have been recommended to do other transcervical procedures (e.g. inserting an IUD; see Recommendation 43), and there is evidence that provision of manual vacuum aspiration by nurses is safe and effective (moderate-certainty evidence). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that this option may help optimize workflow within a facility and decrease waiting times for women. Midwives Recommend Although insufficient direct evidence was found for the safety or effec",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_439",
    "text": "option may help optimize workflow within a facility and decrease waiting times for women. Midwives Recommend Although insufficient direct evidence was found for the safety or effectiveness of this option, midwives have been recommended to do other transcervical procedures (e.g. inserting an IUD; see Recommendation 43), and there is evidence that provision of manual vacuum aspiration by midwives is safe and effective (moderate-certainty evidence). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that this option may help optimize workflow within a facility and decrease waiting times for women. Associate/advanced associate clinicians Recommend Indirect evidence was found for the safety and effectiveness of these clinicians providing vacuum aspiration (moderate- certainty evi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_440",
    "text": "ociate/advanced associate clinicians Recommend Indirect evidence was found for the safety and effectiveness of these clinicians providing vacuum aspiration (moderate- certainty evidence), which includes cervical priming with osmotic dilators for select cases. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that this option may help optimize workflow within a facility and decrease waiting times for women. Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to all types of health workers was reviewed ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_441",
    "text": " updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to all types of health workers was reviewed using GRADE methodology, except for specialist and generalist medical practitioners, which were already “recommend”. After review, the recommendations were upgraded for associate/advanced associate clinicians, midwives and nurses from “suggest” to “recommend”, for auxiliary nurses and ANMs from “recommend against” to “recommend”, and for traditional and complementary medicine professionals from “recommend against” to “suggest”. For pharmacists, pharmacy workers and community health workers, the recommendations remain “recommend against” (not listed). The gestational age for this recommendation was also amended from “beyond 12 weeks” to “12 weeks and above” (≥ 12 weeks) to align this recommendation with Recommen",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_442",
    "text": "t” (not listed). The gestational age for this recommendation was also amended from “beyond 12 weeks” to “12 weeks and above” (≥ 12 weeks) to align this recommendation with Recommendation 18. A summary of the evidence is presented in Supplementary material 3, EtD framework for Cervical priming using medication and osmotic dilators. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_443",
    "text": "for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 96
  },
  {
    "chunk_id": "abortioncare_444",
    "text": "59 KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO CERVICAL PRIMING • Denial of cervical priming as punishment for abortion or because it is part of abortion care may violate the right to non-discrimination and equality. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion Recommendations 11–15: Pain management Recommendation 23–26: Surgical abortion (vacuum aspiration and dilatation and evacuation) 3.3 Pre-abortion Where In a health-care facility.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 97
  },
  {
    "chunk_id": "abortioncare_445",
    "text": "Abortion care guideline, second edition 60 3.3.8 Restrictions (in law or policy) on health workers who may lawfully provide abortion care In a number of countries, law and policy restrict which type of health workers may lawfully provide abortion care (137), most often limiting this to gynaecologists. Since the advent of vacuum aspiration and medical abortion, however, abortion can be safely provided by a wide range of health workers in diverse settings, and safely self- managed in earlier pregnancy (see Recommendations 24, 28, 30, 33). Provider restrictions are inconsistent with WHO’s support for the optimization of the roles of health workers; such restrictions are arbitrary and not evidence based (138). Reflecting States’ obligation to respect, protect and fulfil the right to health, health-care facilities, goods and services must be available, accessible, adequate and of good quality",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 98
  },
  {
    "chunk_id": "abortioncare_446",
    "text": "ecting States’ obligation to respect, protect and fulfil the right to health, health-care facilities, goods and services must be available, accessible, adequate and of good quality (46) . This includes facilities, goods and services for SRH care. Thus, States must ensure an adequate number of medical and professional personnel and skilled providers in the health system as well as adequate stocks of essential medicines (46) . Furthermore, the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, has stressed that abortion law must be evidence based (37) (see Chapter 1, section 1.3.1[i], and also Web annex A: Key international human rights standards on abortion). LAW & POLICY Recommendation 21: Provider restrictions Recommend against regulation on who can provide and manage abortion that is inconsistent with WHO guida",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 98
  },
  {
    "chunk_id": "abortioncare_447",
    "text": "tandards on abortion). LAW & POLICY Recommendation 21: Provider restrictions Recommend against regulation on who can provide and manage abortion that is inconsistent with WHO guidance. Remark: • Where law or policy regulate who may provide or manage abortion, that regulation should be consistent with WHO guidance, which is presented throughout this chapter. Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology. Rationale In order to identify the impacts of provider restrictions on abortion seekers and health workers, a systematic review of studies published between 2010 and 2019 was undertaken, identifying seven studies conduc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 98
  },
  {
    "chunk_id": "abortioncare_448",
    "text": "cts of provider restrictions on abortion seekers and health workers, a systematic review of studies published between 2010 and 2019 was undertaken, identifying seven studies conducted in Australia, Ethiopia, Nepal and the USA. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Provider restrictions. The reviewed evidence showed that restrictions on who can provide and manage abortion resulted in delays to and burdens in accessing abortion. By contrast, expanding the range of health workers who can provide abortion care improved timely access to early medical and surgical abortion; reduced costs, travel and waiting time; shifted components of care away from physicians; made abortion more available including in rural areas and at primary health care level; prevented unsafe self- management of abortion; and reduced system costs. This evi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 98
  },
  {
    "chunk_id": "abortioncare_449",
    "text": "hysicians; made abortion more available including in rural areas and at primary health care level; prevented unsafe self- management of abortion; and reduced system costs. This evidence indicates that provider restrictions produce inefficiencies, administrative burdens and workload burdens within health systems, and reduce in practice the number of available providers. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO PROVIDER RESTRICTIONS • Availability, accessibility, acceptability and quality must be central to the regulation of sexual and reproductive health care. • Abortion regulation should be based on human rights and evidence. • States must ensure an adequate number of medical and professional personnel and skilled providers in the health system as well as adequate stocks of essential medicines. For further information and sources, please refer to Box 1.2 and Web annex A: Key internati",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 98
  },
  {
    "chunk_id": "abortioncare_450",
    "text": "killed providers in the health system as well as adequate stocks of essential medicines. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 98
  },
  {
    "chunk_id": "abortioncare_451",
    "text": "61 3.3.9 Conscientious objection or refusal by health workers to provide abortion care Refusal of abortion care on the basis of conscience operates as a barrier to access to safe and timely abortion (3 [para. 14], 36 [para. 8], 139 [para. 109], 140 [para. 353], 141 [paras 42, 43]), and unregulated conscientious refusal/objection can result in human rights violations, or lead women to seek unsafe abortion (142 [para. 23], 143 [para. 106], 144). In some countries conscientious objection is expressly regulated through employment law, employment contracts or the law on abortion. As a matter of international human rights law, States that allow conscientious objection must organize their health system and abortion provision in a way that ensures that conscientious objection does not result in the refusal of legally available abortion care, and regulate the exercise of conscientious objection i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 99
  },
  {
    "chunk_id": "abortioncare_452",
    "text": "ovision in a way that ensures that conscientious objection does not result in the refusal of legally available abortion care, and regulate the exercise of conscientious objection in a way that reflects best international clinical practice, protects abortion seekers, and ensures that provider refusal does not undermine or hinder access to quality abortion care (145 [para. 12], 146 [para. 28]). WHO has also advised that “health services should be organized in such a way as to ensure that an effective exercise of the freedom of conscience of health professionals in the professional context does not prevent patients from obtaining access to services to which they are entitled under the applicable legislation” (19) . 3.3 Pre-abortion LAW & POLICY Recommendation 22: Conscientious objection Recommend that access to and continuity of comprehensive abortion care be protected against barriers crea",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 99
  },
  {
    "chunk_id": "abortioncare_453",
    "text": ". 3.3 Pre-abortion LAW & POLICY Recommendation 22: Conscientious objection Recommend that access to and continuity of comprehensive abortion care be protected against barriers created by conscientious objection. Remarks: • Health services should be organized in such a way as to ensure the exercise of conscientious objection does not prevent people from accessing available abortion services. • Where conscientious objection is permitted, international human rights law requires States to take steps to ensure that it does not operate as a barrier to access to abortion care. The mere existence of regulation of conscientious objection is not sufficient. In practice, this means that if States permit conscientious objection, they must regulate it in a way that is effective in ensuring that abortion is available and accessible in practice. • International human rights law provides some guidance a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 99
  },
  {
    "chunk_id": "abortioncare_454",
    "text": "ction, they must regulate it in a way that is effective in ensuring that abortion is available and accessible in practice. • International human rights law provides some guidance as to how States can ensure that human rights of abortion seekers are respected, protected and fulfilled. These include: ☐ putting in place clear and enforceable regulation of conscientious objection (147 [paras 30, 31], 148 [para. 41(f)], 149 [para. 37(b)]); ☐ ensuring adequate enforcement of the regulation of conscientious objection, including identifying, addressing and sanctioning non-compliance (147 [paras 30, 31], 148 [para. 41(f)], 149 [para. 37(b)]); ☐ outlining clearly who may object to what components of care (150 [paras 30-31], 148 [para. 41(f)], 3 [para. 43]); ☐ organizing the health system to ensure that sufficient, non-objecting providers are employed and distributed fairly across the country (3); ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 99
  },
  {
    "chunk_id": "abortioncare_455",
    "text": "1], 148 [para. 41(f)], 3 [para. 43]); ☐ organizing the health system to ensure that sufficient, non-objecting providers are employed and distributed fairly across the country (3); ☐ prohibiting institutional claims of conscience (147, 150 [para. 33(c)], 148 [para. 41(f)]); ☐ requiring objectors to provide prompt referral to accessible, non-objecting providers (3 [para. 43], 37 [para. 65(m)], 39 [para. 11], 150 [para. 33(c)], 146 [para. 28]); ☐ requiring conscientious objection to be exercised in a respectful and non-punitive manner; and ☐ prohibiting conscientious objection in urgent or emergency situations (3, para. 43). • Accordingly, States that permit conscientious objection should reform the regulation of conscientious objection to ensure that the human rights of pregnant people are respected, protected and fulfilled, and that abortion is available and accessible. • If it proves imp",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 99
  },
  {
    "chunk_id": "abortioncare_456",
    "text": "conscientious objection to ensure that the human rights of pregnant people are respected, protected and fulfilled, and that abortion is available and accessible. • If it proves impossible to regulate conscientious objection in a way that respects, protects and fulfils abortion seekers’ rights, conscientious objection in abortion provision may become indefensible. In such circumstances, it may be appropriate to consider prohibiting conscientious objection and/or revising national law and policy frameworks that govern health workers’ professional and ethical obligations. Note on updating of the recommendation: This and other law and policy recommendations are not new recommendations. WHO’s 2012 Safe abortion guidance provided a composite recommendation related to law and policy (19); in this guideline, this has been developed into seven separate recommendations using GRADE methodology.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 99
  },
  {
    "chunk_id": "abortioncare_457",
    "text": "Abortion care guideline, second edition 62 Rationale In order to identify the impacts of conscientious objection on abortion seekers and health workers, a systematic review of studies published between 2010 and 2020 was undertaken, identifying 26 studies conducted in Australia, Brazil, Colombia, Ghana, Italy, Mexico, Nigeria, Norway, Portugal, South Africa, Slovakia, Switzerland, Tunisia, the United Kingdom, the USA and Zambia. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for Conscientious objection. The evidence reviewed established that conscientious objection may delay timely access to abortion and abortion care. Delay in care is exacerbated where there is a higher proportion of objecting health workers, and sometimes even in emergency cases where abortion is needed to save a woman’s life. Delays are sometimes deliberately impose",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 100
  },
  {
    "chunk_id": "abortioncare_458",
    "text": " is a higher proportion of objecting health workers, and sometimes even in emergency cases where abortion is needed to save a woman’s life. Delays are sometimes deliberately imposed by objectors. The evidence also suggests that conscientious objection contributes to increased abortion-related morbidity and mortality, and that some health workers claim conscientious objection and refuse abortion in the public sector, while providing abortion for payment in their private practices. The studies showed that conscientious objection imposes increased barriers on populations in specific settings: rural areas; settings where abortion law has recently been changed and there is insufficient clarity on who may object to what aspects of abortion care; places where conscientious objection is not effectively regulated; and settings where objecting health workers intentionally refuse referrals or use b",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 100
  },
  {
    "chunk_id": "abortioncare_459",
    "text": "hat aspects of abortion care; places where conscientious objection is not effectively regulated; and settings where objecting health workers intentionally refuse referrals or use biased counselling, or inaccurate legal and medical information to try to dissuade and obstruct people from accessing abortion (refer to section 3.2.1: Provision of information). Refusal of abortion on the basis of conscience has been shown to impose significant burdens on women and girls, especially uncertainty about whether and where they can access abortion. Some objectors decide whether to provide abortion on a case-by-case basis depending on their view of the reason a woman seeks abortion, which means availability is not clear or consistent. Furthermore, objectors’ referral practices are highly variable. The evidence demonstrated that while most objectors were willing to refer, this was not true for all, wi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 100
  },
  {
    "chunk_id": "abortioncare_460",
    "text": "consistent. Furthermore, objectors’ referral practices are highly variable. The evidence demonstrated that while most objectors were willing to refer, this was not true for all, with some objectors referring on a case-by-case basis. Additionally, referral pathways may be circuitous and burdensome, which imposes additional difficulties and delays. Conscientious objection has significant workload implications for health workers. Where there are many objectors, non-objecting health workers have an increased workload, abortion provision is often stigmatized, and those who do provide abortion care may experience career limitation or discrimination. Unclear, unenforced or non-existent regulation and legal frameworks for conscientious objection can create burdens on health workers, including in navigating challenges associated with their conscience or ethics, cause workplace conflicts, result i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 100
  },
  {
    "chunk_id": "abortioncare_461",
    "text": "for conscientious objection can create burdens on health workers, including in navigating challenges associated with their conscience or ethics, cause workplace conflicts, result in non-clinical staff attempting to claim conscientious objection, and undermine organizational models for the delivery of abortion. To identify whether and how regulation of conscientious objection mitigates its impacts, a systematic review of studies published between 2010 and 2022 was undertaken, identifying 11 studies conducted in Argentina, Australia, Bolivia, Italy, Norway, Mexico, Portugal, South Africa, the United Kingdom, the USA and Zambia. A summary of the evidence from these studies is presented in Supplementary material 1, EtD framework for regulation of Conscientious objection. The evidence reviewed did not identify any country or setting where conscientious objection was regulated in a way that wa",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 100
  },
  {
    "chunk_id": "abortioncare_462",
    "text": " EtD framework for regulation of Conscientious objection. The evidence reviewed did not identify any country or setting where conscientious objection was regulated in a way that was effective in ensuring the availability and accessibility of abortion in practice. Approaches to regulation included some or all of the following: specifying who may exercise conscientious objection; stating whether or not institutions may claim conscientious objection; requiring conscientious objectors to refer abortion seekers to a willing provider; prohibiting conscientious objection in cases of emergency; and specifying how conscientious objection may be exercised (e.g. requirements to declare or register one’s status as a non-providing objector). Across the studies, the regulation of conscientious objection was still associated with refusal of access to abortion; opportunity costs for abortion seekers (in",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 100
  },
  {
    "chunk_id": "abortioncare_463",
    "text": "oviding objector). Across the studies, the regulation of conscientious objection was still associated with refusal of access to abortion; opportunity costs for abortion seekers (including associated delays); disproportionate impacts (especially between public and private health-care provision); and unequally distributed workloads among health workers. The studies identified issues including lack of enforcement of existing regulations, limited accountability for non-compliance, lack of regulatory clarity about whether and how conscientious objection may be exercised, and impositions on health workers’ ethics or beliefs.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 100
  },
  {
    "chunk_id": "abortioncare_464",
    "text": "63 KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO CONSCIENTIOUS OBJECTION • Availability, accessibility, acceptability and quality must be central to the regulation of sexual and reproductive health (SRH) services. • States that allow conscientious objection must organize their health system and abortion provision in a way that ensures that conscientious objection does not hinder access to or result in the refusal of legally available abortion care. • States that allow conscientious objection should regulate the exercise of conscientious objection in a way that reflects best international clinical practice, protects abortion seekers, and ensures that provider refusal does not undermine or hinder access to quality abortion. • Everyone has the right to accurate information on SRH. • Everyone has a right to privacy and confidentiality in SRH services. • Everyone has a right to non-discriminati",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 101
  },
  {
    "chunk_id": "abortioncare_465",
    "text": "abortion. • Everyone has the right to accurate information on SRH. • Everyone has a right to privacy and confidentiality in SRH services. • Everyone has a right to non-discrimination and equality in accessing SRH services. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 101
  },
  {
    "chunk_id": "abortioncare_466",
    "text": "Abortion care guideline, second edition 64 3.4 Abortion Hom e P h a r m a c y C o m m u n i t y o u t r e a c h c e n t r e s P r i m a r y c a r e f a c i l i t y H i g h e r - le v e l fa cility F a c i l i t y - b a s e d h e a l t h w o r k e r s O t h e r h e a l t h w o rk e rsS e lf Abortion Pre-abortion Post-abortion Values & Preferences HOW WHERE WHO WHAT Availability and accessibility of information Supportive health systems Respect for human rights Prim in g , P a in m a n a g e m e n t , Supportive framework of law and policy Context-sp e c iﬁc s e r v i c e - d e l i v e r y a p p r o a c h e s In t e g r a t i o n w i t h i n h e a l t h s y s t e m s C o m m o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n ,",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 102
  },
  {
    "chunk_id": "abortioncare_467",
    "text": " t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d e s i r e d ) Abortion management is needed for both induced and spontaneous abortion, including for clinical indications such as missed abortion and intrauterine fetal demise (fetal death). Recommended management options include medical management, or surgical management using manual or electric vacuum aspiration (MVA or EVA) or dilatation and evacuation (D&E). The method of surgical abortion would depend on gestational age: generally vacuum aspiration at < 14 weeks of gestation and D&E at ≥ 14 weeks, but there is flexibility in the use of these methods between 12 and 16 weeks. Medical abortion regimens include sequential use of mifepristone followed by misoprostol or, in set",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 102
  },
  {
    "chunk_id": "abortioncare_468",
    "text": "s, but there is flexibility in the use of these methods between 12 and 16 weeks. Medical abortion regimens include sequential use of mifepristone followed by misoprostol or, in settings where mifepristone is not available (or is restricted for certain clinical indications), the use of misoprostol alone. A new alternative medical method, in particular using letrozole in combination with misoprostol, is also available. For missed abortion and intrauterine fetal demise (see sections 3.4.5 and 3.4.6), in addition to the options of medical and surgical management, expectant management can be offered as an option on the condition that the woman is first informed of the longer time for expulsion of the pregnancy tissue and the increased risk of incomplete emptying of the uterus (the same applies in the case of incomplete abortion, which is addressed in section 3.5.2 on post-abortion care). Medi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 102
  },
  {
    "chunk_id": "abortioncare_469",
    "text": "e and the increased risk of incomplete emptying of the uterus (the same applies in the case of incomplete abortion, which is addressed in section 3.5.2 on post-abortion care). Medical abortion care for all indications plays a crucial role in providing wider access to safe, effective and acceptable abortion care. This may increase the availability and accessibility of abortion and realization of the right to SRH. Across all resource settings, the use of medical abortion has contributed to the expansion of health worker roles, more efficient use of resources and reduced maternal mortality and morbidity from unsafe abortions. Moreover, medical abortion – particularly in early pregnancy – can now be provided at the primary-care level and on an outpatient basis, or from a pharmacy, which further increases access to abortion care. Medical abortion care",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 102
  },
  {
    "chunk_id": "abortioncare_470",
    "text": "65 reduces the need for skilled surgical abortion providers and offers a non-invasive and highly acceptable and safe option to pregnant women. As a matter of international human rights law, States must provide essential medicines listed under WHO’s Action Programme on Essential Drugs, which include abortion medicines (46, para. 12a). The recommendations presented below address surgical and medical management of abortion. Implementation of all of the recommendations in this section are conditional upon women’s values and preferences, the acceptability of each intervention, and the availability of resources to provide the chosen method safely. It should be noted that a woman’s choice of method for abortion management may be limited or not applicable if she has medical contraindications to one of the methods. The recommendations below relate only to the method of abortion, and should not be",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 103
  },
  {
    "chunk_id": "abortioncare_471",
    "text": "ment may be limited or not applicable if she has medical contraindications to one of the methods. The recommendations below relate only to the method of abortion, and should not be read as suggesting gestational age limits for the availability of abortion. 3.4.1 Methods of surgical abortion The provision of vacuum aspiration includes the assessment of gestational age, cervical priming (if needed), the actual procedure, pain management including the provision of a paracervical block and the assessment of completeness of abortion through the visual inspection of products of conception. Health workers with the skills to perform a bimanual pelvic examination to diagnose and date a pregnancy, and to perform a transcervical procedure such as intrauterine device (IUD) insertion, can be trained to perform vacuum aspiration. Recommended methods of surgical abortion at later gestational ages are v",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 103
  },
  {
    "chunk_id": "abortioncare_472",
    "text": "ervical procedure such as intrauterine device (IUD) insertion, can be trained to perform vacuum aspiration. Recommended methods of surgical abortion at later gestational ages are vacuum aspiration and dilatation and evacuation (D&E). Although the recommendations in this section indicate differences before and after 14 weeks of gestation, it should be noted that there is flexibility in the use of one surgical method versus the other between the gestational ages of 12 and 16 weeks. What CLINICAL SERVICES Recommendation 23: Vacuum aspiration for induced abortion at gestational ages < 14 weeks For surgical abortion at < 14 weeks: a. Recommend vacuum aspiration. b. Recommend against the practice of dilatation and sharp curettage (D&C), including sharp curette checks (i.e. to “complete” the abortion) following vacuum aspiration. Remarks: • Observational studies indicate that vacuum aspiration ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 103
  },
  {
    "chunk_id": "abortioncare_473",
    "text": "arp curettage (D&C), including sharp curette checks (i.e. to “complete” the abortion) following vacuum aspiration. Remarks: • Observational studies indicate that vacuum aspiration is associated with fewer complications than D&C; however, randomized controlled trials were underpowered to detect a difference in complication rates. • No evidence supports the use of sharp curette checks following vacuum aspiration. • The quality of the evidence based on randomized controlled trials is low to moderate. Source: Recommendation 1 carried forward from WHO (2012) (19) . Some of the wording has been revised, and the gestational age range has been changed from “up to 12 to 14 weeks” to “before 14 weeks” (< 14 weeks). 3.4 Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 103
  },
  {
    "chunk_id": "abortioncare_474",
    "text": "Abortion care guideline, second edition 66 Who SERVICE DELIVERY Recommendation 24: Vacuum aspiration for induced abortion at gestational ages < 14 weeks Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Recommend Very low-certainty evidence was found for the effectiveness of this option for components of the task (e.g. assessing uterine size with bimanual examination as part of medical abortion provision). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a These professionals perform transcervical procedures (e.g. IUD insertion) in some settings. The expert panel affirmed that the benefits outweigh possible harms and this option has the potential to increase equitable access to quality abortion care in regions where these professionals constitute a s",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 104
  },
  {
    "chunk_id": "abortioncare_475",
    "text": "hat the benefits outweigh possible harms and this option has the potential to increase equitable access to quality abortion care in regions where these professionals constitute a significant proportion of the health workforce. Auxiliary nurses/ANMs Suggest Condition: In contexts where established health system mechanisms involve auxiliary nurses/ANMs in providing basic emergency obstetric care, and where referral and monitoring systems are strong. Although insufficient direct evidence was found for the safety and effectiveness of this option, the benefits outweigh any possible harms. This option has been shown to be feasible, including at scale in low-resource settings, and has the potential to decrease inequities by extending quality abortion care to rural and underserved populations. Nurses Recommend Evidence was found for the safety and effectiveness (low certainty) and for women’s sa",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 104
  },
  {
    "chunk_id": "abortioncare_476",
    "text": "ies by extending quality abortion care to rural and underserved populations. Nurses Recommend Evidence was found for the safety and effectiveness (low certainty) and for women’s satisfaction (low certainty) with this option. Women often consider care received from nurses as more supportive compared with other health workers (moderate-certainty evidence). This option is feasible and may decrease inequities by extending quality abortion care to underserved populations. Midwives Recommend This task is recognized as a core competency in midwifery.a Evidence was found for the safety and effectiveness (moderate certainty) and for women’s satisfaction with the overall abortion experience (low certainty) with this option. Women often consider care received from midwives as more supportive compared with other health workers (moderate-certainty evidence). This option has been shown to be feasible,",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 104
  },
  {
    "chunk_id": "abortioncare_477",
    "text": "on. Women often consider care received from midwives as more supportive compared with other health workers (moderate-certainty evidence). This option has been shown to be feasible, including in low- resource settings. Associate/advanced associate clinicians Recommend Evidence was found for the safety and effectiveness (moderate certainty) and for women’s satisfaction with the overall abortion experience (low certainty) with this option. This option is feasible in all resource settings, and may decrease inequities by extending quality abortion care to underserved populations. Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which eviden",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 104
  },
  {
    "chunk_id": "abortioncare_478",
    "text": "nt of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to traditional and complementary medicine professionals, auxiliary nurses and auxiliary nurse midwives was reviewed using GRADE methodology. After review, only the recommendation for traditional and complementary medicine professionals was upgraded, from “suggest” to “recommend”; the recommendations for all the other health worker categories remained unchanged. A summary of the evidence is presented in Supplementary material 3, EtD framework for Vacuum aspiration for all indications < 14 weeks. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 104
  },
  {
    "chunk_id": "abortioncare_479",
    "text": "rker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Where In a health-care facility. Both types of vacuum aspiration can be performed in a primary care facility and on an outpatient basis.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 104
  },
  {
    "chunk_id": "abortioncare_480",
    "text": "67 How Implementation considerations • While MVA is more commonly used and more likely in primary care settings, the skills required for EVA are similar, thus the recommendations above apply to the provision of either form of vacuum aspiration. • MVA is used earlier in pregnancy and in the absence of access to a stable source of electricity. • Dilatation and sharp curettage (D&C) should be replaced with MVA. What CLINICAL SERVICES Recommendation 25: Methods of surgical abortion at gestational ages ≥ 14 weeks For surgical abortion at ≥ 14 weeks: Recommend dilatation and evacuation (D&E). Remark: • Vacuum aspiration can be used during a D&E (i.e. for the purpose of amniotomy or tissue removal at the end of the D&E). Source: Recommendation 5 carried forward from WHO (2012) (19) . The wording has been revised to use the word “recommend” to indicate that this is a strong recommendation, and t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 105
  },
  {
    "chunk_id": "abortioncare_481",
    "text": "E). Source: Recommendation 5 carried forward from WHO (2012) (19) . The wording has been revised to use the word “recommend” to indicate that this is a strong recommendation, and the gestational age has been changed from “over 12 to 14 weeks” to “14 weeks and above” (≥ 14 weeks), and medical methods were removed (medical methods at later gestational ages are covered in Recommendation 29 in this guidance). Who SERVICE DELIVERY Recommendation 26: Dilatation and evacuation (D&E) for surgical abortion at gestational ages ≥ 14 weeks Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Suggest Condition: In settings where established health system mechanisms exist to include these health workers in other tasks related to maternal and reproductive health. Although no direct evidence was found for the safety, effectiveness or acceptability of this ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 105
  },
  {
    "chunk_id": "abortioncare_482",
    "text": "clude these health workers in other tasks related to maternal and reproductive health. Although no direct evidence was found for the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a This type of health worker has been suggested (weak recommendation) to do other transcervical procedures, such as cervical priming with osmotic dilators, vacuum aspiration and inserting an IUD (see Recommendations 20, 24 and 43). The expert panel affirmed that this option has the potential to increase equitable access to quality abortion care in regions where these professionals constitute a significant proportion of the health workforce. Midwives Suggest Condition: In settings where established health system mechanisms exist to include these health workers in other",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 105
  },
  {
    "chunk_id": "abortioncare_483",
    "text": " a significant proportion of the health workforce. Midwives Suggest Condition: In settings where established health system mechanisms exist to include these health workers in other tasks related to maternal and reproductive health. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a This type of health worker has been recommended to do other transcervical procedures, such as cervical priming with osmotic dilators, vacuum aspiration and inserting an IUD (see Recommendations 20, 24 and 43). Associate/advanced associate clinicians Suggest Condition: In settings where established health system mechanisms exist to include these health workers in other tasks related to maternal and reproductive health. Althou",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 105
  },
  {
    "chunk_id": "abortioncare_484",
    "text": "s Suggest Condition: In settings where established health system mechanisms exist to include these health workers in other tasks related to maternal and reproductive health. Although no direct evidence was found on the safety or effectiveness of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that the potential benefits outweigh the possible harms, and this option has the potential to increase equitable access to quality abortion care beyond 14 weeks of gestation. Table Continues 3.4 Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 105
  },
  {
    "chunk_id": "abortioncare_485",
    "text": "Abortion care guideline, second edition 68 Type of health worker Recommendation Rationalea Generalist medical practitioners Recommend No direct evidence was found on the safety or effectiveness of this option as compared with provision by specialist medical practitioners. However, it appears to be feasible in both high- and low-resource settings where D&E use is common. Such doctors routinely perform other surgical procedures, such as caesarean section, vacuum aspiration and tubal ligation. The potential benefits of this option outweigh the harms. A specialist provider may not always be available on-site and this option may therefore increase equitable access to quality abortion care. Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 106
  },
  {
    "chunk_id": "abortioncare_486",
    "text": "ioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to associate/advanced associate clinicians (previously only suggested in the context of rigorous research), midwives and traditional and complementary medicine professionals (both previously recommended against) was reviewed using GRADE methodology. After review, the recommendations were upgraded for all of them to a weak recommendation (“suggest”). The gestational age range was also amended from “beyond 12 weeks” to “14 weeks and above” (≥ 14 weeks) to align with Recommendation 25 on this topic. A summary of the evidence is presented in Supplementary material 3, EtD framework for D&E for surgical abortion ≥ 14 weeks. a F",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 106
  },
  {
    "chunk_id": "abortioncare_487",
    "text": "eeks) to align with Recommendation 25 on this topic. A summary of the evidence is presented in Supplementary material 3, EtD framework for D&E for surgical abortion ≥ 14 weeks. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Where In a health-care facility. The procedure can be provided on an o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 106
  },
  {
    "chunk_id": "abortioncare_488",
    "text": "eferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Where In a health-care facility. The procedure can be provided on an outpatient basis. How Implementation considerations • For all providers, skills needed for D&E provision are greater than for a vacuum aspiration done in earlier pregnancy and training needs are higher. • D&E includes the use of vacuum aspiration and therefore skills and knowledge of vacuum aspiration are relevant for this task. • Health workers providing abortion or caring for women undergoing abortion at gestational ages ≥ 12 weeks may have additional needs for professional and mentoring support. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO SURGICAL ABORTION • Health-care facilities, commodities and services must be available, accessible, acceptable and of good quality. This means they must be evidence-based an",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 106
  },
  {
    "chunk_id": "abortioncare_489",
    "text": "ANT TO SURGICAL ABORTION • Health-care facilities, commodities and services must be available, accessible, acceptable and of good quality. This means they must be evidence-based and scientifically and medically appropriate and up to date. • AT < 14 WEEKS OF GESTATION: As dilatation and sharp curettage (D&C) causes pain and suffering to women and is not recommended for use, its use is incompatible with numerous human rights including the right to health. • AT ≥ 14 WEEKS OF GESTATION: States must ensure adequate access to essential medicines in an affordable and non-discriminatory manner. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Table Continued",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 106
  },
  {
    "chunk_id": "abortioncare_490",
    "text": "69 All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Health financing (section 1.4.2) Commodities (section 1.4.4) Recommendations 11–15 on pain management 3.4.2 Medical management of induced abortion Medical management of spontaneous and induced abortion (for both viable and non-viable pregnancies) at early or later gestational ages involves the use of a single-dose regimen or a combination regimen of medicines used in sequence, with specific dosages and routes of administration. The medicines that have been used for some decades for medical abortion are mifepristone in combination with misoprostol, or misoprostol alone. Similar to mifepristone, letrozole can be used in combination with misoprostol for medical abortion at early gestational ages. Letrozole is a third-generation selective aromatase inhibitor. Its mechanism of action involves suppression of est",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 107
  },
  {
    "chunk_id": "abortioncare_491",
    "text": " with misoprostol for medical abortion at early gestational ages. Letrozole is a third-generation selective aromatase inhibitor. Its mechanism of action involves suppression of estrogen levels, which modifies the progesterone receptor concentration, subsequently leading to pregnancy loss. Medical abortion is a process that takes place over a period of up to several days rather than being a discrete procedure. In addition to information provision (including reasons to seek urgent care at any point during the process), medical abortion includes the following components or subtasks: i. assessing eligibility for medical abortion (diagnosing and dating the pregnancy, ruling out medical contraindications); ii. administering the abortion medicines with instructions on their appropriate use and managing the common side-effects; iii. assessing whether the abortion process has had a successful out",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 107
  },
  {
    "chunk_id": "abortioncare_492",
    "text": "stering the abortion medicines with instructions on their appropriate use and managing the common side-effects; iii. assessing whether the abortion process has had a successful outcome and whether any further intervention is required. One health worker can provide the whole package of care for medical abortion, but it is equally possible for the subtasks to be carried out by different health workers and at different locations, including remotely. In addition, given the nature of the medical abortion process, it is also possible for women to manage the process by themselves outside of a health-care facility (e.g. at home), with support if and when needed. Such self-assessment and self-management approaches can be empowering for women and help to triage care, leading to a more woman-centred and more optimal use of health resources. Routes of administration for misoprostol used for medical ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 107
  },
  {
    "chunk_id": "abortioncare_493",
    "text": "e empowering for women and help to triage care, leading to a more woman-centred and more optimal use of health resources. Routes of administration for misoprostol used for medical abortion: • Oral – pills are swallowed immediately • Buccal – pills are placed between the cheek and gums and swallowed after 20 to 30 minutes • Sublingual – pills are placed under the tongue and swallowed after 30 minutes • Vaginal – pills are placed in the vagina Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.4 Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 107
  },
  {
    "chunk_id": "abortioncare_494",
    "text": "Abortion care guideline, second edition 70 What CLINICAL SERVICES Recommendation 27: Medical management of induced abortion at gestational ages < 12 weeks For medical abortion at < 12 weeks: a. Recommend the use of 200 mg mifepristone administered orally, followed 1–2 days later by 800 μg misoprostol administered vaginally, sublingually or buccally. The minimum recommended interval between use of mifepristone and misoprostol is 24 hours.* b. When using misoprostol alone: Recommend the use of 800 μg misoprostol administered buccally, sublingually or vaginally.* c. (NEW) Suggest the use of a combination regimen of letrozole plus misoprostol (letrozole 10 mg orally each day for 3 days followed by misoprostol 800 μg sublingually on the fourth day) as a safe and effective option.* ǂ Remarks: • Evidence from clinical studies demonstrates that the combination regimen (Recommendation 27a) is mor",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 108
  },
  {
    "chunk_id": "abortioncare_495",
    "text": "g sublingually on the fourth day) as a safe and effective option.* ǂ Remarks: • Evidence from clinical studies demonstrates that the combination regimen (Recommendation 27a) is more effective than misoprostol alone. • All routes are included as options for misoprostol administration, in consideration of patient and provider preference. • The suggested combination regimen of letrozole plus misoprostol may be safe and effective up to 14 weeks of gestation. * Repeat doses of misoprostol can be considered when needed to achieve success of the abortion process. In this guideline we do not provide a maximum number of doses of misoprostol. ǂ Further evidence is needed to determine the safety, effectiveness and acceptability of the letrozole plus misoprostol combination regimen at later gestational ages, especially in comparison with that of the mifepristone plus misoprostol combination regimen ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 108
  },
  {
    "chunk_id": "abortioncare_496",
    "text": "bility of the letrozole plus misoprostol combination regimen at later gestational ages, especially in comparison with that of the mifepristone plus misoprostol combination regimen (the available evidence focused on comparison with the use of misoprostol alone). Source: Recommendations 27a and 27b carried forward from WHO (2018) where they were Recommendation 3a (120). Recommendation 27c is new. Rationale for Recommendation 27c (combination regimen of letrozole plus misoprostol) A systematic review assessed the efficacy, safety and acceptability of alternative methods of medical abortion to the standard regimens using mifepristone and/or misoprostol. The literature search identified seven studies, all of which reported on the combination of letrozole plus misoprostol (intervention) versus misoprostol alone (comparison) for medical abortion. No studies were identified that compared letrozo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 108
  },
  {
    "chunk_id": "abortioncare_497",
    "text": "eported on the combination of letrozole plus misoprostol (intervention) versus misoprostol alone (comparison) for medical abortion. No studies were identified that compared letrozole plus misoprostol versus mifepristone plus misoprostol. The study settings included China, Egypt and the Islamic Republic of Iran. A summary of the evidence is presented in Supplementary material 2, EtD framework for New medical methods for abortion. Overall, the evidence favoured the intervention. The use of letrozole in combination with misoprostol showed lower rates of ongoing pregnancy and higher rates of successful abortion, based on low- to very low-certainty evidence. In addition, fewer women experienced side-effects, based on moderate-certainty evidence. Discussion on the cost-effectiveness, equity, feasibility and acceptability favoured the intervention. Letrozole's typical use for infertility and ca",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 108
  },
  {
    "chunk_id": "abortioncare_498",
    "text": "n moderate-certainty evidence. Discussion on the cost-effectiveness, equity, feasibility and acceptability favoured the intervention. Letrozole's typical use for infertility and cancer treatment makes it more readily accessible than mifepristone in certain parts of the world. In addition, the low cost of letrozole is another contributing factor to making this an alternative method for medical abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 108
  },
  {
    "chunk_id": "abortioncare_499",
    "text": "71 Who SERVICE DELIVERY Recommendation 28: Medical management of induced abortion at gestational ages < 12 weeks,* in whole or in part (i.e. performing all or some of the subtasks; see list at start of section 3.4.2) using mifepristone plus misoprostol, or misoprostol aloneǂ Type of health worker Recommendation Rationalea Community health workers (CHWs) Recommend Evidence was found for the safety, effectiveness and acceptability of this option, for all three subtasks of medical abortion (moderate certainty). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Indirect evidence also demonstrated the feasibility and acceptability of CHWs facilitating assessment of eligibility and outcome. Pharmacy workers Recommend Limited evidence was found for the safety, effectiveness, acceptability or feasibility of",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 109
  },
  {
    "chunk_id": "abortioncare_500",
    "text": "ity of CHWs facilitating assessment of eligibility and outcome. Pharmacy workers Recommend Limited evidence was found for the safety, effectiveness, acceptability or feasibility of this option (non-comparative studies). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Indirect evidence on CHWs was applied to support the feasibility of this option. Pharmacists Recommend Although insufficient evidence was found for the safety, effectiveness and acceptability of pharmacists performing the three subtasks of medical abortion, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Dispensing medicines on prescription is within their typical scope of practice. The expert panel affirmed that, with the aid of tools for asse",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 109
  },
  {
    "chunk_id": "abortioncare_501",
    "text": "cies for this type of health worker.a Dispensing medicines on prescription is within their typical scope of practice. The expert panel affirmed that, with the aid of tools for assessment of eligibility and outcome, it would be feasible for pharmacists to provide all three subtasks of medical abortion. Traditional and complementary medicine professionals Recommend Evidence was found for the safety and effectiveness of this option, and for women’s satisfaction with this type of provider and services provided by them (very low certainty). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that the benefits outweigh any possible harms, and the potential to increase equitable access to quality abortion care in regions where these professionals constitute a significant proportion ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 109
  },
  {
    "chunk_id": "abortioncare_502",
    "text": "efits outweigh any possible harms, and the potential to increase equitable access to quality abortion care in regions where these professionals constitute a significant proportion of the health workforce is high. Auxiliary nurses/ANMs Recommend Evidence was found for the safety and effectiveness of this option (moderate certainty). This option is feasible and is already being implemented in some low-resource settings. Nurses Recommend Evidence was found for the safety and effectiveness of this option, and for women’s satisfaction with abortion services with this option (moderate certainty). Midwives Recommend Evidence was found for the safety and effectiveness of this option (moderate certainty). More women are satisfied with the provider when midwives provide medical abortion (moderate- certainty evidence). This option is feasible and is already being implemented in several countries. A",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 109
  },
  {
    "chunk_id": "abortioncare_503",
    "text": " satisfied with the provider when midwives provide medical abortion (moderate- certainty evidence). This option is feasible and is already being implemented in several countries. Associate/advanced associate clinicians Recommend Insufficient direct evidence was found for the effectiveness of these clinicians carrying out components of the task, e.g. assessing gestational age as part of provision of manual vacuum aspiration. Evidence was also found that health worker types with similar or less comprehensive basic training (e.g. midwives, nurses, auxiliary nurse midwives) can provide medical abortion safely and effectively (moderate certainty). This option is feasible and the potential to expand access to underserved populations is high. Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the eviden",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 109
  },
  {
    "chunk_id": "abortioncare_504",
    "text": "rved populations is high. Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Table Continues 3.4 Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 109
  },
  {
    "chunk_id": "abortioncare_505",
    "text": "Abortion care guideline, second edition 72 Type of health worker Recommendation Rationalea Individual/self Pregnant woman, girl or other pregnant person Recommend Please refer to Recommendation 50 in section 3.6.2 for rationale, remarks and implementation considerations for this recommendation and further information on self-management approaches. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to traditional and complementary medicine professionals (previously only recommended in contexts with established health system mechanisms for the participation of these health workers in other tasks related to maternal and reproductive health), pharmacists (previously only suggested in the context of rigorous research), pharmacy workers (previously “recommend against”), community health w",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 110
  },
  {
    "chunk_id": "abortioncare_506",
    "text": "aternal and reproductive health), pharmacists (previously only suggested in the context of rigorous research), pharmacy workers (previously “recommend against”), community health workers (previously only suggested in the context of rigorous research) and individual/self (self- management; previously “suggest”) was reviewed using GRADE methodology. After review, the recommendations were upgraded for all of those health worker categories to “recommend”, including all three subtasks of this intervention. A summary of the evidence is presented in Supplementary material 3, EtD framework for Medical abortion at < 12 weeks. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 110
  },
  {
    "chunk_id": "abortioncare_507",
    "text": "alth worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. * Available evidence for the independent provision of medical abortion by non-physicians is for pregnancy durations up to 10 weeks (70 days). ǂ For this recommendation, the medical abortion regimens covered in the available evidence were mifepristone plus misoprostol, or misoprostol alone (the regimen using letrozole was not included). Wher",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 110
  },
  {
    "chunk_id": "abortioncare_508",
    "text": "ation, the medical abortion regimens covered in the available evidence were mifepristone plus misoprostol, or misoprostol alone (the regimen using letrozole was not included). Where No requirement for location (on-site vs off-site). How Implementation considerations • It is not essential that the person providing the medical abortion should also be trained and competent in vacuum aspiration provision. • Restrictions on prescribing and dispensing authority for some categories of health workers may need to be modified within the regulatory framework of the health system or other mechanisms put in place to allow these providers to make the medicines available to abortion seekers. • Privacy should be ensured in all settings, in particular in places where a private space may be challenging (e.g. pharmacies). • Support tools can be used to assess eligibility and outcome (e.g. high-sensitivity ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 110
  },
  {
    "chunk_id": "abortioncare_509",
    "text": " settings, in particular in places where a private space may be challenging (e.g. pharmacies). • Support tools can be used to assess eligibility and outcome (e.g. high-sensitivity pregnancy tests, checklists). • A range of service-delivery models exist to facilitate the medical abortion process, such as telemedicine or community outreach (see section 3.6.1). • Mechanisms to ensure access to quality medicines need to be set up. Development of tools like point-of- care tests to assess quality could support both the pharmacy worker and the individual. • It is important to note that as with all other medicines, pharmacy workers should dispense mifepristone and misoprostol as indicated by prescription. • The person undergoing medical abortion should have access/referral to emergency care in case this becomes necessary. • As part of the enabling environment, health workers should recognize sel",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 110
  },
  {
    "chunk_id": "abortioncare_510",
    "text": "undergoing medical abortion should have access/referral to emergency care in case this becomes necessary. • As part of the enabling environment, health workers should recognize self-management as a legitimate pathway to abortion care and to adapt health systems to facilitate and support women in their self- management of abortion, e.g. adapting clinical protocols. • Mechanisms need to be established to ensure access or referrals to post-abortion contraception services and provision of contraceptives for women who want them. Table Continued",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 110
  },
  {
    "chunk_id": "abortioncare_511",
    "text": "73 What CLINICAL SERVICES Recommendation 29: Medical management of induced abortion at gestational ages ≥ 12 weeks For medical abortion at ≥ 12 weeks: a. Suggest the use of 200 mg mifepristone administered orally, followed 1–2 days later by repeat doses of 400 μg misoprostol administered buccally, sublingually or vaginally every 3 hours.* ǂ The minimum recommended interval between use of mifepristone and misoprostol is 24 hours. b. When using misoprostol alone: Suggest the use of repeat doses of 400 μg misoprostol administered vaginally, sublingually or buccally every 3 hours.*ǂ Remarks: • The combination regimen (Recommendation 29a) is more effective than use of misoprostol alone. • Evidence suggests that the vaginal route is the most effective. Consideration for patient and provider preference suggests the inclusion of all routes. • Pregnancy tissue should be treated in the same way as",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 111
  },
  {
    "chunk_id": "abortioncare_512",
    "text": "vaginal route is the most effective. Consideration for patient and provider preference suggests the inclusion of all routes. • Pregnancy tissue should be treated in the same way as other biological material unless the individual expresses a desire for it to be managed otherwise. * Misoprostol can be repeated at the noted interval as needed to achieve success of the abortion process. Providers should use caution and clinical judgement to decide the maximum number of doses of misoprostol in pregnant individuals with a prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness for emergency management of uterine rupture must be considered with later gestational age. ǂ The dose of misoprostol should be reduced for induced abortion beyond 24 weeks due to limited data. Clinical judgement should be used to determine the appropriate dosage, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 111
  },
  {
    "chunk_id": "abortioncare_513",
    "text": "l age. ǂ The dose of misoprostol should be reduced for induced abortion beyond 24 weeks due to limited data. Clinical judgement should be used to determine the appropriate dosage, recognizing the greater sensitivity of the uterus to prostaglandins. Source: Recommendation 3b carried forward from WHO (2018) (120) . Who SERVICE DELIVERY Recommendation 30: Medical management of induced abortion at gestational ages ≥ 12 weeks Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 111
  },
  {
    "chunk_id": "abortioncare_514",
    "text": "ough no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, these professionals have been recommended to provide medical abortion at < 12 weeks (Recommendation 28). The potential to increase equitable access to quality abortion care in regions where these professionals form a significant proportion of the health workforce is high. Auxiliary nurses/ANMs Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competenc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 111
  },
  {
    "chunk_id": "abortioncare_515",
    "text": "omplications. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, these health workers have been recommended to provide medical abortion at < 12 weeks (Recommendation 28). This option is feasible and acceptable and has the potential to increase equitable access to quality abortion care. Table Continues 3.4 Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 111
  },
  {
    "chunk_id": "abortioncare_516",
    "text": "Abortion care guideline, second edition 74 Type of health worker Recommendation Rationalea Nurses Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safely and effectiveness of nurses providing this intervention as a whole, these health workers are often responsible for the monitoring and care of women from the time of misoprostol administration to completion of the abortion. Women often find abortion care provided by nurses to be more acceptable (moderate-certainty evidence). Midwives Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient di",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 112
  },
  {
    "chunk_id": "abortioncare_517",
    "text": "re established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safety and effectiveness of midwives providing this intervention as a whole, these health workers are often responsible for the monitoring and care of women from the time of misoprostol administration to completion of the abortion. Women often find abortion care provided by midwives to be more acceptable (moderate-certainty evidence). Associate/advanced associate clinicians Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safety of effectiveness of this option, these clinicians routinel",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 112
  },
  {
    "chunk_id": "abortioncare_518",
    "text": "ble to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safety of effectiveness of this option, these clinicians routinely carry out tasks of similar complexity (e.g. vacuum aspiration and manual removal of placenta) (138). These clinicians are often present at higher-level facilities where care during advanced gestation is provided. A trained specialist medical practitioner may not always be present at higher-level facilities and the potential to sustain services for advanced gestational ages is increased with more than one trained provider on site. Generalist medical practitioners Recommend Although insufficient direct evidence was found for the safety and effectiveness of this option, generalist medical practitioners routinely carry out tasks of similar or greater complexity (e.g. conducting deliveries, manual removal of place",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 112
  },
  {
    "chunk_id": "abortioncare_519",
    "text": "y and effectiveness of this option, generalist medical practitioners routinely carry out tasks of similar or greater complexity (e.g. conducting deliveries, manual removal of placenta, vacuum aspiration). The potential benefits of this option outweigh the harms and the intervention has proven feasible in several settings. A specialist medical practitioner may not always be available on-site and therefore this option may increase equitable access to quality abortion care. Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Notes on updating of the recommendation: This was an existing recommendation for which evidence relating to all health worker categories was reviewed using GRADE methodology, except for specialist and generalist medical practitione",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 112
  },
  {
    "chunk_id": "abortioncare_520",
    "text": "n existing recommendation for which evidence relating to all health worker categories was reviewed using GRADE methodology, except for specialist and generalist medical practitioners, for whom there was already a strong recommendation for this task. After review, the recommendations were upgraded for traditional and complementary medicine professionals and auxiliary nurses/ANMs from “recommend against” to “suggest” with specified conditions. For the other health worker categories reviewed, the recommendations remain unchanged. A summary of the evidence is presented in Supplementary material 3, EtD framework for Medical abortion at ≥ 12 weeks. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 112
  },
  {
    "chunk_id": "abortioncare_521",
    "text": "vidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Where Medical abortion for pregnancies at gestational ages ≥ 12 weeks has been practised and researched as a facility- based procedure during which women should remain under observation until the process is complete. How Implementation consideration • Health workers providing abortion or caring for women undergoing",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 112
  },
  {
    "chunk_id": "abortioncare_522",
    "text": "uring which women should remain under observation until the process is complete. How Implementation consideration • Health workers providing abortion or caring for women undergoing abortion at gestational ages ≥ 12 weeks may have additional needs for professional and mentoring support. Table Continued",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 112
  },
  {
    "chunk_id": "abortioncare_523",
    "text": "75 All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Information provision and counselling (section 3.2.1 and 3.2.2) Determining gestational age (section 3.3.5) Pain management for abortion (section 3.3.6) Self-management of medical abortion (section 3.6.2) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO MEDICAL ABORTION • Everyone has a right to privacy and confidentiality in sexual and reproductive health (SRH) care. • Abortion regulation should be human rights and evidence based. • States must ensure adequate access to essential medicines in an affordable and non- discriminatory manner. • Everyone has the right to scientific progress and right to health, wh",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 113
  },
  {
    "chunk_id": "abortioncare_524",
    "text": "• States must ensure adequate access to essential medicines in an affordable and non- discriminatory manner. • Everyone has the right to scientific progress and right to health, which requires the availability and accessibility, acceptability, and quality of medical abortion. This means that States should ensure access to abortion medicines, and that evidence-based standards and guidelines for the provision and delivery of SRH services, are (i) in place and (ii) routinely updated to incorporate medical advancements. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. 3.4 Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 113
  },
  {
    "chunk_id": "abortioncare_525",
    "text": "Abortion care guideline, second edition 76 3.4.3 Missed abortion Missed abortion is when a pregnancy stops developing, where the embryo/fetus/embryonic tissue or empty gestation sac remains in the uterus and the cervical os is closed. Symptoms may include pain, bleeding or no symptoms at all. If an ultrasound is done, the scan may show an embryo or fetus without cardiac activity, or what appears to be an early developing pregnancy, with only a fluid-filled sac visible within the uterus (151) . Medical, surgical (vacuum aspiration) and expectant management are all options for management of missed abortion. What CLINICAL SERVICES Recommendation 31 (NEW): Medical management of missed abortion at gestational ages < 14 weeks For missed abortion at < 14 weeks, for individuals preferring medical management: Recommend the use of combination mifepristone plus misoprostol over misoprostol alone. ☐",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 114
  },
  {
    "chunk_id": "abortioncare_526",
    "text": " 14 weeks For missed abortion at < 14 weeks, for individuals preferring medical management: Recommend the use of combination mifepristone plus misoprostol over misoprostol alone. ☐ Recommended regimen: 200 mg mifepristone administered orally, followed by 800 μg misoprostol administered by any route (buccal, sublingual, vaginal).* ☐ Alternative regimen: 800 μg misoprostol administered by any route (buccal, sublingual, vaginal). ǂ Remarks: • The decision about the mode of management (expectant, medical or surgical) of missed abortion should be based on the individual’s clinical condition and preference for treatment. • Expectant management can be offered as an option on the condition that the woman, girl or other pregnant person is informed of the longer time for expulsion of the pregnancy tissue and the increased risk of incomplete emptying of the uterus. • Pregnancy tissue should be trea",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 114
  },
  {
    "chunk_id": "abortioncare_527",
    "text": " pregnant person is informed of the longer time for expulsion of the pregnancy tissue and the increased risk of incomplete emptying of the uterus. • Pregnancy tissue should be treated in the same way as other biological material unless the individual expresses a desire for it to be managed otherwise. * The minimum recommended interval between use of mifepristone and misoprostol is 24 hours. ǂ If using the alternative regimen (misoprostol alone), it should be noted that at gestational ages ≥ 9 weeks, evidence shows that repeat dosing of misoprostol is more effective to achieve success of the abortion process. In this guideline we do not provide a maximum number of doses of misoprostol. Rationale A systematic review was undertaken to address this key question. Twenty studies reporting on management for missed abortion were identified by the search strategy. These studies were conducted in ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 114
  },
  {
    "chunk_id": "abortioncare_528",
    "text": "iew was undertaken to address this key question. Twenty studies reporting on management for missed abortion were identified by the search strategy. These studies were conducted in China, Germany, India, Israel, Malaysia, Pakistan, Sweden, Thailand, United Kingdom, USA and Yemen. A summary of the evidence is presented in Supplementary material 2, EtD framework for Medical management of missed abortion at < 14 weeks. Of these studies, 19 were assessed that included one of the following comparisons: • Mifepristone and misoprostol versus misoprostol alone • Medical versus expectant management • Surgical versus medical/expectant management Medical management in comparison to expectant management produced lower rates of ongoing pregnancy and higher rates of successful abortion (uterine evacuation without surgical intervention), based on moderate- to high-certainty evidence. When comparing the ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 114
  },
  {
    "chunk_id": "abortioncare_529",
    "text": " of ongoing pregnancy and higher rates of successful abortion (uterine evacuation without surgical intervention), based on moderate- to high-certainty evidence. When comparing the combination regimen with misoprostol alone, the combination regimen produced higher rates of successful abortion. This recommendation is based on moderate-certainty evidence. Complications and side-effects were also fewer, based on moderate- to high-certainty evidence. Women expressed greater satisfaction with the combination mifepristone plus misoprostol regimen, based on high-certainty evidence. Surgical management in comparison to medical and expectant management produced higher rates of successful abortion, based on low- to moderate-certainty evidence. Discussion of women’s values and preferences underlined the importance of offering the option of all three types of management to the woman. For the medical ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 114
  },
  {
    "chunk_id": "abortioncare_530",
    "text": "te-certainty evidence. Discussion of women’s values and preferences underlined the importance of offering the option of all three types of management to the woman. For the medical regimen, the expert panel determined that given the varied regimens of the included studies, the recommended and suggested regimens for induced abortion at < 12 weeks of gestation can be applied (see Recommendation 27).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 114
  },
  {
    "chunk_id": "abortioncare_531",
    "text": "77 Who Regarding who is recommended to provide medical management of missed abortion at < 14 weeks of gestation, refer to Recommendation 28 for medical management of induced abortion at gestational ages < 12 weeks. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO MANAGEMENT OF MISSED ABORTION • Everyone has a right to privacy and confidentiality in sexual and reproductive health (SRH) care. • Abortion regulation should be human rights and evidence based. • States must ensure adequate access to essential medicines in an affordable and non- discriminatory manner. • Everyone has the right to scientific progress and right to health, which requires the availability and accessibility, acceptability, and quality of medical abortion. This means that States should ensure access to abortion medicines, and that evidence-based standards and guidelines for the provision and delivery of SRH services, are (",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 115
  },
  {
    "chunk_id": "abortioncare_532",
    "text": " abortion. This means that States should ensure access to abortion medicines, and that evidence-based standards and guidelines for the provision and delivery of SRH services, are (i) in place and (ii) routinely updated to incorporate medical advancements. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Commodities (section 1.3.4) Information provision and counselling (sections 3.2.1 and 3.2.2) Recommendation 27: Medical management of induced abortion < 12 weeks Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.4 Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 115
  },
  {
    "chunk_id": "abortioncare_533",
    "text": "Abortion care guideline, second edition 78 3.4.4 Intrauterine fetal demise (IUFD) Fetal demise (fetal death) refers to situations in which the fetus is no longer alive, but the uterus has not yet started to expel its contents and the cervical os remains closed (152) . The diagnosis is made by ultrasound scan following the clinical findings, which can include vaginal bleeding, absent fetal heart sounds on electronic auscultation, a failure to feel fetal movements or a uterus that is significantly smaller than the expected size (152) . IUFD may be managed expectantly, or treated surgically (D&E) or medically. What CLINICAL SERVICES Recommendation 32: Medical management of IUFD at gestational ages ≥ 14 to ≤ 28 weeks For medical management of IUFD at ≥ 14 to ≤ 28 weeks: Suggest the use of combination mifepristone plus misoprostol over misoprostol alone. ☐ Suggested regimen: 200 mg mifepristo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 116
  },
  {
    "chunk_id": "abortioncare_534",
    "text": "ks For medical management of IUFD at ≥ 14 to ≤ 28 weeks: Suggest the use of combination mifepristone plus misoprostol over misoprostol alone. ☐ Suggested regimen: 200 mg mifepristone administered orally, followed 1–2 days later by repeat doses of 400 μg misoprostol administered sublingually or vaginally every 4–6 hours.* ǂ The minimum recommended interval between use of mifepristone and misoprostol is 24 hours. ☐ Alternative regimens: repeat doses of 400 μg misoprostol administered sublingually or vaginally every 4–6 hours.*ǂ Remarks: • Evidence from clinical studies indicates that the combination regimen is more effective than the use of misoprostol alone. • Pregnancy tissue should be treated in the same way as other biological material unless the individual expresses a desire for it to be managed otherwise. * Misoprostol can be repeated at the noted interval as needed to achieve succes",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 116
  },
  {
    "chunk_id": "abortioncare_535",
    "text": "s other biological material unless the individual expresses a desire for it to be managed otherwise. * Misoprostol can be repeated at the noted interval as needed to achieve success of the abortion process. Providers should use caution and clinical judgement to decide the maximum number of doses of misoprostol in pregnant individuals with prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness for emergency management of uterine rupture must be considered with later gestational age. ǂ The dose of misoprostol should be reduced for IUFD beyond 28 weeks due to limited data. Clinical judgement should be used to determine the appropriate dosage, recognizing the greater sensitivity of the uterus to prostaglandins. Source: Recommendation 2 carried forward from WHO (2018) (120). Wording has been revised to match that used for Recommendati",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 116
  },
  {
    "chunk_id": "abortioncare_536",
    "text": "he greater sensitivity of the uterus to prostaglandins. Source: Recommendation 2 carried forward from WHO (2018) (120). Wording has been revised to match that used for Recommendation 31 on missed abortion. Who SERVICE DELIVERY Recommendation 33 (NEW): Medical management of intrauterine fetal demise (IUFD) at gestational ages ≥ 14 to ≤ 28 weeks Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, these prof",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 116
  },
  {
    "chunk_id": "abortioncare_537",
    "text": " of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, these professionals have been recommended to provide medical abortion at < 12 weeks (Recommendation 28). The expert panel affirmed that the potential to increase equitable access to quality abortion care in regions where such professionals constitute a significant proportion of the health workforce is high. Auxiliary nurses/ANMs Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although no direct evidence was found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies fo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 116
  },
  {
    "chunk_id": "abortioncare_538",
    "text": "as found on the safety, effectiveness or acceptability of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, these health workers have been recommended to provide medical abortion at < 12 weeks (Recommendation 28). The expert panel determined that this option is feasible and acceptable with the potential to increase equitable access to quality abortion care. Table Continues",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 116
  },
  {
    "chunk_id": "abortioncare_539",
    "text": "79 Type of health worker Recommendation Rationalea Nurses Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safety and effectiveness of this option, these health workers are often responsible for the monitoring and care of women from the time of misoprostol administration to completion of the abortion. Women often find abortion care provided by nurses to be more acceptable compared with other health workers (moderate- certainty evidence). Midwives Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safety",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 117
  },
  {
    "chunk_id": "abortioncare_540",
    "text": "opriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safety and effectiveness of this option, these health workers are often responsible for the monitoring and care of women from the time of misoprostol administration to completion of the abortion. Women often find abortion care provided by midwives to be more acceptable compared with other health workers (moderate- certainty evidence). Associate/advanced associate clinicians Suggest Condition: In contexts where established and easy access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications. Although insufficient direct evidence was found for the safety and effectiveness of this option, these clinicians routinely carry out tasks of similar complexi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 117
  },
  {
    "chunk_id": "abortioncare_541",
    "text": "other complications. Although insufficient direct evidence was found for the safety and effectiveness of this option, these clinicians routinely carry out tasks of similar complexity, such as vacuum aspiration and manual removal of placentas (138). These clinicians are often present at higher-level facilities where care is provided in advanced gestation. A trained specialist medical practitioner may not always be present at a higher-level facility and the potential to sustain services for advanced gestational ages is increased with more than one trained provider on site. Generalist medical practitioners Recommend Although insufficient direct evidence was found for the safety and effectiveness of this option, these professionals routinely carry out tasks of similar or greater complexity (e.g. conducting deliveries, manual removal of placentas, vacuum aspiration). The potential benefits of",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 117
  },
  {
    "chunk_id": "abortioncare_542",
    "text": "ese professionals routinely carry out tasks of similar or greater complexity (e.g. conducting deliveries, manual removal of placentas, vacuum aspiration). The potential benefits of this option outweigh the harms, and the intervention has proven feasible in several settings. A specialist medical practitioner may not always be available on site and therefore this option may increase equitable access to quality abortion care. Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Note: This is a new recommendation. There was no recommendation on medical management of IUFD in WHO’s 2015 guideline on health worker roles (23), but a clinical services recommendation on this intervention was provided in WHO’s 2018 guideline, Medical management of abortion (120). Due to the lack of direct evidence on this topic an",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 117
  },
  {
    "chunk_id": "abortioncare_543",
    "text": "linical services recommendation on this intervention was provided in WHO’s 2018 guideline, Medical management of abortion (120). Due to the lack of direct evidence on this topic and the similarity between the two tasks, Recommendation 30 for medical abortion at ≥ 12 weeks of gestation was applied here. A summary of the evidence is presented in Supplementary material 3, EtD framework on Medical management of intrauterine fetal demise. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the fe",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 117
  },
  {
    "chunk_id": "abortioncare_544",
    "text": "ary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Where Medical abortion for pregnancies at gestational ages ≥ 12 weeks has been practised and researched as a facility- based procedure during which women should remain under observation until the process is complete. How Implementation consideration • Any regulation around the management/disposal of pregnancy remains and birth or death certificates should not pose a burden or a breach of confidentiality for women or providers. Table Continued 3.4 Abortion women’s values and preferences.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 117
  },
  {
    "chunk_id": "abortioncare_545",
    "text": "Abortion care guideline, second edition 80 KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO MANAGEMENT OF IUFD • Everyone has a right to privacy and confidentiality in sexual and reproductive health (SRH) care. • Abortion regulation should be human rights and evidence based. • States must ensure adequate access to essential medicines in an affordable and non- discriminatory manner. • Everyone has the right to scientific progress and right to health, which requires the availability and accessibility, acceptability, and quality of medical abortion. This means that States should ensure access to abortion medicines, and that evidence-based standards and guidelines for the provision and delivery of SRH services, are (i) in place and (ii) routinely updated to incorporate medical advancements. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human right",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 118
  },
  {
    "chunk_id": "abortioncare_546",
    "text": "in place and (ii) routinely updated to incorporate medical advancements. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. All recommendations relating to law and policy (Recommendations 1,2,3,6,7,21,22) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 118
  },
  {
    "chunk_id": "abortioncare_547",
    "text": "81 3.5 Post-abortion Hom e P h a r m a c y C o m m u n i t y o u t r e a c h c e n t r e s P r i m a r y c a r e f a c i l i t y H i g h e r - le v e l fa cility F a c i l i t y - b a s e d h e a l t h w o r k e r s O t h e r h e a l t h w o rk e rsS e lf Abortion Pre-abortion Post-abortion Values & Preferences HOW WHERE WHO WHAT Availability and accessibility of information Supportive health systems Respect for human rights Prim in g , P a in m a n a g e m e n t , Supportive framework of law and policy Context-sp e c iﬁc s e r v i c e - d e l i v e r y a p p r o a c h e s In t e g r a t i o n w i t h i n h e a l t h s y s t e m s C o m m o d i t i e s F i n a n c e s Li n k s t o o th e r services M e d i c a l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 119
  },
  {
    "chunk_id": "abortioncare_548",
    "text": "l a n d s u r g i c a l m e t h o d s A n t ib i o t i c s C o n t r a c e p t io n , M a n a g i n g c o m p lic a tions I n f o r m a t i o n , c o u n s e l l i n g (wh e r e d e s i r e d ) The post-abortion period is the third and final part of the continuum of care for abortion. Post-abortion care includes any or all of the following, as needed or desired: optional follow-up check-up, management of residual side-effects or complications, and contraception services. When done safely, abortion complications are rare, but they can include incomplete abortion, haemorrhage, infection, uterine perforation, anaesthesia-related complications, uterine rupture. In line with international human rights law and medical best practice, post-abortion care should always be provided regardless of whether abortion is restricted in a particular setting. 3.5.1 Follow-up care after abortion Routine foll",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 119
  },
  {
    "chunk_id": "abortioncare_549",
    "text": "l best practice, post-abortion care should always be provided regardless of whether abortion is restricted in a particular setting. 3.5.1 Follow-up care after abortion Routine follow-up is not necessary following an uncomplicated surgical or medical abortion, if the individual has adequate information about when to seek care for complications and has received any appropriate supplies or information to meet contraceptive needs. However, an optional follow-up visit 7–14 days after the procedure may be offered to provide contraceptive services, emotional support or management of any medical concerns. If the woman chooses to attend a follow-up appointment, then use the contact to: • assess the individual’s recovery and inquire about any signs or symptoms of ongoing pregnancy; • review any available medical records and referral documents; • ask about any symptoms experienced since the procedu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 119
  },
  {
    "chunk_id": "abortioncare_550",
    "text": " and inquire about any signs or symptoms of ongoing pregnancy; • review any available medical records and referral documents; • ask about any symptoms experienced since the procedure; • perform a focused physical examination if needed to assess any complaints; and • assess the individual’s fertility goals and need for contraceptive services. ☐ If no contraceptive method was provided or started at the time of the abortion, provide information on contraception and offer contraceptive counselling and provision of contraceptive services, if desired by the woman. ☐ If a contraceptive method was already started, assess the method used and address any concerns or resupply as needed (122). 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 119
  },
  {
    "chunk_id": "abortioncare_551",
    "text": "Abortion care guideline, second edition 82 What CLINICAL SERVICES Recommendation 34: Follow-up care or additional services after abortion Following uncomplicated surgical abortion or medical abortion: Recommend that there is no medical need for a routine follow-up visit. However, information should be provided about the availability of additional services if they are needed or desired. Remarks: • Women, girls and other pregnant persons must be adequately informed about symptoms of ongoing pregnancy (which may or may not indicate failure of the abortion) and other medical reasons to return for follow-up, such as prolonged heavy bleeding, no bleeding at all with medical management of abortion, pain not relieved by medication, or fever. • The quality of the evidence was low (observational studies and indirect evidence). Source: Recommendation 9 updated from WHO (2012) (19) . Note on updatin",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 120
  },
  {
    "chunk_id": "abortioncare_552",
    "text": "y medication, or fever. • The quality of the evidence was low (observational studies and indirect evidence). Source: Recommendation 9 updated from WHO (2012) (19) . Note on updating of the recommendation: This was an existing recommendation for which an updated literature search was conducted, but GRADE methodology was not applied. The wording of the recommendation was revised to remove the medical abortion regimen that was mentioned (this recommendation now applies to all abortion methods and regimens, see section 3.4) and to use the word “recommend” to make clear this is a strong recommendation. All recommendations relating to law and policy (Recommendations 1,2,3,6,7,21,22) Information provision (section 3.2.1) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 120
  },
  {
    "chunk_id": "abortioncare_553",
    "text": ".1) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO FOLLOW-UP CARE • Regardless of whether abortion is legal, States are required to ensure access to post- abortion care where it is needed. • Post-abortion care must be available on a confidential basis, including in situations where abortion is illegal. • Post-abortion care must be available without the threat of criminal prosecution or punitive measures. States must not require health workers to report persons suspected of undertaking unlawful abortion, or require them to provide any potentially incriminating information during or as a prerequisite to receiving post-abortion care. For further information and sources, please refer to Box 1",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 120
  },
  {
    "chunk_id": "abortioncare_554",
    "text": "re them to provide any potentially incriminating information during or as a prerequisite to receiving post-abortion care. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 120
  },
  {
    "chunk_id": "abortioncare_555",
    "text": "83 3.5.2 Incomplete abortion Incomplete abortion is defined by clinical presence of an open cervical os and bleeding, whereby all products of conception have not been expelled from the uterus, or the expelled products are not consistent with the estimated duration of pregnancy. Common symptoms include vaginal bleeding and abdominal pain. Uncomplicated incomplete abortion can result after an induced or spontaneous abortion (i.e. miscarriage); the management in both cases is the same. Incomplete abortion may be managed expectantly, medically or surgically (vacuum aspiration). Managing uncomplicated incomplete abortion with vacuum aspiration (when uterine size is less than 14 weeks) includes recognizing the condition, assessing uterine size, the actual procedure and pain management. What CLINICAL SERVICES Recommendation 35 and 36: Management of incomplete abortion 35. For incomplete abortio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 121
  },
  {
    "chunk_id": "abortioncare_556",
    "text": "ion, assessing uterine size, the actual procedure and pain management. What CLINICAL SERVICES Recommendation 35 and 36: Management of incomplete abortion 35. For incomplete abortion at < 14 weeks: Recommend either vacuum aspiration or medical management. 36a. For the medical management of incomplete abortion at < 14 weeks uterine size: Suggest the use of 600 μg misoprostol administered orally or 400 μg misoprostol administered sublingually. 36b. For the medical management of incomplete abortion at ≥ 14 weeks uterine size: Suggest the use of repeat doses of 400 μg misoprostol administered sublingually, vaginally or buccally every 3 hours.* Remarks: • The decision about the mode of management of incomplete abortion should be based on the individual’s clinical condition and preference for treatment. • Expectant management of incomplete abortion can be as effective as misoprostol; it can be ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 121
  },
  {
    "chunk_id": "abortioncare_557",
    "text": "on should be based on the individual’s clinical condition and preference for treatment. • Expectant management of incomplete abortion can be as effective as misoprostol; it can be offered as an option on the condition that the woman, girl or other pregnant person is informed of the longer time for expulsion of the pregnancy tissue and the increased risk of incomplete emptying of the uterus. • Recommendation 35 was extrapolated from research conducted in women with reported spontaneous abortion. * Misoprostol can be repeated at the noted interval as needed to achieve success of the abortion process. At gestational ages ≥ 14 weeks, providers should use caution and clinical judgement to decide the maximum number of doses of misoprostol in pregnant individuals with prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness for emergency ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 121
  },
  {
    "chunk_id": "abortioncare_558",
    "text": "f doses of misoprostol in pregnant individuals with prior uterine incision. Uterine rupture is a rare complication; clinical judgement and health system preparedness for emergency management of uterine rupture must be considered with advanced gestational age. Source: Recommendation 35 carried forward from WHO (2012) where it was Recommendation 10 (19) . The wording has been revised to amend the gestational age from “13 weeks or less” to “before 14 weeks” (< 14 weeks). Recommendations 36a and 36b carried forward from WHO (2018) where they were Recommendations 1A and 1B (120) . The gestational ages have also been updated to change the cut-off point from 13 weeks to 14 weeks. 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 121
  },
  {
    "chunk_id": "abortioncare_559",
    "text": "Abortion care guideline, second edition 84 Who SERVICE DELIVERY Recommendation 37: Medical management of uncomplicated incomplete abortion with misoprostol at gestational ages < 14 weeks Type of health worker Recommendation Rationalea Community health workers (CHWs) Recommend No direct evidence was found for this option, but some indirect evidence was found that CHWs can use simple tools and checklists to determine gestational age (based on patient history), and to assess eligibility for and the outcome of medical abortion (low to moderate certainty). CHWs are often involved in advising women seeking abortion care (moderate-certainty evidence). In general, CHW interventions are acceptable and have proved feasible in many contexts. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Pharmacy workers Ph",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 122
  },
  {
    "chunk_id": "abortioncare_560",
    "text": "le in many contexts. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Pharmacy workers Pharmacists Recommend Although insufficient evidence was found for the safety and effectiveness of this option, the skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a In addition, the skills required for managing incomplete abortion with misoprostol are similar to those for provision of medical abortion at < 12 weeks, which is a recommended task for these health workers (see Recommendation 28). Traditional and complementary medicine professionals Recommend Evidence was found for the safety and effectiveness of these professionals providing medical abortion at gestational ages < 12 weeks (low certainty), and the skills required fo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 122
  },
  {
    "chunk_id": "abortioncare_561",
    "text": "end Evidence was found for the safety and effectiveness of these professionals providing medical abortion at gestational ages < 12 weeks (low certainty), and the skills required for managing incomplete abortion with misoprostol are similar. In addition, the skills and knowledge for this task (according to the competency framework) align with the competencies of this type of health worker.a Auxiliary nurses/ANMs Recommend Evidence was found for the safety and effectiveness of these health workers providing medical abortion at gestational ages < 12 weeks (moderate certainty), and the skills required for managing incomplete abortion with misoprostol are similar. Nurses Recommend Indirect evidence was found for the safety, effectiveness and acceptability of nurses providing medical abortion (moderate certainty), and the skills required for managing incomplete abortion with misoprostol are si",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 122
  },
  {
    "chunk_id": "abortioncare_562",
    "text": " safety, effectiveness and acceptability of nurses providing medical abortion (moderate certainty), and the skills required for managing incomplete abortion with misoprostol are similar. The option is feasible and has the potential to increase equitable access to quality abortion care. Midwives Recommend Evidence was found from a low-resource setting for the safety and effectiveness of this option (moderate to high certainty). Women’s overall satisfaction with the provider was high when midwives manage incomplete abortion (moderate- certainty evidence). This option is feasible and has the potential to increase equitable access to quality abortion care. Associate/advanced associate clinicians Recommend Moderate-certainty indirect evidence was found for the safety and effectiveness of medical management of incomplete abortion by midwives, and moderate- certainty evidence was also found for",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 122
  },
  {
    "chunk_id": "abortioncare_563",
    "text": "certainty indirect evidence was found for the safety and effectiveness of medical management of incomplete abortion by midwives, and moderate- certainty evidence was also found for the safety and effectiveness of medical abortion provision by health worker types with similar or less comprehensive basic training. Additionally, direct evidence was found that these clinicians can assess gestational age (by uterine size) as part of provision of manual vacuum aspiration. This option is feasible and the potential to increase equitable access to quality abortion care is high. Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendations for which evidence re",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 122
  },
  {
    "chunk_id": "abortioncare_564",
    "text": "the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendations for which evidence relating to traditional and complementary medicine professionals (previously “suggest”), pharmacists and pharmacy workers (both previously “recommend against”) and community health workers (previously “within the context of rigorous research”) was reviewed using GRADE methodology, since the other health workers already had a strong recommendation for this task. After review, the recommendations were upgraded to “recommend” for all of the reviewed health worker categories. A summary of the evidence is presented in Supplementary material 3, EtD framework on Medical management of incomplete abortion. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 122
  },
  {
    "chunk_id": "abortioncare_565",
    "text": "3, EtD framework on Medical management of incomplete abortion. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 122
  },
  {
    "chunk_id": "abortioncare_566",
    "text": "85 Where No requirement for location (on-site vs off-site). How Implementation considerations • Restrictions on prescribing authority for some categories of providers may need to be modified or other mechanisms put in place for making the medicines available for these providers within the regulatory framework of the health system. • The evacuation of retained products is a signal function of basic emergency obstetric care (EmOC); thus training and implementation of these tasks can be integrated with EmOC services. Who SERVICE DELIVERY Recommendation 38: Vacuum aspiration for management of uncomplicated incomplete abortion at gestational ages < 14 weeks Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Recommend Evidence was found for the effectiveness of these professionals carrying out components of the task, such as assessing uterine s",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 123
  },
  {
    "chunk_id": "abortioncare_567",
    "text": " and complementary medicine professionals Recommend Evidence was found for the effectiveness of these professionals carrying out components of the task, such as assessing uterine size with bimanual examination as part of medical abortion provision (very low certainty). The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a These professionals perform other transcervical procedures (e.g. IUD insertion) in some settings. This option has the potential to increase equitable access to quality abortion care in regions where these professionals constitute a significant proportion of the health workforce. Auxiliary nurses/ANMs Suggest Condition: In contexts where established health system mechanisms involve auxiliary nurses/ANMs in providing basic emergency obstetric care, and where referral and monitoring syste",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 123
  },
  {
    "chunk_id": "abortioncare_568",
    "text": "Condition: In contexts where established health system mechanisms involve auxiliary nurses/ANMs in providing basic emergency obstetric care, and where referral and monitoring systems are strong. Insufficient direct evidence was found for the safety and effectiveness of this option. However, the option of this type of health worker delivering emergency obstetric care (which includes removing retained products as a signal function) or post- abortion care using manual vacuum aspiration has been shown to be feasible in programmes in several low-resource settings. Nurses Recommend Evidence was found for the safety and effectiveness of these health workers providing vacuum aspiration for induced abortion (low certainty), and the skills required for the management of uncomplicated incomplete abortion with vacuum aspiration are similar. The option is feasible, including in low-resource settings.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 123
  },
  {
    "chunk_id": "abortioncare_569",
    "text": "ty), and the skills required for the management of uncomplicated incomplete abortion with vacuum aspiration are similar. The option is feasible, including in low-resource settings. Midwives Recommend Indirect evidence was found for the safety and effectiveness of these health workers providing vacuum aspiration for induced abortion (moderate certainty), and the skills required for the management of uncomplicated incomplete abortion with vacuum aspiration are similar. The option is feasible, including in low-resource settings. Table Continues 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 123
  },
  {
    "chunk_id": "abortioncare_570",
    "text": "Abortion care guideline, second edition 86 Type of health worker Recommendation Rationalea Associate/advanced associate clinicians Recommend Indirect evidence was found for the safety and effectiveness of these clinicians providing of vacuum aspiration for induced abortion (moderate certainty), and the skills required for the management of uncomplicated incomplete abortion with vacuum aspiration are similar. Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to traditional and complementary medicine professionals and for auxiliary nurses and auxiliary nurse midwives was reviewed using GRADE methodology. After revi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 124
  },
  {
    "chunk_id": "abortioncare_571",
    "text": "ich evidence relating to traditional and complementary medicine professionals and for auxiliary nurses and auxiliary nurse midwives was reviewed using GRADE methodology. After review, only the recommendation for traditional and complementary medicine professionals was upgraded from “suggest” to “recommend”. For all the other health worker categories, the recommendations remain unchanged from the previous guidance. A summary of the evidence is presented in Supplementary material 3, EtD framework on Vacuum aspiration for management of incomplete abortion. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competen",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 124
  },
  {
    "chunk_id": "abortioncare_572",
    "text": "l focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Where In a health-care facility. How Implementation considerations • The skills required for the provision of both MVA and EVA are similar, so the recommendations above apply to both. MVA is more commonly used and more likely to be used in primary care settings. • Uncomplicated incomplete abortion can result after an induced or spontaneous abortion (i.e. miscarriage). The management is identical and the ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 124
  },
  {
    "chunk_id": "abortioncare_573",
    "text": "o be used in primary care settings. • Uncomplicated incomplete abortion can result after an induced or spontaneous abortion (i.e. miscarriage). The management is identical and the above recommendations apply to both. • The evacuation of retained products is also a signal function of basic emergency obstetric care (EmOC) and training and implementation can be integrated with EmOC services. KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO MANAGEMENT OF INCOMPLETE ABORTION • States must ensure adequate access to essential medicines in an affordable and non- discriminatory manner. • Regardless of whether abortion is legal, States are required to ensure access to post- abortion care where it is needed. • Post-abortion care must be available on a confidential basis, including in situations where abortion is illegal. • Post-abortion care must be available without the threat of criminal prosecution o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 124
  },
  {
    "chunk_id": "abortioncare_574",
    "text": "re must be available on a confidential basis, including in situations where abortion is illegal. • Post-abortion care must be available without the threat of criminal prosecution or punitive measures. States must not require health workers to report persons suspected of undertaking unlawful abortion, or require them to provide any potentially incriminating information during or as a prerequisite to receiving post-abortion care. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Table Continued",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 124
  },
  {
    "chunk_id": "abortioncare_575",
    "text": "87 All recommendations relating to law and policy (Recommendations 1,2,3,6,7,21,22) Commodities (section 1.4.4) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.5.3 Management of non-life-threatening complications: infection and haemorrhage Initial and basic management includes recognizing the complication, stabilizing the woman, providing oral or parenteral antibiotics and intravenous fluids prior to referral to an appropriate health worker/facility. Who SERVICE DELIVERY Recommendation 39: Initial management of non-life-threatening post-abortion infection* Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Recommend Although no direct evidence was found for the management of post-a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 125
  },
  {
    "chunk_id": "abortioncare_576",
    "text": "n* Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Recommend Although no direct evidence was found for the management of post-abortion infection by these health workers, their basic training covers the skills required for this task. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a The expert panel affirmed that this option is feasible and that it has the potential to increase equitable access to post-abortion care. Auxiliary nurses/ANMs Nurses Midwives Associate/advanced associate clinicians Recommend Although no direct evidence was found for the management of post-abortion infection by these health workers, the management of puerperal sepsis with intramuscular antibiotics, which requires similar skills, is within their typical scope of practice ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 125
  },
  {
    "chunk_id": "abortioncare_577",
    "text": "tion infection by these health workers, the management of puerperal sepsis with intramuscular antibiotics, which requires similar skills, is within their typical scope of practice (138).b Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to traditional and complementary medicine professionals, pharmacists, pharmacy workers and community health workers was reviewed using GRADE methodology. After review, the recommendation was only upgraded for traditional and complementary medicine professionals, from “suggest” to “recommend.” For all other health worker categories reviewed, the recommendations remain “recommend a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 125
  },
  {
    "chunk_id": "abortioncare_578",
    "text": "ed for traditional and complementary medicine professionals, from “suggest” to “recommend.” For all other health worker categories reviewed, the recommendations remain “recommend against” (not listed). A summary of the evidence is presented in Supplementary material 3, EtD framework on Diagnosis and management of abortion-related complications. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 125
  },
  {
    "chunk_id": "abortioncare_579",
    "text": "dge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. * For the pharmacists, pharmacy workers and community health workers, it is important that they are equipped with the knowledge to recognize signs and symptoms of this complication. 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 125
  },
  {
    "chunk_id": "abortioncare_580",
    "text": "Abortion care guideline, second edition 88 Where No requirement for location (on-site vs off-site). How Implementation considerations • It is important that pharmacists, pharmacy workers and community health workers are equipped with the knowledge to recognize signs and symptoms of the complications of unsafe abortion and to know where to refer women in their communities. • Restrictions on prescribing authority for some categories of providers may need to be modified or other mechanisms put in place for allowing such providers to administer the antibiotics within the regulatory framework of the health system. Who SERVICE DELIVERY Recommendation 40: Initial management of non-life-threatening post-abortion haemorrhage* Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Recommend No direct evidence was found for the management of post-aborti",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 126
  },
  {
    "chunk_id": "abortioncare_581",
    "text": "rhage* Type of health worker Recommendation Rationalea Traditional and complementary medicine professionals Recommend No direct evidence was found for the management of post-abortion haemorrhage by these professionals, but their basic training covers the skills required for this task. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a Auxiliary nurses/ANMs Recommend Although no direct evidence was found for the management of post-abortion haemorrhage by these health workers, the initial management of post-partum haemorrhage with intravenous (IV) fluids, which requires similar skills, is a task that these health workers are recommended to do (138). Nurses Midwives Associate/advanced associate clinicians Recommend Although no direct evidence was found for the management of post-abortion haemorrhage by ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 126
  },
  {
    "chunk_id": "abortioncare_582",
    "text": "recommended to do (138). Nurses Midwives Associate/advanced associate clinicians Recommend Although no direct evidence was found for the management of post-abortion haemorrhage by these health workers, the initial management of post-partum haemorrhage with IV fluids, which requires similar skills, is within their typical scope of practice (138). Generalist medical practitioners Specialist medical practitioners Recommend Within their typical scope of practice,b therefore no assessment of the evidence was conducted. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to traditional and complementary medicine professionals, pharmacists, pharmacy workers and community health workers was reviewed using GRADE methodology. After review, the recommendation was only upgraded for traditional a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 126
  },
  {
    "chunk_id": "abortioncare_583",
    "text": "professionals, pharmacists, pharmacy workers and community health workers was reviewed using GRADE methodology. After review, the recommendation was only upgraded for traditional and complementary medicine professionals, from “suggest” to “recommend”. For all other health worker categories reviewed, the recommendations remain “recommend against” (not listed). A summary of the evidence is presented in Supplementary material 3, EtD framework on Diagnosis and management of abortion-related complications. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for ea",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 126
  },
  {
    "chunk_id": "abortioncare_584",
    "text": "ublication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. * For the pharmacists, pharmacy workers and community health workers, it is important that they are equipped with the knowledge to recognize signs and symptoms of this complication.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 126
  },
  {
    "chunk_id": "abortioncare_585",
    "text": "89 Where No requirement for location (on-site vs off-site). How Implementation consideration • Initial management of haemorrhage and infection is also a signal function of basic emergency obstetric care (EmOC) and training and implementation can be integrated with EmOC services. All recommendations relating to law and policy (Recommendations 1,2,3,6,7,21,22) KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO NON-LIFE-THREATENING COMPLICATIONS • Regardless of whether abortion is legal, States are required to ensure access to post- abortion care where it is needed. • Post-abortion care must be available on a confidential basis, including in situations where abortion is illegal. • Post-abortion care must be available without the threat of criminal prosecution or punitive measures. States must not require health workers to report persons suspected of undertaking unlawful abortion, or require them t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 127
  },
  {
    "chunk_id": "abortioncare_586",
    "text": "hout the threat of criminal prosecution or punitive measures. States must not require health workers to report persons suspected of undertaking unlawful abortion, or require them to provide any potentially incriminating information during or as a prerequisite to receiving post-abortion care. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 127
  },
  {
    "chunk_id": "abortioncare_587",
    "text": "Abortion care guideline, second edition 90 3.5.4 Post-abortion contraception Following an induced or spontaneous abortion, ovulation can return as early as 8–10 days later and usually within one month, and thus contraception initiation as soon as possible within the first month is important for women who desire to delay or prevent a future pregnancy (153, 154). All contraceptive options may be considered after an abortion. The client’s wishes are paramount; if the individual wishes to start or resume a contraceptive method, then all contraceptive options may be considered at any point in care and some methods can be initiated at the time of the abortion (155). States are required to ensure there is access to a wide range of modern, safe and affordable contraceptive methods (36 [para. 8], 49 [para. 33]). Criteria laid out in the WHO publications Ensuring human rights in the provision of c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 128
  },
  {
    "chunk_id": "abortioncare_588",
    "text": "wide range of modern, safe and affordable contraceptive methods (36 [para. 8], 49 [para. 33]). Criteria laid out in the WHO publications Ensuring human rights in the provision of contraceptive information and services and Medical eligibility criteria for contraceptive use should be adhered to (156, 157). In-depth consideration of all methods of post-abortion contraception is outside the scope of this guideline. This section addresses the timing of contraception and the health workers who can provide certain methods. The role of self-management approaches with post-abortion contraception will be discussed further in section 3.6.3. What CLINICAL SERVICES Recommendation 41: Medical eligibility criteria for post-abortion contraception The following contraceptive methods may be started immediately (MEC Category 1 – no restrictions) after a surgical or medical abortion (first and second trimes",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 128
  },
  {
    "chunk_id": "abortioncare_589",
    "text": "ortion contraception The following contraceptive methods may be started immediately (MEC Category 1 – no restrictions) after a surgical or medical abortion (first and second trimester, and also after a septic abortion): combined hormonal contraceptives (CHCs), progesterone-only contraceptives (POCs) and barrier methods (condoms, spermicide, diaphragm, cap – note: The diaphragm and cap are unsuitable until 6 weeks after second-trimester abortion) Intrauterine devices (IUDs) may be started immediately after a first-trimester surgical or medical abortion (MEC Category 1 – no restrictions) or after second-trimester abortion (MEC Category 2 – the advantages generally outweigh the risks), but should not be started immediately after septic abortion (MEC Category 4 – insertion of an IUD may substantially worsen the condition). Fertility-awareness-based (FAB) methods: Symptom-based methods should",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 128
  },
  {
    "chunk_id": "abortioncare_590",
    "text": "mediately after septic abortion (MEC Category 4 – insertion of an IUD may substantially worsen the condition). Fertility-awareness-based (FAB) methods: Symptom-based methods should only be started after abortion with “caution” (special counselling may be needed to ensure correct use of the method in this circumstance) and the use of calendar-based methods should be delayed (until the condition is evaluated; alternative temporary methods of contraception should be offered). Notes: • Refer to the box below for an explanation of the MEC categories. • CHCs include combined oral contraceptives (COCs), the contraceptive patch (P), the combined vaginal ring (CVR) and combined injectable contraceptives (CICs). • POCs include progesterone-only pills (POPs), levonorgestrel (LNG) or etonogestrel (ETG) implants, depot medroxyprogesterone acetate (DMPA) injectables, and norethisterone enanthate (NET-",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 128
  },
  {
    "chunk_id": "abortioncare_591",
    "text": "nclude progesterone-only pills (POPs), levonorgestrel (LNG) or etonogestrel (ETG) implants, depot medroxyprogesterone acetate (DMPA) injectables, and norethisterone enanthate (NET-EN) injectables. • IUDs include copper-bearing IUDs (Cu-IUD) and levonorgestrel-releasing IUDs (LNG-IUD). • Symptoms-based methods include the cervical mucus method (also called the ovulation method) and the TwoDay Method, which are both based on the evaluation of cervical mucus, and the sympto-thermal method, which is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day. • Calendar-based methods include the Calendar Rhythm Method (avoiding unprotected intercourse from the first to the last estimated fertile days, after recording the length of several menstrual cycles as a basis for calcu",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 128
  },
  {
    "chunk_id": "abortioncare_592",
    "text": "endar Rhythm Method (avoiding unprotected intercourse from the first to the last estimated fertile days, after recording the length of several menstrual cycles as a basis for calculation) and the Standard Days Method (avoiding unprotected intercourse on cycle days 8–19, for people whose cycles are usually 26–32 days long). Source: Recommendations brought in from WHO’s Medical eligibility criteria for contraceptive use (2015) (157). The wording has been revised to narrative format from the tables in the source guideline.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 128
  },
  {
    "chunk_id": "abortioncare_593",
    "text": "91 Key to MEC categories for contraceptive eligibility • Category 1 – A condition for which there is no restriction for the use of the contraceptive method • Category 2 – A condition where the advantages of using the method generally outweigh the theoretical or proven risks • Category 3 – A condition where the theoretical or proven risks usually outweigh the advantages of using the method • Category 4 – A condition which represents an unacceptable health risk if the contraceptive method is used. CLINICAL SERVICES Recommendation 42: Timing of contraception and surgical abortion For individuals undergoing surgical abortion and wishing to use contraception: Recommend the option of initiating the contraception at the time of surgical abortion. Remark: • The quality of evidence based on randomized controlled trials was very low. Source: Part of Recommendation 13 carried forward from WHO (2012",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 129
  },
  {
    "chunk_id": "abortioncare_594",
    "text": "he time of surgical abortion. Remark: • The quality of evidence based on randomized controlled trials was very low. Source: Part of Recommendation 13 carried forward from WHO (2012) (19) . Only the component of the existing recommendation that is relevant to surgical abortion has been retained, with the word “recommend” used to clarify that it is a strong recommendation and revisions made to include all contraceptive methods). CLINICAL SERVICES Recommendation 43: Timing of contraception and medical abortion For individuals undergoing medical abortion with the combination mifepristone and misoprostol regimen or with misoprostol alone: a. For those who choose to use hormonal contraception (oral contraceptive pills, contraceptive patch, contraceptive ring, contraceptive implant or contraceptive injections): Suggest that they be given the option of starting hormonal contraception immediately",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 129
  },
  {
    "chunk_id": "abortioncare_595",
    "text": "s, contraceptive patch, contraceptive ring, contraceptive implant or contraceptive injections): Suggest that they be given the option of starting hormonal contraception immediately after the first pill of the medical abortion regimen. b. For those who choose to have an IUD inserted: Suggest IUD placement at the time that success of the abortion procedure is determined. Remark (for Recommendations 43a and b): • This recommendation applies to the combination mifepristone plus misoprostol regimen and the use of misoprostol alone. The letrozole plus misoprostol combination regimen is not mentioned here because the included studies informing these recommendations did not assess this regimen. Remarks (for Recommendation 43a only): • Immediate initiation of intramuscular depot medroxyprogesterone acetate (DMPA) is associated with a slight decrease in the effectiveness of medical abortion regime",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 129
  },
  {
    "chunk_id": "abortioncare_596",
    "text": "ion 43a only): • Immediate initiation of intramuscular depot medroxyprogesterone acetate (DMPA) is associated with a slight decrease in the effectiveness of medical abortion regimens (158) . However, immediate initiation of DMPA should still be offered as an available contraceptive method after an abortion. • Indirect evidence was used as a basis for decision-making on initiation of hormonal contraception as an option for individuals undergoing medical abortion with misoprostol alone. • No data were available on the use of combined hormonal contraception (pills or injections) by those undergoing medical abortion. • Individuals who choose to initiate the contraceptive ring should be instructed to check for expulsion of the ring in the event of heavy bleeding during the medical abortion process. Source: Recommendations 4a and 4b carried forward from WHO (2018) (120) . 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 129
  },
  {
    "chunk_id": "abortioncare_597",
    "text": "Abortion care guideline, second edition 92 Who SERVICE DELIVERY Recommendation 44: Insertion and removal of intrauterine devices (IUDs) Type of health worker Recommendation Rationale Traditional and complementary medicine professionals Suggest Condition: In contexts with established health system mechanisms for the participation of these professionals in other tasks related to maternal and reproductive health. Their basic training generally covers the relevant skills needed for this task. This option is probably feasible and may promote continuity of care for women and increase access in regions where these professionals constitute a significant proportion of the health workforce. Auxiliary nurses Suggest Condition: In the context of rigorous research. The recommendation comes originally from the OptimizeMNH guideline (138). ANMs Nurses Midwives Recommend The recommendation comes origina",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 130
  },
  {
    "chunk_id": "abortioncare_598",
    "text": "tion: In the context of rigorous research. The recommendation comes originally from the OptimizeMNH guideline (138). ANMs Nurses Midwives Recommend The recommendation comes originally from the OptimizeMNH guideline (138). Associate/advanced associate clinicians Generalist medical practitioners Specialist medical practitioners Recommend The recommendation comes originally from the OptimizeMNH guideline (138), where this task was considered to be within their typical scope of practice.a Source: Recommendation carried forward from WHO (2015) (23) . a For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Who SERVICE DELIVERY Recommendation 45: Insertion and removal of implants Type of health worker Recommendation Rationale Community health workers Suggest Condition: In the context of rigorous research. The recommendation comes originally from the Op",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 130
  },
  {
    "chunk_id": "abortioncare_599",
    "text": "ants Type of health worker Recommendation Rationale Community health workers Suggest Condition: In the context of rigorous research. The recommendation comes originally from the OptimizeMNH guideline (138). Traditional and complementary medicine professionals Suggest Condition: In contexts with established health system mechanisms for the participation of these professionals in other tasks related to maternal and reproductive health and where training in implant removal is given along with training in insertion. Although insufficient direct evidence was found for the safety and effectiveness of this option, their basic training covers the relevant skills needed for this task. This option may promote continuity of care for women. Auxiliary nurses/ANMs Suggest Condition: In the context of targeted monitoring and evaluation. The recommendation comes originally from the OptimizeMNH guideline",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 130
  },
  {
    "chunk_id": "abortioncare_600",
    "text": "of care for women. Auxiliary nurses/ANMs Suggest Condition: In the context of targeted monitoring and evaluation. The recommendation comes originally from the OptimizeMNH guideline (138). Nurses Midwives Recommend The recommendation comes originally from the OptimizeMNH guideline (138). Associate/advanced associate clinicians Generalist medical practitioners Specialist medical practitioners Recommend The recommendation comes originally from the OptimizeMNH guideline (138), where this task was considered to be within their typical scope of practice.a Source: Recommendation carried forward from WHO (2015) (23) . a For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 130
  },
  {
    "chunk_id": "abortioncare_601",
    "text": "93 How Implementation consideration • The removal of implants can require greater skills than insertion; any health worker trained to independently insert implants should also be well trained on implant removal (23) . Where In a health-care facility or other setting with sterile conditions. Who SERVICE DELIVERY Recommendation 46: Administration of injectable contraceptives (initiation and continuation) Type of health worker Recommendation Rationalea Community health workers (CHWs) Recommend Limited evidence was found for the safety, effectiveness and feasibility of this option. The skills and knowledge for this task (according to the competency framework) align with the competencies for CHWs.a This option is feasible and acceptable given that CHWs provide other components of abortion care. In addition, this option has the potential to increase women’s choices and reduce inequities in con",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 131
  },
  {
    "chunk_id": "abortioncare_602",
    "text": "asible and acceptable given that CHWs provide other components of abortion care. In addition, this option has the potential to increase women’s choices and reduce inequities in contraceptive access. Pharmacy workers Recommend Although no evidence was found for the safety, effectiveness, acceptability or feasibility of this option, administering injections is within their typical scope of practice b and the additional training needs for this task would be minimal. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a This option has the potential to increase women’s choices and reduce inequities in contraceptive access. Pharmacists Recommend Although the available evidence for the safety and effectiveness of this option is of very low certainty, administering injections is within their typical scope of p",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 131
  },
  {
    "chunk_id": "abortioncare_603",
    "text": "ists Recommend Although the available evidence for the safety and effectiveness of this option is of very low certainty, administering injections is within their typical scope of practiceb and the additional training needs for this task would be minimal. This option has the potential to increase women’s choices and reduce inequities in contraceptive access. Traditional and complementary medicine professionals Recommend Their basic training covers the relevant skills needed for this task, hence additional training needs would be minimal. The skills and knowledge for this task (according to the competency framework) align with the competencies for this type of health worker.a This option is feasible and acceptable given that these professionals provide similar services in the existing health system, and thus it may promote continuity of care for women. Auxiliary nurses/ANMs Recommend The r",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 131
  },
  {
    "chunk_id": "abortioncare_604",
    "text": "e given that these professionals provide similar services in the existing health system, and thus it may promote continuity of care for women. Auxiliary nurses/ANMs Recommend The recommendation comes originally from the OptimizeMNH guideline (138). Nurses Midwives Associate/advanced associate clinicians Generalist medical practitioners Specialist medical practitioners Recommend The recommendation comes originally from the OptimizeMNH guideline (138), where this task was considered to be within their typical scope of practice.b Table Continues 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 131
  },
  {
    "chunk_id": "abortioncare_605",
    "text": "Abortion care guideline, second edition 94 Type of health worker Recommendation Rationalea Individual/self Pregnant woman, girl or other pregnant person Recommend Refer to Recommendation 51 in section 3.6.2 for the rationale, remark, implementation considerations and further information about self-management approaches. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence relating to traditional and complementary medicine professionals, pharmacy workers, community health workers and individuals/self (self-administration) was reviewed using GRADE methodology. After review, recommendations for all three of those health worker categories were upgraded from “suggest” to “recommend”. The recommendations for the other health worker categories were not reviewed and remain unchanged, such that all hea",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 132
  },
  {
    "chunk_id": "abortioncare_606",
    "text": " worker categories were upgraded from “suggest” to “recommend”. The recommendations for the other health worker categories were not reviewed and remain unchanged, such that all health worker categories and the individual/self now have a strong recommendation for this task. A summary of the evidence is presented in Supplementary material 3, EtD framework on Delivery of injectable contraceptives. a For this and all health worker recommendations, given the limited evidence for many of the health worker–task combinations, the discussions of the expert panel focused on the competency framework in WHO’s 2011 publication, Sexual and reproductive health: core competencies in primary care (121), which provides information on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 132
  },
  {
    "chunk_id": "abortioncare_607",
    "text": "on on the competencies (including skills and knowledge) required for each task, and also the WHO-INTEGRATE criteria, in particular on the feasibility, equity and acceptability of the intervention and women’s values and preferences. b For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Where No requirement for location (on-site vs off-site). How Implementation considerations • The administration of an injectable contraceptive involves using a syringe and may be intramuscular or subcutaneous. • It is important to have adequate mechanisms for the disposal of used sharps, syringes and needles. • It is important to ensure a consistent supply of the injectables, especially at the point of sale for women to obtain and use on their own. • The investment in initial training is a consideration where the health worker is not already certified to provide ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 132
  },
  {
    "chunk_id": "abortioncare_608",
    "text": " at the point of sale for women to obtain and use on their own. • The investment in initial training is a consideration where the health worker is not already certified to provide injections. It is important to have mechanisms to link the health worker to the health system and ensure a referral pathway. Who SERVICE DELIVERY Recommendation 47: Tubal ligation Type of health worker Recommendation Rationale Nurses Suggest Condition: In the context of rigorous research. The recommendation comes originally from the OptimizeMNH guideline (138). Midwives Suggest Condition: In the context of rigorous research. The recommendation comes originally from the OptimizeMNH guideline (138). Associate/advanced associate clinicians Generalist medical practitioners Specialist medical practitioners Recommend The recommendation comes originally from the OptimizeMNH guideline (138), where this task was conside",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 132
  },
  {
    "chunk_id": "abortioncare_609",
    "text": "ns Generalist medical practitioners Specialist medical practitioners Recommend The recommendation comes originally from the OptimizeMNH guideline (138), where this task was considered to be within their typical scope of practice.a Source: Recommendation carried forward from WHO (2015) (23) . The recommendations will be reviewed for the next update of the WHO guidance on optimizing health worker roles (138) . a For typical scope of work/practice, please refer to Annex 5: Health worker categories and roles. Table Continued",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 132
  },
  {
    "chunk_id": "abortioncare_610",
    "text": "95 KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO POST-ABORTION CONTRACEPTION • Contraception should be provided only where the person has given free and informed consent to receive it. • States must ensure availability of the full range of contraceptive options, including a wide range of modern, safe and affordable methods. • States must ensure adequate access to essential medicines, including contraceptives, in an affordable and non-discriminatory manner. • Everyone has a right to evidence-based information on all aspects of SRH, including contraceptives. • Contraceptive information and services must be provided without discrimination, coercion or violence. • Everyone has a right to privacy and confidentiality in the receipt of contraceptive information and services. • Post-abortion contraceptive information and services should be available and accessible to adolescents without requiring ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 133
  },
  {
    "chunk_id": "abortioncare_611",
    "text": "n the receipt of contraceptive information and services. • Post-abortion contraceptive information and services should be available and accessible to adolescents without requiring parental or guardian authorization. • States must guarantee that practices of conscientious refusal/objection do not infringe on the right to contraceptive information and services. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Free and informed consent (section 1.3.1[v]) Commodities (section 1.4.4) Information provision and counselling (sections 3.2.1 and 3.2.2) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.5 Post-abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 133
  },
  {
    "chunk_id": "abortioncare_612",
    "text": "Abortion care guideline, second edition 96 3.6 Service-delivery options and self-management approaches As indicated throughout this chapter so far, abortion care services can be provided by a range of health workers and some tasks can be managed by individuals themselves. Even for procedures that take place at a health-care facility, some elements of the care (e.g. pre-abortion information and counselling, cervical priming or post-abortion follow-up care) can take place in other locations. Unlike surgical abortion, medical abortion is a process that takes place over a period of several hours or days rather than being a discrete procedure. The process as a whole or its components can take place at different locations including through self-management and/or with the support of different health workers at various stages of the process, making it possible – and in some cases desirable – to ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 134
  },
  {
    "chunk_id": "abortioncare_613",
    "text": "tions including through self-management and/or with the support of different health workers at various stages of the process, making it possible – and in some cases desirable – to obtain care in a range of different settings, through a wide range of different options. This section addresses supported service-delivery approaches (section 3.6.1) and self-management approaches. Self-management approaches addressed in this section include self-management of medical abortion (section 3.6.2), and self-management of post-abortion contraception (section 3.6.3). 3.6.1 Supported service-delivery approaches Medical abortion services can be obtained from and provided or supported by a multitude of actors within the health system. Services may be delivered through a comprehensive model that addresses the full spectrum of abortion care or may include only specific components on the care pathway. Servi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 134
  },
  {
    "chunk_id": "abortioncare_614",
    "text": "system. Services may be delivered through a comprehensive model that addresses the full spectrum of abortion care or may include only specific components on the care pathway. Services could be delivered through the public or private sectors or nongovernmental organizations (NGOs), and may be received at a community- based, off-site location or even at home, and a variety of service-delivery models can co-exist at national, subnational and local levels. Approaches to service delivery are not static and as the role of digital technologies grows and the science and evidence on effective interventions evolves, innovations will also continue to evolve. For this guideline, available evidence on various modalities of providing and/or supporting abortion care were reviewed. Examples of service- delivery approaches that were identified in the systematic reviews conducted for this guideline includ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 134
  },
  {
    "chunk_id": "abortioncare_615",
    "text": "providing and/or supporting abortion care were reviewed. Examples of service- delivery approaches that were identified in the systematic reviews conducted for this guideline included: • Accompaniment models: Where a community health worker provides support by accompanying the individual through the medical abortion process (by phone, secure technological platform, or in person), including providing information, counselling, emotional/moral support and/or logistical support (including referrals to and support interacting with local health-care facilities in the event that care is needed or desired). • Community outreach: This includes health services that mobilize health workers to provide services to the population or to other health workers, away from the location where they usually work and live (159). This is a strategy to mobilize health workers to remote or rural areas, such as mobi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 134
  },
  {
    "chunk_id": "abortioncare_616",
    "text": "tion or to other health workers, away from the location where they usually work and live (159). This is a strategy to mobilize health workers to remote or rural areas, such as mobile clinics. However, documented evidence on the use of this model for abortion care provision is limited. • Digital support tools: These included apps providing information, text messaging reminders, and tools to assist in the assessment of pregnancy duration. • Harm reduction models: Service models in the clinic setting, in which women are supported with pre- abortion information, are told where to find the medicines and how to use them and can return for post- abortion support if needed, but are not actually provided with the medicines to terminate the pregnancy. • Hotlines: This typically refers to telephonic information services that can support women in accessing quality abortion care. Abortion hotlines ma",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 134
  },
  {
    "chunk_id": "abortioncare_617",
    "text": "nes to terminate the pregnancy. • Hotlines: This typically refers to telephonic information services that can support women in accessing quality abortion care. Abortion hotlines may be limited to providing evidence-based information about services or may be linked to other service-delivery models that facilitate access to medicines and support women through the abortion process and after the abortion. • Social marketing: Broadly defined as the application of marketing techniques to social problems and aims to persuade or motivate people to adopt specific sources of action or behaviour which are generally accepted as being beneficial. This approach to marketing has been well studied as a successful model for distribution of health interventions/commodities (e.g. condoms), however, documentation related to quality abortion care (i.e. abortion medicines and instructions) is more limited. It",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 134
  },
  {
    "chunk_id": "abortioncare_618",
    "text": "tribution of health interventions/commodities (e.g. condoms), however, documentation related to quality abortion care (i.e. abortion medicines and instructions) is more limited. It may be an option for increasing access and making care more affordable.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 134
  },
  {
    "chunk_id": "abortioncare_619",
    "text": "97 • Social franchising: This is described as a system of contractual relationships usually run by an NGO which uses the structure of a commercial franchise to achieve social goals. The overarching difference between social and commercial franchising is that social franchising seeks to fulfil a social benefit whereas commercial franchising is driven by profit. However, the limited evidence illustrates the potential inequities of such models (160). • Telemedicine: This is a mode of health service delivery where providers and clients, or providers and consultants, are separated by distance . The interaction may take place in real time (synchronously), using telephone or video link, or asynchronously using a store-and-forward method, when a query is submitted and an answer is provided later (e.g. by email, text or voice/audio message) (161). Across the range of service-delivery options, int",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 135
  },
  {
    "chunk_id": "abortioncare_620",
    "text": "-and-forward method, when a query is submitted and an answer is provided later (e.g. by email, text or voice/audio message) (161). Across the range of service-delivery options, interactions between an abortion seeker and a health worker can take place in person or remotely. After review and assessment of the evidence by the expert panel, it was agreed that there was sufficient quantity and quality of evidence to support the formulation of a specific recommendation in relation to using telemedicine approaches as an alternative to in-person interactions for provision of medical abortion (see Recommendation 48). The available evidence was inadequate to support the formulation of recommendations on any of the other service-delivery models. Instead, given the contextual nature of service-delivery approaches, the heterogeneity of the types of interventions and the overlaps between the approach",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 135
  },
  {
    "chunk_id": "abortioncare_621",
    "text": " service-delivery models. Instead, given the contextual nature of service-delivery approaches, the heterogeneity of the types of interventions and the overlaps between the approaches, a two-part best practice statement was developed to apply to all of them, with reference to service delivery in general, rather than any specific modality/ model of service delivery (see Best Practice Statement 49). What Who SERVICE DELIVERY Recommendation 48 (NEW): Telemedicine approaches to delivering medical abortion care Recommend the option of telemedicine as an alternative to in-person interactions with the health worker to deliver medical abortion services in whole or in part. Remarks: • The above recommendation applies to assessment of eligibility for medical abortion, counselling and/ or instruction relating to the abortion process, providing instruction for and active facilitation of the administr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 135
  },
  {
    "chunk_id": "abortioncare_622",
    "text": "assessment of eligibility for medical abortion, counselling and/ or instruction relating to the abortion process, providing instruction for and active facilitation of the administration of medicines, and follow-up post-abortion care, all through telemedicine. • Hotlines, digital apps or one-way modes of communication (e.g. reminder text messages) that simply provide information were not included in the review of evidence for this recommendation. Rationale A systematic review was undertaken to address this key question. Ten studies reporting on medical abortion provision through telemedicine were identified by the search strategy. Four randomized controlled trials were conducted in Bangladesh, Cambodia, Egypt and Indonesia, and six observational studies took place in Canada, Peru and the USA. In studies comparing telemedicine with in-person medical abortion care services, there was no dif",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 135
  },
  {
    "chunk_id": "abortioncare_623",
    "text": "d Indonesia, and six observational studies took place in Canada, Peru and the USA. In studies comparing telemedicine with in-person medical abortion care services, there was no difference between the two groups in rates of successful abortion or ongoing pregnancies (based on very low-certainty evidence). Referrals for surgical intervention were fewer among women who used telemedicine (based on low-certainty evidence). Satisfaction with telemedicine services was high and comparable to the usual clinical services (based on very low-certainty evidence). A summary of the evidence is presented in Supplementary material 3, EtD framework on Telemedicine. How Implementation consideration • Telemedicine services should include referrals (based on the woman’s location) for medicines (abortion and pain control medicines), any abortion care or post-abortion follow-up required (including for emergenc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 135
  },
  {
    "chunk_id": "abortioncare_624",
    "text": "include referrals (based on the woman’s location) for medicines (abortion and pain control medicines), any abortion care or post-abortion follow-up required (including for emergency care if needed), and for post-abortion contraceptive services, which may apply to both medical and surgical abortion. 3.6 Service-delivery options and self-management approaches",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 135
  },
  {
    "chunk_id": "abortioncare_625",
    "text": "Abortion care guideline, second edition 98 What Who SERVICE DELIVERY Best Practice Statement 49 (NEW) Part 1: There is no single recommended approach to providing abortion services. The choice of specific health worker(s) (from among the recommended options) or management by the individual themself, and the location of service provision (from among the recommended options) will depend on the values and preferences of the woman, girl or other pregnant person, available resources, and the national and local context. A plurality of service-delivery approaches can co-exist within any given context. Part 2: Given that service-delivery approaches can be diverse, it is important to ensure that for the individual seeking care, the range of service-delivery options taken together will provide: • access to scientifically accurate, understandable information at all stages; • access to quality-assur",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 136
  },
  {
    "chunk_id": "abortioncare_626",
    "text": "ng care, the range of service-delivery options taken together will provide: • access to scientifically accurate, understandable information at all stages; • access to quality-assured medicines (including those for pain management); • back-up referral support if desired or needed; • linkages to an appropriate choice of contraceptive services for those who want post-abortion contraception. A summary of the evidence is presented in Supplementary material 3, EtD framework on Medical abortion provided in different settings. How Implementation considerations • Service-delivery approaches should, where feasible, be co-created with the people who will benefit from the intervention. • All models should be tested and adapted for the local context in which they will operate. • Not all service-delivery approaches may function at scale but for those that are being considered for national programmes, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 136
  },
  {
    "chunk_id": "abortioncare_627",
    "text": "pted for the local context in which they will operate. • Not all service-delivery approaches may function at scale but for those that are being considered for national programmes, appropriate pilot testing is needed prior to scaling up. • All service-delivery models should have mechanisms for monitoring quality and ensuring accountability.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 136
  },
  {
    "chunk_id": "abortioncare_628",
    "text": "99 All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO SERVICE-DELIVERY MODELS • States should develop and enforce evidence-based standards and guidelines for the provision and delivery of sexual and reproductive health (SRH) services, and such guidance must be routinely updated to incorporate medical advancements. At the same time, States are required to provide age-appropriate, evidence-based, scientifically accurate comprehensive education for all on SRH. • SRH services must be available, accessible, affordable, acceptable of good quality. This means that delivery of services must be respectful of the culture of individuals, minorities, peoples and communities, and sensitive to gender, age, disability, sexual diversity and life-cycle requirements. • States must take steps to reduce maternal mortality and morbidity",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 137
  },
  {
    "chunk_id": "abortioncare_629",
    "text": "peoples and communities, and sensitive to gender, age, disability, sexual diversity and life-cycle requirements. • States must take steps to reduce maternal mortality and morbidity. • States must make accurate, evidence-based abortion information available to individuals on a confidential basis • States must ensure delivery of services on the basis of non-discrimination and equality. • States must ensure delivery of services in a way that respects the right to scientific progress, meaning that States should ensure access to modern and safe forms of contraception, including emergency contraception, abortion medicines, assisted reproductive technologies, and other SRH goods and services, on the basis of non-discrimination and equality. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Links to related topics/",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 137
  },
  {
    "chunk_id": "abortioncare_630",
    "text": "imination and equality. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion. Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.6 Service-delivery options and self-management approaches",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 137
  },
  {
    "chunk_id": "abortioncare_631",
    "text": "Abortion care guideline, second edition 100 3.6.2 Self-management approaches for medical abortion in whole or in part Self-care, as defined in the Glossary, is a broad-based concept and can encompass numerous actions that are intended to empower the individual to enhance their own health. Self-management approaches are one component of self-care. Given the nature of the medical abortion process, it is possible for women to manage the process by themselves in whole or part. While individuals may conduct some or all elements related to the abortion process (self-assessment of eligibility, self-administration of medicines and self-assessment of the success of the abortion) entirely on their own, more typically, self-management co-exists with interactions with trained health workers or with a health-care facility and in conjunction with service-delivery approaches described in section 3.6.1.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 138
  },
  {
    "chunk_id": "abortioncare_632",
    "text": "lf-management co-exists with interactions with trained health workers or with a health-care facility and in conjunction with service-delivery approaches described in section 3.6.1. It is the individual (i.e. the “self”) who drives the process of deciding which aspects of the abortion care will be self-managed and which aspects will be supported or provided by trained health workers or in a health-care facility. Women may self-manage parts or all of the abortion process for a variety of reasons related to individual circumstances and preferences. For some women, this may be the only feasible option within their context and for others it may represent an active choice. However, from the perspective of the health system, self- management should not be considered a “last resort” option or a substitute for a non-functioning health system. Self-management must be recognized as a potentially em",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 138
  },
  {
    "chunk_id": "abortioncare_633",
    "text": "system, self- management should not be considered a “last resort” option or a substitute for a non-functioning health system. Self-management must be recognized as a potentially empowering and active extension of the health system and task-sharing approaches. A supportive enabling environment as described in Chapter 1, section 1.3, is equally applicable to self-management approaches as it is to other elements of care provision. What Who SELF-MANAGEMENT Recommendation 50: Self-management of medical abortion in whole or in part at gestational ages < 12 weeks For medical abortion at < 12 weeks (using the combination of mifepristone plus misoprostol or using misoprostol alone): Recommend the option of self-management of the medical abortion process in whole or any of the three component parts of the process: • self-assessment of eligibility (determining pregnancy duration; ruling out contrai",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 138
  },
  {
    "chunk_id": "abortioncare_634",
    "text": "nt of the medical abortion process in whole or any of the three component parts of the process: • self-assessment of eligibility (determining pregnancy duration; ruling out contraindications) • self-administration of abortion medicines and management of the abortion process outside of a health- care facility and without the direct supervision of a trained health worker • self-assessment of the success of the abortion. Remarks: • There was more evidence for self-management of medical abortion (with either of the regimens) for pregnancies before 10 weeks of gestation. • This recommendation applies to the combination regimen of mifepristone plus misoprostol, and the use of misoprostol alone. The included studies informing these recommendations did not assess the letrozole plus misoprostol regimen. • All individuals engaging in self-management of medical abortion must also have access to acc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 138
  },
  {
    "chunk_id": "abortioncare_635",
    "text": "nforming these recommendations did not assess the letrozole plus misoprostol regimen. • All individuals engaging in self-management of medical abortion must also have access to accurate information, quality-assured medicines including for pain management, the support of trained health workers and access to a health-care facility and to referral services if they need or desire it. • Restrictions on prescribing and dispensing authority for abortion medicines may need to be modified or other mechanisms put in place for self-management within the regulatory framework of the health system. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence for all of the subtasks was reviewed using GRADE methodology. After review, the recommendations for all subtasks were upgraded to “recommend” – from “suggest” ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 138
  },
  {
    "chunk_id": "abortioncare_636",
    "text": "n for which evidence for all of the subtasks was reviewed using GRADE methodology. After review, the recommendations for all subtasks were upgraded to “recommend” – from “suggest” for self-administration and self- assessment of outcome, and from “only in the context of rigorous research” for self-assessment of eligibility.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 138
  },
  {
    "chunk_id": "abortioncare_637",
    "text": "101 Where No requirement for location (on-site vs off-site). Rationale Two systematic reviews were undertaken to address this key question. The first review focused on the self- assessment of eligibility and self-assessment of success. A total of 14 studies reporting on these two sub-tasks were identified by the search strategy. The four studies on self-assessment of eligibility took place in South Africa, the United Kingdom and the USA. Ten studies on self-assessment of success took place in Austria, Finland, India, Mexico, Nepal, Norway, South Africa, Sweden, Uzbekistan and Viet Nam. The second review was on the self- administration of medicines and included 18 studies, which took place in Albania, Bangladesh, China, France, India, Nigeria, Tunisia, Türkiye and Viet Nam. A summary of the evidence is presented in Supplementary material 2, EtD framework on Self-management of medical abor",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 139
  },
  {
    "chunk_id": "abortioncare_638",
    "text": ", China, France, India, Nigeria, Tunisia, Türkiye and Viet Nam. A summary of the evidence is presented in Supplementary material 2, EtD framework on Self-management of medical abortion. Self-assessment of eligibility: There is low-certainty evidence on the safety, effectiveness and acceptability of self-assessment of eligibility for a medical abortion, using the start date of last menstrual period (LMP) alone or in combination with other tools (e.g. checklists). The expert panel discussed the feasibility of this intervention in certain scenarios such as the woman having regular menses, a known LMP and the availability of validated tools. When they have the necessary information, women are able to determine their eligibility for medical abortion. Given this and taking into account the values and preferences and high acceptability of this approach, the panel determined that the interventio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 139
  },
  {
    "chunk_id": "abortioncare_639",
    "text": "r eligibility for medical abortion. Given this and taking into account the values and preferences and high acceptability of this approach, the panel determined that the intervention was favoured. Self-administration of medicines: There is evidence that the option of self-administering medicines for medical abortion is effective (moderate certainty) and safe (low certainty). Women reported high satisfaction with taking their own medicines for the abortion (very low-certainty evidence). There was high adherence to the medical abortion regimen (low-certainty evidence). The high acceptability and feasibility favoured this intervention. Self-assessment of success: There is high-certainty evidence that self-assessment of abortion outcome/success (using tools such as a low-sensitivity pregnant test or multi-level pregnancy test) is as effective as assessment by a trained health worker. Low-cert",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 139
  },
  {
    "chunk_id": "abortioncare_640",
    "text": "t of abortion outcome/success (using tools such as a low-sensitivity pregnant test or multi-level pregnancy test) is as effective as assessment by a trained health worker. Low-certainty evidence indicated that more women in the self-assessment group expressed satisfaction with the process. How Implementation considerations • Every individual must have access to accurate information about the self-management process as well as other options available within their local context, to enable informed decision making on whether to self- manage all or parts of the process. • Self-assessment of eligibility includes the assessment of pregnancy duration based on LMP. Paper or digital tools to assist recall and calculate duration or checklists may assist in the self-assessment of eligibility. When menstrual cycles are irregular or women have other concerns, she should be encouraged to seek support ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 139
  },
  {
    "chunk_id": "abortioncare_641",
    "text": "duration or checklists may assist in the self-assessment of eligibility. When menstrual cycles are irregular or women have other concerns, she should be encouraged to seek support from a trained health worker where possible. • Self-administration of medicines and management of the medical abortion process involves taking all or some of the abortion medicines without the direct supervision of a health worker. It is important that all sources from which medicines are procured provide quality-assured medicines. • Women should also have information about pain during the process and should be able to obtain medicines for pain management. • Women should also have information about the requirements of managing abortion-related bleeding at home, and should have access/referral to emergency care if this becomes necessary. 3.6 Service-delivery options and self-management approaches",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 139
  },
  {
    "chunk_id": "abortioncare_642",
    "text": "Abortion care guideline, second edition 102 • Self-assessment of the success of abortion can be done using check lists of signs and symptoms. Other tools (e.g. low-sensitivity pregnancy tests), if available, may be used to assist the woman in self-assessing completion. Low-sensitivity urine pregnancy tests are different from ordinary pregnancy tests. The use of a high-sensitivity pregnancy test (a multi-level pregnancy test [MLPT]) alone or in conjunction with checklists has been shown to have a higher sensitivity for detecting successful abortion. Access should be available to a health worker or health-care facility to confirm the success of abortion or to manage side-effects or complications. • As part of the enabling environment, health workers and managers should recognize self-management as a legitimate pathway to abortion care, and should work to adapt health systems to facilitate ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 140
  },
  {
    "chunk_id": "abortioncare_643",
    "text": " enabling environment, health workers and managers should recognize self-management as a legitimate pathway to abortion care, and should work to adapt health systems to facilitate and support women in their self-management of abortion – for example, by adapting clinical protocols used at their facility. • Mechanisms need to be established to ensure access or referrals to post-abortion contraception services and provision of contraception for women who want them. • While self-management can support efficiencies within health systems in the long term, it should not mean that the burden of the cost of health services is simply transferred from the provider or facility to the woman herself. 3.6.3 Self-management approaches for post-abortion contraception All contraceptive options may be considered after an abortion. For further information, refer to section 3.5.4: Post- abortion contraceptio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 140
  },
  {
    "chunk_id": "abortioncare_644",
    "text": "proaches for post-abortion contraception All contraceptive options may be considered after an abortion. For further information, refer to section 3.5.4: Post- abortion contraception. Many family planning methods are entirely self-managed (i.e. self-procured over the counter or online and self-administered) and generally available without a prescription, including barrier methods and some hormonal contraceptives, including some oral contraceptive pills (OCPs), and also emergency contraceptive pills. For methods that have traditionally required a prescription from a doctor and/or administration by a health worker, shifting to include the option of using self-management approaches, such as over-the counter OCPs and self-injection of hormonal contraceptives, may improve continuation of contraceptive use by removing barriers, such as the need to return to a health-care facility every three mo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 140
  },
  {
    "chunk_id": "abortioncare_645",
    "text": "d self-injection of hormonal contraceptives, may improve continuation of contraceptive use by removing barriers, such as the need to return to a health-care facility every three months for a repeat injection. These approaches could expand access to contraception for those facing challenges in accessing health-care settings regularly, and in places where there are shortages of health workers, thus potentially greatly reducing the incidence of unintended pregnancy. What Who SELF-MANAGEMENT Recommendation 51: Self-administration of injectable contraception (initiation and continuation)17 Recommend the option of self-administration of injectable contraception in the post-abortion period. Remark: • The administration of an injectable contraceptive involves using a syringe and may be intramuscular or subcutaneous. Compact pre-filled auto-disable devices have been developed to facilitate the se",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 140
  },
  {
    "chunk_id": "abortioncare_646",
    "text": "n of an injectable contraceptive involves using a syringe and may be intramuscular or subcutaneous. Compact pre-filled auto-disable devices have been developed to facilitate the self- administration process. Source: Recommendation updated from WHO (2015) (23) . Note on updating of the recommendation: This was an existing recommendation for which evidence was reviewed using GRADE methodology. After review, the recommendation was upgraded from “suggest” to “recommend”. Where No requirement for location (on-site vs off-site). 17 Including a recommendation only on injectable contraception here does not imply that post-abortion contraceptive options for women should be limited to this method, or indeed to the methods covered by recommendations presented in section 3.5.4; all contraceptive methods can be considered after an abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 140
  },
  {
    "chunk_id": "abortioncare_647",
    "text": "103 Rationale A systematic review was undertaken to address this key question. Studies with indirect populations (i.e. women of reproductive age willing to initiate or continue with injectable contraceptive) were also considered for inclusion. Seven studies reporting on self-administered injectable contraceptives were identified by the search strategy and included in the reviewed evidence; three randomized controlled trials were conducted in Malawi and the USA and four observational studies were conducted in Senegal, Uganda, the United Kingdom and the USA. The evidence was considered indirect since none of the women included in the reviewed studies were described as seeking contraception post-abortion. A summary of the evidence is presented in Supplementary material 3, EtD framework on Self-administration of injectable contraception. There is evidence that continuation rates for self-adm",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 141
  },
  {
    "chunk_id": "abortioncare_648",
    "text": "y of the evidence is presented in Supplementary material 3, EtD framework on Self-administration of injectable contraception. There is evidence that continuation rates for self-administered injectable contraceptives are higher compared with injectable contraceptives being provided by clinic-based providers (very low- to low-certainty evidence). Satisfaction was higher among the self-administration group (very low- to moderate-certainty evidence). The option may result in time and financial savings for women. In addition, this option may increase choice and autonomy in contraceptive use within a rights-based framework. How Implementation considerations • There must be training in the technique for self-injection. • There must be training in and the provision of mechanisms for the safe and secure storage and disposal of sharps (used injectable contraceptives), especially in settings with h",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 141
  },
  {
    "chunk_id": "abortioncare_649",
    "text": ". • There must be training in and the provision of mechanisms for the safe and secure storage and disposal of sharps (used injectable contraceptives), especially in settings with high HIV prevalence. • The client must be able to procure injectable contraceptives on a regular basis without needing to repeatedly visit a health-care facility. What Who SELF-MANAGEMENT Recommendation 52: Over-the-counter oral contraceptive pills Recommend that over-the-counter oral contraceptive pills (OCPs) should be made available without a prescription for individuals using OCPs. SELF-MANAGEMENT Recommendation 53: Over-the-counter emergency contraceptive pills Recommend making over-the-counter emergency contraceptive pills available without a prescription to individuals who wish to use emergency contraception. SELF-MANAGEMENT Recommendation 54: Condom use The consistent and correct use of male and female c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 141
  },
  {
    "chunk_id": "abortioncare_650",
    "text": "ble without a prescription to individuals who wish to use emergency contraception. SELF-MANAGEMENT Recommendation 54: Condom use The consistent and correct use of male and female condoms is highly effective in preventing the sexual transmission of HIV; reducing the risk of HIV transmission both from men to women and women to men in serodiscordant couples; reducing the risk of acquiring other STIs and associated conditions, including genital warts and cervical cancer; and preventing unintended pregnancy. Source: Recommendations 15, 16 and 18 brought in from WHO (2021) (26) . 3.6 Service-delivery options and self-management approaches",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 141
  },
  {
    "chunk_id": "abortioncare_651",
    "text": "Abortion care guideline, second edition 104 Where No requirement for location (on-site vs off-site). How Implementation considerations for OCPs • Provide up to one year’s supply of pills, depending on the woman’s preference and anticipated use. • Programmes must balance the desirability of giving women maximum access to pills with concerns regarding contraceptive supply and logistics. • The resupply system should be flexible, so that the woman can obtain pills easily in the amount and at the time she requires them.18 18 These are Recommendations 20a, b and c from WHO (2021) (26). KEY HUMAN RIGHTS CONSIDERATIONS RELEVANT TO SELF-MANAGEMENT APPROACHES • Sexual and reproductive health (SRH) care must be available, accessible, acceptable and of good quality. • States must ensure availability of a wide range of modern, safe and affordable contraceptive methods. • States must ensure adequate a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 142
  },
  {
    "chunk_id": "abortioncare_652",
    "text": " accessible, acceptable and of good quality. • States must ensure availability of a wide range of modern, safe and affordable contraceptive methods. • States must ensure adequate access to essential medicines in an affordable and non- discriminatory manner. • States must respect autonomous decision-making, non-discrimination and equality. This means that States should repeal or reform laws and policies that nullify or impair the ability of certain individuals and groups to realize their right to SRH, including the criminalization of abortion or restrictive abortion laws. • States must make accurate, evidence-based abortion information available to individuals on a confidential basis • States must take steps to reduce maternal mortality and morbidity. • In line with human rights requirements, self-management of abortion should not be criminalized. Criminalization of self-management of abo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 142
  },
  {
    "chunk_id": "abortioncare_653",
    "text": "reduce maternal mortality and morbidity. • In line with human rights requirements, self-management of abortion should not be criminalized. Criminalization of self-management of abortion may result in delays in or barriers to seeking assistance or post-abortion care where needed. Self-management of medical abortion should be available as an option on the basis of clinical appropriateness. It should not be restricted for non-clinical reasons such as age. For further information and sources, please refer to Box 1.2 and Web annex A: Key international human rights standards on abortion.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 142
  },
  {
    "chunk_id": "abortioncare_654",
    "text": "105 All recommendations related to law and policy (Recommendations 1,2,3,6,7,21,22) Informed consent (in section 1.3.1: Human rights) Provision of information on quality abortion care (section 3.2.1) Provision of counselling (section 3.2.2) Pain management for abortion (section 3.3.6) Links to related topics/recommendations Services across the continuum of care Pre- abortionPost- abortion Service- delivery models and self- management Foundational information Abortion regulation Abortion 3.6 Service-delivery options and self-management approaches",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 143
  },
  {
    "chunk_id": "abortioncare_655",
    "text": "107 Chapter 4. Dissemination, applicability, research gaps and future updates of the guideline and recommendations 4.1 Dissemination This guideline will be published digitally (both an interactive web-based version and a traditional document available online for download) and in print; see further information in Annex 11. Translation of the guideline into Spanish (in collaboration with the Pan American Health Organization [PAHO]), French and Portuguese is planned. Translations into other United Nations languages will be developed as needed. Several derivative products will be developed based on this updated and consolidated guideline:* • operational guidance containing details on implementation of the recommendations, including strategic considerations for improving access to quality abortion care for youth; • informational materials, such as posters highlighting selected recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 145
  },
  {
    "chunk_id": "abortioncare_656",
    "text": "ations, including strategic considerations for improving access to quality abortion care for youth; • informational materials, such as posters highlighting selected recommendations, which can be placed in health-care facilities and other appropriate places; • pocket charts/cards for health workers, providing the updated recommendations for medical and surgical abortion and post-abortion contraception, and referral cards for referring individuals to other health-care services (adapted for use by different types of health workers and for different literacy levels); • user-friendly decision-support tools for health workers and policy-makers, created with the input of end-users who will be engaged in the process of determining how best to translate the guidance for this purpose (the tools may include digital decision tools in the format of a mobile application [app]); • case studies on quali",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 145
  },
  {
    "chunk_id": "abortioncare_657",
    "text": " determining how best to translate the guidance for this purpose (the tools may include digital decision tools in the format of a mobile application [app]); • case studies on quality abortion care in different humanitarian settings, to demonstrate and highlight the relevant considerations and requirements; • operational guidance on medical management of select clinical indications, such as miscarriage. * Note: Where applicable, WHO will collaborate with relevant United Nations agencies in the dissemination efforts. For example, WHO will collaborate with the Office of the United Nations High Commissioner for Human Rights (OHCHR) to disseminate guidance and tools to support application of a human rights-based approach to sexual and reproductive health, as well as respond to country requests for technical assistance to implement these approaches. 4.2 Implementation and impact evaluation of ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 145
  },
  {
    "chunk_id": "abortioncare_658",
    "text": "roach to sexual and reproductive health, as well as respond to country requests for technical assistance to implement these approaches. 4.2 Implementation and impact evaluation of the guideline Implementation of this guideline requires a multifaceted approach. After the initial publication, translation and dissemination efforts on regional, national and local levels (see Annex 11), it will be important to apply active techniques such as conducting workshops and training programmes to familiarize users with the guideline. Engagement by WHO team members with managers and staff of health-care facilities to build reminders about Chapter 4. Dissemination, applicability, research gaps and future updates of the guideline and recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 145
  },
  {
    "chunk_id": "abortioncare_659",
    "text": "Abortion care guideline, second edition 108 the latest guidance into their clinical support systems will also be crucial. With regard to policy and programme planning, it will be important to work with policy-makers and national and local health officials to ensure implementation of the adopted recommendations at all levels of the health system. Engaging with national ministries and WHO country offices to contextualize the guidelines may facilitate adaptation of the guideline. It is anticipated that the main barrier to implementation of this guideline will be the subject matter – quality abortion care – which is a sensitive and stigmatized topic. This means that it is all the more important to work with stakeholders, including government, policy-makers and advocates for safe and legal abortion, to inform them about the guideline and facilitate open dialogue about the realities of abortio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 146
  },
  {
    "chunk_id": "abortioncare_660",
    "text": "lders, including government, policy-makers and advocates for safe and legal abortion, to inform them about the guideline and facilitate open dialogue about the realities of abortion in their country. Using the Global Abortion Policies Database will facilitate these discussions (116) . Process and impact evaluation will be ongoing during the first year of implementation of this guideline, focusing on the accessibility, acceptance, use, impact and generalizability of the guideline and its recommendations. As an assessment of document uptake, the engagement with the interactive online version of the guideline, the number of downloads of the document from the WHO website, and the number of hard copies of the guidance requested and distributed through the document centre will be monitored. A year after publication, an evaluation of the immediate impact of the guidelines will be undertaken in ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 146
  },
  {
    "chunk_id": "abortioncare_661",
    "text": "ce requested and distributed through the document centre will be monitored. A year after publication, an evaluation of the immediate impact of the guidelines will be undertaken in the form of an online survey. This will be conducted through WHO regional and country offices and through selected respondents from other user groups (e.g. professional societies, NGOs) in order to gauge utilization in-country and whether and how any of the recommendations in the guideline have been implemented or have influenced policy decisions. This short-term impact evaluation will also include an assessment of barriers to effective implementation, which will be important feedback for derivative products and future modifications. 4.3 Research gaps/topics for further research In the course of developing this guideline, during the meetings of the Evidence and Recommendation Review Groups (ERRGs) and the Guide",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 146
  },
  {
    "chunk_id": "abortioncare_662",
    "text": "4.3 Research gaps/topics for further research In the course of developing this guideline, during the meetings of the Evidence and Recommendation Review Groups (ERRGs) and the Guideline Development Group (GDG), several evidence gaps and areas for further research were identified. Law and policy • Impact of abortion laws and policies on people with disabilities and people with diminished capacity who seek abortion • Impact of abortion laws and policies on groups in vulnerable situations and groups with marginalized identities, specifically adolescents and transgender individuals • Impacts, effects and rights-related implications of procedural barriers to abortion in various contexts • Impacts, effects and rights-related implications of making abortion available on the request of the woman, girl or other pregnant person, with no additional restrictions • Impacts, effects, and rights-related",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 146
  },
  {
    "chunk_id": "abortioncare_663",
    "text": "related implications of making abortion available on the request of the woman, girl or other pregnant person, with no additional restrictions • Impacts, effects, and rights-related implications of the decriminalization of self-management of abortion and of assistance with self-management of abortion Clinical services • Efficacy, safety and acceptability of the letrozole plus misoprostol combination regimen across gestational ages and compared with the mifepristone plus misoprostol combination regimen • Effectiveness of using misoprostol alone (i.e. typical/real use outside of study conditions, optimal number of repeat doses) • Efficacy, safety and acceptability of the use of misoprostol alone across gestational ages • Effectiveness, safety and acceptability of outpatient medical abortion at gestational ages ≥ 12 weeks • Safety, effectiveness and acceptability of anti-epileptics and anxio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 146
  },
  {
    "chunk_id": "abortioncare_664",
    "text": " ages • Effectiveness, safety and acceptability of outpatient medical abortion at gestational ages ≥ 12 weeks • Safety, effectiveness and acceptability of anti-epileptics and anxiolytics for pain management for medical abortion at gestational ages ≥ 14 weeks • Management of cervical priming prior to dilatation and evacuation (D&E) at gestational ages ≥ 18 weeks in settings where osmotic dilators are not available",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 146
  },
  {
    "chunk_id": "abortioncare_665",
    "text": "109 • Optimal antibiotic regimens for post-abortion infection prophylaxis • Effective methods for diagnosis and treatment of non-symptomatic ectopic pregnancy • Safety and effectiveness of screening and antibiotic treatment for pelvic inflammatory disease before surgical abortion versus provision of pre- or perioperative prophylactic antibiotics without screening or risk assessment for pelvic inflammatory infection • Effectiveness of telemedicine for medical abortion at gestational ages < 6 weeks • Efficacy, safety and acceptability of all abortion methods and related clinical interventions across gestational ages in transgender, nonbinary and intersex individuals seeking abortion care • Development and adaptation of validated materials to provide individuals engaging in self-management of abortion with the information they need to make informed decisions about the risks/benefits of and ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 147
  },
  {
    "chunk_id": "abortioncare_666",
    "text": "ion of validated materials to provide individuals engaging in self-management of abortion with the information they need to make informed decisions about the risks/benefits of and the alternatives to the use of different medical abortion regimens • Development of effective and user-friendly information for abortion seekers, e.g. leaflets and web pages or information for use in the context of hotlines and telemedicine services • Development and validation of quality training materials for use in training of providers on a range of abortion care services (e.g. to train pharmacists, pharmacy workers and community health workers to effectively provide – or support self-management of – all tasks involved in medical abortion at gestational ages < 12 weeks) • Safety, convenience and acceptability of re-using manual vacuum aspiration (MVA) equipment Service delivery • Safety, effectiveness and f",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 147
  },
  {
    "chunk_id": "abortioncare_667",
    "text": "abortion at gestational ages < 12 weeks) • Safety, convenience and acceptability of re-using manual vacuum aspiration (MVA) equipment Service delivery • Safety, effectiveness and feasibility of expansion of health worker roles for certain abortion care tasks in low- and middle-income settings (e.g. surgical abortion at gestational ages ≥ 12 weeks, vacuum aspiration for incomplete abortion) • Feasibility of pharmacists administering injectable contraception in low- and middle-resource settings (implementation research) • Impact of social marketing and social franchising approaches in abortion care assessed through evaluation research • The most appropriate prescribing and dispensing authorities for abortion medicines, including comparison of self-sourced abortion medicines versus medicines prescribed and/or dispensed by trained health workers • Mechanisms for ensuring individuals who mana",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 147
  },
  {
    "chunk_id": "abortioncare_668",
    "text": "cines, including comparison of self-sourced abortion medicines versus medicines prescribed and/or dispensed by trained health workers • Mechanisms for ensuring individuals who manage medical abortion on their own have access to medicines for pain management and to contraceptive methods • Acceptability of and satisfaction with a range of service-delivery approaches for quality abortion care for transgender, nonbinary and intersex individuals Universal health coverage (UHC), health financing and commodities • Impact of the WHO Model Lists of Essential Medicines changes to the mifepristone plus misoprostol combination regimen assessed through evaluation research Indicators for use in monitoring and evaluation (M&E) of care • Development and validation of indicators that include social and economic disability in addition to physical disability when calculating years living with abortion-rela",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 147
  },
  {
    "chunk_id": "abortioncare_669",
    "text": ") of care • Development and validation of indicators that include social and economic disability in addition to physical disability when calculating years living with abortion-related disability (in line with the growing focus on global burden of disease and disability estimation) • Development and validation of standardized data-verification methods, so that abortion-related data can be presented with a verification score (as part of efforts to address the underreporting of abortion-related data as a result of abortion-related stigma) • Development and increased use of qualitative methods for M&E of quality abortion care to assess barriers to progress and enablers for strengthening health system performance Chapter 4. Dissemination, applicability, research gaps and future updates of the guideline and recommendations",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 147
  },
  {
    "chunk_id": "abortioncare_670",
    "text": "111 References References 1. Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets: global strategy adopted by the 57th World Health Assembly. Geneva: World Health Organization; 2004 (https://iris.who.int/handle/10665/68754 ). 2. Constitution of the World Health Organization. Adopted in 1946, entered into force in 1948. Geneva: World Health Organization; 1946 (https://iris.who.int/handle/10665/268688 ). 3. General Comment No. 22: The right to sexual and reproductive health (Article 12 of the International Covenant on Economic, Social and Cultural Rights). Geneva: United Nations Committee on Economic, Social and Cultural Rights; 2016 (E/C/12/GC/22). 4. General Comment No. 31: The nature of the general legal obligation imposed on States Parties to the Covenant: International Covenant on Civil and Political Rights. New York",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 149
  },
  {
    "chunk_id": "abortioncare_671",
    "text": "22). 4. General Comment No. 31: The nature of the general legal obligation imposed on States Parties to the Covenant: International Covenant on Civil and Political Rights. New York (NY): United Nations Human Rights Committee (80th session); 2004 (CCPR/C/21/ Rev.1/Add.13). 5. IHL and human rights law. International Committee of the Red Cross (ICRC); 2010 (https://www.icrc.org/en/document/ihl-human- rights-law). 6. General Recommendation No. 30: Women in conflict prevention, conflict, and post-conflict situations. United Nations Committee on the Elimination of Discrimination against Women; 2013 (CEDAW/C/GC/30). 7. Maintaining essential health services: operational guidance for the COVID-19 context, interim guidance. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/WHO-2019-nCoV-essential_health_services-2020.2). 8. World Health Organization (WHO), United Nat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 149
  },
  {
    "chunk_id": "abortioncare_672",
    "text": "ce. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/WHO-2019-nCoV-essential_health_services-2020.2). 8. World Health Organization (WHO), United Nations Children’s Fund, United Nations Population Fund. Continuing essential sexual, reproductive, maternal, neonatal, child and adolescent health services during COVID-19 pandemic: practical considerations. New Delhi: WHO Regional Office for South-East Asia; 2020 (https://apps.who.int/iris/rest/bitstreams/1278406/retrieve). 9. Global Health Cluster, World Health Organization (WHO). Working paper on the use of essential packages of health services in protracted emergencies. Geneva: WHO; 2018 (https://www.who.int/health-cluster/about/work/task-teams/EPHS-working-paper.pdf). 10. Global Health Cluster COVID-19 Task Team. Essential health services: a guidance note: how to prioritize and plan essential health services",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 149
  },
  {
    "chunk_id": "abortioncare_673",
    "text": "k/task-teams/EPHS-working-paper.pdf). 10. Global Health Cluster COVID-19 Task Team. Essential health services: a guidance note: how to prioritize and plan essential health services during COVID-19 response in humanitarian settings. Global Health Cluster; 2020 (https://healthcluster.who.int/publications/m/item/essential-health-services ). 11. COVID-19 frequently asked questions [website]. United Nations Population Fund (UNFPA); 2020 (https://www.unfpa.org/covid-19- FAQs). 12. COVID-19 technical brief for maternity services. United Nations Population Fund (UNFPA); 2020 (https://www.unfpa.org/ resources/covid-19-technical-brief-maternity-services). 13. Achieve gender equality to deliver the SDGs [website]. International Institute for Sustainable Development; 2017 (https://sdg.iisd.org/commentary/policy-briefs/achieve-gender-equality-to-deliver-the-sdgs/ ). 14. The global strategy for women’",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 149
  },
  {
    "chunk_id": "abortioncare_674",
    "text": "tional Institute for Sustainable Development; 2017 (https://sdg.iisd.org/commentary/policy-briefs/achieve-gender-equality-to-deliver-the-sdgs/ ). 14. The global strategy for women’s, children’s and adolescents’ health (2016–2030). New York (NY): Every Woman Every Child; 2015 (https://www.who.int/docs/default-source/child-health/the-global-strategy-for-women-s-children-s-and-adolescents- health-2016-2030.pdf ). 15. Quality of care: a process for making strategic choices in health systems. Geneva: World Health Organization; 2006 (https://iris.who.int/handle/10665/43470 ). 16. Bearak J, Popinchalk A, Ganatra B, Moller A-B, Tunçalp Ö, Beavin C, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e61. 17. Fact sheet: preventing unsafe abortion [website]. Geneva: Wo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 149
  },
  {
    "chunk_id": "abortioncare_675",
    "text": "al status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e61. 17. Fact sheet: preventing unsafe abortion [website]. Geneva: World Health Organization; 2020 (https://www.who.int/news-room/ fact-sheets/detail/preventing-unsafe-abortion). 18. Ganatra B, Gerdts C, Rossier C, Johnson BR, Tunçalp Ö, Assifi A, et al. Global, regional, and subregional classification of abortions by safety, 2010–14: estimates from a Bayesian hierarchical model. Lancet. 2017;390(10110):2372-81. 19. Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 149
  },
  {
    "chunk_id": "abortioncare_676",
    "text": "Abortion care guideline, second edition 112 (https://apps.who.int/iris/bitstream/handle/10665/70914/9789241548434_eng.pdf). 20. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-e33. 21. Kassebaum N, Bertozzi-Villa A, Coggeshall M, Shackelford K, Steiner C, Heuton K, et al. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):980-1004. 22. Singh S, Maddow-Zimet I. Facility-based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries. BJOG. 2015;123(9):1489-98. 23. Health worker roles in providing safe abortion care and post-abortion contraception. Geneva: World",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 150
  },
  {
    "chunk_id": "abortioncare_677",
    "text": "rld, 2012: a review of evidence from 26 countries. BJOG. 2015;123(9):1489-98. 23. Health worker roles in providing safe abortion care and post-abortion contraception. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/bitstream/handle/10665/181041/9789241549264_eng.pdf). 24. WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/ handle/10665/145714). 25. Consolidated guideline on sexual and reproductive health and rights of women living with HIV. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/342741 ). 26. WHO guideline on self-care interventions for health and well-being. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342741 ). 27. Human Rights Council, Thirty-fifth session, 6–23 June 2017, Agenda item 3: Promotion and protection of all human right",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 150
  },
  {
    "chunk_id": "abortioncare_678",
    "text": "zation; 2021 (https://iris.who.int/handle/10665/342741 ). 27. Human Rights Council, Thirty-fifth session, 6–23 June 2017, Agenda item 3: Promotion and protection of all human rights, civil, political, economic, social and cultural rights, including the right to development: Report of the Independent Expert on protection against violence and discrimination based on sexual orientation and gender identity: Note by the Secretariat. New York (NY): United Nations General Assembly; 2017 (A/HRC/35/36; https://www.refworld.org/pdfid/593a9b3f4.pdf). 28. Report of the Independent Expert on protection against violence and discrimination based on sexual orientation and gender identity, 12 July 2018. New York (NY): United Nations General Assembly; 2018 (A/73/152; https://undocs.org/A/73/152). 29. Framework on integrated people-centred health services (IPCHS). Geneva: World Health Organization; 2021 (h",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 150
  },
  {
    "chunk_id": "abortioncare_679",
    "text": "tions General Assembly; 2018 (A/73/152; https://undocs.org/A/73/152). 29. Framework on integrated people-centred health services (IPCHS). Geneva: World Health Organization; 2021 (https://www.who. int/teams/integrated-health-services/clinical-services-and-systems/service-organizations-and-integration). 30. World Health Organization (WHO), United Nations Children’s Fund. A vision for primary health care in the 21st century: towards universal health coverage and the Sustainable Development Goals. Geneva: WHO; 2018. (https://apps.who.int/iris/ handle/10665/328065). 31. Altshuler A, Whaley N. The patient perspective: perceptions of the quality of the abortion experience. Curr Opin Obstet Gynecol. 2018;30(6):407-13. 32. International Conference on Population and Development Programme of Action, twentieth anniversary edition. New York (NY): United Nations; 2014 (https://www.unfpa.org/publicatio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 150
  },
  {
    "chunk_id": "abortioncare_680",
    "text": "32. International Conference on Population and Development Programme of Action, twentieth anniversary edition. New York (NY): United Nations; 2014 (https://www.unfpa.org/publications/international-conference-population-and-development-programme- action). 33. Sustainable development: the 17 goals [website]. United Nations Department of Economic and Social Affairs; 2021 (https://sdgs. un.org/goals). 34. International Covenant on Economic, Social and Cultural Rights. Adopted and opened for signature, ratification and accession by General Assembly resolution 2200A (XXI) of 16 December 1966, entry into force 3 January 1976, in accordance with article 27. United Nations; 1966. 35. Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Report to the United Nations General Assembly. New York (NY): United Nations; 2016 (A/HRC",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 150
  },
  {
    "chunk_id": "abortioncare_681",
    "text": "veryone to the enjoyment of the highest attainable standard of physical and mental health. Report to the United Nations General Assembly. New York (NY): United Nations; 2016 (A/HRC/32/32). 36. General Comment No. 36: Article 6 of the International Covenant on Civil and Political Rights, on the right to life. Geneva: United Nations Human Rights Committee (124th session); 2018 (CCPR/C/GC/36). 37. Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Interim report to the General Assembly. New York (NY): United Nations; 2011 (A/66/254). 38. General Recommendation No. 34: The rights of rural women. New York (NY): United Nations Committee on the Elimination of Discrimination against Women; 2016 (CEDAW/C/GC/34).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 150
  },
  {
    "chunk_id": "abortioncare_682",
    "text": "113 39. General Recommendation No. 24: Article 12 of the Convention (Women and health). United Nations Committee on the Elimination of Discrimination against Women; 1999 (A/54/38/Rev.1). 40. General Comment No. 28: Article 3 of the International Covenant on Civil and Political Rights, on the equality of rights between men and women. New York (NY): United Nations Human Rights Committee; 2000 (CCPR/C/21/Rev.1/Add.10). 41. Report of the United Nations Working Group on the issue of discrimination against women in law and in practice to the Human Rights Council. New York (NY): United Nations General Assembly; 2016 (A/HRC/32/44). 42. Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health: sexual and reproductive health rights: challenges and opportunities during the COVID-19 pandemic. United Nations; 2021 (A/76/172). 43. Ge",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 151
  },
  {
    "chunk_id": "abortioncare_683",
    "text": "le standard of physical and mental health: sexual and reproductive health rights: challenges and opportunities during the COVID-19 pandemic. United Nations; 2021 (A/76/172). 43. General Comment No. 4: Adolescent health and development in the context of the Convention on the Rights of the Child. Geneva: United Nations Committee on the Rights of Child; 2003 (CRC/GC/2003/4). 44. Special Rapporteur on extrajudicial, summary or arbitrary executions. Report of the Special Rapporteur on extrajudicial, summary or arbitrary executions on a gender-sensitive approach to arbitrary killings. United Nations; 2017 (A/HRC/35/23). 45. General Comment No. 15: The right of the child to the enjoyment of the highest attainable standard of health (Article 24). Geneva: United Nations Committee on the Rights of the Child; 2013 (CRC/C/GC/15). 46. General Comment No. 14: The right to the highest attainable standa",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 151
  },
  {
    "chunk_id": "abortioncare_684",
    "text": "dard of health (Article 24). Geneva: United Nations Committee on the Rights of the Child; 2013 (CRC/C/GC/15). 46. General Comment No. 14: The right to the highest attainable standard of health (Article 12). Geneva: United Nations Committee on Economic, Social and Cultural Rights; 2000 (E/C.12/2000/4). 47. Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Report of the Special Rapporteur, Paul Hunt. United Nations Economic and Social Council; 2004 (E/CN.4/2004/49). 48. Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment, Juan E. Méndez. Report to the Human Rights Council. New York (NY): United Nations General Assembly; 2013 (A/HRC/22/53). 49. General Comment No. 25: Science and economic, social and cultural rights (Article 15(1)(b), (2), (3) and (4) of the International Cov",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 151
  },
  {
    "chunk_id": "abortioncare_685",
    "text": "ions General Assembly; 2013 (A/HRC/22/53). 49. General Comment No. 25: Science and economic, social and cultural rights (Article 15(1)(b), (2), (3) and (4) of the International Covenant on Economic, Social and Cultural Rights. Geneva: United Nations Committee on Economic, Social and Cultural Rights; 2020 (E/C.12/GC/25). 50. Whelan v. Ireland. United Nations Human Rights Committee; 2017 (CCPR/C/11/D/2425/2014). 51. Mellet v. Ireland. United Nations Human Rights Committee; 2016 (CCPR/C/116/D/2324/2013). 52. General Comment No. 3: Article 6: Women and girls with disabilities. Geneva: United Nations Committee on the Rights of Persons with Disabilities; 2016 (CRPD/C/GC/3). 53. General Comment No. 20: Non-discrimination in economic, social and cultural rights (Article 2, para. 2, of the International Covenant on Economic, Social and Cultural Rights). Geneva: United Nations Committee on Economi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 151
  },
  {
    "chunk_id": "abortioncare_686",
    "text": "ion in economic, social and cultural rights (Article 2, para. 2, of the International Covenant on Economic, Social and Cultural Rights). Geneva: United Nations Committee on Economic, Social and Cultural Rights; 2009 (E/C.12/GC/20). 54. Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Interim report to the Human Rights Council. United Nations Human Rights Council; 2013 (A/HRC/23/42). 55. General Recommendation No. 35: Gender-based violence against women, updating general recommendation No. 19. New York (NY): United Nations Committee on the Elimination of Discrimination against Women; 2017 (CEDAW/C/GC/35). 56. Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment. Report to the Human Rights Council. United Nations; 2008 (A/HRC/7/3). 57. KL v. Peru. United Nations Human Rights",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 151
  },
  {
    "chunk_id": "abortioncare_687",
    "text": "ure and other cruel, inhuman or degrading treatment or punishment. Report to the Human Rights Council. United Nations; 2008 (A/HRC/7/3). 57. KL v. Peru. United Nations Human Rights Committee; 2005 (CCPR/C/85/D/1153/2003). 58. Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Report to the General Assembly. United Nations; 2009 (A/64/272). 59. Convention on the Rights of Persons with Disabilities. Adopted on 13 December 2006, entered into force on 3 May 2008. New York (NY); United Nations (A/RES/61/106). 60. Guaranteeing sexual and reproductive health and rights for all women, in particular women with disabilities. Joint statement by the Committee on the Rights of Persons with Disabilities and the Committee on the Elimination of Discrimination against Women. Adopted on 29 August 2018. United Nations; 2018. Refere",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 151
  },
  {
    "chunk_id": "abortioncare_688",
    "text": "e Committee on the Rights of Persons with Disabilities and the Committee on the Elimination of Discrimination against Women. Adopted on 29 August 2018. United Nations; 2018. References",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 151
  },
  {
    "chunk_id": "abortioncare_689",
    "text": "Abortion care guideline, second edition 114 61. General Recommendation No. 33: Women’s access to justice. New York (NY): United Nations Committee on the Elimination of Discrimination against Women; 2015 (CEDAW/C/GC/33). 62. General Comment No. 20: Implementation of the rights of the child during adolescence. Geneva: United Nations Committee on the Rights of the Child; 2016 (CRC/C/GC/20). 63. Working Group on the issue of discrimination against women in law and in practice. Report to the Human Rights Council. New York (NY): United Nations General Assembly; 2016 (A/HRC/32/44). 64. General Comment No. 3: The Nature of States Parties’ Obligations (Article 2, Para. 1 of the Covenant). United Nations Committee on Economic, Social and Cultural Rights; 1990 (E/19991/12). 65. World Health Organization (WHO) Department of Mental Health and Substance Abuse, Victorian Health Promotion Foundation, Un",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 152
  },
  {
    "chunk_id": "abortioncare_690",
    "text": "nomic, Social and Cultural Rights; 1990 (E/19991/12). 65. World Health Organization (WHO) Department of Mental Health and Substance Abuse, Victorian Health Promotion Foundation, University of Melbourne. Promoting mental health: concepts, emerging evidence, practice: summary report. Geneva: WHO; 2004. 66. Aniteye P, Mayhew S. Shaping legal abortion provision in Ghana: using policy theory to understand provider-related obstacles to policy implementation. Health Res Policy Syst. 2013;11(23). doi:10.1186/1478-4505-11-23. 67. Diniz D, Madeiro A, Rosas C. Conscientious objection, barriers, and abortion in the case of rape: a study among physicians in Brazil. Reprod Health Matters. 2014;22(43):141-8. 68. Fink L, Stanhope K, Rochat R, Bernal O. “The fetus is my patient, too”: attitudes toward abortion and referral among physician conscientious objectors in Bogotá, Colombia. Int Perspect Sex Repr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 152
  },
  {
    "chunk_id": "abortioncare_691",
    "text": "ope K, Rochat R, Bernal O. “The fetus is my patient, too”: attitudes toward abortion and referral among physician conscientious objectors in Bogotá, Colombia. Int Perspect Sex Reprod Health. 2021;42(2):71-80. 69. Convention on the Rights of the Child. New York (NY): United Nations; 1989. 70. General Comment No. 6: Equality and non-discrimination. Geneva: United Nations Committee on the Rights of Persons with Disabilities; 2018 (CRPD/C/GC/6). 71. Convention on the Elimination of All Forms of Discrimination against Women. New York (NY): United Nations; 1979. 72. United Nations Population Fund (UNFPA). International technical guidance on sexuality education: an evidence-informed approach (revised edition). UNESCO, UNAIDS, UNFPA, UNICEF, UN Women, WHO; 2018 (https://www.unfpa.org/publications/ international-technical-guidance-sexuality-education). 73. The prevention and elimination of disres",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 152
  },
  {
    "chunk_id": "abortioncare_692",
    "text": " UNAIDS, UNFPA, UNICEF, UN Women, WHO; 2018 (https://www.unfpa.org/publications/ international-technical-guidance-sexuality-education). 73. The prevention and elimination of disrespect and abuse during facility-based childbirth: WHO Statement. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/134588). 74. Norris A, Bessett D, Steinberg J, Kavanaugh M, De Zordo S, Becker D. Abortion stigma: a reconceptualization of constituents, causes, and consequences. Womens Health Issues. 2011;21(3 Suppl):S49-54. 75. Hanschmidt F, Linde K, Hilbert A, Riedel-Heller S, Kersting A. Abortion stigma: a systematic review. Persp Sex Reprod Health. 2016;48(4):169-77. 76. Kumar A, Hessini L, Mitchell E. Conceptualising abortion stigma. Cult Health Sex. 2009;11(6):625-39. 77. Everybody’s business: strengthening health systems to improve health outcomes: WHO’s framework for action. ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 152
  },
  {
    "chunk_id": "abortioncare_693",
    "text": "Conceptualising abortion stigma. Cult Health Sex. 2009;11(6):625-39. 77. Everybody’s business: strengthening health systems to improve health outcomes: WHO’s framework for action. Geneva: World Health Organization; 2007 (https://apps.who.int/iris/handle/10665/43918). 78. Universal health coverage for sexual and reproductive health: evidence brief. Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/331113 ). 79. UHC compendium 2021. Geneva: World Health Organization; 2021 (https://www.who.int/universal-health-coverage/ compendium). 80. Coast E, Lattof S, Meulen Rodgers Y, Moore B, Poss C. The microeconomics of abortion: a scoping review and analysis of the economic consequences for abortion care-seekers. PLoS One. 2021;16(6):e0252005. 81. Lattof S, Coast E, Rodgers Y, Moore B, Poss C. The mesoeconomics of abortion: a scoping review and analysis of the economic effe",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 152
  },
  {
    "chunk_id": "abortioncare_694",
    "text": "on care-seekers. PLoS One. 2021;16(6):e0252005. 81. Lattof S, Coast E, Rodgers Y, Moore B, Poss C. The mesoeconomics of abortion: a scoping review and analysis of the economic effects of abortion on health systems. PLoS One. 2020;15(11):e0237227. 82. Rodgers Y, Coast E, Lattof S, Poss C, Moore B. The macroeconomics of abortion: a scoping review and analysis of the costs and outcomes. PLoS One. 2021;16(5):e0250692. 83. Cook R, Dickens B, Fathalla M. Reproductive health and human rights: integrating medicine, ethics and law. Oxford: Oxford University Press; 2003.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 152
  },
  {
    "chunk_id": "abortioncare_695",
    "text": "115 84. Billings D, Moreno C, Ramos C, González de León D, Ramı́rez R, Villaseñor Martı́nez L, et al. Constructing access to legal abortion services in Mexico City. Reprod Health Matters. 2002;10(19) :86-94. 85. Villela W, Araújo M. Making legal abortion available in Brazil: partnerships in practice. Reprod Health Matters. 2000;8(16):77-82. 86. Cook R, Ngwena C. Women’s access to health care: the legal framework. Int J Gynecol Obstet. 2006;94(3):216-25. 87. Cook R, Erdman J, Hevia M, Dickens B. Prenatal management of anencephaly. Int J Gynaecol Obstet. 2008;102(3):304-8. 88. Lavelanet A, Johnson B, Ganatra B. Global Abortion Policies Database: a descriptive analysis of the regulatory and policy environment related to abortion. Best Pract Res Clin Obstet Gynaecol. 2020;62:25-35. 89. Assifi A, Kang M, Sullivan E, Dawson A. Abortion care pathways and service provision for adolescents in hig",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 153
  },
  {
    "chunk_id": "abortioncare_696",
    "text": "ted to abortion. Best Pract Res Clin Obstet Gynaecol. 2020;62:25-35. 89. Assifi A, Kang M, Sullivan E, Dawson A. Abortion care pathways and service provision for adolescents in high-income countries: a qualitative synthesis of the evidence. PLoS One. 2020;15(11):e0242015. 90. Iyengar K, Iyengar SD. Elective abortion as a primary health service in rural India: experience with manual vacuum aspiration. Reproductive Health Matters. 2002;10(19):54-63. 91. Cook R, Erdman J, Dickens B. Achieving transparency in implementing abortion laws. Int J Gynecol Obstet. 2007;99(2):157-61. 92. Coast E, Norris A, Moore A, Freeman E. Trajectories of women’s abortion-related care: a conceptual framework. Soc Sci Med. 2018:199-210. 93. Mundigo A, Indriso C. Abortion in the developing world. London and New York: Zed Books; 1999. 94. Concluding Observation: Portugal. Committee on the Elimination of Discriminat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 153
  },
  {
    "chunk_id": "abortioncare_697",
    "text": " 93. Mundigo A, Indriso C. Abortion in the developing world. London and New York: Zed Books; 1999. 94. Concluding Observation: Portugal. Committee on the Elimination of Discrimination against Women; 2015 (CEDAW/C/PRT/CO/8-9). 95. Dzakpasu S, Powell-Jackson T, Campbell OMR. Impact of user fees on maternal health service utilization and related health outcomes: a systematic review. Health Pol Plann. 2014;29(2):137-50. 96. Concluding Observations: Germany. Committee on the Elimination of Discrimination against Women; 2017 (CEDAW/C/DEU/CO/7-8). 97. Concluding Observations: Slovakia. Committee on Economic, Social and Cultural Rights; 2012(E/C.12/SVK/CO/2). 98. Concluding Observations: Austria. Committee on the Elimination of Discrimination against Women; 2013 (CEDAW/C/AUT/CO/7-8). 99. Concluding Observations: Peru. United Nations Committee against Torture; 2013. 100. The world health report 2",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 153
  },
  {
    "chunk_id": "abortioncare_698",
    "text": "nation of Discrimination against Women; 2013 (CEDAW/C/AUT/CO/7-8). 99. Concluding Observations: Peru. United Nations Committee against Torture; 2013. 100. The world health report 2006: working together for health. Geneva: World Health Organization; 2006 (https://apps.who.int/iris/handle/10665/43432). 101. Fact sheet: Universal health coverage (UHC). Geneva: World Health Organization; 2021 (https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc)). 102. National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Health Care Services, Board on Population Health and Public Health Practice, Committee on Reproductive Health Services. Essential clinical competencies for abortion providers (Chapter 3). In: The safety and quality of abortion care in the United States. Washington, DC: National Academies Press (US); 2018 (https://www.ncbi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 153
  },
  {
    "chunk_id": "abortioncare_699",
    "text": "etencies for abortion providers (Chapter 3). In: The safety and quality of abortion care in the United States. Washington, DC: National Academies Press (US); 2018 (https://www.ncbi.nlm.nih.gov/books/NBK507233/). 103. Essential competencies for midwifery practice: 2019 update. International Confederation of Midwives; 2019 (https://www.internationalmidwives.org/our-work/policy-and-practice/essential-competencies-for-midwifery-practice.html). 104. Developing a global competency framework for universal health coverage. Geneva: World Health Organization; 2018 (https://www.who.int/news/item/04-06-2018-developing-a-global-competency-framework-for-universal-health-coverage). 105. WHO global competency and outcomes framework for universal health coverage. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/352711 ). 106. Framework on integrated, people-centred health servic",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 153
  },
  {
    "chunk_id": "abortioncare_700",
    "text": "ework for universal health coverage. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/352711 ). 106. Framework on integrated, people-centred health services: report by the Secretariat. World Health Assembly; 2016 (https://apps.who.int/iris/handle/10665/252698). 107. WHO model list of essential medicines – 21st list, 2019. Geneva: World Health Organization; 2019 (https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06). 108. WHO model list of essential medicines – 22nd list, 2021. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02). References",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 153
  },
  {
    "chunk_id": "abortioncare_701",
    "text": "Abortion care guideline, second edition 116 109. Roadmap for access to medicines, vaccines and health products 2019–2023: comprehensive support for access to medicines, vaccines and other health products. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/330145). 110. Giashuddin M, Kibria M. Forecasting exercise for the 13 reproductive, maternal, newborn, and child health commodities prioritized by the UN Commission on Life-Saving Commodities for Women and Children. Submitted to the United States Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington (VA): Management Sciences for Health; 2014 (https://siapsprogram.org/publication/forecasting-exercise-for-the-13-reproductive- maternal-newborn-and-child-health-commodities-prioritized-by-the-un-commission-on-life-saving-commodities-for-",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 154
  },
  {
    "chunk_id": "abortioncare_702",
    "text": "program.org/publication/forecasting-exercise-for-the-13-reproductive- maternal-newborn-and-child-health-commodities-prioritized-by-the-un-commission-on-life-saving-commodities-for-women- and-children/). 111. Babigumira J, Stergachis A, Kanyok T, Evans L, Hajjou M, Nkansah P, et al. Promoting the quality of medicines: a risk-based resource allocation framework for pharmaceutical quality assurance for medicines regulatory authorities in low- and middle- income countries. Rockville (MD): USP; 2018 (https://www.usp-pqm.org/sites/default/files/pqms/article/risk-based_resource_ allocation_framework_june2018.pdf). 112. List of Stringent Regulatory Authorities, 51st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Technical Report Series 1003. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/258720 ). 113. Marketing authorization",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 154
  },
  {
    "chunk_id": "abortioncare_703",
    "text": "for Pharmaceutical Preparations. WHO Technical Report Series 1003. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/258720 ). 113. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/bitstream/handle/10665/44576/9789241501453_eng.pdf). 114. Enterprise and Industry Directorate-General. A guideline on changing the classification for the supply of a medicinal product for human use. European Commission; 2006 (https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-2/c/ switchguide_160106_en.pdf). 115. World Health Organization (WHO), World Bank, Gavi, Global Fund. Monitoring and evaluation of health systems strengthening: an operational framework. Geneva: World Health Organization; 2009. 116. Global Abortion Policies Database (GAPD) ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 154
  },
  {
    "chunk_id": "abortioncare_704",
    "text": "l Fund. Monitoring and evaluation of health systems strengthening: an operational framework. Geneva: World Health Organization; 2009. 116. Global Abortion Policies Database (GAPD) [website]. Geneva: World Health Organization; undated (http://abortion-policies.srhr.org/). 117. Mutua M, Manderson L, Musenge E, Achia T. Policy, law and post-abortion care services in Kenya. PLoS One. 2018;13(9):e0204240. 118. Rehfuess EA, Stratil JM, Scheel IB, Portela A, Norris SL, Baltussen R. The WHO-INTEGRATE evidence to decision framework version 1.0: integrating WHO norms and values and a complexity perspective. BMJ Glob Health. 2019;4:e000844. 119. Schünemann, H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. GRADEpro.org; 2013 (https://gdt.gradepro.org/app/handbook/ handbook.html). 120. M",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 154
  },
  {
    "chunk_id": "abortioncare_705",
    "text": " for grading the quality of evidence and the strength of recommendations using the GRADE approach. GRADEpro.org; 2013 (https://gdt.gradepro.org/app/handbook/ handbook.html). 120. Medical management of abortion. Geneva: World Health Organization; 2018 ( https://iris.who.int/handle/10665/278968). 121. Sexual and reproductive health: core competencies in primary care. Geneva; World Health Organization; 2011 (http://apps.who.int/iris/bitstream/handle/10665/44507/9789241501002_eng.pdf). 122. Clinical practice handbook for safe abortion. Geneva: World Health Organization; 2014 ( https://iris.who.int/handle/10665/97415 ). 123. Rodek C, Deans A. Red cell alloimmunization. In: Rodek CH and Martin JW, editors. Fetal medicine basic sciences and clinical practice, second edition. London: Churchill Livingstone Elsevier; 2009:559-77. 124. Goldman J, Eckerling B. RH immunization in spontaneous abortion",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 154
  },
  {
    "chunk_id": "abortioncare_706",
    "text": "cine basic sciences and clinical practice, second edition. London: Churchill Livingstone Elsevier; 2009:559-77. 124. Goldman J, Eckerling B. RH immunization in spontaneous abortion. Acta Europaea Fertilitatis. 1972;3(3):253-4. 125. Gavin P. Rhesus sensitization in abortion. Obstet Gynecol. 1972;39(1):37-40. 126. Stern K, Davidsohn I, Masaitis L. Experimental studies on Rh immunization. Am J Clin Pathol. 1956;26(8):833-43. 127. Wiebe E, Campbell M, Aiken A, Albert A. Can we safely stop testing for Rh status and immunizing Rh-negative women having early abortions? A comparison of Rh alloimmunization in Canada and the Netherlands. Contraception X. 2019;1(100001). 128. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (http:// www.who.int/reproductivehealth/publications/maternal_perinatal_health/anc-positive-pregnancy-experienc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 154
  },
  {
    "chunk_id": "abortioncare_707",
    "text": "sitive pregnancy experience. Geneva: World Health Organization; 2016 (http:// www.who.int/reproductivehealth/publications/maternal_perinatal_health/anc-positive-pregnancy-experience/en/). 129. Penney G, Thomson M, Norman J, McKenzie H, Vale L, Smith R, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. BJOG. 1998;105(6):599-604. 130. Duncan C, Reynolds-Wright J, Cameron S. Utility of a routine ultrasound for detection of ectopic pregnancies among women",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 154
  },
  {
    "chunk_id": "abortioncare_708",
    "text": "117 requesting abortion: a retrospective review. BMJ Sex Reprod Health. 2020. doi:10.1136/bmjsrh-2020-200888. 131. Smith G, Stubblefield P, Chirchirillo L, McCarthy M. Pain of first-trimester abortion: its quantification and relations with other variables. Am J Obstet Gynecol. 1979;133(5):489-98. 132. Bélanger E, Melzack R, Lauzon P. Pain of first-trimester abortion: a study of psychosocial and medical predictors. Pain. 1989;36(3):339-50. 133. Renner R, Jensen J, Nichols M, Edelman A. Pain control in first trimester surgical abortion. Cochrane Database Syst Rev. 2009;(2):CD006712. 134. Borgotta L, Nickinovich D. Pain during early abortion. J Reprod Med. 1997;42(5):287-93. 135. Grimes D, Schulz K, Cates W. Prevention of uterine perforation during curettage abortion. JAMA. 1984;251(16):2108-11. 136. Schulz K, Grimes D, Cates W. Measures to prevent cervical injury during suction curettage a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 155
  },
  {
    "chunk_id": "abortioncare_709",
    "text": "ntion of uterine perforation during curettage abortion. JAMA. 1984;251(16):2108-11. 136. Schulz K, Grimes D, Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet. 1983;1(8335):1182-5. 137. Lavelanet A, Johnson B, Ganatra B. Global Abortion Policies Database: a descriptive analysis of the regulatory and policy environment related to abortion. Best Pract Res Clin Obstet Gynaecol. 2020;62:25-35. 138. WHO recommendations: optimizing health worker roles to improve access to key maternal and newborn health interventions through task shifting. Geneva: World Health Organization; 2012 (https://apps.who.int/iris/handle/10665/77764). 139. Concluding Observations: Croatia. United Nations Committee on the Elimination of Discrimination against Women; 1998 (A/53/38). 140. Concluding Observations: Italy. United Nations Committee on the Elimination of Discrimination agai",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 155
  },
  {
    "chunk_id": "abortioncare_710",
    "text": "ommittee on the Elimination of Discrimination against Women; 1998 (A/53/38). 140. Concluding Observations: Italy. United Nations Committee on the Elimination of Discrimination against Women; 1997 (A/52/38 Rev.1). 141. Concluding Observations: Slovakia. United Nations Committee on the Elimination of Discrimination against Women; 2008 (A/63/38). 142. Concluding Observations: Poland. United Nations Committee against Torture; 2013 (CAT/C/POL/CO/5-6). 143. P and S v. Poland, Application No. 57375/08, Decision 30 October 2012, European Court of Human Rights; 2012. 144. International Planned Parenthood Federation European Network (IPPF EN) v. Italy, Decision on the Merits, 10 September 2013. European Committee of Social Rights (2013 (No. 87/2012). 145. Concluding Observations: Poland. Human Rights Committee; 2010 (CCPR/C/POL/CO/6). 146. Concluding Observations: Poland. Committee on Economic, So",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 155
  },
  {
    "chunk_id": "abortioncare_711",
    "text": "al Rights (2013 (No. 87/2012). 145. Concluding Observations: Poland. Human Rights Committee; 2010 (CCPR/C/POL/CO/6). 146. Concluding Observations: Poland. Committee on Economic, Social and Cultural Rights; 2009 (E/C.12/POL/CO/5). 147. Concluding Observations: Hungary. Committee on the Elimination of Discrimination against Women; 2013 (CEDAW/C/HUN/CO/7-8). 148. Concluding Observations: Slovakia. Committee on the Rights of the Child; 2016 (CRC/C/SVK/CO/3-5). 149. Concluding Observations: Poland. Committee on the Elimination of Discrimination against Women; 2014 (CEDAW/C/POL/CO/7-8). 150. Concluding Observations: Romania. Committee on the Elimination of Discrimination against Women; 2017 (CEDAW/C/ROU/CO/7-8). 151. Gemzell-Danielsson K, Ho P, Gómez Ponce de León R, Weeks A, Winikoff B. Misoprostol to treat missed abortion in the first trimester. Int J Gynaecol Obstet. 2007;99 Suppl 2:S182-S5",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 155
  },
  {
    "chunk_id": "abortioncare_712",
    "text": " Gemzell-Danielsson K, Ho P, Gómez Ponce de León R, Weeks A, Winikoff B. Misoprostol to treat missed abortion in the first trimester. Int J Gynaecol Obstet. 2007;99 Suppl 2:S182-S5. 152. Lemmers, M, Verschoor M, Kim B, Hickey M, Vazquez J, et al. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev. 2019(6)CD002253. 153. Lähteenmäki P, Luukkainen T. Return of ovarian function after abortion. Clin Endocrinol. 1978;8:123-32. 154. Schreiber C, Sober S, Ratcliffe S, Creinin M. Ovulation resumption after medical abortion with mifepristone and misoprostol. Contraception. 2011;84(3):230-3. 155. Kim C, Nguyen A, Berry-Bibee E, Ermias Y, Kapp N. Systemic hormonal contraception initiation after abortion: a systematic review and meta-analysis. Contraception. 2021;103(5):291-304. 156. Ensuring human rights in the provision of contraceptive information and services",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 155
  },
  {
    "chunk_id": "abortioncare_713",
    "text": "ion after abortion: a systematic review and meta-analysis. Contraception. 2021;103(5):291-304. 156. Ensuring human rights in the provision of contraceptive information and services: guidance and recommendations. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/102539). References",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 155
  },
  {
    "chunk_id": "abortioncare_714",
    "text": "Abortion care guideline, second edition 118 157. Medical eligibility criteria for contraceptive use, fifth edition. Geneva: World Health Organization; 2015 (https://iris.who.int/handle/10665/181468 ). 158. Raymond E, Weaver M, Louie K, Tan Y, Bousiéguez M, Aranguré-Peraza A, et al. Effects of depot medroxyprogesterone acetate injection timing on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. Obstet Gynecol. 2016;128(4):739-45. 159. de Roodenbeke E, Lucas S, Rouzaut A, Bana F. Outreach services as a strategy to increase access to health workers in remote and rural areas. Technical Report No. 2. Geneva: World Health Organization; 2011 ( https://iris.who.int/handle/10665/44589). 160. Haemmerli M, Santos A, Penn-Kekana L, Lange I, Matovu F, Benova L, et al. How equitable is social franchising? Case studies of three maternal healthcare franchises in Uganda and ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 156
  },
  {
    "chunk_id": "abortioncare_715",
    "text": ". Haemmerli M, Santos A, Penn-Kekana L, Lange I, Matovu F, Benova L, et al. How equitable is social franchising? Case studies of three maternal healthcare franchises in Uganda and India. Health Policy Plan. 2018;33(3):411-9. 161. Global diffusion of eHealth: making universal health coverage achievable. Report of the third global survey on eHealth. Geneva: World Health Organization; 2016 (http://apps.who.int/iris/bitstream/handle/10665/252529/9789241511780-eng.pdf).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 156
  },
  {
    "chunk_id": "abortioncare_716",
    "text": "119 References",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 157
  },
  {
    "chunk_id": "abortioncare_717",
    "text": "Annexes Annexes",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 159
  },
  {
    "chunk_id": "abortioncare_718",
    "text": "Abortion care guideline, second edition 122 Annex 1. External experts and WHO staff involved in guideline development Members of the Evidence and Recommendation Review Groups (ERRGs) There were three ERRGs (expert panels), one for each domain of this guidance: Clinical services, Service delivery, Law and policy. Below each list of ERRG members, additional contributors to the pre-ERRG scoping meetings are listed per domain. Clinical services domain ERRG members Name Affiliation City, country WHO region of residence Expertise Declarations/ conflicts of interest Laura Castleman Planned Parenthood Michigan and University of Michigan Ann Arbor, MI, United States of America (USA) Americas Obstetrics and gynaecology None Suchitra Dalvie Sexual and reproductive health programme consultant Mumbai, India South-East Asia Abortion, advocacy None Michalina Drejza International Youth Alliance for Fami",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 160
  },
  {
    "chunk_id": "abortioncare_719",
    "text": "one Suchitra Dalvie Sexual and reproductive health programme consultant Mumbai, India South-East Asia Abortion, advocacy None Michalina Drejza International Youth Alliance for Family Planning (IYAFP) Poznań, Poland Europe Obstetrics and gynaecology, youth None Kristina Gemzell Danielssona Department of Women’s and Children’s Health, Karolinska Institutet Stockholm, Sweden Europe Obstetrics and gynaecology, abortion research None Laura Gila Fundación Educación Para la Salud Reproductiva (ESAR) (Education Foundation for Reproductive Health) Bogotá, Colombia Americas Abortion, contraception None Selma Hajria TAWHIDA Group for Research and Action on Women’s Health Tunis, Tunisia Eastern Mediterranean Abortion, contraception, research None Guyo Jaldesa University of Nairobi Nairobi, Kenya Africa Obstetrics and gynaecology None Dhammika Pereraa Marie Stopes International London, United Kingdom",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 160
  },
  {
    "chunk_id": "abortioncare_720",
    "text": "raception, research None Guyo Jaldesa University of Nairobi Nairobi, Kenya Africa Obstetrics and gynaecology None Dhammika Pereraa Marie Stopes International London, United Kingdom of Great Britain and Northern Ireland Europe Abortion, contraception None Alongkone Phengsavanh University of Health Sciences Vientiane, Lao People’s Democratic Republic Western Pacific Obstetrics and gynaecology, abortion care None Judiac Ranapea Department of Health Cape Town, South Africa Africa Nursing, nurse training, abortion care None Kitihoun Serge Reproductive Health Unit, Alfred Comlan Quenum Regional Institute of Public Health Ouidah, Benin Africa Abortion, contraception None Human rights adviser Christina Zampas Center for Reproductive Rights Geneva, Switzerland Europe Law, human rights, sex work, forced sterilization None a These members also contributed to the scoping meeting for this domain, in ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 160
  },
  {
    "chunk_id": "abortioncare_721",
    "text": "r Reproductive Rights Geneva, Switzerland Europe Law, human rights, sex work, forced sterilization None a These members also contributed to the scoping meeting for this domain, in advance of the ERRG meetings, along with the following additional contributing experts: Abigail Aiken (University of Texas, USA), Rodica Comendant (Reproductive Health Training Center, Republic of Moldova), Debora Diniz (Instituto de Bioética, Brazil), Angel Foster (University of Ottawa, Canada), Daniel Grossman (University of California, San Francisco, USA), Kinga Jelinksa (Women Help Women, Netherlands), Munir Kassa (Center for International Reproductive Health Training, Ethiopia), Rasha Khoury (Médecins Sans Frontières, Afghanistan), Alice Mark (National Abortion Federation, USA), Mariana Romero (Center for the Study of State and Society, Argentina), Marion Stevens (Sexual and Reproductive Justice Coalition,",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 160
  },
  {
    "chunk_id": "abortioncare_722",
    "text": "), Alice Mark (National Abortion Federation, USA), Mariana Romero (Center for the Study of State and Society, Argentina), Marion Stevens (Sexual and Reproductive Justice Coalition, South Africa), Nadira Sultana (Global Fund – United Nations Office for Projects Services, Bangladesh).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 160
  },
  {
    "chunk_id": "abortioncare_723",
    "text": "123 Service delivery domain ERRG members Name Affiliation City, country WHO region of residence Expertise Declarations/ conflicts of interest Fauzia Akhter Hudaa Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research Bangladesh (ICDDRB) Dhaka, Bangladesh South-East Asia Public health, health systems, abortion None Nana Yaa Appiah Women’s Voices Foundation Accra, Ghana Africa Pharmacy, social marketing, professional development None Karla Berdichevsky Gender Equity and Reproductive Health, Mexico Federal Ministry of Health Mexico City, Mexico Americas Sexual and reproductive health programming, policy and research None Jemima Araba Dennis-Antwi Ghana College of Nurses and Midwives Accra, Ghana Africa Health systems strengthening, maternal health, midwifery, nursing training None Surendra Dhital Independent Pharmacist Kathmandu, Nepal South-East Asia Pharm",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 161
  },
  {
    "chunk_id": "abortioncare_724",
    "text": "es Accra, Ghana Africa Health systems strengthening, maternal health, midwifery, nursing training None Surendra Dhital Independent Pharmacist Kathmandu, Nepal South-East Asia Pharmacy, counselling, safe abortion None Caitlin Gerdtsa Ibis Reproductive Health Oakland, CA, USA Americas Qualitative research, use of technology, access to abortion None Daniel Maceira Economics Department, University of Buenos Aires Buenos Aires, Argentina Americas Health systems research, health programming and policy development None Vinoj Manninga Ipas Development Foundation New Delhi, India South-East Asia Health systems, abortion care None Sybil Nkeiru Generation Initiative for Women and Youth Network (GIWYN) Lagos, Nigeria Africa Human rights activist None Hiromi Obaraa Department of Health Planning and Management, Bureau of International Health Cooperation, National Center for Global Health and Medicine ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 161
  },
  {
    "chunk_id": "abortioncare_725",
    "text": "a Human rights activist None Hiromi Obaraa Department of Health Planning and Management, Bureau of International Health Cooperation, National Center for Global Health and Medicine Tokyo, Japan Western Pacific Health planning and management, Maternal health and abortion policy None Karan Parikh International Youth Alliance for Family Planning (IYAFP) Mumbai, India South-East Asia Clinician, youth None Michelle Remme United Nations University’s International Institute for Global Health (UNU-IIGH) Kuala Lumpur, Malaysia Western Pacific Research, gender, health system financing None Karthik Srinivasanb International Planned Parenthood Federation (IPPF) London, United Kingdom Europe Commodities, health system None Human rights adviser Christina Zampas Center for Reproductive Rights Geneva, Switzerland Europe Law, human rights, sex work, forced sterilization None a These members also contribut",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 161
  },
  {
    "chunk_id": "abortioncare_726",
    "text": "uman rights adviser Christina Zampas Center for Reproductive Rights Geneva, Switzerland Europe Law, human rights, sex work, forced sterilization None a These members also contributed to the scoping meeting(s) for this domain, in advance of the ERRG meetings, along with the following additional contributing experts: Patrick Aboagye (Ghana Health Services, Ghana), Laura Castleman (Ipas, Planned Parenthood and University of Michigan, USA), Amanda Cleeve (Karolinksa Institutet, Sweden), Saida Chowdhury (Independent consultant, USA), Rodica Comendant (Reproductive Health Training Center, Republic of Moldova), Joanna Erdman (Dalhousie University, Canada), Rebecca Gomperts (Women on Waves, Netherlands), Chisale Mhango (University of Malawi, Malawi), Monica Oguttu (Kisumu Medical and Education Trust, Kenya), Paul Mandira (United Nations Population Fund, USA), Mariana Romero (Center for the Study",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 161
  },
  {
    "chunk_id": "abortioncare_727",
    "text": " (University of Malawi, Malawi), Monica Oguttu (Kisumu Medical and Education Trust, Kenya), Paul Mandira (United Nations Population Fund, USA), Mariana Romero (Center for the Study of State and Society, Argentina), Sarmad Soomar (International Youth Alliance for Family Planning, Pakistan). b This member began working for a funding agency before the final ERRG meeting and therefore his involvement in guideline development ended at that point. Annex 1",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 161
  },
  {
    "chunk_id": "abortioncare_728",
    "text": "Abortion care guideline, second edition 124 Law and policy domain ERRG members Name Affiliation City, country WHO region of residence Expertise Declarations/ conflicts of interest Marge Berer International Campaign for Women’s Right to Safe Abortion London, United Kingdom Europe Social science, abortion policy None Joanna Erdmana Schulich School of Law, Dalhousie University Halifax, Canada Americas Human rights, health law and policy None Godfrey Kangaude University of Pretoria and University of Toronto Blantyre, Malawi Africa Sexual and reproductive health and rights law None Akila Radhakrishnan Global Justice Center New York, NY, USA Americas Law and policy None Ruben Avila Reyna International Youth Alliance for Family Planning (IYAFP) Youth Taskforce Nuevo León, Mexico Americas Human rights, advocacy, youth None Chi-Chi Undie Population Council Nairobi, Kenya Africa Abortion and contr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 162
  },
  {
    "chunk_id": "abortioncare_729",
    "text": "for Family Planning (IYAFP) Youth Taskforce Nuevo León, Mexico Americas Human rights, advocacy, youth None Chi-Chi Undie Population Council Nairobi, Kenya Africa Abortion and contraception, policy None Human rights advisers Abhijit Das Centre for Health and Social Justice New Delhi, India South-East Asia Human rights None Sara Hossain Bar of the Supreme Court of Bangladesh Dhaka, Bangladesh South-East Asia Law and policy, human rights None Karima Khalil Maternal and Child Health Consultant New Delhi, India South-East Asia Law and policy, human rights None Primah Kwagala Director, Women’s Probono Initiative Kampala, Uganda Africa Law and policy, human rights None Monica Arango Olaya Faculty of Law, University of Oxford Oxford, United Kingdom Europe Law and policy, human rights None Xian Warner Research and Program Coordinator, The Equality Institute Dili, Timor-Leste Western Pacific Law a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 162
  },
  {
    "chunk_id": "abortioncare_730",
    "text": " Oxford Oxford, United Kingdom Europe Law and policy, human rights None Xian Warner Research and Program Coordinator, The Equality Institute Dili, Timor-Leste Western Pacific Law and policy, human rights None Christina Zampasa Center for Reproductive Rights Geneva, Switzerland Europe Law, human rights, sex work, forced sterilization None a These members also contributed to the scoping meeting(s) for this domain, in advance of the ERRG meetings, along with the following additional contributing experts: Paola Bergallo (University of Torcuato Di Tella, Argentina), Lucia Berro Pizzarossa (University of Groningen, Netherlands), Scott Burris (Temple University, USA), Fiona de Londras (Birmingham University, United Kingdom), Silvia de Zordo (University of Barcelona, Spain), Debora Diniz (Instituto de Bioética, Brazil), Heather Douglas (University of Queensland, Australia), Daniel Grossman (Univ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 162
  },
  {
    "chunk_id": "abortioncare_731",
    "text": "ngdom), Silvia de Zordo (University of Barcelona, Spain), Debora Diniz (Instituto de Bioética, Brazil), Heather Douglas (University of Queensland, Australia), Daniel Grossman (University of California, San Francisco, USA), Selma Hajri (TAWHIDA Group for Research and Action on Women’s Health, Tunisia), Jihan Jacob, Center for Reproductive Rights, Philippines), Minzee Kim (Ewha Womans University, Republic of Korea), Chisale Mhango (University of Malawi, Malawi), Mahesh Puri (Centre for Research on Environment, Health and Population Activities, Nepal), Patricia Schulz (Committee on the Elimination of Discrimination against Women, Switzerland), Patty Skuster (Ipas, USA), Marion Stevens (Sexual and Reproductive Justice Coalition, South Africa), Maya Unnithan (University of Sussex, United Kingdom).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 162
  },
  {
    "chunk_id": "abortioncare_732",
    "text": "125 Members of the Guideline Development Group (GDG), and declarations of interests Name Job title, affiliation City, country WHO region of residence Expertise Declarations/ conflicts of interest Fauzia Akhter Huda Project Coordinator, Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research Bangladesh (ICDDRB) Dhaka, Bangladesh South-East Asia Public health, health systems, abortion None Karla Berdichevsky Director, Gender Equity and Reproductive Health, Mexico Federal Ministry of Health Mexico City, Mexico Americas Sexual and reproductive health programming, policy and research None Marge Berer Coordinator, International Campaign for Women’s Right to Safe Abortion London, United Kingdom Europe Law and policy None Laura Castleman (CHAIR) Associate Medical Director, Planned Parenthood of Michigan and Adjunct Clinical Assistant Professor, University of Mich",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 163
  },
  {
    "chunk_id": "abortioncare_733",
    "text": "d Kingdom Europe Law and policy None Laura Castleman (CHAIR) Associate Medical Director, Planned Parenthood of Michigan and Adjunct Clinical Assistant Professor, University of Michigan Ann Arbor, MI, USA Americas Obstetrics and gynaecology None Michalina Drejza Director on Research and Development, International Youth Alliance for Family Planning (IYAFP) Poznań, Poland Europe Obstetrics and gynaecology, youth None Joanna Erdman Associate Professor, Health Law and Policy, Schulich School of Law, Dalhousie University Halifax, Nova Scotia, Canada Americas Law and policy None Kristina Gemzell Danielsson Head, Department of Women’s and Children’s Health, Karolinska Institutet Stockholm, Sweden Europe Obstetrics and gynaecology, abortion research None Caitlin Gerdts Vice President for Research, Ibis Reproductive Health Oakland, CA, USA Americas Qualitative research None Laura Gil Clinician Bog",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 163
  },
  {
    "chunk_id": "abortioncare_734",
    "text": "gynaecology, abortion research None Caitlin Gerdts Vice President for Research, Ibis Reproductive Health Oakland, CA, USA Americas Qualitative research None Laura Gil Clinician Bogotá, Colombia Americas Clinical None Selma Hajri Founder and President, TAWHIDA Group for Research and Action on Women’s Health Tunis, Tunisia Eastern Mediterranean Abortion, contraception, research None Guyo Jaldesa Associate Professor of Obstetrics and Gynaecology, University of Nairobi Nairobi, Kenya Africa Obstetrics and gynaecology None Godfrey Kangaude Postdoctoral Researcher, University of Pretoria, and Reproductive and Sexual Health Law Fellow, University of Toronto Blantyre, Malawi Africa Sexual and reproductive health and rights law None Vinoj Manning Chief Executive Officer Ipas Development Foundation New Delhi, India South-East Asia Health systems None Hiromi Obara Medical Doctor, Deputy Director, D",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 163
  },
  {
    "chunk_id": "abortioncare_735",
    "text": "ghts law None Vinoj Manning Chief Executive Officer Ipas Development Foundation New Delhi, India South-East Asia Health systems None Hiromi Obara Medical Doctor, Deputy Director, Division of Global Health Policy and Research, Department of Health Planning and Management, Bureau of International Health Cooperation Japan, National Center for Global Health and Medicine, and Project Coordinator, Cambodia, Japan International Cooperation Agency (JICA) Tokyo, Japan Western Pacific Health systems None Alongkone Phengsavanh Vice Dean, Faculty of Medicine, University of Health Sciences Vientiane, Lao People’s Democratic Republic Western Pacific Obstetrics and gynaecology, abortion care None Akila Radhakrishnan President, Global Justice Center New York, NY, USA Americas Law and policy None Continued on the next page Annex 1",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 163
  },
  {
    "chunk_id": "abortioncare_736",
    "text": "Abortion care guideline, second edition 126 Name Job title, affiliation City, country WHO region of residence Expertise Declarations/ conflicts of interest Michelle Remme Research Lead, United Nations University’s International Institute for Global Health (UNU-IIGH) Kuala Lumpur, Malaysia Western Pacific Research, gender, health system financing None Chi Chi Undie Senior Associate, Population Council Nairobi, Kenya Africa Abortion and contraception, policy None Human rights adviser Christina Zampas Associate Director of Global Advocacy, Center for Reproductive Rights Geneva, Switzerland Europe Human rights None GDG meeting observers: • Patricia Lohr, Medical Director, British Pregnancy Advisory Service (BPAS), London, United Kingdom; also member of Royal College of Obstetricians and Gynaecologists (RCOG) Making Abortion Safe Programme Advisory Group • Jaydeep Tank, Secretary General of t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 164
  },
  {
    "chunk_id": "abortioncare_737",
    "text": "London, United Kingdom; also member of Royal College of Obstetricians and Gynaecologists (RCOG) Making Abortion Safe Programme Advisory Group • Jaydeep Tank, Secretary General of the Federation of Obstetrics and Gynaecological Societies of India (FOGSI) and Chair, International Federation of Obstetrics and Gynaecology (FIGO) Working Group for safe abortion, Mumbai, India • Francelle Toedtli, Consultant, United Nations Population Fund (UNFPA), New York, New York, USA • Ann Yates, Lead Midwife Adviser, International Confederation of Midwives (ICM), Head Office, The Hague, the Netherlands Guideline methodologist(s) Clinical services domain: Jeppe Schroll, Consultant, Research Coordinator and Associate Professor, Department of Obstetrics and Gynaecology, Amager Hvidovre Hospital, Copenhagen, Denmark Service delivery domain: Nicholas Henschke and Gemma Villanueva, Senior Systematic Reviewers,",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 164
  },
  {
    "chunk_id": "abortioncare_738",
    "text": "epartment of Obstetrics and Gynaecology, Amager Hvidovre Hospital, Copenhagen, Denmark Service delivery domain: Nicholas Henschke and Gemma Villanueva, Senior Systematic Reviewers, and Yanina Sguassero, Systematic Review, of Cochrane Response Law and policy domain: Maria Rodriguez, Associate Professor, Obstetrics and Gynecology, Oregon Health & Science University (OHSU), Portland, Oregon, USA Evidence Synthesis Team(s) Clinical services domain: • Cochrane Fertility Regulation (CFR) Group, at Oregon Health & Science University (OHSU) ☐ Lead researchers: Alison Edelman, Maria Rodriguez, Makalapua Motu’apuaka, Taylor King ☐ Search strategy support: Robyn Paynter ☐ Team members/review authors: Jessica Atrio, Sharon Cameron, Justin T. Diedrich, Eleanor Drey, Alison Edelman, Katherine Gambir, Bela Ganatra, Jeffrey T.J. Jensen, Nathalie Kapp, Caron Kim, Patricia Lohr, Adrienne E. McKercher, Kar",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 164
  },
  {
    "chunk_id": "abortioncare_739",
    "text": " Cameron, Justin T. Diedrich, Eleanor Drey, Alison Edelman, Katherine Gambir, Bela Ganatra, Jeffrey T.J. Jensen, Nathalie Kapp, Caron Kim, Patricia Lohr, Adrienne E. McKercher, Karen Meckstroth, Chelsea Morroni, Kelly Ann Necastro, Sara J. Newmann, Thoai D. Ngo, Antoinette Nguyen, Mark D.N. Nichols, Regina-Maria Renner, John J. Reynolds-Wright, Tesfaye Tufa, Mulat A. Woldetsadik • WHO Department of Sexual and Reproductive Health and Research (SRH) staff, consultants and Family Planning fellows: ☐ Michelle Chan, Family Planning fellow, University of British Columbia, Vancouver, British Columbia, Canada ☐ Elizabeth Clark, Family Planning fellow, Emory University, Atlanta, Georgia, USA ☐ Teresa DePiñeres, Lead Clinician, Medication Abortion Access Project, Essential Access Health Continued",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 164
  },
  {
    "chunk_id": "abortioncare_740",
    "text": "127 ☐ Margit Endler, Obstetrician and Gynaecologist, Stockholm South Central Hospital, and Researcher, Karolinska Institutet, Stockholm, Sweden ☐ Roopan Gill, Consultant, Preventing Unsafe Abortion Unit, SRH Department, WHO, Geneva, Switzerland; Women’s Health Advisor, Médecins Sans Frontières (MSF), Paris, France ☐ Yelena Korotkaya, Family Planning fellow, University of California, Los Angeles, California, USA ☐ Lemi Tolu, Family Planning fellow, Assistant Professor of Obstetrics and Gynaecology, Saint Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia Service delivery domain: • Cochrane Response ☐ Lead researchers: Nicholas Henschke, Yanina Sguassero and Gemma Villanueva ☐ Search strategy support: Elise Cogo ☐ Team members/review authors: Hanna Bergman, Brian Buckley, Jennifer Petkovic, Chantelle Garritty, Candyce Hamel, Katrin Probyn • WHO SRH staff, consultants and Fam",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 165
  },
  {
    "chunk_id": "abortioncare_741",
    "text": "rt: Elise Cogo ☐ Team members/review authors: Hanna Bergman, Brian Buckley, Jennifer Petkovic, Chantelle Garritty, Candyce Hamel, Katrin Probyn • WHO SRH staff, consultants and Family Planning fellows: ☐ Ferid Abubeker, Family Planning fellow, Assistant Professor of Obstetrics and Gynaecology, Saint Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia ☐ Mekdes Feyssa, Medical Officer, Preventing Unsafe Abortion (PUA) Unit, SRH Department, WHO, Geneva, Switzerland ☐ Roopan Gill, Consultant, PUA Unit, SRH Department, WHO, Geneva, Switzerland; Women’s Health Advisor, Médecins Sans Frontières (MSF), Paris, France ☐ Caron Kim, Medical Officer, PUA Unit, SRH Department, WHO, Geneva, Switzerland ☐ Bianca Stifani, Family Planning fellow, Obstetrician and Gynaecologist, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York, USA ☐ Tesfaye Tufa, Family P",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 165
  },
  {
    "chunk_id": "abortioncare_742",
    "text": "Stifani, Family Planning fellow, Obstetrician and Gynaecologist, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York, USA ☐ Tesfaye Tufa, Family Planning fellow, Assistant Professor of Obstetrics and Gynaecology, Saint Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia • Other contributors: ☐ Ernestina Coast, Professor of Health and International Development, London School of Economics and Political Science, London, United Kingdom ☐ Samantha Lattof, Visiting Fellow, Department of International Development, London School of Economics and Political Science, London, United Kingdom ☐ Brittany Moore, Consultant, Scientific and Technical Division Advisor, Ipas, Chapel Hill, North Carolina, USA ☐ Cheri Poss, Associate Director, Program Evidence, Ipas, Chapel Hill, North Carolina, USA ☐ Yana Rodgers, Professor, Department of Women’s, Gender, and S",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 165
  },
  {
    "chunk_id": "abortioncare_743",
    "text": "Hill, North Carolina, USA ☐ Cheri Poss, Associate Director, Program Evidence, Ipas, Chapel Hill, North Carolina, USA ☐ Yana Rodgers, Professor, Department of Women’s, Gender, and Sexuality Studies, Director of the Center for Women and Work, Rutgers University, New Brunswick, New Jersey, USA Law and policy domain: • The Policy Surveillance Program at the Center for Public Health Law Research (CPHLR), Temple University, Philadelphia, Pennsylvania, USA ☐ Lead researcher: Scott Burris ☐ Team members/review authors: Lindsay Foster Cloud, Adrienne R. Ghorashi, Rachel Rebouché, Patty Skuster • Birmingham Law School, University of Birmingham, Birmingham, United Kingdom ☐ Lead researcher: Fiona de Londras, Chair of Global Legal Studies, Birmingham Law School ☐ Team members/review authors: Alana Farrell, Magdalena Furgalska Annex 1",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 165
  },
  {
    "chunk_id": "abortioncare_744",
    "text": "Abortion care guideline, second edition 128 • WHO SRH staff and consultants: ☐ Amanda Cleeve, Consultant in sexual and reproductive health and preventing unsafe abortion, Stockholm, Sweden ☐ Antonella Lavelanet, Medical Officer, PUA Unit, SRH Department, WHO, Geneva, Switzerland ☐ Maria Rodriguez, Associate Professor, Obstetrics and Gynecology, Oregon Health & Science University (OHSU), Portland, Oregon, USA External Review Group (ERG) Name Affiliation City, country WHO region of residence Expertise Safia Ahsan Reproductive Health Supplies Coalition, PATH Washington, DC, USA Americas Market development, supply chain management Traci Baird EngenderHealth Washington, DC, USA Americas Leadership, women’s health, sexual and reproductive health Sharon Cameron Chalmers Hospital Edinburgh, United Kingdom Europe Obstetrics and gynaecology, abortion, contraception, genital tract infection Jane Ha",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 166
  },
  {
    "chunk_id": "abortioncare_745",
    "text": "exual and reproductive health Sharon Cameron Chalmers Hospital Edinburgh, United Kingdom Europe Obstetrics and gynaecology, abortion, contraception, genital tract infection Jane Harries Women’s Health Research Unit, School of Public Health, University of Cape Town Cape Town, South Africa Africa Abortion, contraception, research Thoai Ngo Population Council New York, NY, USA Americas Research, health policy Mariana Romero Centre for the Study of State and Society (CEDES) Buenos Aires, Argentina Americas Maternal health, abortion, research Rachel Simon-Kumar School of Population Health, University of Auckland and Centre for Asian Health Research and Evaluation (CAHRE) Auckland, New Zealand Europe Social science, gender and economics Beverly Winikoff Gynuity Health Project New York, NY, USA Americas Reproductive choice, contraception, abortion, women’s health External partners (including im",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 166
  },
  {
    "chunk_id": "abortioncare_746",
    "text": "gender and economics Beverly Winikoff Gynuity Health Project New York, NY, USA Americas Reproductive choice, contraception, abortion, women’s health External partners (including implementing partner organizations) who provided feedback on the draft guideline • Rasha Dabash, Ipas, Chapel Hill, North Carolina, USA • Rebecca Wilkins, International Planned Parenthood Federation (IPPF), London, United Kingdom • Bethan Cobley, MSI Reproductive Choices, London, United Kingdom • Steve Luboya, Pathfinder, Watertown, Massachusetts, USA • Eva Lathrop, Population Services International (PSI), Washington, DC, USA",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 166
  },
  {
    "chunk_id": "abortioncare_747",
    "text": "129 Members of the WHO Steering Group Name Department and Unit Expertise Mekdes Daba Feyssa Department of Sexual and Reproductive Health and Research (SRH), Preventing Unsafe Abortion (PUA) Unit, WHO headquarters Abortion, contraception Bela Ganatra SRH, PUA, WHO headquarters Abortion, social science Roopan Gill (during first stages of guideline planning) SRH, PUA, WHO headquarters (formerly) Abortion, contraception, humanitarian settings Heidi Johnston SRH, PUA, WHO headquarters Abortion, demography Rajat Khosla (during first stages of guideline planning) SRH, Director’s Office, WHO headquarters (formerly) Human rights adviser Caron Kima SRH, PUA, WHO headquarters Abortion, contraception, sexual and reproductive health and rights in health emergencies Antonella Lavelanet SRH, PUA, WHO headquarters Abortion, contraception, law and policy, and human rights Lemi Tolu (during the first stag",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 167
  },
  {
    "chunk_id": "abortioncare_748",
    "text": "ve health and rights in health emergencies Antonella Lavelanet SRH, PUA, WHO headquarters Abortion, contraception, law and policy, and human rights Lemi Tolu (during the first stages of guideline planning) SRH, PUA, WHO headquarters (formerly) Abortion, contraception a Responsible technical officer for development of this guideline Members of the WHO Secretariat Name Department and Unit (and region if applicable) Moazzam Ali Department of Sexual and Reproductive Health and Research (SRH), Contraception and Fertility Care (CFC) Unit, WHO headquarters, Geneva, Switzerland Ian Askew SRH, WHO headquarters Chilanga Asmani Reproductive and Maternal Health (RMH) and Ageing, WHO Regional Office for Africa, Brazzaville, Congo Laurence Codjia Department of Health Work Force (HWF), Health Labour Market and Partnerships (HLM) Unit, WHO headquarters, Geneva, Switzerland Ibadat Dhillon Human Resources",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 167
  },
  {
    "chunk_id": "abortioncare_749",
    "text": " Congo Laurence Codjia Department of Health Work Force (HWF), Health Labour Market and Partnerships (HLM) Unit, WHO headquarters, Geneva, Switzerland Ibadat Dhillon Human Resources for Health and Fellowships (HRH), WHO Regional Office for South-East Asia, New Delhi, India Carolin Ekman SRH, Preventing Unsafe Abortion (PUA) Unit, WHO headquarters Claire Garabedian SRH, PUA, WHO headquarters Rodolfo Gómez Ponce de León Latin American Center for Perinatology, Women’s Health and Reproductive Health (CLAP/WR), Pan American Health Organization (PAHO), Montevideo, Uruguay Veloshnee Govender SRH, SRH Integration in Health Systems (SHS) Unit, WHO headquarters Hannah Hatch SRH, PUA, WHO headquarters Lisa Hedman HIS, Essential Medicines and Health Products (EMP) Unit, WHO headquarters Nilmini Hemachandra Reproductive and Maternal Health (RMH), WHO Regional Office for the Eastern Mediterranean, Cair",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 167
  },
  {
    "chunk_id": "abortioncare_750",
    "text": "ntial Medicines and Health Products (EMP) Unit, WHO headquarters Nilmini Hemachandra Reproductive and Maternal Health (RMH), WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt Shogo Kubota Lao People’s Democratic Republic, WHO Country Office, Vientiane, Lao People’s Democratic Republic Laurence Läser SRH, PUA, WHO headquarters Ulrika Loi Rehnström SRH, PUA, WHO headquarters Bruno Meessen Health Systems Governance and Financing (HGF), Health Financing (HEF), WHO headquarters Fahdi Dkhimi HGF, HEF, WHO headquarters Marta Schaaf SRH Director’s Office, WHO headquarters Patricia Titulaer SRH, PUA, WHO headquarters Annex 1",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 167
  },
  {
    "chunk_id": "abortioncare_751",
    "text": "Abortion care guideline, second edition 128 Annex 2. Selected human rights treaties and their treaty monitoring bodies For more detailed information on the how international human rights standards apply to abortion, refer to Web annex A: Key international human rights standards on abortion, available at: https://apps.who.int/iris/handle/10665/349317. Treaty (in chronological order) Abbreviation Year of adoption Year entered into force Treaty monitoring body (TMB)a Abbreviation International Convention on the Elimination of All Forms of Racial Discrimination ICERD 1965 1969 Committee on the Elimination of Racial Discrimination CERD International Covenant on Civil and Political Rights ICCPR 1966 1976 Human Rights Committee HRC International Covenant on Economic, Social and Cultural Rights ICESCR 1966 1976 Committee on Economic, Social and Cultural Rights CESCR Convention on the Elimination",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 168
  },
  {
    "chunk_id": "abortioncare_752",
    "text": " Committee HRC International Covenant on Economic, Social and Cultural Rights ICESCR 1966 1976 Committee on Economic, Social and Cultural Rights CESCR Convention on the Elimination of All Forms of Discrimination against Women CEDAW 1979 1981 Committee on the Elimination of Discrimination against Women CEDAW Convention against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment CAT 1984 1987 Committee against Torture CAT Convention on the Rights of the Child CRC 1989 1990 Committee on the Rights of the Child CRC International Convention on the Protection of the Rights of All Migrant Workers and Members of Their Families ICMW 1990 2003 Committee on Migrant Workers CMW Convention on the Rights of Persons with Disabilities CRPD 2006 2008 Committee on the Rights of Persons with Disabilities CRPD a Also sometimes referred to as “treaty bodies”. Further information on the Core",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 168
  },
  {
    "chunk_id": "abortioncare_753",
    "text": " Persons with Disabilities CRPD 2006 2008 Committee on the Rights of Persons with Disabilities CRPD a Also sometimes referred to as “treaty bodies”. Further information on the Core International Human Rights Instruments and their TMBs is available at: https://www.ohchr.org/EN/ProfessionalInterest/Pages/CoreInstruments.aspx",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 168
  },
  {
    "chunk_id": "abortioncare_754",
    "text": "129 Annex 3. References for the glossary 1. World Health Organization (WHO), United Nations Children’s Fund (UNICEF). Community-based health care, including outreach and campaigns, in the context of the COVID-19 pandemic: interim guidance, May 2020. Technical documents. Geneva: WHO; 2020 (https://apps.who.int/iris/handle/10665/331975). 2. Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012 (http://apps.who.int/iris/bitstream/handle/10665/70914/9789241548434_eng.pdf). 3. International Statistical Classification of Diseases and Related Health Problems, tenth revision (ICD-10), Vol. 2, second edition. Geneva: World Health Organization; 2004 (https://www.who.int/classifications/icd/ICD- 10_2nd_ed_volume2.pdf). 4. Constitution of the World Health Organization. Adopted in 1946. Entered into force in 1948. Geneva: World Health",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 169
  },
  {
    "chunk_id": "abortioncare_755",
    "text": "s://www.who.int/classifications/icd/ICD- 10_2nd_ed_volume2.pdf). 4. Constitution of the World Health Organization. Adopted in 1946. Entered into force in 1948. Geneva: World Health Organization; 1946 (http://www.who.int/about/mission/en/). 5. Everybody’s business: strengthening health systems to improve health outcomes: WHO’s framework for action. Geneva: World Health Organization; 2007 (https://apps.who.int/iris/handle/10665/43918). 6. The World Health Report 2006: working together for health. Geneva: World Health Organization; 2006 (https://apps.who.int/iris/handle/10665/43432). 7. ICD-11 for mortality and morbidity statistics (Version: 09/2020) 2020 (https://icd.who.int/browse11/l-m/en). 8. World Health Organization Department of Mental Health and Substance Abuse, the Victorian Health Promotion Foundation and the University of Melbourne. Promoting mental health: concepts, emerging evi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 169
  },
  {
    "chunk_id": "abortioncare_756",
    "text": "nization Department of Mental Health and Substance Abuse, the Victorian Health Promotion Foundation and the University of Melbourne. Promoting mental health: concepts, emerging evidence, practice: summary report. Geneva: World Health Organization; 2004 (https://apps.who.int/iris/handle/10665/42940). 9. Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017;(1):CD007223. 10. Gemzell-Danielsson K, Ho PC, Gómez Ponce de León R, Weeks A, Winikoff B. Misoprostol to treat missed abor- tion in the first trimester. Int J Gynecol Obstet. 2007;99(Suppl 2):S182-5. 11. Center for Disease Control and Prevention (CDC), Office of the Associate Director for Policy and Strategy. Definition of Policy. Atlanta (GA): CDC; 2015 (https://www.cdc.gov/policy/analysis/process/definition.html). 12. World Health Organization (WHO),",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 169
  },
  {
    "chunk_id": "abortioncare_757",
    "text": " Director for Policy and Strategy. Definition of Policy. Atlanta (GA): CDC; 2015 (https://www.cdc.gov/policy/analysis/process/definition.html). 12. World Health Organization (WHO), United Nations Children’s Fund (UNICEF). A vision for primary health care in the 21st century: towards universal health coverage and the Sustainable Development Goals. Technical documents. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/328065). 13. Quality of care: a process for making strategic choices in health systems. Geneva: World Health Organization; 2006 (https://apps.who.int/iris/handle/10665/43470). 14. WHO guideline on self-care interventions for health and well-being. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240030909). 15. Barone A. Social enterprises. Investopedia [website]; 2020 (https://www.investopedia.com/terms/s/soci",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 169
  },
  {
    "chunk_id": "abortioncare_758",
    "text": "rganization; 2021 (https://www.who.int/publications/i/item/9789240030909). 15. Barone A. Social enterprises. Investopedia [website]; 2020 (https://www.investopedia.com/terms/s/social- enterprise.asp). 16. Public policy and franchising reproductive health: current evidence and future directions: guidance from a technical consultation meeting (unpublished). World Health Organization and USAID; 2007. 17. Koehlmoos T, Gazi R, Hossain S, Zaman K. Social franchising to increase access to and quality of health services in low- and middle-income countries. Cochrane Database Syst Rev. 2009;(1):CD007136. 18. Birkinshaw M. Social marketing for health. Geneva: World Health Organization; 1989 (https://apps.who.int/iris/ bitstream/handle/10665/62146/HMD_89.2.pdf). 19. Global diffusion of eHealth: making universal health coverage achievable. Report of the third global survey on eHealth. Geneva: World H",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 169
  },
  {
    "chunk_id": "abortioncare_759",
    "text": "stream/handle/10665/62146/HMD_89.2.pdf). 19. Global diffusion of eHealth: making universal health coverage achievable. Report of the third global survey on eHealth. Geneva: World Health Organization; 2016 (http://apps.who.int/iris/bitstream/handle/10665/252529/97 89241511780-eng.pdf). 20. WHO guideline: recommendations on digital interventions for health system strengthening. Geneva: World Health Organization; 2019 (https://www.who.int/publications/i/item/9789241550505). Annex 2–3",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 169
  },
  {
    "chunk_id": "abortioncare_760",
    "text": "Abortion care guideline, second edition 130 Annex 4. Guideline development methods and process A. Guideline development working groups Please refer to Annex 1 for the names of members of each of the working groups (and declarations of interests). A summary of the key meetings held is provided at the end of this annex. The WHO Guideline Steering Group The WHO Guideline Steering Group led the guideline development process. Chaired by the WHO Department of Sexual and Reproductive Health and Research (SRH), it was composed of eight staff members from the Department, including seven from the Prevention of Unsafe Abortion (PUA) Unit and the Department’s human rights adviser. Gender, ethics, social accountability and human rights expertise among the Steering Group members ensured that key underlying principles were adequately reflected. The Steering Group members drafted the initial scope of th",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 170
  },
  {
    "chunk_id": "abortioncare_761",
    "text": "human rights expertise among the Steering Group members ensured that key underlying principles were adequately reflected. The Steering Group members drafted the initial scope of the guideline; identified and drafted the priority questions in “PICO” format (population, intervention, comparator, outcome); and identified individuals to be invited to participate as guideline methodologists and as members of the Evidence Synthesis Teams (ESTs), the Evidence and Recommendation Review Groups (ERRGs), the Guideline Development Group (GDG) and the External Review Group (ERG) (see below). The members of these groups and the participation of other external contributors were only confirmed after completion of a process of declaration and management of any conflicts of interest, which was managed by the Steering Group in consultation with the Office of Compliance, Risk Management and Ethics (see sect",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 170
  },
  {
    "chunk_id": "abortioncare_762",
    "text": "declaration and management of any conflicts of interest, which was managed by the Steering Group in consultation with the Office of Compliance, Risk Management and Ethics (see section B). The Steering Group identified the chair of the GDG, and this was confirmed by the other GDG members. The Steering Group oversaw the work of the ESTs, organized the ERRG and GDG meetings, and drafted the recommendations based on the decisions of the ERRGs and GDG. The Steering Group did not determine or agree on the final recommendations as this was the role of the GDG. The Steering Group was responsible for drafting, revising and finalizing the guideline in collaboration with the ERRG, GDG and ERG members and other contributors, and for overseeing the publication and dissemination of the guideline and the development of related implementation tools. Finally, the Steering Group is responsible for monitor",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 170
  },
  {
    "chunk_id": "abortioncare_763",
    "text": "s, and for overseeing the publication and dissemination of the guideline and the development of related implementation tools. Finally, the Steering Group is responsible for monitoring new information and user needs and for determining when the guideline may need to be updated. The WHO Steering Group was supported by the wider WHO Secretariat, which included 19 WHO staff members and consultants from the SRH Department and other departments at WHO headquarters and representatives from WHO regional offices. Guideline methodologists The guideline methodologists worked closely with the WHO Steering Group and members of the Evidence Synthesis Teams (ESTs) to appraise the evidence from systematic reviews using GRADE methodology (see section D). In addition, the guideline methodologists oversaw all methodological issues and were responsible for the GRADE assessments of the certainty of the evide",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 170
  },
  {
    "chunk_id": "abortioncare_764",
    "text": "ethodology (see section D). In addition, the guideline methodologists oversaw all methodological issues and were responsible for the GRADE assessments of the certainty of the evidence. One guideline methodologist was appointed for the Clinical services domain and one for the Law and policy domain, while a team from Cochrane Response served this role for the Service delivery domain. 1 Appreciating that the public health impact of laws and policies is complex, that evidence related to law and policy is not a research area that lends itself to randomized controlled trials or comparative observational studies, and that this evidence cannot be readily synthesized using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, a pragmatic approach was applied (see details in section D). Evidence Synthesis Teams (ESTs) The ESTs planned and conducted the systematic ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 170
  },
  {
    "chunk_id": "abortioncare_765",
    "text": "lopment and Evaluation (GRADE) approach, a pragmatic approach was applied (see details in section D). Evidence Synthesis Teams (ESTs) The ESTs planned and conducted the systematic reviews and prepared the GRADE Evidence-to-Decision (EtD) frameworks (which include evidence summaries, evidence profiles/tables and EtD tables). The ESTs comprised researchers from among WHO staff, consultants and fellows, as well as external collaborating research groups. For the Clinical services domain, the EST was formed of members of the Cochrane Fertility Regulation (CFR) Group, Family Planning fellows (WHO staff or interns), and the responsible technical officer from the Steering Group for this guideline. For the Service delivery domain, the EST comprised staff from Cochrane Response, Family Planning fellows (current and former WHO staff), and the responsible technical officer from the Steering Group. T",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 170
  },
  {
    "chunk_id": "abortioncare_766",
    "text": "ery domain, the EST comprised staff from Cochrane Response, Family Planning fellows (current and former WHO staff), and the responsible technical officer from the Steering Group. The CFR 1 Cochrane Response is an evidence consultancy business operated by the Cochrane Collaboration. It provides tailored and responsive evidence services, and accessible review formats.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 170
  },
  {
    "chunk_id": "abortioncare_767",
    "text": "131 Group and Cochrane Response have updated their systematic reviews to provide the evidence base for many of the recommendations in these two domains. For the Law and policy domain , the EST included WHO consultants as well as external teams based at two centres: • The Policy Surveillance Program at the Center for Public Health Law Research (CPHLR), Temple University, Philadelphia, USA: Researchers within this programme created conceptual frameworks and legal mapping of the various interventions and the systems around them, and identified data for the empirical assessment of laws and policies. • Birmingham Law School, University of Birmingham, United Kingdom: The team in Birmingham provided expertise in health law and policy, human rights, comparative law, and global legal studies. This team conducted systematic reviews to provide the evidence base for the law and policy recommendation",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 171
  },
  {
    "chunk_id": "abortioncare_768",
    "text": "h law and policy, human rights, comparative law, and global legal studies. This team conducted systematic reviews to provide the evidence base for the law and policy recommendations. The Evidence and Recommendation Review Groups (ERRGs) and the Guideline Development Group (GDG) Rather than having one Guideline Development Group (GDG) from the start of the guideline development process, for the development of this wide-ranging consolidated guideline, three separate ERRGs were formed – one for each of the three domains: Clinical services, Service delivery and Law and policy. For the final stage of the process, one GDG was formed comprising 3–4 members from each of the three ERRGs. The three ERRGs had 6–13 members representing all regions and a range of expertise, including one youth representative from the International Youth Alliance for Family Planning (IYAFP). The ERRG members were iden",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 171
  },
  {
    "chunk_id": "abortioncare_769",
    "text": " representing all regions and a range of expertise, including one youth representative from the International Youth Alliance for Family Planning (IYAFP). The ERRG members were identified and invited by the WHO Steering Group, as were the human rights advisers who also contributed to the meetings by ensuring consideration of relevant human rights during recommendation formulation. Each ERRG undertook a detailed review of the evidence, formulated and agreed on draft recommendations during a series of 4–5 online meetings between March 2020 and March 2021. Prior to each meeting, background documents – the EtD frameworks and draft recommendations – were shared with the ERRG members. Consultations via email, Skype, Microsoft Teams, GoToMeeting and Zoom were conducted as needed in between meetings to ensure input was received from each ERRG member for each area under review. In early 2021, repr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 171
  },
  {
    "chunk_id": "abortioncare_770",
    "text": "icrosoft Teams, GoToMeeting and Zoom were conducted as needed in between meetings to ensure input was received from each ERRG member for each area under review. In early 2021, representatives from each ERRG were invited by the WHO Steering Group to join the GDG for the final meeting in late April 2021, during which the draft recommendations from all three ERRGs were presented for review and finalization. The confirmed members of the GDG in turn confirmed the WHO Steering Group’s selection of a chair for the GDG. There were 18 GDG members (14 female, 4 male), representing all six WHO regions and a range of expertise, including a youth representative from IYAFP. A draft of the full guideline document, including the draft recommendations, was shared with all the GDG members to review in advance of the formal meeting, along with other relevant background documents (the EtD frameworks). Durin",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 171
  },
  {
    "chunk_id": "abortioncare_771",
    "text": "he draft recommendations, was shared with all the GDG members to review in advance of the formal meeting, along with other relevant background documents (the EtD frameworks). During the meeting, the GDG reviewed and discussed the evidence and the draft recommendations, with the aim of reaching consensus on the certainty of the supporting evidence and the strength and direction of the new and updated recommendations (see Chapters 2 and 3). Subsequent to the GDG meeting, the members also had an opportunity to review the revised guideline document into which the decisions made during the GDG meeting had been integrated. The External Review Group (ERG) The WHO Steering Group, in consultation with the GDG, identified and confirmed nine technical experts and stakeholders with thematic area expertise relevant to the recommendations presented in this guideline to serve as members of the ERG. The",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 171
  },
  {
    "chunk_id": "abortioncare_772",
    "text": "d and confirmed nine technical experts and stakeholders with thematic area expertise relevant to the recommendations presented in this guideline to serve as members of the ERG. The ERG members were balanced in terms of geographic representation, and had no important conflicts of interest. Following the GDG meeting and the subsequent revisions to the draft guideline, the document was circulated to the ERG members. The role of the ERG members was to provide input regarding the accuracy, clarity of the language, implementation/adaptation considerations, and presentation of the guideline. The ERG also ensured that the GDG decision-making processes had considered and incorporated the contextual values and preferences of persons affected by the recommendations. Recommendations in the document, which had been finalized by the GDG, were not changed based on ERG input other than to improve clarit",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 171
  },
  {
    "chunk_id": "abortioncare_773",
    "text": "s of persons affected by the recommendations. Recommendations in the document, which had been finalized by the GDG, were not changed based on ERG input other than to improve clarity and readability, as needed. All comments from the ERG members were collated by the responsible technical officer and shared with the WHO Steering Group for review. No serious factual errors or concerns were identified that affected any of the recommendations or any major sections of the draft guideline. Annex 4",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 171
  },
  {
    "chunk_id": "abortioncare_774",
    "text": "Abortion care guideline, second edition 132 Meeting observers and external partners In accordance with guidance in the WHO handbook for guideline development, second edition (2014),2 representatives from a range of relevant professional organizations and United Nations agencies were invited to attend the GDG meeting in April 2021 as observers with no role in determining the recommendations (see Annex 1). The invited observers included the United Nations Population Fund (UNFPA), the Royal College of Obstetricians and Gynaecologists (RCOG), the International Federation of Gynecology and Obstetrics (FIGO), the International Confederation of Midwives (ICM) and the International Council of Nurses (ICN), and representatives from all attended except for ICN. In addition, a range of WHO/HRP’s implementing partner organizations were invited to review the draft guideline prior to submission to the",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 172
  },
  {
    "chunk_id": "abortioncare_775",
    "text": "tatives from all attended except for ICN. In addition, a range of WHO/HRP’s implementing partner organizations were invited to review the draft guideline prior to submission to the GRC; these organizations included Ipas, the International Planned Parenthood Federation (IPPF), MSI Reproductive Choices, Pathfinder and Population Services International (PSI). B. Management of declarations and conflicts of interests, and confidentiality In accordance with the WHO handbook for guideline development, all invited members of the ERRGs, GDG, the ESTs, the ERG, and the GDG meeting observers, guideline reviewers representing implementing partner organizations, and other external contributors (e.g. consultants and collaborators) were asked to declare in writing any competing interests (academic, financial or other) at the time of invitation to participate in the guideline development or evidence rev",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 172
  },
  {
    "chunk_id": "abortioncare_776",
    "text": "ators) were asked to declare in writing any competing interests (academic, financial or other) at the time of invitation to participate in the guideline development or evidence review process. This was done by electronic submission of a signed WHO Declaration of Interests (DOI) form along with a copy of their curriculum vitae to the responsible technical officer prior to participation. In addition, internet searches were conducted on each invited member to assess any potential conflicts of interest that had not been disclosed. The management of conflicts of interest was explained to the invited participants, including the fact that no member would be allowed to participate in the meeting(s) if they failed to first complete and sign a DOI form. The responsible technical officer assessed the DOI forms and CVs received with reference to the WHO handbook for guideline development, in consult",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 172
  },
  {
    "chunk_id": "abortioncare_777",
    "text": "rst complete and sign a DOI form. The responsible technical officer assessed the DOI forms and CVs received with reference to the WHO handbook for guideline development, in consultation with the Director of the SRH Department and with the input of the WHO Steering Group, to determine the existence (and severity) of any conflict of interest, and agree upon a management plan. One conflict arose for one ERRG member during the course of guideline development, and this person thus did not attend any meetings thereafter. There were no other cases of any conflict of interest (this is also reported in the ERRG and GDG members lists in Annex 1). Biographical information for all ERRG and GDG members deemed not to have significant conflicts of interest (i.e. conflicts that precluded their participation in the GDG) were posted on the WHO SRH Department’s website for public comment for at least two w",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 172
  },
  {
    "chunk_id": "abortioncare_778",
    "text": "gnificant conflicts of interest (i.e. conflicts that precluded their participation in the GDG) were posted on the WHO SRH Department’s website for public comment for at least two weeks before the start of the respective meetings, with their consent (in 2020 for the ERRGs and in 2021 for the GDG). ERRG and GDG members were confirmed once this process was completed. On confirmation of their eligibility to participate, all ERRG, GDG and ERG experts were instructed to notify the responsible technical officer of any change in relevant interests during the course of their participation in the process. At the start of each meeting, all ERRG and GDG participants had the opportunity to verbally confirm, append or amend any declared interests so that all fellow GDG members and other attendees were made aware. They had a similar opportunity to do the same in writing before submitting comments on dr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 172
  },
  {
    "chunk_id": "abortioncare_779",
    "text": "any declared interests so that all fellow GDG members and other attendees were made aware. They had a similar opportunity to do the same in writing before submitting comments on draft versions of the guideline. Finally, it should be noted that each member of the ERRGs, GDG, ERG, ESTs and each guideline methodologist was asked to sign a confidentiality agreement relating to the guideline development process and outcomes. In addition, the responsible technical officer securely stored all received electronic and printed hard copies of the signed DOI forms and curriculum vitae to ensure that confidentiality was maintained. C. Scope of the guidance: defining topic areas and outcomes of interest In September 2018, an online survey was undertaken to initiate the process of updating WHO guidance on safe abortion. The objectives of this survey were (i) to identify relevant areas that require an u",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 172
  },
  {
    "chunk_id": "abortioncare_780",
    "text": " online survey was undertaken to initiate the process of updating WHO guidance on safe abortion. The objectives of this survey were (i) to identify relevant areas that require an update or new areas that need to be added to the guidance and (ii) to generate suggestions for making the guidelines more user-friendly. The survey was distributed within various networks in the sexual and reproductive health field and resulted in 122 responses. 2 WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014 ( https://apps.who.int/iris/ handle/10665/145714 ).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 172
  },
  {
    "chunk_id": "abortioncare_781",
    "text": "133 Thereafter, scoping meetings for each of the three domains (Clinical services, Service delivery, and Law and policy) were conducted with a range of experts, between November 2018 and June 2019. The purpose of these meetings was to determine the key topic areas that required formulation of key questions in the “PICO” format (population, intervention, comparator, outcomes) and to formulate and discuss these questions. The PICO questions were further reviewed, modified and finalized in the follow-up email exchanges between the WHO Steering Group and the ERRG members for each domain. The topic areas for the final PICOs of each domain, as determined during the scoping meetings, are provided in Box A below. The PICO questions for each domain are provided in Annexes 8, 9 and 10. In addition to the scoping meetings, three technical meetings also focused on issues relating to abortion care in",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 173
  },
  {
    "chunk_id": "abortioncare_782",
    "text": "ICO questions for each domain are provided in Annexes 8, 9 and 10. In addition to the scoping meetings, three technical meetings also focused on issues relating to abortion care in humanitarian settings (June 2019), values and preferences relating to abortion care (September 2019), and youth concerns relating to abortion care (April 2021) (further details on these meetings and issues are presented in Box B at the end of this annex and in the Web annex B: Technical meetings during guideline development). BOX A: Topic areas per domain for development of PICOs for new and updated recommendations Law and policy Criminalization Grounds-based approaches Gestational age limits Mandatory waiting periods Third-party authorization Restrictions on abortion providers Conscientious objection by a health worker Clinical services Rh isoimmunization Pain management for medical and surgical abortion and ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 173
  },
  {
    "chunk_id": "abortioncare_783",
    "text": "horization Restrictions on abortion providers Conscientious objection by a health worker Clinical services Rh isoimmunization Pain management for medical and surgical abortion and for cervical priming Cervical priming prior to surgical abortion Self-management of medical abortion (all subtasks) Medical abortion using new methods (regimens including letrozole) Medical management of missed abortion Follow-up care or additional services after abortion Service delivery Health workers providing services: self, community health workers, pharmacy workers, pharmacists, traditional and complementary medicine professionals, auxiliary nurses, auxiliary nurse midwives, nurses, midwives, associate/advanced associate clinicians, generalist medical practitioners, specialist medical practitioners Services: • Provision of information on safe abortion • Counselling across the continuum of care • Cervical ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 173
  },
  {
    "chunk_id": "abortioncare_784",
    "text": "ans, generalist medical practitioners, specialist medical practitioners Services: • Provision of information on safe abortion • Counselling across the continuum of care • Cervical priming with medication and osmotic dilators prior to surgical abortion • Surgical abortion (vacuum aspiration [VA] and dilatation and evacuation [D&E]) • Medical management of induced abortion (all subtasks; including self-management) • Medical management of intrauterine fetal demise (IUFD) • Medical and surgical management of incomplete abortion • Initial management of non-life-threatening complications • Initiation and continuation of injectable contraceptives (including self-injection) Service-delivery methods: • Community-based outreach models for provision of abortion care • Medical abortion care provided through telemedicine • Harm-reduction counselling on abortion care • Social marketing methods for abo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 173
  },
  {
    "chunk_id": "abortioncare_785",
    "text": "utreach models for provision of abortion care • Medical abortion care provided through telemedicine • Harm-reduction counselling on abortion care • Social marketing methods for abortion services • Self-sourcing of abortion medications online Annex 4",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 173
  },
  {
    "chunk_id": "abortioncare_786",
    "text": "Abortion care guideline, second edition 134 D. Review of the evidence and formulation of recommendations Defining and reviewing priority questions The full list of PICO questions was confirmed during follow-up communications among the WHO Steering Group and the ERRG members after the scoping meetings for each domain, which were described in the previous section. All the PICO questions and related details are provided in Annexes 8, 9 and 10. Systematic review methods (evidence retrieval) A list of all reviews conducted for the development of this guideline is presented in Annex 7. Refer to the published systematic reviews and to the packages of supplementary materials online for information about the specific methods used, including search strategies. Refer to beginning of this annex for information about the Evidence Synthesis Teams (ESTs). Sources for evidence relating to the PICOs of i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 174
  },
  {
    "chunk_id": "abortioncare_787",
    "text": "thods used, including search strategies. Refer to beginning of this annex for information about the Evidence Synthesis Teams (ESTs). Sources for evidence relating to the PICOs of interest for the Clinical services and Service delivery domains included randomized controlled trials (RCTs) as well as non-randomized controlled trials, controlled before-and- after studies, interrupted time series and cohort studies. The following databases were searched from inception to December 2020, without language filters: • Global databases: ClinicalTrials.gov, Cochrane database, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Excerpta Medica database (Embase), POPLINE, PubMed. • Regional databases: African Index Medicus (AIM), Chinese Biomedical Literature Database, Global Index Medicus, Index Medicus for South-East Asia (IMSEAR), Index Medicus for WHO Eastern Mediterranean, Latin Am",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 174
  },
  {
    "chunk_id": "abortioncare_788",
    "text": "Index Medicus (AIM), Chinese Biomedical Literature Database, Global Index Medicus, Index Medicus for South-East Asia (IMSEAR), Index Medicus for WHO Eastern Mediterranean, Latin American and Caribbean Health Sciences Literature (LILACS), Western Pacific Regional Index Medicus. In addition, a search of trial registry sites and organizational websites was conducted, and information from experts in the field was also used to identify any major ongoing or completed but unpublished trials that could be relevant to the guideline recommendations. Data from studies meeting the inclusion criteria were extracted using a standardized form and organized into Summary of Findings tables within the GRADE evidence summaries, using the online GRADE (Grading of Recommendations Assessment, Development and Evaluation) application. 3 For the Law and policy domain, the primary databases searched included Goog",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 174
  },
  {
    "chunk_id": "abortioncare_789",
    "text": "sing the online GRADE (Grading of Recommendations Assessment, Development and Evaluation) application. 3 For the Law and policy domain, the primary databases searched included Google Scholar, JSTOR, Hein Online and PubMed, from 2010 to 2021. For this domain, in addition to RCTs and other types of studies, the reviews also included legal and policy analyses, regulatory documents, and legal and policy reviews. 4 Assessment of the quality and certainty of the evidence for recommendations In accordance with the WHO guideline development process, the GDG formulated the recommendations guided by the quality/certainty of the available evidence. 5 WHO has adopted the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to recommendation development, which defines the quality/ certainty of evidence as the extent to which one can be confident that the reported estimat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 174
  },
  {
    "chunk_id": "abortioncare_790",
    "text": "nd Evaluation (GRADE) approach to recommendation development, which defines the quality/ certainty of evidence as the extent to which one can be confident that the reported estimates of effect (desirable or undesirable) available from the evidence are close to the actual effects of interest. 6 The GRADE approach specifies four levels of certainty of evidence, which should be interpreted as follows: • High – We are very confident that the true effect lies close to that of the estimate of the effect. • Moderate – We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. • Low – Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. • Very low – We have very little confidence in the effect est",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 174
  },
  {
    "chunk_id": "abortioncare_791",
    "text": "nce in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. • Very low – We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. 3 GRADEpro GDT. GRADEpro Guideline Development Tool [Software] (developed by Evidence Prime, Inc.). McMaster University; 2020 (https://gradepro.org/ ). 4 de Londras F, Cleeve A, Rodriguez M, Lavelanet A. Integrating rights and evidence: a technical advance in abortion guideline development. BMJ Glob Health. 2021;6(2):e004141. 5 WHO handbook for guideline development, 2014. 6 Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading the quality of evidence and the strength of recommendations. The GRADE Working Group; 2013 ( https://gdt.gradepro.org/app/handbook/handbook.html ).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 174
  },
  {
    "chunk_id": "abortioncare_792",
    "text": "135 As a baseline, RCTs provide “high-quality” evidence, while non-randomized trials and observational studies provide “low-quality” evidence. This baseline quality rating may be downgraded based on consideration of study design limitations (risk of bias – assessed using the criteria outlined in the Cochrane handbook for systematic reviews of interventions along six domains)7, inconsistency, imprecision, indirectness and publication bias. For observational studies, other considerations, such as magnitude of effect, could lead to upgrading of the rating if there are no limitations that indicated a need for downgrading. The EST members and guideline methodologists, in accordance with standard operating procedures approved by the WHO Steering Group, performed the grading of review evidence. The GRADE approach to appraising the quality of quantitative evidence was used for all the critical o",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_793",
    "text": " approved by the WHO Steering Group, performed the grading of review evidence. The GRADE approach to appraising the quality of quantitative evidence was used for all the critical outcomes identified in the PICO questions, 8 and a GRADE evidence profile (GRADE table) was prepared for each quantitative outcome within each PICO; these are presented in the supplementary materials available online. With regard to the Law and policy domain, there was an existing composite recommendation in the 2012 Safe abortion guidance, which spoke to these issues and related interventions; the topics identified during the scoping process for this updated guideline (see Box A) stemmed from there. However, there was no existing standardized approach for assessing the quality or certainty of the evidence relating to laws and policies on abortion using a rights-based analysis. 9 Therefore, an innovative approac",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_794",
    "text": "dardized approach for assessing the quality or certainty of the evidence relating to laws and policies on abortion using a rights-based analysis. 9 Therefore, an innovative approach was developed to evaluate the evidence that effectively integrated human rights protection and enjoyment as part of health outcomes and analysis, while considering several important factors and their potential interactions. 10 This is in line with WHO’s norms and values, and thus underpins integrated evidence for application within an Evidence-to-Decision (EtD) framework. The outcomes of interest for the Law and policy domain were informed by the conceptual frameworks and legal mapping initially performed by the EST team at Temple University (see section A), which mapped the various interventions and the systems around them and identified empirical research assessing the health effects of laws and policies. T",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_795",
    "text": "niversity (see section A), which mapped the various interventions and the systems around them and identified empirical research assessing the health effects of laws and policies. This mapping emphasized policy surveillance, advancing technology and methods for legal evaluation, teaching policy surveillance methods, and sharing credible scientific data with researchers, policy- makers and the public to make the case for laws that improve health. Next, the team developed causal logic models for the legal interventions on abortion to display plausible pathways from the implementation of the restriction to health and socioeconomic outcomes. The third step involved using the models as a guide to conduct a second rapid scan, in order to identify non-legal studies investigating whether the processes and outcomes posited in the models do, in fact, occur, and with what frequency and severity, and",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_796",
    "text": "id scan, in order to identify non-legal studies investigating whether the processes and outcomes posited in the models do, in fact, occur, and with what frequency and severity, and with what consequences. This evidence, in turn, supported plausible inferences of causality for practical policy and guideline development purposes. The Identifying Data for the Empirical Assessment of Law (IDEAL) method attempts to create an objective framework for crystallizing the various influences and consequences attributable to the impact of specific abortion restrictions, leading to the identification of untapped scientific evidence on plausible effects of the law.11 The quantitative evidence retrieved from all types of studies and documents was assessed for precision, directness and magnitude of effect, while the qualitative evidence was assessed for adequacy, and compiled in an EtD table. An overarch",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_797",
    "text": "es and documents was assessed for precision, directness and magnitude of effect, while the qualitative evidence was assessed for adequacy, and compiled in an EtD table. An overarching Rights Analysis Table, which identified human rights standards relevant to the specific interventions, was applied to the evidence table, leading to the development of a Human Rights to Evidence Table, organized by outcome of interest. The full methods are described in de Londras et al. (2021). 12 Formulation of recommendations and determining the strength of recommendations The WHO Steering Group supervised and finalized the preparation of evidence summaries, including GRADE tables and Summary of Findings tables, for each PICO question. For the Clinical services and Service delivery domains, the evidence summaries followed the new Evidence-to-Decision (EtD) framework, known as the WHO-INTEGRATE 7 Each incl",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_798",
    "text": "estion. For the Clinical services and Service delivery domains, the evidence summaries followed the new Evidence-to-Decision (EtD) framework, known as the WHO-INTEGRATE 7 Each included study is assessed and rated to be at low, high or unclear risk of bias for sequence generation, allocation concealment, blinding of study personnel and participants, attrition, selective reporting and other sources of bias (Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, editors. Cochrane handbook for systematic reviews of interventions, Version 6.2. The Cochrane Collaboration; 2021 [ https://training.cochrane.org/handbook/current] ). 8 Schünemann et al., editors, GRADE Handbook, 2013. 9 Rehfuess E, Stratil JM, Portela A, Baltussen R, Scheel IB, Norris SL. The WHO-INTEGRATE evidence to decision framework version 1.0: integrating WHO norms and values and a complexity perspective. BMJ Glo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_799",
    "text": ", Portela A, Baltussen R, Scheel IB, Norris SL. The WHO-INTEGRATE evidence to decision framework version 1.0: integrating WHO norms and values and a complexity perspective. BMJ Glob Health. 2019;4:e000844. 10 de Londras et al., 2021. 11 Burris S, Ghorashi AR, Cloud LF, Rebouché R, Skuster P, Lavelanet A. Identifying data for the empirical assessment of law (IDEAL): a realist approach to research gaps on the health effects of abortion law. BMJ Glob Health. 2021;6:e005120. 12 de Londras et al., 2021. Annex 4",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 175
  },
  {
    "chunk_id": "abortioncare_800",
    "text": "Abortion care guideline, second edition 136 framework. This new framework is broader and better suited to system-level interventions. The six substantive criteria of the WHO-INTEGRATE framework are the following: balance of health benefits and harms; human rights and sociocultural acceptability; health equity, non-discrimination and equality; societal implications; financial and economic considerations; and feasibility and health system considerations. The additional meta-criterion is quality of evidence (i.e. type, size and limitations of the available studies used as evidence). The WHO-INTEGRATE framework allows for the fact that some interventions are complex and have multiple components interacting synergistically or dissynergistically, may be non-linear in their effects, or may be context dependent. This framework is better able to accommodate recommendation formulation for the Law ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 176
  },
  {
    "chunk_id": "abortioncare_801",
    "text": "tically or dissynergistically, may be non-linear in their effects, or may be context dependent. This framework is better able to accommodate recommendation formulation for the Law and policy domain, as well as the Clinical services and Service delivery domains, thus allowing guideline users to make informed decisions on all interventions. Also integral to the recommendation formulation process across all domains is the values placed on the outcomes and the preferences of the women affected by the recommendations. Taking this into account along with all the criteria of the WHO-INTEGRATE framework, as applied to each intervention for the specified population, new and updated recommendations were formulated by the ERRG and GDG members and qualified as either strong (“recommend”) or weak (“suggest”; with specified conditions for application) recommendations in favour of the intervention, or ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 176
  },
  {
    "chunk_id": "abortioncare_802",
    "text": " ERRG and GDG members and qualified as either strong (“recommend”) or weak (“suggest”; with specified conditions for application) recommendations in favour of the intervention, or as strong recommendations against the intervention/in favour of the comparator. Recommendations were considered “new” (as labelled in the table at the end of the Executive Summary and in Chapter 3) if no recommendation existed in a previous WHO guideline on the specific topic or intervention in question for the specified population. In particular it should be noted that the 2012 Safe abortion guidance provided a composite recommendation related to law and policy; in this guideline, this was developed this into seven separate recommendations, but they are not considered to be “new” (i.e. Recommendations 1,2,3,6,7,21,22). E. Decision-making by the GDG during guideline development The GDG meeting took place in Apr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 176
  },
  {
    "chunk_id": "abortioncare_803",
    "text": "ations, but they are not considered to be “new” (i.e. Recommendations 1,2,3,6,7,21,22). E. Decision-making by the GDG during guideline development The GDG meeting took place in April 2021 to review, revise and finalize the draft recommendations from all three domains that had been prepared by the ERRGs, as described above. Decision-making was based on discussion of the synthesized evidence and the use of the DECIDE Framework .13 The final adoption of each recommendation was made by consensus, defined as full agreement among all GDG participants when at all possible – this is the preferred method. In one instance, voting was used since consensus could not be reached. The decision on how to present the medical abortion regimens was made based on the large majority voting in support of upholding the way it is described and presented in the previous guidelines. WHO staff attending the meetin",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 176
  },
  {
    "chunk_id": "abortioncare_804",
    "text": "ortion regimens was made based on the large majority voting in support of upholding the way it is described and presented in the previous guidelines. WHO staff attending the meeting, EST members, methodologists and meeting observers were not allowed to vote. F. Compilation, review and presentation of the guideline content The WHO responsible technical officer led the writing of the guideline with external/consultant writers, with significant input from the ESTs, the guideline methodologists and other members of the WHO Steering Group. In advance of the GDG meeting, an early draft of the full guideline document was prepared. The guideline methodologists drafted the GRADE evidence summaries and the WHO Steering Group members drafted corresponding Evidence-to-Decision (EtD) frameworks. The full draft and these supplementary materials were shared electronically with all GDG members (see Anne",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 176
  },
  {
    "chunk_id": "abortioncare_805",
    "text": "roup members drafted corresponding Evidence-to-Decision (EtD) frameworks. The full draft and these supplementary materials were shared electronically with all GDG members (see Annex 1) two weeks before the GDG meeting, which was held during the last week of April 2021. Following the GDG meeting, revisions were made to accurately reflect the deliberations and decisions of the GDG members on the recommendations and to incorporate their feedback on the draft. Subsequently, the revised draft guideline was shared electronically with all GDG members for two weeks for further comment. It was simultaneously shared for comment with all members of the External Review Group (ERG), the GDG meeting observers, and the representatives of implementing partner organizations (see section A and Annex 1), who were unconnected with the process of guideline development. Next, the Steering Group carefully eval",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 176
  },
  {
    "chunk_id": "abortioncare_806",
    "text": "entatives of implementing partner organizations (see section A and Annex 1), who were unconnected with the process of guideline development. Next, the Steering Group carefully evaluated the written input of all the reviewers (via email and direct comments/ edits on the draft document) for inclusion in the final guideline document and the revised version was reviewed by the director of the WHO SRH Department and edited for clarity. The final draft was submitted for review at a meeting of the WHO Guidelines Review Committee (GRC) and was fully approved by the GRC in August 2021 after some requested revisions had been completed. 13 Evidence to Decision frameworks (EtDs) for policy makers [website]. Cochrane Norway; 2021 ( https://www.cochrane.no/decide- frameworks-policy-makers ).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 176
  },
  {
    "chunk_id": "abortioncare_807",
    "text": "137 Evidence derived from the systematic reviews in support of the new and updated recommendations was summarized in EtD frameworks to provide the evidence base on effectiveness that informed the new recommendations in this guideline. These EtD frameworks are presented separately in the three packets of supplementary materials available online: https://www.who.int/publications/i/item/9789240039483 • Supplementary material 1: Evidence-to-Decision frameworks for the law and policy recommendations • Supplementary material 2: Evidence-to-Decision frameworks for the clinical service recommendations • Supplementary material 3: Evidence-to-Decision frameworks for the service delivery recommendations and best practice statements. BOX B: Key meetings during guideline development (in Geneva, Switzerland, or online) Scoping meetings: November 2018 – June 2019 Two-day scoping meetings were held for ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 177
  },
  {
    "chunk_id": "abortioncare_808",
    "text": "statements. BOX B: Key meetings during guideline development (in Geneva, Switzerland, or online) Scoping meetings: November 2018 – June 2019 Two-day scoping meetings were held for each of the three domains of this guideline, during which external experts on the subject areas and methodology (see Annex 1) identified the priority topics and the specific areas requiring new or updated recommendations or good practice statements. • Law and policy domain: Geneva, November 2018. This meeting facilitated discussion and the development of new approaches to guideline development for (i) abortion law and policy, and (ii) integration of human rights. • Clinical services domain: Virtual meeting, December 2018. • Service delivery domain: Geneva, June 2019. Technical meetings: (i) Implementation considerations for abortion care in humanitarian settings : A two-day technical meeting was held in Geneva ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 177
  },
  {
    "chunk_id": "abortioncare_809",
    "text": "livery domain: Geneva, June 2019. Technical meetings: (i) Implementation considerations for abortion care in humanitarian settings : A two-day technical meeting was held in Geneva in June 2019. This meeting convened approximately 20 experts in the fields of humanitarian aid, conflict settings, abortion care and human rights (including three youth representatives) together with 20 representatives from the WHO Secretariat. The expert participants came from nine countries in the regions of Africa, the Eastern Mediterranean, Europe and North America. During the meeting participants identified specific barriers and facilitating factors for implementation of safe abortion in humanitarian/emergency settings. Common barriers that were identified included: stigma, the role of social norms and values, the lack of clinical skills and knowledge, and perceived legal barriers. Practices that facilitat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 177
  },
  {
    "chunk_id": "abortioncare_810",
    "text": "rriers that were identified included: stigma, the role of social norms and values, the lack of clinical skills and knowledge, and perceived legal barriers. Practices that facilitate implementation of quality abortion care in these settings are: engagement with key stakeholders (in particular with community and religious leaders), developing a concrete implementation strategy with identification of potential entry points, and ensuring data collection and monitoring. For further details, see Web annex B: Technical meetings during guideline development. (ii) Global abortion values and preferences : An online survey was prepared and disseminated in October and November 2018. In September 2019, a two-day technical meeting was convened in Geneva with a diverse range of stakeholders, including 19 participants from 15 different organizations/countries (including three youth representatives) and ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 177
  },
  {
    "chunk_id": "abortioncare_811",
    "text": "eeting was convened in Geneva with a diverse range of stakeholders, including 19 participants from 15 different organizations/countries (including three youth representatives) and 8 members of the WHO Secretariat. For the first time, this was a meeting focused solely on unpacking the meaning of “values and preferences” in relation to abortion. By the end of the meeting, the information generated from the rich discussions formed a basis for the guideline development discussions on the values and preferences of women, which was one of the key criteria in the recommendation formulation process. For further details, including a summary of the literature review findings, see Web annex B: Technical meetings during guideline development. Annex 4",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 177
  },
  {
    "chunk_id": "abortioncare_812",
    "text": "Abortion care guideline, second edition 138 (iii) Youth concerns relating to abortion care: For each of the scoping and technical meetings for this guideline, mentioned in this box, there were representatives from the International Youth Alliance for Family Planning (IYAFP) to provide a youth perspective, and one representative from IYAFP also served on each ERRG and one on the final GDG. In addition, a dedicated two-day technical meeting was held online in April 2021, bringing together 16 members of the IYAFP Youth for Abortion Taskforce which IYAFP had formed to support and inform the guideline development process, and 4 WHO staff members from the Preventing Unsafe Abortion (PUA) Unit of WHO’s Department of Sexual and Reproductive Health and Research. Participants included youths (up to age 30) with demonstrated leadership skills in the field of adolescent sexual and reproductive healt",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 178
  },
  {
    "chunk_id": "abortioncare_813",
    "text": "exual and Reproductive Health and Research. Participants included youths (up to age 30) with demonstrated leadership skills in the field of adolescent sexual and reproductive health and rights, representing 13 countries across the WHO regions. The meeting discussions centred around three key themes: youth’s values and preferences related to abortion services, addressing barriers and abortion stigma, and scaling up promising practices and interventions. Key issues discussed included the elements of an enabling environment and meaningful youth engagement. IYAFP members are developing a position paper as the main output of the meeting. For further details, see Web annex B: Technical meetings during guideline development. Evidence and Recommendations Review Group (ERRG) meetings: March 2020 – March 2021 The ERRG meetings (4–5 meetings for each of the three domains) all occurred online, each ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 178
  },
  {
    "chunk_id": "abortioncare_814",
    "text": "opment. Evidence and Recommendations Review Group (ERRG) meetings: March 2020 – March 2021 The ERRG meetings (4–5 meetings for each of the three domains) all occurred online, each one taking place across two days, facilitated by the WHO responsible technical officer and other members of the WHO Steering Group. At these meetings, members of the Evidence Synthesis Teams presented their systematic reviews of the evidence, and the ERRG members (see section A and Annex 1) discussed and reviewed the evidence and formulated draft recommendations, implementation considerations and good practice statements to be presented for further review, revision and finalization by the GDG. • Clinical services domain: March 2020, May 2020, June 2020, September 2020, February 2021 • Service delivery domain: Pre-ERRG June 2020, October 2020, January 2021, early March 2021, late March 2021 • Law and policy doma",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 178
  },
  {
    "chunk_id": "abortioncare_815",
    "text": "ay 2020, June 2020, September 2020, February 2021 • Service delivery domain: Pre-ERRG June 2020, October 2020, January 2021, early March 2021, late March 2021 • Law and policy domain: March-April 2020, June 2020, August–September 2020, March 2021. Guideline Development Group (GDG) meeting Online, 27–30 April 2021. During the GDG meeting, the GDG members reviewed, discussed, revised and finalized the draft recommendations, implementation considerations and good practice statements from all three domains. WHO Guidelines Review Committee (GRC) meeting 7 July 2021. BOX B: Continued",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 178
  },
  {
    "chunk_id": "abortioncare_816",
    "text": "139 Annex 5. Health worker categories and roles The health worker types considered in the guideline are described in the table below. Descriptions have been adapted for the purpose of this guideline to be generic enough to apply across settings. They are indicative and illustrative and are not intended as a substitute for the formal definitions of professional bodies or titles used in specific countries. Broad category Description of qualifications and tasks, for the purpose of this guideline Illustrative examples of other terms for these types of health workers (some examples may be specific to a country or regional context) Community health worker (CHW) A person who performs functions related to health-care delivery/information provision and has been trained in some way in the context of the task but has received no formal professional or paraprofessional certificate or tertiary educat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_817",
    "text": "elivery/information provision and has been trained in some way in the context of the task but has received no formal professional or paraprofessional certificate or tertiary education degree. Lay health worker, village health worker, female community health volunteer, trained birth attendant, trained helpline worker, abortion accompanier, hotline counsellor Pharmacy worker Technicians and assistants who perform a variety of tasks associated with dispensing medicinal products under the guidance of a pharmacist. They inventory, prepare and store medications and other pharmaceutical compounds and supplies, and may dispense medicines and drugs to clients and instruct on their use as prescribed by health professionals. Technicians typically receive two or three years of training in a pharmaceutical school, with an award not equivalent to a university degree. Assistants have usually also been ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_818",
    "text": "ls. Technicians typically receive two or three years of training in a pharmaceutical school, with an award not equivalent to a university degree. Assistants have usually also been through two or three years of secondary school with a subsequent period of on-the-job training or apprenticeship. Pharmacy assistant, pharmacy technician dispenser, pharmacist aide, dispensary assistant Pharmacist A health-care practitioner who dispenses medicinal products. A pharmacist can counsel on the proper use and adverse effects of drugs and medicines following prescriptions issued by medical doctors/health-care professionals. Education includes university-level training in theoretical and practical pharmacy, pharmaceutical chemistry or a related field. Chemist, clinical pharmacist, community pharmacist Traditional and complementary medicine professionals A professional of traditional and complementary s",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_819",
    "text": "mistry or a related field. Chemist, clinical pharmacist, community pharmacist Traditional and complementary medicine professionals A professional of traditional and complementary systems of medicine (non-allopathic physician) whose training includes a four- or five-year university degree that teaches human anatomy, physiology, management of normal labour and the pharmacology of modern medicines used in obstetrics and gynaecology, in addition to their systems of medicine. For the purpose of this guideline, these doctors are included with reference to the provision of elements of abortion-related care as per conventional medical practice. Ayush doctor, Ayurvedic physician, doctor of complementary systems of medicine, non-allopathic physician Auxiliary nurse midwife (ANM) and auxiliary nurse An auxiliary nurse is someone trained in basic nursing skills but not in nursing decision-making. An",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_820",
    "text": "ine, non-allopathic physician Auxiliary nurse midwife (ANM) and auxiliary nurse An auxiliary nurse is someone trained in basic nursing skills but not in nursing decision-making. An ANM has basic nursing skills and some midwifery competencies but is not fully qualified as a midwife. The duration of training may vary from a few months up to three years. A period of on-the- job training may be included, and this is sometimes formalized in apprenticeships. Auxiliary midwife, family welfare visitor Nurse A person who has been legally authorized (registered) to practise after examination by a state board of nurse examiners or similar regulatory authority. Education includes three or more years in nursing school, and leads to a university or postgraduate university degree or the equivalent. Registered nurse, clinical nurse specialist, licensed nurse, BSc nurse Midwife A person who has been regi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_821",
    "text": "leads to a university or postgraduate university degree or the equivalent. Registered nurse, clinical nurse specialist, licensed nurse, BSc nurse Midwife A person who has been registered by a state midwifery or similar regulatory authority and has been trained in the essential competencies for midwifery practice. Training typically lasts three or more years in nursing or midwifery school and leads to a university degree or the equivalent. A registered midwife has the full range of midwifery skills, which include abortion. Registered midwife, community midwife, nurse-midwife Advanced associate clinician and associate clinician A professional clinician with basic competencies to diagnose and manage common medical and surgical conditions and also to perform some types of surgery. Training generally requires three or four years post-secondary education in an established higher education inst",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_822",
    "text": " and surgical conditions and also to perform some types of surgery. Training generally requires three or four years post-secondary education in an established higher education institution. The clinician is registered and their practice is regulated by a national or subnational regulatory authority. Assistant medical officer, clinical officer, medical licentiate practitioner, health officer, physician assistant, surgical technician, non-physician clinician, medical assistant, nurse practitioner Generalist medical practitioner A medical doctor who holds a university-level degree in basic medical education but does not have a specialization in obstetrics and gynaecology. Family doctor, general practitioner, medical doctor, physician Specialist medical practitioner A medical doctor with postgraduate clinical training and specialization in obstetrics and gynaecology. Gynaecologist, obstetrici",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_823",
    "text": "l doctor, physician Specialist medical practitioner A medical doctor with postgraduate clinical training and specialization in obstetrics and gynaecology. Gynaecologist, obstetrician Source: adapted with minor revisions from WHO (2015) (18) , including updating some of the names of health worker categories to use current preferred WHO terminology, as presented in the International Standard Classification of Occupations (ISCO), Part III: Definitions of major groups, sub-major groups, minor groups and unit groups, updated 21 June 2016 (available at: https://www.ilo.org/public/english/bureau/stat/isco/isco08/ index.htm ). Annex 5",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 179
  },
  {
    "chunk_id": "abortioncare_824",
    "text": "Abortion care guideline, second edition 140 Annex 6. Monitoring and evaluation of quality abortion care: identification of indicators Methods and preliminary results To achieve consensus on indicators that can be used to effectively document progress in quality abortion care at programmatic and country levels, a scoping review and multiple expert consultation processes have been conducted by scientists from the London School of Hygiene and Tropical Medicine (LSHTM) and WHO. Scoping review: The scoping review yielded a summary of abortion measures and indicators reported over the 10-year period 2008–2018 in scientific literature and materials identified on major non-governmental organization websites. In total, 1999 abstracts and 7 additional relevant documents were screened for indicators, yielding 792 indicators identified from 142 documents. The findings of the scoping review were rece",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 180
  },
  {
    "chunk_id": "abortioncare_825",
    "text": "1999 abstracts and 7 additional relevant documents were screened for indicators, yielding 792 indicators identified from 142 documents. The findings of the scoping review were recently published in BMJ Global Health and the 792 indicators are available on a searchable spreadsheet among the supplementary materials for the publication .1 Consultation meeting: At an initial (virtual) consultation meeting in June 2020, multiple sets of indicators that could be used for global- and programme-level monitoring were presented. These included a sub-set of 17 core indicators that had been selected from among the indicators identified in the scoping review and from among indicators for monitoring abortion care based on measurement initiatives implemented variously by the UNDP-UNFPA-UNICEF- WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 180
  },
  {
    "chunk_id": "abortioncare_826",
    "text": "asurement initiatives implemented variously by the UNDP-UNFPA-UNICEF- WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), the WHO Regional Office for Africa, the Maternal Mortality Initiative (of the WHO Department for Sexual and Reproductive Health and Research) and Ibis Reproductive Health. In total, 52 unique indicators were proposed during the consultation meeting. The WHO health systems strengthening monitoring and evaluation framework was also presented as a potential structure for quality abortion monitoring and evaluation (M&E). Consolidation: During a consolidation phase, a team of LSHTM and WHO scientists eliminated 29 out of the 52 indicators, removing indicators with duplication of information, using as main review criteria (i) relevance within the health systems strengthening monitoring and evaluation framework, and (i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 180
  },
  {
    "chunk_id": "abortioncare_827",
    "text": "removing indicators with duplication of information, using as main review criteria (i) relevance within the health systems strengthening monitoring and evaluation framework, and (ii) feasibility for M&E. Six indicators were added to represent categories in the health system strengthening monitoring and evaluation framework which previously had no associated proposed indicators (such as social protection and infrastructure) and in an effort to align with the Sustainable Development Goals (SDG) targets related to sexual and reproductive health and rights. These six additional indicators were sourced from the original scoping review list of indicators, 2 the Ibis Reproductive Health quality of care indicators, 3 and the WHO Department of maternal, newborn, child and adolescent health (MCA) indicators on respectful care. 4 Online consultation: In an online consultation in March 2021, measure",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 180
  },
  {
    "chunk_id": "abortioncare_828",
    "text": "nd the WHO Department of maternal, newborn, child and adolescent health (MCA) indicators on respectful care. 4 Online consultation: In an online consultation in March 2021, measurement and M&E experts in abortion care were invited to comment on (i) the relevance to abortion programmes of the WHO health systems strengthening monitoring and evaluation framework, (ii) the validity, feasibility, importance and sensitivity to change of each proposed indicator, and (iii) suggestions for alternative indicators. Twenty-two (out of 27) invited experts reviewed a total of 29 consolidated indicators during the online consultation. The 29 indicators were categorized in the health systems strengthening monitoring and evaluation framework areas of governance (5), financing (1), infrastructure (1), information system (1), health workforce (1), intervention access and services readiness (5), interventio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 180
  },
  {
    "chunk_id": "abortioncare_829",
    "text": "tion framework areas of governance (5), financing (1), infrastructure (1), information system (1), health workforce (1), intervention access and services readiness (5), intervention quality and safety (5), coverage of interventions (1), prevalence of risk behaviours and risk factors (1), improved health outcomes and equity (4), responsiveness (2) and social protection (2). Next steps The core team from LSHTM and WHO is currently finalizing the indicator list following review of input gathered during the online consultation, recognizing that the indicator list will require periodic assessment for strengthening and maintaining utility and relevance. A report will be published in due course. 1 Filippi V, Dennis M, Calvert C, Tunçalp Ö, Ganatra B, Kim CR, Ronsmans C. Abortion metrics: a scoping review of abortion measures and indicators. BMJ Global Health. 2021;6(1):e003813. 2 Ibid. 3 Dennis",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 180
  },
  {
    "chunk_id": "abortioncare_830",
    "text": " Calvert C, Tunçalp Ö, Ganatra B, Kim CR, Ronsmans C. Abortion metrics: a scoping review of abortion measures and indicators. BMJ Global Health. 2021;6(1):e003813. 2 Ibid. 3 Dennis A, Blanchard K, Bessenaar T. Identifying indicators for quality abortion care: a systematic literature review. J Fam Plann Reprod Health Care. 2017;43(1):7-15. 4 Quality of care for maternal and newborn health: a monitoring framework for network countries, updated February 2019. Geneva: World Health Organization; 2019 ( https://www.who.int/docs/default-source/mca-documents/qed-quality-of-care-for-maternal-and-newborn- health-a-monitoring-framework-for-network-countries.pdf , accessed 3 September 2021).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 180
  },
  {
    "chunk_id": "abortioncare_831",
    "text": "141 Annex 7. Systematic reviews and links to PICOs and recommendations Topic area Title and authors of review (and reference details, if published) Related PICO numbers(s), as listed in annexes Related recommendation number(s) as presented in the main document Topics scoped for development of new or updated recommendations Law and policy topics For the Evidence-to-Decision (EtD) frameworks, refer to Supplementary material 15 All reviews conducted by the Law and Policy Evidence Synthesis Team for development of this guideline6 Refer to Annex 8 Criminalization7 Impact of criminalization on abortion-related outcomes 1 1 Grounds-based approaches Impact of grounds on abortion-related outcomes 2 2 Gestational age limits Impact of gestational limits on abortion-related outcomes 3 3 Mandatory waiting periods Impact of mandatory waiting periods on abortion-related outcomes 4 6 Third-party authori",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 181
  },
  {
    "chunk_id": "abortioncare_832",
    "text": "its Impact of gestational limits on abortion-related outcomes 3 3 Mandatory waiting periods Impact of mandatory waiting periods on abortion-related outcomes 4 6 Third-party authorization Impact of third-party authorization on abortion-related outcomes 5,6,7,8,9 7 Abortion provider restrictions Impact of provider restrictions on abortion-related outcomes 10 21 Conscientious objection Impact of conscientious objection on abortion-related outcomes 11 22 Clinical service topics For the Evidence-to-Decision (EtD) frameworks, refer to Supplementary material 28 All reviews conducted by the Clinical services Evidence Synthesis Team for development of this guideline Refer to Annex 9 Rh isoimmunization New systematic review: Chan M, Gill R, Kim C. The effect of routine anti-D administration among unsensitized Rh negative individuals who have an abortion. BMJ Sex Reprod Health. 2021 (in press). 1 8",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 181
  },
  {
    "chunk_id": "abortioncare_833",
    "text": "iew: Chan M, Gill R, Kim C. The effect of routine anti-D administration among unsensitized Rh negative individuals who have an abortion. BMJ Sex Reprod Health. 2021 (in press). 1 8 Pain management for surgical abortion Updated review by Cochrane Fertility Regulation (CFR) Group: Renner R-M, Edelman A, McKercher AE, Jensen JTJ, Nichols MDN. Pain control in first trimester surgical abortion. 2020 (forthcoming) New systematic review: DePiñeres T. Pain management regimens for surgical abortion > 14 weeks gestation. 2020 (unpublished) 2, 3 11 & 12 13 & 14 Pain management for medical abortion New review by CFR Group: Reynolds-Wright JJ, Woldetsadik MA, Morroni C, Cameron S. Pain management for medical abortion before 14 weeks’ gestation. 2020 (forthcoming) New systematic review: Korotkaya Y, Kim C. Pain control in second-trimester medical termination of pregnancy: a systematic review. 2019 (un",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 181
  },
  {
    "chunk_id": "abortioncare_834",
    "text": " 14 weeks’ gestation. 2020 (forthcoming) New systematic review: Korotkaya Y, Kim C. Pain control in second-trimester medical termination of pregnancy: a systematic review. 2019 (unpublished) 4, 5 15 16 Cervical priming prior to surgical abortion < 12 weeks Updated review by CFR Group: Kapp N, Nguyen A, Atrio J, Lohr P. Cervical preparation for surgical abortion less than 14 weeks. 2020 (forthcoming) 6a 17 Cervical priming prior to surgical abortion ≥ 12 weeks Updated review by CFR Group: Newmann SJ, Tufa T, Drey E, Meckstroth K, Diedrich JT. Cervical preparation for second trimester dilation and evacuation. 2019 (forthcoming) 6b,7,8,9 18 Other medical methods to induce abortion New systematic review: Tolu L, Kim C. The efficacy, safety, and acceptability of alternative methods of medication abortion to the routine mifepristone and/or misoprostol. 2020 (manuscript in progress) 10,11,12 27",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 181
  },
  {
    "chunk_id": "abortioncare_835",
    "text": "m C. The efficacy, safety, and acceptability of alternative methods of medication abortion to the routine mifepristone and/or misoprostol. 2020 (manuscript in progress) 10,11,12 27c Missed abortion < 14 weeks New systematic review: DePiñeres T. Management options for pregnant individuals with missed abortion < 14 weeks. 2020 (unpublished) 13,14,15 31 5 Supplementary material 1, available at: https://www.who.int/publications/i/item/9789240039483 6 Authors of all seven reviews include: Amanda Cleeve, Fiona de Londras, Alana Farrell, Magdalena Furgalska, Antonella Lavelanet, Maria Isabel Rodriguez. 7 These first three recommendations are presented in Chapter 2. The remainder are presented in Chapter 3. 8 Supplementary material 2, available at: https://www.who.int/publications/i/item/9789240039483 Annex 6–7",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 181
  },
  {
    "chunk_id": "abortioncare_836",
    "text": "Abortion care guideline, second edition 142 Topic area Title and authors of review (and reference details, if published) Related PICO numbers(s), as listed in annexes Related recommendation number(s) as presented in the main document Self-management of medical abortion (eligibility, administration of medications, assessment of outcome) New systematic review: Clark E, Tolu L, Gill R, Kim C. Eligibility and outcome assessment. 2020 (unpublished) New review by CFR Group: Gambir K, Kim C, Necastro KA, Ganatra B, Ngo TD. Self-administered versus provider- administered medical abortion. Cochrane Database Syst Rev. 2020;(3):CD013181. 16 50 (Self- management) Service delivery topics For the Evidence-to-Decision (EtD) frameworks, refer to Supplementary material 39 All reviews conducted by the Service delivery Evidence Synthesis Team for development of this guideline Refer to Annex 10 Provision of",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 182
  },
  {
    "chunk_id": "abortioncare_837",
    "text": "rameworks, refer to Supplementary material 39 All reviews conducted by the Service delivery Evidence Synthesis Team for development of this guideline Refer to Annex 10 Provision of information Updated review by Cochrane Response (on pharmacy workers): Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: information provision by pharmacy workers. 2021 (unpublished) 1 4 Counselling Updated review by Cochrane Response (on traditional and complementary medicine professionals, pharmacists, pharmacy workers and community health workers): Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: pre- and post- abortion counselling. 2021 (unpublished) 2 5 Cervical priming using osmotic dilators",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 182
  },
  {
    "chunk_id": "abortioncare_838",
    "text": "th worker roles in providing safe abortion care and post-abortion contraception: pre- and post- abortion counselling. 2021 (unpublished) 2 5 Cervical priming using osmotic dilators or medication prior to induced surgical abortion Updated review by Cochrane Response (on traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives, nurses or auxiliary nurses/auxiliary nurse midwives): Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Cervical priming using osmotic dilators or medications. 2021 (unpublished) 3 19 & 20 Vacuum aspiration for all indications at < 14 weeks Vacuum aspiration for management of incomplete abortion Updated Cochrane Review (on traditional and complementary medicine professionals, auxiliary nurse midwives, auxiliary nurses, nurses, midwives, associate/advanced associate clinicians): Kim C, Barnard S, P",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 182
  },
  {
    "chunk_id": "abortioncare_839",
    "text": "on traditional and complementary medicine professionals, auxiliary nurse midwives, auxiliary nurses, nurses, midwives, associate/advanced associate clinicians): Kim C, Barnard S, Park MH, Ngo TD. Doctors or mid-level providers for abortion. Cochrane Database Syst Rev. 2021 (forthcoming) 4 & 10 24 & 38 Dilatation and evacuation (D&E) for surgical abortion at ≥ 14 weeks New systematic review (on traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives): Feyssa M, Kim C. Systematic review on effectiveness, safety and acceptability of second trimester abortion by midlevel providers. 2021 (unpublished) 5 26 Medical abortion at < 12 weeks (eligibility, administration of medications, assessment of outcome) Updated Cochrane Review (on traditional and complementary medicine professionals, auxiliary nurse midwives, auxiliary nurses, midwives, nurses, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 182
  },
  {
    "chunk_id": "abortioncare_840",
    "text": "medications, assessment of outcome) Updated Cochrane Review (on traditional and complementary medicine professionals, auxiliary nurse midwives, auxiliary nurses, midwives, nurses, associate/advanced associate clinicians): Kim C, Barnard S, Park MH, Ngo TD. Doctors or mid-level providers for abortion. Cochrane Database Syst Rev. 2021 (forthcoming) New review by Cochrane Response (on pharmacists, pharmacy workers and community health workers): Villanueva G, Cogo E, Petkovic J, Bergman H, Probyn K, Buckley B, et al. Medical abortion facilitation. 2021 (unpublished) 6 28 Medical abortion at ≥ 12 weeks New systematic review (on traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives, nurses, auxiliary nurses): Feyssa M, Kim C. Systematic review on effectiveness, safety and acceptability of second trimester abortion by midlevel providers. 2021 (u",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 182
  },
  {
    "chunk_id": "abortioncare_841",
    "text": "ians, midwives, nurses, auxiliary nurses): Feyssa M, Kim C. Systematic review on effectiveness, safety and acceptability of second trimester abortion by midlevel providers. 2021 (unpublished) 7 30 Medical management of intrauterine fetal demise (IUFD) New review by Cochrane Response: Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: medical management of intrauterine fetal demise (IUFD). 2020 (unpublished) 8 33 Medical management of incomplete abortion Updated review by Cochrane Response: Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: medical management of incomplete abortion. 2020 (unpublished) 9 37 9 Supplementary material 3, available at: https://www.who.int/publication",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 182
  },
  {
    "chunk_id": "abortioncare_842",
    "text": "n care and post-abortion contraception: medical management of incomplete abortion. 2020 (unpublished) 9 37 9 Supplementary material 3, available at: https://www.who.int/publications/i/item/9789240039483",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 182
  },
  {
    "chunk_id": "abortioncare_843",
    "text": "143 Topic area Title and authors of review (and reference details, if published) Related PICO numbers(s), as listed in annexes Related recommendation number(s) as presented in the main document Diagnosis and management of abortion-related complications Updated review by Cochrane Response (on traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives, nurses, auxiliary nurses/auxiliary nurse midwives): Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: diagnosis and management of abortion related complications. 2021 (unpublished) 11 39 & 40 Delivery of injectable contraceptives Updated review by Cochrane Response (on traditional and complementary medicine professionals medicine, pharmacists, pharmacy workers) Villanueva G, Probyn K, Bergma",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 183
  },
  {
    "chunk_id": "abortioncare_844",
    "text": " contraceptives Updated review by Cochrane Response (on traditional and complementary medicine professionals medicine, pharmacists, pharmacy workers) Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: injectable contraception. 2020 (unpublished) 12 46 Telemedicine for provision of medical abortion care (comprehensive abortion care or individual components) Updated review by Cochrane Response: Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: telemedicine. 2020 (unpublished) 13 48 Community-based outreach models for provision of abortion care New systematic review by Cochrane Response: Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 183
  },
  {
    "chunk_id": "abortioncare_845",
    "text": "each models for provision of abortion care New systematic review by Cochrane Response: Villanueva G, Probyn K, Bergman H, Petkovic J, Cogo E, Buckley B, et al. Health worker roles in providing safe abortion care and post-abortion contraception: Community outreach models. 2021 (unpublished) 14 49 (Best practice statement [BPS]) Harm-reduction counselling for persons seeking induced abortion New systematic review: Stifani B, Gill R, Kim C. Harm-reduction counselling to reduce the harms of unsafe abortion: a systematic review. 2021 (manuscript under review) 15 49 (BPS) Social marketing outreach for pregnant women seeking induced abortion New systematic review: Abubeker F, Tufa T, Kim C. Impact of social marketing interventions on safe abortion services. 2021 (unpublished) 16 49 (BPS) Self-sourcing of medications through online services for pregnant women seeking induced abortion New systema",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 183
  },
  {
    "chunk_id": "abortioncare_846",
    "text": "interventions on safe abortion services. 2021 (unpublished) 16 49 (BPS) Self-sourcing of medications through online services for pregnant women seeking induced abortion New systematic review: Abubeker F, Tufa T, Kim C. Safety, effectiveness, and acceptability of self-sourcing of medications for induced abortion. 2021 (unpublished) 17 49 (BPS) Self-administration of injectable contraceptives in the post-abortion period Updated review by Cochrane Response: Villanueva G, Bergman H, Cogo E, Petkovic J, Buckley B, Probyn K, et al. Health worker roles in providing safe abortion care and post-abortion contraception: self- administration of injectable contraceptives. 2020 (unpublished) 18 51 (Self- management) II. Topics not scoped, but an updated evidence review was conducted Prophylactic antibiotics Existing review: Low N, Mueller M, Van Vliet HAAM, Kapp N. Perioperative antibiotics to prevent",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 183
  },
  {
    "chunk_id": "abortioncare_847",
    "text": "cs not scoped, but an updated evidence review was conducted Prophylactic antibiotics Existing review: Low N, Mueller M, Van Vliet HAAM, Kapp N. Perioperative antibiotics to prevent infection after first-trimester abortion. Cochrane Database Syst Rev. 2012;(3):CD005217. (Updated evidence review conducted in 2021) N/A 9 Pre-abortion ultrasound Existing review: Kulier R, Kapp N. Comprehensive analysis of the use of pre-procedure ultrasound for first-and second-trimester abortion. Contraception, 2011;83(1):30-3. (Updated evidence review conducted by Cochrane Response in April 2021) N/A 10 Surgical methods for first trimester abortion Existing review: Kulier R, Cheng L, Fekih A, Hofmeyr GJ, Campana A. Surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev. 2001;(4):CD002900. (Updated evidence review conducted in April 2021) N/A 23 Medical management of induc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 183
  },
  {
    "chunk_id": "abortioncare_848",
    "text": "ds for first trimester termination of pregnancy. Cochrane Database Syst Rev. 2001;(4):CD002900. (Updated evidence review conducted in April 2021) N/A 23 Medical management of induced abortion Existing review: Abubeker FA, Lavelanet A, Rodriguez MI, Kim C. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. BMC Womens Health. 2020;20(1):142. Updated review: Whitehouse K, Brant A, Sporstol Fonhus M, Lavelanet A, Ganatra B, et al. Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis. Contracept X. 2020;2:100037. N/A 27 29 Annex 7",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 183
  },
  {
    "chunk_id": "abortioncare_849",
    "text": "Abortion care guideline, second edition 144 Topic area Title and authors of review (and reference details, if published) Related PICO numbers(s), as listed in annexes Related recommendation number(s) as presented in the main document Medical management of IUFD Existing review: Cleeve A, Fønhus MS, Lavelanet A. A systematic review of the effectiveness, safety, and acceptability of medical management of intrauterine fetal death at 14–28 weeks of gestation. Int J Gynaecol Obstet. 2019;147(3):301-12. N/A 32 Post-abortion follow-up Existing reviews: Grossman D, Ellertson C, Grimes DA, Walker D. Routine follow-up visits after first- trimester induced abortion. Obstet Gynecol. 2004:103(4):738-45. Grossman D, Grindlay K. Alternatives to ultrasound for follow-up after medication abortion: a systematic review. Contraception. 2011:83(6):504-10. (Updated evidence review conducted by Cochrane Respons",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 184
  },
  {
    "chunk_id": "abortioncare_850",
    "text": "K. Alternatives to ultrasound for follow-up after medication abortion: a systematic review. Contraception. 2011:83(6):504-10. (Updated evidence review conducted by Cochrane Response in April 2021) N/A 34 III. Topics for recommendations that were carried forward or brought into this guideline without further review Methods of surgical abortion at gestational ages ≥ 14 weeks Carried forward: Lohr PA, Hayes JL, Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. Cochrane Database Syst Rev. 2008;(1):CD006714. N/A 25 (Recommendation 5 from WHO, 2012) Medical management of incomplete abortion Carried forward: Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017(1);CD007223. N/A 35 36a & 36b (Recommendations 1a and 1b from WHO, 2018) Post-abortion contraception Brought ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 184
  },
  {
    "chunk_id": "abortioncare_851",
    "text": "reatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017(1);CD007223. N/A 35 36a & 36b (Recommendations 1a and 1b from WHO, 2018) Post-abortion contraception Brought in: Refer to Medical eligibility criteria for contraceptive use (WHO, 2015) N/A 41 (Recommendation from the MEC, WHO, 2015) Timing of contraception and surgical abortion Carried forward: N/A N/A 42 (Recommendation 13 from WHO, 2012) Timing of contraception and medical abortion Carried forward: Kim C, Nguyen AT, Berry-Bibee E, Ermias Y, Gaffield ME, Kapp N. Systemic hormonal contraception initiation after abortion: a systematic review and meta-analysis. Contraception. 2021;103(5):291-304. Ermias Y, Berry-Bibee E, Nguyen AT, Curtis K. Post-abortion IUD insertion: a systematic review. 2017 (unpublished) N/A 43 (Recommendations 4a and 4b from WHO, 2018) 44 (Recommendation from WHO, 2015) Insertion and removal of im",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 184
  },
  {
    "chunk_id": "abortioncare_852",
    "text": "ost-abortion IUD insertion: a systematic review. 2017 (unpublished) N/A 43 (Recommendations 4a and 4b from WHO, 2018) 44 (Recommendation from WHO, 2015) Insertion and removal of implants Tubal ligation Carried forward: Refer to OptimizeMNH guideline (WHO, 2012) N/A 45 47 (Recommendations from WHO, 2015) Over-the-counter oral contraceptive pills Over-the-counter emergency contraceptive pills Condom use Brought in: Refer to Self-care interventions for health and well-being (WHO, 2021) N/A 52 (Self- management) 53 (Self- management) 54 (Self- management)",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 184
  },
  {
    "chunk_id": "abortioncare_853",
    "text": "145 Annex 8. Law and policy domain PICO questions PICO: P = population; I = intervention; C = comparator (where applicable*); O = outcome(s)1 * Where a comparator is available, these data have been included, but very few studies that report on abortion-related policy interventions include a comparator of any kind. Abortion regulation Criminalization PICO 1: The impact of criminalization (see Recommendation 1) PICO question: For pregnant people seeking abortion and also for medical professionals providing abortion services, what is the impact of criminalization on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload), system costs (include",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 185
  },
  {
    "chunk_id": "abortioncare_854",
    "text": "referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload), system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees), perceived impact on provider–client relationship, stigmatization of health-care providers (considering the application of the intervention), criminal justice procedures, harassment, anti-abortion sting operations, availability of trained providers, reporting of suspected unlawful abortion? P: Pregnant people seeking abortion; medical professionals providing abortion services I: Criminalization C: None (studies do not need to specify comparator) O:2 • Delayed abortion • Continuation of pregnancy • Opportunity costs (includes psychological opportunity costs) • Unlawful abortion • Self-managed abortion • Referral",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 185
  },
  {
    "chunk_id": "abortioncare_855",
    "text": "comparator) O:2 • Delayed abortion • Continuation of pregnancy • Opportunity costs (includes psychological opportunity costs) • Unlawful abortion • Self-managed abortion • Referral to another provider • Workload implications (including reassignment issues with organization of work, as well as increases or decreases in workload) • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Perceived impact on provider–client relationship • Stigmatization of health-care providers (considering the application of the intervention) • Criminal justice procedures • Harassment • Anti-abortion sting operations • Availability of trained providers • Reporting of suspected unlawful abortion. 1 For further information on the findings of the reviews based on the PICOs presented in this annex, refer to the EtD frameworks in Supplementary ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 185
  },
  {
    "chunk_id": "abortioncare_856",
    "text": "g of suspected unlawful abortion. 1 For further information on the findings of the reviews based on the PICOs presented in this annex, refer to the EtD frameworks in Supplementary material 1. 2 For each of the PICOs in this annex, the outcomes for both populations (pregnant people seeking abortion and medical professionals providing abortion services) have been combined in one list; for more specific information about the outcomes of interest for each review, refer to the EtD frameworks in Supplementary material 1. Annex 8",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 185
  },
  {
    "chunk_id": "abortioncare_857",
    "text": "Abortion care guideline, second edition 146 Grounds-based approaches PICO 2: The impact of grounds-based approaches (see Recommendation 2) PICO question: For pregnant people seeking abortion and also for medical professionals providing abortion services, what is the impact of grounds-based approaches (that limit access to and/or provision of abortion on “grounds” or that prohibit access to abortion) on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, anticipated or experienced family disharmony, anticipated or experienced exposure to interpersonal violence or exploitation, anticipated or experienced reproductive coercion, disproportionate impact, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 186
  },
  {
    "chunk_id": "abortioncare_858",
    "text": " coercion, disproportionate impact, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload), perceived imposition on personal conscience or ethics, perceived impact on provider–client relationship, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees), stigmatization of health-care providers (considering the application of the intervention)? P: Pregnant people seeking abortion; medical professionals providing abortion services I: Grounds-based approaches (that limit access to and/or provision of abortion on “grounds” or that prohibit access to abortion) C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuation of pregnancy • Opportunity costs (includes psychological opportunity costs) • Un",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 186
  },
  {
    "chunk_id": "abortioncare_859",
    "text": " abortion) C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuation of pregnancy • Opportunity costs (includes psychological opportunity costs) • Unlawful abortion • Self-managed abortion • Anticipated or experienced family disharmony • Anticipated or experienced exposure to interpersonal violence or exploitation • Anticipated or experienced reproductive coercion • Disproportionate impact • Referral to another provider • Workload implications (including reassignment issues with organization of work, as well as increases or decreases in workload) • Perceived imposition on personal conscience or ethics • Perceived impact on provider–client relationship • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Stigmatization of health-care providers (considering the application of the interv",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 186
  },
  {
    "chunk_id": "abortioncare_860",
    "text": "ct system costs, and “diversions” from public health systems to paid-for services/private fees) • Stigmatization of health-care providers (considering the application of the intervention).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 186
  },
  {
    "chunk_id": "abortioncare_861",
    "text": "147 Gestational age limits PICO 3: The impact of gestational age limits (see Recommendation 3) PICO question: For pregnant people seeking abortion and also for medical professionals providing abortion services, what is the impact of gestational age limits on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, disqualification from unlawful abortion, disproportionate impact, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload), system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees), perceived impact on provider–client relationship, stigmatization of health-care providers (considering the application of the intervention)? P",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 187
  },
  {
    "chunk_id": "abortioncare_862",
    "text": "s to paid-for services/private fees), perceived impact on provider–client relationship, stigmatization of health-care providers (considering the application of the intervention)? P: Pregnant people seeking abortion; medical professionals providing abortion services I: Gestational age limits C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuation of pregnancy • Opportunity costs (including psychological opportunity costs) • Unlawful abortion • Self-managed abortion • Disqualification from unlawful abortion • Disproportionate impact • Referral to another provider • Workload implications (including reassignment issues with organization of work, as well as increases or decreases in workload) • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Perceived impact on provider–client relatio",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 187
  },
  {
    "chunk_id": "abortioncare_863",
    "text": "workload) • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Perceived impact on provider–client relationship • Stigmatization of health-care providers (considering the application of the intervention). Pre-abortion Mandatory waiting periods PICO 4: The impact of mandatory waiting periods (see Recommendation 6) PICO question: For pregnant people seeking abortion and also medical professional providing abortion services, what is the impact of mandatory waiting periods on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), disproportionate impact, unlawful abortion, self-managed abortion, disqualification from lawful abortion, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 187
  },
  {
    "chunk_id": "abortioncare_864",
    "text": "tion, disqualification from lawful abortion, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload), system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees), perceived impact on provider–client relationship, stigmatization of health-care providers (considering the application of the intervention)? P: People seeking abortion services; medical professionals providing abortion services I: Mandatory waiting periods C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuation of pregnancy Annex 8",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 187
  },
  {
    "chunk_id": "abortioncare_865",
    "text": "Abortion care guideline, second edition 148 • Opportunity costs (including abortion travel and psychological opportunity costs)) • Disproportionate impact • Unlawful abortion • Self-managed abortion • Disqualification from lawful abortion • Referral to another provider • Workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload) • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Perceived impact on provider–client relationship • Stigmatization of health-care providers (considering the application of the intervention). Third-party authorization for abortion (see Recommendation 7) PICO 5: Impact of judicial bypass PICO question: For pregnant people seeking abortion, what is the impact of judicial bypass on delayed abortion, continuation of pregnan",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 188
  },
  {
    "chunk_id": "abortioncare_866",
    "text": "ndation 7) PICO 5: Impact of judicial bypass PICO question: For pregnant people seeking abortion, what is the impact of judicial bypass on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, anticipated or experienced family disharmony, anticipated or experienced exposure to interpersonal violence or exploitation, anticipated or experienced reproductive coercion, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees)? P: Pregnant people seeking abortion I: Judicial bypass C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuation of pregnancy • Opportunity costs (including abortion travel and psychological opportunity costs) • Unlawful abortion • Self-managed abortion • Anticipated or experience",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 188
  },
  {
    "chunk_id": "abortioncare_867",
    "text": "ontinuation of pregnancy • Opportunity costs (including abortion travel and psychological opportunity costs) • Unlawful abortion • Self-managed abortion • Anticipated or experienced family disharmony • Anticipated or experienced exposure to interpersonal violence or exploitation • Anticipated or experienced reproductive coercion • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees). PICO 6: Impact of judicial bypass versus parental consent PICO question: For pregnant people seeking abortion, what is the impact of judicial bypass versus parental consent on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, anticipated or experienced family disharmony, anticipated or experienced exposure to interpersonal violence or exploi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 188
  },
  {
    "chunk_id": "abortioncare_868",
    "text": " opportunity costs), unlawful abortion, self-managed abortion, anticipated or experienced family disharmony, anticipated or experienced exposure to interpersonal violence or exploitation, anticipated or experienced reproductive coercion, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/ private fees)? [P-I-O same as PICO 5 but with a comparator (C) added: parental consent]",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 188
  },
  {
    "chunk_id": "abortioncare_869",
    "text": "149 PICO 7: Impact of parental consent versus parental notification laws/requirements PICO question: For pregnant people seeking abortion, what is the impact of parental consent versus parental notification laws/requirements on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, anticipated or experienced family disharmony, anticipated or experienced exposure to interpersonal violence or exploitation, anticipated or experienced reproductive coercion, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees)? [P and O same as PICO 5; I = parental consent and C = parental notification laws/requirements] PICO 8: Impact of authorization by parent through consent or notification PICO question: For pregnant people seeking abortion, w",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 189
  },
  {
    "chunk_id": "abortioncare_870",
    "text": "nt and C = parental notification laws/requirements] PICO 8: Impact of authorization by parent through consent or notification PICO question: For pregnant people seeking abortion, what is the impact of authorization by parent through consent or notification on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, anticipated or experienced family disharmony, anticipated or experienced exposure to interpersonal violence or exploitation, anticipated or experienced reproductive coercion, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees)? [P-C-O same as PICO 5 but I = authorization by parent through consent or notification] PICO 9: Impact of authorization by spousal consent PICO question: For pregnant people seeking abortion, ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 189
  },
  {
    "chunk_id": "abortioncare_871",
    "text": " as PICO 5 but I = authorization by parent through consent or notification] PICO 9: Impact of authorization by spousal consent PICO question: For pregnant people seeking abortion, what is the impact of authorization by spousal consent on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, anticipated or experienced family disharmony, anticipated or experienced exposure to interpersonal violence or exploitation, anticipated or experienced reproductive coercion, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/ private fees)? [P-C-O same as PICO 5 but I = authorization by spousal consent] Abortion provider restrictions PICO 10: Impact of provider restrictions (see Recommendation 21) PICO question: For pregnant people seeking abortion ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 189
  },
  {
    "chunk_id": "abortioncare_872",
    "text": "thorization by spousal consent] Abortion provider restrictions PICO 10: Impact of provider restrictions (see Recommendation 21) PICO question: For pregnant people seeking abortion and also for medical professionals providing abortion services, what is the impact of provider restrictions on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), disproportionate impact, unlawful abortion, self-managed abortion, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload), system costs (including direct system costs, and “diversions” from public health systems to paid-for services/private fees), perceived imposition on personal conscience or ethics, perceived impact on provider–client relationship, stigmatization of health-care providers (cons",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 189
  },
  {
    "chunk_id": "abortioncare_873",
    "text": "d-for services/private fees), perceived imposition on personal conscience or ethics, perceived impact on provider–client relationship, stigmatization of health-care providers (considering the application of the intervention)? P: Pregnant people seeking abortion; medical professionals providing abortion services I: Provider restrictions C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuation of pregnancy • Opportunity costs (including abortion travel and stigmatization, and psychological opportunity costs) • Disproportionate impact • Unlawful abortion • Self-managed abortion Annex 8",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 189
  },
  {
    "chunk_id": "abortioncare_874",
    "text": "Abortion care guideline, second edition 150 • Referral to another provider • Workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload) • System costs (including direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Perceived imposition on personal conscience or ethics • Perceived impact on provider–client relationship • Stigmatization of health-care providers (considering the application of the intervention). Conscientious objection PICO 11a: Impact of conscientious objection (see Recommendation 22) PICO question: For pregnant people seeking abortion and also medical professionals providing abortion services, what is the impact of conscientious objection on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 190
  },
  {
    "chunk_id": "abortioncare_875",
    "text": "tion services, what is the impact of conscientious objection on delayed abortion, continuation of pregnancy, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, referral to another provider, workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload), system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees), perceived imposition on personal conscience or ethics, perceived impact on provider–client relationship, stigmatization of health-care providers (considering the application of the intervention)? P: Pregnant people seeking abortion; medical professionals providing abortion services I: Conscientious objection/refusal C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 190
  },
  {
    "chunk_id": "abortioncare_876",
    "text": "abortion; medical professionals providing abortion services I: Conscientious objection/refusal C: None (studies do not need to specify comparator) O: • Delayed abortion • Continuation of pregnancy • Opportunity costs (including abortion travel and stigmatization, and psychological opportunity costs) • Unlawful abortion • Self-managed abortion) • Referral to another provider • Workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload) • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Perceived imposition on personal conscience or ethics • Perceived impact on provider–client relationship • Stigmatization of health-care providers (considering the application of the intervention).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 190
  },
  {
    "chunk_id": "abortioncare_877",
    "text": "151 PICO 11b: Impact of regulation of conscientious objection (see Recommendation 22) PICO question: For pregnant people seeking abortion, medical professionals providing abortion services and State actors, what is the impact of regulation of conscientious objection on delayed abortion, denial/refusal, continuation of pregnancy, disproportionate impact, opportunity costs (including psychological opportunity costs), unlawful abortion, self-managed abortion, referral to another provider, workload implications (including reassign - ment, issues with organization of work, as well as increases or decreases in workload), professional or personal repercussions including legal or disciplinary proceedings and professional opportunities, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees), perceived imposition on personal consc",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 191
  },
  {
    "chunk_id": "abortioncare_878",
    "text": "al opportunities, system costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees), perceived imposition on personal conscience or ethics, regulatory clarify, choice of workplace (institution or jurisdiction), choice of specialism or field of practice, perceived impact on provider–client relationship, management of abortion complications, maternal mortality and morbidity, regulatory burdens, political costs, domestic abortion travel, inward abortion travel, outward abortion travel, relationship between state and healthcare providers, availability of Sexual and Reproductive Health (SRH) services and personnel, and relationship between state and potential/ actual abortion seekers? P: Pregnant people seeking abortion; medical professionals providing abortion services, State actors (governments, officials, lawmakers, courts, governmen",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 191
  },
  {
    "chunk_id": "abortioncare_879",
    "text": " actual abortion seekers? P: Pregnant people seeking abortion; medical professionals providing abortion services, State actors (governments, officials, lawmakers, courts, governments of third countries) I: Regulation of conscientious objection to abortion care [i.e., laws, policies and protocols addressing some or all of how, when, who, and according to what process conscientious objection may be exercised] C: None (studies do not need to specify comparator) O: • Delayed abortion • Denial/Refusal • Continuation of pregnancy • Disproportionate impact • Opportunity costs (including abortion travel and stigmatization, and psychological opportunity costs) • Unlawful abortion • Self-managed abortion • Referral to another provider • Workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload) • Professional or personal repercus",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 191
  },
  {
    "chunk_id": "abortioncare_880",
    "text": "other provider • Workload implications (including reassignment, issues with organization of work, as well as increases or decreases in workload) • Professional or personal repercussions incl. legal or disciplinary proceedings and professional opportunities • System costs (includes direct system costs, and “diversions” from public health systems to paid-for services/private fees) • Perceived imposition on personal conscience or ethics (includes implications of the presence, absence, content, clarity or lack of clarity of laws, policies and regulation relating to conscientious objection) • Regulatory clarity • Choice of workplace (institution or jurisdiction) • Choice of specialism or field of practice • Perceived impact on provider–client relationship • Stigmatization of health-care providers (considering the application of the intervention) • Management of abortion complications • Matern",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 191
  },
  {
    "chunk_id": "abortioncare_881",
    "text": "d impact on provider–client relationship • Stigmatization of health-care providers (considering the application of the intervention) • Management of abortion complications • Maternal mortality and morbidity • Regulatory burdens • Political costs Annex 8",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 191
  },
  {
    "chunk_id": "abortioncare_882",
    "text": "Abortion care guideline, second edition 152 • Domestic abortion travel • Inward abortion travel • Outward abortion travel • Relationship between state and healthcare providers • Availability of Sexual and Reproductive Health (SRH) services and personnel • Relationship between state and potential/actual abortion seekers",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 192
  },
  {
    "chunk_id": "abortioncare_883",
    "text": "153 Annex 9. Clinical services domain PICO questions PICO: P = population; I = intervention; C = comparator; O = outcome(s)1 Pre-abortion Rh isoimmunization PICO 1: No anti-D administration in unsensitized Rh-negative individuals seeking abortion (see Recommendation 8 [NEW]) PICO question: For an unsensitized Rh-negative individual seeking abortion at < 12 weeks of gestation, is no administration of anti-D a safe and effective alternative to routine anti-D administration? P: Unsensitized Rh-negative individuals seeking abortion at < 12 weeks (undergoing either medical or surgical abortion) I: No anti-D administration C: Routine anti-D administration O: • Rate of isoimmunization in subsequent pregnancy • Rate of antibody formation after initial pregnancy. Pain management for surgical abortion PICO 2: Pain control for surgical abortion at < 14 weeks of gestation (see Recommendations 11 and",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 193
  },
  {
    "chunk_id": "abortioncare_884",
    "text": " antibody formation after initial pregnancy. Pain management for surgical abortion PICO 2: Pain control for surgical abortion at < 14 weeks of gestation (see Recommendations 11 and 12 [NEW]) PICO question: For a pregnant person seeking surgical abortion at < 14 weeks of gestation, is pain control with any particular method (I) safer, more effective and/or more satisfactory/acceptable compared with pain control with a different method or no pain control (C)? P: Pregnant persons seeking surgical abortion at less than 14 weeks of gestation. I: i. Paracervical block (PCB) (this includes the different concentrations, type [lidocaine], carbonated vs not, depth of injection) ii. PCB with premedication iii. Intravenous (IV) conscious sedation plus PCB iv. General anaesthesia v. Topical anaesthesia (e.g. lidocaine) vi. Non-pharmacological intervention (music, acupuncture, “verbicaine”, etc.) C: i",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 193
  },
  {
    "chunk_id": "abortioncare_885",
    "text": " (IV) conscious sedation plus PCB iv. General anaesthesia v. Topical anaesthesia (e.g. lidocaine) vi. Non-pharmacological intervention (music, acupuncture, “verbicaine”, etc.) C: i. No PCB ii. PCB alone iii. PCB with premedication iv. IV conscious sedation plus PCB O: • Effectiveness (maximum pain as measured by visual analogue scale; VAS) • Anxiety scores using VAS • Safety (complications related to pain control methods, use of supplemental narcotic, use of any additional analgesic medication, duration of recovery time, hospital admission), side-effects • Satisfaction/acceptability. 1 For further information on the findings of the reviews based on the PICOs presented in this annex, refer to the EtD frameworks in Supplementary material 2. Annex 9",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 193
  },
  {
    "chunk_id": "abortioncare_886",
    "text": "Abortion care guideline, second edition 154 PICO 3: Pain control for surgical abortion at ≥ 14 weeks of gestation (see Recommendations 11, 13 and 14 [NEW]) PICO question: For a pregnant person seeking surgical abortion at ≥ 14 weeks of gestation (including cervical priming prior to the procedure), is pain control with any particular method (I) safer, more effective and/or more satisfactory/acceptable compared with pain control with a different method or no pain control (C)? P: Pregnant persons seeking surgical abortion at 14 weeks of gestation or above I: i. PCB (this includes the different concentrations, type [lidocaine], carbonated vs not, depth of injection) ii. PCB with premedication iii. IV conscious sedation plus PCB iv. General anaesthesia v. Topical anaesthesia (e.g. lidocaine) vi. Non-pharmacological intervention (music, acupuncture, “verbicaine”, etc.) C: i. No PCB ii. PCB alo",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 194
  },
  {
    "chunk_id": "abortioncare_887",
    "text": "tion plus PCB iv. General anaesthesia v. Topical anaesthesia (e.g. lidocaine) vi. Non-pharmacological intervention (music, acupuncture, “verbicaine”, etc.) C: i. No PCB ii. PCB alone iii. PCB with premedication iv. IV conscious sedation plus PCB O: • Effectiveness (maximum pain as measured by VAS) • Anxiety scores using VAS • Safety (complications related to pain-control methods, use of supplemental narcotic, use of any additional analgesic medication, duration of recovery time, hospital admission), side-effects • Satisfaction/acceptability. Pain management for medical abortion PICO 4: Pain control for medical abortion at < 14 weeks of gestation (see Recommendation 15) PICO question: For a pregnant person seeking medical abortion at < 14 weeks of gestation, is pain control with any particular (i) pharmacological method (given prophylactically or after onset of pain) or (ii) non-pharmacol",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 194
  },
  {
    "chunk_id": "abortioncare_888",
    "text": "ng medical abortion at < 14 weeks of gestation, is pain control with any particular (i) pharmacological method (given prophylactically or after onset of pain) or (ii) non-pharmacological method safer, more effective and/or more satisfactory/acceptable compared with any other such method or no treatment/placebo? P: Pregnant persons seeking medical abortion at < 14 weeks of gestation I: i. Pharmacological methods (Timing: prophylactic or after onset of pain) • Ibuprofen • Acetaminophen plus codeine • Anti-emetics • Loperamide • Tramadol ii. Non-pharmacological methods (music, acupuncture, “verbicaine”, etc.)",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 194
  },
  {
    "chunk_id": "abortioncare_889",
    "text": "155 C: i. Pharmacological methods (Timing: prophylactic or after onset of pain) • Ibuprofen • Acetaminophen plus codeine • Anti-emetics • Loperamide • Tramadol ii. Non-pharmacological methods (music, acupuncture, “verbicaine”, etc.) iii. No treatment/placebo O: • Effectiveness (maximum pain as measured by VAS) • Safety (complications related to pain-control methods, use of any supplemental narcotic, use of any additional analgesic medication), side-effects • Effectiveness of medical abortion regimen, defined as successful completion without additional surgical intervention • Time to expulsion • Satisfaction/acceptability. PICO 5: Pain control for medical abortion at ≥ 14 weeks of gestation (see Recommendation 16 [NEW]) PICO question: For a pregnant person seeking medical abortion at ≥ 14 weeks of gestation, is pain control with any particular (i) pharmacological method (given prophylacti",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 195
  },
  {
    "chunk_id": "abortioncare_890",
    "text": "6 [NEW]) PICO question: For a pregnant person seeking medical abortion at ≥ 14 weeks of gestation, is pain control with any particular (i) pharmacological method (given prophylactically or after onset of pain) or (ii) non-pharmacological method safer, more effective and/or more satisfactory/acceptable compared with any other such methods or no treatment/placebo? P: Pregnant persons seeking medical abortion at 14 weeks of gestation or above I: i. Pharmacological methods (Timing: prophylactic or after onset of pain) • Pretreatment (ibuprofen, acetaminophen plus codeine, antiemetics, loperamide, tramadol) • IV opiates • PCB ii. Non-pharmacological methods (music, acupuncture, “verbicaine”, etc.) C: i. Pharmacological methods (Timing: prophylactic or after onset of pain) • Pretreatment (ibuprofen, acetaminophen plus codeine, antiemetics, loperamide, tramadol) • IV opiates • PCB ii. Non-pharm",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 195
  },
  {
    "chunk_id": "abortioncare_891",
    "text": "cal methods (Timing: prophylactic or after onset of pain) • Pretreatment (ibuprofen, acetaminophen plus codeine, antiemetics, loperamide, tramadol) • IV opiates • PCB ii. Non-pharmacological methods (music, acupuncture, “verbicaine”, etc.) iii. No treatment/placebo O: • Effectiveness (maximum pain as measured by VAS) • Safety (complications, use of any supplemental narcotic, use of any additional analgesic medication), side-effects • Effectiveness of medical abortion regimen, defined as successful completion without additional surgical intervention • Time to expulsion • Satisfaction/acceptability. Annex 9",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 195
  },
  {
    "chunk_id": "abortioncare_892",
    "text": "Abortion care guideline, second edition 156 Cervical priming PICO 6a: Cervical priming at < 12 weeks of gestation (see Recommendation 17) PICO question: For a pregnant person seeking surgical abortion at < 12 weeks of gestation, is cervical priming effective, safe and acceptable? P: Pregnant persons seeking surgical abortion < 12 weeks I: Cervical priming with medication or mechanical methods C: Cervical priming with placebo, with medication (using different routes, doses or treatment intervals) or with different mechanical methods O: • Effectiveness • Satisfaction/acceptability • Safety. PICO 6b: Cervical priming at ≥ 12 weeks with medications (comparing different regimens) (see Recommendations 18b–d [NEW]) PICO question: For a pregnant person seeking surgical abortion at ≥ 12 weeks of gestation, is cervical priming with mifepristone plus misoprostol or with mifepristone alone a safe, e",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 196
  },
  {
    "chunk_id": "abortioncare_893",
    "text": "CO question: For a pregnant person seeking surgical abortion at ≥ 12 weeks of gestation, is cervical priming with mifepristone plus misoprostol or with mifepristone alone a safe, effective and satisfactory/acceptable alternative to cervical preparation with misoprostol alone? P: Pregnant persons seeking surgical abortion at ≥ 12 weeks I: Cervical priming with i. Mifepristone plus misoprostol [various routes, doses, intervals] ii. Mifepristone alone [various routes, doses, intervals] C: Cervical priming with misoprostol alone [various routes, doses, intervals] O: • Effectiveness (pre-procedure cervical dilatation, need for further dilatation, ease of procedure, time to complete procedure) • Safety (complications, need for additional interventions, pre- and post-procedure pain), side-effects • Satisfaction (client and provider)/acceptability • Cost (comparative cost and cost to the client)",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 196
  },
  {
    "chunk_id": "abortioncare_894",
    "text": ", need for additional interventions, pre- and post-procedure pain), side-effects • Satisfaction (client and provider)/acceptability • Cost (comparative cost and cost to the client). PICO 7: Cervical priming at ≥ 12 weeks with medications compared with mechanical methods (see Recommendation 18b [NEW]) PICO question: For a pregnant person seeking surgical abortion at ≥ 12 weeks of gestation, is cervical priming with medical methods (mifepristone, misoprostol, or both) a safe, effective and satisfactory/acceptable alternative to mechanical methods (laminaria, Foley bulb, Dilapan)? P: Pregnant persons seeking surgical abortion at ≥ 12 weeks I: Cervical priming with medical methods i. Mifepristone alone ii. Misoprostol plus mifepristone iii. Misoprostol alone C: Cervical priming with mechanical methods (i.e. laminaria, Foley bulb, Dilapan) O: • Effectiveness (pre-procedure cervical dilatation",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 196
  },
  {
    "chunk_id": "abortioncare_895",
    "text": "tol plus mifepristone iii. Misoprostol alone C: Cervical priming with mechanical methods (i.e. laminaria, Foley bulb, Dilapan) O: • Effectiveness (pre-procedure cervical dilatation, need for further dilatation, ease of procedure, time to complete procedure) • Safety (complications, need for additional interventions, pre- and post-procedure pain), side-effects",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 196
  },
  {
    "chunk_id": "abortioncare_896",
    "text": "157 • Satisfaction (client and provider)/acceptability • Cost (comparative cost and cost to the client). PICO 8: Cervical priming at ≥ 12 weeks with medication(s) plus laminaria compared with laminaria alone (see Recommendation 18d [NEW]) PICO question: For a pregnant person seeking surgical abortion at ≥ 12 weeks of gestation, is cervical priming with medication(s) plus laminaria a safe, effective and satisfactory/acceptable alternative to cervical preparation with laminaria alone? P: Pregnant persons seeking surgical abortion at ≥ 12 weeks I: Cervical priming with medication(s) plus laminaria i. Mifepristone plus misoprostol plus laminaria ii. Misoprostol plus laminaria iii. Mifepristone plus laminaria C: Cervical priming with laminaria alone O: • Effectiveness (pre-procedure cervical dilatation, need for further dilatation, ease of procedure, time to complete procedure) • Safety (comp",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 197
  },
  {
    "chunk_id": "abortioncare_897",
    "text": "vical priming with laminaria alone O: • Effectiveness (pre-procedure cervical dilatation, need for further dilatation, ease of procedure, time to complete procedure) • Safety (complications, need for additional interventions, pre- and post-procedure pain), side-effects • Satisfaction (client and provider)/acceptability • Cost (comparative cost and cost to the client). PICO 9: Cervical priming at ≥ 12 weeks by mechanical method(s) before dilatation and evacuation (D&E) (see Recommendation 18 [NEW]) PICO question: For a pregnant person seeking surgical abortion (D&E) at ≥ 12 weeks of gestation, is cervical priming with one mechanical method a safe, effective and satisfactory/acceptable alternative to cervical priming with a different mechanical method? P: Pregnant person seeking surgical abortion at ≥ 12 weeks I: Cervical priming with one mechanical method before D&E C: Cervical priming wi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 197
  },
  {
    "chunk_id": "abortioncare_898",
    "text": "ming with a different mechanical method? P: Pregnant person seeking surgical abortion at ≥ 12 weeks I: Cervical priming with one mechanical method before D&E C: Cervical priming with a different mechanical method before D&E O: • Effectiveness (pre-procedure cervical dilatation, need for further dilatation, ease of procedure, time to complete procedure) • Safety (complications, need for additional interventions, pre- and post-procedure pain), side-effects • Satisfaction (client and provider)/acceptability • Cost (comparative cost and cost to the client). Annex 9",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 197
  },
  {
    "chunk_id": "abortioncare_899",
    "text": "Abortion care guideline, second edition 158 Abortion New medical methods for abortion PICO 10: Medical abortion with letrozole plus misoprostol, compared with misoprostol alone (see Recommendation 27c [NEW]) PICO question: For a pregnant person seeking medical abortion, is medical abortion with letrozole plus misoprostol a safe, effective and satisfactory/acceptable alternative to medical abortion with misoprostol alone? P: Pregnant persons seeking medical abortion (all gestational ages) I: Medical abortion with letrozole plus misoprostol [various routes, doses, intervals] C: Medical abortion with misoprostol alone [various routes, doses, intervals] O: • Effectiveness (ongoing pregnancy rate, procedure completed without surgical intervention) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 198
  },
  {
    "chunk_id": "abortioncare_900",
    "text": "d without surgical intervention) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost (comparative and cost to the client). PICO 11: Medical abortion with letrozole plus misoprostol, compared with mifepristone plus misoprostol PICO question: For a pregnant person seeking medical abortion, is medical abortion with letrozole plus misoprostol a safe, effective and satisfactory alternative to medical abortion with mifepristone plus misoprostol? P: Pregnant persons seeking medical abortion (all gestational ages) I: Medical abortion with letrozole plus misoprostol [various routes, doses, intervals] C: Medical abortion with mifepristone plus misoprostol [various routes, doses, intervals] O: • Effectiveness (ongoing pregnancy rate, completed without surgical intervention) • Safety (serious adverse even",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 198
  },
  {
    "chunk_id": "abortioncare_901",
    "text": "mifepristone plus misoprostol [various routes, doses, intervals] O: • Effectiveness (ongoing pregnancy rate, completed without surgical intervention) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost (comparative and cost to the client). PICO 12: Medical abortion with mifepristone plus letrozole, compared with misoprostol alone PICO question: For a pregnant person seeking medical abortion, is medical abortion with mifepristone plus letrozole a safe, effective and satisfactory alternative to medical abortion with misoprostol alone? P: Pregnant person seeking medical abortion I: Medical abortion with mifepristone plus letrozole [various routes, doses, intervals] C: Medical abortion with misoprostol alone [various routes, doses, intervals] O: • Effectiveness (ongoing pregnancy rate, completed w",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 198
  },
  {
    "chunk_id": "abortioncare_902",
    "text": "s letrozole [various routes, doses, intervals] C: Medical abortion with misoprostol alone [various routes, doses, intervals] O: • Effectiveness (ongoing pregnancy rate, completed without surgical intervention) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost (comparative and cost to the client).",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 198
  },
  {
    "chunk_id": "abortioncare_903",
    "text": "159 Missed abortion at < 14 weeks of gestation PICO 13: Medical management of missed abortion with mifepristone plus misoprostol (see Recommendation 31 [NEW]) PICO question: For a pregnant person with missed abortion at < 14 weeks of gestation, is medical management with mifepristone plus misoprostol a safe, effective and satisfactory/acceptable alternative to medical management with misoprostol alone? P: Pregnant persons with missed abortion < 14 weeks I: Medical management with mifepristone plus misoprostol [various routes, doses, intervals] C: Medical management with misoprostol alone [routes, doses, intervals] O: • Effectiveness (failed expulsion/ongoing retained products, completed without surgical intervention) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost of treatment. PICO 14: Me",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 199
  },
  {
    "chunk_id": "abortioncare_904",
    "text": "ntion) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost of treatment. PICO 14: Medical management of missed abortion with all regimens (see Recommendation 31 [NEW]) PICO question: For a pregnant person with missed abortion at < 14 weeks of gestation, is medical management (all regimens) a safe, effective and satisfactory/acceptable alternative to expectant management? P: Pregnant persons with missed abortion < 14 weeks I: Medical management (all regimens) C: Expectant management O: • Effectiveness (failed expulsion/ongoing retained products, completed without surgical intervention) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost of treatment. PICO 15: Surgical management of missed abortion (s",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 199
  },
  {
    "chunk_id": "abortioncare_905",
    "text": " and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost of treatment. PICO 15: Surgical management of missed abortion (see Recommendation 31 [NEW]) PICO question: For a pregnant person with missed abortion at < 14 weeks of gestation, is surgical management a safe, effective and satisfactory/acceptable alternative to medical or expectant management? P: Pregnant persons with missed abortion < 14 weeks I: Surgical management C: • Medical management • Expectant management O: • Effectiveness (failed expulsion/ongoing retained products, completed without surgical intervention • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Satisfaction/acceptability • Cost of treatment. Annex 9",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 199
  },
  {
    "chunk_id": "abortioncare_906",
    "text": "Abortion care guideline, second edition 160 Self-management approaches Self-management of medical abortion (see Recommendation 49) PICO 16: Self-management of medical abortion PICO question: For a pregnant person seeking medical abortion, is self-management of the process of medical abortion (assessing eligibility, administration of mifepristone and/or misoprostol, self-assessing outcome/success), without direct supervision of a trained health worker, a safe, effective and satisfactory/acceptable alternative to medical abortion managed by a trained health worker? P: Pregnant persons seeking medical abortion at any gestational age I: Pregnant persons self-managing the process of medical abortion (in whole) without direct supervision of a trained health worker C: Medical abortion managed by a trained health worker (all medication abortion regimens) O: • Effectiveness (success of abortion w",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 200
  },
  {
    "chunk_id": "abortioncare_907",
    "text": "ut direct supervision of a trained health worker C: Medical abortion managed by a trained health worker (all medication abortion regimens) O: • Effectiveness (success of abortion without need for surgical intervention following the procedure) • Safety (serious adverse events and complications) • Satisfaction/acceptability • Physical and emotional experience (side-effects, positive and negative emotions, internalized stigma), knowing when to seek medical care (unscheduled visits, phone calls to the clinic, emergency visits) • Cost. PICO 16a: Self-assessment of eligibility for MA PICO question: For a pregnant person seeking medical abortion, is self-assessment of eligibility 1 for medical abortion a safe, effective and satisfactory/acceptable alternative to eligibility assessment by a physician or other trained health worker? P: Pregnant persons seeking medical abortion at any gestational ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 200
  },
  {
    "chunk_id": "abortioncare_908",
    "text": "ve and satisfactory/acceptable alternative to eligibility assessment by a physician or other trained health worker? P: Pregnant persons seeking medical abortion at any gestational age I: Pregnant persons self-managing the first part of the medical abortion process by self-assessing their eligibility for medical abortion without direct supervision of a health worker C: Eligibility assessment performed by a trained health worker O: • Proportion of pregnant persons deemed eligible for medical abortion ☐ Proportion of pregnant persons who were deemed ineligible due to gestational age ☐ Proportion of pregnant persons who were deemed ineligible due to contraindications • Accuracy of these assessments when measured against an independent verifier and/or diagnostic standard • Ongoing pregnancy • Completed without surgical intervention • Safety (serious adverse events and complications) • Satisfa",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 200
  },
  {
    "chunk_id": "abortioncare_909",
    "text": "ainst an independent verifier and/or diagnostic standard • Ongoing pregnancy • Completed without surgical intervention • Safety (serious adverse events and complications) • Satisfaction/acceptability • Cost. 1 Eligibility criteria defined as: < 12 weeks; no contraindications; no signs or symptoms of ectopic pregnancy.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 200
  },
  {
    "chunk_id": "abortioncare_910",
    "text": "161 PICO 16b: Self-administering medications for medical abortion PICO question: For a person seeking medical abortion, is self-administration of medications for medical abortion, when provided with instructions for their use from a reliable source, a safe, effective and satisfactory/acceptable alternative to administration of medications by a trained health worker? P: Pregnant persons seeking medical abortion at any gestational ages I: Pregnant persons self-administering the medications for medical abortion (as part of the medical abortion process) without direct supervision by a health worker (but with instructions from a reliable source of health care) C: Administration of medications for medical abortion by a trained health worker O: • Pregnant persons’ adherence to the recommended medical abortion regimen following instructions • Effectiveness (ongoing pregnancy rate, completed with",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 201
  },
  {
    "chunk_id": "abortioncare_911",
    "text": " a trained health worker O: • Pregnant persons’ adherence to the recommended medical abortion regimen following instructions • Effectiveness (ongoing pregnancy rate, completed without surgical intervention) • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment • Physical and emotional experience (side-effects, positive and negative emotions, internalized stigma), knowing when to seek medical care (unscheduled visits, phone calls to the clinics, emergency visits) • Satisfaction/acceptability • Cost (comparative and cost to the client). PICO 16C: Self-assessment of the outcome of the medical abortion process PICO question: For an individual who has undergone medical abortion, is self-assessment of the outcome/success of medical abortion a safe, effective and satisfactory/acceptable alternative to assessment of the outcome/success by",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 201
  },
  {
    "chunk_id": "abortioncare_912",
    "text": "ne medical abortion, is self-assessment of the outcome/success of medical abortion a safe, effective and satisfactory/acceptable alternative to assessment of the outcome/success by a trained health worker? P: Individuals who have undergone medical abortion I: Pregnant persons self-managing the last part of the medical abortion process by self-assessing the outcome/ success of the abortion without direct supervision by a trained health worker C: Assessment of outcome/success of abortion by a trained health worker O: • Effectiveness (proportion of pregnant persons assessed to have successful abortion, accuracy of these assessments when measured against an independent verifier and/or diagnostic standard) • Ongoing pregnancy rate • Completed without surgical intervention • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment; • Physica",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 201
  },
  {
    "chunk_id": "abortioncare_913",
    "text": " pregnancy rate • Completed without surgical intervention • Safety (serious adverse events and complications), side-effects • Expulsion time from initiation of treatment; • Physical and emotional experience (side-effects, positive and negative emotions, internalized stigma), knowing when to seek medical care (unscheduled visits; phone calls to the clinics, emergency visits) • Satisfaction/acceptability • Cost (comparative and cost to the client). Annex 9",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 201
  },
  {
    "chunk_id": "abortioncare_914",
    "text": "Abortion care guideline, second edition 162 Annex 10. Service delivery domain PICO questions PICO: P = population; I = intervention; C = comparator; O = outcome(s)2 Note: For a description of all the health worker categories mentioned in this annex, please refer to Annex 5. Services applicable across the continuum of care Provision of information PICO 1: Pharmacy workers to provide accurate information (see Recommendation 4) PICO question: For a person seeking information about abortion care (before or after treatment/abortion), is information on the availability of safe providers for abortion care (abortion provision, care for complications of abortion, care for incomplete abortion) provided by a pharmacy worker a safe, effective and satisfactory/ acceptable alternative to no provision of information (usual practice)? P: Person seeking information about abortion care before their treatm",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 202
  },
  {
    "chunk_id": "abortioncare_915",
    "text": "er a safe, effective and satisfactory/ acceptable alternative to no provision of information (usual practice)? P: Person seeking information about abortion care before their treatment, or following an incomplete abortion or complications of abortion (including medical or surgical, at any gestational age) I: Information and linkage to abortion services, in the community or in other locations, by pharmacy workers C: No information (usual practice) O: • Effectiveness (pharmacy workers’ correct knowledge of safe abortion and possible complications, of safe post-abortion care, and of indications for referral) • Privacy and confidentiality in provision of information • Accessibility of the services for the person who requires them • Satisfaction with/acceptability of the information and services provided. Counselling PICO 2: Pre- and post-abortion counselling (see Recommendation 5) PICO questi",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 202
  },
  {
    "chunk_id": "abortioncare_916",
    "text": " requires them • Satisfaction with/acceptability of the information and services provided. Counselling PICO 2: Pre- and post-abortion counselling (see Recommendation 5) PICO question: For a pregnant person having an abortion, is pre- and post-abortion counselling provided by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker a safe, effective and satisfactory/acceptable alternative to counselling provided by in-clinic staff? P: Pregnant persons having an abortion I: Pre- and post-abortion counselling by traditional and complementary medicine professionals, pharmacists, pharmacy workers or community health workers C: Counselling provided by in-clinic staff (i.e. generalist or specialist medical practitioners, nurses or midwives) O: • Effectiveness (health workers’ and clients’ correct knowledge of contraceptive options, of safe an",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 202
  },
  {
    "chunk_id": "abortioncare_917",
    "text": "ff (i.e. generalist or specialist medical practitioners, nurses or midwives) O: • Effectiveness (health workers’ and clients’ correct knowledge of contraceptive options, of safe and appropriate abortion services, and of safe post-abortion care) • Satisfaction with/acceptability of the contraception advice provided, and the counselling and services provided • Availability of contraceptive counselling and services • Accessibility of information and method of choice • Privacy and confidentiality of client respected during provision of counselling and services • Participation in provision of counselling and services • Quality of counselling and services • Informed decision-making after provision of counselling and services • Accountability in the provision of counselling and services 2 For further information on the findings of the reviews based on the PICOs presented in this annex, refer to",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 202
  },
  {
    "chunk_id": "abortioncare_918",
    "text": "services • Accountability in the provision of counselling and services 2 For further information on the findings of the reviews based on the PICOs presented in this annex, refer to the EtD frameworks in Supplementary material 3.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 202
  },
  {
    "chunk_id": "abortioncare_919",
    "text": "163 • Mix in types of contraception offered in the counselling. Pre-abortion Cervical priming prior to surgical abortion PICO 3: Cervical priming using osmotic dilators or medication (see Recommendations 19 and 20) PICO question: For a pregnant person having an induced surgical abortion, is provision of cervical priming using osmotic dilators or medication by a traditional and complementary medicine professional, associate/advanced associate clinician, midwife, nurse or auxiliary nurse/auxiliary nurse midwife a safe, effective and satisfactory/ acceptable alternative to provision of cervical priming by a physician? P: Pregnant persons having an induced abortion with vacuum aspiration or D&E I: Cervical priming with i. osmotic dilators provided by traditional and complementary medicine professionals, associate/advanced associated clinicians, midwives, nurses or auxiliary nurse/auxiliary n",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 203
  },
  {
    "chunk_id": "abortioncare_920",
    "text": "with i. osmotic dilators provided by traditional and complementary medicine professionals, associate/advanced associated clinicians, midwives, nurses or auxiliary nurse/auxiliary nurse midwives ii. medications provided by traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives, nurses, auxiliary nurse/auxiliary nurse midwives, pharmacists or pharmacy workers C: Cervical priming performed by physicians with (i) osmotic dilators or (ii) medications O: • Safety (serious adverse events and complications) • Effectiveness (degree of dilatation and provider’s perception of ease of procedure) • Satisfaction/acceptability. Abortion Surgical abortion at gestational ages < 14 weeks PICO 4: Vacuum aspiration for all indications at gestational ages < 14 weeks (see Recommendation 24) PICO question: For a pregnant person seeking induced abortion or treatm",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 203
  },
  {
    "chunk_id": "abortioncare_921",
    "text": "4 weeks PICO 4: Vacuum aspiration for all indications at gestational ages < 14 weeks (see Recommendation 24) PICO question: For a pregnant person seeking induced abortion or treatment for incomplete abortion or miscarriage (i.e. all indications for vacuum aspiration), is provision of vacuum aspiration by a traditional and complementary medicine professional, auxiliary nurse midwife or auxiliary nurse a safe, effective and satisfactory/ acceptable alternative to provision of vacuum aspiration by a physician? P: Pregnant persons seeking an induced abortion or treatment for incomplete abortion or miscarriage I: Vacuum aspiration provided by traditional and complementary medicine professional, auxiliary nurse midwives or auxiliary nurses C: Vacuum aspiration provided by generalist or specialist medical practitioners (obstetricians/gynaecologists) O: • Safety (serious adverse events and compl",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 203
  },
  {
    "chunk_id": "abortioncare_922",
    "text": "ves or auxiliary nurses C: Vacuum aspiration provided by generalist or specialist medical practitioners (obstetricians/gynaecologists) O: • Safety (serious adverse events and complications) • Effectiveness (success of abortion following the procedure • Satisfaction/acceptability. Surgical abortion at later gestational ages PICO 5: Dilatation and evacuation (D&E) for surgical abortion at ≥ 14 weeks (see Recommendation 26) PICO question: For a pregnant person having a surgical abortion (D&E), is provision by a traditional and complementary medicine professional, associate/advanced associate clinician, midwife a safe, effective or satisfactory/acceptable alternative to provision of care by a doctor? P: Pregnant women seeking surgical abortion at ≥ 14 weeks of gestation I: D&E provided by traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 203
  },
  {
    "chunk_id": "abortioncare_923",
    "text": "men seeking surgical abortion at ≥ 14 weeks of gestation I: D&E provided by traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives Annex 10",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 203
  },
  {
    "chunk_id": "abortioncare_924",
    "text": "Abortion care guideline, second edition 164 C: Surgical abortion provided by generalist and specialist medical practitioners O: • Effectiveness (success of abortion following the procedure) • Safety (serious adverse events and complications) • Satisfaction/acceptability. Medical abortion for gestational ages < 12 weeks and its component tasks (see Recommendation 28) PICO 6: Provision of medical abortion care at < 12 weeks PICO question: For a pregnant person seeking medical abortion at < 12 weeks, is provision of medical abortion (i.e. assessment of eligibility, administering quality assured medications, assessment of outcome/success) by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker, a safe, effective and satisfactory/acceptable alternative to provision of medical abortion by a physician? P: Pregnant persons seeking medical ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 204
  },
  {
    "chunk_id": "abortioncare_925",
    "text": "y worker or community health worker, a safe, effective and satisfactory/acceptable alternative to provision of medical abortion by a physician? P: Pregnant persons seeking medical abortion I: Medical abortion provided by traditional and complementary medicine professionals, pharmacists, pharmacy workers or community health workers C: Medical abortion provided by generalist or specialist medical practitioners (obstetrician/gynaecologists) O: • Safety (serious adverse events and complications) • Effectiveness (success of abortion without need for surgical intervention following the treatment) • Satisfaction/acceptability. PICO 6a: Assessment of eligibility for MA PICO question: For a pregnant person seeking medical abortion, is assessment of eligibility for medical abortion by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker a sa",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 204
  },
  {
    "chunk_id": "abortioncare_926",
    "text": "al abortion, is assessment of eligibility for medical abortion by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker a safe, effective and satisfactory/acceptable alternative to – and as accurate as – assessment by a physician? P: Pregnant persons seeking medical abortion I: Eligibility assessment by traditional and complementary medicine professionals, pharmacists, pharmacy workers or community health workers C: Eligibility assessment by generalist or specialist medical practitioners (obstetrician/gynaecologists) O: • Effectiveness (proportion of pregnant persons deemed eligible for medical abortion by provider type and accuracy of these assessments when measured against an independent verifier and/or diagnostic standard) • Safety (serious adverse events, excluding treatment for incomplete abortion or ongoing pregnancy) • Effect",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 204
  },
  {
    "chunk_id": "abortioncare_927",
    "text": "en measured against an independent verifier and/or diagnostic standard) • Safety (serious adverse events, excluding treatment for incomplete abortion or ongoing pregnancy) • Effectiveness (success of abortion following the procedure) • Satisfaction.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 204
  },
  {
    "chunk_id": "abortioncare_928",
    "text": "165 PICO 6b: Administration of medications for MA PICO question: For a pregnant person seeking medical abortion, is administration of medications for medical abortion (i.e. information provision, dispensing of quality assured medications, referral to a reputable source for medications) with instructions for their use by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker a safe, effective and satisfactory/acceptable alternative to administration by a physician? P: Pregnant persons seeking medical abortion I: Administration of medications (i.e. information provision, dispensing of quality assured medications, referral to a reputable source for medications) with instructions for their use by traditional and complementary medicine professionals, pharmacists, pharmacy workers or community health workers C: Administration of medication",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 205
  },
  {
    "chunk_id": "abortioncare_929",
    "text": ") with instructions for their use by traditional and complementary medicine professionals, pharmacists, pharmacy workers or community health workers C: Administration of medications (i.e. information provision, dispensing of quality assured medications, referral to a reputable source for medications) by generalist or specialist medical practitioners O: • Participants understanding of the protocol, as shown by taking the correct regimen • Safety (serious adverse events, excluding treatment for incomplete abortion or ongoing pregnancy) • Effectiveness (success of abortion following the procedure) • Satisfaction. PICO 6C: Accurate assessment of success of the MA process PICO question: For a pregnant person seeking medical abortion, is assessment of the success of the medical abortion process by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community h",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 205
  },
  {
    "chunk_id": "abortioncare_930",
    "text": " medical abortion, is assessment of the success of the medical abortion process by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker a safe, effective and satisfactory/acceptable alternative to – and as accurate as – assessment by a physician? P: Pregnant persons seeking medical abortion I: Assessment of success of abortion by traditional and complementary medicine professionals, pharmacists, pharmacy workers or community health workers C: Assessment of success of abortion by generalist or specialist medical practitioners O: • Effectiveness of the assessment of the outcome (proportion of pregnant persons assessed for success of abortion by provider type and accuracy of these assessments when measured against an independent verifier and/or diagnostic standard) • Effectiveness (success of abortion following the procedure) • Safety",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 205
  },
  {
    "chunk_id": "abortioncare_931",
    "text": "e and accuracy of these assessments when measured against an independent verifier and/or diagnostic standard) • Effectiveness (success of abortion following the procedure) • Safety (serious adverse events, excluding treatment for incomplete abortion or ongoing pregnancy, ectopic pregnancy) • Satisfaction. Management of induced abortion at gestational ages ≥ 12 weeks PICO 7: Provision of abortion care at ≥ 12 weeks (see Recommendation 30) PICO question: For a pregnant person seeking induced abortion, is medical or surgical abortion by a traditional and complementary medicine professional, associate clinician, midwife, nurse, auxiliary nurse, pharmacist, pharmacy worker or community health worker a safe, effective or satisfactory alternative to provision of abortion care by doctors? P: Pregnant women seeking medical or surgical abortion after 12 weeks of gestation I: Medical abortion or su",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 205
  },
  {
    "chunk_id": "abortioncare_932",
    "text": "e or satisfactory alternative to provision of abortion care by doctors? P: Pregnant women seeking medical or surgical abortion after 12 weeks of gestation I: Medical abortion or surgical abortion provided by traditional and complementary medicine professionals, associate clinicians, midwives, nurses, auxiliary nurses, pharmacists, pharmacy workers or community health workers C: Medical abortion or surgical abortion provided by generalist and specialist medical practitioners Annex 10",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 205
  },
  {
    "chunk_id": "abortioncare_933",
    "text": "Abortion care guideline, second edition 166 O: • Effectiveness (success of abortion without need for further medical or surgical intervention) • Safety (serious adverse events and complications) • Satisfaction. Intrauterine fetal demise (IUFD) PICO 8: Medical management of intrauterine fetal demise (IUFD) (see Recommendation 33 [NEW]) PICO question: For a pregnant person diagnosed with intrauterine fetal demise (IUFD), is medical management of IUFD (with mifepristone and misoprostol, or misoprostol alone) provided by a traditional and complementary medicine professional, associate/advanced associate clinician, midwife, nurse, auxiliary nurse/auxiliary nurse midwife, pharmacist, pharmacy worker or community health worker a safe, effective and satisfactory alternative to medical management by a physician? P: Pregnant persons diagnosed with IUFD I: Medical management with mifepristone and m",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 206
  },
  {
    "chunk_id": "abortioncare_934",
    "text": "th worker a safe, effective and satisfactory alternative to medical management by a physician? P: Pregnant persons diagnosed with IUFD I: Medical management with mifepristone and misoprostol or misoprostol alone provided by traditional and complementary medicine professionals, associate/advanced associate clinicians, midwives, nurses, auxiliary nurses/auxiliary nurse midwives, pharmacists, pharmacy workers or community health workers C: Medical management with mifepristone and misoprostol or misoprostol alone provided by generalist or specialist medical practitioners O: • Safety (serious adverse events and complications) • Effectiveness (success of abortion without need for surgical intervention following the procedure) • Satisfaction/acceptability. Post-abortion Incomplete abortion at gestational ages < 14 weeks PICO 9: Management of incomplete abortion with misoprostol (see Recommendat",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 206
  },
  {
    "chunk_id": "abortioncare_935",
    "text": "rocedure) • Satisfaction/acceptability. Post-abortion Incomplete abortion at gestational ages < 14 weeks PICO 9: Management of incomplete abortion with misoprostol (see Recommendation 37) PICO question: For a pregnant person with incomplete abortion, is management of incomplete abortion with misoprostol provided by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker a safe, effective and satisfactory/acceptable alternative to management with misoprostol provided by a physician? P: Pregnant persons with incomplete abortion I: Medical management with misoprostol provided by traditional and complementary medicine professionals, pharmacists, pharmacy workers or community health workers C: Medical management with misoprostol provided by generalist or specialist medical practitioners O: • Safety (serious adverse events and complications",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 206
  },
  {
    "chunk_id": "abortioncare_936",
    "text": " or community health workers C: Medical management with misoprostol provided by generalist or specialist medical practitioners O: • Safety (serious adverse events and complications) • Effectiveness (success of abortion without need for surgical intervention following the procedure) • Satisfaction/acceptability.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 206
  },
  {
    "chunk_id": "abortioncare_937",
    "text": "167 PICO 10: Vacuum aspiration for management of uncomplicated incomplete abortion (see Recommendation 38) PICO question: For a pregnant person seeking an induced abortion, is provision of vacuum aspiration for induced abortion/incomplete abortion/miscarriage (all indications) by traditional and complementary medicine professionals, auxiliary nurses or auxiliary nurse midwives a safe, effective or satisfactory option to provision of vacuum aspiration by physicians? P: Pregnant persons seeking induced abortion I: Vacuum aspiration provided by traditional and complementary medicine professionals, auxiliary nurses or auxiliary nurse midwives C: Vacuum aspiration provided by generalist or specialist medical practitioners (obstetrician/gynaecologists) O: • Effectiveness (success of abortion following the procedure) • Safety (serious adverse events and complications) • Satisfaction/acceptabili",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 207
  },
  {
    "chunk_id": "abortioncare_938",
    "text": "ioners (obstetrician/gynaecologists) O: • Effectiveness (success of abortion following the procedure) • Safety (serious adverse events and complications) • Satisfaction/acceptability. Recognizing and managing complications (see Recommendations 39 and 40) PICO 11: Diagnosis and management of abortion-related complications PICO question: For a person presenting with complication(s) of an induced abortion and in a stable condition, is diagnosis and management of abortion-related complications by a traditional and complementary medicine professional, pharmacist, pharmacy worker or community health worker a safe, effective and satisfactory/ acceptable alternative to – and as accurate as – diagnosis and management by a physician? P: Women presenting with complication(s) of an induced abortion and in a stable condition I: Diagnosis and management of complications by traditional and complementar",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 207
  },
  {
    "chunk_id": "abortioncare_939",
    "text": " a physician? P: Women presenting with complication(s) of an induced abortion and in a stable condition I: Diagnosis and management of complications by traditional and complementary medicine professional, pharmacists, pharmacy workers or community health workers i. Diagnosis and management of infection by traditional and complementary medicine professionals, pharmacists, pharmacy workers, community health workers ii. Diagnosis and management of haemorrhage by traditional and complementary medicine professionals, pharmacists, pharmacy workers, community health workers C: Diagnosis and management of infection and heavy bleeding by generalist and specialist medical practitioners O: • Effectiveness (accurate determination of a complication followed by an offer of correct treatment or referral depending on professional capacity and clinical setting) • Safety (serious adverse events) • Satisfa",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 207
  },
  {
    "chunk_id": "abortioncare_940",
    "text": "ination of a complication followed by an offer of correct treatment or referral depending on professional capacity and clinical setting) • Safety (serious adverse events) • Satisfaction/acceptability. Post-abortion contraception PICO 12: Post-abortion provision of injectable contraceptives (see Recommendation 46) PICO question: For a person in the post-abortion period needing contraception, is provision of injectable contraceptives (initiation or continuation) by a traditional and complementary medicine professional, pharmacy worker or community health worker, a safe, effective and satisfactory/acceptable alternative to provision by a trained health worker? P: Women in the post-abortion period needing contraception I: Delivery of injectable contraceptives, by traditional and complementary medicine professionals, pharmacy workers or community health workers C: Delivery of injectable contr",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 207
  },
  {
    "chunk_id": "abortioncare_941",
    "text": "tion I: Delivery of injectable contraceptives, by traditional and complementary medicine professionals, pharmacy workers or community health workers C: Delivery of injectable contraceptives by trained health workers O: • Contraceptive uptake and continuation Annex 10",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 207
  },
  {
    "chunk_id": "abortioncare_942",
    "text": "Abortion care guideline, second edition 168 • Safety (serious adverse events and complications related to provision of the method) • Effectiveness (method failure) • Satisfaction/acceptability. Service delivery considerations Non-facility-based/outpatient/home-based care PICO 13: Telemedicine (see Recommendation 48) PICO question: For a pregnant person seeking medical abortion, is medical abortion care provided through telemedicine (comprehensive care or individual components) a safe, effective and satisfactory/acceptable alternative to in-person medical abortion care? P: Pregnant persons seeking medical abortion I: Medical abortion care provided through telemedicine, including comprehensive medical abortion care, or any number of the following individual components: • Eligibility assessment for medical abortion through telemedicine • Counselling and/or instructions for medical abortion ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 208
  },
  {
    "chunk_id": "abortioncare_943",
    "text": "re, or any number of the following individual components: • Eligibility assessment for medical abortion through telemedicine • Counselling and/or instructions for medical abortion through telemedicine • Instructions for and active facilitation of medical abortion through telemedicine • Follow-up of medical abortion through telemedicine C: In-person medical abortion care O: • Effectiveness (rates of ongoing pregnancy, success of abortion without need for surgical intervention following the procedure, and of surgical evacuation post abortion) • Safety (serious adverse events and complications) • Satisfaction/acceptability • Rate of adherence to recommended dose regimen (self-reported) • Reported cost of services. PICO 14: Community-based outreach (see Best Practice Statement 49) PICO question: For a pregnant person seeking induced abortion, are community-based outreach models for provision",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 208
  },
  {
    "chunk_id": "abortioncare_944",
    "text": " PICO 14: Community-based outreach (see Best Practice Statement 49) PICO question: For a pregnant person seeking induced abortion, are community-based outreach models for provision of abortion care safe, effective and satisfactory/acceptable alternatives to provision of abortion care in a health-care facility by a trained health worker? P: Pregnant persons seeking induced abortion I: Outreach involving health workers C: Provision of care in a health-care facility by trained health workers O: • Safety (serious adverse events and complications) • Effectiveness (success of abortion without need for surgical intervention following the procedure) • Cost-effectiveness • Increased health seeking behaviours • Satisfaction/acceptability. Setting: • Weak infrastructure • Legally restrictive.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 208
  },
  {
    "chunk_id": "abortioncare_945",
    "text": "169 PICO 15: Harm-reduction counselling (see Best Practice Statement 49) PICO question: For a pregnant person seeking an induced abortion, is harm-reduction counselling on abortion care a safe, effective and satisfactory/acceptable alternative to routine in-clinic service delivery? P: Pregnant persons seeking an induced abortion I: Harm-reduction counselling C: Routine in-clinic service delivery O: • Safety (serious adverse events and complications) • Effectiveness (success of abortion without need for surgical intervention following the procedure) • Satisfaction/acceptability. Setting: • Humanitarian settings • Non-humanitarian settings. PICO 16: Social marketing outreach/communicating safe abortion (see Best Practice Statement 49) PICO question: For a pregnant person seeking an induced abortion, can social marketing outreach provide improved access to safe, effective and satisfactory/a",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 209
  },
  {
    "chunk_id": "abortioncare_946",
    "text": "Practice Statement 49) PICO question: For a pregnant person seeking an induced abortion, can social marketing outreach provide improved access to safe, effective and satisfactory/acceptable induced abortion services compared with provision of abortion care in a health-care facility by a trained health worker? P: Pregnant persons seeking an induced abortion I: Social marketing methods for induced abortion services C: In-clinic abortion service provision O: • Safety (serious adverse events and complications) • Effectiveness (success of abortion without need for surgical intervention following the procedure) • Access (affordability, utilization, client volume, attendance and coverage per population) • Quality of care (abortion methods of choice, quality of information given to pregnant person, provider competence, pregnant person/provider relationship) • Adverse effects (undesirable impacts",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 209
  },
  {
    "chunk_id": "abortioncare_947",
    "text": "are (abortion methods of choice, quality of information given to pregnant person, provider competence, pregnant person/provider relationship) • Adverse effects (undesirable impacts on existing public or private services, inappropriate use of services) • Equitable access or utilization (distribution of access across sociodemographic characteristics) • Cost/service (from a societal perspective or perspective of marketer/franchiser, franchisee or pregnant person/client) • Satisfaction/acceptability. PICO 17: Self-sourcing medications for induced abortion (see Best Practice Statement 49) PICO question: For a pregnant person seeking induced abortion, is self-sourcing of medications through online sources a safe, effective and satisfactory/acceptable alternative to obtaining a prescription and/or medications from a trained health worker? P: Pregnant persons seeking induced abortion I: Pregnant",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 209
  },
  {
    "chunk_id": "abortioncare_948",
    "text": "ective and satisfactory/acceptable alternative to obtaining a prescription and/or medications from a trained health worker? P: Pregnant persons seeking induced abortion I: Pregnant persons self-sourcing medications for an abortion through an online source without a prescription C: Pregnant persons obtain a prescription and/or medications from a health worker (specialist or generalist medical practitioner, traditional and complementary medicine professional, midwife, nurse, auxiliary nurse, auxiliary nurse midwife, pharmacist, pharmacy workers, community health worker) O: • Safety (serious adverse events and complications) Annex 10",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 209
  },
  {
    "chunk_id": "abortioncare_949",
    "text": "Abortion care guideline, second edition 170 • Effectiveness (success of abortion without need for surgical intervention following the procedure) • Quality of medications • Satisfaction/acceptability. Self-management approaches Self-management approaches for post-abortion contraception PICO 18: Post-abortion self-administration of injectable contraceptives (see Recommendation 50) PICO question: For a person in the post-abortion period needing contraception, is self-administration of injectable contraceptives (initiation or continuation) a safe, effective and satisfactory/acceptable alternative to provision by a trained health worker? P: Women in the post-abortion period needing contraception I: Self-administration of injectable contraceptives (initiation or continuation) C: Delivery of injectable contraceptives by trained health workers O: • Contraceptive uptake and continuation • Safety ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 210
  },
  {
    "chunk_id": "abortioncare_950",
    "text": "on of injectable contraceptives (initiation or continuation) C: Delivery of injectable contraceptives by trained health workers O: • Contraceptive uptake and continuation • Safety (serious adverse events and complications related to provision of the method) • Effectiveness (method failure) • Satisfaction/acceptability.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 210
  },
  {
    "chunk_id": "abortioncare_951",
    "text": "171 Annex 11. Details about guideline dissemination and updating Dissemination The full guideline will be published digitally (both an interactive web-based version and a PDF document available online for download) and in print. The recommendations from this guideline will also feature in the annually updated compendium of recommendations approved by the WHO Guidelines Review Committee (GRC), which will be produced by the WHO Department of Sexual and Reproductive Health and Research (SRH) across all thematic areas. The digital versions of the guideline will be available via the WHO website. 1 The links to the digital versions will be disseminated through nongovernmental organization (NGO) partners, the websites of professional associations, and social media platforms. Supplementary materials including the corresponding GRADE Evidence- to-Decision (EtD) frameworks for each of the recommen",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 211
  },
  {
    "chunk_id": "abortioncare_952",
    "text": " of professional associations, and social media platforms. Supplementary materials including the corresponding GRADE Evidence- to-Decision (EtD) frameworks for each of the recommendations are also available online. 2 Print versions of the guideline will be distributed to WHO regional and country offices, NGO partners and professional associations. Translation of the guideline into Spanish (in collaboration with the Pan American Health Organization [PAHO]), French and Portuguese is planned. Translations into other United Nations languages will be developed as needed. Third-party translations into additional languages will be encouraged, provided they comply with WHO guidance on such translations. The guideline will be launched through dissemination meetings in each WHO region, and specific knowledge transfer and adaptation activities and implementation research will take place in select c",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 211
  },
  {
    "chunk_id": "abortioncare_953",
    "text": "ill be launched through dissemination meetings in each WHO region, and specific knowledge transfer and adaptation activities and implementation research will take place in select countries based on need and expressed interest to move ahead with implementation of the recommendations. Additional products will support the launch of the guideline to allow for regional colleagues to disseminate the key information widely. Such products include: • a PowerPoint presentation that summarizes the key messages and new elements to the guideline; • a PowerPoint presentation on the evidence behind selected recommendations; • social media tiles. WHO regional offices and a number of interested agencies and NGO partners are expected to be active partners in the regional, national and local dissemination and adaptation of this guideline and in developing derivative informational materials. Updating This g",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 211
  },
  {
    "chunk_id": "abortioncare_954",
    "text": "ected to be active partners in the regional, national and local dissemination and adaptation of this guideline and in developing derivative informational materials. Updating This guideline will be presented online in an interactive web-based format soon after publication of the standard format version, which will be available for download. The web-based format will allow the guideline to be a “living guideline”, facilitating review of new research evidence to ensure that it can be brought to the GDG for review and then updated as appropriate in the guideline on an ongoing basis. This consolidated guideline currently combines and updates recommendations from three former WHO guidelines on abortion care, 3 and future updates will also cover new related topics, as needed. The rapidly evolving nature of the interventions and approaches for quality abortion care, especially those for self-man",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 211
  },
  {
    "chunk_id": "abortioncare_955",
    "text": "ture updates will also cover new related topics, as needed. The rapidly evolving nature of the interventions and approaches for quality abortion care, especially those for self-management of abortion, calls for a continuous review of the literature. The WHO Guideline Steering Group (see Annex 1) is in the process of developing a database system that will allow for continuous search and review of the evidence. This in turn will help with future updates of the recommendations and will inform any areas that may potentially require a new recommendation. There are many areas for which no evidence was found or which are only supported by low-certainty evidence (see Chapter 4, section 4.3), and in these cases new recommendations or a change in the published recommendation, respectively, may be warranted. Any concern about the validity of an existing recommendation can be communicated promptly t",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 211
  },
  {
    "chunk_id": "abortioncare_956",
    "text": "mmendations or a change in the published recommendation, respectively, may be warranted. Any concern about the validity of an existing recommendation can be communicated promptly to the Prevention of Unsafe Abortion (PUA) Unit at WHO’s Department of Sexual and Reproductive Health and Research (email: srhpua@who.int), after which the PUA 1 Available at: https://www.who.int/publications/i/item/9789240039483 2 Available at: https://www.who.int/publications/i/item/9789240039483 3 Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012 (https://iris.who.int/handle/10665/70914 ). Health worker roles in providing safe abortion care and post-abortion contraception. Geneva: World Health Organization; 2015 (https://iris.who.int/handle/10665/181041 ). Medical management of abortion. Geneva: World Health Organization; 2018 (https://iri",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 211
  },
  {
    "chunk_id": "abortioncare_957",
    "text": "raception. Geneva: World Health Organization; 2015 (https://iris.who.int/handle/10665/181041 ). Medical management of abortion. Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/278968 ). Annex 11",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 211
  },
  {
    "chunk_id": "abortioncare_958",
    "text": "Abortion care guideline, second edition 172 Unit will seek approval from the WHO GRC to undergo the process for a “rapid guidance”, and plans will be made to update the recommendation as needed. All technical products developed during the process of developing this guideline – including full reports of systematic reviews, corresponding search strategies and dates of searches – will be archived for future reference and use. Where there are concerns about the validity of a recommendation based on new evidence, the systematic review addressing the primary question will be updated. To update the review, the search strategy used for the initial review will be re-applied. Any new questions identified following the original scoping exercise for the guideline will undergo a similar process of evidence retrieval, synthesis and application of the GRADE approach in accordance with the standards in ",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 212
  },
  {
    "chunk_id": "abortioncare_959",
    "text": "iginal scoping exercise for the guideline will undergo a similar process of evidence retrieval, synthesis and application of the GRADE approach in accordance with the standards in the WHO handbook for guideline development .4 For further information on the “living guidelines” process, refer to recent publications by Vergara-Merino et al. (2020)5 and Vogel et al. (2019).6 4 WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014 ( https://apps.who.int/iris/ handle/10665/145714 ). 5 Vergara-Merino L, Verdejo C, Carrasco C, Vargas-Peirano M. Living systematic review: new inputs and challenges. Medwave. 2020;20(11):e8092. 6 Vogel J, Dowswell T, Lewin S, Bonet M, Hampson L, Kellie F, et al. Developing and applying a “living guidelines” approach to WHO recommend ations on maternal and perinatal health. BMJ Glob Health. 2019;4(4):e001683.",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 212
  },
  {
    "chunk_id": "abortioncare_960",
    "text": "173 Annex 11",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 213
  },
  {
    "chunk_id": "abortioncare_961",
    "text": "For more information, please contact: Department of Sexual and Reproductive Health and Research World Health Organization 20, avenue Appia 1211 Geneva 27 Switzerland Email: srhhrp@who.int Website: www.who.int/teams/sexual-and-reproductive-health-and-research",
    "source": "WHO Abortioncare Guideline",
    "topic": "abortioncare",
    "page": 214
  },
  {
    "chunk_id": "advancedhiv_962",
    "text": "WHO guidelines on the management of advanced HIV disease",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 1
  },
  {
    "chunk_id": "advancedhiv_963",
    "text": "WHO guidelines on the management of advanced HIV disease",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 2
  },
  {
    "chunk_id": "advancedhiv_964",
    "text": "WHO guidelines on the management of advanced HIV disease ISBN 978-92-4-011816-4 (electronic version) ISBN 978-92-4-011817-1 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaim",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 3
  },
  {
    "chunk_id": "advancedhiv_965",
    "text": "apt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. WHO guidelines on the management of advanced HIV disease. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/. Sales, righ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 3
  },
  {
    "chunk_id": "advancedhiv_966",
    "text": " disease. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/. Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-orders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder . The risk of claims resulting from infringement of any third-party- owned component in the work rests solely with the user . General disclaimers. The designations employed and the presentation of the material in this publication do not i",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 3
  },
  {
    "chunk_id": "advancedhiv_967",
    "text": "ird-party- owned component in the work rests solely with the user . General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 3
  },
  {
    "chunk_id": "advancedhiv_968",
    "text": "and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However , the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader . In no event shall WHO be liable for damages arising from its use. Design and layout: blossom.it",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 3
  },
  {
    "chunk_id": "advancedhiv_969",
    "text": "iii Contents Acknowledgements .............................................................................................................................................iv Abbreviations .......................................................................................................................................................vi Definitions of key terms ....................................................................................................................................vii Executive summary ...........................................................................................................................................viii Summary of recommendations .......................................................................................................................viii Definition of advanced HIV disease .................................................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_970",
    "text": "...........................................................................................viii Definition of advanced HIV disease ..................................................................................................................xii Objectives ..............................................................................................................................................................1 Target audience ....................................................................................................................................................2 Guiding principles .................................................................................................................................................2 Burden of advanced HIV disease .....................................................................................................................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_971",
    "text": "..............................2 Burden of advanced HIV disease ........................................................................................................................3 Providing a package of care for advanced HIV disease .................................................. 5 CD4 testing and WHO clinical staging (new, 2025) ......................................................................................6 .....Rationale for the recommendations.................................................................................................................. 7 .....Implementation considerations .........................................................................................................................8 Providing a package of care for advanced HIV disease (2017) ................................................................11 .....Rationale for the recommend",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_972",
    "text": "...................8 Providing a package of care for advanced HIV disease (2017) ................................................................11 .....Rationale for the recommendation .................................................................................................................11 .....Implementation considerations .......................................................................................................................12 .....Research gaps ....................................................................................................................................................13 .....Components of the package of care for advanced HIV disease ..................................................................14 Clinical management of advanced HIV disease .............................................................17 Background ...................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_973",
    "text": ".......................................14 Clinical management of advanced HIV disease .............................................................17 Background ....................................................................................................................................................18 Management of advanced HIV disease in outpatient settings ...............................................................18 Management of advanced HIV disease in hospital settings ....................................................................19 Planning for discharge and follow-up care (new, 2025) ............................................................................22 Managing opportunistic infections ................................................................................. 25 Background ..........................................................................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_974",
    "text": "nfections ................................................................................. 25 Background ....................................................................................................................................................26 Cryptococcal disease (2018, 2022) ...............................................................................................................27 .....Prevention and screening for cryptococcal disease ......................................................................................27 .....Diagnosing cryptococcal disease .....................................................................................................................29 .....Recommendations on induction, consolidation and maintenance antifungal treatment regimens .........30 Histoplasmosis (2021) .................................................................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_975",
    "text": "ations on induction, consolidation and maintenance antifungal treatment regimens .........30 Histoplasmosis (2021) ...................................................................................................................................36 .....Diagnosis of disseminated histoplasmosis among people living with HIV ................................................37 .....Management of disseminated histoplasmosis ..............................................................................................37 .....Implementation considerations .......................................................................................................................38 .....Research needs ..................................................................................................................................................38 TB in advanced HIV disease (2025) .....................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_976",
    "text": "..........................................................................................................................38 TB in advanced HIV disease (2025) ..............................................................................................................39 .....Screening ............................................................................................................................................................39 .....Diagnosis .............................................................................................................................................................40 .....Prevention ...........................................................................................................................................................42 .....Treatment ..........................................................................................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_977",
    "text": "........................................................................42 .....Treatment ............................................................................................................................................................44 Severe bacterial infections ...........................................................................................................................45 Kaposi’s sarcoma (new, 2025) .......................................................................................................................46 .....Rationale for the recommendations................................................................................................................48 .....Treatment of Kaposi’s sarcoma for children and during pregnancy ...........................................................50 .....Implementation considerations ...........................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_978",
    "text": "t of Kaposi’s sarcoma for children and during pregnancy ...........................................................50 .....Implementation considerations .......................................................................................................................51 .....Research gaps ....................................................................................................................................................51",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 4
  },
  {
    "chunk_id": "advancedhiv_979",
    "text": "iv Other coinfections and comorbidities ............................................................................ 53 Pneumocystis Jirovecii................................................................................................................................................54 Talaromycosis ...........................................................................................................................................................55 MPOX .........................................................................................................................................................................55 Nontuberculous mycobacterial infections ............................................................................................................56 Palliative care ...............................................................................................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 5
  },
  {
    "chunk_id": "advancedhiv_980",
    "text": "..................................................................56 Palliative care ......................................................................................................................................................57 Monitoring advanced HIV disease ....................................................................................................................57 Importance of monitoring advanced HIV disease in programmes ...................................................................57 Key principles for monitoring advanced HIV disease..........................................................................................58 Minimum dataset for advanced HIV disease monitoring ...................................................................................58 Drug–drug interactions .............................................................................",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 5
  },
  {
    "chunk_id": "advancedhiv_981",
    "text": ".............................................................................58 Drug–drug interactions ...........................................................................................................................................60 References ...........................................................................................................................................................64 Acknowledgements WHO gratefully acknowledges the contributions of many individuals and organizations to update these guidelines. This update consolidates relevant WHO guidance published between 2021 and 2025. Those who contributed to the development of the guidelines published during this time frame are acknowledged in the respective source publications. Those acknowledged here contributed to developing the new recommendations on CD4 testing, support interventions for hospital disc",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 5
  },
  {
    "chunk_id": "advancedhiv_982",
    "text": "cknowledged in the respective source publications. Those acknowledged here contributed to developing the new recommendations on CD4 testing, support interventions for hospital discharge and Kaposi sarcoma treatment. Guideline Development Group Chair: Graeme Meintjes (University of Cape Town, South Africa) Methodologist: Roger Chou (Oregon Health & Science University, United States of America) Nadia Sam Agudu (Institute of Human Virology, Nigeria), Ana Alastruey-Izquierdo (Instituto de Salud Carlos III, Spain), Eduardo Arathoon (Asociación de Salud Integral, Guatemala), Maria Ruano Campos (International Training and Education Center for Health, Malawi), Ehui Eboi (University of Abidjan, Côte d’Ivoire), Nelesh Govender (University of Witwatersrand, South Africa), Tom Heller (LightHouse Trust, Malawi), Syed Faisal Mahmood (Aga Khan University Hospital, Pakistan), David Meya (Makerere Univer",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 5
  },
  {
    "chunk_id": "advancedhiv_983",
    "text": "vender (University of Witwatersrand, South Africa), Tom Heller (LightHouse Trust, Malawi), Syed Faisal Mahmood (Aga Khan University Hospital, Pakistan), David Meya (Makerere University, Uganda), Zainab Mohamed (University of Cape Town, South Africa), Lloyd Mulenga (Ministry of Health, Zambia), Andrew Phillips (University College London, United Kingdom), Mark Polizzotto (Australian National University College of Health and Medicine, Australia), Radha Rajasingham (University of Minnesota Medical School, United States of America), Agnes Ronan (Paediatric Adolescent Treatment for Africa, South Africa), Anuradha Subramanian (Maulana Azad Medical College, India), Katayoun Tayeri (Ministry of Health, Islamic Republic of Iran), Stephen Watiti (Worldwide Hospice Care Alliance, Uganda) and Mihoko Yotsumoto (Tokyo Medical University Hospital, Japan). External peer review Alexandra Calmy (Hôpitaux U",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 5
  },
  {
    "chunk_id": "advancedhiv_984",
    "text": "of Iran), Stephen Watiti (Worldwide Hospice Care Alliance, Uganda) and Mihoko Yotsumoto (Tokyo Medical University Hospital, Japan). External peer review Alexandra Calmy (Hôpitaux Universitaires de Genève, Switzerland), Ahmed Cordie (Cairo University Hospital, Egypt), Nikkiah Forbes (National HIV/AIDS and Infectious Disease Programme at the Bahamas Ministry of Health, Bahamas), Yasmin Hardy (Komfo Anokye Teaching Hospital, Ghana), Thuy Le (Duke University, United States of America & Tropical Medicine Research Center for Talaromycosis, Viet Nam), Jeremy Nel (Wits Infectious Diseases Research Institute, South Africa), Alesandro Pasqualatto (Federal University of Health Sciences of Porto Alegre, Brazil), Sam Phiri (Partners in Health, Malawi), Bhawna Rao",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 5
  },
  {
    "chunk_id": "advancedhiv_985",
    "text": "v (National AIDS Control Organization, India), Suilanji Sivile (Ministry of Health, Zambia), Annete Sohn (Therapeutics Research, Education, and AIDS Training in Asia and amfAR, Thailand) and Omar Syarif (community consultant, Netherlands (Kingdom of the)). External contributors Florence Anam (Global Network of People Living with HIV (GNP+), Netherlands (Kingdom of the)), Rachael Burke (London School of Hygiene and Tropical Medicine, United Kingdom), Helen Byakwaga (Infectious Diseases Institute, Uganda), Esther Casas (Southern Africa Medical Unit, Médecins Sans Frontières, South Africa), Renee De Waal (International Epidemiology Databases to Evaluate AIDS/ Centre for Integrated Data and Epidemiological Research, University of Cape Town, South Africa), Sara Gibbons (University of Liverpool, United Kingdom), Joe Jarvis (London School of Hygiene and Tropical Medicine, United Kingdom), Alena",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 6
  },
  {
    "chunk_id": "advancedhiv_986",
    "text": ", University of Cape Town, South Africa), Sara Gibbons (University of Liverpool, United Kingdom), Joe Jarvis (London School of Hygiene and Tropical Medicine, United Kingdom), Alena Kamenshchikova (Maastricht University, Netherlands (Kingdom of the)), Saye Khoo (University of Liverpool, United Kingdom), Peter MacPherson (University of Glasgow, United Kingdom), Catia Marzolini (University of Liverpool, United Kingdom) Nhung Nghiem (John Curtin School of Medical Research, Australian National University, Australia), Gem Patten (International Epidemiology Databases to Evaluate AIDS (IeDEA) / Centre for Integrated Data and Epidemiological and Research, University of Cape Town, South Africa), Daniel Townsend (GNP+, Netherlands (Kingdom of the)), Lara Vojnov (independent consultant, global public health, United States of America), Lauren Walker (University of Liverpool, United Kingdom) and Matth",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 6
  },
  {
    "chunk_id": "advancedhiv_987",
    "text": "therlands (Kingdom of the)), Lara Vojnov (independent consultant, global public health, United States of America), Lauren Walker (University of Liverpool, United Kingdom) and Matthew Wiens (British Columbia Children’s Hospital Research Institute, Canada). Observers Ikechukwu Amamilo (Clinton Health Access Initiative, Nigeria), Jessica Burry (Unitaid, Switzerland), Carmen Perez Casas (Unitaid, Switzerland), James Conroy (Clinton Health Access Initiative, United States of America), Anisa Ghadrshenas (Unitaid, Switzerland), David Lawrence (London School of Hygiene and Tropical Medicine, United Kingdom), Remilekun Peregrino (Aurum Institute, South Africa), Daniel Shodell (Gates Foundation, United States of America) and Amir Shroufi (Global Fund to Fight AIDS, Tuberculosis, and Malaria, Switzerland). WHO staff and consultants Overall coordination Ajay Rangaraj (Department of HIV, TB, Hepatiti",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 6
  },
  {
    "chunk_id": "advancedhiv_988",
    "text": " and Amir Shroufi (Global Fund to Fight AIDS, Tuberculosis, and Malaria, Switzerland). WHO staff and consultants Overall coordination Ajay Rangaraj (Department of HIV, TB, Hepatitis and Sexually Transmitted infections) coordinated the overall consolidation process with Nathan Ford (Department of HIV, TB, Hepatitis and Sexually Transmitted infections) and Cadi Irvine (Department of HIV, TB, Hepatitis and Sexually Transmitted infections) under the leadership of Tereza Kasaeva (Director , Department of HIV, TB, Hepatitis and Sexually Transmitted infections) and Meg Doherty (Director , Science for Health, Science Division). Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes Doroux Aristide Charles Billy, Georges Perrin, Yasmin Dunkley, Pascal Jolivet, Clarice Pinto, Mukta Sharma, Nandita Sugandhi, Marco Vitoria and Elena Vovc. Jasmin Leuterio provided administ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 6
  },
  {
    "chunk_id": "advancedhiv_989",
    "text": "istide Charles Billy, Georges Perrin, Yasmin Dunkley, Pascal Jolivet, Clarice Pinto, Mukta Sharma, Nandita Sugandhi, Marco Vitoria and Elena Vovc. Jasmin Leuterio provided administrative support. Adriana De Putter and Jerome Peron managed the budget and supported commissioning processes. Yann Siegenthaler provided website support. The following consultants also contributed to developing the guidelines: David Breuer edited the text and Blossom.it did the design and layout. WHO regional staff and other WHO headquarters department staff contributing to these guidelines Po-lin Chan (Regional Office for South-East Asia), Viatcheslav Grankov (Regional Office for Europe), Akudo Ezinne Ikpeazu (Regional Office for Africa), Kiyohiko Izumi (Regional Office for the Western Pacific), Muhammad Shahid Jamil (Regional Office for the Eastern Mediterranean), Georges Perrin (Regional Office for Africa) an",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 6
  },
  {
    "chunk_id": "advancedhiv_990",
    "text": "ca), Kiyohiko Izumi (Regional Office for the Western Pacific), Muhammad Shahid Jamil (Regional Office for the Eastern Mediterranean), Georges Perrin (Regional Office for Africa) and Vitaly Smelov (Regional Office for Europe) and Omar Sued (Regional Office for the Americas). Annabel Baddeley , Dennis Falzon , Patricia Hall-Eidson , Alexei Korobitsyn , Fuad Mirzayev and Sabine Verkuijl (Global Programme on Tuberculosis and Lung Health) and Andreas Reis (Health Ethics & Governance Unit, Research for Health Department). Funding WHO used funding provided by the Gates Foundation and Unitaid to develop these guidelines. Funders had no role in the Guideline Development Group’s formulation of the recommendations or writing of the WHO publication.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 6
  },
  {
    "chunk_id": "advancedhiv_991",
    "text": "vi Abbreviations 3HP or 1HP three months or one month of rifapentine and isoniazid 6H or 9H six months or nine months of isoniazid ART antiretroviral therapy BCG bacille Calmette-Guérin CD4 cluster of differentiation subtype 4 (type of white blood cell) CI confidence interval CSF cerebrospinal fluid GRADE Grading of Recommendations Assessment, Development and Evaluation HRZE/2HR or 4HR H – isoniazid R – rifampicin Z – pyrazinamide E – ethambutol 2HR/4HR – 2 or 4 months of isoniazid and rifampicin LF-LAM lateral flow assay – lipoarabinomannan NAAT nucleic acid amplification test RR relative risk TB tuberculosis UNAIDS Joint United Nations Programme on HIV/AIDS",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 7
  },
  {
    "chunk_id": "advancedhiv_992",
    "text": "vii Definitions of key terms Advanced HIV disease For adults, adolescents and children five years and older , advanced HIV disease is defined as a CD4 cell count ≤200 cells/mm3.a At presentation, all children living with HIV younger than five years should be considered as having advanced HIV disease unless they have received ART for more than a year and are clinically stable. Age groups The following definitions for adults, adolescents, children and infants are used in these guidelines for the purpose of implementing recommendations for specific age groups. Countries may have other definitions under national laws: • An adult is a person older than 19 years of age. • An adolescent is a person 10–19 years of age inclusive. • A child is a person one year to younger than 10 years of age. • An infant is a child younger than one year of age. Antiretroviral therapy Antiretroviral therapy (ART) ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 8
  },
  {
    "chunk_id": "advancedhiv_993",
    "text": "inclusive. • A child is a person one year to younger than 10 years of age. • An infant is a child younger than one year of age. Antiretroviral therapy Antiretroviral therapy (ART) refers to using a combination of antiretroviral drugs for treating HIV infection Antiretroviral Antiretroviral drugs refer to the medicines used to treat HIV People-centred care People-centred care is focused and organized around the health needs and expectations of people and communities rather than diseases Point-of-care testing Point-of-care testing is conducted at the site at which clinical care is being provided, with the results being returned to the person being tested or caregiver on the same day as sample collection and test to enable clinical decisions to be made in a timely manner Rapid ART initiation Rapid ART initiation is initiation within seven days of HIV diagnosis, with a preference for startin",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 8
  },
  {
    "chunk_id": "advancedhiv_994",
    "text": "to enable clinical decisions to be made in a timely manner Rapid ART initiation Rapid ART initiation is initiation within seven days of HIV diagnosis, with a preference for starting on the same day as diagnosis Task sharing Task sharing is the rational redistribution of tasks between cadres of health-care workers with longer training and other cadres with shorter training, such as lay providers Treatment failure Lack of clinical or viral response among people who received suboptimal treatment or who received optimal treatment but failed to respond clinically. (refers to both viral and clinical failure)b Viral suppression Viral suppression is a viral load that is undetectable (less than 50 copies/mL) Viral failure Viral failure is defined by a persistently detectable viral load exceeding 1000 copies/ml after at least six months of using ART. a Where CD4 testing is unavailable, advanced HI",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 8
  },
  {
    "chunk_id": "advancedhiv_995",
    "text": "re Viral failure is defined by a persistently detectable viral load exceeding 1000 copies/ml after at least six months of using ART. a Where CD4 testing is unavailable, advanced HIV disease can be defined as a WHO clinical stage 3 or 4 event at presentation for care. AHD is often used interchangeably with the term “AIDS”. b See Table 19 for the WHO definition of clinical, immune and viral failure.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 8
  },
  {
    "chunk_id": "advancedhiv_996",
    "text": "viii Executive summary Advanced HIV disease is the major cause of AIDS-related deaths among people living with HIV. In 2017, WHO recommended a package of care that should be provided to everyone with advanced HIV disease to help to reduce mortality and morbidity, along with rapid initiation of antiretroviral therapy (ART). Subsequently, WHO developed recommendations for the management of cryptococcal disease and histoplasmosis, both important fungal infections in advanced HIV disease, as well as key diagnostic approaches to identify tuberculosis (TB) in advanced HIV disease. These guidelines were integrated into a chapter in the 2021 WHO consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Encouraging HIV programmes to link these clinical recommendations with WHO recommendations for service delivery ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 9
  },
  {
    "chunk_id": "advancedhiv_997",
    "text": "ivery and monitoring: recommendations for a public health approach. Encouraging HIV programmes to link these clinical recommendations with WHO recommendations for service delivery is critical, especially for ensuring sustained engagement as well as reengagement in services to both identify and prevent advanced HIV disease. These 2025 guidelines respond to the need for better approaches to identify advanced HIV disease, improve the poor outcomes of people living with HIV being discharged from hospital and provide updated guidance for treatment for Kaposi’s sarcoma through evidence-informed recommendations. The publication contains recommendations that are from previously published WHO guidelines documents and introduces new recommendations developed in 2025. Summary of recommendations Year of publication Recommendations Providing a package of care for advanced HIV disease 2017 A package o",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 9
  },
  {
    "chunk_id": "advancedhiv_998",
    "text": "troduces new recommendations developed in 2025. Summary of recommendations Year of publication Recommendations Providing a package of care for advanced HIV disease 2017 A package of interventions including screening, treatment and/or prophylaxis for major opportunistic infections, rapid ART initiation and intensified adherence support interventions should be offered to everyone presenting with advanced HIV disease. (Strong recommendation, moderate-certainty evidence) CD4 testing for identifying advanced HIV disease New, 2025 CD4 testing is recommended as the preferred method to identify advanced HIV disease among people living with HIV. (Strong recommendation, moderate-certainty evidence) In settings in which CD4 testing is not yet available, WHO clinical staging can be used to identify advanced HIV disease. (Conditional recommendation, very-low-certainty evidence)",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 9
  },
  {
    "chunk_id": "advancedhiv_999",
    "text": "ix Year of publication Recommendations Interventions to provide at hospital discharge New, 2025 Hospitalized people with HIV may be provided interventions to support transitions to outpatient care and reduce avoidable readmissions. (Conditional recommendation, low-certainty evidence) Interventions may include: • pre-discharge goal setting • medication review • transitional care planning • telephone follow-up • home visits by health-care providers and/or peer supporters • individualized support. Clinical management of cryptococcal meningitis Diagnosis of cryptococcal meningitis 2018 For adults, adolescents and children living with HIV suspected of having a first episode of cryptococcal meningitis, prompt lumbar puncture with measurement of cerebrospinal fluid (CSF) opening pressure and rapid cryptococcal antigen assay is recommended as the preferred diagnostic approach. (Strong recommenda",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 10
  },
  {
    "chunk_id": "advancedhiv_1000",
    "text": "puncture with measurement of cerebrospinal fluid (CSF) opening pressure and rapid cryptococcal antigen assay is recommended as the preferred diagnostic approach. (Strong recommendation, moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) The following diagnostic approaches are recommended according to the context. Settings with ready access to and no contraindication for lumbar puncture 1. If both access to a cryptococcal antigen assay (either lateral flow assay or latex agglutination assay) and rapid results (less than 24 hours) are available: lumbar puncture with rapid CSF cryptococcal antigen assay is the preferred diagnostic approach.a (Strong recommendation, moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) 2. If access to a cryptococcal antigen assay is not available and/or rapid results are n",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 10
  },
  {
    "chunk_id": "advancedhiv_1001",
    "text": "rate-certainty evidence for adults and adolescents and low-certainty evidence for children) 2. If access to a cryptococcal antigen assay is not available and/or rapid results are not available, lumbar puncture with CSF India ink test examination is the preferred diagnostic approach. (Strong recommendation, moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) Settings without immediate access to lumbar puncture or when lumbar puncture is clinically contraindicatedb 1. If both access to a cryptococcal antigen assay and rapid results (less than 24 hours) are available, rapid serum, plasma or whole blood cryptococcal antigen assays are the preferred diagnostic approaches. (Strong recommendation: moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) 2. If a cryptococcal antigen assay is not available and/or r",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 10
  },
  {
    "chunk_id": "advancedhiv_1002",
    "text": "(Strong recommendation: moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) 2. If a cryptococcal antigen assay is not available and/or rapid access to results is not ensured, prompt referral for further investigation and treatment is appropriate. (Strong recommendation, moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) Note: Other diseases that can present with symptoms and signs similar to cryptococcal meningitis (such as viral, bacterial or tuberculous meningitis) should also be considered. Prevention and screening 2018 Overarching principle Screening for plasma, serum or whole blood cryptococcal antigen is the optimal approach for guiding resources in a public health approach and is the preferred approach for identifying infection when managing people 10 years and older presenting with advanced H",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 10
  },
  {
    "chunk_id": "advancedhiv_1003",
    "text": "pproach for guiding resources in a public health approach and is the preferred approach for identifying infection when managing people 10 years and older presenting with advanced HIV disease. a For a first episode, CSF cryptococcal culture is also recommended in parallel with cryptococcal antigen testing if this is feasible. b Contraindications include significant coagulopathy or suspected space-occupying lesion based on focal nervous system signs (excluding cranial nerve VI palsy) or recurrent seizures and, where possible, confirmed by computed tomography. Raised intracranial pressure does not contraindicate lumbar puncture in (suspected) cryptococcal meningitis. Other contraindications include major spinal deformity and refusal by the patient after fully informed consent was sought.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 10
  },
  {
    "chunk_id": "advancedhiv_1004",
    "text": "x Year of publication Recommendations Prevention and screening 2018 Screeningc for cryptococcal antigen followed by pre-emptive antifungal therapy among cryptococcal antigen–positive people to prevent the development of invasive cryptococcal disease is recommended before initiating or reinitiating antiretroviral therapy (ART) for adults and adolescents living with HIV who have a CD4 cell count <100 cells/mm3. (Strong recommendation, moderate-certainty evidence) This may be considered at a higher CD4 cell count threshold of >200 cells/mm3. (Conditional recommendation, moderate-certainty evidence) All people living with HIV with a positive cryptococcal antigen screening should be carefully evaluated for signs and symptoms of meningitis and undergo lumbar puncture, if feasible, with CSF examination and India ink or CSF cryptococcal antigen assay to exclude meningitis. India ink has low sens",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 11
  },
  {
    "chunk_id": "advancedhiv_1005",
    "text": " symptoms of meningitis and undergo lumbar puncture, if feasible, with CSF examination and India ink or CSF cryptococcal antigen assay to exclude meningitis. India ink has low sensitivity and a negative result on India ink should be confirmed by CSF cryptococcal antigen testing or CSF culture. When cryptococcal antigen screening is not available, fluconazole primary prophylaxis should be given to adults and adolescents living with HIV who have a CD4 cell count <100 cells/mm3. (Strong recommendation, moderate-certainty evidence) This may be considered at a higher CD4 cell count threshold of <200 cells/mm3. (Conditional recommendation, moderate-certainty evidence) Treatment Induction therapy 2022 A single high dose (10 mg/kg) of liposomal amphotericin B with 14 days of flucytosine (100 mg/kg per day divided into four doses per day) and fluconazole (1200 mg/daily for adults; 12 mg/kg per da",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 11
  },
  {
    "chunk_id": "advancedhiv_1006",
    "text": "se (10 mg/kg) of liposomal amphotericin B with 14 days of flucytosine (100 mg/kg per day divided into four doses per day) and fluconazole (1200 mg/daily for adults; 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily) should be used as the preferred induction regimen for treating people with cryptococcal meningitis. (Strong recommendation, moderate-certainty evidence for adults and low-certainty evidence for children) Alternative induction regimes 2022 If liposomal amphotericin is not available: A seven-day course of amphotericin B deoxycholate (1 mg/kg per day) and flucytosine (100 mg/kg per day, divided into four doses per day) followed by seven days of fluconazole (1200 mg daily for adults and 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate-certainty evidence for adults and low-certainty evidenc",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 11
  },
  {
    "chunk_id": "advancedhiv_1007",
    "text": " adults and 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate-certainty evidence for adults and low-certainty evidence for children and adolescents) If no amphotericin formulation is available: 14 days of fluconazole (1200 mg daily, 12 mg/kg per day for children and adolescents) and flucytosine (100 mg/kg per day, divided into four doses per day). (Strong recommendation, moderate-certainty evidence) Note: fluconazole and flucytosine is the only recommended oral combination regimen and has been associated with lower mortality compared with amphotericin B deoxycholate and fluconazole If flucytosine is not available: 14 days of liposomal amphotericin B (3–4 mg/kg per day) and fluconazole (1200 mg daily, 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate- certainty evi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 11
  },
  {
    "chunk_id": "advancedhiv_1008",
    "text": " (3–4 mg/kg per day) and fluconazole (1200 mg daily, 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate- certainty evidence) If liposomal amphotericin B and flucytosine are not available: 14 days of amphotericin B deoxycholate (1 mg/kg per day) and fluconazole (1200 mg daily, 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate-certainty evidence) Note: flucytosine-containing regimens are superior , and steps should be taken to ensure access to this drug. Use of adjunctive systemic corticosteroids in treating people with cryptococcal meningitis 2018 Routine use of adjunctive corticosteroid therapy during the induction phase is not recommended in treating adults, adolescents and children who have HIV-associated cryptococcal meningitis. (Strong recommendation, high-cert",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 11
  },
  {
    "chunk_id": "advancedhiv_1009",
    "text": "herapy during the induction phase is not recommended in treating adults, adolescents and children who have HIV-associated cryptococcal meningitis. (Strong recommendation, high-certainty evidence for adults and adolescents and moderate-certainty evidence for children) Consolidation 2018 Fluconazole (800 mg daily for adults or 6–12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily) is recommended for the consolidation phase (for eight weeks following the induction phase). (Strong recommendation, low-certainty evidence) c All people living with HIV with a positive cryptococcal antigen result on screening should be carefully evaluated for signs and symptoms of meningitis and undergo a lumbar puncture if feasible with CSF examination and cryptococcal antigen assay (or India ink if cryptococcal antigen assay is not available) to exclude meningitis.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 11
  },
  {
    "chunk_id": "advancedhiv_1010",
    "text": "xi Year of publication Recommendations Maintenance 2018 Fluconazole (200 mg daily for adults or 6 mg/kg per day for adolescents and children) is recommended for the maintenance phase until immune reconstitution (CD4> 200 cells/mm3) and suppression of viral loads on ART. (Strong recommendation, high-certainty evidence) Timing of ART 2018 Immediate ART initiation is not recommended among adults, adolescents and children living with HIV who have cryptococcal meningitis because of the risk of increased mortality and should be deferred 4–6 weeks from the initiation of antifungal treatment. (Strong recommendation, low-certainty evidence for adults and very-low-certainty evidence for children and adolescents) Histoplasmosis Diagnosis of disseminated histoplasmosis among people living with HIV 2021 Among people living with HIV, disseminated histoplasmosis should be diagnosed by detecting circula",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 12
  },
  {
    "chunk_id": "advancedhiv_1011",
    "text": "smosis Diagnosis of disseminated histoplasmosis among people living with HIV 2021 Among people living with HIV, disseminated histoplasmosis should be diagnosed by detecting circulating Histoplasma antigens. (Conditional recommendation, low-certainty evidence) Induction therapy 2021 Treating people living with HIV for severe or moderately severe histoplasmosis: liposomal amphotericin B, 3.0 mg/kg, for two weeks is recommended. In settings in which liposomal amphotericin B is unavailable, deoxycholate amphotericin B, 0.7–1.0 mg/kg, is recommended for two weeks. (Conditional recommendation, very-low-certainty evidence) 2021 Treating people living with HIV for mild to moderate histoplasmosis: itraconazole 200 mg three times daily for three days and then 200 mg twice daily is recommended (Conditional recommendation, very-low- certainty evidence) Maintenance therapy 2021 Itraconazole 200 mg tw",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 12
  },
  {
    "chunk_id": "advancedhiv_1012",
    "text": "ree times daily for three days and then 200 mg twice daily is recommended (Conditional recommendation, very-low- certainty evidence) Maintenance therapy 2021 Itraconazole 200 mg twice daily for 12 months is recommended. (Conditional recommendation, very-low-certainty evidence) Less than 12 months of therapy can be considered when the person is clinically stable, receiving ART, has suppressed viral load and the immune status has improved. (Conditional recommendation, very-low-certainty evidence) Timing of ART 2021 ART should be initiated as soon as possible among people with disseminated histoplasmosis for whom central nervous system involvement is not suspected or proven. (Conditional recommendation, very-low- certainty evidence) TB treatment for people with TB, HIV and histoplasmosis 2021 People living with HIV who also have TB and histoplasmosis coinfection should receive TB therapy ac",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 12
  },
  {
    "chunk_id": "advancedhiv_1013",
    "text": "certainty evidence) TB treatment for people with TB, HIV and histoplasmosis 2021 People living with HIV who also have TB and histoplasmosis coinfection should receive TB therapy according to WHO treatment guidelines. (Conditional recommendation, very-low-certainty evidence) Kaposi’s Sarcoma Pharmacological treatment of Kaposi’s sarcoma 2025 WHO suggests paclitaxel or pegylated liposomal doxorubicin for pharmacological treatment for people living with HIV with Kaposi’s sarcoma. (Conditional recommendation, low-certainty evidence) Treatment of Mild to moderate Kaposi’s sarcoma 2014 In HIV-infected adults, adolescents and children diagnosed with mild or moderate Kaposi sarcoma, immediate ART initiation is recommended. (Strong recommendation, low-certainty evidence) Treatment of severe or symptomatic Kaposi’s sarcoma 2014 Severe or symptomatic disease: in HIV-infected adults, adolescents and",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 12
  },
  {
    "chunk_id": "advancedhiv_1014",
    "text": "ded. (Strong recommendation, low-certainty evidence) Treatment of severe or symptomatic Kaposi’s sarcoma 2014 Severe or symptomatic disease: in HIV-infected adults, adolescents and children diagnosed with severe symptomatic Kaposi sarcoma, immediate ART initiation in combination with systemic chemotherapy is recommended. (Strong recommendation, low-certainty evidence)",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 12
  },
  {
    "chunk_id": "advancedhiv_1015",
    "text": "xii List of relevant HIV guidelines 1. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, 2017 2. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update 3. Guidelines for diagnosing and managing disseminated histoplasmosis among people living with HIV, 2020 4. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV, 2022 5. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, March 2018: supplement to the 2016 consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV infection, 2018 6. Guidelines on the treatment of skin and oral HIV-associated conditions in children and",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 13
  },
  {
    "chunk_id": "advancedhiv_1016",
    "text": "delines of the use of antiretroviral drugs for treating and preventing HIV infection, 2018 6. Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults, 2014 7. Clinical management and infection prevention and control for mpox: living guideline, 2025 These publications are available on the WHO website: https://www.who.int/teams/global-hiv-hepatitis-and- stis-programmes/guidelines. Definition of advanced HIV disease A consensus process conducted in 2024 involved more than 900 participants, with 47% from the African Region. Nearly half represented civil society or frontline workers, and 44% identified as living with HIV. Consensus supported the clinical use of advanced HIV disease to differentiate levels of care and communicate disease status to individuals. The term advanced HIV disease can also help to inform the public, support health education and mo",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 13
  },
  {
    "chunk_id": "advancedhiv_1017",
    "text": "ase to differentiate levels of care and communicate disease status to individuals. The term advanced HIV disease can also help to inform the public, support health education and monitor programme outcomes. The older term of AIDS remains relevant for advocacy and education purposes. For adults, adolescents and children five years and older , advanced HIV disease is defined as a CD4 cell count ≤200 cells/mm3.a At presentation, all children living with HIV younger than five years should be considered as having advanced HIV disease unless they have received ART for more than a year and are considered clinically stable. a Where CD4 testing is unavailable, advanced HIV disease can be defined as a WHO clinical stage 3 or 4 event at presentation for care.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 13
  },
  {
    "chunk_id": "advancedhiv_1018",
    "text": "1 Objectives These guidelines contribute to achieving the WHO Global Health Sector Strategy (1) for HIV 2022–2030 and the Triple Billion targets, which aim to: ensure universal health coverage for 1 billion more people, protect 1 billion more people from health emergencies and improve health and well-being for 1 billion more people. These guidelines also align with the UNAIDS 95–95– 95 targets, ensuring that 95% of people living with HIV know their HIV status, 95% of those diagnosed receive sustained antiretroviral therapy (ART) and 95% of those receiving ART achieve viral suppression (2). Updated and integrated guidance on advanced HIV disease will help to support countries in remaining on track with the UNAIDS-recommended 2030 targets of reducing the number of people dying from AIDS-related causes by 90% from 2010 (3). Since people with advanced HIV disease are at high risk of severe i",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 14
  },
  {
    "chunk_id": "advancedhiv_1019",
    "text": "S-recommended 2030 targets of reducing the number of people dying from AIDS-related causes by 90% from 2010 (3). Since people with advanced HIV disease are at high risk of severe illness and death, especially in resource-limited settings, these guidelines emphasize early detection, rapid ART initiation and optimized clinical management to reduce morbidity and mortality. By implementing these recommendations, countries can reduce progression to severe illness and mortality, improve treatment outcomes and advance global HIV elimination goals. The objectives of these guidelines are: • to provide evidence-informed clinical recommendations for screening, prophylaxis, treatment and management of opportunistic infections for individuals with advanced HIV disease; • to guide the implementation of the WHO- recommended advanced HIV disease package of care, including rapid diagnostic tools, pre-emp",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 14
  },
  {
    "chunk_id": "advancedhiv_1020",
    "text": "ons for individuals with advanced HIV disease; • to guide the implementation of the WHO- recommended advanced HIV disease package of care, including rapid diagnostic tools, pre-emptive treatment and optimized ART regimens; • to expand guidance to support strengthening health-care provision for both in- and outpatient services for advanced HIV disease; • to strengthen service delivery approaches, ensuring timely identification, referral and management of advanced HIV disease in resource-limited settings; and • to support national decision-makers and health programme planners in adapting and scaling up advanced HIV disease management strategies while integrating them into broader HIV and health system strengthening efforts.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 14
  },
  {
    "chunk_id": "advancedhiv_1021",
    "text": "2 Target audience The guidelines are primarily intended for use by national HIV programme managers. They will also be of interest to the following audiences: • national HIV treatment and prevention advisory boards; • national TB programme managers; • managers of maternal, newborn and child health and sexual and reproductive health and noncommunicable disease programmes (including mental health and substance use); • clinicians and other health service providers; • managers of national laboratory services; • people living with HIV and community- based organizations; • key population networks; and • international and bilateral agencies and organizations that provide financial and technical support to HIV programmes in resource-limited settings. Guiding principles The following principles have informed the development of the updated chapter on management of advanced HIV disease and should gu",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 15
  },
  {
    "chunk_id": "advancedhiv_1022",
    "text": "s in resource-limited settings. Guiding principles The following principles have informed the development of the updated chapter on management of advanced HIV disease and should guide implementation. • The guidelines are based on a public health approach to scaling up the use of antiretroviral drugs and related services along the continuum of HIV prevention, care and treatment. • Efforts should be made to promote an enabling environment and protect the human rights of people who need HIV services, including ensuring informed consent, preventing stigma and discrimination in the provision of services, addressing laws and legislation that criminalize the behaviour of people and promoting gender equity. • Rapid ART initiation, including same-day start, is a programmatic priority for all people living with HIV, regardless of CD4 cell count or immune status. • Early diagnosis and prompt initia",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 15
  },
  {
    "chunk_id": "advancedhiv_1023",
    "text": " initiation, including same-day start, is a programmatic priority for all people living with HIV, regardless of CD4 cell count or immune status. • Early diagnosis and prompt initiation of therapy for major opportunistic infections is essential to improving survival. • People should be promptly referred for HIV testing and care following diagnosis of major opportunistic infections to facilitate prompt HIV diagnosis, linkage to care and uptake of ART. Implementation of the recommendations in these guidelines should be informed by local context, including HIV epidemiology, availability of resources, the organization and capacity of the health system and anticipated cost–effectiveness.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 15
  },
  {
    "chunk_id": "advancedhiv_1024",
    "text": "3 Burden of advanced HIV disease 1 WHO danger signs for adults: respiratory rate ≥30 breaths per minute; heart rate ≥120 beats per minute; or unable to walk unaided. Danger signs for children are any of the following: lethargy or unconsciousness, convulsions; unable to drink or breastfeed; repeated vomiting; age-defined tachycardia; or tachypnoea (8). Introduction Advanced HIV disease is a serious public health issue, including in settings with good coverage of HIV testing and treatment and despite having achieved or made good progress towards the 95–95–95 targets. A recent systematic review analysed evidence from 117 cohorts of people living with HIV in which CD4 cell counts were measured in health-care settings worldwide. The review found that in outpatient settings, a third of all CD4 counts measured (33.5%, 95% confidence interval (CI) 31.5–35.4%) were under 200 cells/mm3. The rate o",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 16
  },
  {
    "chunk_id": "advancedhiv_1025",
    "text": "gs worldwide. The review found that in outpatient settings, a third of all CD4 counts measured (33.5%, 95% confidence interval (CI) 31.5–35.4%) were under 200 cells/mm3. The rate of lower CD4 cell counts was similar among people starting ART (33.5%, 95% CI 32–36%) and people who were already taking ART (31%, 95% CI 24–37%), although it is likely that CD4 testing was offered routinely to people starting ART but only if clinically indicated to the people already taking ART (4). Another study (5) of nationally representative household surveys from 13 countries in Africa found an estimated prevalence of CD4 cell count under 200 cells/mm3 of 10% of adults (age 15 years and older). This corresponds to 1.9 million (95% CI 1.6 million–2.2 million) individuals with advanced HIV disease in sub-Saharan Africa. Men and adults aged 30 years and older were more likely to have CD4 cell count under 200 ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 16
  },
  {
    "chunk_id": "advancedhiv_1026",
    "text": "% CI 1.6 million–2.2 million) individuals with advanced HIV disease in sub-Saharan Africa. Men and adults aged 30 years and older were more likely to have CD4 cell count under 200 cells/ mm3. About three quarters of adults living with HIV in Africa have viral load suppression, the study estimated that 43% of all low CD4 cell counts were among people with viral load suppression (5). This indicates that increasing testing and ART initiation are insufficient to tackle advanced HIV disease. Both reviews above used CD4 cell counts of less than 200 cells/mm3 to define advanced HIV disease. There are an estimated 1.4 million children (age 0–14 years) living with HIV worldwide (6). Children living with HIV younger than five years are considered to have advanced HIV disease unless they have been receiving ART for a year or longer and are clinically stable. Among older children, 30.1% (95% CI 25.4",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 16
  },
  {
    "chunk_id": "advancedhiv_1027",
    "text": " five years are considered to have advanced HIV disease unless they have been receiving ART for a year or longer and are clinically stable. Among older children, 30.1% (95% CI 25.4–34.8%) had advanced HIV disease in outpatient settings (4). There have been large declines in CD4 testing over time among children, which greatly limits the ability to better understand advanced HIV disease in this population (7). Causes of hospital admission and death among people living with HIV Advanced HIV disease is a risk for becoming seriously unwell and requiring admission to hospital. Serious illness1 is often defined by the presence of WHO danger signs, although hospital admission itself may serve as a proxy indicator in settings where formal clinical assessments are limited. A systematic review (9) of studies reporting the cause of hospital admission of people living with HIV from 2014 to 2023 showe",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 16
  },
  {
    "chunk_id": "advancedhiv_1028",
    "text": "ttings where formal clinical assessments are limited. A systematic review (9) of studies reporting the cause of hospital admission of people living with HIV from 2014 to 2023 showed that the commonest causes of hospital admission worldwide were AIDS-defining clinical conditions (42% of all hospital admissions, 95% CI 35–49%), followed by severe bacterial infections (26% of hospital admissions, 95% CI 20–33%). TB was the most common AIDS-defining clinical condition, causing 19% of hospital admissions worldwide among people living with HIV (95% CI 15–23%) (9).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 16
  },
  {
    "chunk_id": "advancedhiv_1029",
    "text": "4 Among those who survive their hospital admission, the period following hospital discharge is also risky. In a systematic review of post-discharge outcomes, 19% of people living with HIV who were discharged from hospital alive were readmitted and 14% died shortly after hospital discharge (the duration of post-discharge follow-up varied by study from 30 days to 12 months) (10). The advanced HIV disease research landscape At a WHO led expert consultation in September 2023, key topics were agreed for advanced HIV disease research. These were implementation research needs for CD4 testing and differentiated service delivery and clinical research needs for eight HIV-associated diseases: TB, cryptococcal meningitis, severe bacterial infections, Pneumocystis pneumonia, toxoplasmosis, cytomegalovirus, histoplasmosis and talaromycosis (11). Priority research gaps in advanced HIV disease were iden",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 17
  },
  {
    "chunk_id": "advancedhiv_1030",
    "text": "severe bacterial infections, Pneumocystis pneumonia, toxoplasmosis, cytomegalovirus, histoplasmosis and talaromycosis (11). Priority research gaps in advanced HIV disease were identified as part of the expert consultation and research roadmap. Research data and reliable monitoring and evaluation systems for advanced HIV disease are urgently needed. Other research gaps included: how best to operationalize point- of-care CD4 testing; the need for improved understanding of the burden of severe bacterial infection and antimicrobial resistance in the context of advanced HIV disease; improved TB diagnostics and TB screening algorithms; treatment guidelines based on modern evidence for Pneumocystis pneumonia, toxoplasmosis and talaromycosis; optimizing inpatient care bundles and inpatient and outpatient linkage to reduce mortality around the time of hospital admission; and qualitative research ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 17
  },
  {
    "chunk_id": "advancedhiv_1031",
    "text": "mosis and talaromycosis; optimizing inpatient care bundles and inpatient and outpatient linkage to reduce mortality around the time of hospital admission; and qualitative research to determine why individuals are still presenting with advanced HIV disease despite widespread access to ART. Most evidence for the management of advanced HIV disease and related conditions arises from studies of adults, and research applicable to infants and children is needed.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 17
  },
  {
    "chunk_id": "advancedhiv_1032",
    "text": "Providing a package of care for advanced HIV disease",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 18
  },
  {
    "chunk_id": "advancedhiv_1033",
    "text": "6 CD4 testing and WHO clinical staging Background WHO introduced HIV clinical staging in 2007 to facilitate rapid identification of the stage of HIV infection in settings in which HIV testing and CD4 testing were very limited or unavailable, primarily as a tool for surveillance (12). This was considered feasible since it served as a guide for health-care workers to identify opportunistic infections and assign a degree of severity of illness. Clinical staging of HIV-related disease for adults and children was categorized into a four-stage system that included standardized descriptors. A systematic review published in 2014 found that against a CD4 cell count threshold of <200 cells/ mm3, the sensitivity of correctly identifying a WHO stage 3 or 4 AIDS-defining illness was 60% and the specificity was 73% (13). This has important implications for providing the WHO-recommended package of care",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 19
  },
  {
    "chunk_id": "advancedhiv_1034",
    "text": "tly identifying a WHO stage 3 or 4 AIDS-defining illness was 60% and the specificity was 73% (13). This has important implications for providing the WHO-recommended package of care for advanced HIV disease (14), since it would result in being unable to provide disease prevention measures. Instead, treatment would more likely be required if a WHO stage 3 or 4 AIDS- defining illness was identified. Through a consensus process in 2016 (15), advanced HIV disease was defined as all adults, adolescents and children younger than five years living with HIV with a CD4 count of ≤200 cells/mm3, considering the higher mortality below this threshold (15, 16). In 2015, WHO recommended ART initiation for all people living with HIV regardless of CD4 count and also recommended using viral load testing as the preferred approach for monitoring the response to ART (17). With the consequent scale-up of viral",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 19
  },
  {
    "chunk_id": "advancedhiv_1035",
    "text": "h HIV regardless of CD4 count and also recommended using viral load testing as the preferred approach for monitoring the response to ART (17). With the consequent scale-up of viral load testing to monitor treatment response, CD4 test use declined substantially in most settings with a high burden of HIV (18). However , viral load testing does not provide information on immune status. WHO clinical staging is being used because of lack of availability of CD4 tests. WHO currently does not provide recommendations on a preferred approach for identifying advanced HIV disease, and programmes primarily relied on the interpretation of the definition of advanced HIV disease. There has been a demand from HIV programmes worldwide and from representatives of civil society for WHO to provide clarity on identifying advanced HIV disease since it will highlight the importance of CD4 testing as well as adv",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 19
  },
  {
    "chunk_id": "advancedhiv_1036",
    "text": "ldwide and from representatives of civil society for WHO to provide clarity on identifying advanced HIV disease since it will highlight the importance of CD4 testing as well as advanced HIV disease, and drive demand for CD4 testing in countries. Thus, there was a need to systematically investigate the accuracy of WHO clinical staging compared with CD4 testing for identifying individuals with advanced HIV disease, to ensure that they urgently receive the WHO-recommended package of care for advanced HIV disease. Recommendations CD4 testing is recommended as the preferred method to identify advanced HIV disease in people living with HIV. (New, 2025) Strong recommendation, moderate certainty evidence. In settings where CD4 testing is not yet available, WHO clinical staging can be used to identify advanced HIV disease in people living with HIV. (New, 2025) Conditional recommendation, very low",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 19
  },
  {
    "chunk_id": "advancedhiv_1037",
    "text": "here CD4 testing is not yet available, WHO clinical staging can be used to identify advanced HIV disease in people living with HIV. (New, 2025) Conditional recommendation, very low certainty evidence. A package of interventions including screening, treatment and/or prophylaxis for major opportunistic infections, rapid ART initiation and intensified adherence support interventions should be offered to everyone presenting with advanced HIV disease. (2017) Strong recommendation, moderate-certainty evidence",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 19
  },
  {
    "chunk_id": "advancedhiv_1038",
    "text": "7 Rationale for the recommendations Balance of benefits and harm A systematic review2 (Web Annex B) (19) was conducted on the diagnostic accuracy of clinical staging for detecting advanced HIV disease against CD4 cell count measurement (laboratory based), which served as the reference standard. Studies were included in which the WHO clinical staging classification was compared at CD4 cell count threshold of <200 or ≤200 cells/mm3; 24 studies were included for review (20–43), the majority (18 studies) conducted in the WHO African Region, with five conducted in the South-East Asia Region and one in the Eastern Mediterranean Region. In relation to the conduct of testing, procedures for WHO clinical staging were largely poorly conducted. Fourteen of 24 studies did not specify who conducted clinical staging, with 10 specifying medically qualified clinicians of various cadres. The CD4 cell cou",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 20
  },
  {
    "chunk_id": "advancedhiv_1039",
    "text": "rgely poorly conducted. Fourteen of 24 studies did not specify who conducted clinical staging, with 10 specifying medically qualified clinicians of various cadres. The CD4 cell count in the included studies was largely measured using laboratory-based flow-cytometry measurement, with two studies reporting the use of a Coulter manual counting method. Overall, pooled sensitivity was 61% (95% CI 48–73%) and pooled specificity was 72% (95% CI 60–81%). The positive likelihood ratio was 2.18 (95% CI 0.28–17.16) and negative likelihood ratio 0.54 (95% CI 0.11–2.56). Of a hypothetical population of 100 000 people living with HIV with a prevalence of advanced HIV disease of 25%, 15 250 (15%) would be correctly classified as having advanced HIV disease, 54 000 (54%) would correctly have advanced HIV disease ruled out, 21 000 (21%) would be falsely classified as having advanced HIV disease when they",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 20
  },
  {
    "chunk_id": "advancedhiv_1040",
    "text": " as having advanced HIV disease, 54 000 (54%) would correctly have advanced HIV disease ruled out, 21 000 (21%) would be falsely classified as having advanced HIV disease when they did not and 9750 (10%) would have advanced HIV disease but not be detected. If half of the people living with HIV being screened had advanced HIV disease, 30 500 (30%) would have advanced HIV disease correctly detected, 36 000 (36%) would have advanced HIV disease correctly excluded, 14 000 (14%) would be wrongly classified as having advanced HIV disease and 19 500 (20%) would have advanced HIV disease but not be detected. The results of the risk of bias assessment in the systematic review reported overall low certainty of evidence. The Guideline Development Group agreed through consensus that the accuracy of clinical staging was low and judged the magnitude of undesirable effects (the magnitude to which the i",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 20
  },
  {
    "chunk_id": "advancedhiv_1041",
    "text": "The Guideline Development Group agreed through consensus that the accuracy of clinical staging was low and judged the magnitude of undesirable effects (the magnitude to which the intended population is being misclassified or not) as being moderate to 2 Twabi HH, Ueno A, Ives J, Murtagh R, Mukoka M, Mortazavi SA, Lawrence DS, Choko AT, Semphere R, Balakasi K, Rangaraj A. Diagnostic accuracy of the WHO clinical staging system for detection of immunologically defined advanced HIV disease: A systematic review and meta‐analysis. HIV medicine. 2025 Sep 18. DOI: https://doi.org/10.1111/hiv.70122 large. This was primarily because of the high rate of both false positives and false negatives. False- positive results could result in unnecessary additional testing with associated harm, such as increasing costs, burden on health-care workers and discomfort and delays for the individual being tested. ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 20
  },
  {
    "chunk_id": "advancedhiv_1042",
    "text": "d result in unnecessary additional testing with associated harm, such as increasing costs, burden on health-care workers and discomfort and delays for the individual being tested. For the increased false negatives, it would result in many cases of advanced HIV disease being missed (20%, as specified previously), resulting in substantially increased morbidity and mortality from missed cases of advanced HIV disease in HIV programmes. The Guideline Development Group judged the overall certainty of evidence supporting clinical staging as being very low, owing to the additional uncertainty of the cadre conducting the clinical staging and heterogeneity in the included studies. The Guideline Development Group judged that the balance of benefits and harm favoured CD4 testing owing to moderate to large potential harm identified with clinical staging. The Group also noted that, despite the very lo",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 20
  },
  {
    "chunk_id": "advancedhiv_1043",
    "text": "hat the balance of benefits and harm favoured CD4 testing owing to moderate to large potential harm identified with clinical staging. The Group also noted that, despite the very low certainty of evidence, there was no doubt that clinical staging is not an accurate method for identifying advanced HIV disease in regular clinical practice. Preferences, acceptability and feasibility The Guideline Development Group found that there was potentially important uncertainty or variability regarding the use of clinical staging to identify advanced HIV disease and that acceptability likely varies; some Guideline Development Group members also noted that it was probably not acceptable in certain contexts, owing to lack of trained workforce, to conduct a full clinical examination or also lack of supporting infrastructure to confirm diagnosis of specific opportunistic infections to stage the individual",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 20
  },
  {
    "chunk_id": "advancedhiv_1044",
    "text": "rained workforce, to conduct a full clinical examination or also lack of supporting infrastructure to confirm diagnosis of specific opportunistic infections to stage the individual correctly. The Guideline Development Group also determined that feasibility of clinical staging might vary. The rationale for the judgement on preferences was informed by evidence provided from the results of an online values and preferences survey (Web Annex C) conducted among people living with HIV and evidence compiled from published literature through a targeted literature search. The respondents expressed a strong desire to be informed about their immune status while receiving routine care and preferred a test that involves drawing a blood sample and provides good accuracy of testing. Half the respondents indicated a preference against undergoing an extended",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 20
  },
  {
    "chunk_id": "advancedhiv_1045",
    "text": "8 physical examination when comparing preferences of receiving a needle prick with a blood draw compared with a detailed physical examination to identify opportunistic infections or establish their risk status. Evidence from an implementation study highlighted that most health-care workers agreed that undergoing training and performing the point-of-care CD4 count was straightforward and easy to perform and agreed that point-of-care CD4 was useful in their daily work and for informing patient management (44). The Guideline Development Group also noted that clinical staging would likely be more acceptable to health-care workers if no CD4 testing was available; however , there was a lack of evidence around health- care worker preferences for clinical staging. A study assessing the feasibility of implementing the WHO-recommended package of care using point-of-care CD4 testing concluded that ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 21
  },
  {
    "chunk_id": "advancedhiv_1046",
    "text": " care worker preferences for clinical staging. A study assessing the feasibility of implementing the WHO-recommended package of care using point-of-care CD4 testing concluded that delivering the package of care, including the point-of-care CD4 test, was considered feasible (44). Resources and cost–effectiveness About 7.5 million CD4 tests were conducted in low- and middle-income countries in 2024, with conventional testing accounting for about 70% and point-of-care tests the remaining 30%. There is considerable unmet need for CD4 testing, with an estimated shortfall of 1.8 million–3.9 million tests (45). The currently available cost per test is about US$ 3 for point-of-care CD4 tests and varies between US$ 2 and US$ 5 for conventional laboratory testing (45). However , various initiatives are underway to help improve demand for CD4 testing. No evidence was available on the direct costs o",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 21
  },
  {
    "chunk_id": "advancedhiv_1047",
    "text": "d US$ 5 for conventional laboratory testing (45). However , various initiatives are underway to help improve demand for CD4 testing. No evidence was available on the direct costs of conducting WHO clinical staging; however , the Guideline Development Group emphasized that the costs are likely to be moderate, owing to costs of missed diagnosis of opportunistic infections, additional testing needs to identify AIDS-defining conditions and personnel time to conduct an extensive physical examination. Relative to CD4 testing, the Guideline Development Group noted that costs were more difficult to judge given the varied levels of CD4 testing availability in settings. Modelling work has demonstrated the incremental benefits of the advanced HIV disease package of care, with the full package demonstrating maximum cost–effectiveness (46). The proper implementation of the package depends on the abil",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 21
  },
  {
    "chunk_id": "advancedhiv_1048",
    "text": "efits of the advanced HIV disease package of care, with the full package demonstrating maximum cost–effectiveness (46). The proper implementation of the package depends on the ability of CD4 testing to correctly identify someone with advanced HIV disease. Equity The Guideline Development Group determined that the equity would likely vary based on the setting. In settings where clinical staging is used, this may reduce equity compared with settings in which populations receive CD4 testing. However , in a setting with no CD4 testing, performing clinical staging would improve equity compared with no formal assessment for advanced HIV disease, even if the test performs poorly. The Guideline Development Group judged that clinical staging would probably reduce equity in most instances. Rationale for recommendations Based on the information presented, the Guideline Development Group chose to de",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 21
  },
  {
    "chunk_id": "advancedhiv_1049",
    "text": " that clinical staging would probably reduce equity in most instances. Rationale for recommendations Based on the information presented, the Guideline Development Group chose to develop two separate recommendations, one on CD4 testing and the other on WHO clinical staging for identifying advanced HIV disease, given the public health importance of timely identification of advanced HIV disease in HIV programmes. Recommendation on CD4 testing The Guideline Development Group noted that since CD4 testing was the reference standard for the primary evidence review, the certainty of CD4 testing to correctly identify someone with advanced HIV disease was high, since the primary means by which CD4 counts are established is through this test. Owing to several sources of uncertainty identified by the Guideline Development Group relating to performance of point-of-care-CD4 testing, costs and access i",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 21
  },
  {
    "chunk_id": "advancedhiv_1050",
    "text": "is through this test. Owing to several sources of uncertainty identified by the Guideline Development Group relating to performance of point-of-care-CD4 testing, costs and access issues, the Guideline Development Group chose to downgrade the certainty of the evidence to moderate. Despite some reported concerns around the performance of point-of-care tests, the performance of these tests far surpassed the performance of clinical staging. CD4 testing has a long history of use within HIV programmes and can also be used as a prognostic test, adding further value to the test results. The Guideline Development Group thus agreed through consensus that CD4 testing should be strongly recommended as the preferred method to identify advanced HIV disease among people living with HIV. Recommendation on WHO clinical staging The Guideline Development Group noted that in settings where no CD4 testing wa",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 21
  },
  {
    "chunk_id": "advancedhiv_1051",
    "text": "to identify advanced HIV disease among people living with HIV. Recommendation on WHO clinical staging The Guideline Development Group noted that in settings where no CD4 testing was available, health-care workers may use clinical staging to identify advanced HIV disease. The Guideline Development Group thus chose to develop a conditional recommendation on the use of clinical staging, consistent with the public health approach, to account for settings with little or no resources available to conduct CD4 testing. Implementation considerations The Guideline Development Group identified several implementation considerations for both CD4 testing and clinical staging (Box 1).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 21
  },
  {
    "chunk_id": "advancedhiv_1052",
    "text": "9 Box 2. Key characteristics of CD4 tests Point-of-care tests • Lower sensitivity and specificity compared with conventional CD4 tests • Test results are semiquantitative (CD4 <200 cells/mm3 or >200 cells/mm3) • Device-free • Challenging to implement in high-volume health-care facilities • Suitable for task-sharing among cadres • Training required for health-care workers before implementation • Can support the rapid return of results in outreach settings • Quality assurance systems required as well as job aids to improve the readability of results Conventional CD4 tests • Gold standard for measuring CD4 counts • Provide quantitative results • Require laboratory infrastructure and personnel • Suitable for implementation in high-volume and high-demand health-care facilities, promoting efficiency in delivering results • Requires laboratory personnel • Less suitable for outreach settings unl",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 22
  },
  {
    "chunk_id": "advancedhiv_1053",
    "text": "entation in high-volume and high-demand health-care facilities, promoting efficiency in delivering results • Requires laboratory personnel • Less suitable for outreach settings unless accompanied by robust sample transport systems • Quality assurance required, but no specific job aids required for health-care workers Key considerations for point- of-care and lab-based tests Programmes should give priority to developing job aids or tools to support the reading of point-of-care test results for health-care workers. Current evidence on point-of-care testing Point-of-care CD4 testing can provide more rapid test results, during a single health-care visit, to enable rapid clinical decision-making (47). This is likely to be critical for people living with advanced HIV disease. Two assays remain on the market and are available for procurement (48). Training and task sharing Health cadres (commun",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 22
  },
  {
    "chunk_id": "advancedhiv_1054",
    "text": " to be critical for people living with advanced HIV disease. Two assays remain on the market and are available for procurement (48). Training and task sharing Health cadres (community health workers, nurses, and laboratory personnel) should undergo training on point-of-care CD4 tests and on conventional CD4 testing. Task-sharing approaches could help to lower implementation costs and improve CD4 coverage within HIV programmes (49–52). Monitoring and quality assurance Implementation of robust monitoring and quality assurance systems to maintain testing standards for CD4 testing is an important component of implementing and scaling up CD4 testing. Integration and referral pathways The Guideline Development Group considered CD4 testing suitable for integrated care initiatives between HIV and other disease programmes or primary health care depending on the specific context. The Guideline Dev",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 22
  },
  {
    "chunk_id": "advancedhiv_1055",
    "text": "considered CD4 testing suitable for integrated care initiatives between HIV and other disease programmes or primary health care depending on the specific context. The Guideline Development Group noted the importance of having clear referral pathways for individuals who are identified to be seriously unwell with advanced HIV disease. Diagnostic networks Box 1. Who needs a CD4 test (adults, adolescents and children)? Indications for CD4 testing in HIV programmes CD4 testing to identify advanced HIV disease among people living with HIV who are: a. initiating or reinitiating ART b. re-engaging in care following disengagement c. have treatment failure or clinically identified treatment failure d. hospitalized or seriously ill or are considered clinically unstable CD4 testing to support the identification of treatment failure when viral load testing is unavailable CD4 testing to assess eligibi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 22
  },
  {
    "chunk_id": "advancedhiv_1056",
    "text": "iously ill or are considered clinically unstable CD4 testing to support the identification of treatment failure when viral load testing is unavailable CD4 testing to assess eligibility to stop co-trimoxazole prophylaxis CD4 testing to assess eligibility for fluconazole prophylaxis",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 22
  },
  {
    "chunk_id": "advancedhiv_1057",
    "text": "10 would need to be optimized in programmes in which more than one type of CD4 test (conventional and point-of-care tests) are being used and ensuring that the type of test is matched to the facility (conventional CD4 tests for higher-volume sites). WHO clinical staging The Guideline Development Group also developed specific implementation considerations for WHO clinical staging. Training Adequate training needs to be provided to health- care workers on conducting WHO clinical staging and giving priority to medical personnel for conducting clinical staging of clients. Clinical protocols Symptom-based diagnosis protocols should be developed along with support for additional diagnostics for opportunistic infections for completeness of clinical staging. Referral pathways Clear referral pathways need to be developed following clinical staging owing to limitations to correctly identify advanc",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 23
  },
  {
    "chunk_id": "advancedhiv_1058",
    "text": "ns for completeness of clinical staging. Referral pathways Clear referral pathways need to be developed following clinical staging owing to limitations to correctly identify advanced HIV disease but also since sites offering clinical staging may not have access to other diagnostics necessary to complete clinical staging. Monitoring, training and quality assurance Programmes should adequately monitor the implementation of clinical staging and develop quality assurance systems, owing to the evidence around a lack of consistency and information on how clinical staging was conducted and who conducted it. Resource priority-setting Improving access to CD4 testing is critical rather than primarily investing resources in training health-care workers on clinical staging owing to the limited improvements in accuracy expected with its use and highly variable costs. Training health- care workers on ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 23
  },
  {
    "chunk_id": "advancedhiv_1059",
    "text": "in training health-care workers on clinical staging owing to the limited improvements in accuracy expected with its use and highly variable costs. Training health- care workers on performing a physical examination may contribute to improved clinical care overall but CD4 testing would have to be scaled up since many individuals with advanced HIV disease may not have any clinically identifiable signs or symptoms of disease but continue to have an elevated risk of developing opportunistic infections. Use of CD4 testing additionally would support the rapid roll-out of testing for advanced HIV disease and improve coverage of screening for advanced HIV disease compared with clinical staging. Research gaps There are research gaps, broadly classified under three main categories: comparative analysis of CD4 testing compared with clinical staging, CD4 testing and clinical staging (Table 1). Table ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 23
  },
  {
    "chunk_id": "advancedhiv_1060",
    "text": "esearch gaps, broadly classified under three main categories: comparative analysis of CD4 testing compared with clinical staging, CD4 testing and clinical staging (Table 1). Table 1. Research needs for CD4 testing and WHO clinical staging CD4 compared with clinical staging CD4 testing Clinical staging Evidence around improved integrated and task-sharing approaches Studies on CD4 testing among children and adolescents (both older and younger than five years) Evaluating the apparent decline in sensitivity of clinical staging over time Comparative analysis of cost–effectiveness of CD4 testing compared with clinical staging in resource-limited settings Budget implication and impact analysis, cost analysis and cost-reduction analysis of CD4 testing in countries Identifying approaches to improve the accuracy of clinical staging in settings where CD4 testing is unavailable Research on the clini",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 23
  },
  {
    "chunk_id": "advancedhiv_1061",
    "text": "reduction analysis of CD4 testing in countries Identifying approaches to improve the accuracy of clinical staging in settings where CD4 testing is unavailable Research on the clinical utility of CD4 testing and clinical staging in a clinical situation of high viral load Diagnostic performance and clinical utility of CD4 testing between individuals Identifying the optimal time period to perform a repeat CD4 test when a client re-engages in care following a period of disengagement from routine care services Understanding the performance of clinical staging for people returning to care following disengagement Mapping of existing CD4 resources in countries with a high burden of HIV Pragmatic studies on CD4 testing in different categories of health facilities – hospitals, clinics and outreach settings Identifying barriers to accessing evaluation for advanced HIV disease Clinical relevance of ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 23
  },
  {
    "chunk_id": "advancedhiv_1062",
    "text": "in different categories of health facilities – hospitals, clinics and outreach settings Identifying barriers to accessing evaluation for advanced HIV disease Clinical relevance of suboptimal immune recovery among individuals receiving ART Further research into the role of the CD4 nadir in predicting progression to advanced HIV disease",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 23
  },
  {
    "chunk_id": "advancedhiv_1063",
    "text": "11 Providing a package of care for advanced HIV disease (2017) To address these leading causes of morbidity and mortality among people with advanced HIV disease, WHO recommends that a package of interventions, including screening, treatment and/or prophylaxis for major opportunistic infections, rapid ART initiation and intensified adherence support interventions, be offered to everyone (all populations and age groups) living with HIV presenting with advanced HIV disease (53). Rationale for the recommendation The rationale for this recommendation is based on two randomized controlled trials: REMSTART (54) and REALITY (55). REMSTART was conducted in the United Republic of Tanzania and Zambia and randomized 1999 ART-naive adults living with HIV with CD4 count <200 cells/mm3 to either standard care or standard care plus enhanced clinic-based care with serum cryptococcal antigen screening and",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 24
  },
  {
    "chunk_id": "advancedhiv_1064",
    "text": "RT-naive adults living with HIV with CD4 count <200 cells/mm3 to either standard care or standard care plus enhanced clinic-based care with serum cryptococcal antigen screening and pre-emptive antifungal treatment for those who tested cryptococcal antigen positive and additional community support (comprising a weekly home or community visit by trained and paid lay workers who delivered ART, provided adherence support and monitored participants for signs and symptoms of drug toxicity or new symptoms). The intervention group had 28% fewer people dying: mortality was 13% in the intervention group versus 18% in the group receiving standard care. REALITY enrolled 1805 mainly adults living with HIV (72 were 5–17 years old) with CD4 counts <100 cells/ mm3 in Kenya, Malawi, Uganda and Zimbabwe. All underwent screening for active TB at enrolment and were then randomized to the standard of care (c",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 24
  },
  {
    "chunk_id": "advancedhiv_1065",
    "text": "s old) with CD4 counts <100 cells/ mm3 in Kenya, Malawi, Uganda and Zimbabwe. All underwent screening for active TB at enrolment and were then randomized to the standard of care (co-trimoxazole) according to national guidelines or an enhanced prophylaxis package: 12 weeks of fluconazole (100 mg once daily), 12 weeks of a fixed-dose combination of co-trimoxazole (800 + 160 mg) + isoniazid (300 mg) + pyridoxine (25 mg) as a scored once-daily tablet, five days of 500 mg of azithromycin once daily and a single dose of 400 mg of albendazole. All drugs were started simultaneously, and ART was offered on the same day as the prophylaxis package (55). The enhanced prophylaxis package at the time of ART initiation reduced mortality by 27% (from 12.2% to 8.9%) over 24 weeks (55). Mortality from Cryptococcus species declined considerably, from 1.5% to 0.4%, and mortality from unascertained causes (m",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 24
  },
  {
    "chunk_id": "advancedhiv_1066",
    "text": "d mortality by 27% (from 12.2% to 8.9%) over 24 weeks (55). Mortality from Cryptococcus species declined considerably, from 1.5% to 0.4%, and mortality from unascertained causes (most people died at home) declined from 6.0% to 3.8%. TB incidence was reduced by 28%, cryptococcal disease by 62% and hospitalization by 17% in the enhanced prophylaxis group versus the standard-of-care group. Most of the deaths in this study occurred within the first three weeks, highlighting the value of early prophylaxis for people with advanced disease (55). Recommendation A package of interventions including screening, treatment and/or prophylaxis for major opportunistic infections, rapid ART initiation and intensified adherence support interventions should be offered to everyone presenting with advanced HIV disease Strong recommendation, moderate certainty evidence.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 24
  },
  {
    "chunk_id": "advancedhiv_1067",
    "text": "12 Implementation considerations Adults Providing a package of essential interventions focuses attention on preventing, diagnosing and treating the most common causes of morbidity and mortality among people with advanced HIV disease. Identifying people with advanced HIV disease who are eligible for elements of a package of care requires CD4 testing. In addition, determining the immune status of people whose treatment is failing according to virological criteria can help in guiding clinical management decisions. Attention should also be paid to other important causes of severe illness not covered by the package, especially in regions in which specific comorbidities and coinfections are prevalent. Of note, increased pill burden and side-effects may affect treatment adherence, and intensified adherence support interventions are an important component of the advanced HIV disease package. To ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 25
  },
  {
    "chunk_id": "advancedhiv_1068",
    "text": "sed pill burden and side-effects may affect treatment adherence, and intensified adherence support interventions are an important component of the advanced HIV disease package. To support treatment adherence, shorter regimens for TB preventive treatment are recommended (56). Identifying suitable screening tools for use is also an important research gap. Table 2 summarizes the specific components of the package of interventions that should be offered to people presenting with advanced HIV disease. Further information on current WHO recommendations is in the chapter on management of opportunistic infections. Additional detailed guidance on using systematic TB screening for people, including screening tools recommended for people living with HIV and diagnostic tools such as lateral flow urine lipoarabinomannan assay (LF- LAM), WHO-approved molecular rapid diagnostics and TB preventive treat",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 25
  },
  {
    "chunk_id": "advancedhiv_1069",
    "text": "ended for people living with HIV and diagnostic tools such as lateral flow urine lipoarabinomannan assay (LF- LAM), WHO-approved molecular rapid diagnostics and TB preventive treatment, are available in the consolidated guidelines and operational handbooks for TB modules 1, 2 and 3 (56–58). Key considerations for managing TB disease are highlighted in the subsection on TB in this publication. Children All children younger than five years (who are not already receiving ART and clinically stable) are considered to have advanced HIV disease. Those who are established on ART and older than two years should not be considered to have advanced disease and should be eligible for multimonth dispensing (8). The main differences in the package of care for children compared with adolescents and adults is that routine cryptococcal antigen screening and pre-emptive therapy are not recommended for chil",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 25
  },
  {
    "chunk_id": "advancedhiv_1070",
    "text": "erences in the package of care for children compared with adolescents and adults is that routine cryptococcal antigen screening and pre-emptive therapy are not recommended for children younger than 10 years because of the low prevalence of cryptococcal meningitis in this age group. However , if a child younger than 10 years presents with signs and symptoms of meningitis, cryptococcal meningitis should still be considered and the appropriate investigations and treatment for this should be implemented (Tables 2, 3). The burden of TB is high among children living with HIV. Table 3 highlights the main recommendations for TB screening. WHO now suggests using integrated treatment decision algorithms for children younger than 10 years and concurrent testing of (1) respiratory samples and (2) stool with molecular WHO-recommended rapid diagnostics along with (3) urine testing using point-of-care ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 25
  },
  {
    "chunk_id": "advancedhiv_1071",
    "text": "ger than 10 years and concurrent testing of (1) respiratory samples and (2) stool with molecular WHO-recommended rapid diagnostics along with (3) urine testing using point-of-care LF-LAM testing for children living with HIV (59, 60). Concurrent use of the multiple sample types and tests should be given priority to maximize opportunities for confirming TB. Treatment for drug-sensitive TB among children comprises a four-drug regimen that includes rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) to be provided with available child-friendly, fixed-dose combinations in dispersible formulations to decrease the pill burden and facilitate administration for young children (61). Drug–drug interactions between rifampicin and lopinavir + ritonavir or dolutegravir need to be considered and ART dosing adjusted accordingly. Additional details are provided in the section on TB. Althou",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 25
  },
  {
    "chunk_id": "advancedhiv_1072",
    "text": "between rifampicin and lopinavir + ritonavir or dolutegravir need to be considered and ART dosing adjusted accordingly. Additional details are provided in the section on TB. Although rapid ART initiation within seven days of diagnosis is a priority, especially for children older than five years, children with severe acute malnutrition, TB meningitis or other severe illnesses need urgent clinical stabilization. However , initiating ART is encouraged as part of the child’s hospitalization, since referral after discharge may lead to loss to follow-up and failure to initiate ART. Among children with signs of or confirmed TB meningitis, ART initiation should be delayed in accordance with existing guidelines. Similarly, ensuring linkage to the facility in which the child will receive ongoing HIV care on discharge is critical. Preventing opportunistic infections in advanced HIV disease among ch",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 25
  },
  {
    "chunk_id": "advancedhiv_1073",
    "text": "ly, ensuring linkage to the facility in which the child will receive ongoing HIV care on discharge is critical. Preventing opportunistic infections in advanced HIV disease among children comprises rapid ART initiation, preventing TB disease with bacille Calmette-Guérin (BCG) vaccination and TB preventive treatment, preventing Pneumocystis jirovecii pneumonia with co-trimoxazole prophylaxis and administering age-appropriate vaccinations and catch-up vaccine administration when indicated (Table 3). Guidelines for managing HIV, TB, routine child health and development interventions (vitamin A, nutritional support, deworming and the Expanded Programme on Immunization) should align as much as possible to prevent multiple visits to health-care services.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 25
  },
  {
    "chunk_id": "advancedhiv_1074",
    "text": "13 At the facility level, centres introducing the advanced HIV disease package for children should provide a child-friendly environment and ensure access to child-specific resources such as drug formulations for children, a mid-upper arm circumference tape, stadiometer , appropriate scales and expertise in phlebotomy for children. Health-care providers should be sensitized on child-specific issues such as growth monitoring and other routine child health interventions. Efforts should additionally be put in place to support and equip parents and caregivers to recognize warning signs and be able to reliably administer the prescribed medications. Clinical considerations The role of presumptive treatment is important in settings in which access to diagnostic tests is limited, especially if the person presenting to care is seriously ill.3 Other clinical conditions, such as elevated body temper",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 26
  },
  {
    "chunk_id": "advancedhiv_1075",
    "text": "t in settings in which access to diagnostic tests is limited, especially if the person presenting to care is seriously ill.3 Other clinical conditions, such as elevated body temperature of ≥39°C, can also be considered based on local epidemiology and clinical judgement. People with advanced HIV disease may start both ART and prophylaxis at the same time (53). However , ART initiation should be deferred when clinical symptoms suggest TB meningitis or cryptococcal meningitis to avoid paradoxical worsening of the existing infection, which can be life-threatening (62). Research gaps Adults Research priorities related to diagnostics remain important. Further research is needed to develop simplified point-of-care diagnostics for TB, severe bacterial infections, Pneumocystis jirovecii pneumonia, toxoplasmosis, cytomegalovirus disease and other opportunistic infections specific to geographical r",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 26
  },
  {
    "chunk_id": "advancedhiv_1076",
    "text": "gnostics for TB, severe bacterial infections, Pneumocystis jirovecii pneumonia, toxoplasmosis, cytomegalovirus disease and other opportunistic infections specific to geographical regions, such as histoplasmosis and talaromycosis. Other research priorities include defining the optimal package of prophylactic interventions for people who have not yet started ART, additional 3 A seriously ill adult is defined as having any of the following danger signs: respiratory rate ≥30 breaths per minute; heart rate ≥120 beats per minute; or unable to walk unaided. prophylaxis for severe bacterial infections, the benefit of primary fluconazole prophylaxis among those with advanced HIV disease for whom cryptococcal antigen screening is not feasible, the optimal pre-emptive treatment strategy for people identified as cryptococcal antigen–positive at screening and approaches to antibiotic therapy within a",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 26
  },
  {
    "chunk_id": "advancedhiv_1077",
    "text": "eening is not feasible, the optimal pre-emptive treatment strategy for people identified as cryptococcal antigen–positive at screening and approaches to antibiotic therapy within a public health approach and, specifically, the independent effect of short-course azithromycin on mortality (trial underway) (55, 63). Programmatic assessment of the intensity of follow-up required and adherence strategies for people with advanced HIV disease are important areas for future implementation research. The optimal management approach for people presenting again for care with advanced HIV disease after treatment interruption may warrant further investigation. Several studies have reported outcomes of providing the advanced HIV disease package in routine care settings, and additional data would be of value (44, 64, 65). In addition, since these trials have not investigated the benefit of an interventi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 26
  },
  {
    "chunk_id": "advancedhiv_1078",
    "text": "HIV disease package in routine care settings, and additional data would be of value (44, 64, 65). In addition, since these trials have not investigated the benefit of an intervention package for infants and children younger than five years, specific components and optimal delivery warrant further research. Finally, region-specific packages of care should be defined and their effectiveness assessed. Children Multiple research gaps exist in addressing prevention and care for children living with advanced HIV disease. Better tools are needed to screen and diagnose TB among children living with HIV. Examples of critical knowledge gaps include better diagnostics, including the need to develop simplified point-of-care diagnostics for pneumonia (including Pneumocystis jirovecii pneumonia) and for cytomegalovirus disease, whether to empirically treat for TB and/or cytomegalovirus disease among c",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 26
  },
  {
    "chunk_id": "advancedhiv_1079",
    "text": "e diagnostics for pneumonia (including Pneumocystis jirovecii pneumonia) and for cytomegalovirus disease, whether to empirically treat for TB and/or cytomegalovirus disease among children living with HIV who present with severe pneumonia and what the optimal package of prophylactic interventions for children living with HIV younger than five years should be.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 26
  },
  {
    "chunk_id": "advancedhiv_1080",
    "text": "14 Components of the package of care for advanced HIV disease Table 2. Components of the WHO-recommended advanced HIV disease package of care for adults, adolescents and children Intervention CD4 cell count Adults Adolescents Children <10 years Screening Systematic screening for TB disease All people living with HIV Yes Yes Yes Cryptococcal antigen screening Recommended for both <200 cells/mm3 and <100 cells/mm3 Yes Yes No Diagnosis Diagnosisa of histoplasmosis with antigen testing All people living with HIV Yes Yes - Concurrent testing with low-complexity automated nucleic acid amplification tests (NAATs) on respiratory samples and LF-LAM on urine should be used as the initial diagnostic strategy for diagnosing TB All people living with HIV Yes, and/or seriously ill or have advanced HIV disease Yes, and/or seriously ill or have advanced HIV disease Yes, and use of low-complexity NAATs o",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 27
  },
  {
    "chunk_id": "advancedhiv_1081",
    "text": "g TB All people living with HIV Yes, and/or seriously ill or have advanced HIV disease Yes, and/or seriously ill or have advanced HIV disease Yes, and use of low-complexity NAATs on stool samples Prophylaxis and presumptive treatment Co-trimoxazole prophylaxis <350 cells/mm3 or clinical stage 3 or 4 Any CD4 count in settings with high prevalence of malaria or severe bacterial infections Yes Yes Yes TB preventive treatment All people living with HIV Yes (3HP preferred) Yes (3HP preferred) Yes Fluconazole pre-emptive therapy for cryptococcal antigen–positive people without evidence of meningitis Recommended for both <200 cells/mm3 and <100 cells/mm3 Yes Yes Not applicable (screening not advised) ART Rapid ART initiation Any Yes Yes Yes Defer if clinical symptoms suggestive of meningitis (TB or cryptococcal) Any Yes Yes Yes Counselling Tailored adherence counselling, home visits if feasible",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 27
  },
  {
    "chunk_id": "advancedhiv_1082",
    "text": "tiation Any Yes Yes Yes Defer if clinical symptoms suggestive of meningitis (TB or cryptococcal) Any Yes Yes Yes Counselling Tailored adherence counselling, home visits if feasible <200 cells/mm3 Yes Yes Yes",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 27
  },
  {
    "chunk_id": "advancedhiv_1083",
    "text": "15 a WHO does not currently recommend routine screening for histoplasmosis. Screen, Treat, Optimize and Prevent AIDS among children and adolescents living with HIV Screen & diagnose Tuberculosis Children younger than 10 years should be systematically screened for TB disease using a symptom screen including any one of cough, fever , poor weight gain, or chest X-ray or both. Adolescents should be screened as per WHO guidelines for adults. Concurrent testing with low-complexity automated NAATs (on respiratory and stool samples), along with LF-LAM testing (on urine samples) as the initial diagnostic strategy for diagnosis of TB in children who have signs or symptoms or screened positive for pulmonary TB. In children with presumptive pulmonary TB, integrated treatment decision algorithms may be used to diagnose pulmonary TB. Cryptococcal infection among adolescents Serum or plasma or blood cr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 28
  },
  {
    "chunk_id": "advancedhiv_1084",
    "text": "n with presumptive pulmonary TB, integrated treatment decision algorithms may be used to diagnose pulmonary TB. Cryptococcal infection among adolescents Serum or plasma or blood cryptococcal antigen screening in individuals with CD4 <200 cells/mm3, followed by CrAg antigen testing of CSF samples from a lumbar puncture if positive or symptomatic. If asymptomatic, consider subclinical meningitis. Managing nutritional needs Conduct nutritional assessment at HIV diagnosis and at regular intervals, thereafter , using age-appropriate anthropometric measurements. Examine for and address other underlying causes of undernutrition (e.g. helminth infections and diarrhoeal disease). Provide nutritional counselling to family members or carers. If undernutrition is present, refer for inpatient management where appropriate. Offer therapeutic or supplementary feeding as indicated to cover the nutrient n",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 28
  },
  {
    "chunk_id": "advancedhiv_1085",
    "text": "y members or carers. If undernutrition is present, refer for inpatient management where appropriate. Offer therapeutic or supplementary feeding as indicated to cover the nutrient needs for growth and development as per WHO guidelines. Treat Tuberculosis, severe pneumonia, severe bacterial infections, cryptococcal meningitis and manage nutritional needs according to WHO guidelines. Optimize Rapid initiation of antiretroviral therapy. Appropriate caregiver counselling for antiretroviral therapy Optimise nutritional needs and monitor nutritional recovery Prevent Co-trimoxazole prophylaxis as per WHO guidelines to prevent bacterial infections and Pneumocystis pneumonia TB preventive treatment as part of a comprehensive package of HIV care to prevent TB Food assistance to prevent TB among household contacts of people with TB in food insecure settings Oral fluconazole prophylaxis to prevent cr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 28
  },
  {
    "chunk_id": "advancedhiv_1086",
    "text": "sive package of HIV care to prevent TB Food assistance to prevent TB among household contacts of people with TB in food insecure settings Oral fluconazole prophylaxis to prevent cryptococcal disease in adolescents Ensure up-to-date vaccinations as per WHO Essential Programme on immunisation recommendations",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 28
  },
  {
    "chunk_id": "advancedhiv_1087",
    "text": "16 Table 3. Screening, diagnosis and prevention components of the package of care for children and adolescents with advanced HIV disease Intervention Disease/ component <5 years 5-9 years 10-19 years Screening and diagnosis TB Yes Yes Yes Cryptococcal disease No No Yes Nutritional assessment & counselling Yes Yes Yes Prevention, prophylaxis and pre-emptive treatment Up-to-date vaccinations as per WHO EPI recommendations Yes Yes Yes Fluconazole prophylaxis Not applicable Not applicable Yes Co-trimoxazole Yes Yes Yes TB preventive treatment Yes Yes Yes Sources of information 1. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022. URL: https://www.who.int/publications/i/item/9789240046764 (*) 2. WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tubercu",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 29
  },
  {
    "chunk_id": "advancedhiv_1088",
    "text": "ization; 2022. URL: https://www.who.int/publications/i/item/9789240046764 (*) 2. WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021 URL: https://www.who.int/publications/i/item/9789240022676 3. Package of care for children and adolescents with advanced HIV disease: stop AIDS. Technical brief. Geneva: World Health Organization; 2020. URL: https://www.who.int/publications/i/item/9789240008045 4. IMAI district clinician manual: hospital care for adolescents and adults: guidelines for the management of illnesses with limited- resources. Geneva: World Health Organization; 2011. URL: https://www.who.int/publications/i/item/9789241548281 5. Handbook: Guidelines for an Integrated Approach to the Nutritional care of HIV-infected children (6 months-14 years). Geneva: World Health Organization; 20",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 29
  },
  {
    "chunk_id": "advancedhiv_1089",
    "text": "/i/item/9789241548281 5. Handbook: Guidelines for an Integrated Approach to the Nutritional care of HIV-infected children (6 months-14 years). Geneva: World Health Organization; 2009. URL: https://www.who.int/publications/i/item/9789241597524 6. Essential Programme on Immunisation(EPI). Geneva: World Health Organization; 2025. URL: https://www.who.int/teams/immunization- vaccines-and-biologicals/essential-programme-on-immunization 7. WHO consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities, second edition. Geneva: World Health Organization; 2025. 8. Food and Nutrition Handbook. Italy: World Food Programme; 2018. URL: https://emergency.unhcr .org/sites/default/files/2024-01/ Food%20and%20Nutrition%20Handbook_WFP%202018.pdf 9. WHO guideline on the prevention and management of wasting and nutritional oedema (acute malnutrition) in infants and children under 5 ye",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 29
  },
  {
    "chunk_id": "advancedhiv_1090",
    "text": "nd%20Nutrition%20Handbook_WFP%202018.pdf 9. WHO guideline on the prevention and management of wasting and nutritional oedema (acute malnutrition) in infants and children under 5 years. Geneva: World Health Organization; 2023. URL: https://www.who.int/publications/i/item/9789240082830 (*) All information sources accessed September 18, 2025",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 29
  },
  {
    "chunk_id": "advancedhiv_1091",
    "text": "Clinical management of advanced HIV disease",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 30
  },
  {
    "chunk_id": "advancedhiv_1092",
    "text": "18 Background People living with HIV, including those with advanced disease or who are seriously ill, may present to health care at a variety of different levels depending on local context. The package of care for people with advanced HIV disease should be offered at both hospitals and decentralized primary care clinics according to the clinical status of the person living with HIV, the skills mix of health-care workers (66), access to diagnostics and treatments and feasibility of transfer . Management of advanced HIV disease in outpatient settings Improving access at peripheral sites through mobile outreach or decentralization should be encouraged to increase access. This approach has been shown to be feasible and acceptable, supported by a range of tools (67, 68). Clear referral criteria should be established so that people who initially present to primary health care or outreach servi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 31
  },
  {
    "chunk_id": "advancedhiv_1093",
    "text": " and acceptable, supported by a range of tools (67, 68). Clear referral criteria should be established so that people who initially present to primary health care or outreach services but require inpatient care can access it in an expedited manner , so that people requiring further investigation or specialist management receive services in a timely manner . Whether a person could be safely managed at a primary care clinic depends on several factors, including local organization of the health service network, how unwell the person is, what diagnostic and treatment resources are available and the cadre, number and skill set of personnel at the primary care level. Consideration should be given to ensuring access to ambulances or other transport, so that people can be rapidly transferred to higher-level facilities when needed. There should be a mechanism for referral and communication back t",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 31
  },
  {
    "chunk_id": "advancedhiv_1094",
    "text": "o ambulances or other transport, so that people can be rapidly transferred to higher-level facilities when needed. There should be a mechanism for referral and communication back to a peripheral clinic following discharge from hospital to ensure appropriate follow-up. Promotion of health literacy is also an important responsibility for programmes and helps to promote better understanding of HIV (69) and advanced HIV disease.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 31
  },
  {
    "chunk_id": "advancedhiv_1095",
    "text": "19 Management of advanced HIV disease in hospital settings Hospitalization from complications relating to HIV infection, including coinfections associated with advanced HIV disease, remains substantial. People who are hospitalized with HIV-related illness have a high risk of death, and this risk persists after discharge from inpatient care (10). When unwell individuals first present to health care, immediately life-threatening conditions should be rapidly identified and treated. Guidance about emergency triage assessment and treatment for children (70) and guidance about emergency management of illness in adolescents and adults is available elsewhere (71). A person might require inpatient care for several reasons: • for close clinical monitoring because of being seriously ill with deteriorating or fluctuating symptoms and clinical status or for higher levels of nursing care such as posit",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 32
  },
  {
    "chunk_id": "advancedhiv_1096",
    "text": "ns: • for close clinical monitoring because of being seriously ill with deteriorating or fluctuating symptoms and clinical status or for higher levels of nursing care such as position change to prevent bedsores, assistance with mobility and pain management; • for advice and case management from professionals with knowledge and substantial clinical decision-making expertise, including making decisions in response to rapidly changing clinical conditions; • for treatments that are typically only delivered or available at a central location (such as supplemental oxygen or intravenous medicines); and • for diagnostic or radiology services or procedures that are typically centralized or only provided at larger health-care facilities. Initial management Many people who present to hospital with advanced HIV disease already know their HIV status, and HIV status should be confidentially asked abou",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 32
  },
  {
    "chunk_id": "advancedhiv_1097",
    "text": "-care facilities. Initial management Many people who present to hospital with advanced HIV disease already know their HIV status, and HIV status should be confidentially asked about at admission. For people who do not know their HIV status, WHO recommends that, in settings with a high burden of HIV, provider-initiated HIV testing and counselling be offered to all people presenting for care in all health-care settings. In settings with a low burden of HIV, people with conditions that could indicate HIV infection should be offered testing (72). Consideration should be given to making HIV testing services for inpatients available on evenings and weekends in all areas of hospitals. HIV testing algorithms and strategies are available to support high-quality testing (72). Although HIV testing should be voluntary and conducted with informed consent, if the person is unconscious, HIV testing may",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 32
  },
  {
    "chunk_id": "advancedhiv_1098",
    "text": "gies are available to support high-quality testing (72). Although HIV testing should be voluntary and conducted with informed consent, if the person is unconscious, HIV testing may be considered when this is clinically judged to be in the person’s best interests for optimal care and the reasoning explained to them when they regain mental capacity (73). Managing ART among people who are seriously ill A seriously ill adult is defined as having any of the following danger signs: respiratory rate ≥30 breaths per minute; heart rate ≥120 beats per minute; or unable to walk unaided. In general terms, in settings with a high burden of HIV, HIV testing should be given priority for individuals suspected to have HIV, and any individual living with HIV who is not receiving ART should start ART as soon as possible. Failure to identify HIV in a timely manner risks increased mortality from opportunisti",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 32
  },
  {
    "chunk_id": "advancedhiv_1099",
    "text": "any individual living with HIV who is not receiving ART should start ART as soon as possible. Failure to identify HIV in a timely manner risks increased mortality from opportunistic infections.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 32
  },
  {
    "chunk_id": "advancedhiv_1100",
    "text": "20 People with central nervous system signs and symptoms should have investigations for meningitis before starting ART. ART initiation should be delayed until after four weeks of TB treatment (TB meningitis) or until four to six weeks from the start of cryptococcal meningitis treatment (8, 74). WHO has no specific recommendation about timing of ART following bacterial meningitis (75) or other central nervous system opportunistic infections because data are lacking. Expert opinion about managing ART among adults with cryptococcal meningitis, including certain situations in which stopping ART among people with cryptococcal meningitis (and restarting once recovered) is suggested, has been summarized (76, 77). The 2025 WHO guidelines on the management of bacterial meningitis (78) state that the choice of antibiotic for bacterial meningitis is either ceftriaxone or cefotaxime as first-line ag",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 33
  },
  {
    "chunk_id": "advancedhiv_1101",
    "text": "2025 WHO guidelines on the management of bacterial meningitis (78) state that the choice of antibiotic for bacterial meningitis is either ceftriaxone or cefotaxime as first-line agents for empirical treatment in suspected cases of acute bacterial infection. However , intravenous ceftriaxone is preferred over cefotaxime during meningococcal and pneumococcal disease epidemics. Further , ampicillin or amoxicillin should be added to the initial empirical regimen in the presence of advanced HIV disease if there is elevated risk of Listeria monocytogenes infection (78). Antibiotics used for empirical therapy can be modified as needed based on CSF or blood culture and antibiotic sensitivity results. The use of intravenous corticosteroids administered as adjunctive treatment for suspected acute bacterial meningitis among children and adults with advanced HIV disease has not proven to be benefici",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 33
  },
  {
    "chunk_id": "advancedhiv_1102",
    "text": "nous corticosteroids administered as adjunctive treatment for suspected acute bacterial meningitis among children and adults with advanced HIV disease has not proven to be beneficial in reducing mortality and morbidity (78). WHO recommends that people with TB start ART as soon as possible and within two weeks of having started TB treatment unless they have TB meningitis (delay ART by 4–6 weeks) or multidrug-resistant TB (initiate ART as soon as possible but within eight weeks). In cases of suspected or confirmed TB meningitis, ART should be delayed for at least four weeks and started within eight weeks (8). One trial showed that giving prednisone concurrent with starting ART to people already receiving treatment for TB reduced the incidence of paradoxical TB immune reconstitution inflammatory syndrome (79); more research is needed to inform guidance. Countries may consider initiating ART",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 33
  },
  {
    "chunk_id": "advancedhiv_1103",
    "text": "t for TB reduced the incidence of paradoxical TB immune reconstitution inflammatory syndrome (79); more research is needed to inform guidance. Countries may consider initiating ART among people living with HIV who present with signs and symptoms suggesting TB, except for those with symptoms suggesting meningitis, while rapidly investigating for TB, with close follow-up within seven days to initiate TB treatment if TB is confirmed. There is no specific recommendation about when to start ART for people in hospital who are seriously ill, who have opportunistic infections other than TB or cryptococcal meningitis or while diagnostic tests are pending and the cause of illness is unclear; two small studies found no statistically significant difference between early and delayed ART among unwell adults (80, 81) . A WHO expert advisory group for children concluded that appropriate care for clinica",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 33
  },
  {
    "chunk_id": "advancedhiv_1104",
    "text": "atistically significant difference between early and delayed ART among unwell adults (80, 81) . A WHO expert advisory group for children concluded that appropriate care for clinical conditions requiring acute management is the first priority, and ART initiation should follow (14). People who have previously been taking ART but who have interrupted treatment should be offered ART reinitiation; if their initial ART regimen was based on non-nucleoside reverse-transcriptase inhibitors, they should restart a dolutegravir-based regimen. It is advised to discuss the reasons for having interrupted care and provide counselling support that might help prevent further interruption. People starting ART in hospital should have the same counselling, information and opportunity to ask questions as people starting ART in primary care settings. Individuals currently taking ART A detailed history about AR",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 33
  },
  {
    "chunk_id": "advancedhiv_1105",
    "text": "ave the same counselling, information and opportunity to ask questions as people starting ART in primary care settings. Individuals currently taking ART A detailed history about ART intake should be taken. An individual who is unwell and has been taking ART for more than six months should have their adherence evaluated and an HIV viral load test, if available. People who are taking a regimen based on non-nucleoside reverse-transcriptase inhibitors and have a viral load greater than 1000 copies/mL should switch immediately after a single elevated viral load to a dolutegravir-containing ART regimen. People with an elevated viral load who are taking a regimen containing dolutegravir or a protease inhibitor should have enhanced adherence counselling for at least one month and a repeat viral load test done at three months or earlier according to local standards (8). Programmes could consider ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 33
  },
  {
    "chunk_id": "advancedhiv_1106",
    "text": "have enhanced adherence counselling for at least one month and a repeat viral load test done at three months or earlier according to local standards (8). Programmes could consider reducing the time for repeat viral load to one month for people with advanced HIV disease to reduce the amount of time with treatment failure. Timing of ART Rapid ART initiation is a critical programmatic action to reduce the risk of progression among individuals with advanced HIV disease and should be provided alongside the WHO-recommended advanced HIV disease package of care (14).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 33
  },
  {
    "chunk_id": "advancedhiv_1107",
    "text": "21 Table 4. Summary of timing of ART for individuals with opportunistic infections and comorbid conditions (8, 58, 82, 83) Clinical status of people living with HIV Timing of ART initiation No signs and symptoms of TB Rapid ART initiation, including starting ART on the same day that a diagnosis is confirmed should be offered to all people living with HIV following clinical assessment. Suspected TB Rapid ART initiation should be offered to all people living with HIV following a confirmed HIV diagnosis and clinical assessment and to people living with HIV with signs and symptoms suggesting TB. Except for central nervous system disease (meningitis), initiate ART while rapidly investigating for TB, with close follow-up within seven days to initiate TB treatment if TB is confirmed. TB disease ART should be started as soon as possible within two weeks of initiating TB treatment, regardless of ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 34
  },
  {
    "chunk_id": "advancedhiv_1108",
    "text": "w-up within seven days to initiate TB treatment if TB is confirmed. TB disease ART should be started as soon as possible within two weeks of initiating TB treatment, regardless of CD4 cell count, among people living with HIV (except for tuberculous meningitis and multidrug-resistant TB) Diagnosed with TB meningitis ART should be delayed at least four weeks (and initiated within eight weeks) after treatment for TB meningitis is initiated. Corticosteroids should be considered adjuvant treatment for TB meningitis, but cryptococcal meningitis should be ruled out since steroid use can lead to more adverse events. Cryptococcal meningitis ART initiation should be deferred by 4–6 weeks from the initiation of antifungal treatment. Histoplasmosis ART should be initiated as soon as possible among people with disseminated histoplasmosis for whom central nervous system involvement is not suspected or",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 34
  },
  {
    "chunk_id": "advancedhiv_1109",
    "text": " treatment. Histoplasmosis ART should be initiated as soon as possible among people with disseminated histoplasmosis for whom central nervous system involvement is not suspected or proven. Kaposi’s sarcoma ART should be rapidly initiated alongside management of Kaposi’s sarcoma. Managing side-effects of treatment Immune reconstitution inflammatory syndrome and adverse antiretroviral drug reactions are both more common in the first few months after starting or changing ART, although drug reactions can occur at any time. After starting ART, immune reconstitution inflammatory syndrome may manifest as a worsening of a previously diagnosed disease (paradoxical immune reconstitution inflammatory syndrome) or present as the unmasking of a previously undiagnosed disease with an unusually heightened inflammation (unmasking immune reconstitution inflammatory syndrome). Consensus definitions for re",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 34
  },
  {
    "chunk_id": "advancedhiv_1110",
    "text": "as the unmasking of a previously undiagnosed disease with an unusually heightened inflammation (unmasking immune reconstitution inflammatory syndrome). Consensus definitions for research purposes exist for TB immune reconstitution inflammatory syndrome and for other opportunistic infections (14, 84, 85). WHO does not have a specific recommendation for managing ART when immune reconstitution inflammatory syndrome is suspected. Most expert guidelines recommend symptomatic treatment (such as analgesia) and reassurance for mild immune reconstitution inflammatory syndrome (85). For individuals with more severe immune reconstitution inflammatory syndrome, especially caused by TB, steroids may be used (85, 86), although a clinical trial conducted in 2023 suggests that benefits may be small to none (87). Steroids should not routinely be used for people with cryptococcal meningitis due to an incr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 34
  },
  {
    "chunk_id": "advancedhiv_1111",
    "text": "gh a clinical trial conducted in 2023 suggests that benefits may be small to none (87). Steroids should not routinely be used for people with cryptococcal meningitis due to an increase in adverse events and delayed clearance of fungus from CSF (88), but some expert guidelines suggest steroids in severe immune reconstitution inflammatory syndrome due to cryptococcal meningitis (77). This is of particular importance when considering a differential diagnosis of TB meningitis – since steroids may be considered for use – thus, ruling out cryptococcal meningitis is critical in this context since steroid use is strictly contraindicated. In general, ART should not be interrupted during immune reconstitution inflammatory syndrome, but advice should be sought from an experienced HIV clinician if possible. ART side-effects associated with currently available drug regimens are usually mild and unlik",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 34
  },
  {
    "chunk_id": "advancedhiv_1112",
    "text": "y syndrome, but advice should be sought from an experienced HIV clinician if possible. ART side-effects associated with currently available drug regimens are usually mild and unlikely to require hospitalization. In the event of severe and life-threatening toxicity or hypersensitivity, ART should be discontinued until symptoms have resolve, and a substitution regimen can be safely initiated. If possible, people who have symptoms of ART toxicity should have laboratory testing as indicated (for example, renal function, liver function or haemoglobin measurement) (8). Specialist advice should be sought if available. WHO recommends monitoring antiretroviral drug toxicity at the national level, so if someone who is seriously ill is identified as having antiretroviral drug toxicity, this should be reported as part of routine pharmacovigilance.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 34
  },
  {
    "chunk_id": "advancedhiv_1113",
    "text": "22 Planning for discharge and follow-up care (new, 2025) Recommendation for improving re-engagement and reducing readmissions Hospitalized people with HIV may be provided interventions to support transitions to outpatient care and reduce avoidable readmissions. Conditional recommendation, low-certainty evidence Interventions may include: • pre-discharge goal setting • medication review • transitional care planning • telephone follow-up • home visits by health-care providers and/or peer supporters • individualized support. The outcomes of people following discharge from hospital are poor . A systematic review up to 2022 found that 19% of people living with HIV were subsequently readmitted to hospital after discharge and 14% had died (10). More recent studies have confirmed that post-discharge outcomes are poor for both adults and children (89–91). Rationale and supporting evidence Linkage",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 35
  },
  {
    "chunk_id": "advancedhiv_1114",
    "text": "arge and 14% had died (10). More recent studies have confirmed that post-discharge outcomes are poor for both adults and children (89–91). Rationale and supporting evidence Linkage to care can be considered a core health- care principle in most settings. However , assessing the effectiveness of programmatic activities (such as transitional care planning, discharge protocols and health-care worker visits) to hospitalized people with HIV provides important information on the activities to which programmes should give priority in the context of limited resources while working across different divisions of a national health programme structure. Recent studies suggest that providing support following hospital discharge can improve outcomes. A systematic review of hospitalized patients with HIV identified 10 studies assessing interventions to improve outcomes following hospital discharge (92).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 35
  },
  {
    "chunk_id": "advancedhiv_1115",
    "text": "rge can improve outcomes. A systematic review of hospitalized patients with HIV identified 10 studies assessing interventions to improve outcomes following hospital discharge (92). Four studies were randomized trials conducted in Spain (93), South Africa (94), the United Republic of Tanzania (95) and the United States of America (96). Six studies were observational designs from Canada (97), the United States of America (98–100), Zambia (101) and Thailand (102). Across the randomized trials, there was no clear evidence of a difference in mortality between those who did and did not receive an intervention (relative risk (RR) 0.98, 95% CI 0.59–1.63); this estimate is imprecise, and there were few deaths with pooled risk differences across the trials, ranging from seven fewer to six more per 100 patients. The interventions might be associated with reduced likelihood of readmissions (RR 0.82,",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 35
  },
  {
    "chunk_id": "advancedhiv_1116",
    "text": "d risk differences across the trials, ranging from seven fewer to six more per 100 patients. The interventions might be associated with reduced likelihood of readmissions (RR 0.82, 95% CI 0.52– 1.30) and might be associated with a slight increase in the likelihood of linkage or retention (RR 1.10, 95% CI 0.95–1.27) although the confidence interval is wide, including no effect. Outcomes were similar across the observational studies, which reported no difference in mortality (RR 1.0, 95% CI 0.63–1.59),",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 35
  },
  {
    "chunk_id": "advancedhiv_1117",
    "text": "23 possibly decreased likelihood of readmissions (RR 0.77, 95% CI 0.48–1.25) and increased likelihood of linkage or retention in care (RR 1.42, 95% CI 1.11–1.81). Pooling all data across study designs gave similar results: no difference in mortality (RR 1.02, 95% CI 0.79–1.32) and a possible reduction in readmissions (RR 0.87, 95% CI 0.69–1.09). Linkage or retention in care increased (RR 1.24, 95% CI 1.07–1.44), which translated into 18 more patients of every hundred (6–30 patients) being linked or retained. The certainty of the evidence was rated as low because of concerns about the risk of bias across the studies and uncertainty around the reported benefits, thus likely small. The systematic review was complemented by an umbrella review that assessed post-discharge interventions among people without HIV hospitalized for comparable chronic conditions. The reviews reported on pre- and po",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 36
  },
  {
    "chunk_id": "advancedhiv_1118",
    "text": "mented by an umbrella review that assessed post-discharge interventions among people without HIV hospitalized for comparable chronic conditions. The reviews reported on pre- and post-discharge interventions, including communication interventions (103), transitional care interventions (104–109) and tele-transitions interventions (110). Individual intervention components included education interventions (103–109), discharge planning needs assessment (109), medication reconciliation (103, 105, 108, 109), linking with community or social care contact (109), case management and health assessment (105, 107, 109), telephone follow-up (104–107, 109, 110), home visits (104–109), peer support (109), needs assessment (108, 109) and telemonitoring (104, 105, 107, 109, 110). A systematic review focusing on medical inpatients – those with cardiac and respiratory diseases – reported a significant reduc",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 36
  },
  {
    "chunk_id": "advancedhiv_1119",
    "text": ", 109) and telemonitoring (104, 105, 107, 109, 110). A systematic review focusing on medical inpatients – those with cardiac and respiratory diseases – reported a significant reduction in hospital readmission associated with education and medical reconciliation interventions for patients with respiratory diseases (RR 0.32; 95% CI 0.18–0.57) and other chronic conditions (RR 0.78; 95% CI 0.64–0.96) (103). A systematic review focusing on multiple chronic conditions reported significant reduction in hospital readmission associated with education, telephone follow-up and home visits interventions (RR 0.84; 95% CI 0.71–0.99) (106). Two systematic reviews focusing on chronic conditions reported significant reduction in readmission associated with multiple pre- and post-discharge interventions (104, 105). One of the reviews showed a significant reduction in readmission associated with education,",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 36
  },
  {
    "chunk_id": "advancedhiv_1120",
    "text": "n readmission associated with multiple pre- and post-discharge interventions (104, 105). One of the reviews showed a significant reduction in readmission associated with education, medical reconciliation, case management, telephone follow-up, home visits and telemonitoring (RR 0.63; 95% CI 0.44–0.91) (105). Another review showed significant reduction in readmission associated with education, telephone follow-up, home visits and telemonitoring interventions but only for patients with heart failure (RR 0.90; 95% CI 0.81–0.99) and patients with chronic obstructive pulmonary disease (RR 0.52, 95% CI 0.32–0.83) (104). A systematic review focusing on older adults with high risk of readmission showed significant reduction in readmission associated with telephone follow-up and telemonitoring (RR 0.59, 95% CI 0.45–0.77) (110). Taking the HIV-specific evidence and the evidence for non-HIV chronic ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 36
  },
  {
    "chunk_id": "advancedhiv_1121",
    "text": "tion in readmission associated with telephone follow-up and telemonitoring (RR 0.59, 95% CI 0.45–0.77) (110). Taking the HIV-specific evidence and the evidence for non-HIV chronic conditions together , the Guideline Development Group considered that the following interventions can be considered to improve linkage to post-hospital care and reduce the occurrence of avoidable readmissions: pre- discharge goal setting and counselling (93, 95–97), medical review (98, 100, 101) , transitional care planning (98, 99), telephone follow-up (93–99, 102) and home visits by a nurse and/or peer supporter (94, 95, 100, 101) . Preferences, acceptability and feasibility Two studies that assessed post-discharge follow-up of people with HIV by telephone or home visit reported that the interventions were acceptable (93, 101). From the umbrella review, two systematic reviews reported on acceptability and sat",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 36
  },
  {
    "chunk_id": "advancedhiv_1122",
    "text": "le with HIV by telephone or home visit reported that the interventions were acceptable (93, 101). From the umbrella review, two systematic reviews reported on acceptability and satisfaction with interventions of patients and/or their caregivers (103, 109). A systematic review focusing on medical inpatients, cardiology and respiratory diseases patients reported a significant association between communication interventions and patient satisfaction (103). A systematic review that included patients with any health conditions reported increased patient satisfaction associated with high complexity interventions (109). It is important to respect privacy and confidentiality: consent should be sought before post-discharge follow-up at home, and if a person would prefer not to have home visits and or telephone calls from the clinic, this should be recorded. Few studies included in the review repor",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 36
  },
  {
    "chunk_id": "advancedhiv_1123",
    "text": "ge follow-up at home, and if a person would prefer not to have home visits and or telephone calls from the clinic, this should be recorded. Few studies included in the review reported on cost, and when this information was available, it was limited to crude data with no economic analysis. The costs likely vary depending on the type or complexity of the intervention, setting etc. Three studies that assessed post-discharge follow- up by telephone or home visit reported that the interventions were feasible (94, 97, 101).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 36
  },
  {
    "chunk_id": "advancedhiv_1124",
    "text": "24 Resource use and equity One study that assessed social worker hospital and home care in the United Republic of Tanzania reported the cost of delivering the intervention to be US$ 22 per person (95). A study from Thailand reported that the intervention (enhanced inpatient rounds and telephone follow-up) was cost neutral (102); a study from the United States of America reported that the intervention (telephone follow-up) saved costs through reduced readmissions (98). All studies relied on existing cadres of non-specialist health personnel and community or peer workers. This supports the feasibility of delivering these interventions. Nevertheless, attention is needed to ensure that resources are not diverted away from the provision of other essential health-care services. In terms of equity, the Guideline Development Group noted that hospitalized patients are a vulnerable group with high",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 37
  },
  {
    "chunk_id": "advancedhiv_1125",
    "text": "ay from the provision of other essential health-care services. In terms of equity, the Guideline Development Group noted that hospitalized patients are a vulnerable group with high mortality. Higher rates of readmission lead to additional costs to the health system and individual that could be directed to serve other health needs, thus highlighting the need to reduce readmissions. Implementation considerations Certain activities, such as medical review and transitional care planning, should be considered as standard of care for all patients before hospital discharge. This includes ensuring that all patients are receiving ART and prophylaxis and have clear information about where to receive follow-up care. Differentiated approaches to support provision should be considered according to the presence of coinfections and comorbidities, including referral to mental health services as appropri",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 37
  },
  {
    "chunk_id": "advancedhiv_1126",
    "text": "rentiated approaches to support provision should be considered according to the presence of coinfections and comorbidities, including referral to mental health services as appropriate. Indirect support, such as nutritional assistance, can be considered as a way to strengthen care engagement (94). It is important to consider which cadres will provide post-discharge support and follow-up. Whenever possible, the existing health workforce could deliver the post-discharge interventions but with consideration of workforce capacity and sustainability. Peer counsellors, volunteers and support groups could also be engaged to provide support. Careful consideration should be given to the resources required for the support activity. This will vary according to context and should not divert resources away from other priority support needs. Referral mechanisms and optimal communication following disch",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 37
  },
  {
    "chunk_id": "advancedhiv_1127",
    "text": " activity. This will vary according to context and should not divert resources away from other priority support needs. Referral mechanisms and optimal communication following discharge back to the peripheral clinic should be reinforced to ensure appropriate follow-up (such as continuation of fluconazole, TB treatment or switching ART regimen when indicated). Referral back to the hospital should be assured for the individuals whose condition deteriorates after discharge. Referral and assessment should not result in unwarranted delays in starting ART and prophylaxis. Research needs Adequately powered randomized controlled trials of interventions are needed to identify effective ways to reduce mortality both during hospitalization and following discharge. These could include biomedical interventions (such as better diagnostics or treatments), process interventions (such as linkage to primar",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 37
  },
  {
    "chunk_id": "advancedhiv_1128",
    "text": "g hospitalization and following discharge. These could include biomedical interventions (such as better diagnostics or treatments), process interventions (such as linkage to primary care services) or social interventions (such as ART adherence support). A priority area for research is identifying interventions to prevent TB mortality; other common comorbidities can be considered according to local prevalence and endemicity. Research studies should consider the often-substantial post-hospital discharge mortality for people living with HIV. More research is needed to identify which interventions are most effective both before and after discharge to reduce avoidable readmissions and improve linkage to primary care in the community. Such research should include assessment of the acceptability and cost– effectiveness of providing support. Further evidence about timing of an ART switch, approp",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 37
  },
  {
    "chunk_id": "advancedhiv_1129",
    "text": " in the community. Such research should include assessment of the acceptability and cost– effectiveness of providing support. Further evidence about timing of an ART switch, appropriate subsequent regimens and actions to be taken on identifying failure to suppress viral loads among people who are seriously ill is a research priority. An important starting-point for research is to better characterize what is currently implemented as standard of care in hospital and following discharge, since this can identify areas that should be strengthened. Such research can include clearly characterizing the health status of people living with HIV at admission and discharge, research and clinical criteria for discharge and risk factors for poor post- discharge outcomes to identify patients who need more intensive follow-up.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 37
  },
  {
    "chunk_id": "advancedhiv_1130",
    "text": "25 Managing opportunistic infections",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 38
  },
  {
    "chunk_id": "advancedhiv_1131",
    "text": "26 Background Fungal priority pathogens for people living with HIV WHO has identified 19 fungal pathogens that are categorized into three priority groups in terms of their impact on public health, antimicrobial resistance, knowledge gaps and epidemiology (Table 5) (111). Several of these pathogens (Cryptococcus spp., Histoplasma spp., Pneumocystis spp., Paracoccidiodes spp. and invasive Talaromyces marneffei often affect people living with HIV. Although treatment guidelines are available for several of the high-burden infections, access to high-quality treatment is lacking in most settings. Importantly, people living with HIV remain susceptible to other pathogens specified in the priority pathogen list. Table 5. WHO list of fungal priority pathogens Critical group High group Medium group Cryptococcus neoformans Nakaseomyces glabrata (Candida glabrata) Scedosporium spp. Candida auris Hist",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 39
  },
  {
    "chunk_id": "advancedhiv_1132",
    "text": ". WHO list of fungal priority pathogens Critical group High group Medium group Cryptococcus neoformans Nakaseomyces glabrata (Candida glabrata) Scedosporium spp. Candida auris Histoplasma spp. Lamentospora prolificans Aspergillus fumigatus Eumycetoma causative agents Coccidiodes spp. Candida albicans Mucorales Pichia kudriavzeveii (Candida krusei) Fusarium spp. Cryptococcus gattii Candida tropicalis Talaromyces marneffei Candida parapsilosis Pneumocystis jirovecii Paracoccidiodes spp. Another WHO report (112) has found that the clinical pipeline of therapeutics for fungal infections approved in the past decade is insufficient considering the key targets and innovation needs. Drug–drug interactions are a major issue with currently available antifungal agents, and child-friendly formulations are lacking. The report also identifies at-risk categories of individuals, which includes people li",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 39
  },
  {
    "chunk_id": "advancedhiv_1133",
    "text": "ssue with currently available antifungal agents, and child-friendly formulations are lacking. The report also identifies at-risk categories of individuals, which includes people living with HIV or advanced HIV disease (112).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 39
  },
  {
    "chunk_id": "advancedhiv_1134",
    "text": "27 Cryptococcal disease (2022) Cryptococcal disease is an important opportunistic infection for people living with advanced HIV. After TB, cryptococcal disease is one of the most common opportunistic infections in advanced HIV disease, accounting for about 152 000 [133 000–219 000] cases in 2020, which resulted in 112 000 related deaths. Globally, this accounts for about 19% of AIDS-related deaths (113). Clinically significant or invasive disease is primarily caused by reactivation of latent infection among immunocompromised individuals, such as people living with HIV, months to years after initial exposure. By far the most common presentation, representing up to 90% of HIV-related cryptococcal disease, is central nervous system involvement. Less frequent disease presentations include pulmonary disease, skin, lymph node and bone involvement (114). Cryptococcal disease is uncommon among c",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 40
  },
  {
    "chunk_id": "advancedhiv_1135",
    "text": "ral nervous system involvement. Less frequent disease presentations include pulmonary disease, skin, lymph node and bone involvement (114). Cryptococcal disease is uncommon among children with HIV (115, 116), even in areas with a high disease burden among adults (117). Mortality from cryptococcal meningitis remains highest in low-income countries (113). The reasons for this high mortality include limited access to lumbar puncture and rapid diagnostic assays, which result in delays in diagnosing cryptococcal disease. Currently available antifungal drugs are costly and unavailable in many settings globally (118) as is intensive care, which is often required. In addition, there is limited ability to monitor and manage treatment-limiting toxicity and the frequent complications of raised intracranial pressure as well as immune reconstitution inflammatory syndrome associated with cryptococcal ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 40
  },
  {
    "chunk_id": "advancedhiv_1136",
    "text": "nage treatment-limiting toxicity and the frequent complications of raised intracranial pressure as well as immune reconstitution inflammatory syndrome associated with cryptococcal meningitis and ART (119–122). A public health approach leading to prevention, earlier diagnosis and improved treatment of cryptococcal disease and its complications is critical to reduce the incidence and associated high mortality of cryptococcal meningitis in low- and middle-income countries. Prevention and screening for cryptococcal disease The 2018 WHO recommendations for diagnosing cryptococcal disease remain unchanged (123). Background Early HIV diagnosis and initiation of ART remains the most important preventive strategy to reduce the incidence of cryptococcal disease and the associated high mortality among people living with HIV (123). Screening for cryptococcal antigenaemia is the optimal approach for ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 40
  },
  {
    "chunk_id": "advancedhiv_1137",
    "text": "uce the incidence of cryptococcal disease and the associated high mortality among people living with HIV (123). Screening for cryptococcal antigenaemia is the optimal approach for guiding resources in a public health approach and is the preferred approach for identifying infection when managing people aged 10 years or older presenting with advanced HIV disease (54, 123). There remains a role for fluconazole primary prophylaxis in settings in which cryptococcal antigen screening is not available. Since 2018, WHO guidelines have recommended that all adults and adolescents living with HIV who have a CD4 cell count <100 cells/mm3 be screened for cryptococcal antigen before ART initiation or reinitiation; cryptococcal antigen screening may also be considered for adults and adolescents living with HIV who have a CD4 cell count <200 cells/mm3. These recommendations were supported by evidence fa",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 40
  },
  {
    "chunk_id": "advancedhiv_1138",
    "text": "al antigen screening may also be considered for adults and adolescents living with HIV who have a CD4 cell count <200 cells/mm3. These recommendations were supported by evidence favouring the clinical benefit and cost– effectiveness of cryptococcal antigen screening. All individuals screening positive for cryptococcal antigen should be given pre-emptive antifungal therapy (fluconazole 800–1200 mg/day for adults and 12 mg/kg per day for adolescents for two weeks) followed by consolidation and maintenance fluconazole therapy (124). Another example for dosing pre-emptive antifungal therapy is the Southern African HIV Clinicians Society guidelines from 2019, recommending 1200 mg for the first two weeks given safety and concerns over breakthrough infection (77).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 40
  },
  {
    "chunk_id": "advancedhiv_1139",
    "text": "28 Summary of recommendations for individuals with a CD4 count <100 cells/mm3 Screeninga for cryptococcal antigen followed by pre-emptive antifungal therapy (3 among cryptococcal antigen– positive people to prevent the development of invasive cryptococcal disease is recommended before initiating or reinitiating ART for adults and adolescents living with HIV who have a CD4 count <100 cells/mm 3. (Strong recommendation; moderate-certainty evidence) When cryptococcal antigen screening is not available, fluconazole primary prophylaxis should be given to adults and adolescents living with HIV who have a CD4 count <100 cells/mm 3. (Strong recommendation; moderate-certainty evidence) Summary of recommendations for individuals with a CD4 count <200 cells/mm3 Screening may be considered at a higher CD4 cell count threshold of <200 cells/mm 3. (Conditional recommendation; moderate-certainty eviden",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 41
  },
  {
    "chunk_id": "advancedhiv_1140",
    "text": "ividuals with a CD4 count <200 cells/mm3 Screening may be considered at a higher CD4 cell count threshold of <200 cells/mm 3. (Conditional recommendation; moderate-certainty evidence) fluconazole primary prophylaxis may be considered at a higher CD4 cell count threshold of <200 cells/mm 3. (Conditional recommendation; moderate-certainty evidence) All people living with HIV testing positive for serum, plasma or whole blood cryptococcal antigen during screening should be carefully evaluated for signs and symptoms of meningitis and undergo lumbar puncture, if feasible, with CSF examination with CSF cryptococcal antigen assay or India Ink preparation to exclude meningitis. India ink has low sensitivity, and a negative result on India ink should be confirmed by CSF cryptococcal antigen testing or CSF culture. These recommendations would apply equally to people who present to care again after ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 41
  },
  {
    "chunk_id": "advancedhiv_1141",
    "text": "ive result on India ink should be confirmed by CSF cryptococcal antigen testing or CSF culture. These recommendations would apply equally to people who present to care again after a period of disengagement from care with advanced HIV disease. Cryptococcal antigen screening followed by pre-emptive therapy would be preferrable over providing fluconazole primary prophylaxis when considering cost, the potential for developing antifungal resistance and concerns about fetal safety among women of childbearing age without access to adequate contraception. Fluconazole primary prophylaxis should be made available in settings in which cryptococcal antigen screening is not available or there may be prolonged delays in receiving the result since cryptococcal disease and mortality peak in the first four weeks among people presenting with a CD4 cell count <100 cells/mm3 (55). This recommendation is bas",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 41
  },
  {
    "chunk_id": "advancedhiv_1142",
    "text": "iving the result since cryptococcal disease and mortality peak in the first four weeks among people presenting with a CD4 cell count <100 cells/mm3 (55). This recommendation is based on a systematic review that found a 70% reduction in mortality from cryptococcal disease among people living with HIV with low CD4 cell counts (95% CI 12–89%); the review also found a 71% reduction in cryptococcal disease incidence; the incidence of serious adverse events did not differ , but some evidence indicated an increased risk of fluconazole- resistant Candida infection (125). National guidelines should determine the optimal duration of prophylaxis based on available resources. The duration of fluconazole primary prophylaxis differed in the randomized trials that support the clinical benefit of this intervention. In the REALITY trial conducted in Kenya, Malawi, Uganda and Zimbabwe, fluconazole (100 mg",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 41
  },
  {
    "chunk_id": "advancedhiv_1143",
    "text": " differed in the randomized trials that support the clinical benefit of this intervention. In the REALITY trial conducted in Kenya, Malawi, Uganda and Zimbabwe, fluconazole (100 mg once daily) was discontinued after 12 weeks (55). In another trial conducted in Uganda in the era of ART, fluconazole (200 mg three times per week) was discontinued when participants’ CD4 cell counts reached 200 cells/mm3 (126). a All people living with HIV with a positive cryptococcal antigen result on screening should be carefully evaluated for signs and symptoms of meningitis and undergo a lumbar puncture if feasible with CSF examination and cryptococcal antigen assay (or India ink if cryptococcal antigen assay is not available) to exclude meningitis.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 41
  },
  {
    "chunk_id": "advancedhiv_1144",
    "text": "29 Lumbar puncture in people suspected with cryptococcal meningitis For adults, adolescents and children living with HIV suspected of having a first episode of cryptococcal meningitis, prompt lumbar puncture with measurement of CSF opening pressure and rapid cryptococcal antigen assay is recommended as the preferred diagnostic approach. (Strong recommendation; moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) The following diagnostic approaches are recommended, according to the context. Settings with ready access to and no contraindication for lumbar puncture 1. If both access to a cryptococcal antigen assay (either lateral flow assay or latex agglutination assay) and rapid results (less than 24 hours) are available, lumbar puncture with rapid CSF cryptococcal antigen assay is the preferred diagnostic approach.a (Strong recommendation; modera",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 42
  },
  {
    "chunk_id": "advancedhiv_1145",
    "text": "nd rapid results (less than 24 hours) are available, lumbar puncture with rapid CSF cryptococcal antigen assay is the preferred diagnostic approach.a (Strong recommendation; moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) 2. If access to a cryptococcal antigen assay is not available and/or rapid results are not available, lumbar puncture with CSF India ink test examination is the preferred diagnostic approach. (Strong recommendation; moderate-certainty evidence for adults and adolescents and low-certainty evidence for children) Settings without immediate access to lumbar puncture or when lumbar puncture is clinically contraindicated such as significant coagulopathy or suspected space- occupying lesion based on focal nervous system signs or recurrent seizures b 1. If both access to a cryptococcal antigen assay and rapid results (less than 24",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 42
  },
  {
    "chunk_id": "advancedhiv_1146",
    "text": "y or suspected space- occupying lesion based on focal nervous system signs or recurrent seizures b 1. If both access to a cryptococcal antigen assay and rapid results (less than 24 hours) are available, rapid serum, plasma or whole blood cryptococcal antigen assays are the preferred diagnostic approaches. (Strong recommendation; moderate-certainty evidence for adults and adolescents and low- certainty evidence for children) 2. If a cryptococcal antigen assay is not available and/or rapid access to results is not ensured, prompt referral for further investigation and treatment is appropriate. (Strong recommendation; moderate- certainty evidence for adults and adolescents and low-certainty evidence for children) Note: Other diseases that can present with symptoms and signs similar to cryptococcal meningitis (such as viral, bacterial or tuberculous meningitis) should also be considered. a F",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 42
  },
  {
    "chunk_id": "advancedhiv_1147",
    "text": "Note: Other diseases that can present with symptoms and signs similar to cryptococcal meningitis (such as viral, bacterial or tuberculous meningitis) should also be considered. a For a first episode, CSF cryptococcal culture is also recommended in parallel with cryptococcal antigen testing if this is feasible b Contraindications include significant coagulopathy or suspected space-occupying lesion based on focal nervous system signs (excluding cranial nerve VI palsy) or recurrent seizures and, where possible, confirmed by computed tomography. Raised intracranial pressure does not contraindicate lumbar puncture in (suspected) cryptococcal meningitis. Other contraindications include major spinal deformity and refusal by the patient after fully informed consent was sought. Recommendations for children These recommendations apply to adults and adolescents with advanced HIV disease. The decisi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 42
  },
  {
    "chunk_id": "advancedhiv_1148",
    "text": "sal by the patient after fully informed consent was sought. Recommendations for children These recommendations apply to adults and adolescents with advanced HIV disease. The decision to not extend these recommendations to children was based on the recognition that cryptococcal disease in this age group is rare, even in countries with high incidence (117, 127). Diagnosing cryptococcal disease The 2018 WHO recommendations remain unchanged for diagnosing cryptococcal disease (123). Background Early diagnosis and treatment of cryptococcal disease is key to reducing mortality from cryptococcal disease. Health-care professionals should have a low threshold for suspecting cryptococcal meningitis among with people with advanced HIV disease. National programmes require appropriate priority- setting is required by to ensure reliable access to rapid diagnostic cryptococcal antigen assays, preferabl",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 42
  },
  {
    "chunk_id": "advancedhiv_1149",
    "text": " advanced HIV disease. National programmes require appropriate priority- setting is required by to ensure reliable access to rapid diagnostic cryptococcal antigen assays, preferably lateral flow assays, for use in CSF, serum, plasma or whole blood. In addition, health-care professionals need to have a low threshold for suspecting cryptococcal meningitis.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 42
  },
  {
    "chunk_id": "advancedhiv_1150",
    "text": "30 Rapid cryptococcal antigen assays in CSF, serum, plasma or whole blood (depending on access to lumbar puncture) are preferred based on the much higher diagnostic accuracy of these rapid cryptococcal antigen assays versus the India ink test and the fact that these rapid assays depend less on the health-care provider’s skills. Advantages of the lateral-flow assay over the latex agglutination assay include its rapid (<10 minutes) turnaround time, cost–effectiveness, minimal training requirements and laboratory infrastructure, no need for refrigerated storage and higher clinical and analytical sensitivity. A serum, plasma or whole-blood cryptococcal antigen test is recommended as an initial diagnostic option in settings in which access to lumbar puncture is limited or contraindicated. The use of serum, plasma or whole blood cryptococcal antigen diagnosis does not replace the need for lumb",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 43
  },
  {
    "chunk_id": "advancedhiv_1151",
    "text": "settings in which access to lumbar puncture is limited or contraindicated. The use of serum, plasma or whole blood cryptococcal antigen diagnosis does not replace the need for lumbar puncture with CSF examination when this is feasible, considering also the important survival benefit of facilitating control of intracranial pressure (128). In low- and middle-income countries, the use of rapid low-cost assays that rely on limited technical skills and laboratory infrastructure facilitates prompt diagnosis and the initiation of antifungal therapy. A low index of suspicion is needed for cryptococcal meningitis in regions with moderate to high HIV prevalence. Limited data from retrospective cohorts suggest that diagnostic performance among children is similar to that of adults (129, 130). The recommendations for adults have therefore been extended to children (Table 6). Table 6. Indications for",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 43
  },
  {
    "chunk_id": "advancedhiv_1152",
    "text": "stic performance among children is similar to that of adults (129, 130). The recommendations for adults have therefore been extended to children (Table 6). Table 6. Indications for cryptococcal antigen testing Lumbar puncture available Lumbar puncture contraindicated or unavailable Rapid cryptococcal antigen test available CSF cryptococcal antigen (preferably lateral flow assay) Serum, plasma or whole-blood antigen cryptococcal antigen (preferably lateral flow assay), treat immediately and refer for further investigation No rapid cryptococcal antigen test available CSF India ink preparation Prompt referral for further investigation Recommendations on induction, consolidation and maintenance antifungal treatment regimens Background Amphotericin B deoxycholate has been known to be associated with several side-effects such as anaemia, nausea, vomiting, rigors, fever , hypertension or hypote",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 43
  },
  {
    "chunk_id": "advancedhiv_1153",
    "text": " regimens Background Amphotericin B deoxycholate has been known to be associated with several side-effects such as anaemia, nausea, vomiting, rigors, fever , hypertension or hypotension, hypoxia and metabolic derangements such as hypokalaemia, hypomagnesaemia and nephrotoxicity (131–133). The 2018 WHO guidelines noted that liposomal amphotericin B was preferred as a formulation over amphotericin B deoxycholate, considering equivalent efficacy and better safety (123). However , access to liposomal amphotericin B remains limited in low- and middle-income countries, mainly because of its high price, lack of registration of the product locally and limited. number of quality-assured manufacturers and the need for close monitoring for seven to 14 doses through intravenous infusion, similar to amphotericin B deoxycholate. A single high- dose liposomal amphotericin B–based regimen is the preferr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 43
  },
  {
    "chunk_id": "advancedhiv_1154",
    "text": "ose monitoring for seven to 14 doses through intravenous infusion, similar to amphotericin B deoxycholate. A single high- dose liposomal amphotericin B–based regimen is the preferred option to treat individuals, with fewer side- effects and adverse events. Flucytosine accessibility, affordability and registration are also limited in low-and middle- income countries. Despite these access challenges, the use of high-dose fluconazole monotherapy is not recommended, considering the limited evidence of improved patient survival with this option (33, 34). WHO continues to recommend the alternative regimens in settings in which single high-dose liposomal amphotericin is unavailable. However , the 2022 WHO Guideline Development Group noted that fluconazole + flucytosine is associated with lower mortality than amphotericin B deoxycholate + fluconazole (134), and efforts should be made to ensure a",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 43
  },
  {
    "chunk_id": "advancedhiv_1155",
    "text": "velopment Group noted that fluconazole + flucytosine is associated with lower mortality than amphotericin B deoxycholate + fluconazole (134), and efforts should be made to ensure access to a flucytosine-containing regimen.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 43
  },
  {
    "chunk_id": "advancedhiv_1156",
    "text": "31 Recommendations for induction therapy for cryptococcal meningitis Induction therapy (123) (2022 recommendations) A single high dose (10 mg/kg) of liposomal amphotericin B with 14 days of flucytosine (100 mg/kg per day divided into four doses per day) and fluconazole (1200 mg/daily for adults; 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily) should be used as the preferred induction regimen for treating people with cryptococcal meningitis. (Strong recommendation, moderate-certainty evidence for adults and low-certainty evidence for children) Alternative induction regimens If liposomal amphotericin B is not available: A seven-day course of amphotericin B deoxycholate (1 mg/kg per day) and flucytosine (100 mg/kg per day, divided into four doses per day) followed by seven days of fluconazole (1200 mg daily for adults and 12 mg/kg per day for children and adol",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 44
  },
  {
    "chunk_id": "advancedhiv_1157",
    "text": "day) and flucytosine (100 mg/kg per day, divided into four doses per day) followed by seven days of fluconazole (1200 mg daily for adults and 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate-certainty evidence for adults and low-certainty evidence for children and adolescents) If no amphotericin B formulations are available: 14 days of fluconazole (1200 mg daily, 12 mg/kg per day for children and adolescents) + flucytosine (100 mg/kg per day, divided into four doses per day). (Strong recommendation, moderate-certainty evidence) Note: fluconazole + flucytosine is the only recommended oral combination regimen and has been associated with lower mortality compared with amphotericin B deoxycholate + fluconazole. If flucytosine is not available: 14 days of liposomal amphotericin (3–4 mg/kg per day) + fluconazole (1200 mg daily, 12",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 44
  },
  {
    "chunk_id": "advancedhiv_1158",
    "text": "ity compared with amphotericin B deoxycholate + fluconazole. If flucytosine is not available: 14 days of liposomal amphotericin (3–4 mg/kg per day) + fluconazole (1200 mg daily, 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate-certainty evidence for adults) If liposomal amphotericin B and flucytosine are not available: 14 days of amphotericin B deoxycholate (1 mg/kg per day) + fluconazole (1200 mg daily, 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily). (Strong recommendation, moderate-certainty evidence) Note: flucytosine-containing regimens are superior , and steps should be taken to ensure access to this drug. Preventing, monitoring and managing amphotericin B deoxycholate toxicity Infusion-related toxicity and side-effects from amphotericin B therapy are barriers to optimal induction treatme",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 44
  },
  {
    "chunk_id": "advancedhiv_1159",
    "text": "nting, monitoring and managing amphotericin B deoxycholate toxicity Infusion-related toxicity and side-effects from amphotericin B therapy are barriers to optimal induction treatment, especially in low- and middle- income countries. Safe administration of amphotericin B should be given priority and may require referral to a centre with access to the recommended package of preventing, monitoring and managing toxicity. Liposomal amphotericin B has fewer risks of drug toxicity than amphotericin B deoxycholate and requires a less intensive package for preventing, monitoring and managing toxicity. The recommended package of preventing, monitoring and managing toxicity should be provided to minimize the serious types of amphotericin B–related toxicity when using amphotericin B deoxycholate–based regimens, especially hypokalaemia, nephrotoxicity and anaemia. A single 10 mg/kg dose of liposomal ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 44
  },
  {
    "chunk_id": "advancedhiv_1160",
    "text": " of amphotericin B–related toxicity when using amphotericin B deoxycholate–based regimens, especially hypokalaemia, nephrotoxicity and anaemia. A single 10 mg/kg dose of liposomal amphotericin B and the seven-day amphotericin B deoxycholate regimen are better tolerated than a 14-day amphotericin deoxycholate regimen, but these regimens still require careful monitoring. Adverse events associated with amphotericin B deoxycholate include hypokalaemia, nephrotoxicity and anaemia (136–138). A protocol for monitoring potassium, magnesium (if available) and creatinine and weekly haemoglobin monitoring is advised, together with a simplified protocol for pre- hydration and electrolyte replacement before each amphotericin B infusion. If clients are also receiving a dolutegravir-based regimen, time-separated supplementation of magnesium is necessary to avoid affecting the absorption of dolutegravir",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 44
  },
  {
    "chunk_id": "advancedhiv_1161",
    "text": "n B infusion. If clients are also receiving a dolutegravir-based regimen, time-separated supplementation of magnesium is necessary to avoid affecting the absorption of dolutegravir (62).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 44
  },
  {
    "chunk_id": "advancedhiv_1162",
    "text": "32 Dose adjustment is needed for people with significant renal impairment. Liposomal, deoxycholate and lipid complex amphotericin B formulations are not interchangeable. Various formulations of amphotericin B are available commercially, including liposomal, deoxycholate and lipid complex formulations. These formulations are not interchangeable. For the indication of cryptococcal meningitis, only amphotericin B deoxycholate and liposomal amphotericin B have been recommended. In health-care settings in which both amphotericin B deoxycholate and liposomal amphotericin B are available, health- care providers must be cautious to avoid mixing up these products since the doses are different and significant adverse events have been reported when the deoxycholate formulation was given at a higher dose than recommended. Table 7. Monitoring single high-dose amphotericin B administration Day 1 2 3 4",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 45
  },
  {
    "chunk_id": "advancedhiv_1163",
    "text": "nts have been reported when the deoxycholate formulation was given at a higher dose than recommended. Table 7. Monitoring single high-dose amphotericin B administration Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Single high-dose liposomal amphotericin B Pre-emptive hydration and electrolyte supplementation (adults and adolescents) 1 litre of normal saline solution with 20 mEq KCl over two hours before infusion X 8-mEq KCl tablets orally (twice daily) X X X Magnesium supplementation if availableᵃ X X X Monitoring (adults, adolescents and children) Serum potassium X X Serum creatinine X X Haemoglobin X Xb a 250-mg tablets of magnesium trisilicate or glycerophosphate twice daily or magnesium chloride 4 mEq twice daily. b If still in hospital.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 45
  },
  {
    "chunk_id": "advancedhiv_1164",
    "text": "33 Table 8. Monitoring of amphotericin B deoxycholate (seven- and 14-day treatment regimens) Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Amphotericin B deoxycholate: seven days Pre-emptive hydration and electrolyte supplementation (adults and adolescents) 1 litre of normal saline solution with 20 mEq KCl over two hours before each controlled infusion X X X X X X X 2 times 8-mEq KCl tablet (twice daily) X X X X X X X Magnesium supplementation if availableᵃ X X X X X X X Monitoring (adults, adolescents and children) Serum potassium X X X X Xb Serum creatinine X X X X Haemoglobin X X Amphotericin B deoxycholate: 14 days Pre-emptive hydration and electrolyte supplementation (adults and adolescents) 1 litre of normal saline solution with 20 mEq KCl over two hours before each controlled infusion X X X X X X X X X X X X X X 2 times 8-mEq KCl tablet (twice daily) X X X X X X X X X X X X X X 1 time 8-mE",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 46
  },
  {
    "chunk_id": "advancedhiv_1165",
    "text": "e solution with 20 mEq KCl over two hours before each controlled infusion X X X X X X X X X X X X X X 2 times 8-mEq KCl tablet (twice daily) X X X X X X X X X X X X X X 1 time 8-mEq KCl tablet (twice daily) X X X X X X X Magnesium supplementation if availableᵃ X X X X X X X X X X X X X X Monitoring (adults, adolescents and children) Serum potassium X X X X X X X Serum creatinine X X X X X X X Haemoglobin X X X a 250-mg tablets of magnesium trisilicate or glycerophosphate twice daily or magnesium chloride 4 mEq twice daily. b If still in hospital. Additional notes: • Amphotericin B is incompatible with normal saline. • Potassium replacement should not be given to people with pre-existing renal impairment or hyperkalaemia. • Careful attention should be given to monitoring the intake and output of fluid and daily weight, especially among children. • Flucytosine: because of concerns about bo",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 46
  },
  {
    "chunk_id": "advancedhiv_1166",
    "text": "rkalaemia. • Careful attention should be given to monitoring the intake and output of fluid and daily weight, especially among children. • Flucytosine: because of concerns about bone marrow suppression, regular monitoring of full blood counts should be considered; guidelines from the Southern African HIV Clinicians Society recommend monitoring full blood counts at baseline and at least weekly for as long as the person is taking flucytosine (21). If standard dose liposomal amphotericin B is being given for 14 days with fluconazole, the incidence of renal dysfunction and electrolyte disturbance is lower than with amphotericin B deoxycholate, but renal function and electrolytes still need to be monitored. In such cases, follow the standard recommendations for amphotericin B deoxycholate.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 46
  },
  {
    "chunk_id": "advancedhiv_1167",
    "text": "34 Drug–drug interactions Drug–drug interactions in the context of concurrent use of amphotericin, flucytosine and fluconazole alongside ART regimens have not been well documented (135). However , individuals receiving tenofovir disoproxil fumarate (TDF)–based regimens who are receiving amphotericin or recently received amphotericin B preparations should be closely monitored for nephrotoxicity. Liposomal preparations of amphotericin B are considered to be safer (133) than deoxycholate but would still require close follow-up. The dose of tenofovir disoproxil fumarate should be adjusted for renal function. Flucytosine may slightly alter levels of TDF in the blood through reduced renal clearance, but this remains a theoretical risk. Haematological parameters should be monitored, and the dose of tenofovir disoproxil fumarate should be adjusted in individuals with reduced renal function who a",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 47
  },
  {
    "chunk_id": "advancedhiv_1168",
    "text": "a theoretical risk. Haematological parameters should be monitored, and the dose of tenofovir disoproxil fumarate should be adjusted in individuals with reduced renal function who are also receiving amphotericin (136). Fluconazole induces cytochrome (CYP)3A4 and P-glycoprotein (137). No dose adjustment of ART is required. Consolidation and maintenance treatment WHO recommends fluconazole at 800 mg/day for eight weeks following an amphotericin B deoxycholate–based induction regimen; these recommendations were based primarily on expert opinion, considering the limited evidence from two trials that compared itraconazole versus fluconazole at lower doses (137, 138). Guidelines from the European AIDS Clinical Society recommend 400 mg for eight weeks after a single loading dose of 800 mg on the first day of therapy (123). Maintenance or secondary prophylaxis until there is evidence of sustained",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 47
  },
  {
    "chunk_id": "advancedhiv_1169",
    "text": " recommend 400 mg for eight weeks after a single loading dose of 800 mg on the first day of therapy (123). Maintenance or secondary prophylaxis until there is evidence of sustained ART-related immune reconstitution is an integral part of managing cryptococcal meningitis. Among ART-naive people, fluconazole was effective at preventing relapse in one randomized controlled trial (139) and was superior to weekly amphotericin B or itraconazole (139, 140). Consolidation Fluconazole (800 mg daily for adults, 6–12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily) is recommended for the consolidation phase (for eight weeks following the induction phase). (Strong recommendation, low-certainty evidence) Maintenance Fluconazole (200 mg daily for adults, 6 mg/kg per day for adolescents and children) is recommended for the maintenance phase until immune reconstitution (CD4 >2",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 47
  },
  {
    "chunk_id": "advancedhiv_1170",
    "text": "idence) Maintenance Fluconazole (200 mg daily for adults, 6 mg/kg per day for adolescents and children) is recommended for the maintenance phase until immune reconstitution (CD4 >200 cells/mm3) and suppression of viral loads on ART. (Strong recommendation, high-certainty evidence) Clinical considerations for managing cryptococcal disease Preventing, monitoring and managing amphotericin B toxicity For people living with HIV receiving amphotericin B–containing regimens for treating cryptococcal disease, a minimum package for preventing, monitoring and managing toxicity is recommended to minimize the serious types of amphotericin B–related toxicity, especially hypokalaemia, nephrotoxicity and anaemia (139–142). Monitoring for and managing raised intracranial pressure Adults, adolescents and children living with HIV with suspected cryptococcal meningitis should have an initial lumbar punctur",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 47
  },
  {
    "chunk_id": "advancedhiv_1171",
    "text": "nitoring for and managing raised intracranial pressure Adults, adolescents and children living with HIV with suspected cryptococcal meningitis should have an initial lumbar puncture and an early repeat lumbar puncture (within 3–5 days) with measurement of CSF opening pressure to assess for raised intracranial pressure regardless of the presence of symptoms or signs of raised intracranial pressure (122, 128). Managing raised intracranial pressure Therapeutic lumbar puncture: relieve pressure by draining a volume sufficient (88, 143) to reduce the CSF pressure to <20 cm or halving the baseline pressure if extremely high; the persistence or recurrence of symptoms or signs of raised intracranial pressure should determine the frequency of repeat therapeutic lumbar puncture (144). For people with persistent symptoms of intracranial pressure, repeat daily therapeutic lumbar puncture (with measu",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 47
  },
  {
    "chunk_id": "advancedhiv_1172",
    "text": "ermine the frequency of repeat therapeutic lumbar puncture (144). For people with persistent symptoms of intracranial pressure, repeat daily therapeutic lumbar puncture (with measurement of CSF opening pressure when available) and CSF drainage, if required, are recommended until the symptoms resolve or the opening pressure is normal for at least two days (123).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 47
  },
  {
    "chunk_id": "advancedhiv_1173",
    "text": "35 Monitoring treatment response Clinical response (including resolution or recurrence of fever , headache and symptoms or signs of raised intracranial pressure) should be assessed daily during the initial two weeks of induction therapy. Among people for whom evidence indicates a sustained clinical response, routine follow-up lumbar puncture after completing induction treatment to assess antifungal treatment response (CSF fungal culture and CSF cryptococcal antigen) or serum or plasma cryptococcal antigen is not recommended in low- and middle-income countries (123). Managing treatment failure For people who present with cryptococcal meningitis relapse, the following steps are recommended: start or restart induction treatment according to the recommendations for induction treatment; manage raised intracranial pressure with therapeutic lumbar puncture; and provide adapted adherence support",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 48
  },
  {
    "chunk_id": "advancedhiv_1174",
    "text": "tion treatment according to the recommendations for induction treatment; manage raised intracranial pressure with therapeutic lumbar puncture; and provide adapted adherence support. If ART has not already started, initiating ART after 4–6 weeks of optimal antifungal therapy is recommended (123). Paradoxical cryptococcal immune reconstitution inflammatory syndrome occurs among 10–50% of people with cryptococcal disease initiating ART (145) and is associated with high mortality (120). The median time to onset in reported cohort studies is 1–10 months but typically is 3–12 weeks after initiating ART (145). Raised intracranial pressure is a common feature of cryptococcal immune reconstitution inflammatory syndrome and an important contributor to high mortality (146). Multiple repeat lumbar puncture may be necessary. Optimizing antifungal therapy and reinduction with an amphotericin-based reg",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 48
  },
  {
    "chunk_id": "advancedhiv_1175",
    "text": "and an important contributor to high mortality (146). Multiple repeat lumbar puncture may be necessary. Optimizing antifungal therapy and reinduction with an amphotericin-based regimen are important if suboptimal antifungal treatment is considered to contribute to developing immune reconstitution inflammatory syndrome (123). Research needs Further research is needed to assess the value of cryptococcal antigen screening at CD4 cell count thresholds between 100 and 200 cells/mm3, which has been suggested to save costs if carried out in inpatient settings. High cryptococcal antigen titres (>1:160) in blood have been found to predict subclinical meningitis. It has been suggested that blood titres could be used to predict meningitis in settings in which lumbar puncture cannot be performed or in which providing lumbar puncture for everyone screening cryptococcal antigen–positive is operational",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 48
  },
  {
    "chunk_id": "advancedhiv_1176",
    "text": "redict meningitis in settings in which lumbar puncture cannot be performed or in which providing lumbar puncture for everyone screening cryptococcal antigen–positive is operationally challenging; the feasibility of this approach should be further investigated in a diversity of settings. Second-generation cryptococcal antigen lateral- flow assays that can give a high or low cryptococcal antigen result need to be evaluated as part of this approach. Research could help to improve the understanding of how to manage relapse or treatment non- response in public health settings, since the current course of action would be referral to a tertiary care centre. In tertiary care settings, intrathecal and intraventricular administration of amphotericin B have been attempted successfully, but further research is needed to establish safety and tolerability. Managing space-occupying lesions among people",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 48
  },
  {
    "chunk_id": "advancedhiv_1177",
    "text": "dministration of amphotericin B have been attempted successfully, but further research is needed to establish safety and tolerability. Managing space-occupying lesions among people with a positive serum cryptococcal antigen test, the concurrent treatment of HIV-associated TB and cryptococcal meningitis and the best approach for treating immune reconstitution inflammatory syndrome are other research needs. WHO has issued a prequalification expression of interest for sustained-release flucytosine to simplify inpatient and outpatient treatment of cryptococcal infections. The role of azoles other than fluconazole, notably voriconazole and isavuconazole, as well as novel oral antifungal agents (such as oral encochleated amphotericin B) for treatment and prophylaxis for cryptococcosis could benefit from further study. There remains a need to better understand the prevalence of cryptococcal dis",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 48
  },
  {
    "chunk_id": "advancedhiv_1178",
    "text": "ated amphotericin B) for treatment and prophylaxis for cryptococcosis could benefit from further study. There remains a need to better understand the prevalence of cryptococcal disease among children and the best diagnostic approach to enable the timely identification of disease. Implementation science research is encouraged on the feasibility and impact of cryptococcal antigen screening delivered together with other components of an advanced ART package (such as TB lipoarabinomannan assay and TB prophylaxis).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 48
  },
  {
    "chunk_id": "advancedhiv_1179",
    "text": "36 Histoplasmosis (2021) Background Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum; the most frequent clinical presentation among people living with HIV is disseminated histoplasmosis. Symptoms of disseminated histoplasmosis are nonspecific and may be indistinguishable from those of other infectious diseases, especially TB, thus complicating diagnosis and treatment (147). Histoplasmosis is highly endemic in some regions of North America, Central America and South America and is also reported in certain countries of Asia and Africa. Histoplasma antigen can be detected in urine, which enables an approach of rapid detection and linkage to treatment and is recommended by WHO as a preferred approach. WHO does not currently recommend routine screening for histoplasmosis, pending further investigation (147). The lack of access to appropriate antifungal therapies and in ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 49
  },
  {
    "chunk_id": "advancedhiv_1180",
    "text": "approach. WHO does not currently recommend routine screening for histoplasmosis, pending further investigation (147). The lack of access to appropriate antifungal therapies and in vitro diagnostics for rapid detection of histoplasmosis and the co-occurrence of other infectious diseases, especially TB, may affect clinical outcomes and underlie the high mortality of disseminated histoplasmosis among people living with HIV (148, 149). Note that TB and histoplasmosis, in addition to being often misclassified, frequently recur together in endemic settings (148, 150). Access to liposomal amphotericin is a significant challenge in many settings worldwide, especially in low- and middle-income settings. Licensing is a key barrier for access to this formulation in addition to highly variable costs (151). An analysis of data from 55 countries showed that 72% of liposomal amphotericin is sold in hig",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 49
  },
  {
    "chunk_id": "advancedhiv_1181",
    "text": "ey barrier for access to this formulation in addition to highly variable costs (151). An analysis of data from 55 countries showed that 72% of liposomal amphotericin is sold in high-income settings and 28% in low-income settings, where the need is the greatest. Additionally, low-income settings continue to purchase conventional amphotericin B deoxycholate or lipid complex formulations in greater quantities than in high-income settings (118). Severe or moderately severe histoplasmosis is defined as the presence of at least one sign or symptom involving vital organs: respiratory or circulatory failure, nervous system signs, renal failure, coagulation anomalies and a general alteration of the WHO performance status greater than 2, in which the person is confined to a bed or chair more than half of the waking hours and only capable of limited self-care (147). In 2020, WHO published Guideline",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 49
  },
  {
    "chunk_id": "advancedhiv_1182",
    "text": "s greater than 2, in which the person is confined to a bed or chair more than half of the waking hours and only capable of limited self-care (147). In 2020, WHO published Guidelines on diagnosing and managing disseminated histoplasmosis among people living with HIV (147). Below are the recommendations, which are all based on evidence reviewed by the Guideline Review Committee (147). Monitoring toxicity of amphotericin B therapy and drug–drug interactions associated with itraconazole use are important for the successful treatment of individuals with histoplasmosis. Renal function monitoring is important to identify, prevent and manage toxicity (such as nephrotoxicity, hypokalaemia, infusion-related reactions and anaemia). Appropriate fluid hydration is necessary to prevent kidney damage through fluid and electrolyte reposition over 4–6 hours.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 49
  },
  {
    "chunk_id": "advancedhiv_1183",
    "text": "37 Diagnosis of disseminated histoplasmosis among people living with HIV Among people living with HIV, disseminated histoplasmosis should be diagnosed by detecting circulating Histoplasma antigens (152). (Conditional recommendation, low-certainty evidence) Management of disseminated histoplasmosis Induction therapy Treating people living with HIV for severe or moderately severe histoplasmosis: liposomal amphotericin B, 3.0 mg/kg, for two weeks is recommended. In settings in which liposomal amphotericin B is unavailable, deoxycholate amphotericin B, 0.7–1.0 mg/kg, is recommended for two weeks (153–155). (Conditional recommendation, very-low-certainty evidence) As a good clinical practice for people with renal failure, or at risk of renal injury, measures to prevent or treat toxicity are recommended. Induction therapy should be given for two weeks. Since deoxycholate amphotericin B may be ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 50
  },
  {
    "chunk_id": "advancedhiv_1184",
    "text": "ilure, or at risk of renal injury, measures to prevent or treat toxicity are recommended. Induction therapy should be given for two weeks. Since deoxycholate amphotericin B may be associated with renal toxicity, therapy may need to be shorter than two weeks based on the clinical assessment of how the person responds to treatment. Involvement of the central nervous system may require extending induction therapy or increasing dosage. Treating people living with HIV for mild to moderate histoplasmosis: itraconazole 200 mg three times daily for three days and then 200 mg twice daily is recommended (156, 157). (Conditional recommendation, very-low-certainty evidence) Maintenance therapy Itraconazole 200 mg twice daily for 12 months is recommended (158–160). (Conditional recommendation, very-low-certainty evidence) Less than 12 months of therapy can be considered when the person is clinically ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 50
  },
  {
    "chunk_id": "advancedhiv_1185",
    "text": "ly for 12 months is recommended (158–160). (Conditional recommendation, very-low-certainty evidence) Less than 12 months of therapy can be considered when the person is clinically stable, receiving ART, has suppressed viral load and the immune status has improved (161). (Conditional recommendation, very- low-certainty evidence) Timing of ART initiation ART should be initiated as soon as possible among people with disseminated histoplasmosis for whom central nervous system involvement is not suspected or proven (81). (Conditional recommendation, very-low- certainty evidence) TB therapy for people with TB, HIV and histoplasmosis People living with HIV who also have TB and histoplasmosis coinfection should receive TB therapy according to WHO treatment guidelines (147). (Conditional recommendation, very-low-certainty evidence)",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 50
  },
  {
    "chunk_id": "advancedhiv_1186",
    "text": "38 Implementation considerations 1. Access to optimal antifungal medicines The WHO Model List of Essential Medicines includes optimal antifungal medicines for treating people with histoplasmosis (conventional amphotericin B and itraconazole). Increased advocacy for drug price reduction is needed, expanding coverage of the global access price of liposomal amphotericin B for leishmaniasis and cryptococcal meningitis, promoting local manufacturing of generic formulations. Additionally, it is important to ensure quality assurance of available generic formulations, ensuring national registration of all antifungal drugs on the WHO Model List of Essential Medicines. Medicines can be procured through joint regional procurement mechanisms such as the PAHO Strategic Fund, ensuring adequate supply chains at the national level and developing proper drug forecasting and monitoring systems. 2. Educati",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 51
  },
  {
    "chunk_id": "advancedhiv_1187",
    "text": "curement mechanisms such as the PAHO Strategic Fund, ensuring adequate supply chains at the national level and developing proper drug forecasting and monitoring systems. 2. Educating and training health-care providers Health-care providers should be trained to have a low threshold for suspecting histoplasmosis among people living with HIV, especially in advanced HIV disease, with the differential diagnosis of TB and other systemic fungal infections. Greater efforts need to be made to educate health-care providers and to provide policy guidance at the national level on managing histoplasmosis among people living with HIV. Effectively implementing guidelines also requires supportive supervision systems and prescribing decision-making aids. Research needs • What is the antigen detection performance outside the context of advanced HIV disease? • Among people with advanced HIV disease, can Hi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 51
  },
  {
    "chunk_id": "advancedhiv_1188",
    "text": "ibing decision-making aids. Research needs • What is the antigen detection performance outside the context of advanced HIV disease? • Among people with advanced HIV disease, can Histoplasma antigen detection be used as a screening approach for histoplasmosis? • Can antigen detection performance be increased by designing new antibodies through significant support in developing basic science on Histoplasma capsulatum? • Will a Histoplasma interferon-gamma release assay be useful to screen for latent histoplasmosis in advanced HIV disease, prevent histoplasmosis-associated immune reconstitution inflammatory syndrome and help to reduce the time to ART initiation among people recently diagnosed with HIV? • Can antigen detection screening studies inform about the true burden of histoplasmosis from a global perspective? • Will Histoplasma antigen detection by lateral flow become the standard di",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 51
  },
  {
    "chunk_id": "advancedhiv_1189",
    "text": "en detection screening studies inform about the true burden of histoplasmosis from a global perspective? • Will Histoplasma antigen detection by lateral flow become the standard diagnostic method for disseminated histoplasmosis among hospitalized people with histoplasmosis, as an outpatient screening tool or both? • How can the specific impact of antigen detection on the incidence and mortality trends of HIV- associated histoplasmosis be evaluated compared with conventional practices for diagnosing histoplasmosis and the future development of more molecular biology assays? • What are the best definitions for severity of disease among people with histoplasmosis? • Among people with a clinical and immune response to therapy, can maintenance antifungal therapy be safely discontinued earlier than 12 months? • Do people with central nervous system involvement have a higher incidence of Histop",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 51
  },
  {
    "chunk_id": "advancedhiv_1190",
    "text": " to therapy, can maintenance antifungal therapy be safely discontinued earlier than 12 months? • Do people with central nervous system involvement have a higher incidence of Histoplasma-related immune reconstitution inflammatory syndrome and associated mortality? In relation to this, what is the optimal time to start ART? • When will Histoplasma antigen detection and liposomal amphotericin B be affordable to people with histoplasmosis in low- and middle- income countries? • What are the outcomes of treating TB and histoplasmosis coinfection? • What is the impact of genetic varieties of Histoplasma on the epidemiology and treatment response to histoplasmosis? • What are the alternative antifungal drugs or alternative treatment stewardship in the pipeline that might help to increase the efficacy and decrease the secondary effects and toxicity of the recommended therapy? • What is the optim",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 51
  },
  {
    "chunk_id": "advancedhiv_1191",
    "text": "ative treatment stewardship in the pipeline that might help to increase the efficacy and decrease the secondary effects and toxicity of the recommended therapy? • What is the optimal dosing for liposomal amphotericin B among people living with HIV with disseminated histoplasmosis?",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 51
  },
  {
    "chunk_id": "advancedhiv_1192",
    "text": "39 TB in advanced HIV disease (2025) People living with HIV are about 13 times more likely to develop TB disease, have poorer TB treatment outcomes and higher mortality during TB treatment than people without HIV (162). The presence of advanced HIV disease (CD4 <200 cells/mm3) among people with disseminated TB is an independent predictor of mortality, in addition to being considered either a WHO clinical stage 3 or 4 AIDS- defining illness. Despite advances in the screening, diagnosis, treatment and prevention of TB disease, TB remains the leading cause of death among people with HIV worldwide and is second to only AIDS- related illnesses for hospitalizations among people living with HIV (8). WHO provides recommendations and practical guidance for people living with HIV of all ages, including advanced HIV disease, for prevention, screening, diagnosis and treatment for TB, including model",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 52
  },
  {
    "chunk_id": "advancedhiv_1193",
    "text": "mendations and practical guidance for people living with HIV of all ages, including advanced HIV disease, for prevention, screening, diagnosis and treatment for TB, including models of care within the guidelines and related operational handbooks contained within the WHO TB Knowledge Sharing Platform (163, 164). This section summarizes key recommendations and considerations for advanced HIV disease. Screening Screening for TB is a critical component of the advanced HIV disease package of care and is part of the algorithm for managing advanced HIV disease. Screening for TB is considered standard care for all people living with HIV (58). Age-appropriate screening should be performed at every health-care visit with a WHO-approved TB symptom screening algorithm along with a combination of screening tools as appropriate, to minimize the risk of missed cases of TB. Screening tools include C-rea",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 52
  },
  {
    "chunk_id": "advancedhiv_1194",
    "text": " a WHO-approved TB symptom screening algorithm along with a combination of screening tools as appropriate, to minimize the risk of missed cases of TB. Screening tools include C-reactive protein, chest X-ray and molecular WHO-recommended rapid diagnostic tests. Interferon-gamma release assays are not considered useful tests for TB screening (58). For children living with HIV, screening opportunities also include visits for vaccination days, during nutritional screening, at maternal health appointments and at food programme visits (60). Screening children for TB can be challenging since they may present with atypical symptoms, thus requiring a strong clinical suspicion of TB for anyone living with HIV in settings with a high TB burden. The risk of over-investigation is outweighed by the benefits of TB treatment (60). TB preventive treatment should be initiated for those screening negative ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 52
  },
  {
    "chunk_id": "advancedhiv_1195",
    "text": " with a high TB burden. The risk of over-investigation is outweighed by the benefits of TB treatment (60). TB preventive treatment should be initiated for those screening negative for TB (56). Recommendations for TB screening for people living with HIV (58) People living with HIV should be systematically screened for TB disease at each visit to a health facility. (Strong recommendation, very-low-certainty evidence) Among adults and adolescents living with HIV, systematic screening for TB disease should be conducted using the WHO-recommended four-symptom screen, and those who report any one of the symptoms of current cough, fever , weight loss or night sweats may have TB and should be evaluated for TB and other diseases. (Strong recommendation, moderate-certainty evidence) Among adults and adolescents living with HIV, C-reactive protein with a cut-off of >5 mg/L may be used to screen for ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 52
  },
  {
    "chunk_id": "advancedhiv_1196",
    "text": "diseases. (Strong recommendation, moderate-certainty evidence) Among adults and adolescents living with HIV, C-reactive protein with a cut-off of >5 mg/L may be used to screen for TB disease. (Conditional recommendation, low-certainty evidence for test accuracy)",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 52
  },
  {
    "chunk_id": "advancedhiv_1197",
    "text": "40 Recommendations for TB screening for people living with HIV (58) Among adults and adolescents living with HIV, molecular WHO-recommended rapid diagnostic tests may be used to screen for TB disease. (Conditional recommendation, moderate-certainty evidence for test accuracy) Adult and adolescent inpatients with HIV in medical wards where the TB prevalence is >10% should be tested systematically for TB disease with a molecular WHO-recommended rapid diagnostic test. (Strong recommendation, moderate-certainty evidence for test accuracy) Among individuals younger than 15 years who are close contacts of someone with TB, systematic screening for TB disease should be conducted using a symptom screen including any one of cough, fever or poor weight gain, or chest X-ray; or both. (Strong recommendation, moderate- to low-certainty evidence for test accuracy) Among children younger than 10 years l",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 53
  },
  {
    "chunk_id": "advancedhiv_1198",
    "text": " of cough, fever or poor weight gain, or chest X-ray; or both. (Strong recommendation, moderate- to low-certainty evidence for test accuracy) Among children younger than 10 years living with HIV, systematic screening for TB disease should be conducted using a symptom screen including any one of current cough, fever , poor weight gain or close contact with a TB patient. (Strong recommendation, low-certainty evidence for test accuracy) Diagnosis TB is frequent among individuals with advanced HIV disease and is a common cause of hospital admission for these individuals. Postmortem studies report a high proportion of undiagnosed TB among people who have died from HIV (165, 166). Establishing a diagnosis of TB is critical for ensuring early initiation of TB treatment and for reducing mortality. However , identifying TB among individuals with low CD4 counts is a challenge, and using a combinat",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 53
  },
  {
    "chunk_id": "advancedhiv_1199",
    "text": "itical for ensuring early initiation of TB treatment and for reducing mortality. However , identifying TB among individuals with low CD4 counts is a challenge, and using a combination of diagnostic tests for individuals with advanced HIV disease is therefore recommended. The recommendations are described in full in the WHO consolidated guidelines on tuberculosis: module 3: diagnosis (59). Clinical diagnosis plays an important role for people with advanced HIV disease since bacteriological confirmation is not always possible. For children, integrated treatment decision algorithms can help guide decisions about starting TB treatment (60). Further investigation is warranted for diagnosing drug-resistant TB. The WHO consolidated guidelines on tuberculosis: module 3: diagnosis provide details on diagnosing and detecting drug-resistant TB (59). Monitoring and evaluation considerations • Monito",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 53
  },
  {
    "chunk_id": "advancedhiv_1200",
    "text": "O consolidated guidelines on tuberculosis: module 3: diagnosis provide details on diagnosing and detecting drug-resistant TB (59). Monitoring and evaluation considerations • Monitor simultaneous specimen collection and turnaround time for the test results in a concurrent testing approach. • Monitor patient access to and loss to follow-up from a second test in a concurrent testing approach. • Monitor patient access to and loss to follow-up from follow-on drug-susceptibility testing among those with a positive LF-LAM result but a negative low-complexity automated NAAT result. • Monitor trends in the discordance rate between the LF-LAM and low-complexity automated NAAT results. If these differences vary from other local or regional patterns, or if the trends change, further investigation is required, and outcomes should be tracked for recurrence over time.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 53
  },
  {
    "chunk_id": "advancedhiv_1201",
    "text": "41 Recommendations for diagnosing TB disease Adults and adolescents For adults and adolescents with HIV who have signs or symptoms, screen positive for TB, are seriously ill or have advanced HIV disease, concurrent testing using low-complexity automated NAATs on respiratory samples and LF-LAM on urine should be used as the initial diagnostic strategy for diagnosing TB rather than low-complexity automated NAATs on respiratory samples alone. (Strong recommendation, low-certainty evidence) Remarks • Serious illness for people living with HIV is defined based on any of the following symptoms: respiratory rate ≥30 breaths per minute, temperature ≥39°C, heart rate ≥120 beats per minute or unable to walk unaided. • Advanced HIV disease is defined for people living with HIV as having a CD4 cell count of <200 cells/ mm3 or presenting with a WHO stage 3 or 4 AIDS-defining illness. • This concurren",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 54
  },
  {
    "chunk_id": "advancedhiv_1202",
    "text": "vanced HIV disease is defined for people living with HIV as having a CD4 cell count of <200 cells/ mm3 or presenting with a WHO stage 3 or 4 AIDS-defining illness. • This concurrent testing recommendation supersedes previous guidance on using LF-LAM for people living with HIV and using a single molecular test for diagnosing TB in this group. • This recommendation is strong despite the low-certainty evidence because the findings indicate large desirable effects (rapid and accurate diagnosis of TB for a highly vulnerable population – people living with HIV – for whom diagnosing TB is often challenging) and small undesirable effects (negative consequences of this testing strategy). • The low-complexity automated NAAT products for which eligible data met the class-based performance criteria for this recommendation were Xpert® MTB/RIF Ultra and Truenat MTB Plus. Data for the performance of Tr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 54
  },
  {
    "chunk_id": "advancedhiv_1203",
    "text": "AAT products for which eligible data met the class-based performance criteria for this recommendation were Xpert® MTB/RIF Ultra and Truenat MTB Plus. Data for the performance of Truenat MTB Plus and MTB-RIF Dx were only available for testing among people living with HIV without concurrent LF-LAM testing. Children with HIV For children with HIV who have signs or symptoms or screen positive for pulmonary TB, concurrent testing using low-complexity automated NAATs on respiratory and stool samples and LF-LAM on urine may be used as the initial diagnostic strategy for diagnosing TB rather than low-complexity automated NAATs on respiratory or stool samples alone. (Conditional recommendation, low-certainty evidence for test accuracy) Remarks • This recommendation gives priority to concurrent testing over molecular testing and LF-LAM in isolation for diagnosing TB among children living with HIV.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 54
  },
  {
    "chunk_id": "advancedhiv_1204",
    "text": "r test accuracy) Remarks • This recommendation gives priority to concurrent testing over molecular testing and LF-LAM in isolation for diagnosing TB among children living with HIV. • Using low-complexity automated NAATs on isolated specimens was also evaluated. The findings supported the use of low-complexity automated NAATs for initial diagnostic testing for TB among children living with HIV with signs or symptoms or who screen positive for pulmonary TB, using sputum, gastric aspirate, stool or nasopharyngeal aspirate rather than smear or culture. • This recommendation is conditional because the findings indicate moderate undesirable effects (reduced specificity, resulting in more false-positive test results) compared with a single test strategy. • The product for which eligible data met the low-complexity automated NAAT class-based performance criteria for this recommendation was Xpert",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 54
  },
  {
    "chunk_id": "advancedhiv_1205",
    "text": "compared with a single test strategy. • The product for which eligible data met the low-complexity automated NAAT class-based performance criteria for this recommendation was Xpert® MTB/RIF Ultra. The performance of Truenat MTB Plus and MTB-RIF Dx for this recommendation could not be assessed, since data were unavailable.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 54
  },
  {
    "chunk_id": "advancedhiv_1206",
    "text": "42 Implementation considerations for diagnosing TB Adults and adolescents living with HIV and children living with HIV • Global and national HIV and TB programmes need to communicate regularly and clearly, indicating responsibilities for concurrent testing for people living with HIV. • Concurrent testing maximizes the diagnostic access and accuracy, is a more efficient way to address the needs of people living with HIV and is preferred even if the testing workload may increase. • A positive result on either test is sufficient to confirm a TB diagnosis. • Loss to follow-up for the second test result should be monitored and prevented. Patients should be given information to understand the concurrent testing approach and the need for follow-up. • The LF-LAM performed in point-of-care settings may be the first positive result and is sufficient to make the initial diagnosis. A respiratory sam",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 55
  },
  {
    "chunk_id": "advancedhiv_1207",
    "text": "ach and the need for follow-up. • The LF-LAM performed in point-of-care settings may be the first positive result and is sufficient to make the initial diagnosis. A respiratory sample is still required for detecting rifampicin resistance. It is also required when the LF-LAM is negative. • Efforts are needed to improve access to LF-LAM. • LF-LAM does not differentiate Mycobacterium tuberculosis from other mycobacterial species. However , the LAM antigen detected in a clinical sample in TB endemic areas is most likely attributable to Mycobacterium tuberculosis. When LF-LAM is commonly positive without positive low-complexity automated NAATs, further investigation of the quality of testing and local epidemiology of non-TB mycobacteria and extrapulmonary TB in the tested population is warranted to understand the difference. • Bands on the LF-LAM test strip should be interpreted using the man",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 55
  },
  {
    "chunk_id": "advancedhiv_1208",
    "text": "f non-TB mycobacteria and extrapulmonary TB in the tested population is warranted to understand the difference. • Bands on the LF-LAM test strip should be interpreted using the manufacturer’s reading card to minimize incorrect results. • LF-LAM test strips must be stored according to the manufacturer’s instructions (such as between 2°C and 30°C) in sealed bags and not used after expiration. • Infrastructure to collect a urine sample privately should be available. Patients should be instructed how to properly and sanitarily collect urine to minimize environmental contamination and prevent false-positive results. • Trained personnel are required to perform the LF-LAM test at the point of care. • Similar to all WHO-recommended TB diagnostics, quality assurance programmes for both tests are required. • LF-LAM is designed to detect mycobacterial LAM antigen in human urine. Other samples (such",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 55
  },
  {
    "chunk_id": "advancedhiv_1209",
    "text": "O-recommended TB diagnostics, quality assurance programmes for both tests are required. • LF-LAM is designed to detect mycobacterial LAM antigen in human urine. Other samples (such as sputum, serum, plasma, CSF and other body fluids) or pooled urine specimens should not be used. Prevention TB preventive treatment TB preventive treatment is a critical component of prophylaxis in the WHO-recommended package of care for advanced HIV disease, along with co- trimoxazole and fluconazole. TB preventive treatment should be rapidly initiated among people with advanced HIV disease, after TB has been ruled out through systematic TB screening with a WHO- recommended approach (56, 58, 164). The short- course TB preventive treatment regimen – three months of weekly isoniazid and rifapentine – is the preferred option for adolescents and adults living with HIV. However , the ART regimen should be consid",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 55
  },
  {
    "chunk_id": "advancedhiv_1210",
    "text": "reatment regimen – three months of weekly isoniazid and rifapentine – is the preferred option for adolescents and adults living with HIV. However , the ART regimen should be considered, and evidence on coadministration of rifapentine and preferred ART regimens is still being generated for children, infants and pregnant women living with HIV.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 55
  },
  {
    "chunk_id": "advancedhiv_1211",
    "text": "43 Recommendations on eligibility for TB preventive treatment Adults and adolescents living with HIV who are unlikely to have TB disease on an appropriate clinical evaluation or according to national guidelines should receive TB preventive treatment as part of a comprehensive package of HIV care. Treatment should also be given to those receiving ART, to pregnant women and to those who have previously been treated for TB, irrespective of the degree of immunosuppression and even if testing for TB infection is unavailable. (Strong recommendation, high-certainty estimates of effect) Infants aged <12 months living with HIV who are in contact with a person with TB and who are unlikely to have TB disease on an appropriate clinical evaluation or according to national guidelines should receive TB preventive treatment. (Strong recommendation, moderate-certainty estimates of effect) Children aged ≥",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 56
  },
  {
    "chunk_id": "advancedhiv_1212",
    "text": "iate clinical evaluation or according to national guidelines should receive TB preventive treatment. (Strong recommendation, moderate-certainty estimates of effect) Children aged ≥12 months living with HIV who are considered unlikely to have TB disease on an appropriate clinical evaluation or according to national guidelines should be offered TB preventive treatment as part of a comprehensive package of HIV prevention and care if they live in a setting with high TB transmission, regardless of contact with TB. (Strong recommendation, low-certainty estimates of effect) All children living with HIV who have successfully completed treatment for TB disease may receive TB preventive treatment. (Conditional recommendation, low-certainty evidence) Recommendations on the choice of TB preventive treatment regimen for people living with HIV Preferred TB preventive treatment regimen among people liv",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 56
  },
  {
    "chunk_id": "advancedhiv_1213",
    "text": "tion, low-certainty evidence) Recommendations on the choice of TB preventive treatment regimen for people living with HIV Preferred TB preventive treatment regimen among people living with HIV For adults and adolescents living with HIV eligible for TB preventive treatment, three months of rifapentine and isoniazid (3HP) is the suggested preferred regimen; six or nine months of isoniazid (6H or 9H) are alternative regimens. (Conditional recommendation, low-certainty evidence) Recommendation on available TB preventive treatment regimensregardless of HIV status The following TB preventive treatment options are recommended regardless of HIV status: six or nine months of daily isoniazid or a three-month regimen of weekly rifapentine plus isoniazid or a three-month regimen of daily isoniazid plus rifampicin. (Strong recommendation, moderate- to high-certainty estimates of effect) The following",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 56
  },
  {
    "chunk_id": "advancedhiv_1214",
    "text": "eekly rifapentine plus isoniazid or a three-month regimen of daily isoniazid plus rifampicin. (Strong recommendation, moderate- to high-certainty estimates of effect) The following alternative TB preventive treatment options may be used regardless of HIV status: a one-month regimen of daily rifapentine plus isoniazid or four months of daily rifampicin. (Conditional recommendation, low- to moderate-certainty estimates of effect) BCG Neonates diagnosed with HIV infection, as confirmed by early virological testing, should not receive BCG vaccination at birth. Vaccination should be delayed until ART has been started and the infant is confirmed to be immunologically stable (CD4% exceeding 25% for children younger than five years; CD4 count of 200/mm3 or higher for children older than five years). The current WHO position paper on BCG vaccination (167) states that children known to be living w",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 56
  },
  {
    "chunk_id": "advancedhiv_1215",
    "text": "an five years; CD4 count of 200/mm3 or higher for children older than five years). The current WHO position paper on BCG vaccination (167) states that children known to be living with HIV should not receive BCG vaccination because they are at increased risk of developing disseminated BCG disease. However , if they are receiving ART, are clinically well and immunologically stable they should be vaccinated. Immunologically stable children have a CD4% exceeding 25% (children younger than five years) or a CD4 count of 200/mm3 or higher (children older than five years). In settings without access to CD4 testing, immunological stability may be assessed clinically based on the absence of new opportunistic infections and any other symptoms (167). The WHO operational handbook on tuberculosis: module 5: management of tuberculosis in children and adolescents details the administration of BCG, impor",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 56
  },
  {
    "chunk_id": "advancedhiv_1216",
    "text": "nd any other symptoms (167). The WHO operational handbook on tuberculosis: module 5: management of tuberculosis in children and adolescents details the administration of BCG, important adverse events and other aspects of the full cascade of care for children and adolescents with or at risk of TB (60).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 56
  },
  {
    "chunk_id": "advancedhiv_1217",
    "text": "44 Treatment It is recommended that TB patients who are living with HIV should receive at least the same duration of daily TB treatment as HIV-negative TB patients. (Strong recommendation, high-certainty evidence) ART should be started as soon as possible within two weeks of initiating TB treatment, regardless of CD4 cell count, among people living with HIV. a Adults and adolescents (Strong recommendation, low- to moderate-certainty evidence) Children and infants (Strong recommendation, very-low-certainty evidence) ART is recommended for all patients with HIV and drug-resistant TB requiring second-line antituberculosis drugs, irrespective of CD4 cell count, as early as possible (within the first eight weeks) following initiation of antituberculosis treatment. (Strong recommendation, very-low-certainty evidence) In patients with tuberculous meningitis, an initial adjuvant corticosteroid t",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 57
  },
  {
    "chunk_id": "advancedhiv_1218",
    "text": "llowing initiation of antituberculosis treatment. (Strong recommendation, very-low-certainty evidence) In patients with tuberculous meningitis, an initial adjuvant corticosteroid therapy with dexamethasone or prednisolone tapered over 6–8 weeks should be used. (Strong recommendation, moderate-certainty evidence) In patients with tuberculous pericarditis, an initial adjuvant corticosteroid therapy may be used. (Conditional recommendation, very-low-certainty evidence) a Except when signs and symptoms of meningitis are present. Treatment Linkage to treatment following diagnosis of TB disease is important, and co-management of TB and HIV requires close attention. Treatment regimens for drug-susceptible TB range from four to six months, which are also applicable to people with advanced HIV disease. There are, however , important considerations such as severity or type of TB disease, level of ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 57
  },
  {
    "chunk_id": "advancedhiv_1219",
    "text": "m four to six months, which are also applicable to people with advanced HIV disease. There are, however , important considerations such as severity or type of TB disease, level of immunosuppression and body weight. More details on the treatment of drug-susceptible and drug-resistant TB are available in the respective treatment guidelines within the WHO TB Knowledge Sharing Platform. Timing of ART initiation is a critical consideration when managing TB disease among people living with HIV while also ruling out signs and symptoms of meningitis. Clinically distinguishing between TB meningitis and cryptococcal meningitis is challenging and is critical if using steroids is being considered, since steroids are recommended for TB meningitis but not for cryptococcal meningitis. Using steroids may also be considered for tuberculous pericarditis as part of initial adjuvant therapy, although the in",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 57
  },
  {
    "chunk_id": "advancedhiv_1220",
    "text": "ended for TB meningitis but not for cryptococcal meningitis. Using steroids may also be considered for tuberculous pericarditis as part of initial adjuvant therapy, although the interaction of steroids and HIV infection is complex and not fully understood. Table 6 provides information on the appropriate timing of ART in the context of TB disease and cryptococcal meningitis. Comprehensive guidance is available from the WHO consolidated guidelines on tuberculosis: module 4: treatment and care (61) .",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 57
  },
  {
    "chunk_id": "advancedhiv_1221",
    "text": "45 Severe bacterial infections Severe bacterial infections are an important cause of mortality for people living with HIV and are a common cause of hospital admission, about 26% (95% CI 20–33%) (8). Severe bacterial infections present a wide range of disease manifestations and causative organisms. This includes pneumonia, bacterial meningitis, bloodstream infections and organ-specific infections. There is generally very limited access in low- and middle-income countries to reliable microbiology diagnostic tools, including blood cultures, and relatively poor assessment of the prevalence of drug- resistant organisms. Consequently, clinical diagnosis is the key tool for screening for severe illness. Common bacterial pathogens include Streptococcus spp., invasive non-typhoidal Salmonella, Escherichia coli and Staphylococcus aureus. The WHO AWaRe antibiotic book provides considerations for ra",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 58
  },
  {
    "chunk_id": "advancedhiv_1222",
    "text": "al pathogens include Streptococcus spp., invasive non-typhoidal Salmonella, Escherichia coli and Staphylococcus aureus. The WHO AWaRe antibiotic book provides considerations for rationale use of antibiotics for all populations (168). Oral co-trimoxazole remains a critical WHO recommendation (8) for use in prophylaxis and is part of the WHO-recommended package of care for advanced HIV disease, although its primary use is in preventing pneumonia caused by Pneumocystis jirovecii (111), but it may provide additional coverage for several bacterial infections. WHO provides several key considerations and knowledge gaps in managing severe bacterial infections (11). • Severe bacterial infections are a priority issue for individuals with advanced HIV disease. • Severe bacterial infections affect both inpatient and outpatient settings, and tiered guidance is essential. • Implementation research can",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 58
  },
  {
    "chunk_id": "advancedhiv_1223",
    "text": " individuals with advanced HIV disease. • Severe bacterial infections affect both inpatient and outpatient settings, and tiered guidance is essential. • Implementation research can help to address gaps in understanding the profile of severe bacterial infections. • Studies are needed to document the causes of premature death among people living with HIV. • Specific guidance on managing severe bacterial infections is needed in inpatient settings. • Antimicrobial resistance implications must be weighed carefully when considering using antimicrobial agents for prophylaxis. • Cost and cost–effectiveness studies and modelling of emergent drug resistance comprise important accompanying evidence for understanding severe bacterial infections. WHO will continue to monitor available evidence for developing further guidance on this topic.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 58
  },
  {
    "chunk_id": "advancedhiv_1224",
    "text": "46 Kaposi’s sarcoma (new, 2025) Recommendation for treatment of Kaposi’s sarcoma (new, 2025) WHO suggests paclitaxel or pegylated liposomal doxorubicin for pharmacological treatment for people living with HIV with Kaposi’s sarcoma. (Conditional recommendation, low-certainty evidence) Recommendation for treatment of mild or moderate Kaposi’s sarcoma (83) (2014) In HIV-infected adults, adolescents and children diagnosed with mild or moderate Kaposi sarcoma, immediate ART initiation is recommended. (Strong recommendation, low-certainty evidence) Recommendation for treatment of severe or symptomatic Kaposi’s sarcoma (83) (2014) Severe or symptomatic disease: in HIV-infected adults, adolescents and children diagnosed with severe symptomatic Kaposi sarcoma, immediate ART initiation in combination with systemic chemotherapy is recommended. (Strong recommendation, low-certainty evidence) Backgro",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 59
  },
  {
    "chunk_id": "advancedhiv_1225",
    "text": "d with severe symptomatic Kaposi sarcoma, immediate ART initiation in combination with systemic chemotherapy is recommended. (Strong recommendation, low-certainty evidence) Background Despite significantly improved availability of ART, HIV- associated Kaposi’s sarcoma remains among the most common type of cancer among people living with HIV. The African continent alone accounts for more than 70% of the burden of disease. HIV-associated Kaposi’s sarcoma among people living with HIV receiving ART has an estimated incidence of 289 per 100 000 person years (169). Survival following diagnosis is poor , with some estimates being 39–44% dying from Kaposi’s sarcoma–related causes, and the rest from other causes (Box 3) (170, 171). ART remains the first-line treatment for everyone with Kaposi’s sarcoma and can help to treat early- stage Kaposi’s sarcoma to achieve regression of lesions and reduce",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 59
  },
  {
    "chunk_id": "advancedhiv_1226",
    "text": " (170, 171). ART remains the first-line treatment for everyone with Kaposi’s sarcoma and can help to treat early- stage Kaposi’s sarcoma to achieve regression of lesions and reduce Kaposi’s sarcoma-related deaths (83); this is also supported by evidence in published literature (173). However , moderate to severe Kaposi’s sarcoma requires additional treatment – ranging from chemotherapy to radiotherapy. The goal is to ensure long-term control of symptoms (Table 9, Box 4).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 59
  },
  {
    "chunk_id": "advancedhiv_1227",
    "text": "47 Box 3. Case definition of Kaposi’s sarcoma (83) (2014) Mild or moderate Kaposi’s sarcoma may include the following: • confined to skin and/or lymph nodes; • no symptomatic visceral disease; • no significant oral disease (does not interfere with chewing or swallowing); • no significant oedema affecting function; and • not functionally disabling or immediately life- threatening. Severe Kaposi’s sarcoma may include the following: • symptomatic visceral disease (pulmonarya or gastrointestinalb); • extensive oral Kaposi’s sarcoma lesions that interfere with chewing or swallowing; • painful or disabling tumour-associated facial, genital or peripheral oedema or ulcerated tumours; • life-threatening or functionally disabling disease; and • progressive c or persistent Kaposi’s sarcoma despite ART. Note: these case definitions are modified from the original ACTG (172) T0 and T1 definitions and ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 60
  },
  {
    "chunk_id": "advancedhiv_1228",
    "text": "disabling disease; and • progressive c or persistent Kaposi’s sarcoma despite ART. Note: these case definitions are modified from the original ACTG (172) T0 and T1 definitions and are intended as a general guide for treatment decision-making (83). Table 9. Tumour–immune system–systemic illness staging system for HIV-related Kaposi’s sarcoma and prognosis in adults (2014) (83) Good prognosis (all the following) Poor prognosis (any of the following) Tumour (T) (T0) Tumour confined to skin and/or lymph nodes and/or minimal oral diseased (T1) Tumour-associated oedema or ulceration; extensive oral Kaposi’s sarcoma; gastrointestinal Kaposi’s sarcoma; Kaposi’s sarcoma in other non-nodal viscera Immune system (I) (I0) CD4 cells ≥150 cells/mm3 (I1) CD4 cell count <150 cells/mm3 Systemic illness (S) (S0) No history of opportunistic infections and/or thrush Absence of B symptomse Performance status",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 60
  },
  {
    "chunk_id": "advancedhiv_1229",
    "text": "CD4 cells ≥150 cells/mm3 (I1) CD4 cell count <150 cells/mm3 Systemic illness (S) (S0) No history of opportunistic infections and/or thrush Absence of B symptomse Performance status: Karnofsky score ≥70 (S1) History of opportunistic infections and/or thrush Presence of B symptomse Performance status: Karnofsky score >70 Other HIV-related illness (such as nervous system disease or lymphoma) a Symptomatic pulmonary Kaposi’s sarcoma, suggested by shortness of breath, haemoptysis or moderate or severe cough, that cannot be attributed to other pulmonary conditions. b Symptomatic gastrointestinal Kaposi’s sarcoma, suggested by bleeding from mouth or rectum, which cannot be attributed to other gastrointestinal conditions. c Progressive disease is defined as: an increase of 25% or more in the size of previously existing lesions and/or the appearance of new lesions or new sites of disease and/or a",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 60
  },
  {
    "chunk_id": "advancedhiv_1230",
    "text": "ns. c Progressive disease is defined as: an increase of 25% or more in the size of previously existing lesions and/or the appearance of new lesions or new sites of disease and/or a change in the character of 25% of more of the skin or oral lesions from macular to plaque-like or nodular . The development of new or increasing symptomatic tumour-associated oedema or effusion is also considered to represent disease progression. d Minimal oral disease defined as non-nodular Kaposi’s sarcoma confined to the palate. e B symptoms: unexplained fever , drenching night sweats, >10% involuntary weight loss or diarrhoea persisting more than two weeks.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 60
  },
  {
    "chunk_id": "advancedhiv_1231",
    "text": "48 Box 4. Staging of Kaposi’s sarcoma for children Children with HIV have a different clinical presentation of disease, thus requiring an alternative approach to staging. Children have been documented to more frequently have lymph node involvement, lymphadenopathies or cytopathies (174). It has been previously documented that the ACTG and modified ACTG staging approach do not correlate well with treatment outcomes (172, 175, 176). Several approaches have been proposed but are similar to the staging included in the 2014 WHO guidelines on treatment of skin and oral HIV-associated conditions in adults and children (83). • Stage I: <10 Kaposi’s sarcoma lesions isolated to the skin without significant associated oedema. • Stage II: ≥10 Kaposi’s sarcoma lesions isolated to the skin, or lesions involving the palate or oral mucosa, subcutaneous nodules, lymph nodes and/or bone marrow (two cytopa",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 61
  },
  {
    "chunk_id": "advancedhiv_1232",
    "text": "ema. • Stage II: ≥10 Kaposi’s sarcoma lesions isolated to the skin, or lesions involving the palate or oral mucosa, subcutaneous nodules, lymph nodes and/or bone marrow (two cytopaenia not otherwise explained). • Stage III: disseminated Kaposi’s sarcoma involving the lymphatics resulting in lymphoedema (“woody” oedema) in the extremities and/or groin. • Stage IV: systemic Kaposi’s sarcoma, defined as pulmonary Kaposi’s sarcoma with noted infiltrates or effusions on chest radiography, abdominal involvement with intra-abdominal nodes, hepatomegaly and/or ascites and/or cardiac involvement with cardiomegaly and associated pericardial effusion. More recent classifications include the Lilongwe paediatric Kaposi’s sarcoma staging system (174, 175, 177), where stage 1 = mild or moderate Kaposi’s sarcoma limited to cutaneous or oral involvement, stage 2 = primarily lymphadenopathic disease, stag",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 61
  },
  {
    "chunk_id": "advancedhiv_1233",
    "text": "rcoma staging system (174, 175, 177), where stage 1 = mild or moderate Kaposi’s sarcoma limited to cutaneous or oral involvement, stage 2 = primarily lymphadenopathic disease, stage 3 = woody oedema Kaposi’s sarcoma and stage 4 = visceral and/or severe or disseminated mucocutaneus disease. Further validation studies of the various staging systems are required to help to improve prognostication for children with Kaposi’s sarcoma. In 2014, WHO provided recommendations on treatment for advanced Kaposi’s sarcoma, noting greatly restricted access to chemotherapeutic agents and concerns relating to ensuring safety, toxicity monitoring and available infrastructure (83). Since 2014, additional evidence is available that supports advances in managing HIV-associated Kaposi’s sarcoma. A systematic review (Web Annex B) summarized the currently available evidence around preferred treatment regimens f",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 61
  },
  {
    "chunk_id": "advancedhiv_1234",
    "text": "t supports advances in managing HIV-associated Kaposi’s sarcoma. A systematic review (Web Annex B) summarized the currently available evidence around preferred treatment regimens for Kaposi’s sarcoma (11). The review identified five randomized trials; no meta- analysis was possible because of wide variation in reporting in the included studies (178–181). Since no meta-analysis was possible, for evaluating the evidence comparisons were split and discussed by the Guideline Development Group as paclitaxel and non-paclitaxel-based treatment comparisons. All arms were conducted with individuals receiving ART concurrently. Rationale for the recommendations Paclitaxel-based treatment comparisons Three interventions were evaluated against paclitaxel. These included: • paclitaxel versus liposomal pegylated doxorubicin; • paclitaxel versus etoposide; and • paclitaxel versus the combination of bleo",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 61
  },
  {
    "chunk_id": "advancedhiv_1235",
    "text": "re evaluated against paclitaxel. These included: • paclitaxel versus liposomal pegylated doxorubicin; • paclitaxel versus etoposide; and • paclitaxel versus the combination of bleomycin and vincristine. Non-paclitaxel-based treatment comparisons Two studies or arms had non-paclitaxel evaluations: • gemcitabine versus the combination of bleomycin and vincristine; and • pegylated liposomal doxorubicin versus liposomal daunorubicin.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 61
  },
  {
    "chunk_id": "advancedhiv_1236",
    "text": "49 Balance of benefits and harm When paclitaxel was compared with liposomal pegylated doxorubicin, paclitaxel showed slightly better or similar tumour response, progression-free survival (17.5% versus 12.2%) and two-year survival (56% versus 46%). These overall benefits were considered to be small. Paclitaxel was associated with moderate increase in harm related to the incidence of toxicity (178, 179). The Guideline Development Group concluded that the balance of benefits and harm was likely similar for both treatments. When paclitaxel was compared with etoposide, paclitaxel was associated with improved progression- free survival (50% versus 20%), mortality (11% versus 26%), and tumour response (34% versus 18%) and fewer adverse events (46% versus 58% of any grade 3 or 4 adverse event). When paclitaxel was compared with bleomycin + vincristine, paclitaxel was associated with improved pro",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1237",
    "text": " and fewer adverse events (46% versus 58% of any grade 3 or 4 adverse event). When paclitaxel was compared with bleomycin + vincristine, paclitaxel was associated with improved progression-free survival (64% versus 44%), mortality (10% versus 19%) and tumour response (91% versus 80%) and similar or decreased adverse events (46% versus 48% of any grade 3 or 4 adverse event). For these two comparisons, the Guideline Development Group concluded that the balance of benefits and harm probably favoured paclitaxel. The overall certainty of evidence was low. Among the non-paclitaxel treatment comparisons, two studies informed the systematic review (180– 182). Gemcitabine compared with combination bleomycin + vincristine showed better complete and partial tumour response (86%) compared with those on bleomycin + vincristine (76%) and improved three-year survival, although this was not statisticall",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1238",
    "text": "e showed better complete and partial tumour response (86%) compared with those on bleomycin + vincristine (76%) and improved three-year survival, although this was not statistically significant. Bleomycin + vincristine was associated with more events related to peripheral neuropathy (grade 3 or 4); 26% with bleomycin + vincristine versus 14% with gemcitabine. There were similar rates of neutropaenia (grade 3 or 4) and anaemia (grade 1 or 2). The overall certainty of evidence in the GRADE (Grading of Recommendations Assessment, Development and Evaluation) assessment was very low. The Guideline Development Group concluded that the balance of benefits and harm would probably favour gemcitabine. One study compared pegylated liposomal doxorubicin with pegylated liposomal daunorubicin. More people on pegylated liposomal doxorubicin 4 The clinical trial that provides evidence on this comparison",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1239",
    "text": "pegylated liposomal doxorubicin with pegylated liposomal daunorubicin. More people on pegylated liposomal doxorubicin 4 The clinical trial that provides evidence on this comparison used two definitions for treatment response: clinical benefit, which was defined as an improvement from baseline in at least one of five AIDS-related Kaposi’s sarcoma symptom categories that lasted for 28 days in the absence of disease progression or severe disease; and defined as an improvement from baseline in at least one AIDS-related Kaposi’s sarcoma symptom category that lasted for 28 days with no worsening of other symptom categories and no increase in medical interventions either before or during that period. experienced clinical benefit (both by protocol4 definition (45%) and conservative definition (37%)) versus liposomal daunorubicin. The median time to response was similar for pegylated liposomal do",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1240",
    "text": "cal benefit (both by protocol4 definition (45%) and conservative definition (37%)) versus liposomal daunorubicin. The median time to response was similar for pegylated liposomal doxorubicin and pegylated liposomal daunorubicin (30 days versus 27 days). Liposomal doxorubicin had higher rates of grade 3 or 4 neutropaenia (30%) than liposomal daunorubicin (16%) but reported similar rates of nausea (any grade). The overall certainty of evidence was very low. The Guideline Development Group concluded that the balance of effects does not favour either the intervention or the comparison. Preferences, acceptability and feasibility A survey was conducted among people living with HIV (Web Annex C). The respondents rated survival and quality of life as the most important outcomes, followed by rapid response to treatment. Avoiding serious adverse events was also a relatively high priority. Treatment",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1241",
    "text": "survival and quality of life as the most important outcomes, followed by rapid response to treatment. Avoiding serious adverse events was also a relatively high priority. Treatment-related toxicity and recurrence were rated as less important. The analysis of the open-ended questions reiterated that financial worries were a major theme, with respondents concerned about the ability to pay hospital bills and afford necessary medications after discharge; how their health conditions financially affected their lifestyle and family was also a recurrent theme. For the comparison of paclitaxel to liposomal doxorubicin, paclitaxel was associated with modest benefits, but there were concerns around increased adverse events; thus, client preferences may vary when deciding to use paclitaxel as a treatment option. However , paclitaxel would be preferred because of the associated benefits along with si",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1242",
    "text": "s; thus, client preferences may vary when deciding to use paclitaxel as a treatment option. However , paclitaxel would be preferred because of the associated benefits along with similar or decreased adverse events versus either etoposide or bleomycin + vincristine. Members of the Guideline Development Group noted that because gemcitabine was associated with some potential benefits and not associated with increased harm, decisions to use gemcitabine may not be sensitive to preferences or values regarding potential benefits versus harm. In the comparison involving pegylated liposomal doxorubicin versus pegylated liposomal daunorubicin, pegylated liposomal doxorubicin is associated with potential clinical benefit but also potential harm (increased neutropaenia); therefore, decisions to use pegylated doxorubicin may be sensitive to preference and values regarding potential benefits versus ha",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1243",
    "text": "but also potential harm (increased neutropaenia); therefore, decisions to use pegylated doxorubicin may be sensitive to preference and values regarding potential benefits versus harm.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 62
  },
  {
    "chunk_id": "advancedhiv_1244",
    "text": "50 The Guideline Development Group concluded that there was probably no important uncertainty or variability when comparing gemcitabine versus bleomycin + vincristine and possibility important uncertainty or variability when comparing pegylated liposomal doxorubicin versus liposomal daunorubicin. The results from the values and preferences survey highlighted the importance of survival, quality of life and rapid treatment response in managing HIV- associated Kaposi’s sarcoma. These priorities suggest a preference for newer , more effective therapies. The Guideline Development Group also concluded that the non-paclitaxel combination was probably feasible to implement in settings that administer chemotherapy. Resources and cost–effectiveness A report (183) on the cost of currently available formulations indicates that using pegylated doxorubicin and gemcitabine is associated with large cost",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 63
  },
  {
    "chunk_id": "advancedhiv_1245",
    "text": "urces and cost–effectiveness A report (183) on the cost of currently available formulations indicates that using pegylated doxorubicin and gemcitabine is associated with large costs. Using paclitaxel or bleomycin + vincristine is associated with moderate costs. The price of daunorubin was found to vary depending on the setting and context. The overall certainty of costs was judged to be moderate (183). A cost–effectiveness analysis of four chemotherapeutic regimens in Kenya found that paclitaxel offers survival benefit and is highly cost- effective compared with bleomycin vincristine in this setting. Pegylated liposomal doxorubicin provides additional life expectancy benefits but only becomes cost-effective if its cost is significantly reduced (184). The systematic review did not identify any cost– effectiveness analysis of gemcitabine versus bleomycin + vincristine. One study was identi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 63
  },
  {
    "chunk_id": "advancedhiv_1246",
    "text": "its cost is significantly reduced (184). The systematic review did not identify any cost– effectiveness analysis of gemcitabine versus bleomycin + vincristine. One study was identified that compared liposomal doxorubicin versus liposomal daunorubicin and reported that pegylated liposomal doxorubicin cost less (US$ 11 976 per respondent) than liposomal daunorubicin (US$ 26 483 per respondent) (Web Annex C). Equity Having additional effective and well-tolerated options for treatment for Kaposi’s sarcoma could improve equity if it increases access to treatment. However , if paclitaxel is widely available and implemented, the impact of additional chemotherapeutic options for Kaposi’s sarcoma is unclear . Treatment of Kaposi’s sarcoma for children and during pregnancy Paclitaxel has shown efficacy in HIV-associated Kaposi sarcoma among children and adolescents in a retrospective cohort of 17 ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 63
  },
  {
    "chunk_id": "advancedhiv_1247",
    "text": "of Kaposi’s sarcoma for children and during pregnancy Paclitaxel has shown efficacy in HIV-associated Kaposi sarcoma among children and adolescents in a retrospective cohort of 17 people (5–21 years old) in the United Republic of Tanzania with an 82% overall survival rate and 71% complete remission with manageable toxicity (185). There is very limited evidence in published literature on Kaposi’s sarcoma among children; a review conducted in 2016 estimated that the incidence is about 67 per 100 000 children living with HIV, about 30 times more frequent than among children generally (186). In Mozambique, a study of 28 children on monthly paclitaxel plus ART achieved long-term remission in 19 cases (68%) (187). Although pegylated liposomal doxorubicin lacks child-specific clinical trial data, its documented efficacy and tolerability for adults with Kaposi’s sarcoma have led to off-label use",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 63
  },
  {
    "chunk_id": "advancedhiv_1248",
    "text": "though pegylated liposomal doxorubicin lacks child-specific clinical trial data, its documented efficacy and tolerability for adults with Kaposi’s sarcoma have led to off-label use for children, especially in severe cases. The WHO Essential Medicines List for Children (188) acknowledges pegylated liposomal doxorubicin as “not approved for use in children” and advises caution because of the absence of formal safety and efficacy data on children. In the context of pregnancy, data are extremely limited, with only limited case reports detailing case management (189–194). The safety of using chemotherapeutics agents in the context of pregnancy would be similar to using these agents for other types of cancer and would have to be considered on a case-by-case basis. Initiation of ART is a priority in this population, along with appropriate monitoring for development of Kaposi’s sarcoma immune re",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 63
  },
  {
    "chunk_id": "advancedhiv_1249",
    "text": "d have to be considered on a case-by-case basis. Initiation of ART is a priority in this population, along with appropriate monitoring for development of Kaposi’s sarcoma immune reconstitution inflammatory syndrome (83). WHO explicitly states that pegylated liposomal doxorubicin is contraindicated, citing potential teratogenicity, and strongly supports pregnancy testing before initiating chemotherapeutic agents, with additional consideration for initiating treatment in the first trimester , which may result in serious fetal adverse effects. The guidance (188) notes: “Avoid use in pregnancy and in women and girls of childbearing potential, unless alternative treatments are ineffective or not tolerated.”",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 63
  },
  {
    "chunk_id": "advancedhiv_1250",
    "text": "51 Implementation considerations Chemotherapeutic treatment for HIV-associated Kaposi’s sarcoma is only for those with Kaposi’s sarcoma diagnosis confirmed by histopathology. Clinical diagnosis of Kaposi’s sarcoma, which is based on the macroscopic appearance of the Kaposi’s sarcoma lesions, has suboptimal positive predictive value – about 23–42% of diagnoses based on clinical suspicion alone are not Kaposi’s sarcoma (195–197) . The Guideline Development Group noted that in special situations in which access to the preferred treatment options is lacking, other available treatments can be considered, noting their limitations and side-effects, such as the combination of bleomycin + vincristine, gemcitabine or etoposide. No specific recommendation was made for these treatment options. • Importance of diagnosis and screening for Kaposi’s sarcoma: correctly identifying Kaposi’s sarcoma is a c",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 64
  },
  {
    "chunk_id": "advancedhiv_1251",
    "text": "poside. No specific recommendation was made for these treatment options. • Importance of diagnosis and screening for Kaposi’s sarcoma: correctly identifying Kaposi’s sarcoma is a challenge in many low- and middle-income settings and is often misdiagnosed as other diseases. Training health-care workers is critical for ensuring accurate clinical diagnosis. Linking to histopathological infrastructure is also important. • Timely ART initiation: ART remains central to the treatment approach for Kaposi’s sarcoma. • Importance of access to cancer treatment: countries should take steps to promote and provide access to cancer treatment (Table 10). • Integrated care models may be considered to distribute limited resources in the most effective manner . • Capacity building and training: important to support and train health-care workers for identifying and managing Kaposi’s sarcoma, identifying and",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 64
  },
  {
    "chunk_id": "advancedhiv_1252",
    "text": "s in the most effective manner . • Capacity building and training: important to support and train health-care workers for identifying and managing Kaposi’s sarcoma, identifying and managing toxicity from treatment and approaches to counselling individuals with Kaposi’s sarcoma. • Monitoring and follow-up: since Kaposi’s sarcoma is known to recur among people previously treated for Kaposi’s sarcoma, regular follow-up and identifying potential adherence challenges in individuals who present to care with Kaposi’s sarcoma recurrence and retreatment are important. • Stigma and psychosocial support: HIV programmes must take steps to support individuals with Kaposi’s sarcoma who report stigmatization through counselling and psychosocial support to ensure that these individuals access and complete treatment for Kaposi’s sarcoma. Research gaps • Effectiveness of targeted therapies: need for clini",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 64
  },
  {
    "chunk_id": "advancedhiv_1253",
    "text": "ng and psychosocial support to ensure that these individuals access and complete treatment for Kaposi’s sarcoma. Research gaps • Effectiveness of targeted therapies: need for clinical trials evaluating targeted therapies and how they affect Kaposi’s sarcoma progression and survival rates, also specifically a trial comparing gemcitabine versus paclitaxel and comparative trials on novel immunotherapy treatment approaches. • Limited data on ART-integrated Kaposi’s sarcoma management: insufficient research on the long-term outcomes of combining ART with chemotherapy or immunotherapy. • Treating children with Kaposi’s sarcoma: lack of specific treatment guidelines and clinical data on the safety and efficacy of Kaposi’s sarcoma therapies for children. • Feasibility studies and cost–effectiveness analysis to support country adoption of treatment strategies. • Understanding the epidemiology, id",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 64
  },
  {
    "chunk_id": "advancedhiv_1254",
    "text": "si’s sarcoma therapies for children. • Feasibility studies and cost–effectiveness analysis to support country adoption of treatment strategies. • Understanding the epidemiology, identification and management of Kaposi’s sarcoma inflammatory cytokine syndrome. • Need for understanding patient-level outcomes and quality-of-life measures in the research on treatment for managing Kaposi’s sarcoma.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 64
  },
  {
    "chunk_id": "advancedhiv_1255",
    "text": "52 Table 10. Commonly used chemotherapy regimens for HIV-associated Kaposi’s sarcoma in adults (83) Regimen Dose per cycle Route Frequency of cycles Paclitaxel 100 mg/m2 Intravenous Every 3–4 weeks Pegylated liposomal doxorubicin 20 mg/m2 Intravenous Every 3 weeks Etoposide 100–200 mg daily for seven days Oral Every 2–3 weeks Bleomycin (B) + vincristine (V) B: 15 U/m2 V: 1.4 mg/m2 (maximum 2 mg) Intravenous Every 3 weeks Gemcitabine (181) 1000 mg/m2 Intravenous Every 2 weeks Liposomal daunorubicin 40 mg/m2 Intravenous Every 2 weeks Doxorubicin (A) + bleomycin (B) + vincristine (V) A: 15–20 mg/m2 B: 10–15 mg/m2 V: 1–1.4mg/m2; maximum 2 mg) Intravenous Every 3–4 weeks Table 11. Major toxicities of chemotherapy drugs used in Kaposi’s sarcoma (83) Drug Common toxicities Less common but serious Etoposide Neutropaenia, thrombocytopaenia, anaemia, alopecia, nausea and vomiting Leukaemia and mye",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 65
  },
  {
    "chunk_id": "advancedhiv_1256",
    "text": "ugs used in Kaposi’s sarcoma (83) Drug Common toxicities Less common but serious Etoposide Neutropaenia, thrombocytopaenia, anaemia, alopecia, nausea and vomiting Leukaemia and myelodysplastic syndromes Liposomal anthracyclines (doxorubicin, daunorubicin) Neutropaenia, thrombocytopaenia, anaemia, myelosuppression and drug may turn urine red Hand-foot syndrome, acute infusion reactions and cardiac toxicity Paclitaxel Neutropaenia, thrombocytopaenia, anaemia, peripheral neuropathy, tiredness and alopecia Serious allergic reactions (anaphylaxis) Vincristine Peripheral neuropathy, constipation and ileus Vesicant skin ulcers if extravasated Bleomycin Pulmonary fibrosis (late), fever , chills and myalgias (infusion reactions) Skin changes, including distal digital necrosis Gemcitabine Leukopaenia, thrombocytopaenia, anaemia, grade 3 or 4 neutropaenia, febrile neutropaenia, somnolence, dyspnoea",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 65
  },
  {
    "chunk_id": "advancedhiv_1257",
    "text": "eactions) Skin changes, including distal digital necrosis Gemcitabine Leukopaenia, thrombocytopaenia, anaemia, grade 3 or 4 neutropaenia, febrile neutropaenia, somnolence, dyspnoea, liver enzyme elevation, flu-like symptoms, nausea and vomiting Thrombocytosis, thrombotic microangiopathy, anaphylactoid reaction, posterior reversible encephalopathy, myocardial infarction, heart failure, arrythmia and hypotension Note: This list is not intended to be comprehensive; alternative drug doses and schedules have been used. Drug doses and schedules may need to be modified for pre-existing organ dysfunction and/or treatment-associated adverse events. The maximum cumulative dose of doxorubicin is 450 mg/m2 and maximum cumulative dose of bleomycin is 400 U/m2 of body surface area. The maximum cumulative dose of pegylated liposomal doxorubicin is unknown; cardiac toxicity has been documented at doses ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 65
  },
  {
    "chunk_id": "advancedhiv_1258",
    "text": "lative dose of bleomycin is 400 U/m2 of body surface area. The maximum cumulative dose of pegylated liposomal doxorubicin is unknown; cardiac toxicity has been documented at doses above 550 mg/m2. The known maximum cumulative dose for liposomal daunorubicin is 550 mg/m2.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 65
  },
  {
    "chunk_id": "advancedhiv_1259",
    "text": "53 Other coinfections and comorbidities",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 66
  },
  {
    "chunk_id": "advancedhiv_1260",
    "text": "54 Individuals with advanced HIV disease have an elevated risk of developing numerous opportunistic infections, and timely identification is critical. WHO recently launched the fungal priority pathogens list, which also includes fungal species that primarily affect people living with HIV (111). Of the 19 fungal pathogens within the WHO fungal priority pathogens list, four opportunistic pathogens in particular cause invasive diseases among people living with HIV: Cryptococcus neoformans, Histoplasma spp., Pneumocystis jirovecii and Talaromyces marneffei. Cryptococcosis and histoplasmosis have been discussed previously in this publication (111). Pneumocystis jirovecii Pneumocystis pneumonia is a leading cause of mortality among hospitalized adults and children living with HIV. Pneumocystis jirovecii is transmitted from person to person through the air . The main ways to prevent and treat t",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 67
  },
  {
    "chunk_id": "advancedhiv_1261",
    "text": "mortality among hospitalized adults and children living with HIV. Pneumocystis jirovecii is transmitted from person to person through the air . The main ways to prevent and treat this infection are co- trimoxazole and rapid early initiation of ART. Diagnosis has traditionally relied upon clinical symptoms, radiographic findings and microscopy because Pneumocystis jirovecii cannot be cultured. Non-culture-based diagnostics on sputum or bronchoalveolar lavage, such as polymerase chain reaction, have entered clinical use, but resource-limited settings often have inadequate infrastructure for these assays. A disease prevalence of 19% has been reported among symptomatic adults living with HIV in Africa (198). It is also important to consider Pneumocystis as part of a differential diagnosis while evaluating other respiratory conditions such as TB and bacterial pneumonia. The use of co-trimoxaz",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 67
  },
  {
    "chunk_id": "advancedhiv_1262",
    "text": "also important to consider Pneumocystis as part of a differential diagnosis while evaluating other respiratory conditions such as TB and bacterial pneumonia. The use of co-trimoxazole for the prevention and treatment of Pneumocystis infections as well as a range of bacterial infections is an important part of the standard package of care for people living with HIV (8). WHO developed recommendations for using co-trimoxazole as prophylaxis, based on moderate-certainty evidence that its use reduces the mortality of people living with HIV, with a CD4 count <350 cells/mm 3 or with a stage 3 or 4 AIDS- defining illness (8). Box 5 summarizes the current guidance for using co- trimoxazole for people living with HIV and those who are severely immunocompromised (199). Box 5. WHO recommendations for co-trimoxazole prophylaxis (2014) Co-trimoxazole prophylaxis is recommended for adults (including pr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 67
  },
  {
    "chunk_id": "advancedhiv_1263",
    "text": " those who are severely immunocompromised (199). Box 5. WHO recommendations for co-trimoxazole prophylaxis (2014) Co-trimoxazole prophylaxis is recommended for adults (including pregnant women) with severe or advanced HIV clinical disease (WHO stage 3 or 4) and/or with CD4 cell count ≤350 cells/mm3. (Strong recommendation, moderate-certainty evidence) In settings where malaria and/or severe bacterial infections are highly prevalent, co-trimoxazole prophylaxis should be initiated regardless of CD4 cell count or WHO stage. (Conditional recommendation, moderate-certainty evidence) Co-trimoxazole prophylaxis may be discontinued for adults (including pregnant women) with HIV who are clinically stable on ART, with evidence of immune recovery and viral suppression. (Conditional recommendation, low-certainty evidence) In settings where malaria and/or severe bacterial infections are highly preval",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 67
  },
  {
    "chunk_id": "advancedhiv_1264",
    "text": "idence of immune recovery and viral suppression. (Conditional recommendation, low-certainty evidence) In settings where malaria and/or severe bacterial infections are highly prevalent, co-trimoxazole prophylaxis should be continued regardless of CD4 cell count or WHO clinical stage. (Conditional recommendation, moderate-certainty evidence) Co-trimoxazole prophylaxis is recommended for infants, children and adolescents with HIV, regardless of clinical and immune conditions. Priority should be given to all children younger than five years old regardless of CD4 cell count or clinical stage and children with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and/or those with CD4 cell count ≤350 cells/mm3. (Strong recommendation, high-certainty evidence) In settings where malaria and/or severe bacterial infections are highly prevalent, co-trimoxazole prophylaxis should be co",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 67
  },
  {
    "chunk_id": "advancedhiv_1265",
    "text": "lls/mm3. (Strong recommendation, high-certainty evidence) In settings where malaria and/or severe bacterial infections are highly prevalent, co-trimoxazole prophylaxis should be continued until adulthood whether or not ART is being taken. (Conditional recommendation, moderate-certainty evidence) In settings of low prevalence for both malaria and bacterial infections, co-trimoxazole prophylaxis may be discontinued for children five years of age and older who are clinically stable and/or virally suppressed on ART for at least six months and CD4 cell count >350 cells/mm3. (Strong recommendation, very-low-certainty evidence)",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 67
  },
  {
    "chunk_id": "advancedhiv_1266",
    "text": "55 Co-trimoxazole prophylaxis is recommended for HIV-exposed infants from four to six weeks of age and should be continued until HIV infection has been excluded by an age-appropriate HIV test to establish final diagnosis after complete cessation of breastfeeding. (Strong recommendation, very- low-certainty evidence) Routine co-trimoxazole prophylaxis should be given to all people living with HIV with TB disease regardless of CD4 cell count. (Strong recommendation, high-certainty evidence) Talaromycosis Talaromycosis is an invasive fungal infection that has been increasingly reported in South-East Asia among individuals with advanced HIV disease. Talaromycosis is understood to be transmitted by inhaling the causative organism, Talaromycosis marneffei (200). The disease is associated with a high mortality rate, with up to one third of individuals diagnosed with talaromycosis dying (201–203",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 68
  },
  {
    "chunk_id": "advancedhiv_1267",
    "text": "ative organism, Talaromycosis marneffei (200). The disease is associated with a high mortality rate, with up to one third of individuals diagnosed with talaromycosis dying (201–203). Despite the association with higher mortality, relatively little is known about its prevalence in the general population. Countries such as China, Thailand and Viet Nam report talaromycosis as a leading cause of HIV-related deaths. It also disproportionately affects poorer or rural areas of affected countries. It is often difficult to identify, regularly mimicking other infections (202, 203). Diagnosis is usually established with fungal culture, but this approach is often subject to delays and consequently late initiation of appropriate treatment. Polymerase chain reaction–based assays have high reported specificity but are not well suited for screening approaches because of lower sensitivity (204). Several ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 68
  },
  {
    "chunk_id": "advancedhiv_1268",
    "text": "riate treatment. Polymerase chain reaction–based assays have high reported specificity but are not well suited for screening approaches because of lower sensitivity (204). Several promising antigen-based tests are undergoing clinical validation, which can in the future enable point-of-care screening for early disease and support early treatment to prevent fulminant disease (205–207). People with advanced HIV disease are at risk of illness and death from a wide range of infectious diseases. Candida spp., Paracoccidioides spp., Coccidioides spp. and Aspergillus fumigatus most commonly cause severe disease for other populations, but they are also important opportunistic pathogens for people living with HIV (111). Severe disease is common among people living with HIV, caused by most of the pathogens on the fungal priority pathogens list. Each country should further assess any additional coin",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 68
  },
  {
    "chunk_id": "advancedhiv_1269",
    "text": "Severe disease is common among people living with HIV, caused by most of the pathogens on the fungal priority pathogens list. Each country should further assess any additional coinfections that are endemic and adapt the package of care to ensure that critical diagnostics, treatment and prevention tools are made available for the diseases afflicting people with advanced HIV disease. WHO will continue to monitor emerging therapeutics and diagnostics to support the response to managing opportunistic infections. Mpox In 2025, WHO published updated recommendations (208) for the management of mpox, including people living with HIV. Studies conducted among people living with HIV and/ or advanced HIV disease have found significantly more severe disease compared with the general population at lower CD4 counts (209). Mortality is higher among individuals with advanced HIV disease (CD4 count <200 c",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 68
  },
  {
    "chunk_id": "advancedhiv_1270",
    "text": " significantly more severe disease compared with the general population at lower CD4 counts (209). Mortality is higher among individuals with advanced HIV disease (CD4 count <200 cells/mm 3) (209). The risk of hospitalization from mpox is 1.79 (95% CI 1.07– 3.00) times higher among people living with HIV and 2.45 (95% CI 1.19–5.02) times higher among those with a CD4 cell count <350 cells/mm 3 (208). The risk of all-cause mortality is 10-fold for people living with HIV who had mpox (208). Rapid initiation of ART (8) remains an important programmatic component in the management of mpox. An expert consensus meeting hosted by WHO concluded that the general mortality reduction benefits of rapid ART initiation extend to patients with mpox, accepting the risk of paradoxical immune reconstitution inflammatory syndrome, and reiterating that delaying ART initiation may possibly be harmful (208). ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 68
  },
  {
    "chunk_id": "advancedhiv_1271",
    "text": "d to patients with mpox, accepting the risk of paradoxical immune reconstitution inflammatory syndrome, and reiterating that delaying ART initiation may possibly be harmful (208). Owing to the nature of disease outbreaks, WHO provides living recommendations that may be updated as new evidence is available for this topic.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 68
  },
  {
    "chunk_id": "advancedhiv_1272",
    "text": "56 WHO recommendations for managing mpox (May 2025) (208) WHO recommends rapid initiation of ART in people with mpox and HIV who are ART naive or have had a prolonged interruption of ART (Strong recommendation, moderate-certainty evidence) • Early HIV testing should be conducted when patients present with suspected or confirmed mpox infection. • The patient should be referred to appropriate services for ART initiation as soon as possible, aiming to provide therapy within seven days of HIV diagnosis, including the offer of same-day start. • In people who are already on ART and with undetectable viral load, ART regimen should be continued without interruption or change. The viral load test result should be less than one year old; if not, a new viral load test should be conducted. Nontuberculous mycobacterial infections Nontuberculous mycobacterial infections, most commonly disseminated myc",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 69
  },
  {
    "chunk_id": "advancedhiv_1273",
    "text": "han one year old; if not, a new viral load test should be conducted. Nontuberculous mycobacterial infections Nontuberculous mycobacterial infections, most commonly disseminated mycobacterium avium complex infections, present a significant challenge for people living with HIV who have profound immunosuppression (CD4 cell count <50 cells/mm3) (210). With the increased availability of highly effective ART, the incidence of mycobacterium avium complex infections has declined over time but is frequently reported in autopsy studies of individuals with HIV who were hospitalized with severe illness (210). The main challenge countries face is timely identification of mycobacterium avium complex infections. TB and mycobacterium avium complex infections may often have similar presentations and result in false-positive acid-fast sputum tests. which may result in an incorrect diagnosis of TB. Microbi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 69
  },
  {
    "chunk_id": "advancedhiv_1274",
    "text": "cterium avium complex infections may often have similar presentations and result in false-positive acid-fast sputum tests. which may result in an incorrect diagnosis of TB. Microbiological culture remains the preferred method (210) to identify mycobacterium avium complex infections but is challenging to implement in most resource-limited settings. Other approaches include radiological imaging. A combination of these approaches helps to establish the severity of disease (211–213). Treatment of mycobacterium avium complex infections includes antibiotics such as azithromycin, ethambutol, rifabutin and rifampicin. The Southern African HIV Clinicians Society provides detailed guidance on managing people living with HIV who have nontuberculous mycobacterial infections (211). WHO will continue to monitor available evidence on nontuberculous mycobacterial infections and provide updates when poss",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 69
  },
  {
    "chunk_id": "advancedhiv_1275",
    "text": "HIV who have nontuberculous mycobacterial infections (211). WHO will continue to monitor available evidence on nontuberculous mycobacterial infections and provide updates when possible.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 69
  },
  {
    "chunk_id": "advancedhiv_1276",
    "text": "57 Palliative care Individuals with advanced HIV disease present a range of symptoms from opportunistic infections or comorbidities or may have no symptoms at all. Implementing a comprehensive palliative care framework (214) will help to reduce health-related suffering and support individuals’ return to health and restoration of immune status. Health conditions such as TB (215) and cryptococcal meningitis and cervical cancer (216, 217) among women living with HIV contribute significant morbidity during illness and during the recovery phase, but little attention is paid to this public health issue (218). Sensitizing health-care workers through validated courses on palliative care helps to support early identification of needs and thus contributes to improving the quality of care (219). Monitoring advanced HIV disease Importance of monitoring advanced HIV disease in programmes Monitoring a",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 70
  },
  {
    "chunk_id": "advancedhiv_1277",
    "text": "ation of needs and thus contributes to improving the quality of care (219). Monitoring advanced HIV disease Importance of monitoring advanced HIV disease in programmes Monitoring advanced HIV disease is essential for reducing mortality among people living with HIV. Effective monitoring ensures that people with advanced HIV disease are rapidly identified and linked to appropriate services, which is important for improving health outcomes and reducing the risk of life-threatening complications. Obtaining different perspectives on the epidemic and the response is key, for example, to assess gender equity and age-specific differences in coverage, to ensure quality of services for specific subgroups, to review current or long-term performance and to compare population-based and programme-based measures of performance. Strengthened national HIV surveillance systems involve standardized reporti",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 70
  },
  {
    "chunk_id": "advancedhiv_1278",
    "text": "nt or long-term performance and to compare population-based and programme-based measures of performance. Strengthened national HIV surveillance systems involve standardized reporting of individuals with advanced HIV disease. This includes tracking whether individuals had a CD4 count test when recommended and tracking the provision of the recommended package of care for advanced HIV disease. The implementation of recommended screening tools and treatment protocols needs to be monitored to ensure comprehensive care. Mortality data can come from clinics, national death registries and cross-referencing other sources, including verbal autopsy methods. Given the challenges and costs of these measurements, routinely collecting programme data is a valuable way to track how the programme affects the epidemic. Additionally, monitoring helps to direct resources to gaps in care, ensuring that popula",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 70
  },
  {
    "chunk_id": "advancedhiv_1279",
    "text": "ollecting programme data is a valuable way to track how the programme affects the epidemic. Additionally, monitoring helps to direct resources to gaps in care, ensuring that populations and areas with the greatest need receive the necessary support. With the rapid expansion of digital health information systems, existing HIV information systems can be expanded and linked to routinely capture and track individual data over time. This improves data quality, simplifies reporting and provides actionable insights at the subnational levels. Electronic medical records can support person- centred care and patient monitoring in addition to (and, typically, as the source of) aggregate reporting of service indicator data. National health information systems enable health-care providers to track patient data in real time, facilitating timely and accurate clinical decision support. By integrating cli",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 70
  },
  {
    "chunk_id": "advancedhiv_1280",
    "text": " National health information systems enable health-care providers to track patient data in real time, facilitating timely and accurate clinical decision support. By integrating clinical decision support tools, health-care providers can make informed decisions about patient care, ensuring that individuals with advanced HIV disease receive the necessary interventions promptly.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 70
  },
  {
    "chunk_id": "advancedhiv_1281",
    "text": "58 Key principles for monitoring advanced HIV disease Focusing on identifying advanced HIV disease at any stage of interaction with the health-care system is fundamental to effective monitoring. This includes identifying advanced HIV disease at diagnosis, re- engagement or reinitiation of care and if a person experiences treatment failure. Regularly monitoring CD4 cell counts during follow- up visits helps track disease progression and the effectiveness of treatment. Additionally, monitoring for high viral load, adherence challenges and opportunistic infections provides valuable insights into the patient’s health status and the need for tailored care. A comprehensive list of priority data elements for advanced HIV disease monitoring is essential for tracking longitudinal information over time. This includes data on CD4 cell counts, viral load, adherence and the presence of opportunistic ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 71
  },
  {
    "chunk_id": "advancedhiv_1282",
    "text": "HIV disease monitoring is essential for tracking longitudinal information over time. This includes data on CD4 cell counts, viral load, adherence and the presence of opportunistic infections. By collecting and analysing these data, health-care providers can identify trends and patterns, enabling them to make informed decisions about patient care and resource allocation. Minimum dataset for advanced HIV disease monitoring A minimum dataset containing data elements for monitoring advanced HIV disease is intended to capture the key events in an individual’s interaction with the health system related to advanced HIV disease, which can then be used to develop a cascade of advanced HIV disease indicators. The minimum dataset was developed as part of the WHO consolidated guidelines on person-centred HIV strategic information (220). The main purpose is to standardize patient information with a s",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 71
  },
  {
    "chunk_id": "advancedhiv_1283",
    "text": " dataset was developed as part of the WHO consolidated guidelines on person-centred HIV strategic information (220). The main purpose is to standardize patient information with a simplified and harmonized set of essential data elements relevant to core patient management and programme monitoring. Standardization also enables programme personnel to compare data across populations, time, geographical areas and settings and provides data for clinical teams to monitor the quality of care longitudinally and along the cascade of HIV services. Table 12 presents a priority list of data elements for monitoring advanced HIV disease for inclusion in national surveillance systems. These data can be used for understanding who is developing advanced HIV disease and where to better direct resources. Advanced HIV disease indicators based on these data elements will be shared through strategic informatio",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 71
  },
  {
    "chunk_id": "advancedhiv_1284",
    "text": "ho is developing advanced HIV disease and where to better direct resources. Advanced HIV disease indicators based on these data elements will be shared through strategic information guidance in due course. Key client categories in people with advanced HIV disease: • people newly diagnosed with HIV; • people re-diagnosed with HIV (those who have tested HIV-positive in the past but have not received ART); • people reinitiating ART after a period of treatment interruption; and • people who experience HIV treatment failure.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 71
  },
  {
    "chunk_id": "advancedhiv_1285",
    "text": "59 Table 12. Minimum dataset of critical data elements for inclusion in national health information systems for monitoring advanced HIV disease Area Data elements Diagnosis of advanced HIV disease HIV test date HIV test result Baseline CD4 test date Baseline CD4 test result Clinical stage at start of ART Advanced HIV disease package of care ART start date Co-trimoxazole prophylaxis start date TB screening date TB screening result TB diagnostic test category TB diagnostic test date Date of TB diagnosis TB treatment start date TB treatment completion date Eligible for TB preventive treatment TB preventive treatment start date TB preventive treatment status Cryptococcal disease diagnostic test date Cryptococcal disease diagnostic test result Cryptococcal disease diagnostic test category Date of start of fluconazole prophylaxis Date started cryptococcal disease treatment induction regimen",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 72
  },
  {
    "chunk_id": "advancedhiv_1286",
    "text": "60 Drug–drug interactions Table 13. Summary table of important drug–drug interactions in treatments recommended by WHO for people living with HIV Protease inhibitors Non-nucleoside reverse-transcriptase inhibitors and integrase strand- transfer inhibitors Nucleoside reverse- transcriptase inhibitors 1 2 3 4 5 6 7 8 9 10 Anti-infective drugs Amphotericin Ba ↔ ↔ ↔ ↔ ♥ ↔ ↔ ↔ ↔ ↔ a ↔ b Fluconazole ↔ c d ↔ ↔ c d ↔ ♥ ⇑ 100% ⇑ d ↔ ⇑ ⇑ ⇑ 74% e Itraconazole ↑ ⇑ d f ↑ ⇑ f ↑ ⇑ d f ↓ 39% ♥ ↓ 61% ⇑ d ↔ ⇑ ⇑ ↔ Rifampicin ⇓ 72% g ⇓ 57% ⇓ 75% h ⇓ 26% i ⇓ 58% ⇓ ⇓ 54% j ⇓ k ⇓ 12% ⇓ 47% Rifapentine ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ l ⇓ k ↔ ↔ Flucytosine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ⇓ ↔ ↔ b Cytotoxic drugs Bleomycin ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Daunorubicin ↔ m ↔ ↔ m ↔ m ♥ ↔ ↔ m ↔ ↔ ↔ ↔ n Doxorubicina ↔ m ↔ ↔ m ↔ m ♥ ↔ ↔ m ↔ ↔ ↔ ↔ b Etoposide ↑↓ o ↑↓ o ↑↓ o ↓ ↓ ↔ ↔ ↔ ↔ ↔ n Gemcitabine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ n Paclitaxel ↑ ↑ ↑ ↑ ↔ ⇓ ⇓ ↔ ↔ ↔ n Vinblastine ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 73
  },
  {
    "chunk_id": "advancedhiv_1287",
    "text": " ↔ m ↔ ↔ ↔ ↔ n Doxorubicina ↔ m ↔ ↔ m ↔ m ♥ ↔ ↔ m ↔ ↔ ↔ ↔ b Etoposide ↑↓ o ↑↓ o ↑↓ o ↓ ↓ ↔ ↔ ↔ ↔ ↔ n Gemcitabine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ n Paclitaxel ↑ ↑ ↑ ↑ ↔ ⇓ ⇓ ↔ ↔ ↔ n Vinblastine ↑ ↑ ↑ ↓ ↓ ⇓ ↔ ↔ ↔ ↔ b Vincristine ↑ ↑ ↑ ↓ ↓ ↔ ↔ ↔ ↔ ↔ b Vinorelbine ↑ ↑ ↑ ↓ ↓ ↔ ↔ ↔ ↔ ↔ a Interactions also apply to liposomal or pegylated liposomal formulations. For additional drug–drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, see http://www.hiv-druginteractions.org (University of Liverpool, United Kingdom). Drugs legend 1 Atazanavir + ritonavir 2 Darunavir + ritonavir 3 Lopinavir + ritonavir 4 Efavirenz 5 Nevirapine 6 Cabotegravir + rilpivirine 7 Dolutegravir 8 Tenofovir alafenamide 9 Tenofovir disoproxil fumarate 10 Zidovudine Colour legend No clinically significant interaction expected These drugs should not be co administered Potential clinically signifi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 73
  },
  {
    "chunk_id": "advancedhiv_1288",
    "text": "de 9 Tenofovir disoproxil fumarate 10 Zidovudine Colour legend No clinically significant interaction expected These drugs should not be co administered Potential clinically significant interaction likely to require additional monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action or monitoring or dosage adjustment is unlikely to be required Legend ↔ No significant effect ↑ Potential increased exposure of the co- administered drug or active metabolite ↓ Potential decreased exposure of the co- administered drug or active metabolite ⇑ Potential increased exposure to antiretroviral drug ⇓ Potential decreased exposure to antiretroviral drug",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 73
  },
  {
    "chunk_id": "advancedhiv_1289",
    "text": "61 Numbers refer to effect on the area under the curve as observed in drug–drug interaction studies.Cabotegravir + rilpivirine: pharmacokinetic interactions shown are mostly with rilpirivine; QT interactions shown are with rilpirivine. Efavirenz: pharmacokinetic interaction data from studies performed with efavirenz 600 mg once daily. Comments a Tenofovir disoproxil fumarate should be avoided with concurrent or recent use of a nephrotoxic agent. If co-administration is unavoidable, monitor renal function closely. b Potential increased risk of zidovudine adverse reactions. c Electrocardiographic monitoring is recommended. d Caution as both drugs can induce QT interval prolongation. e Routine zidovudine dose modification not required but monitor for potential zidovudine toxicity. f The daily dose of itraconazole should not exceed 200 mg with boosted antiretroviral drugs. g The pharmacokine",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 74
  },
  {
    "chunk_id": "advancedhiv_1290",
    "text": "fication not required but monitor for potential zidovudine toxicity. f The daily dose of itraconazole should not exceed 200 mg with boosted antiretroviral drugs. g The pharmacokinetic interaction can be overcome by doubling the atazanavir + ritonavir dose (300/100 mg twice daily). h If no other option, use ritonavir 400 mg twice daily or double dose lopinavir + ritonavir . i Efavirenz 600 mg once daily should be used in the presence of rifampicin; in the absence of rifampicin, efavirenz can be used at 400 mg or 600 mg once daily. j A dose adjustment of dolutegravir to 50 mg twice daily is recommended for treatment- naive or integrase strand-transfer inhibitor– naive people. This dose adjustment should be maintained for two weeks after stopping rifampicin as the inducing effect persists after discontinuation of a strong inducer . Alternatives to rifampicin should be used where possible fo",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 74
  },
  {
    "chunk_id": "advancedhiv_1291",
    "text": "ined for two weeks after stopping rifampicin as the inducing effect persists after discontinuation of a strong inducer . Alternatives to rifampicin should be used where possible for integrase strand-transfer inhibitor–experienced people with certain integrase strand-transfer inhibitor–associated resistance substitutions or clinically suspected integrase strand-transfer inhibitor resistance. k Rifamycins decrease tenofovir alafenamide exposure when given 25 mg. However , the intracellular tenofovir diphosphate (active entity) concentrations are likely to be higher than those observed with tenofovir disoproxil fumarate even without rifampicin, suggesting that using tenofovir alafenamide 25 mg once daily may be acceptable. l Based on dolutegravir interactions studies with rifabutin and rifampicin, consider administering dolutegravir at 50 mg twice daily in the presence of rifapentine. This ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 74
  },
  {
    "chunk_id": "advancedhiv_1292",
    "text": "ceptable. l Based on dolutegravir interactions studies with rifabutin and rifampicin, consider administering dolutegravir at 50 mg twice daily in the presence of rifapentine. This dose adjustment should be maintained for two weeks after stopping rifapentine since the inducing effect persists after discontinuation of a strong inducer . m Daunorubicin and doxorubicin may induce cardiac toxicity including arrhythmias and/or non-specific electrocardiographic abnormalities; caution is warranted in presence of other drugs with potential effects on PR and QT intervals. n Potential increased risk of additive myelosuppression and haematological toxicity. If concomitant treatment is necessary, extra care should be taken in monitoring haematological parameters. o It is difficult to predict: etoposide exposure could potentially increase (inhibition of CYP3A4) or decrease (induction of UGT1A1). Close",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 74
  },
  {
    "chunk_id": "advancedhiv_1293",
    "text": "in monitoring haematological parameters. o It is difficult to predict: etoposide exposure could potentially increase (inhibition of CYP3A4) or decrease (induction of UGT1A1). Close monitoring of etoposide-induced toxicity and efficacy is recommended. Reduce dose if clinically necessary or consider selecting an alternate non- cytochrome 450–inhibiting ART regimen. ♥ Efavirenz prolonged the QT interval above the regulatory threshold of concern in homozygous carriers of the CYP2B6*6/*6 allele (516T variant). Co-administration with a drug with a known risk of torsades de pointe is contraindicated in the efavirenz European label.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 74
  },
  {
    "chunk_id": "advancedhiv_1294",
    "text": "62 Table 14. WHO definitions of clinical, immune and viral failure for the decision to switch ART regimens Failure Definition Comments Clinical failure Adults and adolescents New or recurrent clinical event indicating severe immunodeficiency (WHO clinical stage 4 condition) after six months of effective treatment Children New or recurrent clinical event indicating advanced or severe immunodeficiency (WHO clinical stage 3 and 4 clinical conditions except for TB) after six months of effective treatment The condition must be differentiated from immune reconstitution inflammatory syndrome occurring after initiating ART For adults, certain WHO clinical stage 3 conditions (pulmonary TB and severe bacterial infections) Immune failure (adults) Adults and adolescents CD4 count at 250 cells/mm3 following clinical failure or persistent CD4 cell count below 100 cells/mm3a Without concomitant or rece",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 75
  },
  {
    "chunk_id": "advancedhiv_1295",
    "text": ") Immune failure (adults) Adults and adolescents CD4 count at 250 cells/mm3 following clinical failure or persistent CD4 cell count below 100 cells/mm3a Without concomitant or recent infection to cause a transient decline in the CD4 cell count Immune failure (children) Children Younger than five years Persistent CD4 cell count below 200 cells/mm3 Older than five years Persistent CD4 cell count below 100 cells/mm3 Current WHO clinical and immunological criteria have low sensitivity and positive predictive value for identifying individuals with viral failure. There is currently no proposed alternative definition of treatment failure and no validated alternative definition of immune failure Viral failure Viral load above 1000 copies/mL based on two consecutive viral load measurements three months apart, with adherence support following the first viral load test. ART switch after first viral",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 75
  },
  {
    "chunk_id": "advancedhiv_1296",
    "text": "d above 1000 copies/mL based on two consecutive viral load measurements three months apart, with adherence support following the first viral load test. ART switch after first viral load >1000 copies/mL for those receiving non-nucleoside reverse-transcriptase inhibitor– based regimens An individual must be taking ART for six months before it can be determined that a regimen has failed Individuals with viral load >50 and <1000 copies, maintain ART regimen, enhance adherence counselling and repeat viral load testing after three months Consider switch after second viral load >50 and <1000 copies/mL if people are receiving non-nucleoside reverse-transcriptase inhibitor– based ART a Previous guidelines defined immune failure based on a fall from baseline, which is no longer applicable in the context of CD4- independent treatment initiation.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 75
  },
  {
    "chunk_id": "advancedhiv_1297",
    "text": "63 *A seriously ill adult is defined as having any of the following danger signs: respiratory rate ≥30 breaths per minute; heart rate ≥120 beats per minute; or unable to walk unaided. Other clinical condition, such as temperature ≥39°C combined with other signs such as headache, can also be considered based on local epidemiology and clinical judgement. A seriously ill child is defined as having any of the following danger signs: lethargy or unconsciousness; convulsions; unable to drink or breastfeed; repeated vomiting. Other clinical conditions such as temperature ≥39 and age-defined tachycardia and /or tachypnea can be considered based on clinical judgement. Abbreviations: ART: antiretroviral therapy; CM: cryptococcal meningitis; TB: tuberculosis; TBM: TB meningitis; LC-NAAT: Low-complexity nucleic acid amplification test; LF-LAM: lateral flow- lipoarabinomannan assay; CrAg: cryptococca",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 76
  },
  {
    "chunk_id": "advancedhiv_1298",
    "text": "tococcal meningitis; TB: tuberculosis; TBM: TB meningitis; LC-NAAT: Low-complexity nucleic acid amplification test; LF-LAM: lateral flow- lipoarabinomannan assay; CrAg: cryptococcal antigen test; TPT: TB preventive therapy; CSF: cerebrospinal fluid; LP: lumbar puncture; WHO: World health organisation Take history and examination Offer intensified adherence support for medications Consider home visits and rapid tracing following disengagement Initiating and monitoring ART TB symptoms not present Start TPT Investigations negative for TB Consider alternate diagnosis, start TPT according to recommendations Rule out Histoplasmosis where appropriate Start cotrimoxazole according to WHO recommendations TB symptoms present Concurrent testing with LC-NAAT with urine LF-LAM Investigations positive for TB Start TB treatment CSF CrAg negative or LP not feasible Start pre-emptive treatment for crypto",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 76
  },
  {
    "chunk_id": "advancedhiv_1299",
    "text": "sent Concurrent testing with LC-NAAT with urine LF-LAM Investigations positive for TB Start TB treatment CSF CrAg negative or LP not feasible Start pre-emptive treatment for cryptococcal infection Danger signs* NOT present Screen for symptoms of TB Meningitis symptoms not present if not on ART, perform blood CAg test Blood CrAg positive Where feasible and no contraindications perform LP and CSF CrAg test, treat based on results CSF CrAg positive Treat for cryptoccoal meningitis as per WHO recommendations Screen for symptoms of meningitis Assess for signs of meningitis (headache, confusion, neck rigidity) Meningitis symptoms present Perform blood CrAg, Lumbar puncture, CSF CrAg test, LC-NAAT testing and microscopy Treat according to WHO guidelines as per results Danger signs present/ Seriously illˆ Follow WHO algorithm for HIV inpatient care: Assess, Refer , Diag- nose, Identify, Treat. A",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 76
  },
  {
    "chunk_id": "advancedhiv_1300",
    "text": "py Treat according to WHO guidelines as per results Danger signs present/ Seriously illˆ Follow WHO algorithm for HIV inpatient care: Assess, Refer , Diag- nose, Identify, Treat. ART initiation if no contraindications present Post-discharge care planning: • pre-discharge goal setting • medication review • transitional care planning • telephone follow up • Home visits by healthcare providers or peer supporters • Individualized support Currently on ART Check Viral load, assess for treatment failure. Follow WHO recommended VL algorithm to monitor treatment response Previous on ART (treatment interruption) Offer rapid ART or defer ART where appropriate in presence of CM or TBM ART Naive Offer rapid ART if no contraindication present (e.g., symptoms of meningitis) Advanced HIV disease algorithm",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 76
  },
  {
    "chunk_id": "advancedhiv_1301",
    "text": "64 References 4 1. Global health sector strategies on, respectively, HIV, viral hepatitis, sexually transmitted infections for the period 2022–2030. Geneva: World Health Organization; 2022 (https://iris.who.int/ handle/10665/360348). Licence: CC BY-NC-SA 3.0 IGO. 2. The path that ends AIDS: UNAIDS global AIDS update. Geneva: UNAIDS; 2023 (https://www.unaids.org/sites/default/files/media_ asset/2023-unaids-global-aids-update_en.pdf). 3. Targets: recommended 2030 targets for HIV. Geneva: UNAIDS; 2021 (https://www.unaids.org/en/recommended-2030-targets-for-hiv). 4. Ford N, Kassanjee R, Stelzle D, Jarvis JN, Sued O, Perrin G et al. Global prevalence of advanced HIV disease in healthcare settings: a rapid review. J Int AIDS Soc. 2025;28(2):e26415 (https://doi.org/10.1002/ jia2.26415). 5. Stelzle D, Rangaraj A, Jarvis JN, Razakasoa NH, Perrin G, Low-Beer D et al. Prevalence of advanced HIV dis",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1302",
    "text": "Int AIDS Soc. 2025;28(2):e26415 (https://doi.org/10.1002/ jia2.26415). 5. Stelzle D, Rangaraj A, Jarvis JN, Razakasoa NH, Perrin G, Low-Beer D et al. Prevalence of advanced HIV disease in sub-Saharan Africa: a multi-country analysis of nationally representative household surveys. Lancet Glob Health. 2025;13(3):e437–46 (https://doi. org/10.1016/S2214-109X(24)00538-2). 6. UNAIDS data. Geneva: UNAIDS; 2024 (https://www.unaids.org/en/ resources/documents/2024/2024_unaids_data). 7. Patten G, Malateste K, Moore CB, Sipambo N, Mokone L, Anderegg N et al. Global trends in CD4 measurement and immunosuppression at ART initiation among children with HIV. Pediatr Infect Dis J. 2025 (https://doi.org/10.1097/INF.0000000000004658). 8. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World H",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1303",
    "text": "4658). 8. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342899). Licence: CC BY-NC- SA 3.0 IGO. 9. Burke RM, Sabet N, Ellis J, Rangaraj A, Lawrence DS, Jarvis JN et al. Causes of hospitalisation among people living with HIV worldwide, 2014–23: a systematic review and meta-analysis. Lancet HIV. 2025;12(5):e355–66 (https://doi.org/10.1016/S2352-3018(24)00321-8). 10. Ford N, Patten G, Rangaraj A, Davies M-A, Meintjes G, Ellman T. Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis. Lancet HIV. 2022;9(3):e150–9 (https://doi.org/10.1016/S2352-3018(21)00329-5). 11. The advanced HIV disease research landscape. Geneva: World Health Organization; 2024 (https://iris.who.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1304",
    "text": "t HIV. 2022;9(3):e150–9 (https://doi.org/10.1016/S2352-3018(21)00329-5). 11. The advanced HIV disease research landscape. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376040). Licence: CC BY-NC-SA 3.0 IGO. 12. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007 (https://iris.who.int/handle/10665/43699). 13. Munthali C, Taegtmeyer M, Garner PG, Lalloo DG, Squire SB, Corbett EL et al. Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub‐Saharan Africa: a systematic review and meta‐analysis. J Int AIDS Soc. 2014;17(1):18932 (https://doi. org/10.7448/IAS.17.1.18932). 14. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Healt",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1305",
    "text": "oc. 2014;17(1):18932 (https://doi. org/10.7448/IAS.17.1.18932). 14. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/255884 ). Licence: CC BY-NC-SA 3.0 IGO. 15. Waldrop G, Doherty M, Vitoria M, Ford N. Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy. Trop Med Int Health. 2016;21(9):1124–30 (https://doi.org/10.1111/tmi.12746). 16. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O’Shaughnessy MV et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77 (https://doi.org/10.1001/jama.286.20.2568). 17. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendation",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1306",
    "text": "286(20):2568–77 (https://doi.org/10.1001/jama.286.20.2568). 17. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016 (https:// iris.who.int/handle/10665/208825). Licence: CC BY-NC-SA 3.0 IGO. 18. de Waal R, Wools-Kaloustian K, Brazier E, Althoff KN, Jaquet A, Duda SN et al. Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation. Clin Infect Dis. 2024:ciae548 (https://doi.org/10.1093/cid/ciae548). 19. Twabi HH, Ueno A, Ives J, Murtagh R, Mukoka M, Mortazavi SA et al. Diagnostic accuracy of the WHO clinical staging system for detection of immunologically defined advanced HIV disease: a systematic review and meta-analysis. SSRN. (https://dx.doi.org/10.2139/ ssrn.5140921). 20. Aregay AD, Kidane KM, Aregay ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1307",
    "text": "etection of immunologically defined advanced HIV disease: a systematic review and meta-analysis. SSRN. (https://dx.doi.org/10.2139/ ssrn.5140921). 20. Aregay AD, Kidane KM, Aregay AB, Fenta KA, Woldegebriel AG, Godefay H et al. Prediction of CD4 T‐lymphocyte count using WHO clinical staging among ART‐naïve HIV‐infected adolescents and adults in northern Ethiopia: a retrospective study. AIDS Res Treat. 2020;2020(1):2163486 (https://doi.org/10.1155/2020/2163486). 21. Baldé A, Lièvre L, Maiga AI, Diallo F, Maiga IA, Costagliola D et al. Re-engagement in care of people living with HIV lost to follow-up after initiation of antiretroviral therapy in Mali: who returns to care? PLoS One. 2020;15(9):e0238687 (https://doi.org/10.1371/journal. pone.0238687). 22. Boniphace I, Omari M, Fred RS, Ferdinand M, Marcel T. HIV/AIDS clinical manifestations and their implication for patient clinical staging ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1308",
    "text": "i.org/10.1371/journal. pone.0238687). 22. Boniphace I, Omari M, Fred RS, Ferdinand M, Marcel T. HIV/AIDS clinical manifestations and their implication for patient clinical staging in resource limited settings in Tanzania. Open AIDS J. 2011;5:9 (https://doi.org/10.2174/1874613601105010009). 23. Carter RJ, Dugan K, El-Sadr WM, Myer L, Otieno J, Pungpapong N et al. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defic Syndr . 2010;55(3):404¬10 (https://doi.org/10.1097/ qai.0b013e3181e73f4b). 24. Ebonyi AO, Agbaji OO, Anejo-Okopi JA, Oguche S, Agaba A, Sagay SA et al. Factors associated with a low CD4 count among HIV-1 infected patients at enrolment into HAART in Jos, Nigeria. Br J Med Med Res. 2014;4(13):2536 (https://doi.org/10.9734/BJMMR/2",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1309",
    "text": "l. Factors associated with a low CD4 count among HIV-1 infected patients at enrolment into HAART in Jos, Nigeria. Br J Med Med Res. 2014;4(13):2536 (https://doi.org/10.9734/BJMMR/2014/8469). 25. Edathodu J, Ali B, Alrajhi AA. CD4 validation for the World Health Organization classification and clinical staging of HIV/AIDS in a developing country. International Journal of Infectious Diseases. 2009;13(2):243–6. (https://doi.org/10.1016/j.ijid.2007.12.017). 26. French N, Mujugira A, Nakiyingi J, Mulder D, Janoff E, Gilks C. Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. J Acquir Immune Defic Syndr . 1999;22(5):509–16 (https://doi. org/10.1097/00126334-199912150-00013 ). 27. Gautam H, Saini S, Bhalla P , Singh T. Use of total lymphocyte count to predict absolute CD4 count in ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1310",
    "text": ". 1999;22(5):509–16 (https://doi. org/10.1097/00126334-199912150-00013 ). 27. Gautam H, Saini S, Bhalla P , Singh T. Use of total lymphocyte count to predict absolute CD4 count in HIV-seropositive cases. J Int Assoc Physicians AIDS Care. 2010;9(5):292–5 (https://doi. org/10.1177/1545109710373826). 28. Singh A, Mahajan S, Singh T, Deepti SS. Socio-demographic and clinical profile of HIV/AIDS patients attending the ART centre of Amritsar , Punjab. Int J Community Med Public Health. 2018;5(5):2059– 65. (https://doi.org/10.18203/2394-6040.ijcmph20181723). 29. Ilovi C, Lule G, Obel O, Irimu M. Correlation of WHO clinical staging with CD4 counts in adult HIV/AIDS patients at Kenyatta National Hospital, Nairobi. East Afr Med J. 2011;88(2):65–70. 30. Ingole N, Nataraj G, Mehta P , Paranjpe S, Sarkate P . CD4 counts in laboratory monitoring of HIV disease – experience from western India. J Int As",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1311",
    "text": "Afr Med J. 2011;88(2):65–70. 30. Ingole N, Nataraj G, Mehta P , Paranjpe S, Sarkate P . CD4 counts in laboratory monitoring of HIV disease – experience from western India. J Int Assoc Provid AIDS Care. 2014;13(4):324–7 (https://doi. org/10.1177/2325957412474846). 31. Jaffar S, Birungi J, Grosskurth H, Amuron B, Namara G, Nabiryo C et al. Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda. AIDS Research Ther . 2008;5:4 (https://doi.org/10.1186/1742-6405-5-4). 32. Kagaayi J, Makumbi F, Nakigozi G, Wawer MJ, Gray RH, Serwadda D et al. WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. AIDS. 2007;21(9):1208–10 (https://doi.org/10.1097/ qad.0b013e32810c8dce). 4 All references accessed 1 August 2025.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 77
  },
  {
    "chunk_id": "advancedhiv_1312",
    "text": "65 33. Kassa E, de Wit TFR, Hailu E, Girma M, Messele T, Mariam HG et al. Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. AIDS. 1999;13(3):381–9 (https://doi. org/10.1097/00002030-199902250-00016). 34. Klotz SA, Nguyen HC, Van Pham T, Nguyen LT, Ngo DTA, Vu SN. Clinical features of HIV/AIDS patients presenting to an inner city clinic in Ho Chi Minh City, Vietnam. Int J STD AIDS. 2007;18(7):482–5 (https://doi.org/10.1258/095646207781147265) 35. Lebelonyane R, Mills LA, Mogorosi C, Ussery F, Marukutira T, Theu J et al. Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes. AIDS. 2020;34(15):2223–30 (https://doi.org/10.1097/ QAD.0000000000002627). 36. Morpeth SC, Crump JA, Shao HJ, Ramadhani HO, Kisenge PR, Moylan CA et al. P",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1313",
    "text": "sk factors, and outcomes. AIDS. 2020;34(15):2223–30 (https://doi.org/10.1097/ QAD.0000000000002627). 36. Morpeth SC, Crump JA, Shao HJ, Ramadhani HO, Kisenge PR, Moylan CA et al. Predicting CD4 lymphocyte count <200 cells/mm3 in an HIV type 1-infected African population. AIDS Res Hum Retrovirus. 2007;23(10):1230–6 (https://doi.org/10.1089/aid.2007.0053). 37. Nyagaka B, Musyoki SK, Karani L, Nyamache AK. Characteristics and treatment outcomes of HIV infected elderly patients enrolled in Kisii Teaching and Referral Hospital, Kenya. Afr Health Sci. 2020;20(4):1537–45 (https://doi.org/10.4314/ahs.v20i4.6). 38. Oudenhoven HP , Meijerink H, Wisaksana R, Oetojo S, Indrati A, van der Ven AJ et al. Total lymphocyte count is a good marker for HIV‐ related mortality and can be used as a tool for starting HIV treatment in a resource‐limited setting. Trop Med Int Health. 2011;16(11):1372– 9 (https://",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1314",
    "text": "t is a good marker for HIV‐ related mortality and can be used as a tool for starting HIV treatment in a resource‐limited setting. Trop Med Int Health. 2011;16(11):1372– 9 (https://doi.org/10.1111/j.1365-3156.2011.02870.x). 39. Reda AA, Biadgilign S, Deribew A, Gebre B, Deribe K. Predictors of change in CD4 lymphocyte count and weight among HIV infected patients on anti-retroviral treatment in Ethiopia: a retrospective longitudinal study. PLoS One. 2013;8(4):e58595 (https://doi. org/10.1371/journal.pone.0058595). 40. Sempa JB, Kiragga AN, Castelnuovo B, Kamya MR, Manabe YC. Among patients with sustained viral suppression in a resource- limited setting, CD4 gains are continuous although gender- based differences occur . PLoS One. 2013;8(8):e73190 (https://doi. org/10.1371/journal.pone.0073190). 41. Tassie J-M, Marquardt T, Damisoni H, Odhiambo OD, Mulemba M, Szumilin E et al. Indirect mark",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1315",
    "text": "occur . PLoS One. 2013;8(8):e73190 (https://doi. org/10.1371/journal.pone.0073190). 41. Tassie J-M, Marquardt T, Damisoni H, Odhiambo OD, Mulemba M, Szumilin E et al. Indirect markers to initiate highly active antiretroviral therapy in a rural African setting. AIDS. 2004;18(8):1226–8 (https:// doi.org/10.1097/00002030-200405210-00025). 42. Torpey K, Lartey M, Amenyah R, Addo N, Obeng-Baah J, Rahman Y et al. Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need? Int J STD AIDS. 2009;20(6):395–8 (https://doi.org/10.1258/ ijsa.2008.008333). 43. Visser M, Maartens G, Kossew G, Hussey G. Plasma vitamin A and zinc levels in HIV-infected adults in Cape Town, South Africa. Br J Nutr . 2003;89(4):475–82 (https://doi.org/10.1079/bjn2002806). 44. Gils T, Kamele M, Madonsela T, Bosman S, Ngubane T, Joseph P et al. Implement",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1316",
    "text": "ts in Cape Town, South Africa. Br J Nutr . 2003;89(4):475–82 (https://doi.org/10.1079/bjn2002806). 44. Gils T, Kamele M, Madonsela T, Bosman S, Ngubane T, Joseph P et al. Implementation of the advanced HIV disease care package with point-of-care CD4 testing during tuberculosis case finding: a mixed- methods evaluation. PLoS One. 2023;18(12):e0296197 /https://doi. org/10.1371/journal.pone.0296197). 45. HIV market report. Boston: Clinton Health Access Initiative; 2024 (https://www.clintonhealthaccess.org/wp-content/ uploads/2024/12/2024-HIV-Market-Report_12.20.24.pdf). 46. Hyle E, Maphosa T, Rangaraj A, Feser M, Reddy K, Shroufi A et al. Cost–effectiveness of the WHO-endorsed advanced HIV care package in Malawi. 12th IAS Conference on HIV Science, Brisbane, Australia, 23–26 July 2023 (https://programme.ias2023.org/Abstract/ Abstract/?abstractid=5023). 47. Vojnov L, Markby J, Boeke C, Harri",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1317",
    "text": "12th IAS Conference on HIV Science, Brisbane, Australia, 23–26 July 2023 (https://programme.ias2023.org/Abstract/ Abstract/?abstractid=5023). 47. Vojnov L, Markby J, Boeke C, Harris L, Ford N, Peter T. POC CD4 testing improves linkage to HIV care and timeliness of ART initiation in a public health approach: a systematic review and meta-analysis. PLoS One. 2016;11(5):e0155256 (https://doi.org/10.1371/journal. pone.0155256). 48. WHO list of prequalified in vitro diagnostic products. Geneva: World Health Organization; 2025 (https://extranet.who.int/prequal/vitro- diagnostics/prequalified-vitro-diagnostics). 49. Kaindjee-Tjituka F, Sawadogo S, Mutandi G, Maher AD, Salomo N, Mbapaha C et al. Task-shifting point-of-care CD4+ testing to lay health workers in HIV care and treatment services in Namibia. Afr J Lab Med. 2017;6(1):643 (https://doi.org/10.4102/ajlm.v6i1.643). 50. Vojnov L, Taegtmeyer",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1318",
    "text": "are CD4+ testing to lay health workers in HIV care and treatment services in Namibia. Afr J Lab Med. 2017;6(1):643 (https://doi.org/10.4102/ajlm.v6i1.643). 50. Vojnov L, Taegtmeyer M, Boeke C, Markby J, Harris L, Doherty M et al. Performance of non-laboratory staff for diagnostic testing and specimen collection in HIV programs: a systematic review and meta- analysis. PLoS One. 2019;14(5):e0216277 (https://doi.org/10.1371/ journal.pone.0216277) 51. Van Turha L, Maharaj K, Rose A, Boeke C, Peter TF, Vojnov L et al. Point-of-care CD4+ technology implementation in Free State, South Africa, was associated with improved patient health outcomes. S Afr Med J. 2020;110(2):126–31 (https://doi.org/10.7196/samj.2020. v110i2.13823). 52. Bile EC, Bachanas PJ, Jarvis JN, Maurice F, Makovore V, Chebani L et al. Accuracy of point-of-care HIV and CD4 field testing by lay healthcare workers in the Botswana",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1319",
    "text": "2.13823). 52. Bile EC, Bachanas PJ, Jarvis JN, Maurice F, Makovore V, Chebani L et al. Accuracy of point-of-care HIV and CD4 field testing by lay healthcare workers in the Botswana Combination Prevention Project. J Virol Methods. 2023;311:114647 (https://doi.org/10.1016/j. jviromet.2022.114647). 53. Managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://iris.who. int/handle/10665/255884). Licence: CC BY-NC-SA 3.0 IGO. 54. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173–82 (https:// doi.org/10.1016/S0140-6736(15)60164-7). 55. Hakim J, Musiime V, Szubert ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1320",
    "text": "n Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173–82 (https:// doi.org/10.1016/S0140-6736(15)60164-7). 55. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233–45 (https://doi. org/10.1056/NEJMoa1615822). 56. WHO consolidated guidelines on tuberculosis: module 1: prevention – tuberculosis preventive treatment, second edition. Geneva: World Health Organization; 2024 (https://iris.who.int/ handle/10665/378536). Licence: CC BY-NC-SA 3.0 IGO. 57. WHO consolidated guidelines on tuberculosis: module 3: diagnosis – rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organization; 2024 (https://iris.who.int/ handle/10665/376221). Licence: CC BY-NC-SA 3.0 IGO. 58. Consolidated guidelines on tub",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1321",
    "text": "osis detection, third edition. Geneva: World Health Organization; 2024 (https://iris.who.int/ handle/10665/376221). Licence: CC BY-NC-SA 3.0 IGO. 58. Consolidated guidelines on tuberculosis: module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/340255). Licence: CC BY-NC-SA 3.0 IGO. 59. WHO consolidated guidelines on tuberculosis: module 3: diagnosis. Geneva: World Health Organization; 2025 (https://iris.who.int/ handle/10665/381003). Licence: CC BY-NC-SA 3.0 IGO. 60. WHO operational handbook on tuberculosis: module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/352523). Licence: CC BY-NC-SA 3.0 IGO. 61. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization; 2",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1322",
    "text": "iris.who.int/handle/10665/352523). Licence: CC BY-NC-SA 3.0 IGO. 61. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization; 2025 (https://iris.who. int/handle/10665/380799). Licence: CC BY-NC-SA 3.0 IGO. 62. Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, Meintjes G. Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep. 2013;15(6):583–93 (https://doi. org/10.1007/s11908-013-0378-5). 63. Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F et al. Tuberculosis and histoplasmosis among human immunodeficiency virus–infected patients: a comparative study. Am J Trop Med Hyg. 2014;90(2):216–23 (https://doi.org/10.4269/ajtmh.13-0084). 64. Benzekri NA, Sambou JF, Ndong S, Tamba IT, Faye D, Diallo MB et al. Prevalence, predictors, and management of advanced HIV disease among individuals initiating",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1323",
    "text": "/ajtmh.13-0084). 64. Benzekri NA, Sambou JF, Ndong S, Tamba IT, Faye D, Diallo MB et al. Prevalence, predictors, and management of advanced HIV disease among individuals initiating ART in Senegal, west Africa. BMC Infect Dis. 2019;19(1):261 (https://doi.org/10.1186/s12879-019-3826-5). 65. Tukamuhebwa PM, Gemmell I. A cross-sectional study evaluating the screening, diagnosis and management of advanced HIV disease at the AIDS support organization service centre in Mbarara City, southwestern Uganda. BMC Infect Dis. 2025;25(1):254 (https://doi. org/10.1186/s12879-025-10682-3). 66. Health workforce–related terminology. Geneva: World Health Organization; 2021 (https://cdn.who.int/media/docs/default-source/ health-workforce/hwp/202100608-health-workforce-terminology. pdf?sfvrsn=b5d2808d_3&download=true). 67. The global advanced HIV disease toolkit. Geneva: International AIDS Society and partner",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1324",
    "text": "kforce/hwp/202100608-health-workforce-terminology. pdf?sfvrsn=b5d2808d_3&download=true). 67. The global advanced HIV disease toolkit. Geneva: International AIDS Society and partners; 2025 (https://differentiatedservicedelivery.org/ advanced-hiv-disease-toolkit). 68. Maphosa T, Denoeud-Ndam L, Kapanda L, Khatib S, Chilikutali L, Matiya E et al. Understanding health systems challenges in providing advanced HIV disease (AHD) care in a hub and spoke model: a qualitative analysis to improve AHD care program in Malawi. BMC Health Serv Res. 2024;24(1):244 ( https://doi. org/10.1186/s12913-024-10700-1 ). 69. Perazzo J, Reyes D, Webel A. A systematic review of health literacy interventions for people living with HIV. AIDS Behav. 2017;21:812–21 (https://doi.org/10.1007/s10461-016-1329-6).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 78
  },
  {
    "chunk_id": "advancedhiv_1325",
    "text": "66 70. Emergency triage assessment and treatment (ETAT). Geneva: World Health Organization; 2005 (https://iris.who.int/handle/10665/43386). 71. IMAI district clinician manual: hospital care for adolescents and adults. Geneva: World Health Organization; 2011 (https://iris.who.int/ handle/10665/77751). 72. Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2019 (https://iris.who.int/ handle/10665/336323). Licence: CC BY-NC-SA 3.0 IGO. 73. Identifying common opportunistic infections among people with advanced HIV disease: policy brief. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/375725). 74. Török ME, Yen NTB, Chau TTH, Mai NTH, Phu NH, Mai PP et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374–83 (https://doi.org/10.109",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1326",
    "text": "Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374–83 (https://doi.org/10.1093/cid/cir230). 75. Bremer M, Kadernani YE, Wasserman S, Wilkinson RJ, Davis AG. Strategies for the diagnosis and management of meningitis in HIV-infected adults in resource limited settings. Exp Opin Pharmacother . 2021;22(15):2053–70 ( https://doi.org/10.1080/1465 6566.2021.1940954 ). 76. Alufandika M, Lawrence DS, Boyer-Chammard T, Kanyama C, Ndhlovu CE, Mosepele M et al. A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV- associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. AIDS. 2020;34(9):1425–8 (https://doi. org/10.1097/qad.0000000000002556). 77. Govender NP , Meintjes G, Mangena P , Nel J, Potgieter S, Reddy D et al. Sou",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1327",
    "text": "py adherence and duration. AIDS. 2020;34(9):1425–8 (https://doi. org/10.1097/qad.0000000000002556). 77. Govender NP , Meintjes G, Mangena P , Nel J, Potgieter S, Reddy D et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. S Afr J HIV Med. 2019;20(1):1–16 (https://doi.org/10.4102/sajhivmed.v20i1.1030). 78. WHO guidelines on meningitis diagnosis, treatment and care. Geneva: World Health Organization; 2025 (https://iris.who.int/ handle/10665/381006). Licence: CC BY-NC-SA 3.0 IGO. 79. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J et al. Prednisone for the prevention of paradoxical tuberculosis- associated immune reconstitution inflammatory syndrome. N Engl J Med. 2018;379(20):1915–25 (https://doi.org/10.1056/ NEJMoa1800762). 80. Boniatti MM, Pellegrini JAS, M",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1328",
    "text": "uberculosis- associated immune reconstitution inflammatory syndrome. N Engl J Med. 2018;379(20):1915–25 (https://doi.org/10.1056/ NEJMoa1800762). 80. Boniatti MM, Pellegrini JAS, Marques LS, John JF, Marin LG, Maito LR et al. Early antiretroviral therapy for HIV-infected patients admitted to an intensive care unit (EARTH-ICU): a randomized clinical trial. PLoS One. 2020;15(9):e0239452 (https://doi.org/10.1371/journal. pone.0239452). 81. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575 (https://doi. org/10.1371/journal.pone.0005575). 82. Guidelines for treatment of drug-susceptible tuberculosis and patient care. Geneva: World Health Organization; 2017 (https://iris.who.int/ handle/10665/25505",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1329",
    "text": "nal.pone.0005575). 82. Guidelines for treatment of drug-susceptible tuberculosis and patient care. Geneva: World Health Organization; 2017 (https://iris.who.int/ handle/10665/255052). Licence: CC BY-NC-SA 3.0 IGO. 83. Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. Geneva: World Health Organization; 2014 (https://iris.who.int/handle/10665/136863). 84. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–23 (https://doi.org/10.1016/S1473- 3099(08)70184-1). 85. Management of immune reconstitution inflammatory syndrome. AIDS Institute clinical guidelines. Baltimore: New York State Department of Health AIDS Institute; 2021 (https://www. hivguidelines.org/antiretroviralthera",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1330",
    "text": "n inflammatory syndrome. AIDS Institute clinical guidelines. Baltimore: New York State Department of Health AIDS Institute; 2021 (https://www. hivguidelines.org/antiretroviraltherapy/iris). 86. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381–90 (https://doi. org/10.1097/QAD.0b013e32833dfc68). 87. Donovan J, Bang ND, Imran D, Nghia HD, Burhan E, Huong DT et al. Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults. N Engl J Med. 2023;389(15):1357–67 (https://doi.org/10.1056/ nejmoa2216218). 88. Beardsley J, Wolbers M, Kibengo FM, Ggayi A-BM, Kamali A, Cuc NTK et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374(6):542–54 (https://doi. org/10.1",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1331",
    "text": "bers M, Kibengo FM, Ggayi A-BM, Kamali A, Cuc NTK et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374(6):542–54 (https://doi. org/10.1056/NEJMoa1509024). 89. Knappett M, Nguyen V, Chaudhry M, Trawin J, Kabakyenga J, Kumbakumba E et al. Pediatric post-discharge mortality in resource-poor countries: a systematic review and meta-analysis. EClinicalMedicine. 2024;67:102380 (https://doi.org/10.1016/j. eclinm.2023.102380). 90. Albus SL, Harrison RE, Moudachirou R, Nanan-N’Zeth K, Haba B, Casas EC et al. Poor outcomes among critically ill HIV-positive patients at hospital discharge and post-discharge in Guinea, Conakry: a retrospective cohort study. PLoS ONE. 2023;18(3):e0281425 (https:// doi.org/10.1371/journal.pone.0281425). 91. Wiens MO, Bone JN, Kumbakumba E, Businge S, Tagoola A, Sherine SO et al. Mortality after hospital discharge among childr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1332",
    "text": "281425 (https:// doi.org/10.1371/journal.pone.0281425). 91. Wiens MO, Bone JN, Kumbakumba E, Businge S, Tagoola A, Sherine SO et al. Mortality after hospital discharge among children younger than 5 years admitted with suspected sepsis in Uganda: a prospective, multisite, observational cohort study. Lancet Child Adolesc Health. 2023;7(8):555–66 (https://doi.org/10.1016/s2352- 4642(23)00052-4). 92. Ford N, Rangaraj A, Jarvis JN, Lawrence DS, Chou R, Kamenshchikova A et al. Interventions to support people with HIV following hospital discharge: a systematic review. Open Forum Infect Dis. 2025;12(4):ofaf175 (https://doi.org/10.1093/ofid/ofaf175). 93. Ramos MIG, Garcia MM, de las Aguas Robustillo CM, Pizarraya AG, Morillo-Verdugo R. Influence of CMO pharmaceutical care model- based intervention on readmission rate in high risk HIV patients: the INFARDAR study. Rev Esp Quimioter . 2021;34(5):45",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1333",
    "text": "rillo-Verdugo R. Influence of CMO pharmaceutical care model- based intervention on readmission rate in high risk HIV patients: the INFARDAR study. Rev Esp Quimioter . 2021;34(5):459 (https://doi. org/10.37201/req/025.2021). 94. Hoffmann CJ, Shearer K, Kekana B, Kerrigan D, Moloantoa T, Golub JE et al. Reducing HIV-associated post-hospital mortality through home- based care in South Africa: a randomized controlled trial. Clin Infect Dis. 2024;78(5):1256–63 (https://doi.org/10.1093/cid/ciad727). 95. Peck RN, Issarow B, Kisigo GA, Kabakama S, Okello E, Rutachunzibwa T et al. Linkage case management and posthospitalization outcomes in people with HIV: the Daraja randomized clinical trial. JAMA. 2024;331(12):1025–34 (https://doi.org/10.1001/jama.2024.2177). 96. Giordano TP , Cully J, Amico KR, Davila JA, Kallen MA, Hartman C et al. A randomized trial to test a peer mentor intervention to impr",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1334",
    "text": " (https://doi.org/10.1001/jama.2024.2177). 96. Giordano TP , Cully J, Amico KR, Davila JA, Kallen MA, Hartman C et al. A randomized trial to test a peer mentor intervention to improve outcomes in persons hospitalized with HIV infection. Clin Infect Dis. 2016;63(5):678–86 (https://doi.org/10.1093/cid/ciw322). 97. Eaton AD, Carusone SC, Craig SL, Telegdi E, McCullagh JW, McClure D et al. The ART of conversation: feasibility and acceptability of a pilot peer intervention to help transition complex HIV-positive people from hospital to community. BMJ Open. 2019;9(3):e026674 (https:// doi.org/10.1136/bmjopen-2018-026674). 98. Brizzi MB, Burgos RM, Chiampas TD, Michienzi SM, Smith R, Yanful PK et al. Impact of pharmacist-driven antiretroviral stewardship and transitions of care interventions on persons with human immunodeficiency virus. Open Forum Infect Dis. 2020;7(12):ofaa527 (https://doi.org",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1335",
    "text": "ist-driven antiretroviral stewardship and transitions of care interventions on persons with human immunodeficiency virus. Open Forum Infect Dis. 2020;7(12):ofaa527 (https://doi.org/10.1093/ofid/ofaa073). 99. Nijhawan AE, Zhang S, Chansard M, Gao A, Jain MK, Halm EA. A multicomponent intervention to reduce readmissions among people with HIV. J Acquir Immune Defic Syndr . 2022;90(2):161–9 (https://doi. org/10.1097/qai.0000000000002938). 100. Hill L, Thompson C, Balcombe S, Jain S, He F, Karris‐Young M et al. Effects of a hospital discharge clinic among people with HIV: lack of early follow‐up is associated with 30‐day hospital readmission and decreased retention in care. HIV Med. 2024;25(3):332–42 (https://doi. org/10.1111/hiv.13577). 101. Claassen C, Bwalya C, Mujansi M. Novel post-hospitalization care model to decrease mortality among people living with HIV in Zambia: pilot study. 31st C",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1336",
    "text": "rg/10.1111/hiv.13577). 101. Claassen C, Bwalya C, Mujansi M. Novel post-hospitalization care model to decrease mortality among people living with HIV in Zambia: pilot study. 31st Conference on Retroviruses and Opportunistic Infections, Denver , CO, USA, 3–6 March 2024. 102. Khawcharoenporn T, Damronglerd P , Chunloy K, Sha BE. Enhanced inpatient rounds, appointment reminders, and patient education improved HIV care engagement following hospital discharge. Int J STD AIDS. 2018;29(7):641–9 (https://doi. org/10.1177/0956462417749420). 103. Becker C, Zumbrunn S, Beck K, Vincent A, Loretz N, Müller J et al. Interventions to improve communication at hospital discharge and rates of readmission: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(8):e2119346 (https://doi.org/10.1001/ jamanetworkopen.2021.19346). 104. Bamforth RJ, Chhibba R, Ferguson TW, Sabourin J, Pieroni D, Askin N e",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1337",
    "text": " meta-analysis. JAMA Netw Open. 2021;4(8):e2119346 (https://doi.org/10.1001/ jamanetworkopen.2021.19346). 104. Bamforth RJ, Chhibba R, Ferguson TW, Sabourin J, Pieroni D, Askin N et al. Strategies to prevent hospital readmission and death in patients with chronic heart failure, chronic obstructive pulmonary disease, and chronic kidney disease: a systematic review and meta- analysis. PLoS One. 2021;16(4):e0249542 (https://doi.org/10.1371/ journal.pone.0249542). 105. Chartrand J, Shea B, Hutton B, Dingwall O, Kakkar A, Chartrand M et al. Patient-and family-centred care transition interventions for adults: a systematic review and meta-analysis of RCTs. Int J Qual Health Care. 2023;35(4):mzad102 (https://doi.org/10.1093/intqhc/mzad102). 106. Facchinetti G, D’Angelo D, Piredda M, Petitti T, Matarese M, Oliveti A et al. Continuity of care interventions for preventing hospital readmission of ol",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1338",
    "text": ".1093/intqhc/mzad102). 106. Facchinetti G, D’Angelo D, Piredda M, Petitti T, Matarese M, Oliveti A et al. Continuity of care interventions for preventing hospital readmission of older people with chronic diseases: a meta-analysis. Int J Nurs Stud. 2020;101:103396 (https://doi.org/10.1016/j. ijnurstu.2019.103396).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 79
  },
  {
    "chunk_id": "advancedhiv_1339",
    "text": "67 107. Li Y, Fu MR, Fang J, Zheng H, Luo B. The effectiveness of transitional care interventions for adult people with heart failure on patient- centered health outcomes: a systematic review and meta- analysis including dose-response relationship. Int J Nurs Stud. 2021;117:103902 (https://doi.org/10.1016/j.ijnurstu.2021.103902). 108. Lussier ME, Evans HJ, Wright EA, Gionfriddo MR. The impact of community pharmacist involvement on transitions of care: a systematic review and meta-analysis. J Am Pharmacists Assoc (2003). 2020;60(1):153–62 (https://doi.org/10.1016/j.japh.2019.07.002). 109. Tyler N, Hodkinson A, Planner C, Angelakis I, Keyworth C, Hall A et al. Transitional care interventions from hospital to community to reduce health care use and improve patient outcomes: a systematic review and network meta-analysis. JAMA Netw Open. 2023;6(11):e2344825 (https://doi.org/10.1001/jamanetwor",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1340",
    "text": "unity to reduce health care use and improve patient outcomes: a systematic review and network meta-analysis. JAMA Netw Open. 2023;6(11):e2344825 (https://doi.org/10.1001/jamanetworkopen.2023.44825). 110. Soh YY, Zhang H, Toh JJY, Li X, Wu XV. The effectiveness of tele-transitions of care interventions in high-risk older adults: a systematic review and meta-analysis. Int J Nurs Stud. 2023;139:104428 (https://doi.org/10.1016/j.ijnurstu.2022.104428). 111. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022 (https:// iris.who.int/handle/10665/363682). Licence: CC BY-NC-SA 3.0 IGO. 112. Antifungal agents in clinical and preclinical development. Overview and analysis. Geneva: World Health Organization; 2025 (https://iris. who.int/handle/10665/380498). Licence: CC BY-NC-SA 3.0 IGO. 113. Rajasingham R, Govender NP , ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1341",
    "text": "opment. Overview and analysis. Geneva: World Health Organization; 2025 (https://iris. who.int/handle/10665/380498). Licence: CC BY-NC-SA 3.0 IGO. 113. Rajasingham R, Govender NP , Jordan A, Loyse A, Shroufi A, Denning DW et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis. 2022;22(12):1748–55 ( https://doi.org/10.1016/ S1473-3099(22)00499-6 ). 114. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8(4):515–48 (https://doi.org/10.1128/CMR.8.4.515). 115. Speed BR, Kaldor J. Rarity of cryptococcal infection in children. Pediatr Infect Dis J. 1997;16(5):536–7 (https://doi. org/10.1097/00006454-199705000-00024). 116. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ. Cryptococcosis in human immunodeficiency virus–i",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1342",
    "text": "5):536–7 (https://doi. org/10.1097/00006454-199705000-00024). 116. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ. Cryptococcosis in human immunodeficiency virus–infected children. Pediatr Infect Dis J. 1996;15(9):796–800 (https://doi. org/10.1097/00006454-199609000-00012). 117. Meiring ST, Quan VC, Cohen C, Dawood H, Karstaedt AS, McCarthy KM et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005–2007. AIDS. 2012;26(18):2307–14 (https://doi.org/10.1097/ qad.0b013e3283570567). 118. Lee JSF, Cohen RM, Khan RA, Burry J, Casas EC, Chung HY et al. Paving the way for affordable and equitable liposomal amphotericin B access worldwide. Lancet Glob Health. 2024;12(9):e1552–e9 (https:// doi.org/10.1016/s2214-109x(24)00225-0). 119. Lightowler JV, Cooke GS, Mutevedzi P , Lessells RJ, Newell M-L, Dedicoat ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1343",
    "text": " worldwide. Lancet Glob Health. 2024;12(9):e1552–e9 (https:// doi.org/10.1016/s2214-109x(24)00225-0). 119. Lightowler JV, Cooke GS, Mutevedzi P , Lessells RJ, Newell M-L, Dedicoat M. Treatment of cryptococcal meningitis in Kwazulu-natal, South Africa. PLoS One. 2010;5(1):e8630 (https://doi.org/10.1371/ journal.pone.0008630). 120. Kambugu A, Meya DB, Rhein J, O’Brien M, Janoff EN, Ronald AR et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694–701 (https://doi.org/10.1086/587667). 121. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23(6):701–6 (https:// doi.org/10.1097/QAD.0b013e32832605fe).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1344",
    "text": "sure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23(6):701–6 (https:// doi.org/10.1097/QAD.0b013e32832605fe). 122. Graybill JR, Sobel J, Saag M, Van Der Horst C, Powderly W, Cloud G et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000;30(1):47–54 (https://doi.org/10.1086/313603). 123. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, March 2018: supplement to the 2016 consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018 (https://iris.who.int/ handle/10665/260399). Licence: CC BY-NC-SA 3.0 IGO. 124. Guidelines for diagnosing, preventing and managing cryptococcal dise",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1345",
    "text": "World Health Organization; 2018 (https://iris.who.int/ handle/10665/260399). Licence: CC BY-NC-SA 3.0 IGO. 124. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Geneva: World Health Organization; 2022 (https://iris.who.int/ handle/10665/357088). Licence: CC BY-NC-SA 3.0 IGO. 125. Awotiwon AA, Johnson S, Rutherford GW, Meintjes G, Eshun‐Wilson I. Primary antifungal prophylaxis for cryptococcal disease in HIV‐ positive people. Cochrane Database Syst Rev. 2018;2018(8):CD004773 (https://doi.org/10.1002/14651858.CD004773.pub3). 126. Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double- blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011;11(12):933–41 (https://doi.org/10",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1346",
    "text": "yptococcal disease with fluconazole in HIV-positive Ugandan adults: a double- blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011;11(12):933–41 (https://doi.org/10.1016/S1473-3099(11)70245-6). 127. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2(10):e438–44 (https://doi.org/10.1016/S2352-3018(15)00137-X). 128. Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014;59(11):1607–14 (https:// doi.org/10.1093/cid/ciu596). 129. Likasitwattanakul S, Poneprasert B, Sirisanthana V. Cryptococcosis in HIV-infected children. Southeast Asian J Trop Med Public Health. 2004;35(4):935–9. 130. Abadi J, Nachman S,",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1347",
    "text": "9. Likasitwattanakul S, Poneprasert B, Sirisanthana V. Cryptococcosis in HIV-infected children. Southeast Asian J Trop Med Public Health. 2004;35(4):935–9. 130. Abadi J, Nachman S, Kressel AB, Pirofski L-a. Cryptococcosis in children with AIDS. Clin Infect Dis. 1999;28(2):309–13 (https://doi. org/10.1086/515130). 131. Leenders AC, Reiss P , Portegies P , Clezy K, Hop WC, Hoy J et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS- associated cryptococcal meningitis. AIDS. 1997;11(12):1463–71 (https://doi.org/10.1097/00002030-199712000-00010). 132. Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical t",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1348",
    "text": "doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225–32 (https://doi.org/10.1086/653606). 133. Aguirre JPB, Hamid AMR. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev. 2015(11):CD010481 (https://doi. org/10.1002/14651858.CD010481.pub2). 134. Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7(7):CD005647 (https://doi. org/10.1002/14651858.CD005647.pub3). 135. HIV drug interactions. Liverpool: University of Liverpool; 2025 (https://www.hiv-druginteractions.org/prescribing-resources). 136. Bellmann R, Smuszkiewicz P . Pharmacokine",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1349",
    "text": "). 135. HIV drug interactions. Liverpool: University of Liverpool; 2025 (https://www.hiv-druginteractions.org/prescribing-resources). 136. Bellmann R, Smuszkiewicz P . Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737–79 (https://doi.org/10.1007/s15010-017-1042-z). 137. Mootsikapun P , Chetchotisakd P , Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J Med Assoc Thailand. 2003;86(4):293–8. 138. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337(1):15– 21 (https://doi.org/10.1056/NEJM199707033370103). 139. Bozzette SA, Larsen RA, Chiu J, Leal MAE, Jacob",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1350",
    "text": "ed with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337(1):15– 21 (https://doi.org/10.1056/NEJM199707033370103). 139. Bozzette SA, Larsen RA, Chiu J, Leal MAE, Jacobsen J, Rothman P et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med. 1991;324(9):580–4 (https://doi.org/10.1056/NEJM199102283240902). 140. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999;28(2):291–6 (https://doi.org/10.1086/515110). 141. Guidelines 12.0. London: European AIDS Clinical Society; 2023 (https://www.eacsociety.org/media/guidelines-12.0.pdf). 142. Powderly WG, Saag MS, Cloud GA, Robinson P , Meyer RD, Jacobson JM et al. A ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1351",
    "text": "ndon: European AIDS Clinical Society; 2023 (https://www.eacsociety.org/media/guidelines-12.0.pdf). 142. Powderly WG, Saag MS, Cloud GA, Robinson P , Meyer RD, Jacobson JM et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326(12):793–8 (https://doi.org/10.1056/NEJM199203193261203). 143. Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nature Rev Neurol. 2017;13(1):13–24 (https://doi. org/10.1038/nrneurol.2016.167). 144. Abassi M, Boulware DR, Rhein J. Cryptococcal meningitis: diagnosis and management update. Curr Trop Med Rep. 2015;2:90–9 (https:// doi.org/10.1007/s40475-015-0046-y). 145. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC et a",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1352",
    "text": "s and management update. Curr Trop Med Rep. 2015;2:90–9 (https:// doi.org/10.1007/s40475-015-0046-y). 145. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10(11):791–802 (https://doi. org/10.1016/S1473-3099(10)70170-5).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 80
  },
  {
    "chunk_id": "advancedhiv_1353",
    "text": "68 146. Shelburne III SA, Darcourt J, White Jr AC, Greenberg SB, Hamill RJ, Atmar RL et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(7):1049–52 (https://doi.org/10.1086/428618). 147. Guidelines for diagnosing and managing disseminated histoplasmosis among people living with HIV. Geneva: World Health Organization; 2020 (https://iris.paho.org/handle/10665.2/52304). Licence: CC BY-NC-SA 3.0 IGO. 148. Caceres DH, Valdes A. Histoplasmosis and tuberculosis co-occurrence in people with advanced HIV. J Fungi. 2019;5(3):73 (https://doi. org/10.3390/jof5030073). 149. Pasqualotto AC, Quieroz-Telles F. Histoplasmosis dethrones tuberculosis in Latin America. Lancet Infect Dis. 2018;18(10):1058–60 (https://doi.org/10.1016/s1473-3099(18)30373-6). 150. Pasqualotto A",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1354",
    "text": "Quieroz-Telles F. Histoplasmosis dethrones tuberculosis in Latin America. Lancet Infect Dis. 2018;18(10):1058–60 (https://doi.org/10.1016/s1473-3099(18)30373-6). 150. Pasqualotto AC, Sued O, Reis N, Silva LR, Soares R, Godoy CS et al. Impact of the introduction of a package of care involving early detection of opportunistic infections in people living with HIV/AIDS: a Pan American Health Organization (PAHO) initiative in Brazil. J Fungi. 2023;9(2):195 (https://doi.org/10.1016/j.lana.2025.101085). 151. Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother . 2016;71(12):3599–606 (https://doi.org/10.1093/jac/dkw325). 152. Caceres DH, Knuth M, Derado G, Lindsley MD. Diagnosis of progressive disseminated histoplasmosis in advanced HIV: a meta-analysis of assay analytical performance. J Fungi. 2019;5(3):76 (https://doi",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1355",
    "text": " M, Derado G, Lindsley MD. Diagnosis of progressive disseminated histoplasmosis in advanced HIV: a meta-analysis of assay analytical performance. J Fungi. 2019;5(3):76 (https://doi.org/10.3390/jof5030076). 153. Wheat LJ, Connolly-Stringfield PA, Baker RL, Curfman MF, Eads ME, Israel KS et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore). 1990;69(6):361–74 (https://doi.org/10.1097/00005792-199011000-00004). 154. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105–9 (https://doi.org/10.7326/0003-4819-137-2- 200207160-00008). 155. 155. Wheat LJ, Freifeld AG, Kleiman",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1356",
    "text": "rapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105–9 (https://doi.org/10.7326/0003-4819-137-2- 200207160-00008). 155. 155. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807–25 (https://doi. org/10.1086/521259). 156. Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A et al. Treatment of Histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med. 1997;103(3):223– 32 (https://doi.org/10.1016/s0002-9343(97)00151-4). 157. Wheat J, Hafner R, Korzun AH, Limj MT, Spencer P , Larsen RA et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med. 1995;98(4):336–42 (ht",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1357",
    "text": "Limj MT, Spencer P , Larsen RA et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med. 1995;98(4):336–42 (https://doi.org/10.1016/S0002-9343(99)80311-8). 158. Norris S, Wheat J, McKinsey D, Lancaster D, Katz B, Black J et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med. 1994;96(6):504-8 (https://doi.org/10.1016/0002-9343(94)90089-2). 159. Sharkey-Mathis PK, Velez J, Fetchick R, Graybill JR. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J Acquir Immune Defic Syndr . 1993;6(7):809–19. 160. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1358",
    "text": "eat J, Korzun AH, Hafner R, Skahan KJ, Larsen R et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr . 1997;16(2):100–7 (https://doi.org/10.1097/00042560-199710010-00005). 161. Myint T, Anderson AM, Sanchez A, Farabi A, Hage C, Baddley JW et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore). 2014;93(1):11–8 (https://doi.org/10.1097/ MD.0000000000000016). 162. Global tuberculosis report 2024. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/379339). Licence: CC BY-NC- SA 3.0 IGO. 163. WHO TB Knowledge Sharing Platform [website]. Geneva: World Health Organization; 2025 (https://tbksp.who.int/en). 164. WHO consolidated guidelines on tubercu",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1359",
    "text": "BY-NC- SA 3.0 IGO. 163. WHO TB Knowledge Sharing Platform [website]. Geneva: World Health Organization; 2025 (https://tbksp.who.int/en). 164. WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities. Geneva: World Health Organization; 2024 (https:// iris.who.int/handle/10665/376584). Licence: CC BY-NC-SA 3.0 IGO. 165. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987 (https://doi.org/10.1097/ QAD.0000000000000802). 166. Letang E, Rakislova N, Martinez MJ, Carlos Hurtado J, Carrilho C, Bene R et al. Minimally invasive tissue sampling: a tool to guide efforts to reduce AIDS-related mortality in resource-limited settings. Clin Infect Dis. 2021;73(Suppl. 5):S343–50 (https://doi.org/10.1093/cid/ci",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1360",
    "text": "e tissue sampling: a tool to guide efforts to reduce AIDS-related mortality in resource-limited settings. Clin Infect Dis. 2021;73(Suppl. 5):S343–50 (https://doi.org/10.1093/cid/ciab789). 167. BCG vaccines: WHO position paper – February 2018. Geneva: World Health Organization; 2018 (https://iris.who.int/ handle/10665/260306). Licence: CC BY-NC-SA 3.0 IGO. 168. The WHO AWaRe (access, watch, reserve) antibiotic book. Geneva: World Health Organization; 2022 (https://iris.who.int/ handle/10665/365237). Licence: CC BY-NC-SA 3.0 IGO. 169. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49 (https://doi.org/10.3322/caac.21660). 170. Chagomerana MB, Moser CB, Kang M, Umbleja T, Hughes MD, Campbell TB et al. Mortality an",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1361",
    "text": "85 countries. CA Cancer J Clin. 2021;71(3):209–49 (https://doi.org/10.3322/caac.21660). 170. Chagomerana MB, Moser CB, Kang M, Umbleja T, Hughes MD, Campbell TB et al. Mortality and associated risk factors among people living with HIV with Kaposi sarcoma: A5263/AMC066 and A5264/AMC067. J Acquir Immune Defic Syndr . 2022;91(3):265–73 (https://doi.org/10.1097/qai.0000000000003484). 171. Freeman EE, Semeere A, McMahon DE, Byakwaga H, Laker-Oketta M, Regan S et al. Beyond T staging in the “treat-all” era: severity and heterogeneity of Kaposi sarcoma in east Africa. J Acquir Immune Defic Syndr . 2021;87(5):1119–27 (https://doi.org/10.1097/ qai.0000000000002699). 172. Krown SE, Metroka C, Wernz J. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7(9):",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1362",
    "text": " the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7(9):1201–7 (https://doi.org/10.1200/ JCO.1989.7.9.1201). 173. Sengayi M, Kielkowski D, Egger M, Dreosti L, Bohlius J. Survival of patients with Kaposi’s sarcoma in the South African antiretroviral treatment era: a retrospective cohort study. S Afr Med J. 2017;107(10):871–6. 174. Campbell LR, Silverstein A, Peckham‐Gregory E, Kamiyango W, Villiera J, McAtee CL et al. Divergent clinical presentations and outcomes among children and adolescents with Kaposi sarcoma in Malawi and Tanzania. HIV Med. 2023;24(6):664–75 (https://doi.org/10.1111/ hiv.13455). 175. El-Mallawany NK, Kamiyango W, Villiera J, Slone JS, Kovarik CL, Campbell LR et al. Proposal of a risk-stratification platform to address distinct clinical features ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1363",
    "text": "iv.13455). 175. El-Mallawany NK, Kamiyango W, Villiera J, Slone JS, Kovarik CL, Campbell LR et al. Proposal of a risk-stratification platform to address distinct clinical features of pediatric Kaposi sarcoma in Lilongwe, Malawi. J Glob Oncol. 2017;4:1–7 (https://doi.org/10.1200/ jgo.17.00054). 176. Cox CM, El‐Mallawany NK, Kabue M, Kovarik C, Schutze GE, Kazembe PN et al. Clinical characteristics and outcomes of HIV‐infected children diagnosed with Kaposi sarcoma in Malawi and Botswana. Pediatr Blood Cancer . 2013;60(8):1274–80 (https://doi.org/10.1002/ pbc.24516). 177. Campbell L, El-Mallawany N, Slone J, Malingoti B, Mehta P , Scheurer M et al. Clinical characteristics and successful treatment outcomes of children and adolescents with Kaposi sarcoma in southwestern Tanzania. Pediatr Hematol Oncol. 2022;39(1):28–47 (https://doi.org/1 0.1080/08880018.2021.1936315). 178. Cianfrocca M, Lee",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1364",
    "text": "ldren and adolescents with Kaposi sarcoma in southwestern Tanzania. Pediatr Hematol Oncol. 2022;39(1):28–47 (https://doi.org/1 0.1080/08880018.2021.1936315). 178. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus–associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer . 2010;116(16):3969–77 (https://doi.org/10.1002/cncr .25362). 179. Krown SE, Moser CB, MacPhail P , Matining RM, Godfrey C, Caruso SR et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020;395(10231):1195–207 (https://doi. org/10.1016/S0140-6736(19)33222-2). 180. Busakhala N, Kigen G, Waako P , Strother RM, Chite F, Loehrer P . Three year survival among p",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1365",
    "text": "ancet. 2020;395(10231):1195–207 (https://doi. org/10.1016/S0140-6736(19)33222-2). 180. Busakhala N, Kigen G, Waako P , Strother RM, Chite F, Loehrer P . Three year survival among patients with AIDS-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya. Infect Agents Cancer . 2019;14:1–8 (https://doi.org/10.1186/s13027-019-0242-9). 181. Busakhala NW, Waako PJ, Strother MR, Keter AK, Kigen GK, Asirwa FC et al. Randomized Phase IIA trial of gemcitabine compared with bleomycin plus vincristine for treatment of Kaposi’s sarcoma in patients on combination antiretroviral therapy in western Kenya. J Glob Oncol. 2018;4:1–9 (https://doi.org/10.1200/jgo.17.00077). 182. Cooley T, Henry D, Tonda M, Sun S, O’Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-r",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1366",
    "text": ".1200/jgo.17.00077). 182. Cooley T, Henry D, Tonda M, Sun S, O’Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Oncologist. 2007;12(1):114–23 (https://doi.org/10.1634/theoncologist.12-1-114). 183. Kaposi’s sarcoma: AIDS’ neglected cancer . Geneva: Médecins Sans Frontières; 2023 (https://www.doctorswithoutborders.ca/wp-content/ uploads/2024/07/MSF-report_Kaposis-Sarcoma-AIDS-neglected- cancer-V02.pdf).",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 81
  },
  {
    "chunk_id": "advancedhiv_1367",
    "text": "69 184. Freeman EE, McCann NC, Semeere A, Reddy KP , Laker-Oketta M, Byakwaga H et al. Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost–effectiveness analysis. Lancet Glob Health. 2022;10(8):e1179–88 (https://doi.org/10.1016/s2214-109x(22)00242-x). 185. Adinani H, Campbell L, El-Mallawany NK, Slone J, Mehta P , Bacha J. Use of paclitaxel to successfully treat children, adolescents, and young adults with Kaposi sarcoma in southwestern Tanzania. Children (Basel). 2021;8(4):275 (https://doi.org/10.3390/ children8040275). 186. Rees CA, Keating EM, Lukolyo H, Danysh HE, Scheurer ME, Mehta PS et al. Mapping the epidemiology of Kaposi sarcoma and non‐ Hodgkin lymphoma among children in sub‐Saharan Africa: a review. Pediatr Blood Cancer . 2016;63(8):1325–31 (https://doi.org/10.1002/ pbc.26021). 187. Vaz P , Macassa E, Jani I, Thom",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1368",
    "text": "odgkin lymphoma among children in sub‐Saharan Africa: a review. Pediatr Blood Cancer . 2016;63(8):1325–31 (https://doi.org/10.1002/ pbc.26021). 187. Vaz P , Macassa E, Jani I, Thome B, Mahagaja E, Madede T et al. Treatment of Kaposi sarcoma in human immunodeficiency virus-1–infected Mozambican children with antiretroviral drugs and chemotherapy. Pediatr Infect Dis J. 2011;30(10):891–3 (https://doi. org/10.1097/inf.0b013e318228fb04). 188. The selection and use of essential medicines 2023: Web Annex B: World Health Organization Model List of Essential Medicines for Children – 9th List (2023). Geneva: World Health Organization; 2023 (https://iris.who. int/handle/10665/371091). Licence: CC BY-NC-SA 3.0 IGO. 189. Brunet-Possenti F, Pages C, Rouzier R, Dupin N, Bagot M, Lebbe C. Kaposi’s sarcoma and pregnancy: case report and literature review. Dermatology. 2013;226(4):311–4 (https://doi. org/",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1369",
    "text": "unet-Possenti F, Pages C, Rouzier R, Dupin N, Bagot M, Lebbe C. Kaposi’s sarcoma and pregnancy: case report and literature review. Dermatology. 2013;226(4):311–4 (https://doi. org/10.1159/000349987). 190. Bacha JM, El-Mallawany NK, Slone JS, Wilkinson JP , Mehta PS, Campbell LR. Recommendations for treating life-threatening Kaposi sarcoma during pregnancy in HIV-positive women in low income countries. Int J STD AIDS. 2020;31(8):724–34 (https://doi. org/10.1177/0956462420920160). 191. Bryant AE, Genc M, Hurtado RM, Chen KT. Pulmonary Kaposi’s sarcoma in pregnancy. Am J Perinatol. 2004;21(06):355–63 (https:// doi.org/10.1055/s-2004-831880). 192. Ngwenya S. Massive vulval Kaposi’s sarcoma in pregnancy: case report. Int Med Case Rep J. 2016:227–9 (doi: 10.2147/IMCRJ.S111171). 193. Barnardt P . Pregnancy in a patient with advanced human immunodeficiency virus (HIV) and Kaposi’s sarcoma. J Wom",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1370",
    "text": ". Int Med Case Rep J. 2016:227–9 (doi: 10.2147/IMCRJ.S111171). 193. Barnardt P . Pregnancy in a patient with advanced human immunodeficiency virus (HIV) and Kaposi’s sarcoma. J Womens Health Issues Care. 2013;2:2. 194. Berger P , Dirnhofer S. Kaposi’s sarcoma in pregnant women. Nature. 1995;377(6544):21–2 (doi: 10.1038/377021b0). 195. Amerson E, Woodruff CM, Forrestel A, Wenger M, McCalmont T, LeBoit P et al. Accuracy of clinical suspicion and pathologic diagnosis of Kaposi sarcoma in east Africa. J Acquir Immune Defic Syndr . 2016;71(3):295–301 (https://doi.org/10.1097/qai.0000000000000862). 196. van Bogaert LJ. Clinicopathological proficiency in the diagnosis of Kaposi’s sarcoma. ISRN AIDS. 2012;2012:565463 (https://doi. org/10.5402/2012/565463). 197. Slaught C, Williams V, Grover S, Bigger E, Kayembe M, Chiyapo S et al. A retrospective review of patients with Kaposi’s sarcoma in Botsw",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1371",
    "text": "https://doi. org/10.5402/2012/565463). 197. Slaught C, Williams V, Grover S, Bigger E, Kayembe M, Chiyapo S et al. A retrospective review of patients with Kaposi’s sarcoma in Botswana. Int J Dermatol. 2019;58(6):707-12 (https://doi.org/10.1111/ijd.14305). 198. Wills NK, Lawrence DS, Botsile E, Tenforde MW, Jarvis JN. The prevalence of laboratory-confirmed Pneumocystis jirovecii in HIV- infected adults in Africa: a systematic review and meta-analysis. Med Mycol. 2021;59(8):802–12 (https://doi.org/10.1093/mmy/myab002). 199. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. Geneva: World Health Organization; 2014 (https://iris.who. int/handle/10665/145719). 200. Wong SY, Wong K. Penicillium marneffei infection in AIDS. Pathol Res Int. 2011;",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1372",
    "text": " approach. Geneva: World Health Organization; 2014 (https://iris.who. int/handle/10665/145719). 200. Wong SY, Wong K. Penicillium marneffei infection in AIDS. Pathol Res Int. 2011;2011(1):764293. 201. Narayanasamy S, Dat VQ, Thanh NT, Ly VT, Chan JF-W, Yuen K-Y et al. A global call for talaromycosis to be recognised as a neglected tropical disease. Lancet Glob Health. 2021;9(11):e1618–22 (https:// doi.org/10.1016/s2214-109x(21)00350-8). 202. Jiang J, Meng S, Huang S, Ruan Y, Lu X, Li J et al. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. Clin Microbiol Infect. 2019;25(2):233–41 (https://doi.org/10.1016/j.cmi.2018.04.018). 203. Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Huong Lan NP et al. Epidemiology, seasonality, and predictors of outcome of AIDS- associated Penicillium marneffei infection in Ho Chi Minh ",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1373",
    "text": " Wolbers M, Chi NH, Quang VM, Chinh NT, Huong Lan NP et al. Epidemiology, seasonality, and predictors of outcome of AIDS- associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011;52(7):945–52 ( https://doi.org/10.1093/ cid/cir028). 204. Ning C, Lai J, Wei W, Zhou B, Huang J, Jiang J et al. Accuracy of rapid diagnosis of Talaromyces marneffei: a systematic review and meta- analysis. PLoS One. 2018;13(4):e0195569 (https://doi.org/10.1371/ journal.pone.0195569). 205. Pruksaphon K, Intaramat A, Simsiriwong P , Mongkolsuk S, Ratanabanangkoon K, Nosanchuk JD et al. An inexpensive point-of-care immunochromatographic test for Talaromyces marneffei infection based on the yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin. PLoS Negl Trop Dis. 2021;15(5):e0009058 (https://doi.org/10.1371/journal.pntd.0009058). 206. Chen X, Ou X, Wang",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1374",
    "text": "e specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin. PLoS Negl Trop Dis. 2021;15(5):e0009058 (https://doi.org/10.1371/journal.pntd.0009058). 206. Chen X, Ou X, Wang H, Li L, Guo P , Chen X et al. Talaromyces marneffei Mp1p antigen detection may play an important role in the early diagnosis of talaromycosis in patients with acquired immunodeficiency syndrome. Mycopathologia. 2022;187(2–3):205–15 (https://doi.org/10.1007/s11046-022-00618-9). 207. Thu NTM, Chan JFW, Ly VT, Ngo HT, Hien HTA, Lan NPH et al. Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of talaromycosis. Clin Infect Dis. 2021;73(2):e330–6 (https://doi. org/10.1093/cid/ciaa826). 208. Clinical management and infection prevention and control for mpox: living guideline. Geneva: World Health Organization; 2025 (https:// iris.who.int/handle",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1375",
    "text": "0.1093/cid/ciaa826). 208. Clinical management and infection prevention and control for mpox: living guideline. Geneva: World Health Organization; 2025 (https:// iris.who.int/handle/10665/381567). Licence: CC BY-NC-SA 3.0 IGO. 209. Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401(10380):939–49 (https://doi. org/10.1016/S0140-6736(23)00273-8). 210. Chiang C-H, Tang P-U, Lee GH, Chiang T-H, Chiang C-H, Ma KS-K et al. Prevalence of nontuberculous Mycobacterium infections versus tuberculosis among autopsied HIV patients in sub-Saharan Africa: a systematic review and meta-analysis. Am J Trop Med Hyg. 2021;104(2):628 (https://doi.org/10.4269/ajtmh.20-0973). 211. Dawood H, Richards L, Lutchminarain K, Parker A, Wattrus C, Sipambo N et al. Southern African HIV Clinicians Soci",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1376",
    "text": "Hyg. 2021;104(2):628 (https://doi.org/10.4269/ajtmh.20-0973). 211. Dawood H, Richards L, Lutchminarain K, Parker A, Wattrus C, Sipambo N et al. Southern African HIV Clinicians Society guideline on the management of non-tuberculous mycobacteria in people with HIV. S Afr J HIV Med. 2024;25(1):1657 (https://doi.org/10.4102/ sajhivmed.v25i1.1657). 212. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM- PD). Thorax. 2017;72(Suppl. 2):ii1–ii64 (https://doi.org/10.1136/ thoraxjnl-2017-210927). 213. Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res. 2020;152(3):185–226 (https://doi.org/10.4103/ijmr .IJMR_902_20). 214. Quality health services and palliative care: practical approaches and resourc",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1377",
    "text": "rial diseases. Indian J Med Res. 2020;152(3):185–226 (https://doi.org/10.4103/ijmr .IJMR_902_20). 214. Quality health services and palliative care: practical approaches and resources to support policy, strategy and practice. Geneva: World Health Organization; 2021 (https://iris.who.int/ handle/10665/345674). Licence: CC BY-NC-SA 3.0 IGO. 215. Alene KA, Wangdi K, Colquhoun S, Chani K, Islam T, Rahevar K et al. Tuberculosis related disability: a systematic review and meta- analysis. BMC Med. 2021;19:1–19 (https://doi.org/10.1186/s12916- 021-02063-9). 216. Krakauer EL, Kwete X, Kane K, Afshan G, Bazzett-Matabele L, Bien- Aimé DDR et al. Cervical cancer-associated suffering: estimating the palliative care needs of a highly vulnerable population. JCO Glob Oncol. 2021;7:862–72 (https://doi.org/10.1200/go.21.00025). 217. Krakauer EL, Kane K, Kwete X, Afshan G, Bazzett-Matabele L, Ruthnie Bien-A",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1378",
    "text": "a highly vulnerable population. JCO Glob Oncol. 2021;7:862–72 (https://doi.org/10.1200/go.21.00025). 217. Krakauer EL, Kane K, Kwete X, Afshan G, Bazzett-Matabele L, Ruthnie Bien-Aimé DD et al. Essential package of palliative care for women with cervical cancer: responding to the suffering of a highly vulnerable population. JCO Glob Oncol. 2021;7:873–85 (https://doi. org/10.1200/go.21.00026). 218. Pasquier E, Kunda J, De Beaudrap P , Loyse A, Temfack E, Molloy SF et al. Long-term mortality and disability in cryptococcal meningitis: a systematic literature review. Clin Infect Dis. 2018;66(7):1122–32 (https://doi.org/10.1093/cid/cix870). 219. Rangaraj A, Connor S, Harding R, Pinto C, Chitembo L, Ford N. Advanced HIV disease and health-related suffering – exploring the unmet need of palliative care. Lancet HIV. 2023;10(2):e126–33 (https://doi.org/10.1016/s2352-3018(22)00295-8). 220. Consoli",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1379",
    "text": "HIV disease and health-related suffering – exploring the unmet need of palliative care. Lancet HIV. 2023;10(2):e126–33 (https://doi.org/10.1016/s2352-3018(22)00295-8). 220. Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 (https://iris.who.int/ handle/10665/360948). Licence: CC BY-NC-SA 3.0 IGO.",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 82
  },
  {
    "chunk_id": "advancedhiv_1380",
    "text": "World Health Organization 20 Avenue Appia 1211 Geneva 27 Switzerland who.int",
    "source": "WHO Advancedhiv Guideline",
    "topic": "advancedhiv",
    "page": 83
  },
  {
    "chunk_id": "hivservice_1381",
    "text": "WHO guideline on HIV service delivery Updated guidance on the integration of diabetes, hypertension and mental health services, and interventions to support adherence to antiretroviral therapy",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 1
  },
  {
    "chunk_id": "hivservice_1382",
    "text": "WHO guideline on HIV service delivery Updated guidance on the integration of diabetes, hypertension and mental health services, and interventions to support adherence to antiretroviral therapy",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 3
  },
  {
    "chunk_id": "hivservice_1383",
    "text": "WHO guideline on HIV service delivery: updated guidance on the integration of diabetes, hypertension and mental health services, and interventions to support adherence to antiretroviral therapy ISBN 978-92-4-011387-9 (electronic version) ISBN 978-92-4-011388-6 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo ). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your w",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 4
  },
  {
    "chunk_id": "hivservice_1384",
    "text": "ld be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ( http://www.wipo.int/amc/en/mediation/ rules/). Suggested citation . WHO guideline on HIV service delivery: updated guidance on the integration of diabetes,",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 4
  },
  {
    "chunk_id": "hivservice_1385",
    "text": " Property Organization ( http://www.wipo.int/amc/en/mediation/ rules/). Suggested citation . WHO guideline on HIV service delivery: updated guidance on the integration of diabetes, hypertension and mental health services, and interventions to support adherence to antiretroviral therapy. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data . CIP data are available at https://iris.who.int/. Sales, rights and licensing . To purchase WHO publications, see https://www.who.int/publications/book- orders. To submit requests for commercial use and queries on rights and licensing, see https://www.who. int/copyright. Third-party materials . If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 4
  },
  {
    "chunk_id": "hivservice_1386",
    "text": "ial from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers . The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endor",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 4
  },
  {
    "chunk_id": "hivservice_1387",
    "text": "t approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 4
  },
  {
    "chunk_id": "hivservice_1388",
    "text": "iii Acknowledgements iv Abbreviations vi Definition of key terms vii Executive summary ix 01 Introduction 1 Purpose 2 Scope and target audience 3 Guiding principles 3 Methods for developing these guidelines 4 02 Integration of HIV, diabetes and hypertension care 5 03 Integration of HIV and mental health care 10 04 Implementation considerations and research gaps 14 05 Primary health care and HIV: integration and convergent actions 19 06 Adherence support 21 07 Updating and dissemination 28 08 Guideline development process 30 References 34 Contents Web Annex A: Summary of declarations of interest https://doi.org/10.2471/B09545 Web Annex B: Systematic review abstracts and GRADE evidence profiles https://doi.org/10.2471/B09546 Web Annex C: Client preferences survey https://doi.org/10.2471/B09547 Web Annex D: Evidence-to-decision summary of judgement https://doi.org/10.2471/B09548",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 5
  },
  {
    "chunk_id": "hivservice_1389",
    "text": "iv WHO guideline on HIV service delivery Acknowledgements The World Health Organization (WHO) gratefully acknowledges the contributions of many individuals and organizations to the development of these guidelines. Guideline Development Group Co-chairs: Ana Olga Mocumbi (Universidade Eduardo Mondlane and Instituto Nacional de Saúde, Mozambique) and Nittaya Phanuphak (Institute of HIV Research and Innovation, Thailand). Adele Schwartz Benzaken (AIDS Health Foundation, Brazil), Baker Bakashaba (AIDS Information Centre-Uganda, Uganda), Tom Ellman (Médecins Sans Frontières, South Africa), Ibtissam Khoudri (Ministry of Health, Morocco), Juan Luis Mosqueda (Mexico National AIDS Program, Mexico), Mina Nakawuka (Ministry of Health, Uganda), Jeremy Ross (TREAT Asia/amfAR, Thailand), Daniel Simões (Independent Expert, Portugal), Maureen Syowai (International Center for AIDS Care and Treatment Progr",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 6
  },
  {
    "chunk_id": "hivservice_1390",
    "text": "y of Health, Uganda), Jeremy Ross (TREAT Asia/amfAR, Thailand), Daniel Simões (Independent Expert, Portugal), Maureen Syowai (International Center for AIDS Care and Treatment Programs, United States of America), Ketevan Stvilia (National Centre for Disease Control and Public Health, Georgia), Francois Venter (Ezintsha, University of the Witwatersrand, South Africa), Mihoko Yotsumoto (Tokyo Medical University Hospital, Japan), and Zheng Zhu (Fudan University, China). Methodologist: Roger Chou (Oregon Health & Science University, USA). External peer review group Yacoba Atiase (National Diabetes Management and Research Centre, Ghana) Nadia Badran (Society for Inclusion and Development in Communities (SIDC), Lebanon), Pamela Y. Collins (Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, USA), Charlotte Hanlon (Centre for Clinical Brain Sciences, University of Edinb",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 6
  },
  {
    "chunk_id": "hivservice_1391",
    "text": "n), Pamela Y. Collins (Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, USA), Charlotte Hanlon (Centre for Clinical Brain Sciences, University of Edinburgh, United Kingdom of Great Britain and Northern Ireland), Myo Nyein Aung (Department of Global Health Research, Juntendo University, Japan), Samanta Tresha Lalla-Edward (Ezintsha, Wits Health Consortium, South Africa) Thi Nhan (Viet Nam Administration for Disease Prevention, Viet Nam), Catherine Orrell (Medical Research Council, South Africa), Sobia Qazi (Institute of Public Health, Pakistan), Palmira Santos (Instituto Nacional de Saúde, Mozambique), Shekhar Saxena (Department of Global Health and Population, Havard T. H. Chan School of Public Health, USA), Annette Sohn (TREAT Asia/amfAR, Thailand), Carlos Manuel Benites Villafane (Dirección de Prevención y Control de VIH, Ministerio de Salud, Peru). Externa",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 6
  },
  {
    "chunk_id": "hivservice_1392",
    "text": "ol of Public Health, USA), Annette Sohn (TREAT Asia/amfAR, Thailand), Carlos Manuel Benites Villafane (Dirección de Prevención y Control de VIH, Ministerio de Salud, Peru). External contributors Helen Bygrave (International AIDS Society and Homerton Healthcare NHS Foundation Trust, United Kingdom), Elvin Geng (Washington University in St Louis, USA), Anna Grimsrud (International AIDS Society, Switzerland), Matthew Hickey (University of California, San Francisco (UCSF), USA), Steve Kanters (RainCity Analytics, Canada), Marie-Claire Lavoie (University of Maryland, USA) Noelle Le Tourneau (Washington University in St Louis, USA), Rayner Tan (The National University of Singapore, Singapore), Mervin Tee (The National University of Singapore, Singapore), Dhaneshan Thirugnanasambhandan (The National University of Singapore, Singapore), Joe Tucker (University of North Carolina School of Medicine",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 6
  },
  {
    "chunk_id": "hivservice_1393",
    "text": "l University of Singapore, Singapore), Dhaneshan Thirugnanasambhandan (The National University of Singapore, Singapore), Joe Tucker (University of North Carolina School of Medicine, USA), Ashley Underwood (Washington University in St Louis, USA), and Alexandra Volgina (Global Network of People Living with HIV, the Netherlands) Observers and partners Peter Ehrenkranz (Bill and Melinda Gates Foundation, USA), Carmen Perez Casas (Unitaid, Switzerland), and Vindi Singh (The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 6
  },
  {
    "chunk_id": "hivservice_1394",
    "text": "vAcknowledgements WHO Secretariat Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes Nathan Ford, Clarice Pinto, Elena Vovc and Cadi Irvine coordinated this guidelines process under the leadership of the Department director Meg Doherty. Other technical staff also contributed to these guidelines: Wole Ameyan, Antons Mozalevskis , and Marco Vitoria. WHO headquarters The following staff members from other WHO departments were involved in the guidelines process: Tarun Dua and Neerja Chowdhary (Department of Mental Health and Substance Use), Mai Eltigany and Bianca Hemmingsen (Noncommunicable Diseases Department), and Andreas Reis (Health Ethics & Governance, Research for Health Department). WHO country and regional offices Stela Bivol (Regional Office for Europe), Po-lin Chan (South-East Asia Regional Office), Irvin Romyco (WHO Indonesia), Reshu Agarwal (WHO I",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 7
  },
  {
    "chunk_id": "hivservice_1395",
    "text": "tment). WHO country and regional offices Stela Bivol (Regional Office for Europe), Po-lin Chan (South-East Asia Regional Office), Irvin Romyco (WHO Indonesia), Reshu Agarwal (WHO India), Akudo Ezinne Ikpeazu (Regional Office for Africa), Kiyohiko Izumi (Western Pacific Regional Office), Muhammad Shahid Jamil (Regional Office for the Eastern Mediterranean), and Omar Sued (Pan American Health Organization). Funding source Funding for the development of these guidelines was provided by the Gates Foundation.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 7
  },
  {
    "chunk_id": "hivservice_1396",
    "text": "vi WHO guideline on HIV service delivery Abbreviations AIDS acquired immunodeficiency syndrome ART antiretroviral therapy CI confidence interval DSD differentiated service delivery GAD general anxiety disorder GDG Guideline Development Group GRADE Grading of Recommendations Assessment Development and Evaluation HIV human immunodeficiency virus LMICs low- and middle-income countries mhGAP mental health Gap Action Programme NCDs noncommunicable diseases OR odds ratio PEN WHO package of essential noncommunicable disease interventions PEPFAR United States President’s Emergency Plan for AIDS Relief PICO population intervention comparator outcome PHC primary health care PRISMA Preferred Reporting Items for Systematic reviews and Meta-Analyses SMS short message service UN United Nations UNAIDS Joint United Nations Programme on HIV/AIDS WHO World Health Organization",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 8
  },
  {
    "chunk_id": "hivservice_1397",
    "text": "viiAbbreviations Definition of key terms A public health approach A public health approach addresses the health needs of a population or the collective health status of people rather than focusing primarily on managing individual cases. This approach aims to ensure the widest possible access to high-quality services and medicines at the population level, based on simplified and standardized approaches, and to strike a balance between implementing the best-proven standard of care and what is feasible on a large scale in resource-limited settings. In the context of HIV treatment, this includes simplified treatment regimens that work across populations, free care at the point of service, decentralized and integrated services with task- sharing, and simplified approaches to clinical monitoring. Adherence Adherence is the extent to which a person’s behaviour – such as taking medication, follo",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 9
  },
  {
    "chunk_id": "hivservice_1398",
    "text": "ed services with task- sharing, and simplified approaches to clinical monitoring. Adherence Adherence is the extent to which a person’s behaviour – such as taking medication, following a diet and/or changing lifestyle – aligns with the recommendations agreed upon with a health care provider. Age groups The following definitions for adults, adolescents, children and infants are used in these guidelines for the purpose of implementing recommendations for specific age groups. It is acknowledged that countries may have other definitions under national laws. • An adult is a person older than 19 years of age. • An adolescent is a person 10–19 years of age inclusive. • A child is a person one year to less than 10 years of age. • An infant is a child less than one year of age. ART (antiretroviral therapy) ART refers to a combination of ARV drugs used to treat HIV infection. ARV (antiretroviral) ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 9
  },
  {
    "chunk_id": "hivservice_1399",
    "text": "s of age. • An infant is a child less than one year of age. ART (antiretroviral therapy) ART refers to a combination of ARV drugs used to treat HIV infection. ARV (antiretroviral) ARV drugs refer to the medicines used to treat or prevent HIV. Community health worker A community health worker is a member of the community who is trained to carry out functions related to delivering health care, health promotion and linking the community with the health system, but who does not necessarily have a formal professional or paraprofessional certificate. Differentiated service delivery Differentiated service delivery is an approach that simplifies and adapts HIV services to better serve the needs of people living with HIV and to optimize the available resources in health systems. Enhanced adherence support Enhanced adherence support is a structured approach that provides additional, tailored suppo",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 9
  },
  {
    "chunk_id": "hivservice_1400",
    "text": "V and to optimize the available resources in health systems. Enhanced adherence support Enhanced adherence support is a structured approach that provides additional, tailored support to individuals who are not adhering well to treatment, and which aims to identify and address barriers to adherence through counselling, education and follow-up. HIV HIV refers to the human immunodeficiency virus. There are two types of HIV: HIV-1 and HIV-2. The vast majority of HIV infections globally are HIV-1.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 9
  },
  {
    "chunk_id": "hivservice_1401",
    "text": "viii WHO guideline on HIV service delivery Integrated service delivery Integrated health services are health services that are managed and delivered in a way that ensures people receive a continuum of health promotion, disease prevention, diagnosis, treatment, disease management, rehabilitation and palliative care services at the different levels and sites of care within the health system and according to their needs throughout the life-course. For the purposes of this guideline, the level of integration can vary from close collaboration between HIV and other services to fully integrated chronic disease management Key populations Key populations are groups that have a high risk and disproportionate burden of HIV in all epidemic settings. They frequently face legal and social challenges that increase their vulnerability to HIV, including barriers to accessing HIV prevention, diagnosis, tr",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 10
  },
  {
    "chunk_id": "hivservice_1402",
    "text": "V in all epidemic settings. They frequently face legal and social challenges that increase their vulnerability to HIV, including barriers to accessing HIV prevention, diagnosis, treatment and other health and social services. Key populations include men who have sex with men, people who inject drugs, people in prisons and other closed settings, sex workers and trans and gender diverse people. Lay provider A lay provider is any person who performs functions related to health care delivery and has been trained to deliver specific services but does not possess a formal professional or paraprofessional certificate or tertiary degree. Nonphysician clinician A nonphysician clinician (or health care worker) is a professional health care worker who is able to offer many of the diagnostic and clinical functions of a physician but is not trained as a physician. These types of health care workers a",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 10
  },
  {
    "chunk_id": "hivservice_1403",
    "text": "ssional health care worker who is able to offer many of the diagnostic and clinical functions of a physician but is not trained as a physician. These types of health care workers are often known or as health officers, clinical officers, physician assistants, nurse practitioners or nurse clinicians and are an important cadre for HIV care and treatment in some countries. Nurse A nurse is someone who has been authorized to practise as a nurse or trained in basic nursing skills such as registered nurses, clinical nurse specialists, licensed nurses, auxiliary nurses, dental nurses and primary care nurses. Person-centred care Person-centred care is an approach to care that consciously adopts the perspectives of individuals, caregivers, families and communities as participants in, and beneficiaries of, trusted health systems organized around the comprehensive needs of people rather than individ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 10
  },
  {
    "chunk_id": "hivservice_1404",
    "text": "iduals, caregivers, families and communities as participants in, and beneficiaries of, trusted health systems organized around the comprehensive needs of people rather than individual diseases, and respects social preferences. Point-of-care testing Point-of-care testing is conducted at the site at which clinical care is being provided, with results being returned to the person being tested or caregiver on the same day as sample collection and testing in order to enable clinical decisions to be made in a timely manner. Rapid ART initiation Initiation of ART within seven days of HIV diagnosis. Retention Retention in care refers to the percentage of adults and children living with HIV and receiving ART during a specified follow-up period (12, 24, 36 months, etc.). Task-sharing Task-sharing is the rational redistribution of tasks between cadres of health care workers with longer training and",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 10
  },
  {
    "chunk_id": "hivservice_1405",
    "text": "ecified follow-up period (12, 24, 36 months, etc.). Task-sharing Task-sharing is the rational redistribution of tasks between cadres of health care workers with longer training and other cadres with shorter training such as lay providers, while providing ongoing supervision and support. Viral suppression There are three key categories for HIV viral load measurements: unsuppressed (>1000 copies/mL), suppressed (detected but ≤1000 copies/mL) and undetectable (viral load not detected by test used)",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 10
  },
  {
    "chunk_id": "hivservice_1406",
    "text": "ixDefinition of key terms Executive summary Widespread access to effective antiretroviral therapy has made HIV a chronic condition for millions of people around the world. Optimization of health benefits, however, may require additional services that support the health of the whole person. As people living with HIV live longer, there is a need to pay attention to detecting and managing noncommunicable diseases, in particular diabetes and hypertension. Support for mental health and alcohol and substance use disorders is essential to improve engagement in care, quality of life and other important HIV outcomes. Additional support and counselling for adherence to antiretroviral medications may be an even more important part of chronic care. These guidelines provide new and updated recommendations to support these long-term health needs, the aim of which is to encourage continued improvements",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 11
  },
  {
    "chunk_id": "hivservice_1407",
    "text": "tant part of chronic care. These guidelines provide new and updated recommendations to support these long-term health needs, the aim of which is to encourage continued improvements in sustained access to antiretroviral therapy and support services for people living with HIV over the life course. Service integration reduces fragmented health care delivery and promotes access to a continuum of care that is aligned with people’s lifelong needs, thereby contributing to improved access to needed and varied services and better engagement with care. WHO would like to thank the many individuals who contributed to the development of these guidelines, including individuals working for Ministries of Health, agencies and implementers, health care providers, researchers and representatives from affected communities.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 11
  },
  {
    "chunk_id": "hivservice_1408",
    "text": "x WHO guideline on HIV service delivery Summary of new and updated recommendations Recommendation Updated* recommendation (from 2016) Diabetes and hypertension care should be integrated with HIV services (Strong recommendation, moderate certainty evidence for blood pressure control / very low certainty evidence for diabetes control) New recommendation Mental health care for depression, anxiety and alcohol use disorders should be integrated with HIV services. (Strong recommendation, moderate certainty evidence for depression/ low certainty evidence for anxiety and alcohol use disorder) Updated recommendation (from 2016) Adherence support interventions should be provided to people on antiretroviral therapy (ART) (Strong recommendation, moderate certainty evidence) The following interventions have demonstrated effectiveness in improving adherence and virological suppression: • Counselling (",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 12
  },
  {
    "chunk_id": "hivservice_1409",
    "text": "(Strong recommendation, moderate certainty evidence) The following interventions have demonstrated effectiveness in improving adherence and virological suppression: • Counselling (moderate certainty evidence) • Reminders (moderate certainty evidence) • Tailored support from peers, other lay persons or health workers (moderate certainty evidence) • Education (low certainty evidence) * Previously a conditional recommendation based on very low certainty evidence",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 12
  },
  {
    "chunk_id": "hivservice_1410",
    "text": "01 Introduction",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 13
  },
  {
    "chunk_id": "hivservice_1411",
    "text": "2 WHO guideline on HIV service delivery 1. Introduction Almost 40.8 million people are estimated to be living with HIV, of whom over 31.6 million were on antiretroviral therapy (ART) as of the end of 2024 (1). Optimal use of ART is central to preventing illness and onward HIV transmission. People living with HIV who start treatment early in their infection and are adherent to treatment can expect a near normal life expectancy (2,3). However, sustained adherence to treatment is a challenge for a broad range of individual, interpersonal, community, and structural reasons (4). Mortality owing to noncommunicable diseases (NCDs) claimed at least 43 million lives in 2021, equivalent to 75% of non-pandemic-related deaths globally. Cardiovascular diseases and diabetes are two of the top four NCDs which account for 80% of all premature NCD deaths (5). In addition, there is an increasing burden of",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 14
  },
  {
    "chunk_id": "hivservice_1412",
    "text": "ths globally. Cardiovascular diseases and diabetes are two of the top four NCDs which account for 80% of all premature NCD deaths (5). In addition, there is an increasing burden of mental health conditions. In 2019, 970 million people globally were living with a mental health disorder, with anxiety and depression the most common (6). Simplified service delivery approaches have been promoted as an important way to increase access to care and support long-term delivery of care. Simplified approaches include task-sharing, decentralization, differentiated service delivery and integration of HIV services with other important services for people living with HIV. These guidelines provide new and updated guidance on interventions to support adherence to treatment and integrated service delivery, and explore the following three questions. • Should diabetes and hypertension care be integrated with",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 14
  },
  {
    "chunk_id": "hivservice_1413",
    "text": "terventions to support adherence to treatment and integrated service delivery, and explore the following three questions. • Should diabetes and hypertension care be integrated with HIV services (compared to non-integrated care) for people living with HIV? • Should mental health care be integrated with HIV services (compared to non-integrated care) for people living with HIV? • What adherence support interventions (compared to standard care) should be provided for people living with HIV receiving ART? Note: separate WHO guidelines are available for the screening and treatment of cervical cancer, including among women living with HIV (7). Purpose The purpose of these updated guidelines is to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy, and improve the overall health and quality of life of people living with HIV. In line with WHO’s commitme",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 14
  },
  {
    "chunk_id": "hivservice_1414",
    "text": "V service delivery, promote long-term adherence to antiretroviral therapy, and improve the overall health and quality of life of people living with HIV. In line with WHO’s commitment to person-centred care, these guidelines reflect updated evidence and the broader needs of individuals affected by HIV. Advances in antiretroviral therapy have enabled many individuals living with HIV to reach older age. However, the ageing process in this population is often described as accelerated and accentuated, with some experiencing age-related conditions earlier than expected.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 14
  },
  {
    "chunk_id": "hivservice_1415",
    "text": "31. Introduction There is a high prevalence of diabetes, hypertension and mental health conditions such as anxiety and depression among people living with HIV (8). These conditions share common, modifiable risk factors, including physical inactivity, substance use, unhealthy diets, sleep disturbances and chronic stress. The guidelines provide recommendations supporting integration of services for diabetes, hypertension and mental health conditions (depression and anxiety) with HIV services. Integrated service provision is critical to supporting expanded access to a broad range of essential services. In recent years a growing body of evidence has emerged in support of integrated delivery of HIV, NCDs and mental health services. This expanded evidence base supports a broader and more robust approach to integration with the end- goal being the improvement of treatment outcomes, mental healt",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 15
  },
  {
    "chunk_id": "hivservice_1416",
    "text": "health services. This expanded evidence base supports a broader and more robust approach to integration with the end- goal being the improvement of treatment outcomes, mental health and the overall well-being of people living with HIV. Integrated services are built on the foundation of successful HIV treatment. Optimal adherence to ART remains a persistent challenge (9). Since the previous WHO recommendation was developed in 2016 (10) over 100 trials have evaluated interventions to support adherence. Furthermore, changes in recommended treatment regimens with fewer adverse events and simplified dosing justify a reassessment of adherence-support approaches. These guidelines synthesize emerging evidence to inform scalable interventions that support treatment continuity, reduce mortality and transmission, and enhance engagement with care. Scope and target audience Scope In 2016, WHO issued ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 15
  },
  {
    "chunk_id": "hivservice_1417",
    "text": " scalable interventions that support treatment continuity, reduce mortality and transmission, and enhance engagement with care. Scope and target audience Scope In 2016, WHO issued a strong recommendation on interventions to support adherence and a conditional recommendation on the assessment and management of depression (11). In 2021, WHO issued a recommendation on the integration of HIV, diabetes and hypertension screening and/or care; this was a conditional recommendation based on low certainty evidence (12). Since the issuing of these recommendations there has been an improved understanding of the challenges faced by people living with HIV over the life course, and new evidence has emerged to inform intervention approaches. Key areas for updating the HIV service delivery guidelines were identified through a recent survey of programme managers in high HIV-burden countries. They include",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 15
  },
  {
    "chunk_id": "hivservice_1418",
    "text": "tion approaches. Key areas for updating the HIV service delivery guidelines were identified through a recent survey of programme managers in high HIV-burden countries. They include interventions to support adherence to antiretrovirals; integration of HIV, diabetes and hypertension care; and integration of HIV and mental health care. The information presented in this document is supported by the latest available evidence and aligned with the goal of achieving universal health coverage and improved health outcomes for all. Target audience These guidelines are intended for policy-makers and programme managers involved in the implementation and adaptation of WHO guidelines into national HIV or communicable disease programmes, or integration into primary health care services including NCDs and mental health care. These guidelines will also be of interest to doctors, nurses and other health ca",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 15
  },
  {
    "chunk_id": "hivservice_1419",
    "text": "programmes, or integration into primary health care services including NCDs and mental health care. These guidelines will also be of interest to doctors, nurses and other health care workers, particularly those working in primary care services that are often the first point of contact for people seeking care. These guidelines will also be of interest to community- and faith-based organizations, advocates, civil society organizations, and international and bilateral agencies and organizations that provide technical and financial resources to programmes that support people living with HIV. Guiding principles The following principles were established to guide the implementation of the recommendations: • implementation of the guidelines should contribute to realizing the Sustainable Development Goals by achieving key global and national HIV goals; and • guidelines ought to be based on a publ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 15
  },
  {
    "chunk_id": "hivservice_1420",
    "text": "tion of the guidelines should contribute to realizing the Sustainable Development Goals by achieving key global and national HIV goals; and • guidelines ought to be based on a public health approach in line with the continuum of HIV prevention, care and treatment.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 15
  },
  {
    "chunk_id": "hivservice_1421",
    "text": "4 WHO guideline on HIV service delivery Implementation of the guidelines should be: • accompanied by efforts to promote and protect the human rights of people who need HIV services, including ensuring informed consent, preventing stigma and discrimination in the provision of services, and promoting gender equity and respectful care; • informed by the local context, including HIV epidemiology and prevalence of other comorbidities, values and preferences of providers and beneficiaries, feasibility and acceptability, availability of resources, organization and capacity of the health system, and anticipated cost-effectiveness; and • consistent with Good Practice to promote people-centred care and communication, including ongoing training, mentoring, supportive supervision and monitoring of health workers, to improve the relationships between patients and health care providers. Methods for de",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 16
  },
  {
    "chunk_id": "hivservice_1422",
    "text": "luding ongoing training, mentoring, supportive supervision and monitoring of health workers, to improve the relationships between patients and health care providers. Methods for developing these guidelines These guidelines were developed in accordance with procedures established by the WHO Guidelines Review Committee (3). The recommendations were developed following the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to reviewing evidence and formulating recommendations. Consistent with previous WHO guidelines, these guidelines are based on a public health approach that considers feasibility and effectiveness across a variety of settings. All external contributors to the guidelines, including members of the Guideline Development Group (GDG) and the External Review Group, completed a WHO declaration of interests form in accordance with WHO policy for exp",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 16
  },
  {
    "chunk_id": "hivservice_1423",
    "text": "lines, including members of the Guideline Development Group (GDG) and the External Review Group, completed a WHO declaration of interests form in accordance with WHO policy for experts. The WHO Guideline Steering Group reviewed the declaration of interest forms and the results of the web-based search for each member of the GDG: a management plan was agreed and recorded for each individual and presented at the guidelines meeting ( Web Annex A). The systematic reviews and evidence-to-decision tables were shared in advance and presented at the meetings with discussions facilitated by the methodologist. For the new formulation of recommendations, the GDG met virtually on 8–10 April 2025. The full methods for developing these guidelines are detailed in Section 8 and supporting Web Annexes are available as follows: Web Annex A: Summary of declarations of interest Web Annex B: Systematic review",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 16
  },
  {
    "chunk_id": "hivservice_1424",
    "text": "ping these guidelines are detailed in Section 8 and supporting Web Annexes are available as follows: Web Annex A: Summary of declarations of interest Web Annex B: Systematic review abstracts and GRADE evidence profiles Web Annex C: Client preferences survey Web Annex D: Evidence-to-decision summary of judgements",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 16
  },
  {
    "chunk_id": "hivservice_1425",
    "text": "02 Integration of HIV, diabetes and hypertension care",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 17
  },
  {
    "chunk_id": "hivservice_1426",
    "text": "6 WHO guideline on HIV service delivery 2. Integration of HIV, diabetes and hypertension care Recommendation (updated 2025) Diabetes and hypertension care should be integrated with HIV services Strong recommendation, moderate certainty evidence for blood pressure control / very low certainty evidence for diabetes control Background High blood pressure is a leading risk factor for attributable deaths, accounting for an estimated 10.8 million avoidable deaths in 2019 (14). The number of people living with hypertension has doubled between 1990 and 2019 from 650 million to 1.3 billion (15). In low-income countries, only 26% of adults with hypertension were receiving treatment compared with 58% in high-income countries (16). The latest global estimates for diabetes suggest there are now 828 million people living with diabetes with the greatest increases being in low- and middle-income countri",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 18
  },
  {
    "chunk_id": "hivservice_1427",
    "text": "ies (16). The latest global estimates for diabetes suggest there are now 828 million people living with diabetes with the greatest increases being in low- and middle-income countries (LMICs) (17). In 2022, nearly 450 million adults aged 30 and older remained untreated (59% of those with diabetes); 90% of these individuals lived in LMICs (17). With the successful scale-up of HIV treatment programmes, more people living with HIV are aging and increasingly developing NCDs. In 2021, among people accessing HIV services in PEPFAR-supported countries, 3.6 million or 21% were older adults – defined as 50 years or older. The age structure of people living with HIV continues to shift rapidly: this figure is projected to reach nearly 10 million by 2040 (18). Studies assessing HIV cohorts in sub-Saharan Africa estimate a 5–10% prevalence of diabetes and 20–25% prevalence of hypertension among people",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 18
  },
  {
    "chunk_id": "hivservice_1428",
    "text": "reach nearly 10 million by 2040 (18). Studies assessing HIV cohorts in sub-Saharan Africa estimate a 5–10% prevalence of diabetes and 20–25% prevalence of hypertension among people living with HIV (19–21). These age-related epidemiological trends affecting people living with HIV and NCDs globally mean that considerations about integrated care are urgent issues. WHO guidelines published in 2021 conditionally recommended the integration of diabetes and hypertension care with HIV services. Since then, considerable evidence has become available further supporting the integration of HIV, hypertension and diabetes services urged in this revised recommendation.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 18
  },
  {
    "chunk_id": "hivservice_1429",
    "text": "72. Integration of HIV, diabetes and hypertension care Benefits and harms A systematic review and meta-analysis conducted for these guidelines incorporated evidence from 18 randomized and observational studies (25). Most of the included studies were conducted among adults in sub-Saharan Africa. The extent of integration 1 varied across studies – from integration of both diabetes and hypertension screening and care into existing HIV services to a chronic disease integrated approach which included individuals with any one condition or a combination of HIV, diabetes and hypertension. Outcomes assessed included ART adherence, HIV viral suppression, and control of diabetes and blood pressure. Integration effects were variable, most probably because of contextual heterogeneity related to differences in the integration approaches studied, degree of integration, populations, settings and study d",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 19
  },
  {
    "chunk_id": "hivservice_1430",
    "text": "e variable, most probably because of contextual heterogeneity related to differences in the integration approaches studied, degree of integration, populations, settings and study design, as well as large differences in the level of NCD treatment coverage and effectiveness of the standard of care. Viral suppression was consistently high (>90%) (26, 27) and the overall pooled estimate for viral suppression was 98% (95% CI: 91–99%). Adherence varied across studies: the overall proportion adherent to ART was 89% (95% CI: 79–94%). Evidence from comparative studies was limited, but comparative studies in the review reported improved blood pressure control in integrated arms compared to non-integrated standard of care. Four studies, including three observational studies and one cluster randomized controlled trial, reported on the effect of integrated care settings against an unintegrated compar",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 19
  },
  {
    "chunk_id": "hivservice_1431",
    "text": ". Four studies, including three observational studies and one cluster randomized controlled trial, reported on the effect of integrated care settings against an unintegrated comparator arm on blood pressure as an outcome. There was substantial statistical heterogeneity across all analyses of blood pressure control, which can be explained by differences in study design and intervention type. Blood pressure control rates varied widely, with odds ratios for improved control ranging from 1.3 to 26.5 (46 more per 1000 to 634 more per 1000 achieving control) (28, 29). Studies using a pre-post design showed the strongest effect, with pooled odds ratios of 5.7 (0.7–48.2), translating into an absolute difference of 395 more per 1000 (from 88 fewer to 578 more) for blood pressure control after compared with before integration, indicating a significant improvement in blood pressure control post-int",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 19
  },
  {
    "chunk_id": "hivservice_1432",
    "text": "more per 1000 (from 88 fewer to 578 more) for blood pressure control after compared with before integration, indicating a significant improvement in blood pressure control post-integration. The data on diabetes control was far more limited than for hypertension: the overall proportion of individuals achieving diabetes control was 40% (95% CI: 31–50%). While there is stronger evidence supporting the integration of hypertension services compared to diabetes, the GDG emphasized that these two common NCDs should be considered together in practice, given their shared risk factors and frequent co-occurrence (30). Effects on population health are anticipated to be large, especially in regions with a high prevalence of HIV. As populations age and NCDs become more prevalent, they will account for a larger proportion of disability-adjusted life years. The studies were not designed to evaluate harm",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 19
  },
  {
    "chunk_id": "hivservice_1433",
    "text": " HIV. As populations age and NCDs become more prevalent, they will account for a larger proportion of disability-adjusted life years. The studies were not designed to evaluate harms and none was reported. Given the nature of the integration interventions, the GDG judged important harms to be very unlikely. Feasibility, cost and cost-effectiveness Most studies included in the review were considered to be highly pragmatic (as assessed by the PRECIS-2 tool, which assesses the real-world applicability of the interventions tested in the study). As demonstrated by the 18 studies included in the systematic review, both integration of diabetes and hypertension into existing HIV clinics and the implementation of a chronic disease clinic including HIV, diabetes and hypertension for both people living with and not living with HIV were shown to be feasible (25). Integrated dispensing of medicines is",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 19
  },
  {
    "chunk_id": "hivservice_1434",
    "text": "ic disease clinic including HIV, diabetes and hypertension for both people living with and not living with HIV were shown to be feasible (25). Integrated dispensing of medicines is one form of integrated care. South Africa, home to 7.7 million people living with HIV, has implemented the Central Chronic Medicines Dispensing and Distribution (CCMDD) service providing medicines for ART only, diabetes and hypertension only, and all three since 2014. By mid- 2024, 3.3 million people were receiving their medication refills through CCMDD. This provides an example of a national differentiated service delivery model that integrates the management of HIV, diabetes and hypertension, including integrated medication refills (31). 1 Integration can range from minimal collaboration to full collaboration in an integrated practice.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 19
  },
  {
    "chunk_id": "hivservice_1435",
    "text": "8 WHO guideline on HIV service delivery Studies from South Africa, United Republic of Tanzania and Ethiopia have also highlighted barriers to implementation including lack of staff capacity, unclear guidelines on the delivery of integrated care, lack of equipment, lack of reliable medication supply and lack of support (32-34). Five essential items for effective integrated care for chronic conditions were identified in an international multi-stakeholder Delphi consensus study: • improved data collection and surveillance of diabetes and hypertension among people living with HIV (35); • strengthened drug procurement systems; • availability of equipment and access to diagnostics; • health education; and • enhanced continuity of care. Costs have been itemized for both the chronic disease model (36) and the integration of diabetes and hypertension into existing HIV clinics (37). Integration pr",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 20
  },
  {
    "chunk_id": "hivservice_1436",
    "text": "continuity of care. Costs have been itemized for both the chronic disease model (36) and the integration of diabetes and hypertension into existing HIV clinics (37). Integration providing a chronic disease model for people living with and not living with HIV, which included HIV, diabetes and blood pressure control services, demonstrated significant cost savings from both the health system and patient perspective (33). The INTE-Africa trial, conducted in Uganda and United Republic of Tanzania, reported mean service costs per month of managing two conditions for a single participant. Costs were US$ 39.11 (95% CI: 34.00–44.30) for HIV and diabetes, US$ 32.20 (95% CI: 30.40–34.10) for HIV and hypertension, and US$ 22.70 (95% CI: 21.90–23.40) for diabetes and hypertension. These costs were 34.40% (95% CI: 17.90–41.90%) lower than managing any two conditions separately. The cost of managing an",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 20
  },
  {
    "chunk_id": "hivservice_1437",
    "text": "22.70 (95% CI: 21.90–23.40) for diabetes and hypertension. These costs were 34.40% (95% CI: 17.90–41.90%) lower than managing any two conditions separately. The cost of managing an individual with all three conditions was 48.80% (95% CI: 42.10–55.30%) lower than managing these conditions separately. Out-of-pocket healthcare expenditure per participant per visit was US$ 7.33 (95% CI: 3.70–15.86). This constituted 23.40% (95% CI: 9.90–54.30) of the total monthly service expenditure per patient and 11.70% (95% CI: 7.30–22.10) of their individual total household income. The investigators concluded that integration of HIV services with diabetes and hypertension control reduces both health service and household costs substantially (36). Values and preferences In a 2025 WHO survey conducted among people living with HIV (38), 57% of respondents agreed that diabetes and hypertension care should b",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 20
  },
  {
    "chunk_id": "hivservice_1438",
    "text": " substantially (36). Values and preferences In a 2025 WHO survey conducted among people living with HIV (38), 57% of respondents agreed that diabetes and hypertension care should be offered in the same clinic which they visit for their HIV care. The same survey showed that 64% of respondents preferred integrated care among other options when asked what type of support they would like to receive to be able to re-engage with care and treatment. Respondents indicated that integration was preferred due to stigma and discrimination experienced in non-HIV clinic settings. A scoping review to assess beneficiary perspectives of integrated HIV, diabetes and hypertension care (the majority of respondents were from sub-Saharan Africa) were mostly positive; these included a reduction of stigma, travel and treatment costs (39). In a multi-stakeholder experience of integrated care in the United Republ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 20
  },
  {
    "chunk_id": "hivservice_1439",
    "text": "haran Africa) were mostly positive; these included a reduction of stigma, travel and treatment costs (39). In a multi-stakeholder experience of integrated care in the United Republic of Tanzania the integrated model was viewed positively because of benefits to both client and health system. These included improved quality of care, efficient use of limited resources, cost- and time-saving, reduced duplication of services and fostering of early detection for undiagnosed conditions. Challenges observed included costs for diabetes and hypertension care and inconsistent availability of medications (40).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 20
  },
  {
    "chunk_id": "hivservice_1440",
    "text": "92. Integration of HIV, diabetes and hypertension care Equity and acceptability Adopting an integrated approach to services may increase access to routine diabetes and hypertension care among people living with HIV: this implies that equity will be increased, assuming that integrated care is available and accessible to all who can benefit from it. Rationale for the recommendation The GDG recommended changing the 2016 conditional recommendation on service integration to a strong recommendation because of the considerable additional evidence that has accumulated in recent years demonstrating the benefits of integration. These include, importantly, evidence of potentially large increases in rates of improvement in blood pressure control. The absence of reported or likely harm was an important consideration, as were the estimated cost savings for both health systems and clients. The GDG furt",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 21
  },
  {
    "chunk_id": "hivservice_1441",
    "text": " blood pressure control. The absence of reported or likely harm was an important consideration, as were the estimated cost savings for both health systems and clients. The GDG further noted the potential for cost-savings, high acceptability and feasibility, and the potentially positive impact on equity (including decreased stigma and discrimination).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 21
  },
  {
    "chunk_id": "hivservice_1442",
    "text": "03 Integration of HIV and mental health care",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 22
  },
  {
    "chunk_id": "hivservice_1443",
    "text": "11 3. Integration of HIV and mental health care Recommendation (new 2025) Mental health care for depression, anxiety and alcohol use disorders should be integrated with HIV services (Strong recommendation, moderate certainty evidence for depression/ low certainty evidence for anxiety and alcohol use disorder) Background Mental health and alcohol use disorders are common comorbidities among people living with HIV in LMICs, where service delivery is often fragmented. Integrated care models, delivering mental health, alcohol use and HIV services, offer the potential of improved outcomes across the HIV and mental health care continuum. A high prevalence of mental health conditions has been reported among people living with HIV: one recent systematic review reported a pooled prevalence of 31% (95% CI: 28–34%) for depression, 29% (24–34%) for anxiety, 20% (17–24%) for suicidal ideation, 20% (1",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 23
  },
  {
    "chunk_id": "hivservice_1444",
    "text": "ing with HIV: one recent systematic review reported a pooled prevalence of 31% (95% CI: 28–34%) for depression, 29% (24–34%) for anxiety, 20% (17–24%) for suicidal ideation, 20% (13–28%) for post-traumatic stress disorder, and 44% (31–56%) for psychological distress (41). Other systematic reviews have confirmed a similarly high prevalence of depression (42) and anxiety (43), with rates higher in resource-limited settings; among adolescents in sub-Saharan Africa, the burden of depression and anxiety is substantial and appears to be significantly higher when compared with HIV-negative peers, particularly for depression (44). Alcohol-use disorder is common among people with HIV, and is associated with suboptimal medication adherence, unsafe sexual behaviour and poor mental health status; studies have reported a prevalence of alcohol-use disorder of at least 20% among people with HIV, with a",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 23
  },
  {
    "chunk_id": "hivservice_1445",
    "text": "edication adherence, unsafe sexual behaviour and poor mental health status; studies have reported a prevalence of alcohol-use disorder of at least 20% among people with HIV, with a higher prevalence among men (45). HIV-related stigma is associated with anxiety, depression and suicidal ideation: people living with HIV diagnosed with anxiety were 1.9 times more likely to report HIV-related stigma, while those diagnosed with depression were 1.6 times more likely (46). Gender-based violence is an additional risk factor for both HIV and poor mental health. The double stigma associated with a diagnosis of both HIV and mental health conditions is an important consideration. Poor mental health status is associated with worse HIV care outcomes: individuals without depression are 30% more likely to achieve HIV viral suppression or undetectable viral load compared to individuals with depression (OR",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 23
  },
  {
    "chunk_id": "hivservice_1446",
    "text": " worse HIV care outcomes: individuals without depression are 30% more likely to achieve HIV viral suppression or undetectable viral load compared to individuals with depression (OR 1.3; 95% CI: 1.2–1.5) (47). WHO guidelines published in 2016 conditionally recommended the assessment and management of depression as part of the package of HIV care for all individuals living with HIV (11). In 2021, WHO issued a strong recommendation that psychosocial interventions should be provided to all adolescents and young adults living with HIV (12). Since then, considerable evidence has become available supporting the integration of HIV and mental health care beyond depression.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 23
  },
  {
    "chunk_id": "hivservice_1447",
    "text": "12 WHO guideline on HIV service delivery Benefits and harms A systematic review and meta-analysis incorporated evidence from 46 studies (41 on mental disorders, four on alcohol use and one on alcohol and other substance use) across all age groups (48). Eligible studies included randomized and non-randomized trials examining integrated HIV and mental health or alcohol use interventions in LMICs. While integration approaches vary between studies, the degree of integration evaluated by all studies consisted as a minimum of standardized care provision for all clients in the same setting where both HIV and mental health care were located. Evidence from randomized trials provide evidence that integration may improve retention in HIV care (OR 2.0, 95% CI: 0.9–4.7) (49, 50) and viral suppression (OR 1.6, 95% CI: 0.8–3.2) (49, 51–54). Integration leads to a large reduction in moderate-to-severe d",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 24
  },
  {
    "chunk_id": "hivservice_1448",
    "text": "retention in HIV care (OR 2.0, 95% CI: 0.9–4.7) (49, 50) and viral suppression (OR 1.6, 95% CI: 0.8–3.2) (49, 51–54). Integration leads to a large reduction in moderate-to-severe depression (OR 0.5, 95% CI: 0.3–0.7) (52, 54–58), and may reduce anxiety (mean change in general anxiety disorder (GAD-7) score -3.2, 95% CI: -6.9 to 0.5) (59– 62) and alcohol use (mean change in alcohol use disorder identification score -5.8, 95% CI: -7.8 to -3.7) (63, 64). These findings were supported using a range of measurement scales and findings from nonrandomized studies. The certainty of the evidence was downgraded because of contextual heterogeneity related to differences in the integration approaches evaluated, level of integration, populations, settings, study design and other factors, including standard of care comparisons. Studies that showed greater effectiveness of integrated interventions were t",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 24
  },
  {
    "chunk_id": "hivservice_1449",
    "text": "gration, populations, settings, study design and other factors, including standard of care comparisons. Studies that showed greater effectiveness of integrated interventions were typically conducted among patients who exhibited some level of depression or clinically meaningful depression (having a noticeable impact on symptoms, functioning or quality of life), and when the standard of care arm had no form of integration (as opposed to enhanced usual care or other forms of coordinated care). The GDG consider that these effects are expected to be large in terms of overall population health, especially in regions with a high prevalence of HIV due to its association with mental health-related comorbidities; especially depression, anxiety and alcohol use. No harms were reported by the studies reviewed for these guidelines and were not expected due to the nature of the integration intervention",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 24
  },
  {
    "chunk_id": "hivservice_1450",
    "text": "lly depression, anxiety and alcohol use. No harms were reported by the studies reviewed for these guidelines and were not expected due to the nature of the integration interventions. Although it is important to consider the potential for adverse drug-drug interactions when antidepressant medications are used, such harms could be mitigated by more integrated approaches to screening and care. Feasibility, cost and cost-effectiveness Most of the studies included in the review were considered to be highly pragmatic, supporting feasibility. Nevertheless, feasibility is likely to vary depending on the approach taken to integrate services, costs, availability of training and resources, and other local factors. Adding mental health screening and care to HIV care would probably result in additional costs/burdens from the perspective of the HIV clinic but could lead to a reduction in overall healt",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 24
  },
  {
    "chunk_id": "hivservice_1451",
    "text": "mental health screening and care to HIV care would probably result in additional costs/burdens from the perspective of the HIV clinic but could lead to a reduction in overall health care costs due to increased efficiency and fewer clinic visits. Costs are likely to vary depending on the context and the integration approach adopted, as well as the intensity of management and other factors, including out- of-pocket and other expenses. There may be a need to invest in task-sharing models of care involving community members and peers or the training of routine care providers; these upfront investments need to be considered in the context of long-term cost savings derived from task-sharing, as well costs averted owing to the desirable effects of the intervention. Several studies have found that integration of mental health care into HIV care can be cost-effective. A study from South Africa as",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 24
  },
  {
    "chunk_id": "hivservice_1452",
    "text": "ng to the desirable effects of the intervention. Several studies have found that integration of mental health care into HIV care can be cost-effective. A study from South Africa assessing task-shared, cognitive behavioural therapy for people living with HIV with diagnosed depression concluded that the intervention could improve life expectancy and be cost- effective (65). Another study of group support psychotherapy delivered by trained lay health workers for depression treatment among people with HIV in Uganda concluded that the intervention was very cost- effective (incremental cost-effectiveness ratio of US$ 13 per disability-adjusted life-year averted) (53).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 24
  },
  {
    "chunk_id": "hivservice_1453",
    "text": "133. Integration of HIV and mental health care In 2021, WHO published a menu of cost-effective interventions for mental health care in both the general population and individuals. While not specific to people with HIV, this document provides information on the annual cost of implementation of various interventions, including basic psychosocial support and medication, the corresponding health impact and the average cost-effectiveness ratio (66). A global return on investment analysis (not including substance use disorder or other comorbidities) concluded that there are substantial expected returns on investment in terms of extra years of healthy life leading to increased economic productivity (67). Further research is needed to generate insight into resource requirements and costs. Nevertheless, given the moderate certainty of evidence of the desirable effects of integration and the lack ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 25
  },
  {
    "chunk_id": "hivservice_1454",
    "text": "rch is needed to generate insight into resource requirements and costs. Nevertheless, given the moderate certainty of evidence of the desirable effects of integration and the lack of evidence to suggest any undesirable effects, balanced against the need to invest in task-shared, integrated care models, it is plausible that the benefits of integration would outweigh the investment costs. Values and preferences In a 2025 survey (35) conducted among communities of people living with HIV in support of these guidelines, 58% of respondents agreed and strongly agreed that mental health care should be offered in the same clinic in which antiretrovirals are provided. While 43% of respondents agreed and strongly agreed that stigma was not an important consideration for offering integrated mental health care, 44% responded that integration could reduce stigma and discrimination. Equity and acceptab",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 25
  },
  {
    "chunk_id": "hivservice_1455",
    "text": "hat stigma was not an important consideration for offering integrated mental health care, 44% responded that integration could reduce stigma and discrimination. Equity and acceptability People living with HIV are more likely to receive quality care for comorbid conditions if an integrated approach is taken. This assumes that interventions are available to all who are likely to benefit from them. There are also likely to be improved anticipated health outcomes for people with mental health conditions. A study from Uganda found that integrating depression management into routine HIV care is acceptable among key stakeholders; however, the technical and operational feasibility of integration requires changes at both the organizational and client levels (68). There is also indirect evidence that integrating mental health counselling into chronic disease services at the primary health care lev",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 25
  },
  {
    "chunk_id": "hivservice_1456",
    "text": "h the organizational and client levels (68). There is also indirect evidence that integrating mental health counselling into chronic disease services at the primary health care level in South Africa is highly acceptable among health care workers, with differing views about which model to adopt (69). Rationale for the recommendation The GDG decided to make a strong recommendation for mental health integration, based on the moderate certainty evidence of benefit for people with depression, with an anticipated large benefit in terms of overall population health and lack of reported or likely harms. The GDG also noted the potential for cost- savings, high feasibility and acceptability, and the positive impact on equity. Although feasibility may vary depending on the local context and the integration approach utilized, studies demonstrate successful mental health integration can be achieved i",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 25
  },
  {
    "chunk_id": "hivservice_1457",
    "text": "uity. Although feasibility may vary depending on the local context and the integration approach utilized, studies demonstrate successful mental health integration can be achieved in LMICs.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 25
  },
  {
    "chunk_id": "hivservice_1458",
    "text": "04 Integration of HIV, diabetes, hypertension and mental health care: implementation considerations and research gaps",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 26
  },
  {
    "chunk_id": "hivservice_1459",
    "text": "15 4. Integration of HIV, diabetes, hypertension and mental health care: implementation considerations and research gaps The following WHO resources are available to support integration of HIV, diabetes, hypertension and mental health care (70–73), and include: • integration of noncommunicable diseases into HIV service packages (70); • integration of prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis and sexual and reproductive health programmes (71); • integration of mental health and HIV interventions: key considerations (72); and • mental health Gap Action Programme (mhGAP) operations manual (73). The decision to integrate diabetes and hypertension care into existing HIV programmes or to establish separate chronic disease clinics should be guided by factors such as the relative prevalence of conditions, context, human resources and the capacity of current ser",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 27
  },
  {
    "chunk_id": "hivservice_1460",
    "text": "or to establish separate chronic disease clinics should be guided by factors such as the relative prevalence of conditions, context, human resources and the capacity of current services. In some settings, a combination of both approaches may be appropriate. As noncommunicable diseases become increasingly prevalent, the chronic disease clinic model may offer a more effective and sustainable alternative to vertical programmes. It is important that all users of care services have access to care and treatment for diabetes, hypertension and mental health care irrespective of their HIV status. The GDG identified several key implementation considerations with respect to service delivery, access to medications and equipment, monitoring and evaluation, community engagement, policy environment, and financing and sustainability. Service delivery Which services are provided? Management of NCDs and m",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 27
  },
  {
    "chunk_id": "hivservice_1461",
    "text": "pment, monitoring and evaluation, community engagement, policy environment, and financing and sustainability. Service delivery Which services are provided? Management of NCDs and mental health conditions includes screening, detecting and treating these diseases, as well as providing access to palliative and rehabilitation services care for people in need. Guidelines exist for specific conditions that specify which medication is prescribed, which monitoring investigations are performed and what kind of psychosocial support ought to be provided. WHO clinical guidelines for the management of diabetes, hypertension and mental health conditions are available (23, 74–76).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 27
  },
  {
    "chunk_id": "hivservice_1462",
    "text": "16 WHO guideline on HIV service delivery Who provides the services? Capacity-building for health care workers to diagnose and manage diabetes, hypertension and mental health conditions may be needed; this should include ongoing supervision. Assessment of the need and opportunity for task-sharing to nonphysician health care workers should also be considered, including supervision and support across diseases. WHO hypertension guidelines strongly supports task-sharing to trained nonphysician health care workers and generally supports the integration of NCD care into primary care (74). WHO’s mhGAP also strongly supports the provision of mental health care at primary care and through trained nonphysician clinicians (77). Where are services provided? Integrated services should be decentralized to primary care and the community. Opportunities for out-of-facility services should be considered, i",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 28
  },
  {
    "chunk_id": "hivservice_1463",
    "text": "(77). Where are services provided? Integrated services should be decentralized to primary care and the community. Opportunities for out-of-facility services should be considered, in particular for medication- refill provision for both ART and the management of noncommunicable diseases. Integrated service delivery should also be considered in prisons and other places of detention. When are services provided? Services for diabetes and hypertension may also be differentiated based on whether the client is established on treatment. A clear definition for considering when a person is established on treatment for diabetes and hypertension should be included in national guidelines. Clinical visits for all conditions may be aligned and reduced to three- to six-monthly among established patients (74); and multi-month dispensing should be the goal as for ART (78). If medication availability or cos",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 28
  },
  {
    "chunk_id": "hivservice_1464",
    "text": "ay be aligned and reduced to three- to six-monthly among established patients (74); and multi-month dispensing should be the goal as for ART (78). If medication availability or costs prohibit multi-month dispensing, multi-month prescribing should still be preferred. There is little evidence to support differentiated service models for depression, including identifying individuals who may need closer contact/review and ongoing mental health care. Are medication and equipment available? Forecasting, procurement and supply chain systems for diabetes, hypertension and mental health medications should be strengthened to enable access and multi-month dispensing where appropriate, both in HIV and primary care services. Disease prevention Preventing noncommunicable diseases, including diabetes and hypertension, requires reducing the exposure of individuals and populations to common modifiable ri",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 28
  },
  {
    "chunk_id": "hivservice_1465",
    "text": ". Disease prevention Preventing noncommunicable diseases, including diabetes and hypertension, requires reducing the exposure of individuals and populations to common modifiable risk factors, while strengthening their capacity to make healthier choices and adopt lifestyle patterns that promote good health. The regular interaction between care providers at the ART clinic and people living with HIV presents a valuable opportunity to promote healthy lifestyles from an early age and throughout the life course. By incorporating health education, early intervention and lifestyle counselling into its services, the clinic can strengthen overall disease prevention, management and control. While deaths from noncommunicable diseases mainly occur in adulthood, exposure to risk factors begins in childhood and builds up throughout life, underpinning the importance of legislative and regulatory measure",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 28
  },
  {
    "chunk_id": "hivservice_1466",
    "text": "le diseases mainly occur in adulthood, exposure to risk factors begins in childhood and builds up throughout life, underpinning the importance of legislative and regulatory measures, as appropriate, and health promotion interventions to prevent tobacco use, physical inactivity, unhealthy diet, obesity and harmful use of alcohol, as well as to protect children from the adverse impacts of marketing (79). The WHO package of essential noncommunicable (PEN) disease interventions for primary health care emphasizes counselling as a way to promote the adoption of healthy behaviours and reduce exposure to major risk factors (75). WHO guidelines on physical activity and sedentary behaviour provide evidence-based public health recommendations on the amount of physical activity (frequency, intensity and duration) required to offer significant health benefits and mitigate health risks (80). These gui",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 28
  },
  {
    "chunk_id": "hivservice_1467",
    "text": "ealth recommendations on the amount of physical activity (frequency, intensity and duration) required to offer significant health benefits and mitigate health risks (80). These guidelines note the importance of physical activity in protecting against incident hypertension and type-2 diabetes and in reducing symptoms of anxiety and depression. Consuming a healthy diet throughout a person’s life helps prevent malnutrition in all its forms as well as a range of diet-related noncommunicable diseases and conditions, including diabetes, heart disease, stroke and cancer (81). WHO has also published guidelines to support smoking cessation as a key approach to preventing and controlling NCDs (82, 83).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 28
  },
  {
    "chunk_id": "hivservice_1468",
    "text": "17 Monitoring and evaluation Existing cohort monitoring tools for HIV, including electronic medical records, may be adapted to integrate ongoing diabetes and hypertension outcomes into chronic disease follow-up. If integrated, such cohort databases should be used for appointment setting, tracing and supporting re-engagement in care for all patients with HIV, diabetes, hypertension and mental health conditions. Analysis of retention and outcomes should also be used for quality improvement activities. Community engagement Communities representing people living with HIV, diabetes, hypertension and mental health conditions should be engaged in care delivery design and management; attention should be given to minimizing community stigma while maintaining client privacy and dignity. Opportunities for community engagement in the development and delivery of community-based care, including adhere",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 29
  },
  {
    "chunk_id": "hivservice_1469",
    "text": "zing community stigma while maintaining client privacy and dignity. Opportunities for community engagement in the development and delivery of community-based care, including adherence support and the use of health literacy tools for different chronic conditions, should be considered (84, 85). Financing and sustainability In some settings, medications for the management of diabetes, hypertension and mental health conditions need to be paid for by the recipient of care. Inclusion in national strategies and budgeting of commodities across chronic conditions within health financing and country health insurance plans would facilitate integration of these services. As demonstrated in the costing studies, integration may be cost- saving for the health system and possibly also for clients. Efficiency can be further improved by adopting task-sharing and differentiated service delivery approaches.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 29
  },
  {
    "chunk_id": "hivservice_1470",
    "text": "may be cost- saving for the health system and possibly also for clients. Efficiency can be further improved by adopting task-sharing and differentiated service delivery approaches. Policy environment Policies to enable task-sharing and decentralization of HIV care are now widespread and have supported the scale-up of antiretroviral therapy. Similar policies for the diagnosis and management of diabetes, hypertension and mental health conditions, while supported by WHO guidelines, may not be in place at the national level (74, 77). Pharmacy policy may also need adaptation to allow specific diabetes, hypertension and mental health medication to be available at lower-level facilities. Legal environment For people who use drugs and other substances, it is important to assess and address legal and policy barriers to harm reduction services in order to allow substance use care to be integrated ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 29
  },
  {
    "chunk_id": "hivservice_1471",
    "text": "ho use drugs and other substances, it is important to assess and address legal and policy barriers to harm reduction services in order to allow substance use care to be integrated into primary care settings. 4. Integration of HIV, diabetes, hypertension and mental health care: implementation considerations and research gaps",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 29
  },
  {
    "chunk_id": "hivservice_1472",
    "text": "18 WHO guideline on HIV service delivery Research gaps A significant portion of the research underpinning these guidelines was carried out in sub-Saharan Africa. Moving forwards, implementation science will play a key role in identifying the most effective models for integrating services across diverse contexts, including generalized HIV epidemic settings versus concentrated epidemics. Multiple services can be delivered in a digitally integrated approach or through an application even when clinics and service providers for each service are physically distant. Digitally- integrated HIV and NCD service delivery is an important overarching area of research. There are important scientific questions about how to achieve integrated services based on outcomes indicating the extent and nature of combined service delivery. Once a policy to advance integrated services has been formulated, the matt",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 30
  },
  {
    "chunk_id": "hivservice_1473",
    "text": "ieve integrated services based on outcomes indicating the extent and nature of combined service delivery. Once a policy to advance integrated services has been formulated, the matter of how to address the process (whether through facilitation, task-shifting, process design, etc.) becomes an important scientific question. There are several implementation science research networks which will be reporting on these questions in the coming months and years. The following guideline-related research questions were identified by the GDG: • What is the impact of integrating diabetes care and mental health care on HIV clinical outcomes? Most published evidence to date has focused on services integrating hypertension and HIV. • What are the clinical outcomes and cost-effectiveness of integrating diabetes and hypertension care into existing differentiated service delivery models which reduce the int",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 30
  },
  {
    "chunk_id": "hivservice_1474",
    "text": "HIV. • What are the clinical outcomes and cost-effectiveness of integrating diabetes and hypertension care into existing differentiated service delivery models which reduce the intensity of clinical visits, extend medication refill duration, decentralize and enable task-sharing of care? • What are the effective approaches for integrating substance use/harm reduction services (beyond alcohol use), in particular stimulant/psychoactive substance use? • What are the most effective service delivery models for key populations at higher risk of poor mental health, including sex workers, men who have sex with men, transgender individuals and people who inject drugs? • How can mental health care be differentiated, considering some of the complexities specific to mental health care (such as the need to monitor suicidality, time-limited treatment for many mental health conditions)? • What kinds of ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 30
  },
  {
    "chunk_id": "hivservice_1475",
    "text": "dering some of the complexities specific to mental health care (such as the need to monitor suicidality, time-limited treatment for many mental health conditions)? • What kinds of treatment literacy and psychosocial interventions for diabetes, hypertension and mental health care can be delivered in an integrated setting and by which health care worker cadre? • Which metrics and tools are most effective for monitoring and evaluating integration effectiveness? • Which differentiated care models are effective for the provision of mental health care? • What are the preferred approaches for supporting the mental health needs of children and adolescents? • How can services be digitally integrated and delivered?",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 30
  },
  {
    "chunk_id": "hivservice_1476",
    "text": "05 Primary health care and HIV: integration and convergent actions",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 31
  },
  {
    "chunk_id": "hivservice_1477",
    "text": "20 WHO guideline on HIV service delivery 5. Primary health care and HIV: integration and convergent actions In 2023 WHO published Primary health care and HIV: convergent actions: policy considerations for decision-makers (86). This publication helps decision-makers consider and optimize synergies between existing and future assets and investments intended for both primary health care (PHC) and disease-specific responses, including HIV. PHC is the key mechanism for achieving universal health coverage. The PHC approach aims to maximize the level and distribution of health and well-being through three components: (1) primary care and essential public health functions as the core of integrated health services; (2) multisectoral policy and action; and (3) empowered people and communities. HIV care is already delivered within primary care in the majority of high burden settings. PHC and diseas",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 32
  },
  {
    "chunk_id": "hivservice_1478",
    "text": "multisectoral policy and action; and (3) empowered people and communities. HIV care is already delivered within primary care in the majority of high burden settings. PHC and disease- specific stakeholders should work together to plan a locally responsive strategy to deliver quality, person- centred, integrated services which include HIV care, management of other chronic diseases and mental health care within primary care. Further support can be found through the Universal Health Coverage Partnership, one of WHO’s largest platforms for international cooperation on universal health coverage and PHC (87).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 32
  },
  {
    "chunk_id": "hivservice_1479",
    "text": "06 Adherence support",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 33
  },
  {
    "chunk_id": "hivservice_1480",
    "text": "22 WHO guideline on HIV service delivery 6. Adherence support Recommendation (updated 2025) Adherence support interventions should be provided to people on ART Strong recommendation, moderate certainty evidence The following interventions have demonstrated benefit: – counselling (moderate certainty evidence) – reminders (moderate certainty evidence) – peer and other support (moderate certainty evidence) – education (low certainty evidence) Background Suboptimal adherence to medications is a global challenge, leading to disease progression, poor health outcomes and increased health care costs. In HIV care, suboptimal adherence also has public health risks, including an increased risk of disease transmission due to viral non-suppression and development of drug resistance, making future treatment more complicated and costly. People on ART face multiple barriers to sustained lifelong adheren",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 34
  },
  {
    "chunk_id": "hivservice_1481",
    "text": "to viral non-suppression and development of drug resistance, making future treatment more complicated and costly. People on ART face multiple barriers to sustained lifelong adherence – these factors have been categorized as individual, interpersonal, community-based and structural barriers (4). In 2016, WHO issued a strong recommendation that adherence support interventions should be provided to people on ART (88). This recommendation further indicates that the following interventions (all supported by moderate certainty evidence) are beneficial in improving adherence and viral suppression: • peer counsellors; • mobile phone text messages (SMS); • reminder devices; • cognitive-behavioural therapy; • behavioural skills training and medication adherence training; and • fixed-dose combinations and once-daily regimens. WHO further recommends that enhanced adherence support should be provided",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 34
  },
  {
    "chunk_id": "hivservice_1482",
    "text": " skills training and medication adherence training; and • fixed-dose combinations and once-daily regimens. WHO further recommends that enhanced adherence support should be provided to all individuals with an initial high viral load (>1000 copies/mL) before conducting a second viral load test (88). (Some national guidelines, including those of South Africa, recommend providing enhanced adherence support at a lower threshold of more than 50 copies/mL (89)).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 34
  },
  {
    "chunk_id": "hivservice_1483",
    "text": "236. Adherence support These interventions remain valid as recommended ways to improve adherence and prevent unnecessary ART regimen switches. Nevertheless there were several reasons why it was considered important to update the evidence review in support of adherence interventions. Firstly, uptake and implementation of these adherence support interventions since their recommendation in 2016 have been variable, reflecting differing resource availability. Secondly, since 2016, the standard antiretroviral therapy has evolved, with most individuals now receiving a once-daily fixed-dose combination of tenofovir, lamivudine and dolutegravir. Thirdly, service delivery models of HIV treatment have also evolved, with many people receiving care and support through differentiated service delivery (DSD) models, with less frequent clinical visits and longer drug refills. DSD models support self-mana",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 35
  },
  {
    "chunk_id": "hivservice_1484",
    "text": "any people receiving care and support through differentiated service delivery (DSD) models, with less frequent clinical visits and longer drug refills. DSD models support self-management approaches and underscore the importance of high levels of adherence between clinical interactions. Lastly, with a shift in the communications interface used (from pagers and mobiles to apps and SMS), it is important to differentiate interventions based on communication software rather than device: for example, an app can act as a reminder or provide access to a supporter. Benefits and harms This guideline update is based on an evaluation of the published evidence over the last 10 years on ways to improve adherence as part of a public health approach to ART delivery. The focus was on adherence interventions not yet incorporated into routine HIV care (such as once-daily fixed-dose combination ART) and ref",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 35
  },
  {
    "chunk_id": "hivservice_1485",
    "text": " public health approach to ART delivery. The focus was on adherence interventions not yet incorporated into routine HIV care (such as once-daily fixed-dose combination ART) and reflecting evolving approaches to enhance adherence. A systematic review and network meta- analysis incorporated evidence from 164 randomized trials on the following ART adherence interventions: reminders (interventions that involved using cues to take medications, including SMS, apps, multimedia and other tools on different devices), peer and other supporters (interventions that involved the use of an individual chosen by a clinic or client to support treatment adherence including peer-based support, home visits, treatment assistants and medication managers), client education (including treatment literacy), counselling and complex interventions including three or more interventions (48). Interventions were catego",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 35
  },
  {
    "chunk_id": "hivservice_1486",
    "text": "d medication managers), client education (including treatment literacy), counselling and complex interventions including three or more interventions (48). Interventions were categorized in this way to better reflect underlying approaches and to be more inclusive of support strategies that are feasible in settings with limited resources. Around half the evidence came from studies conducted in LMICs but evidence on all interventions was available in all contexts. The general population included adults living with HIV regardless of prior treatment experience, women, men who have sex with men, people living with TB co-infection, youth and adolescents; the latter were also analysed as a separate population, as were persons with mental health conditions, people who use alcohol and other substances and persons with prior adherence issues. Of note, substance users included people who use drugs, ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 35
  },
  {
    "chunk_id": "hivservice_1487",
    "text": "persons with mental health conditions, people who use alcohol and other substances and persons with prior adherence issues. Of note, substance users included people who use drugs, inject drugs and those with alcohol use. While attention was given to other key populations during the review, no studies were found to focus on other key populations (e.g. sex workers) for the purpose of informing adherence interventions. All interventions probably improved adherence over 48 weeks, with the strongest improvement seen for reminders and supporters. Similar effects were seen for viral suppression, with further evidence supporting counselling. Adherence interventions probably improved adherence and viral suppression in the general adult population relative to standard of care (a single session reviewing the importance of adherence at start of study). Reminders (OR 1.6, 95% CI: 1.2–2.3), counsellin",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 35
  },
  {
    "chunk_id": "hivservice_1488",
    "text": "he general adult population relative to standard of care (a single session reviewing the importance of adherence at start of study). Reminders (OR 1.6, 95% CI: 1.2–2.3), counselling (OR 1.3, 95% CI: 1.0–1.7) and supporters (peer and other types of support) (OR 1.3, 95% CI: 1.1–1.7) all demonstrated statically significant improvements, with reminders causing large improvements in viral suppression. Education alone may not improve adherence (OR 1.1, 95% CI: 0.8–1.7), although education offers additional benefits, including increased confidence in clients’ ability to manage their health (48). There were fewer studies in the review among youth and adolescents, but the available evidence suggested that reminders were an effective intervention with respect to viral suppression (OR 2.9, 95% CI: 1.6–5.6). For individuals who have adherence challenges, supporters (OR 4.8, 95% CI: 2.0–12.2) and co",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 35
  },
  {
    "chunk_id": "hivservice_1489",
    "text": "e an effective intervention with respect to viral suppression (OR 2.9, 95% CI: 1.6–5.6). For individuals who have adherence challenges, supporters (OR 4.8, 95% CI: 2.0–12.2) and counselling (OR 1.8, 95% CI: 1.0–3.5) may improve adherence. The evidence base was more limited for people with mental health issues and people who use substances. For people with mental health conditions, supporters showed the greatest benefit in terms of viral suppression (OR 2.4, 95% CI: 1.3–4.2); for people who use substances there was a trend towards improved adherence with supporters (OR 1.7, 95% CI: 0.8–3.4).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 35
  },
  {
    "chunk_id": "hivservice_1490",
    "text": "24 WHO guideline on HIV service delivery Mortality was low across all the studies and not associated with any particular intervention. Although these studies were not designed to address other harms, serious harms were not expected given the nature of the interventions and not reported. Feasibility, cost and cost-effectiveness Feasibility is likely to vary depending on the type and intensity of adherence support provided as well as the context/setting in which support is provided. Counselling and education have been effectively taken up by numerous national programmes, demonstrating their feasibility for integration into routine service delivery. Several barriers to implementing adherence interventions have been reported, including insufficient training and compensation for lay health workers and risks of unintentional HIV status disclosure (70). Decisions regarding the delivery workforc",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 36
  },
  {
    "chunk_id": "hivservice_1491",
    "text": "n reported, including insufficient training and compensation for lay health workers and risks of unintentional HIV status disclosure (70). Decisions regarding the delivery workforce for adherence interventions – whether based on existing health staff or by introducing new roles – should be guided by the local context and other resources that can be leveraged. Providing adherence support for medication across multiple chronic diseases such as HIV, diabetes and hypertension, may offer opportunities for efficiency (91). The evidence on the cost-effectiveness of adherence support interventions is limited but suggests that providing such support can be cost-effective. However, as with feasibility, cost-effectiveness will vary depending on the specific type and intensity of adherence support and the specific context or setting. Counselling is usually provided after an HIV diagnosis is made, as",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 36
  },
  {
    "chunk_id": "hivservice_1492",
    "text": " will vary depending on the specific type and intensity of adherence support and the specific context or setting. Counselling is usually provided after an HIV diagnosis is made, as part of ART initiation and in the first months on treatment. Importantly, in 2021, WHO issued a Good Practice Statement relating to the offer of same-day ART initiation that includes providing tailored patient education, counselling and support to improve update, treatment adherence and retention (12). Additional counselling interventions may then be targeted to individuals with unsuppressed viral loads or who report specific adherence challenges. Costs for counselling depend on the cadre providing the care and frequency of interventions, which will vary between settings. Counsellors or supporters employed specifically for HIV counselling are cadres that may not be included in existing national health care wor",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 36
  },
  {
    "chunk_id": "hivservice_1493",
    "text": "ions, which will vary between settings. Counsellors or supporters employed specifically for HIV counselling are cadres that may not be included in existing national health care workforce budgets. Counselling and education can be delivered by existing staff. Inclusion of information, education and communication materials may need to accompany counselling and education interventions. The costs of reminders will vary according to the frequency and complexity of the systems (e.g. one- versus two-way systems). SMS systems often depend on client-level electronic medical records/data systems that need maintenance. Associated costs include establishing and maintaining electronic patient records, the design of the reminder interface, and the direct costs of providing the SMS or other reminder intervention. It is possible to leverage the resources needed for reminders for pill-taking for other int",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 36
  },
  {
    "chunk_id": "hivservice_1494",
    "text": "der interface, and the direct costs of providing the SMS or other reminder intervention. It is possible to leverage the resources needed for reminders for pill-taking for other interventions such as education, reminders for clinical visits, adherence counselling, etc. Access may be limited by phone ownership, network availability and privacy considerations. Consent is essential to avoid unintended disclosure. A global systematic review which assessed the cost-effectiveness of ART adherence interventions concluded that counselling and smartphone-based interventions were cost-effective (92). A study from Kenya found that SMS interventions were cost-effective and likely to increase the efficiency of ART programmes by improving HIV treatment outcomes at relatively low costs (93). Evidence on the cost- effectiveness of adherence support interventions is limited but suggests that providing suc",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 36
  },
  {
    "chunk_id": "hivservice_1495",
    "text": " by improving HIV treatment outcomes at relatively low costs (93). Evidence on the cost- effectiveness of adherence support interventions is limited but suggests that providing such support can be cost-effective.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 36
  },
  {
    "chunk_id": "hivservice_1496",
    "text": "256. Adherence support Values and preferences Findings from the values and preferences survey (38) indicate that about half of the respondents agreed or strongly agreed that they should receive support from health care workers on treatment literacy, adherence planning and goal setting; 58% stated that health care workers involved them in identifying barriers to adherence and potential solutions. The preferred location for adherence support may vary by context; in some settings clinic-based support may be favoured due to lower stigma and improved access (94). A study from South Africa, Uganda and Zimbabwe found that offering a range of adherence support interventions enhanced adherence to antiretroviral drugs for HIV prevention, providing indirect support for this approach for antiretroviral therapy (95). Equity and acceptability Adherence support interventions can improve adherence and H",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 37
  },
  {
    "chunk_id": "hivservice_1497",
    "text": "r HIV prevention, providing indirect support for this approach for antiretroviral therapy (95). Equity and acceptability Adherence support interventions can improve adherence and HIV outcomes in persons with adherence challenges, who may also be more likely to face challenges related to other health and social needs that contribute to decreased adherence. Therefore, providing adherence support could have positive impacts on equity, assuming that the interventions are available to all persons who could benefit from them. Equity may be enhanced by considering the utility of adherence support interventions across a broader population in the context of integrated services. Based on the systematic review of interventions conducted for this guideline, 28 studies reported on acceptability (48). Across a variety of treatments, including reminders (SMS and mobile applications), education, counsel",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 37
  },
  {
    "chunk_id": "hivservice_1498",
    "text": "tions conducted for this guideline, 28 studies reported on acceptability (48). Across a variety of treatments, including reminders (SMS and mobile applications), education, counselling and others, acceptability and satisfaction were high (mostly above 85%). A values and preferences survey (38) was carried out to assess preferences for the different adherence interventions; of the 229 responses received 51% were from male respondents: 39% of respondents stated that counselling and treatment literacy were highly preferable adherence interventions; 41% stated a preference for treatment literacy. Preferences for peer support and reminders were mixed with only 7% and 5%, respectively, stating them as preferable interventions. The survey was not specifically aimed at specific populations such as adolescents, pregnant women or key populations for which significant evidence has accrued concernin",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 37
  },
  {
    "chunk_id": "hivservice_1499",
    "text": "rventions. The survey was not specifically aimed at specific populations such as adolescents, pregnant women or key populations for which significant evidence has accrued concerning the role of peer supporters. Respondents placed a strong value on receiving accurate information and stressed the importance of client-provider interaction to support adherence, encouraging clients to set their own treatment goals, and identifying challenges and continuous follow-up. Peer adherence supporters have been reported to be acceptable for adolescents, pregnant women (96–100) and key populations (104, 105). Reminders have been demonstrated to be acceptable to people living with HIV in a number of countries including China (106), Kenya (107), Ethiopia (108) and South Africa (109). SMS interventions have also been reported as acceptable in key populations (110, 111), adolescents (112–116) and pregnant ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 37
  },
  {
    "chunk_id": "hivservice_1500",
    "text": "106), Kenya (107), Ethiopia (108) and South Africa (109). SMS interventions have also been reported as acceptable in key populations (110, 111), adolescents (112–116) and pregnant women (117). Rationale for the recommendation The GDG decided to make a strong recommendation considering the moderate certainty evidence of benefit across a range of interventions, lack of reported or likely harms, the potential for cost-savings, high acceptability including the value of personalized, goal-oriented support across diverse populations and the potential positive impact on equity. Feasibility is likely to depend on the context and available resources; however, given that a number of adherence approaches are supported by evidence, the choice of adherence support can be tailored according to available resources.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 37
  },
  {
    "chunk_id": "hivservice_1501",
    "text": "26 WHO guideline on HIV service delivery Implementation considerations Ensuring continuity of HIV treatment through supportive systems Reliable access to HIV care and a consistent supply of antiretroviral medications are essential for sustaining treatment adherence. Economic constraints are a significant barrier to adherence, and community-based support can play a critical role in helping individuals navigate and manage their treatment effectively. Targeted and timely adherence support To maximize impact, adherence support strategies should be directed towards individuals most at risk of poor adherence. Health care providers are encouraged to adopt a triaged approach – identifying those at risk and tailoring interventions to address their specific barriers. The initial months following diagnosis and treatment initiation are particularly critical, as disengagement from care is more likely",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 38
  },
  {
    "chunk_id": "hivservice_1502",
    "text": "terventions to address their specific barriers. The initial months following diagnosis and treatment initiation are particularly critical, as disengagement from care is more likely during this period; early and targeted support during this period can improve long-term treatment outcomes (118). Adherence strategies should be responsive to changes in clients’ needs and barriers and should therefore be reassessed during normal clinical appointments. Personalized and differentiated adherence support Adherence interventions are enhancements to the standard of care and their application should aim to address expressed adherence barriers. Consideration should be given to combining or sequencing adherence interventions which have been adapted in terms of duration and intensity to suit the needs and preferences of the individual. Family members can be engaged to provide adherence support where co",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 38
  },
  {
    "chunk_id": "hivservice_1503",
    "text": " which have been adapted in terms of duration and intensity to suit the needs and preferences of the individual. Family members can be engaged to provide adherence support where consent is present. Further evidence and examples of peer support models for adolescents living with HIV can be found in the WHO Technical Brief on adolescent-friendly health services (119). Health system and provider support Health provider training and capacity building should be provided in key areas including person-centred approaches, stigma reduction, identifying adherence barriers and setting adherence goals. Opportunities for task-sharing across existing cadres and involving peers are an important part of adherence support but depend on policy and funding. Adherence support systems can be leveraged across comorbid conditions, including diabetes, hypertension and mental health, to improve efficiency and co",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 38
  },
  {
    "chunk_id": "hivservice_1504",
    "text": "epend on policy and funding. Adherence support systems can be leveraged across comorbid conditions, including diabetes, hypertension and mental health, to improve efficiency and continuity of care. Digital and technological tools Digital adherence tools should be leveraged to provide education and literacy where feasible. The use of digital tools must be accompanied by strong data protection measures and clear informed consent processes to prevent unintended disclosure of HIV status. WHO guidelines on emerging digital health interventions provide evidence-based recommendations for various digital health interventions, including SMS-based strategies (120). Certain groups may face challenges in accessing digital technologies, in particular children and elderly people living with HIV: this highlights the importance of offering alternative options for adherence support (121). Promoting self-",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 38
  },
  {
    "chunk_id": "hivservice_1505",
    "text": "technologies, in particular children and elderly people living with HIV: this highlights the importance of offering alternative options for adherence support (121). Promoting self-management and empowerment Fostering self-care and building capacity for self-management should be supported through simplified tools, education and empowerment strategies – particularly where health system capacity is limited.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 38
  },
  {
    "chunk_id": "hivservice_1506",
    "text": "276. Adherence support Research gaps Cost-effectiveness of adherence interventions What is the cost-effectiveness of specific adherence interventions for people living with HIV, including the costs of training, supervision and human resources? How do the costs and scalability of digital reminder systems compare to traditional adherence interventions in resource-limited settings? Tailored interventions for vulnerable populations How can adherence interventions be tailored to effectively support underserved populations, such as children, adolescents, pregnant women, migrants, indigenous population and people who use drugs? What are the unique barriers to treatment adherence faced by specific high-vulnerability groups, and how can interventions be optimized to address these? Education versus counselling interventions What is the comparative effectiveness of education versus counselling inte",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 39
  },
  {
    "chunk_id": "hivservice_1507",
    "text": "oups, and how can interventions be optimized to address these? Education versus counselling interventions What is the comparative effectiveness of education versus counselling interventions in improving treatment adherence among people living with HIV? Which delivery modalities, frequencies and cadres (e.g. peer educators, nurses, community health workers) are most effective in providing education and counselling? Combined interventions The evidence of combined interventions remains limited but suggests that combined interventions would be better positioned to overcome existing barriers. More exploratory studies in populations of interest would serve to better optimize adherence enhancement strategies. Prioritization and resource allocation In resource-constrained environments, which populations should be prioritized for adherence support interventions to achieve the greatest health impa",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 39
  },
  {
    "chunk_id": "hivservice_1508",
    "text": "zation and resource allocation In resource-constrained environments, which populations should be prioritized for adherence support interventions to achieve the greatest health impact? What criteria can be used to determine the allocation of adherence interventions among populations with varying levels of adherence risk? Artificial intelligence-driven adherence tools How can artificial Intelligence help identify people in need of adherence support and target appropriate interventions?",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 39
  },
  {
    "chunk_id": "hivservice_1509",
    "text": "07 Updating and dissemination",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 40
  },
  {
    "chunk_id": "hivservice_1510",
    "text": "29 7. Updating and dissemination 2 HIV Country Intelligence [online database]. Geneva: World Health Organization; 2025 ( https://cfs.hivci.org/ , accessed 3 July 2025). This service delivery guideline is being launched as a web-based product for dissemination and will include a summary of systematic review findings and GRADE evidence profiles presented to the GDG (see Web Annex B). The guideline will be incorporated into the periodic updates of the complete WHO consolidated guidelines on HIV which will be updated in full or in part based on regular scoping exercises of available evidence and experience from country implementation that trigger and shape the need for new guidelines. As the evidence base or user needs change, consideration will be given to producing technical updates on specific subjects. WHO headquarters will work closely with its regional and country offices, national min",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 41
  },
  {
    "chunk_id": "hivservice_1511",
    "text": "eeds change, consideration will be given to producing technical updates on specific subjects. WHO headquarters will work closely with its regional and country offices, national ministries of health and implementing partners to plan for the dissemination, adaptation and implementation of these new recommendations. Key steps in their dissemination will include presenting the recommendations at international conferences; conducting workshops to support country adaptation; developing adaptation tools to assist countries in setting priorities for resource allocation in order to move towards full implementation over time; and conducting briefings and joint planning for dissemination with international and national implementing partners. To monitor uptake, data will be made available through the WHO country intelligence database ,2 which is updated every six months to reflect changes in policy ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 41
  },
  {
    "chunk_id": "hivservice_1512",
    "text": "plementing partners. To monitor uptake, data will be made available through the WHO country intelligence database ,2 which is updated every six months to reflect changes in policy and implementation for all UN Member LMICs and selected high-income countries.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 41
  },
  {
    "chunk_id": "hivservice_1513",
    "text": "08 Guideline development process",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 42
  },
  {
    "chunk_id": "hivservice_1514",
    "text": "31 8. Guideline development process Background The last WHO guidelines on HIV service delivery were published in 2021. Since then, emerging evidence and implementation experience and approaches justify reviewing and updating the service delivery guidelines. A scoping exercise was held with national HIV programme managers, implementing partners and representatives from civil society and academia at a Catalyzing Quality HIV Care (CQUIN) Learning Network meeting in 2024 (122) to help define priority questions for this update; these questions were further developed by the WHO steering group. Three systematic reviews were undertaken to address PICO (Population, Intervention, Comparison, Outcome) questions and complemented by other information sources such as targeted literature searches, programmatic information and primary surveys. Many individuals contributed to the development of the guide",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 43
  },
  {
    "chunk_id": "hivservice_1515",
    "text": "mented by other information sources such as targeted literature searches, programmatic information and primary surveys. Many individuals contributed to the development of the guideline including people living with HIV and representatives of affected communities, representatives from ministries of health, researchers, implementers and health care providers. This information was presented at a virtual GDG meeting convened in April 2025, following WHO standards for guideline development (13). Retrieving, summarizing and presenting the evidence All systematic reviews followed the PRISMA guidelines for reporting systematic reviews and meta-analyses. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to rate the certainty of evidence and determine the strength of recommendations (123). GRADE defines the certainty of evidence as the extent to which o",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 43
  },
  {
    "chunk_id": "hivservice_1516",
    "text": "valuation) approach was used to rate the certainty of evidence and determine the strength of recommendations (123). GRADE defines the certainty of evidence as the extent to which one can be confident that the reported estimates of effect (desirable or undesirable) available from the evidence are close to the actual effects of interest. After the evidence is collected and summarized, GRADE provides explicit criteria for rating the certainty of evidence that include study design, risk of bias, imprecision, inconsistency, indirectness and magnitude of effect. The strength of a recommendation reflects the degree to which the GDG is confident that the desirable effects (potential benefits) of the recommendation outweigh the undesirable effects (potential harm). Desirable effects may include beneficial health outcomes such as reduced morbidity and mortality, reduction of burden on the individu",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 43
  },
  {
    "chunk_id": "hivservice_1517",
    "text": "eigh the undesirable effects (potential harm). Desirable effects may include beneficial health outcomes such as reduced morbidity and mortality, reduction of burden on the individual and/or health services and potential cost-savings. Undesirable effects include those affecting individuals, families, communities or health services as well as the implementation of services that may not be cost-effective within a particular context. Additional considerations include resource use and cost implications of implementing the recommendations and clinical outcomes (such as drug resistance and drug toxicity).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 43
  },
  {
    "chunk_id": "hivservice_1518",
    "text": "32 WHO guideline on HIV service delivery The PRECIS-2 tool3 was used to assess the extent to which the conduct of a given study reflects an explanatory (ideal situation) or a more pragmatic (usual care) context. PRECIS-2 has nine domains – eligibility criteria, recruitment, setting, organization, flexibility (delivery), flexibility (adherence), follow- up, primary outcome and primary analysis – scored from 1 (very explanatory) to 5 (very pragmatic) (124). The level of integration for interventions identified through systematic review was classified using the Standard Framework for Levels of Integrated Healthcare (72). Feasibility and acceptability The pragmatism of studies provided indirect evidence on feasibility from the systematic reviews, obtained using PRECIS-2. Other sources of evidence for feasibility included the UNAIDS database on country adoption of relevant WHO recommendations",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 44
  },
  {
    "chunk_id": "hivservice_1519",
    "text": "ity from the systematic reviews, obtained using PRECIS-2. Other sources of evidence for feasibility included the UNAIDS database on country adoption of relevant WHO recommendations. Key health ministry or partner stakeholders provided insights at the Guidelines Development Group meeting on feasibility in settings with a high burden of HIV infection. In addition, a survey (38) was conducted on 27 March 2025 among people living with HIV to assess the feasibility and acceptability of strategies for delivering HIV services. Dissemination of this survey was supported by the Global Network of People Living with HIV (GNP+). The results of these surveys were used to inform the acceptability and feasibility of the range of questions addressed. Resource use and cost-effectiveness The systematic reviews captured published evidence on resource use including costing, cost-effectiveness and affordabil",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 44
  },
  {
    "chunk_id": "hivservice_1520",
    "text": " of questions addressed. Resource use and cost-effectiveness The systematic reviews captured published evidence on resource use including costing, cost-effectiveness and affordability data. Additional literature reviews were conducted for indirect evidence that could enrich this information. The GDG and External Review Group included representatives from national programmes who also provided perspectives on resource implications in their countries. Ethical considerations Before the GDG meeting, the proposed areas of intervention were reviewed by a WHO staff member with expertise in global health and ethics, and key issues with respect to equity were outlined to the group for consideration when formulating recommendations. Guideline Development Guideline Development Group (GDG) meeting The GDG met virtually on 8–10 April 2025. Using an electronic survey, the group ranked the importance of",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 44
  },
  {
    "chunk_id": "hivservice_1521",
    "text": "mendations. Guideline Development Guideline Development Group (GDG) meeting The GDG met virtually on 8–10 April 2025. Using an electronic survey, the group ranked the importance of each systematic review outcome using the GRADE rating scale from 1 to 9 (125). The systematic reviews and evidence-to-decision tables, prepared in accordance with the GRADE process, were shared in advance and presented at the meetings, where the methodologist facilitated discussions. The group agreed a priori that should a vote be necessary, a two thirds majority would be required for a decision. However, consensus was achieved for all recommendations, and no voting was required. Peer review The draft guidelines were circulated for review to members of the GDG and External Review Group. The WHO Guideline Steering Group reviewed the comments and incorporated them into the final document with due consideration f",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 44
  },
  {
    "chunk_id": "hivservice_1522",
    "text": "eview to members of the GDG and External Review Group. The WHO Guideline Steering Group reviewed the comments and incorporated them into the final document with due consideration for any conflicts of interest relating to External Review Group members. 3 PRagmatic Explanatory Continuum Indicator Summary [webtool]. Dundee, United Kingdom: Health Informatics Centre, University of Dundee; 2016 ( https://www.precis-2.org/ , accessed 3 July 2025).",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 44
  },
  {
    "chunk_id": "hivservice_1523",
    "text": "338. Guideline development process Declarations of interest All external contributors to the guidelines, including members of the GDG and External Review Group, completed a WHO declaration of interests form in accordance with WHO policy for experts. A brief biography of each GDG member was published on the WHO HIV website for a period of 14 days before the first meeting of the group with a description of the objectives of the meeting. No public comments or objections were received. The responsible technical officer reviewed the declaration of interests forms as well as the results of the web-based search for each member of the GDG. The results were shared with the WHO Guideline Steering Group, which reviewed the results, and a management plan was agreed and recorded for each individual. At the start of the guideline development meeting, all conflicts of interest identified and the manage",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 45
  },
  {
    "chunk_id": "hivservice_1524",
    "text": "e results, and a management plan was agreed and recorded for each individual. At the start of the guideline development meeting, all conflicts of interest identified and the management plan for any conflicts of interest were shared with the meeting participants and members were asked to vocalize any additional conflicts or undeclared conflicts. In accordance with the revised WHO policy for experts, a web-based search of GDG members was conducted to identify any potential competing interest. The WHO Guideline Steering Group recorded and reviewed the results of the web-based search to identify any potential competing interest. There were no conflicts of interest that warranted exclusion from the discussion of specific recommendations. Similarly, for the External Review Group the responsible technical officers reviewed all declaration of interest forms in accordance with WHO guideline devel",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 45
  },
  {
    "chunk_id": "hivservice_1525",
    "text": "cific recommendations. Similarly, for the External Review Group the responsible technical officers reviewed all declaration of interest forms in accordance with WHO guideline development policy. Any conflicts of interest identified were considered when interpreting comments from External Review Group members during the external review process.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 45
  },
  {
    "chunk_id": "hivservice_1526",
    "text": "34 WHO guideline on HIV service delivery References 1. Global HIV statistics 2025 (factsheet). New York: UNAIDS; 2025 ( https://www.unaids.org/en/resources/ documents/2025/UNAIDS_FactSheet , accessed 16 July 2025). 2. Trickey A, Sabin CA, Burkholder G et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295–e307. doi:10.1016/S2352-3018(23)00028-0 3. Nsanzimana S, Remera E, Kanters S et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health. 2015;3(3):e169–e177. doi:10.1016/ S2214-109X(14)70364-X 4. Shubber Z, Mills EJ, Nachega JB et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016;13(11):e1002183. doi: 10.1371/ journa",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 46
  },
  {
    "chunk_id": "hivservice_1527",
    "text": " EJ, Nachega JB et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016;13(11):e1002183. doi: 10.1371/ journal.pmed.1002183 5. Global Health Estimates 2021: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2021. Geneva, World Health Organization; 2024 6. Integration of mental health and HIV interventions: key considerations. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2022 ( https://iris.who.int/bitstream/hand le/10665/353571/9789240043176-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 7. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, 2nd ed. Geneva: World Health Organization; 2021 ( https://www.who.int/publications/i/ item/9789240030824, accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IG",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 46
  },
  {
    "chunk_id": "hivservice_1528",
    "text": "ical cancer prevention, 2nd ed. Geneva: World Health Organization; 2021 ( https://www.who.int/publications/i/ item/9789240030824, accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 8. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 ( https:// www.who.int/publications/i/item/9789240031593 , accessed 1 August 2025). 9. Almeida PRS, Rafael CAC, Pimentel V, Abecasis AB, Sebastiao CS, Morais J. Adherence to antiretroviral therapy among HIV-1 patients from sub-Saharan Africa: a systematic review. AIDS Rev. 2024;26(3):102– 110. doi:10.24875/AIDSRev.24000004 10. Kanters S, Park JJ, Chan K et al. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV. 2017;4(1):e31–e40. doi:10.1016/S2352- 3018(16)30",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 46
  },
  {
    "chunk_id": "hivservice_1529",
    "text": "n K et al. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV. 2017;4(1):e31–e40. doi:10.1016/S2352- 3018(16)30206-5 11. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach, 2 nd ed. Geneva: World Health Organization; 2016 (https://www.who.int/publications/i/item/9789241549684 , accessed 3 July 2025). 12. Updated recommendations on service delivery for the treatment and care of people living with HIV. Geneva: World Health Organization; 2021 ( https://www.who.int/publications/i/item/9789240023581 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 13. WHO handbook for guideline development, 2 nd ed. Geneva: World Health Organization; 2014 (https://wkc.who.int/resources/publications/i/item/9789241548960 , accessed 3 July 2025",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 46
  },
  {
    "chunk_id": "hivservice_1530",
    "text": "13. WHO handbook for guideline development, 2 nd ed. Geneva: World Health Organization; 2014 (https://wkc.who.int/resources/publications/i/item/9789241548960 , accessed 3 July 2025). 14. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–1249. doi: 10.1016/S0140-6736(20)30752-2 15. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. doi:10.1016/S0140- 6736(21)01330-1",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 46
  },
  {
    "chunk_id": "hivservice_1531",
    "text": "35References 16. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023 (https://www.who.int/publications/i/item/9789240081062 , accessed 3 July 2025). Licence: CC BY- NC-SA 3.0 IGO. 17. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077–2093. doi: 10.1016/S0140-6736(24)02317-1 18. Hontelez JA, de Vlas SJ, Baltussen R et al. The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS. 2012;26 Suppl 1(0 1):S19–30. doi:10.1097/QAD.0b013e3283558526 19. Bigna JJ, Ndoadoumgue AL, Nansseu JR et al. Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic revie",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 47
  },
  {
    "chunk_id": "hivservice_1532",
    "text": "13e3283558526 19. Bigna JJ, Ndoadoumgue AL, Nansseu JR et al. Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic review and meta-analysis. J Hypertens. 2020;38(9):1659–1668. doi:10.1097/HJH.0000000000002446 20. Isaac Derick K, Khan Z. Prevalence, Awareness, Treatment, Control of Hypertension, and Availability of Hypertension Services for Patients Living With Human Immunodeficiency Virus (HIV) in Sub- Saharan Africa (SSA): A Systematic Review and Meta-analysis. Cureus. 2023;15(4):e37422. doi: 10.7759/ cureus.37422 21. Chang D, Esber A, Dear N et al. Non-communicable diseases in older people living with HIV in four African countries: a cohort study. Lancet HIV. 2022;9 Suppl 1:S5. doi:10.1016/S2352-3018(22)00070-4 22. Moyo-Chilufya M, Maluleke K, Kgarosi K, Muyoyeta M, Hongoro C, Musekiwa A. The burden of non- communicable diseas",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 47
  },
  {
    "chunk_id": "hivservice_1533",
    "text": "ncet HIV. 2022;9 Suppl 1:S5. doi:10.1016/S2352-3018(22)00070-4 22. Moyo-Chilufya M, Maluleke K, Kgarosi K, Muyoyeta M, Hongoro C, Musekiwa A. The burden of non- communicable diseases among people living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis. EClinicalMedicine. 2023;65:102255. doi: 10.1016/j.eclinm.2023.102255 23. Tegegne KD, Adela GA, Kassie GA et al. Prevalence and factors associated with hypertension among peoples living with HIV in East Africa, a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):724. doi:10.1186/s12879-023-08679-x 24. Gizamba JM, Davies J, Africa C et al. Prevalence of obesity, hypertension and diabetes among people living with HIV in South Africa: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):861. doi:10.1186/s12879-023-08736-5 25. Le Tourneau N et al. Integration of HIV care and the adoption of hypert",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 47
  },
  {
    "chunk_id": "hivservice_1534",
    "text": "a: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):861. doi:10.1186/s12879-023-08736-5 25. Le Tourneau N et al. Integration of HIV care and the adoption of hypertension and diabetes services: a systematic review and meta-analysis. AIDS 2024 (submitted). 26. Muddu M, Tusubira AK, Sharma SK, Akiteng AR, Ssinabulya I, Schwartz JI. Integrated Hypertension and HIV Care Cascades in an HIV Treatment Program in Eastern Uganda: A Retrospective Cohort Study. J Acquir Immune Defic Syndr. 2019;81(5):552–561. doi:10.1097/QAI.0000000000002067 27. Gausi B, Berkowitz N, Jacob N, Oni T. Treatment outcomes among adults with HIV/non-communicable disease multimorbidity attending integrated care clubs in Cape Town, South Africa. AIDS Res Ther. 2021;18(1):72. doi:10.1186/s12981-021-00387-3 28. Walsh KF, Lee MH, Martelly S et al. Integrating hypertension services at an HIV clinic in Port-au-P",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 47
  },
  {
    "chunk_id": "hivservice_1535",
    "text": ", South Africa. AIDS Res Ther. 2021;18(1):72. doi:10.1186/s12981-021-00387-3 28. Walsh KF, Lee MH, Martelly S et al. Integrating hypertension services at an HIV clinic in Port-au-Prince, Haiti: A report from the field. J Clin Hypertens (Greenwich). 2018;20(10):1485–1492. doi: 10.1111/ jch.13392 29. Kimera ID, Namugenyi C, Schwartz JI et al. Integrated multi-month dispensing of antihypertensive and antiretroviral therapy to sustain hypertension and HIV control. J Hum Hypertens. 2023;37(3):213– 219. doi:10.1038/s41371-022-00655-3 30. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–610. doi:10.1016/S0140-6736(12)60987-8 31. Liu L, Christie S, Munsamy M et al. Title: Expansion of a national differentiated service delivery model to support people living with HIV and other chronic conditions in South Africa: a descriptive analysis. BMC Health",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 47
  },
  {
    "chunk_id": "hivservice_1536",
    "text": "le: Expansion of a national differentiated service delivery model to support people living with HIV and other chronic conditions in South Africa: a descriptive analysis. BMC Health Serv Res. 2021;21(1):463. doi: 10.1186/s12913-021-06450-z 32. Godongwana M, De Wet-Billings N, Milovanovic M. The comorbidity of HIV, hypertension and diabetes: a qualitative study exploring the challenges faced by healthcare providers and patients in selected urban and rural health facilities where the ICDM model is implemented in South Africa. BMC Health Serv Res. 2021;21(1):647. doi:10.1186/s12913-021-06670-3",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 47
  },
  {
    "chunk_id": "hivservice_1537",
    "text": "36 WHO guideline on HIV service delivery 33. Gooden TE, Mkhoi ML, Mdoe M et al. Barriers and facilitators of people living with HIV receiving optimal care for hypertension and diabetes in Tanzania: a qualitative study with healthcare professionals and people living with HIV. BMC Public Health. 2023;23(1):2235. doi: 10.1186/s12889-023- 17069-6 34. Badacho AS, Mahomed OH. Facilitators and barriers to integration of noncommunicable diseases with HIV care at primary health care in Ethiopia: a qualitative analysis using CFIR. Front Public Health. 2023;11:1247121. doi:10.3389/fpubh.2023.1247121 35. McCombe G, Murtagh S, Lazarus JV et al. Integrating diabetes, hypertension and HIV care in sub- Saharan Africa: a Delphi consensus study on international best practice. BMC Health Serv Res. 2021;21(1):1235. doi:10.1186/s12913-021-07073-0 36. Shiri T, Birungi J, Garrib AV et al. Patient and health pr",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 48
  },
  {
    "chunk_id": "hivservice_1538",
    "text": " consensus study on international best practice. BMC Health Serv Res. 2021;21(1):1235. doi:10.1186/s12913-021-07073-0 36. Shiri T, Birungi J, Garrib AV et al. Patient and health provider costs of integrated HIV, diabetes and hypertension ambulatory health services in low-income settings - an empirical socio-economic cohort study in Tanzania and Uganda. BMC Med. 2021;19(1):230. doi: 10.1186/s12916-021-02094-2 37. Ninsiima M, Basu S, Husain MJ et al. Cost analysis of adding hypertension and diabetes management into routine HIV care in Mbarara and Ibanda districts, Uganda. BMC Health Serv Res. 2024;24(1):1392. doi:10.1186/s12913-024-11825-z 38. WHO guideline on HIV service delivery. Web annex C: client preferences survey. Geneva: World Health Organization; 2025. 39. Singh S, Kirk O, Jaffar S et al. Patient perspectives on integrated healthcare for HIV, hypertension and type 2 diabetes: a sc",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 48
  },
  {
    "chunk_id": "hivservice_1539",
    "text": " survey. Geneva: World Health Organization; 2025. 39. Singh S, Kirk O, Jaffar S et al. Patient perspectives on integrated healthcare for HIV, hypertension and type 2 diabetes: a scoping review. BMJ Open. 2021;11(11):e054629. doi: 10.1136/bmjopen-2021-054629 40. Shayo EH, Murdoch J, Kiwale Z et al. Management of chronic conditions in resource limited settings: multi stakeholders' perception and experiences with receiving and providing integrated HIV, diabetes and hypertension services in Tanzania. BMC Health Serv Res. 2023;23(1):1120. doi: 10.1186/s12913- 023-10123-4 41. Hu FH, Liu P , Jia YJ et al. Prevalence of mental health problems in people living with HIV: a systematic review and meta-analysis. Psychol Health Med. 2025;30(3):397–413. doi:10.1080/13548506.2024.2424998 42. Rezaei S, Ahmadi S, Rahmati J et al. Global prevalence of depression in HIV/AIDS: a systematic review and meta-an",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 48
  },
  {
    "chunk_id": "hivservice_1540",
    "text": "lth Med. 2025;30(3):397–413. doi:10.1080/13548506.2024.2424998 42. Rezaei S, Ahmadi S, Rahmati J et al. Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis. BMJ Support Palliat Care. Dec 2019;9(4):404–412. doi: 10.1136/ bmjspcare-2019-001952 43. Rahmati J, Ahmadi S, Rezaei S et al. The worldwide prevalence of anxiety in acquired immune deficiency syndrome patients: A systematic review and meta-analysis. Med J Islam Repub Iran. 2021;35:101. doi:10.47176/mjiri.35.101 44. Too EK, Abubakar A, Nasambu C et al. Prevalence and factors associated with common mental disorders in young people living with HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2021;24 Suppl 2(Suppl 2):e25705. doi:10.1002/jia2.25705 45. Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. Su",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 48
  },
  {
    "chunk_id": "hivservice_1541",
    "text": "):e25705. doi:10.1002/jia2.25705 45. Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. Subst Abuse Treat Prev Policy. 2019;14(1):52. doi:10.1186/s13011-019-0240-3 46. Armoon B, Fleury MJ, Bayat AH et al. HIV related stigma associated with social support, alcohol use disorders, depression, anxiety, and suicidal ideation among people living with HIV: a systematic review and meta-analysis. Int J Ment Health Syst. 2022;16(1):17. doi:10.1186/s13033-022-00527-w 47. Huang B, Younger A, Gallant MP , O'Grady TJ. Depressive Symptoms and HIV Viral Suppression: A Systematic Review and Meta-analysis. AIDS Behav. 2025;29(3):870–883. doi: 10.1007/s10461-024- 04571-0 48. WHO guideline on HIV service delivery. Web Annex B. Systematic review abstracts and GRADE evidence profiles. Geneva: World Health Organization; 2",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 48
  },
  {
    "chunk_id": "hivservice_1542",
    "text": "i: 10.1007/s10461-024- 04571-0 48. WHO guideline on HIV service delivery. Web Annex B. Systematic review abstracts and GRADE evidence profiles. Geneva: World Health Organization; 2025. 49. Bengtson AM, Filipowicz TR, Mphonda S et al. An Intervention to Improve Mental Health and HIV Care Engagement Among Perinatal Women in Malawi: A Pilot Randomized Controlled Trial. AIDS Behav. 2023;27(11):3559–3570. doi:10.1007/s10461-023-04070-8",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 48
  },
  {
    "chunk_id": "hivservice_1543",
    "text": "37References 50. Wagner GJ, Gwokyalya V, Faherty L et al. Effects of M-DEPTH Model of Depression Care on Maternal HIV Viral Suppression and Adherence to the PMTCT Care Continuum Among HIV-Infected Pregnant Women in Uganda: Results from a Cluster Randomized Controlled Trial at Pregnancy Completion. AIDS Behav. 2023;27(9):2902–2914. doi:10.1007/s10461-023-04014-2 51. Abas M, Nyamayaro P , Bere T et al. Feasibility and Acceptability of a Task-Shifted Intervention to Enhance Adherence to HIV Medication and Improve Depression in People Living with HIV in Zimbabwe, a Low Income Country in Sub-Saharan Africa. AIDS Behav. 2018;22(1):86–101. doi: 10.1007/s10461-016- 1659-4 52. Dow DE, Mmbaga BT, Gallis JA et al. A group-based mental health intervention for young people living with HIV in Tanzania: results of a pilot individually randomized group treatment trial. BMC Public Health. 2020;20(1):1358",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 49
  },
  {
    "chunk_id": "hivservice_1544",
    "text": "-based mental health intervention for young people living with HIV in Tanzania: results of a pilot individually randomized group treatment trial. BMC Public Health. 2020;20(1):1358. doi:10.1186/s12889-020-09380-3 53. Nakimuli-Mpungu E, Musisi S, Wamala K et al. Effectiveness and cost-effectiveness of group support psychotherapy delivered by trained lay health workers for depression treatment among people with HIV in Uganda: a cluster-randomised trial. Lancet Glob Health. 2020;8(3):e387–e398. doi: 10.1016/ S2214-109X(19)30548-0 54. Simms V, Weiss HA, Chinoda S et al. Peer-led counselling with problem discussion therapy for adolescents living with HIV in Zimbabwe: A cluster-randomised trial. PLoS Med. 2022;19(1):e1003887. doi:10.1371/journal.pmed.1003887 55. Kaaya S, Siril H, Fawzi MCS et al. A peer-facilitated psychological group intervention for perinatal women living with HIV and depres",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 49
  },
  {
    "chunk_id": "hivservice_1545",
    "text": "e1003887. doi:10.1371/journal.pmed.1003887 55. Kaaya S, Siril H, Fawzi MCS et al. A peer-facilitated psychological group intervention for perinatal women living with HIV and depression in Tanzania-Healthy Options: A cluster-randomized controlled trial. PLoS Med. 2022;19(12):e1004112. doi:10.1371/journal.pmed.1004112 56. Ndenkeh JJN, Nji AM, Yumo HA, Rothe C, Kroidl A. Depression management and antiretroviral treatment outcome among people living with HIV in Northwest and East regions of Cameroon. BMC Infect Dis. 2022;22(1):732. doi:10.1186/s12879-022-07711-w 57. Ross R, Sawatphanit W, Suwansujarid T, Stidham AW, Drew BL, Creswell JW. The effect of telephone support on depressive symptoms among HIV-infected pregnant women in Thailand: an embedded mixed methods study. J Assoc Nurses AIDS Care. 2013;24(5):e13–24. doi: 10.1016/j.jana.2012.08.005 58. Rotheram-Borus MJ, Richter LM, van Heerden",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 49
  },
  {
    "chunk_id": "hivservice_1546",
    "text": "nant women in Thailand: an embedded mixed methods study. J Assoc Nurses AIDS Care. 2013;24(5):e13–24. doi: 10.1016/j.jana.2012.08.005 58. Rotheram-Borus MJ, Richter LM, van Heerden A et al. A cluster randomized controlled trial evaluating the efficacy of peer mentors to support South African women living with HIV and their infants. PLoS One. 2014;9(1):e84867. doi:10.1371/journal.pone.0084867 59. Han S, Hu Y, Lu H et al. Cognitive behavioral therapy for persons living with HIV in China: A randomized pilot trial. J Affect Disord. 2020;277:640–648. doi: 10.1016/j.jad.2020.08.085 60. Han S, Hu Y, Relf MV et al. Effects of Nurse-Delivered Cognitive Behavioral Intervention on Depression and Anxiety for Persons Living With HIV in China: A Clinical Controlled Trial. J Assoc Nurses AIDS Care. 2021;32(1):79–93. doi:10.1097/JNC.0000000000000213 61. Nyongesa MK, Mwangome E, Mwangi P et al. Adaptatio",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 49
  },
  {
    "chunk_id": "hivservice_1547",
    "text": " With HIV in China: A Clinical Controlled Trial. J Assoc Nurses AIDS Care. 2021;32(1):79–93. doi:10.1097/JNC.0000000000000213 61. Nyongesa MK, Mwangome E, Mwangi P et al. Adaptation, acceptability and feasibility of Problem Management Plus (PM+) intervention to promote the mental health of young people living with HIV in Kenya: formative mixed-methods research. BJPsych Open. 2022;8(5):e161. doi: 10.1192/bjo.2022.564 62. Simms V, Abas MA, Muller M et al. Effect of a brief psychological intervention for common mental disorders on HIV viral suppression: A non-randomised controlled study of the Friendship Bench in Zimbabwe. PLOS Glob Public Health. 2024;4(1):e0001492. doi:10.1371/journal.pgph.0001492 63. Madhombiro M, Kidd M, Dube B et al. Effectiveness of a psychological intervention delivered by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster rando",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 49
  },
  {
    "chunk_id": "hivservice_1548",
    "text": " M, Kidd M, Dube B et al. Effectiveness of a psychological intervention delivered by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster randomized controlled trial. J Int AIDS Soc. 2020;23(12):e25641. doi: 10.1002/jia2.25641 64. Wandera B, Tumwesigye NM, Nankabirwa JI et al. Efficacy of a Single, Brief Alcohol Reduction Intervention among Men and Women Living with HIV/AIDS and Using Alcohol in Kampala, Uganda: A Randomized Trial. J Int Assoc Provid AIDS Care. 2017;16(3):276–285. doi:10.1177/2325957416649669 65. Gandhi AR, Hyle EP , Scott JA et al. The Clinical Impact and Cost-Effectiveness of Clinic-Based Cognitive Behavioral Therapy for People With HIV, Depression, and Virologic Failure in South Africa. J Acquir Immune Defic Syndr. 2023;93(4):333–342. doi: 10.1097/QAI.0000000000003205",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 49
  },
  {
    "chunk_id": "hivservice_1549",
    "text": "38 WHO guideline on HIV service delivery 66. WHO Menu of cost-effective interventions for mental health. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240031081 , accessed 3 July 2025). 67. Chisholm D, Sweeny K, Sheehan P et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3(5):415–424. doi:10.1016/S2215- 0366(16)30024-4 68. Rutakumwa R, Ssebunnya J, Mugisha J et al. Stakeholders' perspectives on integrating the management of depression into routine HIV care in Uganda: qualitative findings from a feasibility study. Int J Ment Health Syst. 2021;15(1):63. doi:10.1186/s13033-021-00486-8 69. Sorsdahl K, Naledi T, Lund C et al. Integration of mental health counselling into chronic disease services at the primary health care level: Formative research on dedicated versus designated strategi",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 50
  },
  {
    "chunk_id": "hivservice_1550",
    "text": "T, Lund C et al. Integration of mental health counselling into chronic disease services at the primary health care level: Formative research on dedicated versus designated strategies in the Western Cape, South Africa. J Health Serv Res Policy. 2021;26(3):172–179. doi:10.1177/1355819620954232 70. Integration of noncommunicable diseases into HIV service packages [technical brief]. Geneva: World Health Organization; 2023 (https://iris.who.int/bitstream/handle/10665/367861/9789240073470-eng. pdf?sequence=1, accessed 3 July 2025). 71. Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes [implementation guidance]. Geneva: World Health Organization; 2023 (https://iris.who.int/bitstream/handle/10665/366691/9789240061682-eng. pdf?sequence=1&isAllowed=y , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 72. ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 50
  },
  {
    "chunk_id": "hivservice_1551",
    "text": "lth Organization; 2023 (https://iris.who.int/bitstream/handle/10665/366691/9789240061682-eng. pdf?sequence=1&isAllowed=y , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 72. Integration of mental health and HIV interventions: key considerations. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2022 ( https://iris.who.int/bitstream/hand le/10665/353571/9789240043176-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 73. mhGAP operations manual. Geneva: World Health Organization; 2018 ( https://iris.who.int/ handle/10665/275386, accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 74. Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization; 2021 (https://iris.who.int/bitstream/handle/10665/344424/9789240033986-eng.pdf , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 75. WHO ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 50
  },
  {
    "chunk_id": "hivservice_1552",
    "text": "s. Geneva: World Health Organization; 2021 (https://iris.who.int/bitstream/handle/10665/344424/9789240033986-eng.pdf , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 75. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva: World Health Organization; 2020 ( https://iris.who.int/bitstream/hand le/10665/334186/9789240009226-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 76. Management of physical health conditions in adults with severe mental disorders. Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/978-92-4-155038-3 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 77. Mental Health, Brain Health and Substance Use. Geneva: World Health Organization; 2025 ( https:// www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action- programme, acces",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 50
  },
  {
    "chunk_id": "hivservice_1553",
    "text": "th and Substance Use. Geneva: World Health Organization; 2025 ( https:// www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action- programme, accessed 3 July 2025). 78. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 ( https://iris. who.int/bitstream/handle/10665/342899/9789240031593-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 79. Global action plan for the prevention and control of noncommunicable diseases 2013–2020 (extended to 2030). Geneva: World Health Organization; 2013 ( https://iris.who.int/bitstream/ handle/10665/94384/9789241506236_eng.pdf?sequence=1 , accessed 3 July 2025). 80. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020 (https",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 50
  },
  {
    "chunk_id": "hivservice_1554",
    "text": "0665/94384/9789241506236_eng.pdf?sequence=1 , accessed 3 July 2025). 80. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020 (https://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 81. Healthy diet. Cairo: WHO Regional Office for the Eastern Mediterranean; 2019 ( https://iris.who.int/ bitstream/handle/10665/325828/EMROPUB_2019_en_23536.pdf , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 50
  },
  {
    "chunk_id": "hivservice_1555",
    "text": "39References 82. WHO Clinical Treatment Guideline for Tobacco Cessation in Adults. Geneva: World Health Organization; 2024 (https://www.who.int/publications/i/item/9789240096431 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 83. HEARTS: Technical package for cardiovascular disease management in primary health care: risk-based CVD management. Geneva: World Health Organization; 2020 ( https://www.who.int/ publications/i/item/9789240001367, accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO 84. WHO framework for meaningful engagement of people living with noncommunicable diseases, and mental health and neurological conditions. Geneva: World Health Organization; 2023 ( https://www. who.int/publications/i/item/9789240073074, accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 85. WHO community engagement framework for quality, people-centred and resilient health services. Geneva: Wo",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 51
  },
  {
    "chunk_id": "hivservice_1556",
    "text": "tem/9789240073074, accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 85. WHO community engagement framework for quality, people-centred and resilient health services. Geneva: World Health Organization; 2017 (https://iris.who.int/bitstream/handle/10665/259280/WHO- HIS-SDS-2017.15-eng.pdf, accessed 3 July 2025). Licence: CC BY NC-SA 3.0 IGO. 86. Primary health care and HIV: convergent actions. Policy considerations for decision-makers. Geneva: World Health Organization; 2023 ( https://www.who.int/publications/i/item/9789240077065 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO 87. Primary Health Care for Global Health Initiatives Toolbox [portal]. Universal Health Coverage Partnership. Geneva: World Health Organization; 2021 ( https://extranet.who.int/uhcpartnership/ primary-health-care-global-health-initiatives-toolbox , accessed 3 July 2025). 88. Consolidated guidelines on HIV p",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 51
  },
  {
    "chunk_id": "hivservice_1557",
    "text": "th Organization; 2021 ( https://extranet.who.int/uhcpartnership/ primary-health-care-global-health-initiatives-toolbox , accessed 3 July 2025). 88. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 ( https://iris. who.int/bitstream/handle/10665/342899/9789240031593-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 89. HIV - Elimination of mother-to-child transmission [dataset]. New York: United Nations Children's Fund; 2024 (https://data.unicef.org/topic/hivaids/emtct/, accessed 3 July 2025). 90. Ma Q, Tso LS, Rich ZC et al. Barriers and facilitators of interventions for improving antiretroviral therapy adherence: a systematic review of global qualitative evidence. J Int AIDS Soc. 2016;19(1):21166. doi:10.7448/IAS.19.1.21166 91. Gumed",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 51
  },
  {
    "chunk_id": "hivservice_1558",
    "text": "rventions for improving antiretroviral therapy adherence: a systematic review of global qualitative evidence. J Int AIDS Soc. 2016;19(1):21166. doi:10.7448/IAS.19.1.21166 91. Gumede SB, de Wit JBF, Venter WDF, Wensing AMJ, Lalla-Edward ST. Intervention strategies to improve adherence to treatment for selected chronic conditions in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2024;27(6):e26266. doi:10.1002/jia2.26266 92. Ahmed A, Dujaili JA, Chuah LH et al. Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models. Appl Health Econ Health Policy. 2023;21(5):731–750. doi:10.1007/s40258-023-00818-4 93. Patel AR, Kessler J, Braithwaite RS et al. Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya. Medicine (Baltimore). 2017;96(7):e6078. doi:10.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 51
  },
  {
    "chunk_id": "hivservice_1559",
    "text": ", Braithwaite RS et al. Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya. Medicine (Baltimore). 2017;96(7):e6078. doi:10.1097/MD.0000000000006078 94. Mudavanhu M, West NS, Schwartz SR et al. Perceptions of Community and Clinic-Based Adherence Clubs for Patients Stable on Antiretroviral Treatment: A Mixed Methods Study. AIDS Behav. 2020;24(4):1197–1206. doi:10.1007/s10461-019-02681-8 95. Roberts ST, Mancuso N, Williams K et al. How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis. J Int AIDS Soc. 2023;26(11):e26189. doi: 10.1002/jia2.26189 96. Bernays S, Tshuma M, Willis N et al. Scaling up peer-led community-based differentiated support for adolescents living with HIV: keeping the needs of youth peer ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 51
  },
  {
    "chunk_id": "hivservice_1560",
    "text": "002/jia2.26189 96. Bernays S, Tshuma M, Willis N et al. Scaling up peer-led community-based differentiated support for adolescents living with HIV: keeping the needs of youth peer supporters in mind to sustain success. J Int AIDS Soc. 2020;23 Suppl 5(Suppl 5):e25570. doi: 10.1002/jia2.25570 97. Kitetele FN, Lelo GM, Akele CE et al. \"The Peer Educator Is the Game-Changer of My Life\": Perceptions of Adolescents Living with HIV in DR Congo on Involving Peer Educators in the Process of HIV Disclosure. Children (Basel). 2022;9(8)doi:10.3390/children9081239 98. Lejone TI, Kopo M, Bachmann N et al. PEBRA trial – effect of a peer-educator coordinated preference- based ART service delivery model on viral suppression among adolescents and young adults living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho. BMC Public Health. 2020;20(1):425. doi:10.1186/s12889-020-08535-6",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 51
  },
  {
    "chunk_id": "hivservice_1561",
    "text": "40 WHO guideline on HIV service delivery 99. Merrill KG, Frimpong C, Burke VM et al. \"Project YES! has given me a task to reach undetectable\": Qualitative findings from a peer mentoring program for youth living with HIV in Zambia. PLoS One. 2023;18(10):e0292719. doi:10.1371/journal.pone.0292719 100. Rencken CA, Harrison AD, Mtukushe B et al. \"Those People Motivate and Inspire Me to Take My Treatment.\" Peer Support for Adolescents Living With HIV in Cape Town, South Africa. J Int Assoc Provid AIDS Care. 2021;20:23259582211000525. doi: 10.1177/23259582211000525 101. Helova A, Onono M, Abuogi LL et al. Experiences, perceptions and potential impact of community- based mentor mothers supporting pregnant and postpartum women with HIV in Kenya: a mixed- methods study. J Int AIDS Soc. 2021;24(11):e25843. doi: 10.1002/jia2.25843 102. Odiachi A, Al-Mujtaba M, Torbunde N et al. Acceptability of men",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 52
  },
  {
    "chunk_id": "hivservice_1562",
    "text": "um women with HIV in Kenya: a mixed- methods study. J Int AIDS Soc. 2021;24(11):e25843. doi: 10.1002/jia2.25843 102. Odiachi A, Al-Mujtaba M, Torbunde N et al. Acceptability of mentor mother peer support for women living with HIV in North-Central Nigeria: a qualitative study. BMC Pregnancy Childbirth. 2021;21(1):545. doi:10.1186/s12884-021-04002-1 103. Wanga I, Helova A, Abuogi LL et al. Acceptability of community-based mentor mothers to support HIV-positive pregnant women on antiretroviral treatment in western Kenya: a qualitative study. BMC Pregnancy Childbirth. 2019;19(1):288. doi:10.1186/s12884-019-2419-z 104. Magidson JF, Joska JA, Belus JM et al. Project Khanya: results from a pilot randomized type 1 hybrid effectiveness-implementation trial of a peer-delivered behavioural intervention for ART adherence and substance use in HIV care in South Africa. J Int AIDS Soc. 2021;24 Suppl 2(",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 52
  },
  {
    "chunk_id": "hivservice_1563",
    "text": "id effectiveness-implementation trial of a peer-delivered behavioural intervention for ART adherence and substance use in HIV care in South Africa. J Int AIDS Soc. 2021;24 Suppl 2(Suppl 2):e25720. doi:10.1002/jia2.25720 105. Rocha-Jimenez T, Pitpitan EV, Cazares R, Smith LR. \"He is the Same as Me\": Key Populations' Acceptability and Experience of a Community-Based Peer Navigator Intervention to Support Engagement in HIV Care in Tijuana, Mexico. AIDS Patient Care STDS. 2021;35(11):449–456. doi:10.1089/apc.2021.0069 106. Ruan Y, Xiao X, Chen J, Li X, Williams AB, Wang H. Acceptability and efficacy of interactive short message service intervention in improving HIV medication adherence in Chinese antiretroviral treatment-naive individuals. Patient Prefer Adherence. 2017;11:221–228. doi: 10.2147/PPA.S120003 107. Aunon FM, Wanje G, Richardson BA et al. Randomized controlled trial of a theory-i",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 52
  },
  {
    "chunk_id": "hivservice_1564",
    "text": "atment-naive individuals. Patient Prefer Adherence. 2017;11:221–228. doi: 10.2147/PPA.S120003 107. Aunon FM, Wanje G, Richardson BA et al. Randomized controlled trial of a theory-informed mHealth intervention to support ART adherence and viral suppression among women with HIV in Mombasa, Kenya: preliminary efficacy and participant-level feasibility and acceptability. BMC Public Health. 2023;23(1):837. doi:10.1186/s12889-023-15638-3 108. Endebu T, Deksisa A, Dugasa W, Mulu E, Bogale T. Acceptability and feasibility of short message service to improve ART medication adherence among people living with HIV/AIDS receiving antiretroviral treatment at Adama hospital medical college, Central Ethiopia. BMC Public Health. 2019;19(1):1315. doi:10.1186/s12889-019-7687-z 109. Georgette N, Siedner MJ, Zanoni B et al. The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promot",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 52
  },
  {
    "chunk_id": "hivservice_1565",
    "text": ". 2019;19(1):1315. doi:10.1186/s12889-019-7687-z 109. Georgette N, Siedner MJ, Zanoni B et al. The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promote HIV Antiretroviral Medication Adherence in KwaZulu-Natal, South Africa. AIDS Behav. 2016;20(11):2629–2638. doi: 10.1007/s10461-016-1287-z 110. Krishnan A, Weikum D, Cravero C, Kamarulzaman A, Altice FL. Assessing mobile technology use and mHealth acceptance among HIV-positive men who have sex with men and transgender women in Malaysia. PLoS One. 2021;16(3):e0248705. doi:10.1371/journal.pone.0248705 111. O'Connor C, Leyritana K, Doyle AM, Lewis JJ, Gill R, Salvana EM. Interactive Mobile Phone HIV Adherence Support for Men Who Have Sex With Men in the Philippines Connect for Life Study: Mixed Methods Approach to Intervention Development and Pilot Testing. JMIR Form Res. 2022;6(2):e30811. doi:10.2196/30811 112. ",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 52
  },
  {
    "chunk_id": "hivservice_1566",
    "text": "x With Men in the Philippines Connect for Life Study: Mixed Methods Approach to Intervention Development and Pilot Testing. JMIR Form Res. 2022;6(2):e30811. doi:10.2196/30811 112. Adhiambo HF, Mwamba C, Lewis-Kulzer J et al. Enhancing engagement in HIV care among adolescents and young adults: A focus on phone-based navigation and relationship building to address barriers in HIV care. PLOS Glob Public Health. 2025;5(1):e0002830. doi: 10.1371/journal.pgph.0002830 113. Cele MA, Archary M. Acceptability of short text messages to support treatment adherence among adolescents living with HIV in a rural and urban clinic in KwaZulu-Natal. South Afr J HIV Med. 2019;20(1):976. doi:10.4102/sajhivmed.v20i1.976",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 52
  },
  {
    "chunk_id": "hivservice_1567",
    "text": "41References 114. Chory A, Callen G, Nyandiko W et al. A Pilot Study of a Mobile Intervention to Support Mental Health and Adherence Among Adolescents Living with HIV in Western Kenya. AIDS Behav. 2022;26(1):232–242. doi:10.1007/s10461-021-03376-9 115. MacCarthy S, Wagner Z, Mendoza-Graf A et al. A randomized controlled trial study of the acceptability, feasibility, and preliminary impact of SITA (SMS as an Incentive To Adhere): a mobile technology-based intervention informed by behavioral economics to improve ART adherence among youth in Uganda. BMC Infect Dis. 2020;20(1):173. doi:10.1186/s12879-020-4896-0 116. Taiwo BO, Kuti KM, Kuhns LM et al. Effect of Text Messaging Plus Peer Navigation on Viral Suppression Among Youth With HIV in the iCARE Nigeria Pilot Study. J Acquir Immune Defic Syndr. 2021;87(4):1086– 1092. doi:10.1097/QAI.0000000000002694 117. Simpson N, Kydd A, Phiri M et al.",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 53
  },
  {
    "chunk_id": "hivservice_1568",
    "text": "n Among Youth With HIV in the iCARE Nigeria Pilot Study. J Acquir Immune Defic Syndr. 2021;87(4):1086– 1092. doi:10.1097/QAI.0000000000002694 117. Simpson N, Kydd A, Phiri M et al. Insaka: mobile phone support groups for adolescent pregnant women living with HIV. BMC Pregnancy Childbirth. 2021;21(1):663. doi: 10.1186/s12884-021-04140-6 118. Rosen S, Grimsrud A, Ehrenkranz P , Katz I. Models of service delivery for optimizing a patient's first six months on antiretroviral therapy for HIV: an applied research agenda. Gates Open Res. 2020;4:116. doi:10.12688/gatesopenres.13159.1 119. Adolescent-friendly health services for adolescents living with HIV: from theory to practice [technical brief]. Geneva: World Health Organization; 2019 ( https://iris.who.int/bitstream/handle/10665/329993/ WHO-CDS-HIV-19.39-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 120. Recommend",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 53
  },
  {
    "chunk_id": "hivservice_1569",
    "text": " Organization; 2019 ( https://iris.who.int/bitstream/handle/10665/329993/ WHO-CDS-HIV-19.39-eng.pdf?sequence=1 , accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 120. Recommendations on digital interventions for health system strengthening [guideline]. Geneva: World Health Organization; 2019 (https://www.who.int/publications/i/item/9789241550505/, accessed 3 July 2025). Licence: CC BY-NC-SA 3.0 IGO. 121. Osingada CP , McMorris BJ, Tracy MF, Nakasujja N, Ngabirano TD, Porta CM. Patient perceptions and predictors of intention to use telehealth for follow-up care: a mixed methods study among adults living with HIV in Kampala, Uganda. BMC Health Serv Res. 2025;25(1):490. doi: 10.1186/s12913-025- 12636-6 122. What we do [network portal]. New York: ICAP at Columbia University/The CQUIN Network; 2025 (https://cquin.icap.columbia.edu/about-cquin/what-we-do/, accessed 3 July 2025). 123. Guyat",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 53
  },
  {
    "chunk_id": "hivservice_1570",
    "text": "at we do [network portal]. New York: ICAP at Columbia University/The CQUIN Network; 2025 (https://cquin.icap.columbia.edu/about-cquin/what-we-do/, accessed 3 July 2025). 123. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD 124. Loudon K, Treweek S, Sullivan F, Donnan P , Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. doi:10.1136/bmj.h2147 125. Guyatt GH, Oxman AD, Kunz R et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400. doi: 10.1016/j.jclinepi.2010.09.012",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 53
  },
  {
    "chunk_id": "hivservice_1571",
    "text": "Global HIV, Hepatitis and Sexually Transmitted Infections Programmes World Health Organization 20 Avenue Appia 1211 Geneva 27 Switzerland www.who.int",
    "source": "WHO Hivservice Guideline",
    "topic": "hivservice",
    "page": 56
  },
  {
    "chunk_id": "infertility_1572",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 1
  },
  {
    "chunk_id": "infertility_1573",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 3
  },
  {
    "chunk_id": "infertility_1574",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility ii Guideline for the prevention, diagnosis and treatment of infertility ISBN 978-92-4-011577-4 (electronic version) ISBN 978-92-4-011578-1 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo ). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons lice",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 4
  },
  {
    "chunk_id": "infertility_1575",
    "text": "anization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ( http://www.wipo.int/amc/en/mediation/rules/ ). Suggested citation . Guideline for the prevention, diagnosis and treatment of infertility. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 4
  },
  {
    "chunk_id": "infertility_1576",
    "text": "diation/rules/ ). Suggested citation . Guideline for the prevention, diagnosis and treatment of infertility. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/ . Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-orders . To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright . Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party- owned component in the work rests solely with the user. General disc",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 4
  },
  {
    "chunk_id": "infertility_1577",
    "text": "obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party- owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by i",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 4
  },
  {
    "chunk_id": "infertility_1578",
    "text": "ed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. Copy editing: Green Ink Design and layout: Lushomo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 4
  },
  {
    "chunk_id": "infertility_1579",
    "text": "iii Contents Foreword . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x Executive summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1.1 Epidemiology and global burden of infertility .............................................. 1 1.2 The need to strengthen global efforts to prevent, diagnose and treat in fertility ............... 4 2. Rationale and methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 5
  },
  {
    "chunk_id": "infertility_1580",
    "text": "l efforts to prevent, diagnose and treat in fertility ............... 4 2. Rationale and methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 2.1 Rationale .............................................................................. 12 2.2 Goals and objectives ................................................................... 12 2.3 Scope ................................................................................. 13 2.4 Target audience ....................................................................... 14 2.5 Guiding principles ..................................................................... 14 2.6 Methods .............................................................................. 15 3. Approach to evaluation and management of infertility . . . . . . . . . . . . . . . . . . . . . 21 3.1 Objective .................................",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 5
  },
  {
    "chunk_id": "infertility_1581",
    "text": "............................ 15 3. Approach to evaluation and management of infertility . . . . . . . . . . . . . . . . . . . . . 21 3.1 Objective .............................................................................. 22 3.2 Indication .............................................................................. 22 3.3 Elements of evaluation and management ................................................. 22 4. Prevention of infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 4.1 Information provision on fertility and infertility for the general po pulation ................... 31 4.2 Information provision for individuals and couples with infertility ............................ 37 4.3 Risk reduction from the use of tobacco ................................................... 41 4.4 Risk reduction from sexually transmitted infections ..",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 5
  },
  {
    "chunk_id": "infertility_1582",
    "text": ".................... 37 4.3 Risk reduction from the use of tobacco ................................................... 41 4.4 Risk reduction from sexually transmitted infections ....................................... 47 5. Diagnosis of infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 5.1 Diagnosis of infertility due to ovulatory dysfunction ....................................... 52 5.2 Confirmation of ovulation ............................................................... 52 5.3 Assessment of reproductive hormones .................................................. 61 5.4 Assessment of ovarian reserve .......................................................... 68 5.5 Diagnosis of infertility due to tubal disease ............................................... 76 5.6 Diagnosis of infertility due to uterine cavity disorder ...............",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 5
  },
  {
    "chunk_id": "infertility_1583",
    "text": " 68 5.5 Diagnosis of infertility due to tubal disease ............................................... 76 5.6 Diagnosis of infertility due to uterine cavity disorder ...................................... 82 5.7 Diagnosis of infertility due to male factors ............................................... 107 5.8 Diagnosis of unexplained infertility ..................................................... 116 6. Treatment of infertility due to ovulatory dysfunction . . . . . . . . . . . . . . . . . . . . . .120 6.1 Treatment of infertility due to ovulatory dysfunction caused by PCOS ...................... 120",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 5
  },
  {
    "chunk_id": "infertility_1584",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility iv 7. Treatment of infertility due to tu bal disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143 7.1 Use of surgery or IVF for treatment of tubal disease ...................................... 143 7.2 Treatment of hydrosalpinx before IVF ................................................... 148 8. Treatment of infertility due to uterine cavity disorder . . . . . . . . . . . . . . . . . . . . . . 154 8.1 Management of uterine septum in females with infertility ................................. 154 9. Treatment of infertility due to mal e factors . . . . . . . . . . . . . . . . . . . . . . . . . . . .159 9.1 Use of antioxidants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .159 9.2 Treatment of varicocele .................",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 6
  },
  {
    "chunk_id": "infertility_1585",
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .159 9.2 Treatment of varicocele ................................................................ 163 10. Treatment of couples with unexplained infertility. . . . . . . . . . . . . . . . . . . . . . . . .181 10.1 First-line management of couples with unexplained infertility ............................. 181 10.2 Second-line management of couples with unexplained infertility .......................... 189 10.3 Third-line management of couples with unexplained infertility ............................ 196 11. Dissemination, lo cal adaptation, im plementation, monitoring and evaluation . . . . . . . 201 11.1 Dissemination ........................................................................ 201 11.2 Local adaptation .............................................",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 6
  },
  {
    "chunk_id": "infertility_1586",
    "text": " . . . . . . 201 11.1 Dissemination ........................................................................ 201 11.2 Local adaptation ..................................................................... 201 11.3 Implementation ...................................................................... 202 11.4 Monitoring and evaluation ............................................................ 202 12. Research gaps, future scope and updating the guideline . . . . . . . . . . . . . . . . . . . .204 12.1 Research gaps ....................................................................... 204 12.2 Future scope and updating this guideline ............................................... 205 Annex 1. Distribution of the causes of infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Annex 2. Members of the GDG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 6
  },
  {
    "chunk_id": "infertility_1587",
    "text": "the causes of infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Annex 2. Members of the GDG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212 Annex 3. Members of the ERG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214 Annex 4. Summary of declared interests from members of the GDG . . . . . . . . . . . . . . . . 217 Annex 5. Summary of declared interests from members of the ERG . . . . . . . . . . . . . . . . 220 Annex 6. Components of female medical history and physical examination . . . . . . . . . . . 224 Annex 7. Components of male medical history and physical examination . . . . . . . . . . . .231 Web Annex A. Evidence to decision tables for approach to the evaluation and management of infertility. https://doi.org/10.2471/B09575. Web Annex B. Evidence to decision tables for prevention of infertili",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 6
  },
  {
    "chunk_id": "infertility_1588",
    "text": "o decision tables for approach to the evaluation and management of infertility. https://doi.org/10.2471/B09575. Web Annex B. Evidence to decision tables for prevention of infertility. https://doi.org/10.2471/B09576. Web Annex C. Evidence to decision tables for diagnosis of infertility. https://doi.org/10.2471/B09577. Web Annex D. Evidence to decision tables for the treatment of infertility due to ovulatory dysfunction, tubal disease and uterine cavity disorder. https://doi.org/10.2471/B09589. Web Annex E. Evidence to decision tables for treatment of infertility due to male factors. https://doi.org/10.2471/B09578. Web Annex F. Evidence to decision tables for treatment of couples with unexplained infertility. https://doi.org/10.2471/B09579.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 6
  },
  {
    "chunk_id": "infertility_1589",
    "text": "v List of tables Table 1. Summary of recommendations and key guidance ......................................... xiii Table 2.1. Evidence to decision framework ....................................................... 17 Table 5.1. Test performance of a single mid-luteal progesterone test ............................... 55 Table 5.2. Absolute effects on 100 women when different combinations of mid-luteal progesterone test with or without ultrasound are provided .............................. 55 Table 5.3. Sensitivity and specificity for AFC, AMH and FSH ........................................ 70 Table 5.4. Absolute effects on 100 women when AFC, AMH and FSH are provided ................... 70 Table 5.5. Results for poor response from a systematic review ..................................... 70 Table 5.6. Sensitivity and specificity of HyCoSy and HSG ........................................",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 7
  },
  {
    "chunk_id": "infertility_1590",
    "text": "or poor response from a systematic review ..................................... 70 Table 5.6. Sensitivity and specificity of HyCoSy and HSG ........................................... 77 Table 5.7. Comparison of 3D US, SIS, 2D US and HSG with hysteroscopy for the diagnosis of uterine cavity disorders ............................................................. 82 Table 5.8. Sensitivity and specificity for 3D US and SIS with 95% CIs from one paired study ........... 85 Table 5.9. Studies comparing 3D US and SIS, and the conditions identified .......................... 85 Table 5.10. Sensitivity and specificity of 3D US and SIS with 95% CIs from unpaired studies ........... 86 Table 5.11. Included studies comparing 3D and 2D US, and the conditions identified ................. 90 Table 5.12. Pooled sensitivity and specificity for 3D and 2D US with 95% CIs ......................... 91 Table",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 7
  },
  {
    "chunk_id": "infertility_1591",
    "text": "ing 3D and 2D US, and the conditions identified ................. 90 Table 5.12. Pooled sensitivity and specificity for 3D and 2D US with 95% CIs ......................... 91 Table 5.13. Included studies comparing SIS and 2D US, and conditions identified .................... 95 Table 5.14. Pooled sensitivity and specificity for SIS and 2D US with 95% CIs ......................... 95 Table 5.15. Included studies comparing HSG and SIS, and conditions identified ..................... 100 Table 5.16. Pooled sensitivity and specificity for HSG and SIS with 95% CIs ......................... 100 Table 5.17. Included studies comparing 2D US and HSG, and conditions identified .................. 104 Table 5.18. Pooled sensitivity and specificity for 2D US and HSG, with 95% CIs from paired studies ... 104 Table A1.1. General categories of infertility (percentages of couples) .......................",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 7
  },
  {
    "chunk_id": "infertility_1592",
    "text": "nsitivity and specificity for 2D US and HSG, with 95% CIs from paired studies ... 104 Table A1.1. General categories of infertility (percentages of couples) ............................... 206 Table A1.2. Specific diagnoses of infertility (percentages of couples) ............................... 208 List of figures Fig. 1.1. Epidemiology and global burden of infertility .............................................. 2 Fig. 1.2. Addressing infertility is central to human rights and global health aspirations ................ 4 Fig. 2.1. Scope and audience .................................................................... 13 Fig. 2.2. Methodology for guideline development ................................................. 15 Fig. 3.1. Elements of evaluation and management ................................................ 22 Fig. 4.1. Information on fertility and infertility .................",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 7
  },
  {
    "chunk_id": "infertility_1593",
    "text": "........ 15 Fig. 3.1. Elements of evaluation and management ................................................ 22 Fig. 4.1. Information on fertility and infertility ..................................................... 32 Fig. 4.2. Recommendations for preventing infertility included in the guideline ....................... 34 Fig. 5.1. Diagnostic algorithm for female-factor and unexplained factor infertility .................... 53 Fig. 5.2. Diagnostic algorithm for the assessment of the uterine cavity .............................. 83 Fig. 5.3. Diagnostic algorithm for male-factor infertility ........................................... 108 Fig. 6.1. Management of anovulatory infertility due to PCOS ...................................... 120 Fig. 10.1. Treatment algorithm for unexplained infertility ......................................... 182 Fig. 12.1. The need to address critical resea",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 7
  },
  {
    "chunk_id": "infertility_1594",
    "text": "......................... 120 Fig. 10.1. Treatment algorithm for unexplained infertility ......................................... 182 Fig. 12.1. The need to address critical research gaps ............................................. 204 Fig. 12.2. Future guideline scope and updates. .................................................. 205 Fig. A1.1. Causes of infertility ................................................................... 208 Fig. A1.2. Specific diagnoses of infertility (male) .................................................. 210 Fig. A1.3. Specific diagnoses of infertility (female) ................................................ 210",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 7
  },
  {
    "chunk_id": "infertility_1595",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility vi Foreword This first WHO Guideline for the prevention, diagnosis and treatment of infertility is grounded in the principles of equity, scientific rigour and respect for human rights. This guideline responds to the urgent need for evidence-based, person-centred, and universally accessible services for managing infertility as an integral part of sexual and reproductive health. Fertility care – which includes prevention, diagnosis and treatment of infertility – should be accessible to all who need it without stigma or discrimination. The recommendations in this guideline are informed by the best available scientific evidence, generated through systematic reviews and robust evaluation of the benefits, harms, values, costs, feasibility and impact on equity. The guideline development process was multidisciplinary and inclus",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 8
  },
  {
    "chunk_id": "infertility_1596",
    "text": "systematic reviews and robust evaluation of the benefits, harms, values, costs, feasibility and impact on equity. The guideline development process was multidisciplinary and inclusive, drawing on the expertise of clinicians, researchers, policy-makers and – critically – the lived experiences of people impacted by infertility. Despite progress within sexual and reproductive health care, many countries still do not include the prevention, diagnosis or treatment of infertility in health policies, financing and services. There is also a pressing need for more research to better understand the epidemiology, causes and optimal management of infertility, with a particular focus on underserved and at-risk populations. This guideline covers multiple topics and provides guidance to facilitate the provision of safe and effective services in clinical settings. Of course, infertility also involves de",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 8
  },
  {
    "chunk_id": "infertility_1597",
    "text": "This guideline covers multiple topics and provides guidance to facilitate the provision of safe and effective services in clinical settings. Of course, infertility also involves decisions far beyond the clinic, including policy, social and non-clinical aspects, all of which must be addressed through evidence-informed interventions. The guideline calls for ongoing evidence generation to inform future editions so that fertility care continues to advance in line with scientific progress and the evolving needs of all people. By centring equity, science and the imperative to provide fertility care as part of universal health coverage, this guideline aims to support countries in delivering high-quality, equitable and effective health care for all. Dr Tedros Adhanom Ghebreyesus Director-General, World Health Organization",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 8
  },
  {
    "chunk_id": "infertility_1598",
    "text": "viiAcknowledgements Acknowledgements The World Health Organization (WHO) and the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) acknowledges the contributions of many individuals and organizations that supported the development of this guideline. Sincere thanks to the members of the Guideline Development Group (GDG): Richard Kennedy (Chair; Birmingham Women’s and Children’s NHS Foundation Trust, United Kingdom of Great Britain and Northern Ireland), Cynthia Farquhar (Co-Chair; Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand), Adam H. Bal en (Leeds Teaching Hospitals, Leeds, United Kingdom), Jacky Boivin (School of Psychology, Cardiff University, Cardiff, United Kingdom), Barbara L. Collura (RESOLVE: The National Infertility Association, McLean, United States of America [",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 9
  },
  {
    "chunk_id": "infertility_1599",
    "text": "ky Boivin (School of Psychology, Cardiff University, Cardiff, United Kingdom), Barbara L. Collura (RESOLVE: The National Infertility Association, McLean, United States of America [USA]), Ben Cohlen (Isala Fertility Centre, Zwolle, the Netherlands), Christopher J. De Jonge (University of Minnesota, Minneapolis, USA), Sandro C. Esteves (ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil), Klaudija Kordic (Fertility Europe [Pan-European organisation representing patients’ associations], Evere, Belgium), Linda C. Giudice (UCSF School of Medicine, San Francisco, USA), Luca Gianaroli (Reproductive Medicine Unit, SISMER, Bologna, Italy), Carin Huyser (Steve Biko Academic Hospital, University of Pretoria, South Africa), Dmitry Kissin (Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, USA), Tansu Kucuk (Department of Obstetrics and Gynaecology",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 9
  },
  {
    "chunk_id": "infertility_1600",
    "text": "ria, South Africa), Dmitry Kissin (Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, USA), Tansu Kucuk (Department of Obstetrics and Gynaecology, Acıbadem Maslak Hospital, Istanbul, Türkiye), Nalini Mahajan (Department of Reproductive Medicine, Mother and Child Hospital, New Delhi, India), Ragaa Mansour (The Egyptian IVF Center, Ma`adi, Cairo, Egypt), Alfred Murage (Aga Khan University Hospital, Nairobi, Kenya), Willem Ombelet (Genk Institute for Fertility Technology, Genk, Belgium), Allan Pacey (Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom), Guido Pennings (Department of Philosophy and Moral Sciences, Ghent University, Ghent, Belgium), Robert W. Rebar (Homer Stryker School of Medicine, Western Michigan University, Kalamazoo, USA), Richard Reindollar (Geisel School of Medicine, Dartmouth, USA), Roberta R",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 9
  },
  {
    "chunk_id": "infertility_1601",
    "text": "Belgium), Robert W. Rebar (Homer Stryker School of Medicine, Western Michigan University, Kalamazoo, USA), Richard Reindollar (Geisel School of Medicine, Dartmouth, USA), Roberta Rizzo (University of Ferrara, Ferrara, Italy), Rita Sembuya (Joyce Fertility Support Centre, Kampala, Uganda), Gamal Serour (Al Azhar University, Cairo, Egypt), Basil Tarlatzis (Aristotle University of Thessaloniki, Thessaloniki, Greece), Carla Tatone (University of L’Aquila, L’Aquila, Italy), Lan N. Vuong (University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam), Marie Lena Windt De Beer (Tygerberg Academic Hospital, Stellenbosch University, Cape Town, South Africa) and Cong Yali (Health Science Centre, Peking University, Beijing, China). Sincere thanks also to the following members of the External Review Group (ERG) , who peer-reviewed the following sections of the guideline. Introd",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 9
  },
  {
    "chunk_id": "infertility_1602",
    "text": "ing University, Beijing, China). Sincere thanks also to the following members of the External Review Group (ERG) , who peer-reviewed the following sections of the guideline. Introduction, methodology and approach to the evaluation and management of infertility: Julia Chain (Human Fertilization and Embryology Authority, London, United Kingdom), Muntaha Gharaibeh (Department of Maternal and Child Health, Jordan University of Science and Technology, Irbid, Jordan), Márcia C. Inhorn (Department of Anthropology, Yale University, New Haven, USA), Karla Torres (Centre for Reproductive Rights, New York, USA) and Sheryl Van der Poel (International Health Consultant, Geneva, Switzerland).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 9
  },
  {
    "chunk_id": "infertility_1603",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility viii Prevention of infertility: Ivonne J. Diaz Yamal (Department of Gynecology and Obstetrics, Central Military Hospital, Bogota, Colombia), Joyce Harper (Institute for Women’s Health, University College London, London, United Kingdom), Tamar Khomasuridze (eastern Europe and Central Asia Regional Office, United Nations Population Fund [UNFPA], Istanbul, Türkiye), Zozo Nene (Department of Obstetrics and Gynaecology, University of Pretoria, Pretoria, South Africa), Promise E. Sefogah (Department of Obstetrics and Gynaecology, University of Ghana Medical School, Accra, Ghana) and Nathalie Ve rmeulen (European Society of Human Reproduction and Embryology [ESHRE], Strombeek-Bever, Belgium). Diagnosis of female infertility: Márcia Mendonça Carneiro (Department of Obstetrics and Gynecology, Federal University of Minas Gerais, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 10
  },
  {
    "chunk_id": "infertility_1604",
    "text": "ryology [ESHRE], Strombeek-Bever, Belgium). Diagnosis of female infertility: Márcia Mendonça Carneiro (Department of Obstetrics and Gynecology, Federal University of Minas Gerais, Minas Gerais, Brazil), Bart C.J.M. Fauser (Reproductive Medicine, University Medical Center Utrecht, Utrecht, the Netherlands), Grigoris F. Grimbizis (Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece), Qiao Jie (Peking University Health Science Center, Peking University Third Hospital, Beijing, China), Neena Malhotra (Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India) and Trinh The Son (Military Institute of Clinical Embryology and Histology, Hanoi, Viet Nam). Treatment of female infertility: Amal Benbella (Reproductive Health Hospital, Ibn Sina University Hospital, Rabat, Morocco), Edgar Mocanu (Department of Ob",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 10
  },
  {
    "chunk_id": "infertility_1605",
    "text": "ology, Hanoi, Viet Nam). Treatment of female infertility: Amal Benbella (Reproductive Health Hospital, Ibn Sina University Hospital, Rabat, Morocco), Edgar Mocanu (Department of Obstetrics and Gynecology, RCSI University of Medicine and Health Sciences, Dublin, Ireland), Sasha Ottey (PCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, USA) and Maria P. Velez (Division of Reproductive Endocrinology and Infertility, McGill University, Montreal, Canada). Diagnosis and treatment of male infertility: Mohan S. Kamath (Department of Reproductive Medicine and Surgery, Christian Medical College, Vellore, Tamil Nadu, India), Ameet Patki (Indian Society for Assisted Reproduction, Mumbai, India), Oleg Tishkevich (Centre of Assisted Reproduction, Minsk, Belarus) and Mónica Vazquez-Levin (Institute of Biology and Experimental Medicine – National Scientific and Technical Resear",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 10
  },
  {
    "chunk_id": "infertility_1606",
    "text": "leg Tishkevich (Centre of Assisted Reproduction, Minsk, Belarus) and Mónica Vazquez-Levin (Institute of Biology and Experimental Medicine – National Scientific and Technical Research Council [IBYME–CONICET], Buenos Aires, Argentina). Diagnosis and treatment of unexplained infertility: David Adamson (The International Committee Monitoring Assisted Reproductive Technologies, Saratoga, USA), Ben Willem Mol (Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia), Olarik Musigavong (Chaophya Abhaibhubejhr Hospital, Prachin Buri, Thailand), Robert J. Norman (Robinson Research Institute, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia) and Mohamed Youssef (Department of Obstetrics and Gynecology, Cairo University, Cairo, Egypt). Special thanks go to the Evidence Synthesis Team , who prepared the Grading of Recommendations Assessmen",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 10
  },
  {
    "chunk_id": "infertility_1607",
    "text": " (Department of Obstetrics and Gynecology, Cairo University, Cairo, Egypt). Special thanks go to the Evidence Synthesis Team , who prepared the Grading of Recommendations Assessment, Development and Evaluation (GRADE) systematic reviews, led by Nancy Santesso (Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada). Sincere thanks also go to the guideline methodologist Romina Brignardello-Petersen (Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada). The following WHO staff were members of the Guideline Steering Group or otherwise reviewed or provided specific inputs: Lianne Gonsalves , Ndema Habib, James Kiarie, Gitau Mburu, Aasa Nihlén and Nandita Thatte (Department of Sexual and Reproductive Health and Research), Anna Coates (Department of Gender Equity and Rights), Daniel McCartney , Remco Peter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 10
  },
  {
    "chunk_id": "infertility_1608",
    "text": "ru, Aasa Nihlén and Nandita Thatte (Department of Sexual and Reproductive Health and Research), Anna Coates (Department of Gender Equity and Rights), Daniel McCartney , Remco Peters and Teodora Elvira Wi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 10
  },
  {
    "chunk_id": "infertility_1609",
    "text": "ixAcknowledgements (Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes), Dongbo Fu and Kerstin Schotte (Health Promotion Department), Elena Fidarova (Department of Management of Noncommunicable Diseases), Lisa Rogers (Department of Nutrition and Food Safety), Lorenzo Mo ja (Department of Health Products Policy and Standards), Meera Thapa Upadhyay (Department of Maternal, Newborn, Child and Adolescent Health and Ageing) and Oleg Kuzmenko (WHO Regional Office for Europe). During the initial stages of guideline planning, the Guideline Steering Group members also included Ian Askew, Rajat Khosla and Thabo Matsaseng (formerly with the Department of Sexual and Reproductive Health and Research). The following consultants provided input at various stages during the development of the guideline: Paula Amato (Department of Obstetrics and Gynecology, Oregon Health an",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 11
  },
  {
    "chunk_id": "infertility_1610",
    "text": "esearch). The following consultants provided input at various stages during the development of the guideline: Paula Amato (Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, USA), Priya Satalkar-Götz (formerly Independent Consultant, Ghent, Belgium) and Jaime Onofre (Independent Consultant, Brussels, Belgium). Special thanks to the WHO Guidelines Review Committee (GRC) Secretariat Marion Blacker and Rebekah Thomas-Bosco (Department of Quality Assurance, Norms and Standards) for their valuable feedback at every stage of the guideline development process. The overall process of generating this guideline was led by Gitau Mburu with the support of James Kiarie and Pascale Allotey (Department of Sexual and Reproductive Health and Research). Therese Curtin provided administrative support. This work received funding from HRP, a cosponsored programme execute",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 11
  },
  {
    "chunk_id": "infertility_1611",
    "text": "ey (Department of Sexual and Reproductive Health and Research). Therese Curtin provided administrative support. This work received funding from HRP, a cosponsored programme executed by the WHO.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 11
  },
  {
    "chunk_id": "infertility_1612",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility x Abbreviations 2D US two-dimensional ultrasound 3D US three-dimensional ultrasound 4D US four-dimensional ultrasound AMH anti-Müllerian Hormone ART assisted reproductive technologies BMI body mass index CI confidence interval COI conflict of interest DOI declaration of interest DTA diagnostic test accuracy E2 estradiol ERG External Review Group EtD evidence to decision FSH follicle-stimulating hormone GDG Guideline Development Group GnRH gonadotrophin-releasing hormone GRADE Grading of Recommendations Assessment, Development and Evaluation GRC Guidelines Review Committee HIC high-income country HOMP high-order multiple pregnancy HPO hypothalamic–pituitary–ovarian HSG hysterosalpingogram HyCoSy hysterosalpingo contrast sonography ICSI intracytoplasmic sperm injection IUI intrauterine insemination IVF in vitro fertilizat",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 12
  },
  {
    "chunk_id": "infertility_1613",
    "text": "mic–pituitary–ovarian HSG hysterosalpingogram HyCoSy hysterosalpingo contrast sonography ICSI intracytoplasmic sperm injection IUI intrauterine insemination IVF in vitro fertilization LH luteinizing hormone LMIC low- and middle-income country LOD laparoscopic ovarian drilling OHSS ovarian hyperstimulation syndrome OR odds ratio OS ovarian stimulation PCOS polycystic ovary syndrome PICO population, intervention, comparator, outcome PRL prolactin RCT randomized controlled trial RD risk difference RR relative risk SDGs Sustainable Development Goals SIS saline infusion sonohysterography S-IUI stimulated intrauterine insemination STI sexually transmitted infection T testosterone TSH thyroid-stimulating hormone U-IUI unstimulated intrauterine insemination US ultrasound WHO World Health Organization",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 12
  },
  {
    "chunk_id": "infertility_1614",
    "text": "xiExecutive summary Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Executive summary Infertility is a disease of the male and female reproductive system defined as the failure to achieve a pregnancy after 12 months of regular unprotected sexual intercourse. Globally, approximately one in six people of reproductive age experience infertility at some stage in their lives. Lifetime prevalence of infertility does not differ between high-income and low- and middle-income countries, or according to world regions, indicating that infertility is a global public health issue affecting people from all regions and countries. Individuals and couples have the right to decide the number, timing and spacing of their children; however, there is a gap between desired and actual fertility in many countries, implying constrai",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 13
  },
  {
    "chunk_id": "infertility_1615",
    "text": "couples have the right to decide the number, timing and spacing of their children; however, there is a gap between desired and actual fertility in many countries, implying constraints to people’s ability to realize their reproductive goals because of a variety of reasons that may include infertility. Therefore, addressing infertility is an important part of enabling individuals and couples to achieve their fertility preferences. The provision of high-quality services for family planning, including services to prevent, diagnose and treat infertility, is one of the core elements of reproductive health. However, access to fertility care remains a challenge in most countries. By acting urgently, countries have an opportunity to respond to the need for services for the prevention, diagnosis and treatment of infertility, and mitigate the many inequities in the availability, accessibility, acce",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 13
  },
  {
    "chunk_id": "infertility_1616",
    "text": "pportunity to respond to the need for services for the prevention, diagnosis and treatment of infertility, and mitigate the many inequities in the availability, accessibility, acceptability and quality of fertility care. This is the first WHO Guideline for the prevention, diagnosis and treatment of infertility , which aims to improve the implementation of evidence-based interventions related to infertility. The objectives of this guideline are: • to provide evidence-based recommendations for the prevention, diagnosis and treatment of infertility; • to provide explicit explanations of all the relevant factors that guided the development of the recommendations in order to maximize the adaptation and implementation of the guideline in different settings; • to provide a source for countries to adopt, adapt or update their national guidelines for the prevention, diagnosis and treatment of inf",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 13
  },
  {
    "chunk_id": "infertility_1617",
    "text": "n of the guideline in different settings; • to provide a source for countries to adopt, adapt or update their national guidelines for the prevention, diagnosis and treatment of infertility. This guideline is primarily intended for use by health care professionals (including physicians, embryologists, nurses, midwives, laboratory specialists and other health care providers) involved in the provision of fertility care. This guideline is of interest to policy-makers responsible for the development of national health (and other) policies, services and financing because its recommendations use a population perspective that considers resource considerations, acceptability, feasibility and impact on equity. This guideline may be used to inform the work of professional patient support, as well as advocacy organizations, funding and philanthropic agencies, civil society, professional societies an",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 13
  },
  {
    "chunk_id": "infertility_1618",
    "text": "line may be used to inform the work of professional patient support, as well as advocacy organizations, funding and philanthropic agencies, civil society, professional societies and other nongovernmental organizations that provide social, financial and technical support to reproductive health programmes. The guideline can also be used as an advocacy tool for evidence-based fertility care for everyone.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 13
  },
  {
    "chunk_id": "infertility_1619",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility xii Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps This guideline was developed according to the methods outlined in the WHO handbook for guideline development. A Guideline Development Group (GDG) was assembled and included a multidisciplinary and regionally diverse set of clinicians, researchers, policy-makers, implementers and representatives of patient groups. Existing or new systematic reviews of the effects of the interventions related to the prevention, diagnosis and treatment of infertility were used to inform the recommendations. The GDG reviewed the evidence and made recommendations. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the evidence and formulate the recommendati",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 14
  },
  {
    "chunk_id": "infertility_1620",
    "text": "ence and made recommendations. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the evidence and formulate the recommendations. An External Review Group (ERG) reviewed the guideline. The recommendations in this guideline cover the prevention of infertility, and the diagnosis and treatment of infertility due to female, male or unexplained factors. However, they do not cover all aspects of infertility and fertility care. It is anticipated that subsequent editions of this guideline will expand the scope of recommendations (see section 12.2). Summary of recommendations Table 1 presents all the recommendations included in this guideline, including the strength of the recommendation and certainty of the evidence supporting each recommendation. These recommendations are also presented in the relevant chapters of the guideline, accompanied",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 14
  },
  {
    "chunk_id": "infertility_1621",
    "text": " of the recommendation and certainty of the evidence supporting each recommendation. These recommendations are also presented in the relevant chapters of the guideline, accompanied by explanations for the judgements, appropriate diagnostic flow charts and treatment algorithms.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 14
  },
  {
    "chunk_id": "infertility_1622",
    "text": "xiiiExecutive summary Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table 1. Summary of recommendations and key guidance General approach and management of infertility Good practice statements on the general approach and management of infertility For males and females being evaluated and managed for infertility, it is good practice to: select diagnostic tests based on the clinical findings from the medical history and physical examination to ensure that evaluation is systematic and cost-effective. (Good practice statement) listen to individuals and couples, respect their preferences, discuss if psychological and social or peer support is needed, and if needed, provide it or refer patients for it. (Good practice statement) base treatment decisions on benefits and harms, patient values and preferences, feasi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 15
  },
  {
    "chunk_id": "infertility_1623",
    "text": "pport is needed, and if needed, provide it or refer patients for it. (Good practice statement) base treatment decisions on benefits and harms, patient values and preferences, feasibility, costs and availability of resources. (Good practice statement) consider the cost-effectiveness of treatment (e.g. least expensive but effective treatments should be provided initially). (Good practice statement) discuss the plan for clinical follow-up and management of potential risks that may occur during infertility treatment. (Good practice statement) document the outcomes of pregnancies resulting from infertility treatment. (Good practice statement) Recommendations for the prevention of infertility Recommendations for information provision on fertility and infertility For the general population of reproductive age, WHO suggests providing information about fertility and infertility using low-cost str",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 15
  },
  {
    "chunk_id": "infertility_1624",
    "text": "rmation provision on fertility and infertility For the general population of reproductive age, WHO suggests providing information about fertility and infertility using low-cost strategies or whenever there is opportunity. (Conditional recommendation, very low certainty of evidence) Remarks: • Low-cost strategies may include information in digital or paper format when opportunities occur in schools, at primary health care centres or at reproductive health (contraceptive, sexual health) clinics.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 15
  },
  {
    "chunk_id": "infertility_1625",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility xiv Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendations for information provision on fertility and infertility (cont.) • Information adapted to local contexts and audiences, including how to reduce risk factors for infertility, lifestyle modification, age-related fertility decline/potential, and timely medical consultation, may increase the likelihood of information uptake and beneficial outcomes. For individuals and couples with infertility, WHO suggests providing low-cost lifestyle advice before and during infertility treatment. (Conditional recommendation, low certainty of evidence) Remark: • Lifestyle advice may include advice to change diet, alcohol intake, smoking, physical activity and/or weight management. Recommendation",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 16
  },
  {
    "chunk_id": "infertility_1626",
    "text": "dation, low certainty of evidence) Remark: • Lifestyle advice may include advice to change diet, alcohol intake, smoking, physical activity and/or weight management. Recommendation for risk reduction from tobacco smoking WHO recommends that brief advice (between 30 seconds and 3 minutes per encounter) be consistently provided by health care providers as a routine practice to all tobacco users accessing any health care settings. (Strong recommendation, moderate certainty of evidence) Remarks: • This is an existing WHO recommendation for the general population that also applies to individuals and couples who are planning a pregnancy, attempting to achieve a pregnancy or with infertility, given the association between infertility and current or previous history of smoking. • Assessment of lifestyle, including the use of tobacco, is part of medical history when evaluating individuals and cou",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 16
  },
  {
    "chunk_id": "infertility_1627",
    "text": "ween infertility and current or previous history of smoking. • Assessment of lifestyle, including the use of tobacco, is part of medical history when evaluating individuals and couples for infertility. • Brief advice is advice to stop using tobacco – usually taking only a few minutes – given to all tobacco users, usually during a routine consultation or interaction. • Brief advice should include informing individuals and couples that (i) use of tobacco, particularly smoking, is associated with a higher risk of infertility; (ii) the risk of infertility due to tobacco smoking is higher among women; and (iii) a range of interventions to assist in cessation of tobacco use exist. • Brief advice should include the 5As: asking about tobacco use; advising to make a quit attempt; assessing readiness to quit; assisting in making a quit plan; and arranging a follow-up. Advice should be tailored or ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 16
  },
  {
    "chunk_id": "infertility_1628",
    "text": "s: asking about tobacco use; advising to make a quit attempt; assessing readiness to quit; assisting in making a quit plan; and arranging a follow-up. Advice should be tailored or personalized based on individual circumstances. • All adults interested in quitting smoking should be offered or referred to interventions to assist in tobacco cessation as recommended by existing WHO guidelines for preventing tobacco use uptake, promoting tobacco cessation or diagnosing and treating tobacco dependence.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 16
  },
  {
    "chunk_id": "infertility_1629",
    "text": "xvExecutive summary Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation for risk reduction from sexually transmitted infections Couples and individuals planning or attempting to achieve pregnancy who are accessing any health care settings should be routinely informed about sexually transmitted infections (STIs), including the risk of infertility when STIs are untreated. Couples and individuals should be encouraged to seek prompt care and treatment if they have symptoms of STIs. (Good practice statement) Remark: • If symptoms of an STI are present, or if infection is confirmed, WHO guideline recommendations on the management of STIs are available. Recommendations for the diagnosis of female-factor infertility Recommendations for the diagnosis of infertility due to ovulatory dysfunction For females ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 17
  },
  {
    "chunk_id": "infertility_1630",
    "text": "ent of STIs are available. Recommendations for the diagnosis of female-factor infertility Recommendations for the diagnosis of infertility due to ovulatory dysfunction For females with infertility but normal findings on history-taking (including regular menstrual cycles) and physical examination, WHO suggests presumptive confirmation of ovulation by measuring the level of mid- luteal serum progesterone rather than performing an ultrasound scan. For females in whom the initial mid-luteal serum progesterone indicates no ovulation, a repeat measurement is suggested to minimize the risk of an inaccurate diagnosis of anovulation. (Conditional recommendation, very low certainty of evidence) Remarks: • Mid-luteal serum progesterone levels are assessed approximately 7 da ys before the expected onset of the next menses, noting that the specific cycle day can vary based on the length of the menstr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 17
  },
  {
    "chunk_id": "infertility_1631",
    "text": "m progesterone levels are assessed approximately 7 da ys before the expected onset of the next menses, noting that the specific cycle day can vary based on the length of the menstrual cycle. • A repeat mid-luteal serum progesterone measurement could be performed in a subsequent menstrual cycle, considering the turnaround time for tests and cycle-to-cycle variations. For females with infertility and suspected anovulation or oligo-ovulation, it is good practice to assess reproductive hormones related to the hypothalamic– pituitary–ovarian (HPO) axis (such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and in some clinical presentations, estradiol (E2) and testosterone [T]). Additional testing (e.g. thyroid-stimulating hormone (TSH), prolactin [PRL]) may also be indicated based on the clinical presentation. The choice of diagnostic tests should be based on clinical find",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 17
  },
  {
    "chunk_id": "infertility_1632",
    "text": " (e.g. thyroid-stimulating hormone (TSH), prolactin [PRL]) may also be indicated based on the clinical presentation. The choice of diagnostic tests should be based on clinical findings from a comprehensive medical history and physical examination, to ensure that evaluation is systematic and cost-effective. (Good practice statement)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 17
  },
  {
    "chunk_id": "infertility_1633",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility xvi Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendations for the diagnosis of infertility due to ovulatory dysfunction (cont.) For females with infertility in whom other causes of anovulation and oligo- ovulation have been ruled out, WHO suggests that a diagnosis of low ovarian reserve should be based on age rather than diagnostic tests. If ovarian reserve diagnostic testing is conducted, WHO suggests using antral follicle count (AFC), anti-Müllerian hormone (AMH) or day 2 or 3 follicle-stimulating hormone (FSH). (Conditional recommendation, very low certainty of evidence) Remarks: • Age is the most important predictor of ovarian reserve. Therefore, ordering an ovarian reserve test in addition to age assessment may not substantia",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 18
  },
  {
    "chunk_id": "infertility_1634",
    "text": "rtainty of evidence) Remarks: • Age is the most important predictor of ovarian reserve. Therefore, ordering an ovarian reserve test in addition to age assessment may not substantially improve the accuracy of diagnosing low ovarian reserve (as assessed by poor response to stimulation). Note that the ability of age to predict ovarian reserve may be limited in some clinical scenarios, such as cases of premature ovarian insufficiency. • Selection of the test to assess ovarian reserve should be based on relative acceptability, availability and resources in local contexts. Recommendation for the diagnosis of infertility due to tubal disease For females with infertility and suspected tubal disease, WHO suggests using either hysterosalpingogram (HSG) or hysterosalpingo contrast sonography (HyCoSy) to assess tubal patency. (Conditional recommendation, low certainty of evidence) Remark: • When sel",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 18
  },
  {
    "chunk_id": "infertility_1635",
    "text": "either hysterosalpingogram (HSG) or hysterosalpingo contrast sonography (HyCoSy) to assess tubal patency. (Conditional recommendation, low certainty of evidence) Remark: • When selecting whether to use HSG or HyCoSy to assess tubal patency, consider feasibility, the availability of trained health care providers and the potential for allergy. Recommendations for the diagnosis of infertility due to uterine cavity disorder For females with infertility who are suspected to have a uterine cavity disorder, WHO suggests assessing the uterine cavity with saline infusion sonohysterography (SIS) rather than three-dimensional ultrasound (3D US) . (Conditional recommendation, low certainty of evidence) Remark: • In settings where 3D US is already available within the existing resources, 3D US may be the preferred option. For females with infertility who are suspected to have a uterine cavity disorde",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 18
  },
  {
    "chunk_id": "infertility_1636",
    "text": "s where 3D US is already available within the existing resources, 3D US may be the preferred option. For females with infertility who are suspected to have a uterine cavity disorder, WHO suggests assessing the uterine cavity with three-dimensional ultrasound (3D US) rather than two-dimensional ultrasound (2D US) where resources are available. (Conditional recommendation, low certainty of evidence) For females with infertility who are suspected to have a uterine cavity disorder, WHO suggests assessing the uterine cavity with saline infusion sonohysterography (SIS) rather than two-dimensional ultrasound (2D US). (Conditional recommendation, low certainty of evidence)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 18
  },
  {
    "chunk_id": "infertility_1637",
    "text": "xviiExecutive summary Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation for the diagnosis of infertility due to uterine cavity disorder (cont.) For females with infertility due to suspected uterine cavity disorder, WHO suggests assessing the uterine cavity with saline infusion sonohysterography (SIS) rather than hysterosalpingogram (HSG). (Conditional recommendation, very low certainty of evidence) Remark: • Health care providers may choose to use 2D US rather than HSG when resources are limited. Follow-up would be required for women who are negative on 2D US but still suspected of uterine cavity disorder because of high rates of false negatives. Recommendations for the diagnosis of male-factor infertility Recommendation for semen analysis For males (in couples with infertility) with one or more",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 19
  },
  {
    "chunk_id": "infertility_1638",
    "text": "gh rates of false negatives. Recommendations for the diagnosis of male-factor infertility Recommendation for semen analysis For males (in couples with infertility) with one or more semen parameters outside the WHO reference ranges, WHO sugg ests repeating the semen analysis after a minimum of 11 weeks. (Conditional recommendation, very low certainty of evidence) For males (in couples with infertility) with all semen parameters within the WHO reference ranges, WHO suggests not repeating the semen analysis. (Conditional recommendation, very low certainty of evidence) Remark: • The latest edition of the WHO laboratory manual for the examination and processing of human semen provides WHO reference ranges for semen parameters and details about the standardized procedures for semen collection and analysis. Recommendation for the diagnosis of unexplained- factor infertility WHO suggests making ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 19
  },
  {
    "chunk_id": "infertility_1639",
    "text": "parameters and details about the standardized procedures for semen collection and analysis. Recommendation for the diagnosis of unexplained- factor infertility WHO suggests making a diagnosis of unexplained infertility in a couple when all the following have occurred: • failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse; • normal physical examination and medical history in both the male and female; • presumptive confirmation of ovulation and patent tubes in the female partner; and • semen parameters that are within the WHO reference ranges in the male partner. (Conditional recommendation, very low certainty of evidence)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 19
  },
  {
    "chunk_id": "infertility_1640",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility xviii Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendations for the treatment of female-factor infertility Recommendations for the treatment of infertility due to ovulatory dysfunction For females with infertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS), WHO suggests using letrozole over clomiphene citrate or metformin. Using letrozole alone rather than with metformin is suggested. (Conditional recommendation, low certainty of evidence for letrozole compared to clomiphene citrate, low certainty evidence for letrozole compared with metformin alone and very low certainty of evidence for letrozole compared to letrozole with metformin) Where off-label use of letrozole is not permitted, use of clomiphene",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 20
  },
  {
    "chunk_id": "infertility_1641",
    "text": "red with metformin alone and very low certainty of evidence for letrozole compared to letrozole with metformin) Where off-label use of letrozole is not permitted, use of clomiphene citrate with metformin rather than clomiphene citrate alone or metformin alone is suggested. (Conditional recommendation, moderate certainty of evidence for clomiphene citrate compared to clomiphene with metformin, very low certainty of evidence for clomiphene citrate compared to metformin) As part of management of polycystic ovary syndrome (PCOS), it is good practice to advise patients on lifestyle interventions such as a healthy diet, regular physical activity and/or weight management. (Good practice statement) For females with infertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS) who have been unsuccessful with oral pharmacological therapies such as letrozole or clomiphene citr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 20
  },
  {
    "chunk_id": "infertility_1642",
    "text": "ertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS) who have been unsuccessful with oral pharmacological therapies such as letrozole or clomiphene citrate with metformin, WHO suggests using gonadotrophins over laparoscopic ovarian drilling (LOD). (Conditional recommendation, low certainty of evidence) For females with infertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS) who have been unsuccessful with pharmacological therapies such as letrozole, clomiphene citrate with metformin or gonadotrophins, WHO suggests in vitro fertilization (IVF) rather than expectant management. (Conditional recommendation, very low certainty of evidence) For females with infertility due to ovulatory dysfunction caused by hyperprolactinaemia, WHO suggests using cabergoline over bromocriptine. (Conditional recommendation, low certainty of evidence) Reco",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 20
  },
  {
    "chunk_id": "infertility_1643",
    "text": "ertility due to ovulatory dysfunction caused by hyperprolactinaemia, WHO suggests using cabergoline over bromocriptine. (Conditional recommendation, low certainty of evidence) Recommendations for the treatment of infertility due to tubal disease For females aged < 35 years with mild-to-moderate tubal disease (Hull and Rutherford grades I and II), WHO suggests surgery rather than in vitro fertilization (IVF). (Conditional recommendation, very low certainty of evidence) Remarks: • After surgery, a reasonable minimum time to wait to achieve pregnancy before pursuing other interventions, such as IVF, is 1 year. • This recommendation does not apply to females who have had previous tubal sterilization.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 20
  },
  {
    "chunk_id": "infertility_1644",
    "text": "xixExecutive summary Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendations for the treatment of infertility due to tubal disease (cont.) For females aged < 35 years with severe tubal disease (Hull and Rutherford grade III), WHO suggests in vitro fertilization (IVF) rather than surgery. (Conditional recommendation, very low certainty of evidence) Remark: • This recommendation does not apply to females who have had previous tubal sterilization. For females aged ≥ 35 years with any tubal disease, WHO suggests in vitro fertilization (IVF) rather than surgery. (Conditional recommendation, very low certainty of evidence) For females with tubal factor infertility due to hydrosalpinx, WHO suggests either salpingectomy or tubal occlusion before provision of in vitro fertilization (IVF). (Conditional recomme",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 21
  },
  {
    "chunk_id": "infertility_1645",
    "text": "males with tubal factor infertility due to hydrosalpinx, WHO suggests either salpingectomy or tubal occlusion before provision of in vitro fertilization (IVF). (Conditional recommendation, very low certainty evidence) Remark: • When selecting whether to use salpingectomy or tubal occlusion, consider feasibility, availability of trained health care providers and presence of adhesions. For females with tubal factor infertility caused by hydrosalpinx, WHO suggests either salpingectomy or tubal occlusion rather than transvaginal aspiration of hydrosalpingeal fluid before provision of in vitro fertilization (IVF). (Conditional recommendation, very low certainty of evidence) Remark: • In settings where salpingectomy and tubal occlusion are not available or feasible, transvaginal aspiration may be offered. Recommendation for the treatment of infertility due to uterine cavity disorder For female",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 21
  },
  {
    "chunk_id": "infertility_1646",
    "text": "and tubal occlusion are not available or feasible, transvaginal aspiration may be offered. Recommendation for the treatment of infertility due to uterine cavity disorder For females with infertility and uterine septum who have no history of recurrent pregnancy loss, WHO suggests that hysteroscopic septum resection (septoplasty) not be performed. (Conditional recommendation, low certainty of evidence)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 21
  },
  {
    "chunk_id": "infertility_1647",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility xx Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendations for the treatment of male-factor infertility Recommendation on the use of antioxidants For males with infertility and one or more semen parameters that are outside the WHO reference ranges who are attempting to achieve pregnancy with or without medically assisted reproduction, the WHO infertility Guideline Development Group (GDG) did not make a recommendation for or against the use of antioxidant supplements. Remark: • Optimal nutrition is important during the pre-pregnancy period for the couple; however, the effects of antioxidant supplements for males with specific male-factor pathologies in couples with infertility are currently not known. Recommendations for the treatmen",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 22
  },
  {
    "chunk_id": "infertility_1648",
    "text": "owever, the effects of antioxidant supplements for males with specific male-factor pathologies in couples with infertility are currently not known. Recommendations for the treatment of varicocele For males with infertility and clinical varicocele, WHO suggests surgical or radiological treatment over expectant management. (Conditional recommendation, low certainty of evidence) Remarks: • Males with clinical varicocele and semen parameters that are outside the WHO reference ranges are more likely to benefit from receiving treatment for varicocele, compared to men with semen parameters within the WHO reference ranges. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART). For males with infertility undergoing treatment of varicocele, WHO suggests using either surgical or radiological tr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 22
  },
  {
    "chunk_id": "infertility_1649",
    "text": "dergoing treatment with assisted reproductive technology (ART). For males with infertility undergoing treatment of varicocele, WHO suggests using either surgical or radiological treatment. (Conditional recommendation, very low certainty of evidence) Remarks: • When selecting whether to use surgical or radiological treatment, consider feasibility, the availability of trained health care providers and patient preferences regarding the type of treatment procedure. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 22
  },
  {
    "chunk_id": "infertility_1650",
    "text": "xxiExecutive summary Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendations for the treatment of varicocele (cont.) For males with infertility undergoing surgical treatment of varicocele, WHO suggests using microscopic surgery rather than other surgical procedures. (Conditional recommendation, very low certainty of evidence) Remarks: • Subinguinal microsurgery is a common surgical varicocelectomy procedure, while other surgical procedures include non-microscopic open approaches (such as inguinal and retroperitoneal) and laparoscopic methods. • In settings where the expertise to perform microscopic surgery is not available, other surgical techniques may be used. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproducti",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 23
  },
  {
    "chunk_id": "infertility_1651",
    "text": " other surgical techniques may be used. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART). For males with infertility undergoing non-microscopic surgical treatment of varicocele, WHO suggests using either inguinal or retroperitoneal surgical procedures. (Conditional recommendation, very low certainty of evidence) Remarks: • When selecting whether to use an inguinal or retroperitoneal surgical procedure, consider feasibility and the availability of trained health care providers. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART). Recommendations for the treatment of unexplained infertility Recommendations for first-line management of couples with unexplained infertility For",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 23
  },
  {
    "chunk_id": "infertility_1652",
    "text": "ed reproductive technology (ART). Recommendations for the treatment of unexplained infertility Recommendations for first-line management of couples with unexplained infertility For couples with unexplained infertility, WHO suggests expectant management rather than unstimulated intrauterine insemination (U-IUI). (Conditional recommendation, low certainty of evidence) Remarks: • Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. • The duration of expectant management was typically 3–6 months in studies informing this recommendation.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 23
  },
  {
    "chunk_id": "infertility_1653",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility xxii Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendations for first-line management of couples with unexplained infertility (cont.) For couples with unexplained infertility, WHO suggests expectant management rather than ovarian stimulation with timed intercourse. (Conditional recommendation, low certainty of evidence) Remarks: • Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. • The duration of expectant management was typically 3–6 months in studies informing this reco",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 24
  },
  {
    "chunk_id": "infertility_1654",
    "text": "and monitoring if pregnancy will occur; however, no medical intervention is provided. • The duration of expectant management was typically 3–6 months in studies informing this recommendation. Recommendations for second-line management of couples with unexplained infertility For couples with unexplained infertility, where expectant management has been unsuccessful, WHO suggests stimulated intrauterine insemination (S-IUI) with either clomiphene citrate or letrozole. (Conditional recommendation, low certainty of evidence) Remarks: • When selecting whether to use clomiphene citrate or letrozole, consider the applicable national laws and regulations related to off-label use of letrozole. • The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing thre",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 24
  },
  {
    "chunk_id": "infertility_1655",
    "text": "UI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. For couples with unexplained infertility, where expectant management has been unsuccessful, WHO suggests stimulated intrauterine insemination (S-IUI) with either clomiphene citrate or letrozole rather than with gonadotrophins. (Conditional recommendation, very low certainty of evidence) Remark: • The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. Recommendations for third-line management of unexplained infertility For couples with unexplained infertility, where stimulated intrauterine insemination (S-IUI) has been unsuccessful",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 24
  },
  {
    "chunk_id": "infertility_1656",
    "text": "ommendations for third-line management of unexplained infertility For couples with unexplained infertility, where stimulated intrauterine insemination (S-IUI) has been unsuccessful, WHO suggests in vitro fertilization (IVF) rather than expectant management. (Conditional recommendation, low certainty of evidence) For couples with unexplained infertility undergoing in vitro fertilization (IVF) after S-IUI has been unsuccessful, WHO recommends using IVF alone rather than IVF with intracytoplasmic sperm injection (ICSI). (Strong recommendation, low certainty of evidence)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 24
  },
  {
    "chunk_id": "infertility_1657",
    "text": "1 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 1 Introduction 1.1 Epidemiology and global burden of infertility Infertility is a disease of the male and female reproductive system, which is defined as the failure to achieve a pregnancy after 12 months of regular unprotected sexual intercourse ( 1, 2). Infertility can be primary or secondary. Primary infertility is when a pregnancy has never been achieved, and secondary infertility is when at least one prior pregnancy has been achieved. Individuals and couples have the right to decide the number, timing and spacing of their children ( 3). Persons of full age, without any limitation due to race, nationality or religion, have the right to marry and found a family (4). However, there is a gap between desired and actual fertility in many settings ( 5), implyin",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 25
  },
  {
    "chunk_id": "infertility_1658",
    "text": "on due to race, nationality or religion, have the right to marry and found a family (4). However, there is a gap between desired and actual fertility in many settings ( 5), implying constraints to people’s ability to realize their reproductive goals because of several reasons that may include infertility. Therefore, addressing infertility is an important part of enabling individuals and couples to achieve their fertility preferences. Addressing infertility will enable individuals and couples to exercise their sexual and reproductive health and rights and achieve their desired family size. Globally, approximately one in six people of reproductive age experience infertility at some stage in their lives ( 6). Lifetime prevalence of infertility is 17.5%, while period prevalence is 12.6%. In addition, infertility prevalence does not differ significantly between high-income and low- and middle",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 25
  },
  {
    "chunk_id": "infertility_1659",
    "text": "time prevalence of infertility is 17.5%, while period prevalence is 12.6%. In addition, infertility prevalence does not differ significantly between high-income and low- and middle-income countries (LMICs), or according to world regions, indicating that infertility is a global public health issue affecting people in all regions and countries (6). Although the overall period and lifetime prevalence is similar across regions, the distribution of the underlying risks of infertility (such as postpartum infections, unsafe abortions and some sexually transmitted infections [STIs]) can vary across countries and regions and potentially cause differences in the patterns of primary versus secondary infertility ( 6–8). Using different definitions and methodological approaches, the numbers of people affected by infertility were estimated to be 186 million individuals in 2004 ( 9) and 48.5 million co",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 25
  },
  {
    "chunk_id": "infertility_1660",
    "text": "ing different definitions and methodological approaches, the numbers of people affected by infertility were estimated to be 186 million individuals in 2004 ( 9) and 48.5 million couples in 2010 (10). (See Fig. 1.1). Classically, each type of infertility can be attributed to congenital or acquired causes ( 11). The former stem from abnormalities in the development of the genital tract in either males or females (11). Infertility in both males and females can be associated with impairments affecting any portion of the hypothalamic–pituitary–gonadal axis and reproductive organs (i.e. testes, ducts and penis in males, and ovaries, uterus, fallopian tubes, cervix and vagina in females). In general terms, these reproductive impairments are often associated with congenital or acquired abnormalities, genetic aberrations, urogenital infections, malignancies, endocrine disturbances, gonadotoxic ex",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 25
  },
  {
    "chunk_id": "infertility_1661",
    "text": "ductive impairments are often associated with congenital or acquired abnormalities, genetic aberrations, urogenital infections, malignancies, endocrine disturbances, gonadotoxic exposures, sexual dysfunction, immunological abnormalities, iatrogenic factors and other physiological factors such as age ( 12, 13). In general, less is known about male causes of infertility than female causes; of those causes that can be identified in the male, fewer are amenable to corrective treatment. Chapter This chapter provides background information on infertility, including its epidemiology and the need to strengthen global efforts to prevent, diagnose and treat it.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 25
  },
  {
    "chunk_id": "infertility_1662",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 2 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. 1.1. Epidemiology and global burden of infertility a See more details in WHO infertility prevalence estimates 1990–2021 (6). b 13.3% became pregnant in the course of study investigations. See details in Cates et al., 1985 (14) and WHO, 1992 (15). HICs 17.8% LMICs 16.5% Infertility is a global public health issue affecting people in all regions and countries. This is evidenced by the fact that infertility prevalence does not differ by WHO world regions or between high-income countries (HICs) and low- and middle-income countries (LMICs). Approximately one in six people of reproductive age experience Infertility can be caused by female, male or unexplained factors; sometimes the cause may ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 26
  },
  {
    "chunk_id": "infertility_1663",
    "text": "-income countries (LMICs). Approximately one in six people of reproductive age experience Infertility can be caused by female, male or unexplained factors; sometimes the cause may not be identified during routine investigations. A large WHO multi-country study involving 8500 couplesb in 25 countries found that infertility was due to: Estimated lifetime prevalence of infertility 17.5% 12.6% Estimated period prevalence of infertility Male factor contributes wholly or in part to 45.1% of infertility cases. 30.6% Female factors alone Male factors alone Both male and female No cause found Lifetime infertility prevalence in: 18.7% 26.3% 10.8% infertility at some stage in their lives.a A large World Health Organization (WHO) multi-country study involving 8500 couples in 25 countries found that infertility was due to female factors alone in 30.6%, both male and female factors in 26.3%, and male ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 26
  },
  {
    "chunk_id": "infertility_1664",
    "text": "n (WHO) multi-country study involving 8500 couples in 25 countries found that infertility was due to female factors alone in 30.6%, both male and female factors in 26.3%, and male factors alone in 18.7% of cases (14, 15). No cause was found in 10.8% of cases (14, 15). The remaining 13.3% became pregnant during investigations. Based on this study, male factors contributed wholly or in part to 45.1% of infertility cases. In this study, the most common identifiable causes of female infertility included anovulatory and oligo-ovulatory disorders (26.1%), endometriosis (4.8%), pelvic (including uterine) adhesions (14.8%), bilateral tubal blockage (17.7%), acquired tubal abnormalities (11.6%) and hyperprolactinemia (6.7%). In this study, rates of infertility due to tubal causes were higher in LMICs compared to high-income countries ( 14–16).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 26
  },
  {
    "chunk_id": "infertility_1665",
    "text": "31 Introduction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Among males, identifiable causes of infertility included varicocele (13.1%), primary testicular failure (12.0%) and accessory gland infection (7.1%). Abnormal semen parameters (morphology and motility) were identified in 9.7% of males diagnosed with infertility ( 14). In this study, male factors contributed wholly or in part to 45.1% of infertility cases (14). However, these multi-country data are relatively old and new patterns may have emerged across high-income, middle-income and low-income settings (see Annex 1. Distribution of the causes of infertility ). In the absence of more recent epidemiological studies, there are knowledge gaps and uncertainty regarding the precise proportions of infertility caused by male, female, both male and femal",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 27
  },
  {
    "chunk_id": "infertility_1666",
    "text": "bsence of more recent epidemiological studies, there are knowledge gaps and uncertainty regarding the precise proportions of infertility caused by male, female, both male and female or unexplained factors in the general population of reproductive age. Many studies and systematic reviews quantifying the relative contributions of these factors are based on clinic samples ( 17) in single countries (18) or on samples with restricted inclusion criteria (6), which together with the varying extents of selection and investigation of each partner, makes it difficult to determine an unbiased prevalence of these causes among global populations of reproductive age. In terms of risk factors, the most consistent predictive factor of infertility is increasing female/ maternal age (19–22). In both males and females, infertility is also associated with lifestyle risk factors such as smoking (23–26), exce",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 27
  },
  {
    "chunk_id": "infertility_1667",
    "text": "actor of infertility is increasing female/ maternal age (19–22). In both males and females, infertility is also associated with lifestyle risk factors such as smoking (23–26), excessive alcohol intake (27, 28), obesity (29), underweight ( 30), as well as sexually transmitted, reproductive tract, and other pelvic infections ( 31, 32), although evidence is not equally strong across these factors ( 33). Exposure to environmental endocrine-disrupting chemicals can interfere with the reproductive system, resulting in poor quantity or quality of gametes, and potentially contributing to infertility ( 34–37); however, definitive conclusions cannot be made based on the available data (37). Several causal diagnoses may be present simultaneously and may be coincidental or causal (e.g. an STI-induced pathology in both male and female partners). The temporal or geographical contribution of specific e",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 27
  },
  {
    "chunk_id": "infertility_1668",
    "text": "e present simultaneously and may be coincidental or causal (e.g. an STI-induced pathology in both male and female partners). The temporal or geographical contribution of specific etiological factors, such as postpartum or post-abortion infections, genital tuberculosis, schistosomiasis, iatrogenic causes and female genital mutilation is uncertain. For many etiologies, there are knowledge gaps in the natural history and sequence of intermediate sequelae that lead to infertility. In summary, the relative prevalence of the causes and risk factors for infertility differ from country to country ( 16) and there is a lack of comprehensive data in many countries. The possibility for multiple factors to contribute to infertility in a couple, as well as variations in definition, data collection methods and outcomes reported in existing studies, continue to pose measurement challenges ( 38, 39). Tem",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 27
  },
  {
    "chunk_id": "infertility_1669",
    "text": "ertility in a couple, as well as variations in definition, data collection methods and outcomes reported in existing studies, continue to pose measurement challenges ( 38, 39). Temporal epidemiological trends in infertility may also be modified by global efforts to address STIs, unsafe abortions and other risk factors, as well as demographic trends. Declining total fertility rates (40, 41), rising maternal and paternal age at first birth ( 42–44) and possible temporal and geographical declines in reported semen parameters (45, 46), could potentially contribute to a greater need for prevention, diagnosis and treatment of infertility; however, the influence of paternal age on fecundity, compared to maternal age (47), is less certain; declines in semen parameters have not been observed universally among all male populations ( 48) and semen parameters per se are not a reliable diagnostic ind",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 27
  },
  {
    "chunk_id": "infertility_1670",
    "text": "47), is less certain; declines in semen parameters have not been observed universally among all male populations ( 48) and semen parameters per se are not a reliable diagnostic indicator of male fertility status ( 49, 50). To quantify causes more clearly, it is necessary to distinguish between the inability to achieve pregnancy, the inability to carry a pregnancy to a live birth and the failure of a live birth to survive, all of which contribute to involuntary childlessness. Although infertility is an important cause of involuntary childlessness, other biomedical (e.g. pr egnancy loss), biopsychosocial (e.g. sexual dysfunction) or non-biomedical (e.g. legal, regulatory, cultural or social) situations may impede individuals’ ability to have children ( 51, 52). Desire or intentions for parenthood in otherwise",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 27
  },
  {
    "chunk_id": "infertility_1671",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 4 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps fertile populations can be modified by multiple concerns (53, 54). A wide variety of people may not be infertile, as they have biological reproductive capacity, but could need interventions to have children and fulfil their fertility preferences. 1 1 Because of the need to refer to biological sex characteristics on clinical grounds, this guideline uses terms such as male and female (in its recommendations), and men and women (in text synthesizing research) to indicate biological sex assigned at birth, and uses “couples” to refer to heterosexual partnerships. However, a wide variety of people, including individuals who are single or who are in same-sex or gender-diverse relationships, may nee",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 28
  },
  {
    "chunk_id": "infertility_1672",
    "text": "ples” to refer to heterosexual partnerships. However, a wide variety of people, including individuals who are single or who are in same-sex or gender-diverse relationships, may need services to fulfil their fertility preferences. Providers of fertility care should consider the needs of, and provide equal care to, all individuals. Overall, better epidemiological data relating to the extent and causes of infertility, and the need for fertility care arising because of different reasons, are required to inform health (and other) policies and services. 1.2 The need to strengthen global efforts to prevent, diagnose and treat infertility Fig. 1.2. Addressing infertility is central to human rights and global health aspirations Fig. X. The need to strengthen global efforts to prevent, diagnose and treat infertility Addressing infertility is central to human rights and global health aspirations: R",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 28
  },
  {
    "chunk_id": "infertility_1673",
    "text": "irations Fig. X. The need to strengthen global efforts to prevent, diagnose and treat infertility Addressing infertility is central to human rights and global health aspirations: Right to health Individuals and couples have the right to decide the number, timing and spacing of their children. Infertility can hinder the achievement of fertility preferences and reproductive goals. Everyone has a right to enjoy the highest attainable standard of physical, mental and social well-being Right to enjoy the benefits of scientific progress and its applications Interventions like assisted reproductive technologies (ARTs) have a role to play in addressing infertility Primary health care (PHC) Ensuring that basic interventions such as fertility education are available at the PHC level will contribute to enhanced service coverageFinancial protection Given the risk of large out-of-pocket costs for pre",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 28
  },
  {
    "chunk_id": "infertility_1674",
    "text": "ions such as fertility education are available at the PHC level will contribute to enhanced service coverageFinancial protection Given the risk of large out-of-pocket costs for preventing, diagnosing or treating infertility, fertility care should be provided while upholding financial protection Equitable access to health care Infertility should be consistently included in health policies, services and financing Universal health coverage (UHC) Prevention, diagnosis and treatment of infertility should be integrated into health services and systems Gender equality Women are often disproportionately affected by the consequences of infertility. Addressing infertility is relevant to gender equality The Universal Declaration of Human Rights (Article 16) states that “men and women of full age, without any limitation due to race, nationality or religion, have the right to marry and found a family",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 28
  },
  {
    "chunk_id": "infertility_1675",
    "text": "aration of Human Rights (Article 16) states that “men and women of full age, without any limitation due to race, nationality or religion, have the right to marry and found a family” (4). A significant proportion of young adults in demographic health surveys express a desire",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 28
  },
  {
    "chunk_id": "infertility_1676",
    "text": "51 Introduction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps for children (55–58) and infertility can prevent the ability of individuals to achieve their preferences regarding the number, timing and spacing of their children. Services for the prevention, diagnosis and treatment of infertility are an essential element of reproductive health care included in the 1994 International Conference on Population and Development call to action, to, among others, achieve universal access to a full range of reproductive health services ( 59). A wide variety of individuals and couples may require infertility management and fertility care services (60); individual circumstances should not lead to discrimination. Addressing infertility is central to the achievement of the right to health. Every human being has a right t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 29
  },
  {
    "chunk_id": "infertility_1677",
    "text": "vices (60); individual circumstances should not lead to discrimination. Addressing infertility is central to the achievement of the right to health. Every human being has a right to the enjoyment of the highest attainable standard of physical, mental and social well-being. Infertility has a negative impact on mental well-being, relationships and quality of life ( 61, 62) and is associated with a high prevalence of intimate partner violence ( 63). Therefore, improving access to prevention, diagnosis and treatment of infertility is needed to mitigate the negative health and psychosocial consequences of infertility. The right to health is closely linked with the right to enjoy the benefits of scientific progress and its applications (64). Although assisted reproductive technologies (ARTs) and a range of other interventions may have a role in partially compensating for postponement of births",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 29
  },
  {
    "chunk_id": "infertility_1678",
    "text": "nd its applications (64). Although assisted reproductive technologies (ARTs) and a range of other interventions may have a role in partially compensating for postponement of births (65-67), demographic changes and declines in total fertility rates should not be used as a basis for restricting or coercing access to fertility care and other reproductive services ( 68); instead, health (and other) policies and services should be aimed at facilitating the achievement of people’s fertility goals and preferences through a rights-based approach (69). Addressing infertility is also relevant to gender equality. Women are often disproportionately affected by the consequences of infertility (62, 70, 71) and tend to bear the blame for infertility in couples (9, 72). Infertility also affects men’s mental health and well-being ( 73), yet its impact is often concealed because of stigma, masculine norms",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 29
  },
  {
    "chunk_id": "infertility_1679",
    "text": "he blame for infertility in couples (9, 72). Infertility also affects men’s mental health and well-being ( 73), yet its impact is often concealed because of stigma, masculine norms ( 74) and low participation of men in infertility studies and services ( 75–77). Many social norms stigmatize infertility and affect reproductive decision-making in women and men. (See Fig. 1.2 ). Addressing infertility is necessary to enhance equitable access to health care . Infertility is not consistently included in health policies, services and financing. Consequently, access to fertility care remains a challenge for many people. Although worldwide provision of in vitro fertilization (IVF) has increased over time ( 78), there are marked disparities in the availability, accessibility, acceptability and quality of services for preventing, diagnosing and treating infertility between regions, countries and po",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 29
  },
  {
    "chunk_id": "infertility_1680",
    "text": "e marked disparities in the availability, accessibility, acceptability and quality of services for preventing, diagnosing and treating infertility between regions, countries and populations (79, 80). Only about half of all couples with infertility seek any form of infertility services (81), but this can vary from country to country (82). Although many reasons prevent access to fertility care, cost is among the most common barriers, particularly in settings that do not have fully funded fertility care ( 80, 83, 84). It is the responsibility of Member States to put in place legislative frameworks, determine eligibility criteria and facilitate equitable access to fertility care for those in need. Member States have an obligation to facilitate access to health care, including preventing infertility and enabling access to diagnostic and treatment services (85, 86). By acting urgently, countri",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 29
  },
  {
    "chunk_id": "infertility_1681",
    "text": "e an obligation to facilitate access to health care, including preventing infertility and enabling access to diagnostic and treatment services (85, 86). By acting urgently, countries have an opportunity to respond to the need for services for the prevention, diagnosis and treatment of infertility and mitigate the many inequities in access to safe and effective fertility care. Efforts to achieve universal health coverage should include measures to address the needs of people with infertility by integrating the prevention, diagnosis and treatment of infertility into sexual and reproductive health services and wider health systems. It is essential to ensure that services for infertility are available, accessible, acceptable and of good quality. This will require having supportive health (and other) policies to ensure that all people have access to services to prevent, diagnose and treat inf",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 29
  },
  {
    "chunk_id": "infertility_1682",
    "text": "acceptable and of good quality. This will require having supportive health (and other) policies to ensure that all people have access to services to prevent, diagnose and treat infertility that they need, when and where they",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 29
  },
  {
    "chunk_id": "infertility_1683",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 6 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps need them. However, in many countries, infertility services and policies are not prioritized or included in health systems, including services or financing (87–89). Achieving universal health coverage will require provision of health financing, trained personnel, medicines, equipment, infrastructure and effective monitoring of services through robust health information systems. Ensuring that fertility care is provided while upholding financial protection is essential given the risk for catastrophic expenditures because of out-of- pocket costs. People often incur large out-of-pocket costs to access services for preventing, diagnosing or treating infertility ( 83, 90). In addition, ensuring th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 30
  },
  {
    "chunk_id": "infertility_1684",
    "text": "ause of out-of- pocket costs. People often incur large out-of-pocket costs to access services for preventing, diagnosing or treating infertility ( 83, 90). In addition, ensuring that basic fertility care interventions are available at the primary health care level will contribute to enhanced service coverage. References 1. International Classification of Diseases, 11th Revision (ICD-11). Geneva: World Health Organization; 2018 (https://www.who.int/ classifications/icd/en/). 2. Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K et al. The international committee for monitoring assisted reproductive technology (ICMART) and the World Health Organization (WHO) revised glossary on ART terminology, 2009. Hum Reprod. 2009;24 (11):2683-7 (https://doi.org/10.1016/j. fertnstert.2009.09.009). 3. Convention on the Elimination of All Forms of Discrimination against Women. T",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 30
  },
  {
    "chunk_id": "infertility_1685",
    "text": "inology, 2009. Hum Reprod. 2009;24 (11):2683-7 (https://doi.org/10.1016/j. fertnstert.2009.09.009). 3. Convention on the Elimination of All Forms of Discrimination against Women. Treaty Series, vol 1249, Part IV; Article 16. New York: United Nations General Assembly; 1979. 4. The Universal Declaration of Human Rights (UDHR). New York: United Nations; 1948. 5. Beaujouan E, Berghammer C. The gap between lifetime fertility intentions and completed fertility in Europe and the United States: a cohort approach. Popul Res Policy Rev. 2019;38:507-35 (ht tps://doi.org/10.1007/s11113- 019 - 09516 -3). 6. Infertility prevalence estimates: 1990–2021. Geneva: World Health Organization; 2023 (https://apps.who.int/iris/handle/10665/366700). 7. Chemaitelly H, Majed A, Abu-Hijleh F, Blondeel K, Matsaseng TC, Kiarie J et al. Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 30
  },
  {
    "chunk_id": "infertility_1686",
    "text": "/10665/366700). 7. Chemaitelly H, Majed A, Abu-Hijleh F, Blondeel K, Matsaseng TC, Kiarie J et al. Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta- analysis and metaregression. Sex Transm Infect. 2021;97(2):157-69 (https://doi.org/10.1136/ sextrans-2020-054515). 8. Larsen U. Primary and secondary infertility in sub-Saharan Africa. Int J Epidemiol. 2000;29(2):285-91 (https://doi.org/10.1093/ ije/29.2.285). 9. Rutstein SO, Shah IH. Infecundity, infertility, and childlessness in developing countries. DHS Comparative Reports No. 9. Calverton, USA: ORC Macro and World Health Organization; 2004 (https://dhsprogram.com/pubs/pdf/CR9/CR9.pdf). 10. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 30
  },
  {
    "chunk_id": "infertility_1687",
    "text": ", Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356 (https://doi. org/10.1371/journal.pmed.1001356). 11. Rowe PJ. Infertility. World Health. 1987:20-1 (https://iris.who.int/handle/10665/53389) 12. Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ. WHO manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 1993 (https://iris. who.int/handle/10665/36983). 13. Rowe PJ, Comhaire FH, Hargreave TB, Mahmoud AM. WHO manual for the standardized investigation and diagnosis of the infertile male. Cambridge: Cambridge University Press; 2000 (https://iris.who.int/handle/10665/42437). 14. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 30
  },
  {
    "chunk_id": "infertility_1688",
    "text": "y Press; 2000 (https://iris.who.int/handle/10665/42437). 14. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 30
  },
  {
    "chunk_id": "infertility_1689",
    "text": "71 Introduction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 15. Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985;2(8455):596-8 (https://doi.org/10.1016/ s0140-6736(85)90594-x). 16. World Health Organization. Infections, pregnancies, and infertility: perspectives on prevention. Fertil Steril. 1987;47(6):964-8 (https:// doi.org/10.1016/S0015-0282(16)59230-9). 17. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13(1):37 (https://doi. org/10.1186/s12958-015-0032-1). 18. Thonneau P, Marchand S, Tallec A, Ferial M-L, Ducot B, Lansac J et al. Incidence and main causes of infertility in a resident population (1 850 000) of three French regions (1988–1989). Hum Reprod. 1991;6(6):811-6 (htt",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 31
  },
  {
    "chunk_id": "infertility_1690",
    "text": "al M-L, Ducot B, Lansac J et al. Incidence and main causes of infertility in a resident population (1 850 000) of three French regions (1988–1989). Hum Reprod. 1991;6(6):811-6 (https://doi. org/10.1093/oxfordjournals.humrep.a137433). 19. Chua S, Danhof N, Mochtar M, Van Wely M, McLernon D, Custers I et al. Age-related natural fertility outcomes in women over 35 years: a systematic review and individual participant data meta-analysis. Hum Reprod. 2020;35(8):1808-20 (https://doi.org/10.1093/humrep/deaa129). 20. Steiner AZ, Jukic AMZ. Impact of female age and nulligravidity on fecundity in an older reproductive age cohort. Fertil Steril. 2016;105(6):1584-8. (https://doi.org/10.1016/j. fertnstert.2016.02.028). 21. Wesselink AK, Rothman KJ, Hatch EE, Mikkelsen EM, Sørensen HT, Wise LA. Age and fecundability in a North American preconception cohort study. Am J Obstet Gynecol. 2017;217(6):667.e",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 31
  },
  {
    "chunk_id": "infertility_1691",
    "text": "Wesselink AK, Rothman KJ, Hatch EE, Mikkelsen EM, Sørensen HT, Wise LA. Age and fecundability in a North American preconception cohort study. Am J Obstet Gynecol. 2017;217(6):667.e1-667.e8 (https://doi.org/10.1016/j.ajog.2017.09.002). 22. ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Update. 2005;11(3):261-76 (https://doi.org/10.1093/humupd/dmi006). 23. Augood C, Duckitt K, Templeton AA. Smoking and female infertility: a systematic review and meta-analysis. Hum Reprod. 1998;13(6):1532-9 (https://doi.org/10.1093/humrep/13.6.1532). 24. Laurent SL, Thompson SJ, Addy C, Garrison CZ, Moore EE. An epidemiologic study of smoking and primary infertility in women. Fertil Steril. 1992;57(3):565-72 (https://doi.org/10.1016/S0015- 0282(16)54901-2). 25. Waylen AL, Metwally M, Jones GL, Wilkinson AJ, Ledger WL. Effects of cigarette smoking upon clinical outcomes of assisted reproduction",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 31
  },
  {
    "chunk_id": "infertility_1692",
    "text": "/doi.org/10.1016/S0015- 0282(16)54901-2). 25. Waylen AL, Metwally M, Jones GL, Wilkinson AJ, Ledger WL. Effects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis. Hum Reprod Update. 2008;15(1):31-44 (https://doi.org/10.1093/ humupd/dmn046). 26. Bundhun PK, Janoo G, Bhurtu A, Teeluck AR, Soogund MZS, Pursun M et al. Tobacco smoking and semen quality in infertile males: a systematic review and meta-analysis. BMC Public Health. 2019;19(1):36 (https://doi.org/10.1186/s12889- 018-6319-3). 27. Ricci E, Al Beitawi S, Cipriani S, Candiani M, Chiaffarino F, Viganò P et al. Semen quality and alcohol intake: a systematic review and meta- analysis. Reprod Biomed Online. 2017;34(1):38- 47 (http://dx.doi.org/10.1016/j.rbmo.2016.09.012). 28. Fan D, Liu L, Xia Q, Wang W, Wu S, Tian G et al. Female alcohol consumption and fecundability: a systematic review and dose-res",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 31
  },
  {
    "chunk_id": "infertility_1693",
    "text": " (http://dx.doi.org/10.1016/j.rbmo.2016.09.012). 28. Fan D, Liu L, Xia Q, Wang W, Wu S, Tian G et al. Female alcohol consumption and fecundability: a systematic review and dose-response meta- analysis. Sci Rep. 2017;7(1):13815 (https://doi. org/10.1038/s41598-017-14261-8). 29. Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol Endocrinol. 2013;11:66 (https://doi.org/10.1186/1477-7827- 11- 66). 30. Boutari C, Pappas PD, Mintziori G, Nigdelis MP, Athanasiadis L, Goulis DG et al. The effect of underweight on female and male reproduction. Metabolism. 2020;107:154229 (https://doi. org/10.1016/j.metabol.2020.154229). 31. Bayoumi RR, Fatemi HM, Hurt L, Serour GI, van der Poel S, Venetis C et al. A critical systematic review and meta-analyses of risk factors for fertility problems in a globalized world. Reprod Bi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 31
  },
  {
    "chunk_id": "infertility_1694",
    "text": "atemi HM, Hurt L, Serour GI, van der Poel S, Venetis C et al. A critical systematic review and meta-analyses of risk factors for fertility problems in a globalized world. Reprod Biomed Online. 2024;48(3):103217 (https://doi. org/10.1016/j.rbmo.2023.04.008). 32. Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak D et al. Risk of ectopic pregnancy and tubal infertility following gonorrhea and chlamydia infections. Clin Infect Dis. 2019;69(9):1621-3 (https://doi.org/10.1093/cid/ciz145).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 31
  },
  {
    "chunk_id": "infertility_1695",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 8 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 33. de Angelis C, Nardone A, Garifalos F, Pivonello C, Sansone A, Conforti A et al. Smoke, alcohol and drug addiction and female fertility. Reprod Biol Endocrinol. 2020;18(1):21 (https://doi. org/10.1186/s12958-020-0567-7). 34. Green MP, Harvey AJ, Finger BJ, Tarulli GA. Endocrine disrupting chemicals: impacts on human fertility and fecundity during the peri- conception period. Environ Res. 2021;194:110694 (https://doi.org/10.1016/j.envres.2020.110694). 35. Segal TR, Giudice LC. Before the beginning: environmental exposures and reproductive and obstetrical outcomes. Fertil Steril. 2019;112(4):613-21 (https://doi.org/10.1016/j. fertnstert.2019.08.001). 36. Gore AC, Chappell VA, Fenton SE, Fla",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 32
  },
  {
    "chunk_id": "infertility_1696",
    "text": "exposures and reproductive and obstetrical outcomes. Fertil Steril. 2019;112(4):613-21 (https://doi.org/10.1016/j. fertnstert.2019.08.001). 36. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS et al. EDC-2: the Endocrine Society’s Second Scientific Statement on Endocrine- Disrupting Chemicals. Endocr Rev. 2015;36(6):E1- E150 (https://doi.org/10.1210/er.2015-1010). 37. State of the science of endocrine disrupting chemicals 2012: summary for decision-makers. Geneva: World Health Organization; 2012 (https://iris.who.int/handle/10665/78102). 38. Barratt CLR, Björndahl L, De Jonge CJ, Lamb DJ, Osorio Martini F, McLachlan R et al. The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities. Hum Reprod Update. 2017;23(6):660-80 (https://doi.org/10.1093/ humupd/dmx021). 39. Cox CM, Thoma",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 32
  },
  {
    "chunk_id": "infertility_1697",
    "text": "he development of global WHO guidance-challenges and future research opportunities. Hum Reprod Update. 2017;23(6):660-80 (https://doi.org/10.1093/ humupd/dmx021). 39. Cox CM, Thoma ME, Tchangalova N, Mburu G, Bornstein MJ, Johnson CL et al. Infertility prevalence and the methods of estimation from 1990 to 2021: a systematic review and meta-analysis. Hum Reprod Open. 2022;2022(4): hoac051 (https://doi. org/10.1093/hropen/hoac051). 40. United Nations Department of Economic and Social Affairs, Population Division. World population prospects 2022: summary of results. UN DESA/POP/2022/TR/NO. 3. New York: United Nations; 2022 (https://www.un.org/development/ desa/pd/content/World-Population- Prospects-2022). 41. Bhattacharjee NV, Schumacher AE, Aali A, Abate YH, Abbasgholizadeh R, Abbasian M et al. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 32
  },
  {
    "chunk_id": "infertility_1698",
    "text": "tacharjee NV, Schumacher AE, Aali A, Abate YH, Abbasgholizadeh R, Abbasian M et al. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2057-99 (https://doi. org/10.1016/s0140-6736(24)00550-6). 42. Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States, 2000–2014. Hyattsville: National Center for Health Statistics; 2016 (https://www.cdc.gov/nchs/data/databriefs/ db232.pdf). 43. Khandwala YS, Zhang CA, Lu Y, Eisenberg ML. The age of fathers in the USA is rising: an analysis of 168 867 480 births from 1972 to 2015. Hum Reprod. 2017;32(10):2110-6 (https://doi. org/10.1093/humrep/dex267). 44. Birth characteristics in England and Wales: 2021. Fareham: Office for National Statistics; 2023 (https://www.ons.gov. uk/peoplepopulationandcomm",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 32
  },
  {
    "chunk_id": "infertility_1699",
    "text": "oi. org/10.1093/humrep/dex267). 44. Birth characteristics in England and Wales: 2021. Fareham: Office for National Statistics; 2023 (https://www.ons.gov. uk/peoplepopulationandcommunity/ birthsdeathsandmarriages/livebirths/bulletins/ birthcharacteristicsinenglandandwales/2021). 45. Gourinat A, Mazeaud C, Hubert J, Eschwege P, Koscinski I. Impact of paternal age on assisted reproductive technology outcomes and offspring health: a systematic review. Andrology. 2023;11(6):973-86 (ht tps://doi.org/10.1111/ andr.13385). 46. Levine H, Jørgensen N, Martino-Andrade A, Mendiola J, Weksler-Derri D, Mindlis I et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update. 2017;23(6):646-59 (https://doi. org/10.1093/humupd/dmx022). 47. Paulson RJ, Milligan RC, Sokol RZ. The lack of influence of age on male fertility. Am J Obstet Gynecol. 2001;184(5):818-22",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 32
  },
  {
    "chunk_id": "infertility_1700",
    "text": "3(6):646-59 (https://doi. org/10.1093/humupd/dmx022). 47. Paulson RJ, Milligan RC, Sokol RZ. The lack of influence of age on male fertility. Am J Obstet Gynecol. 2001;184(5):818-22 (https://doi. org/10.1067/mob.2001.113852). 48. Campbell MJ, Lotti F, Baldi E, Schlatt S, Festin MPR, Björndahl L et al. Distribution of semen examination results 2020: a follow up of data collated for the WHO semen analysis manual 2010. Andrology. 2021;9(3):817-22 (https://doi. org/10.1111/andr.12983).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 32
  },
  {
    "chunk_id": "infertility_1701",
    "text": "91 Introduction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 49. Boeri L, Belladelli F, Capogrosso P, Cazzaniga W, Candela L, Pozzi E et al. Normal sperm parameters per se do not reliably account for fertility: a case-control study in the real-life setting. Andrologia. 2021;53(1):e13861 (https:// doi.org/10.1111/and.13861). 50. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/bitstream/hand le/10665/343208/9789240030787-eng.pdf). 51. Berger MH, Messore M, Pastuszak AW, Ramasamy R. Association between infertility and sexual dysfunction in men and women. Sex Med Rev. 2016;4(4):353-65 (https://doi.org/10.1016/j. sxmr.2016.05.002). 52. Davis MF, Khosla R. Infertility and human rights: a jurisprudential survey ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 33
  },
  {
    "chunk_id": "infertility_1702",
    "text": "ction in men and women. Sex Med Rev. 2016;4(4):353-65 (https://doi.org/10.1016/j. sxmr.2016.05.002). 52. Davis MF, Khosla R. Infertility and human rights: a jurisprudential survey (June 26, 2020). Colum J Gender & L. Paper No. 381-2020 (https://ssrn. com/abstract=3636206). 53. Dillarstone H, Brown LJ, Flores EC. Climate change, mental health, and reproductive decision-making: a systematic review. PLOS Climate. 2023;2(11):e0000236 (https://doi. org/10.1371/journal.pclm.0000236). 54. Boivin J, Buntin L, Kalebic N, Harrison C. What makes people ready to conceive? Findings from the International Fertility Decision-Making Study. Reprod Biomed Soc Online. 2018;6:90-101 (https://doi.org/10.1016/j.rbms.2018.10.012). 55. Having children or not: results from a questionnaire survey about women’s and men’s attitudes towards having children. Örebro: SCB (Statistics Sweden); 2009 (https://www.scb.se/ ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 33
  },
  {
    "chunk_id": "infertility_1703",
    "text": ". Having children or not: results from a questionnaire survey about women’s and men’s attitudes towards having children. Örebro: SCB (Statistics Sweden); 2009 (https://www.scb.se/ be0701-en). 56. Westoff CF. Desired number of children: 2000– 2008. Calverton: USA ICF Macro; 2010 (https:// www.dhsprogram.com/pubs/pdf/CR25/CR25.pdf) 57. Cools S, Strøm M. Ønsker om barn–en spørreundersøkelse om fertilitet, arbeidsliv og familiepolitikk. Institutt for samfunnsforskning; 2020 (https://hdl.handle.net/11250/2645776). 58. Li Q, Yang R, Zhou Z, Qian W, Zhang J, Wu Z et al. Fertility history and intentions of married women, China. Bull World Health Organ. 2024;102(4):244-54 (https://doi.org/10.2471/ blt.23.289736). 59. Programme of action adopted at the International Conference on Population and Development, Cairo, 1994. New York: United Nations Population Fund; 1994. 60. Infertility Fact Sheet [In",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 33
  },
  {
    "chunk_id": "infertility_1704",
    "text": "ogramme of action adopted at the International Conference on Population and Development, Cairo, 1994. New York: United Nations Population Fund; 1994. 60. Infertility Fact Sheet [Internet web page]. Geneva: World Health Organization; 2024 (https://www.who.int/news-room/fact-sheets/ detail/infertility). 61. Luk BH-K, Loke AY. The impact of infertility on the psychological well-being, marital relationships, sexual relationships, and quality of life of couples: a systematic review. J Sex Marital Ther. 2015;41(6):610-25 (https://doi.org/10.1080/00926 23X.2014.958789). 62. Chachamovich JR, Chachamovich E, Ezer H, Fleck MP, Knauth D, Passos EP. Investigating quality of life and health-related quality of life in infertility: a systematic review. J Psychosom Obstet Gynaecol. 2010;31(2):101-10 (https://doi.org/10.3109/016748 2X.2010.481337). 63. Wang Y, Fu Y, Ghazi P, Gao Q, Tian T, Kong F et al. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 33
  },
  {
    "chunk_id": "infertility_1705",
    "text": "ility: a systematic review. J Psychosom Obstet Gynaecol. 2010;31(2):101-10 (https://doi.org/10.3109/016748 2X.2010.481337). 63. Wang Y, Fu Y, Ghazi P, Gao Q, Tian T, Kong F et al. Prevalence of intimate partner violence against infertile women in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health. 2022;10(6):e820-e30 (https://doi.org/10.1016/ s2214-109x(22)00098-5). 64. International Covenant on Economic, Social Cultural Rights (CESCR). New York: United Nations General Assembly; 1966. 65. Fauser BCJM, Adamson GD, Boivin J, Chambers GM, de Geyter C, Dyer S et al. Declining global fertility rates and the implications for family planning and family building: an IFFS consensus document based on a narrative review of the literature. Hum Reprod Update. 2024;10:dmad028 (https://doi.org/10.1093/ humupd/dmad028). 66. Bergsvik J, Fauske A, Hart RK. Ca",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 33
  },
  {
    "chunk_id": "infertility_1706",
    "text": "onsensus document based on a narrative review of the literature. Hum Reprod Update. 2024;10:dmad028 (https://doi.org/10.1093/ humupd/dmad028). 66. Bergsvik J, Fauske A, Hart RK. Can policies stall the fertility fall? A systematic review of the (quasi-) experimental literature. Popul Dev Rev. 2021;47(4):913-64 (ht tps://doi.org/10.1111/ padr.12431).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 33
  },
  {
    "chunk_id": "infertility_1707",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 10 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 67. Lazzari E, Gray E, Chambers GM. The contribution of assisted reproductive technology to fertility rates and parity transition. Demogr Res. 2021;45:1081-96 (https://doi.org/10.4054/ DemRes.2021.45.35). 68. Mburu G, Kamuyango A, Kidula N, Kabra R, Thatte N, Kiarie J et al. Fulfilment of fertility desires for the attainment of Global Sustainable Development Goals. BMJ Glob Health. 2023;8(4):e012322 (https://doi.org/10.1136/ bmjgh-2023-012322). 69. Mburu G, Kiarie J, Allotey P. Towards a nuanced view and response to global fertility trends. Lancet. 2024;403(10440):1953-6 (https://doi. org/10.1016/s0140-6736(24)00490-2). 70. Ying LY, Wu LH, Loke AY. Gender differences in experiences with and",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 34
  },
  {
    "chunk_id": "infertility_1708",
    "text": "to global fertility trends. Lancet. 2024;403(10440):1953-6 (https://doi. org/10.1016/s0140-6736(24)00490-2). 70. Ying LY, Wu LH, Loke AY. Gender differences in experiences with and adjustments to infertility: a literature review. Int J Nurs Stud. 2015;52(10):1640-52 (https://doi.org/10.1016/j. ijnurstu.2015.05.004). 71. Koert E, Takefman J, Boivin J. Fertility quality of life tool: update on research and practice considerations. Hum Fertil. 2021;24(4):236-48 (https://doi.org/10.1080/14647273.2019.1648887). 72. Thoma M, Fledderjohann J, Cox C, Kantum Adageba R. Biological and social aspects of human infertility: a global perspective. Oxford: Oxford University Press; 2021 (https://doi. org/10.1093/acrefore/9780190632366.013.184). 73. Fallara G, Pozzi E, Belladelli F, Boeri L, Capogrosso P, Corona G et al. A systematic review and meta- analysis on the impact of infertility on men’s general ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 34
  },
  {
    "chunk_id": "infertility_1709",
    "text": "0632366.013.184). 73. Fallara G, Pozzi E, Belladelli F, Boeri L, Capogrosso P, Corona G et al. A systematic review and meta- analysis on the impact of infertility on men’s general health. Eur Urol Focus. 2024;10:98-106 (https://doi.org/10.1016/j.euf.2023.07.010). 74. Inhorn MC. Middle Eastern masculinities in the age of new reproductive technologies: male infertility and stigma in Egypt and Lebanon. Med Anthropol Q. 2004;18(2):162-82 (https://doi. org/10.1525/maq.2004.18.2.162). 75. Fisher JR, Hammarberg K. Psychological and social aspects of infertility in men: an overview of the evidence and implications for psychologically informed clinical care and future research. Asian J Androl 2012;14(1):121 (https://doi.org/10.1038/ aja.2011.72). 76. Culley L, Hudson N, Lohan M. Where are all the men? The marginalization of men in social scientific research on infertility. Reprod Biomed Online. 2",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 34
  },
  {
    "chunk_id": "infertility_1710",
    "text": ".org/10.1038/ aja.2011.72). 76. Culley L, Hudson N, Lohan M. Where are all the men? The marginalization of men in social scientific research on infertility. Reprod Biomed Online. 2013;27(3):225-35 (https://doi. org/10.1016/j.rbmo.2013.06.009). 77. De Jonge CJ, Gellatly SA, Vazquez-Levin MH, Barratt CLR, Rautakallio-Hokkanen S. Male attitudes towards infertility: results from a global questionnaire. World J Mens Health. 2023;41(1):204-14 (https://doi.org/10.5534/ wjmh.220099). 78. Adamson GD, Creighton P, de Mouzon J, Zegers- Hochschild F, Dyer S, Chambers GM. How many infants have been born with the help of assisted reproductive technology? Fertil Steril. 2025; S0015-0282(25)00085-8 (https://doi. org/10.1016/j.fertnstert.2025.02.009). 79. Ombelet W. Global access to infertility care in developing countries: a case of human rights, equity and social justice. Facts Views Vis Obgyn. 2011;3(",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 34
  },
  {
    "chunk_id": "infertility_1711",
    "text": "fertnstert.2025.02.009). 79. Ombelet W. Global access to infertility care in developing countries: a case of human rights, equity and social justice. Facts Views Vis Obgyn. 2011;3(4):257-66 (https://pubmed.ncbi.nlm.nih. gov/24753875/). 80. Botha B, Shamley D, Dyer S. Availability, effectiveness and safety of ART in sub-Saharan Africa: a systematic review. Hum Reprod Open. 2018;2018(2):hoy003 (https://doi.org/10.1093/ hropen/hoy003). 81. Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007;22(6):1506-12 (https://doi.org/10.1093/ humrep/dem046). 82. Bell SO, Larson E, Bittle D, Moreau C, Omoluabi E, OlaOlorun FM et al. Care-seeking for difficulties conceiving in sub-Saharan Africa: findings from population-based surveys in eight geographies. Hum Reprod. 2",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 34
  },
  {
    "chunk_id": "infertility_1712",
    "text": "Moreau C, Omoluabi E, OlaOlorun FM et al. Care-seeking for difficulties conceiving in sub-Saharan Africa: findings from population-based surveys in eight geographies. Hum Reprod. 2024;39(8):1712-23 (https://doi. org/10.1093/humrep/deae084). 83. Njagi P, Groot W, Arsenijevic J, Dyer S, Mburu G, Kiarie J. Financial costs of assisted reproductive technology for patients in low-and middle- income countries: a systematic review. Hum Reprod Open. 2023;hoad007 (https://doi. org/10.1093/hropen/hoad007).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 34
  },
  {
    "chunk_id": "infertility_1713",
    "text": "111 Introduction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 84. Chambers GM, Hoang VP, Sullivan EA, Chapman MG, Ishihara O, Zegers-Hochschild F et al. The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: an international analysis. Fertil Steril. 2014;101(1):191-8 (https://doi.org/10.1016/j. fertnstert.2013.09.005). 85. Shah PK, Gher JM. Human rights approaches to reducing infertility. Int J Gynaecol Obstet. 2023;162(1):368-74 (https://doi.org/10.1002/ ijgo.14878). 86. Human rights and infertility: research paper. Geneva: Office of the High Commissioner for Human Rights; 2023 (https://www.ohchr.org/ sites/default/files/documents/issues/women/ Research-Paper-HRs-Infertility.pdf). 87. International Federation of Fertility Societies (IFFS). Inte",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 35
  },
  {
    "chunk_id": "infertility_1714",
    "text": "ghts; 2023 (https://www.ohchr.org/ sites/default/files/documents/issues/women/ Research-Paper-HRs-Infertility.pdf). 87. International Federation of Fertility Societies (IFFS). International Federation of Fertility Societies’ surveillance, 2022: global trends in reproductive policy and practice, 9th edition. Glob Reprod Health. 2022;7(3):e58 (https://doi. org/10.1097/GRH.0000000000000058). 88. Morshed-Behbahani B, Lamyian M, Joulaei H, Rashidi BH, Montazeri A. Infertility policy analysis: a comparative study of selected lower middle- middle- and high-income countries. Global Health. 2020;16(1):104 (https://doi.org/10.1186/ s12992-020-00617-9). 89. Afferri A, Allen H, Booth A, Dierickx S, Pacey A, Balen J. Barriers and facilitators for the inclusion of fertility care in reproductive health policies in Africa: a qualitative evidence synthesis. Hum Reprod Update. 2022;28(2):190-9 (https://do",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 35
  },
  {
    "chunk_id": "infertility_1715",
    "text": "rs and facilitators for the inclusion of fertility care in reproductive health policies in Africa: a qualitative evidence synthesis. Hum Reprod Update. 2022;28(2):190-9 (https://doi. org/10.1093/humupd/dmab040). 90. Elliott PA, Hoffman J, Abad-Santos M, Herndon C, Katz PP, Smith JF. Out-of-pocket costs for men undergoing infertility care and associated financial strain. Urol Pract. 2016;3(4):256-61 (https://doi.org/10.1016/j.urpr.2015.07.010).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 35
  },
  {
    "chunk_id": "infertility_1716",
    "text": "12 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 2 Rationale and methodology This chapter presents information on the rationale, overall goals and methodology used to develop this guideline. 2.1 Rationale This guideline responds to requests from Member States, organizations, institutions and health care providers for evidence-based norms and standards related to infertility. Despite the high burden of disease, infertility is often neglected (1, 2). Management of infertility is continually evolving. Absence of clear guidelines contributes to inconsistent outcomes and variable practices and can exacerbate existing disparities. Implementation of best practices that emphasize cost-effective interventions is a key strategy to reduce disparities in access to services. This guideline underscores the importance of",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 36
  },
  {
    "chunk_id": "infertility_1717",
    "text": "ementation of best practices that emphasize cost-effective interventions is a key strategy to reduce disparities in access to services. This guideline underscores the importance of infertility as a global public health issue. The prevention, diagnosis and treatment of infertility is an integral component of comprehensive sexual and reproductive health, and is aligned with Sustainable Development Goal (SDG) 3, which aims to ensure healthy lives and promote well-being for all at all ages, and SDG 5, which aims to achieve gender equality and empower all women and girls. Prevention, diagnosis and treatment of infertility is also needed to ensure universal access to sexual and reproductive health care, and to achieve universal health coverage. 2.2 Goals and objectives The goal of this guideline is to provide evidence- informed guidance for the prevention, diagnosis and treatment of infertilit",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 36
  },
  {
    "chunk_id": "infertility_1718",
    "text": "e universal health coverage. 2.2 Goals and objectives The goal of this guideline is to provide evidence- informed guidance for the prevention, diagnosis and treatment of infertility to improve the standard of fertility care globally, with a focus on public health perspective. The objectives are: • to provide evidence-based recommendations for the prevention, diagnosis and treatment of infertility; • to provide explicit explanations of all the relevant factors that guided the development of the recommendations in order to maximize the adaptation and implementation of the guideline in different settings; • to provide a source for countries to adopt, adapt or update their national guidelines for the prevention, diagnosis and treatment of infertility. Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 36
  },
  {
    "chunk_id": "infertility_1719",
    "text": "132 Rationale and methodology Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. 2.1. Scope and audience Professional societies and other organizations involved in sexual and reproductive health programmes Health care professionals including physicians, embryologists, nurses, midwives, laboratory specialists, and other health care providers Patient support and advocacy organizations Funding and philanthropic agencies Policy-makers who develop national health policies, services and financing The scope of this guideline includes the prevention, diagnosis and treatment of: Prevention Diagnosis Treatment Female-factor infertility Male-factor infertility Unexplained infertility Intended users of the guideline include: Guideline on the prevention, diagnosis and treatment of infertility Evidence-informed guidance",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 37
  },
  {
    "chunk_id": "infertility_1720",
    "text": "e-factor infertility Unexplained infertility Intended users of the guideline include: Guideline on the prevention, diagnosis and treatment of infertility Evidence-informed guidance to improve the standard of fertility care globally 2.3 Scope This guideline provides recommendations related to prevention, as well as diagnosis and treatment of female-factor (tubal, ovulatory dysfunction and uterine causes), male-factor and unexplained inf ertility. Given that this is the first WHO guideline on the prevention, diagnosis and treatment of infertility, it does not cover all aspects of infertility and important gaps remain. It is anticipated that subsequent editions of this guideline will have an expanded scope, allowing it to address topics that are not included currently, including management of other risk factors (such as obesity, low body weight, excessive intake of alcohol and other substan",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 37
  },
  {
    "chunk_id": "infertility_1721",
    "text": "ng it to address topics that are not included currently, including management of other risk factors (such as obesity, low body weight, excessive intake of alcohol and other substances (including use of cannabis, use of vapes and e-cigarettes, or non-smoked/ smokeless tobacco products, among others) and sexual dysfunction, as well as non-individual risk factors (e.g. environmental and workplace factors), fertility preservation in the context of gonadotoxic therapy, third-party reproduction (donor gametes, surrogacy), fertility care for individuals with pre- existing medical conditions that affect fertility (such as endometriosis and fibroids), or with obstructive, congenital, accessory gland, genital or hormonal abnormalities associated with male infertility, as well as psychosocial support for people with infertility. These topics received relatively limited attention in this first versi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 37
  },
  {
    "chunk_id": "infertility_1722",
    "text": " abnormalities associated with male infertility, as well as psychosocial support for people with infertility. These topics received relatively limited attention in this first version (based on initial scoping) and will be considered in subsequent editions.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 37
  },
  {
    "chunk_id": "infertility_1723",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 14 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 2.4 Target audience This guideline is primarily intended for use by health care professionals, including physicians, embryologists, nurses, midwives, laboratory specialists and other health care providers, involved in the care of individuals or couples with infertility in primary, secondary and tertiary settings in both the private and public sectors. This guideline is of interest to policy-makers responsible for the development of national health (and other) policies, services and financing, as its recommendations use a population perspective that considers resource needs, acceptability, feasibility and impact on equity. The recommendations have been developed through a public health lens.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 38
  },
  {
    "chunk_id": "infertility_1724",
    "text": "s use a population perspective that considers resource needs, acceptability, feasibility and impact on equity. The recommendations have been developed through a public health lens. This guideline can be used to inform the financial and human resources required to deliver adequate, acceptable and equitable fertility care for all populations in need. In addition, this guideline may be used to inform the work of patient support and advocacy organizations, mental health professionals, funding and philanthropic agencies, civil society, professional societies and other nongovernmental organizations that provide social, financial and technical support to sexual and reproductive health programmes. The guideline can also be used as an advocacy tool to ensure adequate, acceptable and equitable fertility care for everyone. (See F ig. 2.1) 2.5 Guiding principles The following principles have informe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 38
  },
  {
    "chunk_id": "infertility_1725",
    "text": "o be used as an advocacy tool to ensure adequate, acceptable and equitable fertility care for everyone. (See F ig. 2.1) 2.5 Guiding principles The following principles have informed the development of this guideline and should guide the implementation of the recommendations: • Development of the guideline responds to unmet need for guidance for a specified audience. • Implementation of the guideline should inform and contribute to national goals and relevant global targets, including attainment of SDG 3 (to ensure healthy lives and promote well-being for all at all ages) and SDG 5 (to achieve gender equality and empower all women and girls). • Implementation of the guideline should ensure that the prevention, diagnosis and treatment of infertility is considered an integral component of sexual and reproductive health and rights and should be aimed at achieving universal health coverage. •",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 38
  },
  {
    "chunk_id": "infertility_1726",
    "text": "iagnosis and treatment of infertility is considered an integral component of sexual and reproductive health and rights and should be aimed at achieving universal health coverage. • Implementation of the guideline needs to be accompanied by efforts to promote and protect the right to health of people with or at risk of infertility. • Implementation of the guideline should be based on a public health approach as a key strategy to reduce access disparities, by ensuring all populations in need of such services are reached with interventions to prevent, diagnose and treat infertility, including populations in low-resource settings. • Implementation of the recommendations in this guideline should be informed by local context , including epidemiology and prevalence of infertility, the values and preferences of local populations or patients and feasibility, as well as the organization and capaci",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 38
  },
  {
    "chunk_id": "infertility_1727",
    "text": " context , including epidemiology and prevalence of infertility, the values and preferences of local populations or patients and feasibility, as well as the organization and capacity of the health system. Other contextual considerations may be related to demographic resilience, fertility and demographic trends, which require policies geared towards the achievement of universal access to sexual and reproductive health and rights.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 38
  },
  {
    "chunk_id": "infertility_1728",
    "text": "152 Rationale and methodology Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. 2.2. Methodology for guideline development Publication, dissemination and implementation of the guideline Methodology for guideline development Determining the scope of the guideline Review and approval of guideline by WHO Guideline Review Committee (GRC) Identifying recommendation questions Evidence retrieval and synthesis Presentation of evidence using GRADE methodology Recommendations drafted by the GDG External review of guideline by External Review Group (ERG) Guideline Development Group (GDG) established 2.6 Methods This guideline was developed in accordance with the 2014 WHO handbook for guideline development (3). (See Fig. 2.2). Guideline Development Group A WHO steering group was convened to facilitate the scoping of ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 39
  },
  {
    "chunk_id": "infertility_1729",
    "text": " in accordance with the 2014 WHO handbook for guideline development (3). (See Fig. 2.2). Guideline Development Group A WHO steering group was convened to facilitate the scoping of the guideline, including priority topics related to the prevention, diagnosis and treatment of infertility. The steering group consisted of WHO staff members from different departments in WHO. A systematic review lead and guideline methodologist were appointed by the WHO steering group. The WHO steering group consulted with experts, clinicians,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 39
  },
  {
    "chunk_id": "infertility_1730",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 16 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps researchers, patient organizations and other key stakeholders and established the WHO Infertility Guideline Development Group (GDG), which included 30 members from different regions and with expertise in different topics related to the prevention, diagnosis and treatment of infertility. The GDG consisted of clinicians, researchers, implementers and patient advocate groups (see Annex 2. Members of the GDG ). A Chair and co- Chair were appointed to lead the GDG meetings. Two leaders were also assigned to each subtopic within the scope of the guideline. External Review Group An External Review Group (ERG) that included 30 clinical experts, policy-makers and patient advocates was established. T",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 40
  },
  {
    "chunk_id": "infertility_1731",
    "text": "ic within the scope of the guideline. External Review Group An External Review Group (ERG) that included 30 clinical experts, policy-makers and patient advocates was established. The ERG reviewed the recommendations and provided feedback on critical implementation considerations (see Annex 3. Members of the ERG). Determining the scope of the guideline and recommendation questions In 2018, the WHO Infertility GDG met virtually to define the scope of this guideline. The WHO GDG provided input, which was used to brainstorm and prioritize questions. The questions were divided into subtopics: prevention and information provision, and diagnosis and treatment of infertility due to female factors, male factors and unexplained factors. Recommendation questions were developed using the population, intervention, comparator, outcome (PICO) framework, related to diagnostic tests, surgical and medical",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 40
  },
  {
    "chunk_id": "infertility_1732",
    "text": "plained factors. Recommendation questions were developed using the population, intervention, comparator, outcome (PICO) framework, related to diagnostic tests, surgical and medical treatments, and information provision (see Web Annexes A–F for the guideline for the prevention, diagnosis and treatment of infertility). The GDG identified outcomes that included live birth rates, ongoing pregnancy rates, clinical pregnancy rates and quality of life, multiple pregnancy, miscarriage, preterm birth and other relevant adverse events. Based on input from a virtual meeting with the GDG, the WHO Steering Group finalized the prioritized PICO questions, which then formed the basis for systematic reviews. Retrieval and synthesis of evidence Systematic reviews were conducted by the Michael G. DeGroote Cochrane Canada Centre at McMaster University. The team took a hierarchical approach and searched for ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 40
  },
  {
    "chunk_id": "infertility_1733",
    "text": "esis of evidence Systematic reviews were conducted by the Michael G. DeGroote Cochrane Canada Centre at McMaster University. The team took a hierarchical approach and searched for published systematic reviews, and then primary studies when no review was available, or updated a review when out-of-date. The systematic reviews assessed the benefits and harms of the interventions (and diagnostic tests), as well as acceptability, feasibility, equity and resource requirements. Searches for randomized or non- randomized studies were conducted from 1990 up to December 2019 in multiple databases including MEDLINE, Embase, Cochrane Central Register of Controlled Trials and LILACS. Additional searches up to 2023 were conducted for selected questions. Based on feedback from the GDG, targeted monitoring of evidence (and an updated search) was conducted for selected guideline questions in which new st",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 40
  },
  {
    "chunk_id": "infertility_1734",
    "text": "ucted for selected questions. Based on feedback from the GDG, targeted monitoring of evidence (and an updated search) was conducted for selected guideline questions in which new studies were likely to be published, allowing results from new studies to potentially be added to evidence summaries. If a study was published after the search and was identified by the GDG to likely have an impact on the recommendation, it was also incorporated into the review. Cochrane methods for conducting systematic reviews ( 4) were followed: using a comprehensive search strategy; duplicate screening of articles; duplicate assessment of risk of bias using study-design-specific tools; data abstraction by one investigator and verification by another; and synthesis through meta-analysis (using RevMan) when possible, otherwise performing a narrative synthesis. Subgroup analyses were conducted when data were ava",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 40
  },
  {
    "chunk_id": "infertility_1735",
    "text": "cation by another; and synthesis through meta-analysis (using RevMan) when possible, otherwise performing a narrative synthesis. Subgroup analyses were conducted when data were available for key parameters that could affect outcomes such as body mass index (BMI) or semen parameters. Because of concerns about the number of retracted papers in the field of reproductive medicine, a search was conducted in the Retraction Watch Database version 1.0.8.0 (https://retractiondatabase. org/) for studies included in the systematic reviews. When a study was retracted or under investigation, it was excluded from the pairwise meta-analyses and new calculations were made, or new analyses were sought in the case of network meta-analyses.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 40
  },
  {
    "chunk_id": "infertility_1736",
    "text": "172 Rationale and methodology Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Presentation of the evidence Tables to facilitate decision-making for recommendations (evidence to decision [EtD] frameworks) were produced for each recommendation and presented to the GDG using the GRADEpro online software (www.gradepro.org/ ). These tables include a summary of the problem – test (diagnostic) accuracy; summary of the evidence for benefits and harms (including for different subgroups); certainty of the evidence; relevant patient values and preferences; and other issues, such as cost, resources, feasibility, equity and acceptability. Table 2.1 illustrates how each of the EtD factors influences a guideline recommendation. Table 2.1. Evidence to decision framework Domain Favours strong recommendations Favours conditio",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 41
  },
  {
    "chunk_id": "infertility_1737",
    "text": " 2.1 illustrates how each of the EtD factors influences a guideline recommendation. Table 2.1. Evidence to decision framework Domain Favours strong recommendations Favours conditional recommendations Balance of benefits and harms Benefits highly outweigh harms or vice versa Benefits and harms are more closely balanced Quality of evidence Higher certainty Lower certainty Values/preferences regarding outcomes Benefits to harms assessment not impacted by variability in values or preferences Variability in values or preferences would impact benefits to harms assessment Acceptability Highly acceptable Low or variable acceptability Costs/resources Cost-saving/cost-effective Costly/cost-ineffective Feasibility Feasible in intended settings Unfeasible or feasibility varies in intended settings Equity Increased equity Decreased equity or effect on equity is variable The certainty of the body of e",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 41
  },
  {
    "chunk_id": "infertility_1738",
    "text": "e in intended settings Unfeasible or feasibility varies in intended settings Equity Increased equity Decreased equity or effect on equity is variable The certainty of the body of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach (5), based on considerations of risk of bias, inconsistency, indirectness, imprecision, publication bias, effect size, dose–response and opposing confounding. Based on these criteria, the overall certainty of evidence was defined as follows: • high (we are very confident that the true effect lies close to that of the estimate of the effect); • moderate (we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); • low (we have limited confidence in the effect estimate: the tr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 41
  },
  {
    "chunk_id": "infertility_1739",
    "text": "s likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); • low (we have limited confidence in the effect estimate: the true effect may be substantially different from the estimate of the effect); • very low (we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect). The evidence about benefits and harms was summarized in the GRADE summary of findings tables and Evidence Profiles that contained the estimates of the effect (in relative and absolute terms), and the assessments of the certainty of evidence (see Web Annexes A–F for the evidence to decision tables). Review of evidence and drafting of recommendations The GDG met virtually to review the evidence. Because of the complexity of developing the",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 41
  },
  {
    "chunk_id": "infertility_1740",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 18 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps recommendations, several subgroup virtual meetings were held with the topic leaders to further review the evidence before or after GDG meetings and draft judgements (with explanations) for each EtD factor, as well as recommendations (with justifications). The GDG assessed the EtDs, judged on different considerations and voted on their agreement or disagreement with the draft recommendations using GRADEpro Panelvoice (www.gradepro.org/panelvoice ). Judgements about benefits and harms were based on the direction and size of the estimated effects and the uncertainty in those effects (GRADE-level evidence), not on whether the effect was statistically significant (i.e. avoiding the misinterpreta",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 42
  },
  {
    "chunk_id": "infertility_1741",
    "text": " size of the estimated effects and the uncertainty in those effects (GRADE-level evidence), not on whether the effect was statistically significant (i.e. avoiding the misinterpretation that “not statistically significant” means “no effect” [ 6]). Making of recommendations During the GDG meetings, judgements for each of the criteria of the EtD made during voting were discussed and the GDG recommendation drafts were confirmed or revised. A methodologist facilitated the process during the GDG meetings, and the Chair and co-Chair led the discussions. Using the GRADE approach, the strength of each recommendation was rated as either strong or conditional. Strong recommendations are presented using the wording “WHO recommends …” , while conditional recommendations are worded as “WHO suggests …” . These were arrived at after consideration of the various domains of the EtD framework. Strong and c",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 42
  },
  {
    "chunk_id": "infertility_1742",
    "text": "commends …” , while conditional recommendations are worded as “WHO suggests …” . These were arrived at after consideration of the various domains of the EtD framework. Strong and conditional recommendations have differing implications, as shown in Table 2.2. Table 2.2. Implications of differing strengths of GRADE recommendations Implications Strong recommendation WHO recommends … Conditional recommendation WHO suggests … For patients Most individuals in this situation would want the recommended course of action and only a small proportion would not. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences. The majority of individuals in this situation would want the suggested course of action, but many would not. For clinicians Most individuals should receive the recommended course of action. Adherence to this recomm",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 42
  },
  {
    "chunk_id": "infertility_1743",
    "text": "s situation would want the suggested course of action, but many would not. For clinicians Most individuals should receive the recommended course of action. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. Clinicians should recognize that different choices will be appropriate for each individual and that clinicians must help each individual arrive at a management decision consistent with the individual’s values and preferences. Decision aids may be useful to help individuals make decisions consistent with their values and preferences. For policy-makers The recommendation can be adopted as policy in most situations. Policy-making will require substantial debate and the involvement of various stakeholders. When addressing patients’ values (for which there was no research evidence available), judgements about the most ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 42
  },
  {
    "chunk_id": "infertility_1744",
    "text": "re substantial debate and the involvement of various stakeholders. When addressing patients’ values (for which there was no research evidence available), judgements about the most important outcomes and the likelihood of variability across people were made by the GDG. It was agreed that, across the recommendation questions, the most important",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 42
  },
  {
    "chunk_id": "infertility_1745",
    "text": "192 Rationale and methodology Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps outcome for people was live birth. It was also agreed that there was probably no important variability across people on how they trade off outcomes. The value placed on these outcomes were considered for all recommendations. All decisions on recommendations were reached by discussion and consensus in virtual meetings, informed by the voting about agreement or disagreement using the GRADEPro online software, including the strength of the recommendations, and where appropriate, the remarks for each recommendation. Before the process, the group decided that any recommendation with less than 80% agreement would undergo discussion and revisions, whereas recommendations with more than 80% agreement would be presented to the GDG for confi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 43
  },
  {
    "chunk_id": "infertility_1746",
    "text": "any recommendation with less than 80% agreement would undergo discussion and revisions, whereas recommendations with more than 80% agreement would be presented to the GDG for confirmation and a plan for addressing minor comments to improve the clarity of the EtD frameworks. In cases where there was disagreement, additional evidence and data were requested and reviewed, additional discussions were held with topic leaders, and recommendations were redrafted and posted for virtual voting, with the goal of reaching a consensus. In all cases, the percentage of panel members in disagreement and their reasons or comments were summarized and shared with the topic leaders. Additional guidance to facilitate the implementation of the guideline recommendations in different settings was also written according to discussions and comments made by the GDG. The full guideline document was circulated to t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 43
  },
  {
    "chunk_id": "infertility_1747",
    "text": "ation of the guideline recommendations in different settings was also written according to discussions and comments made by the GDG. The full guideline document was circulated to the GDG, reviewed and approved. Good practice statements Good practice statements were made in topics where GDG agreed that the guidance was necessary, but a review of the evidence was not warranted because the benefits of the practice were unequivocal and other factors (such as equity) would not have an impact. Good practice statements were rooted in the fact that answers were deemed obvious by the GDG. The methodologist guided the development of good practice statements based on existing GRADE guidance ( 7). Implementation considerations and research gap s Implementation considerations highlighting critical elements that facilitate the appropriate application of recommendations (8) were drafted and presented t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 43
  },
  {
    "chunk_id": "infertility_1748",
    "text": "ions and research gap s Implementation considerations highlighting critical elements that facilitate the appropriate application of recommendations (8) were drafted and presented to the GDG for their input, comments or agreements. Research gaps summarized important questions that needed to be addressed in each topic. Management of conflicts of interest Management of conflicts of interest (COIs) was a priority throughout the guideline development process. Before assuming their roles, all external contributors to the guideline, including members of the GDG, completed a WHO declaration of interests (DOI) form in accordance with WHO policy for experts. A brief biography of each GDG member was published on the WHO website for 14 days before the first meeting of the GDG. No public comments or objections were received. The DOI forms were reviewed by the WHO Secretariat; statements therein were ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 43
  },
  {
    "chunk_id": "infertility_1749",
    "text": "ebsite for 14 days before the first meeting of the GDG. No public comments or objections were received. The DOI forms were reviewed by the WHO Secretariat; statements therein were summarized and a management plan was developed and documented. At the beginning of guideline development, three invited members of the GDG were identified as having COIs. The Secretariat consulted with the Department of Compliance and Risk Management and Ethics and jointly determined that one member could participate fully, a second could participate as temporary adviser and a third was excluded from the GDG. During the development of the guideline, DOIs were updated by each GDG member every 2 years. After analysing the updated DOI, the WHO Secretariat concluded that four GDG members had a COI. These GDG members were not excluded from participating but their votes were not counted on specific PICOs where they h",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 43
  },
  {
    "chunk_id": "infertility_1750",
    "text": "he WHO Secretariat concluded that four GDG members had a COI. These GDG members were not excluded from participating but their votes were not counted on specific PICOs where they had a COI. None of the members of the ERG were determined to have COIs that required exclusion from reviewing the guideline; however, consideration of comments from several ERG members was restricted on several topics based on their declared interests (see Annexes 4 and 5 for the summary of declared interests from members of the GDG and ERG, respectively).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 43
  },
  {
    "chunk_id": "infertility_1751",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 20 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Infertility Fact Sheet [Internet web page]. Geneva: World Health Organization; 2024 (https://www. who.int/news-room/fact-sheets/detail/infertility). 2. Morshed-Behbahani B, Lamyian M, Joulaei H, Rashidi BH, Montazeri A. Infertility policy analysis: a comparative study of selected lower middle- middle- and high-income countries. Global Health. 2020;16(1):104 (https://doi.org/10.1186/ s12992-020-00617-9). 3. WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/ handle/10665/145714). 4. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al. Cochrane handbook for systematic reviews of interventions, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 44
  },
  {
    "chunk_id": "infertility_1752",
    "text": " (https://apps.who.int/iris/ handle/10665/145714). 4. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al. Cochrane handbook for systematic reviews of interventions, second edition. Chichester: John Wiley & Sons; 2019. 5. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [website]. GRADE Working Group; 2013 (https://gdt.gradepro.org/app/ handbook/handbook.html). 6. Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305-7 (https://doi.org/10.1038/ d41586-019-00857-9). 7. Guyatt GH, Alonso-Coello P, Schünemann HJ, Djulbegovic B, Nothacker M, Lange S et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol. 2016;80:3-7 (https://doi.org/10.1016/j.jclinepi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 44
  },
  {
    "chunk_id": "infertility_1753",
    "text": "ange S et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol. 2016;80:3-7 (https://doi.org/10.1016/j.jclinepi.2016.07.006). 8. Lotfi T, Hajizadeh A, Moja L, Akl EA, Piggott T, Kredo T et al. A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. J Clin Epidemiol. 2022;141:161-71 (https://doi.org/10.1016/j. jclinepi.2021.09.028).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 44
  },
  {
    "chunk_id": "infertility_1754",
    "text": "3 Approach to evaluation and management of infertility This chapter provides information on the objective and key steps involved in the clinical assessment and management of infertility. 3.1 Objective 3.2 Indication 3.3 Elements of evaluation and management Chapter Relevant resources Annex 6. Components of female medical history and physical examination Annex 7. Components of male medical history and physical examination Web Annex A. Evidence to decision tables for approach to the evaluation and management of infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 45
  },
  {
    "chunk_id": "infertility_1755",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 22 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 3.1 Objective The objective of a comprehensive evaluation is to facilitate prompt diagnosis and treatment of infertility, while mitigating predisposing risk factors in order to enhance the chances of achieving a pregnancy. 3.2 Indication Evaluation of both the female and male partners is initiated simultaneously to provide prompt diagnosis of infertility before commencing treatment. A diagnosis of infertility is arrived at if there is failure to achieve a pregnancy after 12 months of unprotected intercourse (1). WHO defines infertility as failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. 3.3 Elements of evaluation and management Fig. 3.1. Elem",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 46
  },
  {
    "chunk_id": "infertility_1756",
    "text": "HO defines infertility as failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. 3.3 Elements of evaluation and management Fig. 3.1. Elements of evaluation and management The basic evaluation and management of infertility includes the following components: Initial consultation Taking and recording a medical history Conducting a physical examination Provision of information about pre-pregnancy advice, counselling or care Discussion of diagnosis, etiology and treatment options Conducting a diagnostic evaluation of the male and female reproductive functions Agreeing on and providing treatment for infertility Providing a clinical follow-up and managing the risks of infertility treatment Documenting the outcomes of infertility treatment Identification and referral of patients with coexisting conditions to other services",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 46
  },
  {
    "chunk_id": "infertility_1757",
    "text": "233 Approach to evaluation and management of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Initial consultation The first contact with a health provider is often initiated by patients, especially females, with concerns about a delay or failure to achieve pregnancy. The disproportionate blame for infertility placed on females can result in them seeking care unaccompanied by their male partners. In other cases, infertility may come up in the context of other health issues. Specific complaints and symptoms are identified during the initial consultation. In all cases, it is essential that there is a conducive and private environment to enable individuals and couples to freely discuss their complaints or concerns with the health care provider. It is important for health care providers to anticipate ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 47
  },
  {
    "chunk_id": "infertility_1758",
    "text": "environment to enable individuals and couples to freely discuss their complaints or concerns with the health care provider. It is important for health care providers to anticipate and manage privacy, which can affect (or cause discomfort with) the disclosure of sensitive information among couples with infertility. Interactions with people with infertility may involve some loss of privacy ( 2–4). Although it is helpful to interview the couple together for history-taking, creating opportunities for interviewing each partner separately can be more gender-sensitive because it can avail additional or sensitive information; some questions are better asked when either partner is alone, for example, history of previous sexual partners, pregnancies, STIs and intimate partner violence, among others. These questions can be asked conveniently at the same time as the physical examination is performed",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 47
  },
  {
    "chunk_id": "infertility_1759",
    "text": " sexual partners, pregnancies, STIs and intimate partner violence, among others. These questions can be asked conveniently at the same time as the physical examination is performed (5, 6). Taking and recording medical history A comprehensive history is important in establishing the likelihood of infertility and potential risk factors that could be contributing to it. Some readily apparent causes of infertility can be identified through a comprehensive medical history and examination. It is important for health care providers to be non-judgemental in their approach to history-taking. For females, key aspects of medical history include obstetric history, pregnancy history, duration of attempting to get pregnant, menstrual history, past medical and surgical history, gynaecological history (including previous investigations or treatment for infertility), history of STIs, sexual history (incl",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 47
  },
  {
    "chunk_id": "infertility_1760",
    "text": "menstrual history, past medical and surgical history, gynaecological history (including previous investigations or treatment for infertility), history of STIs, sexual history (including frequency and timing of sex, and sexual dysfunction), childhood and developmental history, family history, occupational history (including history of potential gonadotoxic exposure) and a review of systems, current health status, lifestyle (including tobacco smoking, alcohol and substance use) and medications (see Annex 6. Components of female medical history and physical examination). For males, history typically covers past medical history, reproductive history, sexual history (including STIs, erectile dysfunction, ejaculatory dysfunction and injuries to reproductive organs), duration of attempting to achieve pregnancy, past medical and surgical history (including previous investigations or treatment fo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 47
  },
  {
    "chunk_id": "infertility_1761",
    "text": " dysfunction and injuries to reproductive organs), duration of attempting to achieve pregnancy, past medical and surgical history (including previous investigations or treatment for infertility), childhood and developmental history, family history, occupational history (including history of potential gonadotoxic exposure) and a review of systems, current health status, lifestyle (including tobacco smoking, alcohol and substance use) and medications (see Annex 7. Components of male medical history and physical examination.)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 47
  },
  {
    "chunk_id": "infertility_1762",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 24 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Conducting a physical examination A focused physical examination is essential. The scope and procedures for the physical examination of couples are outlined in the WHO manual for the standardized investigation and diagnosis of the infertile couple (6). For females, a targeted physical examination may include vital signs, BMI, breast examination, thyroid examination, examination of the external genitalia, speculum/ vaginal examination and a bimanual pelvic examination, which includes an examination of the vaginal, cervical, uterine and pelvic anatomy (see Annex 6. Components of female medical history and physical examination). For males, a focused physical examination includes assessment of ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 48
  },
  {
    "chunk_id": "infertility_1763",
    "text": "cervical, uterine and pelvic anatomy (see Annex 6. Components of female medical history and physical examination). For males, a focused physical examination includes assessment of vital signs and BMI, examination of the body characteristics (such as poor virilization, gynaecomastia or obesity), inguinal and genital areas (for scars), external genitalia including the penis (for hypospadias, epispadias, phimosis or curvature), testes (for location, size, texture, consistency, pain, nodules or tenderness), vas deferens and epididymis (if present, absent, inflamed or obstructed), and the spermatic cord and scrotum (for varicocele, hydrocele or cysts) (see Annex 7. Components of male medical history and physical examination). Health care providers should inform patients what the examination will entail, obtain consent and conduct the examination in privacy, under hygienic conditions and in th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 48
  },
  {
    "chunk_id": "infertility_1764",
    "text": "mination). Health care providers should inform patients what the examination will entail, obtain consent and conduct the examination in privacy, under hygienic conditions and in the presence of a chaperone if required. If presence of a chaperone is not feasible (e.g. because of staff shortage), health care providers should obtain consent from the patients to be examined without a chaperone. All findings should be recorded. Conducting a diagnostic evaluation of the male and female reproductive functions The basic diagnostic evaluation includes the following: • Semen analysis. The procedures for the evaluation and interpretation of a semen analysis are included in the WHO laboratory manual for the examination and processing of human semen (7), which is updated regularly (see Chapter 5.4 for recommendations on semen analysis); • Assessment of ovulation and ovulatory function (see Chapter 5.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 48
  },
  {
    "chunk_id": "infertility_1765",
    "text": " processing of human semen (7), which is updated regularly (see Chapter 5.4 for recommendations on semen analysis); • Assessment of ovulation and ovulatory function (see Chapter 5.1 for recommendations on confirmation of ovulation, assessment of reproductive hormones and assessment of ovarian reserve); • Assessment of the fallopian tubes (see Chapter 5.2 for recommendations related to the diagnostic evaluation of fallopian tubes); • Assessment of the uterus (see Chapter 5.3 for recommendations on diagnostic evaluation of the uterine cavity). Good practice statement For males and females being evaluated and managed for infertility, it is good practice to select diagnostic tests based on the clinical findings from the medical history and physical examination to ensure that evaluation is systematic and cost-effective.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 48
  },
  {
    "chunk_id": "infertility_1766",
    "text": "253 Approach to evaluation and management of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Discussion of diagnosis, etiology and treatment options The purpose of the initial and any additional diagnostic tests is to identify the cause(s) of infertility, which could be due to female factors, male factors, a combination of these or unexplained factors, which can then be treated to improve fertility outcomes. There may be specific underlying causes of infertility, such as fibroids, endometriosis, ovarian damage caused by prior ovarian surgery, infection, obstruction, varicocele, chemotherapy and radiation therapy, among others. An important consideration is age-related fertility decline, particularly in females. As the number of oocytes in the ovaries decreases progressively through atresia (8, 9)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 49
  },
  {
    "chunk_id": "infertility_1767",
    "text": "others. An important consideration is age-related fertility decline, particularly in females. As the number of oocytes in the ovaries decreases progressively through atresia (8, 9), fecundity decreases with increasing age (10). Information about the causes of infertility, including age, comorbidities, previous STIs, reproductive tract and other pelvic infections, lifestyle and behavioural factors (including exercise, BMI, diet and the use of alcohol and tobacco products), and environmental and occupational factors, will be helpful to patients (see Chapter 4.2 on information provision for couples with infertility and Chapter 4.3 on risk reduction from use of tobacco). Informing patients about the diagnostic and treatment options is important. When discussing treatment options, it is important to inform patients about the inter-pregnancy interval, the fertility window (as appropriate) and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 49
  },
  {
    "chunk_id": "infertility_1768",
    "text": "treatment options is important. When discussing treatment options, it is important to inform patients about the inter-pregnancy interval, the fertility window (as appropriate) and the likelihood of pregnancy and live birth in the context of parental goals and desired family size. Patients seeking fertility care are often anxious or worried about their diagnosis of infertility (11–13) but the ability of health care providers to identify the psychological and emotional support needs of patients is often suboptimal (14). Patients may require supportive psychosocial services on-site or via referrals. Good practice statement For males and females being evaluated and managed for infertility, it is good practice to listen to individuals and couples, respect their preferences, discuss if psychological and social or peer support is needed, and if needed, provide it or refer patients for it. Provi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 49
  },
  {
    "chunk_id": "infertility_1769",
    "text": "sten to individuals and couples, respect their preferences, discuss if psychological and social or peer support is needed, and if needed, provide it or refer patients for it. Provision of pre-pregnancy advice, counselling or care The goal of providing pre-pregnancy advice, counselling or care for individuals with pregnancy intentions is to reduce the risk of adverse reproductive and obstetric outcomes by improving or optimizing health, addressing modifiable risk factors during the pre-pregnancy or peri-conception period. Providing information on factors that can increase the risk of infertility is an important part of pre-pregnancy advice, counselling and care. It provides an opportunity to assess lifestyle, improve health status and modify behaviours and other individual, behavioural and environmental factors that could contribute to poor pregnancy outcomes around the time of conception",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 49
  },
  {
    "chunk_id": "infertility_1770",
    "text": "prove health status and modify behaviours and other individual, behavioural and environmental factors that could contribute to poor pregnancy outcomes around the time of conception (15). It also provides an opportunity to review medications, immunization status, nutritional status and carrier and other genetic conditions, such as neural tube defects (15). Nutrition is important during pre-pregnancy or the peri-conception period for a couple, and a balanced diet provides many vitamins and trace elements that are essential for good health ( 16). Identification and referral of patients with coexisting conditions to other services Multiple health conditions may affect the ability to achieve pregnancy and subsequent pregnancy outcomes. Such comorbidities may coexist alongside",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 49
  },
  {
    "chunk_id": "infertility_1771",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 26 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps infertility or may contribute to infertility itself. Comorbidities may include communicable (such as STIs) or noncommunicable (such as cancer, cardiovascular disease, diabetes, and poor mental health) conditions. Depending on the capacity of the health care system, patients may need to be referred to other specialities or centres for appropriate management of the identified comorbidities. Some patients with coexisting conditions may be identified and managed easily on-site, while others may require referral to a specialist for a thorough workup and management, to ensure that no comorbidities are missed. Agreeing on and providing treatment for infertility Based on the identified causes of in",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 50
  },
  {
    "chunk_id": "infertility_1772",
    "text": "pecialist for a thorough workup and management, to ensure that no comorbidities are missed. Agreeing on and providing treatment for infertility Based on the identified causes of infertility, it is essential to provide appropriate treatment without unnecessary delay. Treatment is provided after agreeing with patients about the treatment approach and obtaining informed consent, based on collaborative decision-making and transparent information from health care providers about treatment expectations and what is involved. Treatment should be evidence- based and should adhere to the non-maleficence principle (first do no harm); great care must be taken not to induce any pathology in the mother or the offspring ( 5). The diagnostic pathway, referral and management plan for either partner ought to be informed by the results of the tests of the other partner, and be progressively adjusted to opt",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 50
  },
  {
    "chunk_id": "infertility_1773",
    "text": " The diagnostic pathway, referral and management plan for either partner ought to be informed by the results of the tests of the other partner, and be progressively adjusted to optimize efficiency. For example, in some couples presenting initially with an isolated pathology in one partner, a relevant complementary pathology may thereafter be identified in the other partner during investigations, which may alter the overall management plan (5). See the following chapters for recommendations related to treatment of infertility because of ovulatory dysfunction (Chapter 6), tubal disease ( Chapter 7), uterine cavity disorders ( Chapter 8), male factors (Chapter 9) and unexplained factors ( Chapter 10). Good practice statements For males and females being evaluated and managed for infertility, it is good practice to base treatment decisions on benefits and harms, patient values and preference",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 50
  },
  {
    "chunk_id": "infertility_1774",
    "text": "e statements For males and females being evaluated and managed for infertility, it is good practice to base treatment decisions on benefits and harms, patient values and preferences, feasibility, costs and availability of resources. For males and females being evaluated and managed for infertility, it is good practice to consider the cost-effectiveness of treatment (e.g. least expensive but effective treatments should be provided initially).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 50
  },
  {
    "chunk_id": "infertility_1775",
    "text": "273 Approach to evaluation and management of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Providing a clinical follow-up and managing the risks of infertility treatment While IVF and other fertility treatments are generally safe, a variety of risks can be encountered, which may range from minor side-effects to serious complications, such as multiple pregnancy, ovarian hyperstimulation syndrome (OHSS), infections and iatrogenic adverse effects. Infertility patients may also be exposed to a variety of risks due to cross- border reproduction, disease epidemics or natural disasters. Patients with infertility often travel long distances to access fertility care; depending on the health care system context, they may occasionally come under interim care of health care providers who have less knowledg",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 51
  },
  {
    "chunk_id": "infertility_1776",
    "text": " long distances to access fertility care; depending on the health care system context, they may occasionally come under interim care of health care providers who have less knowledge of infertility treatments, for example, in geographically underserved areas. In some countries, the health system may require transfer of patients to other health care providers for ongoing care after infertility treatment has been provided. Although information about the plan for clinical follow-up and management of potential risks that could occur during treatment of infertility and how to mitigate risks is desired by patients ( 17, 18), health care providers do not always provide it ( 19). It is important for health care providers to discuss clinical care plans and how potential risks can be managed with their patients, as part of a wider safety and risk management strategy for fertility care services. Goo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 51
  },
  {
    "chunk_id": "infertility_1777",
    "text": "s to discuss clinical care plans and how potential risks can be managed with their patients, as part of a wider safety and risk management strategy for fertility care services. Good practice statement For males and females being evaluated and managed for infertility, it is good practice to discuss the plan for clinical follow-up and management of potential risks that may occur during infertility treatment. Documenting the outcomes of infertility treatment Many individuals and couples seeking pregnancy are generally highly motivated; however, treatment dropout rates can be high for several reasons (20–22), and among patients who complete their treatment journey, outcomes may vary. Antenatal guideline recommendations are provided by WHO to facilitate a positive pregnancy experience while enhancing continuity and quality of care throughout pregnancy and ensure good outcomes (23). However, r",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 51
  },
  {
    "chunk_id": "infertility_1778",
    "text": "ions are provided by WHO to facilitate a positive pregnancy experience while enhancing continuity and quality of care throughout pregnancy and ensure good outcomes (23). However, reporting of the outcomes of infertility treatment, including of resulting pregnancies, by health care providers is often suboptimal. Improved documentation of outcomes is required to verify the effects of infertility treatment and facilitate monitoring, surveillance and quality improvement of fertility care. Depending on the health care system context and capacity, the following may be required: referrals; integrated reporting or better data connectivity in health information systems, which enables linking ART and other medically assisted reproduction registries; birth and neonatal registries; and other electronic health records. Good practice statement For males and females being evaluated and managed for infe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 51
  },
  {
    "chunk_id": "infertility_1779",
    "text": "sted reproduction registries; birth and neonatal registries; and other electronic health records. Good practice statement For males and females being evaluated and managed for infertility, it is good practice to document the outcomes of pregnancies resulting from infertility treatment.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 51
  },
  {
    "chunk_id": "infertility_1780",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 28 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. International Classification of Diseases, 11th Revision (ICD-11) Geneva: World Health Organization; 2018 (https://www.who.int/ classifications/icd/en/). 2. Steuber KR, Solomon DH. Relational uncertainty, partner interference, and privacy boundary turbulence: explaining spousal discrepancies in infertility disclosures. J Soc Pers Relat. 2012;29(1):3-27 (https://doi. org/10.1177/0265407511406896). 3. Bute JJ. “Nobody thinks twice about asking”: women with a fertility problem and requests for information. Health Commun. 2009;24(8):752-63 (https://doi.org/10.1080/10410230903265920). 4. Inhorn MC. Sexuality, masculinity, and infertility in Egypt: potent troubles in the marital and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 52
  },
  {
    "chunk_id": "infertility_1781",
    "text": "n. Health Commun. 2009;24(8):752-63 (https://doi.org/10.1080/10410230903265920). 4. Inhorn MC. Sexuality, masculinity, and infertility in Egypt: potent troubles in the marital and medical encounters. J Mens Stud. 2002;10(3):343- 59 (https://doi.org/10.3149/jms.1003.343). 5. Rowe PJ, Comhaire FH, Hargreave TB, Mahmoud AM. WHO manual for the standardized investigation and diagnosis of the infertile male. Cambridge: Cambridge University Press; 2000 (https://iris.who.int/handle/10665/42437). 6. Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ, editors. WHO manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 1993 (https://iris.who.int/handle/10665/36983). 7. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/bitstream/hand le/1066",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 52
  },
  {
    "chunk_id": "infertility_1782",
    "text": "83). 7. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/bitstream/hand le/10665/343208/9789240030787-eng.pdf) 8. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772 (https://doi.org/10.1371/journal. pone.0008772). 9. Matsuda F, Inoue N, Manabe N, Ohkura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J Reprod Dev. 2012;58(1):44-50 (https://doi.org/10.1262/jrd.2011-012). 10. Chua S, Danhof N, Mochtar M, Van Wely M, McLernon D, Custers I et al. Age-related natural fertility outcomes in women over 35 years: a systematic review and individual participant data meta-analysis. Hum Reprod. 2020;35(8):1808-20 (https://doi.org/10.1093/humrep/deaa129). 11. Simionescu G, Doroftei B, Mafte",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 52
  },
  {
    "chunk_id": "infertility_1783",
    "text": "ars: a systematic review and individual participant data meta-analysis. Hum Reprod. 2020;35(8):1808-20 (https://doi.org/10.1093/humrep/deaa129). 11. Simionescu G, Doroftei B, Maftei R, Obreja BE, Anton E, Grab D et al. The complex relationship between infertility and psychological distress (review). Exp Ther Med. 2021;21(4):306 (https:// doi.org/10.3892/etm.2021.9737). 12. Greil AL. Infertility and psychological distress: a critical review of the literature. Soc Sci Med. 1997;45(11):1679-704 (https://doi.org/10.1016/ s0277-9536(97)00102-0). 13. Nik Hazlina NH, Norhayati MN, Shaiful Bahari I, Nik Muhammad Arif NA. Worldwide prevalence, risk factors and psychological impact of infertility among women: a systematic review and meta- analysis. BMJ Open. 2022;12(3):e057132 (https:// doi.org/10.1136/bmjopen-2021-057132). 14. Murray S, Awartani KA, Péloquin S. International challenges in patient",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 52
  },
  {
    "chunk_id": "infertility_1784",
    "text": "c review and meta- analysis. BMJ Open. 2022;12(3):e057132 (https:// doi.org/10.1136/bmjopen-2021-057132). 14. Murray S, Awartani KA, Péloquin S. International challenges in patient-centred care in fertility clinics offering assisted reproductive technology: providers’ gaps and attitudes towards addressing the patients’ psychological needs. J Eur CME. 2015;4(1):27578 (https://doi. org/10.3402/jecme.v4.27578). 15. Preconception care: maximizing the gains for maternal and child health. Geneva: World Health Organization; 2013 (https://iris.who.int/ bitstream/handle/10665/340533/WHO-FWC- MCA-13.02-eng.pdf?sequence=1). 16. Vitamin and mineral requirements in human nutrition. Geneva: World Health Organization and Food and Agriculture Organization of the United Nations; 2004 (https://iris.who.int/ handle/10665/42716). 17. Dancet EAF, Nelen WLDM, Sermeus W, De Leeuw L, Kremer JAM, D’Hooghe TM. Th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 52
  },
  {
    "chunk_id": "infertility_1785",
    "text": " and Agriculture Organization of the United Nations; 2004 (https://iris.who.int/ handle/10665/42716). 17. Dancet EAF, Nelen WLDM, Sermeus W, De Leeuw L, Kremer JAM, D’Hooghe TM. The patients’ perspective on fertility care: a systematic review. Hum Reprod Update. 2010;16(5):467-87 (https://doi.org/10.1093/ humupd/dmq004).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 52
  },
  {
    "chunk_id": "infertility_1786",
    "text": "293 Approach to evaluation and management of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 18. von Estorff F, Mochtar MH, Lehmann V, van Wely M. Driving factors in treatment decision-making of patients seeking medical assistance for infertility: a systematic review. Hum Reprod Update. 2024;30(3):341-54 (https:// doi.org/10.1093/humupd/dmae001). 19. Stewart DE, Rosen B, Irvine J, Ritvo P, Shapiro H, Murphy J et al. The disconnect: infertility patients’ information and the role they wish to play in decision making. Medscape Womens Health. 2001;6(4):1 (http://europepmc.org/abstract/ MED/11547268). 20. Gameiro S, Boivin J, Peronace L, Verhaak CM. Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment. Hum Reprod Updat",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 53
  },
  {
    "chunk_id": "infertility_1787",
    "text": ", Peronace L, Verhaak CM. Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment. Hum Reprod Update. 2012;18(6):652-69 (https://doi. org/10.1093/humupd/dms031). 21. Ghorbani M, Hoseini FS, Yunesian M, Salehin S, Keramat A, Nasiri S. A systematic review and meta-analysis on dropout of infertility treatments and related reasons/factors. J Obstet Gynaecol. 2022;42(6):1642-52 (https://doi.org/10.1080/0144 3615.2022.2071604). 22. Shen Q, Wang B, He T, Li S, Peng E, Lei J. Factors associated with discontinuation in fertility treatment: a systematic scoping review. J Assist Reprod Genet. 2024;41:409-21 (https://doi. org/10.1007/s10815-023-02982-x). 23. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (https://www.who.int/ publications/i/item/9789241",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 53
  },
  {
    "chunk_id": "infertility_1788",
    "text": "3-02982-x). 23. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (https://www.who.int/ publications/i/item/9789241549912).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 53
  },
  {
    "chunk_id": "infertility_1789",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 30 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 4 Prevention of infertility This chapter presents several recommendations related to the prevention of infertility. Chapter 4.1 Information provision on fertility and infertility for the general population 4.2 Information provision for individuals and couples with infertility 4.3 Risk reduction from the use of tobacco 4.4 Risk reduction from sexually transmitted infections Relevant resources Web Annex B. Evidence to decision tables for prevention of infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 54
  },
  {
    "chunk_id": "infertility_1790",
    "text": "314 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 4.1 Information provision on fertility and infertility for the general population Recommendation For the general population of reproductive age, WHO suggests providing information about fertility and infertility using low-cost strategies or whenever there is opportunity. (Conditional recommendation, very low certainty of evidence) Remarks: • Low-cost strategies may include information in digital or paper format when opportunities occur in schools, at primary health care centres or at reproductive health (contraceptive, sexual health) clinics. • Information adapted to local contexts and audiences, including how to reduce risk factors for infertility, lifestyle modification, age-related fertility decline/ potential, and timely medica",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 55
  },
  {
    "chunk_id": "infertility_1791",
    "text": "n adapted to local contexts and audiences, including how to reduce risk factors for infertility, lifestyle modification, age-related fertility decline/ potential, and timely medical consultation, may increase the likelihood of information uptake and beneficial outcomes. Background and rationale Education about fertility and infertility can be provided at various stages of the reproductive lifespan, for example, to the general population who may consider conceiving in the future, individuals who are trying to achieve a pregnancy, people who are at high risk of infertility or those who are already experiencing infertility. Information on fertility and infertility can be provided at different time points in relation to risk factors that limit fertility: (i) before the risk factor is present; (ii) when the risk factor is present but not yet fertility-limiting (population is at risk); or (iii",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 55
  },
  {
    "chunk_id": "infertility_1792",
    "text": "on to risk factors that limit fertility: (i) before the risk factor is present; (ii) when the risk factor is present but not yet fertility-limiting (population is at risk); or (iii) when the disease is present (population has infertility). The present recommendation applies to the general population not at risk of infertility. For the general population, fertility education can include information on fertility potential, risk factors for infertility and how to reduce risk factors or improve healthy lifestyle factors in general. The aim of information provision in this (presumed fertile) population is to improve fertility awareness and future pregnancy planning. Fertility awareness is defined as the “understanding of reproduction, fecundity, fecundability, and related individual risk factors (e.g. advanced age, sexual health factors such as sexually transmitted infections (STIs), and life",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 55
  },
  {
    "chunk_id": "infertility_1793",
    "text": "ng of reproduction, fecundity, fecundability, and related individual risk factors (e.g. advanced age, sexual health factors such as sexually transmitted infections (STIs), and lifestyle factors such as smoking, obesity) and non-individual risk factors (e.g. environmental and workplace factors); including the awareness of societal and cultural factors affecting options to meet reproductive family planning, as well as family building needs” (1). Fertility education can be provided through a variety of methods, including information pamphlets, brochures, counselling and online platforms, such as websites, videos or animations, mobile applications or other information tools aimed at increasing public awareness about fertility and infertility. It can be provided individually or in group settings. Other preventive interventions can also be provided to the general population to reduce risk fact",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 55
  },
  {
    "chunk_id": "infertility_1794",
    "text": "t fertility and infertility. It can be provided individually or in group settings. Other preventive interventions can also be provided to the general population to reduce risk factors that go beyond simply education, such as nutrition and fitness and wellness programmes. Recommendations for these types of interventions are not addressed in this guideline but will be in the future. For this recommendation, the GDG addressed the question: should information on fertility and infertility be provided to the general population or people who are not at risk or not?",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 55
  },
  {
    "chunk_id": "infertility_1795",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 32 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. 4.1. Information on fertility and infertility Where to provide fertility information Education enables reproductive planning Schools / educational institutions Integrate into health education Primary care During routine health visits and checkups Sexual health Family planning and reproductive clinics Sexual health Untreated sexually transmitted infections can cause infertility Age-related fertility decline Understanding fertility potential changes with age especially among females Understanding infertility What infertility is, common causes, when to seek help and available support options for individuals and couples Healthy lifestyle Risk factors include: • smoking, • excessive alcohol",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 56
  },
  {
    "chunk_id": "infertility_1796",
    "text": "at infertility is, common causes, when to seek help and available support options for individuals and couples Healthy lifestyle Risk factors include: • smoking, • excessive alcohol use, • obesity, • being underweight, • others (see Chapters 1 and 4 of this guideline). Providing information on fertility and infertility to people of reproductive age helps reduce risk factors and promotes timely care-seeking. It also enables reproductive planning. Key messages Balancing harms and benefits A systematic review was conducted and identified nine trials (10 publications) that reported on the effects of specific information provision interventions on a group of participants. Two trials recruited women presenting at primary care clinics (2) or to donate oocytes ( 3). Two trials recruited women visiting midwives for contraceptive counselling ( 4, 5). Four trials recruited adolescents and young adul",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 56
  },
  {
    "chunk_id": "infertility_1797",
    "text": "ary care clinics (2) or to donate oocytes ( 3). Two trials recruited women visiting midwives for contraceptive counselling ( 4, 5). Four trials recruited adolescents and young adults ( 6–10) and one trial involved women of reproductive age ( 11). One study included men (8). All studies compared an education intervention to a control or no intervention. Specific education interventions addressed in these trials included: • fertility-related brochures ( 3, 6, 8, 9, 11); • fertility-related slide presentations ( 10); • reproductive life plan counselling ( 2–5); • informative fertility awareness videos ( 7); • fertility education chatbot ( 11). When considering the effects of all information provision interventions compared to a control or no intervention, evidence indicated that there may be small benefits. Knowledge is likely increased with education, but intentions to improve pre-pregnanc",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 56
  },
  {
    "chunk_id": "infertility_1798",
    "text": " compared to a control or no intervention, evidence indicated that there may be small benefits. Knowledge is likely increased with education, but intentions to improve pre-pregnancy behaviours or optimally plan for",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 56
  },
  {
    "chunk_id": "infertility_1799",
    "text": "334 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps pregnancy (e.g. advanced intended timing of childbirth or the age of the first or last child) are likely minimally changed or inconsistently affected. The GDG was uncertain about the effects of education on live births (54 more [from 11 fewer to 226 more] per 1000; relative risk [RR]: 2.12; 95% confidence interval [CI]: 0.78–5.71 after 1 year of follow-up; 42 more [from 31 fewer to 146 more] per 1000; RR: 1.22; 95% CI: 0.84–1.76 after 2 years of follow-up) and there were no data on pregnancy. The GDG was also uncertain about whether education may accelerate the timing of childbirth: in one study (8), where the sample mean age was 30–31 years, there was a fivefold increase in new births at 12 months among partnered individuals in th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 57
  },
  {
    "chunk_id": "infertility_1800",
    "text": "te the timing of childbirth: in one study (8), where the sample mean age was 30–31 years, there was a fivefold increase in new births at 12 months among partnered individuals in the intervention group compared to the control group; however, both groups had similar numbers of new births at 24 months. In terms of undesirable effects, the GDG judged that information provision probably results in a trivial increase in anxiety levels compared to no information provision (mean difference: 1.94 higher with education; 95% CI: 1.18–2.7 higher on the State subscale of the State-Trait Anxiety Inventory score; score range: 20–80) (12). Overall, the GDG agreed that there may be greater benefit than harm with fertility information provision, but the certainty of evidence was very low because of few participants or events, high heterogeneity and potential risk of bias because of poor randomization and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 57
  },
  {
    "chunk_id": "infertility_1801",
    "text": "mation provision, but the certainty of evidence was very low because of few participants or events, high heterogeneity and potential risk of bias because of poor randomization and incomplete data. Given that outcomes such as live births and pregnancy are probably the most important to most individuals trying to achieve pregnancy, the GDG agreed that providing education is probably favoured. Other considerations Provision of information requires resources and results in additional costs when applied population- wide. The GDG judged that the resources required for fertility education vary depending on context and the methods used to disseminate information. Some modalities, such as brochures or pamphlets, cost less when compared to other interventions, such as counselling. Therefore, when costs are low, small and uncertain benefits could outweigh the costs but the downsides of high-cost in",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 57
  },
  {
    "chunk_id": "infertility_1802",
    "text": "ss when compared to other interventions, such as counselling. Therefore, when costs are low, small and uncertain benefits could outweigh the costs but the downsides of high-cost interventions would outweigh potential benefits. Regarding equity, the GDG agreed that providing education could be applied across different populations and settings and may not have a differential impact on equity because the whole population would be reached with the intervention. However, differences could emerge if the method of providing education was more resource- intensive (e.g. providing in-person counselling for some populations and information leaflets for other populations). Several studies provided evidence on the acceptability of fertility-related brochures ( 6, 13), reproductive life plan counselling ( 2, 4, 5, 14), chatbot education (11) and a culturally adapted fertility status awareness tool (Fe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 57
  },
  {
    "chunk_id": "infertility_1803",
    "text": "lity of fertility-related brochures ( 6, 13), reproductive life plan counselling ( 2, 4, 5, 14), chatbot education (11) and a culturally adapted fertility status awareness tool (FertiSTAT) ( 15). Based on data from these studies, the GDG judged that both the general population and health care providers would probably find education interventions acceptable. In addition, the GDG judged that providing information to the general population would be feasible in schools, clinics and primary care settings where other health information is being provided and noted that information and education should be adapted and tailored to local contexts, the audience, risk factors and methods of dissemination.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 57
  },
  {
    "chunk_id": "infertility_1804",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 34 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification Overall, there is very-low-certainty evidence for small benefits, such as increased knowledge and improved behaviours, and for trivial harms, such as anxiety, when providing fertility information. Evidence is very uncertain on the effect of information on live births, and no data are available on pregnancies. Providing information may incur varying costs depending on the format or channel used; therefore, when cheaper dissemination methods, such as pamphlets and posters, are used, benefits may likely outweigh the costs in the general population not at risk (i.e. the presumed fertile general population). However, when costly strategies are used, such as counselling, the",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 58
  },
  {
    "chunk_id": "infertility_1805",
    "text": "y likely outweigh the costs in the general population not at risk (i.e. the presumed fertile general population). However, when costly strategies are used, such as counselling, the benefits are unlikely to outweigh the costs. Provision of information adapted and tailored to local contexts and audiences is probably acceptable and probably feasible. Fig. 4.2. Recommendations for preventing infertility included in the guideline Preventing infertility General population of reproductive age Provide fertility information whenever there’s an opportunity in schools / educational institutions, primary health care centres, and contraceptive/ sexual health clinics Individuals and couples with infertility Oﬀer lifestyle advice before and during infertility treatment (e.g., diet, alcohol, smoking, physical activity, weight management) Risk reduction from tobacco smoking Provide brief advice to all to",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 58
  },
  {
    "chunk_id": "infertility_1806",
    "text": "vice before and during infertility treatment (e.g., diet, alcohol, smoking, physical activity, weight management) Risk reduction from tobacco smoking Provide brief advice to all tobacco users in any health- care setting, explaining that smoking is associated with higher infertility risk and that cessation support exists Risk reduction from Sexually transmitted infections (STIs) Routinely inform people planning or attempting pregnancy about infertility risk when STIs are untreated; encourage or refer for prompt care for symptoms",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 58
  },
  {
    "chunk_id": "infertility_1807",
    "text": "354 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Implementation considerations Education messages need to be adapted and tailored to local contexts, risk factors, the audience (e.g. age and sex among others) and available methods of dissemination. For example, educational resources can be co-designed with the participation of the intended target audience, in their contexts. In all contexts providing specific information on age-related fertility decline/potential, and the long-term impact of lifestyle factors will be important. It is important for individuals and couples to obtain accurate information on fertility and infertility from trusted sources to minimize the risk of misinformation (e.g. via social media [16] or online marketing [17]); health care providers have a role in p",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 59
  },
  {
    "chunk_id": "infertility_1808",
    "text": " fertility and infertility from trusted sources to minimize the risk of misinformation (e.g. via social media [16] or online marketing [17]); health care providers have a role in providing educational information that can inform reproductive planning. In implementing this recommendation, health care providers should note that this guideline contains several recommendations for preventing infertility for different population groups and risk factors (See Fig. 4.1 and Fig. 4.2). Research gaps and future guideline update Given the variability in the evidence on the impact of information provision on fertility outcomes, future evaluation of what information works for whom, in which setting and why, will be needed to ascertain the value of providing information to the public according to the context. Future research is required to ascertain whether subpopulations of people (e.g. partnered indi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 59
  },
  {
    "chunk_id": "infertility_1809",
    "text": " ascertain the value of providing information to the public according to the context. Future research is required to ascertain whether subpopulations of people (e.g. partnered individuals, single women of advanced age, among others) may respond differently to fertility information. Fertility education should include men because men also benefit from fertility education; therefore, future studies should include more men as they were underrepresented in the studies evaluated. References 1. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, De Mouzon J, Sokol R et al. The international glossary on infertility and fertility care, 2017. Hum Reprod. 2017;32(9):1786-801 (https://doi.org/10.1093/humrep/dex234). 2. Fooladi E, Weller C, Salehi M, Abhari FR, Stern J. Using reproductive life plan-based information in a primary health care center increased Iranian women’s knowledge of fertility, bu",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 59
  },
  {
    "chunk_id": "infertility_1810",
    "text": "oladi E, Weller C, Salehi M, Abhari FR, Stern J. Using reproductive life plan-based information in a primary health care center increased Iranian women’s knowledge of fertility, but not their future fertility plan: a randomized, controlled trial. Midwifery. 2018;67:77-86 (https://doi. org/10.1016/j.midw.2018.09.011). 3. García D, Vassena R, Prat A, Vernaeve V. Increasing fertility knowledge and awareness by tailored education: a randomized controlled trial. Reprod Biomed Online. 2016;32(1):113-20 (https://doi.org/10.1016/j.rbmo.2015.10.008). 4. Skogsdal Y, Fadl H, Cao Y, Karlsson J, Tydén T. An intervention in contraceptive counseling increased the knowledge about fertility and awareness of preconception health—a randomized controlled trial. Ups J Med Sci. 2019;124(3):203-12 (https://doi.org/10.1080/0300 9734.2019.1653407). 5. Stern J, Larsson M, Kristiansson P, Tydén T. Introducing repr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 59
  },
  {
    "chunk_id": "infertility_1811",
    "text": "—a randomized controlled trial. Ups J Med Sci. 2019;124(3):203-12 (https://doi.org/10.1080/0300 9734.2019.1653407). 5. Stern J, Larsson M, Kristiansson P, Tydén T. Introducing reproductive life plan-based information in contraceptive counselling: an RCT. Hum Reprod. 2013;28(9):2450-61 (https://doi. org/10.1093/humrep/det279). 6. Boivin J, Koert E, Harris T, O’Shea L, Perryman A, Parker K et al. An experimental evaluation of the benefits and costs of providing fertility information to adolescents and emerging adults. Hum Reprod. 2018;33(7):1247-53 (https://doi. org/10.1093/humrep/dey107). 7. Conceição C, Pedro J, Martins MV. Effectiveness of a video intervention on fertility knowledge among university students: a randomised pre- test/post-test study. Eur J Contracept Reprod Health Care. 2017;22(2):107-13 (https://doi.org/10. 1080/13625187.2017.1288903). 8. Maeda E, Boivin J, Toyokawa S, M",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 59
  },
  {
    "chunk_id": "infertility_1812",
    "text": "a randomised pre- test/post-test study. Eur J Contracept Reprod Health Care. 2017;22(2):107-13 (https://doi.org/10. 1080/13625187.2017.1288903). 8. Maeda E, Boivin J, Toyokawa S, Murata K, Saito H. Two-year follow-up of a randomized controlled trial: knowledge and reproductive outcome after online fertility education. Hum Reprod. 2018;33(11):2035-42 (https://doi.org/10.1093/ humrep/dey293).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 59
  },
  {
    "chunk_id": "infertility_1813",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 36 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 9. Maeda E, Nakamura F, Kobayashi Y, Boivin J, Sugimori H, Murata K et al. Effects of fertility education on knowledge, desires and anxiety among the reproductive-aged population: findings from a randomized controlled trial. Hum Reprod. 2016;31(9):2051-60 (https://doi. org/10.1093/humrep/dew133). 10. Williamson LEA, Lawson KL, Downe PJ, Pierson RA. Informed reproductive decision-making: the impact of providing fertility information on fertility knowledge and intentions to delay childbearing. J Obstet Gynaecol Can. 2014;36(5):400-5 (https://doi.org/10.1016/S1701- 2163(15)30585-5). 11. Maeda E, Miyata A, Boivin J, Nomura K, Kumazawa Y, Shirasawa H et al. Promoting fertility awareness and prec",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 60
  },
  {
    "chunk_id": "infertility_1814",
    "text": " 2014;36(5):400-5 (https://doi.org/10.1016/S1701- 2163(15)30585-5). 11. Maeda E, Miyata A, Boivin J, Nomura K, Kumazawa Y, Shirasawa H et al. Promoting fertility awareness and preconception health using a chatbot: a randomized controlled trial. Reprod Biomed Online. 2020;41(6):1133-43 (https://doi.org/10.1016/j.rbmo.2020.09.006). 12. Spielberger CD, Gonzalez-Reigosa F, Martinez- Urrutia A, Natalicio LF, Natalicio DS. The state- trait anxiety inventory. Interam J Psychol. 1971;5:3–4. 13. Boivin J, Sandhu A, Brian K, Harrison C. Fertility-related knowledge and perceptions of fertility education among adolescents and emerging adults: a qualitative study. Hum Fertil. 2019;22(4):291-9 (https://doi.org/10.1080/146472 73.2018.1486514). 14. Bodin M, Tydén T, Käll L, Larsson M. Can reproductive life plan-based counselling increase men’s fertility awareness? Ups J Med Sci. 2018;123(4):255-63 (http",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 60
  },
  {
    "chunk_id": "infertility_1815",
    "text": " 73.2018.1486514). 14. Bodin M, Tydén T, Käll L, Larsson M. Can reproductive life plan-based counselling increase men’s fertility awareness? Ups J Med Sci. 2018;123(4):255-63 (https://doi.org/10.1080/0300 9734.2018.1541948). 15. Bayoumi RR, van der Poel S, El Samani EZ, Boivin J. An evaluation of comprehensiveness, feasibility and acceptability of a fertility awareness educational tool. Reprod Biomed Soc Online. 2018;6:10-21 (https://doi.org/10.1016/j. rbms.2018.06.003). 16. John JN, Gorman S, Scales D, Gorman J. Online misleading information about women’s reproductive health: a narrative review. J Gen Intern Med. 2025;40:1123-31 (https://doi. org/10.1007/s11606-024-09118-6). 17. Copp T, Pickles K, Smith J, Hersch J, Johansson M, Doust J et al. Marketing empowerment: how corporations co-opt feminist narratives to promote non-evidence based health interventions. BMJ. 2024;384:e076710 (htt",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 60
  },
  {
    "chunk_id": "infertility_1816",
    "text": "sch J, Johansson M, Doust J et al. Marketing empowerment: how corporations co-opt feminist narratives to promote non-evidence based health interventions. BMJ. 2024;384:e076710 (https:// doi.org/10.1136/bmj-2023-076710).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 60
  },
  {
    "chunk_id": "infertility_1817",
    "text": "374 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 4.2 Information provision for individuals and couples with infertility Recommendation For individuals and couples with infertility, WHO suggests providing low- cost lifestyle advice before and during infertility treatment. (Conditional recommendation, low certainty of evidence) Remarks: • Lifestyle advice may include advice to change diet, alcohol intake, smoking, physical activity and/or weight management. Background and rationale Lifestyle advice can be provided at various stages of the reproductive lifespan, for example, to the general population who may consider having a child in the future, individuals who are currently trying to achieve pregnancy, people who are at high risk of infertility or those who are already diagnosed w",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 61
  },
  {
    "chunk_id": "infertility_1818",
    "text": "ay consider having a child in the future, individuals who are currently trying to achieve pregnancy, people who are at high risk of infertility or those who are already diagnosed with infertility. The present recommendation refers to individuals with infertility. Modifiable lifestyle behaviours such as diet, physical activity, alcohol intake and smoking may affect fertility ( 1). Although the extent of the impact varies (2), these factors may negatively affect the ability of people with infertility to achieve a pregnancy resulting in a live birth. Providing lifestyle advice regarding these factors to people with infertility is intended to optimize the pre-pregnancy health of women and men with infertility and improve their fertility outcomes, such as achieving a pregnancy or live birth. Lifestyle advice includes provision of information, education or counselling about modifiable lifestyl",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 61
  },
  {
    "chunk_id": "infertility_1819",
    "text": "mprove their fertility outcomes, such as achieving a pregnancy or live birth. Lifestyle advice includes provision of information, education or counselling about modifiable lifestyle behaviours. For people with infertility, lifestyle advice could be provided before beginning infertility treatments such as ovulation induction, intrauterine insemination (IUI) or IVF or when receiving these treatments. Lifestyle advice can be provided individually or in group counselling sessions, through web-based or mobile-based applications, telephone calls, pamphlets, booklets or by a combination of these and other delivery channels. For this recommendation, the GDG addressed the question: should lifestyle advice be provided to people with infertility or not? Balancing harms and benefits A published systematic review provided data for this assessment ( 3). Seven randomized controlled trials (RCTs) publis",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 61
  },
  {
    "chunk_id": "infertility_1820",
    "text": " people with infertility or not? Balancing harms and benefits A published systematic review provided data for this assessment ( 3). Seven randomized controlled trials (RCTs) published up to January 2021 were included in this review. Most couples and women with infertility in the studies received information before and/or while receiving fertility treatment, specifically: before fertility treatment in the intervention group (4, 5); before ovulation induction (6); while receiving IVF, IUI or none (7); before any type of fertility treatment in the intervention group (8); while undergoing IVF treatment ( 9); while having investigations or receiving treatment (10); or before or while undergoing IVF with or without intracytoplasmic sperm injection (ICSI) ( 11). Of these, one study included men and women (11). The types of lifestyle advice included a smartphone coaching programme, individual an",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 61
  },
  {
    "chunk_id": "infertility_1821",
    "text": "ntracytoplasmic sperm injection (ICSI) ( 11). Of these, one study included men and women (11). The types of lifestyle advice included a smartphone coaching programme, individual and group counselling (motivational interviewing) and workouts, or information and behavioural modification. Lifestyle advice was provided for 6–24 months. In terms of desirable effects, the GDG agreed that there are likely small effects on important outcomes, such as live births and clinical pregnancies (RR: 0.90; 95% CI: 0.77–1.06 and",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 61
  },
  {
    "chunk_id": "infertility_1822",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 38 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps RR: 1.17; 95% CI: 0.90–1.53, respectively). There is likely no difference to behavioural changes, although diet-related behaviours (such as fruit intake and lower alcohol intake) may be slightly improved. Evidence suggests no difference to quality of life. In terms of undesirable effects, evidence suggested trivial increases in miscarriages (RR: 1.49; 95% CI: 0.96–2.32, meaning 46 more [from four fewer to 124 more] per 1000 couples) and hypertension during pregnancy (RR: 1.07; 95% CI: 0.66–1.75, meaning 11 more [from 55 fewer to 121 more] per 1000 couples). The overall certainty of evidence was low because of lack of blinding, unclear randomization in some studies and few participants or ev",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 62
  },
  {
    "chunk_id": "infertility_1823",
    "text": "rom 55 fewer to 121 more] per 1000 couples). The overall certainty of evidence was low because of lack of blinding, unclear randomization in some studies and few participants or events. Notably, most of the control groups in the studies also received some form of lifestyle advice. As such, comparisons were more about the effects of more intensive or detailed forms of providing advice than no advice per se. The GDG agreed that couples value pregnancy and live births and that there is probably no important variability in how people value these outcomes. Overall, the GDG judged that the balance of effects probably favours information provision over no provision of information on lifestyle. Other considerations Provision of lifestyle advice involves resources; however, the GDG judged that the costs vary: some lifestyle advice interventions may be costly (such as individual one-to-one counsel",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 62
  },
  {
    "chunk_id": "infertility_1824",
    "text": "vision of lifestyle advice involves resources; however, the GDG judged that the costs vary: some lifestyle advice interventions may be costly (such as individual one-to-one counselling), while others may incur lower costs (e.g. information brochures). The GDG also considered evidence from two studies (12, 13) showing that providing lifestyle advice could be cost-effective. When considering the small increase in pregnancy rates, a low-cost lifestyle advice intervention may be favoured. In relation to equity, the GDG noted that while not all forms and intensities of information delivery would be available everywhere, individuals with infertility could be reached with lifestyle advice through delivery methods available locally. However, differences in equity could emerge if the method of providing lifestyle advice was more resource- intensive (e.g. providing in-person counselling for some p",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 62
  },
  {
    "chunk_id": "infertility_1825",
    "text": "lable locally. However, differences in equity could emerge if the method of providing lifestyle advice was more resource- intensive (e.g. providing in-person counselling for some populations and settings, and information leaflets for other populations and settings). The GDG considered evidence from two studies (6, 11) and agreed that providing lifestyle advice may be acceptable to most couples; however, increased efforts to maintain participation may be needed. The GDG noted that the evidence is from couples before or during treatment, who were also receiving different fertility treatments; therefore, lifestyle advice is likely applicable and acceptable to couples at different treatment stages or receiving a variety of fertility treatments. None of the studies examined the effects in people with infertility who chose not to undergo treatment. Feasibility may be dependent on the intensity",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 62
  },
  {
    "chunk_id": "infertility_1826",
    "text": "riety of fertility treatments. None of the studies examined the effects in people with infertility who chose not to undergo treatment. Feasibility may be dependent on the intensity and timing of the lifestyle advice; intense or multi-component lifestyle advice may be more challenging to provide and use. Summary justification Overall, there is low-certainty evidence that the small improvements in live births and pregnancy and health behaviours may outweigh the trivial harms. Although costs may be greater for some types of lifestyle advice, the benefits may outweigh costs when low-cost lifestyle advice is provided. Providing lifestyle advice is probably acceptable to most people, and feasible.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 62
  },
  {
    "chunk_id": "infertility_1827",
    "text": "394 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Implementation considerations When implementing this guideline, health care providers should try to maintain contact and engagement with patients. Sustained engagement for some populations (e.g. patients who need to manage their weight [ 14]) and some forms of lifestyle advice (e.g. more intensive forms of lifestyle face-to-face advice) may be difficult to maintain unless specific efforts are put in place. The goal should be to respectfully explain lifestyle- related risk factors and provide advice, while remaining sensitive to patient experiences and avoiding placing blame on them. Health care providers should monitor and support compliance and should regularly assess prevalent lifestyle risks (e.g. during clinic visits) to contin",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 63
  },
  {
    "chunk_id": "infertility_1828",
    "text": "iding placing blame on them. Health care providers should monitor and support compliance and should regularly assess prevalent lifestyle risks (e.g. during clinic visits) to continually tailor lifestyle advice. Health care providers should select contextually appropriate lifestyle advice and delivery channels according to prevalent lifestyle risks and audience preferences in different settings. Research gaps and future guideline update Future research and guidance will be needed on the optimal components of lifestyle advice, their timing and intensity. In addition, future studies should include a diverse group of patients, including men, the male and female partners of patients, and men and women of advanced age, among others. Most of the available evidence is about couples who are receiving ART; future studies should include couples with infertility who are not and people not seeking an",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 63
  },
  {
    "chunk_id": "infertility_1829",
    "text": "e, among others. Most of the available evidence is about couples who are receiving ART; future studies should include couples with infertility who are not and people not seeking any medical treatment. Future guidance will be required for specific subgroups, such as those with a high BMI and impaired glucose tolerance, among others. Future research is needed on which lifestyle modification techniques are optimal for achieving the desired effects. References 1. Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol Endocrinol. 2013;11:66 (https://doi.org/10.1186/1477-7827- 11- 66). 2. Homan GF, Davies M, Norman R. The impact of lifestyle factors on reproductive performance in the general population and those undergoing infertility treatment: a review. Hum Reprod Update. 2007;13(3):209-23 (https://doi. org/10.10",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 63
  },
  {
    "chunk_id": "infertility_1830",
    "text": "yle factors on reproductive performance in the general population and those undergoing infertility treatment: a review. Hum Reprod Update. 2007;13(3):209-23 (https://doi. org/10.1093/humupd/dml056). 3. Boedt T, Vanhove AC, Vercoe MA, Matthys C, Dancet E, Lie Fong S. Preconception lifestyle advice for people with infertility. Cochrane Database Syst Rev. 2021;(4):CD008189 (https:// doi.org/10.1002/14651858.CD008189.pub3). 4. Belan M, Carranza-Mamane B, AinMelk Y, Pesant M-H, Duval K, Jean-Denis F et al. Lifestyle modifications in male partners of subfertile couples in which the spouse is obese improves the chances of the couple to conceive. Fertil Steril. 2019;112(3):e213 (https://doi.org/10.1016/j. fertnstert.2019.07.670). 5. Belan M, Carranza-Mamane B, AinMelk Y, Pesant M-H, Duval K, Jean-Denis F et al. A lifestyle intervention targeting women with obesity and infertility improves their ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 63
  },
  {
    "chunk_id": "infertility_1831",
    "text": "19.07.670). 5. Belan M, Carranza-Mamane B, AinMelk Y, Pesant M-H, Duval K, Jean-Denis F et al. A lifestyle intervention targeting women with obesity and infertility improves their fertility outcomes, especially in women with PCOS: a randomized controlled trial. Fertil Steril. 2019;112(3):e40 (https://doi.org/10.1016/j.fertnstert.2019.07.234). 6. Mutsaerts MA, Van Oers AM, Groen H, Burggraaff JM, Kuchenbecker WK, Perquin DA et al. Randomized trial of a lifestyle program in obese infertile women. N Engl J Med. 2016;374:1942-53 (https://doi.org/10.1056/ NEJMoa1505297).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 63
  },
  {
    "chunk_id": "infertility_1832",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 40 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 7. Alibeigi Z, Jafari-Dehkordi E, Kheiri S, Nemati M, Mohammadi-Farsani G, Tansaz M. The impact of traditional medicine-based lifestyle and diet on infertility treatment in women undergoing assisted reproduction: a randomized controlled trial. Complement Med Res. 2020;27(4):230-41 (https://doi.org/10.1159/000505016). 8. Hughes EG, Lamont DA, Beecroft ML, Wilson DM, Brennan BG, Rice SC. Randomized trial of a “stage-of-change” oriented smoking cessation intervention in infertile and pregnant women. Fertil Steril. 2000;74(3):498-503 (https://doi. org/10.1016/s0015-0282(00)00687-7). 9. Rossi BV, Chang G, Berry KF, Hornstein MD, Missmer SA. In vitro fertilization outcomes and alcohol consumption",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 64
  },
  {
    "chunk_id": "infertility_1833",
    "text": "00;74(3):498-503 (https://doi. org/10.1016/s0015-0282(00)00687-7). 9. Rossi BV, Chang G, Berry KF, Hornstein MD, Missmer SA. In vitro fertilization outcomes and alcohol consumption in at‐risk drinkers: the effects of a randomized intervention. Am J Addict. 2013;22(5):481-5 (ht tps://doi.org/10.1111/j.1521- 0391.2013.12019.x). 10. Ng KYB, Wellstead S, Cheong Y, Macklon N. A randomised controlled trial of a personalised lifestyle coaching application in modifying periconceptional behaviours in women suffering from reproductive failures (iPLAN trial). BMC Womens Health. 2018;18(1):196 (https://doi. org/10.1186/s12905-018-0689-7). 11. Oostingh EC, Koster MP, van Dijk MR, Willemsen SP, Broekmans FJ, Hoek A et al. First effective mHealth nutrition and lifestyle coaching program for subfertile couples undergoing in vitro fertilization treatment: a single-blinded multicenter randomized controlle",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 64
  },
  {
    "chunk_id": "infertility_1834",
    "text": "rst effective mHealth nutrition and lifestyle coaching program for subfertile couples undergoing in vitro fertilization treatment: a single-blinded multicenter randomized controlled trial. Fertil Steril. 2020;114(5):945-54 (https://doi. org/10.1016/j.fertnstert.2020.04.051). 12. Oostingh EC, Ophuis RH, Koster MP, Polinder S, Lingsma HF, Laven JS et al. Mobile health coaching on nutrition and lifestyle behaviors for subfertile couples using the smarter pregnancy program: model-based cost-effectiveness analysis. JMIR Mhealth Uhealth. 2019;7(10):e13935 (https://doi.org/10.2196/13935). 13. Van Oers AM, Mutsaerts MA, Burggraaff JM, Kuchenbecker WK, Perquin DA, Koks CA et al. Cost-effectiveness analysis of lifestyle intervention in obese infertile women. Hum Reprod. 2017;32(7):1418-26 (https://doi. org/10.1093/humrep/dex092). 14. Burgess E, Hassmén P, Welvaert M, Pumpa KL. Behavioural treatmen",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 64
  },
  {
    "chunk_id": "infertility_1835",
    "text": "intervention in obese infertile women. Hum Reprod. 2017;32(7):1418-26 (https://doi. org/10.1093/humrep/dex092). 14. Burgess E, Hassmén P, Welvaert M, Pumpa KL. Behavioural treatment strategies improve adherence to lifestyle intervention programmes in adults with obesity: a systematic review and meta-analysis. Clin Obes 2017;7(2):105-14 (https:// doi.org/10.1111/cob.12180).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 64
  },
  {
    "chunk_id": "infertility_1836",
    "text": "414 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 4.3 Risk reduction from the use of tobacco Recommendation WHO recommends that brief advice (between 30 seconds and 3 minutes per encounter) be consistently provided by health care providers as a routine practice to all tobacco users accessing any health care settings. (Strong recommendation, moderate certainty of evidence) Remarks: • This is an existing WHO recommendation for the general population that also applies to individuals and couples who are planning a pregnancy, attempting to achieve a pregnancy or with infertility, given the association between infertility and a current or previous history of smoking. • Assessment of lifestyle, including the use of tobacco, is part of medical history- taking when evaluating individuals a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 65
  },
  {
    "chunk_id": "infertility_1837",
    "text": " infertility and a current or previous history of smoking. • Assessment of lifestyle, including the use of tobacco, is part of medical history- taking when evaluating individuals and couples for infertility. • Brief advice is advice to stop using tobacco – usually taking only a few minutes – given to all tobacco users, usually during a routine consultation or interaction. • Brief advice should include informing individuals and couples that (i) use of tobacco, particularly smoking, is associated with a higher risk of infertility; (ii) the risk of infertility due to tobacco smoking is higher among women; and (iii) a range of interventions to assist in cessation of tobacco use exist. • Brief advice should include the 5As: asking about tobacco use; advising to make a quit attempt; assessing readiness to quit; assisting in making a quit plan; and arranging a follow-up. Advice should be tailor",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 65
  },
  {
    "chunk_id": "infertility_1838",
    "text": "the 5As: asking about tobacco use; advising to make a quit attempt; assessing readiness to quit; assisting in making a quit plan; and arranging a follow-up. Advice should be tailored or personalized based on individual circumstances. • All adults interested in quitting smoking should be offered or referred to interventions to assist in tobacco cessation as recommended by existing WHO guidelines for preventing tobacco use uptake, promoting tobacco cessation or diagnosing and treating tobacco dependence. Background and rationale Tobacco use is highly prevalent among populations of reproductive age ( 1, 2) and is a leading cause of morbidity and mortality globally ( 2–5). Nicotine is the pharmacologically active compound that occurs naturally in the tobacco plant and is typically consumed via inhalation or ingestion. It is highly addictive; a significant number of people who use tobacco reg",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 65
  },
  {
    "chunk_id": "infertility_1839",
    "text": "ompound that occurs naturally in the tobacco plant and is typically consumed via inhalation or ingestion. It is highly addictive; a significant number of people who use tobacco regularly do so because they are addicted to it (6, 7). Tobacco has negative effects on health ( 5). Cigarette smoke contains several chemicals that may act in isolation or cumulatively (8) to negatively affect cellular apoptosis, autophagy, DNA damage, meiosis and signalling (8, 9). These effects of cigarette smoke may be mediated by individual vulnerability, timing and type of exposure ( 8). For this recommendation, the GDG addressed the question: should brief advice about tobacco be provided to couples who are planning a pregnancy, attempting to achieve a pregnancy or with infertility when they access health care settings or not? Balancing harms and benefits A recommendation concerning brief advice to tobacco u",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 65
  },
  {
    "chunk_id": "infertility_1840",
    "text": "tempting to achieve a pregnancy or with infertility when they access health care settings or not? Balancing harms and benefits A recommendation concerning brief advice to tobacco users was published in 2024 in the WHO clinical treatment guideline for tobacco cessation",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 65
  },
  {
    "chunk_id": "infertility_1841",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 42 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps in adults (10). It built on existing WHO guidance, including the actions recommended by the guidelines for implementation of Article 14 of the WHO Framework Convention on Tobacco Control to help tobacco users quit as part of a tobacco control approach (11). The GDG adopted this recommendation by considering the evidence used to make the original recommendation. Evidence of the harms and benefits used to make the original recommendation A systematic review of 13 RCTs comparing the provision of brief advice to no advice to tobacco users provided information about the benefits of brief advice (10). The review found that brief advice slightly increases short-term abstinence from smoking and lik",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 66
  },
  {
    "chunk_id": "infertility_1842",
    "text": "vice to tobacco users provided information about the benefits of brief advice (10). The review found that brief advice slightly increases short-term abstinence from smoking and likely increases it over the long term. However, brief advice probably has little to no effect on quitting attempts. No harms were reported in the systematic review. Subgroup analyses found that the effects were similar across multiple populations. The GDG noted that the evidence reviewed for the original recommendation was not specific to populations planning a pregnancy or attempting to achieve a pregnancy. Applicability of evidence to men and women planning a pregnancy or attempting to achieve a pregnancy To determine whether the evidence from the original systematic review of brief advice would also be beneficial to people planning a pregnancy, or attempting to achieve a pregnancy, we conducted an overview of ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 66
  },
  {
    "chunk_id": "infertility_1843",
    "text": "ence from the original systematic review of brief advice would also be beneficial to people planning a pregnancy, or attempting to achieve a pregnancy, we conducted an overview of reviews published since 2015 and tracked references to other systematic reviews. Four reviews were found that covered smoking and the risk of infertility in men or women. Several reviews published before 2015 reported a positive association between smoking and infertility in women. A 1998 review reported that the odds of infertility among female smokers was 1.6 times (95% CI: 1.3–1.9) the odds in non-smokers (12). In 2011, a comprehensive review of clinical and experimental studies evaluated the effects of exposure to cigarette smoke across different stages of reproduction from folliculogenesis to implantation. The review suggested that cigarette smoking impairs, alters, adversely affects or interferes with nor",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 66
  },
  {
    "chunk_id": "infertility_1844",
    "text": "across different stages of reproduction from folliculogenesis to implantation. The review suggested that cigarette smoking impairs, alters, adversely affects or interferes with normal reproductive functions ( 8). More recently, a review of three non-randomized studies reported that the odds of infertility in female smokers was 1.85 times (95% CI: 1.08–2.14) the odds in non-smokers ( 13). Evidence on infertility and smoking in men was reviewed in a 2016 study, which assessed the association between smoking and semen quality using the 2010 WHO laboratory manual for the examination and processing of human semen. Twenty studies with 5865 men contributed to the analyses (14). It reported that smoking may be associated with a reduction in some semen parameters: semen volume; sperm count; sperm motility; and sperm morphology. A subgroup analysis of a smaller set of studies reported that reducti",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 66
  },
  {
    "chunk_id": "infertility_1845",
    "text": "ed with a reduction in some semen parameters: semen volume; sperm count; sperm motility; and sperm morphology. A subgroup analysis of a smaller set of studies reported that reductions in semen parameters may be greater in moderate and heavy smokers. Although some results were statistically significant, it is not clear whether the magnitude of the reductions in semen parameters is clinically relevant and whether the observed reductions affect fertility, given that semen parameters per se are not a reliable indicator of male fertility status ( 15, 16). Other considerations No research evidence was identified specifically from fertility contexts regarding the feasibility, acceptability, equity, cost or cost-effectiveness of brief advice. In keeping with the recommendation and evidence published in the original recommendation in the WHO clinical treatment guideline for tobacco cessation in a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 66
  },
  {
    "chunk_id": "infertility_1846",
    "text": "iveness of brief advice. In keeping with the recommendation and evidence published in the original recommendation in the WHO clinical treatment guideline for tobacco cessation in adults in 2024 (10), the GDG agreed that brief advice was also supported by its likely feasibility and acceptability, negligible costs, cost-effectiveness and low impact on equity.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 66
  },
  {
    "chunk_id": "infertility_1847",
    "text": "434 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification The GDG adopted the strong recommendation for brief advice for all tobacco smokers from the WHO clinical treatment guideline for tobacco cessation in adults published in 2024 (10). There was moderate certainty of evidence in the general population for the benefits of providing brief advice. Given that there is likely an association of smoking with infertility in women and there may be an association of smoking with reduced semen parameters in men, the GDG decided that this evidence would apply directly to couples who are planning a pregnancy or attempting to achieve a pregnancy. The GDG also agreed with the judgements in the original recommendation that providing brief advice is probably low-cost, feasible, ac",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 67
  },
  {
    "chunk_id": "infertility_1848",
    "text": "regnancy or attempting to achieve a pregnancy. The GDG also agreed with the judgements in the original recommendation that providing brief advice is probably low-cost, feasible, acceptable and would probably have no impact on equity. Implementation considerations Assessment of lifestyle, including the use of tobacco, is part of the medical history-taking (see Chapter 3 and accompanying algorithms in this guideline). This guideline suggests providing information about fertility and infertility using low-cost strategies, or whenever there is an opportunity, including how to reduce risk factors for infertility (see Chapter 4). Despite the need, information on the risks of tobacco smoking, and referral to tobacco cessation services, are not consistently provided by health care providers during the pre-pregnancy period ( 17) at primary health care centres (18, 19), when referring for fertilit",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 67
  },
  {
    "chunk_id": "infertility_1849",
    "text": "essation services, are not consistently provided by health care providers during the pre-pregnancy period ( 17) at primary health care centres (18, 19), when referring for fertility care ( 20), or when providing infertility evaluation and treatment ( 17, 21). Development of specific job aids or tools (such as scripts) for brief advice may be necessary to ensure that messages provided by health care providers are consistent. Brief advice should be tailored or personalized based on individual circumstances and may need to be adapted to local contexts and audiences. Depending on the context, advice may be tailored to the audience to pinpoint the biological functions that are affected by smoking. For more information on the 5As (referred to in the remarks section), see the existing WHO guidance related to disease interventions at the primary health care level ( 22). Health care providers sho",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 67
  },
  {
    "chunk_id": "infertility_1850",
    "text": "on on the 5As (referred to in the remarks section), see the existing WHO guidance related to disease interventions at the primary health care level ( 22). Health care providers should note that not all smokers may be willing to quit; however, those willing to quit may be more receptive to being provided information, and offered or referred to appropriate services aimed at aiding cessation. Providing access to and encouraging the use of effective cessation interventions increases the likelihood of successfully quitting tobacco; however, health care providers should respect individual choice. Repeated brief advice during appointments can allow progressive tailoring of information and dialogue to the specific circumstances and readiness to quit of an individual ( 20); however, health care providers should note that acceptability of persistent information can differ among smokers because it ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 67
  },
  {
    "chunk_id": "infertility_1851",
    "text": "umstances and readiness to quit of an individual ( 20); however, health care providers should note that acceptability of persistent information can differ among smokers because it can evoke guilt, self-blame or frustration ( 23). The goal should be to respectfully provide brief advice, while remaining sensitive to patient experiences and avoiding putting the blame on patients. People who are willing to quit may prefer using some or multiple tobacco cessation interventions. To identify the range of interventions that couples can be informed about, provided with or referred to, health care providers should refer to the WHO clinical treatment guideline for tobacco cessation in adults (10) and other existing WHO guidelines for preventing tobacco use uptake, promoting tobacco cessation or diagnosing and treating tobacco dependence (11, 22, 24). Given that tobacco cessation can be influenced b",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 67
  },
  {
    "chunk_id": "infertility_1852",
    "text": "idelines for preventing tobacco use uptake, promoting tobacco cessation or diagnosing and treating tobacco dependence (11, 22, 24). Given that tobacco cessation can be influenced by social interactions, including with partners ( 25, 26), health",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 67
  },
  {
    "chunk_id": "infertility_1853",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 44 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps care providers should aim to reach both partners in a couple with brief advice, based on individual circumstances. Tobacco use may adversely affect maternal or neonatal outcomes after pregnancy. The WHO guideline on antenatal care provides recommendations regarding the need for health care providers to ask all pregnant women about their tobacco use (past and present) and exposure to second-hand smoke as early as possible in the pregnancy and at every antenatal care visit ( 27). Research gaps and future guideline update Cigarette smoking can have negative effects on a range of reproductive parameters or functions in women (8, 9, 28, 29) or men (14, 30). However, more research is needed in as",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 68
  },
  {
    "chunk_id": "infertility_1854",
    "text": "pdate Cigarette smoking can have negative effects on a range of reproductive parameters or functions in women (8, 9, 28, 29) or men (14, 30). However, more research is needed in assessing and quantifying the risk of infertility in men who smoke or use tobacco. Additionally, the GDG is aware of studies exploring the effects of cessation of tobacco smoking on fecundability in women ( 31–33) and on sperm parameters in men (34–36), which suggests that smoking cessation could have a role in reversing infertility. More research addressing this question would be beneficial for future guideline updates. Future guidance will be required regarding information that should be provided by health care providers regarding tobacco use during assisted reproduction, which is not within the scope of this PICO question because it relates to a slightly different population (i.e. people already diagnosed with",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 68
  },
  {
    "chunk_id": "infertility_1855",
    "text": "acco use during assisted reproduction, which is not within the scope of this PICO question because it relates to a slightly different population (i.e. people already diagnosed with infertility, who are accessing ART). Future guidance will also be required in relation to exposure to secondary smoke, use of vapes and e-cigarettes, non-smoked/smokeless tobacco products, as well as other smoked substances, such as cannabis (see section 12.2). References 1. Jafari A, Rajabi A, Gholian-Aval M, Peyman N, Mahdizadeh M, Tehrani H. National, regional, and global prevalence of cigarette smoking among women/females in the general population: a systematic review and meta-analysis. Environ Health Prev Med. 2021;26(1):5 (https://doi. org/10.1186/s12199-020-00924-y). 2. Vollset S, Tverdal A, Gjessing H. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med. 2006;144(6):381-9",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 68
  },
  {
    "chunk_id": "infertility_1856",
    "text": "s://doi. org/10.1186/s12199-020-00924-y). 2. Vollset S, Tverdal A, Gjessing H. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med. 2006;144(6):381-9 (https://doi.org/10.7326/0003- 4819-144-6-200603210-00004). 3. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923-94 (https://doi.org/10.1016/ s0140-6736(18)32225-6). 4. Rentería E, Jha P, Forman D, Soerjomataram I. The impact of cigarette smoking on life expectancy between 1980 and 2010: a global perspective. Tob Control. 2016;25(5):551-7 (https://doi. org/10.1136/tobaccocontrol-2015-052265). 5. WHO report on the global tobacco epidemic",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 68
  },
  {
    "chunk_id": "infertility_1857",
    "text": "tancy between 1980 and 2010: a global perspective. Tob Control. 2016;25(5):551-7 (https://doi. org/10.1136/tobaccocontrol-2015-052265). 5. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44616). 6. Scragg R, Wellman RJ, Laugesen M, DiFranza JR. Diminished autonomy over tobacco can appear with the first cigarettes. Addict Behav. 2008;33(5):689-98 (https://doi.org/10.1016/j. addbeh.2007.12.002). 7. WHO report on the global tobacco epidemic, 2019: offer help to quit tobacco use. Geneva: World Health Organization; 2019 (https://iris.who. int/handle/10665/326043). 8. Dechanet C, Anahory T, Mathieu Daude JC, Quantin X, Reyftmann L, Hamamah S et al. Effects of cigarette smoking on reproduction. Hum Reprod Update. 2011;17(1):76-95 (https:// doi.org/10.1093/humupd/dmq033).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 68
  },
  {
    "chunk_id": "infertility_1858",
    "text": "454 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 9. Budani MC, Tiboni GM. Ovotoxicity of cigarette smoke: a systematic review of the literature. Reprod Toxicol. 2017;72:164-81 (https://doi. org/10.1016/j.reprotox.2017.06.184). 10. WHO clinical treatment guideline for tobacco cessation in adults. Geneva: World Health Organization; 2024 (https://iris.who.int/ handle/10665/377825). 11. WHO Framework Convention on Tobacco Control. Guidelines for implementation of Article 14. Geneva: World Health Organization; 2013 (https://fctc.who.int/resources/publications/m/ item/guidelines-for-implementation-of-article-14). 12. Augood C, Duckitt K, Templeton AA. Smoking and female infertility: a systematic review and meta-analysis. Hum Reprod. 1998;13(6):1532-9 (https://doi.org/10.1093/humrep/13.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 69
  },
  {
    "chunk_id": "infertility_1859",
    "text": "14). 12. Augood C, Duckitt K, Templeton AA. Smoking and female infertility: a systematic review and meta-analysis. Hum Reprod. 1998;13(6):1532-9 (https://doi.org/10.1093/humrep/13.6.1532). 13. Nik Hazlina NH, Norhayati MN, Shaiful Bahari I, Nik Muhammad Arif NA. Worldwide prevalence, risk factors and psychological impact of infertility among women: a systematic review and meta- analysis. BMJ Open. 2022;12(3):e057132 (https:// doi.org/10.1136/bmjopen-2021-057132). 14. Sharma R, Harlev A, Agarwal A, Esteves SC. Cigarette smoking and semen quality: a new meta-analysis examining the effect of the 2010 World Health Organization Laboratory Methods for the Examination of Human Semen. Eur Urol. 2016;70(4):635-45 (https://doi.org/10.1016/j. eururo.2016.04.010). 15. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (http",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 69
  },
  {
    "chunk_id": "infertility_1860",
    "text": "://doi.org/10.1016/j. eururo.2016.04.010). 15. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/343208). 16. Boeri L, Belladelli F, Capogrosso P, Cazzaniga W, Candela L, Pozzi E et al. Normal sperm parameters per se do not reliably account for fertility: a case-control study in the real-life setting. Andrologia. 2021;53(1):e13861 (https:// doi.org/10.1111/and.13861). 17. Nekuei N, Nasr Esfahani MH, Kazemi A. Preconception counseling in couples undergoing fertility treatment. Int J Fertil Steril. 2012;6(2):79-86. 18. Vogt F, Hall S, Marteau TM. General practitioners’ and family physicians’ negative beliefs and attitudes towards discussing smoking cessation with patients: a systematic review. Addiction. 2005;100(10):1423-31 (ht tps://doi.org/10.1111/ j.1360-0443.2005.01221.x). ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 69
  },
  {
    "chunk_id": "infertility_1861",
    "text": "eliefs and attitudes towards discussing smoking cessation with patients: a systematic review. Addiction. 2005;100(10):1423-31 (ht tps://doi.org/10.1111/ j.1360-0443.2005.01221.x). 19. Heyes T, Long S, Mathers N. Preconception care: practice and beliefs of primary care workers. Fam Pract. 2004;21(1):22-7 (https://doi.org/10.1093/ fampra/cmh106). 20. Hughes EG, Lamont DA, Beecroft ML, Wilson DM, Brennan BG, Rice SC. Randomized trial of a “stage-of-change” oriented smoking cessation intervention in infertile and pregnant women. Fertil Steril. 2000;74(3):498-503 (https://doi. org/10.1016/s0015-0282(00)00687-7). 21. Bolumar F, Olsen J, Boldsen J. Smoking reduces fecundity: a European multicenter study on infertility and subfecundity. The European Study Group on Infertility and Subfecundity. Am J Epidemiol. 1996;143(6):578-87 (https://doi. org/10.1093/oxfordjournals.aje.a008788). 22. Package o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 69
  },
  {
    "chunk_id": "infertility_1862",
    "text": " and subfecundity. The European Study Group on Infertility and Subfecundity. Am J Epidemiol. 1996;143(6):578-87 (https://doi. org/10.1093/oxfordjournals.aje.a008788). 22. Package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization; 2010 (https://iris.who.int/ handle/10665/44260). 23. Butler CC, Pill R, Stott NC. Qualitative study of patients’ perceptions of doctors’ advice to quit smoking: implications for opportunistic health promotion. BMJ. 1998;316(7148):1878-81 (https:// doi.org/10.1136/bmj.316.7148.1878). 24. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy. Geneva: World Health Organization; 2013 (https://iris.who.int/ handle/10665/94555). 25. Gage JD, Everett KD, Bullock L. A theoretical explanation of male partner participation i",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 69
  },
  {
    "chunk_id": "infertility_1863",
    "text": "y. Geneva: World Health Organization; 2013 (https://iris.who.int/ handle/10665/94555). 25. Gage JD, Everett KD, Bullock L. A theoretical explanation of male partner participation in smoking cessation during the transition to fatherhood. J Smok Cessat. 2011;6(2):89-96 (https://doi.org/10.1375/jsc.6.2.89).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 69
  },
  {
    "chunk_id": "infertility_1864",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 46 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 26. McBride CM, Baucom DH, Peterson BL, Pollak KI, Palmer C, Westman E et al. Prenatal and postpartum smoking abstinence a partner-assisted approach. Am J Prev Med. 2004;27(3):232-8 (https://doi.org/10.1016/j. amepre.2004.06.005). 27. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (https://iris.who.int/ handle/10665/250796). 28. Talbot P, Riveles K. Smoking and reproduction: the oviduct as a target of cigarette smoke. Reprod Biol Endocrinol. 2005;3:52 (https://doi. org/10.1186/1477-7827-3-52). 29. Dhage VD, Nagtode N, Kumar D, Bhagat AK. A narrative review on the impact of smoking on female fertility. Cureus. 2024;16(4):e58",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 70
  },
  {
    "chunk_id": "infertility_1865",
    "text": "3:52 (https://doi. org/10.1186/1477-7827-3-52). 29. Dhage VD, Nagtode N, Kumar D, Bhagat AK. A narrative review on the impact of smoking on female fertility. Cureus. 2024;16(4):e58389 (https://doi.org/10.7759/cureus.58389). 30. Bundhun PK, Janoo G, Bhurtu A, Teeluck AR, Soogund MZS, Pursun M et al. Tobacco smoking and semen quality in infertile males: a systematic review and meta-analysis. BMC Public Health. 2019;19(1):36 (https://doi.org/10.1186/s12889- 018-6319-3). 31. Howe G, Westhoff C, Vessey M, Yeates D. Effects of age, cigarette smoking, and other factors on fertility: findings in a large prospective study. Br Med J (Clin Res Ed). 1985;290(6483):1697-700 (https://doi.org/10.1136/bmj.290.6483.1697). 32. Hernáez Á, Wootton RE, Page CM, Skåra KH, Fraser A, Rogne T et al. Smoking and infertility: multivariable regression and Mendelian randomization analyses in the Norwegian Mother, Fa",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 70
  },
  {
    "chunk_id": "infertility_1866",
    "text": "ernáez Á, Wootton RE, Page CM, Skåra KH, Fraser A, Rogne T et al. Smoking and infertility: multivariable regression and Mendelian randomization analyses in the Norwegian Mother, Father and Child Cohort Study. Fertil Steril. 2022;118(1):180-90 (https://doi. org/10.1016/j.fertnstert.2022.04.001). 33. Radin RG, Hatch EE, Rothman KJ, Mikkelsen EM, Sørensen HT, Riis AH et al. Active and passive smoking and fecundability in Danish pregnancy planners. Fertil Steril. 2014;102(1):183-91 (https:// doi.org/10.1016/j.fertnstert.2014.03.018). 34. Trummer H, Habermann H, Haas J, Pummer K. The impact of cigarette smoking on human semen parameters and hormones. Hum Reprod. 2002;17(6):1554-9 (https://doi.org/10.1093/ humrep/17.6.1554). 35. Prentki Santos E, López-Costa S, Chenlo P, Pugliese MN, Curi S, Ariagno J et al. Impact of spontaneous smoking cessation on sperm quality: case report. Andrologia. 201",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 70
  },
  {
    "chunk_id": "infertility_1867",
    "text": "6.1554). 35. Prentki Santos E, López-Costa S, Chenlo P, Pugliese MN, Curi S, Ariagno J et al. Impact of spontaneous smoking cessation on sperm quality: case report. Andrologia. 2011;43(6):431-5 (ht tps://doi.org/10.1111/j.1439 - 0272.2010.01089.x). 36. Kulaksiz D, Toprak T, Tokat E, Yilmaz M, Ramazanoglu MA, Garayev A et al. Sperm concentration and semen volume increase after smoking cessation in infertile men. Int J Impot Res. 2022;34(6):614-9 (https://doi.org/10.1038/ s41443-022-00605-0).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 70
  },
  {
    "chunk_id": "infertility_1868",
    "text": "474 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 4.4 Risk reduction from sexually transmitted infections Good practice statement Couples and individuals planning or attempting to achieve pregnancy who are accessing any health care settings should be routinely informed about sexually transmitted infections (STIs), including the risk of infertility when STIs are untreated. Couples and individuals should be encouraged to seek prompt care and treatment if they have symptoms of STIs. Remark: • If symptoms of an STI are present, or if infection is confirmed, WHO guideline recommendations on the management of STIs are available. Background Variable proportions of infertility are attributable to untreated infections that ascend along the reproductive tract, capable of causing inflammatio",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 71
  },
  {
    "chunk_id": "infertility_1869",
    "text": "STIs are available. Background Variable proportions of infertility are attributable to untreated infections that ascend along the reproductive tract, capable of causing inflammation, abscess, damage, adhesions or permanent scarring to reproductive organs (see Annex 1. Distribution of the causes of infertility ). Several pathogenic mechanisms have been proposed in females ( 1–3) and males (4, 5) for some organisms. However, the speed and extent to which such infections induce these pathogenic processes and progressively alter the anatomy or physiology of reproductive organs differs between organisms and individuals (6): not all reproductive tract infections have been clearly demonstrated to contribute to the pathogenesis of infertility in females ( 7) or males (8). Notably, reproductive tract infections that are associated with infertility may be sexually or non-sexually transmitted (e.g.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 71
  },
  {
    "chunk_id": "infertility_1870",
    "text": "hogenesis of infertility in females ( 7) or males (8). Notably, reproductive tract infections that are associated with infertility may be sexually or non-sexually transmitted (e.g. genital schistosomiasis or tuberculosis) with varying virulence. WHO has quantified the burden of selected curable STIs (9–11) and issued recommendations related to the screening, diagnosis and management of STIs (12). Recommendations for the testing and treatment of people with symptoms, such as vaginal discharge (in females), abdominal pain (in females), urethral discharge (in males) or genital ulcers, including anorectal ulcers (in both males and females), are available from WHO ( 13). Necessity of the message Given some potential uncertainty and variability about the timing, sequence and magnitude of the effects of STIs on the reproductive tract and subsequent infertility ( 15–18), clinicians may not alway",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 71
  },
  {
    "chunk_id": "infertility_1871",
    "text": " uncertainty and variability about the timing, sequence and magnitude of the effects of STIs on the reproductive tract and subsequent infertility ( 15–18), clinicians may not always communicate with patients about these infections. A lack of information about STIs and the consequences of infertility exists, which is often linked to stigma, embarrassment, privacy, lack of centres for sexual health, or lack of communication and counselling from health care providers on sexual issues (19–21). Although health care providers are an important and often preferred source of information on sexually transmitted infections (21, 22), missed opportunities for communicating about STIs and sexual health have been identified in clinical settings ( 22). Consequences The GDG agreed that there would be net positive consequences of communicating about STIs and the risk of infertility, given the risk of infe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 71
  },
  {
    "chunk_id": "infertility_1872",
    "text": "n clinical settings ( 22). Consequences The GDG agreed that there would be net positive consequences of communicating about STIs and the risk of infertility, given the risk of infertility in people with a history of STIs. A systematic review of over 147 studies in populations with infertility found that the prevalence of Neisseria gonorrhoeae was higher in those populations than in the general population globally (2.2% versus 0.8%). Populations with tubal factor infertility, a variety of different types of infertility, unexplained infertility and secondary infertility had the highest prevalence compared to other conditions; prevalence was also",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 71
  },
  {
    "chunk_id": "infertility_1873",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 48 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps higher in women than in men (14). In addition, a systematic review of studies including women with current or a history of infection with N. gonorrhoeae found a greater but small risk of tubal infertility in women compared to women without an STI infection, and a greater risk in women with overt pelvic inflammatory disease (PID) ( 15). A systematic review of case–control studies also found approximately 2.2 greater odds of infertility in males or females with Chlamydia trachomatis (16). Another systematic review found that the prevalence of Trichomonas vaginalis in women attending infertility clinics in the Middle East and North Africa was higher than in a general population of women (17). ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 72
  },
  {
    "chunk_id": "infertility_1874",
    "text": "ound that the prevalence of Trichomonas vaginalis in women attending infertility clinics in the Middle East and North Africa was higher than in a general population of women (17). Untreated N. gonorrhoeae and C. trachomatis infection can lead to PID. A longitudinal follow- up of women in the PEACH trial, which included approximately 800 women, found that the odds of infertility may be approximately two times greater in women with recurrent PID versus women with no recurrent PID (18). The GDG agreed that given the higher prevalence of STIs in women and men with infertility, and the likelihood of temporal precedence (rather than infertility leading to greater STI incidence), routinely informing couples about STIs, including the risk of infertility when untreated, or encouraging that they seek care if they have symptoms of STIs, would result in benefits and little to no harm. The GDG noted ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 72
  },
  {
    "chunk_id": "infertility_1875",
    "text": ", including the risk of infertility when untreated, or encouraging that they seek care if they have symptoms of STIs, would result in benefits and little to no harm. The GDG noted that the burden of STIs varies across countries, but awareness about STIs can contribute towards prevention. The GDG also agreed that informing couples would be acceptable and feasible to both clinicians and couples, and there would be negligible costs or resources required. In addition, it would probably have limited impact on equity. Rationale Overall, the GDG agreed that informing people of the risk of infertility caused by STIs would increase awareness and potentially reduce infertility as evidence found greater prevalence of some types of STIs in people with infertility. Informing couples is acceptable, feasible and requires negligible resources and costs, and probably has no impact on equity. The opportun",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 72
  },
  {
    "chunk_id": "infertility_1876",
    "text": " types of STIs in people with infertility. Informing couples is acceptable, feasible and requires negligible resources and costs, and probably has no impact on equity. The opportunity cost of collecting and summarizing evidence is large. Implementation considerations In implementing this good practice statement, health care providers should note that providing information on factors that can increase the risk of infertility is an important part of pre-pregnancy advice, counselling and care (see Chapter 3). In addition, assessment of previous lifestyle history, including history and management of sexually transmitted, non-sexually transmitted and other reproductive tract infections, is important when evaluating couples for infertility (see Chapter 3). Implementation of this good practice complements other avenues for providing information about fertility and infertility, adapted to local ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 72
  },
  {
    "chunk_id": "infertility_1877",
    "text": "couples for infertility (see Chapter 3). Implementation of this good practice complements other avenues for providing information about fertility and infertility, adapted to local contexts and audiences, when opportunities occur in schools, at primary health care centres or reproductive health (contraceptive, sexual health) clinics (see Chapter 4.1 for the recommendation on information provision on infertility and fertility for the general population). It is important for health care providers to be aware and to communicate to couples and individuals that some reproductive tract infections are not acquired sexually but could also be associated with infertility; therefore, health care providers should also assess for these in the medical history and physical examination. Health care providers should inform couples and individuals that some STIs may be asymptomatic",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 72
  },
  {
    "chunk_id": "infertility_1878",
    "text": "494 Prevention of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps and that diagnostic screening could be indicated. If the symptoms of an STI are present or infection is confirmed, WHO guidelines for the diagnosis and management of STIs are available ( 12, 13, 19, 20). Given that a person with an STI will have contracted it from a sexual partner who also had the infection, health care providers should aim to inform all sexual partners. Awareness and preventive actions can be hindered by a low perception of an STI risk with trusted partners ( 21), a lack of knowledge of a partner’s prior risky sexual behaviours (22), or low awareness or use of STI prevention interventions (12). Following pregnancy, STIs can have a negative impact on maternal and neonatal outcomes. The WHO antenatal guideline provi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 73
  },
  {
    "chunk_id": "infertility_1879",
    "text": "low awareness or use of STI prevention interventions (12). Following pregnancy, STIs can have a negative impact on maternal and neonatal outcomes. The WHO antenatal guideline provides recommendations regarding the identification and management of STIs during pregnancy ( 23) to reduce the risk of adverse reproductive, obstetric and neonatal outcomes. Research gaps and future guideline update Better quantification of the risks of infertility from some sexually transmitted and non-sexually transmitted infections of the reproductive tract is needed. Efforts to improve the quality of the data (e.g. using standardized criteria instead of relying on self-reporting) are also needed. Studies (including modelling) to explore infertility risk reversal after treatment of STIs and other reproductive tract infections are needed. Specific guidance will be required in future regarding screening for STIs",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 73
  },
  {
    "chunk_id": "infertility_1880",
    "text": "lore infertility risk reversal after treatment of STIs and other reproductive tract infections are needed. Specific guidance will be required in future regarding screening for STIs as part of pre-pregnancy care, which is not within the scope of this guideline. References 1. Stephens DS, McGee ZA, Cooper MD. Cytopathic effects of the pathogenic Neisseria. Studies using human fallopian tube organ cultures and human nasopharyngeal organ cultures. Antonie Van Leeuwenhoek. 1987;53(6):575-84 (https://doi. org/10.1007/BF00415519). 2. Linhares IM, Witkin SS. Immunopathogenic consequences of Chlamydia trachomatis 60 kDa heat shock protein expression in the female reproductive tract. Cell Stress Chaperones. 2010;15(5):467-73 (https://doi.org/10.1007/ s12192-010-0171-4). 3. Hirano Y, Shibahara H, Koriyama J, Tokunaga M, Shimada K, Suzuki M. Incidence of sperm‐ immobilizing antibodies in infertile w",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 73
  },
  {
    "chunk_id": "infertility_1881",
    "text": "7-73 (https://doi.org/10.1007/ s12192-010-0171-4). 3. Hirano Y, Shibahara H, Koriyama J, Tokunaga M, Shimada K, Suzuki M. Incidence of sperm‐ immobilizing antibodies in infertile women with past Chlamydia trachomatis infection. Am J Reprod Immunol. 2011;65(2):127-32 (https://doi. org/10.1111/j.1600 - 0897.2010.00883.x). 4. Munoz MG, Witkin SS. Autoimmunity to spermatozoa, asymptomatic Chlamydia trachomatis genital tract infection and γδ T lymphocytes in seminal fluid from the male partners of couples with unexplained infertility. Hum Reprod. 1995;10(5):1070-4 (https://doi. org/10.1093/oxfordjournals.humrep.a136096). 5. Eley A, Pacey AA, Galdiero M, Galdiero M, Galdiero F. Can Chlamydia trachomatis directly damage your sperm? Lancet Infect Dis. 2005;5(1):53-7 (https://doi.org/10.1016/S1473- 3099(04)01254-X). 6. Edwards JL, Apicella MA. The molecular mechanisms used by Neisseria gonorrhoea",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 73
  },
  {
    "chunk_id": "infertility_1882",
    "text": "ge your sperm? Lancet Infect Dis. 2005;5(1):53-7 (https://doi.org/10.1016/S1473- 3099(04)01254-X). 6. Edwards JL, Apicella MA. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev. 2004;17(4):965-81 (https://doi. org/10.1128/CMR.17.4.965-981.2004). 7. Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Am J Obstet Gynecol. 2017;216(1):1-9 (https://doi. org/10.1016/j.ajog.2016.08.008).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 73
  },
  {
    "chunk_id": "infertility_1883",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 50 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 8. Fode M, Fusco F, Lipshultz L, Weidner W. Sexually transmitted disease and male infertility: a systematic review. Eur Urol Focus. 2016;2(4):383- 93 (https://doi.org/10.1016/j.euf.2016.08.002). 9. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One. 2015;10(12):e0143304 (https://doi. org/10.1371/journal.pone.0143304). 10. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World H",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 74
  },
  {
    "chunk_id": "infertility_1884",
    "text": " Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548-62P (https:// doi.org/10.2471/blt.18.228486). 11. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: World Health Organization; 2001 (https://iris.who.int/ handle/10665/66818). 12. Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World Health Organization; 2021 (https://iris.who.int/ handle/10665/342523). 13. Laboratory and point-of-care diagnostic testing for sexually transmitted infections, including HIV. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/374252). 14. Chemaitelly H, Majed A, Abu-Hijleh F, Blondeel K, Matsaseng TC, Kiarie J et al. Global epi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 74
  },
  {
    "chunk_id": "infertility_1885",
    "text": ". Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/374252). 14. Chemaitelly H, Majed A, Abu-Hijleh F, Blondeel K, Matsaseng TC, Kiarie J et al. Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta- analysis and metaregression. Sex Transm Infect. 2021;97(2):157-69 (https://doi.org/10.1136/ sextrans-2020-054515). 15. Whelan J, Eeuwijk J, Bunge E, Beck E. Systematic literature review and quantitative analysis of health problems associated with sexually transmitted Neisseria gonorrhoeae infection. Infect Dis Ther. 2021;10:1887-905 (https://doi. org/10.1007/s40121-021-00481-z). 16. Ahmadi MH, Mirsalehian A, Bahador A. Association of Chlamydia trachomatis with infertility and clinical manifestations: a systematic review and meta-analysis of case-control studies. Infect Dis. 2016;48(7):517-23 (https://doi.org/10.3 109/23744235.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 74
  },
  {
    "chunk_id": "infertility_1886",
    "text": "matis with infertility and clinical manifestations: a systematic review and meta-analysis of case-control studies. Infect Dis. 2016;48(7):517-23 (https://doi.org/10.3 109/23744235.2016.1160421). 17. Harfouche M, Gherbi WS, Alareeki A, Alaama AS, Hermez JG, Smolak A et al. Epidemiology of Trichomonas vaginalis infection in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. EBioMedicine. 2024;106 (https://doi.org/10.1016/j. ebiom.2024.105250). 18. Trent M, Bass D, Ness RB, Haggerty C. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis. 2011;38(9):879-81 (https://doi.org/10.1097/ OLQ.0b013e31821f918c). 19. Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogen",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 74
  },
  {
    "chunk_id": "infertility_1887",
    "text": "OLQ.0b013e31821f918c). 19. Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts). Geneva: World Health Organization; 2024 (https://iris.who.int/ handle/10665/378215). 20. Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/378213). 21. Witte SS, El‐Bassel N, Gilbert L, Wu E, Chang M. Lack of awareness of partner STD risk among heterosexual couples. Perspect Sex Reprod Health. 2010;42(1):49-55 (https://doi. org/10.1363/4204910). 22. Masaro CL, Dahinten VS, Johnson J, Ogilvie G, Patrick DM. Perceptions of sexual partner safety. Sex Transm Dis. 2008;35(6):566-71 (https://",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 74
  },
  {
    "chunk_id": "infertility_1888",
    "text": " (https://doi. org/10.1363/4204910). 22. Masaro CL, Dahinten VS, Johnson J, Ogilvie G, Patrick DM. Perceptions of sexual partner safety. Sex Transm Dis. 2008;35(6):566-71 (https://doi. org/10.1097/OLQ.0b013e3181660c43). 23. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (https://iris.who.int/ handle/10665/250796).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 74
  },
  {
    "chunk_id": "infertility_1889",
    "text": "515 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5 Diagnosis of infertility This chapter provides guidance related to diagnosis of infertility. These are grouped into three main categories: • Female factors – such as ovulation, fallopian tubes, and the uterus • Male factors – issues that may affect sperm health and function • Unexplained factors – when no clear cause is found Male-factor diagnosis Unexplained infertility Female-factor diagnosis Chapter 5.1 Diagnosis of infertility due to ovulatory dysfunction 5.2 Confirmation of ovulation 5.3 Assessment of reproductive hormones 5.4 Assessment of ovarian reserve 5.5 Diagnosis of infertility due to tubal disease 5.6 Diagnosis of infertility due to uterine cavity disorder Relevant resources Figures: diagnostic algorithms 5.1 Female-f",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 75
  },
  {
    "chunk_id": "infertility_1890",
    "text": "reserve 5.5 Diagnosis of infertility due to tubal disease 5.6 Diagnosis of infertility due to uterine cavity disorder Relevant resources Figures: diagnostic algorithms 5.1 Female-factor infertility and unexplained infertility 5.2 Assessment of the uterine cavity 5.3 Male-factor infertility Annex 6. Components of female medical history and physical examination Annex 7. Components of male medical history and physical examination Web Annex C. Evidence to decision tables for diagnosis of infertility 5.7 Diagnosis of infertility due to male factors 5.8 Diagnosis of unexplained infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 75
  },
  {
    "chunk_id": "infertility_1891",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 52 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5.1 Diagnosis of infertility due to ovulatory dysfunction This and subsequent sections contain recommendations related to the diagnosis of infertility due to female-factor (sections 5.1–5.6), male-factor (section 5.7) and unexplained-factor (section 5.8). Recommendations on infertility due to female factors are related to ovulation (sections 5.2–5.4), tubal disease (section 5.5) or uterine cavity disorder (section 5.6). Figure 5.1 below shows how recommendations on female factors and unexplained factors relate to each other, illustrated in a diagnostic algorithm. A diagnostic algorithm related to male factors is presented later in section 5.7. 5.2 Confirmation of ovulation 2 That is, nothin",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 76
  },
  {
    "chunk_id": "infertility_1892",
    "text": "each other, illustrated in a diagnostic algorithm. A diagnostic algorithm related to male factors is presented later in section 5.7. 5.2 Confirmation of ovulation 2 That is, nothing abnormal is detected. Recommendation For females with infertility but normal findings on history-taking (including regular menstrual cycles) and physical examination, WHO suggests presumptive confirmation of ovulation by measuring the level of mid-luteal serum progesterone rather than performing an ultrasound scan. For women in whom the initial mid-luteal serum progesterone indicates no ovulation, a repeat measurement is suggested to minimize the risk of an inaccurate diagnosis of anovulation. (Conditional recommendation, very low certainty of evidence) Remarks: • Mid-luteal serum progesterone levels are assessed approximately 7 days before the expected onset of the next menses, noting that the specific cycle",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 76
  },
  {
    "chunk_id": "infertility_1893",
    "text": "ertainty of evidence) Remarks: • Mid-luteal serum progesterone levels are assessed approximately 7 days before the expected onset of the next menses, noting that the specific cycle day can vary based on the length of the menstrual cycle. • A repeat mid-luteal serum progesterone measurement could be performed in a subsequent menstrual cycle, considering the turnaround time for tests and cycle-to-cycle variations Background and rationale Disorders of ovulation can cause infertility ( 1, 2). In a multi-country study involving 8500 patients in 25 countries, anovulatory and ovulatory disorders accounted for 26.1% of identifiable causes of female infertility ( 3); therefore, a key aspect of management of infertility includes the assessment of ovulation. When a couple presents with a history of failure to achieve a pregnancy, history-taking and a physical examination are conducted in the female",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 76
  },
  {
    "chunk_id": "infertility_1894",
    "text": "includes the assessment of ovulation. When a couple presents with a history of failure to achieve a pregnancy, history-taking and a physical examination are conducted in the female. If these are normal2 (including a history of regular menstrual cycles), ovulation is assessed (see Fig. 5.1 Diagnostic algorithm for female-factor infertility and unexplained infertility). Although a history of regular menstrual cycles may be clinically suggestive of ovulation in most cases, further assessment of ovulation with diagnostic tests may be needed given the small potential for anovulatory menstrual cycles in eumenorrheic women, as reported in studies ( 4–6). 5 Diagnosis of infertility 5 Diagnosis of infertility 53",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 76
  },
  {
    "chunk_id": "infertility_1895",
    "text": "53 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5 Diagnosis of infertilityFig. 5.1. Diagnostic algorithm for female-factor and unexplained factor infertility Provide treatment (see relevant sections in this guideline)k a Infertility is defined as failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. b See section 5.7 and Fig. 5.3 for diagnosis of infertility due to male factors. c See detailed diagnostic algorithm for uterine factors in Fig. 5.2. d Based on clinical findings; see Good Practice Statements in Chapter 3. e Repeat if initial test result shows anovulation. f Follow the pathway for investigating the cause of anovulation. or oligo-ovulation shown on the right side of this chart. g Such as adenomyosis or endometriosis. h See recommendation on semen anal",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 77
  },
  {
    "chunk_id": "infertility_1896",
    "text": "way for investigating the cause of anovulation. or oligo-ovulation shown on the right side of this chart. g Such as adenomyosis or endometriosis. h See recommendation on semen analysis in section 5.7. Unexplained infertility (if semen parameters are within the WHO reference ranges in a male with normal history and physical exam)h Infertility due to tubal blockage or disease Infertility due to uterine cavity abnormality Infertility due to ovulation disordersi Infertility due to reduced ovarian reservej Investigate cause of anovulation/oligo-ovulationf Investigate other causesg Female in a couple with infertilitya Confirm ovulation Normal? Assess with: Mid-luteal progesterone Assess with: Either HSG OR HyCoSy Assess with: Either HSG OR HyCoSy Assess with: SIS (or preferably 3D US if it is available) OR either HSG OR 2D USc Assess/excluded: HPO axis (E2, T, FSH, LH) TSH, PRL Confirm tubal p",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 77
  },
  {
    "chunk_id": "infertility_1897",
    "text": "ess with: Either HSG OR HyCoSy Assess with: SIS (or preferably 3D US if it is available) OR either HSG OR 2D USc Assess/excluded: HPO axis (E2, T, FSH, LH) TSH, PRL Confirm tubal patency Investigate tube patency Investigate uterine cavity Investigate cause of anovulation/ oligo-ovulation Optional investigations d See Section 5.7 for assessment of the male in an infertile coupleb Assess ovarian reserve History + physical examination Male in a couple with infertilitya Female with normal examination findings and medical history History of STI or abdominal/ pelvic surgery Suspected tubal disease History of abnormal uterine bleeding ± pelvic mass on exam Suspected uterine cavity disorder History of absent or irregular periods Suspected ovulation dysfunction Normal? Normal? Uterine cavity abnormality identified? Cause identified? Noe No No NoYes YesYes Yes Assess with: AMH OR AFC OR FSH No i S",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 77
  },
  {
    "chunk_id": "infertility_1898",
    "text": "ar periods Suspected ovulation dysfunction Normal? Normal? Uterine cavity abnormality identified? Cause identified? Noe No No NoYes YesYes Yes Assess with: AMH OR AFC OR FSH No i Such as polycystic ovarian syndrome (PCOS), functional hypothalamic amenorrhoea, premature ovarian insufficiency (POI), hypothyroidism, hyperthyroidism, hyperprolactinaemia, among others see sections 5.1–5.4. j For example, due to advanced age, ovarian surgery, POI. k See Chapters 6–10 for treatment recommendations. 2D US, two-dimensional ultrasound; 3D US, three-dimensional ultrasound; AFC, antral follicle count; AMH, anti-Müllerian hormone; E2, estradiol; FSH, follicle-stimulating hormone; HPO, hypothalamic–pituitary– ovarian; HSG, hysterosalpingogram; HyCoSy, hysterosalpingo contrast sonography; LH, luteinizing hormone; PRL, prolactin; SIS, saline infusion sonohysterography; STI, sexually transmitted infectio",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 77
  },
  {
    "chunk_id": "infertility_1899",
    "text": "ysterosalpingogram; HyCoSy, hysterosalpingo contrast sonography; LH, luteinizing hormone; PRL, prolactin; SIS, saline infusion sonohysterography; STI, sexually transmitted infection; T, testosterone; TSH, thyroid-stimulating hormone. Couple presents with history of failure to achieve a pregnancy 5 Diagnosis of infertility 53 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 77
  },
  {
    "chunk_id": "infertility_1900",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 54 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Historically, several tests have been used to either predict or detect ovulation ( 7–10). Tests that predict impending ovulation (e.g. urine ovulation predictor kits that measure urinary luteinizing hormone [LH] surge levels) could be useful for proper timing of intercourse during the fertile period ( 11), and are increasingly available over the counter ( 12, 13). Tests that are intended to confirm ovulation are important for diagnostic purposes in the context of evaluation of the female. The latter application (related to the confirmation of ovulation) was prioritized by the GDG, given the uncertainty regarding anovulatory menstrual cycles in regularly menstruating women (4, 5). The GDG ag",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 78
  },
  {
    "chunk_id": "infertility_1901",
    "text": "elated to the confirmation of ovulation) was prioritized by the GDG, given the uncertainty regarding anovulatory menstrual cycles in regularly menstruating women (4, 5). The GDG agreed that a key decision when investigating women with infertility and suspected ovarian pathology is whether to perform ultrasound scan or measure mid-luteal serum progesterone level to presumptively confirm ovulation. The GDG noted that existing tests only provide presumptive or indirect evidence of ovulation. For this recommendation, the GDG addressed the question: should mid-luteal progesterone versus ultrasound be used to confirm ovulation in women with infertility but normal exam findings and history, or not? Ultrasound imaging (sonography) involves the generation and transmission of ultrasonic (high-frequency sound) waves from a transducer and processing of a returning echo to generate an image. It is ba",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 78
  },
  {
    "chunk_id": "infertility_1902",
    "text": "(sonography) involves the generation and transmission of ultrasonic (high-frequency sound) waves from a transducer and processing of a returning echo to generate an image. It is based on non-ionizing energy ( 14). Ovulation is indirectly established using ultrasound follicle tracking through a series of ultrasound scans that are performed between mid-follicular phase (day 8/9) to mid-luteal phase (15). The development, growth and morphological changes of follicles are monitored (15, 16). The collapse of the dominant follicle indicates ovulation ( 16–18). Although US examination may be conducted using several approaches (19–21), the transvaginal approach is most commonly used for assessing ovulation ( 22). 3 These thresholds are dependent on the assay used by laboratories and may range from 9.6 to 38 nmol/L (24–26). Progesterone is a steroidal female sex hormone essential for endometrial ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 78
  },
  {
    "chunk_id": "infertility_1903",
    "text": "se thresholds are dependent on the assay used by laboratories and may range from 9.6 to 38 nmol/L (24–26). Progesterone is a steroidal female sex hormone essential for endometrial receptivity, embryogenesis and the successful establishment of pregnancy. It is produced by ovarian granulosa-theca and corpus luteum cells and, during pregnancy, by placental tissue (23). Assessment of the serum progesterone indirectly establishes ovulation by measuring whether the peak (mid-luteal) levels of progesterone are above a specified threshold (24–26). Progesterone levels are measured several days (typically seven) before the expected menses. Levels greater than certain arbitrary thresholds, 3 provide presumptive evidence of ovulation ( 25, 27). Balancing harms and benefits Literature searches were conducted to identify diagnostic accuracy studies addressing mid-luteal progesterone and ultrasound fol",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 78
  },
  {
    "chunk_id": "infertility_1904",
    "text": "f ovulation ( 25, 27). Balancing harms and benefits Literature searches were conducted to identify diagnostic accuracy studies addressing mid-luteal progesterone and ultrasound follicle tracking from 1990 up to September 2019. The accuracy studies could have compared the tests to a presumed gold standard or compared two or more tests to predict the presence or absence of ovulation. An updated search was later conducted in PubMed up to October 2023. No studies comparing both tests to endometrial biopsy were identified. One study compared the accuracy of mid-luteal progesterone to the “gold standard” of ultrasound in women with infertility who also had regular menstrual cycles (28). In this study, which involved 101 women (97 menstrual cycles with ovulation), mid-luteal serum progesterone threshold level of at least 6 ng/ml was compared to transvaginal US. The sensitivity and specificity a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 78
  },
  {
    "chunk_id": "infertility_1905",
    "text": "101 women (97 menstrual cycles with ovulation), mid-luteal serum progesterone threshold level of at least 6 ng/ml was compared to transvaginal US. The sensitivity and specificity are presented in Table 5.1. These results imply that of 100 women, of whom 96 ovulate, 19 would be incorrectly classified as not ovulating (false negative); in addition, one woman would be incorrectly classified as having ovulated (false positive) if mid-luteal progesterone is used to determine ovulation (see Table 5.1).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 78
  },
  {
    "chunk_id": "infertility_1906",
    "text": "555 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table 5.1. Test performance of a single mid-luteal progesterone test Single mid-luteal progesterone test Sensitivity (95% CI) 80% (72–88%) Specificity (95% CI) 71% (not reported) CI, confidence interval. In assessing benefits, the GDG noted that there were fewer true positives and true negatives with mid-luteal progesterone compared to ultrasound (as ultrasound had higher sensitivity and specificity); however, the number of true positives or true negatives could be increased if a repeat mid-luteal progesterone test is performed in women whose initial test results indicate anovulation, as illustrated in Table 5.2. Table 5.2. Absolute effects on 100 women when different combinations of mid-luteal progesterone test with or without ultr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 79
  },
  {
    "chunk_id": "infertility_1907",
    "text": "results indicate anovulation, as illustrated in Table 5.2. Table 5.2. Absolute effects on 100 women when different combinations of mid-luteal progesterone test with or without ultrasound are provided Progesterone only Progesterone + repeat progesterone for women whose results show that they are anovulatory on the initial progesterone test Progesterone followed by US for women whose results show that they are anovulatory on the initial progesterone test True positives 77 81 81 True negatives 3 13 18 False positives 1 6 1 False negatives 19 1 0 Sensitivity 80 80 (first test), 80 (repeat test) 80 (progesterone), 100 (US) Specificity 71 71 (first test), 71 (repeat test) 80 (progesterone), 100 (US) US, ultrasound. Based on these data, the GDG concluded that the benefits of mid-luteal progesterone compared to ultrasound may be trivial when the mid-luteal progesterone measurement is repeated in",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 79
  },
  {
    "chunk_id": "infertility_1908",
    "text": "ased on these data, the GDG concluded that the benefits of mid-luteal progesterone compared to ultrasound may be trivial when the mid-luteal progesterone measurement is repeated in women whose initial test results indicate anovulation. In reaching this conclusion, the GDG considered that ultrasound is not a gold standard per se; it provides presumptive evidence of ovulation, and false positives are possible, given that ultrasonic evidence of luteinization has been documented in unruptured preovulatory follicles ( 15, 29, 30). Regarding harms, the GDG agreed that with the use of a single mid-luteal progesterone measurement approach, the harms of one out of 100 false positives may be trivial; however, 19 out of 100 false negatives may mean that these women (who are ovulating) would undergo unnecessary tests.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 79
  },
  {
    "chunk_id": "infertility_1909",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 56 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps However, if a mid-luteal progesterone measurement were to be repeated in women who were negative (i.e. 22% of women), the number of women who would be incorrectly classified as anovulatory (i.e. false positives) may increase slightly (from 1 to 6 women out of 100), but the women who would have unnecessary investigations for anovulation or oligo-ovulation may be greatly reduced (from 19 to 1 out of 100). Therefore, the GDG concluded that the difference in harms may be trivial when using this testing approach. Considering these benefits and harms, the GDG agreed that the balance of effects of repeating mid-luteal progesterone in women with an initial negative mid-luteal progesterone test resu",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 80
  },
  {
    "chunk_id": "infertility_1910",
    "text": "dering these benefits and harms, the GDG agreed that the balance of effects of repeating mid-luteal progesterone in women with an initial negative mid-luteal progesterone test result may be similar to the balance of effects when performing ultrasound as a single test. The GDG noted that, when mid-luteal progesterone measurement is repeated, 94 out of 100 women will be accurately diagnosed and that 100 women may be accurately diagnosed with ultrasound (assuming that ultrasound has 100% specificity and sensitivity). Although no studies on patient values were available, the GDG reached a consensus that women would value tests capable of correctly assessing ovulation, and they would also value tests with few harms, such as unnecessary tests, frequent travel (e.g. for serial tests) and costs. The GDG judged that there are probably no important uncertainties or variabilities in how much people",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 80
  },
  {
    "chunk_id": "infertility_1911",
    "text": " such as unnecessary tests, frequent travel (e.g. for serial tests) and costs. The GDG judged that there are probably no important uncertainties or variabilities in how much people value these outcomes. The overall certainty of evidence was rated as very low because of the limited number of available studies and the absence of a reference standard. The GDG agreed that both ultrasound and mid- luteal progesterone measurement provide indirect and presumptive confirmation of ovulation. Other considerations Two studies from the United Kingdom showed that the cost differences between mid-luteal progesterone measurement and ultrasound are negligible (31, 32). However, the GDG agreed that in LMICs, the cost differences may be greater, with serum progesterone measurements possibly costing moderately less and resulting in savings. In addition, the GDG judged that the cost difference would not cha",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 80
  },
  {
    "chunk_id": "infertility_1912",
    "text": "s may be greater, with serum progesterone measurements possibly costing moderately less and resulting in savings. In addition, the GDG judged that the cost difference would not change significantly even when the progesterone measurement is repeated in women whose results indicate anovulation on the initial progesterone measurement result. No data on cost-effectiveness were available. However, the guideline panel agreed that, given that there are similar benefits and harms between ultrasound and a strategy that involves repeat progesterone measurement in women whose results indicate anovulation on the initial progesterone test, and the cost of ultrasound is greater than serum progesterone, then cost-effectiveness probably favours the mid-luteal progesterone measurement. The GDG judged that cost-effectiveness would likely not change significantly when the progesterone test is repeated in w",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 80
  },
  {
    "chunk_id": "infertility_1913",
    "text": "s probably favours the mid-luteal progesterone measurement. The GDG judged that cost-effectiveness would likely not change significantly when the progesterone test is repeated in women whose initial progesterone measurement results indicate anovulation. Although there was no direct evidence on the impact of either test on equity, the GDG agreed that a mid-luteal progesterone measurement could probably increase equity because it requires fewer resources and is more widely available than ultrasound. The GDG judged that equity would likely not change significantly even when the progesterone measurement is repeated in women whose initial progesterone measurement results indicate anovulation. In terms of acceptability, one study reported that serial ultrasound is time-consuming, which may lead to frustration in patients and overcrowded waiting rooms (33). No studies assessing the acceptabilit",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 80
  },
  {
    "chunk_id": "infertility_1914",
    "text": "ty, one study reported that serial ultrasound is time-consuming, which may lead to frustration in patients and overcrowded waiting rooms (33). No studies assessing the acceptability of a mid-luteal progesterone measurement were found. In the absence of comparative data, the GDG agreed that although some women would require a repeat measurement, a mid-luteal serum progesterone test is likely more acceptable than transvaginal ultrasound for most patients.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 80
  },
  {
    "chunk_id": "infertility_1915",
    "text": "575 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps No comparative studies were identified on the feasibility of mid-luteal progesterone measurement and US. In the absence of direct evidence, the GDG judged that measuring the level of mid-luteal progesterone is probably feasible to perform; it could also be more feasible than US considering that it requires fewer resources than ultrasound, and ultrasound requires training. Summary justification There is very low certainty evidence indicating that a small number of women may be incorrectly informed that they have not ovulated when using mid-luteal serum progesterone measurement. For women whose results show no ovulation from the initial mid-luteal serum progesterone level, providing an additional mid-luteal serum progesterone measurem",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 81
  },
  {
    "chunk_id": "infertility_1916",
    "text": "esterone measurement. For women whose results show no ovulation from the initial mid-luteal serum progesterone level, providing an additional mid-luteal serum progesterone measurement would likely reduce the number of women referred for additional investigations for anovulation or oligo-ovulation. Measuring the level of mid-luteal progesterone costs less, is more feasible and probably more acceptable compared to performing an US scan. Implementation considerations While regular menstrual cycles are predictive of ovulation in most women ( 4–6), it is important to confirm ovulation for the purpose of arriving at a diagnosis that can be communicated to patients, most of whom have expressed a desire to be informed about the cause of their infertility ( 34). Health care providers should note that similar to ultrasound, serum progesterone level only provides “indirect” or “presumptive” evidenc",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 81
  },
  {
    "chunk_id": "infertility_1917",
    "text": "about the cause of their infertility ( 34). Health care providers should note that similar to ultrasound, serum progesterone level only provides “indirect” or “presumptive” evidence of ovulation. Measurement of serum progesterone indicates the formation of a corpus luteum, but does not provide definitive proof that a mature, fertilizable oocyte has been released from the ovary (35). Additionally, suboptimal timing of sample collection (vis-à-vis menstrual cycle day), pulsatile secretion, circadian effect, assay error, luteinized unruptured follicles and inherent biological heterogeneity all contribute to variability and potential false negative results ( 36-40); hence, the need to repeat it if the initial measurement result indicates no ovulation in women with normal findings on history and physical examination. Considering the normal variation of secreted progesterone in ovulatory menst",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 81
  },
  {
    "chunk_id": "infertility_1918",
    "text": "rement result indicates no ovulation in women with normal findings on history and physical examination. Considering the normal variation of secreted progesterone in ovulatory menstrual cycles (41, 42), and given that the follicular and luteal phases differ in their contribution to this variability (37, 41), health care providers should note that obtaining mid-luteal serum progesterone levels approximately 7 days before the expected onset of the next menses is more informative than obtaining it on a specified cycle day. While mid-luteal serum progesterone levels should be assessed approximately 7 days before the expected onset of the next menses, the specific cycle day can vary based on the length of the cycle, for example, day 21 of a 28-day cycle or day 28 of a 35-day cycle. Research gaps and future guideline update There were limited data on the acceptability of mid-luteal progesterone",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 81
  },
  {
    "chunk_id": "infertility_1919",
    "text": "for example, day 21 of a 28-day cycle or day 28 of a 35-day cycle. Research gaps and future guideline update There were limited data on the acceptability of mid-luteal progesterone measurement or its impact on equity. Implementation research is required to assess the downstream impact of implementing the suggested test for ovulation (mid-luteal progesterone) for women with normal findings on history (including regular menstrual cycles) and physical examination, including regularly menstruating non-hirsute women; such data can inform future considerations. Guidance regarding the role or potential use of LH assessments for the confirmation of ovulation will be required in the future. This recommendation relates to the application of ovulation tests in health care settings and does not relate to direct-to-consumer products, such as fertility tracking wearables and applications, which will r",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 81
  },
  {
    "chunk_id": "infertility_1920",
    "text": "o the application of ovulation tests in health care settings and does not relate to direct-to-consumer products, such as fertility tracking wearables and applications, which will require future guidance.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 81
  },
  {
    "chunk_id": "infertility_1921",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 58 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. World Health Organization. Advances in methods of fertility regulation: report of a WHO scientific group. Geneva: World Health Organization; 1973 (https://iris.who.int/handle/10665/38224). 2. Munro MG, Balen AH, Cho S, Critchley HOD, Díaz I, Ferriani R et al. The FIGO Ovulatory Disorders Classification System. Hum Reprod. 2022;37(10):2446-64 (https://doi.org/10.1093/ humrep/deac180). 3. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 4. Lynch KE, Mumford SL, Schliep KC, Whitcomb BW, Zarek SM, Pollack AZ et al. Assessment of anov",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 82
  },
  {
    "chunk_id": "infertility_1922",
    "text": "on; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 4. Lynch KE, Mumford SL, Schliep KC, Whitcomb BW, Zarek SM, Pollack AZ et al. Assessment of anovulation in eumenorrheic women: comparison of ovulation detection algorithms. Fertil Steril. 2014;102(2):511-8 (https://doi. org/10.1016/j.fertnstert.2014.04.035). 5. Malcolm CE, Cumming DC. Does anovulation exist in eumenorrheic women? Obstet Gynecol. 2003;102(2):317-8 (https://doi.org/10.1016/S0029- 7844(03)00527-1). 6. Chinta P, Rebekah G, Kunjummen AT, Kamath MS. Revisiting the role of serum progesterone as a test of ovulation in eumenorrheic subfertile women: a prospective diagnostic accuracy study. Fertil Steril. 2020;114(6):1315-21 (https://doi. org/10.1016/j.fertnstert.2020.06.030). 7. Leader A, Wiseman D, Taylor PJ. The prediction of ovulation: a comparison of the basal body temperature graph, cervical ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 82
  },
  {
    "chunk_id": "infertility_1923",
    "text": "-21 (https://doi. org/10.1016/j.fertnstert.2020.06.030). 7. Leader A, Wiseman D, Taylor PJ. The prediction of ovulation: a comparison of the basal body temperature graph, cervical mucus score, and real-time pelvic ultrasonography. Fertil Steril. 1985;43(3):385-8 (https://doi.org/10.1016/s0015- 0282(16)48436-0). 8. Garcia JE, Jones GS, Wright GL Jr. Prediction of the time of ovulation. Fertil Steril. 1981;36(3):308-15 (https://doi.org/10.1016/S0015-0282(16)45730-4). 9. Robertson RD, Picker RH, Wilson PC, Saunders DM. Assessment of ovulation by ultrasound and plasma estradiol determinations. Obstet Gynecol. 1979;54(6):686-91. 10. Murray MJ, Meyer WR, Zaino RJ, Lessey BA, Novotny DB, Ireland K et al. A critical analysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating in fertile women. Fertil Steril. 2004;81(5):1333-43 (https://doi. org/10.1016/j.fertn",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 82
  },
  {
    "chunk_id": "infertility_1924",
    "text": "alysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating in fertile women. Fertil Steril. 2004;81(5):1333-43 (https://doi. org/10.1016/j.fertnstert.2003.11.030). 11. Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17β, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. Health Organization, Task Force on Methods for the Determination of the Fertile Period World Special Programme of Research, Development and Research Training in Human Reproduction. Am J Obstet Gynecol. 1980;138(4):383-90 (https://doi. org/10.1016/0002-9378(80)90133-7). 12. Stanford JB, White GL, Hatasaka H. Timing intercourse to achieve pregnancy: Current evidence. Obstet Gynecol. 2002;100(6):1333-41 (https://doi.org/10.1016/S0029-7844(02)02382-7). 13. McGovern PG, Myers ER, Silva S, Coutifaris ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 82
  },
  {
    "chunk_id": "infertility_1925",
    "text": "rcourse to achieve pregnancy: Current evidence. Obstet Gynecol. 2002;100(6):1333-41 (https://doi.org/10.1016/S0029-7844(02)02382-7). 13. McGovern PG, Myers ER, Silva S, Coutifaris C, Carson SA, Legro RS et al. Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril. 2004;82(5):1273-7 (https://doi.org/10.1016/j. fertnstert.2004.03.070). 14. Tole N. Basic physics of ultrasonic imaging. In: Ostensen H, editor. Basic physics of ultrasonic imaging. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/43179). 15. Queenan JT, O’Brien GD, Bains LM, Simpson J, Collins WP, Campbell S. Ultrasound scanning of ovaries to detect ovulation in women. Fertil Steril. 1980;34(2):99-105 (https://doi.org/10.1016/ S0015-0282(16)44889-2). 16. Kerin JF, Edmonds DK, Warnes GM, Cox LW, Seamark RF, Matthews CD et al. Morphological and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 82
  },
  {
    "chunk_id": "infertility_1926",
    "text": "n. Fertil Steril. 1980;34(2):99-105 (https://doi.org/10.1016/ S0015-0282(16)44889-2). 16. Kerin JF, Edmonds DK, Warnes GM, Cox LW, Seamark RF, Matthews CD et al. Morphological and functional relations of Graafian follicle growth to ovulation in women using ultrasonic, laparoscopic and biochemical measurements. Br J Obstet Gynaecol. 1981;88(2):81-90 (https://doi. org/10.1111/j.1471- 0528.1981.tb00947.x).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 82
  },
  {
    "chunk_id": "infertility_1927",
    "text": "595 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 17. de Crespigny LC, O’Herlihy C, Robinson HP. Ultrasonic observation of the mechanism of human ovulation. Am J Obstet Gynecol. 1981;139(6):636-9 (https://doi.org/10.1016/0002- 9378(81)90476-2). 18. Hanna MD, Chizen DR, Pierson RA. Characteristics of follicular evacuation during human ovulation. Ultrasound Obstet Gynecol. 1994;4(6):488-93 (https://doi.org/10.1046/j.1469- 0705.1994.04060488.x). 19. Manual of diagnostic ultrasound. Geneva: World Health Organization; 1995 (https://iris.who.int/ handle/10665/38652). 20. Manual of diagnostic ultrasound, second edition, vol. 1. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/43881). 21. Wall DJ, Reinhold C, Akin EA, Ascher SM, Brook OR, Dassel M et al. ACR Appro",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 83
  },
  {
    "chunk_id": "infertility_1928",
    "text": "edition, vol. 1. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/43881). 21. Wall DJ, Reinhold C, Akin EA, Ascher SM, Brook OR, Dassel M et al. ACR Appropriateness Criteria® female infertility. J Am Coll Radiol. 2020;17(5, Supplement):S113-S24 (https://doi. org/10.1016/j.jacr.2020.01.018). 22. Manual of diagnostic ultrasound, second edition, vol. 2. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 23. Enna SJ, Bylund DB. Progesterone. In: Enna SJ, Bylund DB, editors. xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier; 2007:1–2 (https://doi.org/10.1016/B978- 008055232-3.62470-5). 24. Israel R, Mishell DR, Stone SC, Thorneycroft IH, Moyer DL. Single luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet Gynecol. 1972;112(8):1043-6 (https:// doi.org/10.1016/0002-9378(72)90178-0). 25. Wath",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 83
  },
  {
    "chunk_id": "infertility_1929",
    "text": "yer DL. Single luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet Gynecol. 1972;112(8):1043-6 (https:// doi.org/10.1016/0002-9378(72)90178-0). 25. Wathen N, Perry L, Lilford R, Chard T. Interpretation of single progesterone measurement in diagnosis of anovulation and defective luteal phase: observations on analysis of the normal range. Br Med J (Clin Res Ed). 1984;288(6410):7-9 (http://doi.org/10.1136/ bmj.288.6410.7). 26. Abdulla U, Diver MJ, Hipkin LJ, Davis JC. Plasma progesterone levels as an index of ovulation. Br J Obstet Gynaecol. 1983;90(6):543-8 (https://doi. org/10.1111/j.1471- 0528.1983.tb08965.x). 27. Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ. WHO manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 1993 (https://iris. who.int/handle/10665/36983). 28. Guermandi E, Vegetti W, B",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 83
  },
  {
    "chunk_id": "infertility_1930",
    "text": "ndardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 1993 (https://iris. who.int/handle/10665/36983). 28. Guermandi E, Vegetti W, Bianchi MM, Uglietti A, Ragni G, Crosignani P. Reliability of ovulation tests in infertile women. Obstet Gynecol. 2001;97(1):92-6 (https://doi.org/10.1016/s0029- 7844(00)01083-8). 29. Coulam CB, Hill LM, Breckle R. Ultrasonic evidence for luteinization of unruptured preovulatory follicles. Fertil Steril. 1982;37(4):524-9 (https://doi. org/10.1016/S0015-0282(16)46160-1). 30. Hackelöer BJ, Robinson HP. [Ultrasound examination of the growing ovarian follicle and of the corpus luteum during the normal physiologie menstrual cycle (author’s translation)]. Geburtshilfe Frauenheilkd. 1978;38(3):163-8 (in German). 31. Ojha K, Philips Z, Darne FJ. Diagnosing infertility in a district general hospital: a case-note and cost",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 83
  },
  {
    "chunk_id": "infertility_1931",
    "text": "translation)]. Geburtshilfe Frauenheilkd. 1978;38(3):163-8 (in German). 31. Ojha K, Philips Z, Darne FJ. Diagnosing infertility in a district general hospital: a case-note and cost analysis. Hum Fertil. 2003;6(4):169-73 (https://doi.org/10.1080/1464770312331369443). 32. Cooper NA, Barton PM, Breijer M, Caffrey O, Opmeer BC, Timmermans A et al. Cost- effectiveness of diagnostic strategies for the management of abnormal uterine bleeding (heavy menstrual bleeding and post-menopausal bleeding): a decision analysis. Health Technol Assess. 2014;18(24):1-201 (https://doi. org/10.3310/hta18240). 33. Revelli A, Casano S, Salvagno F, Delle Piane L. Milder is better? Advantages and disadvantages of “mild” ovarian stimulation for human in vitro fertilization. Reprod Biol Endocrinol. 2011;9(1):1-9 (https://doi.org/10.1186/1477-7827-9-144). 34. Dancet EAF, Nelen WLDM, Sermeus W, De Leeuw L, Kremer JAM",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 83
  },
  {
    "chunk_id": "infertility_1932",
    "text": "ion for human in vitro fertilization. Reprod Biol Endocrinol. 2011;9(1):1-9 (https://doi.org/10.1186/1477-7827-9-144). 34. Dancet EAF, Nelen WLDM, Sermeus W, De Leeuw L, Kremer JAM, D’Hooghe TM. The patients’ perspective on fertility care: a systematic review. Hum Reprod Update. 2010;16(5):467-87 (https:// doi.org/10.1093/humupd/dmq004). 5 Diagnosis of infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 83
  },
  {
    "chunk_id": "infertility_1933",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 60 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 35. ESHRE Capri Workshop Group. Diagnosis and management of the infertile couple: missing information. Hum Reprod Update. 2004;10(4):295-307 (https://doi.org/10.1093/ humupd/dmh024). 36. Janssen-Caspers HA, Kruitwagen RF, Wladimiroff JW, de Jong FH, Drogendijk AC. Diagnosis of luteinized unruptured follicle by ultrasound and steroid hormone assays in peritoneal fluid: a comparative study. Fertil Steril. 1986;46(5):823-7 (https://doi.org/10.1016/s0015-0282(16)49819-5). 37. Rahman SA, Grant LK, Gooley JJ, Rajaratnam SMW, Czeisler CA, Lockley SW. Endogenous circadian regulation of female reproductive hormones. J Clin Endocrinol Metab. 2019;104(12):6049-59 (https://doi.org/10.1210/ jc.2019-0080",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 84
  },
  {
    "chunk_id": "infertility_1934",
    "text": " SMW, Czeisler CA, Lockley SW. Endogenous circadian regulation of female reproductive hormones. J Clin Endocrinol Metab. 2019;104(12):6049-59 (https://doi.org/10.1210/ jc.2019-00803). 38. Fujimoto VY, Clifton DK, Cohen NL, Soules MR. Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting. Obstet Gynecol. 1990;76(1):71-8. 39. Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest. 1984;73(6):1638-47 (https://doi.org/10.1172/ jci111370). 40. Steele PA, White GH, Judd SJ. Reliability of a single serum progesterone determination as an indicator of ovulation. Clin Reprod Fertil. 1985;3(2):125-30 (http://europepmc.org/abstract/ MED/4052919). 41. Fehring RJ, Schneider M, Raviele K. Variability in the phases",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 84
  },
  {
    "chunk_id": "infertility_1935",
    "text": "n as an indicator of ovulation. Clin Reprod Fertil. 1985;3(2):125-30 (http://europepmc.org/abstract/ MED/4052919). 41. Fehring RJ, Schneider M, Raviele K. Variability in the phases of the menstrual cycle. J Obstet Gynecol Neonatal Nurs. 2006;35(3):376- 84 (ht tps://doi.org/10.1111/j.1552- 6909.2006.00051.x). 42. Bull JR, Rowland SP, Scherwitzl EB, Scherwitzl R, Danielsson KG, Harper J. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. NPJ Digit Med. 2019;2(1):83 (https://doi.org/10.1038/s41746-019-0152-7).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 84
  },
  {
    "chunk_id": "infertility_1936",
    "text": "615 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5.3 Assessment of reproductive hormones 4 That is, nothing abnormal is detected. 5 An earlier age may be considered, for example, because of international variation in ages at menarche (2, 3) or based on clinical presentation. Good practice statement For females with infertility and suspected anovulation or oligo-ovulation, it is good practice to assess reproductive hormones related to the hypothalamic– pituitary–ovarian (HPO) axis (such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and in some clinical presentations, estradiol (E2), testosterone [T]). Additional testing (e.g. thyroid-stimulating hormone [TSH], prolactin [PRL]) may also be considered based on the clinical presentation. The choice of diagnostic ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 85
  },
  {
    "chunk_id": "infertility_1937",
    "text": "testosterone [T]). Additional testing (e.g. thyroid-stimulating hormone [TSH], prolactin [PRL]) may also be considered based on the clinical presentation. The choice of diagnostic tests should be based on clinical findings from a comprehensive medical history and physical examination to ensure that evaluation is systematic and cost-effective. Background and rationale The clinical pattern of ovulation is influenced by several physiological factors ( 1, 2). When a couple presents with a history of failure to achieve a pregnancy, history-taking and a physical examination are conducted in the female. If these are normal, 4 including a history of regular menstrual cycles, ovulation is assessed (see section 5.2). Diagnostic assessment of the female and male should take place concurrently (see sections 3, 5.5 and 5.7). If the history identifies women who do not have a regular menstrual pattern ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 85
  },
  {
    "chunk_id": "infertility_1938",
    "text": "gnostic assessment of the female and male should take place concurrently (see sections 3, 5.5 and 5.7). If the history identifies women who do not have a regular menstrual pattern (menstrual bleeding at intervals of 28 ± 7 days) further hormonal evaluation is indicated to identify potential causes of anovulation and oligo-ovulation. These women may include those with primary amenorrhea (patients aged over 18 years5 who have never experienced spontaneous vaginal bleeding), secondary amenorrhea (absence of spontaneous vaginal bleeding for 6 months or more in a patient who had previously experienced it) or oligomenorrhea (infrequent or scanty menstruation characterized by spontaneous vaginal bleeding at intervals from 36 days to 6 months) (1). Age of menarche varies ( 3, 4). WHO classifies ovulation disorders into three groups (2) as follows: • Group I: women with amenorrhea and little or n",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 85
  },
  {
    "chunk_id": "infertility_1939",
    "text": "from 36 days to 6 months) (1). Age of menarche varies ( 3, 4). WHO classifies ovulation disorders into three groups (2) as follows: • Group I: women with amenorrhea and little or no evidence of endogenous estrogen activity, including patients with (i) hypogonadotropic ovarian failure, (ii) complete or partial hypopituitarism or (iii) pituitary-hypothalamic dysfunction. Group I is characterized by low or unmeasurable serum and urinary gonadotrophins, and low estrogen levels. Plasma progesterone levels are typically less than 1.0 ng/ml and plasma hydroxyprogesterone are typically less than 0.2 ng/ml. Patients in WHO Group I may have primary or secondary amenorrhoea. • Group II: women with a variety of menstrual cycle disturbances (including amenorrhoea) who exhibit distinct endogenous estrogen activity (urinary estrogens usually less than 10 μg/24 h), whose urinary and serum gonadotrophins",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 85
  },
  {
    "chunk_id": "infertility_1940",
    "text": "ycle disturbances (including amenorrhoea) who exhibit distinct endogenous estrogen activity (urinary estrogens usually less than 10 μg/24 h), whose urinary and serum gonadotrophins are in the normal range and fluctuating, and who may have fairly regular spontaneous menstrual bleeding (i.e. less than 35 days apart), but without ovulation. Patients with galactorrhoea associated with amenorrhoea may be classified under WHO Group II or, rarely, WHO Group",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 85
  },
  {
    "chunk_id": "infertility_1941",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 62 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps I based on laboratory and indirect clinical findings. • Group III: women with primary ovarian failure associated with low endogenous estrogen activity and pathologically elevated serum and urinary gonadotrophins. This WHO diagnostic classification aims to inform clinical management of infertility and does not aim to provide a comprehensive classification ( 1). Other more comprehensive classifications exist ( 5, 6). For this recommendation, the GDG addressed the question: should reproductive hormones versus none be performed for the initial evaluation of women with infertility and suspected anovulation and oligo-ovulation. Considering existing guidance on good practice statements (7), the GD",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 86
  },
  {
    "chunk_id": "infertility_1942",
    "text": " performed for the initial evaluation of women with infertility and suspected anovulation and oligo-ovulation. Considering existing guidance on good practice statements (7), the GDG agreed that it is good practice to evaluate reproductive hormones during the initial evaluation of anovulation and oligo-ovulation, specifically those related to the HPO axis (such as FSH and LH, and in some clinical presentations, E2, T). The GDG agreed that additional testing (e.g. TSH, PRL) may also be considered based on the clinical presentation. The GDG agreed that the choice of diagnostic tests should be based on clinical findings from a comprehensive medical history and physical examination, and should ensure that evaluation is systematic and cost-effective. Necessity of the message Given the importance of hormonal and endocrine causes of female infertility ( 1, 8), the GDG agreed that it is important",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 86
  },
  {
    "chunk_id": "infertility_1943",
    "text": " is systematic and cost-effective. Necessity of the message Given the importance of hormonal and endocrine causes of female infertility ( 1, 8), the GDG agreed that it is important for health care providers to have clear guidance on whether reproductive hormones should be assessed or not in women with infertility and suspected anovulation or oligo-ovulation. Consequences The GDG agreed that normal menstrual function involves the coordinated function of several physiological and structural components: the hypothalamus, the anterior pituitary gland, the ovary and the genital outflow tract composed of the uterus/endometrium, cervix and vagina. The physiological balance between gonadotrophic hormones and ovarian sex steroids is necessary for an orderly ovulatory sequence; failure to ovulate may be the result of a dysfunction at any level of this system. This system involves hormonal function",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 86
  },
  {
    "chunk_id": "infertility_1944",
    "text": "x steroids is necessary for an orderly ovulatory sequence; failure to ovulate may be the result of a dysfunction at any level of this system. This system involves hormonal functions in higher centres in the brain, the HPO axis and the steroid feedback mechanism. In this context, the GDG agreed that measuring the following hormones will identify dysfunction in the ovulatory sequence and inform diagnosis, prognosis and management of anovulation and oligo-ovulation leading to large net positive consequences. FSH and LH The gonadotrophin-releasing hormone (GnRH) stimulates the synthesis and secretion of pituitary gonadotrophin hormones, FSH and LH. FSH and LH stimulate and sustain follicular growth and maturation (differentiation and luteinization) ( 9, 10). In the absence of the FSH and LH hormones, the development of ovarian follicles is impaired at early antral or preovulatory stages, res",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 86
  },
  {
    "chunk_id": "infertility_1945",
    "text": "differentiation and luteinization) ( 9, 10). In the absence of the FSH and LH hormones, the development of ovarian follicles is impaired at early antral or preovulatory stages, respectively (9, 10), although follicular proliferation may not be entirely inhibited (10, 11). Gonadotropins also have a part in sustaining follicular steroidogenesis (10) by mediating aromatization of androgens to estrogens (12). Gonadotropin deficiency can result either from a pituitary abnormality ( 13, 14) or a deficiency of GnRH (14). FSH and LH levels are low or unmeasurable in WHO Group I, normal in WHO Group II and high in WHO Group III. Estradiol Estrogens have an important role in the development of ovarian follicles by regulating gonadotrophin secretion for ovulation ( 15). Ovarian granulosa cells are the key source of serum estrogens in premenopausal women; smaller amounts are produced in peripheral a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 86
  },
  {
    "chunk_id": "infertility_1946",
    "text": "ting gonadotrophin secretion for ovulation ( 15). Ovarian granulosa cells are the key source of serum estrogens in premenopausal women; smaller amounts are produced in peripheral adipose tissue (15, 16). Estrogen regulates FSH secretion through a negative feedback loop on the HPO axis (17): it stimulates the production of GnRH, which in turn stimulates FSH; when FSH levels are high, E2 secretion is inhibited. Estrogens occur",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 86
  },
  {
    "chunk_id": "infertility_1947",
    "text": "635 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps in various isoforms including estrone (E1), 17β-estradiol (E2), estriol (E3) and estetrol (E4) (18). E2 is the main circulating and most potent naturally occurring estrogen in premenopausal women; it is predominantly produced in the ovaries ( 17). E2 levels are low in WHO Group I, normal in WHO Group II and low in WHO Group III. Testosterone Several androgens, including testosterone, are produced in the ovary and the adrenal glands in women (15, 19). Ovarian androgens are generated in thecal cells and mediated by gonadotrophins, particularly LH ( 12, 20, 21). Androgens are also produced in peripheral tissues through local conversion of prohormones ( 15, 22). Ovarian hyperandrogenism, typically featuring high levels of testosterone, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 87
  },
  {
    "chunk_id": "infertility_1948",
    "text": "1). Androgens are also produced in peripheral tissues through local conversion of prohormones ( 15, 22). Ovarian hyperandrogenism, typically featuring high levels of testosterone, is characterized by oligomenorrhoea, hirsutism or acne (23). Progesterone Progesterone is required for the maintenance of pregnancy (24, 25) and is initially produced by the corpus luteum after ovulation ( 24) and later by the fetoplacental unit after implantation (25). Measurement of progesterone is suggested for the assessment of ovulation in this guideline (see section 5.2 on the use of progesterone for presumptive confirmation of ovulation). PRL Hyperprolactinaemia is present in 6.6% of those with infertility ( 26, 27), while hypoprolactinaemia is rare (28). PRL secretion is regulated by multiple factors, including thyroid-releasing hormone (TRH) (29) and dopamine (30). Clinical features of hyperprolactinae",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 87
  },
  {
    "chunk_id": "infertility_1949",
    "text": "prolactinaemia is rare (28). PRL secretion is regulated by multiple factors, including thyroid-releasing hormone (TRH) (29) and dopamine (30). Clinical features of hyperprolactinaemia include oligomenorrhoea, amenorrhoea, infertility and galactorrhoea (31). Symptoms of pituitary mass effect, such as headaches and visual disturbances, may also be present (31). TSH When thyroid antibodies are present, both hypothyroidism and hyperthyroidism are more frequent in women with infertility ( 32). Both hyperthyroidism and hypothyroidism can lead to menstrual disturbances ( 32, 33) and may result in changes in sex hormone binding globulin (SHBG) and sex steroids ( 32). Hyperthyroidism arises when the thyroid gland produces excessive amounts of the thyroid hormones T4 and/or T3. Hyperthyroidism may present with either too scanty (hypomenorrhoea) or too frequent (polymenorrhoea) uterine bleeding, al",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 87
  },
  {
    "chunk_id": "infertility_1950",
    "text": "es excessive amounts of the thyroid hormones T4 and/or T3. Hyperthyroidism may present with either too scanty (hypomenorrhoea) or too frequent (polymenorrhoea) uterine bleeding, alongside other clinical features ranging from subclinical hyperthyroidism, overt hyperthyroidism, Graves’ disease, toxic multinodular goitre and toxic adenoma (32). Hypothyroidism results from an underactive thyroid gland ( 34) and may present with oligomenorrhoea alongside wide-ranging features, from subclinical hypothyroidism, overt hypothyroidism, or with symptoms secondary to pituitary disease ( 13, 32). Hypothyroidism results in excessive hypothalamic secretion of TRH, which increases TSH (29, 32) and can affect PRL secretion (29, 35, 36). International reference standards WHO international reference biological standards for bioassay and immunoassay are available for FSH, LH (37, 38), PRL (38, 39) and TSH (",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 87
  },
  {
    "chunk_id": "infertility_1951",
    "text": " 35, 36). International reference standards WHO international reference biological standards for bioassay and immunoassay are available for FSH, LH (37, 38), PRL (38, 39) and TSH (38, 40). In addition, an international reference biological standard for SHBG, which has clinical utility in interpreting the result of E2 and T, is also available (38). In addition, FSH, LH, E2, PRL and TSH are already included in the WHO model list of essential in vitro diagnostics (41). However, future efforts will be needed to include T in the WHO model list of essential in vitro diagnostics.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 87
  },
  {
    "chunk_id": "infertility_1952",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 64 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Rationale The GDG agreed that measuring these hormones will assist to identify ovulation dysfunction and in selecting appropriate management of infertility. Assessment of these hormones will result in large net positive consequences and the opportunity cost of collecting and summarizing evidence is large. The GDG agreed that the choice of diagnostic tests should be based on clinical findings from a comprehensive medical history and physical examination, and ensure that evaluation is systematic and cost-effective. Implementation considerations The GDG agreed that multiple endocrinopathies may coexist in the same patient, which may require concomitant identification; therefore, the utility of",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 88
  },
  {
    "chunk_id": "infertility_1953",
    "text": "Implementation considerations The GDG agreed that multiple endocrinopathies may coexist in the same patient, which may require concomitant identification; therefore, the utility of each test may depend on the clinical profile. Indiscriminate ordering of tests should be avoided. Interactions between metabolic and reproductive systems may occur in patients (42), including those with anovulation and oligo-ovulation, for example, in polycystic ovary syndrome (PCOS) ( 43). Anovulation and oligo-ovulation may occur in a small proportion of eumenorrhoeic women (such as those with hirsutism and/or obesity) ( 44, 45), whose differential diagnosis can be informed by history-taking and a physical examination. Consequently, selection of diagnostic tests based on clinical findings from medical history-taking and a physical examination is needed to ensure that evaluation is systematic and cost-effecti",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 88
  },
  {
    "chunk_id": "infertility_1954",
    "text": ", selection of diagnostic tests based on clinical findings from medical history-taking and a physical examination is needed to ensure that evaluation is systematic and cost-effective (see Chapter 3. Approach to the evaluation and management of infertility ). Laboratory technical parameters can affect test results, and training and rigorous quality safeguards are necessary to minimize errors. Invalid results may result from cross-reactivity, interference, inter-assay or inter-laboratory variability, sample integrity, stability, storage and handling, and lack of standardization, among other factors. Whenever possible, laboratories should be encouraged to use low-cost matched reagents or international standards, engage in regular reagent and kit renewal, and perform internal and external quality assurance. Health care providers should note that hormones have infradian, circadian and ultradi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 88
  },
  {
    "chunk_id": "infertility_1955",
    "text": "ngage in regular reagent and kit renewal, and perform internal and external quality assurance. Health care providers should note that hormones have infradian, circadian and ultradian rhythms (46–48) that may affect the results or optimal timing of blood draws ( 1). To maintain a high-quality service, laboratories should be accredited to a suitable national or international body, such as the International Organization for Standardization (ISO), with a goal to comply with relevant standards, such as the international standard ISO 15189 (49). It is good practice to evaluate reproductive hormones during the initial evaluation of anovulation and oligo-ovulation, but these may not always ascertain a final diagnosis from a list of differential diagnoses. Further clinical or diagnostic evaluation may be required to fulfil the criteria for specific diagnosis. For example, further assessment of sp",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 88
  },
  {
    "chunk_id": "infertility_1956",
    "text": "rom a list of differential diagnoses. Further clinical or diagnostic evaluation may be required to fulfil the criteria for specific diagnosis. For example, further assessment of specific hormones is required to fulfil the diagnostic criteria for PCOS (50), while further clinical evaluation is required to ensure that no anatomical or organic cause of amenorrhoea exists before making a diagnosis of functional hypothalamic amenorrhoea. In addition, measurement of E2 is essential in interpreting FSH levels, while measurement of SHBG is required to correctly interpret the serum levels of E2 and T. Similarly, when TSH is elevated, measurement of other thyroid parameters, such as serum free T 4 may be needed to make the final diagnosis. Depending on the clinical presentation, other hormonal assessments such as 17-α-hydroxyprogesterone or dehydroepiandrosterone sulfate, among others, may be need",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 88
  },
  {
    "chunk_id": "infertility_1957",
    "text": "he final diagnosis. Depending on the clinical presentation, other hormonal assessments such as 17-α-hydroxyprogesterone or dehydroepiandrosterone sulfate, among others, may be needed to diagnose a range of endocrine conditions associated with anovulation and oligo-ovulation. Health care providers should carefully consider a potential differential diagnosis",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 88
  },
  {
    "chunk_id": "infertility_1958",
    "text": "655 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps based on clinical profile while ordering tests (see Fig. 5.1. Diagnostic algorithm for female-factor infertility and unexplained infertility ). In all cases of amenorrhoea, health care providers should exclude pregnancy as part of infertility investigation. Research gaps and future guideline update Future updating of WHO classification of ovulation disorders is required through the revision procedures of the International Classification of Diseases. References 1. Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ. WHO manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 1993 (https://iris. who.int/handle/10665/36983). 2. Agents stimulating gonadal function in the human. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 89
  },
  {
    "chunk_id": "infertility_1959",
    "text": "and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 1993 (https://iris. who.int/handle/10665/36983). 2. Agents stimulating gonadal function in the human. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1973;514:1-30. 3. World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. I. A multicenter cross-sectional study of menarche. J Adolesc Health Care. 1986;7(4):229-35 (https://doi.org/10.1016/S0197- 0070(86)80014-6). 4. Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol. 1998;148(12):1195-205 (https://doi.org/10.1093/ oxfordjournals.aje.a009609). 5. Balen AH, Tamblyn J, Skorupskaite K, Munro MG. A comprehensive review of the new FIGO classification of",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 89
  },
  {
    "chunk_id": "infertility_1960",
    "text": "8;148(12):1195-205 (https://doi.org/10.1093/ oxfordjournals.aje.a009609). 5. Balen AH, Tamblyn J, Skorupskaite K, Munro MG. A comprehensive review of the new FIGO classification of ovulatory disorders. Hum Reprod Update. 2024;30(3):355-82 (https://doi. org/10.1093/humupd/dmae003). 6. Munro MG, Balen AH, Cho S, Critchley HOD, Díaz I, Ferriani R et al. The FIGO Ovulatory Disorders Classification System. Hum Reprod. 2022;37(10):2446-64 (https://doi.org/10.1093/ humrep/deac180). 7. Guyatt GH, Alonso-Coello P, Schünemann HJ, Djulbegovic B, Nothacker M, Lange S et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol. 2016;80:3-7 (https://doi.org/10.1016/j.jclinepi.2016.07.006). 8. Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine disorders & female infertility. Best Pract Res Clin Endocrinol Metab. 2011;25(6):861- 73 (ht",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 89
  },
  {
    "chunk_id": "infertility_1961",
    "text": "1016/j.jclinepi.2016.07.006). 8. Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine disorders & female infertility. Best Pract Res Clin Endocrinol Metab. 2011;25(6):861- 73 (https://doi.org/10.1016/j.beem.2011.08.001). 9. Markström E, Svensson E, Shao R, Svanberg B, Billig H. Survival factors regulating ovarian apoptosis – dependence on follicle differentiation. Reproduction. 2002;123(1):23-30 (https://doi.org/10.1530/rep.0.1230023). 10. Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev. 1996;17(2):121-55 (https://doi. org/10.1210/edr v-17-2-121). 11. Barnes RB, Namnoum AB, Rosenfield RL, Layman LC. The role of LH and FSH in ovarian androgen secretion and ovarian follicular development: clinical studies in a patient with isolated FSH deficiency and multicystic ovaries. Hum Reprod. 2002;17(1):88-91 (https://doi. org/10.1093/humrep/17",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 89
  },
  {
    "chunk_id": "infertility_1962",
    "text": "ovarian follicular development: clinical studies in a patient with isolated FSH deficiency and multicystic ovaries. Hum Reprod. 2002;17(1):88-91 (https://doi. org/10.1093/humrep/17.1.88). 12. Hillier SG, Whitelaw PF, Smyth CD. Follicular oestrogen synthesis: the ‘two-cell, two- gonadotrophin’ model revisited. Mol Cell Endocrinol. 1994;100(1-2):51-4 (https://doi. org/10.1016/0303-7207(94)90278-x). 13. Karavitaki N, Wass JAH. Disorders of the anterior pituitary gland. 2020. In: Gurnell M, Firth J, Conlon C, Cox T, editors. Oxford textbook of medicine. Oxford: Oxford University Press; 2020:597–603 (https://doi.org/10.1093/ med/9780198746690.003.0244). 14. Ciccone NA, Kaiser UB. The biology of gonadotroph regulation. Curr Opin Endocrinol Diabetes Obes. 2009;16(4):321-7 (https://doi. org/10.1097/MED.0b013e32832d88fb).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 89
  },
  {
    "chunk_id": "infertility_1963",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 66 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 15. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81-151 (https://doi.org/10.1210/ er.2010-0013). 16. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev. 1994;15(3):342-55 (https://doi.org/10.1210/ edrv-15-3-342). 17. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(3 Suppl):S116-S24 (https://doi.org/10.1067/ mjd.2001.117432). 18. Thomas MP, Potter BV. The structural biology of oestrogen metabolism. J Steroid Biochem Mol Biol. 2013;137:27-49 (",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 90
  },
  {
    "chunk_id": "infertility_1964",
    "text": "3 Suppl):S116-S24 (https://doi.org/10.1067/ mjd.2001.117432). 18. Thomas MP, Potter BV. The structural biology of oestrogen metabolism. J Steroid Biochem Mol Biol. 2013;137:27-49 (https://doi.org/10.1016/j. jsbmb.2012.12.014). 19. Burger HG. Androgen production in women. Fertil Steril. 2002;77 Suppl 4:S3-S5 (https://doi. org/10.1016/s0015-0282(02)02985-0). 20. Bogovich K, Richards JS. Androgen biosynthesis in developing ovarian follicles: evidence that luteinizing hormone regulates thecal 17ɑ-hydroxylase and C17–20-lyase activities. Endocrinology. 1982;111(4):1201-8 (https://doi. org/10.1210/endo-111- 4 -1201). 21. Smyth CD, Miró F, Whitelaw PF, Howles CM, Hillier SG. Ovarian thecal/interstitial androgen synthesis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism. Endocrinology. 1993;133(4):1532-8 (https://doi. org/10.1210/en.133.4.1532). 22. Judd HL, Judd GE, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 90
  },
  {
    "chunk_id": "infertility_1965",
    "text": "sis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism. Endocrinology. 1993;133(4):1532-8 (https://doi. org/10.1210/en.133.4.1532). 22. Judd HL, Judd GE, Lucas WE, Yen SSC. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab. 1974;39(6):1020-4 (https://doi. org/10.1210/jcem-39-6-1020). 23. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992;327(3):157-62 (https:// doi.org/10.1056/NEJM199207163270304). 24. Niswender GD, Juengel JL, Silva PJ, Rollyson MK, McIntush EW. Mechanisms controlling the function and life span of the corpus luteum. Physiol Rev. 2000;80(1):1-29 (https://doi. org/10.1152/physrev.2000.80.1.1). 25. Tuckey RC. Progesterone synthesis by the hum",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 90
  },
  {
    "chunk_id": "infertility_1966",
    "text": "lling the function and life span of the corpus luteum. Physiol Rev. 2000;80(1):1-29 (https://doi. org/10.1152/physrev.2000.80.1.1). 25. Tuckey RC. Progesterone synthesis by the human placenta. Placenta. 2005;26(4):273-81 (https://doi. org/10.1016/j.placenta.2004.06.012). 26. Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985;2(8455):596-8 (https://doi.org/10.1016/ s0140-6736(85)90594-x). 27. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 28. Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic–pituitary axis. J Endocrinol Invest. 2007;30(4):268-73 (https://doi. org/10.1007/bf03346292). 29. Galas L, Raoult E, Tonon MC, Okada R, Jenks BG",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 90
  },
  {
    "chunk_id": "infertility_1967",
    "text": " with disorders of the hypothalamic–pituitary axis. J Endocrinol Invest. 2007;30(4):268-73 (https://doi. org/10.1007/bf03346292). 29. Galas L, Raoult E, Tonon MC, Okada R, Jenks BG, Castaño JP et al. TRH acts as a multifunctional hypophysiotropic factor in vertebrates. Gen Comp Endocrinol. 2009;164(1):40-50 (https://doi. org/10.1016/j.ygcen.2009.05.003). 30. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724-63 (https://doi.org/10.1210/ edrv.22.6.0451). 31. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002;20(04):365-74 (https://doi. org/10.1055/s-2002-36709). 32. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702-55 (https://doi.org/10.1210/ er.2009-0041). 33. Doufas AG, Mastorakos G. The hypothalamic–pituitary–thyroid axis and the female re",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 90
  },
  {
    "chunk_id": "infertility_1968",
    "text": "n reproductive health. Endocr Rev. 2010;31(5):702-55 (https://doi.org/10.1210/ er.2009-0041). 33. Doufas AG, Mastorakos G. The hypothalamic–pituitary–thyroid axis and the female reproductive system. Ann N Y Acad Sci. 2000;900:65-76 (https://doi. org/10.1111/j.1749 - 6632.2000.tb06217.x).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 90
  },
  {
    "chunk_id": "infertility_1969",
    "text": "675 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 34. Persani L. Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab. 2012;97(9):3068-78 (https:// doi.org/10.1210/jc.2012-1616). 35. Kanasaki H, Oride A, Mijiddorj T, Kyo S. Role of thyrotropin-releasing hormone in prolactin- producing cell models. Neuropeptides. 2015;54:73-7 (https://doi.org/10.1016/j. npep.2015.08.001). 36. Fekete C, Lechan RM. Central regulation of hypothalamic–pituitary–thyroid axis under physiological and pathophysiological conditions. Endocr Rev. 2014;35(2):159-94 (https://doi. org/10.1210/er.2013-1087). 37. WHO Expert Committee on Biological Standardization: seventy-eighth report. Geneva: World Health Organization; 2024 (https://iris.who. int/handle/10665/376596)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 91
  },
  {
    "chunk_id": "infertility_1970",
    "text": "10/er.2013-1087). 37. WHO Expert Committee on Biological Standardization: seventy-eighth report. Geneva: World Health Organization; 2024 (https://iris.who. int/handle/10665/376596). 38. Health products policy and standards. Catalogue of the WHO international reference standards for biological products. Geneva: World Health Organization; 2024 (www.who.int/teams/health- product-policy-and-standards/standards-and- specifications/norms-and-standards/catalogue). 39. WHO International collaborative study of the proposed 4th International Standard for Prolactin, Human. Geneva: World Health Organization; 2016 (https://iris.who.int/ handle/10665/253053). 40. WHO Expert Committee on Biological Standardization. WHO 4th International Standard for TSH (human, pituitary). Geneva: World Health Organization; 2023 (www.who.int/ publications/m/item/who-bs-2023-2454). 41. The selection and use of essential",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 91
  },
  {
    "chunk_id": "infertility_1971",
    "text": "ternational Standard for TSH (human, pituitary). Geneva: World Health Organization; 2023 (www.who.int/ publications/m/item/who-bs-2023-2454). 41. The selection and use of essential in vitro diagnostics: report of the fourth meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2022 (including the fourth WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373322). 42. Navarro VM, Kaiser UB. Metabolic influences on neuroendocrine regulation of reproduction. Curr Opin Endocrinol Diabetes Obes. 2013;20(4):335-41 (https://doi.org/10.1097/ MED.0b013e32836318ce). 43. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41 (https://doi. org/10.1186/1741-701",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 91
  },
  {
    "chunk_id": "infertility_1972",
    "text": " a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41 (https://doi. org/10.1186/1741-7015-8-41). 44. Azziz R, Carmina E, Sawaya ME. Idiopathic Hirsutism. Endocr Rev. 2000;21(4):347-62 (https:// doi.org/10.1210/edrv.21.4.0401). 45. Oldfield AL, Vanden Brink H, Carter FE, Jarrett BY, Lujan ME. Obesity is associated with alterations in antral follicle dynamics in eumenorrheic women. Hum Reprod. 2023;38(3):459-70 (https:// doi.org/10.1093/humrep/dead007). 46. Lewy H, Naor Z, Ashkenazi IE. From ultradian to infradian rhythms: LH releases patterns in vitro. Chronobiol Int. 1999;16(4):441-50 (https://doi. org/10.3109/07420529908998719). 47. Bittman EL. Timing in the testis. J Biol Rhythms. 2016;31(1):12-36 (https://doi. org/10.1177/0748730415618297). 48. Cargille C, Ross G, Yoshimi T. Daily variations in",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 91
  },
  {
    "chunk_id": "infertility_1973",
    "text": "8998719). 47. Bittman EL. Timing in the testis. J Biol Rhythms. 2016;31(1):12-36 (https://doi. org/10.1177/0748730415618297). 48. Cargille C, Ross G, Yoshimi T. Daily variations in plasma follicle stimulating hormone, luteinizing hormone and progesterone in the normal menstrual cycle. J Clin Endocrinol Metab. 1969;29(1):12-9 (https://doi.org/10.1210/jcem-29- 1-12). 49. Laboratory quality management system: handbook, version 1.1. Geneva: World Health Organization; 2011 (https://iris.who.int/ handle/10665/44665). 50. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25 (https:// doi.org/10.1016/j.fertnstert.2003.10.004).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 91
  },
  {
    "chunk_id": "infertility_1974",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 68 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5.4 Assessment of ovarian reserve Recommendation For females with infertility in whom other causes of anovulation and oligo- ovulation have been ruled out, WHO suggests that a diagnosis of low ovarian reserve should be based on age rather than diagnostic tests. If ovarian reserve diagnostic testing is conducted, WHO suggests using antral follicle count (AFC), anti-Müllerian hormone (AMH) or day 2 or 3 follicle-stimulating hormone (FSH). (Conditional recommendation, very low certainty of evidence) Remarks: • Age is the most important predictor of ovarian reserve. Therefore, ordering an ovarian reserve test in addition to age assessment may not substantially improve the accuracy of diagnosing",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 92
  },
  {
    "chunk_id": "infertility_1975",
    "text": " the most important predictor of ovarian reserve. Therefore, ordering an ovarian reserve test in addition to age assessment may not substantially improve the accuracy of diagnosing low ovarian reserve (as assessed by poor response to stimulation). Note that the ability of age to predict ovarian reserve may be limited in some clinical scenarios, such as cases of premature ovarian insufficiency. • Selection of the test to assess ovarian reserve should be based on relative acceptability, availability and resources in local contexts. Background Disorders of ovulation can cause infertility. In a multi-country study involving 8500 patients in 25 countries, anovulation and oligo-ovulatory disorders accounted for 26.1% of identifiable causes of female infertility ( 1, 2); therefore, a key aspect of management of infertility includes the assessment of ovulation. Ovarian reserve refers to the quan",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 92
  },
  {
    "chunk_id": "infertility_1976",
    "text": " of identifiable causes of female infertility ( 1, 2); therefore, a key aspect of management of infertility includes the assessment of ovulation. Ovarian reserve refers to the quantity of oocytes remaining in a woman’s ovaries that have the potential to yield a pregnancy. The need to quantify the amount of remaining oocytes is based on the fact that the number of oocytes in the ovaries decreases progressively through atresia (3, 4), resulting in declining fecundity over time (5). Age is the most important determinant of reproductive potential; however, women of the same chronological age may have varying quantity and quality of oocytes ( 6, 7), and there is a lack of a reliable metric for assessing oocyte quality. When a couple presents with history of infertility and ovulatory dysfunction is suspected as a cause, several investigations may be undertaken to assess the HPO axis and endocr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 92
  },
  {
    "chunk_id": "infertility_1977",
    "text": "ty. When a couple presents with history of infertility and ovulatory dysfunction is suspected as a cause, several investigations may be undertaken to assess the HPO axis and endocrine hormones, as suggested in Section 5.3 . In this PICO question, the GDG was interested in evaluating the role of ovarian reserve testing in the evaluation of anovulation or oligo-ovulation as a cause of infertility. Conceptually, counting the number of oocytes would provide the definitive indicator of ovarian reserve; however, it can only be directly assessed through the histological examination of entire ovaries. Consequently, there are two overlapping interpretations and application of ovarian reserve testing, that is, ( i) as an indirect indicator of biological reserve and ( ii) as an indication of clinical response to stimulation ( 8, 9). The first is related to the true number of primordial follicles. T",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 92
  },
  {
    "chunk_id": "infertility_1978",
    "text": " indirect indicator of biological reserve and ( ii) as an indication of clinical response to stimulation ( 8, 9). The first is related to the true number of primordial follicles. The second is a functional assessment of ovarian response to stimulation, that is, the quantity of follicles that are at late stages of development and capable of responding to stimulation ( 8), that is, the potential number of oocytes that could potentially be available for retrieval during IVF ( 9). Patients whose biological reserve is low are likely to exhibit a “poor”",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 92
  },
  {
    "chunk_id": "infertility_1979",
    "text": "695 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps response to ovarian stimulation (OS) ( 10); however, there is a lack of consensus on the threshold that constitutes a decreased ovarian reserve. Several tests are used for ovarian reserve testing, including AFC measured sonographically, E2, FSH, and inhibin B, and AMH (11). For this PICO, the GDG was interested in the first application. The GDG agreed that an important decision that health care providers face is whether to use AFC, AMH or FSH. AFC is an ultrasonographic test of ovarian reserve that quantifies the total number of follicles in both ovaries (typically 2–10 mm in diameter) observed during a transvaginal ultrasound scan ( 12), typically during the early follicular phase. The number of antral follicles is interpreted as b",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 93
  },
  {
    "chunk_id": "infertility_1980",
    "text": "typically 2–10 mm in diameter) observed during a transvaginal ultrasound scan ( 12), typically during the early follicular phase. The number of antral follicles is interpreted as being an indirect indicator of the magnitude of the remaining follicular pool based on demonstrated correlations between AFC with histologically determined primordial follicle numbers ( 11). AMH is a glycoprotein produced by the granulosa cells of ovarian follicles (13, 14). AMH declines as the number of ovarian follicles declines with age ( 15, 16), and its levels correlate with the primordial follicular pool (11). FSH is a glycoprotein secreted in the anterior pituitary gland in response to the production of inhibin B by preantral follicles via a negative feedback loop that involves a complex interaction of several factors, including sex steroid hormones (mainly estrogens) and GnRH (17, 18). With advancing age",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 93
  },
  {
    "chunk_id": "infertility_1981",
    "text": "llicles via a negative feedback loop that involves a complex interaction of several factors, including sex steroid hormones (mainly estrogens) and GnRH (17, 18). With advancing age, secretion of early follicular phase inhibin B declines, which partly contributes to increased pituitary FSH secretion, and higher late luteal and early follicular FSH concentrations ( 19–21). Measuring FSH levels (typically around cycle day 3) provides an indirect measure of pool of ovarian follicles (7, 8). For this recommendation, the GDG addressed the question: should AFC versus FSH or AMH be used for the assessment of ovarian reserve in women with infertility in whom other causes of anovulation or oligo-ovulation have been ruled out? Balancing harms and benefits We first searched for systematic reviews published since 2000 and found three reviews published in the early 2000s (22–24). These reviews assesse",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 93
  },
  {
    "chunk_id": "infertility_1982",
    "text": " out? Balancing harms and benefits We first searched for systematic reviews published since 2000 and found three reviews published in the early 2000s (22–24). These reviews assessed FSH, AMH and AFC to predict poor response to ovarian stimulation which can provide indirect evidence for ovarian reserve. More recently, a systematic review and meta-analysis of individual patient data was conducted to assess the effect of adding ovarian reserve tests to age to predict poor response to ovarian stimulation ( 25). This review reported that age was a good predictor of poor response and the addition of tests such as AFC and AMH only marginally improved this prediction. Searches were also previously conducted from 1990 to July 2019 for test accuracy studies and studies measuring health outcomes that directly compared AFC versus FSH versus AMH in the same women. We found a systematic review publish",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 93
  },
  {
    "chunk_id": "infertility_1983",
    "text": "o July 2019 for test accuracy studies and studies measuring health outcomes that directly compared AFC versus FSH versus AMH in the same women. We found a systematic review published in 2023 by Liu et al. (26) with a search date up to May 2022 (26), comparing AMH and AFC, and one study by Jaiswar et al. (27) comparing all three tests. The study by Jaiswar et al. ( 27) was a low risk of bias study that included 100 women with infertility aged < 40 years old in India who received clomiphene citrate stimulation and poor response was defined as < 3 oocytes retrieved. In this study, FSH was measured once per participant, and paired E2 levels were not assessed. Sensitivity and specificity were calculated from this study (with 95% lower and upper confidence intervals [CIs]) as shown in Tables 5.3 and 5.4.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 93
  },
  {
    "chunk_id": "infertility_1984",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 70 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table 5.3. Sensitivity and specificity for AFC, AMH and FSH AFC AMH FSH Sensitivity (95% CI) 78% (64–88%) 80% (67–90%) 63% (48–76%) Specificity (95% CI) 65% (51–76%) 74% (61–84%) 69% (55–79%) AFC, antral follicle count; AMH, anti-Müllerian hormone; CI, confidence interval; FSH, follicle-stimulating hormone. Source: Jaiswar et al., 2015 (27). Table 5.4. Absolute effects on 100 women when AFC, AMH and FSH are provided AFC AMH FSH True positives 36 37 29 True negatives 35 40 37 False positives 19 14 17 False negatives 10 9 17 AFC, antral follicle count; AMH, anti-Müllerian hormone; CI, confidence interval; FSH, follicle-stimulating hormone. Source: Jaiswar et al., 2015 (27). The systematic rev",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 94
  },
  {
    "chunk_id": "infertility_1985",
    "text": "s 10 9 17 AFC, antral follicle count; AMH, anti-Müllerian hormone; CI, confidence interval; FSH, follicle-stimulating hormone. Source: Jaiswar et al., 2015 (27). The systematic review by Liu et al. ( 26) included 42 studies and did not conduct a paired analysis of studies; it pooled studies together that assessed the accuracy of one test and then compared those pooled results to the pooled analysis of the studies that assessed the accuracy of the other test. Studies were conducted in women with infertility to predict poor or high response to IVF treatment. The results for poor response are presented in Table 5.5 (a range of cut-offs were used). Table 5.5. Results for poor response from a systematic review AMH AFC Sensitivity (95% CI) 80% (74–85%) 73% (62–83%) Specificity (95% CI) 81% (75–85%) 85% (78–90%) AFC, antral follicle count; AMH, anti-Müllerian hormone; CI, confidence interval. S",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 94
  },
  {
    "chunk_id": "infertility_1986",
    "text": "FC Sensitivity (95% CI) 80% (74–85%) 73% (62–83%) Specificity (95% CI) 81% (75–85%) 85% (78–90%) AFC, antral follicle count; AMH, anti-Müllerian hormone; CI, confidence interval. Source: Liu et al., 2023 (26). This review (26) showed that per 100 patients tested, and compared to AMH, the use of AFC resulted in two fewer true positives, two more false negatives, three more true negatives and three fewer false positives.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 94
  },
  {
    "chunk_id": "infertility_1987",
    "text": "715 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps In considering desirable effects, the GDG noted that the study comparing all tests and the systematic review comparing AFC to AMH reported differences in false positives and false negatives of about 2–5 women out of 100. The GDG agreed that the benefits of AFC compared to AMH or FSH are trivial. In addition, the GDG considered the systematic reviews of poor response showing that when compared to age, AMH may moderately predict a poor response, AFC could be a good predictor at very low levels and FSH may not be a better predictor, and agreed that the benefits of these tests were trivial. The GDG agreed that when added to age, the benefits of these tests were trivial. In terms of harms, the GDG noted that the comparative study compari",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 95
  },
  {
    "chunk_id": "infertility_1988",
    "text": "ts of these tests were trivial. The GDG agreed that when added to age, the benefits of these tests were trivial. In terms of harms, the GDG noted that the comparative study comparing all tests and the systematic review comparing AFC to AMH found differences in false positives and false negatives of about 2–5 women out of 100. The GDG agreed that the harms of AFC compared to AMH or FSH are trivial. The certainty of the evidence in the comparative accuracy of the tests was low and was further rated to very low because of indirectness by the GDG. The studies did not quantify the numbers of oocytes remaining in a woman’s ovaries; instead, they measured ovarian response to stimulation, which is then taken as an indirect measure of the numbers of oocytes remaining in a woman’s ovaries with the potential to yield a pregnancy. No studies were identified on patient values; however, the GDG agreed",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 95
  },
  {
    "chunk_id": "infertility_1989",
    "text": "rect measure of the numbers of oocytes remaining in a woman’s ovaries with the potential to yield a pregnancy. No studies were identified on patient values; however, the GDG agreed that women would value tests that can identify the diagnosis correctly and would seek to minimize the harms of unnecessary tests, frequent travel (e.g. for serial tests) and costs. The GDG agreed that probably no important uncertainty or variability existed in how much people value these outcomes. Based on these data, the GDG agreed that the balance of effects does not favour any of the tests compared to one another. Other considerations There was no direct research evidence for resources required; however, the GDG agreed that in LMICs the cost differences vary among AFC, AMH and FSH. There was no direct evidence on cost-effectiveness; however, the GDG agreed that given that there are similar benefits and harm",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 95
  },
  {
    "chunk_id": "infertility_1990",
    "text": "Cs the cost differences vary among AFC, AMH and FSH. There was no direct evidence on cost-effectiveness; however, the GDG agreed that given that there are similar benefits and harms with all tests, and the cost differences vary, then cost-effectiveness would vary. No studies reported on health inequities related to any of the three tests; however, the GDG agreed that in some settings certain tests may be more available. Therefore, the impact on equity varies. The GDG considered several studies that assessed the acceptability of these tests to patients ( 8) and providers (28–33) and judged that acceptability varies. The GDG agreed that the feasibility and availability of the different tests varies in different settings and countries. Summary justification Evidence found that there may be little to no difference in the test accuracy of AFC or AMH or day 3 FSH, but this evidence is of very ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 95
  },
  {
    "chunk_id": "infertility_1991",
    "text": "ettings and countries. Summary justification Evidence found that there may be little to no difference in the test accuracy of AFC or AMH or day 3 FSH, but this evidence is of very low certainty. The costs, resources, feasibility and acceptability of FSH, AMH and AFC likely vary across different settings and countries; therefore, the preferred test will be dependent on those factors. Implementation considerations Health care providers should note that ovarian reserve tests are suggested in this guideline as an optional test for diagnostic purposes, during the evaluation of anovulation or oligo-ovulation, where other causes of anovulation or oligo-ovulation have been excluded or have not been identified (e.g. by assessing the HPO axis [E2,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 95
  },
  {
    "chunk_id": "infertility_1992",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 72 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps T, FSH, LH], as well as TSH and PRL), and whose explanation of failure to achieve pregnancy could potentially be related to reduced numbers (or quality) of oocytes. Health care providers should note that the primordial follicles count is the definitive indicator of ovarian reserve; however, it can only be measured directly using histological examination of entire ovaries. For this reason, surrogate markers, such as AFC, AMH and FSH, which may correlate with the primordial follicle count, provide an indirect indication of biological reserve. Health care providers should note that each of these tests have advantages and disadvantages, whose relative importance varies in different settings and",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 96
  },
  {
    "chunk_id": "infertility_1993",
    "text": "tion of biological reserve. Health care providers should note that each of these tests have advantages and disadvantages, whose relative importance varies in different settings and countries; therefore, it is important to consult with the patients when selecting the test, through a process of collaborative decision-making. The application of these tests during IVF treatment, including to predict outcomes, is not within the scope of this diagnostic PICO. Selection of optional test to assess ovarian reserve should be based on relative acceptability, availability and resources in local contexts. In selecting these tests, health care providers should also consider several technical parameters, such as those related to inter- laboratory or inter-observer variability (8, 34), turnaround times for these tests and availability of WHO international assay standards ( 35–37). Technical parameters c",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 96
  },
  {
    "chunk_id": "infertility_1994",
    "text": " to inter- laboratory or inter-observer variability (8, 34), turnaround times for these tests and availability of WHO international assay standards ( 35–37). Technical parameters can affect test results, and training and rigorous quality safeguards are necessary to minimize errors. Correct interpretation of the results of hormonal tests, such as FSH, may require concomitant evaluation of other test results (e.g. E2 [38]) and may be influenced by cycle-to-cycle variations, particularly AMH and AFC ( 8, 35). In the studies reviewed for this recommendation, AFC was assessed in the first half of the menstrual cycle, AMH was cycle-independent and FSH in combination with E2 was assessed on either cycle days 2–3 or cycle days 2–4. Health care providers should consider how these tests fit in with other planned investigations. Selection of diagnostic tests should be based on clinical findings fro",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 96
  },
  {
    "chunk_id": "infertility_1995",
    "text": "cle days 2–4. Health care providers should consider how these tests fit in with other planned investigations. Selection of diagnostic tests should be based on clinical findings from comprehensive medical history and physical examination to ensure that evaluation is systematic and cost-effective (see Chapter 3). For example, the ability of age to predict ovarian reserve may be limited in some clinical scenarios such as cases of premature ovarian insufficiency. Research gaps and future guideline update Data were insufficient to determine if there are subgroups of patients that may benefit more from any of the tests, for example, patients with ovarian endometriomas or other ovarian masses. Future comparative studies among different subgroups are needed to respond to this gap. Given the very low certainty of evidence, future comparative studies assessing ovarian reserve should be better desi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 96
  },
  {
    "chunk_id": "infertility_1996",
    "text": "es among different subgroups are needed to respond to this gap. Given the very low certainty of evidence, future comparative studies assessing ovarian reserve should be better designed and implemented. Future guidance will be required on the role of ovarian reserve testing during IVF, including to predict outcomes and the likelihood of success, as this was not within the scope of this diagnostic PICO. This recommendation relates to application of these tests in health care settings and does not relate to direct-to-consumer tests, for example, AMH tests ( 39), which will require future guidance.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 96
  },
  {
    "chunk_id": "infertility_1997",
    "text": "735 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 2. Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985;2(8455):596-8 (https://doi.org/10.1016/ s0140-6736(85)90594-x). 3. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772 (https://doi.org/10.1371/journal. pone.0008772). 4. Matsuda F, Inoue N, Manabe N, Ohkura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J Reprod Dev. 2012;58(1):44-50 (https://doi.org/10.1262/jrd",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 97
  },
  {
    "chunk_id": "infertility_1998",
    "text": "be N, Ohkura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J Reprod Dev. 2012;58(1):44-50 (https://doi.org/10.1262/jrd.2011-012). 5. Chua S, Danhof N, Mochtar M, Van Wely M, McLernon D, Custers I et al. Age-related natural fertility outcomes in women over 35 years: a systematic review and individual participant data meta-analysis. Hum Reprod. 2020;35(8):1808-20 (https://doi.org/10.1093/humrep/deaa129). 6. Bentzen JG, Forman JL, Johannsen TH, Pinborg A, Larsen EC, Andersen AN. Ovarian antral follicle subclasses and anti-Müllerian hormone during normal reproductive aging. J Clin Endocrinol Metab. 2013;98(4):1602-11 (https://doi. org/10.1210/jc.2012-1829). 7. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 97
  },
  {
    "chunk_id": "infertility_1999",
    "text": "9). 7. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151-7 (https:// doi.org/10.1016/j.fertnstert.2020.09.134). 8. Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(6):698-710 (https://doi. org/10.1093/humupd/dmu062). 9. Ulrich ND, Marsh EE. Ovarian reserve testing: a review of the options, their applications, and their limitations. Clin Obstet Gynecol. 2019;62(2):228-37 (https://doi.org/10.1097/ grf.0000000000000445 ). 10. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 97
  },
  {
    "chunk_id": "infertility_2000",
    "text": "rca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-24 (https:// doi.org/10.1093/humrep/der092). 11. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170-5 (https://doi. org/10.1016/j.fertnstert.2010.04.006). 12. Pache TD, Wladimiroff JW, de Jong FH, Hop WC, Fauser BC. Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil Steril. 1990;54(4):638-42 (https://doi. org/10.1016/s0015-0282(16)53821-7). 13. Rajpert-De Meyts E, Jørgensen N, Graem N, Müller J, Cate RL, Skakkebaek NE. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with di",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 97
  },
  {
    "chunk_id": "infertility_2001",
    "text": "ert-De Meyts E, Jørgensen N, Graem N, Müller J, Cate RL, Skakkebaek NE. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84(10):3836-44 (https://doi.org/10.1210/jcem.84.10.6047). 14. Rey R, Lukas-Croisier C, Lasala C, Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol. 2003;211(1-2):21-31 (https://doi. org/10.1016/j.mce.2003.09.007). 15. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D et al. Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478-83 (https://doi.org/10.1210/jc.2008-0567). 16. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian hormone serum levels: a puta",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 97
  },
  {
    "chunk_id": "infertility_2002",
    "text": "n Endocrinol Metab. 2008;93(9):3478-83 (https://doi.org/10.1210/jc.2008-0567). 16. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357-62 (https://doi.org/10.1016/s0015- 0282(01)02993-4).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 97
  },
  {
    "chunk_id": "infertility_2003",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 74 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 17. Chappel SC, Ulloa-Aguirre A, Coutifaris C. Biosynthesis and secretion of follicle-stimulating hormone. Endocr Rev. 1983;4(2):179-211 (https:// doi.org/10.1210/edrv-4-2-179). 18. Ulloa-Aguirre A, Espinoza R, Damian-Matsumura P, Chappel SC. Immunological and biological potencies of the different molecular species of gonadotrophins. Hum Reprod. 1988;3(4):491-501 (https://doi.org/10.1093/oxfordjournals.humrep. a136734). 19. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 98
  },
  {
    "chunk_id": "infertility_2004",
    "text": "n B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab. 1996;81(7):2742-5 (https://doi. org/10.1210/jcem.81.7.8675606). 20. Reame NE, Wyman TL, Phillips DJ, de Kretser DM, Padmanabhan V. Net increase in stimulatory input resulting from a decrease in inhibin B and an increase in activin A may contribute in part to the rise in follicular phase follicle-stimulating hormone of aging cycling women. J Clin Endocrinol Metab. 1998;83(9):3302-7 (https://doi. org/10.1210/jcem.83.9.5130). 21. Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin E",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 98
  },
  {
    "chunk_id": "infertility_2005",
    "text": "ectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999;84(11):4025-30 (https://doi.org/10.1210/ jcem.84.11.6158). 22. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685-718 (https://doi.org/10.1093/humupd/dml034). 23. Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril. 2005;83(2):291-301 (https://doi.org/10.1016/j. fertnstert.2004.10.011). 24. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in predic",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 98
  },
  {
    "chunk_id": "infertility_2006",
    "text": ". Fertil Steril. 2005;83(2):291-301 (https://doi.org/10.1016/j. fertnstert.2004.10.011). 24. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009;91(3):705-14 (https://doi.org/10.1016/j.fertnstert.2007.12.013). 25. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26-36 (https://doi.org/10.1093/humupd/dms041). 26. Liu Y, Pan Z, Wu Y, Song J, Chen J. Comparison of anti-Müllerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis. J Ovarian Res. 2023;16(1):117 (https://doi.org/10.1186/ s130",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 98
  },
  {
    "chunk_id": "infertility_2007",
    "text": "llerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis. J Ovarian Res. 2023;16(1):117 (https://doi.org/10.1186/ s13048-023-01202-5). 27. Jaiswar SP, Natu SM, Sujata, Sankhwar PL, Manjari G. Prediction of poor ovarian response by biochemical and biophysical markers: a logistic regression model. J Obstet Gynaecol India. 2015;65(6):411-6 (https://doi.org/10.1007/ s13224-014-0639-8). 28. La Marca A, Ferraretti AP, Palermo R, Ubaldi FM. The use of ovarian reserve markers in IVF clinical practice: a national consensus. Gynecol Endocrinol. 2016;32(1):1-5 (https://doi.org/10.310 9/09513590.2015.1102879). 29. Tobler KJ, Shoham G, Christianson MS, Zhao Y, Leong M, Shoham Z. Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide. J Assist Reprod Genet. 2015;32(10):1441-8 (https://doi. o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 98
  },
  {
    "chunk_id": "infertility_2008",
    "text": "ong M, Shoham Z. Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide. J Assist Reprod Genet. 2015;32(10):1441-8 (https://doi. org/10.1007/s10815-015-0562-7).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 98
  },
  {
    "chunk_id": "infertility_2009",
    "text": "755 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 30. Patrizio P, Vaiarelli A, Levi Setti PE, Tobler KJ, Shoham G, Leong M et al. How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. Reprod Biomed Online. 2015;30(6):581-92 (https://doi. org/10.1016/j.rbmo.2015.03.002). 31. Christianson MS, Shoham G, Tobler KJ, Zhao Y, Cordeiro CN, Leong M et al. Measurement of antral follicle count in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey. J Assist Reprod Genet. 2015;32(10):1435-40 (https://doi. org/10.1007/s10815-015-0555-6). 32. Costa M, Chiaffarino F, De Stefano C, Parazzini F. Timing, characteristics and determinants of infertility diagnostic work up before admission to eleven second-level as",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 99
  },
  {
    "chunk_id": "infertility_2010",
    "text": "555-6). 32. Costa M, Chiaffarino F, De Stefano C, Parazzini F. Timing, characteristics and determinants of infertility diagnostic work up before admission to eleven second-level assisted reproductive techniques (ART) centres in Italy. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):53-8 (https:// doi.org/10.1016/j.ejogrb.2012.10.022). 33. Cédrin-Durnerin I, Belaisch-Allart J, Avril C, Pouly JL. Facteurs prédictifs de succès de l’induction d’ovulation par FSH recombinante: résultats de l’étude Indigo [Predictive factors of success in ovulation induction with recombinant FSH: results of Indigo study]. Gynecol Obstet Fertil. 2010;38(2):105-13 (https://doi.org/10.1016/j. gyobfe.2009.12.002) (in French). 34. Manual of diagnostic ultrasound, Vol. 2, second edition. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 35. Li HWR, Robertson DM, Burns C, Ledger WL. Cha",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 99
  },
  {
    "chunk_id": "infertility_2011",
    "text": " diagnostic ultrasound, Vol. 2, second edition. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 35. Li HWR, Robertson DM, Burns C, Ledger WL. Challenges in measuring AMH in the clinical setting. Front Endocrinol. 2021;12:691432 (https://doi.org/10.3389/fendo.2021.691432). 36. Ferguson J, Hockley J, Rigsby P, Burns C. Establishment of a WHO reference reagent for anti-Mullerian hormone. Reprod Biol Endocrinol. 2020;18(1):86 (https://doi.org/10.1186/s12958- 020-00641-9). 37. WHO Expert Committee on Biological Standardization: seventy-eighth report. Geneva: World Health Organization; 2024 (https://iris.who. int/handle/10665/376596). 38. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(2):129-40 (https://doi.org/10.1016/j.ajog.2017.02.027). 39. Johnson A, Thompson R, Nickel B, Shih P, Hammarberg K, Copp T. Websites sel",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 99
  },
  {
    "chunk_id": "infertility_2012",
    "text": " user’s guide. Am J Obstet Gynecol. 2017;217(2):129-40 (https://doi.org/10.1016/j.ajog.2017.02.027). 39. Johnson A, Thompson R, Nickel B, Shih P, Hammarberg K, Copp T. Websites selling direct- to-consumer anti-Mullerian hormone tests. JAMA Netw Open. 2023;6(8):e2330192 (https://doi. org/10.1001/jamanetworkopen.2023.30192).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 99
  },
  {
    "chunk_id": "infertility_2013",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 76 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5.5 Diagnosis of infertility due to tubal disease Recommendation For females with infertility and suspected tubal disease, WHO suggests using either hysterosalpingogram (HSG) or hysterosalpingo contrast sonography (HyCoSy) to assess tubal patency. (Conditional recommendation, low certainty of evidence) Remark: • When selecting whether to use HSG or HyCoSy to assess tubal patency, consider feasibility, the availability of trained health care providers and the potential for allergy. Background and rationale Evaluation of tubal patency is an essential part of investigating the cause of infertility. In a large WHO multi-country study involving 8500 couples in 25 countries, bilateral tubal block",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 100
  },
  {
    "chunk_id": "infertility_2014",
    "text": "on of tubal patency is an essential part of investigating the cause of infertility. In a large WHO multi-country study involving 8500 couples in 25 countries, bilateral tubal blockage contributed to 17.7% of identifiable causes of female infertility (1). The diagnosis of tubal occlusion is generally established by a combination of clinical suspicion based on patient history and confirmatory diagnostic tests. Diagnostic laparoscopy with chromopertubation is considered the reference gold standard for confirming suspected tubal disease because it allows visualization of the fallopian tubes and adjacent pelvic tissue. However, it is invasive and costly, and requires general anaesthesia, making it unsuitable for routine diagnostic assessment of tubal pathology. Alternative options include HSG and HyCoSy. HSG and HyCoSy are typically performed during the follicular phase of the menstrual cycle",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 100
  },
  {
    "chunk_id": "infertility_2015",
    "text": "tine diagnostic assessment of tubal pathology. Alternative options include HSG and HyCoSy. HSG and HyCoSy are typically performed during the follicular phase of the menstrual cycle between cycle days 6 and 10, before the lining gets too thick, which may obscure any pathology, and to avoid interrupting an undiagnosed very early pregnancy. During HSG, iodinated contrast medium is slowly flushed through the uterine cavity and fallopian tubes using a catheter or cannula, resulting in their distension and visualization under fluoroscopic guidance. Still radiographs are performed. HSG uses either oil- or water-soluble contrast medium (2). Opacification of the fallopian tubes with subsequent free intraperitoneal spill is considered a sign of tubal patency. Although HSG is less invasive than laparoscopy, it may result in adverse effects, such as pain, infection, allergic reaction to iodine, as w",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 100
  },
  {
    "chunk_id": "infertility_2016",
    "text": " is considered a sign of tubal patency. Although HSG is less invasive than laparoscopy, it may result in adverse effects, such as pain, infection, allergic reaction to iodine, as well as exposure to ionizing radiation ( 3). During HyCoSy, echogenic distending medium is slowly injected distending the uterine cavity, uterus and fallopian tubes using a catheter or cannula, allowing visualization of the fallopian tubes with the aid of transvaginal or rarely, transabdominal ultrasonography. HyCoSy can be performed with either air-saline or microbubble distending medium. High-contrast echoes in the fallopian tube indicate tubal patency. Although HyCoSy circumvents the risk of iodine allergy and radiation, it may also be complicated by adverse effects, such as pain, infection, or allergy to the distending medium used (3). The GDG agreed that a key decision when investigating women with infertil",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 100
  },
  {
    "chunk_id": "infertility_2017",
    "text": " be complicated by adverse effects, such as pain, infection, or allergy to the distending medium used (3). The GDG agreed that a key decision when investigating women with infertility and suspected tubal disease is whether to use HSG or HyCoSy. For this recommendation, the GDG addressed the question: should HyCoSy versus HSG be used to evaluate women with infertility and suspected tubal disease? Assessment of the uterine cavity is presented in section 5.6 and is not included in this recommendation question.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 100
  },
  {
    "chunk_id": "infertility_2018",
    "text": "775 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Balancing harms and benefits Diagnostic test accuracy We updated a prior systematic review by Maheux- Lacroix et al. (3) on data about the test accuracy of HyCoSy up to July 2019. Eight non-randomized studies (4–11) were included, in which participants received both tests and the results were compared to a gold standard reference (typically laparoscopy). Based on the comparable sensitivity and specificity of the tests (including the respective 95% CIs, as shown in Table 5.6), we calculated the absolute effects on true and false positives, and true and false negatives. The results showed that there is likely little difference in the absolute effects of the two tests. Compared with HSG, HyCoSy likely results in three more true positiv",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 101
  },
  {
    "chunk_id": "infertility_2019",
    "text": "e negatives. The results showed that there is likely little difference in the absolute effects of the two tests. Compared with HSG, HyCoSy likely results in three more true positives, three fewer false negatives, eight fewer true negatives and eight more false positives per 1000. Table 5.6. Sensitivity and specificity of HyCoSy and HSG HyCoSy HSG Sensitivity (95% CI) 0.93 (0.79–0.98) 0.92 (0.74–0.98) Specificity (95% CI) 0.89 (0.79–0.94) 0.90 (0.86–0.93) CI, confidence interval; HyCoSy, hysterosalpingo contrast sonography; HSG, hysterosalpingogram. Effects on health outcomes To assess whether the use of HyCoSy versus HSG could lead to better management and improved outcomes, a systematic review was conducted from 1990 to July 2019, and 12 studies were identified. Very few studies measured benefits; therefore, the evidence is uncertain for the effect on pregnancy or live birth. One study ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 101
  },
  {
    "chunk_id": "infertility_2020",
    "text": "om 1990 to July 2019, and 12 studies were identified. Very few studies measured benefits; therefore, the evidence is uncertain for the effect on pregnancy or live birth. One study ( 12) evaluated clinical pregnancies during a 6-month follow-up period. From that study, there may be 53 fewer clinical pregnancies (from 81 to 14 fewer) per 1000 participants (odds ratio [OR]: 0.61; 95% CI 0.42–0.89) with HyCoSy compared to HSG. A second study (13) with a follow-up period of 3 years showed that HyCoSy may result in 24 fewer clinical pregnancies per 1000 (from 74 fewer to 29 more) (OR: 0.90; 95% CI 0.72–1.13) compared to HSG. Only one study (14) assessed live births and it showed that there may be 16 more (from 35 fewer to 95 more) per 1000 (RR: 1.13; 95% CI 0.71–1.79) with HyCoSy compared to HSG. Adverse effects To assess whether the use of HyCoSy versus HSG could lead to better management and",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 101
  },
  {
    "chunk_id": "infertility_2021",
    "text": "er to 95 more) per 1000 (RR: 1.13; 95% CI 0.71–1.79) with HyCoSy compared to HSG. Adverse effects To assess whether the use of HyCoSy versus HSG could lead to better management and fewer side-effects, a systematic search was conducted and 11 comparative non-randomized studies were included (8, 12, 14–22). There is very-low- certainty evidence for most harms. Compared to HSG, the effects of HyCoSy were uncertain on severe pain (four studies) (74 fewer, [from 239 fewer to 251 more], per 1000, RR: 0.82; 95% CI 0.42–1.61), miscarriages (one study) (20 fewer, [from 39 fewer to 18 more], per 1000, OR: 0.64; 95% CI 0.3–1.35), other adverse effects such as vasovagal reactions, nausea or vomiting, vaginal bleeding and bloating (39 fewer, [from 93 fewer to 70 more], per 1000, five studies; RR: 0.72; 95% CI 0.34–1.5), ectopic pregnancies and anxiety. Although there is radiation exposure with HSG, t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 101
  },
  {
    "chunk_id": "infertility_2022",
    "text": "loating (39 fewer, [from 93 fewer to 70 more], per 1000, five studies; RR: 0.72; 95% CI 0.34–1.5), ectopic pregnancies and anxiety. Although there is radiation exposure with HSG, the GDG did not consider the potential harms to be of great concern but noted the need for future evaluation of its effects on maternal and neonatal outcomes. The certainty of evidence was moderate for differences in the accuracy of the tests and low to very low for the downstream health outcomes. Thus, the overall certainty of the evidence is low. There were no studies on patient values; however, the GDG agreed that women would value better",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 101
  },
  {
    "chunk_id": "infertility_2023",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 78 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps pregnancy and birth outcomes and would seek to minimize harms. Given that the net desirable and undesirable effects between HyCoSy and HSG are trivial, neither test is favoured over the other. Other considerations No data were identified related to costs or cost- effectiveness between HSG and HyCoSy. Although HSG may require a radiographic unit, the GDG considered that HyCoSy is highly operator- dependent (23), but both HSG and HyCoSy require training of health care providers. Thus, the GDG agreed that both tests likely involve similar costs and resources, and there is likely no difference in cost-effectiveness between the two. Given that the costs are similar between HSG and HyCoSy, the GD",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 102
  },
  {
    "chunk_id": "infertility_2024",
    "text": "likely involve similar costs and resources, and there is likely no difference in cost-effectiveness between the two. Given that the costs are similar between HSG and HyCoSy, the GDG agreed that providing one test rather than another would probably have no impact on equity. A systematic search was conducted of other factors related to the acceptability of HSG and HyCoSy. The GDG considered evidence from several studies (21, 24–26) and agreed that both tests are probably acceptable to patients and providers. The GDG agreed that both tests are similarly feasible and require resources and expertise to conduct or interpret, based on the evidence from two studies (23, 27). Summary justification Overall, there was low-certainty evidence for trivial differences in desirable and undesirable effects between the use of HSG or HyCoSy in women who have infertility and suspected tubal disease. The cos",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 102
  },
  {
    "chunk_id": "infertility_2025",
    "text": "-certainty evidence for trivial differences in desirable and undesirable effects between the use of HSG or HyCoSy in women who have infertility and suspected tubal disease. The costs, resources, feasibility and acceptability are probably similar, and choosing either test would probably have no impact on equity. Implementation considerations When selecting a diagnostic method, health care providers should also consider the potential for allergy and the need to evaluate the uterus, ovaries and myometrium in the context of infertility. Health care providers should monitor patients for adverse effects and consider analgesics as appropriate (28). Health care providers should be aware of and monitor patients for potential thyroid dysfunction associated with iodine-based contrast media and should adhere to contraindications of specific products to prevent such harms, especially among patients w",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 102
  },
  {
    "chunk_id": "infertility_2026",
    "text": "ntial thyroid dysfunction associated with iodine-based contrast media and should adhere to contraindications of specific products to prevent such harms, especially among patients with thyroid disease ( 29). To ensure safety, training of health care providers on how to perform HSG or HyCoSy procedures is required. Given equipoise between HSG and HyCoSy, health care providers should seek patients’ preferences in keeping with the principles of shared decision-making. Future studies comparing HSG and HyCoSy should report patient preferences and whether the use of either test improves management and, consequently, the effects on live births to better inform future recommendations. Research gaps and future guideline update Additional data are required on the costs and cost-effectiveness of HSG and HyCoSy, given the lack of evidence on these aspects. Further guidance is required to identify pop",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 102
  },
  {
    "chunk_id": "infertility_2027",
    "text": "update Additional data are required on the costs and cost-effectiveness of HSG and HyCoSy, given the lack of evidence on these aspects. Further guidance is required to identify populations that would benefit from the use of oil-based contrast compared with water-based contrast during HSG. Further guidance is required on the use of either air-saline or microbubble commercial contrast media, probe type (vaginal versus abdominal) and Doppler sonography versus conventional two- dimensional (2D) or three-dimensional (3D) US during HyCoSy. Future guidance is required on the effect of location of tubal pathology (distal versus proximal) on the test performance of both HSG and HyCoSy. Although radiation exposure with HSG is",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 102
  },
  {
    "chunk_id": "infertility_2028",
    "text": "795 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps considered low, there is a need for the evaluation of the potential effects of peri-conceptional radiation exposure on maternal thyroid function and offspring neurodevelopment. Further guidance will be needed on whether prophylactic antibiotics should be used during HyCoSy or HSG. References 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 2. Dreyer K, van Rijswijk J, Mijatovic V, Goddijn M, Verhoeve HR, van Rooij IAJ et al. Oil-based or water-based contrast for hysterosalpingography in infertile women. N Engl J Med. 2017;376(21):2043-52 (https://doi.org/10.1056/ NEJMoa1612337). 3. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 103
  },
  {
    "chunk_id": "infertility_2029",
    "text": "an Rooij IAJ et al. Oil-based or water-based contrast for hysterosalpingography in infertile women. N Engl J Med. 2017;376(21):2043-52 (https://doi.org/10.1056/ NEJMoa1612337). 3. Maheux-Lacroix S, Boutin A, Moore L, Bergeron M-E, Bujold E, Laberge P et al. Hysterosalpingosonography for diagnosing tubal occlusion in subfertile women: a systematic review with meta-analysis. Hum Reprod. 2014;29(5):953-63 (https://doi.org/10.1093/ humrep/deu024). 4. Allahbadia GN. Fallopian tubes and ultrasonography: the Sion experience. Fertil Steril. 1992;58(5):901-7 (https://doi.org/10.1016/ s0015-0282(16)55432-6). 5. Kozarzewski M, Szaflik K, Pertyński T, Banaszczyk R, Radwan J. Ocena wartości klinicznej sonografii dopplerowskiej i sonograficznego środka kontrastowego w badaniu drozności jajowodów [Evaluation of the value of clinical doppler sonography and sonographic contrast media for assessment of tu",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 103
  },
  {
    "chunk_id": "infertility_2030",
    "text": "iej i sonograficznego środka kontrastowego w badaniu drozności jajowodów [Evaluation of the value of clinical doppler sonography and sonographic contrast media for assessment of tubal patency]. Ginekol Pol. 1995;66(11):633-7 (https://pubmed.ncbi.nlm.nih. gov/8698254/) (in Polish). 6. Battaglia C, Artini PG, D’Ambrogio G, Genazzani AD, Genazzani AR, Volpe A. Color Doppler hysterosalpingography in the diagnosis of tubal patency. Fertil Steril. 1996;65(2):317-22 (https:// doi.org/10.1016/s0015-0282(16)58092-3). 7. Reis MM, Soares SR, Cancado ML, Camargos AF. Hysterosalpingo contrast sonography (HyCoSy) with SH U 454 (Echovist) for the assessment of tubal patency. Hum Reprod. 1998;13(11):3049-52 (https://doi.org/10.1093/humrep/13.11.3049). 8. Dijkman AB, Mol BW, van der Veen F, Bossuyt PM, Hogerzeil HV. Can hysterosalpingocontrast- sonography replace hysterosalpingography in the assessment o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 103
  },
  {
    "chunk_id": "infertility_2031",
    "text": ".1093/humrep/13.11.3049). 8. Dijkman AB, Mol BW, van der Veen F, Bossuyt PM, Hogerzeil HV. Can hysterosalpingocontrast- sonography replace hysterosalpingography in the assessment of tubal subfertility? Eur J Radiol. 2000;35(1):44-8 (https://doi.org/10.1016/s0720- 048x(99)00127-8). 9. Socolov D, Lupaşcu IA, Danciu E, Doroftei B, Boian I, Boiculese L et al. Sonohisterosalpingografia versus histerosalpingografia in evaluarea infertilităţii de cauză uterină si tubară [Sonohysterosalpingography versus hysterosalpingography in the evaluation of uterine and tubal infertility]. Rev Med Chir Soc Med Nat Iasi. 2009;113(3):803-8 (https://pubmed. ncbi.nlm.nih.gov/20191836/) (in Romanian). 10. Li H, Chen Y, Xue M, Wang Y, Qu X, Zhang Y. A comparative study between 3D coded contrast imaging and radiographic hysterosalpingography. Chin J Ultrasound Med. 2014;30:923-26. 11. Yang S, Ke X, Luo M, Peng X, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 103
  },
  {
    "chunk_id": "infertility_2032",
    "text": "u X, Zhang Y. A comparative study between 3D coded contrast imaging and radiographic hysterosalpingography. Chin J Ultrasound Med. 2014;30:923-26. 11. Yang S, Ke X, Luo M, Peng X, Guo Y, Qian Y. 全氟 显子宫输卵管四维超声造影评价不孕女性输卵管通 畅性 [Four-dimensional hysterosalpingo-contrast sonography with fluorocarbon in evaluation on fallopian tube patency in infertile women]. Chin J Med Imaging Technol. 2019;35(1):113-6 (https://doi.org/10.13929/j.1003-3289.201806062) (in Chinese). 12. Maheux-Lacroix S, Bergeron C, Moore L, Bergeron M, Lefebvre J, Grenier-Ouellette I et al. Hysterosalpingosonography is not as effective as hysterosalpingography to increase chances of pregnancy. J Obstet Gynaecol Can. 2019;41(5):593-8 (https://doi.org/10.1016/j. jogc.2018.10.001).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 103
  },
  {
    "chunk_id": "infertility_2033",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 80 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 13. Bulletti C, Panzini I, Borini A, Coccia E, Setti PL, Palagiano A. Pelvic factor infertility: diagnosis and prognosis of various procedures. Ann N Y Acad Sci. 2008;1127:73-82 (https://doi.org/10.1196/ annals.1434.020). 14. Ahinko-Hakamaa K, Huhtala H, Tinkanen H. The validity of air and saline hysterosalpingo-contrast sonography in tubal patency investigation before insemination treatment. Eur J Obstet Gynecol Reprod Biol. 2007;132(1):83-7 (https://doi. org/10.1016/j.ejogrb.2006.07.033). 15. Kalogirou D, Antoniou G, Botsis D, Kassanos D, Vitoratos N, Zioris C. Is color Doppler necessary in the evaluation of tubal patency by hysterosalpingo-contrast sonography. Clin Exp Obstet Gynecol. 19",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 104
  },
  {
    "chunk_id": "infertility_2034",
    "text": "ou G, Botsis D, Kassanos D, Vitoratos N, Zioris C. Is color Doppler necessary in the evaluation of tubal patency by hysterosalpingo-contrast sonography. Clin Exp Obstet Gynecol. 1997;24(2):101-3. 16. Stacey C, Bown C, Manhire A, Rose D. HyCoSy--as good as claimed? Br J Radiol. 2000;73(866):133-6 (https://doi.org/10.1259/bjr.73.866.10884724). 17. Hajishafiha M, Zobairi T, Zanjani VR, Ghasemi- Rad M, Yekta Z, Mladkova N. Diagnostic value of sonohysterography in the determination of fallopian tube patency as an initial step of routine infertility assessment. J Ultrasound Med. 2009;28(12):1671-7 (https://doi.org/10.7863/ jum.2009.28.12.1671). 18. Socolov D, Boian I, Boiculese L, Tamba B, Anghelache-Lupascu I, Socolov R. Comparison of the pain experienced by infertile women undergoing hysterosalpingo contrast sonography or radiographic hysterosalpingography. Int J Gynaecol Obstet. 2010;111(3)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 104
  },
  {
    "chunk_id": "infertility_2035",
    "text": "ov R. Comparison of the pain experienced by infertile women undergoing hysterosalpingo contrast sonography or radiographic hysterosalpingography. Int J Gynaecol Obstet. 2010;111(3):256 -9 (https://doi.org/10.1016/j. ijgo.2010.07.018). 19. Dreyer K, Hompes PG, Mijatovic V. Diagnostic accuracy of hysterosalpingo-foam-sonography to confirm tubal occlusion after Essure® placement as treatment for hydrosalpinges. Reprod Biomed Online. 2015;30(4):421-5 (https://doi. org/10.1016/j.rbmo.2014.12.009). 20. Robertshaw IM, Sroga JM, Batcheller AE, Martinez AM, Winter TC 3rd, Sinning K et al. Hysterosalpingo-contrast sonography with a saline-air device is equivalent to hysterosalpingography only in the presence of tubal patency. J Ultrasound Med. 2016;35(6):1215- 22 (https://doi.org/10.7863/ultra.15.08008). 21. Beverley RM, Malik S, Collins RL, Jean K, Sanfilippo JS. Evaluation of tubal patency with ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 104
  },
  {
    "chunk_id": "infertility_2036",
    "text": "ency. J Ultrasound Med. 2016;35(6):1215- 22 (https://doi.org/10.7863/ultra.15.08008). 21. Beverley RM, Malik S, Collins RL, Jean K, Sanfilippo JS. Evaluation of tubal patency with a saline-air device. Can we move back to the office? J Reprod Med. 2018;63(2):120-6. 22. Izhar R, Mansuri FA, Armar NA, Tahir S. Diagnostic accuracy of saline infusion sonohystero-salpingography (SIS) as compared to hystero-salpingography (HSG) in the assessment of sub-fertile women. J Pak Med Assoc. 2019;69(6):777-82. 23. Exacoustos C, Di Giovanni A, Szabolcs B, Romeo V, Romanini ME, Luciano D et al. Automated three-dimensional coded contrast imaging hysterosalpingo-contrast sonography: feasibility in office tubal patency testing. Ultrasound Obstet Gynecol. 2013;41(3):328-35 (https://doi.org/10.1002/uog.11200). 24. Mansour R, Nada A, El-Khayat W, Abdel-Hak A, Inany H. A simple and relatively painless technique",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 104
  },
  {
    "chunk_id": "infertility_2037",
    "text": "trasound Obstet Gynecol. 2013;41(3):328-35 (https://doi.org/10.1002/uog.11200). 24. Mansour R, Nada A, El-Khayat W, Abdel-Hak A, Inany H. A simple and relatively painless technique for hysterosalpingography, using a thin catheter and closing the cervix with the vaginal speculum: a pilot study. Postgrad Med J. 2011;87(1029):468-71 (https://doi.org/10.1136/ pgmj.2010.106658). 25. De Felice C, Rech F, Marini A, Stagnitti A, Valente F, Cipolla V et al. Magnetic resonance hysterosalpingography in the evaluation of tubal patency in infertile women: an observational study. Clin Exp Obstet Gynecol. 2012;39(1):83-8 (http://europepmc.org/abstract/MED/22675963). 26. Hong Q, Cai R, Chen Q, Zhang S, Ai A, Fu Y et al. Three-dimensional HyCoSy with perfluoropropane-albumin microspheres as contrast agents and normal saline injections into the pelvic cavity for morphological assessment of the fallopian t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 104
  },
  {
    "chunk_id": "infertility_2038",
    "text": "dimensional HyCoSy with perfluoropropane-albumin microspheres as contrast agents and normal saline injections into the pelvic cavity for morphological assessment of the fallopian tube in infertile women. J Ultrasound Med. 2017;36(4):741-8 (https://doi. org/10.7863/ultra.16.03041).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 104
  },
  {
    "chunk_id": "infertility_2039",
    "text": "815 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 27. Omurtag K, Grindler NM, Roehl KA, Bates GW Jr , Beltsos AN, Odem RR et al. How members of the Society for Reproductive Endocrinology and Infertility and Society of Reproductive Surgeons evaluate, define, and manage hydrosalpinges. Fertil Steril. 2012;97(5):1095-100 (https://doi. org/10.1016/j.fertnstert.2012.02.026). 28. Hindocha A, Beere L, O’Flynn H, Watson A, Ahmad G. Pain relief in hysterosalpingography. Cochrane Database Syst Rev. 2015;(9):CD006106 (https://doi.org/10.1002/14651858.CD006106. pub3). 29. Bednarczuk T, Brix TH, Schima W, Zettinig G, Kahaly GJ. 2021 European Thyroid Association guidelines for the management of iodine-based contrast media-induced thyroid dysfunction. Eur Thyroid J. 2021;10(4):269-84 (https://doi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 105
  },
  {
    "chunk_id": "infertility_2040",
    "text": "Kahaly GJ. 2021 European Thyroid Association guidelines for the management of iodine-based contrast media-induced thyroid dysfunction. Eur Thyroid J. 2021;10(4):269-84 (https://doi. org/10.1159/000517175).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 105
  },
  {
    "chunk_id": "infertility_2041",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 82 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5.6 Diagnosis of infertility due to uterine cavity disorder This section contains several recommendations related to the diagnostic assessment of the uterine cavity. Figure 5.2. shows how these recommendations relate to each other, illustrated in a diagnostic algorithm. Specific recommendations are presented in the sections that follow, based on head-to-head comparisons of different diagnostics methods. Hierarchy of uterine investigations Hysteroscopy (± laparoscopy) is the gold standard in the assessment of the uterine cavity; however, it is an invasive procedure that may require anaesthesia or sedation, making it unsuitable for routine diagnostic assessment of the uterine cavity. As illus",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 106
  },
  {
    "chunk_id": "infertility_2042",
    "text": "terine cavity; however, it is an invasive procedure that may require anaesthesia or sedation, making it unsuitable for routine diagnostic assessment of the uterine cavity. As illustrated in Fig. 5.2 , this guideline suggests that saline infusion sonohysterography (SIS) should be ordinarily used because of cost considerations, unless 3D US is readily available within existing resources. Where SIS or 3D US are not available, either HSG or 2D US may be used. Table 5.7 shows the comparison of test performance between 3D US, SIS, 2D US and HSG with hysteroscopy for the diagnosis of uterine cavity disorders. Table 5.7. Comparison of 3D US, SIS, 2D US and HSG with hysteroscopy for the diagnosis of uterine cavity disorders 3D US SIS 2D US (paired data with 3D US) HSG (paired data with SIS) Hysteroscopy Sensitivity (95% CI) 96% (59–100) 89% (72–95) 68% (59–75) 72% (56–84) 100% Specificity (95% CI",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 106
  },
  {
    "chunk_id": "infertility_2043",
    "text": "ders 3D US SIS 2D US (paired data with 3D US) HSG (paired data with SIS) Hysteroscopy Sensitivity (95% CI) 96% (59–100) 89% (72–95) 68% (59–75) 72% (56–84) 100% Specificity (95% CI) 94% (77–99) 100% (27–100) 93% (64–99) 93% (66–99) 100% True positives 14 13 10 11 15 False negatives 1 2 5 4 0 False positives 5 0 6 6 0 True negatives 80 85 79 79 85 2D, two-dimensional ultrasound; 3D, three-dimensional; CI, confidence interval; HSG, hysterosalpingogram; SIS, saline infusion sonohysterography; US, ultrasound. 5 Diagnosis of infertility 83",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 106
  },
  {
    "chunk_id": "infertility_2044",
    "text": "835 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5 Diagnosis of infertility Fig. 5.2. Diagnostic algorithm for the assessment of the uterine cavity Female suspected of uterine cavity disorder on medical history and physical examination Investigate the uterine cavitya Use SIS Normal cavity Normal cavity Use 3D US Uterine cavity disorder confirmed Uterine cavity disorder confirmedTreatb Treatb Treatb Treatb Yes No Yes a See Fig. 5.1 for the overall diagnostic algorithm for female-factor infertility. b See recommendations for the treatment of uterine-factor infertility in Chapter 8. c See the Table 5.7 for the comparison of 3D US, SIS, 2D US and HSG with hysteroscopy for the diagnosis of uterine cavity disorders. 2D, two-dimensional; 3D, three-dimensional; HSG, hysterosalpingogram; S",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 107
  },
  {
    "chunk_id": "infertility_2045",
    "text": "the comparison of 3D US, SIS, 2D US and HSG with hysteroscopy for the diagnosis of uterine cavity disorders. 2D, two-dimensional; 3D, three-dimensional; HSG, hysterosalpingogram; SIS, saline infusion sonohysterography; US, ultrasound. Use either HSG OR 2D US 2D USHSG Maybe normal cavity. Follow-up may be needed because of high rates of false negativesc Probably normal cavity Uterine cavity disorder confirmed Uterine cavity disorder confirmed Positive result Positive result Negative result Negative result Negative resultPositive result Positive result Negative result SIS or 3D US not available? Are there resource constraints? 5 Diagnosis of infertility 83 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 107
  },
  {
    "chunk_id": "infertility_2046",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 84 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility who are suspected to have a uterine cavity disorder, WHO suggests assessing the uterine cavity with saline infusion sonohysterography (SIS) rather than three-dimensional ultrasound (3D US). (Conditional recommendation, low certainty of evidence) Remark: • In settings where 3D US is already available within the existing resources, 3D US may be the preferred option. Background and rationale Infertility can be affected by uterine cavity abnormalities. The incidence of intrauterine abnormalities, such as polyps, fibroids, adhesions and congenital malformations, is higher in women with infertility than in the general population ( 1, 2). Therefore, accu",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 108
  },
  {
    "chunk_id": "infertility_2047",
    "text": "uterine abnormalities, such as polyps, fibroids, adhesions and congenital malformations, is higher in women with infertility than in the general population ( 1, 2). Therefore, accurate detection of uterine cavity abnormalities is important in the identification of the cause and subsequent management of infertility. Hysteroscopy is considered the reference gold standard for the assessment of uterine abnormalities because it allows direct visualization of the endometrial cavity, as well as the ability to obtain tissue for histological diagnosis. The procedure involves inserting a flexible, semi-flexible or rigid telescope into the endometrial cavity. To optimize visualization, uterine distension with carbon dioxide or normal saline is typically performed. However, it is an invasive procedure that may require anaesthesia or sedation, making it unsuitable for routine diagnostic assessment of",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 108
  },
  {
    "chunk_id": "infertility_2048",
    "text": "de or normal saline is typically performed. However, it is an invasive procedure that may require anaesthesia or sedation, making it unsuitable for routine diagnostic assessment of the uterine cavity. SIS is a diagnostic procedure that involves the manual installation of saline into the uterine cavity transcervically to act as a negative contrast agent and facilitate enhanced endometrial visualization during transvaginal assessment of the endometrial cavity using ultrasound ( 3, 4). The infusion of sterile isotonic fluid during transvaginal sonography into the uterine cavity facilitates uterine distension and enhanced visual contrast during real-time ultrasonographic examination ( 4, 5). Ultrasonography (US imaging) involves the generation and transmission of ultrasonic (high-frequency sound) waves from a transducer and processing of a returning echo to generate an image. It is based on ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 108
  },
  {
    "chunk_id": "infertility_2049",
    "text": "ging) involves the generation and transmission of ultrasonic (high-frequency sound) waves from a transducer and processing of a returning echo to generate an image. It is based on non-ionizing energy (6). Although ultrasound examination of the myometrium may be performed using a transabdominal transvaginal or more rarely transrectal approach ( 7, 8), the transvaginal approach is most commonly used for assessing uterine abnormalities ( 7–9). 3D US is an enhancement of ultrasonography, which formats the sound wave data into 3D images and enables their offline examination and manipulation ( 9, 10). The GDG agreed that a key decision when investigating women with infertility and suspected uterine pathology is whether to use SIS or 3D US. For this recommendation, the GDG addressed the question: should SIS versus 3D US be used to evaluate women with infertility and suspected uterine cavity abn",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 108
  },
  {
    "chunk_id": "infertility_2050",
    "text": "er to use SIS or 3D US. For this recommendation, the GDG addressed the question: should SIS versus 3D US be used to evaluate women with infertility and suspected uterine cavity abnormality? Balancing harms and benefits De novo searches were conducted to identify diagnostic test accuracy (DTA) studies on SIS and 3D US and to identify studies on health outcomes up to November 2019. We found one study in which women received both SIS and 3D transvaginal ultrasound, and results were compared to the reference standard of hysteroscopy. It determined the sensitivity and specificity of each test to identify fibroids, endometrial polyps, intrauterine synechiae and Müllerian anomalies, as well as arcuate, unicornuate, bicornuate and subseptate uteri (11), as shown in Table 5.8.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 108
  },
  {
    "chunk_id": "infertility_2051",
    "text": "855 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table 5.8. Sensitivity and specificity for 3D US and SIS with 95% CIs from one paired study ( 11) 3D US SIS Sensitivity (95% CI) 74% (60–85%) 88% (76–96%) Specificity (95% CI) 100% (87–100%) 100 (87–100%) 3D, three-dimensional; CI, confidence interval; SIS, saline infusion sonohysterography; US, ultrasound. The search also found comparative studies that included different tests, one of which was either SIS or 3D US. Therefore, one arm of those studies was used to pool the sensitivity and specificity of the two tests. Because of lack of large studies on each uterine anomaly, the synthesized evidence in this recommendation question pooled data related to many uterine abnormalities. Each of the identified studies diagnosed the uterine ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 109
  },
  {
    "chunk_id": "infertility_2052",
    "text": "h uterine anomaly, the synthesized evidence in this recommendation question pooled data related to many uterine abnormalities. Each of the identified studies diagnosed the uterine cavity disorders shown in Table 5.9. Table 5.9. Studies comparing 3D US and SIS, and the conditions identified Test modality Study Condition identified 3D Abdelmagied et al. (12) Cavitary lesions (e.g. polyps in 47%) Aboulghar et al. (11) Fibroids; endometrial polyps; intrauterine synechiae; Müllerian anomalies; arcuate, unicornuate, bicornuate and subseptate uteri (few) Niknejadi et al. (13) Septate uterus (arcuate, subseptate, septate) SIS Alatas et al. (14) Endometrial polyp, uterine anomaly, submucous myoma Ayida et al. (15) Submucosal fibroid, endometrioma, structural abnormality, adhesions. Atrophic endometrium, fibrosis, echogenic endometrium Bartkowiak et al. (16) Submucous myomas, endometrial polyp, se",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 109
  },
  {
    "chunk_id": "infertility_2053",
    "text": "cosal fibroid, endometrioma, structural abnormality, adhesions. Atrophic endometrium, fibrosis, echogenic endometrium Bartkowiak et al. (16) Submucous myomas, endometrial polyp, septate uteri, intrauterine synechiae Fadl et al. (17) Endometrial polyps Guven et al. (18) Endometrial polyps, submucosal myomas Ragni et al. (19) Intrauterine pathology (polyp, myoma, malformation, synechiae, thick endometrial mucosa) Soares et al. (20) Polypoid lesions, uterine malformations, intrauterine adhesions and endometrial hyperplasia Sitimani et al. (21) Endometrial polyp, submucous myoma, intrauterine synechiae or any other (thin endometrium, endometrial hyperplasia)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 109
  },
  {
    "chunk_id": "infertility_2054",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 86 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Test modality Study Condition identified Alborzi et al. (22) Total tubal and uterine pathologies: tubal obstruction. Intracavitary pathologies: Asherman syndrome, endometrial polyps, myomatous uterus. Structural uterine anomalies: septate uterus and other structural uterine anomalies De Felice et al. (23) Abnormalities of the uterine cavity Aboulghar et al. (11) Fibroids; endometrial polyps; intrauterine synechiae; Müllerian anomalies; arcuate, unicornuate, bicornuate and subseptate uteri (few) 3D, three-dimensional; SIS, saline infusion sonohysterography; US, ultrasound. Calculations of sensitivity and specificity were conducted based on unpaired studies, as shown in Table 5.10. Table 5.10",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 110
  },
  {
    "chunk_id": "infertility_2055",
    "text": "al; SIS, saline infusion sonohysterography; US, ultrasound. Calculations of sensitivity and specificity were conducted based on unpaired studies, as shown in Table 5.10. Table 5.10. Sensitivity and specificity of 3D US and SIS with 95% CIs from unpaired studies 3D US SIS Sensitivity (95% CI) 96% (59–100%) 88% (72–95%) Specificity (95% CI) 94 (77–99%) 100 (27–100%) 3D, three-dimensional; CI, confidence interval; SIS, saline infusion sonohysterography; US, ultrasound. Calculations of absolute effects on true and false negatives and positives were based 15% prevalence of uterine cavity disorders in women with infertility. The results showed that there may be one less true positive per 100 with SIS than with 3D US, one more false negative per 100 with SIS than 3D US, five more true negatives per 100 with SIS compared with 3D US and five fewer false positives per 100 with SIS compared with 3D",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 110
  },
  {
    "chunk_id": "infertility_2056",
    "text": " one more false negative per 100 with SIS than 3D US, five more true negatives per 100 with SIS compared with 3D US and five fewer false positives per 100 with SIS compared with 3D US. The GDG agreed that in a population where the prevalence of uterine cavity disorder was 15%, five fewer false positives is a trivial difference in the number of women correctly identified with SIS compared to 3D US; likewise, one more missed woman with uterine cavity disorder (false negative) with SIS is considered trivial. The GDG noted that the synthesized evidence combined the analysis of many uterine abnormalities, and that sensitivity and specificity may differ between anomalies. Additional data for health outcomes, such as adverse events, were obtained from studies (11, 19, 20, 24–28). Based on these data, the GDG judged that the undesirable effects with SIS may be trivial compared to 3D US although ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 110
  },
  {
    "chunk_id": "infertility_2057",
    "text": "adverse events, were obtained from studies (11, 19, 20, 24–28). Based on these data, the GDG judged that the undesirable effects with SIS may be trivial compared to 3D US although the evidence is uncertain. Given the trivial differences in benefits and harms between SIS and 3D US, the GDG judged that the balance of effects probably does not favour one over the other. There were no studies on patient values; however, the GDG agreed that women would likely value tests that can identify the diagnosis correctly and would seek to minimize harms, and that there was probably no important uncertainty or variability in how women value these outcomes. The overall certainty of evidence was low. Other considerations Although comparative data about costs were not available, the GDG agreed that 3D US is likely more expensive than SIS and SIS would probably lead to moderate savings. There were no data ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 110
  },
  {
    "chunk_id": "infertility_2058",
    "text": "gh comparative data about costs were not available, the GDG agreed that 3D US is likely more expensive than SIS and SIS would probably lead to moderate savings. There were no data on cost-effectiveness; however, the GDG agreed that given the trivial differences in benefits and harms but moderate savings with SIS, that SIS is probably",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 110
  },
  {
    "chunk_id": "infertility_2059",
    "text": "875 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps favoured. In addition, the GDG judged that SIS could probably increase equity because it is more widely available than 3D US. Although no data were available, the GDG agreed that SIS and 3D US are likely both acceptable. One study ( 29) provided an analysis of feasibility of 3D US and SIS. The GDG considered that although both require training of health care providers, SIS is probably more feasible than 3D US because 3D US is not as widely available. Summary justification There is low-certainty evidence that there are trivial differences in benefits and harms with SIS compared to 3D US. Although both are acceptable, 3D US likely costs more than SIS and is less available; therefore SIS is suggested. In settings where it is already av",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 111
  },
  {
    "chunk_id": "infertility_2060",
    "text": "rms with SIS compared to 3D US. Although both are acceptable, 3D US likely costs more than SIS and is less available; therefore SIS is suggested. In settings where it is already available within the existing resources, 3D US may be the preferred option. Implementation considerations Training of health care providers is required to ensure the correct assessment, documentation and reporting of uterine cavity assessment (9, 30). Research gaps and future guideline update Because of the lack of large studies on each uterine anomaly, the synthesized evidence in this PICO is based on pooled data related to many uterine abnormalities. Future large studies are required to provide sufficient discriminatory power. Future guidance is required to compare the role of colour, power and spectral Doppler, as well as four- dimensional (4D) ultrasonography in evaluating uterine cavity disorders, including ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 111
  },
  {
    "chunk_id": "infertility_2061",
    "text": "guidance is required to compare the role of colour, power and spectral Doppler, as well as four- dimensional (4D) ultrasonography in evaluating uterine cavity disorders, including different types of Müllerian anomaly disorders ( 31). References 1. Saravelos SH, Cocksedge KA, Li TC. Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: a critical appraisal. Hum Reprod Update. 2008;14(5):415- 29 (https://doi.org/10.1093/humupd/dmn018). 2. Chan Y, Jayaprakasan K, Zamora J, Thornton J, Raine-Fenning N, Coomarasamy A. The prevalence of congenital uterine anomalies in unselected and high-risk populations: a systematic review. Hum Reprod Update. 2011;17(6):761-71 (https://doi.org/10.1093/ humupd/dmr028). 3. Syrop CH, Sahakian V. Transvaginal sonographic detection of endometrial polyps with fluid contrast augmentation. Obstet Gynecol. 1992;79(6):1041-3. 4. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 111
  },
  {
    "chunk_id": "infertility_2062",
    "text": "/10.1093/ humupd/dmr028). 3. Syrop CH, Sahakian V. Transvaginal sonographic detection of endometrial polyps with fluid contrast augmentation. Obstet Gynecol. 1992;79(6):1041-3. 4. Parsons AK, Lense JJ. Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound. 1993;21(2):87-95 (https://doi. org/10.1002/jcu.1870210203). 5. Bonilla‐Musoles F, Simón C, Serra V, Sampaio M, Pellicer A. An assessment of hysterosalpingosonography (HSSG) as a diagnostic tool for uterine cavity defects and tubal patency. J Clin Ultrasound. 1992;20(3):175- 81 (https://doi.org/10.1002/jcu.1870200303). 6. Tole N. Basic physics of ultrasonic imaging. In Ostensen H, editor. Basic physics of ultrasonic imaging. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/43179).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 111
  },
  {
    "chunk_id": "infertility_2063",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 88 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 7. Manual of diagnostic ultrasound. Vol. 2, second edition. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 8. Manual of diagnostic ultrasound. Vol. 1, second edition. Geneva: World Health Organization); 2011 (https://iris.who.int/handle/10665/43881). 9. Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284-98 (https://doi.org/10.1002/ uog.14806). 10. AIUM practice parameter for the performance of a foc",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 112
  },
  {
    "chunk_id": "infertility_2064",
    "text": "rus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284-98 (https://doi.org/10.1002/ uog.14806). 10. AIUM practice parameter for the performance of a focused ultrasound examination in reproductive endocrinology and female infertility. J Ultrasound Med. 2019;38(3):E1-E3 (https://doi.org/10.1002/jum.14952). 11. Aboulghar M, Shoeir I, Momtaz M, El Mohammady M, Ezzat H. A comparative study of 2-dimensional sonohysterography versus 3-dimensional sonohysterography in infertile patients with uterine cavity lesions and abnormalities. Middle East Fertil Soc J. 2011;16(1):67-71 (https://doi.org/10.1016/j. mefs.2010.12.001). 12. Abdelmagied AM, Kamel MA, Stewart EA, AboElHassan AM, Makarem MH. Undiagnosed endometrial abnormalities in women scheduled for IVF: comparing accuracy of 3D ultrasound (US) versus vaginoscopic hysteroscopy (VH). Reprod Sci. 2015;22(1):216A-A. 13. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 112
  },
  {
    "chunk_id": "infertility_2065",
    "text": "ndiagnosed endometrial abnormalities in women scheduled for IVF: comparing accuracy of 3D ultrasound (US) versus vaginoscopic hysteroscopy (VH). Reprod Sci. 2015;22(1):216A-A. 13. Niknejadi M, Akhbari F, Niknejad F, Khalili G, Shiva M. Comparison of two dimensional and live three dimensional ultrasounds for the diagnosis of septated uterus. Iran J Reprod Med. 2014;12(8):547-54. 14. Alatas C, Aksoy E, Akarsu C, Yakin K, Aksoy S, Hayran M. Evaluation of intrauterine abnormalities in infertile patients by sonohysterography. Hum Reprod. 1997;12(3):487-90 (https://doi.org/10.1093/ humrep/12.3.487). 15. Ayida G, Chamberlain P, Barlow D, Kennedy S. Uterine cavity assessment prior to in vitro fertilization: comparison of transvaginal scanning, saline contrast hysterosonography and hysteroscopy. Ultrasound Obstet Gynecol. 1997;10(1):59-62 (https://doi.org/10.1046/j.1469- 0705.1997.10010059.x). 16",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 112
  },
  {
    "chunk_id": "infertility_2066",
    "text": "of transvaginal scanning, saline contrast hysterosonography and hysteroscopy. Ultrasound Obstet Gynecol. 1997;10(1):59-62 (https://doi.org/10.1046/j.1469- 0705.1997.10010059.x). 16. Bartkowiak R, Kaminski P, Wielgos M, Bobrowska K. The evaluation of uterine cavity with saline infusion sonohysterography and hysteroscopy in infertile patients. Neuro Endocrinol Lett. 2006;27(4):523-8. 17. Fadl SA, Sabry AS, Hippe DS, Al-Obaidli A, Yousef RR, Dubinsky TJ. Diagnosing Polyps on Transvaginal Sonography: Is Sonohysterography Always Necessary? Ultrasound Q. 2018;34(4):272-7 (https://doi.org/10.1097/ ruq.0000000000000384 ). 18. Guven MA, Bese T, Demirkiran F, Idil M, Mgoyi L. Hydrosonography in screening for intracavitary pathology in infertile women. Int J Gynaecol Obstet. 2004;86(3):377-83 (https://doi. org/10.1016/j.ijgo.2004.05.005). 19. Ragni G, Diaferia D, Vegetti W, Colombo M, Arnoldi M, Cr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 112
  },
  {
    "chunk_id": "infertility_2067",
    "text": "y pathology in infertile women. Int J Gynaecol Obstet. 2004;86(3):377-83 (https://doi. org/10.1016/j.ijgo.2004.05.005). 19. Ragni G, Diaferia D, Vegetti W, Colombo M, Arnoldi M, Crosignani PG. Effectiveness of sonohysterography in infertile patient work-up: a comparison with transvaginal ultrasonography and hysteroscopy. Gynecol Obstet Invest. 2005;59(4):184-8 (https://doi. org/10.1159/000084294). 20. Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril. 2000;73(2):406-11 (https://doi.org/10.1016/s0015-0282(99)00532-4). 21. Sitimani A, Chawla I, Vohra P. Saline infusion sonography in evaluation of uterine cavity abnormalities in infertility: a comparative study. Int J Reprod Contracept Obstet Gynecol. 2016;5(9):2995-3001 (https://doi. org/10.18203/2",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 112
  },
  {
    "chunk_id": "infertility_2068",
    "text": "nography in evaluation of uterine cavity abnormalities in infertility: a comparative study. Int J Reprod Contracept Obstet Gynecol. 2016;5(9):2995-3001 (https://doi. org/10.18203/2320-1770.ijrcog20162972).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 112
  },
  {
    "chunk_id": "infertility_2069",
    "text": "895 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 22. Alborzi S, Dehbashi S, Khodaee R. Sonohysterosalpingographic screening for infertile patients. Int J Gynaecol Obstet. 2003;82(1):57-62 (https://doi.org/10.1016/s0020- 7292(02)00417-4). 23. De Felice C, Porfiri LM, Savelli S, Alfano G, Pace S, Manganaro L et al. Infertility in women: combined sonohysterography and hysterosalpingography in the evaluation of the uterine cavity. Ultraschall Med. 2009;30(1):52-7 (https://doi.org/10.1055/s-2008-1027728). 24. Hassa H, Öge T, Aydin Y, Korkmazer E, Tokgöz V, Arslan E. IVF Siklusları Öncesi İnfertil Hastalarda Ofis Histeroskopi Yapılması Faydalı mıdır? [Is office hysteroscopy potentially beneficial for infertile patients prior to IVF cycles?] Turkiye Klinikleri Jinekoloji Obstetrik 2013;2",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 113
  },
  {
    "chunk_id": "infertility_2070",
    "text": "fis Histeroskopi Yapılması Faydalı mıdır? [Is office hysteroscopy potentially beneficial for infertile patients prior to IVF cycles?] Turkiye Klinikleri Jinekoloji Obstetrik 2013;23(3):148-53. 25. Grønlund L, Hertz J, Helm P, Colov NP. Transvaginal sonohysterography and hysteroscopy in the evaluation of female infertility, habitual abortion or metrorrhagia. A comparative study. Acta Obstet Gynecol Scand. 1999;78(5):415-8 (https://pubmed.ncbi.nlm.nih. gov/10326887/). 26. Bocca SM, Abuhamad AZ. Use of 3-dimensional sonography to assess uterine anomalies. J Ultrasound Med. 2013;32(1):1-6 (https://doi. org/10.7863/jum.2013.32.1.1). 27. Aremu A, Adetiloye V, Famurewa O, Ibitoye B, Ayoola O, Alao O. Saline contrast sonohysterography findings in Nigerian patients with infertility. Res J Med Sci. 2008;2(3):133-6. 28. Aremu A, Adetiloye A, Ibitoye B, Adekanle D, Bello T. Transabdominal saline con",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 113
  },
  {
    "chunk_id": "infertility_2071",
    "text": "onohysterography findings in Nigerian patients with infertility. Res J Med Sci. 2008;2(3):133-6. 28. Aremu A, Adetiloye A, Ibitoye B, Adekanle D, Bello T. Transabdominal saline contrast sonohysterography: can it replace hysterosalpingography in low resource countries. J Clinic Diagn Res. 2012;6:239-42. 29. Grimbizis GF, Di Spiezio Sardo A, Saravelos SH, Gordts S, Exacoustos C, Van Schoubroeck D et al. The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomalies. Hum Reprod. 2016;31(1):2-7 (https://doi.org/10.1093/ humrep/dev264). 30. Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103-12 (https://doi.org/10",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 113
  },
  {
    "chunk_id": "infertility_2072",
    "text": "trium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103-12 (https://doi.org/10.1002/ uog.7487). 31. Pfeifer SM, Attaran M, Goldstein J, Lindheim SR, Petrozza JC, Rackow BW et al. ASRM müllerian anomalies classification 2021. Fertil Steril. 2021;116(5):1238-52 (https://doi.org/10.1016/j. fertnstert.2021.09.025).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 113
  },
  {
    "chunk_id": "infertility_2073",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 90 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility who are suspected to have a uterine cavity disorder, WHO suggests assessing the uterine cavity with three-dimensional ultrasound (3D US) rather than two-dimensional ultrasound (2D US) where resources are available. (Conditional recommendation, low certainty of evidence) Background and rationale Ultrasound imaging (sonography) involves the generation and transmission of ultrasonic (high-frequency sound) waves from a transducer and processing of a returning echo to generate an image. It is based on non-ionizing energy ( 1). The image is subsequently displayed on a monitor, from which a hard copy may be captured, for example, using thermal printing p",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 114
  },
  {
    "chunk_id": "infertility_2074",
    "text": "e an image. It is based on non-ionizing energy ( 1). The image is subsequently displayed on a monitor, from which a hard copy may be captured, for example, using thermal printing paper ( 1). Although US examination of the myometrium may be performed using a transabdominal transvaginal or more rarely transrectal approach ( 2, 3), a transvaginal approach is more commonly used for assessing uterine abnormalities (2–4). 3D US is an enhancement of ultrasonography, which formats the sound wave data into 3D images and enables their examination offline (4, 5). The GDG agreed that a key decision when investigating women with infertility and suspected uterine pathology is whether to use 3D or 2D US. For this recommendation, the GDG addressed the question: should 3D versus 2D US be used for women with infertility and suspected uterine cavity abnormality? Although advancements in technology have all",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 114
  },
  {
    "chunk_id": "infertility_2075",
    "text": "on, the GDG addressed the question: should 3D versus 2D US be used for women with infertility and suspected uterine cavity abnormality? Although advancements in technology have allowed further enhancements of sonography, including colour, power and spectral Doppler, which allow assessments of endometrial vascularity and blood flow, as well as 4D US, this PICO focuses on 3D US compared to 2D US. Balancing harms and benefits A de novo search was conducted to identify DTA studies on 3D and 2D US up to November 2019. Studies included women who received 3D or 2D US and compared results to the reference standard of hysteroscopy. Because of the lack of large studies on each uterine anomaly, the synthesized evidence in this recommendation question pooled data related to many uterine abnormalities. The identified studies assessed the sensitivity and specificity of uterine cavity disorders as show",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 114
  },
  {
    "chunk_id": "infertility_2076",
    "text": " this recommendation question pooled data related to many uterine abnormalities. The identified studies assessed the sensitivity and specificity of uterine cavity disorders as shown in Table 5.11. Table 5.11. Included studies comparing 3D and 2D US, and the conditions identified Study Condition identified Abdelmagied et al. (6) Cavitary lesions (e.g. polyps in 47%) Aboulghar et al. (7) Fibroids; endometrial polyps; intrauterine synechiae; Müllerian anomalies; arcuate, unicornuate, bicornuate and subseptate uteri (few) Niknejadi et al. (8) Septate uterus (arcuate, subseptate, septate) 2D, two-dimensional; 3D, three-dimensional; CI, confidence interval; US, ultrasound.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 114
  },
  {
    "chunk_id": "infertility_2077",
    "text": "915 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Pooled sensitivity and specificity were calculated across the studies with paired analysis (with 95% lower and upper CIs) as shown in Table 5.12. Table 5.12. Pooled sensitivity and specificity for 3D and 2D US with 95% CIs 3D US 2D US Sensitivity (95% CI) 96% (59–100%) 68% (59–75%) Specificity (95% CI) 94% (77–99%) 93% (64–99%) 2D, two-dimensional; 3D, three-dimensional; CI, confidence interval; US, ultrasound. The GDG noted that 3D US had greater sensitivity and specificity compared to 2D US, although there was overlap in CIs. The GDG noted that the synthesized evidence combined the analysis of many uterine abnormalities, but sensitivity and specificity may differ between anomalies; however, available data are insufficient to provi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 115
  },
  {
    "chunk_id": "infertility_2078",
    "text": "esized evidence combined the analysis of many uterine abnormalities, but sensitivity and specificity may differ between anomalies; however, available data are insufficient to provide discriminatory power. Calculations for the absolute effects on true and false negatives and positives were conducted, assuming a 15% prevalence of uterine cavity disorders among women with infertility. Based on this prevalence, results showed that there may be four more true positives with 3D US compared to 2D US, four fewer false negatives with 3D US compared to 2D US, one more true negative with 3D US compared to 2D US and one fewer false positive with 3D US compared to 2D US. The GDG judged that in a population where 15 out of 100 people have a uterine cavity disorder, four more true positives and four more true negatives was a small number of women correctly identified with and without uterine cavity abn",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 115
  },
  {
    "chunk_id": "infertility_2079",
    "text": "00 people have a uterine cavity disorder, four more true positives and four more true negatives was a small number of women correctly identified with and without uterine cavity abnormality, and that even fewer women were missed (false negatives). Data for health outcomes such as adverse events and complications were available from Soares et al. (9) and Aboulghar et al. ( 7). In terms of harms, data from two RCTs showed that no complications were reported from participants who underwent both procedures. The GDG agreed that adverse events (pain and complications) may be similar between 3D and 2D US, but the evidence is uncertain. There were no data for pregnancy or quality of life outcomes. There were no studies on patient values; however, the GDG agreed that women would value tests that can identify the diagnosis correctly and would seek to minimize harms, and there was probably no import",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 115
  },
  {
    "chunk_id": "infertility_2080",
    "text": "on patient values; however, the GDG agreed that women would value tests that can identify the diagnosis correctly and would seek to minimize harms, and there was probably no important uncertainty or variability in these outcomes. Given the small benefits and trivial harms, the balance of effects probably favoured 3D over 2D US. The GDG judged that the certainty of evidence was low. Other considerations Although comparative data for costs were not available, the GDG judged that 3D US is relatively more expensive than 2D US. In regard to cost-effectiveness, and in the absence of data, the GDG judged that given the small benefits and moderate costs of 3D US, neither 3D nor 2D US is favoured. There were no data on acceptability; however, the GDG judged that 3D US and 2D US are both acceptable. The GDG agreed that 3D US could probably reduce equity because it is less widely available than 2D ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 115
  },
  {
    "chunk_id": "infertility_2081",
    "text": "acceptability; however, the GDG judged that 3D US and 2D US are both acceptable. The GDG agreed that 3D US could probably reduce equity because it is less widely available than 2D US. One study ( 10) reported an analysis of feasibility of 3D and 2D US. The GDG agreed that 3D US is probably feasible, but it requires appropriate probes, software and software maintenance and training of health care providers.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 115
  },
  {
    "chunk_id": "infertility_2082",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 92 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification There is low-certainty evidence that there are small benefits (correct identification of women with uterine cavity disorders) and trivial differences in harms (pain and complications) with 3D US compared to 2D US. In addition, acceptability is likely similar. The additional costs and resources required for 3D US are outweighed by the benefits, and 3D US is suggested where resources permit. Implementation considerations Training is required to ensure that health care providers have the skills to assess safely and correctly document and report findings while evaluating the uterus ( 2, 4, 11, 12). Research gaps and future guideline update Because of the lack of large stud",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 116
  },
  {
    "chunk_id": "infertility_2083",
    "text": "to assess safely and correctly document and report findings while evaluating the uterus ( 2, 4, 11, 12). Research gaps and future guideline update Because of the lack of large studies on each uterine anomaly, the synthesized evidence combined the analysis of many uterine abnormalities. Future large studies are required to provide sufficient discriminatory power. Future guidance is required to compare the role of colour, power and spectral Doppler, as well as 4D ultrasonography. References 1. Tole N. Basic physics of ultrasonic imaging. In Ostensen H, editor. Basic physics of ultrasonic imaging. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/43179). 2. Manual of diagnostic ultrasound. Vol. 2, second edition. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 3. Manual of diagnostic ultrasound. Vol. 1, second edition. Geneva",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 116
  },
  {
    "chunk_id": "infertility_2084",
    "text": "sound. Vol. 2, second edition. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 3. Manual of diagnostic ultrasound. Vol. 1, second edition. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/43881). 4. Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284-98 (https://doi.org/10.1002/ uog.14806). 5. AIUM practice parameter for the performance of a focused ultrasound examination in reproductive endocrinology and female infertility. J Ultrasound Med. 2019;38(3):e1-e3 (https://doi.org/10.1002/jum.14952). 6. Abdelmagied AM, Kamel MA, Stewart EA, AboElHassan AM, Makarem MH. Undiagnos",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 116
  },
  {
    "chunk_id": "infertility_2085",
    "text": "ology and female infertility. J Ultrasound Med. 2019;38(3):e1-e3 (https://doi.org/10.1002/jum.14952). 6. Abdelmagied AM, Kamel MA, Stewart EA, AboElHassan AM, Makarem MH. Undiagnosed endometrial abnormalities in women scheduled for IVF: comparing accuracy of 3D ultrasound (US) versus vaginoscopic hysteroscopy (VH). Reprod Sci. 2015;22(1):216A-A. 7. Aboulghar M, Shoeir I, Momtaz M, El Mohammady M, Ezzat H. A comparative study of 2-dimensional sonohysterography versus 3-dimensional sonohysterography in infertile patients with uterine cavity lesions and abnormalities. Middle East Fertil Soc J. 2011;16(1):67-71. 8. Niknejadi M, Akhbari F, Niknejad F, Khalili G, Shiva M. Comparison of two dimensional and live three dimensional ultrasounds for the diagnosis of septated uterus. Iran J Reprod Med. 2014;12(8):547-54. 9. Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohyste",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 116
  },
  {
    "chunk_id": "infertility_2086",
    "text": "dimensional ultrasounds for the diagnosis of septated uterus. Iran J Reprod Med. 2014;12(8):547-54. 9. Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril. 2000;73(2):406-11 (https://doi.org/10.1016/s0015-0282(99)00532-4).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 116
  },
  {
    "chunk_id": "infertility_2087",
    "text": "935 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 10. Grimbizis GF, Di Spiezio Sardo A, Saravelos SH, Gordts S, Exacoustos C, Van Schoubroeck D et al. The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomalies. Hum Reprod. 2016;31(1):2-7 (https://doi.org/10.1093/ humrep/dev264). 11. Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103- 12 (https://doi.org/10.1002/uog.7487). 12. Good clinical diagnostic practice: a guide for clinicians in developing countries to the clinical diagnosis of disease and t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 117
  },
  {
    "chunk_id": "infertility_2088",
    "text": "0;35(1):103- 12 (https://doi.org/10.1002/uog.7487). 12. Good clinical diagnostic practice: a guide for clinicians in developing countries to the clinical diagnosis of disease and to making proper use of clinical diagnostic services. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/119735). General: Tile 1A",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 117
  },
  {
    "chunk_id": "infertility_2089",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 94 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility who are suspected to have a uterine cavity disorder, WHO suggests assessing the uterine cavity with saline infusion sonohysterography (SIS) rather than two-dimensional ultrasound (2D US). (Conditional recommendation, low certainty of evidence) Background and rationale SIS is a diagnostic procedure that involves the manual installation of saline into the uterine cavity transcervically to act as a negative contrast agent and facilitate enhanced endometrial visualization during transvaginal assessment of the endometrial cavity using ultrasound ( 1, 2). The infusion of sterile isotonic fluid during transvaginal sonography into the uterine cavity facil",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 118
  },
  {
    "chunk_id": "infertility_2090",
    "text": "ring transvaginal assessment of the endometrial cavity using ultrasound ( 1, 2). The infusion of sterile isotonic fluid during transvaginal sonography into the uterine cavity facilitates uterine distension and enhanced visual contrast during real-time ultrasonographic examination ( 2, 3). SIS is also referred to as SHG. Ultrasound imaging (sonography) involves the generation and transmission of ultrasonic (high- frequency sound) waves from a transducer and processing of a returning echo to generate an image. It is based on non-ionizing energy ( 4). The image is subsequently displayed on a monitor, from which a hard copy may be captured, for example, using thermal printing paper ( 4). Although US examination of the myometrium may be performed using a transabdominal transvaginal or more rarely transrectal approach ( 5, 6), the transvaginal approach is more commonly used for assessing uteri",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 118
  },
  {
    "chunk_id": "infertility_2091",
    "text": "the myometrium may be performed using a transabdominal transvaginal or more rarely transrectal approach ( 5, 6), the transvaginal approach is more commonly used for assessing uterine abnormalities ( 5–7). 2D US is the use of ultrasonic data to display the acquired information in two dimensions, B-scan ( 4). For this recommendation, the GDG addressed the question: should SIS (i.e. SHG) versus 3D US be used for women with suspected uterine cavity disorder infertility? The GDG agreed that a key decision when investigating women with infertility and suspected uterine pathology is whether to use SIS or 2D US. Balancing harms and benefits We conducted de novo searches to identify DTA studies on SIS and 2D US up to November 2019. Studies included women who received SIS or 2D transvaginal ultrasound and compared the results to the reference standard of hysteroscopy. Because of the lack of large ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 118
  },
  {
    "chunk_id": "infertility_2092",
    "text": "vember 2019. Studies included women who received SIS or 2D transvaginal ultrasound and compared the results to the reference standard of hysteroscopy. Because of the lack of large studies on each uterine anomaly, the synthesized evidence in this recommendation question pooled data related to many uterine abnormalities. Each identified study assessed sensitivity and specificity to diagnose the uterine cavity disorders shown in Table 5.13 .",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 118
  },
  {
    "chunk_id": "infertility_2093",
    "text": "955 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table 5.13. Included studies comparing SIS and 2D US, and conditions identified Study Conditions identified Alatas et al. (8) Endometrial polyp, uterine anomaly, submucous myoma Ayida et al. (9) Submucosal fibroid, endometrioma, structural abnormality, adhesions, atrophic endometrium, fibrosis, echogenic endometrium Bartkowiak et al. (10) Submucous myomas, endometrial polyp, septate uteri, intrauterine synechiae Fadl et al. (11) Endometrial polyps Guven et al. (12) Endometrial polyps, submucosal myomas Ragni et al. (13) Intrauterine pathology (polyp, myoma, malformation synechiae, thick endometrial mucosa) Soares et al. (14) Polypoid lesions, uterine malformations, intrauterine adhesions and endometrial hyperplasia Sitimani et al. (",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 119
  },
  {
    "chunk_id": "infertility_2094",
    "text": ", malformation synechiae, thick endometrial mucosa) Soares et al. (14) Polypoid lesions, uterine malformations, intrauterine adhesions and endometrial hyperplasia Sitimani et al. (15) Endometrial polyp, submucous myoma, intrauterine synechiae or any other (thin endometrium, endometrial hyperplasia) We calculated the sensitivity and specificity based on paired studies as shown in Table 5.14 . Table 5.14. Pooled sensitivity and specificity for SIS and 2D US with 95% CIs SIS 2D US Sensitivity (95% CI) 88% (72–95%) 56% (34–77%) Specificity (95% CI) 100% (27–100%) 100% (43–100%) 2D, two-dimensional; CI, confidence interval; US, ultrasound. Data for health outcomes such as adverse events were available from Soares et al. ( 14), Hassa et al. (16), Ragni et al. (13) and Aboulghar et al. (17). Calculations for absolute effects on true and false negatives and positives were based on an assumption ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 119
  },
  {
    "chunk_id": "infertility_2095",
    "text": " al. ( 14), Hassa et al. (16), Ragni et al. (13) and Aboulghar et al. (17). Calculations for absolute effects on true and false negatives and positives were based on an assumption of 15% prevalence of uterine cavity disorders in women with infertility. Compared to 2D US, SIS likely results in five more women of 15 out of 100 being correctly identified with a uterine cavity disorder (true positives) and five fewer women of 85 out of 100 being incorrectly identified with uterine cavity disorder (false negatives). There is also likely no difference in true negatives or true positives. In a population where 15 out of 100 people have a uterine cavity disorder, the GDG agreed that five fewer false negatives with SIS (i.e. five more true positives) is a small number of women correctly identified compared to 2D US for uterine cavity pathologies. In terms of adverse effects, evidence from three R",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 119
  },
  {
    "chunk_id": "infertility_2096",
    "text": "(i.e. five more true positives) is a small number of women correctly identified compared to 2D US for uterine cavity pathologies. In terms of adverse effects, evidence from three RCTs (13, 14, 16) in which participants underwent both tests (n = 734), there were two complications",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 119
  },
  {
    "chunk_id": "infertility_2097",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 96 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps with SIS and none with 2D US. In another RCT ( 17) (n = 77), participants did not report any discomfort or pain after undergoing both procedures. Based on these data, the GDG concluded that adverse events (pain and complications) may be similar between SIS and 2D US. The overall certainty of evidence was rated low because of risk of bias, and few events and low total numbers of participants across all the studies. There were no studies on patient values; however, the GDG agreed that women would value tests that can identify the diagnosis correctly and would seek to minimize harms. Given the small benefits and trivial harms of SIS compared to 2D US, SIS is probably favoured. The GDG noted th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 120
  },
  {
    "chunk_id": "infertility_2098",
    "text": "n identify the diagnosis correctly and would seek to minimize harms. Given the small benefits and trivial harms of SIS compared to 2D US, SIS is probably favoured. The GDG noted that the synthesized evidence combined the analysis of many uterine abnormalities, but sensitivity and specificity may differ between anomalies; however, available data are insufficient to provide discriminatory power. Other considerations No data were available on resource requirements; however, the guideline panel agreed that the additional resources required for SIS are negligible. The GDG agreed that given the small benefits, but negligible additional costs of SIS compared to 2D US, that SIS is likely more cost-effective. The GDG agreed that there is probably no impact on equity. Although no data were available on acceptability, the GDG agreed that SIS is likely acceptable. One study (18) provided an analysis",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 120
  },
  {
    "chunk_id": "infertility_2099",
    "text": "reed that there is probably no impact on equity. Although no data were available on acceptability, the GDG agreed that SIS is likely acceptable. One study (18) provided an analysis of feasibility of 2D US but none was available for SIS. The GDG agreed that SIS is probably feasible and requires training of health care providers. Summary justification There is low certainty evidence that there are small benefits and trivial differences in harms with SIS compared to 2D US. The balance of effects favours SIS. In addition, SIS is acceptable and feasible, and has negligible additional resource requirements and impact on equity when compared to 2D US. Implementation considerations Training is required to ensure that health care providers have the skills to safely and correctly assess, document and report diagnostic findings while evaluating the uterus ( 5, 7, 19, 20). Research gaps and future g",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 120
  },
  {
    "chunk_id": "infertility_2100",
    "text": "ealth care providers have the skills to safely and correctly assess, document and report diagnostic findings while evaluating the uterus ( 5, 7, 19, 20). Research gaps and future guideline update Because of the lack of large studies on each uterine anomaly, synthesized evidence combined the analysis of many uterine abnormalities. Future large studies are required to provide sufficient discriminatory power. Future guidance is required to compare the role of colour, power and spectral Doppler, as well as 4D ultrasonography. References 1. Syrop CH, Sahakian V. Transvaginal sonographic detection of endometrial polyps with fluid contrast augmentation. Obstet Gynecol. 1992;79(6):1041-3. 2. Parsons AK, Lense JJ. Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound. 1993;21(2):87-95 (https://doi. org/10.1002/jcu.1870210203).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 120
  },
  {
    "chunk_id": "infertility_2101",
    "text": "975 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 3. Bonilla‐Musoles F, Simón C, Serra V, Sampaio M, Pellicer A. An assessment of hysterosalpingosonography (HSSG) as a diagnostic tool for uterine cavity defects and tubal patency. J Clin Ultrasound. 1992;20(3):175- 81 (https://doi.org/10.1002/jcu.1870200303). 4. Tole N. Basic physics of ultrasonic imaging. In: Ostensen H, editor. Basic physics of ultrasonic imaging. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/43179). 5. Manual of diagnostic ultrasound. Vol. 2, second edition. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 6. Manual of diagnostic ultrasound. Vol. 1, second edition. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/43881)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 121
  },
  {
    "chunk_id": "infertility_2102",
    "text": "ps://iris.who.int/handle/10665/85386). 6. Manual of diagnostic ultrasound. Vol. 1, second edition. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/43881). 7. Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284-98 (https://doi.org/10.1002/ uog.14806). 8. Alatas C, Aksoy E, Akarsu C, Yakin K, Aksoy S, Hayran M. Evaluation of intrauterine abnormalities in infertile patients by sonohysterography. Hum Reprod. 1997;12(3):487-90 (https://doi.org/10.1093/ humrep/12.3.487). 9. Ayida G, Chamberlain P, Barlow D, Kennedy S. Uterine cavity assessment prior to in vitro fertilization: comparison of transvaginal scanning,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 121
  },
  {
    "chunk_id": "infertility_2103",
    "text": "//doi.org/10.1093/ humrep/12.3.487). 9. Ayida G, Chamberlain P, Barlow D, Kennedy S. Uterine cavity assessment prior to in vitro fertilization: comparison of transvaginal scanning, saline contrast hysterosonography and hysteroscopy. Ultrasound Obstet Gynecol. 1997;10(1):59-62 (https://doi.org/10.1046/j.1469- 0705.1997.10010059.x). 10. Bartkowiak R, Kaminski P, Wielgos M, Bobrowska K. The evaluation of uterine cavity with saline infusion sonohysterography and hysteroscopy in infertile patients. Neuro Endocrinol Lett. 2006;27(4):523-8. 11. Fadl SA, Sabry AS, Hippe DS, Al-Obaidli A, Yousef RR, Dubinsky TJ. Diagnosing polyps on transvaginal sonography: is sonohysterography always necessary? Ultrasound Q. 2018;34(4):272-7 (https://doi.org/10.1097/ ruq.0000000000000384 ). 12. Guven MA, Bese T, Demirkiran F, Idil M, Mgoyi L. Hydrosonography in screening for intracavitary pathology in infertile ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 121
  },
  {
    "chunk_id": "infertility_2104",
    "text": ":272-7 (https://doi.org/10.1097/ ruq.0000000000000384 ). 12. Guven MA, Bese T, Demirkiran F, Idil M, Mgoyi L. Hydrosonography in screening for intracavitary pathology in infertile women. Int J Gynaecol Obstet. 2004;86(3):377-83 (https://doi. org/10.1016/j.ijgo.2004.05.005). 13. Ragni G, Diaferia D, Vegetti W, Colombo M, Arnoldi M, Crosignani PG. Effectiveness of sonohysterography in infertile patient work-up: a comparison with transvaginal ultrasonography and hysteroscopy. Gynecol Obstet Invest. 2005;59(4):184-8 (https://doi. org/10.1159/000084294). 14. Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril. 2000;73(2):406-11 (https://doi.org/10.1016/s0015-0282(99)00532-4). 15. Sitimani A, Chawla I, Vohra P. Saline infusion sonography in evaluation of",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 121
  },
  {
    "chunk_id": "infertility_2105",
    "text": "ne cavity diseases. Fertil Steril. 2000;73(2):406-11 (https://doi.org/10.1016/s0015-0282(99)00532-4). 15. Sitimani A, Chawla I, Vohra P. Saline infusion sonography in evaluation of uterine cavity abnormalities in infertility: a comparative study. Int J Reprod Contracept Obstet Gynecol. 2016;5(9):2995-3001 (https://doi. org/10.18203/2320-1770.ijrcog20162972). 16. Hassa H, Öge T, Aydin Y, Korkmazer E, Tokgöz V, Arslan E. IVF Siklusları Öncesi İnfertil Hastalarda Ofis Histeroskopi Yapılması Faydalı mıdır? [Is office hysteroscopy potentially beneficial for infertile patients prior to IVF cycles?] Turkiye Klinikleri Jinekoloji Obstetrik 2013;23(3):148-53. 17. Aboulghar M, Shoeir I, Momtaz M, El Mohammady M, Ezzat H. A comparative study of 2-dimensional sonohysterography versus 3-dimensional sonohysterography in infertile patients with uterine cavity lesions and abnormalities. Middle East Fert",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 121
  },
  {
    "chunk_id": "infertility_2106",
    "text": " A comparative study of 2-dimensional sonohysterography versus 3-dimensional sonohysterography in infertile patients with uterine cavity lesions and abnormalities. Middle East Fertil Soc J. 2011;16(1):67-71 (https://doi.org/10.1016/j. mefs.2010.12.001).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 121
  },
  {
    "chunk_id": "infertility_2107",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 98 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 18. Grimbizis GF, Di Spiezio Sardo A, Saravelos SH, Gordts S, Exacoustos C, Van Schoubroeck D et al. The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomalies. Hum Reprod. 2016;31(1):2-7 (https://doi.org/10.1093/ humrep/dev264). 19. Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103-12 (https://doi.org/10.1002/ uog.7487). 20. Good clinical diagnostic practice: a guide for clinicians in developing countries",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 122
  },
  {
    "chunk_id": "infertility_2108",
    "text": "IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103-12 (https://doi.org/10.1002/ uog.7487). 20. Good clinical diagnostic practice: a guide for clinicians in developing countries to the clinical diagnosis of disease and to making proper use of clinical diagnostic services. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/119735).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 122
  },
  {
    "chunk_id": "infertility_2109",
    "text": "995 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility due to suspected uterine cavity disorder, WHO suggests assessing the uterine cavity with saline infusion sonohysterography (SIS) rather than hysterosalpingogram (HSG). (Conditional recommendation, very low certainty of evidence) Background and rationale HSG and SIS could be potential alternatives in the investigation of the uterine cavity; the GDG agreed that a key decision when investigating women with infertility and suspected uterine pathology is whether to use SIS or HSG. HSG involves the flushing of iodinated contrast medium through the uterine cavity using a catheter or cannula, resulting in the distension of the uterine cavity, and allowing it to be visualized under fluoroscopic gui",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 123
  },
  {
    "chunk_id": "infertility_2110",
    "text": "d contrast medium through the uterine cavity using a catheter or cannula, resulting in the distension of the uterine cavity, and allowing it to be visualized under fluoroscopic guidance using an X-ray. Still radiographs are performed. HSG uses either oil- or water-soluble contrast medium ( 1). SIS is a diagnostic procedure that involves the manual installation of saline into the uterine cavity transcervically to act as a negative contrast agent and facilitate enhanced endometrial visualization during transvaginal assessment of the endometrial cavity using ultrasound ( 2, 3). The infusion of sterile isotonic fluid during transvaginal sonography into the uterine cavity facilitates uterine distension and enhanced visual contrast during real-time ultrasonographic examination ( 3, 4). SIS is also referred to as SHG. HSG and SIS are typically performed during the follicular phase of the menstr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 123
  },
  {
    "chunk_id": "infertility_2111",
    "text": "visual contrast during real-time ultrasonographic examination ( 3, 4). SIS is also referred to as SHG. HSG and SIS are typically performed during the follicular phase of the menstrual cycle before the lining becomes too thick, which may obscure any pathology, and to avoid an undiagnosed very early pregnancy. For this recommendation, the GDG addressed the question: should HSG versus SIS be used for women with infertility and suspected uterine cavity disorder? Although HSG and SIS could be used for assessment of the fallopian tubes, this recommendation focuses on their use for assessing the uterine cavity. The assessment of fallopian tubes is presented in Section 5.5 . Balancing harms and benefits Evidence from a 2015 systematic review by Seshadri et al. (5) was used. The search was then updated to search for new studies from 2014 to November 2019 and no further studies were identified. St",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 123
  },
  {
    "chunk_id": "infertility_2112",
    "text": " 2015 systematic review by Seshadri et al. (5) was used. The search was then updated to search for new studies from 2014 to November 2019 and no further studies were identified. Studies included at least 80% of women who had infertility; women were not specifically suspected of uterine cavity disorders. The studies directly compared women who were assessed with HSG and SIS, and the diagnostic accuracy of both tests reported. The reference standard was hysteroscopy with or without laparoscopy (6). Several studies ( 6–10) assessed sensitivity and specificity in identifying uterine cavity disorders as shown in the Table 5.15. Comparative data for health outcomes, such as adverse events (10) and pain (11–14) were also obtained.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 123
  },
  {
    "chunk_id": "infertility_2113",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 100 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table 5.15. Included studies comparing HSG and SIS, and conditions identified Study Sample size, n Conditions identified Acholonu et al. (7) 149 Polyps, cavitary fibroids, adhesions and septae Alatas et al. (8) 66 Endometrial polyp, uterine anomaly, submucous myoma Alborzi et al. (9) 186 Total tubal and uterine pathologies: tubal obstruction. Intracavitary pathologies: Asherman syndrome, endometrial polyps, myomatous uterus. Structural uterine anomalies: septated uterus and other structural uterine anomalies De Felice et al. (6) 104 Abnormalities of the uterine cavity Soares et al. (10) 65 Polypoid lesions, uterine malformations, intrauterine adhesions and endometrial hyperplasia Pooled se",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 124
  },
  {
    "chunk_id": "infertility_2114",
    "text": "elice et al. (6) 104 Abnormalities of the uterine cavity Soares et al. (10) 65 Polypoid lesions, uterine malformations, intrauterine adhesions and endometrial hyperplasia Pooled sensitivity and specificity estimates with 95% lower and upper CIs were calculated across the studies from the raw data extracted from the studies. Details of the extracted data are shown in the relevant EtD tables in the Web Annexes A–F. Calculations of pooled estimates used a 15% baseline risk of uterine cavity disorder in women with infertility. Table 5.16. Pooled sensitivity and specificity for HSG and SIS with 95% CIs HSG SIS Sensitivity (95% CI) 0.717 (0.555–0.837) 0.894 (0.819–0.940) Specificity (95% CI) 0.931 (0.661–0.989) 1 (0.587–1) CI, confidence interval; HSG, hysterosalpingogram; SIS, sonohysterography. In terms of beneficial effects, the results showed that there are likely two fewer true positives ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 124
  },
  {
    "chunk_id": "infertility_2115",
    "text": "587–1) CI, confidence interval; HSG, hysterosalpingogram; SIS, sonohysterography. In terms of beneficial effects, the results showed that there are likely two fewer true positives per 100 with HSG than SIS, two more false negatives per 100 with HSG than SIS, six fewer true negatives per 100 with HSG than SIS and six more false positives per 100 with HSG than SIS. Based on these data, the GDG agreed that compared to SIS, the desirable benefits of HSG compared to SIS are likely trivial given that the increase in true negatives were trivial with HSG compared to SIS. The GDG noted that the synthesized evidence combined the analysis of many uterine abnormalities, but sensitivity and specificity may differ between anomalies; however, available data are sufficient to provide discriminatory power. In terms of harms, one complication (pelvic pain) was reported with SIS and none with HSG in an RCT",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 124
  },
  {
    "chunk_id": "infertility_2116",
    "text": "omalies; however, available data are sufficient to provide discriminatory power. In terms of harms, one complication (pelvic pain) was reported with SIS and none with HSG in an RCT (10). In another RCT, mean pain scores were lower with SIS compared with HSG when assessed on a scale of 0–10 (mean scores of 2.7 versus 5.8; P <0.0001), where higher scores reflected more pain) (13). Among participants who underwent both procedures, 45 participants reported pain with SIS and 154 reported pain with HSG ( 11, 12). The GDG agreed that compared to SIS, the harms of HSG may be small because of slightly greater false negatives, more false positives and greater pain. There were no studies on patient values; however, the GDG agreed that women would value tests that can identify the diagnosis correctly and would",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 124
  },
  {
    "chunk_id": "infertility_2117",
    "text": "1015 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps seek to minimize harms, and that there is probably no important uncertainty or variability in how much people value these outcomes. Overall, the certainty of evidence was rated very low because of low evidence from diagnostic accuracy data, which also included women who were not recruited into studies on the basis of suspected uterine pathology and very low certainty with harms (such as pain). The GDG agreed that the balance of effects probably favours SIS because HSG may have slightly greater harms (greater false negatives and false positives and pain). Other considerations The GDG judged that although HSG is probably feasible, it involves moderately more resources and costs compared to SIS (e.g. fluoroscopy equipment, radiology f",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 125
  },
  {
    "chunk_id": "infertility_2118",
    "text": "Other considerations The GDG judged that although HSG is probably feasible, it involves moderately more resources and costs compared to SIS (e.g. fluoroscopy equipment, radiology facility), whereas SIS adds minimal additional resources and time to conventional ultrasonography. Given that the equipment required for SIS is more widely available, the GDG agreed that HSG could probably reduce equity, although there were no direct data on this factor. Similarly, no evidence on cost-effectiveness was identified. Nevertheless, the GDG considered that given the moderate costs of HSG, and slightly greater harms, HSG is unlikely to be as cost-effective as SIS. In terms of acceptability, the GDG considered that SIS does not use radiation and does not use iodine contrast. Based on further evidence from two studies (14, 15), the panel concluded that SIS is probably more acceptable and better tolerate",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 125
  },
  {
    "chunk_id": "infertility_2119",
    "text": "ot use radiation and does not use iodine contrast. Based on further evidence from two studies (14, 15), the panel concluded that SIS is probably more acceptable and better tolerated by patients compared to HSG. Summary justification There was very low certainty evidence that the balance of desirable and undesirable effects probably favours SIS over HSG in women who have infertility and suspected uterine cavity disorder. Although HSG is probably feasible, it requires moderate resources related to the need for a radiological unit. SIS is cheaper and probably more acceptable to patients compared to HSG. Given the cost and resource requirements, HSG may probably reduce equity. Implementation considerations Health care providers require training to ensure they have the skills and experience to safely evaluate the uterine cavity using SIS. Health care providers should monitor patients for pain",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 125
  },
  {
    "chunk_id": "infertility_2120",
    "text": "are providers require training to ensure they have the skills and experience to safely evaluate the uterine cavity using SIS. Health care providers should monitor patients for pain, discomfort and other adverse effects and consider analgesics as appropriate. Health care providers should be aware and observe general contraindications for this procedure (e.g. women who are pregnant or who could be pregnant). Research gaps and future guideline updates Current evidence is insufficient to provide sufficient data to separately assess diagnostic accuracy for separate subgroups of uterine cavity pathology, such as polyps, fibroids, adhesions and congenital uterine malformations. Future larger studies are required to circumvent the current lack of statistical power, which limits recommendations to specific subgroups. Further guidance will be needed on whether prophylactic antibiotics should be us",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 125
  },
  {
    "chunk_id": "infertility_2121",
    "text": "rcumvent the current lack of statistical power, which limits recommendations to specific subgroups. Further guidance will be needed on whether prophylactic antibiotics should be used during SIS procedures.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 125
  },
  {
    "chunk_id": "infertility_2122",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 102 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Dreyer K, van Rijswijk J, Mijatovic V, Goddijn M, Verhoeve HR, van Rooij IAJ et al. Oil-based or water-based contrast for hysterosalpingography in infertile women. N Engl J Med. 2017;376(21):2043-52 (https://doi.org/10.1056/ NEJMoa1612337). 2. Syrop CH, Sahakian V. Transvaginal sonographic detection of endometrial polyps with fluid contrast augmentation. Obstet Gynecol. 1992;79(6):1041-3. 3. Parsons AK, Lense JJ. Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound. 1993;21(2):87-95 (https://doi. org/10.1002/jcu.1870210203). 4. Bonilla‐Musoles F, Simón C, Serra V, Sampaio M, Pellicer A. An assessment of hysterosalpingosonography (HSSG) as a ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 126
  },
  {
    "chunk_id": "infertility_2123",
    "text": ". 1993;21(2):87-95 (https://doi. org/10.1002/jcu.1870210203). 4. Bonilla‐Musoles F, Simón C, Serra V, Sampaio M, Pellicer A. An assessment of hysterosalpingosonography (HSSG) as a diagnostic tool for uterine cavity defects and tubal patency. J Clin Ultrasound. 1992;20(3):175- 81 (https://doi.org/10.1002/jcu.1870200303). 5. Seshadri S, El-Toukhy T, Douiri A, Jayaprakasan K, Khalaf Y. Diagnostic accuracy of saline infusion sonography in the evaluation of uterine cavity abnormalities prior to assisted reproductive techniques: a systematic review and meta- analyses. Hum Reprod Update. 2015;21(2):262-74 (https://doi.org/10.1093/humupd/dmu057). 6. De Felice C, Porfiri LM, Savelli S, Alfano G, Pace S, Manganaro L et al. Infertility in women: combined sonohysterography and hysterosalpingography in the evaluation of the uterine cavity. Ultraschall Med. 2009;30(1):52-7 (https://doi.org/10.1055/s-2",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 126
  },
  {
    "chunk_id": "infertility_2124",
    "text": "l. Infertility in women: combined sonohysterography and hysterosalpingography in the evaluation of the uterine cavity. Ultraschall Med. 2009;30(1):52-7 (https://doi.org/10.1055/s-2008-1027728). 7. Acholonu UC, Silberzweig J, Stein DE, Keltz M. Hysterosalpingography versus sonohysterography for intrauterine abnormalities. JSLS. 2011;15(4):471-4 (https://doi. org/10.4293/108680811x13176785203923). 8. Alatas C, Aksoy E, Akarsu C, Yakin K, Aksoy S, Hayran M. Evaluation of intrauterine abnormalities in infertile patients by sonohysterography. Hum Reprod. 1997;12(3):487-90 (https://doi.org/10.1093/ humrep/12.3.487). 9. Alborzi S, Dehbashi S, Khodaee R. Sonohysterosalpingographic screening for infertile patients. Int J Gynaecol Obstet. 2003;82(1):57-62 (https://doi.org/10.1016/s0020- 7292(02)00417-4). 10. Soares SR, Barbosa dos Reis MM, Camargos AF . Diagnostic accuracy of sonohysterography, tr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 126
  },
  {
    "chunk_id": "infertility_2125",
    "text": "J Gynaecol Obstet. 2003;82(1):57-62 (https://doi.org/10.1016/s0020- 7292(02)00417-4). 10. Soares SR, Barbosa dos Reis MM, Camargos AF . Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril. 2000;73(2):406-11 (https://doi.org/10.1016/s0015-0282(99)00532-4). 11. Aremu A, Adetiloye V, Famurewa O, Ibitoye B, Ayoola O, Alao O. Saline contrast sonohysterography findings in Nigerian patients with infertility. Res J Med Sci. 2008;2(3):133-6. 12. Aremu A, Adetiloye A, Ibitoye B, Adekanle D, Bello T. Transabdominal saline contrast sonohysterography: can it replace hysterosalpingography in low resource countries. J Clinic Diagno Res. 2012;6:239-42. 13. Brown SE, Coddington CC, Schnorr J, Toner JP , Gibbons W, Oehninger S. Evaluation of outpatient hysteroscopy, saline infusion hysterosonography, and hyste",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 126
  },
  {
    "chunk_id": "infertility_2126",
    "text": "o Res. 2012;6:239-42. 13. Brown SE, Coddington CC, Schnorr J, Toner JP , Gibbons W, Oehninger S. Evaluation of outpatient hysteroscopy, saline infusion hysterosonography, and hysterosalpingography in infertile women: a prospective, randomized study. Fertil Steril. 2000;74(5):1029-34 (https:// doi.org/10.1016/s0015-0282(00)01541-7). 14. Izhar R, Mansuri FA, Armar NA, Tahir S. Diagnostic accuracy of saline infusion sonohystero-salpingography (SIS) as compared to hystero-salpingography (HSG) in the assessment of sub-fertile women. J Pak Med Assoc. 2019;69(6):777-82. 15. Rezk M, Shawky M. The safety and acceptability of saline infusion sonography versus hysterosalpingography for evaluation of tubal patency in infertile women. Middle East Fertil Soc J. 2015;20(2):108-13 (https://doi.org/10.1016/j. mefs.2014.06.003).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 126
  },
  {
    "chunk_id": "infertility_2127",
    "text": "1035 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility who are suspected to have a uterine cavity disorder, WHO suggests assessing the uterine cavity with either two-dimensional ultrasound (2D US) or hysterosalpingogram (HSG). (Conditional recommendation, very low certainty of evidence) Remark: • Health care providers may choose to use 2D US rather than HSG when resources are limited. Follow-up would be required for women who are negative on 2D US but still suspected of uterine cavity disorder because of high rates of false negatives. Background and rationale Ultrasound imaging (sonography) involves the generation and transmission of ultrasonic (high- frequency sound) waves from a transducer and processing of a returning echo to generate an i",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 127
  },
  {
    "chunk_id": "infertility_2128",
    "text": "ound imaging (sonography) involves the generation and transmission of ultrasonic (high- frequency sound) waves from a transducer and processing of a returning echo to generate an image. It is based on non-ionizing energy ( 1). The image is subsequently displayed on a monitor, from which a hard copy may be captured, for example, using thermal printing paper ( 1). Although ultrasound examination of the myometrium may be performed using a transabdominal, transvaginal or more rarely transrectal approach, the transvaginal approach (2, 3) is more commonly used for assessing uterine abnormalities ( 2–4). 2D US is the use of ultrasonic data to display the acquired information in two dimensions, B-scan ( 1). HSG involves the flushing of iodinated contrast medium through the uterine cavity (and fallopian tubes) using a transcervical catheter or cannula, resulting in the distension of the uterine c",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 127
  },
  {
    "chunk_id": "infertility_2129",
    "text": "s the flushing of iodinated contrast medium through the uterine cavity (and fallopian tubes) using a transcervical catheter or cannula, resulting in the distension of the uterine cavity, and allowing it to be visualized under fluoroscopic guidance using an X-ray. Still radiographs are performed. HSG uses either oil- or water-soluble contrast medium (5). The GDG agreed that guidance on whether to use 2D US or HSG is needed, particularly in settings where 3D US or SIS are not available. Therefore, in this recommendation, the GDG addressed the question: should 2D US versus HSG be used for women with infertility and suspected uterine cavity abnormality? Balancing harms and benefits A de novo search was conducted to identify DTA studies on 2D US and HSG up to November 2019. Studies included at least 80% of women who had infertility (women were not specifically suspected to have uterine cavity",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 127
  },
  {
    "chunk_id": "infertility_2130",
    "text": " identify DTA studies on 2D US and HSG up to November 2019. Studies included at least 80% of women who had infertility (women were not specifically suspected to have uterine cavity disorders). Women received both 2D US and HSG and their results were compared to the reference standard of hysteroscopy. We found two comparative studies ( 6, 7) with useful data that could be pooled, and another study ( 8) from which data could not be pooled because of how the data were reported. The first two of these studies assessed sensitivity and specificity to diagnose the uterine cavity disorders shown in Table 5.17.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 127
  },
  {
    "chunk_id": "infertility_2131",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 104 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table 5.17. Included studies comparing 2D US and HSG, and conditions identified Study Condition identified Alatas et al. (6) Endometrial polyp, uterine anomaly, submucous myoma Soares et al. (7) Polypoid lesions, uterine malformations, intrauterine adhesions and endometrial hyp erplasia We calculated sensitivity and specificity based on paired studies as shown in Table 5.18 . Table 5.18. Pooled sensitivity and specificity for 2D US and HSG, with 95% CIs from paired studies 2D US HSG Sensitivity (95% CI) 40% (21–62%) 60% (38–79%) Specificity (95% CI) 100% (0–100%) 98% (93–100%) 2D, two-dimensional; CI, confidence interval; HSG, hysterosalpingogram; US, ultrasound. Calculations for the absol",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 128
  },
  {
    "chunk_id": "infertility_2132",
    "text": "2%) 60% (38–79%) Specificity (95% CI) 100% (0–100%) 98% (93–100%) 2D, two-dimensional; CI, confidence interval; HSG, hysterosalpingogram; US, ultrasound. Calculations for the absolute effects on true and false negatives and positives were based on a 15% prevalence of uterine cavity disorders in women with infertility. Results showed that there may be three fewer true positives with 2D US, three more false negatives with 2D US, two more true negatives with 2D US and two fewer false positives with 2D US. Based on these data, the GDG agreed that the benefits of 2D US are trivial in correctly identifying uterine cavity pathologies; there were two fewer false positives with 2D US (incorrect diagnosis of uterine cavity disorder). The GDG agreed that there may be more harm (three more false negatives) with 2D US but that this difference was trivial. Data on adverse effects were not reported in ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 128
  },
  {
    "chunk_id": "infertility_2133",
    "text": "ty disorder). The GDG agreed that there may be more harm (three more false negatives) with 2D US but that this difference was trivial. Data on adverse effects were not reported in the studies included. The GDG noted that the synthesized evidence combined the analysis of many uterine abnormalities, but sensitivity and specificity may differ between anomalies; however, available data are insufficient to provide discriminatory power. There were no studies on patient values; however, the GDG agreed that women would value tests that can identify the diagnosis correctly and would seek to minimize harms, and that there was probably no uncertainty or variability on how people value these outcomes. The GDG agreed that the balance of effects does not favour either 2D US or HSG. Certainty of evidence was judged as very low because there was a lack of evidence for adverse events. Other consideration",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 128
  },
  {
    "chunk_id": "infertility_2134",
    "text": "he balance of effects does not favour either 2D US or HSG. Certainty of evidence was judged as very low because there was a lack of evidence for adverse events. Other considerations Although comparative data about costs were not available, the guideline panel agreed that 2D US is less costly than HSG and could lead to moderate savings. There was no direct evidence on cost- effectiveness; however, given that HSG has increased costs, the GDG agreed that cost-effectiveness probably favours 2D US. In addition, the GDG agreed that 2D US could probably increase equity as it requires fewer resources and is more widely available compared to HSG. Although no data were available, the GDG judged that 2D US is probably acceptable. The GDG considered the available analysis on feasibility from one study (9) and agreed that 2D US is probably feasible to perform. HSG requires a radiography unit and trai",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 128
  },
  {
    "chunk_id": "infertility_2135",
    "text": "eptable. The GDG considered the available analysis on feasibility from one study (9) and agreed that 2D US is probably feasible to perform. HSG requires a radiography unit and training, but it is widely available and it is also feasible.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 128
  },
  {
    "chunk_id": "infertility_2136",
    "text": "1055 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification There is very low certainty in the evidence that the balance of effects does not favour either HSG or 2D US. However, there are slightly more false negatives with 2D US that may necessitate following up. Both 2D US and HSG are probably feasible and acceptable, but 2D US likely requires fewer resources, and may be the preferred option in low-resource settings. Implementation considerations Training is required to ensure that health care providers have the skills to safely and correctly assess, document and report US and HSG findings while evaluating the uterus (4, 10–12). Research gaps and future guideline updates Because of the lack of large studies on each uterine anomaly, the synthesized evidence combined th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 129
  },
  {
    "chunk_id": "infertility_2137",
    "text": "hile evaluating the uterus (4, 10–12). Research gaps and future guideline updates Because of the lack of large studies on each uterine anomaly, the synthesized evidence combined the analysis of data related to many uterine abnormalities. Future large studies are required to provide sufficient discriminatory power. Future guidance is required to compare the role of colour, power and spectral Doppler, as well as 4D ultrasonography. References 1. Tole N. Basic physics of ultrasonic imaging. In: Ostensen H, editor. Basic physics of ultrasonic imaging. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/43179). 2. Manual of diagnostic ultrasound. Vol. 2, second edition. Geneva: World Health Organization; 2013 (https://iris.who.int/handle/10665/85386). 3. Manual of diagnostic ultrasound. Vol. 1, second edition. Geneva: World Health Organization; 2011 (https://iris.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 129
  },
  {
    "chunk_id": "infertility_2138",
    "text": "lth Organization; 2013 (https://iris.who.int/handle/10665/85386). 3. Manual of diagnostic ultrasound. Vol. 1, second edition. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/43881). 4. Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284-98 (https://doi.org/10.1002/ uog.14806). 5. Dreyer K, van Rijswijk J, Mijatovic V, Goddijn M, Verhoeve HR, van Rooij IAJ et al. Oil-based or water-based contrast for hysterosalpingography in infertile women. N Engl J Med. 2017;376(21):2043-52 (https://doi.org/10.1056/ NEJMoa1612337). 6. Alatas C, Aksoy E, Akarsu C, Yakin K, Aksoy S, Hayran M. Evaluation of intrauterine abno",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 129
  },
  {
    "chunk_id": "infertility_2139",
    "text": "tile women. N Engl J Med. 2017;376(21):2043-52 (https://doi.org/10.1056/ NEJMoa1612337). 6. Alatas C, Aksoy E, Akarsu C, Yakin K, Aksoy S, Hayran M. Evaluation of intrauterine abnormalities in infertile patients by sonohysterography. Hum Reprod. 1997;12(3):487-90 (https://doi.org/10.1093/ humrep/12.3.487). 7. Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril. 2000;73(2):406-11 (https://doi.org/10.1016/s0015-0282(99)00532-4). 8. Vahdat M, Sariri E, Kashanian M, Najmi Z, Mobasseri A, Marashi M et al. Can combination of hysterosalpingography and ultrasound replace hysteroscopy in diagnosis of uterine malformations in infertile women? Med J Islam Repub Iran. 2016;30:352.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 129
  },
  {
    "chunk_id": "infertility_2140",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 106 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 9. Grimbizis GF, Di Spiezio Sardo A, Saravelos SH, Gordts S, Exacoustos C, Van Schoubroeck D et al. The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomalies. Hum Reprod. 2016;31(1):2-7 (https://doi.org/10.1093/ humrep/dev264). 10. Good clinical diagnostic practice: a guide for clinicians in developing countries to the clinical diagnosis of disease and to making proper use of clinical diagnostic services. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/ handle/10665/119735). 11. Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and in",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 130
  },
  {
    "chunk_id": "infertility_2141",
    "text": ". 11. Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103-12 (https://doi.org/10.1002/ uog.7487). 12. Barnett S. Safety of diagnostic ultrasound. In: Buscarini E, Lutz H, Mirk P, editors. Manual of diagnostic ultrasound, second edition. Geneva: World Health Organization; 2013 (https://iris.who. int/handle/10665/85386).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 130
  },
  {
    "chunk_id": "infertility_2142",
    "text": "1075 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5.7 Diagnosis of infertility due to male factors This section contains recommendations related to the diagnosis of infertility due to male factors, and referral pathways for further evaluation. Figure 5.3 illustrates this in a diagnostic algorithm. Recommendation For males (in couples with infertility) with one or more semen parameters outside the WHO reference ranges, WHO suggests repeating the semen analysis after a minimum of 11 weeks. (Conditional recommendation, very low certainty of evidence) For males (in couples with infertility) with all semen parameters within the WHO reference ranges, WHO suggests not repeating the semen analysis. (Conditional recommendation, very low certainty of evidence) Remark: • The latest edition o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 131
  },
  {
    "chunk_id": "infertility_2143",
    "text": "rameters within the WHO reference ranges, WHO suggests not repeating the semen analysis. (Conditional recommendation, very low certainty of evidence) Remark: • The latest edition of the WHO laboratory manual for the examination and processing of human semen provides WHO reference ranges for semen parameters and details about the standardized procedures for semen collection and analysis. Background and rationale According to the largest multi-country study to date, involving 8500 couples in 25 countries, male factors contribute wholly or in part to 45.1% of infertility cases ( 1) (see Annex 1. Distribution of the causes of infertility ). Therefore, investigation of the male partner is essential in the diagnosis and treatment of infertility (see Fig. 5.3 Diagnostic algorithm for male-factor infertility ). A semen analysis, as outlined in the WHO laboratory manual for the examination and pr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 131
  },
  {
    "chunk_id": "infertility_2144",
    "text": "and treatment of infertility (see Fig. 5.3 Diagnostic algorithm for male-factor infertility ). A semen analysis, as outlined in the WHO laboratory manual for the examination and processing of human semen is recommended for assessing male fertility (2). Notably, semen parameters per se are not a reliable diagnostic indicator of fertility status as shown by several studies ( 3–5). However, when combined with a thorough history and physical examination (6), a basic semen analysis provides valuable information about the male reproductive function. Semen parameters may fall within or outside the reference ranges provided in the WHO laboratory manual for the examination and processing of human semen (2). Spermatogenesis is a biological process ( 7), which displays intraindividual variability of semen parameters in healthy ( 8, 9) and infertile men (10). Given this intraindividual variability, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 131
  },
  {
    "chunk_id": "infertility_2145",
    "text": "sis is a biological process ( 7), which displays intraindividual variability of semen parameters in healthy ( 8, 9) and infertile men (10). Given this intraindividual variability, the WHO laboratory manual for the examination and processing of human semen (2) indicates that “to define an exact baseline of an individual, it may be necessary to examine two or three ejaculates”, citing several studies ( 9, 11–14). Concerns with conducting one test or repeating a test are related to one of two risks: (i) unnecessarily referring men who do not need to be referred for further investigation; or (ii) failing to identify men with infertility who need to be investigated further, leading to underdiagnosis of male factors and delay in treatment.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 131
  },
  {
    "chunk_id": "infertility_2146",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 108 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. 5.3. Diagnostic algorithm for male-factor infertility Any relevant abnormality (see panel) Manage female infertilityh Male in an infertile couple Semen parameters outside the WHO reference rangesb Repeat semen analysis Semen parameters outside the WHO reference ranges Semen parameters within the WHO reference ranges Evaluate the female partnerf Semen parameters within the WHO reference ranges History Components 1 Medical history • Age • Systemic diseases (e.g. diabetes, cirrhosis, hypertension) • Sexually transmitted diseases, tuberculosis, viral infections, genital and systemic bacterial infections, history of fever, respiratory infection, anosmia • Cancers (e.g. testicular cancer, l",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 132
  },
  {
    "chunk_id": "infertility_2147",
    "text": "ansmitted diseases, tuberculosis, viral infections, genital and systemic bacterial infections, history of fever, respiratory infection, anosmia • Cancers (e.g. testicular cancer, lymphoma, leukaemia) • Galactorrhoea, visual disturbances 2 Reproductive history • Age of partner, length of time attempting to conceive • Contraceptive methods and duration • Previous pregnancy or miscarriage (current partner or another partner) • Previous treatments • Treatments or evaluations of female partner 3 Sexual history • Potency, libido, lubricant use • Orgasm, ejaculation, timed intercourse, frequency of sex or masturbation 4 Childhood and development • Cryptorchidism, hernia, testicular trauma, testicular torsion, infection (e.g. mumps) • Sexual development, puberty onset 5 Previous surgery or treatment • Orchidopexy, herniorrhaphy, orchiectomy (e.g. testicular cancer, torsion) • Retroperitoneal and",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 132
  },
  {
    "chunk_id": "infertility_2148",
    "text": "n (e.g. mumps) • Sexual development, puberty onset 5 Previous surgery or treatment • Orchidopexy, herniorrhaphy, orchiectomy (e.g. testicular cancer, torsion) • Retroperitoneal and pelvic surgery (e.g. prostatectomy) • Other inguinal, scrotal or perineal surgery • Bariatric surgery, bladder neck sur gery, transurethral resection of the prostate 6 Family history • Cystic fibrosis, endocrine diseases • Infertility in the family 7 Gonadotoxin exposure • Endocrine-disrupting chemicals (e.g. phthalates, bisphenol A, some pesticides among others) • Some medication (e.g. chemotherapy agents) • Some organic solvents, heavy metals • High temperatures, ionizing r adiation (e.g. high doses above recommended therapeutic or occupational levels) 8 Current health status/lifestyle • Obesity/diet, metabolic syndrome • Anabolic steroids, tobacco smoking, alcohol Physical exam Components 1 Overall body cha",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 132
  },
  {
    "chunk_id": "infertility_2149",
    "text": " occupational levels) 8 Current health status/lifestyle • Obesity/diet, metabolic syndrome • Anabolic steroids, tobacco smoking, alcohol Physical exam Components 1 Overall body characteristics • Poor virilization, gynaecomastia • Obesity, body mass index (BMI) 2 Inguinal and genital areas • Scar 3 Penis • Hypospadias, epispadias, phimosis, curvature 4 Testes • Location, size, consistency, pain/nodules/tenderness 5 Ductal structures (vas, epididymis) • Present/absent • Normal/signs of obstruction or inflammation 6 Spermatic cord/scrotum • Varicocele, hydrocele, cysts Refer to male infertility specialistg Manage as unexplained infertilityi Normal? No or N/A No Yes Contributing factor or condition resolved? (see panel) Yes a See the WHO laboratory manual for the examination and processing of human semen (sixth or latest edition). b Consider post-ejaculate urinalysis to rule out retrogr ade ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 132
  },
  {
    "chunk_id": "infertility_2150",
    "text": "anel) Yes a See the WHO laboratory manual for the examination and processing of human semen (sixth or latest edition). b Consider post-ejaculate urinalysis to rule out retrogr ade ejaculation if low (or no) semen ejaculate volume; see WHO laboratory manual for the examination and processing of human semen (sixth or latest edition). c See Chapter 4 of this guideline, for details on information provision. d Evaluation should include PE and SA regardless of history findings; see Chapter 3. e See Chapter 4, and the WHO guidelines for the management of sexually transmitted infections. f Female evaluation is essential and should proceed regardless of semen analysis outcome; see Chapter 5 for the evaluation of the female. g Health care provider with appropriate qualifications, for example, urologist, clinical andrologist or reproductive medicine specialist with relevant qualifications. h See Ch",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 132
  },
  {
    "chunk_id": "infertility_2151",
    "text": "ale. g Health care provider with appropriate qualifications, for example, urologist, clinical andrologist or reproductive medicine specialist with relevant qualifications. h See Chapters 6, 7 and 8. i See Section 5.8 and Chapter 10. N/A, not applicable; PE, physical examination; SA, semen analysis; WHO, World Health Organization. Any relevant abnormality (see panel) Provide advicec and continue evaluation as clinically indicated (see PE and SA)d Provide specific treatment if signs of genital infectione Medical, reproductive and sexual history Focused physical examination WHO basic semen analysisa Guideline for the prevention, diagnosis and treatment of infertility 108 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 132
  },
  {
    "chunk_id": "infertility_2152",
    "text": "1095 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps In this context, the GDG agreed that there was a need to provide guidance regarding whether two consecutive samples are necessary for all males who are being investigated for infertility by the initial evaluating health care provider. For this recommendation, the GDG addressed the question: should the initial semen analysis be repeated in a male in a couple with infertility? Balancing harms and benefits Within-individual variability of semen analysis A review of the literature published in the WHO laboratory manual for the examination and processing of human semen and in other guidelines published over the last five years up to September 2023 was conducted. The search found three studies that evaluated the within-individual variabi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 133
  },
  {
    "chunk_id": "infertility_2153",
    "text": "man semen and in other guidelines published over the last five years up to September 2023 was conducted. The search found three studies that evaluated the within-individual variability of semen analysis: Blickenstorfer et al. (15), Boeri et al. (16) and Chiu et al. (17). These studies included men who had a repeat analysis within 3 months or later. The studies reported that in men who had: • normozoospermia on the first semen analysis, 27% had pathological results on the second semen analysis (15); • normozoospermia on the first semen analysis, 60% had pathological results on the second semen analysis (16); • normozoospermia on the first semen analysis, 51% had pathological results on the second analysis (17); • pathological results on the first semen analysis, 23% had normozoospermia on the second semen analysis (15); • pathological results on the first semen analysis, 8.5% had normozoo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 133
  },
  {
    "chunk_id": "infertility_2154",
    "text": "• pathological results on the first semen analysis, 23% had normozoospermia on the second semen analysis (15); • pathological results on the first semen analysis, 8.5% had normozoospermia on the second semen analysis (17). The 2010 WHO laboratory manual for the examination and processing of human semen reported that it may be necessary to test two or three ejaculates based on four studies reporting variability in results ( 9, 11–14). The sixth edition of the WHO laboratory manual for the examination and processing of human semen, published in 2021 (2), states that it may be necessary to examine two or three ejaculates to establish a true baseline for an individual. Variation in semen parameters The sixth edition of the WHO laboratory manual for the examination and processing of human semen also reported that semen analysis results can be affected by ejaculate characteristics that depend ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 133
  },
  {
    "chunk_id": "infertility_2155",
    "text": "n of the WHO laboratory manual for the examination and processing of human semen also reported that semen analysis results can be affected by ejaculate characteristics that depend on the following: (i) whether a complete sample is collected; (ii) activity of the accessory sex glands; (iii) time between ejaculates or abstinence or abstention time; (iv) testicle size; (v) endocrine status; (vi) medications (e.g. antihypertensives, antidepressants); (vii) supplements and nonprescribed medications; and (viii) recent (particularly febrile) illness. Timing of semen analysis Spermatogenesis is a complex process involving distinct phases, such as proliferation, meiosis and spermiogenesis, and each phase has its specific duration (18, 19). Spermatogenesis was initially thought to take 64 days ( 7). However, further empirical evidence showed that it takes approximately 74 days, which is equivalent",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 133
  },
  {
    "chunk_id": "infertility_2156",
    "text": "c duration (18, 19). Spermatogenesis was initially thought to take 64 days ( 7). However, further empirical evidence showed that it takes approximately 74 days, which is equivalent to four and a half cycles of the seminiferous epithelium (20), with some likely variability of up to 74 ± 2 days (4.6 cycles) (21). There are still ongoing uncertainties, as suggested by some studies (22, 23). For instance, in an in vivo study (n = 11) that used stable isotope labelling of sperm DNA followed by gas chromatography and mass spectrometry analyses, Misell et al. ( 23) reported that the duration of spermatogenesis, that is, the duration it took to detect labelled sperm, was an average ± standard deviation (SD) of 64 ± 8 days (range: 42–76 days). Other outcomes Other outcomes, such as quality of life, including fear, worry or other psychosocial and psychological impacts, and accuracy and downstream ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 133
  },
  {
    "chunk_id": "infertility_2157",
    "text": "ays (range: 42–76 days). Other outcomes Other outcomes, such as quality of life, including fear, worry or other psychosocial and psychological impacts, and accuracy and downstream consequences of diagnosis were not reported in studies.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 133
  },
  {
    "chunk_id": "infertility_2158",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 110 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Based on this summary of evidence, the GDG agreed that the results of semen analysis may not always be consistent between a first and second (repeat) test. The GDG also agreed that semen parameters outside the WHO reference ranges could be a reflection of the true baseline of an individual or could be due to transient factors not related to infertility (e.g. incomplete sample taken, a febrile illness or intraindividual biological variability). In terms of the benefits of repeating a semen analysis, the GDG agreed that when the first semen analysis results are outside the WHO reference ranges, the benefits of a repeat analysis may be moderate by ruling out a “diagnosis” of male infertility ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 134
  },
  {
    "chunk_id": "infertility_2159",
    "text": " that when the first semen analysis results are outside the WHO reference ranges, the benefits of a repeat analysis may be moderate by ruling out a “diagnosis” of male infertility (in cases where the second test results are within the reference ranges) as it would avoid unnecessary fear or the psychological impact associated with an “abnormal” semen analysis result, and also reduce the risk of an unnecessary referral to infertility specialists. The GDG agreed that when the results of the first semen analysis are within the WHO reference range, the benefits of a repeat analysis may be trivial. This is because diagnosis is based not only on semen analysis but also on complete history-taking and a physical examination. The GDG agreed that the maximum benefit of a repeat test is after a minimum of 11 weeks, aligning with the duration for spermatogenesis. In terms of the harms of repeating a ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 134
  },
  {
    "chunk_id": "infertility_2160",
    "text": "tion. The GDG agreed that the maximum benefit of a repeat test is after a minimum of 11 weeks, aligning with the duration for spermatogenesis. In terms of the harms of repeating a semen analysis, the GDG agreed that when the first analysis is outside the reference ranges, there are no adverse events that would arise from a repeat semen analysis. The GDG agreed that when the results of the first semen analysis are within the WHO reference range, small harms may occur if the second test is outside the reference ranges, which may be due to factors not related to infertility and occurs in many individuals, and may result in unnecessary and high referral rates; it may also cause unnecessary fear or have a psychological impact (false positive). Although some cases may be missed by not doing a repeat test (false negative), the risk of not identifying men with infertility is likely low as the di",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 134
  },
  {
    "chunk_id": "infertility_2161",
    "text": "cal impact (false positive). Although some cases may be missed by not doing a repeat test (false negative), the risk of not identifying men with infertility is likely low as the diagnosis is based not only on the semen analysis but also on comprehensive medical history and physical examination. Additionally, if after investigation of the female partner a couple is infertile (e.g. because of unexplained infertility), additional assessment of sperm will most likely be conducted during the course of treatment. The GDG considered the values of patients; in the absence of specific studies on these, the GDG agreed that men would value confirmation of results that are outside the WHO reference ranges before referral to an infertility specialist. The GDG placed a greater weight on reducing false positives in this PICO because of the downstream consequences, including referrals to specialists and",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 134
  },
  {
    "chunk_id": "infertility_2162",
    "text": "o an infertility specialist. The GDG placed a greater weight on reducing false positives in this PICO because of the downstream consequences, including referrals to specialists and associated costs. Considering all of the judgements, the GDG concluded that the balance of effects favours a repeat test when the first analysis is outside the WHO reference ranges, and that the balance of effects favours NO repeat test when the first analysis is within the WHO reference ranges. Overall, the certainty of evidence was very low because of a lack of evidence for important patient outcomes. Other considerations The GDG considered resource requirements and judged that although there are costs with performing any test, the costs of a semen analysis are negligible. The cost of performing one additional repeat test is also negligible. The GDG agreed that for men whose semen parameters are outside the ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 134
  },
  {
    "chunk_id": "infertility_2163",
    "text": " costs of a semen analysis are negligible. The cost of performing one additional repeat test is also negligible. The GDG agreed that for men whose semen parameters are outside the WHO reference ranges, repeating the test would result in negligible costs and moderate benefits because referral rates are reduced, meaning it is cost-effective; therefore, repeating the test is favoured. However, for men whose parameters are within the WHO reference ranges, even though the costs of testing are negligible, sending men to an infertility specialist based on an abnormal repeat test may result in moderate harms, meaning that repeating the test in this scenario is not cost-effective; therefore, not repeating the test is probably favoured.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 134
  },
  {
    "chunk_id": "infertility_2164",
    "text": "1115 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps The GDG agreed that although there are no direct data on equity, there is potential for inequity in men’s access to and use of infertility testing. However, semen tests are widely available; therefore, requiring a repeat test may not have an impact on equity. There was no evidence identified on acceptability of repeat semen analysis among health providers or patients. However, the GDG agreed that the initial evaluating health care provider would find it acceptable to perform a repeat test in men with results outside the WHO reference ranges before referral, and not to repeat it in men with results within the WHO reference ranges. Both physicians and men would likely find it acceptable to avoid referrals and unnecessary additional t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 135
  },
  {
    "chunk_id": "infertility_2165",
    "text": "l, and not to repeat it in men with results within the WHO reference ranges. Both physicians and men would likely find it acceptable to avoid referrals and unnecessary additional testing. Similarly, there were no identified studies on the feasibility of repeat semen analysis. However, the GDG agreed that performing repeat tests is feasible. The GDG also considered that male infertility specialists (e.g. urologist or clinical andrologist) are often not widely available, and agreed that increasing referral to male infertility specialists may not be feasible in many countries. Summary justification There was very-low-certainty evidence for the benefits and harms of repeating or not repeating semen analysis. Evidence suggests that when a semen analysis test is conducted twice, the semen parameter results may not always be consistent between the first and second test. Evidence also suggests t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 135
  },
  {
    "chunk_id": "infertility_2166",
    "text": "ce suggests that when a semen analysis test is conducted twice, the semen parameter results may not always be consistent between the first and second test. Evidence also suggests that semen parameters outside the WHO reference ranges could be a reflection of the true baseline of an individual or could be due to transient factors not related to infertility (e.g. incomplete sample taken, a febrile illness or intraindividual biological variability). The GDG agreed that when a first test reports semen parameters outside the WHO reference ranges and a repeat test is not conducted and the man is sent for investigation, there is a concern that too many men will be sent for further investigation who did not need to because the results were likely due to transient factors unrelated to infertility (e.g. incomplete sample taken, a febrile illness or intraindividual biological variability). A repeat",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 135
  },
  {
    "chunk_id": "infertility_2167",
    "text": "ause the results were likely due to transient factors unrelated to infertility (e.g. incomplete sample taken, a febrile illness or intraindividual biological variability). A repeat test would minimize the effect of transient factors unrelated to infertility and confirm that parameters are outside the WHO references ranges and are likely related to infertility; therefore, men with two tests reporting parameters that are outside the WHO references ranges would be appropriately sent for further investigation by male infertility specialists.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 135
  },
  {
    "chunk_id": "infertility_2168",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 112 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps When the first test (performed in accordance with the standardized procedures outlined in the WHO laboratory manual for the examination and processing of human semen) reports semen parameters outside the WHO reference ranges and the repeat test shows parameters within the WHO reference ranges, a possible explanation is that the first test was likely outside the WHO reference ranges because of transient factors unrelated to infertility, and the man would not need further investigation or referral to a male infertility specialist. If these men are not investigated or referred to a male infertility specialist, the risk of not identifying men with infertility due to male factors is likely low ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 136
  },
  {
    "chunk_id": "infertility_2169",
    "text": "lity specialist. If these men are not investigated or referred to a male infertility specialist, the risk of not identifying men with infertility due to male factors is likely low because the diagnosis is based not only on semen analysis but also on comprehensive medical history and physical examination. If after investigation of the female partner a couple is infertile (e.g. because of unexplained factors), additional assessment of sperm will most likely be conducted during treatment; therefore, these men will likely be retested and will not be missed. Therefore, the GDG agreed that a repeat test may be conducted if one or more parameters are outside the WHO reference ranges because repeating the semen analysis could reduce unnecessary referral rates and could reduce the negative psychological impact and fear in men and couples associated with a test outside the WHO ranges; the test is ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 136
  },
  {
    "chunk_id": "infertility_2170",
    "text": "s could reduce unnecessary referral rates and could reduce the negative psychological impact and fear in men and couples associated with a test outside the WHO ranges; the test is low-cost and probably acceptable and feasible. The GDG also agreed that given that the minimum duration of spermatogenesis is approximately 11 weeks, repeating the test should align with this time period. If all semen parameters are within the WHO reference ranges and a repeat test is not performed, the risk of not identifying men with infertility is likely low because if after investigation of the female partner a couple is infertile (e.g. because of unexplained infertility), additional assessment of sperm will most likely be conducted during treatment. In addition, if a repeat test is conducted and the parameters are outside the WHO reference ranges, then some men would have been sent for further testing with",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 136
  },
  {
    "chunk_id": "infertility_2171",
    "text": "ed during treatment. In addition, if a repeat test is conducted and the parameters are outside the WHO reference ranges, then some men would have been sent for further testing without need as the parameters could be outside the reference ranges because of transient factors unrelated to infertility. Therefore, the GDG agreed to not repeating the test when a first test is within the WHO reference ranges to reduce unnecessary referral and associated costs and burden, and also agreed that not performing a repeat test is probably acceptable. Implementation considerations Health care providers should note that semen analysis provides partial information related to fertility potential, and that reference range thresholds do not entirely distinguish between fertile and infertile males. This and other limitations may contribute to the shifting of the burden of infertility investigation and manage",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 136
  },
  {
    "chunk_id": "infertility_2172",
    "text": "lds do not entirely distinguish between fertile and infertile males. This and other limitations may contribute to the shifting of the burden of infertility investigation and management to the female partner ( 24), despite male factors contributing wholly or in part to 45.1% of infertility cases (1, 25). In addition, although the odds of a man being infertile increase when more parameters are outside the WHO reference ranges ( 5), the abnormalities themselves (either one or all) are not reliable indicators of fertility status ( 4, 5). Therefore, semen analysis should be performed in conjunction with comprehensive (medical, reproductive and sexual) history-taking, and physical examination. Spermatogenesis is a complex process involving distinct phases, such as proliferation, meiosis and spermiogenesis, each",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 136
  },
  {
    "chunk_id": "infertility_2173",
    "text": "1135 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps with its specific duration ( 18, 19). Repeating a semen analysis after 11 weeks aligns with the estimated time for spermatogenesis to occur. In addition, time is needed for the effect of any modifiable factors on semen parameters to wane (e.g. febrile illnesses, medications, among others). To ensure that the results are valid and provide useful information, the latest edition of the WHO laboratory manual for the examination and processing of human semen outlines standardized procedures for semen collection and analysis. It provides guidance on: (i) semen examination; (ii) sperm preparation and cryopreservation; and (iii) quality assessment and quality control. The evaluation and management of male infertility is a stepwise process ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 137
  },
  {
    "chunk_id": "infertility_2174",
    "text": "examination; (ii) sperm preparation and cryopreservation; and (iii) quality assessment and quality control. The evaluation and management of male infertility is a stepwise process involving comprehensive assessment and consultation to determine appropriate treatment options (see Fig. 5.3 for the diagnostic algorithm for male-factor infertility). Referral of the male to a specialist and further evaluation may identify comorbidities requiring management beyond fertility ( 26, 27). Health care providers should be aware of this and, whenever possible, mitigate contextual issues that may affect the implementation of this recommendation related to the health system (e.g. personnel training and quality control of laboratories), economics (e.g. cost of tests and repeat appointment) and social (e.g. stigma, masculine norms or other cultural) barriers to male testing. In addition, female evaluatio",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 137
  },
  {
    "chunk_id": "infertility_2175",
    "text": "ratories), economics (e.g. cost of tests and repeat appointment) and social (e.g. stigma, masculine norms or other cultural) barriers to male testing. In addition, female evaluation is essential and it should proceed regardless of the outcome of semen analysis. Evaluation and management should be conducted in parallel for both male and female partners, and the investigation of a female partner should not be delayed by repeated semen analyses. At the same time, the diagnostic pathway, referral and management plan for the male partner should be informed by, and be progressively adjusted, based on the results of the tests of the female partner to optimize efficiency (see Chapter 3. Approach to the evaluation and management of patients with infertility ). Research gaps and future guideline update Future studies should assess relevant outcomes, including values, preferences, costs and cost-ef",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 137
  },
  {
    "chunk_id": "infertility_2176",
    "text": "anagement of patients with infertility ). Research gaps and future guideline update Future studies should assess relevant outcomes, including values, preferences, costs and cost-effectiveness of repeat semen testing. Given that semen analysis per se does not entirely rule out the presence of a male-factor cause of infertility, further research is required to determine the downstream outcomes of males with semen samples within and outside the WHO reference ranges, as well as those with borderline semen parameters, to determine if any subsets of these populations could benefit from further advanced tests. Current evidence is of very low certainty. Better-quality data from more studies evaluating the results of semen analysis are needed to improve the certainty of evidence. Current evidence on the estimated time that spermatogenesis takes is based on data from limited old studies. Some unce",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 137
  },
  {
    "chunk_id": "infertility_2177",
    "text": "men analysis are needed to improve the certainty of evidence. Current evidence on the estimated time that spermatogenesis takes is based on data from limited old studies. Some uncertainty exists based on biological plausibility ( 22) and observations from vivo studies ( 23). Impact of sperm maturation and epididymal transport and storage on the duration is uncertain (28) and may require consideration in future studies. Further large studies are required to strengthen the evidence base regarding the duration of spermatogenesis. The diagnostic scope of the guideline recommendation is limited, addressing only a subset of male infertility topics within the broader and evolving field of male infertility investigation. Specifically, this PICO provides guidance to the initial health care provider investigating a couple with infertility; guidance for male infertility specialists will be develope",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 137
  },
  {
    "chunk_id": "infertility_2178",
    "text": "n. Specifically, this PICO provides guidance to the initial health care provider investigating a couple with infertility; guidance for male infertility specialists will be developed in the future. This approach acknowledges the positive momentum in diagnostic interventions for male-factor infertility. Emerging technologies have the potential to advance adjunct diagnostic tests that could complement semen analysis and improve the clinical diagnosis of male infertility; however, these have not been evaluated in this edition of the guideline and will be considered in future editions.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 137
  },
  {
    "chunk_id": "infertility_2179",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 114 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/handle/10665/38679). 2. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/343208). 3. Silber SJ. Spontaneous pregnancy in couples with very severe oligospermia: implications for transmission of Y chromosome deletions. Fertil Steril. 2001;76(3):S10 (https://doi.org/10.1016/ S0015-0282(01)02044-1). 4. Boeri L, Belladelli F, Capogrosso P, Cazzaniga W, Candela L, Pozzi E et al. Normal sperm parameters per se do not reliably a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 138
  },
  {
    "chunk_id": "infertility_2180",
    "text": "10 (https://doi.org/10.1016/ S0015-0282(01)02044-1). 4. Boeri L, Belladelli F, Capogrosso P, Cazzaniga W, Candela L, Pozzi E et al. Normal sperm parameters per se do not reliably account for fertility: a case-control study in the real-life setting. Andrologia. 2021;53(1):e13861 (https:// doi.org/10.1111/and.13861). 5. Guzick DS, Overstreet JW, Factor-Litvak P, Brazil CK, Nakajima ST, Coutifaris C et al. Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med. 2001;345(19):1388-93 (https://doi.org/10.1056/ NEJMoa003005). 6. Rowe PJ, Comhaire FH, Hargreave TB, Mahmoud AM. WHO manual for the standardized investigation and diagnosis of the infertile male. Cambridge: Cambridge University Press; 2000 (https://iris.who.int/handle/10665/42437). 7. Heller CG, Clermont Y. Spermatogenesis in man: an estimate of its duration. Science. 1963;140(3563):184-6 (https://do",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 138
  },
  {
    "chunk_id": "infertility_2181",
    "text": "sity Press; 2000 (https://iris.who.int/handle/10665/42437). 7. Heller CG, Clermont Y. Spermatogenesis in man: an estimate of its duration. Science. 1963;140(3563):184-6 (https://doi.org/10.1126/ science.140.3563.184). 8. Alvarez C, Castilla JA, Martínez L, Ramírez JP, Vergara F, Gaforio JJ. Biological variation of seminal parameters in healthy subjects. Hum Reprod. 2003;18(10):2082-8 (https://doi. org/10.1093/humrep/deg430). 9. Poland ML, Moghissi KS, Giblin PT, Ager JW, Olson JM. Variation of semen measures within normal men. Fertil Steril. 1985;44(3):396-400 (https://doi. org/10.1016/s0015-0282(16)48866-7). 10. Leushuis E, van der Steeg JW, Steures P, Repping S, Bossuyt PM, Blankenstein MA et al. Reproducibility and reliability of repeated semen analyses in male partners of subfertile couples. Fertil Steril. 2010;94(7):2631-5 (https://doi. org/10.1016/j.fertnstert.2010.03.021). 11. Ber",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 138
  },
  {
    "chunk_id": "infertility_2182",
    "text": "ity and reliability of repeated semen analyses in male partners of subfertile couples. Fertil Steril. 2010;94(7):2631-5 (https://doi. org/10.1016/j.fertnstert.2010.03.021). 11. Berman NG, Wang C, Paulsen CA. Methodological issues in the analysis of human sperm concentration data. J Androl. 1996;17(1):68- 73 (https://doi.org/10.1002/j.1939-4640.1996. tb00588.x). 12. Carlsen E, Petersen JH, Andersson AM, Skakkebaek NE. Effects of ejaculatory frequency and season on variations in semen quality. Fertil Steril. 2004;82(2):358-66 (https://doi. org/10.1016/j.fertnstert.2004.01.039). 13. Castilla JA, Alvarez C, Aguilar J, González- Varea C, Gonzalvo MC, Martínez L. Influence of analytical and biological variation on the clinical interpretation of seminal parameters. Hum Reprod. 2006;21(4):847-51 (https://doi. org/10.1093/humrep/dei423). 14. Keel BA. Within- and between-subject variation in semen",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 138
  },
  {
    "chunk_id": "infertility_2183",
    "text": "e clinical interpretation of seminal parameters. Hum Reprod. 2006;21(4):847-51 (https://doi. org/10.1093/humrep/dei423). 14. Keel BA. Within- and between-subject variation in semen parameters in infertile men and normal semen donors. Fertil Steril. 2006;85(1):128-34 (https://doi.org/10.1016/j.fertnstert.2005.06.048). 15. Blickenstorfer K, Voelkle M, Xie M, Fröhlich A, Imthurn B, Leeners B. Are WHO recommendations to perform 2 consecutive semen analyses for reliable diagnosis of male infertility still valid? J Urol. 2019;201(4):783-91 (https://doi.org/10.1016/j.juro.2018.11.001). 16. Boeri L, Pozzi E, Capogrosso P, Fallara G, Belladelli F, Candela L et al. Infertile men with semen parameters above WHO reference limits at first assessment may deserve a second semen analysis: challenging the guidelines in the real- life scenario. PLoS One. 2023;18(1):e0280519 (https://doi.org/10.1371/journa",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 138
  },
  {
    "chunk_id": "infertility_2184",
    "text": "limits at first assessment may deserve a second semen analysis: challenging the guidelines in the real- life scenario. PLoS One. 2023;18(1):e0280519 (https://doi.org/10.1371/journal.pone.0280519).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 138
  },
  {
    "chunk_id": "infertility_2185",
    "text": "1155 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 17. Chiu YH, Edifor R, Rosner BA, Nassan FL, Gaskins AJ, Mínguez-Alarcón L et al. What does a single semen sample tell you? Implications for male factor infertility research. Am J Epidemiol. 2017;186(8):918-26 (https://doi.org/10.1093/aje/ kwx169). 18. Griswold MD. Spermatogenesis: the commitment to meiosis. Physiol Rev. 2016;96(1):1-17 (https:// doi.org/10.1152/physrev.00013.2015). 19. Neto FTL, Bach PV, Najari BB, Li PS, Goldstein M. Spermatogenesis in humans and its affecting factors. Semin Cell Dev Biol. 2016;59:10-26 (https://doi.org/10.1016/j.semcdb.2016.04.009). 20. Heller CH, Clermont Y. Kinetics of the germinal epithelium in man. Recent Prog Horm Res. 1964;20:545-75. 21. Heller C, Heller G, Rowley M. Human spermatogenesis:",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 139
  },
  {
    "chunk_id": "infertility_2186",
    "text": ".2016.04.009). 20. Heller CH, Clermont Y. Kinetics of the germinal epithelium in man. Recent Prog Horm Res. 1964;20:545-75. 21. Heller C, Heller G, Rowley M. Human spermatogenesis: an estimate of the duration of each cell association and of each cell type. Excerpta Medica. 1969;184:1012-18. 22. Amann RP. The cycle of the seminiferous epithelium in humans: a need to revisit? J Androl. 2008;29(5):469-87 (https://doi.org/10.2164/ jandrol.107.004655). 23. Misell LM, Holochwost D, Boban D, Santi N, Shefi S, Hellerstein MK et al. A stable isotope- mass spectrometric method for measuring human spermatogenesis kinetics in vivo. J Urol. 2006;175(1):242-6 (https://doi.org/10.1016/S0022- 5347(05)00053-4). 24. Kimmins S, Anderson RA, Barratt CLR, Behre HM , Catford SR, De Jonge CJ et al. Frequency, morbidity and equity – the case for increased research on male fertility. Nat Rev Urol. 2024;21(2):102",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 139
  },
  {
    "chunk_id": "infertility_2187",
    "text": "nderson RA, Barratt CLR, Behre HM , Catford SR, De Jonge CJ et al. Frequency, morbidity and equity – the case for increased research on male fertility. Nat Rev Urol. 2024;21(2):102-24 (https://doi.org/10.1038/ s41585-023-00820-4). 25. Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985;2(8455):596-8 (https://doi.org/10.1016/ s0140-6736(85)90594-x). 26. Honig SC, Lipshultz LI, Jarow J. Significant medical pathology uncovered by a comprehensive male infertility evaluation. Fertil Steril. 1994;62(5):1028-34 (https://doi.org/10.1016/ S0015-0282(16)57069-1). 27. Kolettis PN, Sabanegh ES. Significant medical pathology discovered during a male infertility evaluation. J Urol. 2001;166(1):178-80 (https://doi. org/10.1016/S0022-5347(05)66104-6). 28. Bustos‐Obregon E, Courot M, Flechon J, Hochereau‐de‐Reviers M, Holstein A. Morphological appraisal of ga",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 139
  },
  {
    "chunk_id": "infertility_2188",
    "text": "l. 2001;166(1):178-80 (https://doi. org/10.1016/S0022-5347(05)66104-6). 28. Bustos‐Obregon E, Courot M, Flechon J, Hochereau‐de‐Reviers M, Holstein A. Morphological appraisal of gametogenesis. Spermatogenetic process in mammals with particular reference to man. Andrologia. 1975;7(2):141-63 (https://doi. org/10.1111/j.1439 - 0272.1975.tb01247.x).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 139
  },
  {
    "chunk_id": "infertility_2189",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 116 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 5.8 Diagnosis of unexplained infertility This section contains recommendations related to the diagnosis of infertility due to unexplained factors. Figure 5.1, near the start of this chapter, illustrates how a diagnosis of unexplained infertility is made. Recommendation WHO suggests making a diagnosis of unexplained infertility in a couple when all the following have occurred: • failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse; • normal physical examination and medical history in both the male and female; • presumptive confirmation of ovulation and patent tubes in the female partner; and • semen parameters that are within the WHO reference ranges in the",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 140
  },
  {
    "chunk_id": "infertility_2190",
    "text": " in both the male and female; • presumptive confirmation of ovulation and patent tubes in the female partner; and • semen parameters that are within the WHO reference ranges in the male partner. (Conditional recommendation, very low certainty of evidence) Background and rationale In a WHO multi-country study conducted in 25 countries and involving 8500 couples, no cause was identified in 10.8% of infertility cases (1). As unexplained infertility is a diagnosis of exclusion, reported prevalence ranges vary widely, as demonstrated in several systematic reviews and meta-analyses from different global regions (2–4). While there may be several detectable and undetectable reproductive defects that could hinder a couple from achieving pregnancy, different settings may apply different tests for exclusion based on the available resources. This WHO guideline contains other conditional recommendati",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 140
  },
  {
    "chunk_id": "infertility_2191",
    "text": "le from achieving pregnancy, different settings may apply different tests for exclusion based on the available resources. This WHO guideline contains other conditional recommendations made based on a review of the evidence (rated as very-low certainty) about which tests to use to: i. investigate anovulation and oligo-ovulation or tubal disease or blockage in females who have a normal physical examination and medical history; ii. investigate uterine cavity abnormality, ovulation disorders and reduced ovarian reserve in females who do not have a normal physical exam and medical history; and iii. assess males. For (ii) and (iii) a diagnosis of infertility is based on the cause found through the investigations. However, for (i), when pathologies have not been identified, infertility remains unexplained, provided semen parameters are within the WHO reference ranges in a male with a normal his",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 140
  },
  {
    "chunk_id": "infertility_2192",
    "text": "ever, for (i), when pathologies have not been identified, infertility remains unexplained, provided semen parameters are within the WHO reference ranges in a male with a normal history and physical examination (see Fig. 5.1). Using a minimum set of criteria is probably feasible, acceptable and reduces costs in most resource settings. Therefore, the GDG agreed that at a minimum, a diagnosis of unexplained infertility should be arrived at if a couple has been unsuccessful in achieving pregnancy after 12 months of regular unprotected sexual intercourse; the physical examination and medical history in both the male and female are normal; ovulation and patent tubes in the female have been presumptively confirmed; and semen parameters are within the WHO reference ranges in the male.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 140
  },
  {
    "chunk_id": "infertility_2193",
    "text": "1175 Diagnosis of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification Given that other recommendations for diagnosing infertility in this guideline are conditional, this recommendation for using a minimum set of tests that can rule out other causes of infertility is also conditional based on the very low certainty of the evidence. The minimum set of tests apply in couples with infertility who have normal physical examinations and medical histories with presumptively confirmed ovulation, tubal patency and semen parameters that are within the WHO reference ranges. The minimum set of tests are feasible, acceptable and require fewer resources to implement in many resource settings. Implementation considerations Specific details and recommendations regarding medical history-taking an",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 141
  },
  {
    "chunk_id": "infertility_2194",
    "text": "cceptable and require fewer resources to implement in many resource settings. Implementation considerations Specific details and recommendations regarding medical history-taking and physical examination in a couple, evaluation of ovarian function, tubal patency and uterine cavity in the female, and semen analysis in the male, are outlined in the relevant chapters of this guideline. Procedures for semen analysis are detailed in the WHO laboratory manual for the examination and processing of human semen (5). Health care providers should ensure that physical examination and medical history-taking are conducted concurrently in both males and females as part of the initial diagnosis of unexplained infertility. If abnormalities affecting reproduction are found, diagnosis of unexplained infertility would not apply, as a cause would have been identified. Health care providers should be aware of,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 141
  },
  {
    "chunk_id": "infertility_2195",
    "text": "normalities affecting reproduction are found, diagnosis of unexplained infertility would not apply, as a cause would have been identified. Health care providers should be aware of, and mitigate, the psychological aspects of infertility, including when causes are unexplained (see Chapter 3 ). Health care providers should also be aware of, and whenever possible mitigate, the contextual issues that may affect the implementation of this recommendation related to the health system (e.g. personnel training and quality control of laboratories), economics (e.g. cost of tests) and social (e.g. stigma, masculine norms or other cultural) barriers to male testing. Research gaps and future guideline update Future studies are required to establish the magnitude of unexplained infertility using the above criteria, as available data are not current, and to understand the causes of infertility. Given tha",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 141
  },
  {
    "chunk_id": "infertility_2196",
    "text": "e required to establish the magnitude of unexplained infertility using the above criteria, as available data are not current, and to understand the causes of infertility. Given that unexplained infertility is a diagnosis of exclusion, the fewer the number of diagnostics tests performed, the more likely infertility might be unexplained, while performing multiple tests could potentially result in an abnormal result, which may or may not be related to the failure to achieve pregnancy, and in the latter scenario, lead to unnecessary intervention. Future research is needed to determine whether any additional tests or criteria (such as an upper limit of female age) should be routine used in the initial evaluation of couples who would otherwise be classified as having unexplained infertility based on the above criteria. Implementation research is encouraged to validate data, document costs and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 141
  },
  {
    "chunk_id": "infertility_2197",
    "text": "couples who would otherwise be classified as having unexplained infertility based on the above criteria. Implementation research is encouraged to validate data, document costs and inform whether the minimum diagnostic criteria should be resource-stratified.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 141
  },
  {
    "chunk_id": "infertility_2198",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 118 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 2. Abangah GH, Rashidian T, Parizad Nasirkandy M, Azami M. A meta-analysis of the prevalence and etiology of infertility in Iran. Int J Fertil Steril. 2023;17(3):160-73 (https://doi.org/10.22074/ ijfs.2023.541991.1215). 3. Abdulla AA, Ahmed M, Oladokun A. Prevalence of infertility in Sudan: a systematic review and meta-analysis. Qatar Med J. 2021;2021(3):47 (https://doi.org/10.5339/qmj.2021.47). 4. Abebe MS, Afework M, Abaynew Y. Primary and secondary infertility in Africa: system",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 142
  },
  {
    "chunk_id": "infertility_2199",
    "text": "review and meta-analysis. Qatar Med J. 2021;2021(3):47 (https://doi.org/10.5339/qmj.2021.47). 4. Abebe MS, Afework M, Abaynew Y. Primary and secondary infertility in Africa: systematic review with meta-analysis. Fertil Res Pract. 2020;6(1):20 (https://doi.org/10.1186/s40738-020-00090-3). 5. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/343208).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 142
  },
  {
    "chunk_id": "infertility_2200",
    "text": "1196-10 Treatment of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 6-10 Treatment of infertility These chapters provide guidance on the treatment of infertility. These treatments are divided into three main groups: Chapters Female-factor treatments 6.1 Treatment of infertility due to ovulatory dysfunction caused by PCOS 7.1 Use of surgery or IVF for treatment of tubal disease 7.2 Treatment of hydrosalpinx before IVF 8.1 Management of uterine septum in females with infertility Male-factor treatments 9.1 Use of antioxidants 9.2 Treatment of varicocele Unexplained infertility treatments 10.1 First-line management of couples with unexplained infertility 10.2 Second-line management of couples with unexplained infertility 10.3 Third-line management of couples with unexplained infertility Relevant res",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 143
  },
  {
    "chunk_id": "infertility_2201",
    "text": "les with unexplained infertility 10.2 Second-line management of couples with unexplained infertility 10.3 Third-line management of couples with unexplained infertility Relevant resources: Figure 6.1 Treatment algorithm for anovulatory infertility due to PCOS Figure 10.1 Treatment algorithm for unexplained infertility Web Annex D. Evidence to decision tables for treatment of infertility due to ovulatory dysfunction, tubal disease and uterine cavity disorder Web Annex E. Evidence to decision tables for treatment of infertility due to male factors Web Annex F. Evidence to decision tables for treatment of couples with unexplained infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 143
  },
  {
    "chunk_id": "infertility_2202",
    "text": "120 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 6 Treatment of infertility due to ovulatory dysfunction 6.1 Treatment of infertility due to ovulatory dysfunction caused by PCOS This section contains recommendations related to the management of infertility due to PCOS. Figure 6.1 shows how these recommendations relate to each other. Specific recommendations are presented in the sections that follow. Fig. 6.1. Management of anovulatory infertility due to PCOS a Baseline investigations: 1. Diagnosis of PCOS according to the Rotter dam criteria (endocrine profile and pelvic ultrasound scan) see Chapter 6.1. 2. Additional assessment tests may be required, including during the pr e-pregnancy period see Chapter 3. 3. Consider assessing tubal patency see Chapter 5.5. 4. Assess the male partner, including semen a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 144
  },
  {
    "chunk_id": "infertility_2203",
    "text": " tests may be required, including during the pr e-pregnancy period see Chapter 3. 3. Consider assessing tubal patency see Chapter 5.5. 4. Assess the male partner, including semen analysis see Chapter 5.7. b As part of the management of PCOS, it is good practice to advise patients on lifestyle interventions, such as healthy diet and regular physical activity. (Good practice statement). c Use repeated cycles based on shared decision-making considering age and resources. d Monitor patients regularly (with US as needed) and manage potential risks that may occur during treatment see Chapter 3 and Chapter 6.1. e If capacity for side-effect management exists. f Use IVF as third-line medical treatment unless other factors (e.g. male factors or tubal factor infertility) exist, and manage potential risks (such as OHSS) that may occur during treatment see Chapter 3 and Chapter 6.1. IVF, in vitro fe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 144
  },
  {
    "chunk_id": "infertility_2204",
    "text": "ors (e.g. male factors or tubal factor infertility) exist, and manage potential risks (such as OHSS) that may occur during treatment see Chapter 3 and Chapter 6.1. IVF, in vitro fertilization; LOD, laparoscopic ovarian drilling; PCOS, polycystic ovary syndrome; US, ultrasound. Provide clinical follow up and document pregnancy outcomes Provide clinical follow up and document pregnancy outcomes Ovulation detected and pregnancy achieved? PCOS Diagnosis: Rotterdam criteriaa Lifestyle modificationsb Letrozole, with monitoring,c,d adjusting dose as needed Gonadotrophin with monitoring,c,d,e adjusting dose as needed IVFf Alternative, if letrozole not available: clomiphene citrate ± metformin Alternative, depending on facilities and skills: LOD Yes Yes No OR OR No Central pathway preferred First-line medical treatment Second-line medical treatment Third-line medical treatment 1 2 3 Ovulation det",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 144
  },
  {
    "chunk_id": "infertility_2205",
    "text": "facilities and skills: LOD Yes Yes No OR OR No Central pathway preferred First-line medical treatment Second-line medical treatment Third-line medical treatment 1 2 3 Ovulation detected and pregnancy achieved? Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 144
  },
  {
    "chunk_id": "infertility_2206",
    "text": "1216 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS), WHO suggests using letrozole over clomiphene citrate or metformin. Using letrozole alone rather than with metformin is suggested. (Conditional recommendation, low certainty of evidence for letrozole compared to clomiphene citrate, low certainty evidence for letrozole compared with metformin alone and very low certainty of evidence for letrozole compared to letrozole with metformin) Where off-label use of letrozole is not permitted, use of clomiphene citrate with metformin rather than clomiphene citrate alone or metformin alone is suggested. (Conditional recommendation, moderate certainty ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 145
  },
  {
    "chunk_id": "infertility_2207",
    "text": "le is not permitted, use of clomiphene citrate with metformin rather than clomiphene citrate alone or metformin alone is suggested. (Conditional recommendation, moderate certainty of evidence for clomiphene citrate compared to clomiphene citrate with metformin, very low certainty of evidence for clomiphene citrate compared to metformin) As part of management of polycystic ovary syndrome (PCOS), it is good practice to advise patients on lifestyle interventions such as healthy diet, regular physical activity and/or weight management. (Good practice statement). Background and rationale PCOS is a common condition affecting 6–13% of women of reproductive age, although the reported prevalence varies depending on the diagnostic criteria ( 1, 2). Many women in the WHO Group II anovulation have PCOS. A diagnosis of PCOS in adults is based on the presence of two of the following three criteria: an",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 145
  },
  {
    "chunk_id": "infertility_2208",
    "text": "diagnostic criteria ( 1, 2). Many women in the WHO Group II anovulation have PCOS. A diagnosis of PCOS in adults is based on the presence of two of the following three criteria: anovulation or oligo-ovulation; clinical or biochemical hyperandrogenism; or polycystic ovary morphology, and exclusion of related disorders (Rotterdam criteria) (3). PCOS has multiple reproductive, metabolic and psychosocial impacts ( 4). Clinical features in PCOS commonly include irregular menstrual cycles, signs of androgen excess, such as hirsutism, and infertility ( 3). PCOS is one of the most common causes of anovulatory infertility ( 5). In addition, the prevalence of other comorbidities, such as obesity (6), impaired glucose tolerance and metabolic syndrome ( 7), is also high among women with PCOS, which may require identification and management. Options for the treatment of infertility in PCOS include li",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 145
  },
  {
    "chunk_id": "infertility_2209",
    "text": "erance and metabolic syndrome ( 7), is also high among women with PCOS, which may require identification and management. Options for the treatment of infertility in PCOS include lifestyle interventions, pharmacological therapies, surgical laparoscopic ovarian diathermy or IVF. Pharmacological therapies include estrogen receptor modulators (such as clomiphene citrate), aromatase inhibitors (such as letrozole), insulin- sensitizing medications (such as metformin) and direct hormonal stimulation of the ovaries (with gonadotrophins). The costs and complexities of these interventions vary significantly (see Fig. 6.1. for the treatment algorithm for anovulatory infertility due to PCOS). Pharmacological options include oral ovulation induction agents such as clomiphene citrate or letrozole, used alone or in combination with metformin. Clomiphene citrate is a selective estrogen receptor modulato",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 145
  },
  {
    "chunk_id": "infertility_2210",
    "text": "e oral ovulation induction agents such as clomiphene citrate or letrozole, used alone or in combination with metformin. Clomiphene citrate is a selective estrogen receptor modulator ( 8) that acts primarily by binding with estrogen receptors at the hypothalamus (9). It is administered orally, typically for 5 days from cycle days 3–7 or 5–9 (10) but can have side-effects, including changes to the endometrium and cervical mucus and hot flushes (11). Ultrasound monitoring is often used to monitor follicular growth during a stimulation cycle (12, 13).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 145
  },
  {
    "chunk_id": "infertility_2211",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 122 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Letrozole is a newer drug that blocks estrogen synthesis; it is also administered orally. It is an aromatase inhibitor (14) that has been used off-label for ovulation induction since 2001 ( 15). It stimulates ovarian follicle development and maturation; compared to clomiphene citrate, it has a short half- life of 2–4 days (16). It is usually administered daily from days 3–7 of the menstrual cycle ( 10). Concerns have been raised about potential teratogenicity (17), although reassuring data regarding safety are emerging (18). Ultrasound may be used to monitor follicular development during a stimulation cycle and to mitigate the risk of multiple pregnancy. Metformin is an antihyperglycaemic ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 146
  },
  {
    "chunk_id": "infertility_2212",
    "text": "erging (18). Ultrasound may be used to monitor follicular development during a stimulation cycle and to mitigate the risk of multiple pregnancy. Metformin is an antihyperglycaemic biguanide drug, which is widely used for lowering insulin levels (19). Women with PCOS often present with insulin resistance and hyperinsulinaemia (20–22). Insulin resistance and/or poor glycaemic control, is hypothesized to have an important role in the pathogenesis of PCOS (23–25). Therefore, metformin is an (off-label) option used as an insulin-sensitizing medication in people with PCOS, as an adjunct to ovulation induction medications (19, 26, 27), but it may cause gastrointestinal side-effects, and rarely, lactic acidosis and liver failure ( 26). It is generally administered daily, and for longer durations, even when used in combination therapy with letrozole or clomiphene citrate (26). For this recommenda",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 146
  },
  {
    "chunk_id": "infertility_2213",
    "text": "er failure ( 26). It is generally administered daily, and for longer durations, even when used in combination therapy with letrozole or clomiphene citrate (26). For this recommendation, the GDG addressed the following questions: (i) should letrozole versus clomiphene citrate or metformin be used for women with infertility due to ovulatory dysfunction caused by PCOS?; (ii) should clomiphene citrate versus clomiphene citrate + metformin or metformin be used for women with infertility due to ovulatory dysfunction caused by PCOS?; and (iii) should letrozole versus letrozole + metformin be used for women with infertility due to ovulatory dysfunction caused by PCOS?. The GDG assessed these oral pharmacological therapies as first-line treatment for PCOS. Balancing harms and benefits Use of monotherapy Two systematic reviews ( 18, 28) and an RCT (29) provided relevant data related to the benefit",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 146
  },
  {
    "chunk_id": "infertility_2214",
    "text": "ies as first-line treatment for PCOS. Balancing harms and benefits Use of monotherapy Two systematic reviews ( 18, 28) and an RCT (29) provided relevant data related to the benefits and harms of letrozole compared to clomiphene citrate. There was a moderate increase in live births with letrozole (RR: 1.52; 95% CI: 1.28–1.82) and likely no difference in these effects based on BMI. Mixed results were observed across undesirable effects: miscarriages (small increase with letrozole); multiple birth rates (trivial decrease with letrozole); OHSS (small decrease with letrozole); and congenital malformations (inconsistent effect between RCTs and non- randomized studies). Given that there is likely no important uncertainty or variability among different populations in how people value benefits (live births) and harms (miscarriages, multiple birth rates and other side-effects), the GDG judged that",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 146
  },
  {
    "chunk_id": "infertility_2215",
    "text": "nty or variability among different populations in how people value benefits (live births) and harms (miscarriages, multiple birth rates and other side-effects), the GDG judged that, overall, the benefits are greater with letrozole and outweigh any harms that may be slightly increased (low-certainty evidence ). The GDG emphasized that clomiphene citrate can be used as an alternative if letrozole is not available. A systematic review and network meta-analysis by Wang et al. (30), which was updated without retracted articles ( 31), provided data comparing letrozole to metformin. Letrozole likely results in more live births (OR: 1.85; 95% CI: 1.02–3.45). The observed increase of 116 more per 1000 was judged by the GDG to be a large desirable effect. The use of letrozole may slightly increase miscarriages (OR: 1.30; 95% CI: 0.54–3.13) and multiple pregnancy (OR: 2.22; 95% CI: 0.47–11.11). Giv",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 146
  },
  {
    "chunk_id": "infertility_2216",
    "text": "GDG to be a large desirable effect. The use of letrozole may slightly increase miscarriages (OR: 1.30; 95% CI: 0.54–3.13) and multiple pregnancy (OR: 2.22; 95% CI: 0.47–11.11). Given the large benefits and small harms, the GDG judged that the balance of effects favours the use of letrozole over metformin ( moderate-certainty evidence). A systematic review by Sharpe et al. ( 32) provided relevant data for comparing metformin with clomiphene citrate. Metformin may result in fewer live births (OR: 0.71; 95% CI: 0.49–1.01), but fewer miscarriages (OR: 0.92; 95% CI: 0.51–1.66)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 146
  },
  {
    "chunk_id": "infertility_2217",
    "text": "1236 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps and fewer multiple pregnancy (OR: 0.29; 95% CI: 0.06–1.43) compared to clomiphene citrate. In addition, the potential benefit of metformin in reducing multiple pregnancy and miscarriages based on a BMI threshold of over or under 30 kg/m2 was inconsistent. The GDG noted that the use of metformin alone is less effective than either clomiphene citrate or letrozole alone. The GDG judged that although there may be fewer harms with metformin alone in some populations, overall, there may be greater benefits with clomiphene citrate (very-low-certainty evidence ). Adjunct use of metformin in combination therapy Two RCTs provided relevant data comparing letrozole in combination with metformin versus letrozole alo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 147
  },
  {
    "chunk_id": "infertility_2218",
    "text": "ery-low-certainty evidence ). Adjunct use of metformin in combination therapy Two RCTs provided relevant data comparing letrozole in combination with metformin versus letrozole alone (33, 34). The addition of metformin to letrozole may result in no difference in effect on live births (RR: 1.00; 95% CI: 0.61–1.65), while clinical pregnancies may increase slightly (by 58 per 1000 [from 58 fewer to 215 more] compared to letrozole alone (RR: 1.15; 95% CI: 0.85–1.56). There are no data to determine the effects based on insulin resistance or BMI (mean BMI in the two included studies was < 30 kg/m2). In terms of undesirable effects, a small increase of miscarriages (60 per 1000 [from 41 fewer to 290 more] may occur when metformin is combined with letrozole compared to letrozole alone (RR 1.50; 95% CI: 0.66 to 3.43). Gastrointestinal side-effects may occur when letrozole is combined with metform",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 147
  },
  {
    "chunk_id": "infertility_2219",
    "text": "en metformin is combined with letrozole compared to letrozole alone (RR 1.50; 95% CI: 0.66 to 3.43). Gastrointestinal side-effects may occur when letrozole is combined with metformin, whereas there may be none with letrozole alone. The GDG noted that although clinical pregnancies may increase when metformin is combined with letrozole, there may be a similar increase in miscarriages and more gastrointestinal effects. Therefore, the balance of effects probably favours letrozole alone (very-low-certainty evidence ). A systematic review ( 32) compared metformin in combination with clomiphene citrate versus clomiphene citrate alone. Evidence showed that there is likely a moderate increase in live births (47 per 1000 [from 12 fewer to 123 more]; RR: 1.20;",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 147
  },
  {
    "chunk_id": "infertility_2220",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 124 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 95% CI: 0.95–1.52) and clinical pregnancies (111 more per 1000 [from 42 to 194 more]; RR: 1.40; 95% CI: 1.15–1.70) with metformin combined with clomiphene citrate compared to clomiphene citrate alone. Analyses using a BMI threshold of approximately < or >30 kg/m2 found similar relative risks for live births and clinical pregnancy, suggesting that there are little to no differences in desirable effects based on BMI. Women with insulin resistance were identified and included in three of the 19 RCTs included in the review and had similar relative risks. In relation to harms, use of clomiphene citrate combined with metformin may slightly reduce OHSS (11 fewer per 1000 [from 11 to 10 fewer]; ri",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 148
  },
  {
    "chunk_id": "infertility_2221",
    "text": "review and had similar relative risks. In relation to harms, use of clomiphene citrate combined with metformin may slightly reduce OHSS (11 fewer per 1000 [from 11 to 10 fewer]; risk difference [RD]: -0.002; 95% CI: -0.033 to -0.027) and multiple pregnancy (8 fewer per 1000 [from 14 fewer to 13 more]; RR: 0.57; 95% CI: 0.19–1.72), but likely increases miscarriages (21 more per 1000 [from 9 fewer to 65 more]; RR: 1.27; 95% CI: 0.88–1.85) and gastrointestinal side- effects (180 more per 1000 [from 78 more to 343 more]; RR: 3.12; 95% CI: 1.92–5.05) compared to clomiphene citrate alone. Although miscarriages and gastrointestinal side-effects are likely greater when metformin is used with clomiphene citrate, the GDG agreed that they are comparatively less serious compared to OHSS and multiple pregnancy, and that there was still an increase in clinical pregnancies. The GDG judged that the use ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 148
  },
  {
    "chunk_id": "infertility_2222",
    "text": " agreed that they are comparatively less serious compared to OHSS and multiple pregnancy, and that there was still an increase in clinical pregnancies. The GDG judged that the use of clomiphene citrate with metformin may have moderate benefits and small harms when compared to clomiphene citrate alone ( moderate- certainty evidence ). Other considerations The GDG judged that it is probably feasible to provide oral medications for ovulation induction and noted that the exact cost of these medications may vary from country to country. Given that the use of letrozole could reduce equity, as it is may be more expensive than clomiphene citrate ( 35), the GDG emphasized that clomiphene citrate can be used if letrozole is not available. The GDG noted that either letrozole or clomiphene citrate may be acceptable for use by physicians in different settings, based on studies conducted among physici",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 148
  },
  {
    "chunk_id": "infertility_2223",
    "text": " is not available. The GDG noted that either letrozole or clomiphene citrate may be acceptable for use by physicians in different settings, based on studies conducted among physicians in China ( 36), Estonia, Denmark, Finland, Iceland, Norway and Sweden ( 37), as well as the United States of America ( 38). In one of these studies, Piltonen et al. ( 37) found that 29% of 382 medical and reproductive endocrinologists and obstetrician-gynaecologists in multiple countries prescribed clomiphene citrate in conjunction with metformin (37). The cost of metformin is generally low, but monitoring of metformin therapy is generally limited once the optimum dose is achieved. Therefore, the GDG judged that the additional resources required to add metformin to clomiphene citrate are probably negligible, and it is probably feasible. Of note, there were no studies reporting the acceptability of these age",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 148
  },
  {
    "chunk_id": "infertility_2224",
    "text": "ources required to add metformin to clomiphene citrate are probably negligible, and it is probably feasible. Of note, there were no studies reporting the acceptability of these agents for ovulation induction among women with PCOS. In addition, the GDG noted that acceptability of letrozole among physicians could depend on its off-label use ( 38), given that it is not currently approved by several regulatory authorities such as the U.S. Food and Drug Administration or European Medicines Agency for ovulation induction ( 26).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 148
  },
  {
    "chunk_id": "infertility_2225",
    "text": "1256 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification Use of monotherapy Overall, there may be greater benefits (live births) with letrozole compared to clomiphene citrate (low-certainty evidence) or metformin (low-certainty evidence), which outweigh any harms that may be slightly increased. Although the potentially higher cost of letrozole could negatively affect equity, it is feasible and probably acceptable to provide. However, letrozole may not be available in all settings for off-label use. Therefore, letrozole is suggested over clomiphene citrate, but clomiphene citrate with metformin can be used where off-label use of letrozole is not permitted or is unavailable. Use of metformin in combination therapy The balance of effects li",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 149
  },
  {
    "chunk_id": "infertility_2226",
    "text": "clomiphene citrate with metformin can be used where off-label use of letrozole is not permitted or is unavailable. Use of metformin in combination therapy The balance of effects likely favours the use of clomiphene citrate with metformin over clomiphene citrate alone. The addition of metformin may result in moderate benefits and small undesirable effects. The use of clomiphene citrate with metformin is feasible and probably acceptable where off-label use (of metformin for PCOS) is allowed, and the additional costs of adding metformin to the stand-alone cost of clomiphene citrate alone is negligible. There was very low certainty evidence that the benefits probably outweigh the harms of using letrozole alone compared to letrozole with metformin. The addition of metformin to letrozole may result in a small increase in clinical pregnancy but a corresponding small increase in miscarriages, re",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 149
  },
  {
    "chunk_id": "infertility_2227",
    "text": "ared to letrozole with metformin. The addition of metformin to letrozole may result in a small increase in clinical pregnancy but a corresponding small increase in miscarriages, resulting in no net effect on live births compared to letrozole alone. In addition, metformin may also increase gastrointestinal side-effects. Implementation considerations Health care providers should consider offering lifestyle advice (e.g. on healthy diet and regular physical activity) as part of the management of PCOS. In addition, health care providers need to be aware of the potential risk of comorbidities, such as impaired glucose tolerance, obesity and metabolic syndrome, among others, in patients with PCOS (6, 7), which may require additional management. Health care providers should be aware of and mitigate the overall impact of stimulating agents such as letrozole or clomiphene citrate by monitoring pat",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 149
  },
  {
    "chunk_id": "infertility_2228",
    "text": "uire additional management. Health care providers should be aware of and mitigate the overall impact of stimulating agents such as letrozole or clomiphene citrate by monitoring patients to optimize achieving a pregnancy, while mitigating undesirable outcomes. Monitoring ovarian stimulation with ultrasound may be considered to assess ovarian response and to mitigate the risk of multiple pregnancies. Health care providers should counsel patients regarding the potential morbidity that may result from multiple gestation. Use of letrozole as an ovulation induction agent is not approved by several regulatory authorities such as the U.S. Food and Drug Administration or the European Medicines Agency (26). The use of metformin in patients with PCOS is also off-label. Health care providers should familiarize themselves with applicable national regulations related to off-label use of medicines for ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 149
  },
  {
    "chunk_id": "infertility_2229",
    "text": "tformin in patients with PCOS is also off-label. Health care providers should familiarize themselves with applicable national regulations related to off-label use of medicines for ovulation induction. Where off-label use of letrozole as an ovulation induction agent is not permitted or is unavailable, health care providers should offer",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 149
  },
  {
    "chunk_id": "infertility_2230",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 126 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps treatment with other ovulation agents, such as clomiphene citrate. Health care providers should take patients’ values and preferences into account as no studies reporting the acceptability of ovulation induction agents among patients with PCOS were identified in the evidence reviewed for this guideline. Research gaps and future guideline update The uncertainty in the evidence related to the use of letrozole or clomiphene citrate in PCOS indicates the need for large, well-designed RCTs to evaluate the use of these agents, used alone or with metformin, in several subgroup populations stratified according to BMI, insulin resistance, PCOS phenotypes, AMH levels, testosterone levels and other r",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 150
  },
  {
    "chunk_id": "infertility_2231",
    "text": " agents, used alone or with metformin, in several subgroup populations stratified according to BMI, insulin resistance, PCOS phenotypes, AMH levels, testosterone levels and other relevant prognostic factors and parameters. Such research will be important in identifying which group of patients benefits most from letrozole, clomiphene citrate or clomiphene citrate with metformin. Although safety data are reassuring, ongoing surveillance on the long-term use of letrozole should be encouraged. Given the lack of data on acceptability among patients, future research should involve patients with PCOS to better understand their values and preferences. A wide array of interventions are often considered in the management of PCOS (39, 40) some of which are not explored in this guideline. References 1. March W, Moore V, Willson K, Phillips D, Norman R, Davies M. The prevalence of polycystic ovary sy",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 150
  },
  {
    "chunk_id": "infertility_2232",
    "text": " of PCOS (39, 40) some of which are not explored in this guideline. References 1. March W, Moore V, Willson K, Phillips D, Norman R, Davies M. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2009;25(2):544-51 (https:// doi.org/10.1093/humrep/dep399). 2. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-55 (https://doi. org/10.1093/humrep/dew218). 3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25 (https:// doi.org/10.1016/j.fertnstert.2003.10.004). 4. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 150
  },
  {
    "chunk_id": "infertility_2233",
    "text": " polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25 (https:// doi.org/10.1016/j.fertnstert.2003.10.004). 4. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41 (https://doi. org/10.1186/1741-7015-8-41). 5. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210-7 (ht tps://doi.org/10.1111/ j.1471-0528.2006.01008.x). 6. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-37 (https://doi. org/10.1093/humupd/dms030). 7. Mo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 150
  },
  {
    "chunk_id": "infertility_2234",
    "text": "central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-37 (https://doi. org/10.1093/humupd/dms030). 7. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta- analysis. Hum Reprod Update. 2010;16(4):347-63 (https://doi.org/10.1093/humupd/dmq001). 8. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212-24 (https://doi.org/10.1093/ humupd/6.3.212).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 150
  },
  {
    "chunk_id": "infertility_2235",
    "text": "1276 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 9. Kurl RN, Morris ID. Differential depletion of cytoplasmic high affinity oestrogen receptors after the in vivo administration of the antioestrogens, clomiphene, MER-25 and tamoxifen. Br J Pharmacol. 1978;62(4):487- 93 (ht tps://doi.org/10.1111/j.1476 -5381.1978. tb07752.x). 10. Lee VCY, Ledger W. Aromatase inhibitors for ovulation induction and ovarian stimulation. Clin Endocrinol. 2011;74(5):537-46 (https://doi. org/10.1111/j.1365-2265.2011.04006.x). 11. Gonen Y, Casper RF. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod. 1990;5(6):670-4 (https://doi.org/10.1093/ oxfordjournals.humrep.a137165). 12. Galazis N, Zertalis M, Haoula Z, Atiomo ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 151
  },
  {
    "chunk_id": "infertility_2236",
    "text": "fect of clomiphene citrate on endometrial growth. Hum Reprod. 1990;5(6):670-4 (https://doi.org/10.1093/ oxfordjournals.humrep.a137165). 12. Galazis N, Zertalis M, Haoula Z, Atiomo W. Is ultrasound monitoring of the ovaries during ovulation induction by clomiphene citrate essential? A systematic review. J Obstet Gynaecol. 2011;31(7):566 -71 (https://doi.org/10.3109/01443 615.2011.596956). 13. National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London: Royal College of Obstetricians & Gynaecologists; 2013:139-81 (https://pubmed. ncbi.nlm.nih.gov/25340218/). 14. Bhatnagar A, Brodie A, Long B, Evans D, Miller W. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001;76(1-5):199-202 (https://doi.org/10.1016/s0960-0760(01)00050-4",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 151
  },
  {
    "chunk_id": "infertility_2237",
    "text": "aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001;76(1-5):199-202 (https://doi.org/10.1016/s0960-0760(01)00050-4). 15. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305-9 (https://doi. org/10.1016/s0015-0282(00)01705-2). 16. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95(9):2006-16 (https:// doi.org/10.1002/cncr.10908). 17. Biljan M, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril. 2005;84:S95 (https://doi.org/10.1016/j. fertnstert.2005.07.230). 18. Pundir J, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 151
  },
  {
    "chunk_id": "infertility_2238",
    "text": " of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril. 2005;84:S95 (https://doi.org/10.1016/j. fertnstert.2005.07.230). 18. Pundir J, Achilli C, Bhide P, Sabatini L, Legro RS, Rombauts L et al. Risk of foetal harm with letrozole use in fertility treatment: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(3):474-85 (https://doi.org/10.1093/ humupd/dmaa055). 19. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012;122(6):253-70 (https://doi.org/10.1042/ CS20110386). 20. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454-60 (https://doi.org/10.1016/j.fertnstert.2004.11.070). 21. Legro RS, Kunselman AR, Dodson WC, Dun",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 151
  },
  {
    "chunk_id": "infertility_2239",
    "text": "ry syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454-60 (https://doi.org/10.1016/j.fertnstert.2004.11.070). 21. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):165-9 (https://doi. org/10.1210/jcem.84.1.5393). 22. Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic- hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619-31 (https://doi.org/10.1093/ humrep/dew243). 23. Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen S. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1992;",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 151
  },
  {
    "chunk_id": "infertility_2240",
    "text": "w243). 23. Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen S. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1992;75(2):577-83 (https://doi. org/10.1210/jcem.75.2.1322430). 24. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41(10):1257-66 (https://doi.org/10.2337/diab.41.10.1257).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 151
  },
  {
    "chunk_id": "infertility_2241",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 128 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 25. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12(7):324-32 (https://doi.org/10.1016/j. molmed.2006.05.006). 26. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence- based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30(1):1-50 (https://doi. org/10.1210/er.2008-0030). 27. Dumitrescu R, Mehedintu C, Briceag I, Purcărea VL, Hudita D. Metformin-clinical pharmacology in PCOs. J Med Life. 2015;8(2):187-92. 28. Franik S, Eltrop SM, Kremer JAM, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syn",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 152
  },
  {
    "chunk_id": "infertility_2242",
    "text": "gy in PCOs. J Med Life. 2015;8(2):187-92. 28. Franik S, Eltrop SM, Kremer JAM, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;5:CD010287 (https://doi. org/10.1002/14651858.CD010287.pub3). 29. Wang L, Wen X, Lv S, Zhao J, Yang T, Yang X. Comparison of endometrial receptivity of clomiphene citrate versus letrozole in women with polycystic ovary syndrome: a randomized controlled study. Gynecol Endocrinol. 2019;35(10):862-5 (https://doi.org/10.1080/09513590.2019.1612358). 30. Wang R, Kim BV, van Wely M, Johnson NP, Costello MF, Zhang H et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017;356:j138 (https://doi.org/10.1136/bmj.j138). 31. Treatment strategies for women with WHO group II anovulation: systematic review and network met",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 152
  },
  {
    "chunk_id": "infertility_2243",
    "text": "nd network meta-analysis. BMJ. 2017;356:j138 (https://doi.org/10.1136/bmj.j138). 31. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2022;379:o2436 (https://doi.org/10.1136/bmj.o2436). 32. Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;12:CD013505 (https://doi. org/10.1002/14651858.CD013505). 33. Liu C, Feng G, Huang W, Wang Q, Yang S, Tan J et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecol Endocrinol. 2017;33(11):872-6 (https://doi.org/10.1080/09513 590.2017.1332174). 34. Pourghasem S, Bazarganipour F, Taghavi SA, Kutenaee MA. The effectiveness of inositol and metformin on infertil",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 152
  },
  {
    "chunk_id": "infertility_2244",
    "text": "7;33(11):872-6 (https://doi.org/10.1080/09513 590.2017.1332174). 34. Pourghasem S, Bazarganipour F, Taghavi SA, Kutenaee MA. The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. Arch Gynecol Obstet. 2019;299(4):1193-9 (https:// doi.org/10.1007/s00404-019-05064-5). 35. Martínez-Núñez JM, Altagracia-Martínez M, Kravzov-Jinich J, Hinojosa-Cruz JC, Sánchez- Sánchez B, Díaz de León-Castañeda C. Economic burden study of anovulation-related female infertility in a Mexican public hospital: a pilot study. Rev Mex Cienc Farm. 2012;43(2):66-72. 36. Deng Y, Wang Y-F, Zhu S-Y, Xue W, Ma X, Ma R-L, et al. Nationwide survey on the usage of ovulation-induction agents among obstetricians and gynecologists in China. Chin Med J (Engl). 2019;132(20):2489 (https://doi.org/10.1097/ CM9.0000000000000450 ). 37. Piltonen TT, Ruokojärvi M, Karro H, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 152
  },
  {
    "chunk_id": "infertility_2245",
    "text": "ents among obstetricians and gynecologists in China. Chin Med J (Engl). 2019;132(20):2489 (https://doi.org/10.1097/ CM9.0000000000000450 ). 37. Piltonen TT, Ruokojärvi M, Karro H, Kujanpää L, Morin-Papunen L, Tapanainen JS et al. Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe. PLoS One. 2019;14(12):e0226074 (https://doi.org/10.1371/ journal.pone.0226074). 38. Malloch L, Rhoton-Vlasak A. An assessment of current clinical attitudes toward letrozole use in reproductive endocrinology practices. Fertil Steril. 2013;100(6):1740-4 (https://doi. org/10.1016/j.fertnstert.2013.08.040). 39. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN et al. WHO recommendations for the management of anovulatory infertility in women with polycystic ovary syndrome (PCOS). Hum Reprod Update. 2016;22(6):687-708 (https:// doi.org/10.109",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 152
  },
  {
    "chunk_id": "infertility_2246",
    "text": "al. WHO recommendations for the management of anovulatory infertility in women with polycystic ovary syndrome (PCOS). Hum Reprod Update. 2016;22(6):687-708 (https:// doi.org/10.1093/humupd/dmw025). 40. Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT et al.; International PCOS Network. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2023;38(9):1655-79 (https://doi. org/10.1093/humrep/dead156).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 152
  },
  {
    "chunk_id": "infertility_2247",
    "text": "1296 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS) who have been unsuccessful with oral pharmacological therapies such as letrozole or clomiphene citrate with metformin, WHO suggests using gonadotrophins over laparoscopic ovarian drilling (LOD). (Conditional recommendation, low certainty of evidence) Background and rationale Treatment options for women who have been unsuccessful with oral pharmacological therapy with letrozole or clomiphene citrate with metformin include surgical treatment with LOD or pharmacological treatment with injectable gonadotrophins. Gonadotropins include naturally occurring LH and FSH from the pituitary, and human",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 153
  },
  {
    "chunk_id": "infertility_2248",
    "text": " include surgical treatment with LOD or pharmacological treatment with injectable gonadotrophins. Gonadotropins include naturally occurring LH and FSH from the pituitary, and human chorionic gonadotrophin (HCG) from the placenta, as well as their recombinant glycoforms, rFSH, rLH and rHCG (1, 2). Human menopausal gonadotrophins (hMGs) contain both FSH and LH ( 3). In females, gonadotrophins influence follicular recruitment, oocyte maturation, E2 secretion, ovulation and progesterone production ( 1). Based on these effects, gonadotrophins are an option for ovulation induction in the treatment of infertility (4). However, they can cause adverse effects, such as multiple gestation and OHSS ( 5), and need to be injected intramuscularly or subcutaneously (6). Recombinant forms differ from urine-derived or serum-derived gonadotrophins in terms of purity and batch- to-batch consistency in biolo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 153
  },
  {
    "chunk_id": "infertility_2249",
    "text": "ected intramuscularly or subcutaneously (6). Recombinant forms differ from urine-derived or serum-derived gonadotrophins in terms of purity and batch- to-batch consistency in biological activity (7). To prevent multiple pregnancies and ovarian hyperstimulation, gonadotrophins are typically administered in individualized, step-up or (rarely) step-down regimens ( 8, 9). Ultrasound is used to monitor follicular growth during a stimulation cycle. LOD is a surgical procedure whereby multiple perforations are made in the ovarian surface and stroma (the inner area of the ovary) to stimulate follicle development and ovulation induction (10, 11). LOD uses several cautery techniques to make perforations (12, 13), and the number and depth of perforations, and dose and duration of energy may vary (11). The precise mechanism through which LOD causes therapeutic effects is unknown, but is postulated t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 153
  },
  {
    "chunk_id": "infertility_2250",
    "text": " number and depth of perforations, and dose and duration of energy may vary (11). The precise mechanism through which LOD causes therapeutic effects is unknown, but is postulated to include changes in both circulating hormones and a pituitary feedback mechanism (14, 15). LOD is typically performed as an outpatient procedure. For this recommendation, the GDG addressed the question: should LOD versus gonadotrophins be used for females with infertility due to ovulatory dysfunction caused by PCOS who fail oral pharmacological therapies such as letrozole or clomiphene citrate with metformin? Balancing harms and benefits A systematic review of RCTs provided data for the benefits and harms of LOD compared with gonadotrophins (16). There is likely little to no differences in live births (RR: 0.98; 95% CI: 0.79–1.21) and clinical pregnancies (RR: 1.02; 95% CI: 0.87–1.19), quality of life or depre",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 153
  },
  {
    "chunk_id": "infertility_2251",
    "text": "rophins (16). There is likely little to no differences in live births (RR: 0.98; 95% CI: 0.79–1.21) and clinical pregnancies (RR: 1.02; 95% CI: 0.87–1.19), quality of life or depression between the two interventions. There may be large reductions in OHSS (RD: -0.02; 95% CI: -0.06 to 0.03) and multiple pregnancies (RR: 0.22; 95% CI: 0.09–0.54) and a small reduction in miscarriages (RR: 0.90; 95% CI: 0.57–1.45) with the use of LOD compared with gonadotrophins. Data on other adverse events were not reported, but the GDG noted that LOD is a surgical procedure requiring general anaesthesia, which could potentially increase the risks of bleeding, infection, thermal damage to adjacent organs and postoperative effects on ovarian reserve and adhesion formation. The GDG agreed that although gonadotrophins may increase the risk of OHSS and multiple pregnancies, these risks could be minimized with a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 153
  },
  {
    "chunk_id": "infertility_2252",
    "text": "on ovarian reserve and adhesion formation. The GDG agreed that although gonadotrophins may increase the risk of OHSS and multiple pregnancies, these risks could be minimized with appropriate treatment regimens, surveillance and monitoring. Therefore, the GDG judged the benefits of LOD to be trivial and its",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 153
  },
  {
    "chunk_id": "infertility_2253",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 130 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps harms small compared to gonadotrophins. The overall certainty of evidence was low. Other considerations Although LOD is probably feasible, it requires training in surgical skills. The review reported costs from three RCTs and found that LOD was generally less costly than gonadotrophins (16). However, a retrospective health-economic evaluation performed from a societal perspective comparing gonadotrophins with LOD ( n = 35), followed by ovulation induction with clomiphene citrate and/ or hMGs, reported that if spontaneous ovulation did not occur within 2 months, then the societal cost per patient was higher after LOD versus gonadotrophins (17). Most of the cost in this retrospective study w",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 154
  },
  {
    "chunk_id": "infertility_2254",
    "text": "ntaneous ovulation did not occur within 2 months, then the societal cost per patient was higher after LOD versus gonadotrophins (17). Most of the cost in this retrospective study was due to productivity loss with LOD (17). Two studies reported the comparative cost-effectiveness of LOD versus gonadotrophins per additional ongoing pregnancy and live birth, but the results were inconsistent ( 17, 18). Based on these data, the GDG agreed that although LOD may cost less and may lead to cost savings because of a lesser need for monitoring (because of mono- ovulation), the harms that may occur with an invasive surgical intervention may lead to additional health care costs. Along with the additional greater training needs for LOD, this would balance out the potential cost savings, probably resulting in little difference in the cost-effectiveness of the two treatments. There were no studies asses",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 154
  },
  {
    "chunk_id": "infertility_2255",
    "text": "eds for LOD, this would balance out the potential cost savings, probably resulting in little difference in the cost-effectiveness of the two treatments. There were no studies assessing equity, but the GDG judged that LOD probably has no impact on equity compared to gonadotrophins. One study that assessed patient preferences reported that couples were willing to accept LOD over ovarian stimulation if both treatments resulted in similar chances of pregnancy (19); based on this finding, the GDG judged that there is probably no variability in how much people value pregnancy, noting that most people would want to minimize adverse effects and would probably opt for the treatment that most increases their chances of pregnancy and live births. Summary justification Gonadotropins may increase live births more than LOD. Although data on undesirable outcomes indicate that LOD has fewer harms, the G",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 154
  },
  {
    "chunk_id": "infertility_2256",
    "text": "regnancy and live births. Summary justification Gonadotropins may increase live births more than LOD. Although data on undesirable outcomes indicate that LOD has fewer harms, the GDG agreed that LOD may cause moderate risks because it is a surgical procedure. Although gonadotrophins may increase the risk of OHSS and multiple pregnancy, these risks could be minimized with adequate monitoring. Gonadotropins are probably feasible, do not require training in surgical skills and may have no impact on equity compared to LOD. Gonadotropins are probably acceptable as they increase the chances of pregnancy and are less invasive compared to LOD, but health care providers should discuss treatment options, particularly in settings where optimal monitoring of gonadotrophin treatment is not possible. Implementation considerations Health care providers should be aware of the risks of ovulation inductio",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 154
  },
  {
    "chunk_id": "infertility_2257",
    "text": "settings where optimal monitoring of gonadotrophin treatment is not possible. Implementation considerations Health care providers should be aware of the risks of ovulation induction, including the occurrence of OHSS and multiple pregnancy on patients and health systems, and consider implementing monitoring strategies (e.g. with ultrasound or hormone measurement) to manage potential harms. Health care providers should counsel patients on treatment options, particularly in settings where optimal monitoring of gonadotrophin treatment is not possible. When gonadotrophins are used, it should be in settings where capacity for the management of side-effects and specified risk mitigation factors are in place (e.g. individualized, step-up or step-down protocols).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 154
  },
  {
    "chunk_id": "infertility_2258",
    "text": "1316 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Research gaps and future guideline update Future studies should report outcomes comprehensively, including cost-effectiveness, time to pregnancy, postoperative effects of LOD on ovarian reserve, thermal damage to adjacent organs, infections, adhesion formation and other longer-term outcomes. Future guidance will be needed on specific dosing regimens for ovulation induction with gonadotrophins. References 1. Lambert A, Talbot JA, Anobile CJ, Robertson WR. Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Mol Hum Reprod. 1998;4(7):619-29 (https://doi. org/10.1093/molehr/4.7.619). 2. Garcia-Campayo V, Boime I. Novel recombinant gonadotropins. Trends Endocrinol Metab. 2001;",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 155
  },
  {
    "chunk_id": "infertility_2259",
    "text": "roduction. Mol Hum Reprod. 1998;4(7):619-29 (https://doi. org/10.1093/molehr/4.7.619). 2. Garcia-Campayo V, Boime I. Novel recombinant gonadotropins. Trends Endocrinol Metab. 2001;12(2):72-7 (https://doi.org/10.1016/S1043- 2760(00)00338-6). 3. Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update. 2004;10(6):453-67 (https://doi.org/10.1093/ humupd/dmh044). 4. Anderson RC, Newton CL, Anderson RA, Millar RP. Gonadotropins and their analogs: current and potential clinical applications. Endocr Rev. 2018;39(6):911-37 (https://doi.org/10.1210/ er.2018-00052). 5. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559-77 (https://doi.org/10.1093/ humupd/8.6.559). 6. De Leo V, Musacchio MC, Di Sabatino A, Tosti C, Morgante G, Petraglia F. Present and future of recombinant gonadotropins",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 155
  },
  {
    "chunk_id": "infertility_2260",
    "text": "2;8(6):559-77 (https://doi.org/10.1093/ humupd/8.6.559). 6. De Leo V, Musacchio MC, Di Sabatino A, Tosti C, Morgante G, Petraglia F. Present and future of recombinant gonadotropins in reproductive medicine. Curr Pharm Biotechnol. 2012;13(3):379- 91 (https://doi.org/10.2174/138920112799361918). 7. Wallach EE, Shoham Z, Insler V. Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil Steril. 1996;66(2):187-201 (https://doi.org/10.1016/ S0015-0282(16)58437-4). 8. Fauser BC, Donderwinkel P, Schoot DC. The step-down principle in gonadotrophin treatment and the role of GnRH analogues. Baillieres Clin Obstet Gynaecol. 1993;7(2):309-30 (https://doi. org/10.1016/s0950-3552(05)80133-6). 9. Shoham Z, Patel A, Jacobs HS. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 155
  },
  {
    "chunk_id": "infertility_2261",
    "text": "6). 9. Shoham Z, Patel A, Jacobs HS. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril. 1991;55(6):1051-6 (https://doi.org/10.1016/s0015- 0282(16)54351-9). 10. Gjönnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril. 1984;41(1):20-5 (https:// doi.org/10.1016/s0015-0282(16)47534-5). 11. Seow K-M, Chang Y-W, Chen K-H, Juan C-C, Huang C-Y, Lin L-T et al. Molecular mechanisms of laparoscopic ovarian drilling and its therapeutic effects in polycystic ovary syndrome. Int J Mol Sci. 2020;21(21):8147 (https://www.mdpi.com/1422- 0067/21/21/8147). 12. Aminimoghaddam S, Pahlevani R, Kazemi M. Electrosurgery and clinical applications of electrosurgical devices in gynecologic procedures. Med J Islam Repub Iran. 2018;32:90 (https://doi.org/10.141",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 155
  },
  {
    "chunk_id": "infertility_2262",
    "text": " S, Pahlevani R, Kazemi M. Electrosurgery and clinical applications of electrosurgical devices in gynecologic procedures. Med J Islam Repub Iran. 2018;32:90 (https://doi.org/10.14196/mjiri.32.90). 13. Law KS, Abbott JA, Lyons SD. Energy sources for gynecologic laparoscopic surgery: a review of the literature. Obstet Gynecol Surv. 2014;69(12):763-76 (https://doi.org/10.1097/ ogx.0000000000000130). 14. Gjønnaess H, Norman N. Endocrine effects of ovarian electrocautery in patients with polycystic ovarian disease. Br J Obstet Gynaecol. 1987;94(8):779-83 (https://doi. org/10.1111/j.1471- 0528.1987.tb03726.x).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 155
  },
  {
    "chunk_id": "infertility_2263",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 132 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 15. Keckstein G, Rossmanith W, Spatzier K, Schneider V, Börchers K, Steiner R. The effect of laparoscopic treatment of polycystic ovarian disease by CO2-laser or Nd:YAG laser. Surg Endosc. 1990;4(2):103-7 (https://doi.org/10.1007/ BF00591271). 16. Bordewijk EM, Ng KYB, Rakic L, Mol BWJ, Brown J, Crawford TJ et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;(2):CD001122 (https://doi. org/10.1002/14651858.CD001122.pub5). 17. De Frène V, Gerris J, Weyers S, Dhont M, Vansteelandt S, Annemans L et al. Gonadotropin therapy versus laparoscopic ovarian drilling in clomiphene citrate-resistant polycysti",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 156
  },
  {
    "chunk_id": "infertility_2264",
    "text": ". 17. De Frène V, Gerris J, Weyers S, Dhont M, Vansteelandt S, Annemans L et al. Gonadotropin therapy versus laparoscopic ovarian drilling in clomiphene citrate-resistant polycystic ovary syndrome patients: a retrospective cost-effectiveness analysis. Gynecol Obstet Invest. 2015;80(3):164-9 (https://doi. org/10.1159/000373888). 18. Nahuis M, Oude Lohuis E, Kose N, Bayram N, Hompes P, Oosterhuis G et al. Long-term follow- up of laparoscopic electrocautery of the ovaries versus ovulation induction with recombinant FSH in clomiphene citrate-resistant women with polycystic ovary syndrome: an economic evaluation. Hum Reprod. 2012;27(12):3577-82 (https://doi.org/10.1093/humrep/des336). 19. Bayram N, van Wely M, van der Veen F, Bossuyt PM. Treatment preferences and trade-offs for ovulation induction in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005;84(",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 156
  },
  {
    "chunk_id": "infertility_2265",
    "text": "er Veen F, Bossuyt PM. Treatment preferences and trade-offs for ovulation induction in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005;84(2):420-5 (https:// doi.org/10.1016/j.fertnstert.2005.02.026).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 156
  },
  {
    "chunk_id": "infertility_2266",
    "text": "1336 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS) who have been unsuccessful with pharmacological therapies such as letrozole, clomiphene citrate with metformin or gonadotrophins, WHO suggests using in vitro fertilization (IVF) rather than expectant management. (Conditional recommendation, very low certainty of evidence) Background and rationale Women with infertility due to PCOS may fail to achieve pregnancy after treatment with letrozole, clomiphene citrate with metformin or gonadotrophins. Therefore, it is important to explore what approach should be followed when gonadotrophins have been unsuccessful. Options for women may include IVF",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 157
  },
  {
    "chunk_id": "infertility_2267",
    "text": "th metformin or gonadotrophins. Therefore, it is important to explore what approach should be followed when gonadotrophins have been unsuccessful. Options for women may include IVF or expectant management. IVF is a procedure where oocytes and sperm are co-incubated outside the human body with the goal of achieving fertilization, after which the embryo is transferred to the uterus. IVF was first reported in humans in the late 1960s (1); in 1978, the first birth resulting from IVF was reported ( 2). IVF is traditionally the next line of treatment when most other approaches have been unsuccessful. The procedure involves several steps: (i) the retrieval of the woman’s oocytes from the ovaries; (ii) exposure of the retrieved oocytes to sperm outside the body for fertilization; (iii) culture of the resulting embryo(s) for 3–5 days; and (iv) transfer of the embryo to the uterus ( 3). Globally, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 157
  },
  {
    "chunk_id": "infertility_2268",
    "text": "retrieved oocytes to sperm outside the body for fertilization; (iii) culture of the resulting embryo(s) for 3–5 days; and (iv) transfer of the embryo to the uterus ( 3). Globally, a significant number of people have conceived through IVF ( 4), but it involves costs (5), and may also have adverse effects, such as multiple pregnancy ( 6, 7) and OHSS, which is a serious and potentially fatal condition ( 8). Ultrasound is typically used to monitor ovarian response and follicular growth during stimulation cycles for IVF ( 9). IVF allows control over the number of embryos transferred, while allowing spare embryos to be cryopreserved for future use, obviating the need for further ovarian stimulation (10). For this recommendation, the GDG addressed the question: should IVF versus expectant management be used for females with infertility due to ovulatory dysfunction caused by PCOS who fail pharma",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 157
  },
  {
    "chunk_id": "infertility_2269",
    "text": "ommendation, the GDG addressed the question: should IVF versus expectant management be used for females with infertility due to ovulatory dysfunction caused by PCOS who fail pharmacological therapies such as letrozole, clomiphene citrate with metformin or gonadotrophins? Balancing harms and benefits The review team conducted a broad de novo search and did not identify any published systematic reviews, RCTs or non-randomized studies comparing IVF/ICSI versus no IVF/ICSI in women with ovulation dysfunction due to PCOS. Evidence from nine non-comparative, single- arm, non-randomized studies among women receiving IVF for ovulation dysfunction due to PCOS were identified (11–19). Of these, only one study (12) reported that women (n = 1508) had been unsuccessful on other treatments. Evidence from observational non-comparative studies indicated that the use of IVF may result in 550 clinical pre",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 157
  },
  {
    "chunk_id": "infertility_2270",
    "text": "ed that women (n = 1508) had been unsuccessful on other treatments. Evidence from observational non-comparative studies indicated that the use of IVF may result in 550 clinical pregnancies (proportion: 0.55; 95% CI: 0.43–0.66) and 520 live births per 1000 women (proportion: 0.52; 95% CI: 0.34–0.70). In terms of undesirable effects, for every 1000 women receiving IVF, there may be 50 cases of OHSS (proportion: 0.05; 95% CI: 0–0.10) and 180 cases of multiple pregnancy (proportion: 0.18; 95% CI: 0.12–0.25) and a low incidence of miscarriages (proportion: 0.16; 95% CI: 0.13–0.20). The GDG noted the difficulty of judging the magnitude of undesirable effects by looking at proportions, but also noted that OHSS and multiple pregnancy are inherently associated with IVF. Although IVF may cause harms such as OHSS and multiple pregnancy, these can be mitigated with appropriate treatment",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 157
  },
  {
    "chunk_id": "infertility_2271",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 134 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps regimens, surveillance, monitoring and policies regarding embryo transfer. Direct evidence is lacking with respect to patients’ values and preferences comparing IVF with no IVF (i.e. expectant management). Indirect evidence from two discrete experimental studies that involved 297 Dutch women with infertility ( n = 206 and n = 91) eligible for IVF showed that acceptability of IVF was increased by its potential to increase pregnancies and live births, but was reduced by out- of-pocket costs and potential risk of OHSS (20, 21). The GDG judged that the benefits of IVF probably outweigh the potential harms for women with infertility due to PCOS when other initial treatments have been unsuccessf",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 158
  },
  {
    "chunk_id": "infertility_2272",
    "text": "SS (20, 21). The GDG judged that the benefits of IVF probably outweigh the potential harms for women with infertility due to PCOS when other initial treatments have been unsuccessful. The overall certainty of evidence was judged to be very low given the lack of appropriate comparative studies. Other considerations IVF is probably feasible but requires investments in health systems because of the costs involved (5, 22). Safe provision of IVF requires specialized equipment and training of health care providers. The GDG judged that resource requirements on health systems and individuals are moderate to large, noting that costs to individuals and the health system may result from the IVF procedure itself or from the management of OHSS, multiple pregnancy and other complications that may result from IVF. IVF probably reduces equity if it is only available to select people, for example, in set",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 158
  },
  {
    "chunk_id": "infertility_2273",
    "text": "e management of OHSS, multiple pregnancy and other complications that may result from IVF. IVF probably reduces equity if it is only available to select people, for example, in settings where IVF facilities are not available or physically or financially accessible. To mitigate the impact on equity, appropriate assisted reproduction policies and services are required to ensure access to those that need it. In the absence of direct evidence on acceptability, values and preferences from patients with PCOS, the GDG agreed that women with infertility value live births over potential harms and considered that ethically, such patients should have options when other treatments have been unsuccessful. Overall, the GDG judged that IVF is probably acceptable if the frequency of OHSS and costs are reduced. Summary justification The higher number of live births, relatively low undesirable effects, fe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 158
  },
  {
    "chunk_id": "infertility_2274",
    "text": "udged that IVF is probably acceptable if the frequency of OHSS and costs are reduced. Summary justification The higher number of live births, relatively low undesirable effects, feasibility and acceptability of IVF probably favours the use of IVF over expectant management. Implementation considerations Women with PCOS undergoing IVF should be informed about the potential benefits, costs and risks of IVF, such as OHSS and multiple pregnancy. Health care providers should consider ways of minimizing potential harms, including through appropriate treatment regimens and protocols, surveillance and monitoring, and policies on the number of embryos to transfer ( 7, 23–26). Given the lack of direct evidence on patients’ values and preferences, health care providers should seek to understand patients’ acceptability of IVF when other treatment options have been unsuccessful, as well as social, cul",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 158
  },
  {
    "chunk_id": "infertility_2275",
    "text": "’ values and preferences, health care providers should seek to understand patients’ acceptability of IVF when other treatment options have been unsuccessful, as well as social, cultural, economic and other concerns that patients may have. Acceptability of IVF may be affected by a range of individual and sociocultural factors ( 27, 28). Health care providers should inform patients about prognostic factors such as female age, duration of subfertility and number of oocytes, among others (29), and support patients to make informed decisions in keeping with the principles of shared decision-making based on their values and preferences. Health care providers should also be aware and, whenever possible, mitigate contextual issues that may affect the implementation of this recommendation related to the health system",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 158
  },
  {
    "chunk_id": "infertility_2276",
    "text": "1356 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps (e.g. availability of IVF facilities, personnel training and quality control of laboratories), economics (e.g. costs of IVF) and sociocultural factors (e.g. religious beliefs related to ART). Research gaps and future guideline update Further guidance will be required on the role of the GnRH agonist trigger, in vitro maturation, single embryo transfer, minimal ovarian stimulation and other prognostic factors, protocols and strategies that may increase the efficiency and effectiveness of IVF, while reducing any potential harms. Future research should involve patients and identify their values, preferences and acceptability of IVF interventions. In addition, future research is needed to assess strategies f",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 159
  },
  {
    "chunk_id": "infertility_2277",
    "text": "Future research should involve patients and identify their values, preferences and acceptability of IVF interventions. In addition, future research is needed to assess strategies for making IVF more affordable (30, 31) given that IVF is economically out of reach for many individuals ( 31, 32). References 1. Edwards RG, Bavister BD, Steptoe PC. Early stages of fertilization in vitro of human oocytes matured in vitro. Nature. 1969;221(5181):632-5 (https://doi.org/10.1038/221632a0). 2. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet. 1978;312(8085):366 (https://doi.org/10.1016/ s0140-6736(78)92957-4). 3. Medical Advisory Secretariat. In vitro fertilization and multiple pregnancies: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(18):1-63 (https://pubmed.ncbi.nlm.nih. gov/23074488). 4. Chambers GM, Dyer S, Zegers-Hochschild F, de Mouzon J, I",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 159
  },
  {
    "chunk_id": "infertility_2278",
    "text": " an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(18):1-63 (https://pubmed.ncbi.nlm.nih. gov/23074488). 4. Chambers GM, Dyer S, Zegers-Hochschild F, de Mouzon J, Ishihara O, Banker M et al. International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014. Hum Reprod. 2021;36(11):2921-34 (https://doi. org/10.1093/humrep/deab198). 5. Collins JA. An international survey of the health economics of IVF and ICSI. Hum Reprod Update. 2002;8(3):265-77 (https://doi.org/10.1093/ humupd/8.3.265). 6. Kerin J, Quinn P, Kirby C, Seamark R, Warnes G, Jeffrey R et al. Incidence of multiple pregnancy after in-vitro fertilisation and embryo transfer. Lancet. 1983;322(8349):537-40 (https://doi. org/10.1016/s0140-6736(83)90569-x). 7. Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertili",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 159
  },
  {
    "chunk_id": "infertility_2279",
    "text": "ancet. 1983;322(8349):537-40 (https://doi. org/10.1016/s0140-6736(83)90569-x). 7. Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet. 2005;365(9473):1807-16 (https://doi.org/10.1016/S0140-6736(05)66478-1). 8. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559-77 (https://doi.org/10.1093/ humupd/8.6.559). 9. Maklad NF. Monitoring follicular development with ultrasound. In: Wolf DP, Quigley MM, editors. Human in vitro fertilization and embryo transfer. Boston, Springer; 1984:119-32 (https://doi. org/10.1007/978-1-4684-4712-5_8). 10. Trounson A, Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature. 1983;305(5936):707-9 (https://doi.org/10.1038/305707a0). 11. Chen YH, Wang Q, Zhang YN,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 159
  },
  {
    "chunk_id": "infertility_2280",
    "text": " pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature. 1983;305(5936):707-9 (https://doi.org/10.1038/305707a0). 11. Chen YH, Wang Q, Zhang YN, Han X, Li DH, Zhang CL. Cumulative live birth and surplus embryo incidence after frozen-thaw cycles in PCOS: how many oocytes do we need? J Assist Reprod Genet. 2017;34(9):1153-9 (https://doi. org/10.1007/s10815-017-0959-6). 12. Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375(6):523-33 (https://doi.org/10.1056/ NEJMoa1513873). 13. Ding W, Zhang FL, Liu XC, Hu LL, Dai SJ, Li G et al. Impact of female obesity on cumulative live birth rates in the first complete ovarian stimulation cycle. Front Endocrinol. 2019;10:516 (https://doi. org/10.3389/fendo.2019.00516).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 159
  },
  {
    "chunk_id": "infertility_2281",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 136 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 14. Kudesia R, Wu H, Hunter Cohn K, Tan L, Lee JA , Copperman AB et al. The effect of female body mass index on in vitro fertilization cycle outcomes: a multi-center analysis. J Assist Reprod Genet. 2018;35(11):2013-23 (https://doi. org/10.1007/s10815-018-1290-6). 15. Li X-L, Huang R, Fang C, Wang Y-F, Liang X-Y. Logistic regression analysis of risk factors associated with spontaneous abortion after in vitro fertilization/intracytoplasmic sperm injection-embryo transfer in polycystic ovary syndrome patients. Reprod Dev Med. 2018;2(02):105-10. 16. Pan X-M, Lin Z, Li N, Wu J-Q, Chen D-Q, Zhu Y-M et al. Effects of body mass index on the outcomes of in vitro fertilization in Chinese patients w",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 160
  },
  {
    "chunk_id": "infertility_2282",
    "text": "od Dev Med. 2018;2(02):105-10. 16. Pan X-M, Lin Z, Li N, Wu J-Q, Chen D-Q, Zhu Y-M et al. Effects of body mass index on the outcomes of in vitro fertilization in Chinese patients with polycystic ovary syndrome: a retrospective cohort study. J Zhejiang Univ Sci B 2018;19(6):490-6 (https://doi.org/10.1631/jzus. B1800113). 17. Sun L, Ye J, Wang Y, Chen Q, Cai R, Fu Y et al. Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Sci Rep. 2018;8(1):13835 (https://doi.org/10.1038/s41598-018-32128-4). 18. Xu Z, Meng L, Pan C, Chen X, Huang X, Yang H. Does oral contraceptives pretreatment affect the pregnancy outcome in polycystic ovary syndrome women undergoing ART with GnRH agonist protocol? Gynecol Endocrinol. 2019;35(2):124-7 (https://doi.org/10.1080/095135 90.2018.1500535). 19. Zhang J, Liu H, Wang Y,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 160
  },
  {
    "chunk_id": "infertility_2283",
    "text": "c ovary syndrome women undergoing ART with GnRH agonist protocol? Gynecol Endocrinol. 2019;35(2):124-7 (https://doi.org/10.1080/095135 90.2018.1500535). 19. Zhang J, Liu H, Wang Y, Mao X, Chen Q, Fan Y et al. Letrozole use during frozen embryo transfer cycles in women with polycystic ovary syndrome. Fertil Steril. 2019;112(2):371-7 (https://doi. org/10.1016/j.fertnstert.2019.04.014). 20. Musters AM, de Bekker-Grob EW, Mochtar MH , van der Veen F, van Mello NM. Women’s perspectives regarding subcutaneous injections, costs and live birth rates in IVF. Hum Reprod. 2011;26(9):2425-31 (https://doi.org/10.1093/ humrep/der177). 21. Braam SC, de Bruin JP, Mol BWJ, van Wely M. The perspective of women with an increased risk of OHSS regarding the safety and burden of IVF: a discrete choice experiment. Hum Reprod Open. 2020;2020(2):hoz034 (https://doi.org/10.1093/ hropen/hoz034). 22. Chambers GM, S",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 160
  },
  {
    "chunk_id": "infertility_2284",
    "text": "risk of OHSS regarding the safety and burden of IVF: a discrete choice experiment. Hum Reprod Open. 2020;2020(2):hoz034 (https://doi.org/10.1093/ hropen/hoz034). 22. Chambers GM, Sullivan EA, Ishihara O, Chapman MG , Adamson GD. The economic impact of assisted reproductive technology: a review of selected developed countries. Fertil Steril. 2009;91(6):2281-94 (https://doi. org/10.1016/j.fertnstert.2009.04.029). 23. Pandian Z, Templeton A, Serour G, Bhattacharya S. Number of embryos for transfer after IVF and ICSI: a Cochrane review. Hum Reprod. 2005;20(10):2681-7 (https://doi. org/10.1093/humrep/dei153). 24. Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;(1):CD012103 (https:// doi.org/10.1002/14651858.CD012103.pub2). 25. Datta AK, Maheshwari A, Felix N, Campbell S, Nargund G. Mild ve",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 160
  },
  {
    "chunk_id": "infertility_2285",
    "text": "chrane reviews. Cochrane Database Syst Rev. 2017;(1):CD012103 (https:// doi.org/10.1002/14651858.CD012103.pub2). 25. Datta AK, Maheshwari A, Felix N, Campbell S, Nargund G. Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper- responders: a systematic review and meta- analysis. Hum Reprod Update. 2021;27(2):229-53 (https://doi.org/10.1093/humupd/dmaa035). 26. Velez MP, Soule A, Gaudet L, Pudwell J, Nguyen P, Ray JG. Multifetal pregnancy after implementation of a publicly funded fertility program. JAMA Netw Open. 2024;7(4):e248496 (https://doi.org/10.1001/ jamanetworkopen.2024.8496). 27. Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update. 2015;21(4):411-26 (https://doi.org/10.1093/humupd/dmv016). 28. Präg P, Mills MC. Cultural determinants influence ass",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 160
  },
  {
    "chunk_id": "infertility_2286",
    "text": "es and global movements in the 21st century. Hum Reprod Update. 2015;21(4):411-26 (https://doi.org/10.1093/humupd/dmv016). 28. Präg P, Mills MC. Cultural determinants influence assisted reproduction usage in Europe more than economic and demographic factors. Hum Reprod. 2017;32(11):2305-14 (https://doi. org/10.1093/humrep/dex298).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 160
  },
  {
    "chunk_id": "infertility_2287",
    "text": "1376 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 29. van Loendersloot LL, van Wely M, Limpens J, Bossuyt PMM, Repping S, van der Veen F. Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. Hum Reprod Update. 2010;16(6):577-89 (https://doi. org/10.1093/humupd/dmq015). 30. Chiware TM, Vermeulen N, Blondeel K, Farquharson R, Kiarie J, Lundin K et al. IVF and other ART in low- and middle-income countries: a systematic landscape analysis. Hum Reprod Update. 2021;27(2):213-28 (https://doi. org/10.1093/humupd/dmaa047). 31. Njagi P, Groot W, Arsenijevic J, Dyer S, Mburu G, Kiarie J. Financial costs of assisted reproductive technology for patients in low-and middle-income countries: a systematic review. Hum Reprod Open. 2",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 161
  },
  {
    "chunk_id": "infertility_2288",
    "text": "senijevic J, Dyer S, Mburu G, Kiarie J. Financial costs of assisted reproductive technology for patients in low-and middle-income countries: a systematic review. Hum Reprod Open. 2023;2023(2):hoad007 (https://doi.org/10.1093/hropen/hoad007). 32. Dyer SJ, Patel M. The economic impact of infertility on women in developing countries – a systematic review. Facts Views Vis Obgyn. 2012;4(2):102-9.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 161
  },
  {
    "chunk_id": "infertility_2289",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 138 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with infertility due to ovulatory dysfunction caused by hyperprolactinaemia, WHO suggests using cabergoline over bromocriptine. (Conditional recommendation, low certainty of evidence) Background and rationale Hyperprolactinaemia is a common endocrine disorder of the hypothalamic–pituitary axis. Normal prolactin (PRL) levels in women and men are below 25 µg/L and 20 µg/L, respectively (1). Data on the global prevalence of hyperprolactinaemia are sparse; however, an analysis of 1607 medically treated patients with hyperprolactinaemia reported a prevalence of 10.8 per 100 000 in men and 29.5 per 100 000 in women, with a peak incidence among women aged 25–34 years ( ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 162
  },
  {
    "chunk_id": "infertility_2290",
    "text": "ally treated patients with hyperprolactinaemia reported a prevalence of 10.8 per 100 000 in men and 29.5 per 100 000 in women, with a peak incidence among women aged 25–34 years ( 2). Although hyperprolactinaemia is diagnosed in less than 1% in the unselected general population, it is reported to occur in 5–17% of women with secondary amenorrhoea (3–6) and in 6.7% of those with infertility ( 7, 8). There are many possible causes of hyperprolactinaemia, including physiological, pharmacological, pathological or idiopathic etiologies (9). Pituitary adenoma or prolactinoma is one of the most frequent pathological cause of hyperprolactinaemia (10). Physiological states such as pregnancy can cause PRL elevation ( 11), while pharmacological causes include side-effects from some antipsychotics, opiates, antihypertensives and antidepressants (12). PRL exerts many physiological functions; clinical",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 162
  },
  {
    "chunk_id": "infertility_2291",
    "text": ", while pharmacological causes include side-effects from some antipsychotics, opiates, antihypertensives and antidepressants (12). PRL exerts many physiological functions; clinical manifestations of hyperprolactinaemia are exerted through its effects on the hypothalamic–pituitary– gonadal axis, mammary glands (i.e. breast) and adenoma mass effects in the region of the sella turcica (13). In women, hyperprolactinaemia often leads to oligomenorrhoea, amenorrhoea, infertility and galactorrhoea (14). These symptoms are related to the physiological actions of PRL on lactogenesis and also result in hypogonadotropic hypogonadism, low estrogen and oligo-ovulation or anovulation. Other symptoms may include headaches and visual disturbances because of local mass effects of pituitary adenomas and prolactinomas ( 14). Dopamine agonists are often the first-line treatment for patients with hyperprolac",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 162
  },
  {
    "chunk_id": "infertility_2292",
    "text": " visual disturbances because of local mass effects of pituitary adenomas and prolactinomas ( 14). Dopamine agonists are often the first-line treatment for patients with hyperprolactinaemia due to a pituitary adenoma ( 1). Pituitary PRL secretion is mainly under inhibitory control by dopamine in the hypothalamic tuberoinfundibular pathway. It is secreted into the hypophyseal portal system and reaches the pituitary lactotrophs where it activates dopamine D2 receptors to suppress PRL secretion (15). Because dopamine inhibits PRL secretion, dopamine agonists, such as bromocriptine and cabergoline, reduce serum PRL levels by directly stimulating dopamine receptors in pituitary lactotrophs, thereby lowering circulating PRL levels. A reduction in PRL levels subsequently leads to the resumption of ovulatory menstrual cycles, shrinking of pituitary prolactinomas, resolution of visual field defect",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 162
  },
  {
    "chunk_id": "infertility_2293",
    "text": "ng PRL levels. A reduction in PRL levels subsequently leads to the resumption of ovulatory menstrual cycles, shrinking of pituitary prolactinomas, resolution of visual field defects and resolution of galactorrhoea (16). For this recommendation, the GDG addressed the question: should cabergoline versus bromocriptine be used for the treatment of anovulatory infertility caused by hyperprolactinaemia? Bromocriptine is the primary dopamine agonist against which newer ergot derivatives are typically compared ( 17); it has side-effects common to all ergot derivatives, such as nausea and vomiting (18). Although it is generally effective, some patients may not tolerate bromocriptine at therapeutic doses (19, 20) and are resistant to it (21). Cabergoline is a newer ergot derivative with a longer half-life allowing it to be taken only once or twice weekly, which may improve therapeutic compliance (",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 162
  },
  {
    "chunk_id": "infertility_2294",
    "text": " resistant to it (21). Cabergoline is a newer ergot derivative with a longer half-life allowing it to be taken only once or twice weekly, which may improve therapeutic compliance (18, 22). The outcomes of",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 162
  },
  {
    "chunk_id": "infertility_2295",
    "text": "1396 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps interest for this recommendation were live births, clinical pregnancy rates and adverse effects of these medications. Although return of ovulation is an important intermediate step towards live births in women with anovulatory infertility secondary to hyperprolactinaemia, it was not independently assessed as an outcome; instead, the GDG prioritized pregnancies and live births as primary outcomes. Balancing harms and benefits A systematic search for randomized and non- randomized studies was conducted in MEDLINE, Embase and the Cochrane Central Register of Controlled Trials from 1990 until June 2019. The search identified five relevant RCTs that compared cabergoline and bromocriptine ( 23–27). There is l",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 163
  },
  {
    "chunk_id": "infertility_2296",
    "text": " Cochrane Central Register of Controlled Trials from 1990 until June 2019. The search identified five relevant RCTs that compared cabergoline and bromocriptine ( 23–27). There is low- quality evidence from these RCTs that cabergoline may be more effective in terms of both biochemical (RR: 1.65; 95% CI: 0.95–2.86) and clinical (RR: 1.46; 95% CI: 1.19–1.78) pregnancy, assessed at 4 and 6–7 weeks of gestation, respectively. In these RCTs, live birth rates were not assessed. In terms of undesirable effects, there is moderate to very-low evidence from RCTs that medication side-effects are likely less common with cabergoline compared to bromocriptine, suggesting that cabergoline is likely more tolerable. Two studies (24, 25) reported on miscarriages, which were rare, but these studies were rated as being of very low quality for failing to report results between comparison groups, incomplete ou",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 163
  },
  {
    "chunk_id": "infertility_2297",
    "text": "(24, 25) reported on miscarriages, which were rare, but these studies were rated as being of very low quality for failing to report results between comparison groups, incomplete outcome data and having very few events. In all studies, the route of administration was oral for both medications, although the GDG noted some variations in the dosages of the two medications administered across the studies. These studies used lower levels of bromocriptine than what is typical in clinical practice. The overall certainty of evidence was rated as low. Data are lacking on patient values and preferences; however, the GDG judged that there is no important uncertainty in how people value the main outcomes. Because patients are likely to prefer the option that is more effective and better tolerated, the GDG judged that the balance of effects probably favours cabergoline compared to bromocriptine. Addit",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 163
  },
  {
    "chunk_id": "infertility_2298",
    "text": "re likely to prefer the option that is more effective and better tolerated, the GDG judged that the balance of effects probably favours cabergoline compared to bromocriptine. Additional considerations There is a lack of studies assessing the acceptability of dopamine agonists among patients. However, given the less frequent oral dosing and better tolerability of cabergoline compared to bromocriptine, the GDG judged that it is probably acceptable. Although there was limited evidence regarding feasibility, the GDG judged that provision of cabergoline, including management of side- effects, is likely feasible. Two studies reported that cabergoline is slightly more expensive than bromocriptine when analysed per tablet ( 28, 29). However, costs are likely to be comparable, given the less frequent dosing schedule of cabergoline (29). Therefore, the GDG concluded that overall, recommending cabe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 163
  },
  {
    "chunk_id": "infertility_2299",
    "text": "let ( 28, 29). However, costs are likely to be comparable, given the less frequent dosing schedule of cabergoline (29). Therefore, the GDG concluded that overall, recommending cabergoline would result in negligible costs compared to bromocriptine, although costs may differ slightly across countries. Summary justification Overall, there is low quality evidence that cabergoline may be more effective in increasing the rate of both clinical and biochemical pregnancy and is likely more tolerable. Live birth rates were not reported in the studies. Because patients are likely to prefer the option that is more effective while having fewer side-effects, the balance of effects probably favours cabergoline. In addition, cabergoline is probably acceptable and is feasible. Although the cost per tablet of cabergoline could be higher than bromocriptine, the dosing regimen can reduce cabergoline costs. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 163
  },
  {
    "chunk_id": "infertility_2300",
    "text": "abergoline is probably acceptable and is feasible. Although the cost per tablet of cabergoline could be higher than bromocriptine, the dosing regimen can reduce cabergoline costs. Therefore, women with ovulatory dysfunction infertility due to hyperprolactinaemia are more likely to benefit more from cabergoline than bromocriptine.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 163
  },
  {
    "chunk_id": "infertility_2301",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 140 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Implementation considerations Once hyperprolactinaemia is confirmed, the primary cause needs to be investigated before initiating treatment with dopamine agonists. Evaluation is aimed at excluding pharmacological or extra-pituitary causes of hyperprolactinaemia, such as medication use, renal failure, primary hypothyroidism and parasellar tumours ( 9), and may include history- taking, visual and physical examination, and laboratory and imaging tests. The higher the level of PRL in general, the greater the likelihood of a pituitary adenoma and the greater the likelihood it will be a macroadenoma. Higher levels of PRL are associated with prolactinomas and macroadenomas (30, 31). Macroadenomas",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 164
  },
  {
    "chunk_id": "infertility_2302",
    "text": "od of a pituitary adenoma and the greater the likelihood it will be a macroadenoma. Higher levels of PRL are associated with prolactinomas and macroadenomas (30, 31). Macroadenomas of the pituitary can be associated with visual field defects and may alter secretion of other pituitary hormones. Clinically significant tumour growth can occur during pregnancy. After commencement of treatment, health care providers should monitor whether dopamine agonists are working effectively, including regularly assessing PRL levels, side-effects and return of ovulation. Further evaluation should be considered if menses do not return, or if new symptoms appear or persist, which may indicate possible pregnancy or persistent hyperprolactinaemia requiring dose adjustment. Research gaps and future guideline update In terms of future research, studies comparing cabergoline and bromocriptine should assess live",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 164
  },
  {
    "chunk_id": "infertility_2303",
    "text": "rprolactinaemia requiring dose adjustment. Research gaps and future guideline update In terms of future research, studies comparing cabergoline and bromocriptine should assess live birth outcomes, as well as patient-centred outcomes, including acceptability and quality of life. Current studies focus on reporting pregnancy rates and normalization of PRL levels. Future research and guidance will be required on whether to discontinue bromocriptine or cabergoline therapy in women who become pregnant after normalization of PRL levels. Such guidance will need to consider the potential risk of continuing dopamine agonists vis-à-vis the risk of recurrence of hyperprolactinaemia on medication withdrawal. References 1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 164
  },
  {
    "chunk_id": "infertility_2304",
    "text": "asanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006;65(2):265-73 (https://doi.org/10.1111/j.1365- 2265.2006.02562.x). 2. Kars M, Souverein PC, Herings RMC, Romijn JA, Vandenbroucke JP, de Boer A et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94(8):2729-34 (https://doi.org/10.1210/jc.2009-0177). 3. Lee DY, Oh YK, Yoon BK, Choi DS. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol. 2012;206(3):213.e1-5 (https:// doi.org/10.1016/j.ajog.2011.12.010). 4. Greer ME, Moraczewski T, Rakoff JS. Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol. 1980;56(1):65-9. 5. Biller BM, Luciano A,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 164
  },
  {
    "chunk_id": "infertility_2305",
    "text": "10.1016/j.ajog.2011.12.010). 4. Greer ME, Moraczewski T, Rakoff JS. Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol. 1980;56(1):65-9. 5. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med. 1999;44(12 Suppl):1075-84 (https:// pubmed.ncbi.nlm.nih.gov/10649814/). 6. Souter I, Baltagi LM, Toth TL, Petrozza JC. Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility. Fertil Steril. 2010;94 (3):1159 - 62 (https://doi.org/10.1016/j. fertnstert.2009.12.017). 7. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/handle/10665/38679).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 164
  },
  {
    "chunk_id": "infertility_2306",
    "text": "1416 Treatment of infertility due to ovulatory dysfunction Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 8. Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985;2(8455):596-8 (https://doi.org/10.1016/ s0140-6736(85)90594-x). 9. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88 (https:// doi.org/10.1210/jc.2010-1692). 10. Gillam MP, Molitch ME. Prolactinomas. In: Hay ID, Wass JA, editors. Clinical endocrine oncology, second edition. Malden, Wiley–Blackwell; 2008:237-45. 11. Mouftafa H, Helvacioglu A, Rizk B, Nawar M, Rizk C, Rizk C et al. Hyperprolactinaemia. In: Rizk B, Garcia-Velasco J, Salla",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 165
  },
  {
    "chunk_id": "infertility_2307",
    "text": "second edition. Malden, Wiley–Blackwell; 2008:237-45. 11. Mouftafa H, Helvacioglu A, Rizk B, Nawar M, Rizk C, Rizk C et al. Hyperprolactinaemia. In: Rizk B, Garcia-Velasco J, Sallam H, Makrigiannakis A, editors. Infertility and assisted reproduction. Cambrige: Cambridge University Press; 2008:270-85. 12. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin. Proc. 2005;80(8):1050-7 (https://doi. org/10.4065/80.8.1050). 13. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523-631 (https://doi.org/10.1152/physrev.2000.80.4.1523). 14. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002;20(4):365-74 (https://doi. org/10.1055/s-2002-36709). 15. Liu X, Tang C, Wen G, Zhong C, Yang J, Zhu J et al. The mechanism and pathways of dopamine and dopamine agonists in pr",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 165
  },
  {
    "chunk_id": "infertility_2308",
    "text": "002;20(4):365-74 (https://doi. org/10.1055/s-2002-36709). 15. Liu X, Tang C, Wen G, Zhong C, Yang J, Zhu J et al. The mechanism and pathways of dopamine and dopamine agonists in prolactinomas. Front Endocrinol. 2019;9:768 (https://doi.org/10.3389/ fendo.2018.00768). 16. Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1(1):33 (https://doi. org/10.1186/2046-4053-1-33). 17. Besser GM, Parke L, Edwards C, Forsyth IA, McNeilly A. Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med J. 1972;3(5828):669- 72 (https://doi.org/10.1136/bmj.3.5828.669). 18. Rains CP, Bryson HM, Fitton A. Cabergoline. Drugs. 1995;49(2):255-79 (https://doi. org/10.2165/00003495-199549020-00009). 19. dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cab",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 165
  },
  {
    "chunk_id": "infertility_2309",
    "text": ", Bryson HM, Fitton A. Cabergoline. Drugs. 1995;49(2):255-79 (https://doi. org/10.2165/00003495-199549020-00009). 19. dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011;14(3):259-65 (https://doi.org/10.1007/s11102-010-0290-z). 20. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14(4):228-38 (https:// doi.org./10.2165/00002018-199614040-00003). 21. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82(3):876-83 (https://doi. org/10.1210/jcem.82.3.3822). 22. Del",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 165
  },
  {
    "chunk_id": "infertility_2310",
    "text": "omas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82(3):876-83 (https://doi. org/10.1210/jcem.82.3.3822). 22. Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633-45 (https://doi. org/10.2165/00003088-200342070-00003). 23. Motazedian S, Babakhani L, Fereshtehnejad S-M, Mojtahedi K. A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. Indian J Med Res. 2010;131(5):670-4 (https://pubmed.ncbi.nlm.nih. gov/20516539/). 24. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. 1995;24(16):753-7. 25. Webster J, Piscitelli G, Polli A, Ferrari CI",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 165
  },
  {
    "chunk_id": "infertility_2311",
    "text": "h cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. 1995;24(16):753-7. 25. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331(14):904-9 (https://doi.org/10.1056/ NEJM199410063311403).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 165
  },
  {
    "chunk_id": "infertility_2312",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 142 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 26. Al-Husaynei AJ, Mahmood IH, Al-Jubori ZS. Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea. Middle East Fertil Soc J. 2008;13(1):33-8. 27. Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med. 2001;40(9):857-61 (https://doi.org/10.2169/ internalmedicine.40.857). 28. Bahceci M, Sismanoglu A, Ulug U. Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol Endocrinol. 2010;26(7):505-8 (https://doi. org/10.3109/09513591003632233). 29. Molitch ME. Cabergol",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 166
  },
  {
    "chunk_id": "infertility_2313",
    "text": "ents with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol Endocrinol. 2010;26(7):505-8 (https://doi. org/10.3109/09513591003632233). 29. Molitch ME. Cabergoline versus bromocriptine: a meta-analysis? Nat Rev Endocrinol. 2011;7(5):254- 5 (https://doi.org/10.1038/nrendo.2011.33). 30. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab. 2000;85(9):3053-7 (https://doi. org/10.1210/jcem.85.9.6798). 31. Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008;31(5):436-44 (https://doi. org/10.1007/BF03346388).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 166
  },
  {
    "chunk_id": "infertility_2314",
    "text": "143 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 7 Treatment of infertility due to tubal disease The following sections 7.1–7.2 present recommendations related to the management of tubal blockage and hydrosalpinx. 7.1 Use of surgery or IVF for treatment of tubal disease Recommendation For females aged < 35 years with mild-to-moderate tubal disease (Hull and Rutherford grades I and II), WHO suggests surgery rather than in vitro fertilization (IVF). (Conditional recommendation, very low certainty of evidence) Remarks: • After surgery, a reasonable minimum time to wait to achieve pregnancy before pursuing other interventions, such as IVF, is 1 year. • This recommendation does not apply to females who have had previous tubal sterilization. For females aged < 35 years with severe tubal disease (Hull and Ruther",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 167
  },
  {
    "chunk_id": "infertility_2315",
    "text": "as IVF, is 1 year. • This recommendation does not apply to females who have had previous tubal sterilization. For females aged < 35 years with severe tubal disease (Hull and Rutherford grade III), WHO suggests in vitro fertilization (IVF) rather than surgery. (Conditional recommendation, very low certainty of evidence) Remark: • This recommendation does not apply to females who have had previous tubal sterilization. For females aged ≥ 35 years with any tubal disease, WHO suggests IVF rather than surgery. (Conditional recommendation, very low certainty of evidence). Background and rationale Tubal factor infertility occurs when some pathology proximally at the uterotubal junction or more distally in the fallopian tube(s), caused by disease, obstruction, damage, scarring, congenital malformations or other factors, prevents oocyte pickup by the fimbriated ends of the tube or sperm access to ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 167
  },
  {
    "chunk_id": "infertility_2316",
    "text": " tube(s), caused by disease, obstruction, damage, scarring, congenital malformations or other factors, prevents oocyte pickup by the fimbriated ends of the tube or sperm access to the oocyte for fertilization in the tube, or impedes the fertilized egg and developing embryo from descending into the uterus, thereby preventing pregnancy or resulting in ectopic pregnancy. Of the different causes, the most prevalent is PID or salpingitis. In a large WHO multi-country study, bilateral tubal occlusion and acquired tubal abnormalities accounted for 17.7% and 11.6%, respectively, of all identifiable causes of female infertility ( 1, 2), although the distribution can vary between high-income, middle-income and low-income settings (see Annex 1. Distribution of the causes of infertility ). Given the role of the fallopian tube in gamete and embryo transport (3), assessment of tubal disease, particula",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 167
  },
  {
    "chunk_id": "infertility_2317",
    "text": " settings (see Annex 1. Distribution of the causes of infertility ). Given the role of the fallopian tube in gamete and embryo transport (3), assessment of tubal disease, particularly tubal patency is important in the investigation of female infertility. Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 167
  },
  {
    "chunk_id": "infertility_2318",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 144 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps The two modalities for managing (or overcoming) tubal factor infertility, such as blockage, are IVF and tubal surgery. IVF is an ART procedure that involves combining eggs and sperm outside the body in a laboratory. The resulting embryos are transferred into the uterine cavity, without the need for open fallopian tubes. Surgical procedures include salpingostomy (formation of an opening at the distal end of an occluded fallopian tube), fimbrioplasty (removal of scar tissue around the distal end of the tube or reconstructing the fimbriae to approximate normal anatomy) and adhesiolysis (performed to remove scar tissue around the tube) (4). Given that fecundity of women decreases with age (5),",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 168
  },
  {
    "chunk_id": "infertility_2319",
    "text": "nstructing the fimbriae to approximate normal anatomy) and adhesiolysis (performed to remove scar tissue around the tube) (4). Given that fecundity of women decreases with age (5), time to pregnancy is an important consideration when comparing surgery versus IVF. Apart from age, other important considerations include site and the extent of the tubal disease. The Hull and Rutherford classification of tubal disease uses clinical descriptive characteristics, including tubal mucosal status, fibrosis and distension, and the extent of peritubal-ovarian adhesions; it groups patients (< 40 years old and excluding endometriosis) according to the prognosis for pregnancy ( 6). Classification according to severity is related to the prognosis for spontaneous (i.e. unassisted) pregnancy after surgery (indicated by the expected 3-year pregnancy rate). Grade I refers to minor disease (with favourable su",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 168
  },
  {
    "chunk_id": "infertility_2320",
    "text": "ed to the prognosis for spontaneous (i.e. unassisted) pregnancy after surgery (indicated by the expected 3-year pregnancy rate). Grade I refers to minor disease (with favourable surgical prognosis of 85% clinical pregnancy rate [CPR] and 69% live birth rate [LBR]/3 years). Grade II indicates intermediate disease (with intermediate surgical prognosis of 72% CPR and 48% LBR/3 years), while grade III indicates severe disease (with unfavourable or poor surgical prognosis of 28% CPR and 9% LBR/3 years) ( 7). For these recommendations, the GDG addressed the question: should surgery versus IVF be used for women with infertility due to tubal disease? For these recommendations, surgical procedures for tubal disease exclude tubal re-anastomosis after sterilization (sterilization reversal). These recommendations assume that no significant male factor exists. Balancing harms and benefits A systemati",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 168
  },
  {
    "chunk_id": "infertility_2321",
    "text": "ude tubal re-anastomosis after sterilization (sterilization reversal). These recommendations assume that no significant male factor exists. Balancing harms and benefits A systematic review of the literature for randomized and non-randomized studies from 1990 to July 2019 was conducted. No RCTs comparing pregnancy rates after tubal surgery versus IVF were identified. Available evidence was identified from comparative non-randomized studies (8–10); the certainty of the evidence was very low because of potential confounding, low number of events and wide CIs, and the heterogeneity of surgical approaches. Studies providing data on tubal re-anastomosis were excluded. The balance of desirable and undesirable effects for tubal surgery or IVF was arrived at considering patient age and the severity of the disease. The overall data showed that compared to IVF, surgery may result in more live birth",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 168
  },
  {
    "chunk_id": "infertility_2322",
    "text": "for tubal surgery or IVF was arrived at considering patient age and the severity of the disease. The overall data showed that compared to IVF, surgery may result in more live births (212 more per 1000 [from 156 to 279 more]; RR: 3.36; 95% CI: 2.74–4.11) over a follow-up duration of at least 5 years and may also result in more clinical pregnancies over the same follow-up period (369 more per 1000 [from 300 to 447 more]; RR: 4.34; 95% CI: 3.72–5.05), suggesting the benefit of surgery in younger patients with a good prognosis based on the Hull and Rutherford classification, that is, grade I or II tubal disease. In addition, surgery may result in fewer miscarriages (10 fewer per 1000 [from 28 fewer to 18 more]; RR: 0.84; 95% CI: 0.54–1.30). Of note, the benefits from surgery were mainly from microsurgical techniques. The GDG judged these desirable effects to be large. In terms of harms, the ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 168
  },
  {
    "chunk_id": "infertility_2323",
    "text": " 0.84; 95% CI: 0.54–1.30). Of note, the benefits from surgery were mainly from microsurgical techniques. The GDG judged these desirable effects to be large. In terms of harms, the data showed that surgery may result in more ectopic pregnancies (120 more per 1000; risk difference (%): 12; 95% CI: 9–15). Data on multiple gestations and OHSS were not reported in the studies included. The GDG noted the absence of data on important outcomes such as bleeding, infection, injury to internal organs and blood vessels, risks of general anaesthesia, OHSS and high-order multiple pregnancy (HOMP). The GDG considered that there is very little risk, if any, of OHSS and HOMP with surgery but IVF may increase the risk of OHSS and HOMP; however, effective strategies to",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 168
  },
  {
    "chunk_id": "infertility_2324",
    "text": "1457 Treatment of infertility due to tubal disease Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps mitigate these risks of IVF, such as elective single embryo transfer, exist. However, the GDG noted that the greater risk of ectopic pregnancy, which may occur with surgery, may be more relevant in rural settings. However, in most cases these can be well managed by instituting heightened awareness and appropriate surveillance. The GDG considered that the outcomes of surgery are highly operator- dependent and may also be dependent on the extent and site of tubal disease. The GDG judged the undesirable effects to be small. Although no evidence was found regarding values, the GDG agreed that women with infertility value pregnancy and live birth highly as the main outcomes of the intervention, as well as minimizing",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 169
  },
  {
    "chunk_id": "infertility_2325",
    "text": "vidence was found regarding values, the GDG agreed that women with infertility value pregnancy and live birth highly as the main outcomes of the intervention, as well as minimizing ris ks. Based on these data, the GDG judged that the overall balance of effects probably does not favour either surgery or IVF. The GDG also noted that IVF outcomes and tubal surgery outcomes may vary in different settings depending on several factors, including the quality of the IVF laboratory and surgeon experience and expertise. In addition, the GDG considered the varying benefits of surgery for different subgroups, noting that the outcomes appear to be potentially influenced by several factors, including age and duration of follow-up. Cumulative pregnancy outcomes with surgery accrue over a longer duration of follow- up that ranges from 1 to 5 years, compared to IVF. Therefore, it is reasonable to offer s",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 169
  },
  {
    "chunk_id": "infertility_2326",
    "text": "ow-up. Cumulative pregnancy outcomes with surgery accrue over a longer duration of follow- up that ranges from 1 to 5 years, compared to IVF. Therefore, it is reasonable to offer surgery to younger patients (< 35 years) with mild and moderate disease (Hull and Rutherford grades I and II) because younger women may have time to explore other assisted reproduction options if pregnancy is not achieved after surgery. Given the resources expended in providing surgery, and the time required to achieve spontaneous (i.e. unassisted) pregnancy after surgery, it is recommended that health providers wait for a reasonable time (at least 1 year) after surgery before providing other interventions such as IVF. Most pregnancies occur within 1–2 years of surgical treatment of distal tubal disease ( 7, 11); therefore, waiting a minimum of 1 year may be reasonable. It should be noted that this recommendatio",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 169
  },
  {
    "chunk_id": "infertility_2327",
    "text": " occur within 1–2 years of surgical treatment of distal tubal disease ( 7, 11); therefore, waiting a minimum of 1 year may be reasonable. It should be noted that this recommendation does not apply to women desiring pregnancy after tubal ligation or sterilization. For younger women aged < 35 years with severe disease (Hull and Rutherford grade III) the harms of surgery probably outweigh its benefits. Although younger women aged < 35 years may have time to explore other assisted reproduction options if pregnancy is not achieved after surgery, severe disease (Hull and Rutherford grade III) has poor prognosis; therefore, IVF is recommended over surgery for these women. Given concerns related to age-related fertility decline, IVF is also suggested over surgery in women aged ≥ 35 years regardless of the severity of tubal disease. For older women ( ≥ 35 years) the additional time required to un",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 169
  },
  {
    "chunk_id": "infertility_2328",
    "text": "y decline, IVF is also suggested over surgery in women aged ≥ 35 years regardless of the severity of tubal disease. For older women ( ≥ 35 years) the additional time required to undergo surgery and wait for spontaneous (i.e. unassisted) pregnancy means that women would be much older before exploring other options such as IVF, should pregnancy not be achieved after surgery; therefore, they would have a much lower chance of achieving pregnancy. For older women, the benefits of IVF probably outweigh the harms compared to surgery. For women who are older, women with severe tubal disease and couples with male-factor infertility, IVF could be offered. The overall certainty of evidence was judged to be very low; all studies included were obs ervational. Other considerations Performing tubal reconstructive surgery with good results requires a well-equipped health system and a high level of exper",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 169
  },
  {
    "chunk_id": "infertility_2329",
    "text": "tudies included were obs ervational. Other considerations Performing tubal reconstructive surgery with good results requires a well-equipped health system and a high level of expertise or training. Although it is probably feasible to train health professionals to provide surgery (12), the resource requirements are often not available or met in many low-resource settings. Thus, the GDG judged that large resources are required for surgery and that compared to IVF, surgery would probably have no or limited effect on equity as IVF also involves high costs to be set up and operate.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 169
  },
  {
    "chunk_id": "infertility_2330",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 146 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Tubal surgery is often a one-time procedure that may be conducted as a minimally invasive outpatient procedure. It is more invasive than IVF. Given the impact of both age and severity of disease on pregnancies and live births, surgery is probably acceptable in younger patients with Hull and Rutherford grade I or II tubal disease, while in severe tubal disease (Hull and Rutherford grade III), IVF would probably be acceptable. Summary justification Surgery may increase pregnancies and live births after 5 years of follow-up more than IVF. Although surgery may increase the risk of ectopic pregnancy, a heightened awareness of its possibility with appropriate surveillance and management may mini",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 170
  },
  {
    "chunk_id": "infertility_2331",
    "text": "ollow-up more than IVF. Although surgery may increase the risk of ectopic pregnancy, a heightened awareness of its possibility with appropriate surveillance and management may minimize this risk. Surgery also may have fewer harms, including reduced risk of OHSS and HOMP. The overall desirable effects of clinical pregnancy and live births probably outweigh the risk of ectopic pregnancy. In addition, surgery is probably feasible to provide, is probably acceptable, and it probably has no impact on equity compared to IVF. Younger women (< 35 y ears) can pursue other assisted reproduction interventions if pregnancy fails to occur after surgery. However, for older women (≥ 35 years), the additional time required to undergo surgery and then receive IVF if surgery fails, means they would be much older and have a further reduced chance of pregnancy. Therefore, for older women the benefits of IVF ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 170
  },
  {
    "chunk_id": "infertility_2332",
    "text": "ndergo surgery and then receive IVF if surgery fails, means they would be much older and have a further reduced chance of pregnancy. Therefore, for older women the benefits of IVF probably outweigh its harms compared to surgery. Although IVF can increase the risk of OHSS and HOMP, these risks can be mitigated by strategies such as single embryo transfer. Time to pregnancy in patients with good, intermediate and poor prognosis (3-year rates) justify an age cut-off of 35 years because this age allows up to 3 years of follow-up at a time when women’s fertility potential is narrowing. The minimum time to wait after surgery before offering IVF is similar to the duration for the definition of infertility for women < 35 years, that is, failure to conceive within 1 year. Although the treatment timeline can be different from the diagnostic timeline, data show that most pregnancies occur within 1–",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 170
  },
  {
    "chunk_id": "infertility_2333",
    "text": "35 years, that is, failure to conceive within 1 year. Although the treatment timeline can be different from the diagnostic timeline, data show that most pregnancies occur within 1–2 years after surgery. Implementation considerations Health care providers should counsel patients, communicate the prognosis, clearly discuss the options and costs of surgery and IVF, and consider patient preferences. In settings where the infrastructure for tubal surgery or IVF does not exist, patient referrals to adequately equipped centres should be considered. Health care providers should be trained to adequately monitor, mitigate and manage the undesirable effects of surgery (such as ectopic pregnancy) and IVF (such as OHSS and HOMP). In implementing this recommendation, health care providers should consider whether patients have hydrosalpinges which may have a negative effect on pregnancy and IVF success",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 170
  },
  {
    "chunk_id": "infertility_2334",
    "text": "HOMP). In implementing this recommendation, health care providers should consider whether patients have hydrosalpinges which may have a negative effect on pregnancy and IVF success rates (13). If hydrosalpinx is present in women planning to undergo IVF, health care providers should implement recommendations related to treatment of hydrosalpinx before IVF, as described in the next section. In addition, these recommendations assume that no significant male factor exists.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 170
  },
  {
    "chunk_id": "infertility_2335",
    "text": "1477 Treatment of infertility due to tubal disease Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Research gaps and future guideline update Ovarian reserve may be an additional factor to consider; however, data were not available on the subgroup of women with decreased ovarian reserve, which should be addressed in future studies. Future studies should also assess important outcomes such as bleeding, infection, injury to internal organs and vessels, risks of general anaesthesia, OHSS and HOMP, and patients’ values, including attitudes towards surgery or IVF, and preferences related to time to pregnancy and desired family size. References 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 171
  },
  {
    "chunk_id": "infertility_2336",
    "text": "rences 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 2. Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985;2(8455):596-8 (https://doi.org/10.1016/ s0140-6736(85)90594-x). 3. Croxatto HB. Physiology of gamete and embryo transport through the fallopian tube. Reprod Biomed Online. 2002;4(2):160-9 (https://doi. org/10.1016/s1472-6483(10)61935-9). 4. Dawood MY. Laparoscopic surgery of the fallopian tubes and ovaries. Semin Laparosc Surg. 1999;6(2):58-67 (https://doi.org/10.1177/155 335069900600204). 5. Chua S, Danhof N, Mochtar M, Van Wely M, McLernon D, Custers I et al. Age-related natural fertility outcomes in women over 35 years: a systematic review and individual participant data meta-anal",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 171
  },
  {
    "chunk_id": "infertility_2337",
    "text": " N, Mochtar M, Van Wely M, McLernon D, Custers I et al. Age-related natural fertility outcomes in women over 35 years: a systematic review and individual participant data meta-analysis. Hum Reprod. 2020;35(8):1808-20 (https://doi.org/10.1093/humrep/deaa129). 6. Rutherford AJ, Jenkins JM. Hull and Rutherford classification of infertility. Hum Fertil. 2002;5(1 Suppl):S41-5 (https://doi.org/10.1080/146472702 2000199911). 7. Akande VA, Cahill DJ, Wardle PG , Rutherford AJ , Jenkins JM. The predictive value of the “Hull & Rutherford” classification for tubal damage. BJOG. 2004;111(11):1236 - 41 (https://doi. org/10.1111/j.1471- 0528.2004.00408.x). 8. Chatterjee S, Chatterjee A, Chowdhury R, Dey S, Ganguly D. Fertility promoting laparoscopic surgery: our experience. J South Asian Fed Obstet Gynecol. 2012;4(1):12-16 (https://doi. org/10.5005/jp-journals-10006-1163). 9. Tomazevic T, Ribic-Pucelj",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 171
  },
  {
    "chunk_id": "infertility_2338",
    "text": "ty promoting laparoscopic surgery: our experience. J South Asian Fed Obstet Gynecol. 2012;4(1):12-16 (https://doi. org/10.5005/jp-journals-10006-1163). 9. Tomazevic T, Ribic-Pucelj M. Ectopic pregnancy following the treatment of tubal infertility. J Reprod Med. 1992;37(7):611-14 (https://pubmed. ncbi.nlm.nih.gov/1522569/). 10. Tomazevic T, Ribic-Pucelj M. Microsurgery and in vitro fertilization/embryo transfer for infertility resulting from distal tubal lesions. J Reprod Med. 1991;36(7):527-30 (https://pubmed.ncbi.nlm.nih. gov/1941789/). 11. Audebert A, Pouly JL, Bonifacie B, Yazbeck C. Laparoscopic surgery for distal tubal occlusions: lessons learned from a historical series of 434 cases. Fertil Steril. 2014;102(4):1203-8 (https://doi. org/10.1016/j.fertnstert.2014.06.047). 12. Christopoulos G, Kelly T, Lavery S, Trew G. Surgical skills of specialty trainees in emergency gynaecological ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 171
  },
  {
    "chunk_id": "infertility_2339",
    "text": "02(4):1203-8 (https://doi. org/10.1016/j.fertnstert.2014.06.047). 12. Christopoulos G, Kelly T, Lavery S, Trew G. Surgical skills of specialty trainees in emergency gynaecological laparoscopic procedures: a national UK survey. J Obstet Gynaecol. 2014;34(5):435-8 (https://doi.org/10.3109/014436 15.2014.901304). 13. Tsiami A, Chaimani A, Mavridis D, Siskou M, Assimakopoulos E, Sotiriadis A. Surgical treatment for hydrosalpinx prior to in‐vitro fertilization embryo transfer: a network meta‐analysis. Ultrasound Obstet Gynecol. 2016;48(4):434-45 (https://doi.org/10.1002/ uog.15900).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 171
  },
  {
    "chunk_id": "infertility_2340",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 148 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 7.2 Treatment of hydrosalpinx before IVF Recommendation For females with tubal factor infertility due to hydrosalpinx, WHO suggests either salpingectomy or tubal occlusion before provision of in vitro fertilization (IVF). (Conditional recommendation, very low certainty evidence) Remark: • When selecting whether to use salpingectomy or tubal occlusion, consider feasibility, availability of trained health care providers and presence of adhesions. Background and rationale In cases of tubal disease or blockage, women may develop hydrosalpinx, a condition where fluid accumulates inside the fallopian tubes. The presence of hydrosalpinx may have a negative effect on successful embryo implantation",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 172
  },
  {
    "chunk_id": "infertility_2341",
    "text": " may develop hydrosalpinx, a condition where fluid accumulates inside the fallopian tubes. The presence of hydrosalpinx may have a negative effect on successful embryo implantation and affect IVF outcomes (1). Therefore, the GDG agreed that guidance is needed regarding the management of hydrosalpinx in patients who are scheduled to undergo IVF. Treatment of hydrosalpinx is aimed at preventing the hydrosalpingeal fluid from reaching the uterine cavity (2). Options for hydrosalpinx treatment include surgically resecting and removing the affected fallopian tubes (salpingectomy), isolating the hydrosalpinx from the uterine cavity using laparoscopic or hysteroscopic tubal occlusion, transvaginal aspiration of hydrosalpingeal fluid under ultrasound guidance or draining the hydrosalpingeal fluid by means of salpingostomy (3). For this recommendation, the GDG addressed the question: should salpi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 172
  },
  {
    "chunk_id": "infertility_2342",
    "text": "alpingeal fluid under ultrasound guidance or draining the hydrosalpingeal fluid by means of salpingostomy (3). For this recommendation, the GDG addressed the question: should salpingectomy or tubal occlusion versus none be used to treat tubal disease due to hydrosalpinx in women due to undergo IVF? Balancing harms and benefits A systematic review published in 2020 was identified, with a search date from inception of the databases up to January 2020 (3). From this systematic review, four RCTs published between 1998 and 2006 provided data for the outcomes (4–7). The results showed that compared to no treatment, conducting salpingectomy or tubal occlusion before IVF may result in slightly greater pregnancies and no difference in ectopic pregnancy and miscarriage. There were 151 more pregnancies (from 58 to 287 more) per 1000 (RR: 2.01; 95% CI: 1.39–2.91), three fewer miscarriages (from 32 f",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 172
  },
  {
    "chunk_id": "infertility_2343",
    "text": "o difference in ectopic pregnancy and miscarriage. There were 151 more pregnancies (from 58 to 287 more) per 1000 (RR: 2.01; 95% CI: 1.39–2.91), three fewer miscarriages (from 32 fewer to 71 more) per 1000 (RR: 0.94; 95% CI: 0.36–2.41) and nine fewer ectopic pregnancies (from 14 fewer to 15 more) per 1000 (RR: 0.39; 95% CI: 0.08–1.97). Live births and quality of life outcomes were not reported. Compared to no treatment before IVF, conducting salpingectomy or tubal occlusion before IVF may result in 10 more conversions to laparotomy (RD: 0.01; 95% CI: -0.02 to 0.03) and 10 more pelvic infections per 1000 (RD: 0.01; 95% CI: -0.02 to 0.03). Although not measured, the GDG noted that the risk of other potential complications, such as visceral injuries, injury to blood vessels and bleeding, may exist with salpingectomy or tubal occlusion conducted before IVF. The GDG agreed that there were mod",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 172
  },
  {
    "chunk_id": "infertility_2344",
    "text": "lications, such as visceral injuries, injury to blood vessels and bleeding, may exist with salpingectomy or tubal occlusion conducted before IVF. The GDG agreed that there were moderate benefits, but small harms, based on the very low certainty of the evidence because of few events or participants. Therefore, the GDG judged that the balance of effects probably favours surgery over no treatment before IVF.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 172
  },
  {
    "chunk_id": "infertility_2345",
    "text": "1497 Treatment of infertility due to tubal disease Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Other considerations No studies documented patient values; however, the GDG agreed that most couples would place higher value on maximizing pregnancy and birth outcomes and minimizing harms. The GDG agreed that the resources for surgery (e.g. equipment) and personnel training would result in moderate costs, although some cost variations between countries is expected. No evidence was found on cost-effectiveness. The GDG noted that because of the costs, treatment with salpingectomy or tubal occlusion before IVF would probably reduce equity in settings with limited public health financing of infertility treatment. The GDG judged that surgery is probably acceptable, noting that while most couples would prefer to av",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 173
  },
  {
    "chunk_id": "infertility_2346",
    "text": "ity in settings with limited public health financing of infertility treatment. The GDG judged that surgery is probably acceptable, noting that while most couples would prefer to avoid invasive treatment, someone with confirmed hydrosalpinx who understands the impact of the condition on their IVF outcome would probably opt for treatment with salpingectomy or tubal occlusion to optimize the chance of success with subsequent IVF. The GDG judged that salpingectomy and tubal occlusion are probably feasible but require surgical facilities and training. Summary justification Compared to no treatment before IVF, salpingectomy or tubal occlusion before IVF may lead to a moderate increase in clinical pregnancies but may have little to no effect on ectopic pregnancy or miscarriage; there is no information about the effects on live births or quality of life. The evidence was uncertain about whether ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 173
  },
  {
    "chunk_id": "infertility_2347",
    "text": "have little to no effect on ectopic pregnancy or miscarriage; there is no information about the effects on live births or quality of life. The evidence was uncertain about whether salpingectomy or tubal occlusion before IVF increases the risk of surgical complications. Despite the moderate additional cost of salpingectomy or tubal occlusion before IVF, both interventions may improve the effectiveness of IVF; therefore, the GDG suggests that either salpingectomy or tubal occlusion be used for the treatment of hydrosalpinx before IVF. Salpingectomy and/or tubal occlusion are probably feasible, and probably acceptable as most patients would likely want to improve IVF outcomes. Implementation considerations Caution should be taken during salpingectomy for hydrosalpinx conducted before IVF to avoid compromising the vascular supply to the ovaries, which could potentially result in suboptimal o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 173
  },
  {
    "chunk_id": "infertility_2348",
    "text": " should be taken during salpingectomy for hydrosalpinx conducted before IVF to avoid compromising the vascular supply to the ovaries, which could potentially result in suboptimal ovarian stimulation. Health care providers may consider several factors to determine whether to offer salpingectomy or tubal occlusion before IVF, for example, the presence of dense adhesions and patient preferences. Health care providers should monitor patients for potential complications after salpingectomy or tubal occlusion. Research gaps and future guideline update Future studies should report outcomes related to live birth rates, complications and quality of life, and should compare the different techniques of salpingectomy or tubal occlusion. Future guidance will be required on subgroups that may benefit optimally, for example, based on whether the hydrosalpinx is communicating or not. Future guidance wil",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 173
  },
  {
    "chunk_id": "infertility_2349",
    "text": "bal occlusion. Future guidance will be required on subgroups that may benefit optimally, for example, based on whether the hydrosalpinx is communicating or not. Future guidance will be required regarding the optimal timing of salpingectomy or tubal occlusion in relation to ovarian stimulation and egg retrieval.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 173
  },
  {
    "chunk_id": "infertility_2350",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 150 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Strandell A, Waldenström U, Nilsson L, Hamberger L. Hydrosalpinx reduces in-vitro fertilization/embryo transfer pregnancy rates. Hum Reprod. 1994;9(5):861-3 (https://doi. org/10.1093/oxfordjournals.humrep.a138606). 2. Palagiano A, Cozzolino M, Ubaldi FM, Palagiano C, Coccia ME. Effects of hydrosalpinx on endometrial implantation failures: evaluating salpingectomy in women undergoing in vitro fertilization. Rev Bras Ginecol Obstet. 2021;43(4):304-10 (https://doi. org/10.1055/s-0040-1722155). 3. Melo P, Georgiou EX, Johnson N, Voorst SF, Strandell A, Mol BWJ et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 174
  },
  {
    "chunk_id": "infertility_2351",
    "text": "P, Georgiou EX, Johnson N, Voorst SF, Strandell A, Mol BWJ et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2020;(10):CD002125 (https://doi. org/10.1002/14651858.CD002125.pub4). 4. Strandell A, Lindhard A, Waldenström U, Thorburn J, Janson P, Hamberger L. Hydrosalpinx and IVF outcome: a prospective, randomized multicentre trial in Scandinavia on salpingectomy prior to IVF. Hum Reprod. 1999;14(11):2762-9 (https://doi.org/10.1093/humrep/14.11.2762). 5. Kontoravdis A, Makrakis E, Pantos K, Botsis D, Deligeoroglou E, Creatsas G. Proximal tubal occlusion and salpingectomy result in similar improvement in in vitro fertilization outcome in patients with hydrosalpinx. Fertil Steril. 2006;86(6):1642-9 (https://doi.org/10.1016/j. fertnstert.2006.05.032). 6. Déchaud H, Daurès JP, Arnal F, Humeau C, Hédon B. Does previous salping",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 174
  },
  {
    "chunk_id": "infertility_2352",
    "text": " with hydrosalpinx. Fertil Steril. 2006;86(6):1642-9 (https://doi.org/10.1016/j. fertnstert.2006.05.032). 6. Déchaud H, Daurès JP, Arnal F, Humeau C, Hédon B. Does previous salpingectomy improve implantation and pregnancy rates in patients with severe tubal factor infertility who are undergoing in vitro fertilization? A pilot prospective randomized study. Fertil Steril. 1998;69(6):1020-5 (https://doi.org/10.1016/s0015- 0282(98)00077-6). 7. Moshin V, Hotineanu A. Reproductive outcome of the proximal tubal occlusion prior to IVF in patients with hydrosalpinx. Abstracts of the 22nd Annual Meeting of ESHRE. Hum Reprod. 2006;21 (Suppl 1):i189-i193 (https://doi.org/10.1093/ oxfordjournals.humrep.a002507).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 174
  },
  {
    "chunk_id": "infertility_2353",
    "text": "1517 Treatment of infertility due to tubal disease Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For females with tubal factor infertility due to hydrosalpinx, WHO suggests either salpingectomy or tubal occlusion rather than transvaginal aspiration of hydrosalpingeal fluid before provision of in vitro fertilization (IVF). (Conditional recommendation, very low certainty of evidence for salpingectomy compared with tubal occlusion, and very low certainty of evidence for transvaginal aspiration compared to no treatment) Remark: • In settings where salpingectomy and tubal occlusion are not available or feasible, transvaginal aspiration may be offered. Background and rationale Options for hydrosalpinx treatment include surgically resecting and removing the affected fallopian tubes (salpingectomy),",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 175
  },
  {
    "chunk_id": "infertility_2354",
    "text": "ginal aspiration may be offered. Background and rationale Options for hydrosalpinx treatment include surgically resecting and removing the affected fallopian tubes (salpingectomy), isolating the hydrosalpinx from the uterine cavity using laparoscopic or hysteroscopic tubal occlusion, transvaginal aspiration of hydrosalpingeal fluid under ultrasound guidance or draining the hydrosalpingeal fluid by means of salpingostomy (1). For this recommendation, the GDG addressed the question: should transvaginal aspiration of hydrosalpingeal fluid versus no treatment be used in tubal disease in women with hydrosalpinx who are due to undergo IVF? Balancing harms and benefits A systematic review published in 2020 was identified, with a search date from inception of the databases up to January 2020 (1). From this systematic review, three RCTs published between 2008 and 2015 provided data for the outcom",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 175
  },
  {
    "chunk_id": "infertility_2355",
    "text": "ied, with a search date from inception of the databases up to January 2020 (1). From this systematic review, three RCTs published between 2008 and 2015 provided data for the outcomes (2–4). The results showed that transvaginal aspiration before IVF may result in a small increase in pregnancies and no differences in ectopic pregnancy or miscarriage compared to no treatment before IVF. There may be 96 more clinical pregnancies (from 12 to 226 more) per 1000 with transvaginal aspiration (RR: 1.64; 95% CI: 1.08–2.51), 12 more miscarriages (from 27 fewer to 118 more) per 1000 (RR: 1.24; 95% CI: 0.46–3.36) and five fewer ectopic pregnancies (from 13 fewer to 54 more) per 1000 (RR: 0.69; 95% CI: 0.10–4.62). Live births and quality of life outcomes were not reported. In addition, there may be no difference in pelvic infection, but a slight increase in multiple pregnancy, which is likely attribut",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 175
  },
  {
    "chunk_id": "infertility_2356",
    "text": "s and quality of life outcomes were not reported. In addition, there may be no difference in pelvic infection, but a slight increase in multiple pregnancy, which is likely attributable to IVF treatment: transvaginal aspiration may result in zero fewer pelvic infections per 1000 (RD: 0; 95% CI: -0.03 to 0.03) and 53 more multiple pregnancies (from 19 fewer to 373 more) per 1000 (RR: 2.33; 95% CI: 0.52–10.32). There may also be an important proportion of women with recurrence after transvaginal aspiration; the number of other major or minor complications is low. Overall, recurrence with or without sclerotherapy occurred in 27% (18–39%). More specifically, without sclerotherapy, recurrence was 53% (46–60%); with sclerotherapy, it was 14% (8–22%). Major complications occurred in 10 out of 1297 (0.7%) and minor complications (e.g. pain, extravasation, ruptured cyst, flush reactions and gastro",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 175
  },
  {
    "chunk_id": "infertility_2357",
    "text": "clerotherapy, it was 14% (8–22%). Major complications occurred in 10 out of 1297 (0.7%) and minor complications (e.g. pain, extravasation, ruptured cyst, flush reactions and gastrointestinal discomfort) in 80 out of 1297 (6%). Based on these data, the GDG judged that there may be small desirable and undesirable effects of transvaginal aspiration compared to no treatment before IVF. The certainty of evidence was judged to be very low because of inconsistent blinding of participants and outcome assessors, loss to follow-up and few events or participants; some studies were not comparative. Although the GDG agreed that most people would place higher value on pregnancy and birth outcomes, while wanting to minimize harms, they judged that the balance of effects probably does not favour either transvaginal aspiration or no treatment.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 175
  },
  {
    "chunk_id": "infertility_2358",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 152 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Other considerations The GDG agreed that the resources for transvaginal aspiration would result in moderate costs. No data were found on cost-effectiveness; however, the GDG considered that transvaginal aspiration would probably not be cost-effective because of the moderate costs, small benefits and small harms. No studies of the impact on health equity were available; however, the GDG judged that in women receiving IVF, the addition of transvaginal aspiration of hydrosalpingeal fluid before IVF would probably reduce equity because of additional costs. No data were identified on acceptability; however, the GDG judged that transvaginal aspiration would probably not be acceptable given that ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 176
  },
  {
    "chunk_id": "infertility_2359",
    "text": "duce equity because of additional costs. No data were identified on acceptability; however, the GDG judged that transvaginal aspiration would probably not be acceptable given that most people would like to avoid an invasive procedure when there may be little benefit compared to harm. Nevertheless, the GDG judged that transvaginal aspiration is probably feasible, noting that ultrasound is available in most settings as a basic tool for gynaecological assessment; training of health care providers is required to perform transvaginal aspiration safely. Summary justification Transvaginal aspiration before IVF may lead to a small increase in clinical pregnancies, but it may have little to no effect on ectopic pregnancy or miscarriage; there are no data about its effects on live births or quality of life. There may be a slight increase in multiple pregnancy when transvaginal aspiration is conduc",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 176
  },
  {
    "chunk_id": "infertility_2360",
    "text": "y or miscarriage; there are no data about its effects on live births or quality of life. There may be a slight increase in multiple pregnancy when transvaginal aspiration is conducted before IVF, and a clinically important proportion of women may experience recurrence after aspiration; however, the rates of other complications are low. As the benefits may be small, the GDG agreed that other procedures for the treatment of hydrosalpinx with greater benefits, that is, salpingectomy or tubal occlusion be used instead of transvaginal aspiration. However, in settings where salpingectomy and tubal occlusion are not available or feasible, transvaginal aspiration may be considered. Implementation considerations Health care providers should monitor patients for potential complications after treatment of hydrosalpinx, including post-aspiration infection, recurrence of fluid accumulation and accumu",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 176
  },
  {
    "chunk_id": "infertility_2361",
    "text": "care providers should monitor patients for potential complications after treatment of hydrosalpinx, including post-aspiration infection, recurrence of fluid accumulation and accumulation of fluid in the endometrial cavity. Health care providers should note that transvaginal aspiration may only be offered if salpingectomy and tubal occlusion are not available or feasible. Research gaps and future guideline update Future guidance comparing transvaginal aspiration with salpingectomy or tubal occlusion should report outcomes related to live birth rates and surgical complications, optimal timing of procedures in relation to ovarian stimulation and oocyte retrieval or embryo transfer, and quality of life. Further guidance will be required regarding whether antibiotic prophylaxis should be used routinely if transvaginal aspiration is provided before IVF.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 176
  },
  {
    "chunk_id": "infertility_2362",
    "text": "1537 Treatment of infertility due to tubal disease Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Melo P, Georgiou EX, Johnson N, Voorst SF, Strandell A, Mol BWJ et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2020;(10):CD002125 (https://doi. org/10.1002/14651858.CD002125.pub4). 2. An J, Ni Y, Liu X, Gao X, Wang Y. Effects of transvaginal aspiration of hydrosalpinx combined auricular point sticking on IVF-ET outcomes [article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(6):682-5 (in Chinese). 3. Hammadieh N, Coomarasamy A, Ola B, Papaioannou S, Afnan M, Sharif K. Ultrasound- guided hydrosalpinx aspiration during oocyte collection improves pregnancy outcome in IVF: a randomized controlled trial. Hum Reprod. 2008",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 177
  },
  {
    "chunk_id": "infertility_2363",
    "text": "ioannou S, Afnan M, Sharif K. Ultrasound- guided hydrosalpinx aspiration during oocyte collection improves pregnancy outcome in IVF: a randomized controlled trial. Hum Reprod. 2008;23(5):1113-7 (https://doi.org/10.1093/ humrep/den071). 4. Fouda UM, Sayed AM. Effect of ultrasound- guided aspiration of hydrosalpingeal fluid during oocyte retrieval on the outcomes of in vitro fertilisation-embryo transfer: a randomised controlled trial (NCT01040351). Gynecol Endocrinol. 2011;27(8):562-7 (https://doi.org/10.3 109/09513590.2010.507290).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 177
  },
  {
    "chunk_id": "infertility_2364",
    "text": "154 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 8 Treatment of infertility due to uterine cavity disorder This section presents recommendations related to the management of uterine cavity disorders. Abnormalities of the uterine cavity may be congenital and acquired; rarely, they have an unknown etiology. Congenital abnormalities stem from aberrations in the development of the genital tract in the female (1). Examples of acquired abnormalities include intrauterine adhesions, adenomas, fibroids or polyps, among others (see the WHO manual for the standardized investigation and diagnosis of the infertile couple [2] and its annexes). This chapter discusses the management of congenital abnormalities of the uterine cavity prioritized by the GDG, specifically uterine septum in women with infertility. Further gui",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 178
  },
  {
    "chunk_id": "infertility_2365",
    "text": ". This chapter discusses the management of congenital abnormalities of the uterine cavity prioritized by the GDG, specifically uterine septum in women with infertility. Further guidance for other uterine conditions will be provided in a subsequent edition of this guideline. 8.1 Management of uterine septum in females with infertility Recommendation For females with infertility and uterine septum who have no history of recurrent pregnancy loss, WHO suggests that hysteroscopic septum resection (septoplasty) not be performed. (Conditional recommendation, low certainty of evidence) Background and rationale Congenital uterine malformations represent a variety of anomalies of the female reproductive tract, which result from the abnormal differentiation, formation, migration, fusion, canalization or resorption of the Müllerian system during the fetal period ( 3). The prevalence of congenital ut",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 178
  },
  {
    "chunk_id": "infertility_2366",
    "text": "lt from the abnormal differentiation, formation, migration, fusion, canalization or resorption of the Müllerian system during the fetal period ( 3). The prevalence of congenital uterine malformations has been estimated at 4.3% in fertile women, 3.5–8.0% in women with infertility and 13–13.3% in women with recurrent pregnancy losses ( 4, 5). Discrepancy in the prevalence rates has been reported in the literature, potentially because of different classifications (4, 6–12) and the use of different diagnostic methods, with variable ability of identifying and distinguishing these uterine malformations (5). There is a lack of a single universally accepted evidence-based system for the definitions and diagnostic criteria of Müllerian anomalies. Uterine malformations include: • Müllerian agenesis, which is characterized by a failure of the Müllerian ducts to develop. • Arcuate uterus, which is c",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 178
  },
  {
    "chunk_id": "infertility_2367",
    "text": "ria of Müllerian anomalies. Uterine malformations include: • Müllerian agenesis, which is characterized by a failure of the Müllerian ducts to develop. • Arcuate uterus, which is characterized by a mild concave indentation at the uterine fundus. • Unicornuate or bicornuate uteri or uterus didelphys, which is characterized by varying abnormalities in fusion or unification defects of the Müllerian ducts. • Subseptate or septate uteri characterized by varying abnormalities in canalization of the Müllerian ducts. Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 178
  },
  {
    "chunk_id": "infertility_2368",
    "text": "1558 Treatment of infertility due to uterine cavity disorder Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Of these malformations, septate, bicornuate and arcuate uteri are the most commonly reported among unselected populations ( 4, 5); however, a septate uterus is likely more prevalent among populations at the highest risk of poor reproductive outcomes (5, 13). A 2011 systematic review and meta-analysis found that presence of a subseptate or septate uterus is associated with reduced fertility (RR: 0.86; 95% CI: 0.77–0.96), increased first-trimester miscarriage rates (RR: 2.9; 95% CI 2.0 0–4.1) and increased preterm births (RR: 2.1; 95% CI 1.5–3.1) (14). In the same meta-analysis, arcuate uteri were associated with increased rates of second-trimester miscarriage (RR: 2.39; 95% CI, 1.33–4.27), while unific",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 179
  },
  {
    "chunk_id": "infertility_2369",
    "text": "2.1; 95% CI 1.5–3.1) (14). In the same meta-analysis, arcuate uteri were associated with increased rates of second-trimester miscarriage (RR: 2.39; 95% CI, 1.33–4.27), while unification defects (unicornuate or bicornuate uteri or uterus didelphys) were associated with increased rates of preterm birth (RR: 2.97; 95% CI: 2.08–4.23) (14). Given that a septate uterus is among the most common uterine malformations (4, 5) and has the most data available from studies, the GDG guideline prioritized management of septate uterus over other uterine anomalies. Options for managing uterine septae include expectant management, or surgery through hysteroscopic septum resection ( 13). Although hysteroscopic septum resection is widely reported in the literature and is not uncommon in clinical practice, there is uncertainty regarding its benefit. For this recommendation, the GDG addressed the question: sh",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 179
  },
  {
    "chunk_id": "infertility_2370",
    "text": " widely reported in the literature and is not uncommon in clinical practice, there is uncertainty regarding its benefit. For this recommendation, the GDG addressed the question: should hysteroscopic metroplasty (resection of uterine septum [“septoplasty”]) versus no treatment (i.e. expectant management) be used for women with infertility and uterine septae? Therefore, the population of interest for this recommendation are women with infertility and without recurrent pregnancy loss. Although the literature often includes women with miscarriage as part of the infertile population (13, 15), this recommendation considered these as separate groups. Balancing harms and benefits Evidence was identified from a recent review (16), a recent RCT (17) and nine non-randomized comparative studies ( 18–26). Low-certainty evidence showed that both the benefits and harms of septoplasty are small. In term",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 179
  },
  {
    "chunk_id": "infertility_2371",
    "text": "eview (16), a recent RCT (17) and nine non-randomized comparative studies ( 18–26). Low-certainty evidence showed that both the benefits and harms of septoplasty are small. In terms of benefits, data showed that providing hysteroscopic septoplasty may increase clinical pregnancies slightly (RR: 1.13; 95% CI: 0.74–1.74; 65 more, [from 130 fewer to 370 more], per 1000), but may have little to no difference on live births compared to expectant management (RR: 0.92; 95% CI: 0.48–1.75; 24 fewer, [from 156 fewer to 225 more], per 1000). In terms of harms, hysteroscopic septoplasty in the context of infertility treatment may result in slightly more multiple pregnancies (RD: 0.06; 95% CI: -0.03 to 0.15; 60 more, [from 30 fewer to 150 more], per 1000) and slightly more miscarriages (RR: 1.83; 95% CI: 0.70–4.81; 249 more, [from 90 fewer to 1000 more], per 1000), and little to no difference in pret",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 179
  },
  {
    "chunk_id": "infertility_2372",
    "text": "30 fewer to 150 more], per 1000) and slightly more miscarriages (RR: 1.83; 95% CI: 0.70–4.81; 249 more, [from 90 fewer to 1000 more], per 1000), and little to no difference in preterm births, ectopic pregnancies or other adverse reproductive outcomes when compared to expectant management. In addition, there may be a small risk of uterine perforation with surgical resection. No reports of fluid overload were reported in one study that evaluated this outcome (17). Most of the studies included contributed equally to most of the outcomes assessed. Most also included populations with infertility without recurrent pregnancy loss. Some studies included women with an arcuate uterus. Despite the heterogeneity of the studies included, the results were quite consistent across studies, except for one study by Li et al. (21), which reported worse results with septoplasty. In this study (21), indicati",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 179
  },
  {
    "chunk_id": "infertility_2373",
    "text": "dies included, the results were quite consistent across studies, except for one study by Li et al. (21), which reported worse results with septoplasty. In this study (21), indications for surgery were (i) septum depth ≥ 10 mm; (ii) septum depth between 5 and 10 mm with unexplained recurrent miscarriage or infertility; and (iii) recurrent failures of IVF and embryo transfer. Notably, this study reported higher miscarriage and lower live birth rates with surgery, which potentially changed the overall result to null in the adjusted analyses. The inclusion of data from women with an arcuate uterus, for which septoplasty may not be indicated, did not seem to affect the balance of effects. These results suggested that there is no clear evidence that the benefits of septoplasty outweigh its harms. The GDG judged that the balance of desirable and undesirable effects probably did not favour eithe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 179
  },
  {
    "chunk_id": "infertility_2374",
    "text": "t there is no clear evidence that the benefits of septoplasty outweigh its harms. The GDG judged that the balance of desirable and undesirable effects probably did not favour either septoplasty or expectant management.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 179
  },
  {
    "chunk_id": "infertility_2375",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 156 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Other considerations Evidence on patient values and acceptability was limited. However, the GDG noted that some women may prefer to avoid invasive surgery, especially when the benefit is small. Among health care providers, acceptability for septoplasty varied. In a randomized study involving 191 gynaecologists from 43 countries, the agreement on the need for surgery once a septate uterus had been diagnosed was low (27). Although hysteroscopic septoplasty is probably feasible, it involves moderate costs. Equipment and training of health care providers are required for the safe provision of hysteroscopic septoplasty, including prevention of fluid overload, which may not be available in all s",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 180
  },
  {
    "chunk_id": "infertility_2376",
    "text": " and training of health care providers are required for the safe provision of hysteroscopic septoplasty, including prevention of fluid overload, which may not be available in all settings. The GDG acknowledged that contextual differences may exist in terms of the costs associated with hysteroscopic septoplasty and may also depend on differences in the availability of funding for infertility treatment. No relevant studies comparing the cost-effectiveness of hysteroscopic septoplasty versus expectant management were found. While limited evidence related to the impact of hysteroscopy on cost- effectiveness (28) or equity exists, the GDG judged that hysteroscopic septoplasty would likely reduce equity if only select people can afford it, which is likely given the potential costs to both individuals and health care systems. Summary justification Low-certainty evidence shows that there may be ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 180
  },
  {
    "chunk_id": "infertility_2377",
    "text": "t people can afford it, which is likely given the potential costs to both individuals and health care systems. Summary justification Low-certainty evidence shows that there may be small undesirable effects with hysteroscopic uterine septum resection, particularly miscarriage, ectopic pregnancy and preterm birth, which balance with the small overall increase in benefits (including clinical pregnancy and live birth) that may result from the procedure. The balance of desirable and undesirable effects probably does not favour either hysteroscopic septoplasty or expectant management for treatment of infertility. Although hysteroscopic septoplasty is probably feasible to provide, it involves moderate cost or resources compared to expectant management. Acceptability of hysteroscopic septoplasty among health providers varies; in the absence of direct evidence from patients, it is possible that s",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 180
  },
  {
    "chunk_id": "infertility_2378",
    "text": "s compared to expectant management. Acceptability of hysteroscopic septoplasty among health providers varies; in the absence of direct evidence from patients, it is possible that some women would likely want to avoid invasive procedures, especially when the benefit is small. Implementation considerations Health care providers should be aware that this recommendation also applies to women with an arcuate uterus, which is regarded as a variant of normal morphology for which hysteroscopic septum resection is generally not indicated. This recommendation does not address intrauterine polyps, a bicornuate uterus or uterine fibroids. Health care providers should take caution regarding different or changing definitions of what constitutes a uterine septum or an arcuate uterus. Definitions of septate and arcuate uteri vary widely (e.g. length, width of septum). Research gaps and future guideline ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 180
  },
  {
    "chunk_id": "infertility_2379",
    "text": " of what constitutes a uterine septum or an arcuate uterus. Definitions of septate and arcuate uteri vary widely (e.g. length, width of septum). Research gaps and future guideline update Large randomized controlled studies are required to provide high-quality evidence on the effects of hysteroscopic septoplasty and to identify specific subgroups with infertility that could benefit from septoplasty. Future studies should be large enough to measure outcomes stratified according to types, depth or width of uterine septae, and other subgroup categories of interest to health practitioners (including those due to undergo IVF). Careful attention to inclusion and exclusion criteria is warranted to ensure that any future studies are meaningful. These efforts should be complemented",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 180
  },
  {
    "chunk_id": "infertility_2380",
    "text": "1578 Treatment of infertility due to uterine cavity disorder Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps by strengthening and consistent use of evidence- based definitions and diagnostic criteria of Müllerian anomalies. This recommendation relates to populations of women with infertility but not those with recurrent pregnancy loss. Future guidance will be required on the role of septoplasty in fertile women (with a septate uterus) who have recurrent pregnancy losses after achieving a pregnancy. In addition, this recommendation does not assess the harms or benefits of septoplasty in women (with a septate uterus) who have implantation failure; future guidance will be required to address this question. References 1. Rowe PJ. Infertility. World Health. 1987:20-1 (https://iris.who.int/handle/10665/53389). 2. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 181
  },
  {
    "chunk_id": "infertility_2381",
    "text": "ation failure; future guidance will be required to address this question. References 1. Rowe PJ. Infertility. World Health. 1987:20-1 (https://iris.who.int/handle/10665/53389). 2. Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ. WHO manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 1993 (https://iris. who.int/handle/10665/36983). 3. Kobayashi A, Behringer RR. Developmental genetics of the female reproductive tract in mammals. Nat Rev Genet. 2003;4(12):969-80 (https://doi.org/10.1038/nrg1225). 4. Grimbizis GF, Gordts S, Di Spiezio Sardo A, Brucker S, De Angelis C, Gergolet M et al. The ESHRE/ESGE consensus on the classification of female genital tract congenital anomalies. Hum Reprod. 2013;28(8):2032-44 (https://doi. org/10.1093/humrep/det098). 5. Chan Y, Jayaprakasan K, Zamora J, Thornton J, Raine-Fenning N, Coomarasamy",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 181
  },
  {
    "chunk_id": "infertility_2382",
    "text": "l tract congenital anomalies. Hum Reprod. 2013;28(8):2032-44 (https://doi. org/10.1093/humrep/det098). 5. Chan Y, Jayaprakasan K, Zamora J, Thornton J, Raine-Fenning N, Coomarasamy A. The prevalence of congenital uterine anomalies in unselected and high-risk populations: a systematic review. Hum Reprod Update. 2011;17(6):761-71 (https://doi.org/10.1093/ humupd/dmr028). 6. Buttram Jr VC, Gibbons WE. Müllerian anomalies: a proposed classification (an analysis of 144 cases). Fertil Steril. 1979;32(1):40-6 (https://doi. org/10.1016/s0015-0282(16)44114-2). 7. The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, Müllerian anomalies and intrauterine adhesions. Fertil Steril. 1988;49(6):944-55 (https://doi.org/10.1016/ s0015-0282(16)59942-7). 8. Acién P, Acién M, Sánchez-Ferrer M. Complex malf",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 181
  },
  {
    "chunk_id": "infertility_2383",
    "text": "llerian anomalies and intrauterine adhesions. Fertil Steril. 1988;49(6):944-55 (https://doi.org/10.1016/ s0015-0282(16)59942-7). 8. Acién P, Acién M, Sánchez-Ferrer M. Complex malformations of the female genital tract. New types and revision of classification. Hum Reprod. 2004;19(10):2377-84 (https://doi.org/10.1093/ humrep/deh423). 9. Oppelt P, Renner SP, Brucker S, Strissel PL, Strick R, Oppelt PG et al. The VCUAM (Vagina Cervix Uterus Adnex-associated Malformation) classification: a new classification for genital malformations. Fertil Steril. 2005;84(5):1493-7 (https://doi.org/10.1016/j.fertnstert.2005.05.036). 10. Gubbini G, Di Spiezio Sardo A, Nascetti D, Marra E, Spinelli M, Greco E et al. New outpatient subclassification system for American Fertility Society classes V and VI uterine anomalies. J Minim Invasive Gynecol. 2009;16(5):554-61 (https://doi.org/10.1016/j.jmig.2009.06.002)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 181
  },
  {
    "chunk_id": "infertility_2384",
    "text": "subclassification system for American Fertility Society classes V and VI uterine anomalies. J Minim Invasive Gynecol. 2009;16(5):554-61 (https://doi.org/10.1016/j.jmig.2009.06.002). 11. Pfeifer SM, Attaran M, Goldstein J, Lindheim SR, Petrozza JC, Rackow BW et al. ASRM müllerian anomalies classification 2021. Fertil Steril. 2021;116(5):1238-52 (https://doi.org/10.1016/j. fertnstert.2021.09.025). 12. Ludwin A, Ludwin I, Coelho Neto MA, Nastri CO, Bhagavath B, Lindheim SR et al. Septate uterus according to ESHRE/ESGE, ASRM and CUME definitions: association with infertility and miscarriage, cost and warnings for women and health care systems. Ultrasound Obstet Gynecol. 2019;54(6):800-14 (https://doi.org/10.1002/ uog.20291). 13. Homer HA, Li T-C, Cooke ID. The septate uterus: a review of management and reproductive outcome. Fertil Steril. 2000;73(1):1-14 (https://doi. org/10.1016/s0015-0282(",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 181
  },
  {
    "chunk_id": "infertility_2385",
    "text": "og.20291). 13. Homer HA, Li T-C, Cooke ID. The septate uterus: a review of management and reproductive outcome. Fertil Steril. 2000;73(1):1-14 (https://doi. org/10.1016/s0015-0282(99)00480-x).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 181
  },
  {
    "chunk_id": "infertility_2386",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 158 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 14. Chan Y, Jayaprakasan K, Tan A, Thornton J, Coomarasamy A, Raine‐Fenning N. Reproductive outcomes in women with congenital uterine anomalies: a systematic review. Ultrasound Obstet Gynecol. 2011;38(4):371-82 (https://doi. org/10.1002/uog.10056). 15. Carrera M, Pérez Millan F, Alcázar JL, Alonso L, Caballero M, Carugno J et al. Effect of hysteroscopic metroplasty on reproductive outcomes in women with septate uterus: systematic review and meta-analysis. J Minim Invasive Gynecol. 2022;29(4):465-75 (https://doi. org/10.1016/j.jmig.2021.10.001). 16. Rikken JFW, Kowalik CR, Emanuel MH, Mol BWJ, Van der Veen F, van Wely M et al. Septum resection for women of reproductive age with a septate ut",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 182
  },
  {
    "chunk_id": "infertility_2387",
    "text": "org/10.1016/j.jmig.2021.10.001). 16. Rikken JFW, Kowalik CR, Emanuel MH, Mol BWJ, Van der Veen F, van Wely M et al. Septum resection for women of reproductive age with a septate uterus. Cochrane Database Syst Rev. 2017;(1):CD008576 (https://doi. org/10.1002/14651858.CD008576.pub4). 17. Rikken JFW, Kowalik CR, Emanuel MH, Bongers MY, Spinder T, Jansen FW et al. Septum resection versus expectant management in women with a septate uterus: an international multicentre open-label randomized controlled trial. Hum Reprod. 2021;36(5):1260-7 (https://doi. org/10.1093/humrep/deab037). 18. Abuzeid O, Zaghmout O, Hebert J, Rocha FG, Abuzeid M. Reproductive outcome in patients with uterine septum or arcuate uterus and a previous live birth [28E]. Obstet Gynecol. 2016;127:50S (https://doi.org/10.1097/01. AOG.0000483853.02828.5c). 19. Ban-Frangež H, Tomaževič T, Virant-Klun I, Verdenik I, Ribič-Pucelj ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 182
  },
  {
    "chunk_id": "infertility_2388",
    "text": "vious live birth [28E]. Obstet Gynecol. 2016;127:50S (https://doi.org/10.1097/01. AOG.0000483853.02828.5c). 19. Ban-Frangež H, Tomaževič T, Virant-Klun I, Verdenik I, Ribič-Pucelj M, Vrtačnik-Bokal E. The outcome of singleton pregnancies after IVF/ ICSI in women before and after hysteroscopic resection of a uterine septum compared to normal controls. Eur J Obstet Gynecol Reprod Biol. 2009;146(2):184-7 (https://doi.org/10.1016/j. ejogrb.2008.04.010). 20. Heinonen PK. Reproductive performance of women with uterine anomalies after abdominal or hysteroscopic metroplasty or no surgical treatment. J Am Assoc Gynecol Laparosc. 1997;4(3):311-17 (https://doi.org/10.1016/s1074- 3804(05)80221-x). 21. Li X, Ouyang Y, Wen Y. O-053. Whether the surgical indications for septate uterus are reasonable in infertile patients before in vitro fertilization? Hum Reprod. 2018;33(Suppl 1):i24. 22. Ruiz MR, Diaz",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 182
  },
  {
    "chunk_id": "infertility_2389",
    "text": ". O-053. Whether the surgical indications for septate uterus are reasonable in infertile patients before in vitro fertilization? Hum Reprod. 2018;33(Suppl 1):i24. 22. Ruiz MR, Diaz PN, Garcia-Guzman R, Iaconianni L, Hernandez J, Palumbo A. Incidence of uterine anomalies in normal and infertile women and the role of histeroscopic metroplasty in improving the outcome of fertility treatment. Hum Reprod. 2010;25(Suppl 1):i332. 23. Yi Y, Li X, Ouyang Y, Lu G. The surgical indications for septate uterus in infertile population before in vitro fertilization. Fertil Steril. 2015;104(3):e178 (https://doi.org/10.1016/j.fertnstert.2015.07.553). 24. Tonguc EA, Var T, Batioglu S. Hysteroscopic metroplasty in patients with a uterine septum and otherwise unexplained infertility. Int J Gynaecol Obstet. 2011;113(2):128-30 (https://doi. org/10.1016/j.ijgo.2010.11.023). 25. Tomaževič T, Ban-Frangež H, Vira",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 182
  },
  {
    "chunk_id": "infertility_2390",
    "text": " uterine septum and otherwise unexplained infertility. Int J Gynaecol Obstet. 2011;113(2):128-30 (https://doi. org/10.1016/j.ijgo.2010.11.023). 25. Tomaževič T, Ban-Frangež H, Virant-Klun I, Verdenik I, Požlep B, Vrtačnik-Bokal E. Septate, subseptate and arcuate uterus decrease pregnancy and live birth rates in IVF/ICSI. Reprod Biomed Online. 2010;21(5):700-5 (https://doi. org/10.1016/j.rbmo.2010.06.028). 26. De Angelis C, Antinori M, Cerusico V, Antinori S. Hysteroscopic surgery prior to IVF. Reprod Biomed Online. 2010;20(suppl):S81-S84. 27. Smit JG, Overdijkink S, Mol BW, Kasius JC, Torrance HL, Eijkemans MJC et al. The impact of diagnostic criteria on the reproducibility of the hysteroscopic diagnosis of the septate uterus: a randomized controlled trial. Hum Reprod. 2015;30(6):1323-30 (https://doi.org/10.1093/ humrep/dev082). 28. Spanish Infertility SWOT Group, Checa M, Bellver J, Bos",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 182
  },
  {
    "chunk_id": "infertility_2391",
    "text": " septate uterus: a randomized controlled trial. Hum Reprod. 2015;30(6):1323-30 (https://doi.org/10.1093/ humrep/dev082). 28. Spanish Infertility SWOT Group, Checa M, Bellver J, Bosch E, Espinós J, Fabregues F et al. Hysteroscopic septum resection and reproductive medicine: A SWOT analysis. Reprod Biomed Online. 2018;37(6):709-15 (https://doi. org/10.1016/j.rbmo.2018.09.013).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 182
  },
  {
    "chunk_id": "infertility_2392",
    "text": "159 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 9 Treatment of infertility due to male factors The following sections 9.1–9.2 present recommendations related to the management of male-factor infertility. 9.1 Use of antioxidants Recommendation For males with infertility and one or more semen parameters that are outside the WHO reference ranges attempting to achieve pregnancy with or without medically assisted reproduction, the WHO infertility Guideline Development Group (GDG) did not make a recommendation for or against the use of antioxidant supplements. Remark: • Optimal nutrition is important during the pre-pregnancy period for the couple; however, the effects of antioxidant supplements for males with specific male- factor pathologies in couples with infertility are currently not known. Background and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 183
  },
  {
    "chunk_id": "infertility_2393",
    "text": "or the couple; however, the effects of antioxidant supplements for males with specific male- factor pathologies in couples with infertility are currently not known. Background and rationale Globally, the main cause of infertility reported in a large WHO multi-country study involving 8500 couples in 25 countries was due to female factors alone in 30.6% of cases, both male and female factors in 26.3% and male factors alone in 18.7% of cases (1). Based on this study, male factors contributed wholly or in part to 45.1% of infertility cases (see Annex 1. Distribution of the causes of infertility ). Reactive oxygen species (ROS), such as superoxide (O2 •-), nitric oxide (NO •) and hydrogen peroxide (H2O2), are by-products of oxygen metabolism under normal physiological conditions ( 2, 3). However, an imbalance in reduction–oxidation reactions is thought to increase intracellular concentration ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 183
  },
  {
    "chunk_id": "infertility_2394",
    "text": "ducts of oxygen metabolism under normal physiological conditions ( 2, 3). However, an imbalance in reduction–oxidation reactions is thought to increase intracellular concentration of ROS and to potentially have a role in disease processes (4, 5). In the context of infertility, oxidative stress may increase the levels of ROS in the male tract or seminal secretions, which is hypothesized to negatively affect male fertility ( 6, 7). Oxidative stress can result from several sources, including seminal leukocytes ( 8, 9). Although there is still a need for definitive evidence (for a validated or certain test, assay or proof) linking reduction–oxidation imbalances with fertility outcomes (8), as indicated in some studies ( 10, 11), it is accepted that oxidative stress is probably an important modulator of human sperm function ( 8). In this context, oral antioxidant therapy has been increasingly",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 183
  },
  {
    "chunk_id": "infertility_2395",
    "text": "ies ( 10, 11), it is accepted that oxidative stress is probably an important modulator of human sperm function ( 8). In this context, oral antioxidant therapy has been increasingly investigated for the possibility that it could ameliorate oxidative stress, and improve human sperm function ( 12), under an overarching hypothesis that individuals exposed to increased oxidative stress may have raised antioxidant requirements. In general, a dietary antioxidant is a substance in foods that significantly decreases the adverse effects of ROS, reactive nitrogen species or both, Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 183
  },
  {
    "chunk_id": "infertility_2396",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 160 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps on normal physiological function in humans ( 13). While fruits and vegetables typically contain safe levels of dietary antioxidants ( 3, 14, 15), the GDG agreed that an important question is whether oral antioxidant supplements are beneficial or harmful for men with male-factor infertility, and what types and amounts of antioxidants are useful for this population. The GDG agreed and noted that clinicians may be suggesting antioxidants for men with infertility, particularly those who have semen parameters outside the WHO reference ranges, and also that men may be asking about whether to take antioxidants, yet there have been uncertainties about the general health effects and potential harms",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 184
  },
  {
    "chunk_id": "infertility_2397",
    "text": "the WHO reference ranges, and also that men may be asking about whether to take antioxidants, yet there have been uncertainties about the general health effects and potential harms of supplementation with antioxidants supplements, as reported in some studies ( 16). In the context of male-factor infertility, an antioxidant is a substance that has the ability to protect spermatozoa against oxidative damage, for example, through neutralizing actions, or by functioning as a component of an antioxidant enzyme (12). These antioxidant properties may also contain membrane stability effects ( 3, 17). Oral antioxidant supplements typically include some types of vitamins, trace elements and other mineral compounds that are chemically synthesized and packaged as pills. They are generally dispensed without prescription, either separately or in any combination among themselves, or in combination with ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 184
  },
  {
    "chunk_id": "infertility_2398",
    "text": "e chemically synthesized and packaged as pills. They are generally dispensed without prescription, either separately or in any combination among themselves, or in combination with other vitamins, trace elements or mineral compounds that do not have antioxidant effects. For this recommendation, the GDG addressed the question: should oral antioxidant supplements versus no oral antioxidant supplements be used by men with infertility and semen parameters outside the WHO reference range? In this recommendation, the GDG was interested in fertility outcomes rather than changes in specific semen parameters. Herbal preparations are not included. Balancing harms and benefits Data were obtained from a systematic review (12) and a targeted search for RCTs. Based on the evidence, the GDG concluded that no recommendation can be made about the use of antioxidant supplements for men in couples with infe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 184
  },
  {
    "chunk_id": "infertility_2399",
    "text": "2) and a targeted search for RCTs. Based on the evidence, the GDG concluded that no recommendation can be made about the use of antioxidant supplements for men in couples with infertility and semen parameters that are outside the WHO reference range attempting to achieve pregnancy with or without medically assisted reproduction (see Web Annexes A–F for the detailed evidence to decision tables). Summary justification The available studies from a systematic review (12) and a targeted search for RCTs up to April 2024 were in men with different pathologies for infertility and evaluated a variety of antioxidants in combination or as a single supplement and in different doses in men with one or more semen parameters outside the WHO reference ranges. This evidence could not be used to inform a recommendation about the use of antioxidants for this population. Research gaps and future guideline u",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 184
  },
  {
    "chunk_id": "infertility_2400",
    "text": "outside the WHO reference ranges. This evidence could not be used to inform a recommendation about the use of antioxidants for this population. Research gaps and future guideline update Overall, stronger evidence is still needed to demonstrate clear reversal of imbalance in reduction–oxidation equilibrium reactions, which forms the basis of the use of oral supplemental antioxidants in men with infertility, while precluding the risk of possible reductive stress ( 18–20). In particular, large, good-quality RCTs on oral supplemental antioxidants are required among men in couples with infertility, particularly men with one or more semen parameters that are outside the WHO reference ranges, noting simple diagnostic tests that can identify men with oxidative stress may also be needed ( 21). Such studies should focus on cases where female factors have been excluded. Such studies should be well‐",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 184
  },
  {
    "chunk_id": "infertility_2401",
    "text": "tests that can identify men with oxidative stress may also be needed ( 21). Such studies should focus on cases where female factors have been excluded. Such studies should be well‐powered",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 184
  },
  {
    "chunk_id": "infertility_2402",
    "text": "1619 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps trials with low risk of attrition and other bias and should report live birth as a primary outcome. Studies should harmonize the types, doses and durations of the antioxidant compounds being tested. Harmonization of eligibility and outcomes would also facilitate comparison, interpretation and pooling of results. Further efforts are required to harmonize regulatory parameters and quality control related to antioxidant formulation, production and storage. Future trials should be independent, be of sufficiently long duration and with adequate patient retention. Future studies should focus on outcomes beyond changes in semen parameters to also include clinical pregnancy and live births. Future studies should focus o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 185
  },
  {
    "chunk_id": "infertility_2403",
    "text": "uate patient retention. Future studies should focus on outcomes beyond changes in semen parameters to also include clinical pregnancy and live births. Future studies should focus on researching compounds at comparable standard doses, formulation, durations and combinations that may undergo evaluation as part of the WHO model list of essential medicines update process (22). Better understanding of the potential for antioxidants to cause reductive stress is also needed. At present, there are several micronutrient compounds included on the WHO model list of essential medicines (22), but the optimal plasma or tissue concentrations of nutrients required to counter oxidant stress in tissues are not known ( 3). Future research is required to address this gap. References 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 185
  },
  {
    "chunk_id": "infertility_2404",
    "text": " research is required to address this gap. References 1. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 2. Aitken J, Fisher H. Reactive oxygen species generation and human spermatozoa: the balance of benefit and risk. Bioessays. 1994;16(4):259-67 (https://doi.org/10.1002/bies.950160409). 3. Vitamin and mineral requirements in human nutrition. Geneva: World Health Organization and Food and Agriculture Organization of the United Nations; 2004 (https://iris.who.int/ handle/10665/42716). 4. Willcox JK, Ash SL, Catignani GL. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr. 2004;44(4):275-95 (https://doi. org/10.1080/10408690490468489). 5. Diplock AT. Antioxidants and disease prevention. Mol Aspects Med. 1994;15(4):293-37",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 185
  },
  {
    "chunk_id": "infertility_2405",
    "text": "ease. Crit Rev Food Sci Nutr. 2004;44(4):275-95 (https://doi. org/10.1080/10408690490468489). 5. Diplock AT. Antioxidants and disease prevention. Mol Aspects Med. 1994;15(4):293-376 (https://doi. org/10.1016/0098-2997(94)90005-1). 6. Mancini A, Oliva A, Vergani E, Festa R, Silvestrini A. The dual role of oxidants in male (in)fertility: every ROSe has a thorn. Int J Mol Sci. 2023;24(5) (https://doi.org/10.3390/ ijms24054994). 7. Sharma RK, Agarwal A. Role of reactive oxygen species in male infertility. Urology. 1996;48(6):835-50 (https://doi.org/10.1016/ s0090-4295(96)00313-5). 8. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/343208). 9. Aitken RJ, Drevet JR, Moazamian A, Gharagozloo P. Male infertility and oxidative stress: a focus on the underlying mechanisms. Antioxidant",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 185
  },
  {
    "chunk_id": "infertility_2406",
    "text": "s://iris.who.int/handle/10665/343208). 9. Aitken RJ, Drevet JR, Moazamian A, Gharagozloo P. Male infertility and oxidative stress: a focus on the underlying mechanisms. Antioxidants (Basel). 2022;11(2):306 (https://doi.org/10.3390/ antiox11020306). 10. Verit FF, Verit A, Kocyigit A, Ciftci H, Celik H, Koksal M. No increase in sperm DNA damage and seminal oxidative stress in patients with idiopathic infertility. Arch Gynecol Obstet. 2006;274(6):339-44 (https://doi.org/10.1007/ s00404-006-0172-9). 11. Aitken RJ. Impact of oxidative stress on male and female germ cells: implications for fertility. Reproduction. 2020;159(4):R189-R201 (https:// doi.org/10.1530/rep-19-0452). 12. de Ligny W, Smits RM, Mackenzie-Proctor R, Jordan V, Fleischer K, de Bruin JP et al. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2022;(5):CD007411 (https:// doi.org/10.1002/14651858.CD007411.pub5).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 185
  },
  {
    "chunk_id": "infertility_2407",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 162 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 13. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes: proposed definition and plan for review of dietary antioxidants and related compounds. Washington, DC: National Academies Press (US); 1998 (https:// doi.org/10.17226/6252). 14. Diplock AT, Charleux JL, Crozier-Willi G, Kok FJ, Rice-Evans C, Roberfroid M et al. Functional food science and defence against reactive oxidative species. Br J Nutr. 1998;80(Suppl 1):S77-S112 (https://doi.org/10.1079/bjn19980106). 15. McKevith B, Kelly C, Stanner S, Hughes J, Buttriss J. The Food Standards Agency’s antioxidants in food programme – a summary. J Hum Nutr Diet. 2003;1",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 186
  },
  {
    "chunk_id": "infertility_2408",
    "text": ".org/10.1079/bjn19980106). 15. McKevith B, Kelly C, Stanner S, Hughes J, Buttriss J. The Food Standards Agency’s antioxidants in food programme – a summary. J Hum Nutr Diet. 2003;16(4):257-63 (https://doi. org/10.1046/j.1365-277x.2003.00436.x). 16. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842-57 (https:// doi.org/10.1001/jama.297.8.842). 17. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet. 1994;344(8924):721-4 (https://doi.org/10.1016/s0140-6736(94)92211-x). 18. Henkel R, Sandhu IS, Agarwal A. The excessive use of antioxidant therapy: a possible cause of male infertility? Andrologia. 2019;51(1):e13162 (ht tps://doi.org/10.1111/and.13162). 19. Moustakli E, Zikopoulos A,",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 186
  },
  {
    "chunk_id": "infertility_2409",
    "text": ". The excessive use of antioxidant therapy: a possible cause of male infertility? Andrologia. 2019;51(1):e13162 (ht tps://doi.org/10.1111/and.13162). 19. Moustakli E, Zikopoulos A, Skentou C, Katopodis P, Domali E, Potiris A et al. Impact of reductive stress on human infertility: underlying mechanisms and perspectives. Int J Mol Sci. 2024;25(21):11802 (https://doi.org/10.3390/ ijms252111802). 20. Caroppo E, Dattilo M. Sperm redox biology challenges the role of antioxidants as a treatment for male factor infertility. F&S Rev. 2022;3(1):90- 104 (https://doi.org/10.1016/j.xfnr.2021.12.001). 21. Aitken RJ. Antioxidant trials-the need to test for stress. Hum Reprod Open. 2021;2021(1):hoab007 (https://doi.org/10.1093/hropen/hoab007). 22. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World H",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 186
  },
  {
    "chunk_id": "infertility_2410",
    "text": "/hropen/hoab007). 22. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/371090).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 186
  },
  {
    "chunk_id": "infertility_2411",
    "text": "1639 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 9.2 Treatment of varicocele This section contains several recommendations related to the management of varicocele regarding treatment, treatment modalities or approaches that should be read together. Recommendation For males with infertility and clinical varicocele, WHO suggests surgical or radiological treatment over expectant management. (Conditional recommendation, low certainty of evidence) Remarks: • Males with clinical varicocele and semen parameters outside the WHO reference ranges are more likely to benefit from receiving treatment for varicocele, compared to men with semen parameters within the WHO reference ranges. • This recommendation applies to males with clinical varicocele in couples with infertil",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 187
  },
  {
    "chunk_id": "infertility_2412",
    "text": "ment for varicocele, compared to men with semen parameters within the WHO reference ranges. • This recommendation applies to males with clinical varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART). Background and rationale Varicoceles are vascular lesions resulting from the dilation and distention of the internal spermatic vein and pampiniform plexus within the spermatic cord in the scrotum. While most varicoceles are left-sided, they may occur on the right or bilaterally (1) and they are a common finding among men being evaluated for infertility. In a large WHO multi-country study involving 8500 couples in 25 countries, varicocele constituted 13.1% of male infertility cases ( 2). In the same study, varicocele was found in 25.4% of male partners with abnormal semen parameters, compared with 11.7% of male partners with normal",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 187
  },
  {
    "chunk_id": "infertility_2413",
    "text": "% of male infertility cases ( 2). In the same study, varicocele was found in 25.4% of male partners with abnormal semen parameters, compared with 11.7% of male partners with normal semen parameters (3). While varicoceles occur more frequently in infertile compared to fertile men, not all men with a varicocele have infertility ( 4). Common symptoms of varicoceles include pain or discomfort. Varicoceles may also have negative (5, 6) and possibly progressive effects ( 7) on semen parameters and sperm function ( 8). The exact mechanisms according to which varicoceles cause negative effect on spermatogenesis are unknown; however, testicular temperature elevation, venous reflux and oxidative stress are hypothesized to have important roles ( 9). Others include reflux of renal and adrenal products, hormonal dysfunction, autoimmunity, apoptosis, hypoxia, genetics, defects in acrosome reaction and",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 187
  },
  {
    "chunk_id": "infertility_2414",
    "text": "o have important roles ( 9). Others include reflux of renal and adrenal products, hormonal dysfunction, autoimmunity, apoptosis, hypoxia, genetics, defects in acrosome reaction and DNA damage, among others (9–13). Despite ongoing research, the pathophysiological mechanisms through which varicoceles impair testicular function remain inconclusive; many of these factors may act in concert. A varicocele may be clinical or subclinical. A subclinical varicocele is not palpable (nor visible) on scrotal examination; it requires additional diagnostic aids to detect. A clinical varicocele is palpable and is diagnosed by physical examination through palpation before and during a Valsalva manoeuvre with the patient in a standing position at room temperature. Clinical varicoceles are further graded as follows: • grade I: palpable during a Valsalva manoeuvre only; • grade II: palpable but not visible;",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 187
  },
  {
    "chunk_id": "infertility_2415",
    "text": "anding position at room temperature. Clinical varicoceles are further graded as follows: • grade I: palpable during a Valsalva manoeuvre only; • grade II: palpable but not visible; • grade III: palpable and visible.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 187
  },
  {
    "chunk_id": "infertility_2416",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 164 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Initial options for management of varicocele include surgical or radiological treatment or expectant management. Surgical treatment involves varicocelectomy, conducted via retroperitoneal or conventional inguinal open techniques, microsurgical inguinal or subinguinal approaches, or laparoscopic repairs (14–16). Radiological treatment involves either varicocele embolization or sclerotherapy. Embolization involves blocking one or more blood vessels or abnormal vascular channels using a coil or a balloon or other embolic agents (17), whereas sclerotherapy involves injecting a sclerosing agent into the spermatic vein, resulting into shrinkage and lumen occlusion ( 18). The goal of both surgica",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 188
  },
  {
    "chunk_id": "infertility_2417",
    "text": "bolic agents (17), whereas sclerotherapy involves injecting a sclerosing agent into the spermatic vein, resulting into shrinkage and lumen occlusion ( 18). The goal of both surgical and radiological treatment is to stop reflux in the internal spermatic vein. The halting of venous reflux is frequently followed by an improvement in semen parameters ( 19, 20). For this guideline, distinction was made between clinical and subclinical varicocele, given the documented link between the treatment of clinical varicoceles and improvement in fertility. Although men with varicoceles may also be candidates for ART, this recommendation does not address the use of surgical or radiological treatment before, or in combination with, ART. GDG agreed that an issue of central concern is whether treatment (surgical or radiological) of a varicocele should be used for the male partner of a couple with infertili",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 188
  },
  {
    "chunk_id": "infertility_2418",
    "text": "ith, ART. GDG agreed that an issue of central concern is whether treatment (surgical or radiological) of a varicocele should be used for the male partner of a couple with infertility who are not undergoing other ART procedures based on (i) whether the varicocele is clinical or not, and (ii) whether semen parameters are within the WHO reference ranges or not. Therefore, for this recommendation, the GDG addressed the question: should surgical or radiological treatment versus no treatment be used for men with clinical varicocele in couples with infertility? Balancing harms and benefits Evidence was obtained from a recent systematic review of RCTs by Persad et al. ( 21). The search date was up to April 2020. The review pooled together studies comparing any repair to no treatment (or non-surgical methods). We included studies from the Persad et al. review with couples experiencing infertility",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 188
  },
  {
    "chunk_id": "infertility_2419",
    "text": "view pooled together studies comparing any repair to no treatment (or non-surgical methods). We included studies from the Persad et al. review with couples experiencing infertility and men who had clinical varicocele; we also performed a subgroup analysis of men with semen parameters within the WHO reference ranges (22–29) or outside the WHO reference ranges (30). Several studies were excluded because of the inclusion of couples with multiple pregnancy losses or recurrent pregnancy loss ( 31), failure to separate clinical from non-clinical varicoceles in analysis (32, 33), undefined eligibility criteria ( 34) or other reason (35) (see Web Annexes A–F). Evidence showed that treatment of varicocele may result in a moderate increase in clinical pregnancies among men with semen parameters outside the WHO reference ranges (RR: 1.94; 95% CI: 1.23–3.05). However, the effect was uncertain among ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 188
  },
  {
    "chunk_id": "infertility_2420",
    "text": "a moderate increase in clinical pregnancies among men with semen parameters outside the WHO reference ranges (RR: 1.94; 95% CI: 1.23–3.05). However, the effect was uncertain among men with subclinical varicocele and semen parameters within the normal range (RR: 1.09; 95% CI: 0.55–2.26). Live births were not reported in the studies. In absence of data on live births, clinical pregnancies were assessed. The GDG noted that the effect of treatment on live births would be expected to be less than the effect on pregnancies; the certainty of evidence from this review was judged to be low. In terms of undesirable effects, in the studies in the review by Persad et al. ( 21) comparing surgical treatments to each other and to radiological treatments (to each other), the incidence of varicocele recurrence was between 3% and 20%. Pain with surgery was approximately 2–20%, testicular atrophy with surg",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 188
  },
  {
    "chunk_id": "infertility_2421",
    "text": "d to radiological treatments (to each other), the incidence of varicocele recurrence was between 3% and 20%. Pain with surgery was approximately 2–20%, testicular atrophy with surgery 0–4%, hydrocele formation with surgery 5–10%, and wound infection approximately 4%. The GDG judged these to be small harms. The GDG agreed that certainty of evidence is low for men with clinical varicocele with semen parameters outside the WHO reference range and very low for men with clinical varicocele with semen parameters within the WHO reference range; overall, the overall certainty of evidence was judged to be very low. Limited data were identified related to patient values on treatment or expectant management. Nevertheless, the GDG judged that patients would likely value pregnancies and live births, and would",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 188
  },
  {
    "chunk_id": "infertility_2422",
    "text": "1659 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps seek to minimize adverse events; probably, no important variability exists in how people value these outcomes. Given that more value is placed on the potential for small benefits and less on adverse events, treatment is probably favoured in men with clinical varicocele with semen parameters outside the normal range. For men with clinical varicocele with semen parameters within the normal range, treatment is probably not favoured. Other considerations Limited data exist concerning the acceptability and feasibility of surgical or radiological treatment of varicocele. However, the GDG judged that surgery would probably be acceptable to men to improve fertility. In addition, the GDG judged that it is probably feasib",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 189
  },
  {
    "chunk_id": "infertility_2423",
    "text": "gical treatment of varicocele. However, the GDG judged that surgery would probably be acceptable to men to improve fertility. In addition, the GDG judged that it is probably feasible to provide varicocele treatment. However, training and expertise is required to ensure safety and minimize complications. Based on data from studies in Kuwait ( 36), China (37) and Canada (38), the GDG judged that surgery involves moderate costs compared to no treatment. However, a variation in costs to individuals and health systems may exist from country to country. Subsequently, the GDG judged that equity may be reduced with treatment if some populations are unable to access it, especially in settings without public financing or insurance cover for infertility treatment. Summary justification Treatment of varicocele may have a small desirable effect by increasing clinical pregnancies, and a small undesira",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 189
  },
  {
    "chunk_id": "infertility_2424",
    "text": " insurance cover for infertility treatment. Summary justification Treatment of varicocele may have a small desirable effect by increasing clinical pregnancies, and a small undesirable effect resulting from complications of surgical or radiological procedures (very low certainty of evidence). Given the higher value that people ascribe to pregnancy compared to the undesirable effects, the balance of effects favours the intervention. Treatment may incur moderate costs and probably reduce equity if some populations cannot access it; however, it is probably acceptable and probably feasible. Implementation considerations This recommendation focuses on treatment of varicocele to improve current fertility among adult males with infertility and clinical varicocele who are not undergoing ART. Treatment of varicocele to improve other outcomes (e.g. to relieve pain or to prevent future reproductive ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 189
  },
  {
    "chunk_id": "infertility_2425",
    "text": "ales with infertility and clinical varicocele who are not undergoing ART. Treatment of varicocele to improve other outcomes (e.g. to relieve pain or to prevent future reproductive problems) is beyond the scope of this recommendation. For optimal benefit, varicocele treatment is suggested for men with infertility intending to conceive if they have (i) a clinical varicocele and (ii) semen parameters that are outside the WHO reference range. In addition, patients should be clearly informed that the impact on live births is unknown. In implementing this recommendation, health care providers should note that it is likely to involve moderate costs and potential exposure to harms associated with surgery or radiological treatments. Results of semen analysis based on the procedures outlined in the WHO manual for the examination and processing of human semen ( 39) should be used to identify men wh",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 189
  },
  {
    "chunk_id": "infertility_2426",
    "text": "l treatments. Results of semen analysis based on the procedures outlined in the WHO manual for the examination and processing of human semen ( 39) should be used to identify men who are likely to benefit from the intervention. After treatment, patients should be monitored for potential complications, such as hydrocele, recurrence and ultimately improvement in fertility status. Research gaps and future guideline update Current evidence is of very low quality. Large, randomized studies are required to provide high-quality evidence. In addition, future studies should include live births as an outcome. The overall impact of the grade of a clinical varicocele (i.e. grade I, II or III) on treatment outcome could not be determined from the current evidence. Future studies should be designed to identify",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 189
  },
  {
    "chunk_id": "infertility_2427",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 166 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps which grades of a clinical varicocele may optimally benefit from treatment, including one-sided versus bilateral varicocele. Further research is needed on the pathophysiological mechanisms and potential new therapies. Future guidance is required in relation to treatment options among infertile men with clinical varicocele who do not respond to surgical or radiological therapy. The evidence reviewed in this recommendation relates to men with clinical varicocele in couples with infertility who are not undergoing ART. Future guidance is required in relation to the role of treatment of varicocele before ART. References 1. Gat Y, Bachar GN, Zukerman Z, Belenky A, Gornish M. Varicocele: a bilate",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 190
  },
  {
    "chunk_id": "infertility_2428",
    "text": "T. Future guidance is required in relation to the role of treatment of varicocele before ART. References 1. Gat Y, Bachar GN, Zukerman Z, Belenky A, Gornish M. Varicocele: a bilateral disease. Fertil Steril. 2004;81(2):424-9 (https://doi.org/10.1016/j. fertnstert.2003.08.010). 2. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/bitstream/ handle/10665/38679/WHO_TRS_820_eng.pdf ). 3. World Health Organization. The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. Fertil Steril. 1992;57(6):1289-93. 4. Redmon JB, Carey P, Pryor JL. Varicocele–the most common cause of male factor infertility? Hum Reprod Update. 2002;8(1):53-8 (https://doi. org/10.1093/humupd/8.1.53). 5. Jensen CFS, Østergren P, Dupree JM, Ohl DA, Sønksen J, Fode M. Varic",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 190
  },
  {
    "chunk_id": "infertility_2429",
    "text": "ause of male factor infertility? Hum Reprod Update. 2002;8(1):53-8 (https://doi. org/10.1093/humupd/8.1.53). 5. Jensen CFS, Østergren P, Dupree JM, Ohl DA, Sønksen J, Fode M. Varicocele and male infertility. Nat Rev Urol. 2017;14(9):523-33 (https://doi. org/10.1038/nrurol.2017.98). 6. Damsgaard J, Joensen UN, Carlsen E, Erenpreiss J, Blomberg Jensen M, Matulevicius V et al. Varicocele is associated with impaired semen quality and reproductive hormone levels: a study of 7035 healthy young men from six european countries. Eur Urol. 2016;70(6):1019-29 (https:// doi.org/10.1016/j.eururo.2016.06.044). 7. Jarow JP. Effects of varicocele on male fertility. Hum Reprod Update. 2001;7(1):59-64 (https://doi. org/10.1093/humupd/7.1.59). 8. Agarwal A, Sharma R, Harlev A, Esteves SC. Effect of varicocele on semen characteristics according to the new 2010 World Health Organization criteria: a systemati",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 190
  },
  {
    "chunk_id": "infertility_2430",
    "text": "umupd/7.1.59). 8. Agarwal A, Sharma R, Harlev A, Esteves SC. Effect of varicocele on semen characteristics according to the new 2010 World Health Organization criteria: a systematic review and meta-analysis. Asian J Androl. 2016;18(2):163-70 (https://doi. org/10.4103/1008-682x.172638). 9. Hassanin AM, Ahmed HH, Kaddah AN. A global view of the pathophysiology of varicocele. Andrology. 2018;6(5):654-61 (https://doi. org/10.1111/andr.12511). 10. Lira Neto FT, Roque M, Esteves SC. Effect of varicocelectomy on sperm deoxyribonucleic acid fragmentation rates in infertile men with clinical varicocele: a systematic review and meta- analysis. Fertil Steril. 2021;116(3):696-712 (https:// doi.org/10.1016/j.fertnstert.2021.04.003). 11. Naughton CK, Nangia AK, Agarwal A. Pathophysiology of varicoceles in male infertility. Hum Reprod Update. 2001;7(5):473-81 (https:// doi.org/10.1093/humupd/7.5.473). ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 190
  },
  {
    "chunk_id": "infertility_2431",
    "text": ".04.003). 11. Naughton CK, Nangia AK, Agarwal A. Pathophysiology of varicoceles in male infertility. Hum Reprod Update. 2001;7(5):473-81 (https:// doi.org/10.1093/humupd/7.5.473). 12. Eisenberg ML, Lipshultz LI. Varicocele- induced infertility: newer insights into its pathophysiology. Indian J Urol. 2011;27(1):58-64 (https://doi.org/10.4103/0970-1591.78428). 13. Wang Y-J, Zhang R-Q, Lin Y-J, Zhang R-G, Zhang W-L. Relationship between varicocele and sperm DNA damage and the effect of varicocele repair: a meta-analysis. Reprod Biomed Online. 2012;25(3):307-14 (https://doi.org/10.1016/j. rbmo.2012.05.002). 14. Baazeem A, Zini A. Surgery illustrated – Surgical atlas microsurgical varicocelectomy. BJU Int. 2009;104(3):420-7 (ht tps://doi.org/10.1111/j.1464 - 410X.2009.008768.x).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 190
  },
  {
    "chunk_id": "infertility_2432",
    "text": "1679 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 15. Diegidio P, Jhaveri JK, Ghannam S, Pinkhasov R, Shabsigh R, Fisch H. Review of current varicocelectomy techniques and their outcomes. BJU Int. 2011;108(7):1157-72 (https://doi. org/10.1111/j.1464-410X.2010.09959.x). 16. Marte A. The history of varicocele: from antiquity to the modern ERA. Int Braz J Urol. 2018;44(3):563-76 (https://doi.org/10.1590/S1677- 5538.IBJU.2017.0386). 17. Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics. 1994;14(3):623-43 (https://doi.org/10.1148/ radiographics.14.3.8066276). 18. Tauber R, Pfeiffer D. Surgical atlas varicocele: antegrade scrotal sclerotherapy. BJU Int. 2006;98(6):1333-44 (ht tps://doi.org/10.1111/ j.1464-41",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 191
  },
  {
    "chunk_id": "infertility_2433",
    "text": " radiographics.14.3.8066276). 18. Tauber R, Pfeiffer D. Surgical atlas varicocele: antegrade scrotal sclerotherapy. BJU Int. 2006;98(6):1333-44 (ht tps://doi.org/10.1111/ j.1464-410X.2006.06579.x). 19. Agarwal A, Deepinder F, Cocuzza M, Agarwal R, Short RA, Sabanegh E et al. Efficacy of varicocelectomy in improving semen parameters: new meta-analytical approach. Urology. 2007;70(3):532-8 (https://doi.org/10.1016/j. urology.2007.04.011). 20. Baazeem A, Belzile E, Ciampi A, Dohle G, Jarvi K, Salonia A et al. Varicocele and male factor infertility treatment: a new meta-analysis and review of the role of varicocele repair. Eur Urol. 2011;60(4):796-808 (https://doi.org/10.1016/j. eururo.2011.06.018). 21. Persad E, O’Loughlin CAA, Kaur S, Wagner G, Matyas N, Hassler-Di Fratta MR et al. Surgical or radiological treatment for varicoceles in subfertile men. Cochrane Database Syst Rev. 2021;4(4):C",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 191
  },
  {
    "chunk_id": "infertility_2434",
    "text": "’Loughlin CAA, Kaur S, Wagner G, Matyas N, Hassler-Di Fratta MR et al. Surgical or radiological treatment for varicoceles in subfertile men. Cochrane Database Syst Rev. 2021;4(4):CD000479 (https://doi. org/10.1002/14651858.CD000479.pub6). 22. Krause W, Müller HH, Schäfer H, Weidner W. Does treatment of varicocele improve male fertility? Results of the ‘Deutsche Varikozelenstudie’, a multicentre study of 14 collaborating centres. Andrologia. 2002;34(3):164-71 (https://doi. org/10.1046/j.1439-0272.2002.00494.x). 23. Nieschlag E, Hertle L, Fischedick A, Abshagen K, Behre H. Update on treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Hum Reprod. 1998;13(8):2147-50 (https://doi.org/10.1093/humrep/13.8.2147). 24. Nieschlag E, Hertle L, Fischedick A, Behre H. Treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Hum Reprod. 1",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 191
  },
  {
    "chunk_id": "infertility_2435",
    "text": "rg/10.1093/humrep/13.8.2147). 24. Nieschlag E, Hertle L, Fischedick A, Behre H. Treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Hum Reprod. 1995;10(2):347-53 (https://doi. org/10.1093/oxfordjournals.humrep.a135941). 25. Ketabchi AA, Mohammad SS, Salajghah S. The effect of varicocelectomy on assisted reproductive technique indications and outcomes based on Kruger strict morphology test: a randomized clinical trial. J Kerman Univ Med Sci. 2018;25(6):519-27. 26. Abdel-Meguid TA, Al-Sayyad A, Tayib A, Farsi HM. Does varicocele repair improve male infertility? An evidence-based perspective from a randomized, controlled trial. Eur Urol. 2011;59(3):455-61 (https://doi.org/10.1016/j. eururo.2010.12.008). 27. Dohle G, editor. Does varicocele repair result in more spontaneous pregnancies? A randomised prospective trial. In: Sixth European Congress of Androlog",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 191
  },
  {
    "chunk_id": "infertility_2436",
    "text": "/j. eururo.2010.12.008). 27. Dohle G, editor. Does varicocele repair result in more spontaneous pregnancies? A randomised prospective trial. In: Sixth European Congress of Andrology, Athens, Greece; 2010 (https://www. cochranelibrary.com/central/doi/10.1002/central/ CN-00774381/full). 28. Ketabchi AA, Salajegheh S. The effects of acupuncture treatment in infertile patients with clinical varicocele. Nephro-Urol Mon. 2018;10(6):e65451 (https://doi.org/10.5812/ numonthly.65451). 29. Madgar I, Weissenberg R, Lunenfeld B, Karasik A, Goldwasser B. Controlled trial of high spermatic vein ligation for varicocele in infertile men. Fertil Steril. 1995;63(1):120-4 (https://doi.org/10.1016/ s0015-0282(16)57306-3). 30. Nilsson S, Edvinsson A, Nilsson B. Improvement of semen and pregnancy rate after ligation and division of the internal spermatic vein: fact or fiction? Br J Urol. 1979;51(6):591-6 (htt",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 191
  },
  {
    "chunk_id": "infertility_2437",
    "text": "son S, Edvinsson A, Nilsson B. Improvement of semen and pregnancy rate after ligation and division of the internal spermatic vein: fact or fiction? Br J Urol. 1979;51(6):591-6 (https://doi. org/10.1111/j.1464 - 410x.1979.tb03609.x).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 191
  },
  {
    "chunk_id": "infertility_2438",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 168 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 31. Ghanaie MM, Asgari SA, Dadrass N, Allahkhah A, Iran-Pour E, Safarinejad MR. Effects of varicocele repair on spontaneous first trimester miscarriage: a randomized clinical trial. Urol J. 2012;9(2):505-13. 32. Yamamoto M, Hibi H, Hirata Y, Miyake K, Ishigaki T. Effect of varicocelectomy on sperm parameters and pregnancy rate in patients with subclinical varicocele: a randomized prospective controlled study. J Urol. 1996;155(5):1636-8. 33. Unal D, Yeni E, Verit A, Karatas OF. Clomiphene citrate versus varicocelectomy in treatment of subclinical varicocele: a prospective randomized study. Int J Urol. 2001;8(5):227-30 (https://doi. org/10.1046/j.14 42-2042.2001.00289.x). 34. Bo J, Wang Y, Q",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 192
  },
  {
    "chunk_id": "infertility_2439",
    "text": "ctomy in treatment of subclinical varicocele: a prospective randomized study. Int J Urol. 2001;8(5):227-30 (https://doi. org/10.1046/j.14 42-2042.2001.00289.x). 34. Bo J, Wang Y, Qian X, Han Y, Liu D, Len J. Controlled trial of high spermatic vein ligation for varicocele in infertile men. Chin J Androl. 1996;10:141-5. 35. Breznik R, Vlaisavuevic V, Borko E. Treatment of varicocele and male fertility. Arch Androl. 1993;30(3):157-60 (https://doi. org/10.3109/01485019308987750). 36. Alkandari MH, Al-Hunayan A. Varicocelectomy: modified loupe-assisted versus microscopic technique – a prospective comparative study. Arab J Urol. 2017;15(1):74-7 (https://doi. org/10.1016/j.aju.2016.12.002). 37. Liu S, Hu C, Jiang N, Wang G. Laparoscopic versus open inguinal spermatic vessel ligation in infertile men with varicocele. Biomed Res. 2018;29(7):1389-93 (https://doi.org/10.4066/ biomedicalresearch.29-",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 192
  },
  {
    "chunk_id": "infertility_2440",
    "text": "ang G. Laparoscopic versus open inguinal spermatic vessel ligation in infertile men with varicocele. Biomed Res. 2018;29(7):1389-93 (https://doi.org/10.4066/ biomedicalresearch.29-17-1789). 38. Kovac JR, Fantus J, Lipshultz LI, Fischer MA, Klinghoffer Z. Cost-effectiveness analysis reveals microsurgical varicocele repair is superior to percutaneous embolization in the treatment of male infertility. Can Urol Assoc J. 2014;8(9-10):E619-E265 (https://doi.org/10.5489/ cuaj.1873). 39. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/343208).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 192
  },
  {
    "chunk_id": "infertility_2441",
    "text": "1699 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For males with infertility undergoing treatment of varicocele, WHO suggests using either surgical or radiological treatment. (Conditional recommendation, very low certainty of evidence) Remarks: • When selecting whether to use surgical or radiological treatment, consider feasibility, the availability of trained health care providers and patient preferences regarding the type of treatment procedure. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART). Background and rationale This guideline suggests surgical or radiological treatment over expectant management of clinical varicocele in men wit",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 193
  },
  {
    "chunk_id": "infertility_2442",
    "text": "isted reproductive technology (ART). Background and rationale This guideline suggests surgical or radiological treatment over expectant management of clinical varicocele in men with infertility, with certainty of evidence that is low (see previous sections of this chapter). Once a decision to treat clinical varicocele has been arrived at, options for treatment include surgical repair or radiological treatment. Surgical treatment involves varicocelectomy, conducted via retroperitoneal or conventional inguinal open techniques, microsurgical inguinal or subinguinal approaches, or laparoscopic repairs (1–3). Radiological treatment involves varicocele embolization or sclerotherapy. Embolization involves blocking one or more blood vessels or abnormal vascular channels using a coil or a balloon, while sclerotherapy involves injecting a sclerosing agent into the spermatic vein, resulting in shri",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 193
  },
  {
    "chunk_id": "infertility_2443",
    "text": " or more blood vessels or abnormal vascular channels using a coil or a balloon, while sclerotherapy involves injecting a sclerosing agent into the spermatic vein, resulting in shrinkage and lumen occlusion ( 4). Surgical repair of varicoceles is widely practised using different techniques; however, it may be complicated by varicocele persistence, recurrence or injury to surrounding tissue; depending on the procedure, it may also require general anaesthesia or a longer time to operate (2, 5). Radiological treatments may be complicated by failure, recurrence, thrombosis, scrotal subcutaneous emphysema, injury to blood vessels, haemorrhage, epididymitis, scrotal pain and allergic reaction to contrast agents ( 5, 6). However, radiological treatments are generally less invasive than most surgical treatments, may be performed under local anaesthesia ( 7), and patients often require a shorter t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 193
  },
  {
    "chunk_id": "infertility_2444",
    "text": "). However, radiological treatments are generally less invasive than most surgical treatments, may be performed under local anaesthesia ( 7), and patients often require a shorter time to recover ( 8). As embolization is intravascular, it may minimize the risks of injury to adjacent vessels and lymphatics. Given the potential advantages and disadvantages of surgical and radiological treatments ( 6), the GDG agreed that there is need for guidance on which treatment modality between the two is preferred. Therefore, for this recommendation, the GDG addressed the question: should surgical versus radiological treatment be used for men with clinical varicocele in couples with infertility? It does not assess the use of these treatments before or in combination with ART. Balancing desirable and undesirable effects Evidence from a recent systematic review of RCTs was included (9). The search date ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 193
  },
  {
    "chunk_id": "infertility_2445",
    "text": " these treatments before or in combination with ART. Balancing desirable and undesirable effects Evidence from a recent systematic review of RCTs was included (9). The search date was up to April 2020. The review pooled together studies comparing surgical versus radiological procedures. From that review, only studies in men with confirmed clinical varicocele were included ( 10–15). Importantly, all included studies directly comparing surgical versus radiological procedures concern the use of non-microsurgical techniques (high or inguinal open methods). Results showed that compared to radiological treatments, surgery may result in 54 more live",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 193
  },
  {
    "chunk_id": "infertility_2446",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 170 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps births (from 37 fewer to 261 more,) per 1000 (RR: 1.49; 95% CI: 0.66–3.37), and likely 28 more pregnancies (from 60 fewer to 155 more) per 1000 (RR: 1.11; 95% CI: 0.76–1.62). The GDG judged these desirable effects of surgical repair to be trivial compared to radiological treatment. In terms of undesirable effects, data showed that surgery may result in 35 more varicocele recurrences or persistence (from 29 fewer to 137 more) per 1000 (RR: 1.25; 95% CI: 0.79–1.98), and 11 fewer complications, such as extravasation, wound infection and hydrocele formation, (from 56 fewer to 68 more) per 1000 (RR: 0.91; 95% CI: 0.53–1.57), when compared to radiological treatments. The GDG judged the magnitude",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 194
  },
  {
    "chunk_id": "infertility_2447",
    "text": ", wound infection and hydrocele formation, (from 56 fewer to 68 more) per 1000 (RR: 0.91; 95% CI: 0.53–1.57), when compared to radiological treatments. The GDG judged the magnitude of these differences to be trivial. The GDG agreed that couples would likely value pregnancies and live births and would want to minimize adverse events, and judged that there was probably no important uncertainty or variability in how much people valued these outcomes. The GDG concluded that the balance of effects probably does not favour either surgery or radiological treatment. The overall certainty of evidence for the effects was very low, primarily because the studies compared non-microscopic surgical methods with radiological treatment, which was considered indirect evidence of the effect of surgery. Studies comparing microsurgical varicocele repair with radiological treatment were lacking. In addition, ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 194
  },
  {
    "chunk_id": "infertility_2448",
    "text": "reatment, which was considered indirect evidence of the effect of surgery. Studies comparing microsurgical varicocele repair with radiological treatment were lacking. In addition, there were few participants and events in the analyses. Despite the evidence being indirect regarding the overall effects of all surgical procedures (i.e. both microsurgical and non-microsurgical methods [retroperitoneal or inguinal vein ligation]), it was still used to inform the recommendation. Other considerations Both surgical and radiological treatments involve costs. A Canadian simulation study ( 16) showed that embolization may be less cost-effective than surgery. However, the GDG considered that given that there are trivial differences in benefits or harms and negligible cost differences, both may have similar cost-effectiveness. The GDG also considered that costs and insurance coverage between surgery ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 194
  },
  {
    "chunk_id": "infertility_2449",
    "text": "fferences in benefits or harms and negligible cost differences, both may have similar cost-effectiveness. The GDG also considered that costs and insurance coverage between surgery and radiological treatment may vary from country to country and that equity may be reduced if some populations are unable to access treatment, especially in those countries and settings with limited public financing of insurance for infertility treatments. No data were found comparing acceptability between surgery and embolization. However, in the absence of data, the GDG judged that both surgical and radiological treatments are probably acceptable. In terms of feasibility, the GDG agreed that both procedures are feasible in most settings. However, training is required to assure safety and minimize complications. However, availability of trained surgeons and interventional radiologists may vary, especially in L",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 194
  },
  {
    "chunk_id": "infertility_2450",
    "text": "ings. However, training is required to assure safety and minimize complications. However, availability of trained surgeons and interventional radiologists may vary, especially in LMICs. Summary justification Overall, there is very-low-certainty evidence that there are trivial differences between surgical and radiological treatments in terms of benefits, harms and costs. Studies comparing microsurgical varicocele repair with radiological treatment were scarce, thus contributing to the GDG’s assessment that the evidence was indirect. Compared to each other, both treatments are probably feasible, acceptable and have little difference in impact on equity.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 194
  },
  {
    "chunk_id": "infertility_2451",
    "text": "1719 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Implementation considerations This recommendation focuses on the treatment of clinical varicocele to improve fertility in men with infertility who are not undergoing ART. This recommendation does not address the role of varicocele treatment before ART. Treatment of clinical varicocele to improve other outcomes (e.g. to relieve pain or to prevent future reproductive problems) is beyond the scope of this recommendation. Health care providers should appropriately monitor all patients after any surgical or radiological treatment procedures. Patients should be monitored for potential complications after treatment, such as hydrocele, recurrence and persistence. Given that there was limited information on all surgical ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 195
  },
  {
    "chunk_id": "infertility_2452",
    "text": ". Patients should be monitored for potential complications after treatment, such as hydrocele, recurrence and persistence. Given that there was limited information on all surgical procedures (i.e. both microsurgical and non-microsurgical methods [retroperitoneal or inguinal vein ligation]), consideration of patient preferences regarding the type of treatment procedure is important. Research gaps and future guideline update Certainty of evidence for this recommendation was very low. Studies comparing microsurgical varicocele repair with radiological treatment were lacking. Future studies should include comparing microsurgical techniques versus embolization, and comparing acceptability between surgery and embolization. Given the small numbers of events and participants and the absence of recent research on embolization, high-quality randomized controlled studies comparing radiological trea",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 195
  },
  {
    "chunk_id": "infertility_2453",
    "text": "ation. Given the small numbers of events and participants and the absence of recent research on embolization, high-quality randomized controlled studies comparing radiological treatments to surgery are needed. Future guidance will be needed regarding the management of recurrence, and persistence after initial treatment with either surgical or radiological treatment. Future guidance will be required to address the role of varicocele treatment before ART. References 1. Baazeem A, Zini A. Surgery Illustrated – Surgical Atlas: Microsurgical varicocelectomy. BJU Int. 2009;104(3):420-7 (ht tps://doi.org/10.1111/j.1464 - 410X.2009.008768.x). 2. Diegidio P, Jhaveri JK, Ghannam S, Pinkhasov R, Shabsigh R, Fisch H. Review of current varicocelectomy techniques and their outcomes. BJU Int. 2011;108(7):1157-72. 3. Marte A. The history of varicocele: from antiquity to the modern ERA. Int Braz J Urol. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 195
  },
  {
    "chunk_id": "infertility_2454",
    "text": "w of current varicocelectomy techniques and their outcomes. BJU Int. 2011;108(7):1157-72. 3. Marte A. The history of varicocele: from antiquity to the modern ERA. Int Braz J Urol. 2018;44:563- 76 (https://doi.org/10.1590/S1677-5538. IBJU.2017.0386). 4. Tauber R, Pfeiffer D. Surgical atlas varicocele: antegrade scrotal sclerotherapy. BJU Int. 2006;98(6):1333-44 (ht tps://doi.org/10.1111/ j.1464-410X.2006.06579.x). 5. Çayan S, Shavakhabov S, Kadioğlu A. Treatment of palpable varicocele in infertile men: a meta- analysis to define the best technique. J Androl. 2009;30(1):33-40 (https://doi.org/10.2164/ jandrol.108.005967). 6. Cassidy D, Jarvi K, Grober E, Lo K. Varicocele surgery or embolization: which is better? Can Urol Assoc J. 2012;6(4):266 (https://pubmed.ncbi. nlm.nih.gov/23093537/). 7. Nabi G, Asterlings S, Greene D, Marsh R. Percutaneous embolization of varicoceles: outcomes and cor",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 195
  },
  {
    "chunk_id": "infertility_2455",
    "text": "Can Urol Assoc J. 2012;6(4):266 (https://pubmed.ncbi. nlm.nih.gov/23093537/). 7. Nabi G, Asterlings S, Greene D, Marsh R. Percutaneous embolization of varicoceles: outcomes and correlation of semen improvement with pregnancy. Urology. 2004;63(2):359-63 (https://doi.org/10.1016/j. urology.2003.09.026). 8. Dewire DM, Thomas Jr AJ, Falk RM, Geisinger MA , Lammert GK. Clinical outcome and cost comparison of percutaneous embolization and surgical ligation of varicocele. J Androl. 1994;15(S6):38S-42S (https://doi. org/10.1002/j.1939-4640.1994.tb01703.x). 9. Persad E, O'Loughlin CAA, Kaur S, Wagner G, Matyas N, Hassler-Di Fratta MR et al. Surgical or radiological treatment for varicoceles in subfertile men. Cochrane Database Syst Rev. 2021;(4):CD000479 (https://doi. org/10.1002/14651858.CD000479.pub6).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 195
  },
  {
    "chunk_id": "infertility_2456",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 172 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 10. Fayez A, El Shantaly K, Abbas M, Hauser S, Müller S, Fathy A. Comparison of inguinal approach, scrotal sclerotherapy and subinguinal antegrade sclerotherapy in varicocele treatment: a randomized prospective study. Urol Int. 2010;85(2):200-3 (https://doi. org/10.1159/000316338). 11. Nieschlag E, Behre H, Schlingheider A, Nashan D, Pohl J, Fischedick A. Surgical ligation vs. angiographic embolization of the vena spermatica: a prospective randomized study for the treatment of varicocele‐related infertility. Andrologia. 1993;25(5):233-7 (https://doi. org/10.1111/j.1439 - 0272.1993.tb02716.x). 12. Yavetz H, Levy R, Papo J, Yogev L, Paz G, Jaffa A et al. Efficacy of varicocele embolization v",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 196
  },
  {
    "chunk_id": "infertility_2457",
    "text": "ologia. 1993;25(5):233-7 (https://doi. org/10.1111/j.1439 - 0272.1993.tb02716.x). 12. Yavetz H, Levy R, Papo J, Yogev L, Paz G, Jaffa A et al. Efficacy of varicocele embolization versus ligation of the left internal spermatic vein for improvement of sperm quality. Int J Androl. 1992;15(4):338-44 (https://www.doi. org/10.1111/j.1365-2605.1992.tb01133.x). 13. Sayfan J, Soffer Y, Orda R. Varicocele treatment: prospective randomized trial of 3 methods. J Urol. 1992;148(5):1447-9 (https://doi.org/10.1016/ s0022-5347(17)36934-3). 14. Nieschlag E, Hertle L, Fischedick A, Abshagen K, Behre H. Update on treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Hum Reprod. 1998;13(8):2147-50 (https://doi.org/10.1093/humrep/13.8.2147). 15. Nieschlag E, Hertle L, Fischedick A, Behre H. Treatment of varicocele: counselling as effective as occlusion of the vena spermatica.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 196
  },
  {
    "chunk_id": "infertility_2458",
    "text": "(https://doi.org/10.1093/humrep/13.8.2147). 15. Nieschlag E, Hertle L, Fischedick A, Behre H. Treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Hum Reprod. 1995;10(2):347-53 (https://doi. org/10.1093/oxfordjournals.humrep.a135941). 16. Kovac JR, Fantus J, Lipshultz LI, Fischer MA, Klinghoffer Z. Cost-effectiveness analysis reveals microsurgical varicocele repair is superior to percutaneous embolization in the treatment of male infertility. Can Urol Assoc J. 2014;8(9–10):E619-E625 (https://doi.org/10.5489/ cuaj.1873).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 196
  },
  {
    "chunk_id": "infertility_2459",
    "text": "1739 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For males with infertility undergoing surgical treatment of varicocele, WHO suggests using microscopic surgery rather than other surgical procedures. (Conditional recommendation, very low certainty of evidence) Remarks: • Subinguinal microsurgery is a common surgical varicocelectomy procedure, while other surgical procedures include non-microscopic open approaches (such as inguinal and retroperitoneal) and laparoscopic methods. • In settings where the expertise to perform microscopic surgery is not available, other surgical techniques may be used. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technolog",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 197
  },
  {
    "chunk_id": "infertility_2460",
    "text": "cal techniques may be used. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART). Background and rationale This guideline suggests the use of either surgical or radiological treatment of varicocele in men with infertility, with certainty of evidence that is low (see previous sections). If surgical methods are selected, further decisions would be needed to choose which surgical methods would be used to treat clinical varicocele. Options for surgical varicocelectomy include retroperitoneal or conventional inguinal open techniques, microsurgical inguinal or subinguinal approaches, or laparoscopic repair ( 1–4). Surgical repair of varicocele using different techniques may be complicated by varicocele persistence, recurrence or injury to surrounding tissue; depending on the procedure, ge",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 197
  },
  {
    "chunk_id": "infertility_2461",
    "text": "). Surgical repair of varicocele using different techniques may be complicated by varicocele persistence, recurrence or injury to surrounding tissue; depending on the procedure, general anaesthesia or longer time to operate may be required ( 2, 5). Postoperative hydrocele formation is a frequent complication of varicocelectomy resulting from the disruption of lymphatic vessels. Different techniques have been developed in an attempt to minimize such complications, for example, to reduce recurrence rates, which may be more common with some surgical approaches ( 6, 7). Microscopic varicocelectomy is typically performed using a subinguinal approach, which involves making a 2–3-cm transverse skin incision centred over the external inguinal ring to approach the spermatic cord, with the aid of an operating microscope, after which the spermatic veins are ligated while preserving the testicular a",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 197
  },
  {
    "chunk_id": "infertility_2462",
    "text": "er the external inguinal ring to approach the spermatic cord, with the aid of an operating microscope, after which the spermatic veins are ligated while preserving the testicular arteries and lymphatics. Microscopic inguinal varicocelectomy is less common and involves making an incision in a way that provides access to the ilioinguinal nerves, applying similar procedural principles of ligating the spermatic veins while preserving the testicular arteries and lymphatics. For this recommendation, the GDG addressed the question: should microscopic varicocelectomy versus other non-microscopic surgical varicocelectomy techniques be used for men with clinical varicocele in couples with infertility? This question was identified by the GDG as a priority and is provided in the context of the recommendation related to the treatment of clinical varicocele in men with infertility. It does not assess ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 197
  },
  {
    "chunk_id": "infertility_2463",
    "text": "dentified by the GDG as a priority and is provided in the context of the recommendation related to the treatment of clinical varicocele in men with infertility. It does not assess the use of surgical treatment before or in combination with ART. Balancing desirable and undesirable effects A systematic review ( 8) reported the effects of surgical and radiological treatment of varicoceles in subfertile men. We used the data from studies that included men with clinical varicocele as reported by the authors of the original studies. Sixteen studies that compared microscopic surgical treatment to other surgery were included ( 9–24). Subinguinal microsurgery was the most common surgical varicocelectomy procedure assessed in the",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 197
  },
  {
    "chunk_id": "infertility_2464",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 174 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps studies. Results showed that there is likely a small increase in pregnancies with microscopic subinguinal surgery (60 more [from 3 to 126 more] per 1000; RR: 1.20; 95% CI: 1.01–1.42) when compared to other surgical approaches. Data on live births and quality of life were not reported. In relation to undesirable effects, microscopic surgery may slightly reduce varicocele recurrence, but the effects on other adverse events, such as hydrocele formation, testicular atrophy, wound infection and haematoma, are very uncertain and not consistently less. Most studies did not report on the randomization or allocation method and had incomplete follow-up; there were few participants or events related ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 198
  },
  {
    "chunk_id": "infertility_2465",
    "text": "ertain and not consistently less. Most studies did not report on the randomization or allocation method and had incomplete follow-up; there were few participants or events related to adverse effects. Because of the uncertainty of the evidence for adverse events, the overall certainty of evidence is rated very low. Although no data on patient values were available, the GDG agreed that most patients valued pregnancy and live births, while seeking to minimize harms. Therefore, based on the likely small increase in pregnancies and decrease in varicocele recurrence, the GDG agreed that microscopic treatment is probably favoured over other treatments. Other considerations Based on data from studies ( 25, 26), the GDG agreed that microscopic surgery may cost slightly more than most non-microscopic surgical approaches (and may vary across countries) and that training may be required; however, th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 198
  },
  {
    "chunk_id": "infertility_2466",
    "text": " agreed that microscopic surgery may cost slightly more than most non-microscopic surgical approaches (and may vary across countries) and that training may be required; however, these additional costs were considered negligible because most other surgical procedures involve large costs. Although a modelling study (25) suggested that microscopic surgery is more cost-effective than non-microscopic surgery, the pregnancy estimates in the model were much higher than reported in the systematic review of RCTs by Persad et al. ( 8). Given the trivial differences in benefits and harms from the systematic review, and the negligible cost differences between microscopic and other procedures in most countries, the GDG judged that cost-effectiveness did not favour either microscopic or other surgical procedures. The GDG judged that microscopic surgical procedures are probably feasible to provide but ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 198
  },
  {
    "chunk_id": "infertility_2467",
    "text": "ed that cost-effectiveness did not favour either microscopic or other surgical procedures. The GDG judged that microscopic surgical procedures are probably feasible to provide but may require expertise, equipment or training to perform safely. As surgical procedures are likely available and involve similar large costs, there is probably no impact on equity. In addition, although there were no data regarding patient preferences for any of the procedures, the GDG agreed that microscopic surgery is probably acceptable to patients. Summary justification There is likely a small increase in pregnancies and trivial decrease in varicocele recurrence with microscopic surgery, but there is no or uncertain evidence for other benefits or harms. Performing microscopic surgery is probably feasible; it requires greater expertise and it may incur negligible additional costs. Microscopic surgery is proba",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 198
  },
  {
    "chunk_id": "infertility_2468",
    "text": "her benefits or harms. Performing microscopic surgery is probably feasible; it requires greater expertise and it may incur negligible additional costs. Microscopic surgery is probably acceptable; given the negligible cost differences between microsurgical and other surgical procedures, there would probably be no impact on equity. Implementation considerations When implementing these recommendations, health care providers should monitor patients for complications to ensure safety. To ensure good-quality outcomes from microscopic surgery, expertise and training may be required. In low-resource and other settings where the expertise to perform microscopic surgery is not available, other surgical techniques may be considered, bearing in mind patients’ preferences.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 198
  },
  {
    "chunk_id": "infertility_2469",
    "text": "1759 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Research gaps and future guideline update Future studies should include live births and quality of life as outcomes, and patient preferences, and should also endeavour to report adverse events alongside desirable outcomes. Blinding of outcome assessors in future studies would be important. Future guidance is needed on the effects of microsurgical versus other treatment modalities in subgroups of patients with recurrent clinical varicoceles. References 1. Baazeem A, Zini A. Surgery illustrated–surgical atlas microsurgical varicocelectomy. BJU Int. 2009;104(3):420-7 (ht tps://doi.org/10.1111/j.1464 - 410X.2009.008768.x). 2. Diegidio P, Jhaveri JK, Ghannam S, Pinkhasov R, Shabsigh R, Fisch H. Review of current vari",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 199
  },
  {
    "chunk_id": "infertility_2470",
    "text": "y. BJU Int. 2009;104(3):420-7 (ht tps://doi.org/10.1111/j.1464 - 410X.2009.008768.x). 2. Diegidio P, Jhaveri JK, Ghannam S, Pinkhasov R, Shabsigh R, Fisch H. Review of current varicocelectomy techniques and their outcomes. BJU Int. 2011;108(7):1157-72 (https://doi. org/10.1111/j.1464-410X.2010.09959.x). 3. Marte A. The history of varicocele: from antiquity to the modern ERA. Int Braz J Urol. 2018;44:563- 76 (https://doi.org/10.1590/S1677-5538. IBJU.2017.0386). 4. Hopps CV, Lemer ML, Schlegel PN, Goldstein M. Intraoperative varicocele anatomy: a microscopic study of the inguinal versus subinguinal approach. J Urol. 2003;170(6 Pt 1):2366-70 (https://doi. org/10.1097/01.ju.0000097400.67715.f8). 5. Çayan S, Shavakhabov S, Kadioğlu A. Treatment of palpable varicocele in infertile men: a meta- analysis to define the best technique. J Androl. 2009;30(1):33-40 (https://doi.org/10.2164/ jandrol.1",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 199
  },
  {
    "chunk_id": "infertility_2471",
    "text": "abov S, Kadioğlu A. Treatment of palpable varicocele in infertile men: a meta- analysis to define the best technique. J Androl. 2009;30(1):33-40 (https://doi.org/10.2164/ jandrol.108.005967). 6. Wang H, Ji Z-G. Microsurgery versus laparoscopic surgery for varicocele: a meta-analysis and systematic review of randomized controlled trials. J Invest Surg. 2020;33(1):40-8 (https://doi.or g/10.1080/08941939.2018.1474979). 7. Ding H, Tian J, Du W, Zhang L, Wang H, Wang Z. Open non-microsurgical, laparoscopic or open microsurgical varicocelectomy for male infertility: a meta-analysis of randomized controlled trials. BJU Int. 2012;110(10):1536-42 (https://doi. org/10.1111/j.1464 - 410X .2012.11093.x). 8. Persad E, O'Loughlin CAA, Kaur S, Wagner G, Matyas N, Hassler-Di Fratta MR et al. Surgical or radiological treatment for varicoceles in subfertile men. Cochrane Database Syst Rev. 2021;(4):CD0004",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 199
  },
  {
    "chunk_id": "infertility_2472",
    "text": "ghlin CAA, Kaur S, Wagner G, Matyas N, Hassler-Di Fratta MR et al. Surgical or radiological treatment for varicoceles in subfertile men. Cochrane Database Syst Rev. 2021;(4):CD000479 (https://doi. org/10.1002/14651858.CD000479.pub6). 9. Al-Kandari AM, Shabaan H, Ibrahim HM, Elshebiny YH, Shokeir AA. Comparison of outcomes of different varicocelectomy techniques: open inguinal, laparoscopic, and subinguinal microscopic varicocelectomy: a randomized clinical trial. Urology. 2007;69(3):417- 20 (https://doi.org/10.1016/j.urology.2007.01.057). 10. Al-Said S, Al-Naimi A, Al-Ansari A, Younis N, Shamsodini A, A-sadiq K et al. Varicocelectomy for male infertility: a comparative study of open, laparoscopic and microsurgical approaches. J Urol. 2008;180(1):266-70 (https://doi. org/10.1016/j.juro.2008.03.050). 11. Bryniarski P, Taborowski P, Rajwa P, Kaletka Z, Życzkowski M, Paradysz A. The comparis",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 199
  },
  {
    "chunk_id": "infertility_2473",
    "text": "cal approaches. J Urol. 2008;180(1):266-70 (https://doi. org/10.1016/j.juro.2008.03.050). 11. Bryniarski P, Taborowski P, Rajwa P, Kaletka Z, Życzkowski M, Paradysz A. The comparison of laparoscopic and microsurgical varicocoelectomy in infertile men with varicocoele on paternity rate 12 months after surgery: a prospective randomized controlled trial. Andrology. 2017;5(3):445-50 (ht tps://doi.org/10.1111/andr.12343). 12. Fang P, Li B, Zheng S, Xu Y, Chen D, Li C et al. Comparison of the curative effect and total cost of different surgical methods for varicocele [Bùtóng shǒushù fāngshì duì jīng suǒ jìngmài qūzhāng de liáoxiào jí zǒng fèiyòng bǐjiào]. Guangdong Med J. 2013;34(15): 2397-9.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 199
  },
  {
    "chunk_id": "infertility_2474",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 176 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 13. Gao H, Li S. Comparative study of the effect of laparoscopic and microscopic ligation of spermatic vein on reproductive hormones and semen quality in patients with varicocele infertility [Fùqiāng jìng yǔ xiǎnwéijìng xià jīng suǒ jìngmài jiézā shù duì jīng suǒ jìngmài qūzhāng xìng bù yù huànzhě shēngzhí jīsù jí jīngyè zhìliàng yǐngxiǎng de duìbǐ yánjiū]. Chinese Community Doctors 2017;33(35):58-60. 14. Gontero P, Pretti G, Fontana F, Zitella A, Marchioro G, Frea B. Inguinal versus subinguinal varicocele vein ligation using magnifying loupe under local anesthesia: which technique is preferable in clinical practice? Urology. 2005;66(5):1075-9 (https://doi.org/10.1016/j.urology.2005.05.009",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 200
  },
  {
    "chunk_id": "infertility_2475",
    "text": "igation using magnifying loupe under local anesthesia: which technique is preferable in clinical practice? Urology. 2005;66(5):1075-9 (https://doi.org/10.1016/j.urology.2005.05.009). 15. Meng J, Li H, Li C. Efficacy evaluation of two minimally invasive procedures for the treatment of varicocele [Liǎng zhǒng wēi chuàng shǒushù fāngshì zhìliáo jīng suǒ jìngmài qūzhāng de xiàoguǒ]. Chin Med Herald 2017;14(15):86-9. 2017;14(15):86-9. 16. Min X, Yaoting X, Wei G, Dujian L, Ruqiang H. Curative effects analysis of spermatic vein ligation under microscope and laparoscope for varicocele treatment. Chin J Androl. 2011;25(4):45‐7 (https:// www.cochranelibrary.com/central/doi/10.1002/ central/CN-01018249/full). 17. Pan F, Pan L, Zhang A, Liu Y, Zhang F, Dai Y. Comparison of two approaches in microsurgical varicocelectomy in Chinese infertile males. Urol Int. 2013;90(4):443-8 (https://doi. org/10.115",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 200
  },
  {
    "chunk_id": "infertility_2476",
    "text": "Pan L, Zhang A, Liu Y, Zhang F, Dai Y. Comparison of two approaches in microsurgical varicocelectomy in Chinese infertile males. Urol Int. 2013;90(4):443-8 (https://doi. org/10.1159/000345606). 18. Pu J, Wu X, Tang W, Chen Z. Comparison of therapeutic effect between microsurgical varicocelectomy and conventional methods in the treatment of primary varicocele [Jīng suǒ jìngmài xiǎn wéi jiézā shù yǔ chuántǒng shǒushù fāngshì zhìliáo yuán fā xìng jīng suǒ jìngmài qūzhāng de liáoxiào bǐjiào]. J Chongqing Med Univ. 2014;39(6):816-9. 19. Punekar S, Gavande P, Swami G, Soni A, Rao S, Kinne J. Comparison of subinguinal microsurgical varicocelectomy (Goldstein's technique) with inguinal varicocelectomy (Ivanissevich's technique). Indian J Urol. 1999;15(1):42‐4 (https:// www.cochranelibrary.com/central/doi/10.1002/ central/CN-01094953/full). 20. Ren Y, Wang F, Kong B, Luo L, Wang P, Li S. A compar",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 200
  },
  {
    "chunk_id": "infertility_2477",
    "text": "echnique). Indian J Urol. 1999;15(1):42‐4 (https:// www.cochranelibrary.com/central/doi/10.1002/ central/CN-01094953/full). 20. Ren Y, Wang F, Kong B, Luo L, Wang P, Li S. A comparative study of low-approach microscopic and laparoscopic varicocelectomy in the treatment of varicocele [Xiǎnwéijìng dīwèi jiézā shù hé fùqiāng jìng jīng suǒ jìngmài gāowèi jiézā shù zhìliáo jīng suǒ jìngmài qūzhāng liáoxiào bǐjiào]. Int Urol Nephrol. 2015;35(3):393-7. 21. Su H, Li T, Fan Y, Li X, Zhao G, Zhang H. The effect of four surgical approaches on the semen quality and pregnancy rate in patients with subclinical varicocele [Bùtóng shǒushù fāngshì duì jīng suǒ jìngmài qūzhāng huànzhě jīngyè zhìliàng hé pèi'ǒu shòuyùn lǜ yǐngxiǎngvolume_up]. Hebei Med Univ J. 2017;23(3):380-4. 22. Yang Z, Ji G, Miao F. Comparison of the results of microsurgical inguinal and transumbilical laparoscopic high ligation in the",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 200
  },
  {
    "chunk_id": "infertility_2478",
    "text": "ngvolume_up]. Hebei Med Univ J. 2017;23(3):380-4. 22. Yang Z, Ji G, Miao F. Comparison of the results of microsurgical inguinal and transumbilical laparoscopic high ligation in the treatment of varicocele [Xiǎnwéijìng fùgǔgōu xià yǔ jīng qí dān kǒng fùqiāng jìng gāowèi jiézā zhìliáo jīng suǒ jìngmài qūzhāng de liáoxiào bǐjiào]. Chin J Primary Med Pharmacy. 2017;2(5):765-8. 23. Zhang Z. Analysis of the effect of microscopy and laparoscopic surgery on varicocele [Xiǎnwéijìng yǔ fùqiāng jìng shǒushù zhìliáo jīng suǒ jìngmài qūzhāng de liáoxiào fēnxī]. Henan Med Res. 2015;24 (11):117-8. 24. Zheng C, Shenmin Y. Comparative study of effect of low-approach microscopic and laparoscopic varicocelectomy in treatment of varicocele. Chin J Androl. 2012;26(3):49‐51 (https://doi. org/10.3969/j.issn.1008-0848.2012.03.013). 25. Kovac JR, Fantus J, Lipshultz LI, Fischer MA, Klinghoffer Z. Cost-effectiven",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 200
  },
  {
    "chunk_id": "infertility_2479",
    "text": "aricocele. Chin J Androl. 2012;26(3):49‐51 (https://doi. org/10.3969/j.issn.1008-0848.2012.03.013). 25. Kovac JR, Fantus J, Lipshultz LI, Fischer MA, Klinghoffer Z. Cost-effectiveness analysis reveals microsurgical varicocele repair is superior to percutaneous embolization in the treatment of male infertility. Can Urol Assoc J. 2014;8(9-10):E619-E625 (https://doi.org/10.5489/ cuaj.1873). 26. Alkandari MH, Al-Hunayan A. Varicocelectomy: modified loupe-assisted versus microscopic technique–a prospective comparative study. Arab J Urol. 2017;15(1):74-7 (https://doi. org/10.1016/j.aju.2016.12.002).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 200
  },
  {
    "chunk_id": "infertility_2480",
    "text": "1779 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For males with infertility undergoing non-microscopic surgical treatment of varicocele, WHO suggests using either inguinal or retroperitoneal surgical procedures. (Conditional recommendation, very low certainty of evidence) Remarks: • When selecting whether to use an inguinal or retroperitoneal surgical procedure, consider feasibility and the availability of trained health care providers. • This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with assisted reproductive technology (ART). Background and rationale Once a decision to treat clinical varicocele has been arrived at, options for treatment include surgical repair or radiological ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 201
  },
  {
    "chunk_id": "infertility_2481",
    "text": "oductive technology (ART). Background and rationale Once a decision to treat clinical varicocele has been arrived at, options for treatment include surgical repair or radiological treatment. Options for surgical varicocelectomy include retroperitoneal or conventional inguinal open techniques, microsurgical inguinal or subinguinal approaches, or laparoscopic repair (1–3). Surgical repair of varicocele using different techniques may be complicated by varicocele recurrence or injury to surrounding tissue; depending on the specific procedure, it may require general anaesthesia, microsurgical expertise or longer operative time ( 2, 4). Postoperative hydrocele formation is a frequent complication of varicocelectomy resulting from the disruption of lymphatic vessels. Different techniques have been developed in an attempt to minimize such complications and to reduce recurrence rates, which may b",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 201
  },
  {
    "chunk_id": "infertility_2482",
    "text": "esulting from the disruption of lymphatic vessels. Different techniques have been developed in an attempt to minimize such complications and to reduce recurrence rates, which may be more common with some surgical approaches (5, 6). This guideline suggests surgical or radiological treatment over expectant management of clinical varicocele in men with infertility, with certainty of evidence that is low. In addition, this WHO infertility guideline suggests microsurgical subinguinal varicocele repair over other surgical procedures to treat clinical varicocele in men in couples with infertility (see previous sections). In settings where the expertise to perform microsurgical subinguinal varicocele repair is unavailable, other surgical techniques may be considered. Such options include inguinal or retroperitoneal procedures. Inguinal varicocelectomy involves an incision over the inguinal canal",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 201
  },
  {
    "chunk_id": "infertility_2483",
    "text": "ble, other surgical techniques may be considered. Such options include inguinal or retroperitoneal procedures. Inguinal varicocelectomy involves an incision over the inguinal canal, starting at the external inguinal ring and extending 3–4 cm laterally parallel to the inguinal ligament, which allows the identification of the spermatic cord and exposure of the enlarged pampiniform veins for ligation ( 7). This is an open surgical procedure, typically performed without a microscope. The conventional non‐magnified open inguinal varicocelectomy is also referred to as the Ivanissevich technique ( 8). Retroperitoneal varicocelectomy, also referred to as suprainguinal, Palomo, high-ligation, highest entry point or abdominal varicocelectomy, is an open varicocelectomy procedure that involves a medial inferior incision to the ipsilateral anterior superior iliac spine through the external and inter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 201
  },
  {
    "chunk_id": "infertility_2484",
    "text": "minal varicocelectomy, is an open varicocelectomy procedure that involves a medial inferior incision to the ipsilateral anterior superior iliac spine through the external and internal oblique fascia to access and ligate the internal spermatic vein ( 9, 10). For this recommendation, the GDG addressed the question: should surgical treatment of clinical varicoceles be performed using conventional non‐magnified open inguinal techniques (Ivanissevich technique) versus a retroperitoneal surgical technique? This recommendation does not assess the use of surgical treatment before or in combination with ART.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 201
  },
  {
    "chunk_id": "infertility_2485",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 178 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Balancing desirable and undesirable effects We used the data from a systematic review ( 9) that addressed the effects of surgical and radiological treatment for clinical varicoceles in subfertile men. We used data from studies that compared inguinal to retroperitoneal surgery among men with clinical varicoceles only ( 11–21). Results showed that there may be no difference in the number of pregnancies with either procedure. There were five more pregnancies (46 fewer to 70 more) per 1000 (RR: 1.02; 95% CI: 0.82–1.27) with inguinal surgery compared to retroperitoneal surgery. There were no data for live births or quality of life. In terms of undesirable effects, the evidence showed that there",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 202
  },
  {
    "chunk_id": "infertility_2486",
    "text": "7) with inguinal surgery compared to retroperitoneal surgery. There were no data for live births or quality of life. In terms of undesirable effects, the evidence showed that there may be no difference with the inguinal approach in varicocele recurrence compared to the retroperitoneal approach (three more [from 64 fewer to 164 more] per 1000; RR: 1.03; 95% CI: 0.43–2.46) or hydrocele formation (two more [from 45 fewer to 161 more] per 1000; RR: 1.03; 95% CI: 0.31–3.47). Evidence is also uncertain for other adverse events, including testicular atrophy, haematoma and wound infection. In addition, most studies did not report the randomization or allocation method and had incomplete follow-up; there were also few participants or events related to desirable and undesirable effects. Given these limitations, the overall certainty of evidence was very low. The GDG agreed that individuals with in",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 202
  },
  {
    "chunk_id": "infertility_2487",
    "text": "articipants or events related to desirable and undesirable effects. Given these limitations, the overall certainty of evidence was very low. The GDG agreed that individuals with infertility place greater value on live births and pregnancies and would likely avoid harms. Since there were trivial differences in desirable effects and harms, and the evidence is very uncertain for other adverse events, the GDG agreed that one procedure is probably not favoured over the other. Other considerations The GDG agreed that there would likely be a negligible difference in the costs between the two techniques. Evidence is uncertain for no differences in benefits and harms between the two procedures; cost differences are probably negligible. Therefore, the GDG agreed that cost-effectiveness does not favour either procedure. The GDG judged that both inguinal and retroperitoneal approaches are similarly ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 202
  },
  {
    "chunk_id": "infertility_2488",
    "text": "ably negligible. Therefore, the GDG agreed that cost-effectiveness does not favour either procedure. The GDG judged that both inguinal and retroperitoneal approaches are similarly available and are likely to involve similar costs; therefore, there would be no impact on equity if either is recommended over the other. No evidence on acceptability was identified. However, the GDG agreed that either procedure is probably acceptable to patients. No specific evidence was available on feasibility. However, the GDG judged that both procedures would be probably feasible given that training, equipment and time required for surgery are probably similar. Summary justification There may be little difference in pregnancies, varicocele recurrence or hydrocele formation with either procedure, and the evidence is uncertain for other harms. Performing either procedure would likely result in similar costs ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 202
  },
  {
    "chunk_id": "infertility_2489",
    "text": "varicocele recurrence or hydrocele formation with either procedure, and the evidence is uncertain for other harms. Performing either procedure would likely result in similar costs and likely be similarly acceptable and feasible, and would probably have no impact on equity. Implementation considerations Health care providers should monitor patients for complications. To ensure the safety of procedures, training of health care providers may be required. Research gaps and future guideline update Future studies should comprehensively report live births, quality of life, patient preferences and adverse events. Future studies should assess whether either procedure evaluated separately improves these outcomes, compared to no treatment. Blinding of outcome assessors in such future studies would be important.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 202
  },
  {
    "chunk_id": "infertility_2490",
    "text": "1799 Treatment of infertility due to male factors Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Baazeem A, Zini A. Surgery illustrated – Surgical atlas microsurgical varicocelectomy. BJU Int. 2009;104(3):420-7 (ht tps://doi.org/10.1111/j.1464 - 410X.2009.008768.x). 2. Diegidio P, Jhaveri JK, Ghannam S, Pinkhasov R, Shabsigh R, Fisch H. Review of current varicocelectomy techniques and their outcomes. BJU Int. 2011;108(7):1157-72 (https://doi. org/10.1111/j.1464-410X.2010.09959.x). 3. Marte A. The history of varicocele: from antiquity to the modern ERA. Int Braz J Urol. 2018;44:563- 76 (https://doi.org/10.1590/S1677-5538. IBJU.2017.0386). 4. Çayan S, Shavakhabov S, Kadioğlu A. Treatment of palpable varicocele in infertile men: a meta- analysis to define the best technique. J Androl. 2009;30(1):",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 203
  },
  {
    "chunk_id": "infertility_2491",
    "text": "538. IBJU.2017.0386). 4. Çayan S, Shavakhabov S, Kadioğlu A. Treatment of palpable varicocele in infertile men: a meta- analysis to define the best technique. J Androl. 2009;30(1):33-40 (https://doi.org/10.2164/ jandrol.108.005967). 5. Wang H, Ji Z-G. Microsurgery versus laparoscopic surgery for varicocele: a meta-analysis and systematic review of randomized controlled trials. J Invest Surg. 2020;33(1):40-8 (https://doi.or g/10.1080/08941939.2018.1474979). 6. Ding H, Tian J, Du W, Zhang L, Wang H, Wang Z. Open non-microsurgical, laparoscopic or open microsurgical varicocelectomy for male infertility: a meta-analysis of randomized controlled trials. BJU Int. 2012;110(10):1536-42 (https://doi. org/10.1111/j.1464 - 410X .2012.11093.x). 7. Turek PJ. Varicocele ligation. In: Smith JA, Howards SS, Preminger GM, Dmochowski R, editors. Hinman’s atlas of urologic surgery revised reprint, fourth e",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 203
  },
  {
    "chunk_id": "infertility_2492",
    "text": "- 410X .2012.11093.x). 7. Turek PJ. Varicocele ligation. In: Smith JA, Howards SS, Preminger GM, Dmochowski R, editors. Hinman’s atlas of urologic surgery revised reprint, fourth edition. Philadelphia. Elsevier/Saunders; 2019. 8. Ivanissevich O. Left varicocele due to reflux; experience with 4,470 operative cases in forty- two years. J Int Coll Surg. 1960;34:742-55. 9. Persad E, O’Loughlin CAA, Kaur S, Wagner G, Matyas N, Hassler-Di Fratta MR et al. Surgical or radiological treatment for varicoceles in subfertile men. Cochrane Database Syst Rev. 2021;(4):CD000479 (https://doi. org/10.1002/14651858.CD000479.pub6). 10. Palomo A. Radical cure of varicocele by a new technique: preliminary report. J Urol. 1949;61(3):604-7 (https://doi.org/10.1016/S0022- 5347(17)69113-4). 11. Barbalias GA, Liatsikos EN, Nikiforidis G, Siablis D. Treatment of varicocele for male infertility: a comparative study",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 203
  },
  {
    "chunk_id": "infertility_2493",
    "text": ":604-7 (https://doi.org/10.1016/S0022- 5347(17)69113-4). 11. Barbalias GA, Liatsikos EN, Nikiforidis G, Siablis D. Treatment of varicocele for male infertility: a comparative study evaluating currently used approaches. Eur Urol. 1998;34(5):393-8 (https:// doi.org/10.1159/000019772). 12. Barry J, Nady M, Ragab G, El-Khalaf B, Abdallah A, Imich AM. Five mm laparoscopic varicocelectomy versus conventional varicocele ligation in young men with symptomatic varicocele: a randomized clinical study. Afr J Urol. 2012;18(1):12‐5 (https:// doi.org/10.1016/j.afju.2012.04.004). 13. Cayan S, Kadioglu TC, Tefekli A, Kadioglu A, Tellaloglu S. Comparison of results and complications of high ligation surgery and microsurgical high inguinal varicocelectomy in the treatment of varicocele. Urology. 2000;55(5):750-4 (https://doi.org/10.1016/s0090- 4295(99)00603-2). 14. Chaudhary IA, Rehmani MA. Varicocelectom",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 203
  },
  {
    "chunk_id": "infertility_2494",
    "text": "gh inguinal varicocelectomy in the treatment of varicocele. Urology. 2000;55(5):750-4 (https://doi.org/10.1016/s0090- 4295(99)00603-2). 14. Chaudhary IA, Rehmani MA. Varicocelectomy: Paloma’s procedure versus Ivanissevich’s procedure. J Coll Physicians Surg Pak. 2000;10(9):334‐7. 15. Fang P, Li B, Zheng S, Xu Y, Chen D, Li C et al. Bùtóng shǒushù fāngshì duì jīng suǒ jìngmài qūzhāng de liáoxiào jí zǒng fèiyòng bǐjiào [Comparison of the curative effect and total cost of different surgical methods for varicocele]. Guangdong Med J. 2013;34(15):2397-9. 16. Pu J, Wu X, Tang W, Chen Z. Jīng suǒ jìngmài xiǎn wéi jiézā shù yǔ chuántǒng shǒushù fāngshì zhìliáo yuán fā xìng jīng suǒ jìngmài qūzhāng de liáoxiào bǐjiào [Comparison of therapeutic effect between microsurgical varicocelectomy and conventional methods in the treatment of primary varicocele]. J Chongqing Med Univ. 2014;39(6):816-19.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 203
  },
  {
    "chunk_id": "infertility_2495",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 180 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 17. Su H, Li T, Fan Y, Li X, Zhao G, Zhang H. The effect of four surgical approaches on the semen quality and pregnancy rate in patients with subclinical varicocele [Bùtóng shǒushù fāngshì duì jīng suǒ jìngmài qūzhāng huànzhě jīngyè zhìliàng hé pèi'ǒu shòuyùn lǜ yǐngxiǎngvolume_up]. Hebei Med Univ J. 2017;23(3):380-4. 18. Sun HB, Liu Y, Yan MB, Li ZD, Gui XG. Comparing three different surgical techniques used in adult bilateral varicocele. Asian J Endosc Surg. 2012;5(1):12-6 (ht tps://doi.org/10.1111/j.1758- 5910.2011.00109.x). 19. Telkar S, Goudar BV, Lamani YP, Ambi U, K oppal R. Laparoscopic versus open varicocelectomy a prospective study. J Clin Diagn Res. 2012;6(2):271‐3. 20. Al-Kanda",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 204
  },
  {
    "chunk_id": "infertility_2496",
    "text": ".2011.00109.x). 19. Telkar S, Goudar BV, Lamani YP, Ambi U, K oppal R. Laparoscopic versus open varicocelectomy a prospective study. J Clin Diagn Res. 2012;6(2):271‐3. 20. Al-Kandari AM, Shabaan H, Ibrahim HM, Elshebiny YH, Shokeir AA. Comparison of outcomes of different varicocelectomy techniques: open inguinal, laparoscopic, and subinguinal microscopic varicocelectomy: a randomized clinical trial. Urology. 2007;69(3):417- 20 (https://doi.org/10.1016/j.urology.2007.01.057). 21. Al-Said S, Al-Naimi A, Al-Ansari A, Younis N, Shamsodini A, A-sadiq K et al. Varicocelectomy for male infertility: a comparative study of open, laparoscopic and microsurgical approaches. J Urol. 2008;180(1):266-70 (https://doi. org/10.1016/j.juro.2008.03.050).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 204
  },
  {
    "chunk_id": "infertility_2497",
    "text": "181 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 10 Treatment of couples with unexplained infertility This section contains recommendations related to the management of unexplained infertility. Figure 10.1 shows how these recommendations relate to each other, illustrated in a diagnostic algorithm. Specific recommendations are presented in the sections that follow. 10.1 First-line management of couples with unexplained infertility Recommendation For couples with unexplained infertility, WHO suggests expectant management rather than unstimulated intrauterine insemination (U-IUI). (Conditional recommendation, low certainty of evidence) Remarks: • Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 205
  },
  {
    "chunk_id": "infertility_2498",
    "text": "nce) Remarks: • Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. • The duration of expectant management was typically 3–6 months in studies informing this recommendation. Background and rationale Unexplained infertility is diagnosed when there is failure to achieve pregnancy after 12 months of regular unprotected intercourse, and when investigations fail to identify a cause in either the female or male partner (such as tubal disease or uterine cavity abnormalities, ovulation dysfunction in the female partner, or semen parameters that are outside the WHO reference ranges in the male partner) (see s ection 5.8 for the criteria fo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 205
  },
  {
    "chunk_id": "infertility_2499",
    "text": "abnormalities, ovulation dysfunction in the female partner, or semen parameters that are outside the WHO reference ranges in the male partner) (see s ection 5.8 for the criteria for diagnosis of unexplained infertility). For this recommendation, the GDG addressed the question: should U-IUI versus expectant management be used for couples with unexplained infertility? This was assessed in the context of first-line management of unexplained infertility. Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. While the likelihood of spontaneous (i.e. unassisted) pregnancy without medical intervention among couples with unexplained infertility varies from study to study ( 1–6), it is typically greater than zero but less than that of fertile couples (5). Therefore, expectant management could reduce overtreatment (7",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 205
  },
  {
    "chunk_id": "infertility_2500",
    "text": "tility varies from study to study ( 1–6), it is typically greater than zero but less than that of fertile couples (5). Therefore, expectant management could reduce overtreatment (7) as some couples with infertility may conceive during expectant management (8–10). Based on this possibility for spontaneous (i.e. unassisted) pregnancy, couples with unexplained infertility are advised on lifestyle, provided information regarding their most fertile days and monitored if they will become pregnant, but are not provided any treatment (see Fig. 10.1 for the treatment algorithm for unexplained infertility). Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 205
  },
  {
    "chunk_id": "infertility_2501",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 182 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. 10.1. Treatment algorithm for unexplained infertility Alternative: gonadotrophinsg First-line medical treatment Second-line medical treatment Third-line medical treatment 1 2 3 Unexplained infertility Expectant managementc,d S-IUIe Clomiphene citrate OR letrozole,f with monitoring. Adjust dose as required. IVF without ICSI Provide clinical follow-up; document pregnancy outcomes Provide clinical follow-up; document pregnancy outcomes Provide clinical follow-up; document pregnancy outcomes Further advanced evaluation and managementh Yes Yes Yes OR No No No Pregnancy detected? Pregnancy detected? Pregnancy detected? See Section 5.8 for diagnosisa,b a Infertility is defined as failure to ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 206
  },
  {
    "chunk_id": "infertility_2502",
    "text": "luation and managementh Yes Yes Yes OR No No No Pregnancy detected? Pregnancy detected? Pregnancy detected? See Section 5.8 for diagnosisa,b a Infertility is defined as failure to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse. b Criteria for the diagnosis of unexplained infertility: • failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse; • normal physical examination and medical history in both the male and female; • presumptive confirmation of ovulation and patent tubes in the female partner; and • semen parameters that are within the WHO r eference ranges in the male partner. c Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitorin",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 206
  },
  {
    "chunk_id": "infertility_2503",
    "text": " expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. d The duration of expectant management was typically 3–6 months in studies informing this recommendation. e The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. f If off-label use of letrozole is allowed. g If capacity for side-effect management exists. h Individualized approach or under research conditions. ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; S-IUI, stimulated intrauterine insemination.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 206
  },
  {
    "chunk_id": "infertility_2504",
    "text": "18310 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps IUI is a fertility treatment that places processed sperm directly into the uterus at the time of ovulation. In IUI, the male partner’s semen is processed using established standards (10) and the sperm placed into the uterus with a suitable transcervical catheter around the time of ovulation. Thus, IUI bypasses the cervix and increases the number of motile sperm that reach the uterus and the fallopian tubes. To ensure accurate timing of the insemination, cycle monitoring is performed through ultrasound assessment of follicle growth or by monitoring the preovulatory LH levels. IUI can occur in a natural cycle (U-IUI) or after ovarian stimulation with a medication such as clomiphene citrate, letrozole or gona",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 207
  },
  {
    "chunk_id": "infertility_2505",
    "text": "h or by monitoring the preovulatory LH levels. IUI can occur in a natural cycle (U-IUI) or after ovarian stimulation with a medication such as clomiphene citrate, letrozole or gonadotrophins. Balancing harms and benefits A systematic review with network meta-analysis by Wang et al. (12) provided evidence for expectant management versus U-IUI. We also extracted results from pairwise meta-analyses and examined the primary studies included in the review for additional outcomes. The evidence showed that the benefits of U-IUI are likely trivial when compared to expectant management, with only 28 more live births (from 58 fewer to 160 more) per 1000 (OR: 1.21; 95% CI: 0.61–2.43) and 26 more clinical pregnancies (from 55 fewer to 148 more) per 1000 women treated (OR: 1.20; 95% CI: 0.61–2.36). In the studies where desirable outcomes were observed, clinical pregnancies occurred within 3–6 months’",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 207
  },
  {
    "chunk_id": "infertility_2506",
    "text": " 55 fewer to 148 more) per 1000 women treated (OR: 1.20; 95% CI: 0.61–2.36). In the studies where desirable outcomes were observed, clinical pregnancies occurred within 3–6 months’ duration. The differences in undesirable effects are also trivial between U-IUI and expectant management. Compared to expectant management, U-IUI may result in a trivial increase in ectopic pregnancy (15 more, ranging from 18 fewer to 279 more per 1000; OR: 1.70; 95% CI: 0.15–19.35), pain (42 more [from five fewer to 155 more], per 1000; OR: 2.43; 95% CI: 0.84–7.07) and bleeding (36 more [from six fewer to 149 more], per 1000; OR: 2.52; 95% CI: 0.77–8.20). However, U-IUI may reduce miscarriages (140 fewer [from 235 fewer to 32 more], per 1000; OR: 0.45; 95% CI: 0.17–1.16) and may slightly reduce preterm birth (22 fewer [from 119 fewer to 209 more], per 1000; OR: 0.84; 95% CI: 0.23–3.06), depression (12 fewer [",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 207
  },
  {
    "chunk_id": "infertility_2507",
    "text": " per 1000; OR: 0.45; 95% CI: 0.17–1.16) and may slightly reduce preterm birth (22 fewer [from 119 fewer to 209 more], per 1000; OR: 0.84; 95% CI: 0.23–3.06), depression (12 fewer [from 21 fewer to 38 more], per 1000; OR: 0.49; 95% CI: 0.09–2.70) and hospitalizations (10 fewer [from 12 fewer to 36 more], per 1000; OR: 0.19; 95% CI: 0.01–4.07). There may be no differences in gastrointestinal symptoms (vomiting and bloating) between U-IUI and expectant management. Because of lack of sufficient studies reporting outcomes according to age, a planned subgroup analysis according to age was not performed by Wang et al. (12); only one study reported these data. The GDG considered that people with unexplained infertility highly value live births and do not desire negative outcomes, and that these values are unlikely to vary among different groups. Given the trivial benefits and trivial harms, the ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 207
  },
  {
    "chunk_id": "infertility_2508",
    "text": " highly value live births and do not desire negative outcomes, and that these values are unlikely to vary among different groups. Given the trivial benefits and trivial harms, the GDG judged that the balance of effects probably does not favour either U-IUI or expectant management. Other considerations The GDG considered evidence from two studies (4, 13) showing that U-IUI requires personnel, laboratory equipment, materials, medication and overhead costs, and judged that the procedure is associated with moderate costs compared to expectant management. The GDG judged that U-IUI is probably feasible and noted that although the U-IUI technique itself is not complex, training is still needed to perform it correctly and ensure optimal timing of the insemination. The GDG considered evidence from one study ( 14) showing that U-IUI was acceptable to most women if it increases the chances of pregn",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 207
  },
  {
    "chunk_id": "infertility_2509",
    "text": "and ensure optimal timing of the insemination. The GDG considered evidence from one study ( 14) showing that U-IUI was acceptable to most women if it increases the chances of pregnancy; however, data showed that it has minimal benefits compared to expectant management. Because of the costs involved, U-IUI may result in decreased equity compared to expectant management, especially in settings where fertility treatment is not publicly funded. Given that U-IUI involves costs and yet it has trivial benefits, the GDG concluded that cost-effectiveness probably favours expectant management.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 207
  },
  {
    "chunk_id": "infertility_2510",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 184 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification U-IUI may have trivial benefits on live births and pregnancies compared to expectant management and trivial differences in adverse events. Although U-IUI is probably acceptable and feasible, it is not cost-effective and may reduce equity compared to expectant management. Therefore, expectant management was suggested rather than U-IUI. Implementation considerations Couples with unexplained infertility should be informed of the rationale and success rate with expectant management, noting that age and ovarian reserve may have an impact on the outcomes of expectant management. Unstimulated IUI is no better than expectant management and is not recommended. Health care prov",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 208
  },
  {
    "chunk_id": "infertility_2511",
    "text": "age and ovarian reserve may have an impact on the outcomes of expectant management. Unstimulated IUI is no better than expectant management and is not recommended. Health care providers should inform couples regarding the duration of expectant management, and counsel them regarding the possibility of offering second-line treatments if expectant management is not successful. Adequate counselling and education regarding expectant management and its duration is essential given that some couples with unexplained infertility may have low confidence with spontaneous (i.e. unassisted) pregnancy (15). Research gaps and future guideline update Future guidance will require availability of sufficient data from studies to perform subgroup analyses for prognostic factors, such as age, duration of unexplained infertility and ovarian reserve, among others, for example, using prognostic models or other ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 208
  },
  {
    "chunk_id": "infertility_2512",
    "text": "perform subgroup analyses for prognostic factors, such as age, duration of unexplained infertility and ovarian reserve, among others, for example, using prognostic models or other approaches. References 1. Collins JA, Burrows EA, Willan AR. The prognosis for live birth among untreated infertile couples. Fertil Steril. 1995;64(1):22-8 (https://doi. org/10.1016/S0015-0282(16)57650-X). 2. Steures P, van der Steeg JW, Hompes PGA, Habbema JDF, Eijkemans MJC, Broekmans FJ et al. Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial. Lancet. 2006;368(9531):216-21 (https://doi. org/10.1016/S0140-6736(06)69042-9). 3. Farquhar CM, Liu E, Armstrong S, Arroll N, Lensen S, Brown J. Intrauterine insemination with ovarian stimulation versus expectant management f",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 208
  },
  {
    "chunk_id": "infertility_2513",
    "text": "rg/10.1016/S0140-6736(06)69042-9). 3. Farquhar CM, Liu E, Armstrong S, Arroll N, Lensen S, Brown J. Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial. Lancet. 2018;391(10119):441-50 (https://doi.org/10.1016/S0140-6736(17)32406-6). 4. Wordsworth S, Buchanan J, Mollison J, Harrild K, Robertson L, Tay C et al. Clomifene citrate and intrauterine insemination as first-line treatments for unexplained infertility: are they cost-effective? Hum Reprod. 2010;26(2):369-75 (https://doi. org/10.1093/humrep/deq315). 5. Guzick D, Sullivan M, Adamson GD, Cedars M, Falk R, Peterson E et al. Efficacy of treatment for unexplained infertility. Fertil Steril. 1998;70(2):207-13 (https://doi.org/10.1016/S0015- 0282(98)00177-0). 6. McLernon DJ, Lee AJ, Maheshwari A, van Eekelen R, va",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 208
  },
  {
    "chunk_id": "infertility_2514",
    "text": "of treatment for unexplained infertility. Fertil Steril. 1998;70(2):207-13 (https://doi.org/10.1016/S0015- 0282(98)00177-0). 6. McLernon DJ, Lee AJ, Maheshwari A, van Eekelen R, van Geloven N, Putter H et al. Predicting the chances of having a baby with or without treatment at different time points in couples with unexplained subfertility. Hum Reprod. 2019;34(6):1126-38 (https://doi. org/10.1093/humrep/dez049).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 208
  },
  {
    "chunk_id": "infertility_2515",
    "text": "18510 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 7. Kersten FA, Hermens RP, Braat DD, Hoek A, Mol BW, Goddijn M et al. Overtreatment in couples with unexplained infertility. Hum Reprod. 2015;30(1):71-80 (https://doi.org/10.1093/ humrep/deu262). 8. Evers JL, de Haas HW, Land JA, Dumoulin JC , Dunselman GA. Treatment-independent pregnancy rate in patients with severe reproductive disorders. Hum Reprod. 1998;13(5):1206-9 (https://doi.org/10.1093/ humrep/13.5.1206). 9. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol. 2004;103(1):51-6 (https://doi. org/10.1097/01.AOG.0000100153.24061.45). 10. van der Steeg JW, Steures P, Eijkemans MJ, Habbema JD, Hompes PG, Broekmans FJ et al. Pregnancy is predictable: a large-s",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 209
  },
  {
    "chunk_id": "infertility_2516",
    "text": "(https://doi. org/10.1097/01.AOG.0000100153.24061.45). 10. van der Steeg JW, Steures P, Eijkemans MJ, Habbema JD, Hompes PG, Broekmans FJ et al. Pregnancy is predictable: a large-scale prospective external validation of the prediction of spontaneous pregnancy in subfertile couples. Hum Reprod. 2007;22(2):536-42 (https://doi. org/10.1093/humrep/del378). 11. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/343208). 12. Wang R, Danhof NA, Tjon‐Kon‐Fat RI, Eijkemans MJ, Bossuyt PM, Mochtar MH et al. Interventions for unexplained infertility: a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2019;(9):CD012692 (https://doi.org/10.1002/14651858.CD012692. pub2). 13. Goverde AJ, McDonnell J, Vermeiden JP, Schats R, Rutten FF, Schoemaker J. Intrauterine insemin",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 209
  },
  {
    "chunk_id": "infertility_2517",
    "text": "se Syst Rev. 2019;(9):CD012692 (https://doi.org/10.1002/14651858.CD012692. pub2). 13. Goverde AJ, McDonnell J, Vermeiden JP, Schats R, Rutten FF, Schoemaker J. Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis. Lancet. 2000;355(9197):13-8 (https://doi.org/10.1016/ S0140-6736(99)04002-7). 14. Weiss NS, Schreurs AMF, van der Veen F, Hompes PGA, Lambalk CB, Mol BW et al. Women's perspectives on ovulation induction with or without IUI as treatment for normogonadotrophic anovulation: a discrete choice experiment. Hum Reprod Open. 2017;2017(3):hox021 (https://doi.org/10.1093/ hropen/hox021). 15. Dreischor F, Laan ETM, Peeters F, Peeraer K, Lambalk CB, Goddijn M et al. The needs of subfertile couples continuing to attempt natural conception: in-depth interviews. Hum Reprod Open. 2022;2022(4):h",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 209
  },
  {
    "chunk_id": "infertility_2518",
    "text": "M, Peeters F, Peeraer K, Lambalk CB, Goddijn M et al. The needs of subfertile couples continuing to attempt natural conception: in-depth interviews. Hum Reprod Open. 2022;2022(4):hoac037 (https://doi. org/10.1093/hropen/hoac037).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 209
  },
  {
    "chunk_id": "infertility_2519",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 186 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For couples with unexplained infertility, WHO suggests expectant management rather than ovarian stimulation with timed intercourse. (Conditional recommendation, low certainty of evidence) Remarks: • Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. • The duration of expectant management was typically 3–6 months in studies informing this recommendation. Background and rationale Expectant management refers to monitoring t",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 210
  },
  {
    "chunk_id": "infertility_2520",
    "text": "ided. • The duration of expectant management was typically 3–6 months in studies informing this recommendation. Background and rationale Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided (see the previous section for the rationale for expectant management). Ovarian Stimulation (OS) refers to the pharmacological treatment to induce the development of (typically multiple, and ideally three or fewer) ovarian follicles and hence oocytes available for fertilization. Commonly used medications for ovarian stimulation include clomiphene citrate, letrozole and gonadotrophin modulators ( 1–4). Because of their mechanism of action and effec",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 210
  },
  {
    "chunk_id": "infertility_2521",
    "text": "ization. Commonly used medications for ovarian stimulation include clomiphene citrate, letrozole and gonadotrophin modulators ( 1–4). Because of their mechanism of action and effects on follicle development, medications used for ovarian stimulation such as clomiphene citrate, letrozole or gonadotrophins may increase the risk of adverse events, such as multiple pregnancy and OHSS ( 1, 5) (see Chapter 6.1 for details on the mechanisms of actions of these medications). When ovarian stimulation is provided in combination with timed intercourse, couples with unexplained infertility are prescribed ovarian stimulation medications and advised to have sexual intercourse during the fertile period, which is typically a few ( ≈6) days up to and including the day of ovulation (6–8). For this recommendation, the GDG addressed the question: should ovarian stimulation with timed intercourse versus expec",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 210
  },
  {
    "chunk_id": "infertility_2522",
    "text": "w ( ≈6) days up to and including the day of ovulation (6–8). For this recommendation, the GDG addressed the question: should ovarian stimulation with timed intercourse versus expectant management be used for couples with unexplained infertility? It was assessed in the context of first-line management for unexplained infertility. Balancing harms and benefits A systematic review by Wang et al. ( 9) provided data for this comparison. The review included 13 RCTs comparing ovarian stimulation using several medications (e.g. clomiphene citrate, letrozole, or gonadotrophins) with timed intercourse or IUI to no treatment. Results comparing ovarian stimulation with timed intercourse versus expectant management were extracted. Data for additional relevant outcomes were extracted from the primary studies included in the network meta-analysis. The analysis reported that although ovarian stimulation ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 210
  },
  {
    "chunk_id": "infertility_2523",
    "text": "acted. Data for additional relevant outcomes were extracted from the primary studies included in the network meta-analysis. The analysis reported that although ovarian stimulation with timed intercourse likely results in 77 more clinical pregnancies (from 1 fewer to 180 more) per 1000 women treated (OR: 1.64; 95% CI: 0.99–2.73) and one more live birth (from 74 fewer to 117 more) (OR: 1.01; 95% CI: 0.51–1.98), when compared to expectant management. In the studies where desirable outcomes were observed, clinical pregnancies occurred within 3–6 months’ duration. In terms of harms, ovarian stimulation likely results in 12 more multiple pregnancies (from zero to 48 more) (OR: 3.07; 95% CI: 1.00–9.41),",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 210
  },
  {
    "chunk_id": "infertility_2524",
    "text": "18710 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps and may result in 156 more miscarriages (from 190 fewer to 654 more) per 1000 women treated (OR: 2.08; 95% CI: 0.16–26.37) compared to expectant management. Slight increases in pain (205 more [from 75 to 416 more] per 1000; OR: 9.55; 95% CI: 3.66–24.91) and nausea (107 more [from 24 to 287 more] per 1000; OR: 5.92; 95% CI: 1.99–17.59) may occur, but there may be no difference in anxiety (OR: 1.09; 95% CI: 0.63–1.87), depression (OR: 0.98; 95% CI: 0.24–3.97) or hospitalization (OR: 0.95; 95% CI: 0.13–6.84). There were no data on OHSS. A planned subgroup analysis according to age was not conducted in the systematic review by Wang et al. ( 9) because of lack of sufficient studies reporting outcomes according ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 211
  },
  {
    "chunk_id": "infertility_2525",
    "text": "HSS. A planned subgroup analysis according to age was not conducted in the systematic review by Wang et al. ( 9) because of lack of sufficient studies reporting outcomes according to age; only one study reported these data. The GDG judged that ovarian stimulation with timed intercourse may result in small benefits and moderate undesirable effects. The GDG also judged that people with unexplained infertility highly value live births and do not desire negative outcomes, and that these values are unlikely to vary among different groups. Therefore, the balance of effects probably favours expectant management over ovarian stimulation with timed intercourse. The overall certainty of evidence was low. Other considerations The GDG judged that although ovarian stimulation with timed intercourse is probably feasible, it involves moderate resources because of the cost of medications, ultrasound mon",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 211
  },
  {
    "chunk_id": "infertility_2526",
    "text": "ions The GDG judged that although ovarian stimulation with timed intercourse is probably feasible, it involves moderate resources because of the cost of medications, ultrasound monitoring or hormone assays (10). The GDG noted that the costs of stimulating agents vary from country to country, but are likely higher for gonadotrophins. Although the costs of some medications, such as clomiphene citrate, could be low, overall, ovarian stimulation would probably reduce equity, especially in settings where fertility treatments are not publicly financed. Based on data presented from two studies ( 11, 12), the GDG judged that the acceptability of ovarian stimulation among patients varies. Summary justification Overall, there is low certainty evidence for small desirable effects and moderate undesirable effects with ovarian stimulation with timed intercourse compared to expectant management. In ad",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 211
  },
  {
    "chunk_id": "infertility_2527",
    "text": "there is low certainty evidence for small desirable effects and moderate undesirable effects with ovarian stimulation with timed intercourse compared to expectant management. In addition, ovarian stimulation with timed intercourse involves moderate costs, which may reduce equity compared to expectant management, and its acceptability varies. Therefore, the undesirable consequences of ovarian stimulation with timed intercourse probably outweigh the desirable consequences; therefore, expectant management is suggested. Implementation considerations Health care providers implementing expectant management should counsel couples on lifestyle and their most fertile days and monitor if they will become pregnant. Health care providers should inform couples about the duration and potential outcomes of expectant management, and ensure that couples understand the rationale for expectant management. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 211
  },
  {
    "chunk_id": "infertility_2528",
    "text": " care providers should inform couples about the duration and potential outcomes of expectant management, and ensure that couples understand the rationale for expectant management. They should also counsel patients about the possibility of offering second-line treatments if expectant management is not successful. Research gaps and future guideline update Further guidance is needed on whether and how the duration of unexplained infertility, age, ovarian reserve and other prognostic factors can further inform expectant management.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 211
  },
  {
    "chunk_id": "infertility_2529",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 188 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Lee VCY, Ledger W. Aromatase inhibitors for ovulation induction and ovarian stimulation. Clin Endocrinol. 2011;74(5):537-46 (https://doi. org/10.1111/j.1365-2265.2011.04006.x). 2. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212-24 (https://doi.org/10.1093/ humupd/6.3.212). 3. Casarini L, Brigante G, Simoni M, Santi D. Clinical applications of gonadotropins in the female: assisted reproduction and beyond. Prog Mol Biol Transl Sci. 2016;143:85-119 (https://doi. org/10.1016/bs.pmbts.2016.08.002). 4. Prodromidou A, Anagnostou E, Mavrogianni D, Liokari E, Dimitroulia E, Draka",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 212
  },
  {
    "chunk_id": "infertility_2530",
    "text": "nd beyond. Prog Mol Biol Transl Sci. 2016;143:85-119 (https://doi. org/10.1016/bs.pmbts.2016.08.002). 4. Prodromidou A, Anagnostou E, Mavrogianni D, Liokari E, Dimitroulia E, Drakakis P et al. Past, present, and future of gonadotropin use in controlled ovarian stimulation during assisted reproductive techniques. Cureus. 2021;13(6):e15663 (https://doi.org/10.7759/ cureus.15663). 5. Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5):S188-S193 (https://doi.org/10.1016/j. fertnstert.2008.08.034). 6. Dunson DB, Baird DD, Wilcox AJ, Weinberg CR. Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. Hum Reprod. 1999;14(7):1835-9 (https://doi.org/10.1093/humrep/14.7.1835). 7. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 212
  },
  {
    "chunk_id": "infertility_2531",
    "text": "of ovulation. Hum Reprod. 1999;14(7):1835-9 (https://doi.org/10.1093/humrep/14.7.1835). 7. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med. 1995;333(23):1517-21 (https://doi.org/10.1056/ nejm199512073332301). 8. France JT, Graham FM, Gosling L, Hair P, Knox BS. Characteristics of natural conceptual cycles occurring in a prospective study of sex preselection: fertility awareness symptoms, hormone levels, sperm survival, and pregnancy outcome. Int J Fertil. 1992;37(4):244-55. 9. Wang R, Danhof NA, Tjon‐Kon‐Fat RI, Eijkemans MJ, Bossuyt PM, Mochtar MH et al. Interventions for unexplained infertility: a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2019;(9):CD012692 (https://doi.org/10.1002/14651858.CD012692. pub2). 10. Wor",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 212
  },
  {
    "chunk_id": "infertility_2532",
    "text": "for unexplained infertility: a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2019;(9):CD012692 (https://doi.org/10.1002/14651858.CD012692. pub2). 10. Wordsworth S, Buchanan J, Mollison J, Harrild K, Robertson L, Tay C et al. Clomifene citrate and intrauterine insemination as first-line treatments for unexplained infertility: are they cost-effective? Hum Reprod. 2010;26(2):369-75 (https://doi. org/10.1093/humrep/deq315). 11. Bhattacharya S, Harrild K, Mollison J, Wordsworth S, Tay C, Harrold A et al. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial. BMJ. 2008;337:a716 (https://doi. org/10.1136/bmj.a716). 12. Barrière P, Avril C, Benmahmoud-Zoubir A, Bénard N, Dejager S. Patient perceptions and understanding of treatment instructions for ovarian stimul",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 212
  },
  {
    "chunk_id": "infertility_2533",
    "text": "://doi. org/10.1136/bmj.a716). 12. Barrière P, Avril C, Benmahmoud-Zoubir A, Bénard N, Dejager S. Patient perceptions and understanding of treatment instructions for ovarian stimulation during infertility treatment. Reprod Biomed Online. 2019;9:37-47 (https://doi. org/10.1016/j.rbms.2019.08.003).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 212
  },
  {
    "chunk_id": "infertility_2534",
    "text": "18910 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 10.2 Second-line management of couples with unexplained infertility Recommendation For couples with unexplained infertility, where expectant management has been unsuccessful, WHO suggests stimulated intrauterine insemination (S-IUI) with either clomiphene citrate or letrozole. (Conditional recommendation, low certainty of evidence) Remarks: • When selecting whether to use clomiphene citrate or letrozole, consider the applicable national laws and regulations related to off-label use of letrozole. • The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to si",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 213
  },
  {
    "chunk_id": "infertility_2535",
    "text": "es is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. Background and rationale This guideline suggests expectant management as first-line management in couples with unexplained infertility rather than ovarian stimulation with timed intercourse or U-IUI. S-IUI involves the use of ovarian stimulation medications to increase the number of mature oocytes available for fertilization. Commonly used medications for ovarian stimulation include anti-estrogens (e.g. clomiphene citrate), aromatase inhibitors (e.g. letrozole) and gonadotrophins (e.g. FSH and LH) (see Chapter 6.1 for a description of these agents and their mechanisms of actions). For this recommendation, the GDG addressed the question: should S-IUI with letrozole versus S-IUI with clomiphene citrate ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 213
  },
  {
    "chunk_id": "infertility_2536",
    "text": "ription of these agents and their mechanisms of actions). For this recommendation, the GDG addressed the question: should S-IUI with letrozole versus S-IUI with clomiphene citrate be used for couples with unexplained infertility? It was assessed in the context of second-line management of unexplained infertility. Balancing harms and benefits We used evidence from two systematic reviews: Wang et al. (1) for the effects of expectant management compared to S-IUI and existing RCT data comparing clomiphene citrate to letrozole in S-IUI from a review by Eskew et al. ( 2). Eight eligible RCTs were identified by the review authors, but only six investigated ovulation stimulation paired with IUI (3–8). One of the studies, Badawy et al. ( 8) was retracted; therefore, it is not included in this analysis. Another study by Badawy et al. ( 9) was excluded because it focused on stimulation for timed in",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 213
  },
  {
    "chunk_id": "infertility_2537",
    "text": "s, Badawy et al. ( 8) was retracted; therefore, it is not included in this analysis. Another study by Badawy et al. ( 9) was excluded because it focused on stimulation for timed intercourse rather than IUI and it is under investigation (10). Data showed that there are likely greater pregnancies with S-IUI than expectant management (approximately 100–200 more per 1000) but likely little to no difference between the ovarian stimulation drugs. There may also be little to no difference in live births between the drugs. Compared to clomiphene citrate, stimulation with letrozole may result in similar number of live births per 1000 pregnancies (RR: 1.00; 95% CI: 081–1.22) and likely 80 more biochemical pregnancies [from 43 fewer to 272 more] per 1000 (RR: 1.32; 95% CI: 0.83–2.09). In terms of harms, there may be little to no difference in harms or adverse events between letrozole and clomiphene",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 213
  },
  {
    "chunk_id": "infertility_2538",
    "text": "om 43 fewer to 272 more] per 1000 (RR: 1.32; 95% CI: 0.83–2.09). In terms of harms, there may be little to no difference in harms or adverse events between letrozole and clomiphene citrate, but greater harms compared to expectant management (e.g. OHSS may occur in 11 per 1000 with ovarian stimulation but not with expectant management). Compared with clomiphene citrate, letrozole may result in similar outcomes in terms of miscarriage (134 fewer, [from 224 fewer to 106 more] per 1000; RR: 0.52; 95% CI: 0.20–1.34), multiple (twin) pregnancies (17 fewer per 1000; RR: 0.76; 95% CI: 0.22–2.64), ectopic pregnancies and congenital anomalies. Based on 599 participants in one",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 213
  },
  {
    "chunk_id": "infertility_2539",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 190 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps study, the review ( 2) reported similar rates of abdominal bloating (16.8% versus 18.6%), breast pain (6.4% ver sus 7.2%) and headache (34.9% versus 41.9%) between clomiphene citrate and letrozole. Hot flushes (30.9% versus 16.8%) and constipation (9.4% versus 2.7%) were higher with clomiphene citrate, while joint and limb pain were more common with letrozole (5.8% versus 2.7%). In the RCTs, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. Overall, the certainty of the evidence was low because the numbers of events in the analyses were small. Although data on patient values were not available, the GDG judged that pe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 214
  },
  {
    "chunk_id": "infertility_2540",
    "text": " Overall, the certainty of the evidence was low because the numbers of events in the analyses were small. Although data on patient values were not available, the GDG judged that people highly value live births and seek to minimize harms, such as multiple pregnancy, miscarriage or congenital anomalies. Given the moderate benefits and small increase in harms compared to expectant management, but trivial differences in harms and benefits between the drugs, the GDG judged that the balance of effects probably favours S-IUI but does not favour either letrozole or clomiphene citrate. Other considerations Stimulation with either clomiphene citrate or letrozole is feasible; it requires similar access to specialist care and ultrasound monitoring. The GDG judged that use of clomiphene citrate and letrozole is probably acceptable (11), but noted that the acceptability of letrozole may also depend on",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 214
  },
  {
    "chunk_id": "infertility_2541",
    "text": "and ultrasound monitoring. The GDG judged that use of clomiphene citrate and letrozole is probably acceptable (11), but noted that the acceptability of letrozole may also depend on whether off-label use is permitted (12). The cost and access to letrozole may vary substantially between countries; although it could be more expensive compared to clomiphene citrate in some contexts, the GDG agreed that relative to the overall cost of IUI, choosing letrozole would have negligible effects on overall costs and equity in access. No evidence on cost-effectiveness was found; however, the GDG judged that given the trivial differences in benefits and harms and negligible differences in costs, cost-effectiveness probably does not favour either medication. Summary justification There are likely moderate benefits and small harms with S-IUI compared to expectant management but there may be little differ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 214
  },
  {
    "chunk_id": "infertility_2542",
    "text": "es not favour either medication. Summary justification There are likely moderate benefits and small harms with S-IUI compared to expectant management but there may be little difference in live births and likely little difference in pregnancies between letrozole and clomiphene citrate. There may also be little difference in adverse effects, such as miscarriage, multiple pregnancy and ectopic pregnancy. Relative to the cost of S-IUI, cost differences between clomiphene citrate and letrozole would probably have no impact on equity; both are acceptable and feasible to provide. Implementation considerations Health care providers should be aware and mitigate the potential risks of stimulating agents, including clomiphene citrate and letrozole. Health care providers should consider monitoring ovarian response with US to minimize the risk of multifollicular development and multiple pregnancy. He",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 214
  },
  {
    "chunk_id": "infertility_2543",
    "text": "hene citrate and letrozole. Health care providers should consider monitoring ovarian response with US to minimize the risk of multifollicular development and multiple pregnancy. Health care providers may consider switching clomiphene citrate and letrozole based on patient symptoms and ultrasound monitoring. Relevant stakeholders should familiarize themselves with applicable national laws and regulations related to the off-label use of letrozole. Research gaps and future guideline update Future research and guidance will be required on the timing of IUI in stimulated cycles, and whether to use single or double IUI in stimulated cycles. Ongoing research and surveillance of fetal outcomes should be encouraged. Future research is required regarding the impact of age and other prognostic factors on the outcome of stimulated IUI.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 214
  },
  {
    "chunk_id": "infertility_2544",
    "text": "19110 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Wang R, Danhof NA, Tjon‐Kon‐Fat RI, Eijkemans MJ, Bossuyt PM, Mochtar MH et al. Interventions for unexplained infertility: a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2019;(9):CD012692 (https://doi.org/10.1002/14651858.CD012692. pub2). 2. Eskew AM, Bedrick BS, Hardi A, Stoll CRT, Colditz GA, Tuuli MG et al. Letrozole compared with clomiphene citrate for unexplained infertility: a systematic review and meta-analysis. Obstet Gynecol. 2019;133(3):437-44 (https://doi. org/10.1097/aog.0000000000003105). 3. Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med. 2015;3",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 215
  },
  {
    "chunk_id": "infertility_2545",
    "text": "00000003105). 3. Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med. 2015;373(13):1230-40 (https://doi.org/10.1056/NEJMoa1414827). 4. Barroso G, Menocal G, Felix H, Rojas-Ruiz JC, Arslan M, Oehninger S. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial. Fertil Steril. 2006;86(5):1428-31 (https://doi.org/10.1016/j. fertnstert.2006.03.044 ). 5. Fouda UM, Sayed AM. Extended letrozole regimen versus clomiphene citrate for superovulation in patients with unexplained infertility undergoing intrauterine insemination: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9:84 (https://doi. org/10.1186/1477",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 215
  },
  {
    "chunk_id": "infertility_2546",
    "text": "ation in patients with unexplained infertility undergoing intrauterine insemination: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9:84 (https://doi. org/10.1186/1477-7827-9-84). 6. Ibrahim MI, Moustafa RA, Abdel-Azeem AA . Letrozole versus clomiphene citrate for superovulation in Egyptian women with unexplained infertility: a randomized controlled trial. Arch Gynecol Obstet. 2012;286(6):1581-7 (https://doi.org/10.1007/s00404-012-2478-0). 7. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril. 2004;82(6):1561-3 (https://doi. org/10.1016/j.fertnstert.2004.04.070). 8. Badawy A, Elnashar A, Totongy M. Clomiphene citrate or aromatase inhibitors combined with gonadotropins for superovulation in women undergoing intrauterine insemination: a prospective randomised trial [retracted",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 215
  },
  {
    "chunk_id": "infertility_2547",
    "text": ". Clomiphene citrate or aromatase inhibitors combined with gonadotropins for superovulation in women undergoing intrauterine insemination: a prospective randomised trial [retracted]. J Obstet Gynaecol. 2010;30(6):617-21 (https://doi.org/10.31 09/01443615.2010.497873). 9. Badawy A, Shokeir T, Allam AF, Abdelhady H. Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility. Acta Obstet Gynecol Scand. 2009;88(2):187-91 (https://doi. org/10.1080/00016340802638199). 10. Editor’s Note: Badawy A, Shokeir T, Allam AF and Abdelhady H. Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility. Acta Obstet Gynecol Scand. 2021 (https://doi. org/10.1111/aogs.14195). 11. Deng Y, Wang Y-F, Zhu S-Y, Xue W, Ma X, Ma R- L et al. Nationwide survey on the usage of ovulation-induction age",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 215
  },
  {
    "chunk_id": "infertility_2548",
    "text": "stet Gynecol Scand. 2021 (https://doi. org/10.1111/aogs.14195). 11. Deng Y, Wang Y-F, Zhu S-Y, Xue W, Ma X, Ma R- L et al. Nationwide survey on the usage of ovulation-induction agents among obstetricians and gynecologists in China. Chin Med J (Engl). 2019;132(20):2489 (https://doi.org/10.1097/ CM9.0000000000000450 ). 12. Malloch L, Rhoton-Vlasak A. An assessment of current clinical attitudes toward letrozole use in reproductive endocrinology practices. Fertil Steril. 2013;100(6):1740-4 (https://doi. org/10.1016/j.fertnstert.2013.08.040)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 215
  },
  {
    "chunk_id": "infertility_2549",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 192 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For couples with unexplained infertility, where expectant management has been unsuccessful, WHO suggests S-IUI with either clomiphene citrate or letrozole rather than with gonadotrophins. (Conditional recommendation, very low certainty of evidence) Remark: • The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. Background and rationale Ovarian Stimulation is a pharmacological treatment used to induce the development of (typically multiple and ideally three or fewer) ovarian follicles; hence more oocytes availa",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 216
  },
  {
    "chunk_id": "infertility_2550",
    "text": "le Ovarian Stimulation is a pharmacological treatment used to induce the development of (typically multiple and ideally three or fewer) ovarian follicles; hence more oocytes available for fertilization. Commonly used medications for ovarian stimulation include anti-estrogens (e.g. clomiphene citrate), aromatase inhibitors (e.g. letrozole) and gonadotrophins (e.g. FSH and LH) (1–4). In the previous section, this WHO guideline suggests the use of S-IUI with either letrozole or clomiphene citrate for ovarian stimulation (conditional recommendation, low certainty of evidence). While both clomiphene citrate and letrozole are oral medications, gonadotrophins are injected. Because of their mechanism of action and effects on follicle development, medications used for ovarian stimulation such as clomiphene citrate, letrozole or gonadotrophins, may increase the risk of multiple pregnancy to varyin",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 216
  },
  {
    "chunk_id": "infertility_2551",
    "text": "cts on follicle development, medications used for ovarian stimulation such as clomiphene citrate, letrozole or gonadotrophins, may increase the risk of multiple pregnancy to varying extents; gonadotrophins may also increase the risk of OHSS (1) (further details on these ovulation-stimulating agents are described in Section 6.1). Given the potential differences in benefits, the GDG considered it a priority to determine whether to preferentially provide the oral medications (letrozole or clomiphene citrate) or gonadotrophins as stimulation agents for treatment of unexplained infertility. For this recommendation, the GDG addressed the question: should S-IUI with gonadotrophins versus S-IUI with clomiphene citrate or S-IUI with letrozole be used in couples with unexplained infertility? This was assessed in the context of second-line management of unexplained infertility. Balancing harms and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 216
  },
  {
    "chunk_id": "infertility_2552",
    "text": "or S-IUI with letrozole be used in couples with unexplained infertility? This was assessed in the context of second-line management of unexplained infertility. Balancing harms and benefits To compare clomiphene citrate with gonadotrophins, evidence was obtained from a review by Athaullah et al. ( 5), consisting of five RCTs (6–10) that compared stimulation with clomiphene citrate versus gonadotrophins in patients with unexplained infertility undergoing IUI. The results showed that compared to gonadotrophins, clomiphene citrate may result in 105 fewer live births (from 193 fewer to 79 more), (OR: 0.51; 95% CI: 0.18–1.47), and 90 fewer pregnancies (from 137 to one fewer) per 1000 women (OR: 0.44; 95% CI: 0.19–0.99). The mean pregnancy rate per cycle was 25% with gonadotrophins and 8% with clomiphene citrate. However, clomiphene citrate may also result in 97 fewer miscarriages (from 185 few",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 216
  },
  {
    "chunk_id": "infertility_2553",
    "text": "9). The mean pregnancy rate per cycle was 25% with gonadotrophins and 8% with clomiphene citrate. However, clomiphene citrate may also result in 97 fewer miscarriages (from 185 fewer to 254 more), (OR: 0.46; 95% CI: 0.06–3.33) and 140 fewer multiple pregnancies (from 230 fewer to 198 more), per 1000 pregnancies (OR: 0.37; 95% CI: 0.06–2.43). None of the RCTs reported cases of OHSS. The GDG noted that the higher pregnancy rate that may occur with gonadotrophins was at the expense of a higher multiple pregnancy rate and other adverse effects. Based on these data, the GDG concluded that the balance of effects probably favours clomiphene citrate over gonadotrophins. The certainty of the evidence was considered very low because of very few events across the RCTs.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 216
  },
  {
    "chunk_id": "infertility_2554",
    "text": "19310 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps To compare letrozole with gonadotrophins, a new search and review of evidence were conducted. Three eligible RCTs comparing letrozole to gonadotrophins in patients with unexplained infertility were identified (11–13). The evidence showed that letrozole may result in fewer live births and pregnancies compared to gonadotrophins: 103 fewer live births (from 138 to 57 fewer), (RR: 0.59; 95% CI: 0.45–0.77) and 108 fewer clinical pregnancies (from 150 to 57 fewer), per 1000 women treated (RR: 0.64; 95% CI: 0.50–0.81). The GDG judged that the magnitude of these effects was small. Letrozole may also result in moderate reductions in undesirable effects. Evidence suggests 140 fewer multiple pregnancies (from 193 to ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 217
  },
  {
    "chunk_id": "infertility_2555",
    "text": "at the magnitude of these effects was small. Letrozole may also result in moderate reductions in undesirable effects. Evidence suggests 140 fewer multiple pregnancies (from 193 to 40 fewer), (RR: 0.44; 95% CI: 0.23–0.84), 32 fewer miscarriages (from 86 fewer to 48 more), (RR: 0.84; 95% CI: 0.57–1.24), and six fewer cases of OHSS, (from 11 fewer to 34 more per 1000), (RR: 0.43; 95% CI: 0.05–4.07). In the RCTs, different numbers of cycles were provided, which ranged from one to six, with more recent studies providing 3–6 cycles. The GDG noted that although pregnancy and live birth rates are higher with gonadotrophins compared to letrozole, this comes at the expense of higher multiple pregnancy rates. The GDG judged that most patients value live births and would want to minimize serious side-effects, and that these values likely do not differ among couples with unexplained infertility. Thus",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 217
  },
  {
    "chunk_id": "infertility_2556",
    "text": "ed that most patients value live births and would want to minimize serious side-effects, and that these values likely do not differ among couples with unexplained infertility. Thus, the GDG concluded that the balance of effects probably favours letrozole over gonadotrophins. The certainty of the evidence was low because of few events and wide CIs. Other considerations Ovarian stimulation involves the cost of medications, ultrasound monitoring, hormone assays and skilled personnel. Although the overall cost of S-IUI may vary from country to country, the GDG agreed that the cost of oral agents is considerably lower than that of gonadotrophins; moderate savings would be achieved with the use of either clomiphene citrate or letrozole compared to gonadotrophins. The GDG considered studies showing the importance of treatment costs to couples and health systems ( 11, 14–16) and judged that use ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 217
  },
  {
    "chunk_id": "infertility_2557",
    "text": "itrate or letrozole compared to gonadotrophins. The GDG considered studies showing the importance of treatment costs to couples and health systems ( 11, 14–16) and judged that use of oral agents would be expected to increase equity of access to fertility treatment as they are considerably cheaper than gonadotrophins. Based on two studies ( 17, 18), the GDG judged that ovarian stimulation with IUI is probably feasible. Variations in gonadotrophin treatment protocols (e.g. doses) can affect the ability of health systems to respond to the complications of gonadotrophins, such as OHSS. Health systems capacity to implement gonadotrophins safely and manage their potential side-effects varies widely. While using low-dose gonadotrophins could reduce the risk of HOMP and OHSS, this is applied inconsistently across different jurisdictions and studies. On the other hand, the GDG judged that clomiph",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 217
  },
  {
    "chunk_id": "infertility_2558",
    "text": "ose gonadotrophins could reduce the risk of HOMP and OHSS, this is applied inconsistently across different jurisdictions and studies. On the other hand, the GDG judged that clomiphene citrate and letrozole have similar feasibility, in contexts where the off-label use of letrozole is permitted. Although direct evidence from patients was lacking, the GDG noted that the injectable nature of gonadotrophins, the need for more frequent monitoring (because of the higher risk of multiple follicle recruitment and the associated risks of multiple pregnancy and OHSS) and refrigerated storage requirements could potentially reduce their acceptability. Summary justification Although there may be slightly fewer pregnancies and live births when providing S-IUI with either clomiphene citrate or letrozole, these oral agents may have fewer adverse effects compared to gonadotrophins. In addition, clomiphene",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 217
  },
  {
    "chunk_id": "infertility_2559",
    "text": "d live births when providing S-IUI with either clomiphene citrate or letrozole, these oral agents may have fewer adverse effects compared to gonadotrophins. In addition, clomiphene citrate and letrozole are less expensive compared to gonadotrophins, and their use is likely to result in moderate resource savings and higher equity; they are probably acceptable and feasible.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 217
  },
  {
    "chunk_id": "infertility_2560",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 194 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Implementation considerations This guideline suggests that clomiphene citrate or letrozole are preferable to gonadotrophins as stimulation agents during S-IUI. When gonadotrophins are used, it should be in settings where capacity for the management of side-effects and specified risk mitigation factors are in place (e.g. low-dose, step-up protocols) and where the use of clomiphene citrate or letrozole is not feasible. Couples should be informed of the success rate, risks and costs associated with these options. Health care providers should be aware of and mitigate the potential risks of stimulating agents and should consider monitoring ovarian response with ultrasound to minimize the risk o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 218
  },
  {
    "chunk_id": "infertility_2561",
    "text": "alth care providers should be aware of and mitigate the potential risks of stimulating agents and should consider monitoring ovarian response with ultrasound to minimize the risk of multiple pregnancy. Relevant stakeholders should familiarize themselves with applicable national laws and regulations related to the off-label use of letrozole for ovulation induction. Where off-label use is allowed, health professionals should inform their clients, discuss the evidence and address possible concerns or side-effects, and discuss any alternatives. Research gaps and future guideline update Future guidance is required on how to take into account prognostic factors, such as the age of the female partner and duration of infertility, during S-IUI, for example, using prognostic models. Future research and guidance will be required on the timing of IUI in stimulated cycles, and whether to use single o",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 218
  },
  {
    "chunk_id": "infertility_2562",
    "text": "nfertility, during S-IUI, for example, using prognostic models. Future research and guidance will be required on the timing of IUI in stimulated cycles, and whether to use single or double IUI in stimulated cycles. References 1. Lee VCY, Ledger W. Aromatase inhibitors for ovulation induction and ovarian stimulation. Clin Endocrinol. 2011;74(5):537-46 (https://doi. org/10.1111/j.1365-2265.2011.04006.x). 2. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212-24 (https://doi.org/10.1093/ humupd/6.3.212). 3. Casarini L, Brigante G, Simoni M, Santi D. Clinical applications of gonadotropins in the female: assisted reproduction and beyond. Prog Mol Biol Transl Sci. 2016;143:85-119 (https://doi. org/10.1016/bs.pmbts.2016.08.002). 4. Prodromidou A, Anagnostou E, Mavrogianni D, Liokari E, Dimitro",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 218
  },
  {
    "chunk_id": "infertility_2563",
    "text": "eproduction and beyond. Prog Mol Biol Transl Sci. 2016;143:85-119 (https://doi. org/10.1016/bs.pmbts.2016.08.002). 4. Prodromidou A, Anagnostou E, Mavrogianni D, Liokari E, Dimitroulia E, Drakakis P et al. Past, present, and future of gonadotropin use in controlled ovarian stimulation during assisted reproductive techniques. Cureus. 2021;13(6):e15663 (https://doi.org/10.7759/ cureus.15663). 5. Athaullah N, Proctor M, Johnson N. Oral versus injectable ovulation induction agents for unexplained subfertility. Cochrane Database Syst Rev. 2002;(3):CD003052 (https://doi. org/10.1002/14651858.CD003052). 6. Ecochard R, Mathieu C, Royere D, Blache G, Rabilloud M, Czyba JC. A randomized prospective study comparing pregnancy rates after clomiphene citrate and human menopausal gonadotropin before intrauterine insemination. Fertil Steril. 2000;73(1):90-3 (https://doi. org/10.1016/s0015-0282(99)00474-",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 218
  },
  {
    "chunk_id": "infertility_2564",
    "text": "ncy rates after clomiphene citrate and human menopausal gonadotropin before intrauterine insemination. Fertil Steril. 2000;73(1):90-3 (https://doi. org/10.1016/s0015-0282(99)00474-4). 7. Karlström P-O, Bergh T, Lundkvist Ö. A prospective randomized trial of artificial insemination versus intercourse in cycles stimulated with human menopausal gonadotropin or clomiphene citrate. Fertil Steril. 1993;59(3):554-9 (https://doi.org/10.1016/S0015- 0282(16)55799-9). 8. Balasch J, Ballescá JL, Pimentel C, Creus M, Fábregues F, Vanrell JA. Late low-dose pure follicle stimulating hormone for ovarian stimulation in intra-uterine insemination cycles. Hum Reprod. 1994;9(10):1863-6 (https://doi. org/10.1093/oxfordjournals.humrep.a138349).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 218
  },
  {
    "chunk_id": "infertility_2565",
    "text": "19510 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 9. Nakajima A, Smith L, Wong B, Scott J, Cumming D, Tartaryn I. A randomized trial of CC plus IUI versus rFSH plus IUI for the treatment of subfertility. Fertil Steril (Suppl). 1999;72:208. 10. Karlstrom P, Berkurezion M, Bergh T, Lundkvist O. An extended prospective randomized trial of artificial insemination versus intercourse in cycles stimulated with human menopausal gonadotropins (hMG) or clomiphene citrate (CC). Fertil Steril. 1998;70:942. 11. Baysoy A, Serdaroglu H, Jamal H, Karatekeli E, Ozornek H, Attar E. Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination. Reprod Biomed Online. 2006;13(2):208-12 (https://doi. org/10.1016/S1472-6483(10)60617-7). 12. Diamo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 219
  },
  {
    "chunk_id": "infertility_2566",
    "text": "us human menopausal gonadotrophin in women undergoing intrauterine insemination. Reprod Biomed Online. 2006;13(2):208-12 (https://doi. org/10.1016/S1472-6483(10)60617-7). 12. Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med. 2015;373(13):1230-40 (https://doi.org/10.1056/NEJMoa1414827). 13. Gregoriou O, Vlahos NF, Konidaris S, Papadias K, Botsis D, Creatsas GK. Randomized controlled trial comparing superovulation with letrozole versus recombinant follicle-stimulating hormone combined with intrauterine insemination for couples with unexplained infertility who had failed clomiphene citrate stimulation and intrauterine insemination. Fertil Steril. 2008;90(3):678-83 (https://doi.org/10.1016/j. fertnstert.2007.06.099). 14. Wordsworth S, Buchanan J, Mollison J, Harrild K, Robertson L, Tay ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 219
  },
  {
    "chunk_id": "infertility_2567",
    "text": "rauterine insemination. Fertil Steril. 2008;90(3):678-83 (https://doi.org/10.1016/j. fertnstert.2007.06.099). 14. Wordsworth S, Buchanan J, Mollison J, Harrild K, Robertson L, Tay C et al. Clomifene citrate and intrauterine insemination as first-line treatments for unexplained infertility: are they cost-effective? Hum Reprod. 2010;26(2):369-75 (https://doi. org/10.1093/humrep/deq315). 15. Dyer SJ, Patel M. The economic impact of infertility on women in developing countries-a systematic review. Facts Views Vis Obgyn. 2012;4(2):102-9. 16. Nahar P. The link between infertility and poverty: evidence from Bangladesh. Hum Fertil. 2012;15(1):18-26 (https://doi.org/10.3109/146472 73.2012.658111). 17. Barrière P, Avril C, Benmahmoud-Zoubir A, Bénard N, Dejager S. Patient perceptions and understanding of treatment instructions for ovarian stimulation during infertility treatment. Reprod Biomed Onl",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 219
  },
  {
    "chunk_id": "infertility_2568",
    "text": "C, Benmahmoud-Zoubir A, Bénard N, Dejager S. Patient perceptions and understanding of treatment instructions for ovarian stimulation during infertility treatment. Reprod Biomed Online. 2019;9:37-47 (https:// pmc.ncbi.nlm.nih.gov/articles/PMC6976931/). 18. Deng Y, Wang Y-F, Zhu S-Y, Xue W, Ma X, Ma R- L et al. Nationwide survey on the usage of ovulation-induction agents among obstetricians and gynecologists in China. Chin Med J. 2019;132(20):2489 (https://doi.org/10.1097/ CM9.0000000000000450 ).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 219
  },
  {
    "chunk_id": "infertility_2569",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 196 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 10.3 Third-line management of couples with unexplained infertility Recommendation For couples with unexplained infertility, where stimulated intrauterine insemination (S-IUI) has been unsuccessful, WHO suggests in vitro fertilization (IVF) rather than expectant management. (Conditional recommendation, low certainty of evidence) Background and rationale For couples with unexplained infertility who fail to achieve pregnancy with S-IUI, options for management include IVF or expectant management. Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and most fertile days ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 220
  },
  {
    "chunk_id": "infertility_2570",
    "text": " refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no treatment is provided (see s ection 10.1 for the rationale for expectant management). Conventional IVF is an insemination procedure where oocytes and sperm are co-incubated outside the human body with the goal of achieving fertilization, after which the embryo is transferred to the uterus. IVF allows control over the number of embryos transferred, while allowing spare embryos to be cryopreserved for future use, obviating the need for further ovarian stimulation ( 1). However, IVF involves costs ( 2, 3) and may have undesirable outcomes (4) warranting its comparison with expectant management. For this recommendation, the GDG addressed th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 220
  },
  {
    "chunk_id": "infertility_2571",
    "text": "n ( 1). However, IVF involves costs ( 2, 3) and may have undesirable outcomes (4) warranting its comparison with expectant management. For this recommendation, the GDG addressed the question: should IVF (with or without ICSI) versus no treatment be used for couples with unexplained infertility? Balancing harms and benefits Evidence was reviewed from a network meta- analysis (5), two RCTs (6, 7) and a non-randomized study (8). When comparing IVF to expectant management, IVF may result in 204 more clinical pregnancies (from 40 to 407 more), (OR: 3.03; 95% CI: 1.32–6.94) and 106 more live births (from 27 fewer to 300 more), (OR: 1.88; 95% CI: 0.81–4.38), but 10 more multiple pregnancies (from two fewer to 53 more), per 1000 women treated (OR: 2.66; 95% CI: 0.68–10.43). This difference was considered moderate, and the GDG noted the possibility of further mitigating the risk of multiple pregn",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 220
  },
  {
    "chunk_id": "infertility_2572",
    "text": ", per 1000 women treated (OR: 2.66; 95% CI: 0.68–10.43). This difference was considered moderate, and the GDG noted the possibility of further mitigating the risk of multiple pregnancy through the adoption of elective single embryo transfer. In the studies, one to six cycles of IVF were provided. The GDG concluded that the balance of effects probably favours IVF over expectant management and judged the certainty of the evidence to be low. Other considerations When comparing IVF to expectant management, the GDG judged that IVF is feasible because the infrastructure can be developed and training provided, making it possible to implement it with strong collaborations and support. IVF is expensive and may not be readily accessible in some settings because of lack of infrastructure and its high cost. Thus, IVF likely reduces equity compared to expectant management. Data on the values and acce",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 220
  },
  {
    "chunk_id": "infertility_2573",
    "text": "adily accessible in some settings because of lack of infrastructure and its high cost. Thus, IVF likely reduces equity compared to expectant management. Data on the values and acceptability of IVF compared to expectant management; however, the GDG acknowledged that the trade-offs patients undergoing infertility treatments are willing to make may vary depending on different factors, including burden, effectiveness, safety and financial costs ( 9). Thus, although values were not directly assessed, the GDG agreed that patients are likely to value live births highly while avoiding side-effects, and this is unlikely to vary among different patient groups. In addition, the GDG judged that for patients who have been unsuccessful with other treatments, IVF is probably acceptable; ethically, such patients should have options when other treatments have been unsuccessful.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 220
  },
  {
    "chunk_id": "infertility_2574",
    "text": "19710 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification In couples with unexplained infertility, there may be large benefits in live births and clinical pregnancies with IVF compared to expectant management. Although there may be a moderate risk of multiple pregnancy, the balance of effects probably favours IVF compared to expectant management. Although IVF is expensive, it reduces time to pregnancy, which may be of greater benefit for couples with unexplained infertility where S-IUI has been unsuccessful. Although IVF may probably reduce equity, it is probably acceptable and probably feasible. Implementation considerations In implementing these recommendations, health care providers should consider and mitigate the risks associated with I",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 221
  },
  {
    "chunk_id": "infertility_2575",
    "text": "cceptable and probably feasible. Implementation considerations In implementing these recommendations, health care providers should consider and mitigate the risks associated with IVF, such as OHSS, and the surgical risks associated with oocyte retrieval. Health care providers should provide information about benefits, costs and the potential risks of IVF to couples with unexplained infertility undergoing IV F. Research gaps and future guideline update Future research and guidance on how to incorporate possible prognostic factors is needed, including the age of the female partner and the duration of infertility ( 10, 11). Future research and guidance are needed to determine the optimal or maximum number of IVF cycles that should be provided. Further research and guidance on management options when IVF fails to achieve pregnancy in couples with unexplained infertility is needed. References",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 221
  },
  {
    "chunk_id": "infertility_2576",
    "text": "ycles that should be provided. Further research and guidance on management options when IVF fails to achieve pregnancy in couples with unexplained infertility is needed. References 1. Trounson A, Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature. 1983;305(5936):707-9 (https://doi.org/10.1038/305707a0). 2. Collins JA. An international survey of the health economics of IVF and ICSI. Hum Reprod Update. 2002;8(3):265-77 (https://doi.org/10.1093/ humupd/8.3.265). 3. Chambers GM, Sullivan EA, Ishihara O, Chapman MG , Adamson GD. The economic impact of assisted reproductive technology: a review of selected developed countries. Fertil Steril. 2009;91(6):2281-94 (https://doi. org/10.1016/j.fertnstert.2009.04.029). 4. Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari A. Obstetric and perinatal outcomes in singleton pregnancies resulti",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 221
  },
  {
    "chunk_id": "infertility_2577",
    "text": "tps://doi. org/10.1016/j.fertnstert.2009.04.029). 4. Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari A. Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(5):485-503 (https://doi. org/10.1093/humupd/dms018). 5. Wang R, Danhof NA, Tjon‐Kon‐Fat RI, Eijkemans MJ, Bossuyt PM, Mochtar MH et al. Interventions for unexplained infertility: a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2019;(9):CD012692 (https://doi.org/10.1002/14651858.CD012692. pub2). 6. Foong SC, Fleetham JA, O’Keane JA, Scott SG, Tough SC, Greene CA. A prospective randomized trial of conventional in vitro fertilization versus intracytoplasmic sperm injection in unexplained infertility. J Assist Reprod Genet. 2006;23(3):137- 40 (https://doi.org/10.1007/s10815-005-9008-y). 7. Dang VQ, Vuong L",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 221
  },
  {
    "chunk_id": "infertility_2578",
    "text": "ation versus intracytoplasmic sperm injection in unexplained infertility. J Assist Reprod Genet. 2006;23(3):137- 40 (https://doi.org/10.1007/s10815-005-9008-y). 7. Dang VQ, Vuong LN, Luu TM, Pham TD, Ho TM, Ha AN et al. Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial. Lancet. 2021;397(10284):1554-63 (https://doi. org/10.1016/S0140-6736(21)00535-3).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 221
  },
  {
    "chunk_id": "infertility_2579",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 198 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 8. Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF, Jamieson DJ. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA. 2015;313(3):255-63 (https://doi.org/10.1001/ jama.2014.17985). 9. Dancet EA, D’Hooghe TM, van der Veen F, Bossuyt P, Sermeus W, Mol B-W et al. “Patient- centered fertility treatment”: what is required? Fertil Steril. 2014;101(4):924-6 (https://doi. org/10.1016/j.fertnstert.2013.12.045). 10. Brandes M, Hamilton CJ, van der Steen JO, de Bruin JP, Bots RS, Nelen WL et al. Unexplained infertility: overall ongoing pregnancy rate and mode of conception. Hum Reprod. 2011;26(2):360 -8 (https://doi.org/10.1093/ humrep/deq349). 11. Mc",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 222
  },
  {
    "chunk_id": "infertility_2580",
    "text": "s RS, Nelen WL et al. Unexplained infertility: overall ongoing pregnancy rate and mode of conception. Hum Reprod. 2011;26(2):360 -8 (https://doi.org/10.1093/ humrep/deq349). 11. McLernon DJ, Lee AJ, Maheshwari A, van Eekelen R, van Geloven N, Putter H et al. Predicting the chances of having a baby with or without treatment at different time points in couples with unexplained subfertility. Hum Reprod. 2019;34(6):1126-38 (https://doi. org/10.1093/humrep/dez049).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 222
  },
  {
    "chunk_id": "infertility_2581",
    "text": "19910 Treatment of couples with unexplained infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Recommendation For couples with unexplained infertility undergoing in vitro fertilization (IVF) after stimulated intrauterine insemination (S-IUI) has been unsuccessful, WHO recommends using IVF alone rather than IVF with intracytoplasmic sperm injection (ICSI). (Strong recommendation, low certainty of evidence) Background and rationale Conventional IVF is an insemination procedure where oocytes and sperm are co-incubated outside the human body with the goal of achieving fertilization. Introduced in 1992, ICSI involves injecting a single sperm into an oocyte with the goal of achieving fertilization ( 1, 2). It is often performed as an additional procedure to conventional IVF for male-factor infertility. Ho",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 223
  },
  {
    "chunk_id": "infertility_2582",
    "text": "a single sperm into an oocyte with the goal of achieving fertilization ( 1, 2). It is often performed as an additional procedure to conventional IVF for male-factor infertility. However, the rationale for the use of ICSI for non-male-factor infertility, including unexplained infertility, is unclear ( 3), and the procedure increases costs ( 4). The GDG agreed that guidance was needed regarding the addition of ICSI to conventional IVF in the management of unexplained infertility. For this recommendation the GDG addressed the question: should IVF versus ICSI be used for couples with unexplained infertility in whom other treatments have been unsuccessful? Balancing harms and benefits Evidence was reviewed from two RCTs ( 5, 6) and a non-randomized observational study (3). In the studies, the IVF/ICSI cycles provided ranged from one to six. Evidence showed that, when comparing IVF to ICSI for",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 223
  },
  {
    "chunk_id": "infertility_2583",
    "text": "RCTs ( 5, 6) and a non-randomized observational study (3). In the studies, the IVF/ICSI cycles provided ranged from one to six. Evidence showed that, when comparing IVF to ICSI for the treatment of unexplained infertility, IVF likely results in up to 28 fewer clinical pregnancies (from 66 fewer to 18 more), (RR: 0.93; 95% CI: 0.82–1.06), and likely up to 28 fewer live births (from 72 fewer to 24 more), per 1000 (RR: 0.91; 95% CI: 0.78–1.06) compared to ICSI. These differences were considered trivial by the GDG. There may also be little or no difference in adverse effects when comparing IVF with ICSI, such as multiple pregnancy (RR: 0.87; 95% CI: 0.62–1.21), although the studies were unclear on whether a similar number of embryos were transferred in all participants; miscarriages (RR: 0.96; 95% CI: 0.58–1.61); ectopic pregnancies (RR: 1.00; 95% CI: 0.42–2.38); and OHSS (RR: 1.17; 95% CI: ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 223
  },
  {
    "chunk_id": "infertility_2584",
    "text": " number of embryos were transferred in all participants; miscarriages (RR: 0.96; 95% CI: 0.58–1.61); ectopic pregnancies (RR: 1.00; 95% CI: 0.42–2.38); and OHSS (RR: 1.17; 95% CI: 0.39–3.45). The GDG judged these differences in both benefits and undesirable effects to be trivial; the evidence was of low quality because of small events contributing to the data, and the risk of confounding for adverse events from the comparative non-randomized study. Other considerations When comparing IVF to ICSI, the GDG considered that ICSI requires additional laboratory resources, personnel, time and expertise compared to IVF. Therefore, the use of IVF is expected to lead to large cost savings compared to ICSI. A 2013 modelling study (7), which compared all IVF versus a 50:50 split between IVF and ICSI, found a 3% increase in cumulative births from ICSI for an additional cost of US$ 1763. However, the ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 223
  },
  {
    "chunk_id": "infertility_2585",
    "text": "ng study (7), which compared all IVF versus a 50:50 split between IVF and ICSI, found a 3% increase in cumulative births from ICSI for an additional cost of US$ 1763. However, the GDG noted that these data did not necessarily show that ICSI was cost- effective. Given the trivial differences in live births and clinical pregnancies and the high additional cost of ICSI, the GDG judged that IVF is probably more cost-effective than ICSI for the treatment of unexplained infertility. The GDG judged that if IVF is recommended, it would lead to increased equity and significant cost savings compared to ICSI. In addition, the GDG judged that IVF is probably feasible, and probably more feasible than ICSI, given the additional training, expertise and resources necessary for ICSI. Based on existing GRADE criteria (8), the GDG made a strong recommendation despite the low certainty of evidence, given th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 223
  },
  {
    "chunk_id": "infertility_2586",
    "text": "nal training, expertise and resources necessary for ICSI. Based on existing GRADE criteria (8), the GDG made a strong recommendation despite the low certainty of evidence, given that the two interventions being compared may have equivalent benefits (low or very low certainty in benefits), while one option (in this case IVF) is less risky or less costly.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 223
  },
  {
    "chunk_id": "infertility_2587",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 200 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Summary justification In couples with unexplained infertility, IVF and ICSI likely result in similar clinical pregnancies and live births, and similar harms such as miscarriage, OHSS and ectopic pregnancy. However, the costs and resources needed for ICSI are considerably higher. Compared to ICSI, IVF results in large cost savings and is probably more cost- effective. In addition, IVF is probably more feasible compared to ICSI. Implementation considerations Health care providers should note that unexplained infertility implies semen parameters that are within the WHO reference ranges as indicated in the WHO laboratory manual for the examination and processing of human semen (9). Research ga",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 224
  },
  {
    "chunk_id": "infertility_2588",
    "text": "ility implies semen parameters that are within the WHO reference ranges as indicated in the WHO laboratory manual for the examination and processing of human semen (9). Research gaps and future guideline update Future research and guidance are needed to determine the optimal or maximum number of IVF cycles that should be provided. Further research and guidance is needed on further advanced evaluation and management options that are available when IVF fails to achieve pregnancy in couples with unexplained infertility. References 1. Palermo G, Joris H, Devroey P, Van Steirteghem AC . Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992;340(8810):17-18 (https://doi. org/10.1016/0140-6736(92)92425-f). 2. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, De Mouzon J, Sokol R et al. The international glossary on infertility and fertility care, 201",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 224
  },
  {
    "chunk_id": "infertility_2589",
    "text": "10.1016/0140-6736(92)92425-f). 2. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, De Mouzon J, Sokol R et al. The international glossary on infertility and fertility care, 2017. Hum Reprod. 2017;32(9):1786-801 (https://doi.org/10.1093/humrep/dex234). 3. Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF, Jamieson DJ. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA. 2015;313(3):255-63 (https://doi. org/10.1001/jama.2014.17985). 4. Collins JA. An international survey of the health economics of IVF and ICSI. Hum Reprod Update. 2002;8(3):265-77 (https://doi.org/10.1093/ humupd/8.3.265). 5. Foong SC, Fleetham JA, O’Keane JA, Scott SG, Tough SC, Greene CA. A prospective randomized trial of conventional in vitro fertilization versus intracytoplasmic sperm injection in unexplained infertility. J Assist Reprod Genet. 2006;23(3):137- 40 (http",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 224
  },
  {
    "chunk_id": "infertility_2590",
    "text": "spective randomized trial of conventional in vitro fertilization versus intracytoplasmic sperm injection in unexplained infertility. J Assist Reprod Genet. 2006;23(3):137- 40 (https://doi.org/10.1007/s10815-005-9008-y). 6. Dang VQ, Vuong LN, Luu TM, Pham TD, Ho TM, Ha AN et al. Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial. Lancet. 2021;397(10284):1554-63 (https://doi.org/10.1016/ S0140-6736(21)00535-3). 7. Vitek WS, Galárraga O, Klatsky PC, Robins JC, Carson SA, Blazar AS. Management of the first in vitro fertilization cycle for unexplained infertility: a cost-effectiveness analysis of split in vitro fertilization-intracytoplasmic sperm injection. Fertil Steril. 2013;100(5):1381-8.e1 (https://doi. org/10.1016/j.fertnster",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 224
  },
  {
    "chunk_id": "infertility_2591",
    "text": "ertility: a cost-effectiveness analysis of split in vitro fertilization-intracytoplasmic sperm injection. Fertil Steril. 2013;100(5):1381-8.e1 (https://doi. org/10.1016/j.fertnstert.2013.06.035). 8. Neumann I, Santesso N, Akl EA, Rind DM, Vandvik PO, Alonso-Coello P et al. A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. J Clin Epidemiol. 2016;72:45- 55 (https://doi.org/10.1016/j.jclinepi.2015.11.017). 9. WHO laboratory manual for the examination and processing of human semen, sixth edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/343208).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 224
  },
  {
    "chunk_id": "infertility_2592",
    "text": "20111 Dissemination, local adaptation, implementation, monitoring and evaluation Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 11 Dissemination, lo cal adaptation, im plementation, monitoring and evaluation This chapter provides information on how the guideline recommendations could be adapted, implemented and continuously monitored. 11.1 Dissemination The recommendations in this guideline will be disseminated through a broad network of international partners, including WHO country and regional offices, ministries of health, WHO collaborating centres, other United Nations agencies, international development agencies, universities, professional societies and nongovernmental organizations, including non-state actors in official relations with WHO. The guideline will be published on the WHO website in English",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 225
  },
  {
    "chunk_id": "infertility_2593",
    "text": ", professional societies and nongovernmental organizations, including non-state actors in official relations with WHO. The guideline will be published on the WHO website in English; the executive summary will be available in all six United Nations languages. A summary of recommendations aimed at policy-makers, programme managers and health care providers will be developed and disseminated in the six United Nations languages. A commentary summarizing the guideline recommendations will be published in English in an open access academic journal. The guideline will also be disseminated through a global fertility care community of practice. Infographics, social media kits and web stories will be developed, and webinars and scientific sessions organized to further raise awareness of the guideline. 11.2 Local adaptation The recommendations in this guideline have been developed for a global audi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 225
  },
  {
    "chunk_id": "infertility_2594",
    "text": "ars and scientific sessions organized to further raise awareness of the guideline. 11.2 Local adaptation The recommendations in this guideline have been developed for a global audience. It is expected that countries will adapt the recommendations to suit their national needs, based on local contexts, through inclusive engagement of all local partners, including national and subnational governments, civil society, patient organizations and professional societies of various health care providers involved in fertility care. It is anticipated that national adaptation will be based on the epidemiological profile related to the burden of infertility and needs assessments, and will consider the capacity of the health care system, required resources, as well as the local health, social, cultural and economic contexts. Guideline adaptation may involve translation into national or local languages.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 225
  },
  {
    "chunk_id": "infertility_2595",
    "text": "care system, required resources, as well as the local health, social, cultural and economic contexts. Guideline adaptation may involve translation into national or local languages. In 2023, WHO published updated estimates on the global prevalence of infertility ( 1), which will be useful to countries adapting these guidelines. In settings lacking the local data needed for adaptation, the recommendations in this guideline could be adopted as presented because evidence has been assessed globally. Countries will be encouraged to hold key stakeholder consultations to inform the decisions to introduce the guideline recommendations into national programmes. During adaptation, policy-makers are expected to consider how the recommendations in this guideline align and complement existing WHO guidance on other issues related to sexual and reproductive health. Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 225
  },
  {
    "chunk_id": "infertility_2596",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 202 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 11.3 Implementation Successful implementation of the recommendations in this guideline will require endorsement by multiple stakeholders at the country level, including ministries of health, local professional societies, nongovernmental organizations, civil society and patient groups. For effective use of these recommendations, it is essential that the health systems at the country level create an enabling environment for the prevention, diagnosis and treatment of infertility. This may include, for example, ensuring that infertility is included in relevant government departments, health and other policies (e.g. educational or social), strategic plans, services and financing, as well as ens",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 226
  },
  {
    "chunk_id": "infertility_2597",
    "text": "ing that infertility is included in relevant government departments, health and other policies (e.g. educational or social), strategic plans, services and financing, as well as ensuring that fertility care medicines are included in essential medicines list, training health care providers on infertility, modifying health information systems to incorporate data on infertility and developing national clinical guidelines on infertility. WHO has updated its model lists of essential medicines (2) and the WHO model list of essential in vitro diagnostics (3) to include relevant medications and reproductive hormone-related infertility care; countries will be encouraged to consult these when quantifying, costing and procuring relevant supplies. Political support is essential, as is the need to embed a reproductive rights-based approach to implementation. Providers of fertility care should consider",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 226
  },
  {
    "chunk_id": "infertility_2598",
    "text": "uring relevant supplies. Political support is essential, as is the need to embed a reproductive rights-based approach to implementation. Providers of fertility care should consider the needs of, and provide equal care to, all individuals. Demographic trends such as total fertility rates should not be used to prioritize or deprioritize guideline implementation; rather, efforts should aim to support individuals and couples achieve their fertility preferences, reproductive goals and aspirations ( 4). Additionally, implementation research should be encouraged to inform guideline adaptation, implementation and continuous quality improvement. Adaptation of the recommendations into digital and app format is also encouraged, where feasible. 11.4 Monitoring and evaluation WHO will aim to collect regular feedback from key stakeholders to understand the usefulness and impact of this guideline. WHO ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 226
  },
  {
    "chunk_id": "infertility_2599",
    "text": "raged, where feasible. 11.4 Monitoring and evaluation WHO will aim to collect regular feedback from key stakeholders to understand the usefulness and impact of this guideline. WHO will monitor the uptake of the guideline in national policies and programmes by reviewing the number of countries that have adapted or endorsed it. Implementation research related to this guideline, including to evaluate how practice is aligned with the recommendations, will be encouraged. Monitoring and evaluation should be built into the implementation process to provide important lessons to continually improve implementation. The implementation of the guideline recommendations should involve national programmes (and relevant partners) collecting and reporting data on services provided to prevent, diagnose or treat infertility. This may require review of existing health information systems, including ART and ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 226
  },
  {
    "chunk_id": "infertility_2600",
    "text": "rs) collecting and reporting data on services provided to prevent, diagnose or treat infertility. This may require review of existing health information systems, including ART and other medically assisted reproduction (MAR) registries, which capture data related to fertility care, medical electronic records and other patient electronic reporting and vital registration systems, to ensure that service provision data are adequately captured and reported. WHO plans to develop a core and expanded set of indicators for the prevention, diagnosis and treatment of infertility, which will aid monitoring and impact evaluation. Some indicators that can be used to monitor progress may already be available in the existing health management information systems, national surveillance systems or ART and other MAR registries that capture data related to fertility care; for others, periodic surveys or eval",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 226
  },
  {
    "chunk_id": "infertility_2601",
    "text": "alth management information systems, national surveillance systems or ART and other MAR registries that capture data related to fertility care; for others, periodic surveys or evaluations may be required.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 226
  },
  {
    "chunk_id": "infertility_2602",
    "text": "20311 Dissemination, local adaptation, implementation, monitoring and evaluation Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Infertility prevalence estimates: 1990–2021. Geneva: World Health Organization; 2023 (https://apps.who.int/iris/handle/10665/366700). 2. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/371090). 3. The selection and use of essential in vitro diagnostics: report of the fourth meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2022 (including the fourth WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2023 (https://iris.who.int/handle/1066",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 227
  },
  {
    "chunk_id": "infertility_2603",
    "text": "rts on In Vitro Diagnostics, 2022 (including the fourth WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373322). 4. Mburu G, Kiarie J, Allotey P. Towards a nuanced view and response to global fertility trends. Lancet. 2024;403(10440):1953-56 (https://doi. org/10.1016/s0140-6736(24)00490-2).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 227
  },
  {
    "chunk_id": "infertility_2604",
    "text": "204 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 12 Research gaps, future scope and updating the guideline This chapter provides a summary of research gaps and future updating of this guideline. 12.1 Research gaps The recommendations in this guideline are based on the best global evidence available at the time of compilation. The GDG identified important gaps in research that need to be addressed through primary research studies and RCTs of interventions. Research gaps for specific interventions are many and are summarized under each relevant section throughout this guideline. Overall, relatively few studies from LMICs were identified. Additionally, there was a dearth of studies on patient values, preferences and acceptability of different interventions. Data on the costs and cost-effectiveness of interve",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 228
  },
  {
    "chunk_id": "infertility_2605",
    "text": "tified. Additionally, there was a dearth of studies on patient values, preferences and acceptability of different interventions. Data on the costs and cost-effectiveness of interventions were suboptimal for most interventions and very few studies assessed the feasibility of introducing interventions in different settings. Less emphasis was placed in studies regarding the effect of interventions on live birth rate (and not just on biochemical or clinical pregnancy rate). These gaps affected the quality of evidence underlying the many recommendations. Some of these research gaps are crucial and results from these studies will be needed to update the guideline in the future. WHO will continue to track relevant results from the research community. Fig. 12.1. The need to address critical research gaps These gaps affected the quality of evidence underlying many recommendations. Some are crucia",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 228
  },
  {
    "chunk_id": "infertility_2606",
    "text": "ults from the research community. Fig. 12.1. The need to address critical research gaps These gaps affected the quality of evidence underlying many recommendations. Some are crucial and results from studies addressing these gaps will be needed to update the guideline in the future. Key research gaps identified include: Relatively few studies from low- and middle-income countries (LMICs) were identified Studies on patient values, preferences and acceptability of different interventions were lacking Data on costs and cost-effectiveness were suboptimal for most interventions Very few studies assessed the feasibility of introducing interventions in different settings Limited emphasis in studies regarding the effect of interventions on live birth rate (and not just on biochemical or clinical pregnancy rate) Chapter",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 228
  },
  {
    "chunk_id": "infertility_2607",
    "text": "20512 Research gaps, future scope and updating the guideline Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 12.2 Future scope and updating this guideline Given that this is the first WHO guideline on the prevention, diagnosis and treatment of infertility, it does not cover all aspects of infertility, and important gaps remain. It is anticipated that subsequent editions of this guideline will have an expanded scope, allowing future recommendations to address topics that are not currently included. These include management of other personal risk factors (such as obesity, low body weight, excessive intake of alcohol and other substances, including use of cannabis, vapes and e-cigarettes or non- smoked and smokeless tobacco products, among others), sexual dysfunction as well as non-personal risk factors (e.g. e",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 229
  },
  {
    "chunk_id": "infertility_2608",
    "text": "ces, including use of cannabis, vapes and e-cigarettes or non- smoked and smokeless tobacco products, among others), sexual dysfunction as well as non-personal risk factors (e.g. environmental and workplace factors), fertility preservation in the context of gonadotoxic therapy, third-party reproduction (donor gametes, surrogacy), fertility care for individuals with pre-existing medical conditions that affect fertility (such as endometriosis and fibroids), or with obstructive, congenital, accessory gland, genital or hormonal abnormalities associated with male infertility, as well as psychosocial support for people with infertility. Future guidance will be needed for advanced sperm function testing, sperm retrieval techniques for obstructive and non-obstructive azoospermia, ART modalities, and non-invasive therapeutic approaches beyond antioxidant supplements. Guidance is also needed on th",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 229
  },
  {
    "chunk_id": "infertility_2609",
    "text": "al techniques for obstructive and non-obstructive azoospermia, ART modalities, and non-invasive therapeutic approaches beyond antioxidant supplements. Guidance is also needed on the use of adjunct IVF “add-ons”, and how to further minimize multiple pregnancies. These topics received relatively limited attention in this initial guideline (based on the initial scoping by the GDG) and will need to be considered in subsequent editions. Similarly, subsequent editions of this guideline will need to consider expansion of critical outcomes, as appropriate, to incorporate outcomes that are increasingly important to patients, such as time to pregnancy. Non-personal risk factors such as environmental and workplace factors Expanded guidance on advanced diagnosis and treatment modalities for male- factor infertility is also needed. New interventions in infertility are emerging, including the use of A",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 229
  },
  {
    "chunk_id": "infertility_2610",
    "text": " Expanded guidance on advanced diagnosis and treatment modalities for male- factor infertility is also needed. New interventions in infertility are emerging, including the use of AI, equipment technology, and medical treatments. WHO will track such developments for potential inclusion in subsequent updates of the guideline. Fertility care for individuals with pre- existing medical conditions that affect fertility (such as endometriosis and fibroids) Fertility preservation in the context of gonadotoxic therapy Male infertility due to obstructive, congenital, accessory gland, genital or hormonal abnormalities Third-party reproduction including: • donor gametes • surrogacy Management of other personal risk factors such as: obesity, low body weight, excessive intake of alcohol and other substances, including the use of cannabis, vapes and e-cigarettes or non-smoked/smokeless tobacco products",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 229
  },
  {
    "chunk_id": "infertility_2611",
    "text": " such as: obesity, low body weight, excessive intake of alcohol and other substances, including the use of cannabis, vapes and e-cigarettes or non-smoked/smokeless tobacco products Future guideline editions need to address topics that are not currently included in this edition. These could include: Addressing sexual dysfunction, IVF “add ons” and multiple pregnancies Psychosocial support for people with infertility Fig. 12.2. Future guideline scope and updates.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 229
  },
  {
    "chunk_id": "infertility_2612",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 206 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps An expanded guideline is expected to be available in five years. Feedback from key stakeholders will help guide the next edition of this guideline. WHO Secretariat, in consultation with technical experts, will continue to follow research development in infertility, particularly for questions in which the certainty of evidence was found to be of low or very low certainty. New and experimental interventions in infertility are emerging, including use of artificial intelligence, equipment technology, medical treatments (such as uterine transplants), among others. WHO will track these and other developments for potential consideration in subsequent updates of the guideline. If the guideline mer",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 230
  },
  {
    "chunk_id": "infertility_2613",
    "text": "ts (such as uterine transplants), among others. WHO will track these and other developments for potential consideration in subsequent updates of the guideline. If the guideline merits an update in the interim, or if new evidence emerges or other important developments arise that may have an impact on the validity of current recommendations in this version, the Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing will coordinate the guideline update, adhering to the formal procedures outlined in the WHO handbook for guideline development (1). Reference 1. WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/ handle/10665/145714).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 230
  },
  {
    "chunk_id": "infertility_2614",
    "text": "207Annex 1. Distribution of the causes of infertility Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Annex 1. Distribution of the causes of infertility Table A1.1. General categories of infertility (percentages of couples)a,b,c,d,e High- income countries Regions in LMICs Average LMICs Average across all countriesfAfrica Asia Latin America Eastern Mediterranean Female cause only 31.00 37.00 34.00 25.00 25.00 30.25 30.62 Male cause only 22.00 8.00 13.00 22.00 19.00 15.5 18.75 Causes found in both 21.00 35.00 24.00 30.00 38.00 31.75 26.37 No cause found in either 14.00 5.00 13.00 10.00 3.00 7.75 10.87 Became pregnant during the course of the study 12.00 15.00 16.00 13.00 15.00 14.75 13.37 Total 100.00 100.00 100.00 100.00 100.00 100.00 99.98 a Data adapted from Cates et al., 1985 (1); see also WHO, 1992 (2). b",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 231
  },
  {
    "chunk_id": "infertility_2615",
    "text": "e of the study 12.00 15.00 16.00 13.00 15.00 14.75 13.37 Total 100.00 100.00 100.00 100.00 100.00 100.00 99.98 a Data adapted from Cates et al., 1985 (1); see also WHO, 1992 (2). b Study involved 8500 couples in 33 medical centres in 25 countries representing high-, middle- and low-income countries. c 8500 couples were enrolled and just over 5800 (≈69%) completed the investigation to the point of a diagnosis being made for both partners. d Couples were admitted to the study if they had been infertile for at least 1 year (i.e. inclusion criteria). e Classifications of income categories of countries as at the time of the original study. f The average across all countries was derived by summing the prevalence in the “high-income countries” and “average LMICs” columns and dividing this by 2.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 231
  },
  {
    "chunk_id": "infertility_2616",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 208 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. A1.1. Causes of infertilitya a Data adapted from Cates et al., 1985 (1); see also WHO, 1992 (2). 31% Female cause only Male cause only Causes found in both No cause found in either Became pregnant during the course of the study 22% 30.25% 30.62% 18.75% 26.37% 10.87% 13.37% 15.5% 21% 31.75% 14% 7.75% 12% 14.75% Average across all countries High-income countries Average low- and middle-income countries",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 232
  },
  {
    "chunk_id": "infertility_2617",
    "text": "209 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Table A1.2. Specific diagnoses of infertility (percentages of couples) a,b,c,d,e,f High- income countries LMICs Average LMICs Average across all countriesgAfrica Asia Latin America Eastern Mediterranean Female diagnosis No demonstrable cause 40.00 16.00 31.00 35.00 26.00 27.00 33.50 Bilateral tubal occlusion 11.00 49.00 14.00 15.00 20.00 24.50 17.75 Pelvic adhesions 13.00 24.00 13.00 17.00 13.00 16.75 14.87 Acquired tubal abnormality 12.00 12.00 12.00 12.00 9.00 11.25 11.62 Anovulatory regular cyclesh 10.00 14.00 9.00 9.00 15.00 11.75 10.87 Anovulatory oligomenorrhoeah 9.00 3.00 7.00 9.00 11.00 7.50 8.25 Ovulatory oligomenorrhoeah 7.00 4.00 11.00 5.00 8.00 7.00 7.00 Hyperprolactinaemia 7.00 5.00 7.00 8.00 6.00 6.50 6.75 Endometriosis 6.00 1.00 10.00 3.00 1.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 233
  },
  {
    "chunk_id": "infertility_2618",
    "text": ".00 9.00 11.00 7.50 8.25 Ovulatory oligomenorrhoeah 7.00 4.00 11.00 5.00 8.00 7.00 7.00 Hyperprolactinaemia 7.00 5.00 7.00 8.00 6.00 6.50 6.75 Endometriosis 6.00 1.00 10.00 3.00 1.00 3.75 4.87 Male diagnosis No demonstrable cause 49.00 46.00 58.00 41.00 28.00 43.25 46.12 Varicocele 11.00 20.00 10.00 19.00 12.00 15.25 13.12 Primary testicular failure 10.00 7.00 11.00 13.00 25.00 14.00 12.00 Accessory gland infection 7.00 11.00 3.00 12.00 3.00 7.25 7.12 Abnormal sperm morphologyi 8.00 5.00 3.00 4.00 3.00 3.75 5.87 Low sperm motilityi 3.00 1.00 5.00 8.00 5.00 4.75 3.87 a Data adapted from Cates et al., 1985 (1); see also WHO, 1992 (2). b Study involved 8500 couples in 33 medical centres in 25 countries representing high-, middle- and low-income settings. c 8500 couples were enrolled and just over 5800 (≈69%) completed the investigation to the point of a diagnosis being made for both partner",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 233
  },
  {
    "chunk_id": "infertility_2619",
    "text": "g high-, middle- and low-income settings. c 8500 couples were enrolled and just over 5800 (≈69%) completed the investigation to the point of a diagnosis being made for both partners. d Couples were admitted to the study if they had been infertile for at least 1 year (i.e. inclusion criteria). e Classifications of income categories of countries as at the time of the original study. f Not all diagnostic categories were listed in the original publication; some patients had more than one diagnosis or cause. g The average across all countries was derived by summing the prevalence in the “high-income countries” and “average LMICs” columns and dividing this by 2. h Categories merged and reported under anovulatory and oligo-ovulatory disorders in this guideline, with a total prevalence of 26.1% across all countries. i Categories merged and reported under abnormal semen parameters in this guideli",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 233
  },
  {
    "chunk_id": "infertility_2620",
    "text": "oligo-ovulatory disorders in this guideline, with a total prevalence of 26.1% across all countries. i Categories merged and reported under abnormal semen parameters in this guideline, with a total of 9.7% across all countries.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 233
  },
  {
    "chunk_id": "infertility_2621",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 210 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Fig. A1.2. Specific diagnoses of infertility (male)a Fig. A1.3. Specific diagnoses of infertility (female)a No demonstrable cause Bilateral tubal occlusion Pelvic adhesions Acquired tubal abnormality Anovulatory regular cycles Anovulatory oligomenorrhoea Ovulatory oligomenorrhoea Hyperprolactinaemia Endometriosis High-income countries Low- and middle-income countries 27% 7% 7% 7% 9% 11% 13% 12%10% 24.50% 40% Female diagnosis 3.75% 6% 6.50% 7.50% 11.75% 11.25% 16.75% No demonstrable cause Varicocele Primary testicular failure Accessory gland infection Abnormal sperm morphology Low sperm motility High-income countries Low- and middle-income countries 43.25% 7% 14% 49% Male diagnosis 4.75% 3%",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 234
  },
  {
    "chunk_id": "infertility_2622",
    "text": "ular failure Accessory gland infection Abnormal sperm morphology Low sperm motility High-income countries Low- and middle-income countries 43.25% 7% 14% 49% Male diagnosis 4.75% 3% 3.75% 7.25% 15.25% 11%10% 8% a Data adapted from Cates et al., 1985 (1); see also WHO, 1992 (2).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 234
  },
  {
    "chunk_id": "infertility_2623",
    "text": "211 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps References 1. Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985;2(8455):596-8 (https://doi.org/10.1016/ s0140-6736(85)90594-x). 2. Recent advances in medically assisted conception: report of a WHO Scientific Group. Geneva: World Health Organization; 1992 (https://iris.who.int/handle/10665/38679).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 235
  },
  {
    "chunk_id": "infertility_2624",
    "text": "212 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Annex 2. Members of the GDG Adam H. Balen Leeds Teaching Hospitals, Leeds United Kingdom of Great Britain and Northern Ireland Ragaa Mansour The Egyptian IVF Center, Ma`adi Cairo Egypt Jacky Boivin School of Psychology, Cardiff University Cardiff United Kingdom Alfred Murage Aga Khan University Hospital Nairobi Kenya Barbara Collura RESOLVE: The National Infertility Association McLean, VI United States of America (USA) Willem Ombelet Genk Institute for Fertility Technology Genk Belgium Ben Cohlen Isala Fertility Centre Zwolle The Netherlands Allan Pacey Faculty of Biology, Medicine and Health, University of Manchester Manchester United Kingdom Christopher J. De Jonge University of Minnesota Minneapolis USA Guido Pennings Department of Philosophy and Moral S",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 236
  },
  {
    "chunk_id": "infertility_2625",
    "text": "e and Health, University of Manchester Manchester United Kingdom Christopher J. De Jonge University of Minnesota Minneapolis USA Guido Pennings Department of Philosophy and Moral Sciences, Ghent University Ghent Belgium Sandro C. Esteves ANDROFERT, Andrology and Human Reproduction Clinic Campinas Brazil Robert W. Rebar Homer Stryker School of Medicine, Western Michigan University Kalamazoo USA Cynthia Farquhar University of Auckland Auckland New Zealand Richard Reindollar Geisel School of Medicine Dartmouth USA Richard Kennedy Birmingham Women’s and Children’s NHS Foundation Trust Birmingham United Kingdom Roberta Rizzo University of Ferrara Ferrara Italy",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 236
  },
  {
    "chunk_id": "infertility_2626",
    "text": "213 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Klaudija Kordic Fertility Europe (Pan-European organisation representing patients’ associations) Evere Belgium Rita Sembuya Joyce Fertility Support Centre Kampala Uganda Linda Giudice UCSF School of Medicine San Francisco USA Gamal Serour Al Azhar University Cairo Egypt Luca Gianaroli Reproductive Medicine Unit, S.I.S.Me.R. Bologna Italy Basil Tarlatzis Aristotle University of Thessaloniki Thessaloniki Greece Carin Huyser Steve Biko Academic Hospital, University of Pretoria South Africa Carla Tatone University of L’Aquila L’Aquila Italy Dmitry Kissin Division of Reproductive Health, Centers for Disease Control and Prevention Atlanta USA Lan N. Vuong University of Medicine and Pharmacy Ho Chi Minh City Viet Nam Tansu Kucuk Department of Obstetrics and Gynaec",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 237
  },
  {
    "chunk_id": "infertility_2627",
    "text": "h, Centers for Disease Control and Prevention Atlanta USA Lan N. Vuong University of Medicine and Pharmacy Ho Chi Minh City Viet Nam Tansu Kucuk Department of Obstetrics and Gynaecology, Acıbadem Maslak Hospital Istanbul Türkiye Marie Lena Windt De Beer Tygerberg Academic Hospital, Stellenbosch University Cape Town South Africa Nalini Mahajan Department of Reproductive Medicine, Mother and Child Hospital New Delhi India Cong Yali Health Science Centre, Peking University Beijing China The following GDG members contributed to the initial part of the guideline but later stepped down: Anna Krawczack (Fertility Europe [Pan-European organisation representing patients’ associations], Evere, Belgium), Lars Björndahl (Karolinska Institutet, Stockholm, Sweden), Kersti Lundin (Sahlgrenska University Hospital, Gothenburg, Sweden), Rebecca Sokol (Keck School of Medicine, University of Southern Califo",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 237
  },
  {
    "chunk_id": "infertility_2628",
    "text": "arolinska Institutet, Stockholm, Sweden), Kersti Lundin (Sahlgrenska University Hospital, Gothenburg, Sweden), Rebecca Sokol (Keck School of Medicine, University of Southern California, Los Angeles, USA) and Roy Farquharson (Liverpool Women’s NHS Foundation Trust, Liverpool, United Kingdom).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 237
  },
  {
    "chunk_id": "infertility_2629",
    "text": "214 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Annex 3. Members of the ERG Introduction, methods and approach to the evaluation and management of infertility Julia Chain Human Fertilization and Embryology Authority London United Kingdom of Great Britain and Northern Ireland Karla Torres Centre for Reproductive Rights New York USA Muntaha Gharaibeh Department of Maternal & Child Health, Jordan University of Science and Technology Irbid Jordan Sheryl Van der Poel International Health Consultant Geneva Switzerland Márcia C. Inhorn Department of Anthropology, Yale University New Haven United States of America (USA) Prevention of infertility Joyce Harper Institute for Women’s Health, University College London London United Kingdom Zozo Nene Department of Obstetrics & Gynaecology University of Pretoria Pretor",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 238
  },
  {
    "chunk_id": "infertility_2630",
    "text": "nfertility Joyce Harper Institute for Women’s Health, University College London London United Kingdom Zozo Nene Department of Obstetrics & Gynaecology University of Pretoria Pretoria South Africa Ivonne J. Diaz Yamal, Department of Gynecology and Obstetrics, Central Military Hospital Bogota Colombia Nathalie Vermeulen European Society of Human Reproduction and Embryology Strombeek-Bever Belgium Promise E. Sefogah Department of Obstetrics & Gynaecology, University of Ghana Medical School, Accra Ghana Tamar Khomasuridze Eastern Europe and Central Asia Regional Office, United Nations Population Fund (UNFPA) Istanbul Türkiye",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 238
  },
  {
    "chunk_id": "infertility_2631",
    "text": "215 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Diagnosis of female infertility Grigoris F. Grimbizis Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki Thessaloniki Greece Bart C.J.M. Fauser Reproductive Medicine, University Medical Center Utrecht Utrecht The Netherlands Trinh The Son Military Institute of Clinical Embryology and Histology Hanoi Viet Nam Qiao Jie Peking University Health Science Center, Peking University Third Hospital Beijing China Márcia Mendonça Carneiro Department of Obstetrics and Gynecology, Federal University of Minas Gerais Minas Gerais Brazil Neena Malhotra Department of Obstetrics and Gynecology, All India Institute of Medical Sciences New Delhi India Treatment of female infertility Amal Benbella Reproductive Health Hospital, IbnSina University Hospi",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 239
  },
  {
    "chunk_id": "infertility_2632",
    "text": "tetrics and Gynecology, All India Institute of Medical Sciences New Delhi India Treatment of female infertility Amal Benbella Reproductive Health Hospital, IbnSina University Hospital Rabat Morocco Sasha Ottey PCOS Challenge: The National Polycystic Ovary Syndrome Association Atlanta, Georgia USA Edgar Mocanu Department of Obstetrics and Gynecology, RCSI University of Medicine and Health Sciences Dublin Ireland Maria P. Velez Division of Reproductive Endocrinology and Infertility, McGill University, Montreal Canada Male infertility (diagnosis and treatment) Ameet Patki Indian Society for Assisted Reproduction Mumbai India Mónica Vazquez-Levin Institute of Biology and Experimental Medicine – National Scientific and Technical Research Council (IBYME–CONICET) Buenos Aires Argentina Mohan S. Kamath Department of Reproductive Medicine and Surgery, Christian Medical College, Vellore Tamil Nadu",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 239
  },
  {
    "chunk_id": "infertility_2633",
    "text": "and Technical Research Council (IBYME–CONICET) Buenos Aires Argentina Mohan S. Kamath Department of Reproductive Medicine and Surgery, Christian Medical College, Vellore Tamil Nadu India Oleg Tishkevich Centre of Assisted Reproduction Minsk Belarus",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 239
  },
  {
    "chunk_id": "infertility_2634",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 216 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Unexplained infertility (diagnosis and treatment) David Adamson The International Committee Monitoring Assisted Reproductive Technologies, Saratoga California USA Robert J Norman Faculty of Health and Medical Sciences, The University of Adelaide Adelaide Australia Ben Willem Mol Department of Obstetrics and Gynaecology, Monash University Melbourne Australia Mohamed Youssef Department of Obstetrics and Gynecology, Cairo University Cairo Egypt Olarik Musigavong Chaophya Abhaibhubejhr Hospital Prachin Buri Thailand",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 240
  },
  {
    "chunk_id": "infertility_2635",
    "text": "217 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Annex 4. Summary of declared interests from members of the GDG GDG membera Affiliation Nature of declared interestb Adam H. Balen Leeds Teaching Hospitals, Leeds, United Kingdom of Great Britain and Northern Ireland Shareholding, Consulting or Chair (CARE Fertility, Leeds, United Kingdom, and UK Innovation and Research Board); Advisory board membership, (Novo Nordisk Pharmaceuticals). Director and/ or Partner (Balance Reproductive Health Ltd; Partner Balance Mind Ltd, and Balance Fertility Ltd); Trustee, Chair or Past Chair (British Fertility Society, NHS England IVF Pricing Development Expert Advisory Group); Fellows’ Representative, RCOG Council (until 2023). Guideline member (PCOS Global Guideline Group); Member, FIGO Steering Group on Anovulatory Infert",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 241
  },
  {
    "chunk_id": "infertility_2636",
    "text": "opment Expert Advisory Group); Fellows’ Representative, RCOG Council (until 2023). Guideline member (PCOS Global Guideline Group); Member, FIGO Steering Group on Anovulatory Infertility. No amounts declared for these roles. Jacky Boivin School of Psychology, Cardiff University, Cardiff, United Kingdom Non-monetary support £250 (ESHRE). Research support (£100 219, Merck Serono Ltd, paid to Cardiff University) non-interventional investigator led study on treatment planning. Consulting (£14 907, Ferring Pharmaceutical UK, United Kingdom, the Netherlands, Global). Public statements (total: £1750). Speaker fees (£26 107, Ferring Pharmaceutical, Merck, Gedeon-Richter, British Fertility Society, IVI-RMA). Barbara Collura The National Infertility Association (RESOLVE), Washington DC, United States of America (USA) Employment (Resolve); non-monetary support valued >US$ 1000; public statements. Be",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 241
  },
  {
    "chunk_id": "infertility_2637",
    "text": "ura The National Infertility Association (RESOLVE), Washington DC, United States of America (USA) Employment (Resolve); non-monetary support valued >US$ 1000; public statements. Ben Cohlen Isala Fertility Centre, Zwolle, the Netherlands Research support for clinic projects (grants) from Merck (US$ 30 000), Ferring (US$ 10 000), Gideon Richter (US$ 10 000). Christopher J. De Jonge University of Minnesota, Minneapolis, USA No interests declared. Sandro C. Esteves ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil Research support grant (Merck) US$ 90 000. Speaker fees (Merck, US$ 20 000; MedE.A./Med.E.A, US$ 9000). Non-monetary support valued at over US$ 1000 (Merck KGaA). Public statements. Cynthia Farquhar University of Auckland, Auckland, New Zealand No interest declared. Richard Kennedy Birmingham Women’s and Children’s NHS Foundation Trust, United Kingdom No interest",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 241
  },
  {
    "chunk_id": "infertility_2638",
    "text": "thia Farquhar University of Auckland, Auckland, New Zealand No interest declared. Richard Kennedy Birmingham Women’s and Children’s NHS Foundation Trust, United Kingdom No interest declared.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 241
  },
  {
    "chunk_id": "infertility_2639",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 218 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps GDG membera Affiliation Nature of declared interestb Klaudija Kordic Fertility Europe (Pan- European organisation representing patients’ associations), Evere, Belgium No interest declared. Linda Giudice UCSF School of Medicine, San Francisco, USA Investments in stocks (Merck), US$ 5000, (Pfizer) US$ 5000. Public statements as President of IFFS. Speaker fees (IBSA Pharma). Luca Gianaroli Reproductive Medicine Unit, S.I.S.Me.R., Bologna, Italy Employment and stakeholder in SISMER (up to 2024); consulting; non-monetary support valued at over US$ 1000; speaker fees; public statements; investments up to 2020 except in SISMER. Non- recurring fees from Merck, Theramex, InMed, MedThink. Consultant",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 242
  },
  {
    "chunk_id": "infertility_2640",
    "text": "ary support valued at over US$ 1000; speaker fees; public statements; investments up to 2020 except in SISMER. Non- recurring fees from Merck, Theramex, InMed, MedThink. Consultant at Interdisciplinary Institute of Reproductive Medicine (IIRM) and at ART Fertility Clinic and Next Clinic (since 2025). Carin Huyser Steve Biko Academic Hospital, University of Pretoria, South Africa No interest declared. Dmitry Kissin Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, USA No interest declared. Tansu Kucuk Department of Obstetrics and Gynaecology, Acıbadem Maslak Hospital, Istanbul, Türkiye No interest declared. Nalini Mahajan Department of Reproductive Medicine, Mother and Child Hospital, New Delhi, India No interest declared. Ragaa Mansour The Egyptian IVF Center, Ma`adi, Cairo, Egypt No interest declared. Alfred Murage Aga Khan University Hospital, Nairob",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 242
  },
  {
    "chunk_id": "infertility_2641",
    "text": "ospital, New Delhi, India No interest declared. Ragaa Mansour The Egyptian IVF Center, Ma`adi, Cairo, Egypt No interest declared. Alfred Murage Aga Khan University Hospital, Nairobi, Kenya No interest declared. Willem Ombelet Genk Institute for Fertility Technology, Genk, Belgium No interest declared. Allan Pacey Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom Monetary support to employer valued at over US$ 1000 for consultancy/public speaking (Carrot Fertility [current], Cryos International [current], IBSA Institut Biochimique SA, Mealis Group). Several unpaid positions: Member of Advisory Board of Progress Educational Trust; Co-Chair, UKNEQAS Reproductive Sciences Advisory Committee; Member, Science Media Centre Advisory Board; Patron, Fertility Alliance (United Kingdom).",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 242
  },
  {
    "chunk_id": "infertility_2642",
    "text": "219 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps GDG membera Affiliation Nature of declared interestb Guido Pennings Department of Philosophy and Moral Sciences, Ghent University, Ghent, Belgium Non-monetary support valued at over US$ 1000 (Merck). Honorarium of speaker fees (Merck, US$ 2000; Teva Pharma, US$ 2000). Consulting fees (IVIRMA for membership of Ethics Committee, €20 000; Cryos Int. for membership of External Scientific Advisory Committee, €8000). Speakers fees (Gedeon Richter, €2000). Robert Rebar Homer Stryker School of Medicine, Western Michigan University, Kalamazoo, USA Employment (Lecturer WMU; editorial honorariums [NEJM Journal Watch Editor]) US$ 2500, honorarium (Contraception Journal deputy editor), US$ 3000. Honorarium (Associate editor Obs Gyn Clinical Alert), US$ 1600); consulting",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 243
  },
  {
    "chunk_id": "infertility_2643",
    "text": "riums [NEJM Journal Watch Editor]) US$ 2500, honorarium (Contraception Journal deputy editor), US$ 3000. Honorarium (Associate editor Obs Gyn Clinical Alert), US$ 1600); consulting (BSMB for several clinical trials (Myovant; US$ 6000) up to 2020. Richard Reindollar Geisel School of Medicine, Dartmouth, New Hampshire, USA No interest declared. Roberta Rizzo University of Ferrara, Ferrara, Italy No interest declared. Rita Sembuya Joyce Fertility Support Centre, Kampala, Uganda No interest declared. Gamal Serour Al Azhar University, Cairo, Egypt No interest declared. Basil Tarlatzis Aristotle University of Thessaloniki, Thessaloniki, Greece Consulting; non-monetary support valued at >US$ 1000; research support for unrestricted research grants (Merk Serono) and Travel grants (MSD), honorariums (IBSA; Ferring - company sponsored speakers bureau); Advisory board (Ovascience). Carla Tatone Univ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 243
  },
  {
    "chunk_id": "infertility_2644",
    "text": " unrestricted research grants (Merk Serono) and Travel grants (MSD), honorariums (IBSA; Ferring - company sponsored speakers bureau); Advisory board (Ovascience). Carla Tatone University of L’Aquila, L’Aquila, Italy No interest declared. Lan N. Vuong University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam Research support/grants (2018–2020), valued at US$ 49 478 (Ferring). Non-monetary support valued at over US$ 1000 (Merck, for public education workshops). Speaker fees from Ferring (two conferences per year valued at US$ 500-1700), MSD (US$ 500–700), Merck (US$ 500–700) and ARD (US$ 3000). Travel support (including meeting registration fees) from Ferring, MSD and Merck. Marie Lena Windt De Beer Tygerberg Academic Hospital, Stellenbosch University, Cape Town, South Africa No interest declared. Cong Yali Health Science Centre, Peking University, Beijing, China No interests declare",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 243
  },
  {
    "chunk_id": "infertility_2645",
    "text": "rg Academic Hospital, Stellenbosch University, Cape Town, South Africa No interest declared. Cong Yali Health Science Centre, Peking University, Beijing, China No interests declared. a The following GDG members contributed to the initial part of the guideline but later stepped down: Lars Björndahl (Karolinska Institutet, Stockholm, Sweden), Roy Farquharson (Liverpool Women’s NHS Foundation Trust, Liverpool, United Kingdom), Anna Krawczack (Fertility Europe [Pan-European organisation representing patients’ associations], Evere, Belgium), Kersti Lundin (Sahlgrenska University Hospital, Gothenburg, Sweden) and Rebecca Sokol (Keck School of Medicine, University of Southern California, Los Angeles, USA). b The published interests exclude declared income from employment with public, regulatory, non-profit or nongovernmental organizations, academic institutions or universities, or public hospit",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 243
  },
  {
    "chunk_id": "infertility_2646",
    "text": "shed interests exclude declared income from employment with public, regulatory, non-profit or nongovernmental organizations, academic institutions or universities, or public hospitals.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 243
  },
  {
    "chunk_id": "infertility_2647",
    "text": "220 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Annex 5. Summary of declared interests from members of the ERG ERG membera Affiliation Nature of declared interest David Adamson The International Committee Monitoring Assisted Reproductive Technologies, Saratoga, United States of America (USA) Consultant manuscript author fees over US$ 1000 (Organon), 2024. Conference speaker fees (ESHRE) US$ 5000 annually ongoing); Founder and CEO (ARC Fertility). Amal Benbella Reproductive Health Hospital, IbnSina University Hospital, Rabat, Morocco No interest declared. Márcia Mendonça Carneiro Department of Obstetrics and Gynecology, Federal University of Minas Gerais, Minas Gerais, Brazil Travel grants and honorariums for speaker fees and lectures (Ferring, Organon, Johnson and Johnson, Boehringer), with a total amoun",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 244
  },
  {
    "chunk_id": "infertility_2648",
    "text": "University of Minas Gerais, Minas Gerais, Brazil Travel grants and honorariums for speaker fees and lectures (Ferring, Organon, Johnson and Johnson, Boehringer), with a total amount of less than US$ 10 000 in the last 4 years; ongoing lectures, 2024. Julia Chain Human Fertilization and Embryology Authority, London, United Kingdom of Great Britain and Northern Ireland No interests declared. Ivonne J. Diaz Yamal Department of Gynecology and Obstetrics, Central Military Hospital, Bogota, Colombia No interests declared. Bart C.J.M. Fauser Reproductive Medicine, University Medical Center Utrecht, Utrecht, the Netherlands Consultant (Ferring, Celmatix, Univfy ReproNovo Vortex Imaging) amounts not disclosed; all current. Member of DSMB (Myovant), current; Co-chair (COGI) amounts not disclosed, current. Author fees (UpToDate) amount not disclosed, current. Muntaha Gharaibeh Department of Materna",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 244
  },
  {
    "chunk_id": "infertility_2649",
    "text": "nt. Member of DSMB (Myovant), current; Co-chair (COGI) amounts not disclosed, current. Author fees (UpToDate) amount not disclosed, current. Muntaha Gharaibeh Department of Maternal & Child Health, Jordan University of Science and Technology, Irbid, Jordan No interests declared. Grigoris F. Grimbizis Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece No interests declared.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 244
  },
  {
    "chunk_id": "infertility_2650",
    "text": "221 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps ERG membera Affiliation Nature of declared interest Joyce Harper Institute for Women’s Health, University College London, London, United Kingdom Paid talks (Gedeon Richter), £4000, ceased; conference speaker fees (Cook IVF), £2000, ceased; manuscript author fees (Ferring) £2000; ceased. Márcia C. Inhorn Department of Anthropology, Yale University, New Haven, USA No interests declared. Mohan S. Kamath Department of Reproductive Medicine and Surgery, Christian Medical College, Vellore, Tamil Nadu, India Research grants support via CMC Vellore (ICMR) (US$ 110 000 for whole project, ongoing 2023– 2026). Journal editorial honorarium (€3000 paid to employer annually; ongoing 2023–2025). Several unpaid honorary editorial positions (ESHRE journals, ISAR journals an",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 245
  },
  {
    "chunk_id": "infertility_2651",
    "text": "ngoing 2023– 2026). Journal editorial honorarium (€3000 paid to employer annually; ongoing 2023–2025). Several unpaid honorary editorial positions (ESHRE journals, ISAR journals and Cochrane Gynaecology and Fertility groups); all ongoing. Tamar Khomasuridze Eastern Europe and Central Asia Regional Office, United Nations Population Fund (UNFPA), Istanbul, Türkiye No interests declared. Neena Malhotra Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India Research grant support (Ferring Pharmaceuticals) for a multicentre randomized controlled trial assessing the efficacy and safety of follitropin delta versus follitropin alfa (GONAL-F) in controlled ovarian stimulation for ART; no personal income received, grant provided solely to conduct IVF for individuals. Edgar Mocanu Department of Obstetrics and Gynaecology, RCSI University of Medicine and H",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 245
  },
  {
    "chunk_id": "infertility_2652",
    "text": "for ART; no personal income received, grant provided solely to conduct IVF for individuals. Edgar Mocanu Department of Obstetrics and Gynaecology, RCSI University of Medicine and Health Sciences, Dublin, Ireland Scientific/research adviser fees (Cryos) €4000 per year, ceased. Conference travel and accommodation support (Merck) value not declared, ceased. President (IFFS) income not declared; current. Ben W. Mol Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia Consultant fees (Merck KGaA, Organon and Norgine); amounts not disclosed, all current. Research grant (NHMRC); amount not disclosed, current. Travel grants (Merck KGaA); amount not disclosed, current. Stock Options (ObsEva); amounts not declared; current. Olarik Musigavong Chaophya Abhaibhubejhr Hospital, Prachin Buri, Thailand No interests declared. Zozo Nene Department of Obstetrics & Gynaecology U",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 245
  },
  {
    "chunk_id": "infertility_2653",
    "text": "; amounts not declared; current. Olarik Musigavong Chaophya Abhaibhubejhr Hospital, Prachin Buri, Thailand No interests declared. Zozo Nene Department of Obstetrics & Gynaecology University of Pretoria, Pretoria, South Africa ESHRE Conference sponsorship 2024 (Ferring Pharmaceuticals), 2024; travel and accommodation only.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 245
  },
  {
    "chunk_id": "infertility_2654",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 222 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps ERG membera Affiliation Nature of declared interest Robert J. Norman Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia Consultancy fees (an IVF unit in Hanoi, Viet Nam, with no ownership of the IVF unit itself, minor income declared, ongoing). Sasha Ottey PCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, USA Non-monetary support (Androgen Excess and PCOS Society, Jones Foundation Infertility Counselors Conference [JFICC], Fertility Empowerment International Conference [FEI]). Conference travel costs (AE-PCOS annual meeting) 2023; (FEI), 2024; and (JFICC), 2024. Ameet Patki Indian Society for Assisted Reproduction, Mumbai, Ind",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 246
  },
  {
    "chunk_id": "infertility_2655",
    "text": "national Conference [FEI]). Conference travel costs (AE-PCOS annual meeting) 2023; (FEI), 2024; and (JFICC), 2024. Ameet Patki Indian Society for Assisted Reproduction, Mumbai, India No interests declared. Jie Qiao Peking University Health Science Center, Peking University Third Hospital, Beijing, China No interests declared. Promise E. Sefogah Department of Obstetrics & Gynaecology, University of Ghana Medical School, Accra, Ghana Research grant and Research Fellowship Training Grant (Fogarty International Center, Northern Pacific Global Health), US$ 10 000; 2023. Trinh The Son Military Institute of Clinical Embryology and Histology, Hanoi, Viet Nam No interests declared. Oleg Tishkevich Centre of Assisted Reproduction, Minsk, Belarus Acting Chairman of the Board (Belarusian Medical Society for Human Reproduction, 2021–2024), current. No other declared interest. Karla Torres Centre for ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 246
  },
  {
    "chunk_id": "infertility_2656",
    "text": "roduction, Minsk, Belarus Acting Chairman of the Board (Belarusian Medical Society for Human Reproduction, 2021–2024), current. No other declared interest. Karla Torres Centre for Reproductive Rights, Geneva, Switzerland No interests declared. Sheryl Van der Poel International Health Consultant, Geneva, Switzerland Travel reimbursements (Carrot Fertility, USA); several flights and/or hotel, no current travel. Stock options (Carrot Fertility, USA), US$ 4500, current; Stock options (Bea Fertility, United Kingdom), US$ 365, current. Adviser (Fertility Basics, USA), unpaid, current. Mónica Vazquez-Levin Institute of Biology and Experimental Medicine –National Scientific and Technical Research Council, (IBYME–CONICET), Buenos Aires, Argentina Consultant fees related to Spanish translation of WHO Semen Manual sixth edition (WHO); current.",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 246
  },
  {
    "chunk_id": "infertility_2657",
    "text": "223 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps ERG membera Affiliation Nature of declared interest Maria P. Velez Division of Reproductive Endocrinology and Infertility, McGill University, Montreal, Canada No interests declared. Nathalie Vermeulen European Society of Human Reproduction and Embryology, Strombeek- Bever, Belgium No interests declared. Mohamed Youssef Department of Obstetrics and Gynaecology, Cairo University, Cairo, Egypt No interests declared. a Several ERG members declared current income from employment, including those working with public, regulatory, non-profit and nongovernmental organizations, academic institutions and universities, or public hospitals; these are not included above. Annex 5",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 247
  },
  {
    "chunk_id": "infertility_2658",
    "text": "224 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Annex 6. Components of female medical history and physical examination1 1 Form developed for a standardized investigation, diagnosis and management of the infertile female Personal information Full name Date of birth Age Address Contact information (phone, email) Occupation Marital or relationship status Relevant dates for evaluation Date of history taking Date Month Year Date of birth of male partner Date Month Year Date of birth of female partner Date Month Year",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 248
  },
  {
    "chunk_id": "infertility_2659",
    "text": "225 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Infertility history Infertility ☐ Primary ☐ Secondary Duration of infertility infertility/attempting to achieve pregnancy years If secondary, months since last pregnancy months Previous investigation(s) and/or treatments for infertility ☐ No ☐ Yes If yes, please specify: Previous pregnancy ☐ Current partner ☐ Another partner Previous miscarriage ☐ Current partner ☐ Another partner Treatments/evaluations of the male partner Please specify: 1. Sexual history Sexual activity and practices Frequency of sexual activity ☐ Regular ☐ Irregular ☐ Rarely Timing of intercourse ☐ Spontaneous ☐ Around ovulation Pain during intercourse (dyspareunia) ☐ Yes ☐ No Presence of sexual anxiety ☐ Yes ☐ No Stress ☐ Yes ☐ No Psychological barriers to sexual function ☐ Yes ☐ No Use",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 249
  },
  {
    "chunk_id": "infertility_2660",
    "text": "☐ Around ovulation Pain during intercourse (dyspareunia) ☐ Yes ☐ No Presence of sexual anxiety ☐ Yes ☐ No Stress ☐ Yes ☐ No Psychological barriers to sexual function ☐ Yes ☐ No Use of sexual performance enhancers or lubricants ☐ Yes ☐ No Prolonged abstinence ☐ Yes ☐ No If yes, please specify duration: days months Perceived quality of sexual activity ☐ Normal ☐ Inadequate Previous or current sexual dysfunction ☐ Yes ☐ No 2. Menstrual history Age at menarche years old Cycle characteristics",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 249
  },
  {
    "chunk_id": "infertility_2661",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 226 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Length of cycle days ☐ Regular ☐ Irregular Duration of bleeding days Flow ☐ Light ☐ Moderate ☐ Heavy Dysmenorrhea (painful periods) ☐ Yes ☐ No Severity /10 Intermenstrual spotting ☐ Yes ☐ No 3. Obstetric history Total number of pregnancies Number of live births Number of miscarriages Number of stillbirths Number of ectopic pregnancies Termination of pregnancy ☐ Yes ☐ No If yes how many: History of complications during pregnancy (e.g. preeclampsia, gestational diabetes) Specify: 4. Contraceptive history Previous contraceptive methods used Specify: Type Specify: Duration of use Date of cessation: specify: Use of emergency contraception ☐ Yes ☐ No 5. Childhood and development history Pubertal",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 250
  },
  {
    "chunk_id": "infertility_2662",
    "text": "ontraceptive methods used Specify: Type Specify: Duration of use Date of cessation: specify: Use of emergency contraception ☐ Yes ☐ No 5. Childhood and development history Pubertal development Age at onset of puberty: Sexual development ☐ Normal ☐ Delayed History of ovarian or uterine abnormality ☐ Yes ☐ No Treatment for ovarian or uterine abnormality ☐ Medical ☐ Surgical Congenital anomaly ☐ Yes ☐ No If yes, please specify:",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 250
  },
  {
    "chunk_id": "infertility_2663",
    "text": "227 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Vaginal anomalies ☐ Yes ☐ No If yes, please specify: Pathology possibly causing ovarian or uterine damage Pelvic inflammatory disease (PID) ☐ Yes ☐ No Endometriosis ☐ Yes ☐ No Polycystic ovarian syndrome (PCOS) ☐ Yes ☐ No Ovarian torsion ☐ Yes ☐ No ☐ Left ☐ Right Surgery on reproductive organs ☐ Yes ☐ No If yes, please specify: 6. Medical history a. History of disease ☐ None ☐ Diabetes ☐ Hypertension ☐ Thyroid disorders ☐ Autoimmune diseases ☐ Neurologic disease ☐ Fibrocystic of the pancreas ☐ Chronic respiratory tract disease ☐ Tuberculosis (or exposure) ☐ Uterine fibroids ☐ Ovarian cysts ☐ Other, please specify: b. History of infection ☐ None High fever in past 6 months ☐ Yes ☐ No Urinary infection ☐ Yes ☐ No Sexually transmitted disease (STI) ☐ Yes ☐ No ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 251
  },
  {
    "chunk_id": "infertility_2664",
    "text": "ian cysts ☐ Other, please specify: b. History of infection ☐ None High fever in past 6 months ☐ Yes ☐ No Urinary infection ☐ Yes ☐ No Sexually transmitted disease (STI) ☐ Yes ☐ No ☐ Syphilis ☐ Gonorrhoea ☐ Chlamydia ☐ HPV (human papillomavirus) ☐ Trichomoniasis ☐ Herpes simplex virus (HSV) ☐ Cervicitis ☐ Other, specify: c. History of surgery ☐ None Retroperitoneal and/or pelvic surgery ☐ Hysterectomy ☐ Salpingectomy ☐ Pelvic adhesion surgery ☐ Oophorectomy ☐ Myomectomy (fibroid removal) Inguinal or perineal surgery ☐ Inguinal hernia repair ☐ Endometriosis surgery ☐ Tubal ligation ☐ Tubal ligation reversal ☐ Cyst removal (e.g. ovarian or pelvic cysts) ☐ Laparoscopy (diagnostic or therapeutic)",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 251
  },
  {
    "chunk_id": "infertility_2665",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 228 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Bariatric, bladder, or prostate surgery ☐ Bariatric surgery ☐ Uterine reconstruction ☐ Transvaginal or abdominal bladder surgery Cranial surgery ☐ Pituitary surgery Spinal surgery ☐ Spinal cord surgery Urethral and genital reconstruction ☐ Vaginal reconstruction ☐ Urethral surgery Sympathetic nervous system surgery ☐ Sympathectomy ☐ Other, please specify: d. Occupational history Current occupation Specify: Duration years months Work Environment ☐ Indoors ☐ Outdoors Exposure to ☐ extreme temperatures ☐ poor ventilation ☐ noise Exposure to chemicals ☐ solvents ☐ heavy metals ☐ toxic substances at work If yes, specify the substances: Exposure to radiation ☐ Yes ☐ No If yes, specify the source",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 252
  },
  {
    "chunk_id": "infertility_2666",
    "text": "ation ☐ noise Exposure to chemicals ☐ solvents ☐ heavy metals ☐ toxic substances at work If yes, specify the substances: Exposure to radiation ☐ Yes ☐ No If yes, specify the source/type: If yes, specify if doses were above recommended occupational levels ☐ Yes ☐ No e. History of gonadotoxic medication ☐ ß-blockers ☐ Finasteride ☐ Opioids ☐ Chemotherapy ☐ Calcium blockers ☐ Serotonin reuptake inhibitors ☐ Anabolic steroids Prescription medications ☐ Immunosuppressants (e.g. glucocorticoids, calcineurin inhibitors) ☐ Anti-epileptic drugs (AEDs) ☐ Serotonin reuptake inhibitors (SSRIs) ☐ Thiazide ☐ Other, specify: ☐ Cimetidine ☐ Allopurinol ☐ Sulfasalazine ☐ Colchicine ☐ Nitrofurantoin f. Lifestyle History Physical activity ☐ Regular ☐ Irregular ☐ Rarely Diet ☐ Balanced ☐ High-protein ☐ Vegetarian ☐ Vegan ☐ Keto ☐ Mediterranean ☐ Processed ☐ Please specify:",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 252
  },
  {
    "chunk_id": "infertility_2667",
    "text": "229 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Smoking or use of tobacco products including electronic cigarette? ☐ Yes ☐ No Number of cigarettes Per day: Number of years smoking: Consumption of alcohol ☐ Yes ☐ No If yes, how often: ☐ Regular ☐ Irregular ☐ Rarely How much? (units/week) Use recreational drugs? ☐ Yes ☐ No If yes, which ones (specify): Frequency ☐ Regular ☐ Irregular ☐ Rarely Recent stressors or changes in life ☐ Yes ☐ No If yes, specify: g. Family history Infertility in the family ☐ Yes ☐ No Genetic or hereditary conditions ☐ Cystic fibrosis ☐ Kartagener syndrome ☐ Endometriosis ☐ PCOS ☐ Other, specify: Family history of early menopause ☐ Yes ☐ No Endocrine diseases ☐ Yes ☐ No If yes, specify: 7. General physical examination Height (cm) BMI Weight (kg) Blood pressure (mmHG) General physic",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 253
  },
  {
    "chunk_id": "infertility_2668",
    "text": "istory of early menopause ☐ Yes ☐ No Endocrine diseases ☐ Yes ☐ No If yes, specify: 7. General physical examination Height (cm) BMI Weight (kg) Blood pressure (mmHG) General physical examination ☐ Normal ☐ Abnormal If abnormal specify: Signs of virilization ☐ Yes ☐ No If yes, specify: Signs of hypoestrogenism ☐ Yes ☐ No If yes, specify: Signs of hyperandrogenism ☐ Yes ☐ No If yes, specify:",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 253
  },
  {
    "chunk_id": "infertility_2669",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 230 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Skin changes ☐ Yes ☐ No If yes, specify: Thyroid examination ☐ Normal ☐ Enlarged thyroid (goiter) ☐ Thyroid nodules 8. Gynecological examination External genitalia (vulva) ☐ Normal ☐ Scars ☐ Lacerations ☐ Other, specify: Vagina ☐ Normal ☐ Atrophic (dryness, thinning) ☐ Narrowed ☐ Abnormal discharge. If present, specify: Cervix ☐ Normal ☐ Ectropion (cervical eversion) ☐ Cervical scars ☐ Other, specify: Uterus ☐ Normal ☐ Enlarged ☐ Fibroids (size and location) ☐ Retroverted ☐ Anomalies, specify: Ovaries ☐ Normal ☐ Polycystic (PCO) ☐ Enlarged ☐ Tender ☐ Cystic lesions, specify size and type: Fallopian tubes ☐ Patency (confirmed by ) ☐ Blocked (if known) ☐ Abnormalities, specify: Pelvic examin",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 254
  },
  {
    "chunk_id": "infertility_2670",
    "text": "Polycystic (PCO) ☐ Enlarged ☐ Tender ☐ Cystic lesions, specify size and type: Fallopian tubes ☐ Patency (confirmed by ) ☐ Blocked (if known) ☐ Abnormalities, specify: Pelvic examination Tenderness: ☐ Yes ☐ No If yes specify location: Thickened uterus: ☐ Yes ☐ No Cystic or mass lesions: ☐ Yes ☐ No If yes specify size: Specify location: Palpable adnexal masses: ☐ Yes ☐ No If yes specify location: Other: Specify: Rectal examination (if performed) ☐ Normal ☐ Tender ☐ Masses ☐ Abnormal ☐ Soft swelling ☐ Hard swelling ☐ Other, specify: 9. Additional information",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 254
  },
  {
    "chunk_id": "infertility_2671",
    "text": "231 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Annex 7. Components of male medical history and physical examination1 1 Adapted from the WHO manual for the standardized investigation, diagnosis and management of the infertile male. Personal information Full name Date of birth Age Address Contact information (phone, email) Occupation Marital or relationship status Relevant dates for evaluation Date of history taking Date Month Year Date of birth of male partner Date Month Year Date of birth of female partner Date Month Year",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 255
  },
  {
    "chunk_id": "infertility_2672",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 232 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Infertility history Infertility ☐ Primary ☐ Secondary Duration of infertility/attempting to achieve pregnancy years If secondary, months since last impregnation months Previous investigation (s) and/or treatments for infertility ☐ No ☐ Yes If yes, please specify: Contraceptive methods used Please specify: Duration of contraception use: Previous pregnancy ☐ Current partner ☐ Another partner Previous miscarriage ☐ Current partner ☐ Another partner Treatments/evaluations of the female partner Please specify: 1. Sexual history Sexual activity and practices Frequency of sexual activity ☐ Regular ☐ Irregular ☐ Rarely Timing of intercourse ☐ Spontaneous ☐ Around ovulation Erectile dysfunction ☐ Y",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 256
  },
  {
    "chunk_id": "infertility_2673",
    "text": "al history Sexual activity and practices Frequency of sexual activity ☐ Regular ☐ Irregular ☐ Rarely Timing of intercourse ☐ Spontaneous ☐ Around ovulation Erectile dysfunction ☐ Yes ☐ No ☐ Normal ☐ Inadequate Ejaculatory dysfunction ☐ Yes ☐ No Pain during intercourse ☐ Yes ☐ No Presence of sexual anxiety ☐ Yes ☐ No Stress ☐ Yes ☐ No Psychological barriers to sexual function ☐ Yes ☐ No Use of sexual performance enhancers or lubricants ☐ Yes ☐ No Prolonged abstinence ☐ Yes ☐ No If yes, please specify duration: days months Perceived quality of sexual activity ☐ Normal ☐ Inadequate Previous or current sexual dysfunction ☐ Yes ☐ No 2. Childhood and development history Pubertal development Age at onset of puberty:",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 256
  },
  {
    "chunk_id": "infertility_2674",
    "text": "233 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Sexual development ☐ Normal ☐ Delayed History of undescended testicle ☐ Yes ☐ No ☐ Left ☐ Right Treatment of undescended testicle ☐ Yes ☐ No ☐ Medical ☐ Surgical Epispadia ☐ Yes ☐ No Hypospadia ☐ Yes ☐ No Pathology possibly causing testicular damage ☐ Yes ☐ No Injury ☐ Left ☐ Right Torsion ☐ Left ☐ Right Orchitis: mumps ☐ Left ☐ Right Orchitis: other ☐ Left ☐ Right 3. Medical history a. History of disease ☐ None ☐ Diabetes ☐ Hypertension ☐ Thyroid disorders ☐ Autoimmune diseases ☐ Neurologic disease ☐ Fibrocystic of the pancreas ☐ Chronic respiratory tract disease ☐ Tuberculosis (or exposure) ☐ Other, please specify: b. History of infection ☐ None High fever in past 6 months ☐ Yes ☐ No Urinary infection ☐ Yes ☐ No Epididymitis ☐ Yes ☐ No If yes, specify: ☐ ",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 257
  },
  {
    "chunk_id": "infertility_2675",
    "text": "or exposure) ☐ Other, please specify: b. History of infection ☐ None High fever in past 6 months ☐ Yes ☐ No Urinary infection ☐ Yes ☐ No Epididymitis ☐ Yes ☐ No If yes, specify: ☐ Left ☐ Right Orchitis ☐ Yes ☐ No If yes, specify: ☐ Left ☐ Right Sexually transmitted disease (STI) ☐ Yes ☐ No ☐ Syphilis ☐ Gonorrhoea ☐ Chlamydia ☐ Other, specify: Treatment for STIs ☐ Yes ☐ No If yes, specify treatment: Symptoms of current infection ☐ Yes ☐ No ☐ Discharge ☐ Testicular pain ☐ Fever ☐ Other, specify:",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 257
  },
  {
    "chunk_id": "infertility_2676",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 234 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps c. History of surgery ☐ None Retroperitoneal and/or pelvic surgery ☐ Prostate ☐ Bladder neck Inguinal, scrotal or perineal surgery ☐ Herniorraphy ☐ Inguinal hernia repair ☐ Hydrocele ☐ Vasectomy ☐ Epididymal cyst removal ☐ Orchiectomy ☐ Varicocele repair ☐ Testicular surgery ☐ Vasectomy reversal Sperm retrieval ☐ PESA ☐ MESA ☐ Electroejaculation ☐ TESE ☐ Penile vibratory stimulation Bariatric, bladder, or prostate surgery ☐ Bariatric surgery ☐ Transurethral resection of the prostate (TURP) Cranial surgery ☐ Pituitary surgery Spinal surgery ☐ Spinal cord surgery Urethral and genital reconstruction ☐ Hypospadias repair ☐ Urethral structures surgery Hernia treatment ☐ Yes ☐ No Sympathetic ner",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 258
  },
  {
    "chunk_id": "infertility_2677",
    "text": "tary surgery Spinal surgery ☐ Spinal cord surgery Urethral and genital reconstruction ☐ Hypospadias repair ☐ Urethral structures surgery Hernia treatment ☐ Yes ☐ No Sympathetic nervous system surgery ☐ Sympathectomy ☐ Other, please specify: d. Occupational history Current occupation Specify: Duration years months Work environment ☐ Indoors ☐ Outdoors Exposure to ☐ Extreme temperatures ☐ Poor ventilation ☐ Noise Exposure to chemicals ☐ Solvents ☐ Heavy metals ☐ Toxic substances at work If yes, specify the substances: Exposure to radiation ☐ Yes ☐ No If yes, specify the source/type: If yes, specify if doses were above recommended occupational levels ☐ Yes ☐ No",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 258
  },
  {
    "chunk_id": "infertility_2678",
    "text": "235 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps e. History of gonadotoxic medication ☐ ß-blockers ☐ Finasteride ☐ Opioids ☐ Chemotherapy ☐ Calcium blockers ☐ Serotonin reuptake inhibitors ☐ Anabolic steroids Prescription medications ☐ Immunosuppressants (e.g. glucocorticoids, calcineurin inhibitors) ☐ Anti-epileptic drugs (AEDs) ☐ Selective serotonin reuptake inhibitors (SSRIs) ☐ Thiazide ☐ Other, specify: ☐ Cimetidine ☐ Allopurinol ☐ Sulfasalazine ☐ Colchicine ☐ Nitrofurantoin f. Lifestyle History Physical activity ☐ Regular ☐ Irregular ☐ Rarely Diet ☐ Balanced ☐ High-protein ☐ Vegetarian ☐ Vegan ☐ Keto ☐ Mediterranean ☐ Processed ☐ Please specify: Smoking or use of tobacco products including electronic cigarette? ☐ Yes ☐ No Number of cigarettes Per day: Number of years smoking: Consumption of alcohol ☐",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 259
  },
  {
    "chunk_id": "infertility_2679",
    "text": "ssed ☐ Please specify: Smoking or use of tobacco products including electronic cigarette? ☐ Yes ☐ No Number of cigarettes Per day: Number of years smoking: Consumption of alcohol ☐ Yes ☐ No If yes, how often: ☐ Regular ☐ Irregular ☐ Rarely How much? (units/week) Use recreational drugs? ☐ Yes ☐ No If yes, which ones (specify): Frequency: ☐ Regular ☐ Irregular ☐ Rarely Recent stressors or changes in life ☐ Yes ☐ No If yes, specify: g. Family history Infertility in the family ☐ Yes ☐ No Genetic or hereditary conditions ☐ Cystic fibrosis ☐ Kartagener syndrome ☐ Varicocele ☐ Other, specify: Endocrine diseases ☐ Yes ☐ No If yes, specify:",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 259
  },
  {
    "chunk_id": "infertility_2680",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 236 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps 4. General physical examination Height (cm) BMI Weight (kg) Blood pressure (mmHg) General physical examination ☐ Normal Abno rmal ☐ Hypoandrogenism ☐ Hyperandrogenism Signs of virilization ☐ Normal Abno rmal ☐ Testicular enlargement ☐ Other, specify: 5. Uro-genital examination Penis ☐ Normal ☐ Scars ☐ Hypospadias ☐ Plaques ☐ Epispadias ☐ Curvature ☐ Other, specify: Testes S i d e : L e f t - R i g h t Palpable in the scrotum ☐ Both palpable ☐ Abnormal L ☐ R ☐ Palpable in inguinal region ☐ Both palpable ☐ Abnormal L ☐ R ☐ ☐ Both palpable ☐ Thickened L ☐ R ☐ ☐ Cystic/Nodule L ☐ R ☐ ☐ Tender L ☐ R ☐ Volume (ml) Left: Right: Device used for measurement ☐ Prader orchidometer ☐ Pachymeter ☐ Othe",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 260
  },
  {
    "chunk_id": "infertility_2681",
    "text": " L ☐ R ☐ ☐ Both palpable ☐ Thickened L ☐ R ☐ ☐ Cystic/Nodule L ☐ R ☐ ☐ Tender L ☐ R ☐ Volume (ml) Left: Right: Device used for measurement ☐ Prader orchidometer ☐ Pachymeter ☐ Other Epididymis ☐ Both normal ☐ Thickened L ☐ R ☐ ☐ Cystic L ☐ R ☐ ☐ Tender L ☐ R ☐ Vas deferens ☐ Both normal ☐ Non palpable L ☐ R ☐ ☐ Thickened L ☐ R ☐ Spermatic cord/Scrotum ☐ Normal ☐ Hydrocele L ☐ R ☐ ☐ Hernia L ☐ R ☐ Varicocele ☐ Normal ☐ Grade III L ☐ R ☐ ☐ Grade II L ☐ R ☐ ☐ Grade I L ☐ R ☐ ☐ Subclinical L ☐ R ☐ Inguinal examination ☐ Normal ☐ Lymphadenopaty L ☐ R ☐",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 260
  },
  {
    "chunk_id": "infertility_2682",
    "text": "237 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps Scrotal skin ☐ Normal ☐ Infectious scars L ☐ R ☐ ☐ Surgical scars L ☐ R ☐ Rectal examination Prostate ☐ Normal ☐ Soft swelling ☐ Tender ☐ Hard swelling ☐ Other ☐ Palpable ☐ Abnormal Seminal vesicles ☐ Normal ☐ Soft swelling ☐ Tender ☐ Hard swelling ☐ Other ☐ Palpable ☐ Abnormal 6. Additional information",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 261
  },
  {
    "chunk_id": "infertility_2683",
    "text": "Guideline for the prevention, diagnosis and treatment of infertility 238 Executive summary Intro Rationale & methodology Approach & management Prevention Diagnosis Treatment Dissemination Research gaps For further information, please contact: Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing: Advancing Life Course Health and Reproduction (LHR) Human Reproduction Programme (HRP) World Health Organization Avenue Appia 20 CH-1211, Geneva 27 Switzerland Email: srhcfc@who.int Website: https://www.who.int/health-topics/infertility www.who.int",
    "source": "WHO Infertility Guideline",
    "topic": "infertility",
    "page": 262
  }
]